Because	O
there	O
exist	O
normal	O
regions	O
in	O
the	O
lung	O
with	O
ARDS	O
and	O
because	O
PLV	O
in	O
the	O
normal	O
lung	O
results	O
in	O
worsened	O
gas	O
exchange	O
,	O
we	O
postulated	O
that	O
the	O
optimal	O
dose	O
of	O
PFC	O
for	O
PLV	O
may	O
be	O
less	O
than	O
the	O
functional	B-PROC
residual	I-PROC
capacity	I-PROC
(	O
FRC	B-PROC
)	O
dose	O
in	O
the	O
lung	O
with	O
limited	O
disease	O
.	O

Sepsis	O
,	O
MOSF	O
,	O
and	O
lung	O
superinfection	O
with	O
Pseudomonas	O
or	O
Candida	O
species	O
may	O
be	O
also	O
important	O
factors	O
in	O
the	O
development	B-PROC
of	O
AL	O
in	O
critically	O
ill	O
children	O
.	O

Each	O
of	O
the	O
mutants	O
was	O
found	O
to	O
contain	O
a	O
single	O
point	B-PROC
mutation	I-PROC
in	O
the	O
S	O
protein	O
(	O
Cys155Phe	O
,	O
Met195Val	O
,	O
Arg196Ser	O
,	O
Asp208Asn	O
or	O
Leu209Pro	O
),	O
indicating	O
that	O
these	O
amino	O
acids	O
are	O
affecting	O
the	O
sialic	O
acid	O
binding	O
site	O
.	O

TITLE	O
:	O
Neutralization	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
:	O
preparation	O
of	O
monoclonal	O
antibody	B-PROC
that	O
shows	O
cell	O
tropism	B-PROC
in	O
neutralizing	O
activity	O
after	O
viral	B-PROC
absorption	I-PROC
into	O
the	O
cells	O
.	O

ABSTRACT	O
:	O
Feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
infection	O
of	O
feline	O
macro	O
-	O
phages	O
is	O
enhanced	O
by	O
mouse	O
anti	O
-	O
FIPV	O
monoclonal	O
antibody	B-PROC
(	O
MAb	O
).	O

These	O
findings	O
indicated	O
that	O
the	O
FIPV	O
replication	O
mechanism	O
differs	O
between	O
feline	O
macrophages	O
and	O
CrFK	O
/	O
fcwf	O
-	O
4	O
cells	O
and	O
that	O
a	O
neutralizing	O
epitope	O
that	O
can	O
prevent	O
FIPV	O
infection	O
of	O
feline	O
macrophages	O
after	O
viral	B-PROC
absorption	I-PROC
is	O
present	O
on	O
M	O
protein	O
.	O

As	O
judged	O
by	O
their	O
colabeling	O
with	O
antibodies	O
to	O
E	O
and	O
to	O
Rab	O
-	O
1	O
,	O
a	O
marker	O
for	O
the	O
intermediate	O
compartment	O
and	O
endoplasmic	O
reticulum	O
,	O
the	O
E	O
protein	O
accumulates	O
in	O
and	O
induces	O
curvature	O
into	O
these	O
pre	O
-	O
Golgi	O
membranes	O
where	O
coronaviruses	O
have	O
been	O
shown	O
earlier	O
to	O
assemble	O
by	O
budding	B-PROC
.	O

TITLE	O
:	O
Contributions	O
of	O
Fas	O
-	O
Fas	O
ligand	B-PROC
interactions	O
to	O
the	O
pathogenesis	B-PROC
of	O
mouse	O
hepatitis	O
virus	O
in	O
the	O
central	O
nervous	O
system	O
.	O

ABSTRACT	O
:	O
The	O
pathogenesis	B-PROC
of	O
the	O
neurotropic	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
in	O
Fas	O
-	O
deficient	O
mice	O
suggested	O
that	O
Fas	O
-	O
mediated	O
cytotoxicity	O
may	O
be	O
required	O
during	O
viral	O
clearance	O
after	O
the	O
loss	O
of	O
perforin	O
-	O
mediated	O
cytotoxicity	O
.	O

ABSTRACT	O
:	O
First	O
,	O
to	O
determine	O
whether	O
the	O
severity	O
of	O
shock	O
,	O
as	O
measured	O
by	O
systemic	O
hypotension	O
and	O
metabolic	B-PROC
acidosis	O
,	O
is	O
significantly	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
acute	O
lung	O
injury	O
in	O
patients	O
with	O
severe	O
trauma	O
.	O

Both	O
fluids	O
were	O
analyzed	O
for	O
protein	O
carbonyl	O
concentrations	O
as	O
a	O
measure	O
of	O
protein	B-PROC
oxidation	B-PROC
and	O
thiobarbituric	O
acid	O
-	O
reactive	O
substances	O
as	O
a	O
measure	O
of	O
lipid	B-PROC
peroxidation	I-PROC
.	O

High	O
protein	O
carbonyl	O
concentrations	O
in	O
plasma	O
as	O
well	O
as	O
bronchial	O
aspirates	O
indicate	O
that	O
oxidation	B-PROC
is	O
not	O
restricted	O
to	O
the	O
lungs	O
.	O

In	O
all	O
groups	O
of	O
patients	O
,	O
the	O
changes	O
in	O
the	O
lavage	O
enzymatic	O
activities	O
were	O
paralleled	O
by	O
manifold	O
increased	O
BALF	O
concentrations	O
of	O
fibrinopeptide	O
A	O
and	O
D	O
-	O
dimer	O
,	O
reflecting	O
in	O
vivo	O
coagulation	B-PROC
processes	O
.	O

Within	O
the	O
overall	O
number	O
of	O
patients	O
with	O
pneumonia	O
,	O
changes	O
in	O
the	O
alveolar	O
hemostatic	B-PROC
balance	B-PROC
were	O
more	O
prominent	O
in	O
alveolar	O
and	O
interstitial	O
pneumonia	O
than	O
in	O
bronchopneumonia	O
.	O

In	O
contrast	O
,	O
PCT	O
is	O
generally	O
not	O
induced	O
by	O
severe	O
viral	B-PROC
infections	I-PROC
or	O
inflammatory	O
reactions	O
of	O
non	O
-	O
infectious	O
origin	O
.	O

The	O
techniques	O
used	O
included	O
lung	O
rest	O
,	O
pulmonary	O
physiotherapy	O
,	O
diuresis	B-PROC
to	O
dry	O
weight	O
using	O
hemofiltration	O
if	O
needed	O
,	O
minimal	O
anticoagulation	B-PROC
,	O
and	O
optimal	O
systemic	O
oxygen	O
delivery	O
.	O

Prone	O
ventilation	O
in	O
postinjury	O
patients	O
with	O
ARDS	O
may	O
improve	O
oxygenation	B-PROC
but	O
has	O
the	O
potential	O
for	O
significant	O
complications	O
.	O

TITLE	O
:	O
Cocaine	O
causes	O
increased	O
type	B-PROC
I	I-PROC
interferon	B-PROC
secretion	I-PROC
by	O
both	O
L929	O
cells	O
and	O
murine	O
macrophages	O
.	O

Here	O
,	O
we	O
present	O
evidence	O
that	O
cocaine	O
stimulates	O
the	O
secretion	B-PROC
of	O
an	O
antiviral	O
product	O
that	O
is	O
neutralized	O
by	O
anti	O
-	O
interferon	O
(	O
anti	O
-	O
IFN	O
).	O

The	O
increase	O
in	O
IFN	O
secretion	B-PROC
was	O
most	O
pronounced	O
when	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
the	O
IFN	O
inducer	O
poly	O
(	O
I	O
.	O
C	O
).	O

TITLE	O
:	O
Immunogenicity	O
of	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
spike	O
protein	O
expressed	B-PROC
in	O
plants	O
.	O

During	O
the	O
experimental	O
period	O
(	O
4	O
hrs	O
),	O
arterial	O
blood	B-PROC
gases	I-PROC
,	O
lung	O
mechanics	O
,	O
and	O
peripheral	O
neutrophil	O
and	O
platelet	O
counts	O
were	O
measured	O
.	O

Dual	O
-	O
labeling	O
experiments	O
demonstrated	O
colocalization	O
of	O
the	O
majority	O
of	O
p1a	O
-	O
22	O
in	O
replication	O
complexes	O
with	O
the	O
helicase	O
,	O
nucleocapsid	O
,	O
and	O
3C	O
-	O
like	O
proteinase	B-PROC
,	O
as	O
well	O
as	O
with	O
p1a	O
-	O
10	O
,	O
-	O
12	O
,	O
and	O
-	O
15	O
.	O

The	O
lungs	O
of	O
the	O
anti	O
-	O
CD18	O
-	O
treated	O
animals	O
showed	O
minor	O
signs	O
of	O
inflammation	O
and	O
PMN	B-PROC
infiltration	O
whereas	O
controls	O
had	O
interstitial	O
and	O
intra	O
-	O
alveolar	O
edema	O
and	O
a	O
large	O
number	O
of	O
granulocytes	O
.	O

28	O
%	O
total	O
sleep	B-PROC
time	O
[	O
TST	O
])	O
and	O
a	O
reduced	O
proportion	O
of	O
REM	B-PROC
sleep	B-PROC
(	O
10	O
+/-	O

Sleep	B-PROC
,	O
as	O
it	O
is	O
conventionally	O
measured	O
,	O
was	O
identified	O
only	O
in	O
a	O
subgroup	O
of	O
critically	O
ill	O
patients	O
requiring	O
mechanical	O
ventilation	O
and	O
was	O
severely	O
disrupted	O
.	O

The	O
disease	O
is	O
characterised	O
by	O
splenomegaly	O
,	O
intestinal	O
haemorrhage	O
,	O
sudden	O
death	B-PROC
and	O
immunosuppression	B-PROC
.	O

The	O
mechanisms	O
of	O
HEV	O
immunopathogenesis	O
and	O
immunosuppression	B-PROC
are	O
not	O
fully	O
understood	O
.	O

Types	O
I	O
and	O
II	O
interferons	O
(	O
IFN	O
)	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
interleukin	O
-	O
6	O
and	O
tumour	O
necrosis	B-PROC
-	O
like	O
factors	O
(	O
TNF	O
)	O
are	O
released	O
at	O
the	O
peak	O
of	O
the	O
infection	O
.	O

Nearly	O
complete	O
elimination	B-PROC
of	O
viral	B-PROC
infection	I-PROC
and	O
illness	O
was	O
observed	O
in	O
chicks	O
receiving	O
cells	O
enriched	O
in	O
alphabeta	O
lymphocytes	O
.	O

TITLE	O
:	O
Coronavirus	O
-	O
induced	O
membrane	B-PROC
fusion	I-PROC
requires	O
the	O
cysteine	O
-	O
rich	O
domain	O
in	O
the	O
spike	O
protein	O
.	O

We	O
show	O
that	O
the	O
cytoplasmic	O
tail	O
is	O
not	O
required	O
for	O
fusion	O
but	O
has	O
the	O
capacity	O
to	O
enhance	O
membrane	B-PROC
fusion	I-PROC
activity	I-PROC
.	O

The	O
results	O
indicate	O
that	O
the	O
carboxyl	O
-	O
terminus	O
of	O
the	O
spike	O
transmembrane	O
anchor	O
contains	O
at	O
least	O
two	O
distinct	O
domains	O
,	O
both	O
of	O
which	O
are	O
necessary	O
for	O
full	O
membrane	B-PROC
fusion	I-PROC
.	O

We	O
analyzed	O
the	O
nucleotide	O
sequence	O
of	O
a	O
highly	O
virulent	O
strain	O
MHV	O
-	O
2	O
M	O
-	O
coding	O
region	O
and	O
demonstrated	O
that	O
MHV	O
-	O
2	O
had	O
a	O
unique	O
amino	O
acid	O
,	O
Asn	O
,	O
at	O
position	O
2	O
at	O
the	O
conserved	O
O	O
-	O
glycosylation	B-PROC
site	O
.	O

TITLE	O
:	O
Characterization	O
of	O
protection	O
against	O
coronavirus	O
infection	O
by	O
noninternal	O
image	O
antiidiotypic	O
antibody	B-PROC
.	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
have	O
reported	O
protective	O
vaccination	O
of	O
mice	O
against	O
a	O
coronavirus	O
infection	O
using	O
rabbit	O
polyclonal	O
noninternal	O
image	O
Ab2gamma	O
anti	O
-	O
idiotypic	O
(	O
anti	O
-	O
Id	O
)	O
antibody	B-PROC
specific	O
for	O
a	O
virus	O
-	O
neutralizing	O
and	O
protective	O
monoclonal	O
antibody	B-PROC
(	O
mAb	O
)	O
7	O
-	O
10A	O
against	O
the	O
viral	O
surface	O
S	O
glycoprotein	O
.	O

To	O
characterize	O
further	O
the	O
mechanisms	O
involved	O
in	O
the	O
induction	O
of	O
protective	O
immunity	B-PROC
by	O
this	O
noninternal	O
image	O
anti	O
-	O
Id	O
,	O
plasma	O
and	O
splenocytes	O
from	O
Ab2gamma	O
-	O
immunized	O
BALB	O
/	O
c	O
mice	O
were	O
passively	O
transferred	O
to	O
naive	O
BALB	O
/	O
c	O
mice	O
,	O
followed	O
by	O
viral	O
challenge	O
.	O

However	O
,	O
unlike	O
the	O
polyclonal	O
Ab2gamma	O
,	O
they	O
were	O
not	O
capable	O
of	O
inducing	O
a	O
protective	O
immune	B-PROC
response	I-PROC
.	O

The	O
virus	B-PROC
neutralization	I-PROC
assay	O
was	O
performed	O
by	O
inoculating	O
24	O
-	O
to	O
-	O
25	O
-	O
day	O
-	O
old	O
turkey	O
embryos	O
via	O
the	O
amniotic	O
route	O
and	O
by	O
assessing	O
the	O
embryo	O
infectivity	O
on	O
the	O
basis	O
of	O
gross	O
intestinal	O
lesions	O
and	O
intestinal	O
maltase	O
activity	O
at	O
72	O
hr	O
postinoculation	O
.	O

TITLE	O
:	O
High	O
mortality	O
and	O
growth	B-PROC
depression	O
experimentally	O
produced	O
in	O
young	O
turkeys	O
by	O
dual	O
infection	O
with	O
enteropathogenic	O
Escherichia	O
coli	O
and	O
turkey	O
coronavirus	O
.	O

Turkeys	O
inoculated	O
with	O
only	O
R98	O
/	O
5	O
did	O
not	O
develop	O
clinically	O
apparent	O
disease	O
,	O
and	O
only	O
mild	O
disease	O
and	O
moderate	O
growth	B-PROC
depression	O
were	O
observed	O
in	O
turkeys	O
inoculated	O
with	O
only	O
TCV	O
.	O

Approximately	O
half	O
the	O
deaths	B-PROC
were	O
the	O
result	O
of	O
problems	O
associated	O
with	O
the	O
reproductive	B-PROC
tract	O
or	O
trauma	O
,	O
including	O
injuries	O
acquired	O
during	O
fighting	O
or	O
mating	B-PROC
.	O

ABSTRACT	O
:	O
The	O
acute	O
disappearance	O
of	O
neutrophils	O
from	O
the	O
circulation	B-PROC
can	O
be	O
associated	O
with	O
pulmonary	O
leukostasis	O
,	O
lung	O
injury	O
,	O
and	O
respiratory	O
distress	O
.	O

To	O
determine	O
whether	O
a	O
low	O
concentration	O
of	O
mature	O
neutrophils	O
in	O
the	O
peripheral	O
blood	O
soon	O
after	O
birth	B-PROC
is	O
associated	O
with	O
an	O
increase	O
in	O
subsequent	O
respiratory	O
distress	O
in	O
premature	O
infants	O
.	O

Indirect	O
immunofluorescence	O
microscopy	O
showed	O
that	O
E	O
is	O
localized	O
to	O
the	O
Golgi	O
complex	O
in	O
cells	O
transiently	O
expressing	O
IBV	O
E	O
.	O
When	O
coexpressed	O
with	O
IBV	O
M	O
,	O
both	O
from	O
cDNA	O
and	O
in	O
IBV	O
infection	O
,	O
the	O
two	O
proteins	O
are	O
colocalized	O
in	O
Golgi	O
membranes	O
,	O
near	O
the	O
coronavirus	O
budding	B-PROC
site	O
.	O

Thus	O
,	O
even	O
though	O
IBV	O
E	O
is	O
present	O
at	O
low	O
levels	O
in	O
virions	O
,	O
it	O
is	O
apparently	O
expressed	B-PROC
at	O
high	O
levels	O
in	O
infected	O
cells	O
near	O
the	O
site	O
of	O
virus	B-PROC
assembly	I-PROC
.	O

The	O
positive	O
signals	O
with	O
the	O
recombinant	O
PAS16	O
antibody	B-PROC
were	O
similar	O
to	O
those	O
with	O
the	O
monoclonal	O
antibody	B-PROC
.	O

TITLE	O
:	O
Genetic	O
manipulation	O
of	O
equine	O
arteritis	O
virus	O
using	O
full	O
-	O
length	O
cDNA	O
clones	O
:	O
separation	O
of	O
overlapping	O
genes	O
and	O
expression	B-PROC
of	O
a	O
foreign	O
epitope	O
.	O

To	O
investigate	O
the	O
importance	O
of	O
the	O
overlapping	O
gene	B-PROC
arrangement	I-PROC
in	O
the	O
viral	O
life	O
-	O
cycle	O
and	O
to	O
facilitate	O
the	O
genetic	O
manipulation	O
of	O
the	O
viral	O
genome	O
,	O
a	O
series	O
of	O
mutant	O
full	O
-	O
length	O
cDNA	O
clones	O
was	O
constructed	O
in	O
which	O
either	O
EAV	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
4	O
and	O
5	O
or	O
ORFs	O
5	O
and	O
6	O
or	O
ORFs	O
4	O
,	O
5	O
,	O
and	O
6	O
were	O
separated	O
by	O
newly	O
introduced	O
AflII	O
restriction	O
endonuclease	O
cleavage	B-PROC
sites	O
.	O

In	O
an	O
effort	B-PROC
to	O
maximize	O
IFN	O
-	O
alpha	O
antiviral	O
efficacy	O
,	O
we	O
have	O
explored	O
the	O
therapeutic	O
potential	O
of	O
murine	O
IFN	O
-	O
alpha2	O
(	O
mIFNalpha2	O
)	O
selectively	O
expressed	B-PROC
in	O
the	O
liver	O
.	O

Four	O
patients	O
required	O
mechanical	O
ventilation	O
because	O
of	O
respiratory	O
insufficiency	O
and	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
of	O
whom	O
three	O
died	B-PROC
.	O

All	O
patients	O
who	O
died	B-PROC
required	O
haemofiltration	O
because	O
of	O
acute	O
renal	O
failure	O
.	O

This	O
report	O
presents	O
the	O
cases	O
of	O
three	O
patients	O
with	O
serious	O
zinc	O
chloride	O
inhalation	B-PROC
and	O
ARDS	O
,	O
the	O
last	O
of	O
whom	O
survived	O
after	O
prolonged	O
intensive	O
care	O
,	O
videothoracoscopic	O
excision	O
of	O
emphysema	O
bullae	O
,	O
and	O
recurrent	O
chemical	O
pleurodesis	O
.	O

All	O
randomized	O
controlled	O
trials	O
of	O
elective	O
high	O
frequency	O
jet	O
ventilation	O
versus	O
conventional	O
ventilation	O
in	O
preterm	O
infants	O
born	O
at	O
less	O
than	O
35	O
weeks	O
GA	O
or	O
with	O
a	O
birth	B-PROC
weight	O
less	O
than	O
2000	O
gms	O
with	O
respiratory	O
distress	O
were	O
included	O
in	O
the	O
systematic	O
review	O
.	O

55	O
,	O
0	O
.	O
88	O
;	O
Typical	O
RD	O
-	O
0	O
.	O
03	O
,	O
95	O
%	O
CI	O
-	O
0	O
.	O
05	O
,	O
-	O
0	O
.	O
01	O
),	O
and	O
chronic	O
lung	O
disease	O
or	O
death	B-PROC
at	O
36	O
weeks	O
(	O
Typical	O
RR	O
0	O
.	O
84	O
,	O
95	O
%	O
CI	O
0	O
.	O
75	O
,	O
0	O
.	O
93	O
;	O
Typical	O
RD	O
-	O
0	O
.	O
06	O
,	O
95	O
%	O
CI	O
-	O
0	O
.	O
09	O
,	O
-	O
0	O
.	O
03	O
).	O

RESULTS	O
:	O
Clinically	O
,	O
as	O
the	O
severity	O
of	O
VOL	O
increased	O
,	O
the	O
amount	O
of	O
ascites	O
observed	O
during	O
autopsy	O
increased	O
significantly	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
the	O
time	O
from	O
hospitalization	O
to	O
death	B-PROC
was	O
significantly	O
longer	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

The	O
virus	O
infected	O
a	O
very	O
limited	O
part	O
of	O
the	O
brain	O
,	O
especially	O
Purkinje	O
cells	O
in	O
the	O
cerebellum	O
and	O
many	O
neurons	O
in	O
the	O
pons	O
,	O
without	O
inducing	O
an	O
overt	O
immunologic	B-PROC
reaction	I-PROC
from	O
the	O
host	O
.	O

In	O
the	O
groups	O
immunized	O
with	O
CL	O
antigen	O
at	O
an	O
HA	O
titer	O
of	O
1000	O
or	O
250	O
,	O
HI	O
antibody	B-PROC
titers	O
were	O
40	O
to	O
160	O
and	O
SN	O
titers	O
were	O
80	O
to	O
640	O
.	O

This	O
demonstration	O
opens	O
up	O
the	O
possibility	O
of	O
employing	O
this	O
infectious	O
cDNA	O
as	O
a	O
vector	O
for	O
vaccine	O
development	B-PROC
in	O
human	O
,	O
porcine	O
,	O
canine	O
,	O
and	O
feline	O
species	O
susceptible	O
to	O
group	O
1	O
coronaviruses	O
.	O

TITLE	O
:	O
Dying	B-PROC
with	O
acute	O
respiratory	O
failure	O
or	O
multiple	O
organ	O
system	O
failure	O
with	O
sepsis	O
.	O

Families	O
of	O
42	O
%	O
of	O
the	O
patients	O
who	O
died	B-PROC
reported	O
one	O
or	O
more	O
substantial	O
burden	O
.	O

Approximately	O
85	O
participants	O
were	O
selected	O
for	O
their	O
collective	O
expertise	O
in	O
critical	O
care	O
,	O
pulmonary	O
medicine	O
,	O
cardiovascular	O
medicine	O
and	O
surgery	O
,	O
pediatrics	O
,	O
nursing	B-PROC
,	O
biostatistics	O
,	O
and	O
medical	O
economics	O
.	O

In	O
this	O
study	O
,	O
the	O
benefit	O
of	O
having	O
a	O
heterologous	O
antigen	O
expressed	B-PROC
on	O
the	O
surface	O
of	O
a	O
live	O
vector	O
rather	O
than	O
intracellularly	O
was	O
evaluated	O
.	O

An	O
""""	O
Optimal	O
Volume	O
Strategy	O
""""	O
with	O
HFOV	O
was	O
utilized	O
to	O
recruit	O
alveoli	O
and	O
optimize	O
lung	B-PROC
volume	I-PROC
.	O

Results	O
suggest	O
that	O
RBCV	O
may	O
play	O
a	O
causative	O
role	O
in	O
outbreaks	O
of	O
shipping	O
fever	B-PROC
in	O
cattle	O
.	O

No	O
deaths	B-PROC
were	O
observed	O
in	O
the	O
control	O
(	O
SHAM	O
)	O
group	O
.	O

To	O
overcome	O
these	O
unwanted	O
side	O
effects	O
,	O
we	O
developed	O
a	O
technique	O
of	O
perfluorocarbon	O
vaporisation	O
in	O
analogy	O
to	O
the	O
application	O
of	O
inhalation	B-PROC
anaesthetic	O
agents	O
.	O

The	O
patient	O
also	O
developed	O
a	O
subclavian	O
vein	O
thrombosis	O
with	O
extension	O
to	O
the	O
cephalic	O
and	O
basilic	O
veins	O
secondary	O
to	O
placement	O
of	O
a	O
pulmonary	O
artery	O
catheter	O
;	O
anticoagulation	B-PROC
with	O
heparin	O
was	O
required	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
acute	O
effects	O
of	O
an	O
increased	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
on	O
splanchnic	O
tissue	O
perfusion	O
.	O

Splanchnic	O
blood	B-PROC
flow	I-PROC
was	O
measured	O
using	O
primed	O
continuous	O
infusion	O
of	O
indocyanine	O
green	O
dye	O
with	O
hepatic	O
venous	O
sampling	O
and	O
systemic	O
hemodynamics	B-PROC
by	O
routine	O
monitoring	O
.	O

TITLE	O
:	O
Detection	O
and	O
differentiation	B-PROC
of	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
and	O
transmissible	O
gastroenteritis	O
virus	O
in	O
clinical	O
samples	O
by	O
multiplex	O
RT	O
-	O
PCR	O
.	O

To	O
prevent	O
the	O
development	B-PROC
of	O
renal	O
or	O
cardiopulmonary	O
failure	O
in	O
these	O
patients	O
,	O
decompression	O
should	O
be	O
considered	O
for	O
acute	O
,	O
tense	O
abdominal	O
distension	O
.	O

Sequences	O
corresponding	O
to	O
the	O
viral	O
nucleocapsid	O
region	O
were	O
amplified	O
by	O
reverse	O
-	O
transcription	B-PROC
polymerase	O
chain	O
reaction	O
from	O
the	O
cortex	O
,	O
dura	O
mater	O
,	O
pancreas	O
,	O
lungs	O
,	O
third	O
eyelid	O
,	O
and	O
the	O
heart	O
muscle	O
in	O
four	O
cases	O
.	O

The	O
dynamic	O
equilibrium	B-PROC
of	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
under	O
physiological	O
conditions	O
is	O
a	O
consequence	O
of	O
the	O
balance	B-PROC
between	O
the	O
regulation	B-PROC
of	I-PROC
synthesis	I-PROC
and	O
degradation	O
of	O
ECM	O
components	O
.	O

TITLE	O
:	O
A	O
potential	O
role	O
for	O
tumour	O
necrosis	B-PROC
factor	O
-	O
alpha	O
in	O
synergy	O
between	O
porcine	O
respiratory	O
coronavirus	O
and	O
bacterial	O
lipopolysaccharide	O
in	O
the	O
induction	O
of	O
respiratory	O
disease	O
in	O
pigs	O
.	O

Despite	O
this	O
,	O
the	O
patient	O
died	B-PROC
several	O
days	O
later	O
of	O
spontaneous	O
intracranial	O
haemorrhage	O
.	O

Detailed	O
immunophenotyping	O
,	O
in	O
situ	O
hybridization	B-PROC
for	O
EBV	O
early	O
RNA	O
-	O
1	O
(	O
EBER1	O
)	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
analyses	O
for	O
immunoglobulin	B-PROC
(	O
Ig	O
)	O
heavy	O
chain	O
and	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	B-PROC
)-	O
gamma	O
gene	B-PROC
rearrangements	I-PROC
were	O
performed	O
on	O
paraffin	O
-	O
embedded	O
tissue	O
from	O
all	O
patients	O
.	O

Two	O
patients	O
died	B-PROC
of	O
multi	O
-	O
organ	O
failure	O
.	O

Infection	O
of	O
the	O
human	O
astrocytic	O
cell	O
line	O
U	O
-	O
373MG	O
by	O
the	O
OC43	O
strain	O
of	O
human	O
coronavirus	O
caused	O
an	O
upregulation	B-PROC
of	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
alpha	O
,	O
and	O
MCP	O
-	O
1	O
mRNA	B-PROC
expression	B-PROC
.	O

ABSTRACT	O
:	O
Septic	O
shock	O
is	O
characterized	O
by	O
a	O
decrease	O
in	O
systemic	B-PROC
vascular	I-PROC
resistance	I-PROC
.	O

In	O
the	O
host	O
infected	O
by	O
endotoxin	O
(	O
lipopolysaccharide	O
,	O
LPS	O
),	O
the	O
expression	B-PROC
and	O
release	O
of	O
proinflammatory	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
(	O
TNFalpha	O
)	O
rapidly	O
increases	O
,	O
and	O
this	O
cytokine	B-PROC
production	I-PROC
is	O
regulated	O
by	O
agents	O
elevating	O
cyclic	O
AMP	O
.	O

ABSTRACT	O
:	O
The	O
viruses	O
associated	O
most	O
frequently	O
with	O
the	O
""""	O
common	O
cold	B-PROC
""""	O
are	O
rhinoviruses	O
and	O
coronaviruses	O
.	O

As	O
leukocytosis	O
is	O
typically	O
absent	O
in	O
ornithosis	O
,	O
C	O
-	O
reactive	O
protein	O
,	O
interleukin	O
6	O
and	O
procalcitonin	O
were	O
used	O
as	O
infection	O
parameters	O
in	O
order	O
to	O
monitor	O
clinical	O
development	B-PROC
.	O

Inhaled	B-PROC
NO	O
improved	O
PaO2	O
in	O
all	O
groups	O
;	O
however	O
,	O
the	O
increase	O
in	O
PaO2	O
was	O
greatest	O
in	O
the	O
HFOV	O
+	O
PLV	O
group	O
(	O
p	O
<	O
.	O
05	O
).	O

Because	O
inflammatory	O
mediators	O
such	O
as	O
tumor	O
necrosis	B-PROC
factor	O
(	O
TNF	O
)-	O
alpha	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
produced	O
within	O
the	O
lungs	O
have	O
been	O
implicated	O
in	O
sepsis	O
-	O
induced	O
ARDS	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
role	O
of	O
these	O
mediators	O
in	O
pancreatitis	O
-	O
induced	O
ARDS	O
using	O
a	O
model	O
whereby	O
ascites	O
from	O
animals	O
with	O
pancreatitis	O
is	O
transferred	O
to	O
otherwise	O
healthy	O
animals	O
resulting	O
in	O
pulmonary	O
injury	O
.	O

Healthy	O
animals	O
administered	O
intravenous	O
ascites	O
were	O
randomized	O
to	O
receive	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
the	O
p38	O
mitogen	O
activated	O
kinase	B-PROC
inhibitor	I-PROC
CNI	O
-	O
1493	O
(	O
1	O
mg	O
/	O
kg	O
)	O
or	O
vehicle	O
.	O

During	O
each	O
infusion	O
of	O
AmBd	O
over	O
the	O
next	O
3	O
d	O
,	O
the	O
patient	O
developed	O
rigor	O
,	O
chill	O
and	O
elevated	B-PROC
temperature	I-PROC
which	O
was	O
managed	O
with	O
meperidine	O
.	O

TITLE	O
:	O
Identification	O
of	O
mouse	O
hepatitis	O
virus	O
papain	O
-	O
like	O
proteinase	B-PROC
2	O
activity	O
.	O

Cleavage	B-PROC
of	O
MP1	O
and	O
release	O
of	O
a	O
150	O
-	O
kDa	O
intermediate	O
,	O
p150	O
,	O
are	O
likely	O
to	O
be	O
important	O
for	O
embedding	O
the	O
replicase	O
complex	O
in	O
cellular	O
membranes	O
.	O

Pulse	B-PROC
-	O
labeling	O
experiments	O
showed	O
that	O
newly	O
synthesized	O
,	O
unglycosylated	O
M	O
protein	O
interacted	O
with	O
N	O
protein	O
in	O
a	O
pre	O
-	O
Golgi	O
compartment	O
,	O
which	O
is	O
part	O
of	O
the	O
MHV	O
budding	B-PROC
site	O
.	O

Sequence	O
analysis	O
of	O
the	O
S	O
gene	B-PROC
deletion	I-PROC
region	O
of	O
the	O
three	O
PRCV	O
isolates	O
revealed	O
identical	O
deletions	O
between	O
nt	O
105	O
-	O
752	O
,	O
which	O
differ	O
from	O
deletions	O
previously	O
reported	O
among	O
PRCV	O
strains	O
.	O

Therefore	O
,	O
the	O
reduced	O
severity	O
of	O
TGE	O
observed	O
in	O
this	O
herd	O
may	O
be	O
due	O
to	O
the	O
ongoing	O
PRCV	O
infections	O
,	O
which	O
induce	O
antibodies	O
cross	B-PROC
-	I-PROC
reactive	I-PROC
with	O
TGEV	O
and	O
result	O
in	O
decreased	O
disease	O
severity	O
.	O

ABSTRACT	O
:	O
Formaldehyde	O
is	O
a	O
physiological	O
intermediary	O
metabolite	O
taking	O
part	O
in	O
many	O
biological	B-PROC
process	I-PROC
in	O
the	O
body	O
.	O

Ingestion	O
can	O
lead	O
to	O
immediate	O
deleterious	O
effects	O
on	O
almost	O
all	O
systems	O
of	O
the	O
body	O
including	O
gastrointestinal	O
tract	O
,	O
central	O
nervous	O
system	O
,	O
cardiovascular	O
system	O
and	O
hepato	O
-	O
renal	O
system	O
,	O
causing	O
gastrointestinal	O
hemorrhage	O
,	O
cardiovascular	O
collapse	O
,	O
unconsciousness	O
or	O
convulsions	O
,	O
severe	O
metabolic	B-PROC
acidosis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
expression	B-PROC
of	O
the	O
biliary	O
glycoprotein	O
1	O
(	O
a	O
)	O
(	O
Bgp1	O
(	O
a	O
),	O
the	O
main	O
virus	O
receptor	O
)	O
decreased	O
only	O
in	O
IFN	O
-	O
gamma	O
-	O
activated	O
A	O
/	O
J	O
mouse	O
macrophages	O
,	O
in	O
contrast	O
to	O
the	O
expression	B-PROC
of	O
the	O
Bgp2	O
(	O
alternative	O
receptor	O
),	O
which	O
was	O
not	O
influenced	O
by	O
IFN	O
-	O
gamma	O
activation	O
.	O

The	O
synthesis	B-PROC
of	O
both	O
viral	O
mRNA	O
and	O
virus	O
particles	O
was	O
delayed	O
only	O
in	O
IFN	O
-	O
gamma	O
-	O
activated	O
A	O
/	O
J	O
mouse	O
macrophages	O
compared	O
with	O
susceptible	O
BALB	O
/	O
c	O
macrophages	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
possible	O
roles	O
of	O
apoptosis	B-PROC
in	O
the	O
murine	O
retinopathy	O
induced	O
by	O
coronavirus	O
.	O

The	O
number	O
of	O
apoptotic	O
events	O
was	O
significantly	O
elevated	O
in	O
infected	O
eyes	O
from	O
BALB	O
/	O
c	O
and	O
CD	O
-	O
1	O
mouse	O
strains	O
,	O
reaching	B-PROC
a	O
maximum	O
at	O
days	O
6	O
through	O
10	O
,	O
and	O
returning	O
to	O
normal	O
levels	O
at	O
day	O
20	O
.	O

The	O
development	B-PROC
of	O
apoptosis	B-PROC
,	O
regulative	O
gene	B-PROC
expression	I-PROC
,	O
and	O
viral	O
clearance	O
were	O
similar	O
in	O
both	O
retinal	O
degeneration	O
-	O
susceptible	O
(	O
BALB	O
/	O
c	O
)	O
and	O
-	O
resistant	O
(	O
CD	O
-	O
1	O
)	O
mice	O
.	O

ABSTRACT	O
:	O
Respiratory	O
tract	O
infections	O
with	O
viruses	O
and	O
Pasteurella	O
spp	O
.	O
were	O
determined	O
sequentially	O
among	O
26	O
cattle	O
that	O
died	B-PROC
during	O
two	O
severe	O
epizootics	O
of	O
shipping	O
fever	B-PROC
pneumonia	O
.	O

Development	B-PROC
of	O
appropriate	O
control	O
measures	O
could	O
help	O
reduce	O
the	O
incidence	O
of	O
respiratory	O
tract	O
disease	O
.	O

TITLE	O
:	O
RNase	O
L	O
-	O
independent	O
specific	O
28S	O
rRNA	O
cleavage	B-PROC
in	O
murine	O
coronavirus	O
-	O
infected	O
cells	O
.	O

In	O
certain	O
combination	O
of	O
cells	O
and	O
viruses	O
,	O
pretreatment	O
of	O
virus	O
-	O
infected	O
cells	O
with	O
interferon	O
activates	O
a	O
cellular	O
endoribonuclease	O
,	O
RNase	O
L	O
,	O
that	O
causes	O
rRNA	B-PROC
degradation	I-PROC
.	O

Furthermore	O
,	O
MHV	O
-	O
induced	O
28S	O
rRNA	O
cleavage	B-PROC
occurred	O
in	O
MHV	O
-	O
infected	O
DBT	O
cells	O
that	O
do	O
not	O
show	O
apoptotic	O
signs	O
,	O
including	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
DNA	B-PROC
fragmentation	I-PROC
.	O

ABSTRACT	O
:	O
Brome	O
mosaic	O
virus	O
(	O
BMV	O
)	O
encodes	O
two	O
RNA	B-PROC
replication	I-PROC
proteins	O
:	O
1a	O
,	O
which	O
contains	O
RNA	B-PROC
capping	B-PROC
and	O
helicase	O
-	O
like	O
domains	O
,	O
and	O
2a	O
,	O
which	O
is	O
related	O
to	O
polymerases	O
.	O

The	O
helicase	O
mutants	O
showed	O
no	O
function	O
in	O
any	O
assays	O
used	O
:	O
they	O
were	O
strongly	O
defective	O
in	O
template	O
recruitment	O
for	O
RNA	B-PROC
replication	I-PROC
,	O
as	O
measured	O
by	O
1a	O
-	O
induced	O
stabilization	O
of	O
RNA3	O
,	O
and	O
they	O
synthesized	O
no	O
detectable	O
negative	O
-	O
strand	O
or	O
subgenomic	O
RNA	O
.	O

Capping	B-PROC
domain	O
mutants	O
divided	O
into	O
two	O
groups	O
.	O

Using	O
recombination	B-PROC
assays	O
based	O
on	O
EDI	O
RNA	O
and	O
full	O
-	O
length	O
EAV	O
genomes	O
containing	O
specific	O
mutations	O
,	O
the	O
rates	O
of	O
homologous	O
RNA	O
recombination	B-PROC
in	O
the	O
3	O
'-	O
and	O
5	O
'-	O
proximal	O
regions	O
of	O
the	O
EAV	O
genome	O
were	O
studied	O
.	O

ABSTRACT	O
:	O
Demyelination	O
is	O
the	O
pathologic	O
hallmark	O
of	O
the	O
human	O
immune	O
-	O
mediated	O
neurologic	O
disease	O
multiple	O
sclerosis	O
,	O
which	O
may	O
be	O
triggered	O
or	O
exacerbated	O
by	O
viral	B-PROC
infections	I-PROC
.	O

ABSTRACT	O
:	O
Gene	O
transfer	O
to	O
differentiated	B-PROC
airway	O
epithelia	O
with	O
existing	O
viral	O
vectors	O
is	O
very	O
inefficient	O
when	O
they	O
are	O
applied	O
to	O
the	O
apical	O
surface	O
.	O

However	O
,	O
at	O
16	O
and	O
24	O
weeks	O
of	O
age	O
,	O
a	O
higher	O
antibody	B-PROC
titer	O
was	O
consistently	O
associated	O
with	O
a	O
lower	O
ADG	O
.	O

These	O
data	O
demonstrated	O
that	O
the	O
genome	O
-	O
length	O
negative	O
-	O
strand	O
RNA	O
serves	O
as	O
a	O
template	O
for	O
subgenomic	O
mRNA	B-PROC
synthesis	I-PROC
.	O

ABSTRACT	O
:	O
Transgenic	O
plants	O
represent	O
an	O
inexpensive	O
alternative	O
to	O
classical	O
fermentation	B-PROC
systems	O
for	O
production	O
of	O
recombinant	O
subunit	O
vaccines	O
.	O

TITLE	O
:	O
[	O
Oxidative	B-PROC
phosphorylation	I-PROC
defects	O
with	O
neonatal	O
presentation	O
:	O
review	O
of	O
our	O
caseload	O
].	O

We	O
report	O
9	O
newborns	O
diagnosed	O
as	O
oxidatic	O
phosporilation	O
deficit	O
during	O
the	O
last	O
8	O
years	O
in	O
our	O
hospital	O
by	O
means	O
of	O
clinical	O
,	O
metabolic	B-PROC
,	O
pathological	O
and	O
molecular	O
studies	O
,	O
among	O
other	O
evaluations	O
.	O

TITLE	O
:	O
Detection	O
of	O
antibody	B-PROC
to	O
turkey	O
coronavirus	O
by	O
antibody	B-PROC
-	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
utilizing	O
infectious	O
bronchitis	O
virus	O
antigen	O
.	O

ABSTRACT	O
:	O
An	O
antibody	B-PROC
-	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
detection	O
of	O
antibody	B-PROC
to	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
utilizing	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
antigen	O
was	O
developed	O
.	O

In	O
both	O
experiments	O
and	O
within	O
IBV	O
challenge	O
serotype	O
,	O
broilers	O
given	O
MD	O
vaccines	O
(	O
in	O
ovo	O
or	O
at	O
hatch	B-PROC
)	O
and	O
IB	O
vaccines	O
at	O
hatch	B-PROC
had	O
protection	O
rates	O
to	O
IBV	O
challenges	O
that	O
were	O
not	O
significantly	O
less	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
05	O
)	O
than	O
IB	O
protection	O
rates	O
of	O
groups	O
that	O
received	O
only	O
IB	O
vaccines	O
at	O
hatch	B-PROC
.	O

Analysis	O
of	O
these	O
data	O
shows	O
that	O
administration	O
of	O
high	O
-	O
titered	O
MD	O
vaccines	O
either	O
in	O
ovo	O
or	O
at	O
hatch	B-PROC
did	O
not	O
affect	O
the	O
efficacy	O
of	O
an	O
IB	O
vaccination	O
(	O
serotypes	O
Ark	O
and	O
Mass	O
)	O
given	O
by	O
eyedrop	O
at	O
hatch	B-PROC
.	O

TITLE	O
:	O
Redesign	O
of	O
primer	O
and	O
application	O
of	O
the	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
and	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
test	O
to	O
the	O
DE072	O
strain	O
of	O
infectious	O
bronchitis	O
virus	O
.	O

In	O
this	O
situation	O
,	O
the	O
abnormal	O
ventilation	B-PROC
-	I-PROC
perfusion	I-PROC
ratio	I-PROC
is	O
improved	O
by	O
inhaled	B-PROC
NO	O
,	O
limiting	O
arterial	O
hypoxia	O
.	O

The	O
expression	B-PROC
of	O
corresponding	O
FGF	O
receptors	O
was	O
significantly	O
increased	O
in	O
lesion	O
areas	O
during	O
the	O
initial	O
stage	O
of	O
remyelination	B-PROC
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
a	O
66	O
-	O
year	O
-	O
old	O
caucasian	O
woman	O
suffering	O
from	O
polymyositis	O
with	O
the	O
anti	O
-	O
Jo	O
-	O
1	O
antibody	B-PROC
.	O

Shortly	O
after	O
admission	O
to	O
our	O
hospital	O
,	O
despite	O
the	O
fact	O
that	O
the	O
patient	O
was	O
given	O
intravenous	O
pulse	B-PROC
methylprednisolone	O
(	O
1000	O
mg	O
/	O
day	O
for	O
3	O
consecutive	O
days	O
),	O
she	O
developed	O
severe	O
,	O
ventilatory	O
-	O
dependent	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

In	O
addition	O
to	O
high	O
-	O
dose	O
methylprednisolone	O
the	O
patient	O
was	O
given	O
intravenous	O
pulse	B-PROC
cyclophosphamide	O
fortnightly	O
for	O
six	O
weeks	O
and	O
afterwards	O
every	O
4	O
weeks	O
.	O

All	O
symptoms	O
resolved	O
and	O
arterial	O
blood	B-PROC
gases	I-PROC
returned	O
to	O
normal	O
.	O

Intravenous	O
pulse	B-PROC
cyclophosphamide	O
was	O
probably	O
a	O
life	O
saving	O
therapy	O
.	O

ABSTRACT	O
:	O
Previously	O
we	O
reported	O
an	O
impaired	O
energy	B-PROC
balance	I-PROC
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
during	O
an	O
acute	O
disease	O
exacerbation	O
,	O
but	O
limited	O
data	O
are	O
available	O
on	O
the	O
underlying	O
mechanisms	O
.	O

On	O
admission	O
,	O
the	O
dietary	B-PROC
intake	I-PROC
/	O
resting	O
energy	B-PROC
expenditure	I-PROC
(	O
REE	O
)	O
ratio	O
was	O
severely	O
depressed	O
(	O
1	O
.	O
28	O
[	O
0	O
.	O
57	O
]),	O
but	O
gradually	O
restored	O
until	O
Day	O
7	O
(	O
1	O
.	O
65	O
[	O
0	O
.	O
45	O
],	O
p	O
=	O
0	O
.	O
005	O
versus	O
Day	O
1	O
).	O

In	O
addition	O
,	O
the	O
dietary	B-PROC
intake	I-PROC
/	O
REE	O
ratio	O
was	O
not	O
only	O
inversely	O
related	O
with	O
LN	O
leptin	O
(-	O
0	O
.	O
74	O
,	O
p	O
=	O
0	O
.	O
037	O
),	O
but	O
also	O
with	O
sTNF	O
-	O
R55	O
(	O
r	O
=	O
-	O
0	O
.	O
93	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
on	O
day	O
seven	O
.	O

In	O
this	O
study	O
,	O
the	O
immunoprophylactic	O
effects	O
of	O
chicken	O
egg	O
yolk	O
immunoglobulin	B-PROC
(	O
Ig	O
Y	O
)	O
against	O
PEDV	O
were	O
investigated	O
in	O
neonatal	O
pigs	O
.	O

TITLE	O
:	O
The	O
leader	O
RNA	O
of	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
contains	O
an	O
enhancer	O
-	O
like	O
element	O
for	O
subgenomic	O
mRNA	B-PROC
transcription	B-PROC
.	O

Results	O
from	O
both	O
CAT	O
activity	O
and	O
mRNA	O
transcripts	O
detected	O
by	O
RT	O
-	O
PCR	O
showed	O
that	O
a	O
5	O
'-	O
proximal	O
sequence	O
of	O
35	O
nucleotides	O
(	O
nt	O
)	O
at	O
nt	O
25	O
to	O
59	O
is	O
a	O
cis	O
-	O
acting	O
sequence	O
required	O
for	O
subgenomic	O
RNA	O
transcription	B-PROC
,	O
while	O
the	O
consensus	O
repeat	O
sequence	O
of	O
the	O
leader	O
RNA	O
does	O
not	O
have	O
such	O
effect	O
.	O

Hantavirus	O
-	O
specific	O
antibodies	O
were	O
detected	O
in	O
patient	O
sera	O
,	O
and	O
virus	O
RNA	O
was	O
detected	O
by	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
.	O

In	O
an	O
effort	B-PROC
to	O
optimize	O
the	O
expression	B-PROC
,	O
we	O
have	O
constructed	O
several	O
BAV	O
-	O
3	O
recombinants	O
carrying	O
the	O
hemagglutinin	O
esterase	O
(	O
HE	O
)	O
gene	O
of	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
in	O
the	O
E3	O
region	O
with	O
or	O
without	O
exogenous	O
transcription	B-PROC
control	O
elements	O
.	O

The	O
introduction	O
of	O
a	O
SV40	O
early	O
promoter	O
or	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
immediate	O
early	O
(	O
IE	O
)	O
promoter	O
into	O
the	O
expression	B-PROC
cassette	O
changed	O
the	O
kinetics	O
of	O
the	O
HE	O
expression	B-PROC
.	O

Outcome	O
was	O
satisfactory	O
in	O
two	O
patients	O
while	O
four	O
patients	O
died	B-PROC
secondary	O
to	O
multiorgan	O
failure	O
.	O

ABSTRACT	O
:	O
Published	O
evidence	O
of	O
pathogenetic	O
mechanisms	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
mycoplasmal	O
lung	O
infections	O
suggests	O
that	O
the	O
pulmonary	O
injury	O
is	O
related	O
to	O
a	O
cell	B-PROC
-	I-PROC
mediated	I-PROC
immune	I-PROC
response	I-PROC
.	O

He	O
received	O
a	O
total	O
of	O
eight	O
injections	O
;	O
four	O
hours	O
after	O
the	O
seventh	O
injection	O
,	O
he	O
presented	O
with	O
pyrexia	B-PROC
associated	O
with	O
chills	O
,	O
sweating	O
,	O
headache	O
,	O
and	O
vomiting	O
,	O
which	O
quickly	O
resolved	O
.	O

Excluding	O
26	O
patients	O
whose	O
cause	O
of	O
death	B-PROC
may	O
not	O
have	O
been	O
trauma	O
related	O
,	O
the	O
odds	O
ratio	O
was	O
1	O
.	O
04	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
69	O
to	O
1	O
.	O
55	O
).	O

This	O
study	O
suggests	O
that	O
a	O
soluble	O
mediator	O
from	O
direct	O
liver	O
injury	O
leads	O
to	O
neutrophilic	B-PROC
lung	O
inflammation	O
and	O
this	O
is	O
associated	O
with	O
the	O
thawing	O
phase	O
of	O
cryoablation	O
.	O

Only	O
those	O
viruses	O
that	O
carried	O
the	O
S	O
gene	O
in	O
the	O
left	O
to	O
right	O
orientation	O
expressed	B-PROC
the	O
S	O
gene	O
.	O

Moreover	O
,	O
TGEV	O
-	O
specific	O
secretory	B-PROC
IgA	O
was	O
detected	O
in	O
the	O
small	O
intestine	O
and	O
in	O
the	O
lungs	O
of	O
the	O
immunized	O
animals	O
.	O

These	O
newly	O
emerging	O
RBCV	O
isolates	O
exhibited	O
distinct	O
phenotypic	O
features	O
that	O
differentiated	B-PROC
them	O
from	O
enteropathogenic	O
bovine	O
coronaviruses	O
(	O
EBCV	O
).	O

These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
RBCV	O
strains	O
have	O
evolved	O
to	O
selectivelyreplicate	O
in	O
respiratory	O
tissues	O
and	O
that	O
HE	O
may	O
play	O
a	O
role	O
in	O
this	O
tissue	B-PROC
tropism	B-PROC
.	O

In	O
the	O
case	O
of	O
systemic	O
immunodeficiencies	O
such	O
as	O
the	O
antibody	B-PROC
deficiency	O
syndrome	O
,	O
HIV	O
infection	O
or	O
immunosuppressive	O
therapy	O
,	O
the	O
indication	O
for	O
antibiotic	O
treatment	O
is	O
more	O
liberally	O
established	O
.	O

S	O
(	O
A59	O
)	O
R13	O
,	O
expressing	O
the	O
A59	O
spike	O
gene	O
,	O
replicated	O
to	O
a	O
somewhat	O
lower	O
titer	O
and	O
induced	O
moderate	O
to	O
severe	O
hepatitis	O
with	O
zonal	O
necrosis	B-PROC
,	O
similar	O
to	O
MHV	O
-	O
A59	O
.	O

TITLE	O
:	O
The	O
RNA	O
structures	O
engaged	O
in	O
replication	O
and	O
transcription	B-PROC
of	O
the	O
A59	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
.	O

Right	B-PROC
ventricular	I-PROC
function	I-PROC
was	O
evaluated	O
by	O
using	O
a	O
fast	O
response	O
thermistor	O
pulmonary	O
artery	O
catheter	O
that	O
allowed	O
measurement	O
of	O
right	B-PROC
ventricular	I-PROC
ejection	I-PROC
fraction	O
and	O
calculation	O
of	O
right	O
ventricular	O
end	O
-	O
diastolic	O
and	O
end	O
-	O
systolic	O
volumes	O
.	O

4	O
mm	O
Hg	O
(	O
p	O
<	O
.	O
05	O
),	O
pulmonary	B-PROC
vascular	I-PROC
resistance	I-PROC
index	O
from	O
353	O
+/-	O

Our	O
final	O
diagnosis	O
was	O
ARDS	O
induced	O
by	O
fulminant	O
influenza	O
(	O
A	O
/	O
Hong	O
Kong	O
/	O
68	O
(	O
H3	O
N2	O
))	O
virus	O
pneumonia	O
,	O
because	O
the	O
antibody	B-PROC
titers	O
of	O
H3	O
N2	O
influenza	O
of	O
paired	O
sera	O
showed	O
a	O
128	O
-	O
fold	O
increase	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
results	O
of	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
with	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
),	O
minimal	O
sedation	O
,	O
and	O
pressure	O
supported	O
ventilation	O
.	O

Patients	O
with	O
a	O
mean	O
BD	O
of	O
less	O
than	O
-	O
6	O
mmol	O
/	O
L	O
during	O
the	O
first	O
24	O
hours	O
were	O
compared	O
with	O
patients	O
with	O
a	O
mean	O
BD	O
of	O
more	O
than	O
-	O
6	O
mmol	O
/	O
L	O
.	O
Despite	O
adequate	O
resuscitation	O
with	O
good	O
maintenance	O
of	O
urinary	O
output	O
,	O
the	O
patients	O
in	O
the	O
group	O
with	O
a	O
mean	O
BD	O
of	O
less	O
than	O
-	O
6	O
mmol	O
/	O
L	O
had	O
more	O
florid	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
P	O
=	O
.	O
004	O
),	O
had	O
more	O
prevalent	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
P	O
=	O
.	O
012	O
),	O
and	O
experienced	O
more	O
severe	O
multiple	O
organ	O
dysfunction	O
(	O
P	O
<	O
.	O
001	O
)	O
compared	O
with	O
patients	O
in	O
the	O
group	O
with	O
a	O
mean	O
BD	O
of	O
more	O
than	O
-	O
6	O
mmol	O
/	O
L	O
.	O
The	O
results	O
suggest	O
that	O
abnormal	O
elevation	O
of	O
the	O
BD	O
after	O
burn	O
injuries	O
represents	O
a	O
malperfusion	O
state	O
,	O
which	O
may	O
not	O
be	O
recognized	O
if	O
only	O
""""	O
traditional	O
""""	O
parameters	O
,	O
such	O
as	O
UO	O
,	O
are	O
followed	O
.	O

ABSTRACT	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
(	O
NO	O
)	O
is	O
a	O
relatively	O
new	O
modality	O
in	O
the	O
management	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Seven	O
patients	O
died	B-PROC
and	O
3	O
survived	O
.	O

There	O
were	O
no	O
complications	O
associated	O
with	O
the	O
use	O
of	O
inhaled	B-PROC
NO	O
.	O

Furthermore	O
,	O
no	O
possible	O
recombination	B-PROC
site	O
on	O
S1	O
gene	O
among	O
Massachusetts	O
41	O
,	O
Arkansas	O
99	O
,	O
and	O
JMK	O
was	O
detected	O
in	O
the	O
isolate	O
.	O

ABSTRACT	O
:	O
Nosocomial	O
viral	B-PROC
infections	I-PROC
account	O
for	O
at	O
least	O
5	O
%	O
of	O
the	O
total	O
of	O
NI	O
and	O
reach	B-PROC
23	O
%	O
in	O
pediatric	O
wards	O
.	O

Lung	O
injury	O
occurs	O
only	O
in	O
the	O
setting	O
of	O
a	O
severe	O
systemic	O
inflammatory	B-PROC
response	I-PROC
and	O
an	O
inadequate	O
leukocyte	O
response	O
at	O
the	O
primary	O
site	O
of	O
infection	O
.	O

ABSTRACT	O
:	O
Neutralizing	O
antibodies	O
represent	O
a	O
major	O
host	B-PROC
defense	I-PROC
mechanism	I-PROC
against	O
viral	B-PROC
infections	I-PROC
.	O

In	O
mammals	O
,	O
passive	B-PROC
immunity	I-PROC
is	O
provided	O
by	O
neutralizing	O
antibodies	O
passed	O
to	O
the	O
offspring	O
via	O
the	O
placenta	O
or	O
the	O
milk	O
as	O
immunoglobulin	B-PROC
G	O
and	O
secreted	B-PROC
immunoglobulin	B-PROC
A	O
.	O
With	O
the	O
long	O
-	O
term	O
goal	O
of	O
producing	O
virus	O
-	O
resistant	O
livestock	O
,	O
we	O
have	O
generated	O
mice	O
carrying	O
transgenes	O
that	O
encode	O
the	O
light	O
and	O
heavy	O
chains	O
of	O
an	O
antibody	B-PROC
that	O
is	O
able	O
to	O
neutralize	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
-	O
JHM	O
).	O

In	O
vitro	O
analysis	O
of	O
milk	O
derived	O
from	O
different	O
transgenic	O
lines	O
revealed	O
a	O
linear	O
correlation	O
between	O
antibody	B-PROC
expression	B-PROC
and	O
virus	O
-	O
neutralizing	O
activity	O
,	O
indicating	O
that	O
the	O
recombinant	O
antibody	B-PROC
is	O
the	O
major	O
determinant	O
of	O
MHV	O
-	O
JHM	O
neutralization	O
in	O
murine	O
milk	O
.	O

This	O
finding	O
led	O
us	O
to	O
test	O
more	O
directly	O
the	O
role	O
of	O
hnRNP	O
A1	O
by	O
analysis	O
of	O
MHV	O
replication	O
and	O
RNA	B-PROC
synthesis	I-PROC
in	O
a	O
murine	O
cell	O
line	O
that	O
does	O
not	O
express	O
this	O
protein	O
.	O

The	O
results	O
of	O
in	O
situ	O
hybridization	B-PROC
for	O
the	O
detection	O
of	O
TGEV	O
were	O
compared	O
with	O
virus	O
isolation	O
(	O
VI	O
),	O
a	O
fluorescent	O
antibody	B-PROC
test	O
(	O
FAT	O
),	O
and	O
transmission	O
electron	O
microscopy	O
(	O
TEM	O
).	O

Experimental	O
introduction	O
of	O
the	O
A528V	O
mutation	O
into	O
the	O
wild	O
-	O
type	O
spike	O
protein	O
resulted	O
in	O
the	O
loss	O
of	O
MAb	O
binding	O
of	O
the	O
mutant	O
protein	O
,	O
confirming	O
that	O
the	O
single	O
point	B-PROC
mutation	I-PROC
was	O
responsible	O
for	O
the	O
escape	O
of	O
BCV	O
from	O
immunological	O
selective	O
pressure	O
.	O

The	O
RBCV	O
isolation	O
-	O
positive	O
cattle	O
that	O
developed	O
fatal	O
SFP	O
had	O
minimal	O
serum	O
IN	O
and	O
HAI	O
antibodies	O
during	O
the	O
course	O
of	O
disease	O
development	B-PROC
.	O

Increasing	O
the	O
intracellular	O
level	O
of	O
mitochondrial	O
aconitase	O
by	O
iron	O
supplementation	O
resulted	O
in	O
increased	O
RNA	O
-	O
binding	B-PROC
activity	I-PROC
in	O
cell	O
extracts	O
and	O
increased	O
virus	O
production	O
as	O
well	O
as	O
viral	B-PROC
protein	I-PROC
synthesis	I-PROC
at	O
early	O
hours	O
of	O
infection	O
.	O

It	O
would	O
appear	O
that	O
serum	O
TNF	O
-	O
alpha	O
has	O
little	O
impact	O
on	O
the	O
pathogenesis	B-PROC
of	O
ALI	O
after	O
EL	O
,	O
whereas	O
serum	O
IL	O
-	O
6	O
may	O
be	O
more	O
important	O
.	O

CONCLUSIONS	O
:	O
It	O
would	O
appear	O
that	O
serum	O
TNF	O
-	O
alpha	O
has	O
little	O
impact	O
on	O
the	O
pathogenesis	B-PROC
of	O
ALI	O
after	O
EL	O
,	O
whereas	O
serum	O
IL	O
-	O
6	O
may	O
be	O
more	O
important	O
.	O

MHC	B-PROC
class	O
II	O
molecule	O
expression	B-PROC
by	O
gut	O
-	O
associated	O
IPC	O
suggests	O
that	O
these	O
cells	O
may	O
be	O
the	O
in	O
vivo	O
mucosal	O
counterparts	O
of	O
the	O
dendritic	O
cells	O
recently	O
shown	O
to	O
produce	O
IFN	O
-	O
alpha	O
after	O
in	O
vitro	O
viral	O
induction	O
.	O

The	O
third	O
domain	O
of	O
E	O
that	O
plays	O
a	O
crucial	O
role	O
in	O
virus	O
budding	B-PROC
is	O
a	O
putative	O
transmembrane	O
domain	O
present	O
at	O
the	O
N	O
-	O
terminal	O
region	O
,	O
because	O
deletion	O
of	O
the	O
domain	O
resulted	O
in	O
a	O
free	O
distribution	O
of	O
the	O
mutant	O
protein	O
and	O
in	O
dysfunctional	O
viral	B-PROC
assembly	I-PROC
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
the	O
immunogenicity	O
of	O
chimeric	O
987P	O
fimbriae	O
on	O
a	O
Salmonella	O
vaccine	O
strain	O
was	O
improved	O
by	O
optimizing	O
fimbrial	O
expression	B-PROC
.	O

Constructs	O
with	O
the	O
pagC	O
promoter	O
were	O
shown	O
to	O
drive	O
increased	O
expression	B-PROC
of	O
chimeric	O
987P	O
fimbriae	O
in	O
macrophages	O
as	O
well	O
as	O
in	O
Mg	O
(	O
2	O
+)-	O
poor	O
media	O
,	O
mimicking	O
a	O
major	O
environmental	O
signal	O
found	O
in	O
Salmonella	O
-	O
containing	O
endocytic	O
vacuoles	O
of	O
macrophages	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
L	O
-	O
arginine	O
[	O
correction	O
of	O
F	O
-	O
arginine	O
]	O
and	O
phosphodiesterase	B-PROC
inhibitor	I-PROC
(	O
dipyridamole	O
)	O
to	O
wean	B-PROC
from	O
inhaled	B-PROC
nitric	O
oxide	O
.	O

Exogeous	O
NO	O
may	O
lead	O
to	O
down	B-PROC
regulation	B-PROC
of	O
endogenous	O
NO	O
production	O
,	O
and	O
further	O
lead	O
to	O
rapid	O
hydrolization	O
of	O
cyclic	O
guanosine	O
3	O
',	O
5	O
'	O
monophosphate	O
(	O
cGMP	O
),	O
the	O
smooth	O
muscle	O
relaxant	O
,	O
by	O
the	O
enzyme	O
phosphodiesterase	B-PROC
.	O

Moreover	O
L	O
-	O
Arginine	O
,	O
the	O
precursor	O
for	O
the	O
formation	B-PROC
of	O
endogenous	O
NO	O
,	O
has	O
been	O
found	O
to	O
be	O
deficient	O
in	O
neonates	O
with	O
PPHN	O
,	O
so	O
we	O
speculated	O
that	O
by	O
inhibiting	O
phosphodiesterase	B-PROC
and	O
administrating	O
L	O
-	O
Arginine	O
smooth	O
muscle	O
relaxation	O
occurred	O
,	O
and	O
consequent	O
weaning	B-PROC
from	O
iNO	O
was	O
achieved	O
.	O

Subchronic	O
repeated	O
exposure	O
studies	O
by	O
the	O
peroral	O
route	O
show	O
only	O
renal	O
physiological	O
compensatory	O
effects	O
,	O
secondary	O
to	O
reduced	O
water	B-PROC
consumption	I-PROC
.	O

However	O
,	O
chest	O
radiography	O
and	O
arterial	O
blood	B-PROC
gas	I-PROC
sampling	O
appear	O
to	O
be	O
useful	O
,	O
while	O
short	O
-	O
term	O
spirometry	O
measurements	O
do	O
not	O
.	O

A	O
total	O
of	O
21	O
and	O
30	O
patients	O
were	O
diagnosed	O
as	O
having	O
Pneumocystis	O
carinii	O
and	O
bacterial	O
pneumonia	O
,	O
respectively	O
,	O
of	O
whom	O
13	O
and	O
eight	O
died	B-PROC
during	O
their	O
ICU	O
stay	O
(	O
p	O
=	O
0	O
.	O
01	O
).	O

Here	O
we	O
demonstrate	O
with	O
haemagglutination	B-PROC
and	O
haemagglutination	B-PROC
-	O
inhibition	B-PROC
assays	O
that	O
TGEV	O
and	O
E	O
.	O
coli	O
K99	O
differ	O
in	O
their	O
sialic	O
acid	O
binding	O
activities	O
with	O
respect	O
to	O
the	O
type	O
and	O
amount	O
of	O
sialic	O
acid	O
residues	O
required	O
on	O
the	O
erythrocytes	O
surface	O
as	O
well	O
as	O
with	O
respect	O
to	O
the	O
type	O
of	O
sialoglycoconjugate	O
preferentially	O
recognized	O
.	O

ABSTRACT	O
:	O
A	O
56	O
-	O
year	O
-	O
old	O
Japanese	O
male	O
was	O
admitted	O
to	O
Toyohashi	O
Municipal	O
Hospital	O
because	O
of	O
fever	B-PROC
,	O
cough	O
,	O
and	O
dyspnea	O
.	O

Anasarcous	O
skin	O
lesions	O
exhibited	O
a	O
separated	O
epidermis	O
,	O
expanded	O
scale	O
-	O
sacs	O
,	O
and	O
an	O
edematous	O
dermis	O
accompanied	O
by	O
hemorrhage	O
and	O
necrosis	B-PROC
.	O

Cross	O
-	O
virus	B-PROC
neutralization	I-PROC
testing	O
and	O
entire	O
S1	O
sequence	O
analysis	O
on	O
selected	O
isolates	O
further	O
confirmed	O
that	O
fact	O
,	O
and	O
we	O
divided	O
the	O
viruses	O
into	O
the	O
DE072	O
serotype	O
and	O
two	O
other	O
unique	O
groups	O
.	O

Those	O
macrophages	O
also	O
had	O
adequate	O
bactericidal	B-PROC
activity	I-PROC
,	O
indicating	O
that	O
IBV	O
and	O
IBDV	O
infections	O
had	O
not	O
affected	O
their	O
phagocytic	O
activity	O
or	O
bactericidal	O
function	O
.	O

However	O
,	O
when	O
E	O
.	O
coli	O
antisera	O
raised	O
in	O
IBDV	O
-	O
infected	O
and	O
,	O
especially	O
,	O
that	O
produced	O
in	O
IBDV	O
plus	O
IBV	O
-	O
infected	O
chickens	O
were	O
supplemented	O
,	O
the	O
percentage	O
of	O
phagocytosis	B-PROC
and	O
number	O
of	O
bacteria	O
ingested	O
per	O
phagocyte	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
less	O
.	O

TITLE	O
:	O
Feeding	B-PROC
behavior	I-PROC
during	O
sialodacryoadenitis	O
viral	B-PROC
infection	I-PROC
in	O
rats	O
.	O

ABSTRACT	O
:	O
Sialodacryoadenitis	O
(	O
SDA	O
)	O
is	O
a	O
highly	O
contagious	O
common	O
viral	B-PROC
infection	I-PROC
in	O
rats	O
,	O
akin	O
to	O
mumps	O
in	O
humans	O
.	O

Several	O
MMP	O
activities	O
are	O
upregulated	O
in	O
acute	O
lung	O
injury	O
models	O
but	O
the	O
exact	O
role	O
that	O
these	O
MMPs	O
play	O
in	O
the	O
development	B-PROC
of	O
the	O
lung	O
injury	O
is	O
unclear	O
due	O
to	O
the	O
absence	O
of	O
specific	O
inhibitors	O
.	O

In	O
the	O
WT	O
mice	O
there	O
was	O
upregulation	B-PROC
of	O
gelatinase	O
B	O
and	O
stromelysin	O
1	O
in	O
the	O
injured	O
lungs	O
which	O
,	O
as	O
expected	O
,	O
was	O
absent	O
in	O
the	O
genetically	O
deficient	O
gelatinase	O
B	O
-	O
and	O
stromelysin	O
1	O
-	O
deficient	O
mice	O
,	O
respectively	O
.	O

We	O
studied	O
the	O
effects	O
of	O
ANP	O
infusion	O
(	O
10	O
ng	O
/	O
kg	O
/	O
min	O
for	O
1	O
hour	O
)	O
and	O
of	O
inhalation	B-PROC
of	O
NO	O
(	O
20	O
ppm	O
for	O
1	O
hour	O
)	O
on	O
hemodynamic	B-PROC
and	O
respiratory	O
patient	O
parameters	O
,	O
as	O
well	O
as	O
the	O
effects	O
on	O
plasma	O
levels	O
of	O
ANP	O
,	O
guanosine	O
3	O
',	O
5	O
'-	O
cyclic	O
monophosphate	O
,	O
nitrate	O
and	O
endothelin	O
-	O
1	O
.	O

3	O
.	O
6	O
kPa	O
,	O
P	O
<	O
0	O
.	O
05	O
),	O
a	O
small	O
increase	O
in	O
oxygenation	B-PROC
(	O
PaO2	O
/	O
FiO2	O
from	O
17	O
.	O
7	O
+/-	O

The	O
sudden	O
appearance	O
of	O
these	O
vascular	O
lesions	O
during	O
the	O
PRRSV	O
outbreak	O
and	O
their	O
abrupt	O
disappearance	O
after	O
the	O
abortion	O
storm	O
,	O
along	O
with	O
the	O
immunohistochemical	O
localization	B-PROC
of	O
PRRSV	O
-	O
positive	O
macrophages	O
adjacent	O
to	O
the	O
proliferating	O
capillaries	O
,	O
suggest	O
that	O
PRRSV	O
likely	O
played	O
a	O
role	O
in	O
the	O
development	B-PROC
of	O
these	O
unusual	O
lesions	O
.	O

ABSTRACT	O
:	O
Chicks	O
hatched	O
with	O
high	O
levels	O
of	O
maternal	O
antibody	B-PROC
had	O
excellent	O
protection	O
(>	O
95	O
%)	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
challenge	O
at	O
1	O
day	O
of	O
age	O
,	O
but	O
not	O
at	O
7	O
days	O
(<	O
30	O
%).	O

There	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
oxygenation	B-PROC
index	O
from	O
baseline	O
to	O
end	O
lavage	O
in	O
both	O
CMV	O
groups	O
,	O
as	O
well	O
as	O
all	O
of	O
the	O
animals	O
that	O
were	O
rotated	O
.	O

ABSTRACT	O
:	O
Infection	O
models	O
were	O
developed	O
for	O
adult	O
cows	O
and	O
for	O
young	O
calves	O
using	O
the	O
same	O
strain	O
of	O
bovine	O
coronavirus	O
(	O
BCV	O
),	O
which	O
for	O
the	O
first	O
time	O
allows	O
experimental	O
reproduction	B-PROC
of	O
winter	O
dysentery	O
(	O
WD	O
)	O
in	O
seronegative	O
lactating	O
cows	O
.	O

Such	O
treatment	O
regimens	O
designed	O
to	O
protect	O
the	O
heart	O
can	O
,	O
however	O
,	O
often	O
lead	O
to	O
lung	O
injury	O
and	O
,	O
in	O
fact	O
,	O
several	O
compounds	O
with	O
known	O
iron	B-PROC
chelating	I-PROC
properties	O
can	O
induce	O
severe	O
lung	O
dysfunction	O
and	O
injury	O
.	O

Interrupter	O
resistance	B-PROC
(	O
Rint	O
),	O
additional	O
tissue	O
viscoelastic	O
resistance	B-PROC
(	O
deltaR	O
),	O
and	O
quasi	O
-	O
static	O
elastance	O
(	O
Est	O
)	O
of	O
lung	O
(	O
L	O
)	O
and	O
chest	O
wall	O
were	O
assessed	O
by	O
means	O
of	O
the	O
rapid	O
end	O
-	O
inspiratory	B-PROC
occlusion	B-PROC
method	O
in	O
two	O
groups	O
of	O
seven	O
healthy	O
paralyzed	O
subjects	O
anesthetized	O
with	O
diazepam	O
or	O
isoflurane	O
.	O

They	O
underwent	O
ventilation	O
with	O
a	O
fixed	O
pattern	O
and	O
hyperoxic	O
gas	O
mixtures	O
with	O
different	O
fractions	O
of	O
inspired	B-PROC
carbon	O
dioxide	O
(	O
FICO2	O
)	O
to	O
produce	O
a	O
partial	O
pressures	O
of	O
arterial	O
carbon	O
dioxide	O
(	O
PaCO2	O
)	O
of	O
24	O
.	O
4	O
+/-	O

Changes	O
of	O
PaCO2	O
from	O
20	O
-	O
65	O
mmHg	O
cause	O
increasing	O
bronchodilation	B-PROC
in	O
anesthetized	O
,	O
paralyzed	O
subjects	O
,	O
this	O
effect	O
being	O
attenuated	O
or	O
abolished	O
by	O
drugs	O
(	O
e	O
.	O
g	O
.,	O
halogenated	O
anesthetics	O
)	O
that	O
depress	O
smooth	O
muscle	B-PROC
tone	I-PROC
substantially	O
.	O

The	O
carbon	O
dioxide	O
bronchodilating	O
effects	O
are	O
probably	O
direct	O
for	O
peripheral	O
structures	O
and	O
are	O
paralleled	O
by	O
a	O
tendency	O
of	O
lung	O
tissue	O
resistance	B-PROC
to	O
decrease	O
.	O

TITLE	O
:	O
Recombinant	O
equine	O
arteritis	O
virus	O
as	O
an	O
expression	B-PROC
vector	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
the	O
unique	O
gene	B-PROC
expression	I-PROC
strategy	O
of	O
the	O
Nidovirales	O
could	O
be	O
utilized	O
to	O
convert	O
them	O
into	O
viral	O
expression	B-PROC
vectors	O
by	O
introduction	O
of	O
an	O
additional	O
transcription	B-PROC
unit	O
into	O
the	O
EAV	O
genome	O
directing	O
the	O
synthesis	B-PROC
of	O
an	O
extra	O
subgenomic	O
mRNA	O
.	O

ABSTRACT	O
:	O
Evaluation	O
of	O
success	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
,	O
EMCO	O
)	O
in	O
the	O
treatment	O
of	O
acute	O
respiratory	O
failure	O
in	O
mature	O
neonates	O
.	O

In	O
12	O
consecutive	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
/	O
or	O
circulatory	B-PROC
failure	O
of	O
different	O
etiology	O
who	O
met	O
the	O
indication	O
criteria	O
the	O
method	O
of	O
venoarterial	O
EMCO	O
was	O
used	O
.	O

The	O
increase	O
in	O
PCO2	O
had	O
no	O
significant	O
effect	O
on	O
splanchnic	O
blood	B-PROC
flow	I-PROC
or	O
indices	O
of	O
perfusion	O
and	O
metabolism	B-PROC
.	O

Our	O
results	O
suggest	O
that	O
acute	O
moderate	O
changes	O
in	O
PCO2	O
have	O
no	O
major	O
effect	O
on	O
splanchnic	O
perfusion	O
and	O
metabolism	B-PROC
.	O

Viral	O
RNA	O
was	O
detected	O
in	O
faeces	O
by	O
reverse	O
-	O
transcriptase	B-PROC
PCR	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
plasma	O
antiviral	O
antibodies	O
by	O
immunofluorescence	O
.	O

The	O
development	B-PROC
of	O
brief	O
mild	O
episodes	O
of	O
dyspnea	O
is	O
considered	O
to	O
be	O
common	O
after	O
delivery	O
of	O
gemcitabin	O
.	O

Addition	O
of	O
the	O
general	O
caspase	O
inhibitor	O
z	O
-	O
VAD	O
-	O
FMK	O
to	O
the	O
culture	O
media	O
showed	O
inhibition	B-PROC
of	O
the	O
hallmarks	O
of	O
apoptosis	B-PROC
and	O
increase	O
of	O
the	O
release	O
of	O
virus	O
to	O
the	O
culture	O
media	O
at	O
16	O
h	O
postinfection	O
.	O

Screening	O
of	O
11	O
IBV	O
-	O
encoded	O
proteins	O
suggested	O
that	O
a	O
58	O
-	O
kDa	O
mature	O
cleavage	B-PROC
product	O
could	O
induce	O
apoptotic	O
changes	O
in	O
cells	O
transiently	O
expressing	O
the	O
protein	O
.	O

The	O
N	O
protein	O
was	O
expressed	B-PROC
under	O
control	O
of	O
the	O
vaccinia	O
virus	O
promoter	O
P7	O
.	O
5	O
in	O
chicken	O
embryo	O
fibroblast	O
cell	O
cultures	O
as	O
seen	O
in	O
immunofluorescence	O
assay	O
and	O
in	O
rFPV	O
-	O
inoculated	O
specific	O
-	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chickens	O
by	O
detecting	O
antibodies	O
with	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

We	O
also	O
determined	O
that	O
cleavage	B-PROC
recognition	O
site	O
sequence	O
does	O
not	O
correlate	O
with	O
pathogenicity	O
because	O
attenuated	O
and	O
pathogenic	O
isolates	O
(	O
different	O
passages	O
of	O
the	O
same	O
virus	O
)	O
contain	O
identical	O
cleavage	B-PROC
recognition	O
site	O
sequences	O
.	O

Cleavage	B-PROC
recognition	O
site	O
sequence	O
does	O
correlate	O
with	O
viruses	O
in	O
different	O
geographic	O
regions	O
,	O
which	O
may	O
be	O
an	O
important	O
characteristic	O
to	O
examine	O
in	O
epidemiologic	O
studies	O
.	O

Thus	O
,	O
the	O
number	O
of	O
basic	O
residues	O
around	O
the	O
cleavage	B-PROC
recognition	O
site	O
does	O
not	O
appear	O
to	O
correlate	O
with	O
increased	O
cleavability	O
,	O
host	O
cell	O
range	O
,	O
and	O
increased	O
virulence	B-PROC
as	O
it	O
does	O
with	O
envelope	O
glycoproteins	O
in	O
orthomyxoviruses	O
and	O
paramyxoviruses	O
.	O

Dialytic	O
treatment	O
is	O
necessary	O
to	O
correct	O
hydroelectrolytic	O
imbalance	O
and	O
renal	B-PROC
function	I-PROC
alterations	O
and	O
it	O
may	O
be	O
a	O
pathogenetic	O
therapy	O
by	O
myoglobin	O
removal	O
.	O

Beside	O
this	O
,	O
continuous	O
renal	O
replacement	O
therapy	O
allows	O
a	O
successful	O
management	O
of	O
critically	O
ill	O
patients	O
with	O
severe	O
hemodynamic	B-PROC
conditions	O
.	O

Four	O
patients	O
with	O
ALI	O
(	O
40	O
%)	O
and	O
10	O
patients	O
with	O
ARDS	O
(	O
59	O
%)	O
died	B-PROC
.	O

The	O
PL1pro	O
-	O
mediated	O
cleavage	B-PROC
was	O
slow	O
and	O
significantly	O
suppressed	O
by	O
a	O
non	O
-	O
proteolytic	B-PROC
activity	O
of	O
PL2pro	O
.	O

TITLE	O
:	O
Surfactant	O
and	O
inhaled	B-PROC
nitric	O
oxide	O
in	O
rats	O
alleviate	O
acute	O
lung	O
injury	O
induced	O
by	O
intestinal	O
ischemia	O
and	O
reperfusion	O
.	O

The	O
authors	O
hypothesize	O
that	O
a	O
combined	O
surfactant	O
and	O
inhaled	B-PROC
nitric	O
oxide	O
(	O
iNO	O
)	O
may	O
alleviate	O
I	O
/	O
R	O
-	O
induced	O
ALI	O
.	O

The	O
combined	O
surfactant	O
and	O
iNO	O
treatment	O
alleviated	O
rat	O
ALI	O
induced	O
by	O
I	O
/	O
R	O
,	O
and	O
exerted	B-PROC
effects	O
better	O
than	O
the	O
use	O
of	O
surfactant	O
or	O
iNO	O
alone	O
.	O

TITLE	O
:	O
Antibody	B-PROC
testing	O
against	O
canine	O
coronavirus	O
by	O
immunoperoxidase	O
plaque	O
staining	O
.	O

Striking	O
results	O
were	O
seen	O
with	O
a	O
mAb	O
(	O
1F8	O
)	O
reactive	O
with	O
the	O
positively	O
signaling	B-PROC
molecule	O
Ly49H	O
,	O
present	O
in	O
MCMV	O
-	O
resistant	O
C57BL	O
/	O
6	O
mice	O
.	O

Rats	O
aged	O
1	O
and	O
2	O
weeks	O
were	O
generally	O
similar	O
in	O
terms	O
of	O
mortality	O
and	O
mean	O
time	O
to	O
death	B-PROC
,	O
regardless	O
of	O
inoculation	O
route	O
,	O
except	O
for	O
the	O
oral	O
route	O
,	O
which	O
had	O
little	O
effect	O
.	O

These	O
findings	O
suggest	O
that	O
HFOV	O
has	O
beneficial	O
effects	O
on	O
oxygenation	B-PROC
and	O
ventilation	O
,	O
and	O
may	O
be	O
a	O
safe	O
and	O
effective	O
rescue	O
therapy	O
for	O
patients	O
with	O
severe	O
oxygenation	B-PROC
failure	O
.	O

All	O
serum	O
samples	O
from	O
mice	O
held	O
in	O
the	O
control	O
boxes	O
were	O
positive	O
for	O
antibody	B-PROC
to	O
MHV	O
,	O
whereas	O
sera	O
from	O
all	O
mice	O
held	O
in	O
filtered	O
boxes	O
were	O
negative	O
for	O
antibody	B-PROC
to	O
any	O
of	O
the	O
four	O
viruses	O
.	O

TITLE	O
:	O
Analysis	O
of	O
early	O
deaths	B-PROC
after	O
isolated	O
lung	O
transplantation	O
.	O

In	O
experiment	O
2	O
,	O
2	O
-	O
day	O
-	O
old	O
piglets	O
fed	O
HCC	O
containing	O
antibody	B-PROC
titers	O
of	O
1	O
:	O
512	O
,	O
1	O
:	O
128	O
and	O
1	O
:	O
32	O
,	O
and	O
UCC	O
were	O
inoculated	O
with	O
PED	O
virus	O
,	O
and	O
survival	O
rates	O
after	O
challenge	O
were	O
100	O
,	O
75	O
,	O
50	O
and	O
0	O
%,	O
respectively	O
.	O

Acute	O
lung	O
injury	O
results	O
in	O
reduced	O
lung	B-PROC
compliance	I-PROC
and	O
a	O
marked	O
decrease	O
in	O
the	O
volume	O
of	O
functional	O
lung	O
.	O

Detection	O
of	O
HCoV	O
-	O
229E	O
and	O
HCoV	O
-	O
OC43	O
in	O
clinical	O
specimens	O
is	O
possible	O
using	O
this	O
method	O
:	O
348	O
respiratory	O
specimens	O
(	O
202	O
sputum	O
and	O
146	O
nasal	O
aspirates	O
)	O
were	O
tested	O
with	O
this	O
RT	O
-	O
PCR	O
-	O
hybridization	B-PROC
and	O
12	O
human	O
coronavirus	O
are	O
detected	O
(	O
3	O
%).	O

Outcomes	O
included	O
maximum	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
,	O
ventilator	O
days	O
,	O
pneumonia	O
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Therefore	O
,	O
there	O
was	O
no	O
evidence	O
of	O
compensatory	O
growth	B-PROC
over	O
the	O
period	O
studied	O
.	O

Impaired	O
fat	O
digestibility	O
and	O
dietary	O
energy	O
utilization	O
in	O
PEMS	O
-	O
afflicted	O
birds	O
are	O
likely	O
contributors	O
to	O
stunted	O
growth	B-PROC
and	O
reduced	O
recovery	O
rates	O
.	O

Recent	O
work	O
has	O
shown	O
that	O
either	O
virus	O
-	O
specific	O
CD4	O
(+)	O
or	O
CD8	O
(+)	O
T	O
cells	O
are	O
able	O
to	O
mediate	O
demyelination	O
and	O
also	O
that	O
the	O
antibody	B-PROC
response	I-PROC
is	O
crucial	O
for	O
clearing	O
infectious	O
virus	O
.	O

TITLE	O
:	O
Fas	O
/	O
Fas	O
ligand	B-PROC
system	O
mediates	O
epithelial	O
injury	O
,	O
but	O
not	O
pulmonary	O
host	O
defenses	O
,	O
in	O
response	O
to	O
inhaled	B-PROC
bacteria	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
specific	O
antibody	B-PROC
titre	O
against	O
all	O
three	O
antigens	O
in	O
the	O
serum	O
of	O
the	O
vaccinated	O
animals	O
(	O
even	O
in	O
the	O
presence	O
of	O
pre	O
-	O
existing	O
antibody	B-PROC
)	O
which	O
was	O
accompanied	O
by	O
increased	O
levels	O
of	O
protective	O
antibodies	O
to	O
rotavirus	O
,	O
coronavirus	O
and	O
E	O
coli	O
F5	O
(	O
K99	O
)	O
in	O
their	O
colostrum	O
and	O
milk	O
for	O
at	O
least	O
28	O
days	O
.	O

In	O
involves	O
earlier	O
(	O
the	O
first	O
days	O
following	O
the	O
onset	O
of	O
respiratory	O
failure	O
)	O
use	O
of	O
surfactant	O
,	O
its	O
combined	O
bolus	O
intratracheal	O
or	O
intrabronchial	O
administration	O
in	O
doses	O
of	O
200	O
-	O
400	O
mg	O
/	O
m2	O
,	O
followed	O
by	O
continuous	O
(	O
5	O
-	O
day	O
)	O
aerosol	O
inhalation	B-PROC
in	O
doses	O
of	O
20	O
-	O
30	O
mg	O
/	O
h	O
for	O
children	O
and	O
30	O
-	O
75	O
mg	O
/	O
h	O
for	O
adults	O
until	O
pronounced	O
clinical	O
and	O
X	O
-	O
ray	O
effects	O
are	O
shown	O
.	O

Weaning	B-PROC
was	O
performed	O
using	O
either	O
T	O
-	O
tube	O
trials	O
or	O
pressure	O
support	O
weaning	B-PROC
.	O

Hemodynamic	B-PROC
performance	O
,	O
as	O
well	O
as	O
pressor	O
and	O
sedative	O
needs	O
,	O
was	O
assessed	O
after	O
discontinuing	O
neuromuscular	B-PROC
blockade	I-PROC
Mean	O
age	O
was	O
58	O
+/-	O

The	O
model	O
is	O
parameterized	O
for	O
transmissible	O
gastroenteritis	O
,	O
a	O
viral	B-PROC
disease	I-PROC
affecting	O
pigs	O
,	O
and	O
selection	O
for	O
resistance	B-PROC
to	O
this	O
disease	O
on	O
a	O
structured	O
pig	O
farm	O
is	O
simulated	O
.	O

ABSTRACT	O
:	O
Expression	B-PROC
of	O
negative	O
-	O
strand	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
transcripts	O
in	O
MHV	O
-	O
infected	O
cells	O
results	O
in	O
the	O
accumulation	O
of	O
positive	O
-	O
strand	O
DI	O
RNAs	O
(	O
M	O
.	O
Joo	O
et	O
al	O
.,	O
1996	O
,	O
J	O
.	O
Virol	O
.	O

In	O
a	O
fraction	O
of	O
transfected	O
cells	O
expressing	O
coronavirus	O
N	O
proteins	O
,	O
we	O
observed	O
multinucleate	O
cells	O
and	O
dividing	O
cells	O
with	O
nucleoli	O
(	O
which	O
are	O
only	O
present	O
during	O
interphase	B-PROC
).	O

One	O
patient	O
died	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
6	O
days	O
after	O
surgery	O
.	O

Overall	O
complication	O
rate	O
,	O
including	O
wound	O
dehiscence	B-PROC
and	O
secondary	O
grafting	O
,	O
was	O
18	O
percent	O
.	O

ABSTRACT	O
:	O
Toxic	O
epidermal	O
necrolysis	O
(	O
TEN	O
)	O
is	O
a	O
rare	O
severe	O
acute	O
exfoliative	O
drug	O
-	O
induced	O
skin	O
disorder	O
which	O
has	O
recently	O
been	O
ascribed	O
to	O
alterations	O
in	O
the	O
control	O
of	O
keratinocyte	B-PROC
apoptosis	I-PROC
,	O
mediated	O
by	O
an	O
interaction	O
between	O
the	O
cell	O
surface	O
death	B-PROC
receptor	O
Fas	O
and	O
its	O
respective	O
ligand	B-PROC
.	O

Eight	O
patients	O
were	O
healed	O
and	O
1	O
died	B-PROC
of	O
septic	O
shock	O
and	O
multiple	O
organ	O
failure	O
.	O

Complete	O
wound	B-PROC
healing	I-PROC
occurred	O
after	O
an	O
average	O
of	O
12	O
days	O
.	O

TITLE	O
:	O
Complete	O
genome	O
sequence	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
PUR46	O
-	O
MAD	B-PROC
clone	O
and	O
evolution	B-PROC
of	O
the	O
purdue	O
virus	O
cluster	O
.	O

TITLE	O
:	O
Molecular	O
determinants	O
of	O
species	O
specificity	O
in	O
the	O
coronavirus	O
receptor	O
aminopeptidase	O
N	O
(	O
CD13	O
):	O
influence	O
of	O
N	O
-	O
linked	O
glycosylation	B-PROC
.	O

Following	O
MHV	O
infection	O
,	O
chemokines	O
including	O
CXC	O
chemokine	O
ligand	B-PROC
(	O
CXCL	O
)	O
10	O
(	O
IFN	O
inducible	O
protein	O
10	O
kDa	O
),	O
CXCL9	O
(	O
monokine	O
induced	O
by	O
IFN	O
-	O
gamma	O
),	O
and	O
CC	O
chemokine	O
ligand	B-PROC
5	O
(	O
RANTES	O
)	O
are	O
expressed	B-PROC
during	O
both	O
acute	O
and	O
chronic	O
stages	O
of	O
disease	O
suggesting	O
a	O
role	O
for	O
these	O
molecules	O
in	O
disease	O
exacerbation	O
.	O

We	O
concluded	O
that	O
IBV	O
vaccination	O
strategies	O
should	O
aim	O
at	O
high	O
and	O
uniform	O
antibody	B-PROC
titers	O
in	O
the	O
broiler	O
breeders	O
.	O

8	O
and	O
mean	O
oxygenation	B-PROC
index	O
[	O
OI	O
]	O
of	O
42	O
+/-	O

Evaluation	O
for	O
weaning	B-PROC
should	O
occur	O
when	O
adequate	O
oxygenation	B-PROC
can	O
be	O
maintained	O
on	O
40	O
%	O
oxygen	O
and	O
a	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
of	O
8	O
cm	O
H	O
(	O
2	O
)	O
O	O
.	O
Pressure	O
support	O
levels	O
between	O
5	O
and	O
20	O
cm	O
H	O
(	O
2	O
)	O
O	O
(	O
above	O
5	O
cm	O
H	O
(	O
2	O
)	O
O	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
)	O
are	O
used	O
for	O
weaning	B-PROC
and	O
titrated	O
to	O
keep	O
the	O
respiratory	O
rate	O
<	O
35	O
breaths	O
/	O
min	O
.	O

Increased	O
numbers	O
of	O
T	O
cells	O
,	O
monocytes	O
,	O
macrophages	O
,	O
NK	O
cells	O
,	O
eosinophils	O
,	O
and	O
RANTES	O
-	O
and	O
eotaxin	O
-	O
positive	O
cells	O
,	O
but	O
not	O
neutrophils	O
,	O
were	O
observed	O
during	O
common	O
cold	B-PROC
in	O
allergic	O
and	O
nonallergic	O
patients	O
,	O
and	O
increased	O
numbers	O
of	O
mast	O
cells	O
in	O
allergic	O
patients	O
.	O

What	O
immunologic	B-PROC
factors	I-PROC
can	O
induce	O
prolonged	O
eosinophil	O
influx	O
and	O
whether	O
this	O
may	O
increase	O
the	O
risk	O
of	O
subsequent	O
allergen	O
-	O
induced	O
hypersensitivity	B-PROC
reactions	I-PROC
must	O
be	O
studied	O
further	O
.	O

TITLE	O
:	O
A	O
comparison	O
of	O
lymphatic	O
tissues	O
from	O
cats	O
with	O
spontaneous	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
),	O
cats	O
with	O
FIP	O
virus	B-PROC
infection	I-PROC
but	O
no	O
FIP	O
,	O
and	O
cats	O
with	O
no	O
infection	O
.	O

The	O
present	O
case	O
demonstrated	O
that	O
HIV	O
infection	O
was	O
not	O
an	O
essential	O
factor	O
in	O
the	O
development	B-PROC
of	O
bullous	O
changes	O
.	O

Using	O
targeted	B-PROC
recombination	B-PROC
we	O
previously	O
demonstrated	O
that	O
the	O
S	O
gene	O
of	O
the	O
highly	O
neurovirulent	O
MHV	O
-	O
4	O
conferred	O
a	O
dramatic	O
increase	O
in	O
neurovirulence	O
to	O
the	O
mildly	O
neurovirulent	O
MHV	O
-	O
A59	O
.	O

Toxic	O
shock	O
syndrome	O
is	O
defined	O
as	O
a	O
multi	O
organ	O
failure	O
syndrome	O
with	O
a	O
rapid	O
onset	O
,	O
fever	B-PROC
,	O
rash	O
followed	O
by	O
desquamation	O
,	O
vomiting	O
and	O
diarrhea	O
,	O
hypotension	O
,	O
conjunctivitis	O
and	O
strawberry	O
tongue	O
.	O

The	O
streptococcal	O
strains	O
involved	O
in	O
north	O
america	O
use	O
to	O
produce	O
the	O
toxin	O
erythrogenic	O
A	O
,	O
the	O
european	O
cases	O
seem	O
to	O
be	O
more	O
related	O
to	O
strains	O
secreting	B-PROC
the	O
B	O
toxin	O
with	O
a	O
dysregulation	O
of	O
the	O
mechanisms	O
which	O
control	O
the	O
secretion	B-PROC
of	O
the	O
toxin	O
.	O

Using	O
double	O
immunofluorescence	O
labeling	O
,	O
we	O
show	O
that	O
during	O
acute	O
infection	O
with	O
murine	O
hepatitis	O
virus	O
,	O
MHC	B-PROC
class	O
I	O
is	O
expressed	B-PROC
in	O
vivo	O
by	O
oligodendrocytes	O
,	O
neurons	O
,	O
microglia	O
,	O
and	O
endothelia	O
,	O
and	O
MHC	B-PROC
class	O
II	O
is	O
expressed	B-PROC
only	O
by	O
microglia	O
.	O

Respiratory	O
complications	O
induced	O
by	O
opiates	O
,	O
often	O
used	O
in	O
injections	O
,	O
are	O
related	O
to	O
central	O
alveolar	O
hypoventilation	O
and	O
/	O
or	O
the	O
development	B-PROC
of	O
injury	O
from	O
pulmonary	O
edema	O
or	O
pneumonia	O
.	O

In	O
1997	O
,	O
a	O
large	O
outbreak	O
of	O
enterovirus	O
71	O
(	O
EV	O
-	O
71	O
)	O
associated	O
HFMD	O
resulted	O
in	O
41	O
deaths	B-PROC
due	O
to	O
severe	O
left	O
ventricular	O
dysfunction	O
and	O
central	O
nervous	O
system	O
infection	O
with	O
extensive	O
damage	O
to	O
the	O
medulla	O
and	O
pons	O
.	O

Biopsies	O
of	O
the	O
olfactory	B-PROC
mucosa	O
in	O
patients	O
that	O
complain	O
of	O
dysosmia	O
after	O
viral	B-PROC
infection	I-PROC
fall	O
into	O
two	O
categories	O
:	O
one	O
in	O
which	O
no	O
olfactory	B-PROC
epithelium	O
is	O
seen	O
and	O
another	O
in	O
which	O
the	O
epithelium	O
is	O
disordered	O
and	O
populated	O
mainly	O
by	O
immature	O
neurons	O
.	O

We	O
have	O
used	O
intranasal	O
inoculation	O
with	O
an	O
olfactory	B-PROC
bulb	O
line	O
variant	O
of	O
MHV	O
to	O
study	O
the	O
consequences	O
of	O
viral	B-PROC
infection	I-PROC
on	O
peripheral	O
olfactory	B-PROC
structures	O
.	O

The	O
changes	O
that	O
develop	O
after	O
inoculation	O
with	O
MHV	O
OBLV	O
closely	O
resemble	O
the	O
disordering	O
of	O
the	O
olfactory	B-PROC
epithelium	O
in	O
some	O
patient	O
biopsies	O
.	O

ABSTRACT	O
:	O
Feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
is	O
a	O
common	O
cause	O
of	O
death	B-PROC
in	O
cats	O
.	O

Together	O
with	O
virus	B-PROC
neutralization	I-PROC
data	O
,	O
it	O
appears	O
that	O
GA98	O
arose	O
from	O
immune	O
selection	O
caused	O
by	O
DE072	O
vaccine	O
use	O
.	O

The	O
results	O
indicate	O
that	O
humoral	O
and	O
cellular	B-PROC
immunities	I-PROC
to	O
TCV	O
are	O
elicited	O
in	O
turkeys	O
following	O
infection	O
with	O
TCV	O
.	O

In	O
addition	O
,	O
two	O
stable	O
intermediate	O
cleavage	B-PROC
products	O
with	O
molecular	O
masses	O
of	O
160	O
and	O
132	O
kDa	O
,	O
respectively	O
,	O
were	O
identified	O
in	O
IBV	O
-	O
infected	O
cells	O
.	O

To	O
determine	O
how	O
B	O
cells	O
mediate	O
viral	O
clearance	O
,	O
we	O
first	O
assessed	O
CD4	O
(+)	O
T	B-PROC
cell	I-PROC
activation	I-PROC
in	O
the	O
absence	O
of	O
B	O
cells	O
as	O
APC	O
.	O

VO2lung	O
can	O
account	O
for	O
the	O
elevated	O
metabolic	B-PROC
rate	I-PROC
in	O
low	O
-	O
birthweight	O
infants	O
with	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
effects	O
of	O
C1	O
inhibitor	O
(	O
INH	O
)	O
administration	O
and	O
r	O
-	O
SP	O
-	O
C	O
surfactant	O
application	O
on	O
oxygenation	B-PROC
and	O
lung	O
histology	O
in	O
an	O
acute	O
respiratory	O
distress	O
syndrome	O
model	O
.	O

TITLE	O
:	O
Inactivation	O
of	O
expression	B-PROC
of	O
gene	O
4	O
of	O
mouse	O
hepatitis	O
virus	O
strain	O
JHM	O
does	O
not	O
affect	O
virulence	B-PROC
in	O
the	O
murine	O
CNS	O
.	O

Virus	O
lacking	O
gene	O
4	O
expression	B-PROC
replicated	O
in	O
tissue	O
culture	O
cells	O
with	O
similar	O
kinetics	O
to	O
recombinant	O
virus	O
in	O
which	O
gene	O
4	O
expression	B-PROC
was	O
not	O
disrupted	O
.	O

These	O
results	O
establish	O
a	O
targeted	B-PROC
recombination	B-PROC
system	O
for	O
inserting	O
mutations	O
into	O
MHV	O
-	O
JHM	O
.	O

Srr7	O
showed	O
apparently	O
reduced	O
neurovirulence	O
relative	O
to	O
the	O
wild	O
-	O
type	O
(	O
wt	O
)	O
JHMV	O
in	O
terms	O
of	O
the	O
LD50	O
and	O
survival	O
time	O
,	O
while	O
the	O
others	O
showed	O
slightly	O
reduced	O
virulence	B-PROC
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
between	O
these	O
viruses	O
in	O
the	O
potential	O
to	O
induce	O
apoptosis	B-PROC
in	O
cultured	O
cells	O
.	O

TITLE	O
:	O
The	O
regulation	B-PROC
of	O
interleukin	O
-	O
8	O
by	O
hypoxia	O
in	O
human	O
macrophages	O
--	O
a	O
potential	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

IL	O
-	O
8	O
and	O
other	O
proinflammatory	O
mediator	O
expression	B-PROC
was	O
measured	O
by	O
ELISA	O
,	O
northern	O
blotting	O
or	O
multi	O
-	O
probe	O
RNase	O
protection	O
assay	O
.	O

In	O
human	O
monocyte	O
derived	O
macrophages	O
hypoxia	O
rapidly	O
upregulated	O
IL	O
-	O
8	O
protein	O
(	O
within	O
2	O
hours	O
)	O
and	O
mRNA	B-PROC
expression	B-PROC
(	O
within	O
30	O
mins	O
).	O

Acute	O
hypoxia	O
,	O
a	O
clinically	O
relevant	O
stimulus	O
,	O
rapidly	O
and	O
selectively	O
upregulates	O
IL	O
-	O
8	O
in	O
macrophages	O
associated	O
with	O
a	O
novel	O
pattern	O
of	O
transcription	B-PROC
factor	O
activation	O
.	O

Endotoxin	O
induced	O
a	O
severe	O
lung	O
injury	O
characterised	O
by	O
a	O
decrease	O
in	O
mean	O
systemic	O
blood	B-PROC
pressure	I-PROC
and	O
an	O
increase	O
in	O
pulmonary	O
artery	O
pressure	O
,	O
hypoxia	O
,	O
and	O
an	O
increase	O
in	O
pulmonary	O
myeloperoxidase	O
activity	O
.	O

Pentobarbital	O
was	O
then	O
administered	O
,	O
resulting	O
in	O
excellent	O
control	O
of	O
behavioral	B-PROC
,	O
autonomic	O
,	O
and	O
psychiatric	O
symptoms	O
and	O
in	O
rapid	O
reduction	O
or	O
avoidance	O
of	O
benzodiazepines	O
.	O

In	O
contrast	O
,	O
the	O
L2	O
-	O
MHV3	O
strain	O
induces	O
the	O
development	B-PROC
of	O
a	O
fulminant	O
hepatitis	O
,	O
leading	O
to	O
death	B-PROC
within	O
3	O
days	O
.	O

Intestinal	O
contents	O
or	O
intestines	O
from	O
affected	O
turkey	O
poults	O
and	O
inoculated	O
turkey	O
embryos	O
contained	O
coronaviruses	O
as	O
revealed	O
by	O
electron	O
microscopy	O
or	O
were	O
positive	O
for	O
turkey	O
coronavirus	O
by	O
immunofluorescent	O
antibody	B-PROC
assay	O
.	O

They	O
also	O
indicate	O
that	O
genetic	O
RNA	O
recombination	B-PROC
(	O
especially	O
the	O
nonhomologous	O
one	O
)	O
is	O
a	O
major	O
factor	O
responsible	O
for	O
the	O
emergence	O
of	O
new	O
viral	O
strains	O
or	O
species	O
.	O

Nevertheless	O
,	O
the	O
previously	O
proposed	O
model	O
of	O
genetic	B-PROC
recombination	I-PROC
in	O
BMV	O
still	O
had	O
one	O
weakness	O
:	O
it	O
could	O
not	O
really	O
explain	O
the	O
role	O
of	O
RNA	O
structure	O
in	O
nonhomologous	O
recombination	B-PROC
.	O

That	O
is	O
why	O
in	O
this	O
review	O
we	O
present	O
and	O
thoroughly	O
discuss	O
all	O
results	O
concerning	O
nonhomologous	O
recombination	B-PROC
in	O
BMV	O
that	O
have	O
been	O
obtained	O
until	O
now	O
.	O

ABSTRACT	O
:	O
A	O
dietary	O
deficiency	O
of	O
Arg	O
may	O
suppress	O
chick	O
immune	O
system	O
functions	O
;	O
however	O
,	O
research	O
evaluating	O
immune	B-PROC
function	I-PROC
responsiveness	O
of	O
commercial	O
broilers	O
fed	O
dietary	O
Arg	O
levels	O
near	O
NRC	O
(	O
1994	O
)	O
recommendations	O
is	O
sparse	O
.	O

Although	O
increased	O
dietary	O
Arg	O
improved	O
BW	O
gain	O
in	O
Experiment	O
1	O
,	O
minimal	O
effects	O
were	O
noted	O
in	O
growth	B-PROC
and	O
immune	O
system	O
parameters	O
throughtout	O
this	O
study	O
.	O

ABSTRACT	O
:	O
Respiratory	O
distress	O
syndrome	O
(	O
RDS	O
)	O
and	O
development	B-PROC
of	O
bronchopulmonary	O
dysplasia	O
(	O
BPD	O
)	O
are	O
characterized	O
by	O
endothelial	O
cell	O
damage	O
.	O

However	O
,	O
experimental	O
evidence	O
suggests	O
that	O
repeated	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
collapse	O
and	O
reexpansion	O
contributes	O
to	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

Increases	O
in	O
cytokine	O
expression	B-PROC
and	O
cellular	O
nitration	O
can	O
lead	O
to	O
tissue	O
damage	O
and	O
are	O
consistent	O
with	O
the	O
differences	O
between	O
genotypes	O
in	O
the	O
early	O
onset	O
of	O
pathology	O
and	O
mortality	O
in	O
Ron	O
tk	O
-/-	O
mice	O
.	O

In	O
view	O
of	O
the	O
potential	O
of	O
DNA	O
vaccines	O
to	O
induce	O
cell	O
-	O
mediated	O
responses	O
,	O
their	O
efficacy	O
to	O
induce	O
protective	O
immunity	B-PROC
in	O
cats	O
was	O
evaluated	O
.	O

Thus	O
,	O
one	O
of	O
the	O
most	O
important	O
changes	O
in	O
the	O
process	O
of	O
improving	O
the	O
efficacy	O
of	O
pain	O
treatment	O
is	O
to	O
introduce	O
pain	O
assessment	O
as	O
the	O
fifth	O
vital	O
sign	O
in	O
addition	O
to	O
the	O
traditional	O
four	O
vital	O
signs	O
(	O
temperature	O
,	O
pulse	B-PROC
,	O
blood	B-PROC
pressure	I-PROC
and	O
respiratory	O
rate	O
).	O

Adult	O
sheep	O
(	O
n	O
=	O
13	O
)	O
received	O
an	O
LD50	O
smoke	O
inhalation	B-PROC
and	O
40	O
%	O
TBSA	O
third	O
degree	O
cutaneous	O
flame	O
burn	O
injury	O
.	O

Serum	O
antibody	B-PROC
prevalence	O
averaged	O
70	O
%	O
(	O
167	O
/	O
240	O
)	O
during	O
the	O
spring	O
collection	O
period	O
and	O
25	O
%	O
(	O
46	O
/	O
185	O
)	O
during	O
the	O
autumn	O
collection	O
period	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
is	O
characterised	O
by	O
capillary	B-PROC
permeability	I-PROC
and	O
pulmonary	O
oedema	O
formation	B-PROC
and	O
may	O
complicate	O
a	O
variety	O
of	O
medical	O
and	O
surgical	O
illnesses	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
the	O
E	O
protein	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
localized	O
to	O
the	O
Golgi	O
complex	O
when	O
expressed	B-PROC
exogenously	O
from	O
cDNA	O
.	O

Virus	O
protein	O
levels	O
were	O
shown	O
to	O
be	O
dependent	O
on	O
transcription	B-PROC
and	O
translation	B-PROC
regulation	B-PROC
.	O

In	O
addition	O
,	O
the	O
demonstrated	O
ability	O
to	O
express	O
viral	O
proteins	O
fused	O
to	O
fluorescent	O
markers	O
in	O
in	O
live	O
cells	O
will	O
allow	O
us	O
to	O
follow	O
specific	O
proteins	O
or	O
complexes	O
during	O
the	O
course	O
of	O
infection	O
and	O
to	O
determine	O
if	O
exogenously	O
expressed	B-PROC
proteins	O
are	O
able	O
to	O
target	O
to	O
sites	O
of	O
active	O
viral	B-PROC
replication	I-PROC
.	O

His	O
absorbed	O
-	O
dose	O
distribution	O
throughout	O
the	O
body	O
was	O
very	O
inhomogeneous	O
because	O
of	O
the	O
closeness	O
of	O
the	O
standing	B-PROC
point	O
to	O
the	O
mixing	O
tank	O
.	O

There	O
is	O
currently	O
a	O
vast	O
literature	O
available	O
on	O
the	O
changes	O
in	O
thyroid	B-PROC
function	I-PROC
tests	O
that	O
occur	O
during	O
non	O
-	O
thyroidal	O
illness	O
.	O

There	O
is	O
consensus	O
that	O
severe	O
maternal	O
hypertension	O
(	O
blood	B-PROC
pressure	I-PROC
>	O
or	O
=	O
170	O
/	O
110	O
mmHg	O
)	O
should	O
be	O
treated	O
to	O
minimize	O
the	O
risk	O
of	O
acute	O
cerebrovascular	O
complications	O
.	O

ABSTRACT	O
:	O
Contributions	O
of	O
humoral	O
and	O
cellular	B-PROC
immunity	I-PROC
in	O
controlling	O
neurotropic	O
mouse	O
hepatitis	O
virus	O
persistence	O
within	O
the	O
CNS	O
were	O
determined	O
in	O
B	O
cell	O
-	O
deficient	O
J	O
(	O
H	O
)	O
D	O
and	O
syngeneic	O
H	O
-	O
2	O
(	O
d	O
)	O
B	O
cell	O
+	O
Ab	O
-	O
deficient	O
mice	O
.	O

Virus	O
clearance	O
followed	O
similar	O
kinetics	O
in	O
all	O
mice	O
,	O
confirming	O
initial	O
control	O
of	O
virus	B-PROC
replication	I-PROC
by	O
cellular	B-PROC
immunity	I-PROC
.	O

Ten	O
patients	O
were	O
admitted	O
to	O
Lampoon	O
Provincial	O
Hospital	O
with	O
a	O
history	O
of	O
high	O
fever	B-PROC
,	O
watery	O
diarrhea	O
,	O
severe	O
myalgia	O
and	O
ecchymosis	O
rashes	O
.	O

The	O
methods	O
of	O
choice	O
adopted	O
for	O
early	O
diagnosis	O
of	O
interstitial	O
lung	O
disease	O
are	O
high	O
-	O
resolution	O
computed	O
tomography	O
scan	O
and	O
pulmonary	B-PROC
function	I-PROC
tests	O
,	O
which	O
should	O
be	O
performed	O
during	O
both	O
initial	O
evaluation	O
of	O
polymyositis	O
/	O
dermatomyositis	O
and	O
follow	O
-	O
up	O
.	O

Because	O
anti	O
-	O
JO1	O
antibody	B-PROC
is	O
considered	O
to	O
be	O
a	O
marker	O
of	O
interstitial	O
lung	O
disease	O
in	O
polymyositis	O
/	O
dermatomyositis	O
,	O
close	O
pulmonary	O
follow	O
-	O
up	O
of	O
anti	O
-	O
JO1	O
-	O
positive	O
patients	O
with	O
polymyositis	O
is	O
therefore	O
required	O
for	O
early	O
detection	O
of	O
subclinical	O
impairment	O
.	O

The	O
ideal	O
vector	O
should	O
efficiently	O
transduce	O
non	O
-	O
dividing	O
cells	O
with	O
minimal	O
toxicity	O
,	O
thus	O
endowing	O
the	O
system	O
with	O
persistent	O
transgene	O
expression	B-PROC
.	O

Activation	O
of	O
antiviral	O
genes	O
mediated	O
by	O
doxycycline	O
-	O
dependent	O
mIFN	O
(	O
alpha	O
)	O
expression	B-PROC
was	O
also	O
observed	O
at	O
low	O
HD	O
-	O
TET	O
-	O
IFN	O
doses	O
.	O

We	O
showed	O
previously	O
that	O
adoptive	O
transfer	O
of	O
MHV	O
-	O
immune	O
splenocytes	O
depleted	O
of	O
either	O
CD4	O
or	O
CD8	O
T	O
cells	O
to	O
infected	O
RAG1	O
(-/-)	O
recipients	O
(	O
mice	O
deficient	O
in	O
recombination	B-PROC
activation	O
gene	O
1	O
)	O
resulted	O
in	O
demyelination	O
.	O

TITLE	O
:	O
In	O
vitro	O
and	O
in	O
vivo	O
expression	B-PROC
of	O
foreign	O
genes	O
by	O
transmissible	O
gastroenteritis	O
coronavirus	O
-	O
derived	O
minigenomes	O
.	O

The	O
large	O
cloning	O
capacity	O
and	O
the	O
tissue	B-PROC
specificity	I-PROC
of	O
the	O
TGEV	O
-	O
derived	O
minigenomes	O
suggest	O
that	O
these	O
virus	O
vectors	O
are	O
very	O
promising	O
for	O
vaccine	O
development	B-PROC
.	O

The	O
determination	O
of	O
relative	O
rate	O
constants	O
for	O
a	O
set	O
of	O
corresponding	O
HCoV	O
,	O
TGEV	O
and	O
MHV	O
3CL	O
(	O
pro	O
)	O
cleavage	B-PROC
sites	O
revealed	O
a	O
conserved	O
ranking	O
of	O
these	O
sites	O
.	O

Mp	O
-	O
associated	O
HPS	O
was	O
diagnosed	O
in	O
this	O
case	O
by	O
clinical	O
and	O
laboratory	O
findings	O
,	O
including	O
a	O
bone	O
marrow	O
aspiration	O
specimen	O
and	O
serum	O
Mp	O
antibody	B-PROC
titer	O
.	O

Combined	O
vaccination	O
consists	O
in	O
parallel	O
double	O
immunization	O
of	O
females	O
on	O
days	O
70	O
-	O
75	O
of	O
gestation	B-PROC
intramuscularly	O
and	O
intranasally	O
and	O
on	O
days	O
90	O
-	O
95	O
of	O
gestation	B-PROC
intramuscularly	O
.	O

ABSTRACT	O
:	O
Using	O
the	O
whole	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
for	O
detecting	O
the	O
antibody	B-PROC
against	O
IBV	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
is	O
a	O
routine	O
work	O
in	O
poultry	O
industry	O
.	O

The	O
relative	O
risk	O
for	O
combined	O
morbidity	O
(	O
death	B-PROC
,	O
intracranial	O
hemorrhage	O
,	O
chronic	O
lung	O
disease	O
)	O
was	O
increased	O
(	O
3	O
.	O
0	O
,	O
P	O
=.	O
019	O
)	O
when	O
compared	O
with	O
matched	O
control	O
infants	O
.	O

At	O
different	O
postinoculation	O
day	O
(	O
PID	O
)	O
and	O
postchallenge	O
day	O
(	O
PCD	B-PROC
)	O
virus	O
-	O
specific	O
antibody	B-PROC
-	O
secreting	B-PROC
cells	O
(	O
ASC	O
)	O
in	O
gut	O
associated	O
lymphoid	O
tissues	O
(	O
duodenum	O
and	O
ileum	O
lamina	O
propria	O
and	O
mesenteric	O
lymph	O
nodes	O
)	O
and	O
systemic	O
locations	O
(	O
blood	O
and	O
spleen	O
)	O
were	O
assessed	O
by	O
enzyme	O
-	O
linked	O
immunospot	O
(	O
ELISPOT	O
).	O

In	O
contrast	O
with	O
this	O
pattern	O
,	O
the	O
DTH	B-PROC
response	O
against	O
BSA	O
was	O
unaffected	O
following	O
E5	O
exposure	O
,	O
but	O
was	O
significantly	O
decreased	O
after	O
E12	O
exposure	O
to	O
lead	O
.	O

While	O
cellular	B-PROC
immunity	I-PROC
initially	O
eliminates	O
infectious	O
virus	O
,	O
CNS	O
viral	O
persistence	O
is	O
predominantly	O
controlled	O
by	O
humoral	B-PROC
immunity	I-PROC
.	O

Using	O
this	O
approach	O
,	O
we	O
found	O
that	O
the	O
chimeric	O
virus	O
containing	O
the	O
BCV	O
S	O
protein	O
on	O
the	O
virion	O
surface	O
entered	O
and	O
replicated	O
in	O
HRT	O
-	O
18	O
cells	O
;	O
this	O
was	O
specifically	O
blocked	O
by	O
prior	O
treatment	O
of	O
the	O
virus	O
with	O
a	O
neutralizing	O
antibody	B-PROC
specific	O
to	O
the	O
BCV	O
S	O
protein	O
,	O
indicating	O
that	O
the	O
BCV	O
S	O
protein	O
is	O
responsible	O
for	O
initiating	O
chimeric	O
virus	B-PROC
infection	I-PROC
.	O

In	O
contrast	O
,	O
the	O
effects	O
of	O
nitric	O
oxide	O
on	O
pulmonary	O
inflammatory	B-PROC
response	I-PROC
are	O
much	O
less	O
known	O
in	O
vivo	O
.	O

Vascular	O
immunotargeting	O
of	O
the	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)-	O
generating	O
enzyme	O
glucose	O
oxidase	O
(	O
GOX	O
)	O
to	O
the	O
pulmonary	O
endothelium	O
causes	O
an	O
acute	O
oxidative	O
lung	O
injury	O
in	O
mice	O
.(	O
1	O
)	O
In	O
the	O
present	O
study	O
we	O
compared	O
the	O
pulmonary	O
thrombosis	O
and	O
leukocyte	O
transmigration	O
caused	O
by	O
GOX	O
targeting	B-PROC
to	O
the	O
endothelial	O
antigens	O
platelet	O
-	O
endothelial	O
cell	B-PROC
adhesion	I-PROC
molecule	O
(	O
PECAM	O
)	O
and	O
thrombomodulin	O
(	O
TM	O
).	O

Both	O
anti	O
-	O
PECAM	O
and	O
anti	O
-	O
TM	O
delivered	O
similar	O
amounts	O
of	O
(	O
125	O
)	O
I	O
-	O
GOX	O
to	O
the	O
lungs	O
and	O
caused	O
a	O
dose	O
-	O
dependent	O
,	O
tissue	O
-	O
selective	O
lung	O
injury	O
manifested	O
within	O
2	O
to	O
4	O
hours	O
by	O
high	O
lethality	O
,	O
vascular	O
congestion	O
,	O
polymorphonuclear	O
neutrophil	O
(	O
PMN	B-PROC
)	O
sequestration	O
in	O
the	O
pulmonary	O
vasculature	O
,	O
severe	O
pulmonary	O
edema	O
,	O
and	O
tissue	O
oxidation	B-PROC
,	O
yet	O
at	O
an	O
equal	O
dose	O
,	O
anti	O
-	O
TM	O
/	O
GOX	O
inflicted	O
more	O
severe	O
lung	O
injury	O
than	O
anti	O
-	O
PECAM	O
/	O
GOX	O
.	O

These	O
polymorphisms	B-PROC
led	O
to	O
42	O
amino	O
acid	O
changes	O
at	O
38	O
distinct	O
sites	O
.	O

TITLE	O
:	O
Platanus	O
acerifolia	O
pollinosis	O
and	O
food	O
allergy	B-PROC
.	O

On	O
the	O
contrary	O
low	O
inhibition	B-PROC
was	O
observed	O
when	O
plant	O
-	O
derived	O
food	O
allergens	O
were	O
used	O
as	O
free	O
phase	O
and	O
P	O
.	O
acerifolia	O
pollen	O
extract	O
as	O
solid	O
phase	O
.	O

2	O
.	O
8	O
)	O
to	O
(	O
26	O
+/-	O
4	O
)	O
kPa	O
and	O
dynamic	O
lung	B-PROC
compliance	I-PROC
(	O
Cdyn	O
)	O
from	O
(	O
14	O
.	O
8	O
+/-	O
0	O
.	O
7	O
)	O
to	O
(	O
8	O
.	O
6	O
+/-	O
0	O
.	O
6	O
)	O
mL	O
.	O
kPa	O
-	O
1	O
.	O

Pharmacodynamics	O
of	O
iNO	O
in	O
this	O
model	O
was	O
related	O
to	O
improvement	O
in	O
gas	O
exchange	O
,	O
Cdyn	O
,	O
PVRI	O
,	O
and	O
suppression	B-PROC
of	O
proinflammatory	O
cytokine	O
expression	B-PROC
in	O
the	O
lungs	O
,	O
and	O
its	O
adverse	O
effect	O
was	O
mainly	O
confined	O
to	O
MetHb	O
at	O
higher	O
NO	O
dose	O
.	O

Twenty	O
patients	O
with	O
severe	O
ARDS	O
were	O
switched	O
from	O
VC	O
-	O
CRV	O
to	O
PC	O
-	O
IRV	B-PROC
if	O
they	O
failed	O
to	O
maintain	O
SaO	O
(	O
2	O
)	O
>	O
90	O
%	O
by	O
the	O
following	O
criteria	O
:	O
peak	O
inspiratory	B-PROC
pressure	O
(	O
PIP	O
)	O
>	O
35	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
FIO	O
(	O
2	O
)	O
=	O
60	O
%,	O
and	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
10	O
cm	O
H	O
(	O
2	O
)	O
O	O
.	O
The	O
values	O
of	O
PIP	O
,	O
mean	O
airway	O
pressure	O
,	O
minute	O
volumes	O
,	O
and	O
lung	O
injury	O
score	O
in	O
VC	O
-	O
CRV	O
were	O
43	O
.	O
9	O
+/-	O

TITLE	O
:	O
Differentiation	B-PROC
of	O
mouse	O
hepatitis	O
viruses	O
in	O
animal	O
facilities	O
in	O
Japan	O
by	O
use	O
of	O
nucleotide	O
analysis	O
of	O
the	O
nucleocapsid	O
gene	O
.	O

Nucleotide	O
sequencing	O
was	O
performed	O
directly	O
on	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
products	O
amplified	O
by	O
reverse	B-PROC
transcription	B-PROC
(	O
RT	B-PROC
)	O
and	O
polymerase	O
chain	O
reaction	O
(	O
RT	B-PROC
-	O
PCR	O
)	O
analysis	O
from	O
fecal	O
samples	O
or	O
isolated	O
viruses	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
blood	O
detoxification	B-PROC
by	O
sorbent	O
therapy	O
long	O
has	O
been	O
applied	O
in	O
treatment	O
of	O
hepatic	O
failure	O
and	O
encephalopathy	O
,	O
starting	O
with	O
hemoperfusion	O
columns	O
and	O
more	O
recently	O
with	O
the	O
currently	O
marketed	O
Liver	O
Dialysis	O
Unit	O
.	O

It	O
is	O
proposed	O
that	O
the	O
ExPLIs	O
may	O
be	O
considered	O
a	O
prototype	O
of	O
potent	O
suppressors	O
of	O
specific	O
endotoxin	O
-	O
induced	O
inflammatory	B-PROC
responses	I-PROC
,	O
with	O
potential	O
implications	O
for	O
the	O
therapy	O
of	O
subsequent	O
severe	O
inflammation	O
.	O

Mutagenesis	B-PROC
was	O
also	O
used	O
to	O
investigate	O
cleavage	B-PROC
between	O
Gly	O
-	O
904	O
and	O
Val	O
-	O
905	O
,	O
a	O
cleavage	B-PROC
site	O
predicted	O
to	O
produce	O
a	O
precursor	O
of	O
p65	O
,	O
p72	O
,	O
that	O
was	O
detected	O
in	O
cells	O
infected	O
with	O
MHV	O
strain	O
JHM	O
,	O
but	O
not	O
with	O
MHV	O
-	O
A59	O
.	O

Ischemia	O
of	O
central	O
chemoreceptors	O
or	O
integration	B-PROC
of	O
their	O
informations	O
could	O
be	O
one	O
of	O
mechanism	O
.	O

The	O
difference	O
of	O
PaO	B-PROC
(	O
2	O
)	O
before	O
and	O
during	O
SI	O
were	O
(	O
65	O
+/-	O
40	O
)	O
mm	O
Hg	O
and	O
(	O
52	O
+/-	O
25	O
)	O
mm	O
Hg	O
respectively	O
in	O
the	O
5P	O
(	O
m	O
)	O
and	O
6P	O
(	O
m	O
)	O
group	O
,	O
being	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
1P	O
(	O
m	O
)	O
group	O
[(-	O
5	O
+/-	O

TITLE	O
:	O
A	O
biomimetic	O
approach	O
to	O
the	O
synthesis	B-PROC
of	O
an	O
antiviral	O
marine	O
steroidal	O
orthoester	O
.	O

ABSTRACT	O
:	O
Transfusion	O
-	O
related	O
acute	O
lung	O
injury	O
(	O
TRALI	O
)	O
is	O
a	O
syndrome	O
that	O
includes	O
dyspnea	O
,	O
hypotension	O
,	O
bilateral	O
pulmonary	O
edema	O
,	O
and	O
fever	B-PROC
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
membrane	O
(	O
M	O
)	O
protein	O
is	O
the	O
most	O
abundant	O
virion	O
protein	O
and	O
the	O
key	O
component	O
in	O
viral	B-PROC
assembly	I-PROC
and	O
morphogenesis	B-PROC
.	O

There	O
was	O
a	O
progressive	O
improvement	O
in	O
PaO	B-PROC
(	O
2	O
)/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
FIO	O
(	O
2	O
))	O
ratio	O
which	O
reached	O
significance	O
after	O
12	O
h	O
[	O
121	O
(	O
81	O
-	O
151	O
)	O
to	O
258	O
(	O
187	O
-	O
329	O
)	O
torr	O
;	O
p	O
<	O
0	O
.	O
05	O
].	O

Their	O
evolution	B-PROC
has	O
remained	O
severe	O
under	O
antibiotherapy	O
comprising	O
beta	O
-	O
lactam	O
or	O
vancomycin	O
associated	O
with	O
an	O
aminoside	O
.	O

Children	O
(	O
ages	O
2	O
-	O
12	O
)	O
with	O
normal	O
tympanograms	O
before	O
onset	O
of	O
illness	O
had	O
bilateral	O
tympanometry	O
daily	O
except	O
weekends	O
for	O
2	O
weeks	O
after	O
the	O
onset	O
of	O
a	O
cold	B-PROC
.	O

Pathogenic	O
bacteria	O
(	O
Streptococcus	O
pneumoniae	O
,	O
Haemophilus	O
influenzae	O
,	O
or	O
Moraxella	O
catarrhalis	O
)	O
were	O
detected	O
in	O
nasopharyngeal	O
secretion	B-PROC
in	O
29	O
(	O
34	O
%)	O
of	O
the	O
86	O
colds	O
;	O
the	O
bacteria	O
were	O
in	O
high	O
titer	O
(>	O
or	O
=	O
10	O
(	O
3	O
)	O
cfu	O
/	O
mL	O
)	O
in	O
26	O
of	O
the	O
29	O
positive	O
specimens	O
.	O

TITLE	O
:	O
Comparison	O
of	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
,	O
immunohistochemistry	O
,	O
and	O
in	O
situ	O
hybridization	B-PROC
for	O
the	O
detection	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
pigs	O
.	O

Antigen	O
and	O
nucleic	O
acid	O
of	O
PEDV	O
were	O
detected	O
in	O
15	O
/	O
15	O
,	O
13	O
/	O
15	O
,	O
and	O
14	O
/	O
15	O
of	O
the	O
intestinal	O
and	O
fecal	O
samples	O
from	O
the	O
PEDV	O
-	O
inoculated	O
pigs	O
by	O
RT	O
-	O
PCR	O
,	O
immunohistochemistry	O
,	O
and	O
in	O
situ	O
hybridization	B-PROC
,	O
respectively	O
.	O

Although	O
RT	O
-	O
PCR	O
identified	O
the	O
presence	O
of	O
PEDV	O
more	O
frequently	O
than	O
the	O
other	O
methods	O
,	O
when	O
only	O
formalin	O
-	O
fixed	O
tissues	O
are	O
submitted	O
,	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	B-PROC
would	O
be	O
useful	O
methods	O
for	O
the	O
detection	O
of	O
PEDV	O
antigen	O
and	O
nucleic	O
acid	O
.	O

The	O
infant	O
was	O
diagnosed	O
with	O
congenital	O
Guillain	O
-	O
Barré	O
syndrome	O
,	O
was	O
treated	O
with	O
intravenous	O
immunoglobulin	B-PROC
and	O
showed	O
clinical	O
improvement	O
within	O
48	O
hours	O
of	O
treatment	O
.	O

Patients	O
who	O
tested	O
negative	O
for	O
influenza	O
or	O
respiratory	O
syncytial	O
virus	O
had	O
nasal	O
swab	O
samples	O
tested	O
for	O
rhinovirus	O
,	O
coronavirus	O
OC43	O
,	O
and	O
coronavirus	O
229E	O
by	O
reverse	O
-	O
transcription	B-PROC
polymerase	O
chain	O
reaction	O
and	O
for	O
coronaviruses	O
by	O
serologic	O
testing	O
.	O

3	O
weeks	O
later	O
the	O
lung	B-PROC
function	I-PROC
was	O
normalized	O
and	O
the	O
chemotherapy	O
resumed	O
.	O

It	O
is	O
characterized	O
by	O
the	O
acute	O
onset	O
of	O
diffuse	O
,	O
bilateral	O
pulmonary	O
infiltrates	O
secondary	O
to	O
noncardiogenic	O
pulmonary	O
edema	O
,	O
refractory	O
hypoxia	O
,	O
and	O
decreased	O
lung	B-PROC
compliance	I-PROC
.	O

Early	O
identification	O
and	O
treatment	O
of	O
the	O
underlying	O
disorder	O
,	O
along	O
with	O
aggressive	B-PROC
supportive	O
care	O
,	O
are	O
essential	O
.	O

Many	O
patients	O
who	O
survive	O
ARDS	O
have	O
permanent	O
,	O
mild	O
to	O
moderate	O
impairment	O
of	O
lung	B-PROC
function	I-PROC
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
replication	O
-	O
induced	O
p38	O
mitogen	O
-	O
activated	O
protein	B-PROC
kinase	I-PROC
activation	I-PROC
promotes	O
interleukin	B-PROC
-	I-PROC
6	I-PROC
production	I-PROC
and	O
virus	B-PROC
replication	I-PROC
in	O
cultured	O
cells	O
.	O

Enhancement	O
of	O
virus	O
-	O
specific	O
protein	B-PROC
synthesis	I-PROC
through	O
virus	O
-	O
induced	O
eIF4E	O
activation	O
has	O
not	O
been	O
reported	O
in	O
any	O
other	O
viruses	O
.	O

TITLE	O
:	O
Detection	O
of	O
rodent	O
coronaviruses	O
by	O
use	O
of	O
fluorogenic	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

ABSTRACT	O
:	O
Reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
have	O
proved	O
useful	O
for	O
the	O
detection	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
rat	O
coronavirus	O
(	O
RCV	O
)	O
in	O
acutely	O
infected	O
animals	O
and	O
contaminated	O
biomaterials	O
.	O

Static	O
compliance	O
(	O
C	O
(	O
stat	O
))	O
and	O
resistance	B-PROC
(	O
R	O
(	O
rs	O
))	O
were	O
measured	O
every	O
3	O
min	O
.	O

ABSTRACT	O
:	O
Abdominal	O
Compartment	O
Syndrome	O
(	O
ACS	O
)	O
has	O
multiple	O
causes	O
,	O
and	O
decompressive	O
laparotomy	O
has	O
been	O
the	O
most	O
frequent	O
modality	O
to	O
prevent	O
worsening	O
cardiovascular	O
,	O
respiratory	O
,	O
and	O
renal	B-PROC
function	I-PROC
.	O

As	O
a	O
first	O
step	O
to	O
elucidate	O
their	O
significance	O
,	O
we	O
deleted	O
the	O
group	O
-	O
specific	O
genes	O
from	O
the	O
group	O
2	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
genome	O
via	O
a	O
novel	O
targeted	B-PROC
recombination	B-PROC
system	O
based	O
on	O
host	O
switching	O
(	O
L	O
.	O
Kuo	O
,	O
G	O
.	O
J	O
.	O
Godeke	O
,	O
M	O
.	O
J	O
.	O
Raamsman	O
,	O
P	O
.	O
S	O
.	O
Masters	O
,	O
and	O
P	O
.	O
J	O
.	O
M	O
.	O
Rottier	O
,	O
2000	O
,	O
J	O
.	O
Virol	O
.	O
74	O
,	O
1393	O
-	O
1406	O
).	O

Therapy	O
involved	O
a	O
sequential	O
algorithmic	O
approach	O
that	O
included	O
pulmonary	O
artery	O
oximetry	O
,	O
""""	O
best	O
-	O
PEEP	O
""""	O
determination	O
,	O
optimization	O
of	O
cardiac	B-PROC
function	I-PROC
,	O
limitation	O
of	O
VO	O
(	O
2	O
),	O
transfusion	O
to	O
hematocrit	O
of	O
35	O
%,	O
frequent	O
bronchoscopy	O
,	O
rational	O
diuresis	B-PROC
and	O
,	O
if	O
the	O
FiO	O
(	O
2	O
)	O
was	O
>	O
0	O
.	O
50	O
,	O
a	O
trial	O
of	O
IPP	O
with	O
every	O
-	O
6	O
-	O
hour	O
rotations	O
.	O

One	O
sign	O
of	O
fescue	O
toxicosis	O
in	O
cattle	O
is	O
severe	O
hyperthermia	B-PROC
.	O

Our	O
results	O
demonstrate	O
that	O
,	O
within	O
24	O
hours	O
after	O
transfection	B-PROC
,	O
intermolecular	O
recombination	B-PROC
by	O
mutant	O
integrase	O
is	O
at	O
least	O
as	O
efficient	O
as	O
intramolecular	O
recombination	B-PROC
.	O

This	O
result	O
strengthens	O
a	O
functional	O
role	O
for	O
the	O
N	O
-	O
terminal	O
domain	O
in	O
recombination	B-PROC
in	O
addition	O
to	O
its	O
arm	O
-	O
type	O
DNA	O
-	O
binding	B-PROC
activity	I-PROC
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
low	O
level	O
integrative	O
recombination	B-PROC
by	O
wild	O
-	O
type	O
integrase	O
is	O
stimulated	O
when	O
purified	O
integration	B-PROC
host	O
factor	O
is	O
co	O
-	O
transfected	O
.	O

They	O
were	O
genetically	O
close	O
to	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
but	O
differed	O
in	O
their	O
gene	O
sequence	O
from	O
all	O
the	O
serotypes	O
of	O
IBV	O
previously	O
identified	O
in	O
domestic	O
fowl	O
,	O
and	O
serological	O
tests	O
with	O
six	O
known	O
IBV	O
types	O
showed	O
little	O
cross	B-PROC
reactivity	I-PROC
.	O

The	O
cELISA	O
utilized	O
a	O
recombinant	O
baculovirus	O
(	O
Autographa	O
californica	O
nuclear	O
polyhedrosis	O
virus	O
)-	O
expressed	B-PROC
TCV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
and	O
biotin	O
-	O
labeled	O
TCV	O
N	O
protein	O
-	O
specific	O
monoclonal	O
antibody	B-PROC
.	O

These	O
findings	O
provide	O
additional	O
evidence	O
suggesting	O
a	O
possible	O
role	O
for	O
EPEC	O
in	O
the	O
pathogenesis	B-PROC
of	O
PEMS	O
.	O

TITLE	O
:	O
Genetic	O
and	O
antigenic	B-PROC
diversity	I-PROC
in	O
avian	O
infectious	O
bronchitis	O
virus	O
isolates	O
of	O
the	O
1940s	O
.	O

This	O
article	O
will	O
provide	O
an	O
overview	O
on	O
how	O
these	O
molecules	O
regulate	O
T	O
cell	O
and	O
macrophage	O
trafficking	B-PROC
into	O
the	O
CNS	O
of	O
MHV	O
-	O
infected	O
mice	O
and	O
illustrate	O
the	O
delicate	O
balance	B-PROC
that	O
exists	O
with	O
regards	O
to	O
expression	B-PROC
of	O
chemokines	O
and	O
their	O
receptors	O
as	O
it	O
relates	O
to	O
both	O
host	B-PROC
defense	I-PROC
and	O
disease	O
development	B-PROC
.	O

Control	O
calves	O
tended	O
to	O
have	O
a	O
greater	O
average	O
respiration	B-PROC
rate	O
compared	O
with	O
treated	O
(	O
28	O
.	O
7	O
vs	O
.	O
26	O
.	O
8	O
breaths	O
/	O
min	O
).	O

ABSTRACT	O
:	O
The	O
key	O
enzyme	O
in	O
coronavirus	O
polyprotein	O
processing	O
is	O
the	O
viral	O
main	O
proteinase	B-PROC
,	O
M	O
(	O
pro	O
),	O
a	O
protein	O
with	O
extremely	O
low	O
sequence	O
similarity	O
to	O
other	O
viral	O
and	O
cellular	O
proteinases	O
.	O

Interactions	O
involving	O
the	O
N	O
-	O
terminus	O
and	O
the	O
alpha	O
-	O
helical	O
domain	O
stabilize	O
the	O
loop	O
in	O
the	O
orientation	O
required	O
for	O
trans	O
-	O
cleavage	B-PROC
activity	O
.	O

ABSTRACT	O
:	O
A	O
79	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
persistent	O
nonproductive	O
cough	O
and	O
high	O
fever	B-PROC
.	O

ABSTRACT	O
:	O
The	O
relationship	O
(	O
s	O
)	O
between	O
viral	O
virulence	B-PROC
and	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
expression	B-PROC
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
of	O
mice	O
undergoing	O
lethal	O
and	O
sublethal	O
infections	O
with	O
neurotropic	O
mouse	O
hepatitis	O
virus	O
was	O
investigated	O
.	O

By	O
contrast	O
,	O
MMP	O
-	O
9	O
protein	B-PROC
activity	I-PROC
was	O
associated	O
with	O
the	O
infiltration	O
of	O
neutrophils	O
into	O
the	O
CNS	O
.	O

To	O
avoid	O
ventilator	O
-	O
associated	O
lung	O
injury	O
there	O
is	O
emphasis	O
on	O
targeting	B-PROC
ventilator	O
management	O
based	O
on	O
measurement	O
of	O
pulmonary	O
mechanics	O
.	O

Based	O
on	O
this	O
new	O
understanding	O
,	O
the	O
potential	O
targets	O
for	O
intervention	O
to	O
ameliorate	O
the	O
systemic	O
inflammatory	B-PROC
response	I-PROC
have	O
proliferated	O
.	O

TITLE	O
:	O
[	O
The	O
pathogenic	O
role	O
of	O
macrophage	O
migration	B-PROC
inhibitory	O
factor	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
].	O

There	O
is	O
a	O
potential	O
role	O
for	O
a	O
combined	O
therapy	O
with	O
inhaled	B-PROC
nitric	O
oxide	O
and	O
surfactant	O
replacement	O
in	O
reperfusion	O
injury	O
after	O
lung	O
transplantation	O
.	O

He	O
was	O
treated	O
with	O
positive	O
pressure	O
ventilation	O
,	O
beta	O
-	O
adrenergic	B-PROC
agonists	I-PROC
,	O
and	O
corticosteroids	O
.	O

The	O
BCV	O
fecal	O
and	O
nasal	O
shedding	O
detected	O
by	O
ELISA	O
and	O
RT	O
-	O
PCR	O
were	O
statistically	O
correlated	O
with	O
ELISA	O
antibody	B-PROC
seroconversion	O
(	O
P	O
<	O
0	O
.	O
0001	O
);	O
however	O
,	O
BCV	O
fecal	O
and	O
nasal	O
shedding	O
were	O
not	O
significantly	O
related	O
to	O
clinical	O
signs	O
.	O

Severity	O
of	O
changes	O
revealed	O
by	O
computed	O
tomographic	O
imaging	O
seems	O
to	O
be	O
associated	O
mainly	O
with	O
the	O
high	O
inspiratory	B-PROC
pressures	O
required	O
and	O
the	O
length	O
of	O
mechanical	O
ventilation	O
.	O

The	O
patient	O
subsequently	O
developed	O
severe	O
ischemic	O
necrosis	B-PROC
of	O
the	O
skin	O
and	O
soft	O
tissue	O
surrounding	O
the	O
catheter	O
site	O
.	O

In	O
this	O
series	O
of	O
3	O
patients	O
,	O
etanercept	O
(	O
Enbrel	O
;	O
Immunex	O
,	O
Seattle	O
,	O
WA	O
),	O
a	O
soluble	O
,	O
dimeric	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
-	O
binding	O
protein	O
,	O
was	O
administered	O
to	O
3	O
consecutive	O
pediatric	O
allogeneic	O
BMT	O
recipients	O
with	O
IPS	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
by	O
Western	O
Blotting	O
the	O
antibody	B-PROC
responses	I-PROC
against	O
the	O
three	O
major	O
structural	O
proteins	O
of	O
Canine	O
coronavirus	O
(	O
CCoV	O
)	O
in	O
dogs	O
naturally	O
infected	O
.	O

Both	O
pulmonary	B-PROC
vascular	I-PROC
resistance	I-PROC
index	O
and	O
mean	O
pulmonary	O
arterial	B-PROC
pressure	I-PROC
were	O
reduced	O
by	O
a	O
mean	O
of	O
26	O
%	O
and	O
18	O
%	O
respectively	O
after	O
the	O
administration	O
of	O
a	O
single	O
dose	O
of	O
DETA	O
/	O
NO	O
(	O
150	O
micromol	O
).	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
whether	O
a	O
high	O
respiratory	O
rate	O
induces	O
significant	O
intrinsic	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEPi	O
)	O
in	O
these	O
patients	O
.	O

She	O
underwent	O
successful	O
electrophysiologic	O
mapping	O
and	O
transcatheter	O
radiofrequency	O
ablation	O
of	O
an	O
accessory	O
conduction	B-PROC
pathway	B-PROC
,	O
resulting	O
in	O
termination	O
of	O
the	O
tachycardia	O
.	O

The	O
case	O
illustrates	O
the	O
proactive	O
use	O
of	O
ECMO	O
during	O
a	O
procedure	O
in	O
which	O
severe	O
hemodynamic	B-PROC
instability	O
could	O
be	O
predicted	O
.	O

TITLE	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
:	O
more	O
than	O
a	O
selective	O
pulmonary	O
vasodilator	O
.	O

CONCLUSIONS	O
:	O
During	O
HFOV	O
in	O
burn	O
patients	O
,	O
postresuscitation	O
edema	O
of	O
the	O
supraglottic	O
upper	O
airway	O
may	O
cause	O
expiratory	B-PROC
upper	O
airway	O
obstruction	O
.	O

ABSTRACT	O
:	O
Canine	O
coronavirus	O
(	O
CCV	O
)	O
UWSMN	O
-	O
1	O
was	O
originally	O
identified	O
from	O
an	O
outbreak	O
of	O
fatal	O
gastroenteritis	O
in	O
breeding	B-PROC
colonies	O
.	O

In	O
conclusion	O
,	O
sialodacryoadenitis	O
virus	B-PROC
infection	I-PROC
in	O
rats	O
was	O
associated	O
with	O
increased	O
frequency	O
of	O
hepatic	O
mtDNA	O
deletions	O
.	O

Immune	B-PROC
function	I-PROC
examined	O
in	O
vitro	O
showed	O
recovery	O
of	O
the	O
autologous	O
immune	O
system	O
was	O
severely	O
impaired	O
.	O

These	O
results	O
suggest	O
that	O
fast	O
neutrons	O
in	O
doses	O
higher	O
than	O
8	O
to	O
10	O
Gy	O
cause	O
complete	O
abrogation	O
of	O
the	O
human	O
immune	O
system	O
,	O
which	O
may	O
lead	O
to	O
fatal	O
outcome	O
even	O
if	O
autologous	O
hematopoiesis	B-PROC
recovers	O
.	O

The	O
roles	O
of	O
transplantation	O
,	O
autologous	O
hematopoietic	O
recovery	O
,	O
chimerism	O
,	O
immune	O
suppression	B-PROC
,	O
and	O
immune	B-PROC
function	I-PROC
are	O
discussed	O
.	O

The	O
patient	O
died	B-PROC
nine	O
months	O
later	O
due	O
to	O
respiratory	O
complications	O
.	O

Because	O
enhanced	O
release	O
of	O
inflammatory	O
mediators	O
by	O
AMPhi	O
may	O
contribute	O
to	O
ARDS	O
after	O
severe	O
trauma	O
,	O
inhibition	B-PROC
of	O
intracellular	O
signaling	B-PROC
pathways	B-PROC
represents	O
a	O
target	O
to	O
attenuate	O
organ	O
injury	O
under	O
those	O
conditions	O
.	O

This	O
conserved	O
multifunctional	O
protein	O
is	O
also	O
efficient	O
in	O
inducing	O
NDV	O
-	O
specific	O
antibody	B-PROC
in	O
chickens	O
.	O

Positioning	O
the	O
patient	O
prone	O
,	O
we	O
observed	O
a	O
prompt	O
increase	O
in	O
intracranial	B-PROC
pressure	I-PROC
,	O
which	O
resulted	O
in	O
pharmacological	O
intervention	O
(	O
mannitol	O
).	O

Treating	O
the	O
patient	O
by	O
intermittent	O
prone	O
position	O
,	O
by	O
continuous	O
extracorporeal	O
lung	O
assist	O
and	O
aerosolized	O
prostacyclin	O
administration	O
in	O
the	O
following	O
period	O
,	O
lung	B-PROC
function	I-PROC
improved	O
and	O
ARDS	O
was	O
treated	O
successfully	O
.	O

ABSTRACT	O
:	O
This	O
study	O
takes	O
advantage	O
of	O
fibroblast	O
growth	B-PROC
factor	O
2	O
(	O
FGF2	O
)	O
knock	O
-	O
out	O
mice	O
to	O
determine	O
the	O
contribution	O
of	O
FGF2	O
to	O
the	O
regeneration	B-PROC
of	O
oligodendrocytes	O
in	O
the	O
adult	O
CNS	O
.	O

These	O
studies	O
demonstrate	O
that	O
the	O
FGF2	O
genotype	O
regulates	O
oligodendrocyte	O
regeneration	B-PROC
and	O
that	O
FGF2	O
appears	O
to	O
inhibit	O
oligodendrocyte	O
lineage	O
differentiation	B-PROC
during	O
remyelination	B-PROC
.	O

ABSTRACT	O
:	O
Patients	O
with	O
acute	O
lung	O
injury	O
after	O
smoke	O
inhalation	B-PROC
often	O
develop	O
pneumonia	O
subsequently	O
complicated	O
by	O
sepsis	O
.	O

CONCLUSIONS	O
:	O
This	O
animal	O
model	O
closely	O
resembles	O
hyperdynamic	O
sepsis	O
in	O
humans	O
and	O
may	O
be	O
of	O
great	O
value	O
for	O
studies	O
of	O
sepsis	O
with	O
smoke	O
inhalation	B-PROC
.	O

TITLE	O
:	O
Superimposition	O
of	O
post	O
-	O
streptococcal	O
acute	O
glomerulonephritis	O
on	O
the	O
course	O
of	O
IgA	O
nephropathy	O
:	O
predominance	O
of	O
Th1	O
type	O
immune	B-PROC
response	I-PROC
.	O

Renal	O
biopsy	O
showed	O
severe	O
glomerular	O
mesangial	O
proliferation	O
,	O
segmental	O
endocapillary	O
proliferation	O
and	O
crescent	O
formation	B-PROC
.	O

HFOV	O
effectively	O
improves	O
oxygenation	B-PROC
without	O
haemodynamic	O
compromise	O
.	O

Molecularly	O
cloned	O
viruses	O
recognized	O
the	O
MHV	O
receptor	O
(	O
MHVR	O
)	O
for	O
docking	B-PROC
and	O
entry	O
,	O
and	O
pretreatment	O
of	O
cells	O
with	O
monoclonal	O
antibodies	O
against	O
MHVR	O
blocked	O
virus	O
entry	O
and	O
replication	O
.	O

Fewer	O
infants	O
randomized	O
to	O
the	O
EARL	O
group	O
required	O
oxygen	O
use	O
or	O
died	B-PROC
at	O
36	O
weeks	O
(	O
combined	O
outcome	O
29	O
%	O
vs	O
64	O
%,	O
p	O
=	O
0	O
.	O
021	O
),	O
and	O
there	O
was	O
a	O
lower	O
incidence	O
of	O
any	O
intraventricular	O
hemorrhage	O
in	O
this	O
group	O
(	O
43	O
vs	O
82	O
%,	O
p	O
=	O
0	O
.	O
008	O
).	O

The	O
ordered	O
nature	O
of	O
the	O
ELS	O
,	O
as	O
indicated	O
by	O
both	O
elastin	B-PROC
and	O
amyloid	O
stains	O
,	O
together	O
with	O
little	O
morphological	O
evidence	O
of	O
inflammation	O
or	O
edema	O
,	O
suggests	O
that	O
this	O
cohort	O
of	O
ARDS	O
may	O
represent	O
another	O
form	O
of	O
conformational	O
disease	O
.	O

ABSTRACT	O
:	O
During	O
the	O
past	O
20	O
years	O
,	O
ICU	O
risk	O
-	O
prediction	O
models	O
have	O
undergone	O
significant	O
development	B-PROC
,	O
validation	O
,	O
and	O
refinement	O
.	O

The	O
consensus	O
transcription	B-PROC
-	O
associated	O
sequence	O
of	O
IBV	O
,	O
CTTAACAA	O
,	O
was	O
highly	O
conserved	O
in	O
the	O
TCV	O
genome	O
with	O
regard	O
to	O
nucleotide	O
sequence	O
and	O
location	O
in	O
terms	O
of	O
the	O
initiation	O
codons	O
of	O
the	O
genes	O
5	O
and	O
N	O
.	O
The	O
similarities	O
between	O
the	O
predicted	O
amino	O
acid	O
sequences	O
of	O
ORFs	O
5a	O
and	O
5b	O
of	O
TCV	O
isolates	O
and	O
the	O
homologous	O
genes	O
of	O
IBV	O
strains	O
were	O
85	O
.	O
4	O
%	O
to	O
94	O
.	O
0	O
%.	O

TITLE	O
:	O
Detection	O
of	O
mouse	O
hepatitis	O
virus	B-PROC
infection	I-PROC
by	O
assay	O
of	O
anti	O
-	O
liver	O
autoantibodies	O
.	O

Bone	O
-	O
marrow	O
release	O
of	O
leukocytes	O
and	O
platelets	O
is	O
an	O
important	O
component	O
of	O
the	O
systemic	O
inflammatory	B-PROC
response	I-PROC
.	O

These	O
viruses	O
expressed	B-PROC
the	O
EGFP	O
gene	O
from	O
an	O
mRNA	O
of	O
slightly	O
slower	O
electrophoretic	O
mobility	O
than	O
mRNA	O
4	O
.	O

Isogenic	O
EGFP	O
-	O
expressing	O
viruses	O
that	O
differ	O
only	O
in	O
the	O
spike	O
gene	O
and	O
express	O
either	O
the	O
spike	O
gene	O
of	O
the	O
highly	O
neurovirulent	O
MHV	O
-	O
4	O
strain	O
or	O
the	O
more	O
weakly	O
neurovirulent	O
MHV	O
-	O
A59	O
strain	O
were	O
compared	O
;	O
the	O
difference	O
in	O
virulence	B-PROC
and	O
patterns	O
of	O
spread	O
of	O
viral	O
antigen	O
reflected	O
the	O
differences	O
between	O
parental	O
viruses	O
expressing	O
each	O
of	O
these	O
spike	O
genes	O
.	O

We	O
detected	O
apoptosis	B-PROC
by	O
electronmicroscopy	O
in	O
olfactory	B-PROC
neurons	O
during	O
acute	O
infection	O
with	O
MHV	O
-	O
A59	O
.	O

In	O
addition	O
,	O
efficient	O
cell	O
-	O
to	O
-	O
cell	B-PROC
fusion	I-PROC
is	O
not	O
necessary	O
for	O
virulence	B-PROC
.	O

The	O
entry	O
oxygenation	B-PROC
index	O
(	O
OI	O
)	O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
:	O
control	O
11	O
.	O
9	O
+/-	O
2	O
.	O
2	O
vs	O
iNO	O
10	O
.	O
8	O
+/-	O
1	O
.	O
50	O
.	O

The	O
incidence	O
of	O
other	O
acute	O
complications	O
as	O
well	O
as	O
early	O
neonatal	O
death	B-PROC
,	O
were	O
comparable	O
between	O
the	O
groups	O
.	O

15	O
.	O
8	O
years	O
)	O
presented	O
with	O
severe	O
hypoxemia	O
(	O
Pa	O
(	O
O2	O
)/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
ratio	O
=	O
156	O
+/-	O

A	O
cl	O
-	O
2	O
mutant	O
,	O
srr7	O
,	O
of	O
the	O
MHV	O
JHM	O
virus	O
(	O
JHMV	O
)	O
was	O
digested	B-PROC
with	O
proteinase	B-PROC
K	O
after	O
treatment	O
with	O
soMHVR	O
,	O
and	O
the	O
resultant	O
S	O
protein	O
was	O
analyzed	O
by	O
Western	O
blotting	O
using	O
monoclonal	O
antibody	B-PROC
(	O
MAb	O
)	O
10G	O
,	O
specific	O
for	O
the	O
membrane	O
-	O
anchored	O
S2	O
subunit	O
.	O

There	O
is	O
no	O
published	O
method	O
known	O
to	O
us	O
of	O
determining	O
the	O
time	O
of	O
origin	O
of	O
these	O
markers	O
except	O
that	O
the	O
injury	O
causing	O
astrogliosis	O
must	O
have	O
occurred	O
at	O
least	O
4	O
days	O
before	O
death	B-PROC
(	O
Del	O
Bigio	O
and	O
Becker	O
,	O
1994	O
).	O

A	O
preponderance	O
of	O
deaths	B-PROC
in	O
the	O
neonatal	O
period	O
is	O
also	O
found	O
for	O
congenital	O
anomalies	O
,	O
a	O
category	O
that	O
logically	O
should	O
include	O
infants	O
who	O
experienced	O
prenatal	O
hypoxia	O
or	O
ischemia	O
;	O
this	O
distribution	O
of	O
age	O
of	O
death	B-PROC
is	O
very	O
different	O
from	O
that	O
for	O
SIDS	O
,	O
which	O
mostly	O
spares	O
the	O
first	O
month	O
and	O
peaks	O
between	O
2	O
and	O
3	O
months	O
of	O
age	O
.	O

The	O
geometric	O
mean	O
of	O
the	O
hemagglutination	B-PROC
inhibition	B-PROC
antibody	B-PROC
titer	O
was	O
34	O
.	O
2	O
before	O
vaccination	O
in	O
test	O
cows	O
.	O

TITLE	O
:	O
Neutralizing	O
antibody	B-PROC
decay	O
and	O
lack	O
of	O
contact	O
transmission	O
after	O
inoculation	O
of	O
3	O
-	O
and	O
4	O
-	O
day	O
-	O
old	O
piglets	O
with	O
porcine	O
respiratory	O
coronavirus	O
.	O

Evidence	O
from	O
animal	O
models	O
shows	O
acute	O
non	O
-	O
immune	O
lung	O
injury	O
increases	O
organ	O
immunogenicity	O
by	O
enhancing	O
MHC	B-PROC
Class	O
II	O
expression	B-PROC
.	O

Under	O
physiological	O
circumstances	O
,	O
secretory	B-PROC
phospholipase	B-PROC
A	I-PROC
(	O
2	O
)	O
type	O
I	O
(	O
sPLA	O
(	O
2	O
)-	O
I	O
)	O
is	O
activated	O
by	O
trypsinogen	O
,	O
but	O
the	O
extent	O
of	O
this	O
activation	O
in	O
acute	O
pancreatitis	O
is	O
unclear	O
.	O

This	O
observation	O
raises	O
questions	O
as	O
to	O
the	O
theory	O
of	O
generalized	O
zymogen	B-PROC
activation	I-PROC
being	O
a	O
principle	O
mechanism	O
involved	O
in	O
the	O
pathogenesis	B-PROC
of	O
distant	O
organ	O
damage	O
in	O
acute	O
pancreatitis	O
.	O

ABSTRACT	O
:	O
Recent	O
laboratory	O
studies	O
have	O
demonstrated	O
that	O
immune	B-PROC
responses	I-PROC
differ	O
between	O
male	O
and	O
female	O
rodents	O
,	O
and	O
some	O
clinical	O
studies	O
have	O
suggested	O
gender	O
differences	O
regarding	O
incidence	O
and	O
mortality	O
from	O
sepsis	O
.	O

Analyses	O
of	O
the	O
subcellular	O
distribution	O
of	O
cytochrome	B-PROC
c	I-PROC
,	O
procaspase	O
-	O
9	O
,	O
and	O
Apaf	O
-	O
1	O
suggested	O
an	O
aberrant	O
apoptosome	B-PROC
formation	I-PROC
in	O
the	O
vicinity	O
of	O
the	O
mitochondria	O
,	O
which	O
could	O
be	O
a	O
cell	O
type	O
-	O
specific	O
event	O
.	O

We	O
conclude	O
that	O
the	O
combination	O
of	O
HFOV	O
with	O
iNO	O
causes	O
a	O
greater	O
improvement	O
in	O
oxygenation	B-PROC
than	O
either	O
treatment	O
strategy	O
alone	O
in	O
children	O
with	O
severe	O
AHRF	O
.	O

One	O
third	O
of	O
patients	O
died	B-PROC
early	O
.	O

Patients	O
were	O
treated	O
as	O
soon	O
as	O
possible	O
with	O
supine	O
-	O
prone	O
/	O
prone	O
-	O
supine	O
positioning	O
every	O
8	O
h	O
until	O
clinical	O
improvement	O
or	O
death	B-PROC
occurred	O
.	O

To	O
study	O
whether	O
toroviruses	O
use	O
a	O
similar	O
transcription	B-PROC
mechanism	O
,	O
we	O
characterized	O
the	O
5	O
'	O
termini	O
of	O
the	O
genome	O
and	O
the	O
four	O
sg	O
mRNAs	O
of	O
Berne	O
virus	O
(	O
BEV	O
).	O

We	O
have	O
previously	O
demonstrated	O
high	O
level	O
expression	B-PROC
of	O
the	O
B	O
-	O
subunit	O
of	O
Escherichia	O
coli	O
heat	O
-	O
labile	O
enterotoxin	O
and	O
the	O
spike	O
protein	O
of	O
swine	O
transmissible	O
gastroenteritis	O
in	O
corn	O
,	O
and	O
have	O
demonstrated	O
that	O
these	O
antigens	O
delivered	O
in	O
the	O
seed	O
elicit	O
protective	O
immune	B-PROC
responses	I-PROC
.	O

However	O
,	O
the	O
truncated	O
form	O
exhibited	O
more	O
severe	O
effects	O
on	O
syncytia	O
formation	B-PROC
,	O
virus	O
production	O
,	O
and	O
synthesis	B-PROC
of	O
viral	O
RNA	O
and	O
viral	O
proteins	O
.	O

ABSTRACT	O
:	O
A	O
7	O
-	O
year	O
-	O
old	O
boy	O
with	O
Down	O
syndrome	O
developed	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
a	O
respiratory	O
infection	O
with	O
Mycoplasma	O
pneumoniae	O
with	O
an	O
unusually	O
high	O
agglutination	B-PROC
titre	O
(	O
1	O
:	O
10240	O
).	O

JHMV	O
infection	O
of	O
antibody	B-PROC
-	O
deficient	O
mice	O
confirmed	O
a	O
primary	O
role	O
of	O
cellular	B-PROC
immunity	I-PROC
and	O
a	O
redundant	O
role	O
for	O
humoral	B-PROC
immunity	I-PROC
during	O
acute	O
infection	O
.	O

Thus	O
,	O
cell	O
-	O
mediated	O
immune	B-PROC
responses	I-PROC
control	O
acute	O
infection	O
,	O
whereas	O
humoral	B-PROC
immunity	I-PROC
maintains	O
viral	O
persistence	O
.	O

Later	O
,	O
in	O
vivo	O
expression	B-PROC
was	O
demonstrated	O
by	O
the	O
detection	O
of	O
IBV	O
-	O
specific	O
serum	O
immunoglobulin	B-PROC
G	O
and	O
neutralization	O
antibodies	O
in	O
the	O
sera	O
of	O
chickens	O
immunized	O
with	O
rFPV	O
-	O
S1	O
.	O

Surprisingly	O
,	O
the	O
S	O
protein	O
of	O
recombinant	O
MHV	O
-	O
A59	O
virions	O
with	O
a	O
mutation	O
,	O
H716D	O
,	O
that	O
precluded	O
cleavage	B-PROC
between	O
S1	O
and	O
S2	O
could	O
also	O
be	O
triggered	O
to	O
undergo	O
a	O
conformational	B-PROC
change	I-PROC
at	O
37	O
degrees	O
C	O
by	O
soluble	O
receptor	O
at	O
neutral	O
pH	O
or	O
by	O
pH	O
8	O
alone	O
.	O

The	O
trans	O
-	O
processing	O
activity	O
of	O
the	O
purified	O
recombinant	O
3CL	O
(	O
pro	O
)	O
(	O
pp1a	O
residues	O
2832	O
to	O
3126	O
)	O
was	O
used	O
to	O
identify	O
another	O
cleavage	B-PROC
site	O
,	O
(	O
6441	O
)	O
KVNHE	O
downward	O
arrow	O
LYHVA	O
(	O
6450	O
),	O
in	O
the	O
C	O
-	O
terminal	O
pp1ab	O
region	O
.	O

The	O
properties	O
of	O
the	O
GAV	O
3CL	O
(	O
pro	O
)	O
define	O
a	O
novel	O
RNA	O
virus	O
proteinase	B-PROC
variant	O
that	O
bridges	O
the	O
gap	O
between	O
the	O
distantly	O
related	O
chymotrypsin	O
-	O
like	O
cysteine	O
proteinases	O
of	O
coronaviruses	O
and	O
potyviruses	O
.	O

The	O
latter	O
possibility	O
where	O
axonal	O
injury	O
leads	O
to	O
other	O
changes	O
is	O
raised	O
from	O
the	O
rather	O
unexpected	O
similarity	O
between	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
and	O
MS	O
where	O
axonal	O
injury	O
,	O
oligodendrocyte	B-PROC
apoptosis	I-PROC
and	O
demyelination	O
are	O
all	O
present	O
.	O

TITLE	O
:	O
A	O
protocol	O
for	O
improved	O
glycaemic	O
control	O
following	O
corticosteroid	O
therapy	O
in	O
diabetic	O
pregnancies	B-PROC
.	O

Treatment	O
of	O
sensitive	O
Balb	O
/	O
cJ	O
mice	O
with	O
neutralizing	O
anti	O
-	O
TGF	O
-	O
beta	O
antibody	B-PROC
could	O
increase	O
the	O
STAT1	O
alpha	O
/	O
beta	O
ratio	O
to	O
<	O
1	O
.	O
0	O
in	O
spleens	O
,	O
predicting	O
enhanced	O
rates	O
of	O
survival	O
.	O

To	O
investigate	O
signals	O
that	O
regulate	O
OP	O
proliferation	O
in	O
response	O
to	O
demyelination	O
we	O
used	O
murine	O
hepatitis	O
virus	O
-	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
infection	O
of	O
adult	O
mice	O
to	O
induce	O
focal	O
demyelination	O
throughout	O
the	O
spinal	O
cord	O
followed	O
by	O
spontaneous	O
remyelination	B-PROC
.	O

Hyperinflated	O
tissue	O
increased	O
up	O
to	O
2	O
.	O
9	O
+/-	O
4	O
.	O
0	O
%	O
with	O
PEEP	O
30	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
with	O
inspiration	B-PROC
.	O

Lung	O
recruitment	O
maneuvers	O
improve	O
oxygenation	B-PROC
by	O
expanding	O
collapsed	O
alveoli	O
without	O
inducing	O
too	O
much	O
hyperinflation	O
in	O
ALI	O
/	O
ARDS	O
patients	O
.	O

BOOP	O
is	O
characterized	O
by	O
perivascular	O
/	O
peribronchiolar	O
leukocyte	O
infiltration	O
leading	O
to	O
the	O
development	B-PROC
of	O
intra	O
-	O
alveolar	O
fibrosis	O
.	O

In	O
contrast	O
,	O
pulmonary	O
edema	O
fluid	O
surfactant	O
protein	O
D	O
,	O
but	O
not	O
surfactant	O
protein	O
A	O
,	O
was	O
lower	O
in	O
patients	O
with	O
worse	O
oxygenation	B-PROC
,	O
as	O
measured	O
by	O
the	O
alveolar	O
-	O
arterial	O
oxygen	O
difference	O
(	O
p	O
=	O
.	O
01	O
)	O
and	O
was	O
lower	O
in	O
the	O
patients	O
who	O
died	B-PROC
(	O
2646	O
ng	O
/	O
mL	O
)	O
compared	O
with	O
those	O
who	O
survived	O
(	O
5503	O
ng	O
/	O
mL	O
;	O
p	O
=	O
.	O
02	O
).	O

TITLE	O
:	O
Kinetics	O
of	O
virus	O
-	O
specific	O
CD8	O
+	O
-	O
T	O
-	O
cell	B-PROC
expansion	I-PROC
and	O
trafficking	B-PROC
following	O
central	O
nervous	O
system	O
infection	O
.	O

Death	B-PROC
usually	O
results	O
from	O
multisystem	O
organ	O
failure	O
rather	O
than	O
respiratory	O
failure	O
alone	O
.	O

INO	O
delivered	O
at	O
doses	O
of	O
5	O
to	O
20	O
ppm	O
during	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
increases	O
Pao2	O
/	O
Fio2	O
and	O
may	O
be	O
a	O
safe	O
and	O
effective	O
rescue	O
therapy	O
for	O
patients	O
with	O
severe	O
oxygenation	B-PROC
failure	O
.	O

Serum	O
levels	O
of	O
SP	O
-	O
A	O
in	O
patients	O
dying	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
are	O
double	O
serum	O
levels	O
of	O
survivors	O
.	O

A	O
higher	O
PaO	B-PROC
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
was	O
observed	O
in	O
the	O
surfactant	O
group	O
2	O
h	O
after	O
the	O
first	O
dose	O
(	O
58	O
from	O
baseline	O
vs	O
.	O
9	O
),	O
at	O
48	O
h	O
there	O
was	O
a	O
trend	O
towards	O
a	O
higher	O
ratio	O
(	O
38	O
from	O
baseline	O
vs	O
.	O
22	O
).	O

This	O
improvement	O
is	O
sustained	O
only	O
in	O
the	O
subgroup	O
of	O
patients	O
without	O
pneumonia	O
and	O
that	O
with	O
an	O
initial	O
PaO	B-PROC
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
higher	O
than	O
65	O
RESULTS	O
:	O
In	O
the	O
pilot	O
study	O
the	O
PaO	B-PROC
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
increased	O
by	O
a	O
mean	O
of	O
100	O
at	O
48	O
h	O
(	O
n	O
=	O
19	O
).	O

This	O
improvement	O
is	O
sustained	O
only	O
in	O
the	O
subgroup	O
of	O
patients	O
without	O
pneumonia	O
and	O
that	O
with	O
an	O
initial	O
PaO	B-PROC
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
higher	O
than	O
65	O

RESULTS	O
:	O
Positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
averaged	O
16	O
.	O
6	O
+/-	O
4	O
mbar	O
in	O
the	O
high	O
PEEP	O
and	O
7	O
.	O
6	O
+/-	O
2	O
.	O
2	O
mbar	O
in	O
the	O
low	O
PEEP	O
group	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
series	O
of	O
potent	O
,	O
selective	O
HIV	O
-	O
1	O
N	O
-	O
acylthiocarbamate	O
(	O
ATC	O
)	O
nonnucleoside	O
reverse	B-PROC
transcriptase	I-PROC
inhibitors	I-PROC
(	O
NNRTIs	O
)	O
is	O
described	O
.	O

ABSTRACT	O
:	O
An	O
indirect	O
liquid	O
-	O
phase	O
blocking	O
(	O
LPB	O
)	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
chicken	O
and	O
rabbit	O
affinity	O
purified	O
immunoglobulin	B-PROC
G	O
(	O
IgG	O
)	O
has	O
been	O
developed	O
to	O
detect	O
and	O
estimate	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
antigen	O
concentration	O
directly	O
in	O
infected	O
allantoic	O
fluid	O
.	O

ABSTRACT	O
:	O
Fibrinogen	O
-	O
like	O
protein	O
2	O
/	O
fibroleukin	O
(	O
Fgl2	O
)	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
both	O
experimental	O
and	O
human	O
fulminant	O
hepatic	O
failure	O
.	O

The	O
diagnosis	O
was	O
confirmed	O
by	O
the	O
increased	O
antibody	B-PROC
-	O
titer	O
to	O
M	O
.	O
pneumoniae	O
later	O
.	O

Increased	B-PROC
capillary	I-PROC
permeability	I-PROC
is	O
a	O
cause	O
of	O
hypoxemia	O
in	O
lung	O
injury	O
.	O

The	O
systemic	O
host	B-PROC
response	I-PROC
to	O
invading	O
microorganisms	O
,	O
often	O
termed	O
the	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
SIRS	O
),	O
includes	O
changes	O
in	O
heart	O
rate	O
,	O
respiratory	O
rate	O
,	O
body	O
temperature	O
,	O
and	O
circulating	O
white	O
blood	O
cell	O
numbers	O
.	O

The	O
MBL	O
exerts	B-PROC
its	O
function	O
by	O
directly	O
binding	O
to	O
microbial	O
surfaces	O
through	O
its	O
carbohydrate	O
recognition	O
domains	O
,	O
followed	O
by	O
direct	O
opsonization	B-PROC
or	O
complement	B-PROC
activation	I-PROC
via	O
MBL	O
-	O
associated	O
serine	O
proteases	O
(	O
MASP	O
)-	O
1	O
and	O
-	O
2	O
.	O

The	O
complement	B-PROC
activation	I-PROC
was	O
directly	O
associated	O
with	O
the	O
concentration	O
of	O
MBL	O
in	O
serum	O
,	O
indicating	O
neutralization	O
of	O
the	O
virus	O
before	O
the	O
humoral	O
antibody	B-PROC
response	I-PROC
took	O
over	O
.	O

To	O
separately	O
evaluate	O
each	O
effector	O
function	O
specifically	O
in	O
the	O
context	O
of	O
CD8	O
(+)	O
T	O
cells	O
,	O
pathogenesis	B-PROC
was	O
analyzed	O
in	O
mice	O
deficient	O
in	O
both	O
perforin	O
and	O
IFN	O
-	O
gamma	O
(	O
PKO	O
/	O
GKO	O
)	O
or	O
selectively	O
reconstituted	O
for	O
each	O
function	O
by	O
transfer	O
of	O
CD8	O
(+)	O
T	O
cells	O
.	O

Uncontrolled	O
infection	O
was	O
associated	O
with	O
limited	O
MHC	B-PROC
class	O
I	O
up	B-PROC
-	I-PROC
regulation	B-PROC
and	O
an	O
absence	O
of	O
class	O
II	O
expression	B-PROC
on	O
microglia	O
,	O
coinciding	O
with	O
decreased	O
CD4	O
(+)	O
T	O
cells	O
in	O
CNS	O
infiltrates	O
.	O

The	O
inability	O
of	O
perforin	O
-	O
mediated	O
mechanisms	O
to	O
control	O
virus	O
in	O
the	O
absence	O
of	O
IFN	O
-	O
gamma	O
coincided	O
with	O
reduced	O
class	O
I	O
expression	B-PROC
.	O

The	O
data	O
further	O
imply	O
that	O
IFN	O
-	O
gamma	O
plays	O
a	O
crucial	O
role	O
in	O
pathogenesis	B-PROC
by	O
regulating	O
the	O
balance	B-PROC
between	O
virus	B-PROC
replication	I-PROC
in	O
oligodendrocytes	O
,	O
CD8	O
(+)	O
T	O
cell	O
effector	O
function	O
,	O
and	O
demyelination	O
.	O

Mixed	O
breed	B-PROC
sheep	O
.	O

The	O
results	O
indicate	O
that	O
chicken	O
lines	O
may	O
differ	O
greatly	O
in	O
their	O
susceptibility	O
to	O
fatal	O
IB	O
nephritis	O
and	O
that	O
resistance	B-PROC
is	O
likely	O
to	O
be	O
under	O
the	O
control	O
of	O
immune	B-PROC
responses	I-PROC
to	O
viral	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
CC	O
chemokine	O
ligand	B-PROC
3	O
(	O
CCL3	O
)	O
regulates	O
CD8	O
(+)-	O
T	O
-	O
cell	O
effector	O
function	O
and	O
migration	B-PROC
following	O
viral	B-PROC
infection	I-PROC
.	O

ABSTRACT	O
:	O
Chemokines	O
induce	O
the	O
directional	O
migration	B-PROC
of	O
targeted	B-PROC
populations	O
of	O
leukocytes	O
during	O
periods	B-PROC
of	O
inflammation	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
showed	O
that	O
an	O
intraperitoneal	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
resulted	O
in	O
acute	O
hepatic	O
failure	O
accompanying	O
extremely	O
elevated	O
viral	O
growth	B-PROC
in	O
the	O
liver	O
in	O
interferon	O
-	O
gamma	O
-	O
deficient	O
BALB	O
/	O
c	O
(	O
BALB	O
-	O
GKO	O
),	O
but	O
not	O
C57BL	O
/	O
6	O
(	O
B6	O
-	O
GKO	O
)	O
mice	O
.	O

ABSTRACT	O
:	O
Vascular	B-PROC
endothelial	I-PROC
growth	B-PROC
factor	I-PROC
(	O
VEGF	O
),	O
an	O
angiogenic	B-PROC
and	O
chemotactic	O
peptide	O
,	O
is	O
abundantly	O
expressed	B-PROC
in	O
normal	O
lung	O
tissue	O
,	O
especially	O
in	O
alveolar	O
and	O
bronchial	O
epithelium	O
,	O
glandular	O
cells	O
of	O
the	O
bronchi	O
,	O
and	O
activated	O
alveolar	O
macrophages	O
.	O

Samples	O
from	O
septic	O
patients	O
lacked	O
or	O
showed	O
only	O
sparse	O
immunoreaction	B-PROC
on	O
bronchial	O
and	O
alveolar	O
epithelium	O
,	O
whereas	O
this	O
reaction	O
was	O
strong	O
in	O
all	O
control	O
samples	O
.	O

RESULTS	O
:	O
Compared	O
with	O
expression	B-PROC
in	O
nonseptic	O
control	O
individuals	O
(	O
n	O
=	O
10	O
),	O
pulmonary	O
VEGF	O
expression	B-PROC
as	O
determined	O
by	O
ELISA	O
was	O
significantly	O
(	O
P	O
<.	O
001	O
)	O
decreased	O
in	O
septic	O
patients	O
(	O
n	O
=	O
8	O
).	O

Treatment	O
of	O
injured	O
sheep	O
with	O
BBS	O
-	O
2	O
attenuated	O
the	O
increases	O
in	O
tracheal	O
blood	B-PROC
flow	I-PROC
and	O
plasma	O
NOx	O
levels	O
,	O
and	O
significantly	O
attenuated	O
all	O
the	O
pulmonary	O
pathologies	O
that	O
were	O
noted	O
.	O

In	O
this	O
two	O
-	O
step	O
process	O
,	O
we	O
first	O
constructed	O
by	O
targeted	B-PROC
recombination	B-PROC
a	O
mutant	O
of	O
FIPV	O
,	O
designated	O
mFIPV	O
,	O
in	O
which	O
the	O
ectodomain	O
of	O
the	O
spike	O
glycoprotein	O
was	O
replaced	O
by	O
that	O
of	O
MHV	O
.	O

The	O
r	O
-	O
wtFIPV	O
was	O
indistinguishable	O
from	O
its	O
parental	O
virus	O
FIPV	O
79	O
-	O
1146	O
not	O
only	O
for	O
its	O
growth	B-PROC
characteristics	O
in	O
tissue	O
culture	O
but	O
also	O
in	O
cats	O
,	O
exhibiting	O
a	O
highly	O
lethal	O
phenotype	O
.	O

All	O
patients	O
presented	O
with	O
fever	B-PROC
(	O
temperature	O
,	O
>	O
38	O
degrees	O
C	O
for	O
over	O
24	O
hours	O
),	O
and	O
most	O
presented	O
with	O
rigor	O
,	O
dry	O
cough	O
,	O
dyspnea	O
,	O
malaise	O
,	O
headache	O
,	O
and	O
hypoxemia	O
.	O

TITLE	O
:	O
Clinical	O
study	O
of	O
Japanese	O
spotted	O
fever	B-PROC
and	O
its	O
aggravating	O
factors	O
.	O

The	O
diagnosis	O
was	O
determined	O
by	O
confirming	O
an	O
increase	O
of	O
specific	O
antibody	B-PROC
.	O

She	O
had	O
severe	O
anasarca	O
and	O
markedly	O
decreased	O
synthetic	O
liver	B-PROC
function	I-PROC
.	O

Clinical	O
end	O
points	O
included	O
the	O
need	O
for	O
intensive	O
care	O
and	O
death	B-PROC
.	O

CONCLUSIONS	O
:	O
Although	O
the	O
data	O
support	O
a	O
key	O
role	O
for	O
neutrophil	O
elastase	O
in	O
the	O
pathogenesis	B-PROC
of	O
ARDS	O
,	O
further	O
study	O
is	O
needed	O
to	O
fully	O
define	O
the	O
actions	O
of	O
neutrophil	O
elastase	O
,	O
and	O
how	O
these	O
actions	O
affect	O
host	O
functions	O
,	O
before	O
we	O
can	O
exploit	O
this	O
knowledge	O
for	O
therapeutic	O
benefit	O
.	O

To	O
review	O
the	O
cross	B-PROC
-	I-PROC
talk	I-PROC
between	O
coagulation	B-PROC
and	O
inflammation	O
that	O
may	O
affect	O
this	O
response	O
.	O

During	O
the	O
last	O
decade	O
,	O
case	O
reports	O
and	O
observational	O
studies	O
of	O
HFOV	O
in	O
patients	O
failing	O
conventional	O
ventilation	O
strategies	O
have	O
suggested	O
improved	O
oxygenation	B-PROC
in	O
adult	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

An	O
activated	O
complex	O
of	O
tissue	O
factor	O
and	O
factor	O
VIIa	O
triggers	O
procoagulant	O
activity	O
in	O
the	O
lung	O
,	O
with	O
subsequent	O
thrombin	O
formation	B-PROC
and	O
fibrin	O
deposition	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
beneficial	O
effects	O
of	O
exogenous	O
surfactant	O
supplementation	O
(	O
ESS	O
)	O
and	O
partial	O
liquid	O
ventilation	O
(	O
PLV	O
)	O
in	O
treating	O
acute	O
lung	O
injury	O
induced	O
by	O
wood	O
smoke	O
inhalation	B-PROC
.	O

After	O
the	O
induction	O
of	O
acute	O
lung	O
injury	O
by	O
wood	O
smoke	O
inhalation	B-PROC
,	O
animals	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
conventional	O
mechanical	O
ventilation	O
(	O
CMV	O
)	O
or	O
PLV	O
with	O
or	O
without	O
ESS	O
pretreatment	O
.	O

In	O
addition	O
,	O
both	O
the	O
PLV	O
and	O
ESS	O
-	O
PLV	O
groups	O
displayed	O
significant	O
improvements	O
in	O
dynamic	O
lung	B-PROC
compliance	I-PROC
and	O
in	O
their	O
histologic	O
outcomes	O
.	O

Sepsis	O
and	O
its	O
sequelae	O
represent	O
a	O
continuum	O
of	O
clinical	O
syndrome	O
encompassing	O
systemic	O
inflammation	O
,	O
coagulopathy	O
,	O
and	O
hemodynamic	B-PROC
abnormalities	O
.	O

From	O
October	O
2000	O
through	O
April	O
2001	O
,	O
we	O
tested	O
1803	O
respiratory	O
samples	O
for	O
HCoV	O
by	O
reverse	O
-	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
.	O

Calves	O
that	O
were	O
seronegative	O
or	O
had	O
low	O
antibody	B-PROC
titers	O
against	O
BoTV	O
(<	O
or	O
=	O
1	O
:	O
10	O
hemagglutination	B-PROC
inhibition	B-PROC
units	O
)	O
at	O
arrival	O
seroconverted	O
to	O
BoTV	O
(>	O
4	O
-	O
fold	O
increase	O
in	O
titer	O
);	O
these	O
calves	O
were	O
more	O
likely	O
to	O
shed	O
virus	O
than	O
calves	O
that	O
were	O
seropositive	O
against	O
BoTV	O
at	O
arrival	O
.	O

In	O
contrast	O
,	O
the	O
rTGEV	O
replication	O
level	O
in	O
the	O
lungs	O
and	O
gut	O
of	O
infected	O
piglets	O
and	O
virulence	B-PROC
were	O
significantly	O
reduced	O
.	O

Severe	O
stomatitis	O
due	O
to	O
methotrexate	O
(	O
MTX	O
)	O
occurred	O
probably	O
due	O
to	O
altered	O
pharmacokinetics	B-PROC
usually	O
observed	O
in	O
DS	O
patients	O
.	O

In	O
DS	O
patients	O
,	O
superfluous	O
toxicities	O
due	O
to	O
MTX	O
and	O
AraC	O
treatment	O
have	O
been	O
reported	O
,	O
and	O
these	O
toxicities	O
have	O
been	O
considered	O
due	O
to	O
altered	O
pharmacokinetics	B-PROC
in	O
patients	O
with	O
DS	O
.	O

These	O
results	O
show	O
that	O
blockade	O
of	O
coagulation	B-PROC
attenuates	O
acute	O
lung	O
and	O
renal	O
injury	O
in	O
established	O
Gram	O
-	O
negative	O
sepsis	O
accompanied	O
by	O
antiinflammatory	O
effects	O
of	O
therapy	O
.	O

We	O
tested	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
samples	O
obtained	O
from	O
HSCT	O
recipients	O
with	O
acute	O
pulmonary	O
infiltrates	O
for	O
HRV	O
(	O
n	O
=	O
122	O
)	O
and	O
coronavirus	O
(	O
n	O
=	O
46	O
)	O
by	O
reverse	O
-	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
.	O

Persistent	O
fever	B-PROC
,	O
cough	O
,	O
progressive	O
radiographic	O
changes	O
of	O
chest	O
and	O
lymphopenia	O
were	O
noted	O
in	O
all	O
patients	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
test	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
DeltaStream	O
pump	O
for	O
ECMO	O
in	O
animals	O
with	O
normal	O
lung	B-PROC
function	I-PROC
and	O
experimental	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

In	O
animals	O
with	O
ALI	O
,	O
hemodynamics	B-PROC
remained	O
stable	O
and	O
gas	O
transfer	O
across	O
the	O
extracorporeal	O
oxygenators	O
was	O
optimal	O
,	O
but	O
only	O
in	O
2	O
animals	O
was	O
a	O
marked	O
increase	O
in	O
PaO2	O
observed	O
.	O

After	O
the	O
initial	O
phase	O
of	O
exponential	O
growth	B-PROC
,	O
the	O
rate	O
of	O
confirmed	O
cases	O
fell	O
to	O
less	O
than	O
20	O
per	O
day	O
by	O
April	O
28	O
.	O

Age	O
and	O
chronic	O
hepatitis	O
B	O
virus	B-PROC
infection	I-PROC
treated	O
with	O
lamivudine	O
were	O
independent	O
significant	O
risk	O
factors	O
for	O
progression	O
to	O
ARDS	O
(	O
p	O
=	O
0	O
.	O
001	O
).	O

Evidence	O
of	O
infection	O
with	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
human	O
metapneumovirus	O
was	O
sought	O
by	O
reverse	O
-	O
transcriptase	B-PROC
PCR	O
and	O
serology	O
.	O

The	O
patient	O
did	O
well	O
and	O
was	O
eventually	O
extubated	O
and	O
eating	B-PROC
a	O
regular	O
diet	O
.	O

Therefore	O
,	O
fnRT	O
-	O
PCR	O
assays	O
specific	O
for	O
Sendai	O
virus	O
and	O
PVM	O
were	O
developed	O
by	O
targeting	B-PROC
primer	O
andprobe	O
sequences	O
to	O
unique	O
regions	O
of	O
the	O
Sendai	O
virus	O
nucleocapsid	O
(	O
NP	O
)	O
gene	O
and	O
the	O
PVM	O
attachment	O
(	O
G	O
)	O
gene	O
,	O
respectively	O
.	O

Initial	O
experiments	O
used	O
a	O
cecal	O
homogenate	O
inoculum	O
from	O
the	O
clinical	O
cases	O
that	O
contained	O
H	O
.	O
hepaticus	O
and	O
MHV	O
-	O
G	O
to	O
reproduce	O
the	O
development	B-PROC
of	O
peritonitis	O
and	O
pleuritis	O
in	O
IFN	O
-	O
gamma	O
KO	O
mice	O
.	O

Several	O
reports	O
have	O
indicated	O
the	O
principle	O
effect	O
of	O
biologically	O
active	O
lipids	O
on	O
the	O
pathogenesis	B-PROC
of	O
TRALI	O
.	O

On	O
the	O
basis	O
of	O
comparative	O
genomics	O
,	O
the	O
homology	O
search	O
,	O
phylogenetic	O
analyses	O
,	O
and	O
multi	O
-	O
sequence	O
alignment	O
were	O
used	O
to	O
predict	O
CD13	O
related	O
interacting	O
domains	O
and	O
binding	O
sites	O
in	O
the	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
Molecular	O
modeling	O
and	O
docking	B-PROC
simulation	O
methods	O
were	O
employed	O
to	O
address	O
the	O
interaction	O
feature	O
between	O
CD13	O
and	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
in	O
validating	O
the	O
bioinformatics	O
predictions	O
.	O

Bioinformatics	O
analyses	O
were	O
performed	O
to	O
search	O
the	O
homologous	O
proteins	O
of	O
the	O
SARS	O
-	O
CoV	O
3CL	O
proteinase	B-PROC
from	O
the	O
GenBank	O
and	O
PDB	O
database	O
.	O

The	O
tested	O
virtual	O
screening	O
indicated	O
that	O
73	O
available	O
proteinase	B-PROC
inhibitors	O
in	O
the	O
MDDR	O
database	O
might	O
dock	O
into	O
both	O
the	O
binding	O
pockets	O
of	O
the	O
TGEV	O
Mpro	O
and	O
the	O
SARS	O
-	O
CoV	O
3CL	O
proteinase	B-PROC
.	O

Novel	O
aggressive	B-PROC
therapeutic	O
approaches	O
to	O
these	O
lung	O
disorders	O
are	O
required	O
,	O
and	O
prevention	O
of	O
NE	O
release	O
may	O
be	O
considered	O
as	O
a	O
promising	O
strategy	O
for	O
disease	O
outcome	O
.	O

Here	O
,	O
we	O
report	O
the	O
results	O
of	O
our	O
studies	O
identifying	O
and	O
characterizing	O
this	O
cleavage	B-PROC
site	O
.	O

To	O
determine	O
the	O
approximate	O
position	O
of	O
the	O
cleavage	B-PROC
site	O
,	O
we	O
expressed	B-PROC
constructs	O
that	O
extended	O
various	O
distances	O
upstream	O
from	O
the	O
previously	O
defined	O
C	O
-	O
terminal	O
end	O
of	O
MP1	O
.	O

Therefore	O
,	O
murine	O
coronavirus	O
PLP2	O
cleaves	O
the	O
replicase	O
polyprotein	O
between	O
glycine	O
2840	O
and	O
alanine	O
2841	O
,	O
and	O
the	O
critical	O
determinants	O
for	O
PLP2	O
recognition	O
and	O
processing	O
occupy	O
the	O
P6	O
,	O
P2	O
,	O
and	O
P1	O
positions	O
of	O
the	O
cleavage	B-PROC
site	O
.	O

In	O
the	O
meantime	O
,	O
more	O
than	O
7	O
,	O
000	O
cases	O
have	O
been	O
observed	O
worldwide	O
,	O
predominantly	O
in	O
China	O
and	O
Hong	O
Kong	O
,	O
but	O
also	O
in	O
Taiwan	O
,	O
Canada	O
,	O
Singapore	O
,	O
and	O
the	O
USA	O
,	O
and	O
many	O
other	O
countries	O
,	O
and	O
more	O
than	O
600	O
of	O
these	O
patients	O
died	B-PROC
from	O
RDS	O
.	O

All	O
presented	O
with	O
fever	B-PROC
,	O
hepatomegaly	O
,	O
and	O
splenomegaly	O
;	O
in	O
addition	O
,	O
all	O
had	O
at	O
least	O
two	O
of	O
the	O
following	O
:	O
anemia	O
,	O
neutropenia	O
,	O
or	O
thrombocytopenia	O
.	O

A	O
total	O
of	O
seven	O
patients	O
(	O
63	O
%)	O
died	B-PROC
.	O

The	O
chest	O
roentgenogram	O
may	O
be	O
normal	O
initially	O
but	O
at	O
a	O
later	O
stage	O
progressive	O
consolidations	O
in	O
the	O
majority	O
of	O
peripheral	O
parts	O
of	O
the	O
lung	O
are	O
observed	O
,	O
which	O
cannot	O
be	O
differentiated	B-PROC
from	O
pneumonias	O
of	O
other	O
origin	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
is	O
the	O
predominant	O
inducer	O
of	O
neutralizing	O
antibodies	O
and	O
has	O
been	O
implicated	O
in	O
virulence	B-PROC
and	O
host	O
cell	O
tropism	B-PROC
.	O

Both	O
acid	O
and	O
neutral	O
sphingomyelinases	O
were	O
activated	O
within	O
4	O
h	O
.	O
These	O
signal	B-PROC
transduction	I-PROC
events	O
were	O
associated	O
with	O
alteration	O
in	O
the	O
oxygen	O
defense	O
system	O
.	O

Standardized	O
individual	O
case	O
inventory	O
was	O
adopted	O
to	O
conduct	B-PROC
investigation	O
on	O
index	O
cases	O
and	O
on	O
persons	O
who	O
had	O
close	O
contact	O
with	O
index	O
cases	O
in	O
Guangdong	O
province	O
.	O

In	O
order	O
to	O
prevent	O
iatrogenic	O
infection	O
,	O
sense	B-PROC
on	O
self	O
-	O
protection	O
among	O
health	O
care	O
workers	O
must	O
be	O
strengthened	O
.	O

The	O
classical	O
antiviral	O
approach	O
as	O
single	O
treatment	O
for	O
viral	B-PROC
diseases	I-PROC
should	O
be	O
reviewed	O
in	O
this	O
occasion	O
;	O
immunomodulatory	O
therapies	O
could	O
play	O
an	O
important	O
role	O
in	O
SARS	O
therapy	O
.	O

To	O
confirm	O
that	O
this	O
was	O
the	O
case	O
,	O
a	O
set	O
of	O
minigenomes	O
was	O
expressed	B-PROC
that	O
included	O
an	O
expression	B-PROC
cassette	O
for	O
an	O
mRNA	O
including	O
the	O
beta	O
-	O
glucuronidase	O
gene	O
(	O
GUS	O
)	O
plus	O
variable	O
sequence	O
fragments	O
from	O
the	O
5	O
'	O
end	O
of	O
the	O
virus	O
genome	O
potentially	O
including	O
Psi	O
.	O

To	O
explore	O
if	O
the	O
least	O
expressed	B-PROC
ORF	O
,	O
ORF	O
3b	O
,	O
which	O
encodes	O
a	O
nonstructural	O
protein	O
,	O
is	O
evolutionarily	O
conserved	O
and	O
functionally	O
indispensable	O
for	O
viral	O
propagation	O
in	O
cultured	O
cells	O
,	O
the	O
Beaudette	O
strain	O
of	O
IBV	O
was	O
propagated	O
in	O
chicken	O
embryonated	O
eggs	O
for	O
three	O
passages	O
and	O
then	O
adapted	O
to	O
a	O
monkey	O
kidney	O
cell	O
line	O
,	O
Vero	O
.	O

Comparison	O
of	O
the	O
complete	O
genome	O
sequences	O
(	O
27	O
.	O
6	O
kb	O
)	O
of	O
isolates	O
p20c22	O
and	O
p36c12	O
(	O
from	O
passages	O
20	O
and	O
36	O
,	O
respectively	O
)	O
revealed	O
that	O
p36c12	O
contains	O
three	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
,	O
two	O
in	O
the	O
195	O
-	O
kDa	O
protein	O
(	O
encoded	O
by	O
gene	O
1	O
)	O
and	O
one	O
in	O
the	O
S	O
protein	O
,	O
in	O
addition	O
to	O
the	O
frameshifting	O
3b	O
product	O
.	O

There	O
is	O
an	O
urgent	O
need	O
for	O
the	O
government	O
to	O
support	O
free	O
-	O
ranging	O
poultry	O
farmers	O
by	O
providing	O
subsidised	O
vaccinations	O
and	O
technical	O
support	O
in	O
order	O
to	O
develop	O
and	O
stimulate	O
economic	O
development	B-PROC
in	O
impoverished	O
rural	O
areas	O
of	O
South	O
Africa	O
.	O

(	O
2	O
)	O
The	O
majority	O
of	O
clinical	O
manifestations	O
were	O
fever	B-PROC
(	O
100	O
%	O
cases	O
),	O
and	O
there	O
were	O
no	O
obvious	O
respiratory	O
symptoms	O
in	O
more	O
than	O
half	O
of	O
the	O
patients	O
(	O
53	O
.	O
7	O
%)	O
at	O
early	O
SARS	O
stage	O
(	O
day	O
1	O
to	O
day	O
3	O
),	O
accompanied	O
by	O
leucopenia	O
(	O
52	O
.	O
6	O
%)	O
and	O
lymphopenia	O
(	O
68	O
.	O
4	O
%).	O

(	O
3	O
)	O
Timely	O
administration	O
of	O
Ribavirin	O
,	O
Methylprednisolone	O
,	O
immunoenhancer	O
(	O
such	O
as	O
interferon	O
alpha	O
-	O
2b	O
,	O
thymosin	O
-	O
alpha1	O
)	O
to	O
SARS	O
patients	O
was	O
efficacious	O
to	O
certain	O
extent	O
in	O
controlling	O
the	O
development	B-PROC
of	O
the	O
disease	O
.	O

TITLE	O
:	O
[	O
Death	B-PROC
risk	O
factors	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
].	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
recently	O
recognized	O
febrile	B-PROC
respiratory	O
illness	O
that	O
first	O
appeared	O
in	O
southern	O
China	O
in	O
November	O
2002	O
,	O
has	O
since	O
spread	O
to	O
several	O
countries	O
,	O
and	O
has	O
resulted	O
in	O
more	O
than	O
8000	O
cases	O
and	O
more	O
than	O
750	O
deaths	B-PROC
.	O

In	O
Shanxi	O
province	O
,	O
the	O
SARS	O
epidemic	O
seemed	O
to	O
have	O
had	O
the	O
following	O
stages	O
:	O
importation	O
of	O
the	O
first	O
case	O
,	O
gradual	O
increase	O
of	O
the	O
number	O
of	O
cases	O
to	O
reach	B-PROC
the	O
peak	O
and	O
decreasing	O
.	O

25	O
confirmed	O
cases	O
died	B-PROC
with	O
a	O
mortality	O
rate	O
of	O
8	O
.	O
7	O
%.	O

Only	O
3	O
of	O
16	O
(	O
19	O
%)	O
of	O
the	O
deaths	B-PROC
within	O
the	O
ALI	O
group	O
were	O
directly	O
related	O
to	O
ALI	O
.	O

No	O
correlation	O
was	O
found	O
between	O
the	O
severity	O
of	O
head	O
injury	O
(	O
GCS	O
score	O
,	O
Marshall	O
score	O
,	O
or	O
intracranial	O
abnormality	O
)	O
and	O
development	B-PROC
of	O
ALI	O
.	O

The	O
development	B-PROC
of	O
ALI	O
is	O
a	O
critical	O
independent	O
factor	O
affecting	O
mortality	O
in	O
patients	O
suffering	O
traumatic	O
brain	O
injury	O
and	O
is	O
associated	O
with	O
a	O
worse	O
long	O
-	O
term	O
neurologic	O
outcome	O
in	O
survivors	O
.	O

CONCLUSIONS	O
:	O
The	O
development	B-PROC
of	O
ALI	O
is	O
a	O
critical	O
independent	O
factor	O
affecting	O
mortality	O
in	O
patients	O
suffering	O
traumatic	O
brain	O
injury	O
and	O
is	O
associated	O
with	O
a	O
worse	O
long	O
-	O
term	O
neurologic	O
outcome	O
in	O
survivors	O
.	O

One	O
patient	O
died	B-PROC
of	O
progressive	O
respiratory	O
failure	O
;	O
pathological	O
examination	O
of	O
the	O
lung	O
showed	O
diffuse	O
alveolar	O
damage	O
.	O

ARDS	O
was	O
characterized	O
by	O
ease	O
of	O
derecruitment	O
of	O
alveoli	O
and	O
paucity	O
of	O
airway	O
secretion	B-PROC
,	O
bronchospasm	O
,	O
or	O
dynamic	O
hyperinflation	O
.	O

The	O
syndrome	O
has	O
been	O
defined	O
as	O
SARS	O
(	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
)	O
by	O
WHO	O
,	O
and	O
is	O
characterized	O
by	O
an	O
incubation	O
period	O
between	O
1	O
and	O
10	O
days	O
(	O
average	O
5	O
days	O
)	O
and	O
by	O
a	O
febrile	B-PROC
phase	O
that	O
usually	O
lasts	O
approximately	O
3	O
days	O
.	O

In	O
terms	O
of	O
traditional	O
Chinese	O
medicine	O
theory	O
,	O
SARS	O
is	O
referred	O
to	O
""""	O
infectious	O
febrile	B-PROC
disease	O
""","	O
the	O
therapeutic	O
strategies	O
of	O
integrative	O
traditional	O
Chinese	O
and	O
western	O
on	O
SARS	O
have	O
been	O
shown	O
effective	O
,	O
and	O
traditional	O
Chinese	O
medicine	O
played	O
a	O
positive	O
role	O
in	O
it	O
.	O

This	O
study	O
indicates	O
that	O
the	O
Salmonella	O
cya	O
crp	O
pgtE	O
vector	O
and	O
the	O
spiC	O
promoter	O
can	O
be	O
used	O
successfully	O
to	O
improve	O
immune	B-PROC
responses	I-PROC
toward	O
heterologous	O
antigens	O
.	O

Seven	O
patients	O
who	O
developed	O
ARDS	O
complicated	O
with	O
multiple	O
organs	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
died	B-PROC
.	O

(	O
2	O
)	O
The	O
initial	O
temperature	O
was	O
(	O
38	O
.	O
3	O
+/-	O
0	O
.	O
6	O
)	O
degrees	O
C	O
,	O
while	O
the	O
highest	O
was	O
(	O
39	O
.	O
2	O
+/-	O
0	O
.	O
6	O
)	O
degrees	O
C	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
with	O
fever	B-PROC
duration	O
of	O
(	O
9	O
.	O
0	O
+/-	O
4	O
.	O
2	O
)	O
days	O
.	O

Also	O
included	O
is	O
a	O
summation	B-PROC
of	O
the	O
clinical	O
features	O
of	O
SARS	O
.	O

RESULTS	O
:	O
(	O
1	O
)	O
SARS	O
appears	O
to	O
have	O
high	O
infectivity	O
;	O
(	O
2	O
)	O
the	O
most	O
common	O
symptom	O
is	O
fever	B-PROC
;	O
(	O
3	O
)	O
the	O
count	O
of	O
leukocyte	O
is	O
normal	O
or	O
decreased	O
;	O
(	O
4	O
)	O
most	O
patients	O
(	O
35	O
/	O
45	O
,	O
77	O
.	O
8	O
%)	O
had	O
experienced	O
a	O
24	O
-	O
hour	O
fever	B-PROC
prior	O
to	O
the	O
abnormal	O
chest	O
X	O
-	O
ray	O
changes	O
which	O
showed	O
progression	O
of	O
pulmonary	O
infiltrates	O
within	O
48	O
hours	O
in	O
71	O
.	O
1	O
%	O
(	O
32	O
/	O
45	O
)	O
of	O
the	O
patients	O
and	O
,	O
(	O
5	O
)	O
the	O
percentage	O
of	O
patients	O
who	O
developed	O
severe	O
pneumonia	O
(	O
24	O
.	O
4	O
%)	O
is	O
higher	O
than	O
those	O
who	O
developed	O
typical	O
pneumonia	O
.	O

CONCLUSIONS	O
:	O
The	O
damage	O
of	O
cellular	B-PROC
immunity	I-PROC
is	O
probably	O
an	O
important	O
mechanism	O
of	O
pathogenesis	B-PROC
of	O
SARS	O
.	O

ABSTRACT	O
:	O
Acute	O
Chest	O
Syndrome	O
(	O
ACS	O
)	O
describes	O
a	O
syndrome	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
new	O
pulmonary	O
infiltrate	O
on	O
a	O
chest	O
X	O
-	O
ray	O
,	O
fever	B-PROC
,	O
and	O
respiratory	O
symptoms	O
and	O
is	O
the	O
leading	O
cause	O
of	O
death	B-PROC
and	O
hospitalization	O
in	O
sickle	O
cell	O
disease	O
(	O
SCD	O
).	O

Lung	O
puncture	O
was	O
performed	O
immediately	O
after	O
the	O
patient	O
died	B-PROC
,	O
and	O
the	O
autopsy	O
was	O
done	O
after	O
12	O
h	O
.	O
The	O
specimens	O
from	O
lymph	O
nodes	O
,	O
spleen	O
,	O
small	O
intestine	O
,	O
colon	O
and	O
bone	O
marrow	O
were	O
studied	O
by	O
immunohistochemical	O
technique	O
.	O

TITLE	O
:	O
Recombinant	O
avian	O
infectious	O
bronchitis	O
virus	O
expressing	O
a	O
heterologous	O
spike	O
gene	O
demonstrates	O
that	O
the	O
spike	O
protein	O
is	O
a	O
determinant	O
of	O
cell	O
tropism	B-PROC
.	O

Genomic	O
DNA	O
and	O
mRNA	O
analyses	O
of	O
the	O
transformed	O
plantlets	O
confirmed	O
the	O
integration	B-PROC
of	O
the	O
foreign	O
cDNA	O
into	O
the	O
potato	O
genome	O
,	O
as	O
well	O
as	O
its	O
transcription	B-PROC
.	O

GMSA	O
and	O
competition	O
experiments	O
demonstrated	O
binding	O
to	O
both	O
HNF4	O
and	O
IE1	O
.	O
2	O
fragments	O
could	O
be	O
competed	O
with	O
the	O
cold	B-PROC
specific	O
oligonucleotides	O
but	O
not	O
with	O
the	O
same	O
amount	O
of	O
non	O
-	O
specific	O
oligos	O
nucleotides	O
.	O

The	O
factor	O
HNF4	O
binds	O
to	O
mfgl2	O
promoter	O
and	O
serves	O
as	O
an	O
essential	O
transcription	B-PROC
factor	O
for	O
mfgl2	O
/	O
fibroleukin	O
expression	B-PROC
in	O
response	O
to	O
MHV	O
-	O
3	O
N	O
protein	O
.	O

Safety	O
issues	O
involving	O
breathing	B-PROC
-	O
circuit	O
filters	O
.	O

This	O
raises	O
safety	O
concerns	O
about	O
the	O
SARS	O
virus	O
being	O
carried	O
by	O
droplets	O
that	O
exit	O
from	O
the	O
exhalation	B-PROC
limb	O
of	O
the	O
ventilator	O
.	O

Patient	O
3	O
was	O
a	O
19	O
-	O
yr	O
-	O
old	O
male	O
with	O
pretransplant	O
Hct	O
of	O
43	O
%	O
who	O
received	O
a	O
cadaveric	O
renal	O
transplant	O
after	O
23	O
.	O
5	O
-	O
h	O
cold	B-PROC
-	O
ischemia	O
;	O
3	O
.	O
5	O
L	O
normal	O
saline	O
was	O
given	O
during	O
surgery	O
.	O

Preferential	O
distribution	O
of	O
nitric	O
oxide	O
and	O
PGI	O
(	O
2	O
)	O
to	O
ventilated	O
areas	O
of	O
the	O
lung	O
causes	O
selective	O
pulmonary	O
vasodilation	B-PROC
,	O
improved	O
ventilation	O
/	O
perfusion	O
matching	O
,	O
and	O
decreased	O
hypoxemia	O
.	O

The	O
inhaled	B-PROC
aerosol	O
particles	O
had	O
a	O
mass	O
median	O
diameter	O
of	O
3	O
.	O
1	O
micro	O
m	O
.	O
Emitted	O
dose	O
was	O
67	O
+/-	O

The	O
damage	O
of	O
liver	B-PROC
function	I-PROC
in	O
the	O
severe	O
SARS	O
patients	O
may	O
have	O
close	O
relationship	O
with	O
age	O
.	O

CONCLUSIONS	O
:	O
Severe	O
damage	O
to	O
the	O
pulmonary	O
and	O
immunological	O
systems	O
is	O
responsible	O
for	O
the	O
clinical	O
features	O
of	O
SARS	O
and	O
may	O
lead	O
to	O
the	O
death	B-PROC
of	O
patients	O
.	O

The	O
level	O
of	O
serum	O
IL	O
is	O
closely	O
related	O
to	O
cell	O
immunity	B-PROC
in	O
SARS	O
patients	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
stimulate	O
the	O
development	B-PROC
of	O
drugs	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
based	O
on	O
the	O
atomic	O
coordinates	O
of	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	B-PROC
determined	O
recently	O
[	O
Science	O
13	O
(	O
May	O
)	O
(	O
2003	O
)	O
(	O
online	O
)],	O
studies	O
of	O
docking	B-PROC
KZ7088	O
(	O
a	O
derivative	O
of	O
AG7088	O
)	O
and	O
the	O
AVLQSGFR	O
octapeptide	O
to	O
the	O
enzyme	O
were	O
conducted	O
.	O

Postmortem	O
examination	O
of	O
1	O
patient	O
revealed	O
marked	O
edema	O
with	O
foci	O
of	O
hemorrhage	O
and	O
hyaline	O
membrane	O
formation	B-PROC
in	O
the	O
lungs	O
,	O
hemorrhage	O
necrosis	B-PROC
and	O
a	O
obvious	O
decline	O
of	O
cells	O
in	O
lymph	O
glands	O
.	O

Thus	O
,	O
to	O
develop	O
and	O
expression	B-PROC
protein	I-PROC
fragment	O
from	O
spike	O
protein	O
gene	O
are	O
the	O
purposes	O
of	O
this	O
experiment	O
.	O

Of	O
these	O
cases	O
,	O
36	O
cases	O
develop	O
to	O
ARDS	O
and	O
11	O
cases	O
died	B-PROC
with	O
severity	O
ARDS	O
.	O

Paired	O
t	O
-	O
test	O
using	O
statistical	O
software	O
SPSS	O
10	O
.	O
0	O
was	O
employed	O
to	O
compare	O
the	O
respiratory	O
frequency	O
and	O
pulse	B-PROC
O	O
(	O
2	O
)	O
saturation	O
(	O
SpO	O
(	O
2	O
))	O
before	O
and	O
after	O
noninvasive	O
ventilation	O
with	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
on	O
the	O
33	O
patients	O
.	O

Among	O
them	O
,	O
18	O
patients	O
who	O
presented	O
with	O
SpO	O
(	O
2	O
)	O
of	O
90	O
%	O
-	O
93	O
%	O
at	O
rest	O
under	O
O	O
(	O
2	O
)	O
inhalation	B-PROC
5	O
L	O
/	O
min	O
were	O
further	O
recorded	O
for	O
their	O
SpO	O
(	O
2	O
)	O
during	O
slight	O
physical	O
movement	B-PROC
and	O
CPAP	O
.	O

Among	O
5	O
possible	O
risk	O
factors	O
,	O
3	O
were	O
recognized	O
as	O
death	B-PROC
-	O
related	O
,	O
turning	O
out	O
to	O
be	O
thrombocytopenia	O
,	O
age	O
(>	O
50	O
yrs	O
)	O
and	O
underlying	O
diseases	O
.	O

Management	O
with	O
corticosteroids	O
effectively	O
ameliorated	O
and	O
suppressed	O
the	O
development	B-PROC
of	O
pulmonary	O
fibrosis	O
.	O

The	O
level	O
of	O
neutrophilic	B-PROC
granulocyte	O
was	O
0	O
.	O
75	O
+/-	O

Among	O
the	O
61	O
patients	O
,	O
4	O
died	B-PROC
.	O

Traditional	O
Chinese	O
medicine	O
(	O
TCM	O
)	O
regards	O
SARS	O
as	O
one	O
of	O
epidemic	O
febrile	B-PROC
diseases	O
.	O

Among	O
the	O
275	O
contacts	O
of	O
the	O
index	O
case	O
,	O
41	O
fell	O
ill	O
of	O
SARS	O
with	O
an	O
attack	O
rate	O
of	O
14	O
.	O
9	O
%	O
and	O
5	O
deaths	B-PROC
with	O
a	O
fatality	O
rate	O
of	O
12	O
.	O
2	O
%.	O

ABSTRACT	O
:	O
Orthorhombic	O
and	O
rhombohedral	O
single	O
nanocrystalline	O
KNbO3	O
with	O
different	O
morphologies	O
was	O
synthesized	O
respectively	O
at	O
a	O
relatively	O
low	O
temperature	O
by	O
simply	O
changing	O
the	O
reaction	O
solvent	O
;	O
a	O
conceivable	O
reaction	O
process	O
was	O
illustrated	O
based	O
on	O
the	O
finding	O
of	O
a	O
hexahedral	O
intermediate	O
product	O
during	O
the	O
formation	B-PROC
of	O
KNbO3	O
.	O

Those	O
of	O
nonresponsiveness	O
had	O
higher	O
dosage	O
and	O
needed	O
longer	O
time	O
to	O
reach	B-PROC
stable	O
.	O

The	O
specific	O
IgG	O
antibody	B-PROC
didn	O
'	O
t	O
emerge	O
in	O
some	O
patients	O
in	O
the	O
early	O
stage	O
of	O
the	O
disease	O
,	O
and	O
the	O
negative	O
results	O
didn	O
'	O
t	O
indicate	O
that	O
they	O
were	O
not	O
infected	O
.	O

RESULTS	O
:	O
97	O
.	O
7	O
%	O
of	O
them	O
knew	O
SARS	O
was	O
one	O
infectious	O
disease	O
,	O
73	O
.	O
0	O
%	O
of	O
them	O
knew	O
it	O
spread	O
via	O
saliva	O
,	O
94	O
.	O
4	O
%	O
of	O
them	O
knew	O
fever	B-PROC
was	O
the	O
early	O
symptom	O
,	O
86	O
.	O
8	O
%	O
of	O
them	O
thought	O
the	O
best	O
prevalent	O
method	O
was	O
opening	O
the	O
windows	O
and	O
respiring	O
fresh	O
air	O
,	O
90	O
.	O
0	O
%	O
of	O
them	O
thought	O
it	O
could	O
be	O
cured	O
.	O

In	O
addition	O
,	O
administration	O
of	O
limitin	O
to	O
mice	O
suppressed	O
MHV	O
-	O
induced	O
hepatitis	O
and	O
HSV	O
-	O
induced	O
death	B-PROC
.	O

Here	O
,	O
we	O
determined	O
the	O
sequence	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
isolate	O
Frankfurt	O
1	O
,	O
and	O
characterized	O
key	O
RNA	O
elements	O
and	O
protein	O
functions	O
involved	O
in	O
viral	B-PROC
genome	I-PROC
expression	I-PROC
.	O

(	O
1	O
)	O
Fever	B-PROC
above	O
38	O
.	O
5	O
centigrade	O
,	O
dry	O
cough	O
,	O
short	O
of	O
breath	O
,	O
headache	O
,	O
myalgia	O
,	O
diarrhea	O
in	O
SARS	O
were	O
more	O
common	O
in	O
SARS	O
patients	O
than	O
those	O
in	O
CAP	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

These	O
data	O
demonstrate	O
that	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
,	O
in	O
particular	O
L1114R	O
,	O
within	O
HR1	O
of	O
the	O
JHM	O
spike	O
reduced	O
the	O
ability	O
of	O
MHV	O
to	O
spread	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Expression	B-PROC
of	O
chemokine	O
receptors	O
on	O
activated	O
T	O
cells	O
is	O
important	O
in	O
allowing	O
these	O
cells	O
to	O
traffic	O
into	O
and	O
accumulate	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
of	O
MHV	O
-	O
infected	O
mice	O
.	O

Specimens	O
of	O
the	O
lungs	O
,	O
spleens	O
and	O
lymph	O
nodes	O
were	O
obtained	O
from	O
autopsy	O
of	O
3	O
SARS	O
cases	O
to	O
investigate	O
the	O
expression	B-PROC
of	O
the	O
immune	O
cells	O
and	O
their	O
activities	O
with	O
double	O
immunohistochemical	O
staining	O
(	O
DAB	O
and	O
AP	O
)	O
by	O
using	O
14	O
immune	O
cell	O
markers	O
and	O
their	O
active	O
antigens	O
.	O

The	O
functions	O
of	O
many	O
of	O
these	O
polypeptides	O
,	O
including	O
the	O
Nsp9	O
-	O
Nsp10	O
replicase	O
-	O
cleavage	B-PROC
products	O
,	O
are	O
still	O
unknown	O
.	O

ABSTRACT	O
:	O
Malaria	O
represents	O
a	O
medical	O
emergency	O
because	O
it	O
may	O
rapidly	O
progress	O
to	O
complications	O
and	O
death	B-PROC
without	O
prompt	O
and	O
appropriate	O
treatment	O
.	O

Clinical	O
deterioration	O
usually	O
appears	O
3	O
-	O
7	O
days	O
after	O
onset	O
of	O
fever	B-PROC
.	O

The	O
intravascular	O
volume	O
should	O
be	O
maintained	O
at	O
the	O
lowest	O
level	O
sufficient	O
for	O
adequate	O
systemic	O
perfusion	O
to	O
prevent	O
development	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

RESULTS	O
:	O
(	O
1	O
)	O
Sixty	O
-	O
three	O
of	O
70	O
cases	O
of	O
SARS	O
recovered	O
and	O
seven	O
cases	O
died	B-PROC
,	O
with	O
a	O
case	O
-	O
fatality	O
ratio	O
of	O
10	O
%.	O

We	O
also	O
demonstrate	O
that	O
scIHF2	O
is	O
stably	O
expressed	B-PROC
in	O
HeLa	O
cells	O
,	O
that	O
it	O
is	O
localized	O
primarily	O
in	O
the	O
cell	O
nucleus	O
and	O
that	O
it	O
triggers	O
integrative	O
recombination	B-PROC
in	O
mammalian	O
cells	O
by	O
wild	O
-	O
type	O
integrase	O
.	O

It	O
has	O
been	O
presented	O
without	O
significative	O
differences	O
all	O
the	O
clinics	O
signs	O
and	O
laboratory	O
examinations	O
;	O
the	O
breeding	B-PROC
signs	O
for	O
the	O
younger	O
2	O
years	O
group	O
compared	O
with	O
the	O
2	O
years	O
older	O
;	O
the	O
age	O
correlation	O
(<	O
and	O
>	O
2	O
years	O
)	O
and	O
season	O
(	O
winter	O
-	O
summer	O
)	O
with	O
the	O
16	O
%	O
for	O
the	O
first	O
in	O
VIGE	O
(	O
62	O
.	O
5	O
%	O
rotavirus	O
);	O
the	O
absence	O
of	O
health	O
systems	O
at	O
the	O
NOVIGE	O
(	O
70	O
%)	O
and	O
with	O
both	O
(	O
29	O
%);	O
and	O
others	O
epidemiology	O
considerations	O
of	O
the	O
sequence	O
.	O

ABSTRACT	O
:	O
Porcine	O
organs	O
,	O
cells	O
and	O
tissues	O
provide	O
a	O
viable	O
source	O
of	O
transplants	O
in	O
humans	O
,	O
though	O
there	O
is	O
some	O
concern	O
of	O
public	O
health	O
risk	O
from	O
adaptation	B-PROC
of	O
swine	O
infectious	O
agents	O
in	O
humans	O
.	O

In	O
this	O
review	O
we	O
present	O
information	O
on	O
selected	O
exogenous	O
viruses	O
,	O
highlighting	O
their	O
characteristics	O
,	O
pathogenesis	B-PROC
of	O
viral	B-PROC
infections	I-PROC
in	O
swine	O
,	O
methods	O
for	O
their	O
detection	O
,	O
and	O
the	O
potential	O
xenozoonoses	O
risk	O
they	O
present	O
.	O

Patients	O
with	O
SARS	O
may	O
have	O
digestive	B-PROC
system	O
manifestations	O
;	O
diarrhea	O
is	O
the	O
most	O
common	O
symptom	O
.	O

TITLE	O
:	O
Sudden	O
death	B-PROC
of	O
an	O
infant	O
with	O
bronchopulmonary	O
dysplasia	O
and	O
bilateral	O
cervical	O
lymphadenopathy	O
--	O
a	O
vagal	O
death	B-PROC
?	O

The	O
cause	O
of	O
death	B-PROC
was	O
established	O
as	O
being	O
acute	O
cardiac	O
and	O
pulmonary	O
failure	O
due	O
to	O
severe	O
BPD	O
,	O
rather	O
than	O
mechanical	O
asphyxia	O
.	O

For	O
this	O
reason	O
,	O
anatomical	O
examination	O
of	O
the	O
cervical	O
portion	O
of	O
the	O
vagus	O
and	O
its	O
path	O
may	O
be	O
of	O
great	O
significance	O
when	O
analyzing	O
the	O
cause	O
of	O
death	B-PROC
in	O
the	O
cases	O
of	O
sudden	O
infant	O
death	B-PROC
.	O

Oxygen	O
therapy	O
and	O
PEEP	O
,	O
though	O
dramatically	O
improve	O
lung	O
mechanics	O
and	O
oxygenation	B-PROC
,	O
are	O
not	O
innocuous	O
and	O
may	O
adversely	O
affect	O
cardiovascular	B-PROC
function	I-PROC
and	O
even	O
induce	O
pulmonary	O
parenchymal	O
injury	O
.	O

These	O
were	O
associated	O
with	O
a	O
improvement	O
of	O
the	O
patients	O
'	O
clinical	O
conditions	O
including	O
hepatic	O
encephalopathy	O
,	O
deranged	O
hemodynamic	B-PROC
situation	O
,	O
as	O
well	O
as	O
renal	O
and	O
respiratory	B-PROC
function	I-PROC
,	O
thus	O
resulted	O
into	O
marked	O
decrease	O
of	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
score	O
(	O
from	O
9	O
.	O
72	O
+-	O
1	O
.	O
89	O
to	O
6	O
.	O
98	O
+-	O
2	O
.	O
34	O
),	O
and	O
improving	O
outcome	O
:	O
9	O
patients	O
were	O
able	O
to	O
be	O
discharged	O
from	O
the	O
hospital	O
or	O
bridged	O
to	O
successful	O
liver	O
transplantation	O
.	O

All	O
the	O
results	O
suggest	O
strongly	O
that	O
there	O
may	O
be	O
a	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
SIRS	O
)	O
in	O
most	O
SARS	O
patients	O
in	O
early	O
stage	O
,	O
and	O
the	O
liver	O
damage	O
is	O
only	O
its	O
partial	O
signs	O
.	O

In	O
addition	O
to	O
replicating	O
the	O
genomic	O
RNA	O
,	O
a	O
key	O
feature	O
of	O
this	O
complex	O
is	O
a	O
unique	O
transcription	B-PROC
process	I-PROC
that	O
results	O
in	O
the	O
synthesis	B-PROC
of	O
a	O
nested	O
set	O
of	O
six	O
to	O
eight	O
subgenomic	O
mRNAs	O
.	O

The	O
transfection	B-PROC
of	O
vector	O
RNA	O
and	O
human	O
coronavirus	O
nucleocapsid	O
protein	O
mRNA	O
into	O
BHK	O
-	O
21	O
cells	O
resulted	O
in	O
the	O
expression	B-PROC
of	O
the	O
CAT	O
,	O
LUC	O
,	O
and	O
GFP	O
reporter	O
proteins	O
.	O

In	O
summary	O
,	O
we	O
describe	O
a	O
new	O
class	O
of	O
eukaryotic	O
,	O
multigene	O
expression	B-PROC
vectors	O
that	O
are	O
based	O
on	O
the	O
human	O
coronavirus	O
229E	O
and	O
have	O
the	O
ability	O
to	O
transduce	O
human	O
dendritic	O
cells	O
.	O

The	O
model	O
was	O
defined	O
by	O
investigating	O
,	O
during	O
the	O
natural	O
history	O
of	O
ARDS	O
,	O
the	O
relationship	O
among	O
the	O
three	O
fundamental	O
elements	O
of	O
a	O
disease	O
process	O
pathogenesis	B-PROC
,	O
structural	O
alterations	O
,	O
and	O
functional	O
consequences	O
.	O

TITLE	O
:	O
High	O
-	O
dose	O
pulse	B-PROC
versus	O
nonpulse	O
corticosteroid	O
regimens	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Most	O
impressively	O
,	O
when	O
combined	O
with	O
subthreshold	O
zardaverine	O
,	O
iloprost	O
suppressed	O
oedema	O
formation	B-PROC
to	O
<	O
15	O
%	O
and	O
shunt	O
flow	O
to	O
approximately	O
8	O
%.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
some	O
immunological	O
patterns	O
involved	O
in	O
natural	O
and	O
acquired	O
resistance	B-PROC
against	O
MHV3	O
using	O
the	O
original	O
model	O
of	O
genetically	O
modified	O
lines	O
of	O
mice	O
selected	O
for	O
high	O
(	O
HIII	O
)	O
and	O
low	O
(	O
LIII	O
)	O
antibody	B-PROC
responsiveness	O
.	O

The	O
transfer	O
of	O
anti	O
-	O
MHV	O
antibodies	O
to	O
susceptible	O
HIII	O
mice	O
was	O
capable	O
of	O
conferring	O
resistance	B-PROC
to	O
MHV3	O
,	O
providing	O
the	O
antibodies	O
were	O
present	O
before	O
virus	B-PROC
infection	I-PROC
and	O
in	O
large	O
amounts	O
.	O

ABSTRACT	O
:	O
Reductive	O
metabolism	B-PROC
of	O
carbon	O
tetrachloride	O
(	O
CCl	O
(	O
4	O
))	O
is	O
thought	O
to	O
cause	O
lipid	B-PROC
peroxidation	I-PROC
which	O
results	O
in	O
hepatic	O
injury	O
.	O

Heme	O
oxygenase	B-PROC
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
(	O
EC	O
1	O
.	O
14	O
.	O
99	O
.	O
3	O
),	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
heme	B-PROC
catabolism	B-PROC
,	O
is	O
known	O
to	O
be	O
induced	O
by	O
oxidative	O
stress	O
and	O
to	O
confer	O
protection	O
against	O
oxidative	O
tissue	O
injuries	O
.	O

CCl	O
(	O
4	O
)	O
treatment	O
(	O
1	O
mL	O
/	O
kg	O
,	O
intraperitoneally	O
)	O
produced	O
severe	O
hepatic	O
injury	O
in	O
rats	O
as	O
revealed	O
by	O
significant	O
increases	O
in	O
serum	O
alanine	O
transaminase	O
(	O
ALT	O
)	O
(	O
EC	O
2	O
.	O
6	O
.	O
1	O
.	O
2	O
)	O
activity	O
and	O
hepatic	O
malondialdehyde	O
(	O
MDA	O
)	O
content	O
,	O
severe	O
liver	O
cell	O
injury	O
,	O
and	O
increases	O
in	O
hepatic	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
mRNA	B-PROC
expression	B-PROC
and	O
DNA	O
binding	B-PROC
activity	I-PROC
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
).	O

In	O
an	O
effort	B-PROC
to	O
establish	O
a	O
screening	O
program	O
for	O
high	O
risk	O
personal	O
,	O
the	O
distribution	O
of	O
HLA	O
class	O
I	O
and	O
II	O
alleles	O
in	O
case	O
and	O
control	O
groups	O
was	O
examined	O
for	O
the	O
presence	O
of	O
an	O
association	O
to	O
a	O
genetic	O
susceptibly	O
or	O
resistance	B-PROC
to	O
SARS	O
coronavirus	O
infection	O
.	O

Serum	O
was	O
analyzed	O
for	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
procalcitonin	O
.	O
and	O
measurements	O
:	O
EBC	O
NO	O
(	O
2	O
)(-)	O
correlated	O
well	O
with	O
VT	O
(	O
milliliters	O
per	O
kilogram	O
of	O
BW	O
;	O
r	O
=	O
0	O
.	O
79	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
expiratory	B-PROC
minute	O
volume	O
(	O
r	O
=	O
0	O
.	O
60	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
but	O
not	O
with	O
other	O
ventilatory	O
parameters	O
or	O
parameters	O
of	O
pulmonary	O
(	O
EBC	O
IL	O
-	O
6	O
,	O
EBC	O
IL	O
-	O
8	O
)	O
or	O
systemic	O
(	O
serum	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
procalcitonin	O
)	O
inflammation	O
.	O

TITLE	O
:	O
Enhanced	O
virulence	B-PROC
mediated	O
by	O
the	O
murine	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
strain	O
JHM	O
,	O
is	O
associated	O
with	O
a	O
glycine	O
at	O
residue	O
310	O
of	O
the	O
spike	O
glycoprotein	O
.	O

By	O
immunofluorescence	O
confocal	O
microscopy	O
,	O
Pol	O
colocalized	O
with	O
viral	O
proteins	O
at	O
replication	O
complexes	O
,	O
distinct	O
from	O
sites	O
of	O
virion	B-PROC
assembly	I-PROC
,	O
over	O
the	O
entire	O
course	O
of	O
infection	O
.	O

ABSTRACT	O
:	O
Heterogeneous	O
nuclear	O
ribonucleoprotein	O
(	O
hnRNP	O
)	O
A1	O
has	O
previously	O
been	O
shown	O
to	O
bind	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
RNA	O
at	O
the	O
3	O
'	O
end	O
of	O
both	O
plus	O
and	O
minus	O
strands	O
and	O
modulate	O
MHV	O
RNA	B-PROC
synthesis	I-PROC
.	O

TITLE	O
:	O
Canadian	O
clinical	O
practice	O
guidelines	O
for	O
nutrition	B-PROC
support	O
in	O
mechanically	O
ventilated	O
,	O
critically	O
ill	O
adult	O
patients	O
.	O

This	O
guideline	O
was	O
peer	O
-	O
reviewed	O
and	O
endorsed	O
by	O
official	O
representatives	O
of	O
the	O
Canadian	O
Critical	O
Care	O
Society	O
,	O
Canadian	O
Critical	O
Care	O
Trials	O
Group	O
,	O
Dietitians	O
of	O
Canada	O
,	O
Canadian	O
Association	O
of	O
Critical	O
Care	O
Nurses	O
,	O
and	O
the	O
Canadian	O
Society	O
for	O
Clinical	O
Nutrition	B-PROC
.	O

This	O
guideline	O
is	O
a	O
joint	O
venture	O
of	O
the	O
Canadian	O
Critical	O
Care	O
Society	O
,	O
the	O
Canadian	O
Critical	O
Trials	O
Group	O
,	O
the	O
Canadian	O
Society	O
for	O
Clinical	O
Nutrition	B-PROC
,	O
and	O
Dietitians	O
of	O
Canada	O
.	O

The	O
Canadian	O
Critical	O
Care	O
Society	O
and	O
the	O
Institute	O
of	O
Nutrition	B-PROC
,	O
Metabolism	B-PROC
,	O
and	O
Diabetes	O
of	O
the	O
Canadian	O
Institutes	O
of	O
Health	O
Research	O
provided	O
funding	O
for	O
development	B-PROC
of	O
this	O
guideline	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
influence	O
of	O
the	O
acute	O
blood	B-PROC
gas	I-PROC
analysis	O
index	O
change	O
on	O
the	O
prognosis	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

RESULTS	O
:	O
Seven	O
cases	O
of	O
SARS	O
death	B-PROC
patients	O
were	O
all	O
infected	O
secondly	O
and	O
5	O
cases	O
were	O
polyinfection	O
.	O

The	O
retrospective	O
analyses	O
were	O
made	O
on	O
12	O
dead	B-PROC
cases	O
and	O
32	O
recovered	O
cases	O
with	O
SARS	O
.	O

There	O
were	O
1	O
-	O
5	O
other	O
basic	O
diseases	O
in	O
5	O
cases	O
of	O
death	B-PROC
group	O
.	O

Five	O
cases	O
were	O
infected	O
with	O
bacteria	O
in	O
12	O
dead	B-PROC
cases	O
,	O
among	O
them	O
3	O
were	O
infected	O
with	O
fungus	O
and	O
2	O
were	O
septicemia	O
.	O

Other	O
risk	O
factors	O
include	O
the	O
decline	O
of	O
immune	B-PROC
function	I-PROC
,	O
secondary	O
infection	O
,	O
complications	O
and	O
use	O
of	O
invasive	O
ventilation	O
.	O

The	O
first	O
imported	O
SARS	O
case	O
introduced	O
to	O
Beijing	O
had	O
infected	O
9	O
people	O
within	O
the	O
family	O
and	O
at	O
the	O
hospital	O
,	O
with	O
two	O
of	O
whom	O
died	B-PROC
of	O
the	O
same	O
disease	O
.	O

Among	O
them	O
,	O
14	O
died	B-PROC
with	O
a	O
fatality	O
of	O
8	O
.	O
0	O
%.	O

The	O
brains	O
were	O
evaluated	O
for	O
gene	B-PROC
expression	I-PROC
using	O
in	O
situ	O
hybridization	B-PROC
and	O
enzyme	O
histochemistry	O
10	O
weeks	O
after	O
surgery	O
.	O

The	O
clinical	O
symptoms	O
in	O
patients	O
of	O
recovery	O
stage	O
were	O
atypical	O
,	O
they	O
occasionally	O
manifested	O
as	O
limb	O
weakness	O
or	O
heaviness	O
in	O
17	O
,	O
chest	O
stuffiness	O
or	O
pain	O
in	O
13	O
,	O
low	O
fever	B-PROC
in	O
11	O
,	O
cough	O
in	O
12	O
and	O
expectoration	O
in	O
11	O
.	O

TITLE	O
:	O
How	O
the	O
SARS	O
vaccine	O
effort	B-PROC
can	O
learn	B-PROC
from	O
HIV	O
-	O
speeding	O
towards	O
the	O
future	O
,	O
learning	B-PROC
from	O
the	O
past	O
.	O

Multinucleated	O
cells	O
were	O
shown	O
to	O
be	O
both	O
type	O
II	O
pneumocytes	O
and	O
macrophages	O
by	O
pancytokeratin	O
,	O
thyroid	O
transcription	B-PROC
factor	O
-	O
1	O
,	O
and	O
CD68	O
staining	O
.	O

ABSTRACT	O
:	O
Fas	O
ligand	B-PROC
(	O
FasL	O
)-	O
induced	O
lung	O
inflammation	O
has	O
recently	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
acute	O
respiratory	O
disease	O
syndrome	O
(	O
ARDS	O
).	O

Pretreatment	O
with	O
a	O
FasL	O
antagonist	B-PROC
,	O
a	O
decoy	O
receptor	O
3	O
analogue	O
(	O
DcR3	O
analogue	O
),	O
reduced	O
neutrophil	O
infiltration	O
into	O
the	O
airspace	O
and	O
resulted	O
in	O
a	O
highly	O
significant	O
reduction	O
in	O
the	O
levels	O
of	O
GM	O
-	O
CSF	O
,	O
MIP	O
-	O
2	O
and	O
KC	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
.	O

Plasma	O
levels	O
of	O
interleukin	O
(	O
IL	O
)-	O
1	O
beta	O
,	O
IL	O
-	O
2	O
,	O
IL	O
-	O
4	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
12	O
p70	O
,	O
interferon	O
gamma	O
(	O
IFN	O
gamma	O
),	O
and	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
were	O
determined	O
by	O
quantitative	O
ELISA	O
during	O
the	O
course	O
of	O
disease	O
respectively	O
.	O

Epidemiologic	O
findings	O
,	O
integral	O
to	O
defining	O
an	O
animal	O
-	O
human	O
linkage	B-PROC
,	O
may	O
be	O
confirmed	O
by	O
laboratory	O
studies	O
;	O
once	O
animal	O
host	O
(	O
s	O
)	O
are	O
confirmed	O
,	O
interventions	O
may	O
be	O
needed	O
to	O
prevent	O
further	O
animal	O
-	O
to	O
-	O
human	O
transmission	O
.	O

The	O
incidence	O
of	O
nasal	O
discharge	O
at	O
3	O
and	O
5	O
days	O
after	O
IB	O
virus	B-PROC
infection	I-PROC
was	O
used	O
to	O
assess	O
the	O
clinical	O
effect	O
of	O
the	O
IB	O
infection	O
,	O
while	O
mortality	O
,	O
body	O
weight	O
uniformity	O
and	O
E	O
.	O
coli	O
lesions	O
at	O
7	O
days	O
following	O
E	O
.	O
coli	O
inoculation	O
were	O
used	O
as	O
parameters	O
for	O
colibacillosis	O
.	O

One	O
preterm	O
infant	O
developed	O
jejunal	O
perforation	O
and	O
another	O
developed	O
necrotizing	O
enterocolitis	O
with	O
ileal	O
perforation	O
shortly	O
after	O
birth	B-PROC
.	O

We	O
cloned	O
some	O
expressed	B-PROC
sequence	O
tags	O
and	O
identified	O
one	O
complementary	O
DNA	O
fragment	O
.	O

ABSTRACT	O
:	O
The	O
reverse	B-PROC
transcription	B-PROC
(	O
RT	O
)-	O
PCR	O
protocols	O
of	O
two	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
network	O
laboratories	O
(	O
WHO	O
SARS	O
network	O
laboratories	O
at	O
The	O
University	O
of	O
Hong	O
Kong	O
[	O
WHO	O
-	O
HKU	O
]	O
and	O
at	O
the	O
Bernhard	O
-	O
Nocht	O
Institute	O
in	O
Hamburg	O
,	O
Germany	O
[	O
WHO	O
-	O
Hamburg	O
])	O
were	O
evaluated	O
for	O
rapid	O
diagnosis	O
of	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
)	O
associated	O
with	O
SARS	O
in	O
Hong	O
Kong	O
.	O

This	O
54	O
year	O
-	O
old	O
man	O
was	O
infected	O
during	O
the	O
Air	O
France	O
flight	B-PROC
from	O
Hanoi	O
to	O
Paris	O
via	O
Bangkok	O
by	O
the	O
index	O
case	O
,	O
who	O
himself	O
had	O
been	O
contaminated	O
at	O
the	O
French	O
hospital	O
in	O
Hanoi	O
and	O
who	O
was	O
hospitalized	O
in	O
a	O
critical	O
state	O
in	O
the	O
Tourcoing	O
hospital	O
shortly	O
after	O
his	O
arrival	O
in	O
France	O
.	O

ABSTRACT	O
:	O
To	O
proceed	O
the	O
retrospective	O
analysis	O
of	O
the	O
dead	B-PROC
reasons	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
in	O
order	O
to	O
provide	O
experience	O
for	O
decreasing	O
mortality	O
of	O
SARS	O
patients	O
in	O
clinic	O
.	O

CONCLUSIONS	O
:	O
Age	O
and	O
basic	O
diseases	O
are	O
sensitive	O
indexes	O
for	O
predicting	O
dead	B-PROC
tendency	O
of	O
SARS	O
.	O

Twenty	O
-	O
five	O
SARS	O
patients	O
with	O
respiratory	O
dysfunction	O
treated	O
with	O
NIPPV	O
were	O
studied	O
retrospectively	O
in	O
order	O
to	O
evaluate	O
the	O
influences	O
within	O
24	O
hours	O
after	O
initiation	O
of	O
ventilatory	O
support	O
on	O
their	O
physiological	O
indices	O
and	O
oxygenation	B-PROC
.	O

Renilla	O
and	O
firefly	O
luciferase	O
expression	B-PROC
cassettes	O
,	O
each	O
provided	O
with	O
viral	B-PROC
transcription	B-PROC
regulatory	O
sequences	O
(	O
TRSs	O
),	O
were	O
inserted	O
at	O
several	O
genomic	O
positions	O
,	O
both	O
independently	O
in	O
different	O
viruses	O
and	O
combined	O
within	O
one	O
viral	O
genome	O
.	O

In	O
all	O
cases	O
high	O
expression	B-PROC
levels	O
of	O
the	O
foreign	O
genes	O
were	O
observed	O
without	O
severe	O
effects	O
on	O
viral	B-PROC
replication	I-PROC
in	O
vitro	O
.	O

Expression	B-PROC
levels	O
increased	O
when	O
the	O
luciferase	O
gene	O
was	O
inserted	O
closer	O
to	O
the	O
3	O
'	O
end	O
of	O
the	O
genome	O
.	O

This	O
study	O
provides	O
a	O
basic	O
understanding	O
of	O
the	O
enzyme	O
catalysis	O
and	O
a	O
full	O
substrate	O
specificity	O
spectrum	O
for	O
SARS	O
3C	O
-	O
like	O
proteinase	B-PROC
,	O
which	O
are	O
helpful	O
for	O
structural	O
-	O
based	O
inhibitor	O
design	O
against	O
SARS	O
and	O
other	O
coronavirus	O
.	O

This	O
report	O
summarizes	O
results	O
of	O
an	O
investigation	O
conducted	O
by	O
public	O
health	O
authorities	O
in	O
Guangdong	O
Province	O
,	O
which	O
compared	O
the	O
seroprevalence	O
of	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-PROC
in	O
animal	O
traders	O
(	O
i	O
.	O
e	O
.,	O
workers	O
in	O
live	O
animal	O
markets	O
)	O
with	O
that	O
of	O
persons	O
in	O
control	O
groups	O
.	O

Establishment	O
of	O
a	O
carrier	O
state	O
in	O
IBV	O
infection	O
and	O
the	O
potential	O
for	O
the	O
persistent	O
virus	O
to	O
undergo	O
mutations	O
and	O
recombination	B-PROC
in	O
chicken	O
tissues	O
have	O
important	O
consequences	O
for	O
disease	O
management	O
.	O

In	O
the	O
second	O
experiment	O
,	O
IBV	O
exposure	O
of	O
1	O
-	O
day	O
-	O
old	O
maternal	O
antibody	B-PROC
-	O
positive	O
chicks	O
led	O
to	O
periodic	O
virus	O
shedding	O
from	O
the	O
trachea	O
and	O
cloaca	O
in	O
all	O
chickens	O
until	O
77	O
days	O
;	O
however	O
,	O
internal	O
organs	O
(	O
lungs	O
and	O
kidneys	O
)	O
of	O
only	O
one	O
of	O
seven	O
birds	O
(	O
killed	O
at	O
175	O
DPI	O
)	O
were	O
virus	O
positive	O
,	O
suggesting	O
that	O
presence	O
of	O
antibody	B-PROC
at	O
the	O
time	O
of	O
infection	O
protects	O
internal	O
organs	O
from	O
IBV	O
infection	O
.	O

When	O
the	O
lung	O
and	O
kidney	O
isolates	O
of	O
IBV	O
from	O
the	O
latter	O
experiment	O
were	O
compared	O
with	O
the	O
parent	O
-	O
vaccine	O
virus	O
,	O
no	O
changes	O
in	O
their	O
antigenicity	O
,	O
tissue	B-PROC
tropism	B-PROC
,	O
or	O
the	O
nucleotide	O
sequence	O
of	O
the	O
S1	O
glycoprotein	O
gene	O
were	O
observed	O
.	O

Because	O
of	O
sequence	O
differences	O
in	O
the	O
annealing	O
position	O
of	O
the	O
detection	O
probe	O
,	O
the	O
Arkansas	O
,	O
Connecticut	O
,	O
Beaudette	O
,	O
and	O
Massachusetts	O
41	O
strains	O
could	O
be	O
differentiated	B-PROC
.	O

TITLE	O
:	O
Characterization	O
of	O
infectious	O
bronchitis	O
virus	O
isolates	O
by	O
slot	O
blot	O
hybridization	B-PROC
.	O

ABSTRACT	O
:	O
We	O
used	O
slot	O
blot	O
hybridization	B-PROC
of	O
the	O
hypervariable	O
regions	O
of	O
the	O
S1	O
subunit	O
of	O
spike	O
peplomer	O
gene	O
to	O
identify	O
and	O
characterize	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strains	O
.	O

This	O
slot	O
blot	O
hybridization	B-PROC
procedure	O
was	O
specific	O
and	O
reproducible	O
,	O
and	O
strain	O
typing	O
was	O
consistent	O
with	O
the	O
S1	O
sequencing	O
of	O
the	O
IBV	O
genome	O
.	O

METHODS	O
:	O
We	O
abstracted	O
data	O
from	O
the	O
medical	O
and	O
nursing	B-PROC
records	O
on	O
the	O
clinical	O
features	O
,	O
treatment	O
and	O
nursing	B-PROC
care	O
of	O
36	O
patients	O
(	O
21	O
women	O
,	O
15	O
men	O
)	O
in	O
whom	O
SARS	O
was	O
diagnosed	O
and	O
who	O
were	O
admitted	O
to	O
the	O
Queen	O
Mary	O
Hospital	O
in	O
Hong	O
Kong	O
between	O
March	O
15	O
and	O
April	O
15	O
,	O
2003	O
.	O

Also	O
,	O
the	O
worry	O
and	O
fear	O
of	O
an	O
outbreak	O
of	O
SARS	O
among	O
staff	O
working	O
in	O
the	O
nursing	B-PROC
home	O
was	O
considered	O
to	O
be	O
high	O
.	O

The	O
life	O
signs	O
,	O
pulmonary	B-PROC
ventilation	I-PROC
parameters	O
,	O
arterial	O
blood	B-PROC
gas	I-PROC
analysis	O
were	O
monitored	O
and	O
blood	O
levels	O
of	O
TXB2	O
,	O
6	O
-	O
keto	O
-	O
PGF1	O
alpha	O
in	O
both	O
groups	O
were	O
determined	O
in	O
the	O
fixed	O
time	O
points	O
.	O

In	O
this	O
paper	O
,	O
the	O
system	O
is	O
further	O
improved	O
by	O
taking	O
the	O
prediction	O
of	O
cleavage	B-PROC
sites	O
of	O
viral	O
proteinases	O
in	O
polyproteins	O
into	O
account	O
.	O

TITLE	O
:	O
A	O
simple	O
approximate	O
mathematical	O
model	O
to	O
predict	O
the	O
number	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
cases	O
and	O
deaths	B-PROC
.	O

ABSTRACT	O
:	O
To	O
discuss	O
the	O
false	O
-	O
positive	O
of	O
serological	O
diagnostic	O
testing	O
for	O
coronavirus	O
antibody	B-PROC
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
),	O
66	O
normal	O
individual	O
and	O
31	O
SLE	O
with	O
non	O
-	O
SARS	O
patients	O
were	O
detected	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
antibody	B-PROC
and	O
RNA	O
by	O
enzymelinked	O
immunosorbent	O
assays	O
(	O
ELISA	O
)	O
and	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

All	O
samples	O
of	O
positive	O
SARS	O
-	O
CoV	O
-	O
IgG	O
and	O
IgM	O
antibody	B-PROC
were	O
negative	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
development	B-PROC
of	O
IgG	O
and	O
IgM	O
against	O
SARS	O
CoV	O
and	O
characteristics	O
of	O
changes	O
of	O
antibody	B-PROC
titers	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
to	O
search	O
the	O
opportunity	O
for	O
collecting	O
specific	O
anti	O
-	O
serum	O
from	O
convalescent	O
patients	O
with	O
SARS	O
.	O

In	O
animal	O
and	O
isolated	O
lung	O
studies	O
,	O
endotoxin	O
produces	O
acute	O
lung	O
injury	O
that	O
is	O
associated	O
with	O
increases	O
in	O
cytokines	O
and	O
inducible	O
NOS	O
mRNA	B-PROC
expression	B-PROC
,	O
suggesting	O
that	O
NO	O
is	O
toxic	O
to	O
the	O
lung	O
in	O
endotoxin	O
shock	O
.	O

Supportive	O
care	O
and	O
vigorous	O
management	O
of	O
hyperthermia	B-PROC
should	O
produce	O
a	O
satisfactory	O
outcome	O
.	O

However	O
,	O
whether	O
MHV	O
can	O
directly	O
induce	O
oligodendrocyte	B-PROC
apoptosis	I-PROC
has	O
not	O
been	O
documented	O
.	O

Despite	O
worsening	O
the	O
anemia	O
in	O
renal	O
failure	O
patients	O
by	O
causing	O
hemolysis	B-PROC
,	O
ribavirin	O
is	O
well	O
tolerated	O
after	O
dosage	O
adjustment	O
.	O

All	O
were	O
having	O
positive	O
results	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
ribonucleic	O
acid	O
by	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
performed	O
on	O
their	O
nasopharyngeal	O
aspirates	O
or	O
stool	O
samples	O
.	O

A	O
total	O
of	O
7	O
patients	O
(	O
15	O
%)	O
required	O
mechanical	O
ventilation	O
,	O
and	O
8	O
(	O
17	O
%)	O
died	B-PROC
.	O

Infantile	O
beri	O
-	O
beri	O
was	O
recognized	O
as	O
the	O
main	O
cause	O
of	O
death	B-PROC
accounting	O
for	O
40	O
%	O
of	O
all	O
infant	O
mortality	O
.	O

BAL	O
fluid	O
obtained	O
from	O
RDS	O
but	O
not	O
CLD	O
patients	O
was	O
proapoptotic	O
to	O
neutrophils	O
(	O
apoptosis	B-PROC
ratio	O
BAL	O
fluid	O
/	O
saline	O
control	O
:	O
day	O
1	O
,	O
RDS	O
9	O
.	O
8	O
(	O
5	O
.	O
5	O
)	O
v	O
CLD	O
1	O
.	O
2	O
(	O
0	O
.	O
1	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
);	O
day	O
2	O
,	O
RDS	O
4	O
.	O
32	O
(	O
2	O
.	O
8	O
)	O
v	O
CLD	O
0	O
.	O
5	O
(	O
0	O
.	O
4	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)).	O

Times	O
between	O
symptoms	O
and	O
treatment	O
and	O
time	O
to	O
reach	B-PROC
maximal	O
radiographic	O
score	O
from	O
admission	O
and	O
treatment	O
day	O
were	O
determined	O
.	O

RESULTS	O
:	O
Larger	O
maximal	O
radiographic	O
scores	O
,	O
lower	O
Sao2	B-PROC
at	O
maximal	O
radiographic	O
change	O
,	O
longer	O
time	O
from	O
treatment	O
to	O
maximal	O
radiographic	O
score	O
(	O
P	O
<.	O
01	O
),	O
and	O
diffuse	O
consolidation	O
at	O
maximal	O
radiographic	O
score	O
were	O
associated	O
with	O
oxygen	O
supplementation	O
.	O

Young	O
patients	O
start	O
with	O
fever	B-PROC
,	O
chills	O
,	O
malaise	O
,	O
headache	O
,	O
or	O
myalgia	O
;	O
cough	O
and	O
dyspnoea	O
follow	O
.	O

Of	O
4060	O
patients	O
with	O
fever	B-PROC
275	O
cases	O
were	O
admitted	O
to	O
the	O
isolated	O
ward	O
,	O
145	O
cases	O
were	O
diagnosed	O
as	O
SARS	O
(	O
3	O
.	O
75	O
percent	O
),	O
29	O
belonged	O
to	O
suspected	O
cases	O
,	O
and	O
in	O
101	O
cases	O
SARS	O
was	O
ruled	O
out	O
.	O

Ninety	O
-	O
three	O
cases	O
were	O
non	O
-	O
SARS	O
-	O
pneumonia	O
,	O
2	O
were	O
epidemic	O
encephalitis	O
,	O
8	O
were	O
epidemic	O
cerebrospinal	O
meningitis	O
,	O
and	O
3	O
cases	O
were	O
epidemic	O
hemorrhagic	O
fever	B-PROC
.	O

ABSTRACT	O
:	O
The	O
specificities	O
and	O
sensitivities	O
of	O
five	O
recombinant	O
proteins	O
of	O
the	O
surface	O
protective	O
antigen	O
(	O
SpaA	O
)	O
of	O
Erysipelothrix	O
rhusiopathiae	O
were	O
examined	O
by	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
the	O
aim	O
of	O
developing	O
a	O
reliable	O
serological	O
test	O
for	O
the	O
detection	O
of	O
protective	O
antibody	B-PROC
against	O
E	O
.	O
rhusiopathiae	O
.	O

One	O
patient	O
died	B-PROC
and	O
histology	O
in	O
this	O
patient	O
showed	O
severe	O
interstitial	O
pulmonary	O
fibrosis	O
.	O

According	O
to	O
the	O
time	O
of	O
the	O
occurrence	O
of	O
complications	O
,	O
we	O
divide	O
the	O
courses	O
of	O
the	O
disease	O
into	O
three	O
stages	O
:	O
early	O
phase	O
(	O
first	O
4	O
days	O
)	O
with	O
ARDS	O
,	O
kidney	O
failure	O
,	O
shock	O
,	O
encephalopathy	O
and	O
hemorrhage	O
of	O
the	O
digestive	B-PROC
tract	O
;	O
middle	O
phase	O
(	O
5	O
-	O
15	O
days	O
)	O
with	O
bacterial	O
infection	O
and	O
fungous	O
infection	O
;	O
late	O
phase	O
(	O
15	O
days	O
after	O
the	O
onset	O
)	O
with	O
abscess	O
.	O

ARDS	O
,	O
kidney	O
failure	O
,	O
and	O
shock	O
occurred	O
within	O
4	O
days	O
,	O
encephalopathy	O
within	O
6	O
days	O
(	O
average	O
4	O
.	O
8	O
+/-	O
0	O
.	O
9	O
days	O
),	O
abscesses	O
after	O
14	O
days	O
,	O
systemic	O
bacterial	O
infection	O
and	O
fungous	O
infection	O
within	O
half	O
a	O
month	O
(	O
average	O
14	O
.	O
6	O
+/-	O
1	O
.	O
1	O
days	O
,	O
14	O
.	O
8	O
+/-	O
0	O
.	O
9	O
days	O
respectively	O
),	O
and	O
death	B-PROC
within	O
6	O
days	O
.	O

Inflammatory	O
chemokines	O
play	O
both	O
beneficial	O
and	O
harmful	O
roles	O
in	O
infectious	O
diseases	B-PROC
caused	I-PROC
by	I-PROC
viruses	I-PROC
.	O

So	O
,	O
an	O
efficient	O
potato	O
transformation	B-PROC
system	O
mediated	O
by	O
Agrobacterium	O
fumefaciens	O
was	O
established	O
.	O

ABSTRACT	O
:	O
Outbreaks	O
of	O
SARS	O
affected	O
more	O
than	O
8	O
,	O
400	O
people	O
,	O
and	O
caused	O
more	O
than	O
900	O
deaths	B-PROC
worldwide	O
but	O
came	O
to	O
an	O
end	O
in	O
July	O
,	O
2003	O
.	O

To	O
determine	O
if	O
the	O
N	O
protein	O
is	O
involved	O
in	O
the	O
regulation	B-PROC
of	O
cellular	O
signal	B-PROC
transduction	I-PROC
,	O
an	O
ELISA	O
-	O
based	O
assay	O
on	O
transcription	B-PROC
factors	O
was	O
used	O
.	O

We	O
also	O
found	O
that	O
SARS	O
-	O
CoV	O
N	O
protein	O
does	O
not	O
activate	O
NF	O
-	O
kappaB	O
pathway	B-PROC
,	O
demonstrating	O
that	O
activation	O
of	O
important	O
cellular	O
pathways	B-PROC
by	O
SAS	O
-	O
CoV	O
N	O
protein	O
is	O
selective	O
.	O

Clinical	O
manifestations	O
included	O
fever	B-PROC
in	O
31	O
patients	O
(	O
97	O
%),	O
followed	O
by	O
cough	O
,	O
dyspnea	O
,	O
chill	O
,	O
headache	O
,	O
sore	O
throat	O
,	O
diarrhea	O
,	O
rhinorrhea	O
,	O
and	O
otalgia	O
.	O

Twenty	O
-	O
eight	O
patients	O
survived	O
and	O
4	O
patients	O
died	B-PROC
.	O

This	O
approach	O
,	O
combined	O
with	O
the	O
random	O
screening	O
of	O
licensed	O
compounds	O
or	O
existing	O
compound	O
libraries	O
,	O
should	O
result	O
in	O
the	O
identification	O
of	O
novel	O
lead	O
compounds	O
and	O
the	O
expeditious	O
development	B-PROC
of	O
antiviral	O
drugs	O
.	O

RESULTS	O
:	O
Immunohistochemistry	O
identified	O
positive	O
monoclonal	O
antibody	B-PROC
against	O
SARS	O
-	O
CoV	O
nuceeocapsid	O
(	O
N	O
)	O
protein	O
in	O
the	O
alveolar	O
epithelium	O
and	O
the	O
infiltrating	O
monocytes	O
or	O
macrophages	O
in	O
the	O
lung	O
,	O
spleen	O
and	O
lymph	O
nodes	O
;	O
the	O
presence	O
of	O
the	O
antibody	B-PROC
was	O
also	O
detected	O
in	O
the	O
serous	O
gland	O
epithelium	O
of	O
the	O
trachea	O
/	O
bronchus	O
,	O
squamous	O
epithelium	O
of	O
the	O
esophagus	O
,	O
the	O
gastric	O
parietal	O
cells	O
,	O
the	O
epithelium	O
of	O
the	O
intestinal	O
tract	O
,	O
acidophilic	O
cells	O
in	O
the	O
parathyroids	O
and	O
pituitary	O
,	O
acinus	O
cells	O
in	O
the	O
pancreas	O
,	O
adrenal	O
cortical	O
cells	O
,	O
sweat	O
gland	O
cells	O
,	O
small	O
vessel	O
endothelium	O
,	O
bone	O
marrow	O
promyelocytes	O
,	O
epithelial	O
cells	O
of	O
the	O
distal	O
convoluted	O
tubule	O
of	O
the	O
kidney	O
,	O
brain	O
neurons	O
,	O
and	O
the	O
hepatocytes	O
near	O
the	O
central	O
vein	O
.	O

In	O
-	O
flight	B-PROC
transmission	O
occurred	O
only	O
in	O
one	O
of	O
the	O
three	O
flights	O
with	O
symptomatic	O
SARS	O
patients	O
on	O
board	O
.	O

Partially	O
ecologic	O
study	O
based	O
on	O
short	O
-	O
term	O
exposure	O
demonstrated	O
that	O
SARS	O
patients	O
from	O
regions	O
with	O
moderate	O
APIs	O
had	O
an	O
84	O
%	O
increased	O
risk	O
of	O
dying	B-PROC
from	O
SARS	O
compared	O
to	O
those	O
from	O
regions	O
with	O
low	O
APIs	O
(	O
RR	O
=	O
1	O
.	O
84	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
41	O
-	O
2	O
.	O
40	O
).	O

Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
used	O
as	O
a	O
case	O
example	O
because	O
it	O
is	O
an	O
emerging	O
infection	O
and	O
a	O
prime	O
example	O
of	O
the	O
type	O
of	O
disease	O
that	O
pharmacists	O
may	O
encounter	O
in	O
daily	O
practice	O
(	O
e	O
.	O
g	O
.,	O
easily	O
transmitted	O
,	O
resembles	O
the	O
common	O
cold	B-PROC
).	O

TITLE	O
:	O
[	O
B	O
cell	O
subsets	O
and	O
the	O
expression	B-PROC
of	O
CD40	O
in	O
peripheral	O
blood	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

Together	O
,	O
these	O
results	O
colocalize	O
FIPV	O
replication	O
,	O
lymphocyte	O
depletion	O
in	O
tissues	O
,	O
and	O
alterations	O
in	O
cytokine	O
transcription	B-PROC
and	O
translation	B-PROC
.	O

A	O
delayed	B-PROC
type	I-PROC
hypersensitivity	I-PROC
skin	O
response	O
to	O
N	O
protein	O
was	O
observed	O
in	O
these	O
vaccinated	O
cats	O
,	O
showing	O
that	O
cell	B-PROC
mediated	I-PROC
immunity	I-PROC
against	O
the	O
FIPV	O
antigen	O
was	O
induced	O
.	O

In	O
conclusion	O
,	O
rhinovirus	O
infection	O
is	O
the	O
most	O
prevalent	O
respiratory	O
viral	B-PROC
infection	I-PROC
in	O
infants	O
.	O

Swollen	O
Golgi	O
sacs	O
contained	O
virus	O
nucleocapsids	O
at	O
different	O
stages	O
of	O
maturation	B-PROC
.	O

Mechanically	O
-	O
ventilated	O
children	O
with	O
peak	O
inspiratory	B-PROC
pressure	O
greater	O
than	O
or	O
equal	O
to	O
30	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
FiO	O
(	O
2	O
)	O
greater	O
than	O
or	O
equal	O
to	O
0	O
.	O
5	O
,	O
and	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
less	O
than	O
or	O
equal	O
to	O
200	O
were	O
included	O
in	O
the	O
study	O
.	O

CONCLUSION	O
:	O
Prone	O
positioning	O
during	O
mechanical	O
ventilation	O
of	O
children	O
with	O
severe	O
hypoxemia	O
may	O
improve	O
the	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
in	O
the	O
first	O
hour	O
.	O

Forty	O
-	O
one	O
of	O
them	O
died	B-PROC
,	O
with	O
a	O
case	O
-	O
fatality	O
ratio	O
of	O
8	O
.	O
7	O
%.	O

We	O
predict	O
important	O
structural	O
attributes	O
of	O
potential	O
anti	O
-	O
SARS	O
-	O
CoV	O
RdRp	O
nucleotide	O
analog	O
inhibitors	O
:	O
hydrogen	O
-	O
bonding	O
capability	O
for	O
the	O
2	O
'	O
and	O
3	O
'	O
groups	O
of	O
the	O
sugar	O
ring	O
and	O
C3	O
'	O
endo	O
sugar	O
puckering	O
,	O
and	O
the	O
absence	O
of	O
a	O
hydrophobic	O
binding	O
pocket	O
for	O
non	O
-	O
nucleoside	O
analog	O
inhibitors	O
similar	O
to	O
those	O
observed	O
in	O
hepatitis	O
C	O
virus	O
RdRp	O
and	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
reverse	O
transcriptase	B-PROC
.	O

Influenza	O
viruses	O
also	O
cause	O
pandemics	O
,	O
during	O
which	O
the	O
rates	O
of	O
illness	O
and	O
death	B-PROC
can	O
be	O
expected	O
to	O
be	O
much	O
higher	O
.	O

Autopsies	O
were	O
performed	O
on	O
three	O
patients	O
who	O
died	B-PROC
9	O
-	O
15	O
days	O
after	O
the	O
onset	O
of	O
the	O
illness	O
,	O
and	O
the	O
clinical	O
and	O
laboratory	O
features	O
reviewed	O
.	O

Matching	O
was	O
done	O
with	O
respect	O
to	O
age	O
,	O
sex	O
,	O
the	O
presence	O
of	O
co	O
-	O
morbidities	O
,	O
lactate	O
dehydrogenase	O
level	O
and	O
the	O
use	O
of	O
pulse	B-PROC
steroid	O
therapy	O
.	O

RESULTS	O
:	O
The	O
addition	O
of	O
lopinavir	O
/	O
ritonavir	O
as	O
initial	O
treatment	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
overall	O
death	B-PROC
rate	O
(	O
2	O
.	O
3	O
%)	O
and	O
intubation	O
rate	O
(	O
0	O
%),	O
when	O
compared	O
with	O
a	O
matched	O
cohort	O
who	O
received	O
standard	O
treatment	O
(	O
15	O
.	O
6	O
%	O
and	O
11	O
.	O
0	O
%	O
respectively	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
a	O
lower	O
rate	O
of	O
use	O
of	O
methylprednisolone	O
at	O
a	O
lower	O
mean	O
dose	O
.	O

Recent	O
advances	O
have	O
been	O
made	O
in	O
our	O
knowledge	O
of	O
some	O
of	O
these	O
,	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
,	O
influenza	O
A	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
and	O
Ebola	O
virus	O
.	O

Research	O
efforts	O
to	O
mitigate	O
their	O
effects	O
have	O
concentrated	O
on	O
improved	O
surveillance	O
and	O
diagnostic	O
capabilities	O
,	O
as	O
well	O
as	O
on	O
the	O
development	B-PROC
of	O
vaccines	O
and	O
antiviral	O
agents	O
.	O

Presenting	O
symptoms	O
included	O
fever	B-PROC
(	O
100	O
%),	O
cough	O
(	O
69	O
.	O
0	O
%),	O
chills	O
or	O
rigor	O
(	O
62	O
.	O
1	O
%),	O
and	O
shortness	O
of	O
breath	O
(	O
41	O
.	O
4	O
%).	O

Most	O
patients	O
with	O
clinical	O
deterioration	O
responded	O
to	O
pulse	B-PROC
corticosteroid	O
therapy	O
(	O
14	O
out	O
of	O
17	O
)	O
but	O
six	O
complicated	O
with	O
nosocomial	O
infections	O
.	O

The	O
inability	O
of	O
expressed	B-PROC
R1	O
(	O
1	O
)	O
to	O
work	O
as	O
a	O
receptor	O
was	O
due	O
to	O
the	O
inaccessibility	O
of	O
virions	O
to	O
R1	O
(	O
1	O
);	O
however	O
,	O
these	O
were	O
accessible	O
using	O
the	O
MHVR	O
-	O
specific	O
monoclonal	O
antibody	B-PROC
CC1	O
.	O

Luciferase	O
expression	B-PROC
,	O
which	O
is	O
dependent	O
on	O
viral	O
RNA	B-PROC
replication	I-PROC
and	O
RNA	O
-	O
dependent	O
mRNA	B-PROC
synthesis	I-PROC
,	O
was	O
measured	O
in	O
intact	O
yeast	O
cells	O
.	O

Researchers	O
now	O
think	O
that	O
the	O
SARS	O
virus	O
split	O
from	O
group	O
2	O
coronaviruses	O
,	O
and	O
that	O
this	O
happened	O
relatively	O
recently	O
on	O
the	O
scale	O
of	O
coronavirus	O
evolution	B-PROC
.	O

In	O
a	O
1	O
-	O
year	O
community	O
-	O
based	O
study	O
,	O
we	O
prospectively	O
investigated	O
the	O
possible	O
virologic	O
cause	O
of	O
acute	O
respiratory	O
infections	O
in	O
107	O
symptomatic	O
case	O
episodes	O
and	O
91	O
symptom	O
-	O
free	O
control	O
periods	B-PROC
.	O

A	O
defined	O
pattern	O
of	O
HRCT	O
findings	O
is	O
observed	O
in	O
different	O
phases	O
of	O
SARS	O
,	O
which	O
is	O
characterized	O
by	O
focal	O
ground	O
-	O
glass	O
and	O
crazy	O
paving	O
patterns	O
in	O
a	O
scattered	O
distribution	O
at	O
presentation	O
,	O
followed	O
by	O
development	B-PROC
of	O
interstitial	O
thickening	O
,	O
consolidation	O
,	O
pleural	O
reaction	O
,	O
and	O
scarring	O
.	O

TITLE	O
:	O
[	O
Evaluation	O
on	O
the	O
functions	O
and	O
cost	O
of	O
'	B-PROC
fever	I-PROC
clinics	O
'	O
during	O
the	O
period	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
epidemics	O
in	O
Beijing	O
].	O

Information	O
related	O
to	O
patients	O
with	O
fever	B-PROC
needs	O
to	O
improve	O
regarding	O
its	O
completeness	O
and	O
accuracy	O
.	O

ABSTRACT	O
:	O
Paroxetine	O
,	O
a	O
selective	O
serotonin	O
reuptake	B-PROC
inhibitor	O
(	O
SSRI	O
)	O
may	O
be	O
given	O
in	O
severe	O
cases	O
of	O
maternal	O
depression	O
and	O
panic	O
disorders	O
during	O
pregnancy	O
.	O

There	O
were	O
two	O
major	O
manifestations	O
of	O
near	O
-	O
drowning	O
in	O
the	O
Dead	B-PROC
Sea	O
:	O
electrolyte	O
imbalance	O
and	O
acute	O
lung	O
injury	O
.	O

Health	O
care	O
worker	O
training	O
in	O
use	O
of	O
personal	O
protective	O
equipment	O
and	O
management	O
of	O
patients	O
with	O
SARS	O
and	O
establishing	O
fever	B-PROC
clinics	O
and	O
designated	O
SARS	O
wards	O
in	O
hospitals	O
predated	O
the	O
steepest	O
decline	O
in	O
cases	O
.	O

Of	O
the	O
13	O
patients	O
treated	O
with	O
corticosteroids	O
alone	O
,	O
5	O
(	O
38	O
.	O
5	O
%)	O
were	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
,	O
3	O
(	O
23	O
.	O
1	O
%)	O
required	O
intubation	O
and	O
mechanical	O
ventilation	O
,	O
and	O
1	O
(	O
7	O
.	O
7	O
%)	O
died	B-PROC
.	O

Development	B-PROC
of	O
a	O
set	O
of	O
legal	O
and	O
ethical	O
recommendations	O
becomes	O
even	O
more	O
essential	O
when	O
,	O
as	O
was	O
true	O
with	O
SARS	O
and	O
will	O
undoubtedly	O
be	O
the	O
case	O
with	O
future	O
epidemics	O
,	O
scientific	O
uncertainty	O
is	O
pervasive	O
and	O
urgent	O
public	O
health	O
action	O
is	O
required	O
.	O

ABSTRACT	O
:	O
How	O
chemokines	O
shape	O
the	O
immune	B-PROC
response	I-PROC
to	O
viral	B-PROC
infection	I-PROC
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
has	O
largely	O
been	O
considered	O
within	O
the	O
context	O
of	O
recruitment	O
and	O
activation	O
of	O
antigen	O
-	O
specific	O
lymphocytes	O
.	O

This	O
element	O
,	O
beginning	O
immediately	O
downstream	O
of	O
the	O
nucleocapsid	O
gene	O
stop	O
codon	O
,	O
was	O
shown	O
to	O
be	O
essential	O
for	O
virus	B-PROC
replication	I-PROC
.	O

Additionally	O
,	O
we	O
have	O
identified	O
a	O
pseudoknot	O
loop	O
insertion	B-PROC
mutation	I-PROC
that	O
appears	O
to	O
point	O
to	O
a	O
genetic	O
interaction	O
between	O
the	O
pseudoknot	O
and	O
a	O
distant	O
region	O
of	O
the	O
genome	O
.	O

This	O
process	O
is	O
regulated	O
by	O
transcription	B-PROC
-	O
regulating	O
sequences	O
(	O
TRSs	O
)	O
preceding	O
each	O
mRNA	O
,	O
including	O
a	O
highly	O
conserved	O
core	O
sequence	O
(	O
CS	O
)	O
with	O
high	O
identity	O
to	O
sequences	O
present	O
in	O
the	O
virus	O
genome	O
and	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
leader	O
(	O
TRS	O
-	O
L	O
).	O

Finally	O
,	O
lactam	O
12	O
induces	O
apoptosis	B-PROC
selectively	O
in	O
Jurkat	O
T	O
and	O
simian	O
virus	O
40	O
-	O
transformed	O
,	O
but	O
not	O
in	O
nontransformed	O
NK	O
and	O
parental	O
normal	O
fibroblast	O
,	O
cells	O
.	O

Using	O
genetic	O
,	O
biochemical	O
,	O
and	O
cell	O
imaging	O
approaches	O
,	O
the	O
role	O
of	O
autophagy	B-PROC
in	O
DMV	O
formation	B-PROC
and	O
MHV	O
replication	O
was	O
investigated	O
.	O

The	O
most	O
common	O
symptom	O
were	O
fever	B-PROC
(	O
100	O
.	O

Chimeric	O
TNF	O
antibody	B-PROC
,	O
infliximab	O
,	O
should	O
be	O
evaluated	O
for	O
treatment	O
of	O
acute	O
pancreatitis	O
.	O

A	O
4	O
-	O
item	O
symptom	O
score	O
based	O
on	O
the	O
presence	O
of	O
cough	O
before	O
or	O
concomitant	O
with	O
fever	B-PROC
,	O
myalgia	O
,	O
diarrhea	O
,	O
and	O
rhinorrhea	O
or	O
sore	O
throat	O
detects	O
SARS	O
with	O
100	O
%	O
sensitivity	O
and	O
75	O
.	O
9	O
%	O
specificity	O
;	O
a	O
6	O
-	O
item	O
clinical	O
score	O
based	O
on	O
lymphopenia	O
(<	O
1	O
.	O
0x10	O
(	O
9	O
)/	O
L	O
),	O
thrombocytopenia	O
(<	O
150x10	O
(	O
9	O
)/	O
L	O
)	O
and	O
the	O
4	O
symptom	O
items	O
detects	O
SARS	O
with	O
100	O
%	O
sensitivity	O
and	O
86	O
.	O
3	O
%	O
specificity	O
.	O

The	O
development	B-PROC
of	O
the	O
response	O
to	O
SARS	O
raised	O
a	O
number	O
of	O
more	O
general	O
issues	O
relevant	O
to	O
future	O
infectious	O
epidemic	O
threats	O
.	O

Positive	O
body	O
fluid	O
cultures	O
were	O
obtained	O
in	O
42	O
out	O
of	O
98	O
patients	O
and	O
of	O
these	O
,	O
14	O
patients	O
had	O
microbiological	O
diagnosis	O
established	O
by	O
blood	O
culture	O
,	O
another	O
14	O
by	O
endotracheal	O
secretion	B-PROC
culture	O
,	O
eight	O
by	O
urine	O
culture	O
and	O
in	O
the	O
remaining	O
six	O
patients	O
based	O
upon	O
wound	O
cultures	O
.	O

Multiorgan	O
failure	O
was	O
seen	O
in	O
18	O
%	O
of	O
patients	O
who	O
died	B-PROC
from	O
ARDS	O
.	O

Polio	O
eradication	O
and	O
elimination	B-PROC
of	O
neonatal	O
tetanus	O
are	O
making	O
slow	O
progress	O
,	O
obstacles	O
to	O
the	O
control	O
of	O
these	O
diseases	O
are	O
ongoing	O
armed	O
conflicts	O
in	O
regions	O
with	O
high	O
prevalence	O
and	O
under	O
financing	O
of	O
programs	O
.	O

ABSTRACT	O
:	O
The	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
transcription	B-PROC
factor	O
plays	O
a	O
key	O
role	O
in	O
the	O
induction	O
of	O
pro	O
-	O
inflammatory	O
gene	B-PROC
expression	I-PROC
,	O
leading	O
to	O
the	O
synthesis	B-PROC
of	O
cytokines	O
,	O
adhesion	O
molecules	O
,	O
chemokines	O
,	O
growth	B-PROC
factors	O
and	O
enzymes	O
.	O

Virus	O
entered	O
cells	O
by	O
endocytosis	B-PROC
or	O
membrane	B-PROC
fusion	I-PROC
and	O
was	O
released	O
through	O
a	O
budding	B-PROC
process	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
cytotoxic	O
T	O
-	O
cell	O
response	O
to	O
gp33	O
-	O
41	O
exerts	B-PROC
a	O
strong	O
immune	O
pressure	O
that	O
quickly	O
selects	O
epitope	O
escape	O
mutants	O
to	O
gp33	O
-	O
41	O
.	O

The	O
overall	O
diagnostic	O
accuracy	O
of	O
HCU	O
was	O
lower	O
compared	O
with	O
conventional	O
TTE	O
(	O
137	O
/	O
171	O
vs	O
.	O
158	O
/	O
171	O
clinical	O
questions	O
solved	O
:	O
P	O
=	O
0	O
.	O
002	O
),	O
reaching	B-PROC
80	O
%	O
and	O
92	O
%,	O
respectively	O
.	O

Clinical	O
manifestation	O
,	O
chest	O
X	O
-	O
ray	O
,	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
pulmonary	B-PROC
function	I-PROC
of	O
4	O
cases	O
with	O
bronchiolitis	O
obliterans	O
were	O
retrospectively	O
analyzed	O
.	O

METHODS	O
:	O
Clinical	O
manifestation	O
,	O
chest	O
X	O
-	O
ray	O
,	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
pulmonary	B-PROC
function	I-PROC
of	O
4	O
cases	O
with	O
bronchiolitis	O
obliterans	O
were	O
retrospectively	O
analyzed	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
dose	O
response	O
of	O
inhaled	B-PROC
nitric	O
oxide	O
(	O
iNO	O
)	O
for	O
surfactant	O
-	O
treated	O
rabbits	O
with	O
meconium	O
aspiration	O
-	O
induced	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
hypoxemic	O
respiratory	O
failure	O
(	O
HRF	O
),	O
and	O
variation	O
of	O
measured	O
iNO	O
by	O
continuous	O
NO	O
delivery	O
in	O
pressure	O
support	O
ventilation	O
(	O
PSV	O
).	O

The	O
major	O
clinical	O
features	O
included	O
diffuse	O
amyotrophy	B-PROC
,	O
bilateral	O
facial	O
paresis	O
,	O
and	O
fasciculations	O
,	O
suggesting	O
motor	O
neuropathy	O
.	O

There	O
were	O
no	O
statistical	O
differences	O
in	O
the	O
peak	O
temperature	O
and	O
duration	O
of	O
fever	B-PROC
,	O
other	O
accompanying	O
symptoms	O
,	O
leucopenia	O
;	O
however	O
,	O
the	O
time	O
from	O
initial	O
pulmonary	O
infiltrates	O
to	O
radiographic	O
recovery	O
shortened	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

No	O
differences	O
were	O
found	O
in	O
maximum	O
number	O
of	O
lung	O
fields	O
involved	O
,	O
duration	O
from	O
the	O
onset	O
of	O
fever	B-PROC
to	O
the	O
occurrence	O
of	O
pulmonary	O
infiltrates	O
and	O
time	O
from	O
the	O
initial	O
pulmonary	O
infiltrate	O
to	O
its	O
peak	O
among	O
the	O
multiple	O
transmission	O
generations	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

No	O
statistical	O
differences	O
were	O
found	O
in	O
modes	O
of	O
oxygen	O
therapy	O
and	O
sorts	B-PROC
of	O
antibiotics	O
prescribed	O
among	O
the	O
various	O
transmission	O
generations	O
(	O
P	O
>	O
0	O
.	O
05	O
);	O
however	O
,	O
as	O
with	O
the	O
advanced	O
transmission	O
generations	O
,	O
the	O
number	O
of	O
cases	O
prescribed	O
with	O
methylprednisolone	O
,	O
human	O
gamma	O
-	O
globulin	O
,	O
interferon	O
-	O
alpha	O
,	O
antiviral	O
drugs	O
(	O
oral	O
ribavirin	O
or	O
oseltamivir	O
)	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
time	O
from	O
admission	O
to	O
starting	O
these	O
medication	O
shortened	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
genotype	O
,	O
single	O
nucleotide	O
polymorphism	B-PROC
and	O
phylogeny	O
of	O
these	O
SARS	O
-	O
CoV	O
strains	O
were	O
analyzed	O
by	O
molecular	O
biological	O
,	O
bioinformatic	O
and	O
epidemiological	O
methods	O
.	O

SARS	O
associated	O
coronavirus	O
specific	O
RNA	O
fragment	O
was	O
found	O
positive	O
by	O
RT	O
-	O
PCR	O
in	O
1	O
case	O
;	O
1	O
case	O
was	O
positive	O
for	O
both	O
IgM	O
and	O
IgG	O
antibodies	O
to	O
the	O
virus	O
;	O
1	O
case	O
was	O
positive	O
for	O
only	O
IgM	O
antibody	B-PROC
and	O
another	O
2	O
cases	O
were	O
positive	O
for	O
only	O
IgG	O
antibody	B-PROC
.	O

Overall	O
,	O
12	O
.	O
2	O
%	O
(	O
6	O
/	O
49	O
)	O
of	O
the	O
patients	O
died	B-PROC
,	O
all	O
of	O
whom	O
had	O
diffuse	O
air	O
-	O
space	O
opacification	O
on	O
the	O
last	O
chest	O
radiograph	O
.	O

Six	O
patients	O
were	O
alive	O
but	O
ventilated	O
(	O
11	O
.	O
3	O
%;	O
95	O
%	O
confidence	O
interval	O
5	O
.	O
3	O
-	O
22	O
.	O
6	O
)	O
and	O
14	O
had	O
died	B-PROC
(	O
25	O
.	O
9	O
%;	O
CI	O
16	O
.	O
1	O
-	O
38	O
.	O
9	O
).	O

Metachromatic	O
scores	O
yielded	O
significantly	O
different	O
results	O
between	O
controls	O
and	O
principals	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
demonstrating	O
a	O
significant	O
disappearance	O
of	O
metachromatic	B-PROC
granules	I-PROC
from	O
lung	O
MCs	O
in	O
principals	O
.	O

Inflammatory	O
mediators	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
ARDS	O
,	O
which	O
is	O
the	O
primary	O
cause	O
of	O
death	B-PROC
in	O
these	O
conditions	O
.	O

Symptoms	O
and	O
signs	O
of	O
the	O
children	O
were	O
much	O
less	O
severe	O
and	O
aggressive	B-PROC
than	O
adults	O
cases	O
.	O

Untreated	O
SCID	O
mice	O
exhibited	O
uncontrolled	O
virus	B-PROC
replication	I-PROC
in	O
all	O
CNS	O
cell	O
types	O
but	O
had	O
little	O
or	O
no	O
demyelination	O
.	O

This	O
approach	O
includes	O
nested	O
primer	O
sets	O
targeted	B-PROC
to	O
conserve	O
regions	O
of	O
human	O
parainfluenza	O
virus	O
haemagglutinin	O
,	O
human	O
coronavirus	O
spike	O
protein	O
,	O
and	O
human	O
enterovirus	O
and	O
rhinovirus	O
polyprotein	O
genes	O
.	O

We	O
review	O
our	O
current	O
progress	O
on	O
this	O
literature	O
database	O
and	O
software	O
,	O
the	O
technical	O
system	O
and	O
data	O
organization	O
involved	O
,	O
the	O
approach	O
used	O
to	O
populate	O
the	O
literature	O
system	O
,	O
and	O
ongoing	O
development	B-PROC
plans	O
to	O
bring	O
this	O
system	O
to	O
the	O
physician	O
via	O
mobile	O
technologies	O
.	O

Treatment	O
included	O
isolation	O
,	O
good	O
ventilation	O
of	O
the	O
ward	O
,	O
bed	O
rest	O
,	O
supportive	O
regimens	O
,	O
low	O
volume	O
oxygen	O
inhalation	B-PROC
,	O
use	O
of	O
Chinese	O
traditional	O
medicine	O
,	O
antibiotics	O
to	O
prevent	O
bacterial	O
infection	O
,	O
and	O
anti	O
-	O
inflammation	O
therapy	O
.	O

In	O
our	O
HCl	O
ALI	O
model	O
,	O
SL	O
improved	O
oxygenation	B-PROC
and	O
quasi	O
-	O
static	O
lung	B-PROC
compliance	I-PROC
over	O
C	O
.	O
The	O
pulmonary	B-PROC
function	I-PROC
effects	O
of	O
SL	O
were	O
further	O
enhanced	O
by	O
the	O
addition	O
of	O
Lidocaine	O
to	O
the	O
surfactant	O
suspension	O
.	O

Matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
-	O
mass	O
spectrometry	O
determination	O
showed	O
that	O
relative	O
molecular	O
weight	O
of	O
intact	O
N	O
protein	O
is	O
45	O
929	O
Da	O
,	O
which	O
is	O
very	O
close	O
to	O
its	O
theoretically	O
calculated	O
molecular	O
weight	O
45	O
935	O
Da	O
based	O
on	O
the	O
amino	O
acid	O
sequence	O
deduced	O
from	O
the	O
genome	O
with	O
the	O
first	O
amino	O
acid	O
methionine	O
at	O
the	O
N	O
-	O
terminus	O
depleted	O
and	O
second	O
,	O
serine	O
,	O
acetylated	O
,	O
indicating	O
that	O
phosphorylation	B-PROC
does	O
not	O
happen	O
at	O
all	O
in	O
the	O
predicted	O
phosphorylation	B-PROC
sites	O
within	O
infected	O
cells	O
nor	O
in	O
virus	O
particles	O
.	O

ABSTRACT	O
:	O
We	O
have	O
expressed	B-PROC
a	O
series	O
of	O
truncated	O
spike	O
(	O
S	O
)	O
glycoproteins	O
of	O
SARS	O
-	O
CoV	O
and	O
found	O
that	O
the	O
N	O
-	O
terminus	O
14	O
-	O
502	O
residuals	O
were	O
sufficient	O
to	O
bind	O
to	O
SARS	O
-	O
CoV	O
susceptible	O
Vero	O
E6	O
cells	O
.	O

The	O
prominence	O
of	O
mitotic	O
activity	O
of	O
hepatocytes	O
is	O
unique	O
and	O
may	O
be	O
due	O
to	O
a	O
hyperproliferative	O
state	O
with	O
or	O
without	O
disruption	O
of	O
cell	B-PROC
cycle	I-PROC
by	O
the	O
coronavirus	O
.	O

Given	O
the	O
potential	O
of	O
G	O
-	O
CSF	O
to	O
directly	O
induce	O
anti	O
-	O
inflammatory	O
cytokines	O
in	O
vitro	O
,	O
significant	O
associations	O
of	O
endogenous	O
G	O
-	O
CSF	O
levels	O
with	O
these	O
mediators	O
early	O
in	O
the	O
development	B-PROC
of	O
severe	O
lung	O
injury	O
suggest	O
an	O
endogenous	O
anti	O
-	O
inflammatory	O
role	O
of	O
G	O
-	O
CSF	O
in	O
vivo	O
.	O

TITLE	O
:	O
Three	O
-	O
color	O
flow	O
cytometry	O
detection	B-PROC
of	I-PROC
virus	I-PROC
-	O
specific	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
in	O
the	O
cat	O
.	O

TITLE	O
:	O
Detection	O
of	O
feline	O
coronavirus	O
antibody	B-PROC
,	O
feline	O
immunodeficiency	O
virus	O
antibody	B-PROC
,	O
and	O
feline	O
leukemia	O
virus	O
antigen	O
in	O
ascites	O
from	O
cats	O
with	O
effusive	O
feline	O
infectious	O
peritonitis	O
.	O

Change	O
of	O
clinical	O
behaviour	B-PROC
and	O
practices	O
during	O
the	O
epidemic	O
;	O
anxiety	O
level	O
of	O
primary	O
care	O
doctors	O
.	O

Key	O
elements	O
in	O
this	O
process	O
are	O
the	O
so	O
-	O
called	O
transcription	B-PROC
-	O
regulating	O
sequences	O
(	O
TRSs	O
),	O
which	O
determine	O
a	O
base	O
-	O
pairing	O
interaction	O
between	O
sense	B-PROC
and	O
antisense	O
viral	O
RNA	O
that	O
is	O
essential	O
for	O
leader	O
-	O
to	O
-	O
body	O
joining	O
.	O

The	O
importance	O
of	O
the	O
LTH	O
was	O
supported	O
by	O
the	O
results	O
of	O
a	O
mutagenesis	B-PROC
study	O
using	O
an	O
EAV	O
molecular	O
clone	O
.	O

Unlike	O
unresolving	O
MHV	O
-	O
JHM	O
infections	O
,	O
the	O
clearance	O
of	O
WTR13	O
and	O
S4R22	O
infections	O
coincided	O
with	O
strong	O
IFN	O
-	O
gamma	O
transcription	B-PROC
and	O
an	O
increase	O
in	O
the	O
number	O
of	O
CD8	O
T	O
cells	O
infiltrating	O
into	O
the	O
CNS	O
.	O

Increased	O
apoptosis	B-PROC
appeared	O
to	O
contribute	O
to	O
the	O
diminished	O
presence	O
of	O
CD8	O
T	O
cells	O
in	O
MHV	O
-	O
JHM	O
-	O
infected	O
brain	O
with	O
the	O
consequence	O
of	O
a	O
lower	O
potential	O
for	O
IFNgamma	O
production	O
and	O
antiviral	O
activity	O
.	O

ABSTRACT	O
:	O
Chloroquine	O
and	O
related	O
anti	O
-	O
malarial	O
drugs	O
appear	O
to	O
promote	O
apoptosis	B-PROC
in	O
T	O
-	O
cells	O
by	O
suppressing	O
NF	O
-	O
kappa	O
-	O
B	O
,	O
which	O
enhances	O
the	O
expression	B-PROC
of	O
anti	O
-	O
apoptotic	O
proteins	O
(	O
e	O
.	O
g	O
.,	O
Bcl	O
-	O
2	O
).	O

Thus	O
,	O
chloroquine	O
has	O
found	O
applications	O
in	O
autoimmune	O
diseases	O
where	O
it	O
apparently	O
facilitates	O
apoptosis	B-PROC
of	O
abnormally	O
persistent	O
T	O
-	O
cell	O
clones	O
.	O

The	O
mode	O
of	O
action	O
of	O
chloroquine	O
in	O
prevention	O
of	O
malaria	O
is	O
not	O
known	O
,	O
but	O
it	O
may	O
be	O
to	O
minimize	O
replication	O
of	O
the	O
parasite	O
in	O
the	O
liver	O
cells	O
,	O
which	O
occurs	O
before	O
invasion	O
of	O
the	O
erythrocytes	O
,	O
by	O
facilitating	O
premature	O
apoptosis	B-PROC
of	O
the	O
infected	O
host	O
cells	O
.	O

Fever	B-PROC
with	O
or	O
without	O
chills	O
and	O
rigors	O
,	O
headache	O
,	O
abdominal	O
pain	O
and	O
vomiting	O
were	O
the	O
four	O
commonest	O
presenting	O
complaints	O
for	O
P	O
.	O
falciparum	O
infections	O
.	O

Aggressive	B-PROC
and	O
appropriate	O
therapy	O
is	O
life	O
saving	O
.	O

The	O
isolated	O
case	O
of	O
death	B-PROC
from	O
P	O
.	O
vivax	O
infection	O
argues	O
against	O
complacency	O
in	O
the	O
management	O
of	O
even	O
the	O
""""	O
benign	O
""""	O
form	O
of	O
the	O
infection	O
.	O

We	O
isolated	O
epitope	O
-	O
specific	O
T	O
cells	O
with	O
an	O
IFN	O
-	O
gamma	O
capture	O
assay	O
or	O
MHC	B-PROC
class	O
I	O
/	O
peptide	O
tetramers	O
and	O
identified	O
different	O
clonotypes	O
by	O
Vbeta	O
chain	O
sequence	O
analysis	O
.	O

ABSTRACT	O
:	O
We	O
report	O
on	O
the	O
role	O
of	O
specific	O
CD8	O
(+)	O
T	O
cells	O
in	O
the	O
pathogenesis	B-PROC
of	O
a	O
highly	O
lethal	O
human	O
viral	B-PROC
disease	I-PROC
,	O
hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	O
).	O

Lack	O
of	O
understanding	O
of	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
has	O
prevented	O
the	O
rational	O
development	B-PROC
of	O
a	O
therapy	O
against	O
this	O
disease	O
.	O

Here	O
we	O
show	O
extensive	O
SCV	O
antigen	O
expression	B-PROC
in	O
type	O
1	O
pneumocytes	O
of	O
experimentally	O
infected	O
cynomolgus	O
macaques	O
(	O
Macaca	O
fascicularis	O
)	O
at	O
4	O
d	O
postinfection	O
(	O
d	O
.	O
p	O
.	O
i	O
.),	O
indicating	O
that	O
this	O
cell	O
type	O
is	O
the	O
primary	O
target	O
for	O
SCV	O
infection	O
early	O
in	O
the	O
disease	O
,	O
and	O
explaining	O
the	O
subsequent	O
pulmonary	O
damage	O
.	O

This	O
created	O
difficulties	O
in	O
helping	O
patients	O
and	O
their	O
families	O
prepare	O
for	O
death	B-PROC
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
produced	O
new	O
recombinant	O
viruses	O
with	O
each	O
one	O
of	O
these	O
S	O
gene	B-PROC
mutations	I-PROC
by	O
site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
and	O
targeted	B-PROC
recombination	B-PROC
and	O
studied	O
the	O
effect	O
of	O
each	O
individual	O
mutation	O
on	O
the	O
pathogenesis	B-PROC
of	O
the	O
virus	O
.	O

Cells	O
infected	O
with	O
HSV	O
-	O
1	O
demonstrated	O
cell	B-PROC
cycle	I-PROC
arrest	I-PROC
at	O
the	O
G	O
(	O
1	O
)/	O
S	O
transition	O
;	O
however	O
,	O
treatment	O
with	O
GA	O
resulted	O
in	O
a	O
cell	B-PROC
cycle	I-PROC
distribution	O
pattern	O
identical	O
to	O
that	O
of	O
untreated	O
cells	O
,	O
indicating	O
a	O
restoration	O
of	O
cell	B-PROC
growth	B-PROC
in	O
HSV	O
-	O
1	O
-	O
infected	O
cells	O
by	O
GA	O
treatment	O
.	O

The	O
antiviral	O
mechanism	O
of	O
GA	O
appears	O
to	O
be	O
associated	O
with	O
Hsp90	O
inactivation	O
and	O
cell	B-PROC
cycle	I-PROC
restoration	O
,	O
which	O
indicates	O
that	O
GA	O
exhibits	O
broad	O
-	O
spectrum	O
antiviral	O
activity	O
.	O

Analyses	O
of	O
these	O
full	O
-	O
length	O
sequences	O
showed	O
a	O
positive	O
selection	O
occurring	O
during	O
SARS	O
-	O
CoV	O
virus	O
evolution	B-PROC
.	O

These	O
results	O
provide	O
insights	O
into	O
understanding	O
the	O
immunological	O
characteristics	O
of	O
spike	O
protein	O
and	O
the	O
development	B-PROC
of	O
subunit	O
vaccines	O
against	O
SARS	O
-	O
CoV	O
.	O

We	O
constructed	O
specific	O
siRNAs	O
targeting	B-PROC
the	O
S	O
gene	O
in	O
SARS	O
-	O
CoV	O
.	O
We	O
demonstrated	O
that	O
the	O
siRNAs	O
could	O
effectively	O
and	O
specifically	O
inhibit	O
gene	B-PROC
expression	I-PROC
of	O
Spike	O
protein	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

Cholesterol	O
depletions	O
reduced	O
plaque	O
development	B-PROC
2	O
-	O
to	O
20	O
-	O
fold	O
,	O
depending	O
on	O
the	O
infecting	O
MHV	O
strain	O
,	O
while	O
supplementations	O
increased	O
susceptibility	O
2	O
-	O
to	O
10	O
-	O
fold	O
.	O

However	O
,	O
coronavirus	O
D	O
-	O
RNA	B-PROC
expression	I-PROC
vectors	O
display	O
an	O
inherent	O
instability	O
following	O
serial	O
passage	O
with	O
helper	O
virus	O
,	O
resulting	O
in	O
the	O
eventual	O
loss	O
of	O
the	O
heterologous	O
genes	O
.	O

ABSTRACT	O
:	O
To	O
compare	O
the	O
physiological	B-PROC
effects	I-PROC
and	O
the	O
clinical	O
efficacy	O
of	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
vs	O
standard	O
medical	O
treatment	O
in	O
elderly	O
patients	O
(>	O
or	O
=	O
75	O
years	O
)	O
with	O
acute	O
hypoxemic	O
respiratory	O
failure	O
related	O
to	O
cardiogenic	O
pulmonary	O
edema	O
.	O

Within	O
1	O
h	O
,	O
noninvasive	O
continuous	O
positive	O
airway	O
pressure	O
led	O
to	O
decreased	O
respiratory	O
rate	O
(	O
respiratory	O
rate	O
,	O
27	O
+/-	O
7	O
vs	O
35	O
+/-	O
6	O
breaths	O
/	O
min	O
;	O
p	O
=	O
0	O
.	O
009	O
),	O
and	O
improved	O
oxygenation	B-PROC
(	O
PaO	B-PROC
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
),	O
306	O
+/-	O
104	O
vs	O
157	O
+/-	O
71	O
;	O
p	O
=	O
0	O
.	O
004	O
)	O
compared	O
with	O
baseline	O
,	O
whereas	O
no	O
differences	O
were	O
observed	O
within	O
the	O
standard	O
treatment	O
group	O
.	O

New	O
oxygenators	O
with	O
significantly	O
decreased	O
blood	O
resistance	B-PROC
allow	O
the	O
clinical	O
application	O
of	O
pumpless	O
arteriovenous	O
extracorporeal	O
lung	O
assist	O
(	O
ECLA	O
).	O

Here	O
,	O
we	O
describe	O
the	O
development	B-PROC
and	O
validation	O
of	O
an	O
oligonucleotide	O
resequencing	O
array	O
for	O
interrogating	O
the	O
entire	O
30	O
-	O
kb	O
SARS	O
-	O
CoV	O
genome	O
in	O
a	O
rapid	O
,	O
cost	O
-	O
effective	O
fashion	O
.	O

We	O
demonstrate	O
that	O
array	O
-	O
based	O
resequencing	O
-	O
by	O
-	O
hybridization	B-PROC
is	O
a	O
fast	O
,	O
reliable	O
,	O
and	O
economical	O
alternative	O
to	O
capillary	O
sequencing	O
for	O
obtaining	O
SARS	O
-	O
CoV	O
genomic	O
sequence	O
on	O
a	O
population	O
scale	O
,	O
making	O
this	O
an	O
ideal	O
platform	O
for	O
the	O
global	O
monitoring	O
of	O
SARS	O
-	O
CoV	O
and	O
other	O
small	O
-	O
genome	O
pathogens	O
.	O

Besides	O
infectious	O
causes	O
and	O
drug	O
hypersensitivity	B-PROC
to	O
methotrexate	O
or	O
acitretin	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
sometimes	O
due	O
to	O
a	O
pulmonary	O
capillary	O
leak	O
syndrome	O
,	O
is	O
a	O
rare	O
cause	O
of	O
pneumonitis	O
in	O
the	O
course	O
of	O
psoriasis	O
,	O
and	O
may	O
be	O
fatal	O
.	O

A	O
subject	O
inhaled	B-PROC
saline	O
mist	O
and	O
exhaled	B-PROC
through	O
three	O
oxygen	O
masks	O
to	O
illustrate	O
the	O
pattern	O
of	O
dispersal	O
of	O
pulmonary	O
gas	O
.	O

TITLE	O
:	O
Risk	O
factors	O
for	O
wheezing	O
in	O
a	O
subtropical	O
environment	O
:	O
role	O
of	O
respiratory	O
viruses	O
and	O
allergen	O
sensitization	B-PROC
.	O

ABSTRACT	O
:	O
Fever	B-PROC
as	O
a	O
somatised	O
symptom	O
is	O
not	O
commonly	O
described	O
.	O

There	O
were	O
3	O
deaths	B-PROC
(	O
25	O
%);	O
2	O
were	O
above	O
65	O
years	O
old	O
and	O
1	O
was	O
37	O
years	O
old	O
with	O
acute	O
myeloid	O
leukaemia	O
on	O
chemotherapy	O
.	O

TITLE	O
:	O
Prolonged	O
disturbances	O
of	O
in	O
vitro	O
cytokine	B-PROC
production	I-PROC
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
treated	O
with	O
ribavirin	O
and	O
steroids	O
.	O

We	O
wished	O
to	O
know	O
whether	O
evaluation	O
of	O
in	O
vitro	O
cytokine	B-PROC
production	I-PROC
could	O
contribute	O
to	O
improved	O
understanding	O
of	O
disease	O
pathogenesis	B-PROC
and	O
to	O
better	O
patient	O
management	O
.	O

Numbers	O
of	O
unstimulated	O
and	O
mitogen	O
-	O
stimulated	O
cytokine	O
-	O
secreting	B-PROC
peripheral	O
blood	O
mononuclear	O
cells	O
were	O
measured	O
repeatedly	O
during	O
and	O
after	O
hospitalization	O
in	O
13	O
patients	O
with	O
SARS	O
using	O
enzyme	O
-	O
linked	O
immunospot	O
technology	O
.	O

Outbreak	O
of	O
SARS	O
in	O
Dongcheng	O
District	O
started	O
on	O
March	O
14	O
,	O
2003	O
with	O
a	O
peak	O
in	O
mid	O
-	O
and	O
late	O
April	O
,	O
and	O
dropped	O
in	O
early	O
May	O
.	O
A	O
total	O
of	O
572	O
reported	O
cases	O
were	O
collected	O
during	O
this	O
period	O
in	O
Dongcheng	O
District	O
,	O
Beijing	O
,	O
and	O
99	O
of	O
them	O
were	O
excluded	O
from	O
SARS	O
,	O
because	O
of	O
diagnosis	O
of	O
common	O
cold	B-PROC
,	O
regular	O
pneumonia	O
,	O
measles	O
and	O
rubella	O
,	O
etc	O
.	O

The	O
comprehensive	O
disease	O
control	O
strategy	O
proposed	O
includes	O
the	O
creation	O
of	O
a	O
hospital	O
infrastructure	O
specific	O
to	O
the	O
containment	O
of	O
biological	O
threats	O
;	O
an	O
advisory	O
coalition	O
of	O
disease	O
control	O
specialists	O
;	O
the	O
development	B-PROC
of	O
a	O
biological	O
threat	O
-	O
and	O
-	O
containment	O
simulation	O
laboratory	O
and	O
three	O
specific	O
programmes	O
in	O
patient	O
safety	O
,	O
risk	O
assessment	O
and	O
community	O
mobilization	O
.	O

The	O
same	O
recombinant	O
proteins	O
were	O
also	O
applied	O
to	O
a	O
newly	O
developed	O
platform	O
for	O
the	O
development	B-PROC
of	O
a	O
15	O
-	O
min	O
rapid	O
test	O
.	O

TITLE	O
:	O
Effects	O
of	O
infection	O
with	O
transmissible	O
gastroenteritis	O
virus	O
on	O
concomitant	O
immune	B-PROC
responses	I-PROC
to	O
dietary	O
and	O
injected	O
antigens	O
.	O

Given	O
the	O
highly	O
contagious	O
and	O
acute	O
nature	O
of	O
the	O
disease	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
the	O
development	B-PROC
of	O
diagnostic	O
assays	O
that	O
can	O
detect	O
SARS	O
-	O
CoV	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
a	O
major	O
antigenic	O
determinant	O
for	O
use	O
in	O
the	O
development	B-PROC
of	O
a	O
rapid	O
serological	O
diagnostic	O
test	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
infection	O
and	O
to	O
study	O
the	O
immune	B-PROC
response	I-PROC
during	O
SARS	O
coronavirus	O
infection	O
in	O
humans	O
,	O
we	O
cloned	O
the	O
full	O
length	O
and	O
six	O
truncated	O
fragments	O
of	O
the	O
nucleocapsid	O
gene	O
,	O
expressed	B-PROC
them	O
,	O
and	O
purified	O
them	O
as	O
glutathione	O
S	O
-	O
transferase	O
-	O
tagged	O
recombinant	O
proteins	O
.	O

Viral	O
antigen	O
and	O
nucleic	O
acid	O
were	O
detected	O
in	O
bronchiolar	O
epithelial	O
cells	O
during	O
peak	O
viral	B-PROC
replication	I-PROC
.	O

Less	O
common	O
symptoms	O
include	O
sputum	B-PROC
production	I-PROC
,	O
sore	O
throat	O
,	O
coryza	O
,	O
dizziness	O
,	O
nausea	O
,	O
vomiting	O
and	O
diarrhoea	O
.	O

A	O
retrospective	O
study	O
carried	O
out	O
of	O
72	O
probable	O
SARS	O
patients	O
has	O
shown	O
that	O
cases	O
who	O
received	O
pulse	B-PROC
methylprendisolone	O
did	O
not	O
differ	O
in	O
cumulative	O
steroid	O
dosage	O
or	O
adverse	O
reactions	O
,	O
although	O
the	O
former	O
patients	O
had	O
less	O
oxygen	O
requirement	O
,	O
better	O
radiographic	O
outcome	O
,	O
and	O
less	O
likelihood	O
of	O
requiring	O
rescue	O
pulse	B-PROC
steroid	O
therapy	O
than	O
their	O
counterparts	O
.	O

Avascular	O
necrosis	B-PROC
of	O
the	O
hip	O
has	O
been	O
reported	O
as	O
another	O
complication	O
.	O

These	O
included	O
an	O
enhanced	O
disease	O
surveillance	O
system	O
,	O
expanded	O
laboratory	O
diagnostic	O
capacity	O
,	O
heightened	O
infection	O
control	O
in	O
hospitals	O
and	O
residential	O
institutions	O
for	O
the	O
elderly	O
,	O
intensive	O
contact	O
tracing	O
coupled	O
with	O
medical	O
surveillance	O
at	O
designated	O
medical	O
centres	O
,	O
quarantine	O
of	O
close	O
contacts	O
by	O
way	O
of	O
home	O
confinement	O
,	O
formation	B-PROC
of	O
multidisciplinary	O
investigation	O
and	O
response	O
teams	O
,	O
and	O
public	O
education	O
and	O
communication	O
.	O

To	O
prevent	O
spread	O
in	O
the	O
region	O
and	O
beyond	O
,	O
port	O
health	O
measures	O
targeted	B-PROC
at	O
both	O
entry	O
and	O
exit	O
health	O
screenings	O
were	O
also	O
carried	O
out	O
together	O
with	O
regional	O
and	O
international	O
liaison	O
.	O

As	O
data	O
generated	O
from	O
some	O
viral	O
systems	O
other	O
than	O
coronaviruses	O
suggested	O
that	O
viral	O
N	O
-	O
N	O
self	O
-	O
interactions	O
may	O
be	O
necessary	O
for	O
subsequent	O
formation	B-PROC
of	O
the	O
nucleocapsid	O
and	O
assembly	O
of	O
the	O
viral	O
particles	O
,	O
we	O
decided	O
to	O
investigate	O
SARS	O
-	O
CoV	O
N	O
-	O
N	O
interaction	O
.	O

Gene	O
-	O
based	O
vaccination	O
for	O
the	O
SARS	O
-	O
CoV	O
elicits	O
effective	O
immune	B-PROC
responses	I-PROC
that	O
generate	O
protective	O
immunity	B-PROC
in	O
an	O
animal	O
model	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
transmissible	O
febrile	B-PROC
respiratory	O
illness	O
caused	O
by	O
a	O
recently	O
discovered	O
coronavirus	O
.	O

In	O
addition	O
,	O
constant	O
exposure	O
of	O
naive	O
mice	O
to	O
infected	O
mice	O
,	O
via	O
the	O
use	O
of	O
serial	O
sentinels	O
,	O
prolonged	O
viral	B-PROC
transmission	I-PROC
.	O

Based	O
on	O
6	O
strains	O
with	O
accurate	O
date	O
of	O
host	O
death	B-PROC
,	O
we	O
estimated	O
a	O
time	O
of	O
the	O
last	O
common	O
ancestor	O
,	O
which	O
is	O
coincident	O
with	O
epidemic	O
investigations	O
,	O
and	O
an	O
evolution	B-PROC
rate	O
in	O
the	O
same	O
range	O
as	O
that	O
reported	O
for	O
the	O
HIV	O
-	O
1	O
virus	O
.	O

Cytokine	O
profile	O
of	O
SARS	O
patients	O
showed	O
marked	O
elevation	O
of	O
Th1	O
cytokine	O
interferon	O
(	O
IFN	O
)-	O
gamma	O
,	O
inflammatory	O
cytokines	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
12	O
for	O
at	O
least	O
2	O
weeks	O
after	O
disease	O
onset	O
,	O
but	O
there	O
was	O
no	O
significant	O
elevation	O
of	O
inflammatory	O
cytokine	O
tumour	O
necrosis	B-PROC
factor	O
(	O
TNF	O
)-	O
alpha	O
,	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	O
-	O
10	O
,	O
Th1	O
cytokine	O
IL	O
-	O
2	O
and	O
Th2	O
cytokine	O
IL	O
-	O
4	O
.	O

The	O
index	O
case	O
-	O
patient	O
(	O
patient	O
A	O
),	O
who	O
had	O
worked	O
in	O
the	O
French	O
hospital	O
of	O
Hanoi	O
,	O
Vietnam	O
,	O
was	O
the	O
most	O
probable	O
source	O
of	O
transmission	O
for	O
the	O
three	O
other	O
confirmed	O
cases	O
;	O
two	O
had	O
been	O
exposed	O
to	O
patient	O
A	O
while	O
on	O
the	O
Hanoi	O
-	O
Paris	O
flight	B-PROC
of	O
March	O
22	O
-	O
23	O
.	O

After	O
its	O
causative	O
agent	O
,	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
was	O
confirmed	O
,	O
laboratory	O
methods	O
,	O
including	O
virus	O
isolation	O
,	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
serologic	O
methods	O
,	O
have	O
been	O
quickly	O
developed	O
.	O

Fever	B-PROC
developed	O
on	O
the	O
first	O
day	O
of	O
illness	O
onset	O
,	O
and	O
both	O
respiratory	O
symptoms	O
and	O
radiographic	O
changes	O
occurred	O
on	O
day	O
4	O
.	O

Cerebrospinal	O
fluid	O
tested	O
positive	O
for	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
by	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
.	O

There	O
was	O
no	O
evidence	O
of	O
viral	B-PROC
shedding	I-PROC
at	O
delivery	O
.	O

The	O
present	O
paper	O
discusses	O
the	O
prediction	O
of	O
protein	B-PROC
-	I-PROC
protein	I-PROC
interaction	I-PROC
using	O
normal	O
mode	O
analysis	O
and	O
examples	O
of	O
applications	O
are	O
given	O
.	O

The	O
CC	O
chemokine	O
ligand	B-PROC
(	O
CCL	O
)	O
5	O
is	O
localized	O
in	O
white	O
matter	O
tracts	O
undergoing	O
demyelination	O
,	O
suggesting	O
that	O
this	O
chemokine	O
participates	O
in	O
the	O
pathogenesis	B-PROC
of	O
disease	O
by	O
attracting	O
inflammatory	O
cells	O
into	O
the	O
CNS	O
.	O

ABSTRACT	O
:	O
The	O
114	O
-	O
day	O
epidemic	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
swept	O
29	O
countries	O
,	O
affected	O
a	O
reported	O
8	O
,	O
098	O
people	O
,	O
left	O
774	O
patients	O
dead	B-PROC
and	O
almost	O
paralyzed	O
the	O
Asian	O
economy	O
.	O

TITLE	O
:	O
Protective	O
effects	O
of	O
preischemic	O
treatment	O
with	O
pioglitazone	O
,	O
a	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
gamma	O
ligand	B-PROC
,	O
on	O
lung	O
ischemia	O
-	O
reperfusion	O
injury	O
in	O
rats	O
.	O

TITLE	O
:	O
Dissection	O
study	O
on	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
3C	O
-	O
like	O
protease	O
reveals	O
the	O
critical	O
role	O
of	O
the	O
extra	O
domain	O
in	O
dimerization	O
of	O
the	O
enzyme	O
:	O
defining	O
the	O
extra	O
domain	O
as	O
a	O
new	O
target	O
for	O
design	O
of	O
highly	O
specific	O
protease	B-PROC
inhibitors	I-PROC
.	O

Because	O
disrupted	O
virions	O
also	O
induced	O
type	O
1	O
immune	B-PROC
responses	I-PROC
,	O
we	O
conclude	O
that	O
structural	O
elements	O
of	O
virions	O
inherently	O
contribute	O
to	O
IFN	O
-	O
gamma	O
-	O
dependent	O
isotype	B-PROC
switching	I-PROC
by	O
inactivated	O
viruses	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
secretory	B-PROC
phospholipase	O
A2	O
in	O
acute	O
chest	O
syndrome	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
caused	O
by	O
a	O
highly	O
infectious	O
novel	O
coronavirus	O
(	O
CoV	O
),	O
predominantly	O
presents	O
with	O
severe	O
pneumonitis	O
leading	O
to	O
respiratory	O
failure	O
and	O
death	B-PROC
in	O
approximately	O
10	O
%	O
of	O
victims	O
.	O

We	O
tested	O
the	O
inhibitory	O
activity	O
against	O
infection	O
of	O
two	O
sets	O
of	O
peptides	O
corresponding	O
to	O
sequences	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
HR1	O
and	O
HR2	O
regions	O
and	O
investigated	O
the	O
interactions	O
between	O
the	O
HR1	O
and	O
HR2	O
peptides	O
by	O
surface	O
plasmon	O
resonance	O
,	O
sedimentation	O
equilibration	O
analysis	O
,	O
circular	O
dichroism	O
,	O
native	O
polyacrylamide	O
-	O
gel	O
electrophoresis	O
,	O
size	O
exclusion	O
high	O
-	O
performance	O
liquid	O
chromatography	O
,	O
and	O
computer	O
-	O
aided	O
homology	O
modelling	O
and	O
molecule	O
docking	B-PROC
analysis	O
.	O

We	O
focused	O
on	O
using	O
synthetic	O
peptides	O
for	O
developing	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
,	O
which	O
aimed	O
to	O
block	O
viral	O
invasion	O
by	O
eliciting	O
an	O
immune	B-PROC
response	I-PROC
specific	O
to	O
the	O
native	O
SARS	O
-	O
CoV	O
S	O
protein	O
.	O

Synthetic	O
peptides	O
can	O
elicit	O
specific	O
antibodies	O
to	O
SARS	O
-	O
CoV	O
.	O
The	O
study	O
provides	O
insights	O
for	O
the	O
future	O
development	B-PROC
of	O
SARS	O
vaccine	O
via	O
the	O
synthetic	O
-	O
peptide	O
-	O
based	O
approach	O
.	O

Whilst	O
serum	O
total	O
LD	O
could	O
only	O
achieve	O
AUC	O
of	O
0	O
.	O
68	O
(	O
CI	O
=	O
0	O
.	O
59	O
-	O
0	O
.	O
77	O
)	O
for	O
predicting	O
death	B-PROC
,	O
LD1	O
isoenzyme	O
was	O
found	O
to	O
be	O
the	O
best	O
biochemical	O
prognostic	O
indicator	O
with	O
AUC	O
of	O
0	O
.	O
84	O
(	O
CI	O
=	O
0	O
.	O
75	O
-	O
0	O
.	O
90	O
),	O
sensitivity	O
of	O
62	O
%	O
(	O
CI	O
=	O
46	O
-	O
76	O
%),	O
specificity	O
of	O
93	O
%	O
(	O
CI	O
=	O
83	O
-	O
98	O
%)	O
at	O
cut	O
-	O
off	O
activity	O
of	O
>	O
or	O
=	O
80	O
U	O
L	O
(-	O
1	O
).	O

Apart	O
from	O
age	O
,	O
serum	O
LD1	O
activity	O
was	O
the	O
best	O
prognostic	O
indicator	O
for	O
predicting	O
death	B-PROC
in	O
patients	O
with	O
SARS	O
compared	O
with	O
serum	O
total	O
LD	O
activity	O
,	O
haemoglobin	O
concentration	O
,	O
leucocyte	O
and	O
lymphocyte	O
counts	O
.	O

This	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
-	O
hybridization	B-PROC
assay	O
gave	O
a	O
high	O
specificity	O
and	O
a	O
sensitivity	O
of	O
0	O
.	O
5	O
50	O
%	O
Tissue	O
Culture	O
Infective	O
Dose	O
per	O
ml	O
.	O

Four	O
types	O
were	O
identified	O
:	O
good	O
water	O
repellency	O
and	O
water	O
resistance	B-PROC
,	O
poor	O
air	O
permeability	O
(	O
Type	O
A	O
PPC	O
);	O
good	O
water	O
repellency	O
and	O
air	O
permeability	O
,	O
poor	O
water	O
resistance	B-PROC
(	O
Type	O
B	O
PPC	O
);	O
poor	O
water	O
repellency	O
,	O
poor	O
water	O
resistance	B-PROC
,	O
and	O
fair	O
air	O
permeability	O
(	O
Type	O
C	O
PPC	O
);	O
and	O
good	O
water	O
repellency	O
,	O
poor	O
air	O
permeability	O
,	O
and	O
fair	O
water	O
resistance	B-PROC
(	O
Type	O
D	O
PPC	O
).	O

Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
progress	O
toward	O
understanding	O
the	O
epidemic	O
was	O
addressed	O
,	O
and	O
other	O
sessions	O
were	O
presented	O
concerning	O
immune	O
therapy	O
and	O
immunopotentiation	B-PROC
of	O
disease	O
,	O
siRNA	O
and	O
gene	B-PROC
silencing	I-PROC
,	O
host	O
responses	O
to	O
pathogen	O
infections	O
,	O
as	O
well	O
as	O
the	O
use	O
of	O
genetic	O
engineering	O
to	O
circumvent	O
and	O
direct	O
the	O
immune	B-PROC
response	I-PROC
.	O

TITLE	O
:	O
Ocular	B-PROC
screening	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Our	O
study	O
did	O
not	O
demonstrate	O
any	O
ocular	B-PROC
manifestations	O
in	O
patients	O
with	O
SARS	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
rapid	O
development	B-PROC
and	O
implementation	O
of	O
an	O
innovative	O
emergency	O
medical	O
services	O
(	O
EMS	O
)	O
command	O
,	O
control	O
,	O
and	O
tracking	O
system	O
to	O
mitigate	O
the	O
risk	O
of	O
iatrogenic	O
spread	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
among	O
health	O
care	O
facilities	O
,	O
health	O
care	O
workers	O
,	O
and	O
patients	O
in	O
Ontario	O
,	O
Canada	O
,	O
as	O
a	O
result	O
of	O
interfacility	O
patient	O
transfers	O
.	O

Prevalence	O
of	O
symptoms	O
of	O
acute	O
upper	O
respiratory	O
infection	O
in	O
people	O
with	O
positive	O
antibody	B-PROC
against	O
SARS	O
-	O
CoV	O
was	O
higher	O
(	O
49	O
.	O
28	O
%)	O
than	O
that	O
in	O
those	O
with	O
negative	O
antibody	B-PROC
(	O
30	O
.	O
35	O
%).	O

Positive	O
rate	O
of	O
SARS	O
-	O
CoV	O
RNA	O
was	O
100	O
%	O
(	O
8	O
/	O
8	O
),	O
67	O
.	O
7	O
%	O
(	O
21	O
/	O
31	O
),	O
47	O
.	O
4	O
%	O
(	O
27	O
/	O
57	O
)	O
and	O
40	O
.	O
0	O
%	O
(	O
2	O
/	O
5	O
)	O
on	O
the	O
10	O
-	O
19	O
,	O
20	O
-	O
29	O
,	O
30	O
-	O
39	O
and	O
40	O
-	O
55	O
days	O
after	O
onset	O
of	O
fever	B-PROC
,	O
respectively	O
,	O
with	O
values	O
of	O
logarithm	O
of	O
SARS	O
-	O
CoV	O
RNA	O
load	O
of	O
6	O
.	O
06	O
+/-	O

Preparation	O
should	O
include	O
correcting	O
coagulopathy	O
,	O
minimizing	O
preexisting	O
encephalopathy	O
,	O
preventing	O
sepsis	O
,	O
and	O
optimizing	O
renal	B-PROC
function	I-PROC
.	O

Secondary	O
outcomes	O
included	O
mortality	O
,	O
days	O
alive	O
and	O
meeting	O
oxygenation	B-PROC
criteria	O
for	O
extubation	O
,	O
and	O
days	O
patients	O
were	O
alive	O
following	O
a	O
successful	O
unassisted	O
ventilation	O
test	O
.	O

Furthermore	O
,	O
male	O
and	O
female	O
reproductive	B-PROC
organs	O
were	O
infected	O
within	O
6	O
weeks	O
of	O
the	O
beginning	O
of	O
exposure	O
.	O

This	O
fragment	O
was	O
highly	O
expressed	B-PROC
,	O
and	O
the	O
purified	O
fragment	O
C	O
could	O
detect	O
all	O
33	O
SARS	O
patient	O
serum	O
samples	O
tested	O
,	O
collected	O
from	O
7	O
to	O
60	O
days	O
after	O
the	O
onset	O
of	O
fever	B-PROC
,	O
but	O
had	O
no	O
reactivity	O
with	O
all	O
66	O
healthy	O
human	O
serum	O
samples	O
tested	O
.	O

ABSTRACT	O
:	O
Sixty	O
-	O
nine	O
fecal	O
samples	O
from	O
diarrheic	O
puppies	O
were	O
examined	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
assays	O
for	O
the	O
M	O
and	O
the	O
S	O
genes	O
of	O
canine	O
coronaviruses	O
(	O
CCoVs	O
).	O

We	O
show	O
that	O
the	O
success	O
of	O
these	O
control	O
measures	O
is	O
determined	O
as	O
much	O
by	O
the	O
proportion	O
of	O
transmission	O
occurring	O
prior	O
to	O
the	O
onset	O
of	O
overt	O
clinical	O
symptoms	O
(	O
or	O
via	O
asymptomatic	O
infection	O
)	O
as	O
the	O
inherent	O
transmissibility	O
of	O
the	O
etiological	O
agent	O
(	O
measured	O
by	O
the	O
reproductive	B-PROC
number	O
R	O
(	O
0	O
)).	O

The	O
emergence	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
in	O
late	O
2002	O
and	O
the	O
recent	O
outbreaks	O
of	O
avian	O
influenza	O
in	O
Asia	O
are	O
timely	O
reminders	O
of	O
the	O
ever	O
present	O
risks	O
from	O
respiratory	O
viral	B-PROC
diseases	I-PROC
.	O

However	O
,	O
during	O
the	O
past	O
2	O
to	O
3	O
years	O
and	O
largely	O
for	O
commercial	O
reasons	O
,	O
there	O
has	O
been	O
a	O
decline	O
in	O
interest	O
in	O
their	O
further	O
development	B-PROC
by	O
major	O
drug	O
companies	O
.	O

If	O
it	O
remained	O
>	O
300	O
mm	O
Hg	O
,	O
weaning	B-PROC
was	O
started	O
.	O

Obesity	O
-	O
related	O
excess	O
mortality	O
was	O
verified	O
mainly	O
for	O
the	O
youngest	O
patients	O
(	O
odds	O
ratio	O
,	O
2	O
.	O
5	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
6	O
-	O
6	O
.	O
1	O
)	O
and	O
for	O
the	O
patients	O
with	O
a	O
probability	O
of	O
intensive	O
care	O
unit	O
death	B-PROC
of	O
11	O
-	O
50	O
%	O
(	O
odds	O
ratio	O
,	O
2	O
.	O
6	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
2	O
-	O
5	O
.	O
5	O
).	O

Yet	O
,	O
there	O
have	O
been	O
no	O
corresponding	O
changes	O
in	O
payments	O
for	O
nursing	B-PROC
services	O
by	O
the	O
National	O
Health	O
Insurance	O
system	O
in	O
Taiwan	O
such	O
as	O
increasing	O
nurse	O
fees	O
for	O
inpatient	O
services	O
.	O

We	O
have	O
established	O
a	O
continuous	O
colorimetric	O
assay	O
for	O
SARS	O
3CL	O
proteinase	B-PROC
and	O
applied	O
it	O
to	O
study	O
the	O
enzyme	O
catalytic	O
mechanism	O
.	O

DNA	O
vaccines	O
are	O
an	O
attractive	O
approach	O
for	O
SARS	O
vaccine	O
development	B-PROC
,	O
as	O
they	O
offer	O
many	O
advantages	O
over	O
conventional	O
vaccines	O
,	O
including	O
stability	O
,	O
simplicity	O
,	O
and	O
safety	O
.	O

Our	O
investigators	O
have	O
previously	O
shown	O
that	O
DNA	O
vaccination	O
with	O
antigen	O
linked	O
to	O
calreticulin	O
(	O
CRT	O
)	O
dramatically	O
enhances	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
class	O
I	O
presentation	O
of	O
linked	O
antigen	O
to	O
CD8	O
(+)	O
T	O
cells	O
.	O

Vaccination	O
with	O
naked	O
CRT	O
/	O
N	O
DNA	O
generated	O
the	O
most	O
potent	O
N	O
-	O
specific	O
humoral	O
and	O
T	O
-	O
cell	O
-	O
mediated	O
immune	B-PROC
responses	I-PROC
in	O
vaccinated	O
C57BL	O
/	O
6	O
mice	O
among	O
all	O
of	O
the	O
DNA	O
constructs	O
tested	O
.	O

We	O
also	O
expressed	B-PROC
recombinant	O
N	O
proteins	O
in	O
Escherichia	O
coli	O
and	O
prepared	O
N	O
protein	O
-	O
specific	O
polyclonal	O
antibodies	O
.	O

ABSTRACT	O
:	O
In	O
2003	O
,	O
critical	O
care	O
and	O
infectious	O
disease	O
experts	O
representing	O
11	O
international	O
organizations	O
developed	O
management	O
guidelines	O
for	O
severe	O
sepsis	O
and	O
septic	O
shock	O
that	O
would	O
be	O
of	O
practical	O
use	O
for	O
the	O
bedside	O
clinician	O
,	O
under	O
the	O
auspices	O
of	O
the	O
Surviving	O
Sepsis	O
Campaign	O
,	O
an	O
international	O
effort	B-PROC
to	O
increase	O
awareness	O
and	O
improve	O
outcome	O
in	O
severe	O
sepsis	O
.	O

Key	O
recommendations	O
,	O
listed	O
by	O
category	O
and	O
not	O
by	O
hierarchy	O
,	O
include	O
early	O
goal	O
-	O
directed	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
hrs	O
after	O
recognition	O
;	O
appropriate	O
diagnostic	O
studies	O
to	O
ascertain	O
causative	O
organisms	O
before	O
starting	O
antibiotics	O
;	O
early	O
administration	O
of	O
broad	O
-	O
spectrum	O
antibiotic	O
therapy	O
;	O
reassessment	O
of	O
antibiotic	O
therapy	O
with	O
microbiology	O
and	O
clinical	O
data	O
to	O
narrow	O
coverage	O
,	O
when	O
appropriate	O
;	O
a	O
usual	O
7	O
-	O
10	O
days	O
of	O
antibiotic	O
therapy	O
guided	O
by	O
clinical	O
response	O
;	O
source	O
control	O
with	O
attention	O
to	O
the	O
method	O
that	O
balances	O
risks	O
and	O
benefits	O
;	O
equivalence	O
of	O
crystalloid	O
and	O
colloid	O
resuscitation	O
;	O
aggressive	B-PROC
fluid	O
challenge	O
to	O
restore	O
mean	O
circulating	O
filling	O
pressure	O
;	O
vasopressor	O
preference	O
for	O
norepinephrine	O
and	O
dopamine	O
;	O
cautious	O
use	O
of	O
vasopressin	O
pending	O
further	O
studies	O
;	O
avoiding	O
low	O
-	O
dose	O
dopamine	O
administration	O
for	O
renal	O
protection	O
;	O
consideration	O
of	O
dobutamine	O
inotropic	O
therapy	O
in	O
some	O
clinical	O
situations	O
;	O
avoidance	O
of	O
supranormal	O
oxygen	O
delivery	O
as	O
a	O
goal	O
of	O
therapy	O
;	O
stress	O
-	O
dose	O
steroid	O
therapy	O
for	O
septic	O
shock	O
;	O
use	O
of	O
recombinant	O
activated	O
protein	O
C	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
high	O
risk	O
for	O
death	B-PROC
;	O
with	O
resolution	O
of	O
tissue	O
hypoperfusion	O
and	O
in	O
the	O
absence	O
of	O
coronary	O
artery	O
disease	O
or	O
acute	O
hemorrhage	O
,	O
targeting	B-PROC
a	O
hemoglobin	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
;	O
appropriate	O
use	O
of	O
fresh	O
frozen	O
plasma	O
and	O
platelets	O
;	O
a	O
low	O
tidal	O
volume	O
and	O
limitation	O
of	O
inspiratory	B-PROC
plateau	O
pressure	O
strategy	O
for	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
application	O
of	O
a	O
minimal	O
amount	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
in	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
a	O
semirecumbent	O
bed	O
position	O
unless	O
contraindicated	O
;	O
protocols	O
for	O
weaning	B-PROC
and	O
sedation	O
/	O
analgesia	B-PROC
,	O
using	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
with	O
daily	O
interruptions	O
/	O
lightening	O
;	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
;	O
maintenance	O
of	O
blood	O
glucose	O
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
;	O
equivalence	O
of	O
continuous	O
veno	O
-	O
veno	O
hemofiltration	O
and	O
intermittent	O
hemodialysis	O
;	O
lack	O
of	O
utility	O
of	O
bicarbonate	O
use	O
for	O
pH	O
>	O
or	O
=	O
7	O
.	O
15	O
;	O
use	O
of	O
deep	O
vein	O
thrombosis	O
/	O
stress	O
ulcer	O
prophylaxis	O
;	O
and	O
consideration	O
of	O
limitation	O
of	O
support	O
where	O
appropriate	O
.	O

Five	O
of	O
the	O
six	O
patients	O
had	O
normal	O
chest	O
radiographs	O
,	O
and	O
four	O
had	O
symptoms	O
such	O
as	O
myalgia	O
,	O
chills	O
,	O
coughing	O
,	O
and	O
feeling	O
feverish	B-PROC
.	O

Cells	O
infected	O
with	O
MVA	O
/	O
Sor	O
MVA	O
/	O
S	O
-	O
HA	O
synthesized	O
a	O
200	O
-	O
kDa	O
protein	O
,	O
which	O
was	O
recognized	O
by	O
antibody	B-PROC
raised	O
against	O
a	O
synthetic	O
peptide	O
of	O
SARS	O
-	O
CoV	O
S	O
or	O
the	O
epitope	O
tag	O
in	O
Western	O
blot	O
analyses	O
.	O

The	O
spread	O
of	O
the	O
airborne	O
,	O
virus	O
-	O
laden	O
aerosols	O
generated	O
by	O
the	O
index	O
patient	O
was	O
modeled	O
with	O
the	O
use	O
of	O
airflow	B-PROC
-	O
dynamics	O
studies	O
,	O
including	O
studies	O
performed	O
with	O
the	O
use	O
of	O
computational	O
fluid	O
-	O
dynamics	O
and	O
multizone	O
modeling	O
.	O

RESULTS	O
:	O
A	O
mean	O
of	O
5100	O
persons	O
per	O
day	O
(	O
95	O
%	O
CI	O
4580	O
to	O
5610	O
)	O
underwent	O
fever	B-PROC
screening	O
at	O
the	O
outpatient	O
and	O
emergency	O
department	O
(	O
ED	O
)	O
entrances	O
to	O
the	O
hospital	O
,	O
of	O
which	O
35	O
per	O
day	O
(	O
95	O
%	O
CI	O
30	O
to	O
40	O
)	O
were	O
referred	O
for	O
further	O
evaluation	O
for	O
suspected	O
or	O
probable	O
SARS	O
.	O

We	O
discuss	O
the	O
unique	O
methodologic	O
and	O
logistical	O
challenges	O
faced	O
by	O
researchers	O
who	O
attempt	O
to	O
conduct	B-PROC
controlled	O
trials	O
of	O
therapeutic	O
agents	O
during	O
an	O
outbreak	O
of	O
a	O
novel	O
or	O
unknown	O
infectious	O
pathogen	O
.	O

All	O
confirmed	O
SARS	O
cases	O
demonstrated	O
seroconversion	O
or	O
fourfold	O
rise	O
in	O
IgG	O
antibody	B-PROC
titer	O
;	O
no	O
control	O
was	O
positive	O
.	O

The	O
etiologic	O
agent	O
of	O
SARS	O
was	O
named	O
'	O
SARS	O
-	O
associated	O
coronavirus	O
'	O
(	O
SARS	O
-	O
CoV	O
)	O
that	O
can	O
be	O
detected	O
with	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
.	O

Sustained	O
response	O
to	O
treatment	O
was	O
defined	O
as	O
(	O
1	O
)	O
defervescence	O
for	O
>	O
or	O
=	O
4	O
consecutive	O
days	O
,	O
(	O
2	O
)	O
resolution	O
of	O
lung	O
consolidation	O
by	O
>	O
25	O
%,	O
and	O
(	O
3	O
)	O
oxygen	O
independence	O
by	O
the	O
fourth	O
day	O
without	O
fever	B-PROC
.	O

There	O
were	O
15	O
deaths	B-PROC
(	O
mortality	O
rate	O
10	O
.	O
9	O
%),	O
most	O
with	O
significant	O
co	O
-	O
morbidities	O
,	O
whereas	O
122	O
(	O
88	O
.	O
4	O
%)	O
had	O
been	O
discharged	O
home	O
4	O
months	O
after	O
the	O
outbreak	O
onset	O
.	O

Pathogens	O
that	O
can	O
survive	O
in	O
these	O
small	O
airborne	O
particles	O
may	O
cause	O
infection	O
if	O
they	O
are	O
inhaled	B-PROC
.	O

No	O
particular	O
allele	O
appeared	O
to	O
be	O
associated	O
with	O
either	O
the	O
development	B-PROC
of	O
FIP	O
,	O
resistance	B-PROC
to	O
FCoV	O
,	O
or	O
the	O
carrier	O
status	O
.	O

A	O
strong	O
positive	O
result	O
would	O
be	O
useful	O
in	O
the	O
diagnosis	O
of	O
FIP	O
(	O
in	O
conjunction	O
with	O
other	O
biochemical	O
and	O
cytological	O
testing	O
),	O
but	O
positive	O
results	O
would	O
be	O
of	O
limited	O
value	O
in	O
monitoring	O
FCoV	O
infection	O
in	O
healthy	O
cats	O
as	O
the	O
antibody	B-PROC
titre	O
could	O
not	O
be	O
reliably	O
compared	O
with	O
those	O
obtained	O
with	O
IFA	O
.	O

The	O
immunogenicity	O
of	O
the	O
recombinant	O
MVA	O
-	O
M	O
was	O
evaluated	O
in	O
the	O
murine	O
model	O
which	O
revealed	O
an	O
effect	O
of	O
the	O
vector	O
on	O
the	O
Th1	O
/	O
Th2	O
balance	B-PROC
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
clinical	O
characteristics	O
and	O
prognostic	O
changes	O
of	O
rehabilitating	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
through	O
regular	O
lung	B-PROC
function	I-PROC
tests	O
and	O
lung	O
imaging	O
studies	O
after	O
discharge	O
and	O
to	O
retrospectively	O
analyze	O
the	O
treatment	O
data	O
of	O
these	O
patients	O
.	O

Medical	O
examination	O
was	O
also	O
carried	O
out	O
for	O
313	O
people	O
who	O
had	O
close	O
contact	O
with	O
the	O
29	O
antibody	B-PROC
positive	O
health	O
care	O
professionals	O
,	O
but	O
no	O
clinical	O
SARS	O
was	O
found	O
.	O

(	O
1	O
)	O
During	O
inhalation	B-PROC
,	O
the	O
concentration	O
of	O
PFIB	O
remained	O
stable	O
;	O
(	O
2	O
)	O
After	O
inhalation	B-PROC
,	O
blood	O
arterial	O
oxygen	B-PROC
partial	I-PROC
pressure	I-PROC
fell	O
gradually	O
,	O
and	O
eventually	O
met	O
the	O
criteria	O
for	O
diagnosing	O
ARDS	O
;	O
(	O
3	O
)	O
The	O
level	O
of	O
IL	O
-	O
8	O
in	O
serum	O
rises	O
significantly	O
after	O
inhalation	B-PROC
(	O
P	O
<	O
0	O
.	O
05	O
),	O
whereas	O
that	O
of	O
IL	O
-	O
6	O
was	O
not	O
obviously	O
altered	O
(	O
P	O
>	O
0	O
.	O
05	O
);	O
(	O
4	O
)	O
Within	O
6	O
hours	O
after	O
inhalation	B-PROC
,	O
no	O
abnormality	O
in	O
canine	O
was	O
observed	O
,	O
but	O
afterwards	O
symptoms	O
gradually	O
appeared	O
,	O
and	O
typical	O
breath	O
of	O
ARDS	O
,	O
such	O
as	O
high	O
frequency	O
and	O
lower	O
level	O
could	O
be	O
seen	O
in	O
later	O
phase	O
;	O
(	O
5	O
)	O
Pathological	O
examination	O
showed	O
severe	O
congestion	O
,	O
edema	O
and	O
atelectasis	O
in	O
most	O
part	O
of	O
both	O
lungs	O
,	O
and	O
signs	O
of	O
anoxia	O
in	O
other	O
organs	O
.	O

Culture	O
cells	O
initially	O
contained	O
five	O
times	O
more	O
N	O
-	O
than	O
R	O
-	O
gene	O
RNA	O
,	O
but	O
the	O
respective	O
levels	O
converged	O
during	O
4	O
days	O
of	O
virus	B-PROC
replication	I-PROC
.	O

Both	O
assays	O
rely	O
on	O
reverse	B-PROC
transcription	B-PROC
and	O
amplification	O
of	O
extracted	O
RNA	O
.	O

In	O
contrast	O
,	O
during	O
FIP	O
disease	O
,	O
fAGP	O
underwent	O
several	O
modifications	O
in	O
the	O
sialic	O
acid	O
content	O
,	O
including	O
decreased	O
expression	B-PROC
of	O
both	O
alpha	O
(	O
2	O
-	O
6	O
)-	O
linked	O
and	O
alpha	O
(	O
2	O
-	O
3	O
)-	O
linked	O
sialic	O
acid	O
(	O
76	O
and	O
44	O
%,	O
respectively	O
when	O
compared	O
to	O
non	O
-	O
pathological	O
feline	O
AGP	O
).	O

Neutrophil	O
engraftment	B-PROC
was	O
as	O
expected	O
and	O
the	O
patient	O
was	O
discharged	O
without	O
signs	O
of	O
acute	O
GvHD	O
.	O

TITLE	O
:	O
[	O
SARS	O
prevention	O
and	O
nursing	B-PROC
in	O
traditional	O
Chinese	O
medicine	O
].	O

The	O
study	O
presents	O
nursing	B-PROC
interventions	O
based	O
on	O
traditional	O
Chinese	O
medicine	O
(	O
TCM	O
),	O
including	O
daily	O
care	O
,	O
diets	O
,	O
massage	O
care	O
,	O
exercise	O
,	O
and	O
Chinese	O
psychosocial	O
care	O
.	O

Serum	O
samples	O
were	O
collected	O
between	O
1993	O
and	O
2001	O
from	O
119	O
animals	O
in	O
a	O
single	O
clan	O
for	O
which	O
behavioral	B-PROC
data	O
on	O
social	O
structure	O
were	O
available	O
and	O
from	O
121	O
hyenas	O
ill	O
several	O
other	O
clans	O
.	O

Canine	O
(	O
distemper	O
virus	O
and	O
FECV	O
/	O
FIPV	O
antibody	B-PROC
prevalence	O
varied	O
considerably	O
over	O
time	O
,	O
whereas	O
FIV	O
,	O
FPLV	O
/	O
CPV	O
,	O
and	O
FCV	O
had	O
a	O
stable	O
,	O
apparently	O
endemic	O
temporal	O
pattern	O
.	O

The	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
release	O
Elispot	O
assay	O
revealed	O
that	O
only	O
SARS	O
-	O
CoV	O
-	O
specific	O
peptides	O
S1203	O
and	O
S978	O
induced	O
a	O
high	O
frequency	O
of	O
IFN	O
-	O
gamma	O
-	O
secreting	B-PROC
T	O
-	O
cell	O
response	O
in	O
HLA	O
-	O
A2	O
(+)	O
donors	O
who	O
had	O
fully	O
recovered	O
from	O
SARS	O
-	O
CoV	O
infection	O
;	O
such	O
a	O
T	O
-	O
cell	O
epitope	O
-	O
specific	O
response	O
was	O
not	O
observed	O
in	O
HLA	O
-	O
A2	O
(+)	O
healthy	O
donors	O
or	O
in	O
HLA	O
-	O
A2	O
(-)	O
donors	O
who	O
had	O
been	O
infected	O
with	O
SARS	O
-	O
CoV	O
after	O
full	O
recovery	O
.	O

Coronavirus	O
replication	O
and	O
transcription	B-PROC
are	O
highly	O
specialized	O
processes	O
of	O
cytoplasmic	O
RNA	B-PROC
synthesis	I-PROC
that	O
localize	O
to	O
virus	O
-	O
induced	O
membrane	O
structures	O
and	O
were	O
recently	O
proposed	O
to	O
involve	O
a	O
complex	O
enzymatic	O
machinery	O
that	O
,	O
besides	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
,	O
helicase	O
,	O
and	O
protease	O
activities	O
,	O
also	O
involves	O
a	O
series	O
of	O
RNA	O
-	O
processing	O
enzymes	O
that	O
are	O
not	O
found	O
in	O
most	O
other	O
RNA	O
virus	O
families	O
.	O

MHV	O
replication	O
inhibited	O
hyperphosphorylation	O
of	O
the	O
retinoblastoma	O
protein	O
(	O
pRb	O
),	O
the	O
event	O
that	O
is	O
necessary	O
for	O
cell	B-PROC
cycle	I-PROC
progression	I-PROC
through	O
late	O
G	O
(	O
1	O
)	O
and	O
into	O
the	O
S	B-PROC
phase	I-PROC
.	O

In	O
addition	O
,	O
targeted	B-PROC
viral	B-PROC
protein	I-PROC
synthesis	I-PROC
,	O
plaque	O
diameter	O
,	O
and	O
cytopathic	O
effect	O
were	O
significantly	O
reduced	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
budding	B-PROC
at	O
the	O
endoplasmic	O
reticulum	O
-	O
Golgi	O
intermediate	O
compartment	O
(	O
ERGIC	O
)	O
requires	O
accumulation	O
of	O
the	O
viral	O
envelope	O
proteins	O
at	O
this	O
point	O
in	O
the	O
secretory	B-PROC
pathway	I-PROC
.	O

Although	O
critical	O
residues	O
for	O
CS1	O
cleavage	B-PROC
have	O
been	O
mapped	O
in	O
vitro	O
,	O
the	O
requirements	O
for	O
cleavage	B-PROC
have	O
not	O
been	O
studied	O
in	O
infected	O
cells	O
.	O

Transplantation	O
of	O
glial	O
-	O
committed	O
progenitor	O
cells	O
into	O
the	O
T8	O
spinal	O
cord	O
of	O
MHV	O
-	O
infected	O
mice	O
demonstrating	O
complete	O
hindlimb	O
paralysis	O
resulted	O
in	O
migration	B-PROC
of	O
cells	O
up	O
to	O
12	O
mm	O
from	O
the	O
implantation	B-PROC
site	O
and	O
remyelination	B-PROC
of	O
up	O
to	O
67	O
%	O
of	O
axons	O
.	O

Expression	B-PROC
of	O
viral	O
antigens	O
was	O
much	O
lower	O
in	O
infected	O
cells	O
treated	O
with	O
nelfinavir	O
than	O
in	O
untreated	O
infected	O
cells	O
.	O

The	O
resulting	O
close	O
apposition	O
of	O
fusion	O
peptide	O
and	O
spike	O
transmembrane	O
domain	O
facilitates	O
membrane	B-PROC
fusion	I-PROC
.	O

TITLE	O
:	O
Induction	O
of	O
enhanced	O
green	O
fluorescent	O
protein	B-PROC
expression	B-PROC
in	O
response	O
to	O
lesions	O
in	O
the	O
nervous	O
system	O
.	O

Anti	O
-	O
SARS	O
antibodies	O
were	O
determined	O
by	O
anti	O
-	O
SARS	O
specific	O
antibody	B-PROC
detection	O
kit	O
and	O
ELISA	O
method	O
.	O

IgM	O
antibody	B-PROC
was	O
negative	O
in	O
all	O
the	O
samples	O
.	O

It	O
is	O
concluded	O
that	O
the	O
anti	O
-	O
SARS	O
IgG	O
antibody	B-PROC
positive	O
rate	O
in	O
children	O
was	O
obvious	O
higher	O
than	O
that	O
in	O
adults	O
.	O

ABSTRACT	O
:	O
A	O
TaqMan	O
fluorogenic	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
was	O
developed	O
for	O
the	O
detection	O
and	O
quantitation	O
of	O
canine	O
coronavirus	O
(	O
CCoV	O
)	O
RNA	O
in	O
the	O
faeces	O
of	O
naturally	O
or	O
experimentally	O
infected	O
dogs	O
.	O

TITLE	O
:	O
Experimental	O
human	O
metapneumovirus	O
infection	O
of	O
cynomolgus	O
macaques	O
(	O
Macaca	O
fascicularis	O
)	O
results	O
in	O
virus	B-PROC
replication	I-PROC
in	O
ciliated	O
epithelial	O
cells	O
and	O
pneumocytes	O
with	O
associated	O
lesions	O
throughout	O
the	O
respiratory	O
tract	O
.	O

Inhibition	B-PROC
of	O
vacuolar	B-PROC
acidification	I-PROC
impaired	O
infection	O
by	O
SARS	O
-	O
CoV	O
S	O
-	O
bearing	O
pseudotypes	O
,	O
indicating	O
that	O
S	O
-	O
mediated	O
entry	O
requires	O
low	O
pH	O
.	O
Finally	O
,	O
infection	O
by	O
SARS	O
-	O
CoV	O
S	O
pseudotypes	O
but	O
not	O
by	O
vesicular	O
stomatitis	O
virus	O
G	O
pseudotypes	O
was	O
efficiently	O
inhibited	O
by	O
a	O
rabbit	O
serum	O
raised	O
against	O
SARS	O
-	O
CoV	O
particles	O
and	O
by	O
sera	O
from	O
SARS	O
patients	O
,	O
demonstrating	O
that	O
SARS	O
-	O
CoV	O
S	O
is	O
a	O
target	O
for	O
neutralizing	O
antibodies	O
and	O
that	O
such	O
antibodies	O
are	O
generated	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
patients	O
.	O

ABSTRACT	O
:	O
Fiber	O
-	O
optic	O
bronchoscopy	O
is	O
widely	O
used	O
for	O
the	O
early	O
diagnosis	O
of	O
inhalation	B-PROC
injury	O
.	O

The	O
excessive	O
life	O
response	O
to	O
serious	O
clinical	O
insults	O
,	O
such	O
as	O
sepsis	O
,	O
severe	O
pancreatitis	O
,	O
trauma	O
and	O
shock	O
,	O
is	O
called	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
SIRS	O
).	O

Once	O
SIRS	O
occurs	O
,	O
people	O
may	O
often	O
die	O
from	O
serious	O
complications	O
such	O
as	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
disseminated	O
intravascular	O
coagulation	B-PROC
(	O
DIC	O
)	O
and	O
multiple	O
organ	O
failure	O
(	O
MOF	O
).	O

Since	O
its	O
discovery	O
in	O
2000	O
,	O
ACE2	O
has	O
been	O
implicated	O
in	O
heart	B-PROC
function	I-PROC
,	O
hypertension	O
and	O
diabetes	O
,	O
with	O
its	O
effects	O
being	O
mediated	O
,	O
in	O
part	O
,	O
through	O
its	O
ability	O
to	O
convert	O
angiotensin	O
II	O
to	O
angiotensin	O
-(	O
1	O
-	O
7	O
).	O

Lessons	O
learned	B-PROC
during	O
this	O
outbreak	O
will	O
help	O
in	O
the	O
planning	O
and	O
execution	O
of	O
infection	O
control	O
measures	O
,	O
should	O
another	O
outbreak	O
occur	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
new	O
disease	O
that	O
caused	O
large	O
outbreaks	O
in	O
several	O
countries	O
in	O
the	O
first	O
half	O
of	O
2003	O
,	O
resulting	O
in	O
infection	O
in	O
more	O
than	O
8000	O
people	O
and	O
more	O
than	O
900	O
deaths	B-PROC
.	O

ABSTRACT	O
:	O
Nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
a	O
transcription	B-PROC
factor	O
which	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
induction	O
of	O
genes	O
involved	O
in	O
the	O
response	O
to	O
injury	O
and	O
inflammation	O
.	O

Additionally	O
,	O
calpain	O
I	O
inhibitor	O
treatment	O
significantly	O
prevented	O
the	O
activation	B-PROC
of	I-PROC
NF	I-PROC
-	I-PROC
kappaB	I-PROC
as	O
suggested	O
by	O
the	O
inhibition	B-PROC
of	O
IkappaB	O
-	O
alpha	O
;	O
degradation	O
in	O
the	O
pancreas	O
tissues	O
after	O
cerulein	O
administration	O
.	O

In	O
cardiothoracic	O
surgery	O
,	O
inhaled	B-PROC
vasodilators	O
have	O
been	O
shown	O
to	O
improve	O
pulmonary	B-PROC
circulation	B-PROC
when	O
severe	O
pulmonary	O
hypertension	O
is	O
present	O
.	O

Several	O
treatment	O
modalities	O
were	O
tried	O
with	O
limited	O
success	O
to	O
treat	O
SARS	O
and	O
a	O
variety	O
of	O
experimental	O
drugs	O
are	O
under	O
development	B-PROC
.	O

Therefore	O
,	O
evaluation	O
for	O
food	O
allergy	B-PROC
should	O
be	O
considered	O
among	O
patients	O
with	O
recalcitrant	O
or	O
otherwise	O
unexplained	O
acute	O
severe	O
asthma	O
exacerbations	O
;	O
asthma	O
triggered	O
by	O
ingestion	O
of	O
particular	O
foods	O
;	O
and	O
asthma	O
and	O
other	O
manifestations	O
of	O
food	O
allergy	B-PROC
(	O
eg	O
,	O
anaphylaxis	O
,	O
moderate	O
to	O
severe	O
atopic	O
dermatitis	O
).	O

Participants	O
described	O
their	O
experiences	O
during	O
the	O
outbreak	O
and	O
highlighted	O
several	O
themes	O
about	O
values	O
inherent	O
to	O
medical	O
professionalism	O
that	O
arose	O
during	O
this	O
crisis	O
including	O
the	O
balance	B-PROC
between	O
care	O
of	O
patients	O
and	O
accepted	O
personal	O
risk	O
,	O
confidentiality	O
,	O
appropriate	O
interactions	O
between	O
physicians	O
and	O
patients	O
,	O
ethical	O
research	O
conduct	B-PROC
,	O
and	O
role	O
modelling	O
of	O
professionalism	O
for	O
junior	O
doctors	O
.	O

The	O
exact	O
pathophysiology	O
of	O
arsenic	O
polyneuropathy	O
remains	O
unclear	O
and	O
a	O
interference	O
with	O
pyruvate	B-PROC
oxidation	B-PROC
has	O
been	O
postulated	O
.	O

For	O
other	O
virus	O
families	O
like	O
the	O
picornaviruses	O
it	O
is	O
known	O
that	O
pathology	O
is	O
related	O
to	O
proteolytic	B-PROC
cleavage	B-PROC
of	O
host	O
proteins	O
by	O
viral	O
proteinases	O
.	O

A	O
neural	B-PROC
network	I-PROC
was	O
trained	O
to	O
recognise	O
the	O
cleavage	B-PROC
sites	O
in	O
the	O
genomes	O
obtaining	O
a	O
sensitivity	O
of	O
87	O
.	O
0	O
%	O
and	O
a	O
specificity	O
of	O
99	O
.	O
0	O
%.	O

This	O
article	O
provides	O
a	O
summary	O
of	O
our	O
work	O
with	O
such	O
cytokines	O
,	O
which	O
includes	O
attempts	O
to	O
define	O
optimum	O
dosing	O
schedules	O
that	O
lead	O
to	O
optimal	O
primary	O
and	O
lasting	O
memory	B-PROC
antigen	O
-	O
specific	O
immune	B-PROC
responses	I-PROC
.	O

TITLE	O
:	O
Altered	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
expression	B-PROC
in	O
different	O
leukocytes	O
with	O
increment	O
of	O
immunosuppressive	O
mediators	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

TITLE	O
:	O
[	O
The	O
cloning	O
,	O
expression	B-PROC
,	O
purification	O
and	O
identification	O
of	O
SARS	O
virus	O
S2	O
gene	O
and	O
study	O
on	O
its	O
immunological	O
characteristics	O
].	O

The	O
Trx	O
-	O
S2	O
fusion	O
protein	O
was	O
expressed	B-PROC
in	O
E	O
.	O
coli	O
.	O

A	O
subunit	O
vaccine	O
candidate	O
directed	O
against	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
and	O
expressed	B-PROC
in	O
corn	O
seed	O
has	O
been	O
developed	O
for	O
oral	O
delivery	O
to	O
swine	O
.	O

TITLE	O
:	O
Susceptibility	O
to	O
SARS	O
coronavirus	O
S	O
protein	O
-	O
driven	O
infection	O
correlates	O
with	O
expression	B-PROC
of	O
angiotensin	O
converting	O
enzyme	O
2	O
and	O
infection	O
can	O
be	O
blocked	O
by	O
soluble	O
receptor	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
verified	O
if	O
the	O
fulminant	O
hepatitis	O
induced	O
by	O
MHV3	O
could	O
be	O
related	O
to	O
an	O
impairment	O
of	O
innate	B-PROC
immunity	B-PROC
.	O

Thus	O
,	O
a	O
clear	O
differentiation	B-PROC
between	O
the	O
two	O
conditions	O
is	O
needed	O
,	O
especially	O
for	O
those	O
patients	O
who	O
are	O
under	O
active	O
anti	O
-	O
cancer	O
treatment	O
.	O

By	O
multivariate	O
analysis	O
,	O
underlying	O
disease	O
and	O
initial	O
CRP	O
level	O
were	O
predictive	O
of	O
death	B-PROC
.	O

Positive	O
virologic	O
test	O
results	O
in	O
patient	O
groups	O
were	O
associated	O
with	O
mechanical	O
ventilation	O
or	O
death	B-PROC
(	O
p	O
<	O
0	O
.	O
001	O
),	O
suggesting	O
a	O
correlation	O
between	O
viral	O
load	O
and	O
disease	O
severity	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
life	O
-	O
threatening	O
ailment	O
characterized	O
by	O
severe	O
lung	O
injury	O
involving	O
inflammatory	O
cell	O
recruitment	O
to	O
the	O
lung	O
,	O
cytokine	B-PROC
production	I-PROC
,	O
surfactant	O
dysfunction	O
,	O
and	O
up	B-PROC
-	I-PROC
regulation	B-PROC
of	O
nitric	O
oxide	O
synthase	O
2	O
(	O
NOS2	O
)	O
resulting	O
in	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
.	O

NOS2	O
-/-	O
animals	O
exhibited	O
significantly	O
less	O
physiologic	O
lung	O
dysfunction	O
and	O
loss	O
of	O
SP	O
-	O
B	O
expression	B-PROC
than	O
did	O
WT	O
animals	O
.	O

Furthermore	O
,	O
administration	O
of	O
NO	O
donors	O
,	O
independent	O
of	O
cytokine	O
stimulation	O
,	O
decreased	O
SP	O
-	O
B	O
promoter	O
activity	O
and	O
mRNA	B-PROC
expression	B-PROC
in	O
mouse	O
lung	O
epithelial	O
cells	O
.	O

An	O
hour	O
of	O
NPPV	O
therapy	O
led	O
to	O
significant	O
increases	O
in	O
PaO	B-PROC
(	O
2	O
)	O
and	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
and	O
a	O
decrease	O
in	O
respiratory	O
rate	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

S2	O
undergoes	O
more	O
significant	O
structural	O
fluctuation	O
than	O
S1	O
during	O
the	O
400	O
ps	O
molecular	B-PROC
dynamics	I-PROC
simulations	O
because	O
it	O
is	O
located	O
at	O
the	O
open	O
mouth	O
of	O
the	O
catalytic	O
cleft	O
,	O
while	O
S1	O
is	O
situated	O
in	O
the	O
very	O
bottom	O
of	O
this	O
cleft	O
.	O

Mpro	O
may	O
still	O
maintain	O
its	O
proteolytic	B-PROC
activity	O
while	O
it	O
is	O
partially	O
unfolded	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
provided	O
an	O
opportunity	O
to	O
study	O
the	O
antibody	B-PROC
response	I-PROC
of	O
infected	O
individuals	O
to	O
the	O
causative	O
virus	O
,	O
SARS	O
coronavirus	O
.	O

These	O
two	O
plasmids	O
also	O
inhibited	O
viral	B-PROC
replication	I-PROC
as	O
shown	O
by	O
titer	O
assays	O
and	O
by	O
an	O
examination	O
of	O
viral	O
RNA	O
and	O
protein	O
levels	O
.	O

Furthermore	O
,	O
studies	O
in	O
a	O
new	O
human	O
cell	O
culture	O
model	O
have	O
indicated	O
that	O
the	O
presence	O
of	O
ACE2	O
alone	O
is	O
not	O
sufficient	O
for	O
maintaining	O
viral	B-PROC
infection	I-PROC
.	O

After	O
conducting	B-PROC
extensive	O
literature	O
searches	O
and	O
evaluations	O
,	O
pharmacists	O
prepared	O
administration	O
and	O
dosing	O
guidelines	O
for	O
the	O
two	O
investigational	O
drugs	O
,	O
ribavirin	O
and	O
interferon	O
alfacon	O
-	O
1	O
,	O
that	O
were	O
being	O
used	O
to	O
treat	O
the	O
syndrome	O
.	O

ABSTRACT	O
:	O
An	O
immunocomb	O
-	O
based	O
dot	O
-	O
ELISA	O
,	O
employing	O
specially	O
designed	O
apparatus	O
,	O
was	O
used	O
to	O
measure	O
the	O
antibody	B-PROC
status	O
for	O
the	O
three	O
major	O
poultry	O
diseases	O
--	O
Newcastle	O
disease	O
,	O
infectious	O
bursal	O
disease	O
and	O
infectious	O
bronchitis	O
--	O
in	O
single	O
test	O
sera	O
.	O

Pooled	O
sera	O
,	O
taken	O
at	O
the	O
first	O
and	O
last	O
sampling	O
,	O
were	O
examined	O
for	O
antibody	B-PROC
titres	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
and	O
the	O
individual	O
sera	O
from	O
all	O
four	O
samplings	O
were	O
examined	O
for	O
the	O
presence	O
and	O
/	O
or	O
titres	O
of	O
antibodies	O
against	O
avian	O
pneumovirus	O
(	O
APV	O
),	O
Mycoplasma	O
gallisepticum	O
,	O
Mycoplasma	O
synoviae	O
and	O
Ornithobacterium	O
rhinotracheale	O
.	O

EE	O
indices	O
were	O
also	O
calculated	O
by	O
dividing	O
the	O
EE	O
ratios	O
of	O
inoculated	O
embryonated	O
chicken	O
eggs	O
by	O
the	O
mean	O
EE	O
ratio	O
of	O
uninoculated	O
controls	O
,	O
or	O
in	O
the	O
case	O
of	O
virus	B-PROC
neutralization	I-PROC
tests	O
by	O
the	O
mean	O
EE	O
ratio	O
of	O
eggs	O
inoculated	O
with	O
virus	O
alone	O
.	O

HFOV	O
was	O
safe	O
,	O
and	O
was	O
highly	O
effective	O
in	O
correcting	O
oxygenation	B-PROC
failure	O
associated	O
with	O
ARDS	O
in	O
burn	O
patients	O
,	O
and	O
can	O
be	O
successfully	O
used	O
as	O
an	O
intra	O
-	O
operative	O
ventilation	O
modality	O
for	O
burn	O
patients	O
.	O

Of	O
>	O
10	O
,	O
000	O
agents	O
tested	O
,	O
approximately	O
50	O
compounds	O
were	O
found	O
active	O
at	O
10	O
microM	O
;	O
among	O
these	O
compounds	O
,	O
two	O
are	O
existing	O
drugs	O
(	O
Reserpine	O
13	O
and	O
Aescin	O
5	O
)	O
and	O
several	O
are	O
in	O
clinical	O
development	B-PROC
.	O

While	O
the	O
reports	O
were	O
triggered	O
by	O
SARS	O
,	O
and	O
focus	O
on	O
many	O
issues	O
arising	O
from	O
SARS	O
,	O
they	O
all	O
clearly	O
acknowledge	O
that	O
concerns	O
regarding	O
public	O
health	O
in	O
this	O
country	O
are	O
long	O
-	O
standing	B-PROC
.	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
large	O
database	O
on	O
clinical	O
presentation	O
,	O
treatment	O
and	O
prognosis	O
of	O
all	O
clinical	O
diagnosed	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
cases	O
in	O
Beijing	O
during	O
the	O
2003	O
""""	O
crisis	O
""","	O
in	O
order	O
to	O
conduct	B-PROC
further	O
clinical	O
studies	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
region	O
of	O
the	O
APN	O
gene	O
that	O
encodes	O
a	O
stretch	O
of	O
amino	O
acid	O
residues	O
,	O
essential	O
for	O
its	O
HCoV	O
-	O
229E	O
receptor	B-PROC
function	I-PROC
(	O
amino	O
acids	O
260	O
-	O
353	O
).	O

We	O
identified	O
seven	O
polymorphisms	B-PROC
,	O
including	O
four	O
intron	O
3	O
and	O
three	O
exon	O
4	O
variations	O
.	O

Apart	O
from	O
the	O
already	O
known	O
C956T	O
exon	O
4	O
mutation	O
,	O
the	O
six	O
other	O
polymorphisms	B-PROC
have	O
not	O
yet	O
been	O
described	O
.	O

Antiviral	O
activity	O
was	O
estimated	O
by	O
the	O
inhibition	B-PROC
of	O
the	O
SARS	O
-	O
CoV	O
cytopathic	O
effect	O
in	O
Vero	O
E6	O
cells	O
,	O
determined	O
by	O
a	O
tetrazolium	O
-	O
based	O
colorimetric	O
method	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
characterisation	O
of	O
neutralising	O
monoclonal	O
antibody	B-PROC
to	O
the	O
SARS	O
-	O
coronavirus	O
.	O

Monoclonal	O
antibody	B-PROC
reagents	O
that	O
recognise	O
specific	O
antigens	O
on	O
SARS	O
-	O
CoV	O
are	O
needed	O
urgently	O
.	O

TITLE	O
:	O
[	O
Protective	O
effect	O
of	O
specific	O
antibody	B-PROC
in	O
serum	O
of	O
convalescent	O
patient	O
with	O
SARS	O
].	O

At	O
day	O
240	O
,	O
all	O
patients	O
were	O
still	O
positive	O
for	O
anti	O
-	O
nucleocapsid	O
protein	O
IgG	O
antibody	B-PROC
.	O

Since	O
the	O
present	O
ELISA	O
is	O
more	O
convenient	O
and	O
economical	O
than	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
,	O
it	O
may	O
serve	O
as	O
an	O
alternative	O
tool	O
for	O
the	O
early	O
diagnosis	O
of	O
SARS	O
CoV	O
infection	O
in	O
laboratories	O
with	O
limited	O
resources	O
and	O
expertise	O
and	O
for	O
mass	O
screening	O
for	O
the	O
reservoir	O
of	O
SARS	O
CoV	O
.	O
Further	O
studies	O
on	O
serial	O
clinical	O
specimens	O
should	O
reveal	O
the	O
duration	O
of	O
nucleocapsid	O
protein	O
shedding	O
and	O
may	O
reveal	O
a	O
higher	O
detection	O
rate	O
in	O
SARS	O
patients	O
.	O

TITLE	O
:	O
Potent	O
and	O
selective	O
inhibition	B-PROC
of	O
SARS	O
coronavirus	O
replication	O
by	O
aurintricarboxylic	O
acid	O
.	O

ABSTRACT	O
:	O
The	O
importance	O
of	O
rapid	O
diagnosis	O
of	O
influenza	O
has	O
increased	O
with	O
the	O
availability	O
of	O
neuraminidase	B-PROC
inhibitors	I-PROC
,	O
which	O
need	O
to	O
be	O
commenced	O
within	O
48	O
hr	O
of	O
symptom	O
onset	O
.	O

TITLE	O
:	O
Prophylactic	O
and	O
therapeutic	O
effects	O
of	O
small	O
interfering	O
RNA	O
targeting	B-PROC
SARS	O
-	O
coronavirus	O
.	O

Chemically	O
synthesized	O
siRNA	O
duplexes	O
targeting	B-PROC
SARS	O
-	O
CoV	O
genomic	O
RNA	O
are	O
potent	O
agents	O
for	O
inhibition	B-PROC
of	O
the	O
viral	B-PROC
infection	I-PROC
and	O
replication	O
.	O

The	O
detection	O
of	O
S	O
-	O
protein	O
by	O
immunoassays	O
was	O
difficult	O
using	O
human	O
convalescent	O
sera	O
,	O
suggesting	O
that	O
the	O
protein	O
may	O
not	O
elicit	O
strong	O
humoral	B-PROC
immune	I-PROC
response	I-PROC
in	O
virus	O
-	O
infected	O
patients	O
.	O

The	O
high	O
-	O
throughput	O
capacity	O
of	O
this	O
procedure	O
and	O
the	O
safety	O
of	O
using	O
SARS	O
pseudoviruses	O
should	O
make	O
possible	O
large	O
-	O
scale	O
analyses	O
of	O
neutralizing	O
antibody	B-PROC
responses	I-PROC
against	O
SARS	O
-	O
CoV	O
.	O

Reverse	O
-	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
was	O
useful	O
in	O
diagnosing	O
SARS	O
in	O
older	O
patients	O
,	O
but	O
the	O
role	O
of	O
serological	O
tests	O
in	O
individual	O
elderly	O
is	O
limited	O
.	O

Matched	O
controls	O
were	O
obtained	O
from	O
patients	O
who	O
died	B-PROC
of	O
other	O
causes	O
over	O
the	O
same	O
interval	O
.	O

ABSTRACT	O
:	O
This	O
study	O
established	O
a	O
modified	O
alkaline	O
phosphatase	O
-	O
labelled	O
avidin	O
-	O
biotin	O
-	O
complex	O
(	O
ABC	O
-	O
AP	O
)	O
method	O
for	O
diagnosis	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
Mycoplasma	O
pulmonis	O
infection	O
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
wax	O
-	O
embedded	O
sections	O
,	O
murine	O
antibody	B-PROC
-	O
positive	O
serum	O
being	O
used	O
as	O
the	O
primary	O
reagent	O
.	O

Stepwise	O
reduction	O
of	O
the	O
mean	O
airway	O
pressure	O
(	O
26	O
cm	O
H	O
(	O
2	O
)	O
O	O
),	O
and	O
oscillating	O
frequencies	O
(	O
3	O
.	O
5	O
Hz	O
),	O
as	O
well	O
as	O
increasing	O
the	O
oscillating	O
amplitudes	O
(	O
95	O
cm	O
H	O
(	O
2	O
)	O
O	O
)	O
resulted	O
in	O
an	O
unchanged	O
Pa	O
(	O
co	O
(	O
2	O
)),	O
but	O
oxygenation	B-PROC
worsened	O
.	O

The	O
HCoV	O
-	O
229E	O
virus	O
particle	O
showed	O
a	O
binding	O
and	O
redistribution	O
pattern	O
that	O
was	O
similar	O
to	O
that	O
caused	O
by	O
the	O
anti	O
-	O
CD13	O
antibody	B-PROC
:	O
the	O
virus	O
bound	O
to	O
the	O
cell	O
evenly	O
when	O
incubated	O
on	O
ice	O
but	O
became	O
colocalized	O
with	O
caveolin	O
-	O
1	O
at	O
37	O
degrees	O
C	O
;	O
importantly	O
,	O
the	O
virus	O
also	O
caused	O
sequestration	O
of	O
CD13	O
to	O
the	O
caveolin	O
-	O
1	O
-	O
positive	O
area	O
.	O

A	O
caveolin	O
-	O
1	O
knockdown	O
by	O
RNA	B-PROC
interference	I-PROC
also	O
reduced	O
the	O
HCoV	O
-	O
229E	O
infection	O
considerably	O
.	O

The	O
crisis	O
was	O
successfully	O
managed	O
by	O
a	O
Standard	O
Operation	O
Procedure	O
(	O
SOP	O
)	O
that	O
included	O
:	O
(	O
a	O
)	O
containment	O
of	O
SARS	O
patients	O
on	O
a	O
special	O
floor	O
and	O
evacuation	O
of	O
the	O
patients	O
from	O
the	O
infected	O
and	O
near	O
-	O
around	O
floors	O
;	O
(	O
b	O
)	O
sorting	B-PROC
of	O
the	O
hospital	O
into	O
areas	O
and	O
floors	O
to	O
avoid	O
cross	O
contact	O
of	O
people	O
;	O
(	O
c	O
)	O
triage	O
of	O
patients	O
into	O
groups	O
according	O
to	O
risks	O
;	O
(	O
d	O
)	O
closure	O
of	O
the	O
emergency	O
room	O
and	O
outpatient	O
clinics	O
;	O
and	O
(	O
e	O
)	O
set	O
up	O
of	O
an	O
outdoor	O
fever	B-PROC
screening	O
station	O
and	O
emergency	O
service	O
.	O

The	O
central	O
argument	O
in	O
this	O
case	O
is	O
that	O
crisis	O
managerial	O
behavior	O
is	O
the	O
result	O
of	O
how	O
managers	O
channel	O
and	O
distribute	O
the	O
attention	O
of	O
their	O
crisis	O
sense	B-PROC
.	O

What	O
risk	O
issues	O
and	O
actions	O
they	O
take	O
depends	O
on	O
the	O
crisis	O
sense	B-PROC
and	O
on	O
how	O
management	O
responds	O
to	O
leadership	O
,	O
resource	O
,	O
and	O
execution	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
show	O
that	O
SARS	O
-	O
CoV	O
N	O
is	O
capable	O
of	O
inducing	O
apoptosis	B-PROC
of	O
COS	O
-	O
1	O
monkey	O
kidney	O
cells	O
in	O
the	O
absence	O
of	O
growth	B-PROC
factors	O
by	O
down	O
-	O
regulating	O
ERK	O
(	O
extracellular	O
-	O
signal	O
-	O
regulated	O
kinase	O
),	O
up	O
-	O
regulating	O
JNK	O
(	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
)	O
and	O
p38	O
MAPK	O
(	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
)	O
pathways	B-PROC
,	O
and	O
affecting	O
their	O
downstream	O
effectors	O
.	O

SARS	O
-	O
CoV	O
N	O
expression	B-PROC
also	O
down	O
-	O
regulated	O
phospho	O
-	O
Akt	O
and	O
Bcl	O
-	O
2	O
levels	O
,	O
and	O
activated	O
caspases	O
3	O
and	O
7	O
.	O

Three	O
deaths	B-PROC
occurred	O
among	O
the	O
12	O
patients	O
,	O
giving	O
a	O
case	O
fatality	O
rate	O
of	O
25	O
%.	O

At	O
the	O
height	O
of	O
the	O
epidemic	O
,	O
curtailment	O
of	O
patient	O
movement	B-PROC
stopped	O
all	O
transfers	O
for	O
rehabilitation	O
,	O
and	O
physiatrists	O
had	O
to	O
function	O
as	O
general	O
internists	O
.	O

TITLE	O
:	O
Potent	O
inhibition	B-PROC
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SCOV	O
)	O
infection	O
and	O
replication	O
by	O
type	O
I	O
interferons	O
(	O
IFN	O
-	O
alpha	O
/	O
beta	O
)	O
but	O
not	O
by	O
type	O
II	O
interferon	O
(	O
IFN	O
-	O
gamma	O
).	O

The	O
type	O
I	O
IFN	O
receptor	B-PROC
signaling	B-PROC
pathway	B-PROC
in	O
host	O
cells	O
is	O
mainly	O
involved	O
in	O
the	O
inhibition	B-PROC
of	O
SCoV	O
infection	O
and	O
replication	O
.	O

Birds	O
were	O
monitored	O
clinically	O
and	O
euthanatized	O
at	O
1	O
,	O
4	O
,	O
7	O
,	O
and	O
14	O
days	O
postinfection	O
and	O
tissues	O
were	O
collected	O
for	O
virus	O
isolation	O
,	O
histopathologic	O
examination	O
,	O
in	O
situ	O
hybridization	B-PROC
(	O
ISH	O
),	O
and	O
immunohistochemistry	O
(	O
IHC	O
).	O

TITLE	O
:	O
A	O
single	O
amino	O
acid	O
mutation	O
in	O
the	O
spike	O
protein	O
of	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
hampers	O
its	O
maturation	B-PROC
and	O
incorporation	O
into	O
virions	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

Throat	O
or	O
nasopharyngeal	O
swab	O
for	O
SARS	O
-	O
CoV	O
by	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
real	O
-	O
time	O
PCR	O
was	O
positive	O
in	O
40	O
of	O
the	O
47	O
patients	O
(	O
85	O
%)	O
in	O
whom	O
the	O
test	O
was	O
performed	O
.	O

7	O
.	O
5	O
)	O
with	O
severe	O
ARDS	O
(	O
ie	O
,	O
mean	O
Pao	B-PROC
(	O
2	O
)/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
[	O
Fio	O
(	O
2	O
)]	O
ratio	O
,	O
91	O
+/-	O

HFOV	O
was	O
discontinued	O
within	O
4	O
h	O
in	O
19	O
patients	O
(	O
12	O
%)	O
because	O
of	O
difficulties	O
with	O
oxygenation	B-PROC
,	O
ventilation	O
,	O
or	O
hemodynamics	B-PROC
.	O

Multivariate	O
analysis	O
was	O
performed	O
using	O
Cox	O
regression	O
model	O
with	O
death	B-PROC
as	O
the	O
outcome	O
of	O
interest	O
.	O

TITLE	O
:	O
Viral	O
evolution	B-PROC
and	O
the	O
emergence	O
of	O
SARS	O
coronavirus	O
.	O

Developments	O
in	O
the	O
dissection	O
of	O
the	O
human	O
immune	B-PROC
response	I-PROC
to	O
SARS	O
indicate	O
that	O
serological	O
tests	O
on	O
convalescent	O
sera	O
are	O
essential	O
to	O
confirm	O
SARS	O
infection	O
,	O
given	O
the	O
sub	O
-	O
optimal	O
predictive	O
value	O
of	O
molecular	O
detection	O
tests	O
performed	O
during	O
acute	O
SARS	O
illness	O
.	O

We	O
observed	O
that	O
the	O
effects	O
of	O
receiving	O
low	O
tidal	O
volume	O
+	O
PEEP	O
ventilation	O
were	O
not	O
as	O
good	O
as	O
prone	O
position	O
+	O
low	O
tidal	O
volume	O
+	O
PEEP	O
ventilation	O
in	O
the	O
dorsal	O
area	O
of	O
the	O
rabbit	O
lung	O
compared	O
to	O
the	O
results	O
of	O
effective	O
local	O
area	O
lung	O
blood	B-PROC
perfusion	I-PROC
index	O
between	O
two	O
ventilation	O
modes	O
,	O
there	O
showed	O
significantly	O
differences	O
in	O
statistics	O
.	O

TITLE	O
:	O
A	O
subcutaneously	O
injected	O
UV	O
-	O
inactivated	O
SARS	O
coronavirus	O
vaccine	O
elicits	O
systemic	O
humoral	B-PROC
immunity	I-PROC
in	O
mice	O
.	O

We	O
observed	O
that	O
the	O
UV	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
virion	O
elicited	O
a	O
high	O
level	O
of	O
humoral	B-PROC
immunity	I-PROC
,	O
resulting	O
in	O
the	O
generation	O
of	O
long	O
-	O
term	O
antibody	B-PROC
secreting	B-PROC
and	O
memory	B-PROC
B	O
cells	O
.	O

We	O
found	O
that	O
85	O
.	O
9	O
%	O
of	O
serum	O
samples	O
contained	O
NAbs	O
against	O
SARS	O
-	O
CoV	O
and	O
that	O
most	O
of	O
the	O
NAb	O
activities	O
could	O
be	O
attributed	O
to	O
immunoglobulin	B-PROC
G	O
.	O
The	O
NAbs	O
became	O
detectable	O
first	O
at	O
5	O
-	O
10	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
,	O
and	O
their	O
levels	O
peaked	O
at	O
20	O
-	O
30	O
days	O
and	O
then	O
were	O
sustained	O
for	O
>	O
150	O
days	O
.	O

Both	O
psychiatric	O
and	O
posttraumatic	O
morbidities	O
were	O
associated	O
with	O
higher	O
scores	O
on	O
coping	O
efforts	O
including	O
self	O
-	O
distraction	O
,	O
behavioral	B-PROC
disengagement	O
,	O
social	O
support	O
,	O
venting	O
,	O
planning	O
,	O
and	O
self	O
-	O
blame	O
(	O
all	O
p	O
<.	O
001	O
),	O
but	O
not	O
with	O
direct	O
exposure	O
factors	O
such	O
as	O
contact	O
with	O
suspected	O
SARS	O
patients	O
or	O
working	O
in	O
fever	B-PROC
rooms	O
/	O
tentages	O
.	O

In	O
light	O
of	O
observations	O
that	O
three	O
Chinese	O
herbal	O
formulations	O
recommended	O
for	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
specifically	O
inhibited	O
the	O
release	O
of	O
HMGB1	O
from	O
innate	O
immune	O
cells	O
,	O
we	O
hypothesize	O
that	O
HMGB1	O
might	O
occupy	O
a	O
pathogenic	O
role	O
in	O
SARS	O
by	O
mediating	O
an	O
injurious	O
pulmonary	O
inflammatory	B-PROC
response	I-PROC
.	O

Predictors	O
for	O
SARS	O
on	O
the	O
basis	O
of	O
history	O
(	O
step	O
1	O
)	O
included	O
previous	O
contact	O
with	O
a	O
patient	O
with	O
SARS	O
and	O
the	O
presence	O
of	O
fever	B-PROC
,	O
myalgia	O
,	O
and	O
malaise	O
.	O

In	O
step	O
2	O
,	O
haziness	O
or	O
pneumonic	O
consolidation	O
on	O
chest	O
radiographs	O
and	O
low	O
lymphocyte	O
and	O
platelet	O
counts	O
,	O
in	O
addition	O
to	O
a	O
positive	O
contact	O
history	O
and	O
fever	B-PROC
were	O
associated	O
with	O
a	O
higher	O
probability	O
of	O
SARS	O
.	O

Diminished	O
CD8alpha	O
-	O
DC	O
activation	O
correlated	O
with	O
reduced	O
IFN	O
-	O
gamma	O
expression	B-PROC
by	O
virus	O
-	O
specific	O
T	O
cells	O
accompanied	O
by	O
increased	O
IL	B-PROC
-	I-PROC
10	I-PROC
production	I-PROC
suggesting	O
that	O
CCL3	O
contributes	O
to	O
an	O
effective	O
host	B-PROC
response	I-PROC
to	O
viral	B-PROC
infection	I-PROC
by	O
enhancing	O
the	O
T	B-PROC
cell	I-PROC
activation	I-PROC
potential	O
of	O
DC	O
.	O

The	O
focus	O
of	O
the	O
17th	O
International	O
Conference	O
on	O
Antiviral	O
Research	O
was	O
the	O
discovery	O
and	O
development	B-PROC
of	O
antiviral	O
agents	O
(	O
chemistry	O
,	O
biology	O
,	O
animal	O
models	O
and	O
clinical	O
trial	O
results	O
)	O
against	O
a	O
variety	O
of	O
human	O
infectious	O
agents	O
including	O
HIV	O
,	O
herpes	O
viruses	O
,	O
hepatitis	O
viruses	O
,	O
respiratory	O
viruses	O
and	O
emerging	O
/	O
re	O
-	O
emerging	O
pathogens	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
encodes	O
proteins	O
required	O
for	O
RNA	O
transcription	B-PROC
and	O
genome	O
replication	O
as	O
large	O
polyproteins	O
that	O
are	O
proteolytically	O
processed	O
by	O
virus	O
-	O
encoded	O
proteinases	O
to	O
produce	O
mature	O
replicase	O
proteins	O
.	O

ABSTRACT	O
:	O
CEACAM1a	O
glycoproteins	O
are	O
members	O
of	O
the	O
immunoglobulin	B-PROC
(	O
Ig	O
)	O
superfamily	O
and	O
the	O
carcinoembryonic	O
antigen	O
family	O
.	O

Autopsy	O
demonstrated	O
severe	O
hemophagocytosis	O
in	O
the	O
bone	O
marrow	O
and	O
histopathology	O
indicating	O
a	O
marked	O
increase	O
in	O
vascular	B-PROC
permeability	I-PROC
in	O
both	O
lungs	O
and	O
kidneys	O
.	O

It	O
belongs	O
to	O
the	O
seasonal	O
febrile	B-PROC
diseases	O
in	O
traditional	O
Chinese	O
medicine	O
.	O

TITLE	O
:	O
[	O
Development	B-PROC
of	O
the	O
integrated	O
TCM	O
hepatology	O
with	O
western	O
medicine	O
].	O

The	O
increase	O
in	O
pulmonary	O
and	O
airway	O
vascular	B-PROC
permeability	I-PROC
and	O
the	O
decrease	O
in	O
partial	O
oxygen	O
pressure	O
of	O
arterial	O
blood	O
induced	O
by	O
an	O
intravenous	O
injection	O
of	O
OA	O
were	O
drastically	O
ameliorated	O
by	O
the	O
oral	O
administration	O
of	O
tranilast	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

This	O
is	O
the	O
first	O
report	O
to	O
prove	O
that	O
tranilast	O
prevents	O
pulmonary	O
and	O
airway	O
vascular	B-PROC
permeability	I-PROC
and	O
hypoxemia	O
induced	O
by	O
OA	O
.	O

More	O
than	O
94	O
%	O
of	O
cases	O
with	O
SARS	O
could	O
produce	O
IgG	O
antibody	B-PROC
when	O
they	O
were	O
infected	O
by	O
SARS	O
-	O
CoV	O
.	O
Detecting	O
SARS	O
-	O
CoV	O
IgG	O
could	O
provide	O
a	O
diagnostic	O
evidence	O
for	O
case	O
confirmation	O
.	O

The	O
decrease	O
of	O
arterial	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
occurred	O
in	O
26	O
patients	O
(	O
49	O
.	O
1	O
%).	O

The	O
situation	O
,	O
especially	O
lymphopenia	O
and	O
thrombocytopenia	O
,	O
could	O
not	O
be	O
reversed	O
in	O
patients	O
who	O
died	B-PROC
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
molecular	O
mechanism	O
of	O
interferon	O
alpha2b	O
(	O
IFNalpha2b	O
)	O
inhibiting	O
the	O
SARS	O
virus	B-PROC
replication	I-PROC
.	O

The	O
results	O
showed	O
that	O
the	O
cDNA	O
chip	O
could	O
be	O
used	O
to	O
detect	O
the	O
viral	O
RNA	O
transcription	B-PROC
level	O
.	O

RESULTS	O
:	O
Fifty	O
per	O
cent	O
of	O
the	O
participants	O
were	O
not	O
concerned	O
about	O
travelling	O
to	O
Toronto	O
,	O
while	O
the	O
other	O
50	O
%	O
expressed	B-PROC
some	O
concern	O
ranging	O
from	O
mild	O
to	O
serious	O
.	O

Vital	O
signs	O
,	O
clinical	O
symptoms	O
and	O
arterial	O
blood	B-PROC
gas	I-PROC
measured	O
before	O
and	O
at	O
the	O
end	O
of	O
HD	O
were	O
compared	O
.	O

This	O
hairpin	O
structure	O
likely	O
juxtaposes	O
the	O
viral	O
and	O
cellular	O
membranes	O
,	O
thus	O
facilitating	O
membrane	B-PROC
fusion	I-PROC
and	O
subsequent	O
viral	O
entry	O
.	O

TITLE	O
:	O
Survey	O
of	O
stress	B-PROC
reactions	I-PROC
among	O
health	O
care	O
workers	O
involved	O
with	O
the	O
SARS	O
outbreak	O
.	O

Requests	O
from	O
hospitals	O
,	O
quarantined	O
individuals	O
,	O
and	O
febrile	B-PROC
citizens	O
accounted	O
for	O
23	O
%,	O
18	O
%,	O
and	O
59	O
%	O
of	O
SARS	O
-	O
related	O
transports	O
.	O

Under	O
quarantine	O
,	O
SARS	O
-	O
like	O
symptoms	O
developed	O
in	O
68	O
paramedics	O
,	O
including	O
cough	O
(	O
53	O
[	O
78	O
%]),	O
myalgia	O
(	O
33	O
[	O
48	O
%]),	O
fatigue	O
(	O
30	O
[	O
44	O
%]),	O
headache	O
(	O
29	O
[	O
43	O
%]),	O
fever	B-PROC
(	O
11	O
[	O
16	O
%]),	O
and	O
shortness	O
of	O
breath	O
(	O
7	O
[	O
10	O
%]).	O

Thus	O
,	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)/	O
Akt	O
pathway	B-PROC
is	O
activated	O
in	O
virus	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

However	O
,	O
depletion	O
of	O
AQP1	O
did	O
not	O
affect	O
lung	O
edema	O
formation	B-PROC
,	O
lung	O
vascular	B-PROC
permeability	I-PROC
,	O
or	O
lung	O
histology	O
.	O

TITLE	O
:	O
In	O
vitro	O
inhibition	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
by	O
chloroquine	O
.	O

The	O
IC50	O
of	O
chloroquine	O
for	O
inhibition	B-PROC
of	O
SARS	O
-	O
CoV	O
in	O
vitro	O
approximates	O
the	O
plasma	O
concentrations	O
of	O
chloroquine	O
reached	O
during	O
treatment	O
of	O
acute	O
malaria	O
.	O

7	O
.	O
6	O
degrees	O
C	O
,	O
suggesting	O
that	O
coronary	O
virus	B-PROC
infection	I-PROC
,	O
which	O
has	O
been	O
considered	O
to	O
cause	O
SARS	O
by	O
now	O
,	O
may	O
be	O
most	O
active	O
at	O
9	O
degrees	O
C	O
-	O
24	O
degrees	O
C	O
.	O
(	O
2	O
)	O
Occupational	O
hygiene	O
in	O
hospital	O
proved	O
to	O
be	O
an	O
important	O
socio	O
-	O
behavior	O
factor	O
for	O
SARS	O
outbreak	O
.	O

In	O
this	O
species	O
,	O
proinflammatory	O
chemokines	O
may	O
coordinate	O
a	O
rapid	O
and	O
highly	O
effective	O
innate	O
antiviral	B-PROC
response	I-PROC
in	O
the	O
lung	O
,	O
but	O
NK	O
cells	O
and	O
adaptive	O
cellular	B-PROC
immunity	I-PROC
are	O
not	O
required	O
for	O
viral	O
clearance	O
.	O

This	O
study	O
also	O
provides	O
information	O
useful	O
for	O
designing	O
SARS	O
vaccines	O
and	O
understanding	O
the	O
SARS	O
pathogenesis	B-PROC
.	O

We	O
explored	O
the	O
possible	O
contribution	O
of	O
contaminated	O
hospital	O
surfaces	O
to	O
SARS	O
transmission	O
by	O
swabbing	O
surfaces	O
in	O
2	O
hospitals	O
and	O
testing	O
the	O
swab	O
samples	O
by	O
reverse	O
-	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
viral	O
culture	O
.	O

ABSTRACT	O
:	O
Ampligen	O
[	O
polyI	O
:	O
polyC12U	O
]	O
is	O
a	O
mismatched	O
double	O
-	O
stranded	O
RNA	O
that	O
acts	O
by	O
inducing	O
interferon	B-PROC
production	I-PROC
(	O
immunomodulator	O
)	O
and	O
by	O
activating	O
an	O
intracellular	O
enzyme	O
(	O
RNase	O
-	O
L	O
)	O
against	O
viral	O
RNA	O
transcripts	O
(	O
antiviral	O
).	O

SARS	O
-	O
CoV	O
specific	O
gene	B-PROC
expression	I-PROC
changes	O
were	O
examined	O
by	O
high	O
-	O
density	O
oligonucleotide	O
array	O
analysis	O
.	O

Nucleocapsid	O
protein	O
(	O
NP	O
)	O
of	O
SARS	O
-	O
CoV	O
(	O
SARS_NP	O
)	O
functions	O
in	O
enveloping	O
the	O
entire	O
genomic	O
RNA	O
and	O
interacts	O
with	O
viron	O
structural	O
proteins	O
,	O
thus	O
playing	O
important	O
roles	O
in	O
the	O
process	O
of	O
virus	B-PROC
particle	I-PROC
assembly	I-PROC
and	O
release	O
.	O

Such	O
presently	O
observed	O
SARS_NP	O
-	O
hCypA	O
interaction	O
model	O
might	O
provide	O
a	O
new	O
hint	O
for	O
facilitating	O
the	O
understanding	O
of	O
another	O
possible	O
SARS	O
-	O
CoV	O
infection	O
pathway	B-PROC
against	O
human	O
cell	O
.	O

Briefly	O
,	O
we	O
performed	O
virtual	O
screening	O
of	O
a	O
database	O
of	O
small	O
molecules	O
against	O
SARS	O
3CLpro	O
,	O
analyzed	O
inhibitor	O
-	O
protease	O
complexes	O
,	O
and	O
identified	O
several	O
covalent	B-PROC
and	O
non	O
-	O
covalent	B-PROC
inhibitors	O
.	O

ABSTRACT	O
:	O
The	O
worldwide	O
epidemic	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
2003	O
was	O
caused	O
by	O
a	O
novel	O
coronavirus	O
called	O
SARS	O
-	O
CoV	O
.	O
Coronaviruses	O
and	O
their	O
closest	O
relatives	O
possess	O
extremely	O
large	O
plus	O
-	O
strand	O
RNA	O
genomes	O
and	O
employ	O
unique	O
mechanisms	O
and	O
enzymes	O
in	O
RNA	B-PROC
synthesis	I-PROC
that	O
separate	O
them	O
from	O
all	O
other	O
RNA	O
viruses	O
.	O

As	O
well	O
,	O
1	O
-	O
10	O
microM	O
of	O
each	O
compound	O
inhibited	O
viral	B-PROC
replication	I-PROC
in	O
Vero	O
E6	O
cell	O
culture	O
.	O

Abnormalities	O
of	O
forced	B-PROC
vital	I-PROC
capacity	I-PROC
(	O
FVC	B-PROC
),	O
forced	B-PROC
expiratory	I-PROC
volume	I-PROC
in	O
one	O
second	O
(	O
FEV1	O
),	O
FEV1	O
/	O
FVC	B-PROC
and	O
TL	O
,	O
CO	O
were	O
detected	O
in	O
seven	O
(	O
15	O
%),	O
12	O
(	O
26	O
%),	O
one	O
(	O
2	O
%)	O
and	O
18	O
(	O
39	O
%)	O
patients	O
,	O
respectively	O
.	O

Comparison	O
of	O
the	O
measured	O
exercise	O
capacity	O
with	O
resting	O
pulmonary	B-PROC
function	I-PROC
tests	O
showed	O
many	O
cases	O
of	O
discordance	O
in	O
impairment	O
.	O

In	O
conclusion	O
,	O
pulmonary	B-PROC
function	I-PROC
defects	O
were	O
detected	O
in	O
half	O
of	O
the	O
recovered	O
severe	O
acute	O
respiratory	O
syndrome	O
patients	O
3	O
months	O
after	O
hospital	O
discharge	O
,	O
but	O
the	O
impairment	O
was	O
mild	O
in	O
almost	O
all	O
cases	O
.	O

These	O
data	O
suggest	O
that	O
CKLF1	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
these	O
important	O
diseases	O
and	O
the	O
study	O
also	O
implies	O
that	O
gene	O
electro	O
-	O
transfer	O
in	O
vivo	O
could	O
serve	O
as	O
a	O
valuable	O
approach	O
for	O
evaluating	O
the	O
function	O
of	O
a	O
novel	O
gene	O
in	O
animals	O
.	O

The	O
principal	O
lesions	O
consisted	O
of	O
acute	O
alveolar	O
exudative	O
inflammation	O
,	O
hyperplasia	O
of	O
alveolar	O
epithelium	O
,	O
necrosis	B-PROC
,	O
alveolar	O
hyaline	O
membrane	O
formation	B-PROC
,	O
alveolar	O
desquamation	O
and	O
focal	O
fibroplasia	O
.	O

We	O
performed	O
surface	O
-	O
enhanced	O
laser	O
desorption	O
ionization	O
time	O
-	O
of	O
-	O
flight	B-PROC
mass	O
spectrometry	O
on	O
89	O
sera	O
collected	O
from	O
28	O
SARS	O
patients	O
,	O
72	O
sera	O
from	O
51	O
control	O
patients	O
with	O
various	O
viral	O
or	O
bacterial	O
infections	O
,	O
and	O
10	O
sera	O
from	O
apparently	O
healthy	O
individuals	O
.	O

The	O
antibody	B-PROC
library	O
of	O
Fab	O
fragment	O
from	O
a	O
convalescent	O
patient	O
infected	O
with	O
SARS	O
conronavirus	O
was	O
constructed	O
.	O

RESULTS	O
:	O
The	O
antibody	B-PROC
library	O
of	O
Fab	O
fragment	O
from	O
a	O
convalescent	O
patient	O
infected	O
with	O
SARS	O
conronavirus	O
was	O
constructed	O
.	O

TITLE	O
:	O
Synthesis	B-PROC
and	O
characterization	O
of	O
a	O
native	O
,	O
oligomeric	O
form	O
of	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
glycoprotein	O
.	O

While	O
the	O
expressed	B-PROC
full	O
-	O
length	O
S	O
glycoprotein	O
was	O
exclusively	O
cell	O
associated	O
,	O
a	O
truncation	O
of	O
S	O
by	O
excluding	O
the	O
C	O
-	O
terminal	O
transmembrane	O
and	O
cytoplasmic	O
tail	O
domains	O
resulted	O
in	O
the	O
expression	B-PROC
of	O
an	O
endoplasmic	O
reticulum	O
-	O
localized	O
glycoprotein	O
(	O
gp160	O
)	O
as	O
well	O
as	O
a	O
Golgi	O
-	O
specific	O
form	O
(	O
gp170	O
)	O
which	O
was	O
ultimately	O
secreted	B-PROC
into	O
the	O
cell	O
culture	O
medium	O
.	O

There	O
is	O
discordant	O
phylogenetic	O
clustering	O
of	O
SARS	O
-	O
CoV	O
and	O
coronaviruses	O
sequences	O
,	O
throughout	O
the	O
genome	O
,	O
compatible	O
with	O
either	O
ancient	O
recombination	B-PROC
events	O
or	O
altered	O
evolutionary	O
rates	O
in	O
different	O
lineages	O
,	O
or	O
a	O
combination	O
of	O
both	O
.	O

Oxygenation	B-PROC
improved	O
slightly	O
during	O
tracheal	O
gas	O
insufflation	O
,	O
and	O
this	O
improvement	O
remained	O
after	O
stopping	O
tracheal	O
insufflation	O
.	O

Involvement	O
of	O
more	O
than	O
one	O
lung	O
zone	O
at	O
baseline	O
chest	O
radiography	O
was	O
an	O
independent	O
predictor	O
of	O
ICU	O
admission	O
and	O
/	O
or	O
death	B-PROC
(	O
odds	O
ratio	O
,	O
3	O
.	O
16	O
;	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
07	O
,	O
9	O
.	O
32	O
;	O
P	O
=	O
.	O
037	O
)	O
after	O
adjustments	O
for	O
other	O
significant	O
factors	O
(	O
ie	O
,	O
patient	O
age	O
,	O
and	O
baseline	O
neutrophil	O
count	O
and	O
lactate	O
dehydrogenase	O
level	O
).	O

Only	O
patients	O
who	O
died	B-PROC
and	O
underwent	O
autopsy	O
could	O
be	O
included	O
in	O
this	O
study	O
,	O
so	O
these	O
results	O
may	O
not	O
apply	O
to	O
less	O
severe	O
cases	O
of	O
ARDS	O
.	O

Although	O
significant	O
increases	O
in	O
Vd	O
(	O
phys	O
)	O
resulted	O
with	O
PPV	O
combined	O
with	O
TIVA	O
,	O
these	O
adverse	O
changes	O
were	O
much	O
less	O
compared	O
with	O
isoflurane	O
inhalation	B-PROC
and	O
PPV	O
.	O

Willingness	O
to	O
pay	O
(	O
WTP	O
)	O
to	O
reduce	O
the	O
risk	O
of	O
infection	O
and	O
death	B-PROC
from	O
SARS	O
is	O
elicited	O
using	O
contingent	O
valuation	O
methods	O
.	O

9	O
,	O
hospitalized	O
from	O
April	O
to	O
June	O
2003	O
,	O
were	O
reviewed	O
,	O
targeted	B-PROC
on	O
the	O
use	O
of	O
glucocorticoids	O
.	O

The	O
influencing	O
factors	O
of	O
bone	O
density	O
included	O
age	O
,	O
dosage	O
summation	B-PROC
,	O
and	O
length	O
of	O
ictus	O
therapy	O
.	O

Statistics	O
showed	O
that	O
serum	O
IgG	O
was	O
not	O
related	O
with	O
avascular	O
necrosis	B-PROC
of	O
femoral	O
head	O
and	O
osteoporosis	O
.	O

SARS	O
virus	O
may	O
not	O
affect	O
the	O
pathogenesis	B-PROC
of	O
avascular	O
necrosis	B-PROC
of	O
femoral	O
head	O
and	O
osteoporosis	O
.	O

Epitopes	O
inducing	O
protective	O
humoral	O
responses	O
to	O
virus	B-PROC
infection	I-PROC
were	O
located	O
mainly	O
in	O
the	O
M	O
protein	O
and	O
a	O
region	O
spanning	O
residues	O
13	O
-	O
877	O
of	O
the	O
S	O
protein	O
.	O

Our	O
results	O
showed	O
that	O
the	O
antibodies	O
could	O
efficiently	O
and	O
specifically	O
bind	O
to	O
their	O
corresponding	O
proteins	O
from	O
E	O
.	O
coli	O
expressed	B-PROC
or	O
lysate	O
of	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
-	O
E6	O
cells	O
by	O
Western	O
blot	O
analysis	O
.	O

ABSTRACT	O
:	O
Intranasal	O
inhalation	B-PROC
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
)	O
in	O
the	O
immunocompetent	O
mouse	O
strain	O
129SvEv	O
resulted	O
in	O
infection	O
of	O
conducting	B-PROC
airway	O
epithelial	O
cells	O
followed	O
by	O
rapid	O
clearance	O
of	O
virus	O
from	O
the	O
lungs	O
and	O
the	O
development	B-PROC
of	O
self	O
-	O
limited	O
bronchiolitis	O
.	O

Lessons	O
learned	B-PROC
while	O
using	O
the	O
cyberspace	O
method	O
are	O
discussed	O
,	O
including	O
guidance	O
for	O
organizing	O
a	O
long	O
-	O
distance	O
research	O
team	O
,	O
the	O
central	O
place	O
of	O
trust	O
,	O
and	O
the	O
time	O
when	O
e	O
-	O
mail	O
communication	O
demands	O
to	O
be	O
supplemented	O
with	O
face	O
-	O
to	O
-	O
face	O
interaction	O
.	O

Univariate	O
analysis	O
revealed	O
that	O
control	O
calves	O
with	O
intranasal	O
BRD	O
on	O
entry	O
to	O
the	O
feedlot	O
and	O
those	O
with	O
antibody	B-PROC
titer	O
<	O
20	O
were	O
significantly	O
more	O
likely	O
to	O
be	O
treated	O
for	O
BRD	O
.	O

RESULTS	O
:	O
Intranasal	O
BCV	O
(	O
125	O
/	O
407	O
[	O
31	O
%])	O
and	O
serum	O
antibody	B-PROC
titers	O
>	O
or	O
=	O
20	O
against	O
BCV	O
(	O
246	O
/	O
396	O
[	O
62	O
%])	O
were	O
identified	O
in	O
calves	O
entering	O
the	O
feedlot	O
.	O

The	O
affected	O
animals	O
were	O
in	O
multiple	O
breeding	B-PROC
colonies	O
comprising	O
more	O
than	O
4000	O
mice	O
representing	O
more	O
than	O
50	O
site	O
-	O
specific	O
strains	O
,	O
lines	O
,	O
and	O
sublines	O
.	O

Infections	O
may	O
occur	O
by	O
direct	O
contact	O
with	O
blood	O
or	O
tissues	O
of	O
infected	O
animal	O
during	O
handling	O
and	O
cutting	O
up	O
preys	O
and	O
when	O
preparing	O
or	O
eating	B-PROC
meat	O
,	O
or	O
also	O
when	O
bitten	O
by	O
injured	O
animal	O
.	O

ABSTRACT	O
:	O
Reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
with	O
specific	O
primers	O
for	O
the	O
S1	O
gene	O
of	O
IBV	O
and	O
for	O
the	O
fusion	O
protein	B-PROC
cleavage	I-PROC
site	O
of	O
NDV	O
was	O
used	O
for	O
detection	O
of	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
,	O
the	O
family	O
Coronaviridae	O
)	O
and	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
)	O
genomes	O
.	O

TITLE	O
:	O
Efficient	O
assembly	O
and	O
release	O
of	O
SARS	O
coronavirus	O
-	O
like	O
particles	O
by	O
a	O
heterologous	O
expression	B-PROC
system	O
.	O

In	O
this	O
sense	B-PROC
,	O
the	O
SARS	O
scare	O
,	O
despite	O
the	O
remarkable	O
speed	O
with	O
which	O
it	O
was	O
played	O
out	O
in	O
the	O
modern	O
global	O
news	O
media	O
,	O
resonates	O
with	O
the	O
meanings	O
attributed	O
to	O
other	O
epidemics	O
of	O
infectious	O
diseases	O
throughout	O
history	O
.	O

TITLE	O
:	O
Intracellular	B-PROC
localization	I-PROC
and	O
protein	O
interactions	O
of	O
the	O
gene	O
1	O
protein	O
p28	O
during	O
mouse	O
hepatitis	O
virus	B-PROC
replication	I-PROC
.	O

For	O
the	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
the	O
first	O
proteolytic	B-PROC
processing	I-PROC
event	O
of	O
the	O
replicase	O
polyprotein	O
liberates	O
an	O
amino	O
-	O
terminal	O
28	O
-	O
kDa	O
product	O
(	O
p28	O
).	O

We	O
used	O
immunofluorescence	O
confocal	O
microscopy	O
to	O
show	O
that	O
p28	O
localizes	O
to	O
viral	B-PROC
replication	I-PROC
complexes	O
in	O
the	O
cytoplasm	O
during	O
early	O
times	O
postinfection	O
.	O

The	O
periods	B-PROC
of	O
coronaviruses	O
activation	O
were	O
accompanied	O
by	O
their	O
detection	O
in	O
patient	O
material	O
by	O
electron	O
-	O
microscopy	O
,	O
a	O
sharp	O
increase	O
of	O
immune	B-PROC
response	I-PROC
of	O
patients	O
as	O
well	O
as	O
in	O
the	O
number	O
of	O
nosocomial	O
infections	O
and	O
the	O
proportion	O
of	O
the	O
monoinfection	O
of	O
the	O
coronavirus	O
nature	O
.	O

ABSTRACT	O
:	O
High	O
-	O
level	O
protein	B-PROC
expression	B-PROC
is	O
an	O
important	O
means	O
of	O
obtaining	O
large	O
amounts	O
of	O
viral	O
proteins	O
to	O
investigate	O
further	O
their	O
biological	O
properties	O
.	O

TITLE	O
:	O
High	O
-	O
throughput	O
screening	O
identifies	O
inhibitors	O
of	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	B-PROC
.	O

During	O
the	O
outbreak	O
,	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
was	O
documented	O
in	O
346	O
patients	O
and	O
73	O
of	O
them	O
died	B-PROC
.	O

Autopsy	O
was	O
performed	O
in	O
9	O
of	O
the	O
suspected	O
SARS	O
patients	O
who	O
died	B-PROC
during	O
the	O
outbreak	O
,	O
but	O
SARS	O
was	O
the	O
cause	O
of	O
death	B-PROC
in	O
only	O
1	O
of	O
these	O
patients	O
.	O

Her	O
condition	O
deteriorated	O
rapidly	O
and	O
she	O
died	B-PROC
on	O
May	O
2	O
,	O
11	O
days	O
after	O
the	O
onset	O
of	O
fever	B-PROC
.	O

Our	O
data	O
suggest	O
that	O
the	O
large	O
S	O
glycoprotein	O
of	O
SARS	O
-	O
CoV	O
may	O
use	O
both	O
ACE2	O
and	O
CD209L	O
in	O
virus	B-PROC
infection	I-PROC
and	O
pathogenesis	B-PROC
.	O

ABSTRACT	O
:	O
A	O
total	O
of	O
1	O
,	O
068	O
asymptomatic	O
close	O
contacts	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
(	O
SARS	O
)	O
from	O
the	O
2003	O
epidemic	O
in	O
Hong	O
Kong	O
were	O
serologically	O
tested	O
,	O
and	O
2	O
(	O
0	O
.	O
19	O
%)	O
were	O
positive	O
for	O
SARS	O
coronavirus	O
immunoglobulin	B-PROC
G	O
antibody	B-PROC
.	O

One	O
hour	O
of	O
NPPV	O
therapy	O
led	O
to	O
significant	O
increases	O
in	O
PaO	B-PROC
(	O
2	O
),	O
SpO	O
(	O
2	O
)	O
and	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
),	O
and	O
decrease	O
in	O
respiratory	O
rate	O
(	O
all	O
P	O
<	O
0	O
.	O
01	O
).	O

In	O
a	O
longitudinal	O
cross	O
-	O
sectional	O
study	O
,	O
we	O
determined	O
the	O
prevalence	O
of	O
virus	O
in	O
bodily	O
excretions	B-PROC
and	O
time	O
of	O
seroconversion	O
in	O
discharged	O
patients	O
with	O
SARS	O
.	O

The	O
results	O
showed	O
that	O
the	O
cells	O
transfected	O
with	O
pEGFP	O
-	O
optS	O
expressed	B-PROC
S	O
-	O
EGFP	O
fusion	O
protein	O
at	O
a	O
higher	O
level	O
compared	O
with	O
those	O
transfected	O
with	O
pEGFP	O
-	O
S	O
,	O
which	O
contains	O
wildtype	O
SARS	O
-	O
CoV	O
spike	O
gene	O
sequence	O
.	O

A	O
similar	O
reduction	O
in	O
macrophage	O
infiltration	O
into	O
the	O
CNS	O
was	O
observed	O
in	O
both	O
CCL2	O
(-/-)	O
and	O
CCR2	O
(-/-)	O
mice	O
when	O
compared	O
to	O
wild	O
-	O
type	O
mice	O
,	O
indicating	O
that	O
both	O
CCL2	O
and	O
CC	O
chemokine	O
receptor	O
2	O
(	O
CCR2	O
)	O
contribute	O
to	O
macrophage	O
migration	B-PROC
and	O
accumulation	O
within	O
the	O
CNS	O
following	O
MHV	O
infection	O
.	O

All	O
15	O
patients	O
had	O
fever	B-PROC
,	O
3	O
(	O
20	O
%)	O
had	O
chills	O
,	O
and	O
11	O
(	O
73	O
%)	O
had	O
cough	O
.	O

ABSTRACT	O
:	O
To	O
promote	O
viral	O
entry	O
,	O
replication	O
,	O
release	O
,	O
and	O
spread	O
to	O
neighboring	O
cells	O
,	O
many	O
cytolytic	O
animal	O
viruses	O
encode	O
proteins	O
responsible	O
for	O
modification	O
of	O
host	O
cell	B-PROC
membrane	I-PROC
permeability	I-PROC
and	O
for	O
formation	B-PROC
of	O
ion	O
channels	O
in	O
host	O
cell	O
membranes	O
during	O
their	O
life	O
cycles	O
.	O

Site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
studies	O
revealed	O
that	O
two	O
cysteine	O
residues	O
of	O
the	O
E	O
protein	O
were	O
essential	O
for	O
oligomerization	O
,	O
leading	O
to	O
induction	O
of	O
membrane	B-PROC
permeability	I-PROC
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
glycoprotein	O
alone	O
can	O
mediate	O
the	O
membrane	B-PROC
fusion	I-PROC
required	O
for	O
virus	O
entry	O
and	O
cell	B-PROC
fusion	I-PROC
.	O

To	O
attempt	O
to	O
determine	O
the	O
clinical	O
efficacy	O
of	O
pentaglobin	O
,	O
an	O
IgM	O
-	O
enriched	O
immunoglobulin	B-PROC
preparation	O
,	O
on	O
12	O
severe	O
SARS	O
patients	O
who	O
continued	O
to	O
deteriorate	O
despite	O
corticosteroid	O
and	O
ribavirin	O
therapy	O
.	O

CNS	O
-	O
derived	O
secondary	O
CD8	O
+	O
T	O
cells	O
exhibited	O
increased	O
cytolytic	O
activity	O
and	O
IFN	O
-	O
gamma	O
expression	B-PROC
per	O
cell	O
compared	O
with	O
primary	O
CD8	O
+	O
T	O
cells	O
.	O

Unlike	O
primary	O
CD8	O
+	O
T	O
cells	O
,	O
persisting	O
secondary	O
CD8	O
+	O
T	O
cells	O
retained	O
ex	O
vivo	O
cytolytic	O
activity	O
and	O
expressed	B-PROC
high	O
levels	O
of	O
IFN	O
-	O
gamma	O
following	O
Ag	O
stimulation	O
.	O

The	O
virus	O
was	O
first	O
identified	O
by	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
and	O
showed	O
a	O
distinct	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
pattern	O
from	O
previously	O
described	O
Israeli	O
isolates	O
.	O

TITLE	O
:	O
A	O
study	O
on	O
SARS	O
awareness	O
and	O
health	O
-	O
seeking	O
behaviour	B-PROC
-	O
findings	O
from	O
a	O
sampled	O
population	O
attending	O
National	O
Healthcare	O
Group	O
Polyclinics	O
.	O

In	O
particular	O
,	O
the	O
retired	O
with	O
lower	O
educational	O
levels	O
were	O
likely	O
to	O
be	O
oblivious	O
both	O
to	O
the	O
symptoms	O
of	O
SARS	O
and	O
the	O
possible	O
consequences	O
of	O
travelling	O
by	O
inappropriate	O
transport	B-PROC
.	O

TITLE	O
:	O
High	O
-	O
yield	O
expression	B-PROC
of	O
recombinant	O
SARS	O
coronavirus	O
nucleocapsid	O
protein	O
in	O
methylotrophic	O
yeast	O
Pichia	O
pastoris	O
.	O

The	O
expression	B-PROC
level	O
and	O
activation	O
were	O
detected	O
by	O
SDS	O
-	O
PAGE	O
and	O
Western	O
-	O
blot	O
respectively	O
.	O

CONCLUSIONS	O
:	O
Active	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	O
(	O
rSCoVN	O
)	O
protein	O
can	O
be	O
successfully	O
expressed	B-PROC
in	O
recombinant	O
methylotrophic	O
yeast	O
P	O
.	O
pastoris	O
GS115	O
.	O

Measured	O
variables	O
upon	O
admission	O
included	O
APACHE	O
II	O
score	O
,	O
the	O
ratio	O
of	O
the	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
in	O
arterial	O
blood	O
to	O
the	O
fraction	O
of	O
oxygen	O
in	O
inspired	B-PROC
gas	O
(	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)),	O
and	O
plasma	O
levels	O
of	O
free	O
T3	O
(	O
fT3	O
)	O
and	O
free	O
thyroxine	O
(	O
fT4	O
),	O
and	O
TSH	O
levels	O
.	O

Thyroid	B-PROC
function	I-PROC
was	O
further	O
evaluated	O
at	O
discharge	O
.	O

We	O
examine	O
mathematically	O
the	O
impact	O
of	O
isolation	O
and	O
quarantine	O
on	O
the	O
control	O
of	O
SARS	O
during	O
the	O
outbreaks	O
in	O
Toronto	O
,	O
Hong	O
Kong	O
,	O
Singapore	O
and	O
Beijing	O
using	O
a	O
deterministic	O
model	O
that	O
closely	O
mimics	O
the	O
data	O
for	O
cumulative	O
infected	O
cases	O
and	O
SARS	O
-	O
related	O
deaths	B-PROC
in	O
the	O
first	O
three	O
regions	O
but	O
not	O
in	O
Beijing	O
until	O
mid	O
-	O
April	O
,	O
when	O
China	O
started	O
to	O
report	O
data	O
more	O
accurately	O
.	O

ABSTRACT	O
:	O
Specific	O
immunoglobulin	B-PROC
G	O
antibody	B-PROC
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
was	O
detected	O
in	O
maternal	O
blood	O
,	O
umbilical	O
blood	O
,	O
and	O
amniotic	O
fluid	O
from	O
a	O
pregnant	O
SARS	O
patient	O
.	O

These	O
results	O
suggest	O
that	O
SYNCRIP	O
may	O
be	O
directly	O
involved	O
in	O
MHV	O
RNA	B-PROC
replication	I-PROC
as	O
a	O
positive	O
regulator	O
.	O

The	O
presence	O
or	O
absence	O
of	O
disseminated	O
intravascular	O
coagulation	B-PROC
should	O
not	O
influence	O
the	O
decision	O
to	O
administer	O
recombinant	O
human	O
activated	O
protein	O
C	O
.	O
Heparin	O
should	O
be	O
withheld	O
during	O
administration	O
of	O
recombinant	O
human	O
activated	O
protein	O
C	O
.	O
CONCLUSIONS	O
:	O
Recombinant	O
human	O
activated	O
protein	O
C	O
is	O
recommended	O
in	O
patients	O
at	O
high	O
risk	O
of	O
death	B-PROC
(	O
septic	O
shock	O
,	O
sepsis	O
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
of	O
>/=	O
25	O
,	O
and	O
sepsis	O
-	O
induced	O
multiorgan	O
failure	O
)	O
and	O
no	O
absolute	O
contraindication	O
related	O
to	O
bleeding	O
risk	O
or	O
relative	O
contraindication	O
that	O
outweighs	O
the	O
potential	O
benefit	O
.	O

ABSTRACT	O
:	O
In	O
2003	O
,	O
critical	O
care	O
and	O
infectious	O
disease	O
experts	O
representing	O
11	O
international	O
organizations	O
developed	O
management	O
guidelines	O
for	O
mechanical	O
ventilation	O
in	O
sepsis	O
-	O
induced	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
that	O
would	O
be	O
of	O
practical	O
use	O
for	O
the	O
bedside	O
clinician	O
,	O
under	O
the	O
auspices	O
of	O
the	O
Surviving	O
Sepsis	O
Campaign	O
,	O
an	O
international	O
effort	B-PROC
to	O
increase	O
awareness	O
and	O
improve	O
outcome	O
in	O
severe	O
sepsis	O
.	O

Weaning	B-PROC
protocols	O
should	O
be	O
in	O
place	O
that	O
include	O
spontaneous	O
breathing	B-PROC
trials	O
and	O
criteria	O
for	O
initiating	O
such	O
trials	O
.	O

Because	O
HCoV	O
-	O
NL63	O
has	O
a	O
low	O
pathogenicity	O
and	O
is	O
able	O
to	O
grow	O
easily	O
in	O
cell	O
culture	O
,	O
this	O
virus	O
can	O
be	O
a	O
powerful	O
tool	O
to	O
study	O
SARS	O
coronavirus	O
pathogenesis	B-PROC
.	O

Early	O
decreased	O
soluble	O
L	O
-	O
selectin	B-PROC
concentrations	O
after	O
multiple	O
trauma	O
may	O
signal	O
an	O
increased	O
likelihood	O
of	O
lung	O
injury	O
and	O
ARDS	O
.	O

We	O
used	O
Cox	O
proportional	O
hazard	O
modelling	O
to	O
analyze	O
potential	O
predictors	O
of	O
survival	O
recorded	O
at	O
the	O
time	O
of	O
presentation	O
,	O
including	O
viral	O
load	O
from	O
nasopharyngeal	O
specimens	O
(	O
measured	O
by	O
quantitative	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
[	O
PCR	O
]	O
of	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
).	O

Thirty	O
-	O
two	O
patients	O
(	O
24	O
.	O
1	O
%)	O
met	O
the	O
criteria	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
24	O
patients	O
(	O
18	O
.	O
0	O
%)	O
died	B-PROC
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
microarrays	O
to	O
gain	O
a	O
global	O
view	O
of	O
the	O
transcriptional	B-PROC
responses	O
of	O
the	O
lung	O
to	O
LPS	O
in	O
a	O
mouse	O
model	O
of	O
ALI	O
that	O
mimics	O
ALI	O
in	O
humans	O
.	O

Macrophages	O
from	O
mice	O
with	O
different	O
genetic	O
backgrounds	O
behave	O
differently	O
at	O
the	O
molecular	O
level	O
and	O
comparison	O
of	O
the	O
patterns	O
of	O
non	O
-	O
activated	O
and	O
IFN	O
-	O
gamma	O
-	O
activated	O
A	O
/	O
J	O
or	O
BALB	O
/	O
c	O
mouse	O
macrophages	O
revealed	O
,	O
for	O
instance	O
,	O
an	O
up	B-PROC
-	I-PROC
regulation	B-PROC
and	O
a	O
down	B-PROC
-	I-PROC
regulation	B-PROC
of	O
genes	O
coding	O
for	O
biological	O
functions	O
such	O
as	O
enzymatic	O
reactions	O
,	O
nucleic	O
acid	O
synthesis	B-PROC
and	O
transport	B-PROC
,	O
protein	B-PROC
synthesis	I-PROC
,	O
transport	B-PROC
and	O
metabolism	B-PROC
,	O
cytoskeleton	O
arrangement	O
and	O
extracellular	O
matrix	O
,	O
phagocytosis	B-PROC
,	O
resistance	B-PROC
and	O
susceptibility	O
to	O
infection	O
and	O
tumors	O
,	O
inflammation	O
,	O
and	O
cell	B-PROC
differentiation	I-PROC
or	O
activation	O
.	O

In	O
this	O
respect	O
,	O
a	O
down	B-PROC
-	I-PROC
regulation	B-PROC
of	O
the	O
main	O
murine	O
hepatitis	O
virus	O
3	O
receptor	O
gene	O
was	O
detected	O
only	O
in	O
IFN	O
-	O
gamma	O
-	O
activated	O
macrophages	O
of	O
resistant	O
mice	O
.	O

The	O
WHO	O
physician	O
died	B-PROC
from	O
respiratory	O
failure	O
on	O
day	O
19	O
.	O

The	O
current	O
outbreak	O
of	O
avian	O
influenza	O
in	O
South	O
East	O
Asia	O
has	O
resulted	O
in	O
a	O
small	O
number	O
of	O
human	O
deaths	B-PROC
.	O

It	O
has	O
also	O
been	O
established	O
suppression	B-PROC
of	O
imports	O
from	O
these	O
countries	O
.	O

This	O
genetic	O
system	O
is	O
based	O
on	O
the	O
bacteriophage	O
lambda	O
regulatory	B-PROC
circuit	I-PROC
,	O
in	O
which	O
the	O
viral	O
repressor	O
cI	O
is	O
specifically	O
cleaved	O
to	O
initiate	O
the	O
lysogenic	O
-	O
to	O
-	O
lytic	B-PROC
switch	I-PROC
.	O

Activation	O
of	O
circulating	O
neutrophils	O
and	O
transmigration	O
into	O
the	O
alveolar	O
airspace	O
are	O
associated	O
with	O
development	B-PROC
of	O
acute	O
lung	O
injury	O
,	O
and	O
inhibitors	O
of	O
neutrophil	B-PROC
recruitment	I-PROC
attenuate	O
lung	O
damage	O
in	O
many	O
experimental	O
models	O
.	O

Titers	O
of	O
both	O
specific	O
IgG	O
antibody	B-PROC
and	O
neutralizing	O
antibody	B-PROC
peaked	O
at	O
about	O
six	O
weeks	O
after	O
first	O
vaccination	O
,	O
with	O
the	O
maximum	O
value	O
of	O
1	O
:	O
81	O
920	O
and	O
1	O
:	O
20	O
480	O
,	O
respectively	O
.	O

After	O
that	O
,	O
serum	O
antibody	B-PROC
levels	O
remained	O
at	O
a	O
plateau	O
or	O
had	O
a	O
slight	O
decrease	O
,	O
though	O
two	O
boosters	O
were	O
given	O
in	O
the	O
succedent	O
4	O
to	O
5	O
weeks	O
.	O

Although	O
cell	B-PROC
cycle	I-PROC
control	I-PROC
is	O
fairly	O
well	O
characterized	O
in	O
terms	O
of	O
checkpoints	O
and	O
control	O
molecules	O
(	O
e	O
.	O
g	O
.,	O
cyclins	O
),	O
in	O
recent	O
years	O
several	O
researchers	O
have	O
demonstrated	O
that	O
the	O
nucleolus	O
is	O
also	O
involved	O
in	O
cell	B-PROC
cycle	I-PROC
control	I-PROC
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
pathogenesis	B-PROC
,	O
disease	O
and	O
vaccines	O
:	O
an	O
update	O
.	O

Numerous	O
approaches	O
to	O
the	O
development	B-PROC
of	O
SARS	O
-	O
CoV	O
vaccines	O
have	O
been	O
undertaken	O
,	O
and	O
there	O
is	O
evidence	O
that	O
antibodies	O
to	O
the	O
spike	O
protein	O
may	O
be	O
protective	O
from	O
replication	O
and	O
pathology	O
in	O
animal	O
models	O
.	O

The	O
availability	O
of	O
reverse	O
genetic	O
systems	O
has	O
made	O
it	O
possible	O
to	O
engineer	O
and	O
recover	B-PROC
coronavirus	O
variants	O
that	O
contain	O
multiple	O
genetically	O
stable	O
mutations	O
that	O
grow	O
well	O
in	O
culture	O
but	O
are	O
attenuated	O
for	O
replication	O
,	O
virulence	B-PROC
or	O
both	O
.	O

TITLE	O
:	O
Use	O
of	O
simple	O
laboratory	O
features	O
to	O
distinguish	O
the	O
early	O
stage	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
from	O
dengue	O
fever	B-PROC
.	O

The	O
T	O
variant	O
from	O
the	O
SNP	O
C	O
-	O
1543T	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
transcription	B-PROC
rate	O
(	O
1	O
.	O
8	O
-	O
fold	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
by	O
the	O
reporter	O
gene	O
assay	O
.	O

TITLE	O
:	O
Exogenous	O
nitric	O
oxide	O
donor	O
and	O
related	O
compounds	O
protect	O
against	O
lung	O
inflammatory	B-PROC
response	I-PROC
after	O
hemorrhagic	O
shock	O
and	O
resuscitation	O
.	O

These	O
data	O
suggest	O
that	O
limiting	O
inducible	O
NO	O
synthase	O
-	O
generated	O
NO	O
availability	O
with	O
the	O
exogenous	O
NO	O
donor	O
,	O
sodium	O
nitroprusside	O
,	O
may	O
reduce	O
lung	O
injury	O
after	O
severe	O
hemorrhage	O
,	O
possibly	O
,	O
among	O
other	O
effects	O
,	O
by	O
downregulating	O
the	O
expression	B-PROC
of	O
inflammatory	O
cytokines	O
.	O

The	O
major	O
immunoglobulin	B-PROC
G	O
subclass	O
recognizing	O
N	O
protein	O
was	O
immunoglobulin	B-PROC
G2a	O
,	O
and	O
stimulated	O
splenocytes	O
secreted	B-PROC
high	O
levels	O
of	O
gamma	O
interferon	O
and	O
IL	O
-	O
2	O
in	O
response	O
to	O
N	O
protein	O
.	O

8	O
.	O
19	O
%	O
for	O
up	O
to	O
6	O
h	O
.	O
In	O
vitro	O
and	O
in	O
vivo	O
experiments	O
with	O
saline	O
and	O
surfactants	O
suggest	O
that	O
the	O
mechanism	B-PROC
of	I-PROC
action	I-PROC
of	O
the	O
nebulized	O
saline	O
relates	O
to	O
modification	O
of	O
the	O
physical	O
properties	O
of	O
the	O
airway	O
-	O
lining	O
fluid	O
,	O
notably	O
surface	O
tension	O
.	O

Recent	O
evidence	O
shows	O
that	O
activated	O
leukocytes	O
and	O
chemokines	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
ARDS	O
.	O

Here	O
we	O
show	O
that	O
the	O
progenitor	O
oligodendrocytes	O
(	O
central	O
glial	O
4	O
[	O
CG	O
-	O
4	O
]	O
cells	O
)	O
derived	O
from	O
newborn	O
rat	O
brain	O
were	O
permissive	O
to	O
MHV	O
infection	O
,	O
which	O
resulted	O
in	O
cell	B-PROC
death	I-PROC
,	O
although	O
viral	B-PROC
replication	I-PROC
was	O
restricted	O
.	O

Potential	O
pathophysiologic	O
mechanisms	O
linking	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
inhaled	B-PROC
nitric	O
oxide	O
,	O
methemoglobin	O
,	O
and	O
carboxyhemoglobin	O
are	O
discussed	O
.	O

Since	O
carboxyhemoglobin	O
has	O
a	O
negative	O
influence	O
on	O
oxygen	O
-	O
carrying	O
capacity	O
,	O
this	O
effect	O
may	O
potentially	O
offset	O
the	O
beneficial	O
influence	O
(	O
if	O
any	O
)	O
of	O
inhaled	B-PROC
nitric	O
oxide	O
on	O
arterial	O
PO2	B-PROC
.	O

In	O
conclusion	O
,	O
our	O
findings	O
,	O
at	O
least	O
,	O
suggest	O
that	O
E	O
-	O
CR1	O
is	O
likely	O
involved	O
in	O
immune	O
pathogenesis	B-PROC
of	O
SARS	O
disease	O
.	O

Although	O
the	O
hospital	O
leadership	O
made	O
an	O
effort	B-PROC
to	O
meet	O
the	O
conditions	O
of	O
'	O
accountability	O
for	O
reasonableness	O
',	O
they	O
acknowledged	O
that	O
the	O
decision	O
making	O
was	O
not	O
ideal	O
.	O

SARS	O
-	O
CoV	O
was	O
detected	O
in	O
lung	O
(	O
100	O
%),	O
bowel	O
(	O
73	O
%),	O
liver	O
(	O
41	O
%),	O
and	O
kidney	O
(	O
38	O
%)	O
in	O
19	O
patients	O
who	O
died	B-PROC
of	O
SARS	O
,	O
with	O
the	O
highest	O
viral	O
loads	O
observed	O
in	O
lung	O
(	O
1	O
.	O
0	O
x	O
10	O
(	O
10	O
)	O
copies	O
/	O
g	O
)	O
and	O
bowel	O
(	O
2	O
.	O
7	O
x	O
10	O
(	O
9	O
)	O
copies	O
/	O
g	O
).	O

This	O
chapter	O
focuses	O
on	O
some	O
of	O
the	O
known	O
features	O
and	O
presents	O
some	O
current	O
questions	O
regarding	O
genome	O
replication	O
strategy	O
,	O
the	O
cis	O
-	O
acting	O
elements	O
necessary	O
for	O
genome	O
replication	O
[	O
as	O
inferred	O
from	O
defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
molecules	O
],	O
the	O
minimum	O
sequence	O
requirements	O
for	O
autonomous	B-PROC
replication	I-PROC
of	O
an	O
RNA	O
replicon	O
,	O
and	O
the	O
importance	O
of	O
gene	O
order	O
in	O
genome	O
replication	O
.	O

To	O
explain	O
the	O
discovery	O
of	O
subgenome	O
-	O
length	O
minus	O
strands	O
,	O
a	O
related	O
model	O
,	O
called	O
the	O
replicon	O
model	O
,	O
was	O
proposed	O
:	O
The	O
subgenomic	O
mRNAs	O
would	O
be	O
produced	O
initially	O
by	O
leader	O
-	O
primed	O
transcription	B-PROC
and	O
then	O
replicated	O
into	O
minus	O
-	O
strand	O
templates	O
that	O
would	O
in	O
turn	O
be	O
transcribed	O
into	O
subgenomic	O
mRNAs	O
.	O

We	O
review	O
the	O
experimental	O
evidence	O
that	O
led	O
us	O
to	O
formulate	O
a	O
third	O
model	O
proposing	O
that	O
the	O
discontinuous	O
event	O
in	O
coronavirus	O
RNA	B-PROC
synthesis	I-PROC
occurs	O
during	O
minus	O
strand	O
synthesis	B-PROC
.	O

In	O
its	O
current	O
state	O
targeted	B-PROC
RNA	O
recombination	B-PROC
offers	O
a	O
versatile	O
and	O
powerful	O
method	O
for	O
the	O
site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
of	O
the	O
downstream	O
third	O
of	O
the	O
coronavirus	O
genome	O
,	O
which	O
encodes	O
all	O
the	O
viral	O
structural	O
proteins	O
.	O

The	O
development	B-PROC
of	O
this	O
system	O
is	O
described	O
,	O
with	O
an	O
emphasis	O
on	O
recent	O
improvements	O
,	O
and	O
multiple	O
applications	O
of	O
this	O
technique	O
to	O
the	O
study	O
of	O
coronavirus	O
molecular	O
biology	O
and	O
pathogenesis	B-PROC
are	O
reviewed	O
.	O

With	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
genome	O
the	O
efficient	O
(>	O
40	O
microg	O
per	O
106	O
cells	O
)	O
and	O
stable	O
(>	O
20	O
passages	O
)	O
expression	B-PROC
of	O
the	O
foreign	O
genes	O
has	O
been	O
shown	O
.	O

He	O
developed	O
increasing	O
serum	O
levels	O
of	O
specific	O
antibodies	O
against	O
the	O
recombinant	O
nucleocapsid	O
protein	O
of	O
CoV	O
-	O
HKU1	O
,	O
with	O
immunoglobulin	B-PROC
M	O
(	O
IgM	O
)	O
titers	O
of	O
1	O
:	O
20	O
,	O
1	O
:	O
40	O
,	O
and	O
1	O
:	O
80	O
and	O
IgG	O
titers	O
of	O
<	O
1	O
:	O
1	O
,	O
000	O
,	O
1	O
:	O
2	O
,	O
000	O
,	O
and	O
1	O
:	O
8	O
,	O
000	O
in	O
the	O
first	O
,	O
second	O
and	O
fourth	O
weeks	O
of	O
the	O
illness	O
,	O
respectively	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
prove	O
whether	O
the	O
treatment	O
of	O
soluble	O
pAPN	O
could	O
enhance	O
the	O
antibody	B-PROC
production	I-PROC
against	O
PEDV	O
in	O
guinea	O
pigs	O
,	O
rabbits	O
and	O
sows	O
.	O

In	O
50	O
%	O
of	O
the	O
fatal	O
cases	O
,	O
renal	O
insuficiency	O
,	O
requiring	O
the	O
use	O
of	O
the	O
extracorporeal	O
elimination	B-PROC
method	O
was	O
reported	O
while	O
,	O
on	O
the	O
other	O
hand	O
,	O
none	O
of	O
the	O
survivors	O
suffered	O
from	O
renal	O
insufficiency	O
.	O

Currently	O
,	O
two	O
distinct	O
forms	O
of	O
ventilator	O
-	O
associated	O
lung	O
injury	O
are	O
recognized	O
to	O
produce	O
alveolar	O
stress	O
failure	O
and	O
have	O
been	O
termed	O
low	O
-	O
volume	B-PROC
lung	I-PROC
injury	O
(	O
intratidal	O
alveolar	O
recruitment	O
and	O
derecruitment	O
)	O
and	O
high	O
-	O
volume	B-PROC
lung	I-PROC
injury	O
(	O
alveolar	O
stretch	O
and	O
overdistension	O
).	O

Airway	O
pressure	O
release	O
ventilation	O
is	O
a	O
mode	O
of	O
mechanical	O
ventilation	O
that	O
maintains	O
lung	B-PROC
volume	I-PROC
to	O
limit	O
intra	O
tidal	O
recruitment	O
/	O
derecruitment	O
and	O
improves	O
gas	O
exchange	O
while	O
limiting	O
over	O
distension	O
.	O

In	O
fact	O
,	O
their	O
emergential	O
success	O
may	O
be	O
better	O
explained	O
by	O
the	O
development	B-PROC
of	O
large	O
industry	O
poultry	O
flocks	O
increasing	O
the	O
risks	O
of	O
epizootics	O
,	O
dietary	O
habits	O
,	O
economic	O
and	O
demographic	O
constraints	O
,	O
and	O
negligence	O
in	O
the	O
surveillance	O
and	O
reporting	O
of	O
the	O
first	O
cases	O
.	O

TITLE	O
:	O
RT	O
-	O
PCR	O
-	O
based	O
dot	O
blot	O
hybridization	B-PROC
for	O
the	O
detection	O
and	O
differentiation	B-PROC
between	O
porcine	O
epidemic	O
diarrhea	O
virus	O
and	O
transmissible	O
gastroenteritis	O
virus	O
in	O
fecal	O
samples	O
using	O
a	O
non	O
-	O
radioactive	O
digoxigenin	O
cDNA	O
probe	O
.	O

Understanding	O
epidemiology	O
and	O
disease	O
transmission	O
is	O
vital	O
to	O
nursing	B-PROC
care	O
.	O

ABSTRACT	O
:	O
Tracheoesophageal	O
fistula	O
is	O
an	O
uncommon	O
complication	O
usually	O
associated	O
with	O
chronic	O
usage	O
of	O
ventilator	O
and	O
pressure	O
necrosis	B-PROC
of	O
the	O
tracheoesophageal	O
wall	O
.	O

Methylprednisolone	O
pulse	B-PROC
therapy	O
followed	O
by	O
a	O
maintenance	O
dosage	O
was	O
given	O
due	O
to	O
persistence	O
of	O
bilateral	O
pulmonary	O
fibrosis	O
.	O

She	O
was	O
weaned	B-PROC
from	O
the	O
ventilator	O
soon	O
after	O
the	O
surgery	O
and	O
discharged	O
34	O
days	O
after	O
the	O
operation	O
.	O

Labor	B-PROC
occurred	O
spontaneously	O
at	O
term	O
,	O
and	O
a	O
healthy	O
female	O
baby	O
was	O
delivered	O
with	O
no	O
evidence	O
of	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
R	O
(	O
replicase	O
)	O
protein	O
is	O
the	O
uniquely	O
defined	O
non	O
-	O
structural	O
protein	O
(	O
NSP	O
)	O
responsible	O
for	O
RNA	B-PROC
replication	I-PROC
,	O
mutation	O
rate	O
or	O
fidelity	O
,	O
regulation	B-PROC
of	O
transcription	B-PROC
in	O
coronaviruses	O
and	O
many	O
other	O
ssRNA	O
viruses	O
.	O

We	O
report	O
the	O
epidemiologic	O
linkage	B-PROC
of	O
SARS	O
within	O
an	O
extended	O
family	O
.	O

ABSTRACT	O
:	O
Knowledge	O
of	O
the	O
evolution	B-PROC
of	O
pathogens	O
is	O
of	O
great	O
medical	O
and	O
biological	O
significance	O
to	O
the	O
prevention	O
,	O
diagnosis	O
,	O
and	O
therapy	O
of	O
infectious	O
diseases	O
.	O

A	O
human	O
phage	O
antibody	B-PROC
library	O
consisting	O
of	O
1	O
.	O
3	O
x	O
10	O
(	O
6	O
)	O
clones	O
was	O
constructed	O
by	O
electrotransformation	O
and	O
60	O
percent	O
of	O
the	O
clones	O
contained	O
Fab	O
genes	O
.	O

The	O
prepared	O
recombinant	O
N	O
protein	O
and	O
mAbs	O
against	O
N	O
protein	O
lay	O
the	O
foundation	O
for	O
further	O
development	B-PROC
of	O
early	O
diagnosis	O
assays	O
for	O
SARS	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
function	O
of	O
lymphocytes	O
and	O
the	O
expression	B-PROC
pattern	O
of	O
24	O
repertoire	O
TCR	B-PROC
Vbeta	O
in	O
the	O
convalescent	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
after	O
treatment	O
by	O
combination	O
of	O
traditional	O
Chinese	O
and	O
Western	O
medicine	O
.	O

And	O
the	O
expressions	O
of	O
TCR	B-PROC
Vbeta4	O
,	O
Vbeta22	O
and	O
Vbeta23	O
in	O
SARS	O
patients	O
treated	O
with	O
glucocorticoid	O
(>	O
1	O
000	O
U	O
)	O
were	O
higher	O
than	O
those	O
in	O
SARS	O
patients	O
without	O
treatment	O
.	O

TITLE	O
:	O
Immune	B-PROC
responses	I-PROC
with	O
DNA	O
vaccines	O
encoded	O
different	O
gene	O
fragments	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
in	O
BALB	O
/	O
c	O
mice	O
.	O

However	O
,	O
pcDNAM	O
stimulated	O
the	O
highest	O
cellular	B-PROC
immune	I-PROC
response	I-PROC
than	O
other	O
plasmids	O
,	O
and	O
pcDNASa	O
-	O
pcDNASb	O
stimulated	O
the	O
highest	O
humoral	B-PROC
immune	I-PROC
response	I-PROC
in	O
week	O
12	O
.	O

Structural	O
genomics	O
has	O
sought	O
to	O
deduce	O
protein	B-PROC
function	I-PROC
based	O
on	O
three	O
-	O
dimensional	O
homology	O
.	O

Based	O
on	O
tertiary	O
structural	O
comparisons	O
,	O
we	O
propose	O
the	O
s2m	O
RNA	O
binds	O
one	O
or	O
more	O
proteins	O
possessing	O
an	O
oligomer	O
-	O
binding	O
-	O
like	O
fold	O
,	O
and	O
we	O
suggest	O
a	O
possible	O
mechanism	O
for	O
SARS	O
viral	O
RNA	O
hijacking	O
of	O
host	O
protein	B-PROC
synthesis	I-PROC
,	O
both	O
based	O
upon	O
observed	O
s2m	O
RNA	O
macromolecular	O
mimicry	O
of	O
a	O
relevant	O
ribosomal	O
RNA	O
fold	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
evidence	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
infection	O
among	O
close	O
contacts	O
to	O
SARS	O
patients	O
and	O
the	O
level	O
of	O
sera	O
IgG	O
antibody	B-PROC
in	O
SARS	O
cases	O
.	O

Of	O
the	O
196	O
patients	O
,	O
34	O
(	O
17	O
.	O
3	O
%)	O
met	O
the	O
World	O
Health	O
Organization	O
criteria	O
for	O
probable	O
SARS	O
with	O
positive	O
results	O
of	O
serologic	O
testing	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
nasopharyngeal	O
or	O
throat	O
swabs	O
for	O
SARS	O
-	O
CoV	O
,	O
or	O
both	O
.	O

TITLE	O
:	O
Limitations	O
of	O
forehead	O
infrared	O
body	O
temperature	O
detection	O
for	O
fever	B-PROC
screening	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
alternative	O
measurement	O
methodology	O
for	O
infrared	O
body	O
thermometry	O
to	O
increase	O
accuracy	O
for	O
outdoor	O
fever	B-PROC
screening	O
during	O
the	O
2003	O
SARS	O
epidemic	O
.	O

The	O
highest	O
rate	O
of	O
stress	B-PROC
reaction	I-PROC
syndrome	O
was	O
observed	O
in	O
the	O
group	O
that	O
originally	O
worked	O
in	O
a	O
high	O
-	O
risk	O
unit	O
,	O
and	O
the	O
conscripted	O
group	O
experienced	O
the	O
most	O
severe	O
distress	O
on	O
average	O
.	O

Information	O
on	O
age	O
,	O
onset	O
and	O
duration	O
of	O
clinical	O
signs	O
,	O
and	O
lesion	O
localization	B-PROC
at	O
the	O
postmortem	O
examination	O
in	O
cats	O
belonging	O
to	O
the	O
7	O
categories	O
of	O
disease	O
were	O
analyzed	O
to	O
create	O
a	O
practical	O
list	O
of	O
differential	O
diagnoses	O
.	O

Additionally	O
,	O
we	O
found	O
that	O
the	O
individuals	O
who	O
had	O
lung	O
fibrosis	O
showed	O
some	O
spontaneous	B-PROC
recovery	I-PROC
.	O

Finally	O
,	O
some	O
of	O
the	O
subjects	O
developed	O
femoral	O
head	O
necrosis	B-PROC
.	O

HMGB1	O
expression	B-PROC
in	O
the	O
lung	O
was	O
found	O
to	O
be	O
increased	O
within	O
4	O
h	O
of	O
hemorrhage	O
and	O
then	O
remained	O
elevated	O
for	O
more	O
than	O
72	O
h	O
after	O
blood	O
loss	O
.	O

Neutrophils	O
appeared	O
to	O
contribute	O
to	O
the	O
increase	O
in	O
posthemorrhage	O
pulmonary	O
HMGB1	O
expression	B-PROC
since	O
no	O
change	O
in	O
lung	O
HMGB1	O
levels	O
was	O
found	O
after	O
hemorrhage	O
in	O
mice	O
made	O
neutropenic	O
with	O
cyclophosphamide	O
.	O

Blockade	O
of	O
HMGB1	O
by	O
administration	O
of	O
anti	O
-	O
HMGB1	O
antibodies	O
prevented	O
hemorrhage	O
-	O
induced	O
increases	O
in	O
nuclear	B-PROC
translocation	B-PROC
of	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
lungs	O
and	O
pulmonary	O
levels	O
of	O
proinflammatory	O
cytokines	O
,	O
including	O
keratinocyte	O
-	O
derived	O
chemokine	O
,	O
IL	O
-	O
6	O
,	O
and	O
IL	O
-	O
1	O
beta	O
.	O

These	O
results	O
demonstrate	O
that	O
hemorrhage	O
results	O
in	O
increased	O
HMGB1	O
expression	B-PROC
in	O
the	O
lungs	O
,	O
primarily	O
through	O
neutrophil	O
sources	O
,	O
and	O
that	O
HMGB1	O
participates	O
in	O
hemorrhage	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

Extensive	O
cellular	O
apoptosis	B-PROC
(	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
deoxyuridine	O
triphosphate	O
nick	O
-	O
end	O
labelling	O
staining	O
),	O
including	O
endothelial	O
and	O
alveolar	O
type	O
II	O
cells	O
,	O
was	O
demonstrated	O
,	O
and	O
vascular	O
bed	O
density	O
(	O
CD31	O
immunostaining	O
)	O
decreased	O
in	O
ARDS	O
lungs	O
as	O
compared	O
with	O
controls	O
.	O

The	O
Toronto	O
critical	O
care	O
community	O
has	O
learned	B-PROC
important	O
lessons	O
from	O
SARS	O
,	O
which	O
will	O
help	O
in	O
preparation	O
for	O
future	O
disease	O
outbreaks	O
.	O

The	O
main	O
clinical	O
manifestations	O
were	O
fever	B-PROC
,	O
cough	O
,	O
minor	O
or	O
serious	O
dyspnea	O
,	O
nausea	O
,	O
signs	O
of	O
injury	O
to	O
other	O
organs	O
,	O
and	O
so	O
on	O
.	O

Its	O
sensitivity	O
was	O
about	O
31	O
PFU	O
/	O
ml	O
and	O
had	O
no	O
cross	B-PROC
reaction	I-PROC
with	O
other	O
respiratory	O
viruses	O
.	O

TITLE	O
:	O
[	O
Potent	O
neutralization	O
antibody	B-PROC
elicited	O
in	O
mice	O
by	O
SARS	O
-	O
associated	O
coronavirus	O
spike	O
protein	O
S1	O
domain	O
].	O

TITLE	O
:	O
Expression	B-PROC
and	O
purification	O
of	O
SARS	O
coronavirus	O
membrane	O
protein	O
.	O

We	O
also	O
demonstrate	O
that	O
,	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
,	O
the	O
orf7a	O
protein	O
is	O
expressed	B-PROC
and	O
retained	O
intracellularly	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
provide	O
a	O
structural	O
and	O
cellular	O
framework	O
in	O
which	O
to	O
explore	O
the	O
role	O
of	O
orf7a	O
in	O
SARS	O
-	O
CoV	O
pathogenesis	B-PROC
.	O

We	O
describe	O
a	O
case	O
of	O
varicella	O
infection	O
in	O
a	O
previously	O
healthy	O
young	O
adult	O
complicated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
rhabdomyolysis	O
,	O
acute	O
hepatitis	O
and	O
disseminated	O
intravascular	O
coagulation	B-PROC
(	O
DIC	O
).	O

TITLE	O
:	O
High	O
-	O
dose	O
hydrocortisone	O
reduces	O
expression	B-PROC
of	O
the	O
pro	O
-	O
inflammatory	O
chemokines	O
CXCL8	O
and	O
CXCL10	O
in	O
SARS	O
coronavirus	O
-	O
infected	O
intestinal	O
cells	O
.	O

Electric	O
mobility	O
shift	O
assay	O
revealed	O
increased	O
DNA	O
binding	B-PROC
activity	I-PROC
of	O
the	O
cellular	B-PROC
transcription	I-PROC
factors	O
activator	O
protein	O
1	O
(	O
AP	O
-	O
1	O
)	O
and	O
nuclear	O
factor	O
(	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
in	O
SARS	O
-	O
CoV	O
infected	O
cells	O
.	O

This	O
is	O
the	O
first	O
animal	O
-	O
human	O
zoonotic	O
pair	O
of	O
coronaviruses	O
that	O
can	O
be	O
analyzed	O
in	O
order	O
to	O
gain	O
insights	O
into	O
the	O
processes	O
of	O
adaptation	B-PROC
of	O
a	O
nonhuman	O
coronavirus	O
to	O
a	O
human	O
host	O
,	O
which	O
is	O
important	O
for	O
understanding	O
the	O
interspecies	O
transmission	O
events	O
that	O
led	O
to	O
the	O
origin	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
outbreak	O
.	O

ABSTRACT	O
:	O
Human	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
were	O
selected	O
from	O
semisynthetic	O
antibody	B-PROC
phage	O
display	O
libraries	O
by	O
using	O
whole	O
irradiated	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
virions	O
as	O
target	O
.	O

The	O
identification	O
of	O
these	O
membrane	O
-	O
active	O
regions	O
,	O
which	O
are	O
capable	O
of	O
modifying	O
the	O
biophysical	O
properties	O
of	O
phospholipid	O
membranes	O
,	O
supports	O
their	O
direct	O
role	O
in	O
SARS	O
CoV	O
-	O
mediated	O
membrane	B-PROC
fusion	I-PROC
,	O
as	O
well	O
as	O
facilitating	O
the	O
future	O
development	B-PROC
of	O
SARS	O
CoV	O
entry	O
inhibitors	O
.	O

CONCLUSIONS	O
:	O
The	O
anti	O
-	O
SARS	O
-	O
CoV	O
nucleocapsid	O
McAbs	O
were	O
developed	O
and	O
these	O
McAbs	O
may	O
be	O
useful	O
in	O
the	O
development	B-PROC
of	O
diagnosis	O
assays	O
and	O
basic	O
research	O
of	O
SARS	O
.	O

Serological	O
examination	O
using	O
blood	O
samples	O
collected	O
on	O
the	O
12th	O
and	O
28th	O
hospital	O
days	O
revealed	O
elevation	O
of	O
anti	O
-	O
L	O
.	O
pneumophila	O
serogroup	O
I	O
antibody	B-PROC
.	O

The	O
data	O
,	O
however	O
,	O
suggest	O
that	O
the	O
antiviral	O
activity	O
of	O
IFN	O
against	O
SARS	O
-	O
CoV	O
virus	O
is	O
independent	O
of	O
MxA	O
expression	B-PROC
.	O

Recently	O
,	O
siRNA	O
-	O
induced	O
RNA	B-PROC
interference	I-PROC
(	O
RNAi	B-PROC
)	O
may	O
provide	O
a	O
new	O
approach	O
to	O
therapy	O
for	O
pathogenic	O
viruses	O
,	O
e	O
.	O
g	O
.	O
HIV	O
and	O
HCV	O
.	O

PGF	O
was	O
defined	O
as	O
(	O
1	O
)	O
diffuse	O
alveolar	O
opacities	O
developing	O
within	O
72	O
h	O
of	O
transplantation	O
,	O
(	O
2	O
)	O
an	O
arterial	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
PaO2	O
/	O
FiO2	O
)	O
ratio	O
of	O
<	O
200	O
beyond	O
48	O
h	O
postoperatively	O
,	O
and	O
(	O
3	O
)	O
no	O
other	O
secondary	O
cause	O
of	O
graft	O
dysfunction	O
.	O

However	O
,	O
the	O
immune	O
-	O
pathogenesis	B-PROC
of	O
SARS	O
is	O
poorly	O
understood	O
.	O

To	O
understand	O
the	O
host	B-PROC
response	I-PROC
to	O
this	O
pathogen	O
,	O
we	O
investigated	O
the	O
gene	B-PROC
expression	I-PROC
profiles	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
derived	O
from	O
SARS	O
patients	O
,	O
and	O
compared	O
with	O
healthy	O
controls	O
.	O

Cough	O
,	O
rhinorrhea	O
,	O
tachypnea	O
,	O
fever	B-PROC
,	O
abnormal	O
breath	O
sounds	O
,	O
and	O
hypoxia	O
were	O
the	O
most	O
common	O
findings	O
associated	O
with	O
HCoV	O
-	O
NH	O
infection	O
.	O

Superinfection	O
after	O
the	O
immune	O
injury	O
is	O
the	O
main	O
cause	O
of	O
death	B-PROC
.	O

ABSTRACT	O
:	O
To	O
characterize	O
enzymatic	B-PROC
activity	I-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
and	O
its	O
four	O
site	O
-	O
directed	O
mutants	O
.	O

SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
showed	O
substantial	O
pH	O
and	O
temperature	O
-	O
triggered	O
activity	O
switches	O
,	O
and	O
site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
analysis	O
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
revealed	O
that	O
substitutions	O
of	O
His41	O
,	O
Cys145	O
,	O
and	O
His163	O
resulted	O
in	O
complete	O
loss	O
of	O
enzymatic	B-PROC
activity	I-PROC
,	O
while	O
replacement	O
of	O
Met162	O
with	O
Ala	O
caused	O
strongly	O
increased	O
activity	O
.	O

By	O
allowing	O
patients	O
with	O
acute	O
lung	O
injury	O
to	O
breathe	O
spontaneously	O
,	O
one	O
can	O
expect	O
improvement	O
in	O
gas	O
exchange	O
and	O
in	O
systemic	O
blood	B-PROC
flow	I-PROC
,	O
on	O
the	O
basis	O
of	O
both	O
experimental	O
and	O
clinical	O
trials	O
.	O

In	O
addition	O
,	O
by	O
increasing	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
lung	B-PROC
volume	I-PROC
,	O
as	O
will	O
occur	O
when	O
airway	O
pressure	O
release	O
ventilation	O
is	O
used	O
,	O
recruitment	O
of	O
collapsed	O
or	O
consolidated	O
lung	O
is	O
likely	O
to	O
occur	O
,	O
especially	O
in	O
juxtadiaphragmatic	O
lung	O
regions	O
.	O

Specific	O
antibody	B-PROC
response	I-PROC
to	O
this	O
purified	O
recombinant	O
N	O
protein	O
was	O
100	O
%	O
positive	O
in	O
the	O
SARS	O
patients	O
'	O
sera	O
,	O
while	O
none	O
of	O
the	O
control	O
sera	O
from	O
30	O
healthy	O
people	O
gave	O
a	O
positive	O
reaction	O
in	O
the	O
same	O
assay	O
.	O

The	O
potential	O
mutability	O
of	O
the	O
SARS	O
-	O
CoV	O
genome	O
may	O
lead	O
to	O
new	O
SARS	O
outbreaks	O
and	O
several	O
regions	O
of	O
the	O
viral	O
genomes	O
open	O
reading	O
frames	O
have	O
been	O
identified	O
which	O
may	O
contribute	O
to	O
the	O
severe	O
virulence	B-PROC
of	O
the	O
virus	O
.	O

Four	O
serotype	O
-	O
specific	O
chimeric	O
oligonucleotides	O
were	O
designed	O
,	O
one	O
each	O
for	O
the	O
Massachusetts	O
,	O
Connecticut	O
,	O
Arkansas	O
,	O
and	O
Delaware	O
/	O
Georgia	O
98	O
serotypes	O
,	O
and	O
tested	O
for	O
their	O
ability	O
to	O
mediate	O
specific	O
cleavage	B-PROC
of	O
target	O
RNA	O
from	O
known	O
homologous	O
and	O
heterologous	O
strains	O
of	O
IBV	O
.	O

Specific	O
cleavage	B-PROC
of	O
target	O
RNAs	O
by	O
each	O
chimeric	O
oligonucleotide	O
was	O
verified	O
using	O
agarose	O
gel	O
analysis	O
and	O
RRT	O
-	O
PCR	O
.	O

By	O
closely	O
paralleling	O
the	O
clinical	O
development	B-PROC
of	O
pulmonary	O
injury	O
,	O
this	O
model	O
should	O
prove	O
invaluable	O
in	O
the	O
study	O
of	O
human	O
ARDS	O
.	O

TITLE	O
:	O
Virtual	O
screening	O
of	O
novel	O
noncovalent	O
inhibitors	O
for	O
SARS	O
-	O
CoV	O
3C	O
-	O
like	O
proteinase	B-PROC
.	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-PROC
is	O
considered	O
as	O
a	O
potential	O
drug	O
design	O
target	O
for	O
the	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

We	O
have	O
built	O
a	O
""""	O
flexible	O
""""	O
three	O
-	O
dimensional	O
model	O
for	O
SARS	O
3C	O
-	O
like	O
proteinase	B-PROC
by	O
homology	O
modeling	O
and	O
multicanonical	O
molecular	B-PROC
dynamics	I-PROC
method	O
and	O
used	O
the	O
model	O
for	O
virtual	O
screening	O
of	O
chemical	O
databases	O
.	O

Forty	O
compounds	O
were	O
purchased	O
and	O
tested	O
by	O
HPLC	O
and	O
colorimetric	O
assay	O
against	O
SARS	O
3C	O
-	O
like	O
proteinase	B-PROC
.	O

TITLE	O
:	O
Cerebro	O
-	O
pulmonary	O
interactions	O
during	O
the	O
application	O
of	O
low	O
levels	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
.	O

In	O
recruiters	O
(=	O
6	O
patients	O
),	O
elastance	O
decreased	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
PaO	B-PROC
(	O
2	O
)	O
increased	O
(	O
P	O
<	O
0	O
.	O
005	O
),	O
while	O
in	O
non	O
-	O
recruiters	O
(=	O
6	O
patients	O
)	O
elastance	O
and	O
PaCO	O
(	O
2	O
)	O
significantly	O
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

This	O
patient	O
required	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
up	O
to	O
18	O
mm	O
/	O
Hg	O
)	O
and	O
fractional	O
inspiratory	B-PROC
oxygen	O
(	O
up	O
to	O
100	O
%).	O

Nevertheless	O
,	O
the	O
transcription	B-PROC
factor	O
interferon	O
regulatory	O
factor	O
3	O
(	O
IRF	O
-	O
3	O
),	O
which	O
is	O
essential	O
for	O
IFN	O
-	O
beta	O
promoter	O
activity	O
,	O
was	O
transported	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
early	O
after	O
infection	O
with	O
SARS	O
-	O
CoV	O
.	O
However	O
,	O
at	O
a	O
later	O
time	O
point	O
in	O
infection	O
,	O
IRF	O
-	O
3	O
was	O
again	O
localized	O
in	O
the	O
cytoplasm	O
.	O

TITLE	O
:	O
Role	O
of	O
nucleotides	O
immediately	O
flanking	O
the	O
transcription	B-PROC
-	O
regulating	O
sequence	O
core	O
in	O
coronavirus	O
subgenomic	O
mRNA	B-PROC
synthesis	I-PROC
.	O

The	O
average	O
fever	B-PROC
abatement	O
time	O
was	O
4	O
.	O
44	O
+/-	O

All	O
assays	O
yielded	O
results	O
by	O
detecting	O
SARS	O
coronavirus	O
targeting	B-PROC
the	O
BNI	O
-	O
1	O
region	O
in	O
less	O
than	O
2	O
hours	O
.	O

Thus	O
,	O
development	B-PROC
of	O
vaccines	O
from	O
different	O
local	O
strains	O
is	O
necessary	O
to	O
control	O
infectious	O
bronchitis	O
in	O
poultry	O
.	O

Urine	O
UA	O
and	O
creatinine	O
levels	O
were	O
available	O
for	O
43	O
patients	O
;	O
the	O
serum	O
cytokines	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
),	O
IL	O
-	O
8	O
,	O
and	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
were	O
measured	O
in	O
16	O
patients	O
.	O

After	O
adjustments	O
for	O
age	O
and	O
sex	O
,	O
high	O
FE	O
UA	O
was	O
significantly	O
associated	O
with	O
the	O
lowest	O
blood	O
oxygenation	B-PROC
(	O
P	O
=	O
0	O
.	O
001	O
;	O
r	O
=	O
-	O
0	O
.	O
624	O
).	O

This	O
review	O
focuses	O
on	O
the	O
comparative	O
pathogenesis	B-PROC
of	O
CoV	O
infections	O
,	O
including	O
the	O
factors	O
that	O
accentuate	O
CoV	O
respiratory	O
disease	O
,	O
with	O
emphasis	O
on	O
livestock	O
and	O
poultry	O
.	O

This	O
motif	O
is	O
missing	O
from	O
the	O
spike	O
protein	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
resulting	O
in	O
high	O
level	O
of	O
surface	O
expression	B-PROC
of	O
the	O
spike	O
protein	O
when	O
it	O
is	O
expressed	B-PROC
on	O
its	O
own	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
3a	O
can	O
bind	O
to	O
the	O
spike	O
protein	O
and	O
through	O
this	O
interaction	O
,	O
it	O
may	O
be	O
able	O
to	O
cause	O
the	O
spike	O
protein	O
to	O
become	O
internalized	O
,	O
resulting	O
in	O
a	O
decrease	O
in	O
its	O
surface	O
expression	B-PROC
.	O

Human	O
cell	O
lines	O
were	O
infected	O
with	O
Cytomegalovirus	O
,	O
Human	O
Herpesvirus	O
-	O
6	O
,	O
Camelpox	O
virus	O
,	O
SARS	O
coronavirus	O
or	O
Yellow	O
fever	B-PROC
virus	O
.	O

Low	O
level	O
of	O
immunity	B-PROC
among	O
unaffected	O
healthcare	O
workers	O
reinforces	O
the	O
need	O
for	O
adequate	O
personal	O
protection	O
and	O
other	O
infection	O
control	O
measures	O
in	O
hospitals	O
to	O
prevent	O
future	O
epidemics	O
.	O

To	O
avoid	O
the	O
enhancement	O
antibody	B-PROC
issue	O
,	O
genes	O
encoding	O
the	O
nucleocapsid	O
,	O
membrane	O
,	O
and	O
envelope	O
protein	O
of	O
SARS	O
-	O
CoV	O
were	O
cloned	O
and	O
their	O
expressions	O
in	O
mammalian	O
cells	O
were	O
determined	O
.	O

In	O
addition	O
,	O
ADS	O
-	O
MVA	O
induced	O
potent	O
immune	B-PROC
responses	I-PROC
which	O
very	O
likely	O
protected	O
Chinese	O
rhesus	O
monkeys	O
from	O
pathogenic	O
SARS	O
-	O
CoV	O
challenge	O
.	O

The	O
models	O
arising	O
from	O
the	O
molecular	B-PROC
dynamics	I-PROC
simulations	O
were	O
tested	O
for	O
evolutionary	O
conservation	O
using	O
13	O
coronavirus	O
protein	O
E	O
homologous	O
sequences	O
.	O

Thirty	O
-	O
two	O
acute	O
-	O
care	O
hospitals	O
were	O
required	O
to	O
report	O
their	O
previous	O
day	O
'	O
s	O
unscheduled	O
admissions	O
for	O
11	O
syndromes	O
(	O
pneumonia	O
,	O
hemoptysis	O
,	O
respiratory	O
distress	O
,	O
acute	O
neurologic	O
illness	O
,	O
nontraumatic	O
paralysis	O
,	O
sepsis	O
and	O
nontraumatic	O
shock	O
,	O
fever	B-PROC
with	O
rash	O
,	O
fever	B-PROC
of	O
unknown	O
cause	O
,	O
acute	O
gastrointestinal	O
illness	O
,	O
and	O
possible	O
cutaneous	O
anthrax	O
,	O
and	O
suspected	O
illness	O
clusters	O
).	O

The	O
importance	O
of	O
CT	O
scans	O
in	O
patients	O
with	O
ARDS	O
has	O
been	O
reviewed	O
recently	O
(	O
9	O
),	O
but	O
unfortunately	O
there	O
has	O
been	O
no	O
experience	O
of	O
CT	O
in	O
patients	O
with	O
smoke	O
inhalation	B-PROC
injury	O
.	O

The	O
patient	O
'	O
s	O
nine	O
-	O
year	O
-	O
old	O
sister	O
had	O
died	B-PROC
from	O
a	O
similar	O
syndrome	O
two	O
weeks	O
earlier	O
.	O

For	O
this	O
application	O
,	O
it	O
is	O
critical	O
for	O
thermal	O
imagers	O
to	O
be	O
able	O
to	O
identify	O
febrile	B-PROC
from	O
normal	O
subjects	O
accurately	O
.	O

tl	O
/	O
CH	O
/	O
LDT3	O
/	O
03	O
had	O
a	O
spike	O
protein	O
gene	O
with	O
95	O
%	O
identity	O
to	O
that	O
of	O
a	O
Chinese	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
isolate	O
,	O
although	O
more	O
extensive	O
sequencing	O
revealed	O
the	O
possibility	O
that	O
this	O
strain	O
may	O
have	O
undergone	O
recombination	B-PROC
.	O

By	O
day	O
7	O
,	O
crude	O
odds	O
ratio	O
of	O
death	B-PROC
was	O
1	O
.	O
73	O
per	O
5	O
%	O
of	O
AO	O
%	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
or	O
2	O
.	O
93	O
per	O
lung	O
zone	O
opacified	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

The	O
patients	O
were	O
placed	O
in	O
prone	O
position	O
for	O
2	O
h	O
.	O
The	O
effect	O
of	O
different	O
time	O
(	O
pre	O
-	O
PPV	O
,	O
PPV	O
0	O
.	O
5	O
h	O
,	O
PPV	O
2	O
h	O
)	O
on	O
oxygenation	B-PROC
,	O
respiratory	B-PROC
mechanics	I-PROC
and	O
hemodynamics	B-PROC
were	O
observed	O
.	O

These	O
data	O
are	O
the	O
first	O
to	O
demonstrate	O
that	O
LPS	O
-	O
induced	O
CD14	O
-	O
dependent	O
and	O
-	O
independent	O
(	O
CD11b	O
-	O
dependent	O
)	O
signaling	B-PROC
pathways	B-PROC
in	O
the	O
lung	O
are	O
entirely	O
dependent	O
on	O
TLR4	O
and	O
that	O
blocking	O
TLR4	O
might	O
be	O
beneficial	O
in	O
lung	O
diseases	O
caused	O
by	O
LPS	O
from	O
gram	O
-	O
negative	O
pathogens	O
.	O

By	O
Western	O
blot	O
analysis	O
and	O
immunoprecipitation	O
experiments	O
,	O
we	O
showed	O
that	O
all	O
the	O
antibodies	O
are	O
specific	O
and	O
highly	O
sensitive	O
to	O
both	O
the	O
native	O
and	O
denatured	O
forms	O
of	O
the	O
full	O
-	O
length	O
S	O
protein	O
expressed	B-PROC
in	O
virus	O
-	O
infected	O
cells	O
and	O
transfected	O
cells	O
,	O
respectively	O
.	O

The	O
clinical	O
symptoms	O
associated	O
with	O
these	O
zoonotic	O
transmissions	O
range	O
from	O
mild	O
respiratory	O
illnesses	O
and	O
conjunctivitis	O
to	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
sometimes	O
resulting	O
in	O
death	B-PROC
.	O

Development	B-PROC
of	O
virus	O
diagnostic	O
tests	O
,	O
antiviral	O
strategies	O
,	O
and	O
vaccines	O
for	O
each	O
of	O
these	O
pathogens	O
is	O
crucial	O
to	O
limit	O
their	O
impact	O
.	O

Probable	O
environmental	O
causes	O
for	O
airborne	O
transmission	O
associated	O
with	O
the	O
air	O
movements	B-PROC
between	O
flats	O
in	O
Block	O
E	O
are	O
identified	O
.	O

These	O
results	O
suggest	O
that	O
M	O
.	O
gallisepticum	O
can	O
persist	O
in	O
chickens	O
without	O
development	B-PROC
of	O
resistance	B-PROC
despite	O
several	O
treatments	O
with	O
enrofloxacin	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
factors	O
relating	O
to	O
the	O
practice	O
of	O
habitual	O
and	O
volitional	O
health	O
behaviors	B-PROC
against	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
among	O
Chinese	O
adolescents	O
in	O
Hong	O
Kong	O
.	O

These	O
factors	O
included	O
perceived	O
threat	O
of	O
SARS	O
,	O
perceived	O
benefits	O
and	O
barriers	O
in	O
practicing	O
SARS	O
preventive	O
health	O
behaviors	B-PROC
,	O
cues	O
to	O
action	O
,	O
knowledge	O
of	O
SARS	O
,	O
and	O
self	O
-	O
efficacy	O
.	O

About	O
54	O
.	O
8	O
%	O
of	O
respondents	O
reported	O
practicing	O
all	O
three	O
recommended	O
habitual	O
health	O
behaviors	B-PROC
.	O

Results	O
of	O
hierarchical	O
regression	O
analyses	O
showed	O
that	O
habitual	O
health	O
behaviors	B-PROC
against	O
SARS	O
were	O
related	O
to	O
perceived	O
health	O
threat	O
and	O
environmental	O
cues	O
.	O

The	O
Health	O
Belief	O
Model	O
is	O
useful	O
in	O
understanding	O
Chinese	O
adolescents	O
'	O
practice	O
of	O
health	O
behaviors	B-PROC
,	O
especially	O
volitional	O
health	O
behaviors	B-PROC
.	O

Partitioned	O
respiratory	B-PROC
mechanics	I-PROC
were	O
determined	O
during	O
iso	O
-	O
flow	O
(	O
0	O
.	O
91	O
L	O
.	O
s	O
(-	O
1	O
))	O
experiments	O
(	O
V	O
(	O
T	O
)	O
varied	O
within	O
0	O
.	O
2	O
-	O
1	O
.	O
0	O
L	O
),	O
along	O
with	O
haemodynamics	O
,	O
gas	O
exchange	O
,	O
and	O
EELV	O
.	O

Compared	O
with	O
SR	O
(	O
BAS	O
),	O
pronation	B-PROC
/	O
SR	O
(	O
PP	O
)	O
resulted	O
in	O
reduced	O
peak	O
/	O
plateau	O
P	O
(	O
L	O
)	O
at	O
V	O
(	O
T	O
)	O
s	O
>	O
or	O
=	O
0	O
.	O
6	O
L	O
;	O
static	O
lung	O
elastance	O
and	O
additional	O
lung	O
resistance	B-PROC
decreased	O
and	O
chest	O
wall	O
elastance	O
(	O
in	O
prone	O
position	O
)	O
increased	O
;	O
EELV	O
increased	O
(	O
23	O
-	O
33	O
%);	O
V	O
(	O
T	O
)/	O
EELV	O
decreased	O
(	O
27	O
-	O
33	O
%);	O
arterial	O
oxygen	B-PROC
tension	I-PROC
/	O
inspiratory	B-PROC
oxygen	O
fraction	O
and	O
arterial	O
carbon	B-PROC
dioxide	I-PROC
tension	I-PROC
improved	O
(	O
21	O
-	O
43	O
/	O
10	O
-	O
14	O
%,	O
respectively	O
),	O
and	O
shunt	O
fraction	O
/	O
physiological	O
dead	B-PROC
space	O
decreased	O
(	O
21	O
-	O
50	O
/	O
20	O
-	O
47	O
%,	O
respectively	O
).	O

In	O
early	O
/	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
pronation	B-PROC
under	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
optimisation	O
may	O
reduce	O
ventilator	O
-	O
induced	O
lung	O
injury	O
risk	O
.	O

In	O
retrospect	O
,	O
many	O
patients	O
survived	O
due	O
to	O
careful	O
nursing	B-PROC
.	O

Monoclonal	O
antibodies	O
(	O
Mabs	O
)	O
and	O
established	O
drugs	O
,	O
such	O
as	O
interferons	O
and	O
HIV	O
proteinase	B-PROC
inhibitors	O
,	O
are	O
also	O
discussed	O
in	O
relation	O
to	O
anti	O
-	O
SARS	O
clinical	O
use	O
.	O

TITLE	O
:	O
The	O
protein	O
X4	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
is	O
expressed	B-PROC
on	O
both	O
virus	O
-	O
infected	O
cells	O
and	O
lung	O
tissue	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
patients	O
and	O
inhibits	O
growth	B-PROC
of	O
Balb	O
/	O
c	O
3T3	O
cell	O
line	O
.	O

Despite	O
anticoagulation	B-PROC
,	O
immunosuppression	B-PROC
,	O
plasmapheresis	O
and	O
antibiotic	O
therapy	O
,	O
she	O
developed	O
cutaneous	O
gangrene	O
,	O
retroperitoneal	O
hematoma	O
,	O
ileus	O
,	O
and	O
acute	O
respiratory	O
and	O
renal	O
failure	O
that	O
resulted	O
in	O
death	B-PROC
.	O

TITLE	O
:	O
General	B-PROC
anesthesia	I-PROC
with	O
remifentanil	O
for	O
Cesarean	O
section	O
in	O
a	O
patient	O
with	O
HELLP	O
syndrome	O
.	O

In	O
a	O
future	O
outbreak	O
,	O
rapidly	O
and	O
accurately	O
distinguishing	O
SARS	O
from	O
other	O
common	O
febrile	B-PROC
respiratory	O
illnesses	O
(	O
FRIs	O
)	O
could	O
be	O
difficult	O
.	O

The	O
conserved	O
core	O
sequence	O
of	O
the	O
native	O
cleavage	B-PROC
site	O
is	O
optimized	O
for	O
high	O
hydrolysis	O
activity	O
.	O

A	O
better	O
understanding	O
of	O
the	O
SARS	O
-	O
CoV	O
growth	B-PROC
kinetics	O
in	O
Vero	O
E6	O
cells	O
is	O
crucial	O
to	O
help	O
elucidate	O
the	O
mechanism	O
of	O
antiviral	O
activity	O
of	O
selective	O
antiviral	O
agents	O
.	O

In	O
this	O
study	O
,	O
the	O
growth	B-PROC
kinetics	O
of	O
SARS	O
-	O
CoV	O
in	O
Vero	O
E6	O
cells	O
were	O
studied	O
by	O
quantitation	O
of	O
intra	O
-	O
and	O
extracellular	O
viral	O
RNA	O
load	O
as	O
well	O
as	O
extracellular	O
virus	O
yield	O
at	O
different	O
time	O
points	O
post	O
-	O
infection	O
.	O

In	O
these	O
patients	O
,	O
HFOV	O
has	O
consistently	O
been	O
shown	O
to	O
improve	O
oxygenation	B-PROC
without	O
obvious	O
increases	O
in	O
complications	O
measured	O
.	O

HFOV	O
produced	O
a	O
slower	O
and	O
less	O
robust	O
reversal	O
of	O
oxygenation	B-PROC
failure	O
in	O
those	O
with	O
smoke	O
inhalation	B-PROC
compared	O
with	O
patients	O
with	O
burns	O
alone	O
.	O

ABSTRACT	O
:	O
To	O
review	O
the	O
use	O
of	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
with	O
adjunctive	O
therapies	O
(	O
inhaled	B-PROC
nitric	O
oxide	O
[	O
iNO	O
]	O
and	O
prone	O
positioning	O
[	O
PP	O
])	O
in	O
adult	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

As	O
a	O
result	O
,	O
various	O
salvage	O
therapies	O
aimed	O
at	O
improving	O
oxygenation	B-PROC
,	O
including	O
HFOV	O
,	O
iNO	O
,	O
and	O
PP	O
alone	O
or	O
in	O
combination	O
,	O
have	O
been	O
evaluated	O
in	O
patients	O
with	O
refractory	O
ARDS	O
.	O

It	O
reliably	O
improves	O
oxygenation	B-PROC
and	O
provides	O
adequate	O
ventilation	O
at	O
lower	O
peak	O
pressures	O
than	O
conventional	O
ventilation	O
.	O

As	O
expected	O
,	O
virus	O
-	O
specific	O
CTL	O
responses	O
and	O
T	B-PROC
cell	I-PROC
proliferation	I-PROC
were	O
induced	O
from	O
human	O
T	O
cells	O
.	O

SARS	O
-	O
N	O
and	O
SARS	O
-	O
M	O
DNA	O
vaccines	O
and	O
SCID	O
-	O
PBL	O
/	O
hu	O
mouse	O
model	O
will	O
be	O
important	O
in	O
the	O
development	B-PROC
of	O
protective	O
vaccines	O
.	O

Rabies	O
immunoglobulin	B-PROC
,	O
injected	O
into	O
and	O
around	O
bite	B-PROC
wounds	O
,	O
provides	O
added	O
safety	O
for	O
the	O
severely	O
exposed	O
.	O

TITLE	O
:	O
Longitudinally	O
profiling	O
neutralizing	O
antibody	B-PROC
response	I-PROC
to	O
SARS	O
coronavirus	O
with	O
pseudotypes	O
.	O

Expressed	B-PROC
3a	O
protein	O
was	O
reported	O
to	O
localize	O
to	O
Golgi	O
complex	O
in	O
SARS	O
-	O
CoV	O
infected	O
cells	O
.	O

The	O
localization	B-PROC
pattern	O
was	O
similar	O
in	O
different	O
transfected	O
cells	O
.	O

Furthermore	O
,	O
pretreatment	O
with	O
oxymatrine	O
significantly	O
alleviated	O
oleic	O
acid	O
-	O
induced	O
lung	O
injury	O
accompanied	O
by	O
reduction	O
of	O
lung	O
index	O
and	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
,	O
decreases	O
in	O
serum	O
TNF	O
-	O
alpha	O
level	O
and	O
inhibition	B-PROC
of	O
phosphorylated	O
p38	O
MAPK	O
.	O

TITLE	O
:	O
Retrospective	O
evidence	O
that	O
the	O
MHC	B-PROC
(	O
B	O
haplotype	O
)	O
of	O
chickens	O
influences	O
genetic	O
resistance	B-PROC
to	O
attenuated	O
infectious	O
bronchitis	O
vaccine	O
strains	O
in	O
chickens	O
.	O

The	O
histologic	O
evolution	B-PROC
of	O
SARS	O
coincided	O
with	O
the	O
different	O
stages	O
of	O
DAD	O
:	O
acute	O
,	O
proliferative	O
organizing	O
,	O
and	O
fibrotic	O
stages	O
.	O

SARS	O
cannot	O
be	O
differentiated	B-PROC
from	O
the	O
other	O
etiologies	O
of	O
DAD	O
by	O
morphologic	O
examination	O
alone	O
.	O

Virally	O
induced	O
increases	O
in	O
interleukin	O
-	O
6	O
and	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
mRNA	O
and	O
protein	B-PROC
expression	B-PROC
correlated	O
with	O
the	O
genomic	O
induction	O
of	O
acute	O
-	O
phase	O
proteins	O
.	O

*	O
Coordinated	O
processes	O
to	O
move	B-PROC
appropriate	O
people	O
and	O
resources	O
into	O
place	O
when	O
a	O
health	O
crisis	O
requires	O
such	O
action	O
.	O

The	O
arterial	O
oxygen	B-PROC
tension	I-PROC
/	O
fractional	O
inspired	B-PROC
oxygen	O
ratio	O
,	O
lung	O
injury	O
score	O
,	O
and	O
chest	O
radiograph	O
scores	O
correlated	O
with	O
EVLW	O
(	O
r2	O
=	O
0	O
.	O
27	O
,	O
r2	O
=	O
0	O
.	O
18	O
,	O
and	O
r2	O
=	O
0	O
.	O
28	O
,	O
respectively	O
;	O
all	O
P	O
<	O
0	O
.	O
0001	O
).	O

Of	O
the	O
395	O
patients	O
who	O
had	O
received	O
both	O
lung	B-PROC
function	I-PROC
test	O
and	O
HRCT	O
scanning	O
,	O
55	O
(	O
13	O
.	O
92	O
%)	O
had	O
abnormalities	O
both	O
in	O
the	O
lung	B-PROC
function	I-PROC
and	O
HRCT	O
.	O

An	O
indirect	O
antibody	B-PROC
ELISA	O
method	O
was	O
developed	O
and	O
clinical	O
positive	O
and	O
negative	O
sera	O
for	O
their	O
antibodies	O
against	O
GST	O
-	O
N2	O
fusion	O
protein	O
were	O
assayed	O
.	O

TITLE	O
:	O
Microarray	O
and	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analyses	O
of	O
differential	O
human	O
gene	B-PROC
expression	I-PROC
patterns	O
induced	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
infection	O
of	O
Vero	O
cells	O
.	O

Other	O
genes	O
displaying	O
altered	O
transcription	B-PROC
included	O
those	O
associated	O
with	O
host	O
translation	B-PROC
,	O
cellular	B-PROC
metabolism	I-PROC
,	O
cell	B-PROC
cycle	I-PROC
,	O
signal	B-PROC
transduction	I-PROC
,	O
transcriptional	B-PROC
regulation	I-PROC
,	O
protein	O
trafficking	B-PROC
,	I-PROC
protein	I-PROC
modulators	O
,	O
and	O
cytoskeletal	O
proteins	O
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
genes	O
expression	B-PROC
of	O
SARS	O
coronavirus	O
by	O
synthetic	O
small	O
interfering	O
RNAs	O
.	O

The	O
downregulation	B-PROC
effect	O
was	O
in	O
correlation	O
with	O
the	O
concentrations	O
of	O
the	O
siRNA	O
duplexes	O
in	O
a	O
range	O
of	O
0	O
approximately	O
60	O
nM	O
.	O
Our	O
results	O
also	O
showed	O
that	O
many	O
inactive	O
siRNA	O
duplexes	O
may	O
be	O
brought	O
to	O
life	O
simply	O
by	O
unpairing	O
the	O
5	O
'	O
end	O
of	O
the	O
antisense	O
strands	O
.	O

The	O
important	O
role	O
of	O
the	O
about	O
38	O
-	O
residues	O
cytoplasmic	O
domain	O
in	O
the	O
assembly	O
of	O
and	O
membrane	B-PROC
fusion	I-PROC
by	O
this	O
approximately	O
1300	O
amino	O
acids	O
long	O
protein	O
is	O
discussed	O
.	O

Furthermore	O
,	O
co	O
-	O
expression	B-PROC
of	O
3a	O
,	O
membrane	O
and	O
envelope	O
proteins	O
using	O
the	O
baculovirus	O
system	O
showed	O
that	O
both	O
full	O
-	O
length	O
and	O
truncated	O
3a	O
can	O
be	O
assembled	O
into	O
virus	O
-	O
like	O
particles	O
.	O

BCoV	O
antibody	B-PROC
titre	O
in	O
50	O
%	O
of	O
all	O
cattle	O
was	O
<	O
or	O
=	O
100	O
as	O
detected	O
by	O
ELISA	O
while	O
27	O
.	O
1	O
%	O
of	O
the	O
cattle	O
had	O
high	O
titres	O
ranging	O
between	O
1	O
,	O
600	O
and	O
25	O
,	O
600	O
.	O

TITLE	O
:	O
Quantitative	O
analysis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
-	O
infected	O
cells	O
using	O
proteomic	O
approaches	O
:	O
implications	O
for	O
cellular	O
responses	O
to	O
virus	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Evaluation	O
by	O
indirect	O
immunofluorescent	O
assay	O
and	O
enzyme	O
linked	O
immunosorbent	O
assay	O
of	O
the	O
dynamic	O
changes	O
of	O
serum	O
antibody	B-PROC
responses	I-PROC
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Taken	O
together	O
,	O
this	O
study	O
provides	O
insights	O
into	O
the	O
maturation	B-PROC
process	O
of	O
the	O
SARS	O
3CL	O
(	O
pro	O
)	O
from	O
the	O
polyprotein	O
and	O
design	O
of	O
new	O
structure	O
-	O
based	O
inhibitors	O
.	O

In	O
contrast	O
,	O
only	O
1	O
of	O
278	O
healthy	O
subjects	O
enrolled	O
in	O
the	O
study	O
was	O
found	O
to	O
be	O
positive	O
for	O
the	O
IgG	O
antibody	B-PROC
.	O

Mice	O
were	O
first	O
infected	O
with	O
recombinant	O
vaccinia	O
virus	O
expressing	O
a	O
non	O
-	O
cross	B-PROC
-	I-PROC
reactive	I-PROC
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
epitope	O
,	O
designated	O
p18	O
.	O

HIV	O
-	O
specific	O
memory	B-PROC
CD8	O
+	O
T	O
cells	O
were	O
recruited	O
early	O
into	O
the	O
CNS	O
as	O
components	O
of	O
the	O
innate	B-PROC
immune	I-PROC
response	I-PROC
,	O
preceding	O
CD8	O
+	O
T	O
cells	O
specific	O
for	O
the	O
dominant	O
coronavirus	O
epitope	O
,	O
designated	O
pN	O
.	O
Although	O
pN	O
-	O
specific	O
T	O
-	O
cell	O
numbers	O
gradually	O
exceeded	O
bystander	O
p18	O
-	O
specific	O
CD8	O
+	O
T	O
-	O
cell	O
numbers	O
,	O
both	O
populations	O
peaked	O
concurrently	O
within	O
the	O
CNS	O
.	O

By	O
contrast	O
,	O
bystander	O
CD8	O
+	O
T	O
-	O
cell	O
numbers	O
declined	O
to	O
background	O
numbers	O
following	O
control	O
of	O
CNS	O
virus	B-PROC
replication	I-PROC
.	O

Whereas	O
virus	O
-	O
induced	O
MMP	O
-	O
3	O
expression	B-PROC
was	O
restricted	O
to	O
CNS	O
resident	O
astrocytes	O
,	O
MMP	O
-	O
12	O
mRNA	O
was	O
expressed	B-PROC
by	O
both	O
inflammatory	O
cells	O
and	O
CNS	O
resident	O
cells	O
.	O

During	O
inflammation	O
TIMP	O
-	O
1	O
mRNA	O
was	O
most	O
prominently	O
expressed	B-PROC
by	O
infiltrating	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
protocols	O
of	O
WHO	O
network	O
laboratories	O
facilitated	O
development	B-PROC
of	O
rapid	O
diagnosis	O
for	O
SARS	O
coronavirus	O
(	O
CoV	O
)	O
using	O
reverse	B-PROC
transcription	B-PROC
(	O
RT	O
)-	O
PCR	O
assays	O
.	O

This	O
study	O
highlights	O
the	O
high	O
throughput	O
and	O
performance	O
of	O
automatic	O
RNA	O
extraction	O
in	O
coordination	B-PROC
with	O
standardized	O
real	O
-	O
time	O
PCR	O
assays	O
suitable	O
for	O
large	O
-	O
scale	O
routine	O
diagnosis	O
in	O
case	O
of	O
future	O
SARS	O
epidemic	O
.	O

A	O
critical	O
challenge	O
to	O
scientists	O
from	O
various	O
disciplines	O
worldwide	O
is	O
to	O
study	O
the	O
specificity	O
of	O
cleavage	B-PROC
activity	O
of	O
SARS	O
-	O
related	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
use	O
the	O
knowledge	O
obtained	O
from	O
the	O
study	O
for	O
effective	O
inhibitor	O
design	O
to	O
fight	O
the	O
disease	O
.	O

Previous	O
data	O
suggested	O
that	O
CD4	O
(+)	O
T	O
cells	O
may	O
support	O
CD8	O
(+)	O
T	O
cells	O
through	O
secretion	B-PROC
of	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
).	O

Compared	O
to	O
the	O
pre	O
-	O
SARS	O
period	O
,	O
medical	O
centers	O
and	O
regional	O
hospitals	O
dropped	O
5	O
.	O
2	O
%	O
and	O
4	O
.	O
1	O
%	O
in	O
market	O
share	O
for	O
childbirth	B-PROC
services	O
during	O
the	O
peak	O
SARS	O
period	O
,	O
while	O
district	O
hospitals	O
and	O
clinics	O
increased	O
2	O
.	O
1	O
%	O
and	O
7	O
.	O
1	O
%,	O
respectively	O
.	O

The	O
three	O
major	O
themes	O
explicated	O
were	O
:	O
the	O
various	O
emotions	O
experienced	O
in	O
caring	O
for	O
SARS	O
patients	O
,	O
the	O
concept	O
of	O
uncertainty	O
and	O
revisiting	O
the	O
'	O
taken	O
for	O
granted	O
'	O
features	O
of	O
nursing	B-PROC
.	O

Childhood	O
asthma	O
was	O
observed	O
in	O
40	O
,	O
4	O
%	O
of	O
children	O
without	O
any	O
associated	O
factor	O
wether	O
at	O
birth	B-PROC
or	O
in	O
PICU	O
related	O
to	O
such	O
outcome	O
.	O

Childhood	O
asthma	O
was	O
observed	O
in	O
40	O
,	O
4	O
%	O
of	O
children	O
without	O
any	O
associated	O
factor	O
wether	O
at	O
birth	B-PROC
or	O
in	O
PICU	O
related	O
to	O
such	O
outcome	O
.	O

Using	O
peak	O
ALT	O
>	O
5XULN	O
as	O
a	O
cut	O
-	O
off	O
and	O
after	O
adjusting	O
for	O
potential	O
confounding	O
factors	O
,	O
the	O
odds	O
ratio	O
of	O
peak	O
ALT	O
>	O
5X	O
ULN	O
for	O
oxygen	O
desaturation	O
was	O
3	O
.	O
24	O
(	O
95	O
%	O
CI	O
1	O
.	O
23	O
-	O
8	O
.	O
59	O
,	O
P	O
=	O
0	O
.	O
018	O
),	O
ICU	O
care	O
was	O
3	O
.	O
70	O
(	O
95	O
%	O
CI	O
1	O
.	O
38	O
-	O
9	O
.	O
89	O
,	O
P	O
=	O
0	O
.	O
009	O
),	O
mechanical	O
ventilation	O
was	O
6	O
.	O
64	O
(	O
95	O
%	O
CI	O
2	O
.	O
22	O
-	O
19	O
.	O
81	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
death	B-PROC
was	O
7	O
.	O
34	O
(	O
95	O
%	O
CI	O
2	O
.	O
28	O
-	O
24	O
.	O
89	O
,	O
P	O
=	O
0	O
.	O
001	O
).	O

The	O
antigenicity	O
and	O
immunoreactivity	B-PROC
of	O
all	O
the	O
peptides	O
were	O
tested	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

It	O
is	O
interesting	O
to	O
find	O
that	O
P8	O
and	O
P9	O
peptides	O
inhibited	O
syncytia	O
formation	B-PROC
,	O
suggesting	O
that	O
the	O
P8	O
and	O
P9	O
spanning	O
regions	O
may	O
provide	O
a	O
good	O
target	O
for	O
anti	O
-	O
SARS	O
-	O
CoV	O
drug	O
design	O
.	O

While	O
the	O
efficacy	O
of	O
different	O
treatments	O
could	O
not	O
be	O
evaluated	O
from	O
this	O
retrospective	O
study	O
,	O
a	O
higher	O
value	O
of	O
C	O
-	O
reactive	O
protein	O
was	O
associated	O
with	O
the	O
development	B-PROC
of	O
respiratory	O
failure	O
and	O
subsequent	O
intubation	O
.	O

Of	O
6	O
/	O
27	O
children	O
with	O
cryptogenic	O
WS	O
,	O
1	O
had	O
idiopathic	O
WS	O
,	O
3	O
had	O
normal	O
psychomotor	B-PROC
development	B-PROC
and	O
2	O
had	O
psychomotor	O
retardation	O
,	O
without	O
epileptic	O
fits	O
and	O
still	O
receiving	O
AED	O
.	O

Synthetic	O
ACTH	O
can	O
have	O
many	O
side	O
effects	O
,	O
even	O
death	B-PROC
.	O

During	O
the	O
course	O
of	O
illness	O
,	O
he	O
developed	O
clinical	O
features	O
compatible	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
that	O
may	O
have	O
complicated	O
the	O
recovery	O
of	O
his	O
underlying	O
hypersensitivity	B-PROC
reaction	I-PROC
,	O
which	O
was	O
subsequently	O
controlled	O
with	O
intravenous	O
immune	O
globulin	O
and	O
corticosteroids	O
.	O

They	O
were	O
assessment	O
of	O
risk	O
,	O
formulation	O
of	O
operational	O
guidelines	O
,	O
implementation	O
of	O
infection	O
control	O
measures	O
,	O
education	O
and	O
training	O
of	O
staff	O
,	O
conducting	B-PROC
audits	O
and	O
carrying	O
out	O
environmental	O
improvement	O
work	O
.	O

Hereditary	O
hemochromatosis	O
is	O
now	O
a	O
complex	O
entity	O
with	O
various	O
clinicopathological	O
forms	O
based	O
on	O
mutations	O
in	O
the	O
HFE	O
gene	O
and	O
other	O
iron	O
-	O
homeostatic	B-PROC
genes	O
such	O
as	O
transferrin	O
receptor	O
2	O
and	O
ferroportin	O
1	O
.	O

RESULTS	O
:	O
Positive	O
viral	O
staining	O
was	O
only	O
found	O
in	O
the	O
lung	O
tissue	O
taken	O
from	O
the	O
patients	O
who	O
died	B-PROC
in	O
the	O
early	O
stage	O
of	O
the	O
disease	O
,	O
usually	O
less	O
than	O
10	O
days	O
after	O
symptom	O
onset	O
.	O

Because	O
of	O
coagulation	B-PROC
failure	O
commencement	O
of	O
artificial	O
liver	O
support	O
with	O
the	O
MARS	O
-	O
system	O
(	O
molecule	O
adsorbent	O
recirculating	O
system	O
).	O

In	O
the	O
sequel	O
development	B-PROC
of	O
abscessing	O
pneumonia	O
on	O
the	O
right	O
side	O
with	O
a	O
pleural	O
empyema	O
.	O

ABSTRACT	O
:	O
The	O
expression	B-PROC
of	O
the	O
genomic	O
information	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
)	O
involves	O
synthesis	B-PROC
of	O
a	O
nested	O
set	O
of	O
subgenomic	O
RNAs	O
(	O
sgRNAs	O
)	O
by	O
discontinuous	O
transcription	B-PROC
.	O

Moreover	O
,	O
one	O
rare	O
species	O
of	O
sgRNA	O
has	O
the	O
junction	O
sequence	O
AAA	O
,	O
indicating	O
that	O
its	O
transcription	B-PROC
could	O
result	O
from	O
a	O
noncanonical	O
transcription	B-PROC
signal	O
.	O

49	O
.	O
6	O
%	O
had	O
fever	B-PROC
and	O
non	O
specific	O
symptoms	O
.	O

ABSTRACT	O
:	O
During	O
the	O
spring	O
and	O
summer	O
of	O
2003	O
,	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
mobilized	O
the	O
resources	O
of	O
the	O
entire	O
agency	O
in	O
a	O
concerted	O
effort	B-PROC
to	O
meet	O
the	O
challenges	O
posed	O
by	O
the	O
outbreak	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
).	O

In	O
addition	O
,	O
a	O
phylogenetic	O
tree	O
based	O
on	O
these	O
ORF7	O
DNA	O
sequences	O
was	O
generated	O
,	O
and	O
the	O
tree	O
topology	O
suggests	O
that	O
possible	O
recombination	B-PROC
events	O
happened	O
in	O
the	O
evolutionary	O
history	O
of	O
TGEV	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
main	O
protease	O
represents	O
an	O
attractive	O
target	O
for	O
the	O
development	B-PROC
of	O
novel	O
anti	O
-	O
SARS	O
agents	O
.	O

TITLE	O
:	O
Differential	O
maturation	B-PROC
and	O
subcellular	O
localization	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
surface	O
proteins	O
S	O
,	O
M	O
and	O
E	O
.	O
ABSTRACT	O
:	O
Post	B-PROC
-	I-PROC
translational	B-PROC
modifications	I-PROC
and	O
correct	O
subcellular	O
localization	B-PROC
of	O
viral	O
structural	O
proteins	O
are	O
prerequisites	O
for	O
assembly	O
and	O
budding	B-PROC
of	O
enveloped	O
viruses	O
.	O

The	O
N	O
-	O
glycosylation	B-PROC
profile	O
and	O
the	O
absence	O
of	O
O	O
-	O
glycosylation	B-PROC
on	O
M	O
protein	O
relate	O
SARS	O
-	O
CoV	O
to	O
the	O
previously	O
described	O
group	O
1	O
and	O
3	O
coronaviruses	O
.	O

Pulse	B-PROC
-	O
chase	O
labelling	O
and	O
confocal	O
microscopy	O
in	O
the	O
presence	O
of	O
protein	B-PROC
translation	B-PROC
inhibitor	O
cycloheximide	O
revealed	O
that	O
the	O
E	O
protein	O
has	O
a	O
short	O
half	O
-	O
life	O
of	O
30	O
min	O
.	O

For	O
this	O
approach	O
,	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
(	O
N	O
)	O
or	O
envelope	O
spike	O
protein	O
(	O
S	O
)	O
genes	O
were	O
cloned	O
between	O
the	O
RV	O
glycoprotein	O
G	O
and	O
polymerase	B-PROC
L	I-PROC
genes	O
.	O

A	O
single	O
inoculation	O
with	O
the	O
RV	O
-	O
based	O
vaccine	O
expressing	O
SARS	O
-	O
CoV	O
S	O
protein	O
induced	O
a	O
strong	O
SARS	O
-	O
CoV	O
-	O
neutralizing	O
antibody	B-PROC
response	I-PROC
.	O

The	O
primary	O
determinant	O
of	O
the	O
pantropism	O
is	O
the	O
enhanced	O
proteolytic	B-PROC
cleavability	O
of	O
the	O
fusion	O
(	O
F	O
)	O
protein	O
of	O
F1	O
-	O
R	O
,	O
which	O
allows	O
the	O
virus	O
to	O
undergo	O
multiple	O
rounds	O
of	O
replication	O
in	O
many	O
different	O
organs	O
,	O
whereas	O
wild	O
-	O
type	O
virus	O
can	O
only	O
undergo	O
multiple	O
rounds	O
of	O
replication	O
in	O
the	O
lungs	O
.	O

The	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
(	O
N	O
),	O
three	O
N	O
fragments	O
(	O
N1	O
,	O
N2	O
,	O
and	O
N3	O
)	O
and	O
the	O
intraviral	O
domain	O
of	O
the	O
membrane	O
protein	O
(	O
M2	O
)	O
were	O
cloned	O
and	O
expressed	B-PROC
in	O
Escherichia	O
coli	O
as	O
histidine	O
-	O
tagged	O
proteins	O
.	O

The	O
results	O
show	O
that	O
this	O
inactivated	O
vaccine	O
can	O
induce	O
effective	O
concomitant	O
humoral	O
and	O
mucosal	B-PROC
immunity	I-PROC
against	O
SARS	O
-	O
CoV	O
infection	O
,	O
is	O
safe	O
in	O
monkeys	O
,	O
and	O
the	O
vaccine	O
maybe	O
a	O
good	O
candidate	O
for	O
clinical	O
trials	O
.	O

Inhibition	B-PROC
of	O
the	O
infectivity	O
of	O
SARS	O
-	O
CoV	O
by	O
MBL	O
in	O
fetal	O
rhesus	O
kidney	O
cells	O
(	O
FRhK	O
-	O
4	O
)	O
was	O
also	O
observed	O
.	O

Negative	O
cases	O
would	O
be	O
analyzed	O
with	O
primers	O
yielding	O
a	O
383	O
-	O
bp	O
product	O
(	O
to	O
exdude	O
detrimental	O
effect	O
of	O
the	O
storage	B-PROC
conditions	O
)	O
followed	O
by	O
nucleotide	O
sequencing	O
of	O
the	O
positive	O
cases	O
.	O

Although	O
stability	O
and	O
delivery	O
problems	O
must	O
be	O
overcome	O
,	O
a	O
hammerhead	O
ribozyme	O
targeted	B-PROC
to	O
the	O
IBV	O
nucleocapsid	O
mRNA	O
most	O
likely	O
has	O
antiviral	O
activity	O
and	O
may	O
be	O
an	O
effective	O
therapeutic	O
/	O
prophylactic	O
reagent	O
in	O
the	O
future	O
.	O

TITLE	O
:	O
Study	O
on	O
the	O
resistance	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
.	O

APHS	O
did	O
not	O
affect	O
the	O
replication	O
of	O
feline	O
immunodeficiency	O
virus	O
,	O
HIV	O
-	O
2	O
and	O
a	O
HIV	O
-	O
1	O
strain	O
resistant	O
to	O
non	B-PROC
-	I-PROC
nucleoside	I-PROC
reverse	I-PROC
transcriptase	I-PROC
inhibitors	I-PROC
(	O
NNRTI	O
).	O

These	O
results	O
suggest	O
that	O
the	O
N	O
protein	B-PROC
oligomerization	I-PROC
involves	O
the	O
C	O
-	O
terminal	O
residues	O
285	O
-	O
422	O
,	O
and	O
this	O
region	O
is	O
a	O
good	O
target	O
for	O
mutagenic	O
studies	O
to	O
disrupt	O
N	O
protein	O
self	O
-	O
association	O
and	O
virion	B-PROC
assembly	I-PROC
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
novel	O
infectious	O
disease	O
which	O
is	O
characterized	O
by	O
an	O
overaggressive	O
immune	B-PROC
response	I-PROC
.	O

Chemokines	O
are	O
important	O
inflammatory	O
mediators	O
and	O
regulate	O
disease	O
due	O
to	O
viral	B-PROC
infection	I-PROC
.	O

To	O
determine	O
whether	O
RANTES	O
play	O
an	O
role	O
in	O
the	O
process	O
of	O
SARS	O
,	O
THP	O
-	O
1	O
cells	O
were	O
incubated	O
with	O
heat	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
and	O
ELISA	O
was	O
used	O
to	O
test	O
RANTES	O
levels	O
in	O
the	O
supernatants	O
;	O
Then	O
the	O
effect	O
of	O
dexamethasone	O
on	O
the	O
induced	O
secretion	B-PROC
was	O
evaluated	O
.	O

ABSTRACT	O
:	O
In	O
this	O
report	O
,	O
the	O
antiviral	O
activity	O
of	O
80R	O
immunoglobulin	B-PROC
G1	O
(	O
IgG1	O
),	O
a	O
human	O
monoclonal	O
antibody	B-PROC
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
that	O
acts	O
as	O
a	O
viral	O
entry	O
inhibitor	O
in	O
vitro	O
,	O
was	O
investigated	O
in	O
vivo	O
in	O
a	O
mouse	O
model	O
.	O

IBV	O
3a	O
protein	O
is	O
expressed	B-PROC
in	O
infected	O
cells	O
but	O
is	O
not	O
detected	O
in	O
virions	O
.	O

Our	O
results	O
suggest	O
that	O
IBV	O
3a	O
is	O
partially	O
targeted	B-PROC
to	O
a	O
novel	O
domain	O
of	O
the	O
smooth	O
ER	O
.	O

Much	O
more	O
perturbation	O
of	O
cellular	O
gene	B-PROC
transcription	I-PROC
was	O
observed	O
after	O
infection	O
by	O
SARS	O
-	O
CoV	O
than	O
after	O
infection	O
by	O
HCoV	O
-	O
229E	O
.	O

The	O
lack	O
of	O
antiviral	O
cytokine	O
response	O
against	O
a	O
background	O
of	O
intense	O
chemokine	O
up	B-PROC
-	I-PROC
regulation	B-PROC
could	O
represent	O
a	O
mechanism	O
of	O
immune	B-PROC
evasion	I-PROC
by	O
SARS	O
-	O
CoV	O
.	O

The	O
assessment	O
included	O
lung	B-PROC
volumes	I-PROC
(	O
TLC	O
,	O
VC	O
,	O
RV	O
,	O
FRC	B-PROC
),	O
spirometry	O
(	O
FVC	B-PROC
,	O
FEV1	O
),	O
carbon	O
monoxide	O
transfer	O
factor	O
(	O
TLCO	O
adjusted	O
for	O
haemoglobin	O
),	O
inspiratory	B-PROC
and	O
expiratory	B-PROC
respiratory	O
muscle	B-PROC
strength	I-PROC
(	O
Pimax	O
and	O
Pemax	O
),	O
6	O
minute	O
walk	O
distance	O
(	O
6MWD	O
),	O
chest	O
radiographs	O
,	O
and	O
HRQoL	O
by	O
SF	O
-	O
36	O
questionnaire	O
.	O

At	O
6	O
months	O
33	O
subjects	O
(	O
30	O
%)	O
had	O
abnormal	O
chest	O
radiographs	O
;	O
four	O
(	O
3	O
.	O
6	O
%),	O
eight	O
(	O
7	O
.	O
4	O
%),	O
and	O
17	O
(	O
15	O
.	O
5	O
%)	O
patients	O
had	O
FVC	B-PROC
,	O
TLC	O
,	O
and	O
TLCO	O
below	O
80	O
%	O
of	O
predicted	O
values	O
;	O
and	O
15	O
(	O
13	O
.	O
9	O
%)	O
and	O
24	O
(	O
22	O
.	O
2	O
%)	O
had	O
Pimax	O
and	O
Pemax	O
values	O
below	O
80	O
cm	O
H2O	O
,	O
respectively	O
.	O

The	O
functional	O
disability	O
appears	O
out	O
of	O
proportion	O
to	O
the	O
degree	O
of	O
lung	B-PROC
function	I-PROC
impairment	O
and	O
may	O
be	O
related	O
to	O
additional	O
factors	O
such	O
as	O
muscle	O
deconditioning	O
and	O
steroid	O
myopathy	O
.	O

RESULTS	O
:	O
An	O
increase	O
of	O
each	O
10	O
microg	O
/	O
m3	O
over	O
a	O
5	O
-	O
day	O
moving	B-PROC
average	O
of	O
PM10	O
,	O
SO2	O
and	O
NO2	O
corresponded	O
to	O
1	O
.	O
06	O
(	O
1	O
.	O
00	O
-	O
1	O
.	O
12	O
),	O
0	O
.	O
74	O
(	O
0	O
.	O
48	O
-	O
1	O
.	O
13	O
)	O
and	O
1	O
.	O
22	O
(	O
1	O
.	O
01	O
-	O
1	O
.	O
48	O
)	O
relative	O
risks	O
(	O
RRs	O
)	O
of	O
daily	O
SARS	O
mortality	O
,	O
respectively	O
.	O

Under	O
higher	O
relative	O
humidity	O
,	O
the	O
exhaled	B-PROC
liquid	O
droplets	O
evaporate	O
slowly	O
.	O

We	O
have	O
developed	O
a	O
multitarget	O
real	O
-	O
time	O
Taqman	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
for	O
the	O
quantitative	O
detection	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
sequences	O
of	O
the	O
Taqman	O
probes	O
with	O
a	O
minor	O
groove	O
binder	O
and	O
the	O
corresponding	O
primers	O
were	O
based	O
on	O
the	O
sequences	O
of	O
the	O
N	O
gene	O
,	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
3	O
,	O
and	O
ORF	O
8	O
.	O

In	O
addition	O
,	O
general	O
activation	O
of	O
endothelial	O
cells	O
,	O
represented	O
by	O
major	B-PROC
histocompatibility	I-PROC
complex	B-PROC
II	I-PROC
upregulation	B-PROC
,	O
was	O
observed	O
in	O
all	O
cases	O
.	O

In	O
this	O
sense	B-PROC
,	O
then	O
,	O
we	O
suggest	O
that	O
immunosenescence	O
is	O
contagious	O
.	O

Antibodies	O
recognizing	O
domain	O
III	O
could	O
significantly	O
inhibit	O
the	O
enzymatic	B-PROC
activity	I-PROC
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

In	O
vitro	O
and	O
in	O
vivo	O
frameshifting	O
assays	O
showed	O
that	O
the	O
SARS	O
-	O
CoV	O
frameshift	O
signal	O
is	O
functionally	O
similar	O
to	O
other	O
viral	O
frameshift	O
signals	O
:	O
it	O
promotes	O
efficient	O
frameshifting	O
in	O
all	O
of	O
the	O
standard	O
assay	O
systems	O
,	O
and	O
it	O
is	O
sensitive	O
to	O
a	O
drug	O
and	O
a	O
genetic	B-PROC
mutation	I-PROC
that	O
are	O
known	O
to	O
affect	O
frameshifting	O
efficiency	O
of	O
a	O
yeast	O
virus	O
.	O

There	O
is	O
increasing	O
laboratory	O
evidence	O
that	O
ventilating	O
ARDS	O
models	O
with	O
relatively	O
low	O
tidal	O
volumes	O
and	O
high	O
levels	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
is	O
clinically	O
beneficial	O
.	O

In	O
addition	O
to	O
its	O
structural	O
role	O
,	O
it	O
has	O
been	O
described	O
as	O
an	O
RNA	O
-	O
binding	O
protein	O
that	O
might	O
be	O
involved	O
in	O
coronavirus	O
RNA	B-PROC
synthesis	I-PROC
.	O

Here	O
,	O
we	O
report	O
a	O
reverse	O
genetic	O
approach	O
to	O
elucidate	O
the	O
role	O
of	O
N	O
in	O
coronavirus	O
replication	O
and	O
transcription	B-PROC
.	O

In	O
contrast	O
,	O
vector	O
RNAs	O
encoding	O
a	O
functional	O
N	O
protein	O
were	O
able	O
to	O
carry	O
out	O
both	O
replication	O
and	O
transcription	B-PROC
.	O

Demyelination	O
does	O
not	O
develop	O
in	O
infected	O
RAG1	O
-/-	O
(	O
recombination	B-PROC
activation	O
gene	O
-	O
deficient	O
)	O
mice	O
but	O
can	O
be	O
induced	O
by	O
several	O
experimental	O
interventions	O
,	O
including	O
adoptive	O
transfer	O
of	O
virus	O
-	O
specific	O
T	O
cells	O
or	O
antibodies	O
.	O

All	O
eight	O
animals	O
showed	O
a	O
transient	O
fever	B-PROC
2	O
-	O
3	O
days	O
after	O
inoculation	O
.	O

Finally	O
,	O
histopathological	O
changes	O
of	O
interstitial	O
pneumonia	O
were	O
found	O
in	O
the	O
lungs	O
during	O
the	O
60	O
days	O
after	O
viral	O
inoculation	O
:	O
these	O
changes	O
were	O
less	O
marked	O
at	O
later	O
time	O
points	O
,	O
indicating	O
that	O
an	O
active	O
healing	B-PROC
process	I-PROC
together	O
with	O
resolution	O
of	O
an	O
acute	B-PROC
inflammatory	I-PROC
response	I-PROC
was	O
taking	O
place	O
in	O
these	O
animals	O
.	O

TITLE	O
:	O
Characterization	O
of	O
monoclonal	O
antibody	B-PROC
against	O
SARS	O
coronavirus	O
nucleocapsid	O
antigen	O
and	O
development	B-PROC
of	O
an	O
antigen	O
capture	O
ELISA	O
.	O

Development	B-PROC
of	O
a	O
Western	O
blot	O
assay	O
for	O
detection	O
of	O
antibodies	O
against	O
coronavirus	O
causing	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

We	O
established	O
one	O
hybridoma	O
cell	O
line	O
secreting	B-PROC
specific	O
mAb	O
and	O
evaluated	O
this	O
mAb	O
with	O
murine	O
leukemia	O
virus	O
pseudotyped	O
with	O
SARS	O
-	O
CoV	O
spike	O
protein	O
(	O
MLV	O
/	O
SARS	O
-	O
CoV	O
).	O

Bioactivity	O
assay	O
results	O
(	O
in	O
vitro	O
tests	O
)	O
demonstrated	O
that	O
some	O
of	O
these	O
compounds	O
are	O
potent	O
and	O
selective	O
inhibitors	O
against	O
SARS	O
coronavirus	O
3CL	O
protease	O
with	O
IC50	O
values	O
ranging	O
from	O
0	O
.	O
95	O
to	O
17	O
.	O
50	O
microM	O
.	O
Additionally	O
,	O
isatin	O
4o	O
exhibited	O
more	O
potent	O
inhibition	B-PROC
for	O
SARS	B-PROC
coronavirus	I-PROC
protease	I-PROC
than	O
for	O
other	O
proteases	O
including	O
papain	O
,	O
chymotrypsin	O
,	O
and	O
trypsin	O
.	O

RESULTS	O
:	O
All	O
agreed	O
SARS	O
had	O
changed	O
their	O
clinical	O
behaviour	B-PROC
.	O

Antigens	O
of	O
SARS	O
-	O
CoV	O
and	O
HCoV	O
-	O
OC43	O
were	O
more	O
cross	B-PROC
-	I-PROC
reactive	I-PROC
than	O
were	O
those	O
of	O
SARS	O
-	O
CoV	O
and	O
HCoV	O
-	O
229E	O
.	O

Then	O
the	O
recombinant	O
eukaryotic	O
expression	B-PROC
vector	O
pCI	O
-	O
neo	O
/	O
nsp2	O
was	O
transfected	O
into	O
COS	O
-	O
7	O
cells	O
using	O
lipofectin	O
reagent	O
to	O
express	O
the	O
nsp2	O
protein	O
.	O

TITLE	O
:	O
Potent	O
and	O
specific	O
inhibition	B-PROC
of	O
SARS	O
-	O
CoV	O
antigen	O
expression	B-PROC
by	O
RNA	B-PROC
interference	I-PROC
.	O

At	O
24	O
,	O
48	O
and	O
72	O
hours	O
post	O
transfection	B-PROC
,	O
the	O
green	O
fluorescence	O
was	O
observed	O
through	O
a	O
fluorescence	O
microscope	O
.	O

The	O
RNA	O
levels	O
of	O
SARS	O
-	O
CoV	O
N	O
were	O
determined	O
by	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Our	O
results	O
demonstrate	O
that	O
RNAi	B-PROC
mediated	O
silencing	O
of	O
SARS	O
-	O
CoV	O
gene	O
could	O
effectively	O
inhibit	O
expression	B-PROC
of	O
SARS	O
-	O
CoV	O
antigen	O
,	O
hence	O
RNAi	B-PROC
based	O
strategy	O
should	O
be	O
further	O
explored	O
as	O
a	O
more	O
efficacious	O
antiviral	O
therapy	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

We	O
retrospectively	O
analyzed	O
data	O
from	O
n	O
=	O
25	O
ARDS	O
patients	O
who	O
received	O
iNO	O
,	O
and	O
underwent	O
chest	O
CT	O
within	O
72	O
h	O
prior	O
to	O
inhaled	B-PROC
treatment	O
.	O

From	O
4	O
-	O
7	O
d	O
,	O
the	O
unspecific	O
symptoms	O
became	O
weak	O
;	O
however	O
,	O
the	O
rates	O
of	O
low	O
respiratory	O
tract	O
symptoms	O
,	O
such	O
as	O
cough	O
(	O
24	O
.	O
18	O
%),	O
sputum	B-PROC
production	I-PROC
(	O
14	O
.	O
26	O
%),	O
chest	O
distress	O
(	O
21	O
.	O
04	O
%)	O
and	O
shortness	O
of	O
breath	O
(	O
9	O
.	O
23	O
%)	O
increased	O
,	O
so	O
did	O
the	O
abnormal	O
rates	O
on	O
chest	O
radiograph	O
or	O
CT	O
.	O

On	O
the	O
34th	O
day	O
after	O
birth	B-PROC
,	O
urine	O
volume	O
suddenly	O
decreased	O
and	O
hypotension	O
,	O
oliguria	O
,	O
and	O
generalized	O
edema	O
developed	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
also	O
known	O
as	O
noncardiogenic	O
pulmonary	O
edema	O
,	O
is	O
a	O
severe	O
complication	O
in	O
cirrhotic	O
patients	O
undergoing	O
microwave	O
coagulation	B-PROC
therapy	O
(	O
MCT	O
)	O
for	O
liver	O
tumor	O
.	O

The	O
water	B-PROC
balance	I-PROC
and	O
sodium	O
administration	O
have	O
to	O
be	O
closely	O
monitored	O
to	O
prevent	O
cirrhotic	O
patients	O
undergoing	O
MCT	O
from	O
developing	O
ARDS	O
.	O

The	O
inhibitory	O
activity	O
of	O
the	O
extract	O
was	O
also	O
not	O
reduced	O
after	O
pronase	O
digestion	B-PROC
.	O

Furosemide	O
has	O
been	O
shown	O
to	O
improve	O
pulmonary	B-PROC
gas	I-PROC
exchange	I-PROC
and	O
intrapulmonary	O
shunt	O
by	O
a	O
nondiuretic	O
mechanism	O
in	O
animal	O
models	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
ratio	O
of	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
(	O
PaO2	O
)	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
FIO2	O
)	O
improved	O
in	O
the	O
furosemide	O
-	O
treated	O
group	O
within	O
24	O
hours	O
(	O
from	O
180	O
to	O
264	O
;	O
P	O
=	O
.	O
01	O
).	O

TITLE	O
:	O
The	O
pathogenesis	B-PROC
of	O
ventilator	O
-	O
associated	O
pneumonia	O
:	O
its	O
relevance	O
to	O
developing	O
effective	O
strategies	O
for	O
prevention	O
.	O

These	O
results	O
indicated	O
that	O
two	O
signaling	B-PROC
pathways	B-PROC
of	O
JNK	O
and	O
PI3K	O
/	O
Akt	O
were	O
important	O
for	O
the	O
establishment	O
of	O
persistence	O
in	O
Vero	O
E6	O
cells	O
.	O

Serum	O
levels	O
of	O
Hsp60	O
detected	O
within	O
30	O
min	O
after	O
trauma	O
correlate	O
with	O
the	O
development	B-PROC
of	O
ALI	O
.	O

CONCLUSIONS	O
:	O
Serum	O
levels	O
of	O
Hsp60	O
detected	O
within	O
30	O
min	O
after	O
trauma	O
correlate	O
with	O
the	O
development	B-PROC
of	O
ALI	O
.	O

Those	O
who	O
worried	O
about	O
contracting	O
SARS	O
were	O
more	O
likely	O
to	O
have	O
improved	O
health	O
-	O
seeking	O
behaviors	B-PROC
.	O

HCoV	O
-	O
229E	O
infection	O
was	O
facilitated	O
by	O
crossing	O
APN	O
transgenic	O
mice	O
into	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	B-PROC
(	O
Stat	O
)	O
1	O
null	O
mice	O
and	O
by	O
adaptation	B-PROC
of	O
HCoV	O
-	O
229E	O
to	O
grow	O
in	O
primary	O
APN	O
transgenic	O
,	O
Stat1	O
null	O
fibroblasts	O
.	O

The	O
poor	O
induction	O
of	O
IFN	O
-	O
beta	O
,	O
a	O
key	O
component	O
of	O
innate	B-PROC
immunity	B-PROC
,	O
and	O
the	O
ability	O
of	O
the	O
virus	O
to	O
induce	O
chemokines	O
could	O
explain	O
aspects	O
of	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
.	O

Withdrawal	O
of	O
FP	O
in	O
COPD	O
patients	O
using	O
SFC	O
resulted	O
in	O
acute	O
and	O
persistent	O
deterioration	O
in	O
lung	B-PROC
function	I-PROC
and	O
dyspnoea	O
and	O
in	O
an	O
increase	O
in	O
mild	O
exacerbations	O
and	O
percentage	O
of	O
disturbed	O
nights	O
.	O

A	O
total	O
of	O
1	O
,	O
755	O
SARS	O
cases	O
with	O
298	O
deaths	B-PROC
were	O
reported	O
.	O

The	O
epidemic	O
,	O
however	O
,	O
created	O
a	O
strong	O
sense	B-PROC
of	O
unity	O
among	O
all	O
sectors	O
of	O
the	O
population	O
in	O
the	O
fight	O
against	O
the	O
disease	O
.	O

The	O
aim	O
of	O
this	O
research	O
is	O
to	O
determine	O
the	O
levels	O
of	O
anxiety	O
,	O
depression	O
,	O
and	O
sleep	B-PROC
quality	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
nursing	B-PROC
staff	O
experienced	O
before	O
and	O
after	O
a	O
SARS	O
prevention	O
program	O
.	O

TITLE	O
:	O
Monitoring	O
of	O
right	O
-	O
sided	O
heart	B-PROC
function	I-PROC
.	O

TITLE	O
:	O
The	O
interaction	O
between	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-PROC
and	O
a	O
dimeric	O
inhibitor	O
by	O
capillary	O
electrophoresis	O
.	O

ABSTRACT	O
:	O
3C	O
-	O
like	O
proteinase	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
has	O
been	O
demonstrated	O
to	O
be	O
a	O
key	O
target	O
for	O
drug	O
design	O
against	O
SARS	O
.	O

The	O
interaction	O
between	O
SARS	O
coronavirus	O
3C	O
-	O
like	O
(	O
3CL	O
)	O
proteinase	B-PROC
and	O
an	O
octapeptide	O
interface	O
inhibitor	O
was	O
studied	O
by	O
affinity	O
capillary	O
electrophoresis	O
(	O
ACE	O
).	O

Although	O
coagulation	B-PROC
abnormalities	O
are	O
common	O
in	O
these	O
patients	O
,	O
clinically	O
overt	O
thromboembolic	O
events	O
are	O
rarely	O
reported	O
.	O

The	O
virally	O
encoded	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
Pro	O
))	O
has	O
been	O
presumed	O
critical	O
for	O
the	O
viral	B-PROC
replication	I-PROC
of	O
SARS	O
-	O
CoV	O
in	O
infected	O
host	O
cells	O
.	O

Patients	O
who	O
underwent	O
urgent	O
surgical	O
treatment	O
and	O
/	O
or	O
died	B-PROC
in	O
the	O
hospital	O
had	O
higher	O
peak	O
CRP	O
levels	O
(	O
25	O
.	O
1	O
+/-	O
12	O
.	O
3	O
vs	O
.	O
16	O
.	O
1	O
+/-	O
7	O
.	O
4	O
mg	O
/	O
dl	O
,	O
P	O
=	O
0	O
.	O
010	O
)	O
than	O
those	O
who	O
did	O
not	O
.	O

In	O
this	O
study	O
we	O
evaluated	O
the	O
manufacturing	O
process	O
of	O
an	O
immunoglobulin	B-PROC
preparation	O
(	O
OCTAGAM	O
,	O
manufactured	O
by	O
Octapharma	O
Pharmazeutika	O
Produktionsges	O
.	O
m	O
.	O
b	O
.	O

Some	O
human	O
and	O
physical	O
environment	O
factors	O
played	O
statistical	O
significant	O
roles	O
in	O
different	O
periods	B-PROC
during	O
SARS	O
epidemics	O
.	O

IgG	O
antibody	B-PROC
level	O
showed	O
a	O
35	O
.	O
8	O
%	O
decrease	O
within	O
one	O
year	O
.	O

RESULTS	O
:	O
IgG	O
antibody	B-PROC
was	O
detected	O
positive	O
on	O
each	O
testing	O
of	O
all	O
the	O
convalescent	O
patients	O
and	O
its	O
peak	O
appeared	O
35	O
days	O
after	O
recovery	O
.	O

IgG	O
antibody	B-PROC
level	O
showed	O
a	O
35	O
.	O
8	O
%	O
decrease	O
within	O
one	O
year	O
.	O

TITLE	O
:	O
[	O
Study	O
on	O
the	O
RNA	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
associated	O
coronavirus	O
in	O
the	O
blood	O
and	O
excretion	B-PROC
of	O
convalescent	O
patients	O
with	O
SARS	O
].	O

To	O
address	O
the	O
significance	O
of	O
the	O
immunosuppression	B-PROC
associated	O
with	O
lung	O
contusion	O
,	O
we	O
investigated	O
how	O
the	O
consecutive	O
addition	O
of	O
moderate	O
or	O
severe	O
sepsis	O
affected	O
survival	O
after	O
blunt	O
chest	O
trauma	O
.	O

TITLE	O
:	O
Antibody	B-PROC
avidity	O
maturation	B-PROC
during	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
infection	O
.	O

11	O
.	O
6	O
%)	O
among	O
serum	O
samples	O
collected	O
<	O
or	O
=	O
50	O
days	O
after	O
fever	B-PROC
onset	O
,	O
intermediate	O
(	O
mean	O
+/-	O

Concern	O
for	O
the	O
transfer	O
of	O
donor	O
antileukocyte	O
antibodies	O
has	O
prompted	O
major	O
changes	O
in	O
the	O
management	O
of	O
the	O
blood	B-PROC
supply	I-PROC
in	O
some	O
countries	O
;	O
however	O
,	O
recent	O
studies	O
have	O
suggested	O
alternative	O
pathophyslological	O
mechanisms	O
for	O
TRALI	O
related	O
to	O
the	O
shelf	O
life	O
of	O
cellular	O
blood	O
products	O
.	O

Surviving	O
SARS	O
patients	O
were	O
seen	O
at	O
least	O
twice	O
within	O
3	O
months	O
after	O
discharge	O
and	O
underwent	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
IgG	O
antibody	B-PROC
testing	O
,	O
pulmonary	B-PROC
function	I-PROC
testing	O
,	O
and	O
chest	O
radiography	O
and	O
/	O
or	O
high	O
-	O
resolution	O
CT	O
(	O
HRCT	O
)	O
examinations	O
at	O
Chinese	O
PLA	O
General	O
Hospital	O
.	O

For	O
these	O
patients	O
,	O
51	O
of	O
53	O
patients	O
with	O
positive	O
SARS	O
-	O
CoV	O
IgG	O
results	O
and	O
a	O
lung	O
diffusion	O
abnormality	O
underwent	O
pulmonary	B-PROC
function	I-PROC
testing	O
after	O
approximately	O
1	O
month	O
.	O

ABSTRACT	O
:	O
To	O
establish	O
a	O
new	O
technique	O
for	O
SARS	O
-	O
CoV	O
antibody	B-PROC
test	O
to	O
detect	O
infection	O
of	O
severer	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

SARS	O
antibody	B-PROC
could	O
be	O
detected	O
since	O
the	O
sixth	O
day	O
after	O
onset	O
,	O
and	O
the	O
titer	O
increased	O
from	O
1	O
:	O
40	O
to	O
1	O
:	O
600	O
on	O
the	O
ninth	O
day	O
.	O

The	O
tissue	B-PROC
tropism	B-PROC
of	O
SARS	O
-	O
CoV	O
includes	O
not	O
only	O
the	O
lung	O
,	O
but	O
also	O
the	O
gastrointestinal	O
tract	O
,	O
kidney	O
and	O
liver	O
.	O

Here	O
we	O
demonstrate	O
the	O
synthesis	B-PROC
of	O
dendrimer	O
-	O
like	O
DNA	O
-	O
based	O
,	O
fluorescence	O
-	O
intensity	O
-	O
coded	O
nanobarcodes	O
,	O
which	O
contain	O
a	O
built	O
-	O
in	O
code	O
and	O
a	O
probe	O
for	O
molecular	B-PROC
recognition	I-PROC
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	O
3	O
binding	O
to	O
macrophages	O
correlates	O
with	O
resistance	B-PROC
to	O
experimental	O
infection	O
.	O

Incorporation	O
of	O
the	O
S1	O
fragment	O
into	O
plant	O
genomes	O
as	O
well	O
as	O
its	O
transcription	B-PROC
was	O
confirmed	O
by	O
PCR	O
and	O
RT	O
-	O
PCR	O
analyses	O
.	O

The	O
detailed	O
pathology	O
of	O
SARS	O
-	O
CoV	O
infection	O
and	O
the	O
host	B-PROC
response	I-PROC
to	O
the	O
viral	B-PROC
infection	I-PROC
are	O
still	O
not	O
known	O
.	O

In	O
vitro	O
experiments	O
of	O
chromatin	O
condensation	O
and	O
DNA	B-PROC
fragmentation	I-PROC
suggested	O
that	O
the	O
3a	O
protein	O
may	O
trigger	O
apoptosis	B-PROC
.	O

An	O
attempt	O
to	O
wean	B-PROC
from	O
the	O
ventilator	O
failed	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
homogeneous	O
screening	O
assay	O
for	O
automated	O
detection	O
of	O
antiviral	O
agents	O
active	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
.	O

Viroporins	O
are	O
a	O
growing	O
family	O
of	O
viral	O
proteins	O
able	O
to	O
enhance	O
membrane	B-PROC
permeability	I-PROC
,	O
promoting	O
virus	O
budding	B-PROC
.	O

Initially	O
,	O
the	O
MHV	O
E	O
gene	O
was	O
inducibly	O
expressed	B-PROC
in	O
Escherichia	O
coli	O
cells	O
,	O
leading	O
to	O
the	O
arrest	O
of	O
bacterial	O
growth	B-PROC
,	O
cell	O
lysis	B-PROC
and	O
permeabilization	O
to	O
different	O
compounds	O
.	O

The	O
average	O
number	O
of	O
crossovers	O
per	O
recombinant	O
was	O
5	O
and	O
the	O
average	O
number	O
of	O
point	B-PROC
mutations	I-PROC
was	O
1	O
.	O
3	O
,	O
leading	O
mostly	O
to	O
non	O
-	O
synonymous	O
amino	O
acid	O
changes	O
.	O

RNA	B-PROC
interference	I-PROC
of	O
virus	O
-	O
specific	O
genes	O
has	O
emerged	O
as	O
a	O
potential	O
antiviral	O
mechanism	O
.	O

However	O
,	O
there	O
was	O
an	O
obvious	O
improvement	O
in	O
total	O
lung	B-PROC
capacity	I-PROC
(	O
TLC	O
)	O
and	O
diffusing	O
capacity	O
of	O
the	O
lung	O
for	O
carbon	O
monoxide	O
(	O
DLCO	O
)	O
with	O
the	O
elapse	O
of	O
time	O
,	O
and	O
also	O
a	O
significant	O
difference	O
was	O
found	O
between	O
the	O
later	O
stage	O
and	O
the	O
earlier	O
stage	O
.	O

ABSTRACT	O
:	O
To	O
date	O
,	O
the	O
pathogenesis	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
humans	O
is	O
still	O
not	O
well	O
understood	O
.	O

TITLE	O
:	O
Comprehensive	O
antibody	B-PROC
epitope	O
mapping	O
of	O
the	O
nucleocapsid	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
:	O
insight	O
into	O
the	O
humoral	B-PROC
immunity	I-PROC
of	O
SARS	O
.	O

CONCLUSIONS	O
:	O
The	O
antigenic	O
structures	O
identified	O
for	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	O
,	O
the	O
epitope	O
-	O
specific	O
mAbs	O
,	O
and	O
the	O
serum	O
antibody	B-PROC
profile	O
in	O
SARS	O
patients	O
have	O
potential	O
use	O
in	O
the	O
clinical	O
diagnosis	O
and	O
understanding	O
of	O
the	O
protective	O
immunity	B-PROC
to	O
SARS	O
-	O
CoV	O
.	O

This	O
inhibition	B-PROC
suggested	O
that	O
ATA	O
could	O
be	O
developed	O
as	O
potent	O
anti	O
-	O
viral	O
drug	O
.	O

ABSTRACT	O
:	O
Because	O
phosphorylation	B-PROC
of	O
the	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
nucleocapsid	O
protein	O
(	O
N	O
)	O
may	O
regulate	O
its	O
multiple	O
roles	O
in	O
viral	B-PROC
replication	I-PROC
,	O
the	O
dynamics	O
of	O
N	O
phosphorylation	B-PROC
were	O
examined	O
.	O

The	O
EVW	O
allows	O
breath	O
-	O
by	O
-	O
breath	O
estimates	O
of	O
frequency	O
dependence	O
of	O
lung	O
and	O
total	O
respiratory	O
resistance	B-PROC
(	O
R	O
)	O
and	O
elastance	O
(	O
E	O
)	O
from	O
0	O
.	O
2	O
to	O
8	O
Hz	O
.	O

We	O
demonstrated	O
that	O
ACE2	O
,	O
heterologously	O
expressed	B-PROC
in	O
HEK293	O
cells	O
and	O
endogenously	O
expressed	B-PROC
in	O
Huh7	O
cells	O
,	O
undergoes	O
metalloproteinase	O
-	O
mediated	O
,	O
phorbol	O
ester	O
-	O
inducible	O
ectodomain	O
shedding	O
.	O

ABSTRACT	O
:	O
Bovine	O
torovirus	O
(	O
BoTV	O
)	O
is	O
a	O
pleomorphic	O
virus	O
with	O
a	O
spike	O
-	O
bearing	O
envelope	O
and	O
a	O
linear	O
,	O
non	O
-	O
segmented	O
,	O
positive	O
-	O
sense	B-PROC
single	O
-	O
stranded	O
RNA	O
genome	O
.	O

Nine	O
broad	O
categories	O
were	O
identified	O
:	O
uncertainty	O
,	O
information	O
control	O
,	O
feelings	O
of	O
anger	O
and	O
guilt	O
,	O
lack	O
of	O
preparation	O
and	O
fear	O
of	O
death	B-PROC
,	O
feelings	O
of	O
isolation	O
and	O
loneliness	O
,	O
physical	O
effects	O
,	O
support	O
,	O
change	O
of	O
perspective	O
of	O
life	O
,	O
and	O
change	O
of	O
perspective	O
of	O
nursing	B-PROC
.	O

Neutrophil	B-PROC
activation	I-PROC
by	O
the	O
perfusate	O
was	O
assayed	O
using	O
dihydrorhodamine	O
-	O
123	O
fluorescence	O
.	O

Exogenous	O
immunosuppression	B-PROC
,	O
specific	O
allograft	O
factors	O
,	O
and	O
extensive	O
contact	O
with	O
the	O
healthcare	O
system	O
all	O
predispose	O
transplant	O
patients	O
to	O
emerging	O
infections	O
.	O

TITLE	O
:	O
Nuclear	O
/	O
nucleolar	O
localization	B-PROC
properties	O
of	O
C	O
-	O
terminal	O
nucleocapsid	O
protein	O
of	O
SARS	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Different	O
forms	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
-	O
based	O
vaccines	O
for	O
generation	O
of	O
neutralizing	O
antibody	B-PROC
response	I-PROC
against	O
SARS	O
-	O
CoV	O
were	O
compared	O
using	O
a	O
mouse	O
model	O
.	O

DNA	O
vaccine	O
control	O
and	O
oral	O
Salmonella	O
-	O
S	O
-	O
DNA	O
-	O
control	O
showed	O
no	O
neutralizing	O
antibody	B-PROC
against	O
SARS	O
-	O
CoV	O
.	O
Sera	O
of	O
the	O
mice	O
immunized	O
with	O
i	O
.	O
m	O
.	O

Six	O
patients	O
developed	O
a	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
,	O
and	O
five	O
died	B-PROC
.	O

Rates	O
of	O
rejection	O
,	O
decline	O
in	O
forced	B-PROC
expiratory	I-PROC
volume	I-PROC
(	O
L	O
)	O
in	O
1	O
s	O
(	O
FEV	O
-	O
1	O
)	O
and	O
bacterial	O
and	O
fungal	O
superinfection	O
were	O
compared	O
at	O
the	O
3	O
-	O
month	O
primary	O
endpoint	O
.	O

Results	O
obtained	O
by	O
the	O
recombinant	O
S	O
(	O
rS	O
)-	O
based	O
IgG	O
ELISA	O
using	O
the	O
regenerated	O
S	O
prepared	O
by	O
dialysis	O
with	O
decreasing	O
concentrations	O
of	O
urea	O
or	O
direct	O
addition	O
of	O
different	O
coating	O
buffers	O
,	O
followed	O
by	O
addition	O
of	O
different	O
regeneration	B-PROC
buffer	O
,	O
identified	O
4	O
M	O
urea	O
and	O
1	O
M	O
sarcosine	O
for	O
plate	O
coating	O
and	O
no	O
regeneration	B-PROC
buffer	O
as	O
the	O
most	O
optimal	O
conditions	O
for	O
antibody	B-PROC
detection	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
PCR	O
and	O
real	O
-	O
time	O
loop	O
-	O
mediated	O
amplification	O
assays	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
detection	O
.	O

To	O
develop	O
a	O
safe	O
,	O
simple	O
,	O
and	O
reliable	O
screening	O
method	O
for	O
SARS	O
diagnosis	O
and	O
epidemiological	O
study	O
,	O
two	O
recombinant	O
SARS	O
-	O
CoV	O
nucleocapsid	O
proteins	O
(	O
N	O
'	O
protein	O
and	O
(	O
N	O
)	O
Delta	O
(	O
121	O
)	O
protein	O
)	O
were	O
expressed	B-PROC
in	O
Escherichia	O
coli	O
,	O
purified	O
by	O
affinity	O
chromatography	O
,	O
and	O
used	O
as	O
antigens	O
for	O
indirect	O
,	O
immunoglobulin	B-PROC
G	B-PROC
enzyme	I-PROC
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISA	O
).	O

These	O
results	O
demonstrate	O
that	O
combination	O
of	O
the	O
DNA	O
vaccine	O
and	O
the	O
whole	O
killed	O
virus	O
vaccine	O
can	O
be	O
used	O
to	O
enhance	O
the	O
magnitude	O
and	O
change	O
the	O
bias	O
of	O
the	O
immune	B-PROC
responses	I-PROC
to	O
SARS	O
-	O
CoV	O
.	O

Notably	O
,	O
injection	O
of	O
SARS	O
-	O
CoV	O
Spike	O
into	O
mice	O
worsens	O
acute	O
lung	O
failure	O
in	O
vivo	O
that	O
can	O
be	O
attenuated	O
by	O
blocking	O
the	O
renin	O
-	O
angiotensin	O
pathway	B-PROC
.	O

We	O
can	O
hinder	O
the	O
vicious	O
cycle	O
of	O
virus	B-PROC
infection	I-PROC
through	O
water	O
contamination	O
in	O
ponds	O
by	O
providing	O
good	O
human	O
,	O
pig	O
and	O
chicken	O
sanitation	O
.	O

TITLE	O
:	O
Identification	O
of	O
critical	O
active	O
-	O
site	O
residues	O
in	O
angiotensin	O
-	O
converting	O
enzyme	O
-	O
2	O
(	O
ACE2	O
)	O
by	O
site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
.	O

In	O
situ	O
hybridization	B-PROC
for	O
coronavirus	O
was	O
negative	O
in	O
all	O
subjects	O
.	O

A	O
questionnaire	O
survey	O
was	O
conducted	O
and	O
serum	O
samples	O
were	O
collected	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
antibody	B-PROC
.	O

The	O
impact	O
of	O
individual	O
behaviors	B-PROC
on	O
an	O
outbreak	O
was	O
investigated	O
through	O
mathematical	O
approaches	O
.	O

Indirect	O
immunofluorescence	O
studies	O
revealed	O
a	O
preferential	O
expression	B-PROC
of	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE	O
-	O
2	O
),	O
the	O
functional	O
receptor	O
of	O
SARS	O
-	O
CoV	O
,	O
on	O
the	O
apical	O
surface	O
.	O

Active	O
P	O
-	O
PMO	O
were	O
effective	O
when	O
administered	O
at	O
any	O
time	O
prior	O
to	O
peak	O
viral	O
synthesis	B-PROC
and	O
exerted	B-PROC
sustained	O
antiviral	O
effects	O
while	O
present	O
in	O
culture	O
medium	O
.	O

Two	O
P	O
-	O
PMO	O
targeting	B-PROC
the	O
viral	B-PROC
transcription	B-PROC
-	O
regulatory	O
sequence	O
(	O
TRS	O
)	O
region	O
in	O
the	O
5	O
'	O
untranslated	O
region	O
were	O
the	O
most	O
effective	O
inhibitors	O
tested	O
.	O

This	O
study	O
supported	O
the	O
conceptual	O
framework	O
that	O
specified	O
perceived	O
health	O
threats	O
and	O
efficacy	O
beliefs	O
as	O
the	O
two	O
core	O
dimensions	O
of	O
motivating	O
factors	O
in	O
adopting	O
SARS	O
preventive	O
behaviors	B-PROC
.	O

Clinically	O
,	O
human	O
metapneumovirus	O
was	O
found	O
to	O
be	O
second	O
to	O
human	O
respiratory	O
syncytial	O
virus	O
alone	O
,	O
as	O
a	O
cause	O
of	O
respiratory	O
tract	O
infections	O
,	O
while	O
duration	O
of	O
virus	O
excretion	B-PROC
appeared	O
to	O
correlate	O
with	O
severity	O
of	O
infection	O
,	O
and	O
virus	O
load	O
in	O
NPA	O
with	O
the	O
stage	O
of	O
respiratory	O
infection	O
.	O

To	O
evaluate	O
this	O
quantitative	O
RT	O
-	O
PCR	O
,	O
cRNA	O
standards	O
were	O
constructed	O
by	O
in	O
vitro	O
transcription	B-PROC
of	O
SARS	O
-	O
CoV	O
Frankfurt	O
1	O
RNA	O
using	O
T7	O
RNA	O
polymerase	O
,	O
followed	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

SDS	O
-	O
PAGE	O
and	O
Western	O
blot	O
showed	O
that	O
the	O
N	O
protein	O
was	O
expressed	B-PROC
at	O
a	O
level	O
of	O
3mg	O
/	O
ml	O
of	O
culture	O
medium	O
.	O

Conversely	O
,	O
canine	O
enteric	O
coronavirus	O
(	O
CECV	O
)	O
shows	O
considerable	O
genetic	O
and	O
antigenic	B-PROC
diversity	I-PROC
but	O
causes	O
only	O
mild	O
,	O
self	O
-	O
limiting	O
diarrhoea	O
in	O
puppies	O
.	O

ABSTRACT	O
:	O
To	O
study	O
whether	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
could	O
be	O
excreted	O
from	O
digestive	B-PROC
system	O
.	O

No	O
significant	O
difference	O
of	O
mean	O
age	O
and	O
day	O
(	O
form	O
onset	O
of	O
the	O
fever	B-PROC
to	O
the	O
time	O
of	O
initial	O
radiographs	O
taken	O
)	O
was	O
found	O
between	O
the	O
patients	O
with	O
and	O
without	O
abnormal	O
initial	O
chest	O
radiographs	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

We	O
used	O
a	O
digital	O
infrared	O
thermal	O
imaging	O
(	O
DITI	O
)	O
system	O
(	O
Telesis	O
Spectrum	O
9000	O
MB	O
)	O
to	O
conduct	B-PROC
mass	O
screening	O
of	O
patients	O
and	O
visitors	O
who	O
entered	O
the	O
hospital	O
to	O
identify	O
those	O
with	O
fever	B-PROC
.	O

The	O
findings	O
suggests	O
that	O
infrared	O
thermography	O
was	O
an	O
effective	O
and	O
reliable	O
tool	O
ideal	O
for	O
mass	O
-	O
screening	O
patients	O
with	O
fever	B-PROC
in	O
the	O
initial	O
phase	O
of	O
screening	O
for	O
SARS	O
patients	O
at	O
a	O
busy	O
hospital	O
which	O
sees	B-PROC
approximately	O
3	O
,	O
000	O
outpatients	O
every	O
weekday	O
during	O
the	O
SARS	O
epidemic	O
.	O

ABSTRACT	O
:	O
Both	O
viral	O
effect	O
and	O
immune	O
-	O
mediated	O
mechanism	O
are	O
involved	O
in	O
the	O
pathogenesis	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
.	O

Taken	O
together	O
,	O
we	O
have	O
demonstrated	O
that	O
the	O
anti	O
-	O
S2	O
Abs	O
in	O
SARS	O
patient	O
sera	O
cause	O
cytotoxic	O
injury	O
as	O
well	O
as	O
enhance	O
immune	O
cell	B-PROC
adhesion	I-PROC
to	O
epithelial	O
cells	O
.	O

Post	O
-	O
operatively	O
,	O
mediastinopleural	O
irrigation	B-PROC
with	O
saline	O
was	O
performed	O
once	O
or	O
twice	O
a	O
day	O
until	O
a	O
culture	O
of	O
pleural	O
effusion	O
became	O
negative	O
.	O

At	O
autopsy	O
,	O
a	O
severe	O
interstitial	O
type	O
-	O
2	O
HSV	O
pneumonitis	O
with	O
extensive	O
necrotic	B-PROC
areas	O
was	O
found	O
,	O
in	O
association	O
with	O
gastro	O
-	O
intestinal	O
involvement	O
.	O

Hepatic	O
inflammation	O
was	O
observed	O
in	O
most	O
animals	O
,	O
predominantly	O
as	O
a	O
multifocal	O
lymphocytic	O
hepatitis	O
accompanied	O
by	O
necrosis	B-PROC
of	O
individual	O
hepatocytes	O
.	O

We	O
now	O
describe	O
a	O
series	O
of	O
patients	O
that	O
did	O
not	O
fit	O
World	O
Health	O
Organisation	B-PROC
(	O
WHO	O
)	O
case	O
definitions	O
for	O
SARS	O
at	O
initial	O
assessment	O
.	O

TITLE	O
:	O
Mutagenesis	B-PROC
of	O
the	O
murine	O
hepatitis	O
virus	O
nsp1	O
-	O
coding	O
region	O
identifies	O
residues	O
important	O
for	O
protein	B-PROC
processing	I-PROC
,	O
viral	O
RNA	B-PROC
synthesis	I-PROC
,	O
and	O
viral	B-PROC
replication	I-PROC
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
LSECtin	O
is	O
N	O
-	O
linked	O
glycosylated	O
and	O
that	O
glycosylation	B-PROC
is	O
required	O
for	O
cell	O
surface	O
expression	B-PROC
.	O

In	O
the	O
most	O
severe	O
cases	O
,	O
the	O
fetal	O
condition	O
of	O
markedly	O
elevated	O
pulmonary	B-PROC
vascular	I-PROC
resistance	I-PROC
persists	O
after	O
birth	B-PROC
and	O
is	O
associated	O
with	O
hypoxemic	O
respiratory	O
failure	O
and	O
severe	O
disturbances	O
in	O
cardiac	O
performance	O
.	O

Our	O
work	O
will	O
help	O
shed	O
light	O
on	O
the	O
molecular	O
mechanism	O
of	O
the	O
virus	B-PROC
assembly	I-PROC
and	O
provide	O
valuable	O
information	O
pertaining	O
to	O
rationalization	O
of	O
future	O
anti	O
-	O
viral	O
strategies	O
.	O

Twelve	O
patients	O
died	B-PROC
.	O

TITLE	O
:	O
Quality	O
assurance	O
for	O
the	O
diagnostics	O
of	O
viral	B-PROC
diseases	I-PROC
to	O
enhance	O
the	O
emergency	O
preparedness	O
in	O
Europe	O
.	O

Since	O
first	O
description	O
of	O
the	O
disease	O
there	O
have	O
been	O
few	O
changes	O
in	O
the	O
diagnostic	O
criteria	O
except	O
for	O
newer	O
recommendations	O
of	O
fever	B-PROC
of	O
at	O
least	O
4	O
instead	O
of	O
5	O
days	O
duration	O
.	O

Our	O
study	O
provides	O
genetic	O
evidence	O
for	O
the	O
important	O
role	O
of	O
alpha	O
-	O
helical	O
packing	O
in	O
promoting	O
S	O
glycoprotein	O
-	O
mediated	O
membrane	B-PROC
fusion	I-PROC
.	O

We	O
showed	O
that	O
both	O
peptides	O
(	O
M1	O
-	O
31	O
and	O
M132	O
-	O
161	O
)	O
were	O
able	O
to	O
induce	O
high	O
titers	O
of	O
antibody	B-PROC
responses	I-PROC
in	O
the	O
immunized	O
rabbits	O
,	O
highlighting	O
their	O
antigenicity	O
and	O
immunogenicity	O
.	O

TITLE	O
:	O
Performance	O
of	O
single	O
-	O
step	O
gel	O
-	O
based	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
equivalent	O
to	O
that	O
of	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assays	O
for	O
detection	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
.	O

TITLE	O
:	O
A	O
framework	O
for	O
capturing	O
the	O
interactions	O
between	O
laypersons	O
'	O
understanding	O
of	O
disease	O
,	O
information	O
gathering	O
behaviors	B-PROC
,	O
and	O
actions	O
taken	O
during	O
an	O
epidemic	O
.	O

TITLE	O
:	O
Emerging	O
infections	O
and	O
pregnancy	O
:	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
monkeypox	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
and	O
bioterrorism	O
.	O

ABSTRACT	O
:	O
To	O
confirm	O
an	O
infection	O
with	O
the	O
new	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
causing	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
diagnostic	O
assays	O
for	O
detection	O
of	O
SARS	O
-	O
CoV	O
specific	O
antibody	B-PROC
are	O
necessary	O
.	O

In	O
the	O
mid	O
-	O
1970s	O
,	O
the	O
development	B-PROC
of	O
the	O
sheep	O
model	O
of	O
ARDS	O
and	O
later	O
,	O
the	O
porcine	O
model	O
,	O
led	O
to	O
the	O
discovery	O
of	O
a	O
wide	O
variety	O
of	O
inflammatory	O
lipid	O
mediators	O
,	O
cytokines	O
,	O
and	O
proteases	O
,	O
to	O
name	O
but	O
a	O
few	O
.	O

(	O
3	O
)	O
Pulmonary	B-PROC
function	I-PROC
testing	O
reveals	O
marked	O
impairment	O
soon	O
after	O
ARDS	O
.	O

This	O
study	O
is	O
aimed	O
at	O
investigating	O
the	O
capability	O
of	O
SARS	O
-	O
CoV	O
to	O
activate	O
IFN	O
-	O
alpha	O
and	O
-	O
gamma	O
expression	B-PROC
in	O
lymphomonocytes	O
(	O
PBMC	O
)	O
from	O
healthy	O
donors	O
,	O
evaluating	O
whether	O
viral	B-PROC
replication	I-PROC
is	O
necessary	O
for	O
this	O
activation	O
.	O

This	O
study	O
provides	O
evidence	O
that	O
SARS	O
-	O
CoV	O
is	O
able	O
to	O
induce	O
in	O
normal	O
PBMC	O
a	O
coordinate	O
induction	O
of	O
IFN	O
-	O
alpha	O
and	O
-	O
gamma	O
gene	B-PROC
expression	I-PROC
.	O

Virus	B-PROC
replication	I-PROC
is	O
not	O
necessary	O
for	O
IFN	O
induction	O
since	O
efficient	O
IFN	O
expression	B-PROC
could	O
be	O
obtained	O
also	O
by	O
the	O
cocultivation	O
of	O
normal	O
PBMC	O
with	O
fixed	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

Possible	O
reasons	O
for	O
the	O
SARS	O
-	O
associated	O
lymphopenia	O
may	O
be	O
direct	O
infection	O
of	O
lymphocytes	O
by	O
SARS	O
-	O
CoV	O
,	O
lymphocyte	O
sequestration	O
in	O
the	O
lung	O
or	O
cytokine	O
-	O
mediated	O
lymphocyte	O
trafficking	B-PROC
.	O

There	O
may	O
also	O
be	O
immune	O
-	O
mediated	O
lymphocyte	O
destruction	O
,	O
bone	O
marrow	O
or	O
thymus	O
suppression	B-PROC
,	O
or	O
apoptosis	B-PROC
.	O

To	O
eliminate	O
these	O
confounding	O
variables	O
,	O
this	O
study	O
evaluates	O
the	O
association	O
between	O
delayed	O
Tx	O
and	O
serious	O
,	O
well	O
-	O
defined	O
respiratory	O
complications	O
(	O
ventilator	O
-	O
associated	O
pneumonia	O
[	O
VAP	O
]	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
[	O
ARDS	O
])	O
and	O
death	B-PROC
in	O
a	O
cohort	O
of	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admissions	O
with	O
less	O
severe	O
(	O
Injury	O
Severity	O
Score	O
[	O
ISS	O
]	O
<	O
25	O
)	O
blunt	O
trauma	O
who	O
received	O
no	O
Tx	O
within	O
the	O
initial	O
48	O
hours	O
after	O
admission	O
.	O

Surprisingly	O
,	O
a	O
carboxyl	O
-	O
terminal	O
truncation	O
of	O
17	O
amino	O
acids	O
substantially	O
increased	O
S	O
glycoprotein	O
-	O
mediated	O
cell	O
-	O
to	O
-	O
cell	B-PROC
fusion	I-PROC
suggesting	O
that	O
the	O
terminal	O
17	O
amino	O
acids	O
regulated	O
the	O
S	O
fusogenic	O
properties	O
.	O

Other	O
typical	O
pathological	O
changes	O
included	O
hemorrhagic	O
necrosis	B-PROC
in	O
lymph	O
nodes	O
and	O
spleen	O
and	O
hydropic	O
degeneration	O
in	O
the	O
liver	O
.	O

To	O
examine	O
potential	O
apoptotic	O
mechanisms	O
related	O
to	O
SARS	O
,	O
we	O
investigated	O
features	O
of	O
apoptosis	B-PROC
induced	O
by	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
host	O
cells	O
.	O

ABSTRACT	O
:	O
This	O
contribution	O
reviews	O
the	O
synthesis	B-PROC
of	O
a	O
range	O
of	O
experimental	O
drugs	O
designed	O
for	O
and	O
aiming	O
at	O
antiviral	O
chemotherapy	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)-	O
induced	O
human	O
disease	O
conditions	O
.	O

This	O
14	O
-	O
3	O
-	O
3	O
-	O
mediated	O
transport	B-PROC
of	O
the	O
phosphorylated	O
N	O
protein	O
and	O
its	O
possible	O
implications	O
in	O
interfering	O
with	O
the	O
cellular	O
machinery	O
are	O
discussed	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
several	O
members	O
within	O
the	O
order	O
Nidovirales	O
localizes	O
to	O
the	O
nucleolus	O
during	O
infection	O
and	O
after	O
transfection	B-PROC
of	O
cells	O
with	O
N	O
genes	O
.	O

One	O
pair	O
-	O
Abs	O
,	O
consisting	O
of	O
N	O
protein	O
-	O
specific	O
rabbit	O
polyclonal	O
antibody	B-PROC
and	O
SARS	O
-	O
CoV	O
N	O
protein	O
-	O
specific	O
mAb	O
,	O
was	O
selected	O
to	O
construct	O
a	O
sandwich	O
ELISA	O
-	O
kit	O
.	O

Moreover	O
,	O
the	O
protease	O
-	O
mediated	O
entry	O
facilitated	O
a	O
100	O
-	O
to	O
1	O
,	O
000	O
-	O
fold	O
higher	O
efficient	O
infection	O
than	O
did	O
the	O
endosomal	O
pathway	B-PROC
used	O
in	O
the	O
absence	O
of	O
proteases	O
.	O

We	O
defined	O
patients	O
with	O
a	O
fever	B-PROC
of	O
over	O
38	O
degrees	O
C	O
and	O
respiratory	O
symptoms	O
as	O
""""	O
cases	O
with	O
acute	O
respiratory	O
symptoms	O
.	O

TITLE	O
:	O
[	O
A	O
preliminary	O
study	O
of	O
the	O
structure	O
prediction	O
and	O
expression	B-PROC
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
].	O

The	O
denatured	O
inclusion	O
bodies	O
were	O
purified	O
with	O
Ni	O
-	O
NTA	O
chelate	O
agarose	O
and	O
its	O
purity	O
can	O
reach	B-PROC
90	O
%.	O

The	O
neutralizing	O
antibody	B-PROC
titer	O
of	O
the	O
87	O
positive	O
sera	O
was	O
analyzed	O
quantitatively	O
by	O
neutralization	O
assay	O
.	O

This	O
result	O
could	O
be	O
useful	O
for	O
the	O
development	B-PROC
and	O
quality	O
control	O
of	O
SARS	O
vaccines	O
.	O

To	O
further	O
characterize	O
the	O
role	O
of	O
glycosylation	B-PROC
and	O
identify	O
residues	O
important	O
for	O
its	O
function	O
as	O
an	O
interacting	O
partner	O
of	O
ACE2	O
,	O
we	O
have	O
cloned	O
,	O
expressed	B-PROC
and	O
characterized	O
various	O
soluble	O
fragments	O
of	O
S	O
containing	O
RBD	O
,	O
and	O
mutated	O
all	O
potential	O
glycosylation	B-PROC
sites	O
and	O
32	O
other	O
residues	O
.	O

Mutation	O
of	O
each	O
of	O
these	O
sites	O
to	O
either	O
alanine	O
or	O
glutamine	O
,	O
as	O
well	O
as	O
mutation	O
of	O
residue	O
318	O
to	O
alanine	O
in	O
longer	O
fragments	O
resulted	O
in	O
the	O
same	O
decrease	O
of	O
molecular	O
weight	O
(	O
by	O
approximately	O
3	O
kDa	O
)	O
suggesting	O
that	O
all	O
glycosylation	B-PROC
sites	O
are	O
functional	O
.	O

The	O
finding	O
that	O
most	O
of	O
the	O
mutations	O
(	O
23	O
out	O
of	O
34	O
including	O
glycosylation	B-PROC
sites	O
)	O
do	O
not	O
affect	O
the	O
RBD	O
binding	O
function	O
indicates	O
possible	O
mechanisms	O
for	O
evasion	O
of	O
immune	B-PROC
responses	I-PROC
.	O

On	O
the	O
contrary	O
,	O
a	O
lot	O
of	O
IFN	O
-	O
stimulated	O
genes	O
like	O
PKR	O
,	O
GBP	O
-	O
1	O
and	O
2	O
,	O
CXCL	O
-	O
10	O
and	O
11	O
,	O
and	O
JAK	B-PROC
/	O
STAT	O
signal	B-PROC
pathway	I-PROC
were	O
downregulated	O
in	O
the	O
acute	O
severe	O
case	O
compared	O
to	O
the	O
convalescent	O
case	O
.	O

CONCLUSIONS	O
:	O
Gene	B-PROC
expression	I-PROC
in	O
SARS	O
patients	O
mirrors	O
a	O
host	O
state	O
of	O
inflammation	O
and	O
anti	O
-	O
viral	O
immunity	B-PROC
at	O
the	O
transcription	B-PROC
level	O
,	O
and	O
understanding	O
of	O
gene	B-PROC
expression	I-PROC
profiles	O
may	O
make	O
contribution	O
to	O
further	O
studies	O
of	O
the	O
SARS	O
pathogenesis	B-PROC
.	O

TITLE	O
:	O
Recent	O
highlights	O
in	O
the	O
development	B-PROC
of	O
new	O
antiviral	O
drugs	O
.	O

TITLE	O
:	O
Design	O
of	O
wide	O
-	O
spectrum	O
inhibitors	O
targeting	B-PROC
coronavirus	O
main	O
proteases	O
.	O

In	O
this	O
study	O
,	O
a	O
recombinant	O
protein	O
(	O
rS268	O
,	O
corresponding	O
to	O
residues	O
268	O
-	O
1255	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
)	O
was	O
expressed	B-PROC
in	O
Escherichia	O
coli	O
and	O
was	O
purified	O
to	O
near	O
homogeneity	O
.	O

Evidence	O
present	O
suggests	O
that	O
the	O
dominant	O
Vero	O
cell	O
-	O
adapted	O
IBV	O
strain	O
may	O
be	O
derived	O
from	O
the	O
chicken	O
embryo	O
passages	O
by	O
selection	O
of	O
and	O
potential	O
recombination	B-PROC
between	O
the	O
minor	O
variants	O
.	O

Further	O
experiments	O
showed	O
that	O
there	O
is	O
more	O
than	O
one	O
function	O
domain	O
in	O
the	O
N	O
protein	O
responsible	O
for	O
NF	B-PROC
-	I-PROC
kappaB	I-PROC
activation	I-PROC
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
genome	O
polymorphism	B-PROC
:	O
a	O
bioinformatics	O
study	O
.	O

Recent	O
large	O
epidemiologic	O
studies	O
have	O
shown	O
that	O
sleep	B-PROC
apnea	O
affects	O
about	O
16	O
%	O
of	O
men	O
and	O
5	O
%	O
of	O
women	O
between	O
30	O
and	O
65	O
years	O
of	O
age	O
.	O

Enhanced	O
platelet	O
activity	O
and	O
aggregation	O
,	O
leukocyte	B-PROC
adhesion	I-PROC
and	O
accumulation	O
of	O
endothelial	O
cells	O
are	O
common	O
in	O
both	O
obstructive	O
apnea	O
and	O
atherosclerosis	O
.	O

More	O
studies	O
are	O
needed	O
to	O
understand	O
the	O
mechanisms	O
underlying	O
the	O
relationship	O
between	O
sleep	B-PROC
apnea	O
and	O
cardiovascular	O
disease	O
,	O
but	O
clinicians	O
should	O
be	O
aware	O
of	O
this	O
link	O
and	O
should	O
attempt	O
to	O
identify	O
patients	O
with	O
these	O
syndromes	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
on	O
the	O
sound	O
filtering	O
characteristics	O
of	O
injured	O
lungs	O
.	O

Apoptosis	B-PROC
is	O
likely	O
mediated	O
by	O
the	O
mitochondrial	O
pathway	B-PROC
,	O
as	O
demonstrated	O
by	O
its	O
inhibition	B-PROC
using	O
Bcl	O
-	O
2	O
,	O
and	O
by	O
the	O
activation	O
of	O
the	O
caspase	O
cascade	O
,	O
resulting	O
in	O
PARP	O
cleavage	B-PROC
.	O

The	O
detection	O
limit	O
was	O
10	O
(	O
0	O
)	O
copies	O
/	O
microL	O
.	O
The	O
results	O
of	O
the	O
asymmetric	O
multiplex	O
nested	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
were	O
in	O
agreement	O
with	O
the	O
results	O
of	O
the	O
microarray	O
hybridization	B-PROC
;	O
no	O
hybridization	B-PROC
signal	O
was	O
lost	O
as	O
happened	O
with	O
applicons	O
from	O
symmetric	O
amplifications	O
.	O

The	O
results	O
indicated	O
that	O
apart	O
from	O
the	O
two	O
subunits	O
of	O
cellular	O
RNA	O
polymerase	O
complex	O
,	O
BTF3	O
and	O
ATF5	O
,	O
this	O
nsp10	O
protein	O
was	O
also	O
able	O
to	O
interact	O
specifically	O
with	O
the	O
NADH	O
4L	O
subunit	O
and	O
cytochrome	B-PROC
oxidase	O
II	O
.	O

He	O
had	O
endotracheal	O
tube	O
(	O
artificially	O
ventilated	O
)	O
and	O
hypovolemic	O
shock	O
with	O
circulatory	B-PROC
insufficiency	O
(	O
blood	B-PROC
pressure	I-PROC
was	O
supported	O
by	O
3	O
catecholamines	O
).	O

RESULTS	O
:	O
Eleven	O
patients	O
(	O
12	O
%)	O
had	O
mild	O
impairment	O
of	O
FVC	B-PROC
,	O
20	O
(	O
21	O
%)	O
had	O
mild	O
impairment	O
of	O
FEV1	O
,	O
5	O
(	O
5	O
%)	O
had	O
mild	O
impairment	O
of	O
the	O
FEV1	O
/	O
FVC	B-PROC
ratio	O
,	O
and	O
17	O
(	O
18	O
%)	O
had	O
mild	O
impairment	O
of	O
the	O
D	O
(	O
LCO	O
).	O

Using	O
transmission	O
electronic	O
microscopy	O
and	O
nested	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
,	O
the	O
causative	O
pathogen	O
was	O
identified	O
in	O
cultures	O
of	O
a	O
brain	O
tissue	O
specimen	O
obtained	O
from	O
the	O
patient	O
with	O
SARS	O
.	O

When	O
patients	O
deteriorate	O
clinically	O
despite	O
treatment	O
with	O
ribavirin	O
and	O
corticosteroids	O
,	O
rescue	O
treatment	O
with	O
convalescent	O
plasma	O
and	O
immunoglobulin	B-PROC
may	O
be	O
beneficial	O
.	O

Seroconversion	O
for	O
antibody	B-PROC
against	O
SARS	O
-	O
CoV	O
was	O
observed	O
in	O
all	O
patients	O
.	O

The	O
findings	O
that	O
antibody	B-PROC
to	O
HTLV	O
can	O
be	O
detected	O
in	O
blood	O
samples	O
collected	O
from	O
SARS	O
patients	O
provide	O
important	O
information	O
for	O
safe	O
handling	O
of	O
blood	O
products	O
.	O

The	O
binding	O
behaviors	B-PROC
of	O
modified	O
oligodeoxynucleotides	O
to	O
the	O
complementary	O
sequence	O
were	O
studied	O
by	O
UV	O
,	O
CD	O
,	O
and	O
molecular	B-PROC
dynamics	I-PROC
simulation	O
.	O

CONCLUSIONS	O
:	O
SARS	O
patients	O
have	O
higher	O
body	O
temperature	O
and	O
longer	O
duration	O
of	O
high	O
fever	B-PROC
.	O

TITLE	O
:	O
[	O
Expression	B-PROC
of	O
the	O
recombinant	O
SARS	O
coronavirus	O
nucleocapsid	O
protein	O
in	O
Pichia	O
pastoris	O
and	O
identification	O
of	O
its	O
bioactivity	O
].	O

The	O
specificity	O
of	O
the	O
amplicons	O
was	O
assessed	O
by	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
and	O
sequence	O
analysis	O
.	O

ABSTRACT	O
:	O
Sirolimus	O
is	O
a	O
new	O
potent	O
immunosuppressive	O
drug	O
used	O
in	O
organ	O
transplantation	O
;	O
its	O
major	O
advantage	O
is	O
the	O
absence	O
of	O
deterioration	O
in	O
renal	B-PROC
function	I-PROC
.	O

Passive	O
transfer	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-PROC
from	O
the	O
mother	O
was	O
considered	O
as	O
a	O
possibility	O
.	O

Passive	O
transfer	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-PROC
from	O
the	O
mother	O
was	O
considered	O
as	O
a	O
possibility	O
.	O

ABSTRACT	O
:	O
Polymorphisms	B-PROC
of	O
human	O
Fc	O
gamma	O
-	O
receptor	O
IIA	O
(	O
FcgammaRIIA	O
)	O
and	O
mannose	O
-	O
binding	O
lectin	O
(	O
MBL	O
)	O
genes	O
have	O
been	O
associated	O
with	O
susceptibility	O
to	O
or	O
severity	O
of	O
some	O
infectious	O
diseases	O
.	O

In	O
order	O
to	O
investigate	O
whether	O
these	O
genetic	O
factors	O
might	O
influence	O
susceptibility	O
to	O
infection	O
with	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
Cov	O
)	O
as	O
well	O
as	O
the	O
course	O
and	O
severity	O
of	O
the	O
infection	O
,	O
we	O
evaluated	O
polymorphisms	B-PROC
of	O
FcgammaRIIA	O
and	O
MBL	O
genes	O
in	O
DNA	O
samples	O
from	O
a	O
group	O
of	O
approximately	O
180	O
people	O
from	O
Hong	O
Kong	O
who	O
were	O
infected	O
with	O
SARS	O
-	O
Cov	O
.	O

These	O
included	O
132	O
patients	O
who	O
had	O
moderate	O
course	O
of	O
SARS	O
infection	O
(	O
home	O
subgroup	O
),	O
26	O
patients	O
with	O
a	O
severe	O
course	O
requiring	O
treatment	O
in	O
an	O
intensive	O
care	O
ward	O
(	O
ICU	O
subgroup	O
)	O
and	O
a	O
subgroup	O
of	O
22	O
patients	O
who	O
died	B-PROC
from	O
SARS	O
(	O
deceased	B-PROC
subgroup	O
).	O

In	O
comparison	O
with	O
controls	O
,	O
a	O
significant	O
difference	O
in	O
linear	O
trend	O
distribution	O
of	O
FcgammaRIIA	O
genotypes	O
was	O
seen	O
among	O
the	O
severe	O
SARS	O
patients	O
(	O
ICU	O
and	O
deceased	B-PROC
subgroups	O
)	O
without	O
co	O
-	O
morbidity	O
,	O
and	O
the	O
incidence	O
of	O
FcgammaRIIA	O
-	O
H	O
/	O
H131	O
was	O
lower	O
in	O
these	O
patients	O
as	O
well	O
.	O

In	O
each	O
group	O
,	O
seizures	O
occurring	O
during	O
three	O
different	O
periods	B-PROC
were	O
compared	O
.	O

Characterization	O
of	O
an	O
Appr	O
-	O
1	O
"""-"	O
pase	O
-	O
deficient	O
HCoV	O
-	O
229E	O
mutant	O
revealed	O
no	O
significant	O
effects	O
on	O
viral	O
RNA	B-PROC
synthesis	I-PROC
and	O
virus	O
titer	O
,	O
and	O
no	O
reversion	O
to	O
the	O
wild	O
-	O
type	O
sequence	O
was	O
observed	O
when	O
the	O
mutant	O
virus	O
was	O
passaged	O
in	O
cell	O
culture	O
.	O

The	O
loss	O
of	O
expression	B-PROC
of	O
the	O
firefly	O
luciferase	O
was	O
found	O
to	O
result	O
from	O
various	O
,	O
often	O
large	O
deletions	O
of	O
the	O
gene	O
,	O
probably	O
due	O
to	O
RNA	O
recombination	B-PROC
.	O

Described	O
here	O
are	O
issues	O
related	O
to	O
progress	O
in	O
vaccine	O
development	B-PROC
and	O
the	O
obstacles	O
that	O
lie	O
ahead	O
for	O
both	O
researchers	O
and	O
regulatory	O
agencies	O
.	O

ABSTRACT	O
:	O
The	O
S1	O
genes	O
of	O
isolates	O
of	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
from	O
commercial	O
chickens	O
in	O
the	O
US	O
and	O
Israel	O
(	O
20	O
isolates	O
from	O
each	O
country	O
)	O
were	O
studied	O
using	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
and	O
sequencing	O
.	O

Vaccination	O
with	O
commercial	O
live	O
strains	O
Massachusetts	O
(	O
Mass	O
),	O
Arkansas	O
(	O
Ark	O
)	O
or	O
DE	O
/	O
072	O
/	O
92	O
,	O
generally	O
produced	O
immunity	B-PROC
against	O
vaccine	O
-	O
related	O
field	O
isolates	O
displaying	O
high	O
S1	O
sequence	O
similarities	O
(>	O
or	O
=	O
90	O
%)	O
to	O
the	O
respective	O
vaccine	O
strains	O
.	O

TITLE	O
:	O
Diffusion	O
-	O
weighted	O
MR	O
study	O
of	O
femoral	O
head	O
avascular	O
necrosis	B-PROC
in	O
severe	O
acute	O
respiratory	O
syndrome	O
patients	O
.	O

The	O
duration	O
of	O
pulse	B-PROC
treatment	O
was	O
(	O
28	O
+/-	O

Our	O
results	O
showed	O
that	O
STR2	O
protein	B-PROC
expression	B-PROC
with	O
the	O
use	O
of	O
an	O
138	O
base	O
-	O
pair	O
intron	O
addition	O
increased	O
by	O
1	O
.	O
9	O
-,	O
2	O
.	O
5	O
-,	O
and	O
4	O
.	O
1	O
-	O
fold	O
in	O
Vero	O
E6	O
,	O
QBI	O
-	O
293A	O
cells	O
,	O
and	O
CHO	O
/	O
dhFr	B-PROC
-	O
cells	O
(	O
dihydrofolate	O
reductase	O
[	O
dhfr	B-PROC
]	O
gene	O
deficient	O
CHO	O
cells	O
),	O
respectively	O
.	O

TITLE	O
:	O
Early	O
enhanced	O
expression	B-PROC
of	O
interferon	O
-	O
inducible	O
protein	O
-	O
10	O
(	O
CXCL	O
-	O
10	O
)	O
and	O
other	O
chemokines	O
predicts	O
adverse	O
outcome	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Reverse	B-PROC
transcription	B-PROC
and	O
real	O
-	O
time	O
quantitative	O
PCR	O
and	O
immunohistochemical	O
staining	O
were	O
performed	O
to	O
analyze	O
the	O
production	O
of	O
IP	O
-	O
10	O
in	O
lung	O
tissue	O
at	O
autopsy	O
.	O

RESULTS	O
:	O
Increases	O
in	O
IP	O
-	O
10	O
,	O
MIG	O
,	O
and	O
IL	O
-	O
8	O
during	O
the	O
first	O
week	O
after	O
onset	O
of	O
fever	B-PROC
were	O
associated	O
with	O
adverse	O
outcome	O
(	O
intensive	O
care	O
unit	O
admission	O
or	O
death	B-PROC
)	O
in	O
the	O
univariate	O
analysis	O
.	O

ABSTRACT	O
:	O
Tumor	O
necrosis	B-PROC
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
blocking	O
drugs	O
improve	O
therapy	O
for	O
rheumatic	O
diseases	O
,	O
but	O
the	O
risk	O
of	O
additional	O
immunosuppression	B-PROC
and	O
infection	O
is	O
unclear	O
.	O

We	O
provide	O
genetic	O
evidence	O
to	O
support	O
that	O
3a	O
is	O
functionally	O
related	O
to	O
clathrin	B-PROC
-	I-PROC
mediated	I-PROC
endocytosis	I-PROC
.	O

TITLE	O
:	O
The	O
performance	O
of	O
RT	O
-	O
PCR	O
compared	O
with	O
a	O
rapid	O
serological	O
assay	O
for	O
acute	O
dengue	O
fever	B-PROC
in	O
a	O
diagnostic	O
laboratory	O
.	O

The	O
role	O
of	O
nutrition	B-PROC
in	O
the	O
management	O
of	O
ARDS	O
has	O
traditionally	O
been	O
supportive	O
.	O

Recent	O
research	O
has	O
demonstrated	O
the	O
potential	O
of	O
certain	O
dietary	O
oils	O
(	O
eg	O
,	O
fish	O
oil	O
,	O
borage	O
oil	O
)	O
to	O
modulate	O
pulmonary	O
inflammation	O
,	O
thereby	O
improving	O
lung	B-PROC
compliance	I-PROC
and	O
oxygenation	B-PROC
,	O
and	O
reducing	O
time	O
on	O
mechanical	O
ventilation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
acute	O
lung	O
injury	O
on	O
the	O
gut	O
epithelium	O
and	O
examine	O
mechanisms	O
underlying	O
changes	O
in	O
crypt	O
proliferation	O
and	O
apoptosis	B-PROC
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
virus	O
non	O
-	O
structural	O
protein	O
15	O
is	O
a	O
Mn2	O
+-	O
dependent	O
endoribonuclease	O
with	O
specificity	O
for	O
cleavage	B-PROC
at	O
uridylate	O
residues	O
.	O

Nineteen	O
of	O
the	O
mutants	O
were	O
soluble	O
and	O
were	O
analyzed	O
for	O
enzymatic	B-PROC
activity	I-PROC
.	O

A	O
mutant	O
in	O
the	O
N	O
terminus	O
of	O
Nsp15	O
was	O
impaired	O
in	O
hexamer	O
formation	B-PROC
and	O
had	O
low	O
endoribonuclease	O
activity	O
,	O
suggesting	O
that	O
oligomerization	O
is	O
required	O
for	O
endoribonuclease	O
activity	O
.	O

The	O
survey	O
was	O
conducted	O
during	O
July	O
and	O
August	O
2003	O
,	O
approximately	O
two	O
months	O
after	O
Hong	O
Kong	O
was	O
removed	O
from	O
the	O
World	O
Health	O
Organisation	B-PROC
SARS	O
Infected	O
Areas	O
list	O
,	O
and	O
was	O
designed	O
to	O
examine	O
student	O
confidence	O
in	O
BLS	O
skills	O
,	O
their	O
perceptions	O
of	O
the	O
risks	O
associated	O
with	O
performing	O
BLS	O
and	O
their	O
willingness	O
to	O
perform	O
BLS	O
in	O
varying	O
situations	O
.	O

The	O
response	O
rate	O
for	O
the	O
individual	O
GP	O
survey	O
was	O
48	O
per	O
cent	O
(	O
184	O
/	O
381	O
)	O
and	O
the	O
response	O
rate	O
for	O
the	O
practice	O
organisation	B-PROC
survey	O
was	O
54	O
per	O
cent	O
(	O
74	O
/	O
136	O
).	O

In	O
addition	O
,	O
resistance	B-PROC
to	O
infection	O
of	O
zona	O
-	O
intact	O
and	O
laser	O
-	O
microdissected	O
oocytes	O
was	O
compared	O
.	O

According	O
to	O
World	O
Health	O
Organisation	B-PROC
(	O
WHO	O
)	O
this	O
appears	O
to	O
be	O
the	O
first	O
severe	O
and	O
easily	O
transmissible	O
new	O
disease	O
to	O
emerge	O
in	O
the	O
21st	O
century	O
.	O

This	O
represents	O
an	O
increase	O
of	O
119	O
new	O
cases	O
and	O
8	O
new	O
deaths	B-PROC
compared	O
with	O
9	O
May	O
2003	O
(	O
China	O
(	O
85	O
),	O
Taiwan	O
(	O
23	O
),	O
and	O
Hong	O
Kong	O
(	O
7	O
)	O
represented	O
the	O
overwhelming	O
majority	O
,	O
with	O
one	O
additional	O
case	O
each	O
reported	O
from	O
France	O
,	O
Malaysia	O
,	O
Singapore	O
,	O
and	O
the	O
United	O
States	O
).	O

ISH	O
-	O
IHC	O
double	O
staining	O
showed	O
that	O
positive	O
signals	O
of	O
both	O
ISH	O
(	O
purple	O
-	O
blue	O
NBT	O
-	O
BCIP	O
and	O
IHC	O
(	O
red	O
-	O
brown	O
,	O
AEC	O
expressed	B-PROC
in	O
the	O
cytoplasms	O
(	O
purple	O
and	O
red	O
).	O

RESULTS	O
:	O
Three	O
hybridoma	O
cell	O
lines	O
(	O
8A5	O
,	O
8H6	O
and	O
4A2	O
)	O
stable	O
in	O
secreting	B-PROC
specific	O
monoclonal	O
antibodies	O
were	O
successfully	O
obtained	O
.	O

TITLE	O
:	O
Contribution	O
of	O
trafficking	B-PROC
signals	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
infectious	O
bronchitis	O
virus	O
spike	O
protein	O
to	O
virus	B-PROC
infection	I-PROC
.	O

Our	O
results	O
suggest	O
that	O
the	O
endocytosis	B-PROC
signal	O
of	O
IBV	O
S	O
is	O
essential	O
for	O
productive	O
virus	B-PROC
infection	I-PROC
.	O

SCV	O
also	O
failed	O
to	O
induce	O
DC	O
maturation	B-PROC
(	O
CD86	O
expression	B-PROC
)	O
or	O
enhance	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
class	O
II	O
expression	B-PROC
.	O

This	O
information	O
can	O
be	O
used	O
as	O
a	O
footprint	O
for	O
tracing	O
the	O
epidemiology	O
of	O
infections	O
and	O
monitor	O
viral	O
evolution	B-PROC
.	O

Five	O
fragments	O
targeted	B-PROC
at	O
the	O
SNV	O
loci	O
were	O
amplified	O
directly	O
from	O
clinical	O
samples	O
by	O
using	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
before	O
sequencing	O
the	O
amplified	O
products	O
.	O

Fourteen	O
cases	O
were	O
finally	O
cured	O
,	O
and	O
2	O
died	B-PROC
of	O
severe	O
blast	O
injury	O
of	O
the	O
lungs	O
and	O
severe	O
systemic	O
infection	O
.	O

Immunohistochemistry	O
demonstrated	O
abundant	O
IgG	O
precipitation	B-PROC
in	O
the	O
seminiferous	O
epithelium	O
of	O
SARS	O
testes	O
,	O
indicating	O
possible	O
immune	B-PROC
response	I-PROC
as	O
the	O
cause	O
for	O
the	O
damage	O
.	O

TITLE	O
:	O
In	O
silico	O
analysis	O
of	O
ORF1ab	O
in	O
coronavirus	O
HKU1	O
genome	O
reveals	O
a	O
unique	O
putative	O
cleavage	B-PROC
site	O
of	O
coronavirus	O
HKU1	O
3C	O
-	O
like	O
protease	O
.	O

Although	O
polymorphisms	B-PROC
in	O
Toll	O
-	O
like	O
receptors	O
play	O
a	O
contributory	O
role	O
in	O
determining	O
cellular	O
activation	O
,	O
other	O
factors	O
are	O
involved	O
as	O
well	O
.	O

Here	O
,	O
we	O
assess	O
the	O
conformational	O
flexibility	O
of	O
the	O
M	O
(	O
pro	O
)	O
by	O
analysis	O
of	O
multiple	O
crystal	O
structures	O
(	O
including	O
two	O
new	O
crystal	O
forms	O
)	O
and	O
by	O
molecular	B-PROC
dynamics	I-PROC
(	O
MD	O
)	O
calculations	O
.	O

Lung	O
injury	O
and	O
injury	O
severity	O
scores	O
,	O
patient	O
age	O
,	O
ECMO	O
duration	O
and	O
oxygenation	B-PROC
indices	O
pre	O
-	O
ECMO	O
(	O
PaO2	O
/	O
FiO2	O
)	O
were	O
similar	O
in	O
both	O
the	O
survivor	O
and	O
non	O
-	O
survivor	O
groups	O
.	O

Noninvasive	O
management	O
was	O
successful	O
in	O
averting	O
death	B-PROC
and	O
endotracheal	O
intubation	O
in	O
79	O
.	O
2	O
%	O
of	O
the	O
acute	O
episodes	O
.	O

RESULTS	O
:	O
Noninvasive	O
management	O
was	O
successful	O
in	O
averting	O
death	B-PROC
and	O
endotracheal	O
intubation	O
in	O
79	O
.	O
2	O
%	O
of	O
the	O
acute	O
episodes	O
.	O

PaO2	O
/	O
FIO2	O
increases	O
were	O
also	O
significantly	O
related	O
with	O
increases	O
in	O
functional	B-PROC
residual	I-PROC
capacity	I-PROC
(	O
R2	O
=	O
0	O
.	O
60	O
).	O

ABSTRACT	O
:	O
Design	O
,	O
synthesis	B-PROC
,	O
and	O
biological	O
evaluation	O
of	O
peptidomimetic	O
severe	O
acute	O
respiratory	O
syndrome	O
chymotrypsin	O
-	O
like	O
protease	O
(	O
SARS	O
-	O
3CLpro	O
)	O
inhibitors	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
are	O
described	O
.	O

TITLE	O
:	O
Struggle	O
for	O
implementation	O
of	O
new	O
strategies	O
in	O
intensive	O
care	O
medicine	O
:	O
anticoagulation	B-PROC
,	O
insulin	O
,	O
and	O
lower	O
tidal	O
volumes	O
.	O

Expression	B-PROC
of	O
GFP	O
was	O
detected	O
in	O
Vero	O
E6	O
cells	O
infected	O
with	O
the	O
VLP	O
(	O
GFP	O
-	O
PS580	O
),	O
indicating	O
that	O
GFP	O
-	O
PS580	O
RNA	O
can	O
be	O
assembled	O
into	O
the	O
VLPs	O
.	O

TITLE	O
:	O
Modulation	O
of	O
the	O
immune	B-PROC
response	I-PROC
to	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
spike	O
glycoprotein	O
by	O
gene	O
-	O
based	O
and	O
inactivated	O
virus	O
immunization	O
.	O

ABSTRACT	O
:	O
Although	O
the	O
initial	O
isolates	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
are	O
sensitive	O
to	O
neutralization	O
by	O
antibodies	O
through	O
their	O
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
variants	O
of	O
S	O
have	O
since	O
been	O
identified	O
that	O
are	O
resistant	O
to	O
such	O
inhibition	B-PROC
.	O

TITLE	O
:	O
Acquisition	O
of	O
macrophage	O
tropism	B-PROC
during	O
the	O
pathogenesis	B-PROC
of	O
feline	O
infectious	O
peritonitis	O
is	O
determined	O
by	O
mutations	O
in	O
the	O
feline	O
coronavirus	O
spike	O
protein	O
.	O

To	O
identify	O
the	O
genetic	O
determinants	O
of	O
the	O
FIPV	O
79	O
-	O
1146	O
macrophage	O
tropism	B-PROC
,	O
we	O
exchanged	O
regions	O
of	O
its	O
genome	O
with	O
the	O
corresponding	O
parts	O
of	O
FECV	O
79	O
-	O
1683	O
,	O
after	O
which	O
the	O
ability	O
of	O
the	O
FIPV	O
/	O
FECV	O
hybrid	O
viruses	O
to	O
infect	O
macrophages	O
was	O
tested	O
.	O

ABSTRACT	O
:	O
Only	O
a	O
relatively	O
few	O
mutations	O
in	O
its	O
spike	O
protein	O
allow	O
the	O
murine	O
coronavirus	O
to	O
switch	O
from	O
a	O
murine	O
-	O
restricted	O
tropism	B-PROC
to	O
an	O
extended	O
host	O
range	O
by	O
being	O
passaged	O
in	O
vitro	O
.	O

One	O
such	O
virus	O
that	O
we	O
studied	O
had	O
acquired	O
two	O
putative	O
heparan	O
sulfate	O
-	O
binding	O
sites	O
while	O
preserving	O
another	O
site	O
in	O
the	O
furin	O
-	O
cleavage	B-PROC
motif	O
.	O

The	O
prokaryotic	O
expression	B-PROC
vector	O
pQEN	O
containing	O
N	O
gene	O
was	O
constructed	O
and	O
transformed	O
into	O
the	O
E	O
.	O
coli	O
.	O

Intravaginal	O
or	O
intranasal	O
immunization	O
by	O
HIV	O
-	O
NS	O
with	O
diameters	O
ranging	O
360	O
to	O
1230	O
nm	O
significantly	O
induced	O
vaginal	O
antibody	B-PROC
responses	I-PROC
.	O

SARS	O
-	O
CoV	O
receptor	O
ACE	O
-	O
2	O
gene	O
was	O
successfully	O
cloned	O
and	O
eukaryotic	O
expressed	B-PROC
,	O
and	O
used	O
to	O
establish	O
syncytia	O
inhibition	B-PROC
assay	O
for	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-PROC
assay	O
.	O

RESULTS	O
:	O
The	O
recombinant	O
plasmid	O
pcDNA4	O
/	O
ACE	O
-	O
2	O
could	O
express	O
ACE	O
-	O
2	O
protein	O
in	O
eukaryotic	O
cells	O
and	O
induce	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
between	O
S	O
protein	O
-	O
and	O
ACE2	O
-	O
expressing	O
cells	O
.	O

CONCLUSIONS	O
:	O
SARS	O
-	O
CoV	O
receptor	O
ACE	O
-	O
2	O
gene	O
was	O
successfully	O
cloned	O
and	O
eukaryotic	O
expressed	B-PROC
,	O
and	O
used	O
to	O
establish	O
syncytia	O
inhibition	B-PROC
assay	O
for	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-PROC
assay	O
.	O

The	O
emerging	O
zoonotic	O
diseases	O
that	O
have	O
seized	O
headlines	O
in	O
papers	O
around	O
the	O
world	O
give	O
prominence	O
to	O
veterinarians	O
and	O
the	O
skills	O
they	O
bring	O
to	O
bear	O
in	O
fighting	O
current	O
outbreaks	O
and	O
preventing	O
future	O
outbreaks	O
of	O
these	O
diseases	O
,	O
such	O
as	O
SARS	O
,	O
Ebola	O
,	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
and	O
even	O
HIV	O
/	O
AIDS	O
.	O

However	O
,	O
the	O
pathophysiological	O
significance	O
of	O
the	O
anti	O
-	O
N	O
antibodies	O
in	O
SARS	O
pathogenesis	B-PROC
is	O
largely	O
unknown	O
.	O

Of	O
the	O
travel	O
-	O
associated	O
systemic	O
infections	O
presenting	O
with	O
fever	B-PROC
,	O
diarrhea	O
occurs	O
in	O
patients	O
with	O
malaria	O
,	O
dengue	O
fever	B-PROC
and	O
SARS	O
.	O

TITLE	O
:	O
Intestinal	O
circulation	B-PROC
,	O
oxygenation	B-PROC
and	O
metabolism	B-PROC
is	O
not	O
affected	O
by	O
oleic	O
acid	O
lung	O
injury	O
.	O

ELISA	O
,	O
Western	O
-	O
blotting	O
and	O
neutralization	O
assay	O
detected	O
specific	O
antibody	B-PROC
against	O
SARS	O
coronavirus	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
one	O
-	O
step	O
,	O
real	O
-	O
time	O
,	O
quantitative	O
reverse	O
transcriptase	B-PROC
PCR	O
assays	O
for	O
absolute	O
quantitation	O
of	O
human	O
coronaviruses	O
OC43	O
and	O
229E	O
.	O

Only	O
GST	O
tagged	O
RBD	O
was	O
soluble	O
expressed	B-PROC
in	O
BL21	O
(	O
DE3	O
),	O
and	O
the	O
protein	O
was	O
purified	O
by	O
AKTA	O
Prime	O
Chromatography	O
system	O
.	O

The	O
ELISA	O
data	O
showed	O
that	O
GST	O
/	O
RBD	O
antigen	O
had	O
positive	O
reaction	O
with	O
anti	O
-	O
RBD	O
mouse	O
monoclonal	O
antibody	B-PROC
1A5	O
.	O

The	O
case	O
fatality	O
rate	O
of	O
SARS	O
in	O
Beijing	O
was	O
7	O
.	O
66	O
%,	O
and	O
had	O
an	O
ascending	O
trend	O
while	O
the	O
age	O
of	O
cases	O
was	O
getting	O
older	O
,	O
and	O
a	O
descending	O
trend	O
while	O
the	O
epidemic	O
development	B-PROC
.	O

The	O
risk	O
of	O
death	B-PROC
increases	O
with	O
the	O
increment	O
of	O
age	O
of	O
SARS	O
patients	O
.	O

There	O
was	O
no	O
difference	O
in	O
time	O
to	O
seroconversion	O
between	O
the	O
patients	O
who	O
survived	O
(	O
n	O
=	O
14	O
)	O
and	O
those	O
who	O
died	B-PROC
(	O
n	O
=	O
6	O
).	O

ABSTRACT	O
:	O
We	O
applied	O
artificial	O
neural	O
networks	O
(	O
ANN	O
)	O
for	O
the	O
prediction	O
of	O
targets	O
of	O
immune	B-PROC
responses	I-PROC
that	O
are	O
useful	O
for	O
study	O
of	O
vaccine	O
formulations	O
against	O
viral	B-PROC
infections	I-PROC
.	O

ABSTRACT	O
:	O
Pyrrolobenzoxazepinones	O
(	O
PBOs	O
)	O
represent	O
a	O
new	O
class	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
nonnucleoside	O
reverse	O
transcriptase	B-PROC
(	O
RT	O
)	O
inhibitors	O
(	O
NNRTIs	O
)	O
whose	O
prototype	O
is	O
5	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
relationship	O
between	O
antimicrobial	O
resistance	B-PROC
and	O
antimicrobial	O
use	O
in	O
a	O
university	O
hospital	O
in	O
Taiwan	O
.	O

Increasing	O
trends	O
of	O
incidences	O
of	O
several	O
of	O
these	O
bacteria	O
causing	O
all	O
nosocomial	O
infections	O
or	O
nosocomial	O
bloodstream	B-PROC
infections	O
were	O
noted	O
from	O
1991	O
to	O
2003	O
.	O

TITLE	O
:	O
Effect	O
of	O
mutations	O
in	O
the	O
mouse	O
hepatitis	O
virus	O
3	O
'(+)	O
42	O
protein	O
binding	O
element	O
on	O
RNA	B-PROC
replication	I-PROC
.	O

Additionally	O
we	O
have	O
identified	O
a	O
role	O
for	O
the	O
3	O
'-	O
terminal	O
42	O
-	O
nucleotide	O
host	O
protein	O
binding	O
element	O
in	O
RNA	B-PROC
replication	I-PROC
and	O
transcription	B-PROC
using	O
DI	O
RNA	B-PROC
replication	I-PROC
assays	O
and	O
targeted	B-PROC
recombination	B-PROC
and	O
by	O
directly	O
constructing	O
mutants	O
in	O
this	O
protein	O
binding	O
element	O
using	O
a	O
recently	O
described	O
MHV	O
reverse	O
genetic	O
system	O
.	O

We	O
studied	O
host	O
-	O
pathogen	O
interactions	O
using	O
native	O
lung	O
tissue	O
and	O
a	O
model	O
of	O
well	O
-	O
differentiated	B-PROC
cultures	O
of	O
primary	O
human	O
airway	O
epithelia	O
.	O

To	O
determine	O
the	O
significance	O
of	O
the	O
SARS	O
-	O
CoV	O
group	O
-	O
specific	O
ORFs	O
in	O
virus	B-PROC
replication	I-PROC
in	O
vitro	O
and	O
in	O
mice	O
,	O
we	O
systematically	O
deleted	O
five	O
of	O
the	O
eight	O
group	O
-	O
specific	O
ORFs	O
,	O
ORF3a	O
,	O
OF3b	O
,	O
ORF6	O
,	O
ORF7a	O
,	O
and	O
ORF7b	O
,	O
and	O
characterized	O
recombinant	O
virus	B-PROC
replication	I-PROC
and	O
gene	B-PROC
expression	I-PROC
in	O
vitro	O
.	O

These	O
data	O
suggest	O
that	O
ORF3a	O
plays	O
little	O
role	O
in	O
the	O
targeting	B-PROC
of	O
S	O
localization	B-PROC
in	O
the	O
rER	O
/	O
Golgi	O
apparatus	O
.	O

In	O
order	O
to	O
produce	O
a	O
large	O
amount	O
of	O
ScFv	O
H12	O
,	O
pET28a	O
-	O
H12	O
expression	B-PROC
vector	O
was	O
constructed	O
and	O
ScFv	O
H12	O
was	O
expressed	B-PROC
at	O
yield	O
about	O
30	O
%	O
of	O
total	O
proteins	O
in	O
E	O
.	O
coli	O
.	O

Although	O
the	O
SARS	O
outbreak	O
lasted	O
less	O
than	O
1	O
year	O
,	O
it	O
resulted	O
in	O
significant	O
morbidity	O
and	O
mortality	O
and	O
impacted	O
nursing	B-PROC
practices	O
.	O

He	O
also	O
explores	O
monotherapy	O
versus	O
combination	O
therapy	O
,	O
the	O
efficacy	O
of	O
rapid	O
initiation	O
of	O
treatment	O
,	O
and	O
short	O
-	O
course	O
therapy	O
as	O
a	O
hedge	O
against	O
antimicrobial	O
resistance	B-PROC
.	O

We	O
also	O
obtained	O
an	O
estimate	O
of	O
the	O
basic	O
reproductive	B-PROC
number	O
for	O
influenza	O
in	O
a	O
commercial	O
airliner	O
:	O
the	O
median	O
value	O
is	O
10	O
.	O
4	O
.	O

These	O
studies	O
demonstrate	O
that	O
progenitor	O
cell	O
-	O
mediated	O
remyelination	B-PROC
is	O
not	O
the	O
result	O
of	O
modulating	O
the	O
composition	O
of	O
the	O
cellular	O
infiltrate	O
nor	O
cytokine	O
expression	B-PROC
by	O
virus	O
-	O
specific	O
T	O
cells	O
and	O
suggest	O
that	O
remyelination	B-PROC
may	O
not	O
depend	O
on	O
amelioration	O
of	O
the	O
inflammatory	B-PROC
response	I-PROC
or	O
alteration	O
of	O
cytokine	B-PROC
secretion	I-PROC
by	O
virus	O
-	O
specific	O
T	O
cells	O
.	O

TITLE	O
:	O
Subcellular	O
localization	B-PROC
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
is	O
a	O
viral	O
RNA	O
-	O
binding	O
protein	O
with	O
multiple	O
functions	O
in	O
terms	O
of	O
virus	B-PROC
replication	I-PROC
and	O
modulating	O
cell	O
signalling	B-PROC
pathways	B-PROC
.	O

Retrospective	O
analysis	O
in	O
eight	O
patients	O
with	O
severe	O
lung	O
failure	O
requiring	O
interhospital	O
transport	B-PROC
,	O
in	O
whom	O
implementation	O
of	O
an	O
iLA	O
system	O
at	O
a	O
tertiary	O
hospital	O
for	O
air	O
/	O
ground	O
transportation	O
was	O
performed	O
.	O

Here	O
,	O
we	O
characterized	O
temporal	O
changes	O
in	O
N	O
protein	O
-	O
specific	O
and	O
S	O
glycoprotein	O
-	O
specific	O
neutralizing	O
antibody	B-PROC
(	O
Nab	O
)	O
responses	O
in	O
infected	O
patients	O
who	O
have	O
either	O
recovered	O
from	O
or	O
succumbed	O
to	O
SARS	O
-	O
CoV	O
infection	O
.	O

Previously	O
,	O
the	O
differences	O
between	O
virulent	O
field	O
PEDV	O
strains	O
and	O
a	O
Vero	O
cell	O
culture	O
adapted	O
PEDV	O
DR13	O
strain	O
were	O
determined	O
using	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
analysis	O
(	O
RFLP	O
),	O
and	O
PEDV	O
shedding	O
patterns	O
in	O
pigs	O
were	O
reported	O
.	O

PEDV	O
shedding	O
was	O
monitored	O
every	O
day	O
and	O
virus	O
levels	O
were	O
measured	O
using	O
a	O
quantitative	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
method	O
.	O

TITLE	O
:	O
Age	O
-	O
and	O
gender	O
-	O
related	O
difference	O
of	O
ACE2	O
expression	B-PROC
in	O
rat	O
lung	O
.	O

Radiographic	O
scores	O
correlated	O
with	O
the	O
ratio	O
of	O
PaO2	O
to	O
the	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
,	O
lymphocyte	O
count	O
,	O
lactate	O
dehydrogenase	O
level	O
,	O
and	O
neutrophil	O
count	O
at	O
each	O
milestone	O
and	O
in	O
terms	O
of	O
changes	O
between	O
milestones	O
(	O
P	O
<	O
.	O
01	O
for	O
all	O
correlation	O
coefficients	O
,	O
except	O
for	O
radiographic	O
score	O
and	O
neutrophil	O
count	O
between	O
the	O
first	O
two	O
milestones	O
).	O

However	O
,	O
it	O
is	O
now	O
clear	O
that	O
endemic	O
diseases	O
as	O
well	O
as	O
newly	O
emerging	O
ones	O
(	O
e	O
.	O
g	O
.,	O
severe	O
acute	O
respiratory	O
syndrome	O
[	O
SARS	O
]),	O
reemerging	O
ones	O
(	O
e	O
.	O
g	O
.,	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
),	O
and	O
even	O
deliberately	O
disseminated	O
infectious	O
diseases	O
(	O
e	O
.	O
g	O
.,	O
anthrax	O
from	O
bioterrorism	O
)	O
continue	O
to	O
pose	O
a	O
substantial	O
threat	O
throughout	O
the	O
world	O
.	O

Apparently	O
,	O
their	O
HE	O
genes	O
were	O
inactivated	O
during	O
cell	O
culture	O
adaptation	B-PROC
.	O

Yet	O
the	O
expression	B-PROC
of	O
HE	O
was	O
rapidly	O
lost	O
during	O
serial	O
cell	O
culture	O
passaging	O
.	O

However	O
,	O
in	O
combination	O
with	O
JHM	O
S	O
,	O
the	O
expression	B-PROC
of	O
HE	O
,	O
regardless	O
of	O
whether	O
it	O
retained	O
esterase	O
activity	O
or	O
not	O
,	O
resulted	O
in	O
increased	O
viral	O
spread	O
within	O
the	O
central	O
nervous	O
system	O
and	O
in	O
increased	O
neurovirulence	O
.	O

We	O
found	O
that	O
PLpro	O
recognizes	O
the	O
consensus	O
cleavage	B-PROC
sequence	O
LXGG	O
,	O
which	O
is	O
also	O
the	O
consensus	O
sequence	O
recognized	O
by	O
cellular	O
deubiquitinating	B-PROC
enzymes	O
.	O

The	O
N	O
-	O
terminal	O
part	O
of	O
this	O
cellular	O
receptor	O
(	O
soR	O
)	O
is	O
sufficient	O
for	O
S	O
binding	O
and	O
for	O
subsequent	O
induction	O
of	O
the	O
conformational	O
changes	O
required	O
for	O
virus	O
-	O
cell	O
membrane	B-PROC
fusion	I-PROC
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
of	O
human	O
ciliated	O
airway	O
epithelia	O
:	O
role	O
of	O
ciliated	O
cells	O
in	O
viral	O
spread	O
in	O
the	O
conducting	B-PROC
airways	O
of	O
the	O
lungs	O
.	O

Infection	O
was	O
highly	O
cytolytic	O
,	O
as	O
infected	O
ciliated	O
cells	O
were	O
necrotic	B-PROC
and	O
shed	O
over	O
time	O
onto	O
the	O
luminal	O
surface	O
of	O
the	O
epithelium	O
.	O

However	O
,	O
a	O
real	O
-	O
time	O
-	O
imaging	O
analysis	O
of	O
Simian	O
virus	O
40	O
(	O
SV40	O
)	O
'	O
s	O
entry	O
in	O
cells	O
has	O
indicated	O
the	O
existence	O
of	O
caveolar	O
endocytosis	B-PROC
during	O
virus	O
entry	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
devastating	O
disease	O
process	O
characterized	O
by	O
severe	O
acute	O
lung	O
injury	O
,	O
inflammatory	O
cell	O
recruitment	O
to	O
the	O
lung	O
,	O
upregulation	B-PROC
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
increased	O
oxidative	O
stress	O
.	O

Using	O
reciprocal	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
to	O
generate	O
HO	O
-	O
1	O
-	O
chimeric	O
mice	O
,	O
we	O
found	O
that	O
absence	O
of	O
HO	O
-	O
1	O
in	O
the	O
lung	O
parenchyma	O
,	O
not	O
in	O
bone	O
marrow	O
-	O
derived	O
inflammatory	O
cells	O
,	O
was	O
responsible	O
for	O
enhanced	O
SP	O
-	O
B	O
downregulation	B-PROC
and	O
severe	O
physiologic	O
lung	O
dysfunction	O
.	O

These	O
findings	O
suggest	O
a	O
possible	O
role	O
of	O
S	O
and	O
S2	O
protein	O
in	O
SARS	O
-	O
CoV	O
induced	O
apoptosis	B-PROC
and	O
the	O
molecular	O
pathogenesis	B-PROC
of	O
SARS	O
.	O

Further	O
studies	O
by	O
immunoblot	O
and	O
confocal	O
microscopy	O
analyses	O
revealed	O
the	O
expression	B-PROC
and	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
localization	B-PROC
of	O
the	O
recombinant	O
SARS	O
6	O
protein	O
in	O
mammalian	O
cells	O
.	O

Expression	B-PROC
of	O
SARS	O
6	O
protein	O
in	O
mammalian	O
cells	O
elicits	O
biological	O
activity	O
of	O
stimulating	O
cellular	O
DNA	B-PROC
synthesis	I-PROC
.	O

In	O
addition	O
,	O
other	O
anti	O
-	O
viral	O
treatment	O
,	O
RNA	B-PROC
interference	I-PROC
,	O
monoclonal	O
antibody	B-PROC
,	O
synthetic	O
peptides	O
,	O
and	O
vaccines	O
are	O
being	O
developed	O
.	O

Diffuse	O
spasticity	O
,	O
dementia	O
,	O
vegetative	O
state	O
,	O
or	O
death	B-PROC
ensues	O
.	O

Some	O
aspects	O
of	O
the	O
epidemiology	O
and	O
clinical	O
manifestations	O
of	O
feline	O
infectious	O
peritonitis	O
appear	O
different	O
to	O
the	O
disease	O
encountered	O
in	O
Europe	O
and	O
North	O
America	O
,	O
most	O
notably	O
the	O
over	O
-	O
representation	O
of	O
specific	O
breeds	B-PROC
and	O
the	O
presence	O
of	O
immune	O
-	O
mediated	O
haemolytic	O
anaemia	O
.	O

Pooled	O
tissue	O
samples	O
(	O
trachea	O
,	O
kidney	O
,	O
caecal	O
tonsils	O
and	O
cloacal	O
swabs	O
)	O
from	O
164	O
broiler	O
and	O
53	O
layer	O
flocks	O
located	O
throughout	O
New	O
Zealand	O
were	O
collected	O
in	O
transport	B-PROC
medium	O
containing	O
antibiotics	O
.	O

TITLE	O
:	O
Neutralizing	O
antibody	B-PROC
response	I-PROC
and	O
SARS	O
severity	O
.	O

ABSTRACT	O
:	O
Using	O
the	O
Taiwan	O
nationwide	O
laboratory	O
-	O
confirmed	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
database	O
,	O
we	O
analyzed	O
neutralizing	O
antibody	B-PROC
in	O
relation	O
to	O
clinical	O
outcomes	O
.	O

the	O
rapid	O
development	B-PROC
of	O
multiorgan	O
failure	O
following	O
the	O
above	O
-	O
mentioned	O
identifiable	O
precipitating	O
factors	O
,	O
the	O
involvement	O
of	O
unusual	O
organs	O
such	O
as	O
bowel	O
,	O
reproductive	B-PROC
organs	O
,	O
and	O
bone	O
marrow	O
,	O
complicating	O
features	O
of	O
disseminated	O
intravascular	O
coagulation	B-PROC
in	O
20	O
%	O
of	O
cases	O
,	O
the	O
acute	O
(	O
adult	O
)	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
one	O
third	O
of	O
patients	O
,	O
and	O
severe	O
thrombocytopenia	O
;	O
these	O
not	O
being	O
encountered	O
in	O
the	O
simple	O
/	O
classic	O
APS	O
.	O

These	O
results	O
show	O
that	O
respiratory	O
virus	B-PROC
infection	I-PROC
-	O
particularly	O
influenza	O
virus	B-PROC
infection	I-PROC
during	O
epidemic	O
periods	B-PROC
-	O
is	O
common	O
among	O
patients	O
hospitalized	O
for	O
acute	O
cardiorespiratory	O
failure	O
.	O

This	O
study	O
describes	O
the	O
first	O
example	O
of	O
inhibitors	O
targeting	B-PROC
the	O
dimeric	O
interface	O
of	O
SARS	O
3CL	O
proteinase	B-PROC
,	O
providing	O
a	O
novel	O
strategy	O
for	O
drug	O
design	O
against	O
SARS	O
and	O
other	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Autocleavage	O
assay	O
and	O
peptide	O
-	O
based	O
cleavage	B-PROC
assay	O
were	O
used	O
to	O
study	O
the	O
substrate	O
specificity	O
of	O
3CL	O
protease	O
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

The	O
deletion	O
of	O
either	O
P4	O
or	O
P2	O
'	O
residue	O
in	O
the	O
substrate	O
would	O
decrease	O
its	O
cleavage	B-PROC
efficiency	O
dramatically	O
.	O

Crosslinking	O
studies	O
demonstrate	O
the	O
formation	B-PROC
of	O
dimers	O
,	O
tetramers	O
,	O
and	O
higher	O
multimers	O
of	O
IBV	O
-	O
N	O
.	O
A	O
model	O
for	O
coronavirus	O
shell	O
formation	B-PROC
is	O
proposed	O
in	O
which	O
dimerization	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
IBV	O
-	O
N	O
leads	O
to	O
oligomerization	O
of	O
the	O
IBV	O
-	O
nucleocapsid	O
protein	O
and	O
viral	O
RNA	O
condensation	O
.	O

Here	O
we	O
show	O
that	O
SARS	O
-	O
CoV	O
,	O
but	O
not	O
HCoV	O
-	O
NL63	O
,	O
utilizes	O
the	O
enzymatic	B-PROC
activity	I-PROC
of	O
the	O
cysteine	O
protease	O
cathepsin	O
L	O
to	O
infect	O
ACE2	O
-	O
expressing	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
replicase	O
-	O
transcriptase	B-PROC
complex	O
is	O
an	O
assembly	O
of	O
viral	O
and	O
cellular	O
proteins	O
that	O
mediate	O
the	O
synthesis	B-PROC
of	O
genome	O
and	O
subgenome	O
-	O
sized	O
mRNAs	O
in	O
the	O
virus	O
-	O
infected	O
cell	O
.	O

Finally	O
,	O
our	O
analysis	O
of	O
viral	O
RNA	B-PROC
synthesis	I-PROC
in	O
ts	O
mutant	O
virus	O
-	O
infected	O
cells	O
allows	O
us	O
to	O
discriminate	O
three	O
phenotypes	O
with	O
regard	O
to	O
the	O
inability	O
of	O
specific	O
mutants	O
to	O
synthesize	O
viral	O
RNA	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
.	O

Doxorubicin	O
induced	O
apoptosis	B-PROC
of	O
human	O
hepatocellular	O
carcinoma	O
(	O
HepG2	O
)	O
was	O
studied	O
using	O
the	O
integrated	O
microfluidic	O
device	O
with	O
concentration	O
generator	O
.	O

We	O
found	O
that	O
caspase	B-PROC
-	I-PROC
9	I-PROC
activity	I-PROC
was	O
12	O
-	O
fold	O
higher	O
in	O
virus	O
-	O
infected	O
cells	O
than	O
in	O
mock	O
-	O
infected	O
cells	O
at	O
24	O
h	O
postinfection	O
(	O
p	O
.	O
i	O
.).	O

The	O
objective	O
of	O
the	O
experiment	O
was	O
to	O
evaluate	O
effects	O
of	O
increased	O
milk	O
replacer	O
feeding	O
on	O
growth	B-PROC
,	O
intake	O
,	O
feed	O
efficiency	O
,	O
and	O
health	O
parameters	O
in	O
stressed	O
calves	O
.	O

Using	O
consensus	O
fold	O
recognition	O
with	O
the	O
3D	O
-	O
JURY	O
meta	O
-	O
predictor	O
followed	O
by	O
model	O
building	O
and	O
refinement	O
,	O
we	O
developed	O
a	O
structural	O
model	O
for	O
the	O
single	O
PLpro	O
present	O
in	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SCoV	O
)	O
genome	O
,	O
based	O
on	O
significant	O
structural	O
relationships	O
to	O
the	O
catalytic	O
core	O
domain	O
of	O
HAUSP	O
,	O
a	O
ubiquitin	B-PROC
-	O
specific	O
protease	O
(	O
USP	O
).	O

However	O
,	O
it	O
is	O
presently	O
unknown	O
whether	O
the	O
amount	O
of	O
transfused	O
blood	O
is	O
independently	O
associated	O
with	O
development	B-PROC
of	O
ARDS	O
in	O
patients	O
with	O
severe	O
trauma	O
.	O

The	O
association	O
between	O
the	O
amount	O
of	O
transfused	O
blood	O
and	O
the	O
development	B-PROC
of	O
ARDS	O
remained	O
significant	O
in	O
a	O
multivariable	O
logistic	O
regression	O
model	O
accounting	O
for	O
differences	O
in	O
severity	O
of	O
illness	O
,	O
type	O
of	O
trauma	O
,	O
race	O
,	O
gender	O
,	O
and	O
base	O
deficit	O
(	O
p	O
=	O
0	O
.	O
002	O
;	O
odds	O
ratio	O
,	O
14	O
.	O
4	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
3	O
.	O
2	O
-	O
78	O
.	O
7	O
).	O

We	O
have	O
had	O
many	O
lessons	O
and	O
learn	B-PROC
on	O
control	O
measures	O
,	O
public	O
health	O
,	O
economic	O
impacts	O
,	O
human	O
rights	O
,	O
international	O
cooperation	O
and	O
infectious	O
diseases	O
.	O

Recently	O
,	O
many	O
outbreaks	O
of	O
virus	O
zoonoses	O
are	O
reported	O
in	O
the	O
world	O
,	O
which	O
include	O
West	B-PROC
Nile	I-PROC
virus	B-PROC
disease	I-PROC
,	O
avian	O
influenza	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Patients	O
were	O
reported	O
in	O
29	O
countries	O
,	O
and	O
around	O
800	O
people	O
died	B-PROC
,	O
although	O
a	O
majority	O
of	O
these	O
cases	O
were	O
in	O
Asian	O
countries	O
.	O

The	O
simvastatin	O
and	O
control	O
groups	O
underwent	O
60	O
min	O
of	O
superior	O
mesenteric	O
artery	O
occlusion	B-PROC
and	O
90	O
min	O
of	O
reperfusion	O
.	O

Pathology	O
from	O
the	O
second	O
surgery	O
showed	O
transmural	O
ischemic	O
necrosis	B-PROC
with	O
angioinvasion	O
of	O
a	O
fungal	O
organism	O
.	O

She	O
was	O
discharged	O
to	O
a	O
nursing	B-PROC
home	O
without	O
evidence	O
of	O
recurrent	O
infection	O
.	O

After	O
adjustment	O
for	O
important	O
confounders	O
,	O
development	B-PROC
of	O
acute	O
lung	O
injury	O
was	O
associated	O
with	O
a	O
statistically	O
significant	O
increase	O
in	O
hospital	O
mortality	O
(	O
odds	O
ratio	O
,	O
1	O
.	O
63	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
03	O
-	O
2	O
.	O
57	O
).	O

TITLE	O
:	O
7a	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
inhibits	O
cellular	O
protein	B-PROC
synthesis	I-PROC
and	O
activates	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

TITLE	O
:	O
Time	O
course	O
and	O
cellular	B-PROC
localization	I-PROC
of	O
SARS	O
-	O
CoV	O
nucleoprotein	O
and	O
RNA	O
in	O
lungs	O
from	O
fatal	O
cases	O
of	O
SARS	O
.	O

Antibody	B-PROC
titers	O
were	O
measured	O
by	O
plaque	O
reduction	O
neutralization	O
test	O
.	O

The	O
purified	O
inactivated	O
SARS	O
vaccine	O
could	O
induce	O
high	O
levels	O
of	O
neutralizing	O
antibody	B-PROC
,	O
and	O
protect	O
the	O
monkeys	O
from	O
the	O
challenge	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
SARS	O
vaccine	O
prepared	O
in	O
the	O
study	O
appeared	O
to	O
be	O
safe	O
in	O
monkeys	O
.	O

There	O
were	O
no	O
biologically	O
significant	O
differences	O
between	O
control	O
and	O
vector	O
groups	O
for	O
complete	O
blood	O
count	O
,	O
serum	O
chemistry	O
,	O
and	O
neutralizing	O
anti	O
-	O
AAV2	O
antibody	B-PROC
levels	O
.	O

Importantly	O
,	O
no	O
abnormal	O
behavior	O
was	O
observed	O
in	O
any	O
group	O
in	O
videotaped	O
neurological	O
assessment	O
,	O
where	O
behaviors	B-PROC
were	O
quantified	O
before	O
administration	O
and	O
at	O
multiple	O
time	O
points	O
afterward	O
.	O

Cytokines	O
and	O
chemokines	O
that	O
best	O
predicted	O
the	O
combination	O
of	O
acid	O
and	O
small	O
gastric	O
particles	O
were	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
1	O
(	O
6	O
h	O
)	O
and	O
MCP	O
-	O
1	O
(	O
24	O
h	O
)	O
in	O
rats	O
,	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
/	O
macrophage	O
inflammatory	O
protein	O
2	O
(	O
5	O
h	O
)	O
and	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
/	O
MCP	O
-	O
1	O
(	O
24	O
h	O
)	O
in	O
wild	O
-	O
type	O
mice	O
,	O
and	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
/	O
macrophage	O
inflammatory	O
protein	O
2	O
(	O
5	O
h	O
)	O
and	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
/	O
keratinocyte	O
-	O
derived	O
cytokine	O
(	O
24	O
h	O
)	O
in	O
MCP	O
-	O
1	O
(-/-)	O
mice	O
.	O

Computer	O
tomography	O
observations	O
demonstrated	O
that	O
spontaneous	O
breathing	B-PROC
improves	O
gas	O
exchange	O
by	O
redistribution	O
of	O
ventilation	O
and	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
gas	O
to	O
dependent	O
,	O
juxtadiaphragmatic	O
lung	O
regions	O
and	O
thereby	O
promotes	O
alveolar	O
recruitment	O
.	O

Despite	O
this	O
,	O
healthcare	O
worker	O
awareness	O
of	O
clinical	O
syndromes	O
associated	O
with	O
respiratory	O
pathogens	O
that	O
require	O
airborne	O
precautions	O
,	O
combined	O
with	O
the	O
use	O
of	O
standard	O
precautions	O
for	O
all	O
patients	O
,	O
and	O
contact	O
/	O
droplet	O
precautions	O
for	O
patients	O
with	O
undifferentiated	O
febrile	B-PROC
respiratory	O
illness	O
should	O
be	O
effective	O
in	O
interrupting	O
the	O
transmission	O
of	O
respiratory	O
pathogens	O
within	O
the	O
intensive	O
care	O
unit	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
5	O
-	O
membered	O
iminocyclitol	O
derivative	O
was	O
found	O
to	O
be	O
a	O
potent	O
and	O
selective	O
inhibitor	O
of	O
the	O
glycoprotein	O
-	O
processing	O
alpha	O
-	O
glucosidase	O
with	O
a	O
Ki	O
value	O
of	O
53	O
nM	O
.	O
This	O
compound	O
was	O
further	O
derivatized	O
to	O
antiviral	O
agents	O
against	O
Japanese	O
encephalitis	O
virus	O
,	O
dengue	O
virus	O
serotype	O
2	O
(	O
DEN	O
-	O
2	O
),	O
human	O
SARS	O
coronavirus	O
,	O
and	O
human	O
beta	O
-	O
hexosaminidase	O
(	O
Ki	O
=	O
2	O
.	O
6	O
nM	O
),	O
a	O
new	O
target	O
for	O
the	O
development	B-PROC
of	O
osteoarthritis	O
therapeutics	O
.	O

The	O
concentrations	O
of	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
in	O
BALF	O
and	O
plasma	O
,	O
as	O
well	O
as	O
plasma	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
and	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
,	O
also	O
were	O
decreased	O
in	O
eNOS	O
-	O
Tg	O
mice	O
.	O

The	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
IL	O
-	O
10	O
and	O
transforming	O
growth	B-PROC
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
of	O
serum	O
and	O
BALF	O
were	O
measured	O
by	O
ELISA	O
.	O

Growth	B-PROC
in	O
suckling	O
-	O
mouse	O
brain	O
of	O
""""	O
IBV	O
-	O
like	O
""""	O
viruses	O
from	O
patients	O
with	O
upper	O
respiratory	O
tract	O
disease	O
.	O

The	O
surface	O
glycoprotein	O
is	O
a	O
major	O
virulence	B-PROC
factor	O
in	O
most	O
coronavirus	O
infections	O
.	O

TITLE	O
:	O
Bidirectional	O
virus	O
secretion	B-PROC
and	O
nonciliated	O
cell	O
tropism	B-PROC
following	O
Andes	O
virus	B-PROC
infection	I-PROC
of	O
primary	O
airway	O
epithelial	O
cell	O
cultures	O
.	O

Infection	O
is	O
usually	O
initiated	O
after	O
inhalation	B-PROC
of	O
rodent	O
excreta	O
containing	O
virus	O
particles	O
,	O
but	O
human	O
-	O
to	O
-	O
human	O
transmission	O
has	O
been	O
documented	O
.	O

Postmortem	O
tissue	O
samples	O
show	O
high	O
levels	O
of	O
viral	O
antigen	O
within	O
the	O
respiratory	O
endothelium	O
,	O
but	O
it	O
is	O
not	O
clear	O
how	O
the	O
virus	O
can	O
traverse	O
the	O
respiratory	O
epithelium	O
in	O
order	O
to	O
initiate	O
infection	O
in	O
the	O
microvasculature	B-PROC
.	O

Specific	O
alleviation	O
of	O
the	O
tropism	B-PROC
barrier	O
by	O
redirecting	O
MHV	O
to	O
a	O
tumor	O
-	O
specific	O
receptor	O
could	O
lead	O
to	O
a	O
virus	O
with	O
appealing	O
properties	O
for	O
tumor	O
therapy	O
.	O

To	O
demonstrate	O
that	O
MHV	O
can	O
be	O
retargeted	O
to	O
a	O
nonnative	O
receptor	O
on	O
human	O
cells	O
,	O
we	O
produced	O
bispecific	O
adapter	O
proteins	O
composed	O
of	O
the	O
N	O
-	O
terminal	O
D1	O
domain	O
of	O
mCEACAM1a	O
linked	O
to	O
a	O
short	O
targeting	B-PROC
peptide	O
,	O
the	O
six	O
-	O
amino	O
-	O
acid	O
His	O
tag	O
.	O

Our	O
results	O
show	O
that	O
MHV	O
can	O
be	O
genetically	O
redirected	O
via	O
adapters	O
composed	O
of	O
the	O
S	O
protein	O
binding	O
part	O
of	O
mCEACAM1a	O
and	O
a	O
targeting	B-PROC
peptide	O
recognizing	O
a	O
nonnative	O
receptor	O
expressed	B-PROC
on	O
human	O
cells	O
,	O
consequently	O
leading	O
to	O
rapid	O
cell	B-PROC
death	I-PROC
.	O

Both	O
S260	O
-	O
600	O
and	O
S397	O
-	O
796	O
exhibited	O
different	O
receptor	O
binding	B-PROC
activity	I-PROC
.	O

The	O
S260	O
-	O
600	O
fragment	O
probably	O
contains	O
the	O
important	O
receptor	O
binding	O
domain	O
and	O
could	O
be	O
a	O
potential	O
candidate	O
for	O
the	O
development	B-PROC
of	O
SARS	O
vaccine	O
and	O
anti	O
-	O
SARS	O
therapeutics	O
.	O

RESULTS	O
:	O
The	O
recombinant	O
proteins	O
S260	O
-	O
600	O
and	O
S397	O
-	O
796	O
were	O
efficiently	O
expressed	B-PROC
in	O
an	O
insoluble	O
form	O
in	O
E	O
.	O
coli	O
.	O

CONCLUSIONS	O
:	O
Both	O
S260	O
-	O
600	O
and	O
S397	O
-	O
796	O
exhibited	O
different	O
receptor	O
binding	B-PROC
activity	I-PROC
.	O

TITLE	O
:	O
Significant	O
redox	B-PROC
insensitivity	O
of	O
the	O
functions	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
glycoprotein	O
:	O
comparison	O
with	O
HIV	O
envelope	O
.	O

During	O
three	O
consecutive	O
winter	O
-	O
spring	O
seasons	O
,	O
49	O
symptomatic	O
lung	O
transplant	O
recipients	O
with	O
suspected	O
respiratory	O
viral	B-PROC
infection	I-PROC
,	O
and	O
26	O
asymptomatic	O
patients	O
were	O
investigated	O
for	O
presence	O
of	O
respiratory	O
viruses	O
either	O
in	O
56	O
nasopharyngeal	O
aspirate	O
or	O
72	O
bronchoalveolar	O
lavage	O
samples	O
taken	O
at	O
different	O
times	O
after	O
transplantation	O
.	O

Because	O
clinical	O
features	O
and	O
periods	B-PROC
of	O
activity	O
for	O
many	O
viruses	O
overlap	O
,	O
laboratory	O
confirmation	O
of	O
influenza	O
is	O
recommended	O
for	O
cases	O
involving	O
seriously	O
ill	O
or	O
institutionalized	O
patients	O
.	O

Antibodies	O
were	O
not	O
detected	O
within	O
the	O
first	O
7	O
days	O
of	O
illness	O
,	O
but	O
IgG	O
titre	O
increased	O
dramatically	O
on	O
day	O
15	O
,	O
reaching	B-PROC
a	O
peak	O
on	O
day	O
60	O
,	O
and	O
remained	O
high	O
until	O
day	O
180	O
from	O
when	O
it	O
declined	O
gradually	O
until	O
day	O
720	O
.	O

Immunoglobulin	B-PROC
kappa	O
light	O
chain	O
(	O
m	O
/	O
z	O
24	O
505	O
)	O
positively	O
correlated	O
with	O
viral	O
load	O
.	O

However	O
,	O
vaccines	O
administered	O
by	O
this	O
route	O
are	O
subject	O
to	O
proteolysis	B-PROC
in	O
the	O
gastrointestinal	O
tract	O
.	O

Expression	B-PROC
of	O
candidate	O
vaccine	O
antigens	O
in	O
edible	O
recombinant	O
plant	O
material	O
offers	O
an	O
inexpensive	O
means	O
to	O
deliver	O
large	O
doses	O
of	O
vaccines	O
in	O
encapsulated	O
forms	O
.	O

Certain	O
plant	O
tissues	O
can	O
also	O
stably	O
store	O
antigens	O
for	O
extensive	O
periods	B-PROC
of	O
time	O
at	O
ambient	O
temperatures	O
,	O
obviating	O
the	O
need	O
for	O
a	O
cold	B-PROC
-	O
chain	O
during	O
vaccine	O
storage	B-PROC
and	O
distribution	O
,	O
and	O
so	O
further	O
limiting	O
costs	O
.	O

Antigens	O
can	O
be	O
expressed	B-PROC
from	O
transgenes	O
stably	O
incorporated	O
into	O
a	O
host	O
plant	O
'	O
s	O
nuclear	O
or	O
plastid	O
genome	O
,	O
or	O
from	O
engineered	O
plant	O
viruses	O
infected	O
into	O
plant	O
tissues	O
.	O

Fusions	O
to	O
carrier	O
molecules	O
can	O
stabilize	O
the	O
expressed	B-PROC
antigen	O
,	O
aid	O
in	O
antigen	O
enrichment	O
or	O
purification	O
strategies	O
,	O
and	O
facilitate	O
delivery	O
to	O
effector	O
sites	O
in	O
the	O
gastrointestinal	O
tract	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
inhibits	O
the	O
activity	O
of	O
cyclin	O
-	O
cyclin	O
-	O
dependent	O
kinase	O
complex	O
and	O
blocks	O
S	B-PROC
phase	I-PROC
progression	O
in	O
mammalian	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
prove	O
that	O
the	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
can	O
inhibit	O
S	B-PROC
phase	I-PROC
progression	O
in	O
mammalian	O
cell	O
lines	O
.	O

These	O
data	O
suggest	O
that	O
the	O
S	B-PROC
phase	I-PROC
inhibitory	O
activity	O
of	O
the	O
N	O
protein	O
may	O
have	O
major	O
significance	O
during	O
viral	O
pathogenesis	B-PROC
.	O

A	O
Risk	O
Analysis	O
Framework	O
is	O
presented	O
to	O
facilitate	O
the	O
rapid	O
integration	B-PROC
of	O
HCWs	O
'	O
experiences	O
into	O
practice	O
guidelines	O
.	O

No	O
hfgl2	O
expression	B-PROC
was	O
found	O
either	O
in	O
the	O
liver	O
tissue	O
or	O
in	O
the	O
PBMC	O
from	O
normal	O
donors	O
.	O

PCA	O
significantly	O
increased	O
in	O
PBMC	O
in	O
patients	O
with	O
severe	O
AOC	O
hepatitis	O
B	O
.	O
The	O
molecular	O
and	O
cellular	O
results	O
reported	O
here	O
in	O
both	O
mice	O
and	O
patients	O
with	O
severe	O
viral	O
hepatitis	O
suggest	O
that	O
virus	O
-	O
induced	O
hfgl2	O
prothrombinase	O
/	O
fibroleukin	O
expression	B-PROC
and	O
the	O
coagulation	B-PROC
activity	O
associated	O
with	O
the	O
encoded	O
fgl2	O
protein	O
play	O
a	O
pivotal	O
role	O
in	O
initiating	O
severe	O
hepatitis	O
.	O

PCA	O
significantly	O
increased	O
in	O
PBMC	O
in	O
patients	O
with	O
severe	O
AOC	O
hepatitis	O
B	O
.	O
CONCLUSIONS	O
:	O
The	O
molecular	O
and	O
cellular	O
results	O
reported	O
here	O
in	O
both	O
mice	O
and	O
patients	O
with	O
severe	O
viral	O
hepatitis	O
suggest	O
that	O
virus	O
-	O
induced	O
hfgl2	O
prothrombinase	O
/	O
fibroleukin	O
expression	B-PROC
and	O
the	O
coagulation	B-PROC
activity	O
associated	O
with	O
the	O
encoded	O
fgl2	O
protein	O
play	O
a	O
pivotal	O
role	O
in	O
initiating	O
severe	O
hepatitis	O
.	O

We	O
postulate	O
that	O
the	O
administration	O
of	O
the	O
innovative	O
TCM	O
may	O
have	O
beneficial	O
immunomodulatory	O
effects	O
for	O
preventing	O
viral	B-PROC
infections	I-PROC
including	O
SARS	O
.	O

These	O
results	O
provide	O
a	O
novel	O
idea	O
for	O
further	O
studying	O
the	O
pharmacology	O
of	O
TCM	O
and	O
exploring	O
the	O
mechanism	O
of	O
SARS	O
virus	B-PROC
infection	I-PROC
.	O

RESULTS	O
:	O
Presenting	O
symptoms	O
on	O
admission	O
included	O
fever	B-PROC
(	O
97	O
.	O
7	O
%	O
of	O
probable	O
cases	O
,	O
84	O
.	O
4	O
%	O
of	O
excluded	O
cases	O
),	O
chills	O
(	O
39	O
.	O
5	O
%	O
vs	O
18	O
.	O
8	O
%),	O
cough	O
with	O
sputum	B-PROC
production	I-PROC
(	O
16	O
.	O
3	O
%	O
vs	O
40	O
.	O
6	O
%),	O
dry	O
cough	O
(	O
23	O
.	O
3	O
%	O
vs	O
9	O
.	O
4	O
%),	O
dyspnea	O
(	O
18	O
.	O
6	O
%	O
vs	O
9	O
.	O
4	O
%),	O
diarrhea	O
(	O
14	O
.	O
0	O
%	O
vs	O
none	O
),	O
rhinorrhea	O
(	O
2	O
.	O
3	O
%	O
vs	O
none	O
),	O
and	O
myalgia	O
(	O
7	O
.	O
0	O
%	O
vs	O
6	O
.	O
6	O
%).	O

We	O
administered	O
a	O
survey	O
to	O
healthcare	O
workers	O
to	O
determine	O
risk	O
factors	O
associated	O
with	O
development	B-PROC
of	O
headaches	O
(	O
frequency	O
,	O
headache	O
subtypes	O
and	O
duration	O
of	O
face	O
-	O
mask	O
wear	O
)	O
and	O
the	O
impact	O
of	O
headaches	O
(	O
sick	O
days	O
,	O
headache	O
frequency	O
and	O
use	O
of	O
abortive	O
/	O
preventive	O
headache	O
medications	O
).	O

Multivariate	O
logistic	O
regression	O
showed	O
that	O
pre	O
-	O
existing	O
headaches	O
[	O
P	O
=	O
0	O
.	O
041	O
,	O
OR	O
=	O
1	O
.	O
97	O
(	O
95	O
%	O
CI	O
1	O
.	O
03	O
-	O
3	O
.	O
77	O
)]	O
and	O
continuous	O
use	O
of	O
the	O
N95	O
face	O
-	O
mask	O
exceeding	O
4	O
h	O
[	O
P	O
=	O
0	O
.	O
053	O
,	O
OR	O
=	O
1	O
.	O
85	O
(	O
95	O
%	O
CI	O
0	O
.	O
99	O
-	O
3	O
.	O
43	O
)]	O
were	O
associated	O
with	O
development	B-PROC
of	O
headaches	O
.	O

Multivariate	O
logistic	O
regression	O
showed	O
that	O
pre	O
-	O
existing	O
headaches	O
[	O
P	O
=	O
0	O
.	O
041	O
,	O
OR	O
=	O
1	O
.	O
97	O
(	O
95	O
%	O
CI	O
1	O
.	O
03	O
-	O
3	O
.	O
77	O
)]	O
and	O
continuous	O
use	O
of	O
the	O
N95	O
face	O
-	O
mask	O
exceeding	O
4	O
h	O
[	O
P	O
=	O
0	O
.	O
053	O
,	O
OR	O
=	O
1	O
.	O
85	O
(	O
95	O
%	O
CI	O
0	O
.	O
99	O
-	O
3	O
.	O
43	O
)]	O
were	O
associated	O
with	O
development	B-PROC
of	O
headaches	O
.	O

The	O
clinical	O
presentation	O
of	O
these	O
6	O
patients	O
was	O
as	O
follows	O
:	O
3	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
acute	O
enteric	O
disease	O
resulting	O
in	O
severe	O
dehydration	O
associated	O
with	O
upper	O
respiratory	O
symptoms	O
;	O
1	O
had	O
fever	B-PROC
,	O
otitis	O
,	O
and	O
febrile	B-PROC
seizure	O
;	O
1	O
had	O
a	O
sample	O
obtained	O
to	O
investigate	O
failure	O
to	O
thrive	O
;	O
and	O
1	O
had	O
a	O
sample	O
obtained	O
for	O
exploration	O
of	O
X	B-PROC
-	I-PROC
linked	I-PROC
agammaglobulinemia	O
and	O
hyperleucocytosis	O
.	O

TITLE	O
:	O
Typing	O
infectious	O
bronchitis	O
virus	O
strains	O
using	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
and	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
analysis	O
to	O
compare	O
the	O
3	O
'	O
7	O
.	O
5	O
kb	O
of	O
their	O
genomes	O
.	O

Thirty	O
four	O
patients	O
of	O
mean	O
age	O
14	O
.	O
7	O
years	O
completed	O
both	O
pulmonary	B-PROC
function	I-PROC
and	O
maximal	O
aerobic	O
capacity	O
tests	O
at	O
6	O
months	O
.	O

Absolute	O
and	O
mass	O
related	O
peak	O
V	O
o	O
(	O
2	O
)	O
in	O
the	O
patient	O
group	O
remained	O
impaired	O
at	O
15	O
months	O
despite	O
normalisation	O
of	O
lung	B-PROC
function	I-PROC
in	O
all	O
patients	O
.	O

The	O
key	O
intermediate	O
(+)-	O
12a	O
was	O
utilized	O
for	O
the	O
synthesis	B-PROC
of	O
unnatural	O
five	O
-	O
membered	O
ring	O
heterocyclic	O
carbocyclic	O
nucleosides	O
.	O

Recently	O
,	O
a	O
patient	O
who	O
inhaled	B-PROC
CHX	O
solution	O
died	B-PROC
from	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

SARS	O
-	O
CoV	O
infections	O
were	O
detected	O
by	O
using	O
enzyme	O
immunoassays	O
and	O
confirmed	O
by	O
a	O
combination	O
of	O
Western	O
blot	O
assays	O
,	O
neutralizing	O
antibody	B-PROC
tests	O
,	O
and	O
commercial	O
SARS	O
tests	O
.	O

TITLE	O
:	O
Functional	O
peptide	O
microarrays	O
for	O
specific	O
and	O
sensitive	O
antibody	B-PROC
diagnostics	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
phosphorylation	B-PROC
status	O
of	O
p90RSK	O
,	O
which	O
is	O
a	O
well	O
-	O
known	O
substrate	O
of	O
these	O
signaling	B-PROC
pathways	B-PROC
,	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

This	O
is	O
the	O
first	O
detailed	O
report	O
regarding	O
regulation	B-PROC
of	O
p90RSK	O
phosphorylation	B-PROC
by	O
virus	B-PROC
infection	I-PROC
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
virulent	O
viral	B-PROC
infection	I-PROC
that	O
affects	O
a	O
number	O
of	O
organs	O
and	O
systems	O
.	O

Epitopes	O
at	O
the	O
N	O
-	O
terminus	O
of	O
the	O
membrane	O
protein	O
and	O
the	O
C	O
-	O
terminus	O
of	O
nucleocapsid	O
protein	O
elicited	O
strong	O
antibody	B-PROC
responses	I-PROC
.	O

For	O
instance	O
,	O
extraordinary	O
shelf	O
life	O
and	O
a	O
chemical	O
stability	O
that	O
allows	O
convenient	O
fridge	O
storage	B-PROC
.	O

Both	O
pGL3	O
-	O
5	O
'	O
UTR	O
containing	O
full	O
sequence	O
and	O
pGL3	O
-	O
5	O
'	O
UTR	O
-	O
1	O
containing	O
three	O
stem	O
-	O
loops	O
of	O
3	O
'	O
termini	O
expressed	B-PROC
the	O
luciferase	O
well	O
.	O

Transfected	O
with	O
expression	B-PROC
luciferase	O
plasmid	O
pGL3	O
-	O
5	O
'	O
UTR	O
in	O
which	O
SARS	O
-	O
CoV	O
5	O
'	O
UTR	O
acts	O
as	O
the	O
promoter	O
,	O
the	O
luciferase	O
could	O
express	O
in	O
five	O
cell	O
lines	O
in	O
different	O
degrees	O
.	O

Ranked	O
by	O
the	O
luciferase	B-PROC
activity	I-PROC
from	O
the	O
highest	O
to	O
the	O
lowest	O
,	O
the	O
order	O
is	O
A549	O
,	O
HepG2	O
,	O
ECV304	O
,	O
HeLa	O
and	O
Vero	O
E6	O
.	O

In	O
this	O
report	O
we	O
examined	O
the	O
contribution	O
of	O
IFN	O
-	O
inducible	O
phosphorylation	B-PROC
-	O
activation	O
of	O
specific	O
signaling	B-PROC
effectors	O
to	O
protection	O
from	O
infection	O
by	O
a	O
SARS	O
-	O
related	O
murine	O
coronavirus	O
,	O
MHV	O
-	O
1	O
.	O

Finally	O
,	O
the	O
sera	O
of	O
vaccinated	O
mice	O
contained	O
antibodies	O
to	O
S	O
,	O
further	O
suggesting	O
a	O
role	O
for	O
this	O
protein	O
in	O
conferring	O
protective	O
immunity	B-PROC
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

Expression	B-PROC
and	O
characterization	O
of	O
a	O
range	O
of	O
bacterially	O
expressed	B-PROC
forms	O
of	O
this	O
enzyme	O
suggest	O
that	O
the	O
active	O
X	O
domain	O
comprises	O
pp1a	O
/	O
pp1ab	O
residues	O
Asp	O
(	O
1320	O
)-	O
Ser	O
(	O
1486	O
).	O

TITLE	O
:	O
Two	O
-	O
year	O
prospective	O
study	O
of	O
the	O
humoral	B-PROC
immune	I-PROC
response	I-PROC
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
In	O
a	O
cohort	O
study	O
of	O
56	O
convalescent	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
titers	O
of	O
immunoglobulin	B-PROC
G	O
(	O
IgG	O
)	O
antibodies	O
and	O
neutralizing	O
antibodies	O
(	O
NAbs	O
)	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
were	O
assessed	O
at	O
regular	O
intervals	O
(	O
at	O
1	O
,	O
4	O
,	O
7	O
,	O
10	O
,	O
16	O
,	O
and	O
24	O
months	O
after	O
the	O
onset	O
of	O
disease	O
)	O
by	O
use	O
of	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
neutralization	O
assay	O
.	O

The	O
CXC	O
chemokine	O
ligand	B-PROC
10	O
(	O
CXCL10	O
)	O
is	O
expressed	B-PROC
following	O
MHV	O
infection	O
and	O
signals	O
T	O
cells	O
to	O
migrate	O
into	O
the	O
CNS	O
.	O

Anti	O
-	O
CXCR3	O
treatment	O
during	O
chronic	O
disease	O
correlated	O
with	O
improved	O
motor	B-PROC
skills	I-PROC
and	O
reduced	O
demyelination	O
.	O

Toll	O
-	O
like	O
receptors	O
4	O
and	O
9	O
,	O
which	O
correlate	O
with	O
the	O
induction	O
of	O
inflammatory	B-PROC
response	I-PROC
,	O
were	O
upregulated	O
by	O
SARS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Balancing	B-PROC
infection	O
control	O
practices	O
and	O
family	O
-	O
centred	O
care	O
in	O
a	O
cohort	O
of	O
paediatric	O
suspected	O
severe	O
acute	O
respiratory	O
syndrome	O
patients	O
in	O
Hong	O
Kong	O
.	O

ABSTRACT	O
:	O
The	O
study	O
sought	O
to	O
identify	O
factors	O
involved	O
in	O
the	O
emergence	O
,	O
prevention	O
and	O
elimination	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
Hong	O
Kong	O
during	O
11	O
March	O
to	O
22	O
May	O
2003	O
.	O

Challenge	O
virus	O
was	O
rapidly	O
controlled	O
in	O
vaccinated	O
Ab	O
-	O
deficient	O
mice	O
coincident	O
with	O
accelerated	O
recruitment	O
of	O
memory	B-PROC
CD8	O
+	O
T	O
cells	O
and	O
enhanced	O
effector	O
function	O
compared	O
with	O
primary	O
CD8	O
+	O
T	O
cell	O
responses	O
.	O

Previous	O
influenza	O
pandemics	O
have	O
arrived	O
with	O
little	O
or	O
no	O
warning	O
,	O
but	O
the	O
current	O
widespread	O
circulation	B-PROC
of	O
H5N1	O
viruses	O
among	O
avian	O
populations	O
and	O
their	O
potential	O
for	O
increased	O
transmission	O
to	O
humans	O
and	O
other	O
mammalian	O
species	O
may	O
afford	O
us	O
an	O
unprecedented	O
opportunity	O
to	O
prepare	O
for	O
the	O
next	O
pandemic	O
threat	O
.	O

This	O
information	O
is	O
very	O
important	O
for	O
the	O
development	B-PROC
SARS	O
diagnostic	O
kits	O
and	O
a	O
vaccine	O
.	O

In	O
vivo	O
,	O
untreated	O
MHV	O
-	O
3	O
-	O
infected	O
mice	O
all	O
developed	O
clinical	O
and	O
biochemical	O
signs	O
of	O
acute	O
viral	O
hepatitis	O
and	O
died	B-PROC
by	O
day	O
4	O
post	O
infection	O
.	O

In	O
conclusion	O
,	O
targeted	B-PROC
delivery	O
of	O
ribavirin	O
to	O
the	O
liver	O
alters	O
the	O
course	O
of	O
MHV	O
-	O
3	O
infection	O
as	O
demonstrated	O
by	O
prolonged	O
survival	O
,	O
improved	O
behavior	O
,	O
and	O
reduced	O
signs	O
of	O
histologically	O
evident	O
disease	O
,	O
as	O
well	O
as	O
inhibition	B-PROC
of	O
viral	B-PROC
replication	I-PROC
and	O
production	O
of	O
inflammatory	O
cytokines	O
in	O
vitro	O
.	O

An	O
increased	O
concentration	O
of	O
NO	O
in	O
exhaled	B-PROC
air	O
has	O
been	O
reported	O
in	O
airway	O
diseases	O
,	O
characterized	O
by	O
airway	O
inflammation	O
,	O
such	O
as	O
bronchial	O
asthma	O
,	O
where	O
its	O
concentration	O
is	O
related	O
to	O
bronchial	O
hyperresponsiveness	O
and	O
sputum	O
eosinophilia	O
.	O

Clinical	O
application	O
of	O
exhaled	B-PROC
NO	O
measurement	O
include	O
monitoring	O
compliance	O
and	O
response	O
to	O
treatment	O
,	O
disease	O
activity	O
,	O
diagnosis	O
of	O
asthma	O
,	O
and	O
the	O
prediction	O
of	O
acute	O
exacerbations	O
.	O

A	O
truncated	O
version	O
of	O
S	O
glycoprotein	O
,	O
containing	O
only	O
the	O
ecto	O
-	O
domain	O
,	O
as	O
well	O
as	O
a	O
His	O
-	O
tagged	O
full	O
-	O
length	O
version	O
were	O
cloned	O
and	O
expressed	B-PROC
in	O
a	O
serum	O
-	O
free	O
insect	O
cell	O
line	O
,	O
ExpresSF	O
+.	O

HIV	O
-	O
1	O
promoted	O
frameshifting	O
was	O
also	O
compared	O
between	O
Escherichia	O
coli	O
and	O
a	O
human	O
T	O
-	O
cell	O
line	O
expression	B-PROC
systems	O
.	O

TITLE	O
:	O
The	O
relationship	O
between	O
the	O
feline	O
coronavirus	O
antibody	B-PROC
titre	O
and	O
the	O
age	O
,	O
breed	B-PROC
,	O
gender	O
and	O
health	O
status	O
of	O
Australian	O
cats	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
relationship	O
between	O
Feline	O
Coronavirus	O
(	O
FCoV	O
)	O
antibody	B-PROC
titres	O
and	O
age	O
,	O
breed	B-PROC
,	O
gender	O
and	O
health	O
status	O
of	O
Australian	O
cats	O
Retrospective	O
study	O
Results	O
from	O
two	O
serological	O
tests	O
that	O
measure	O
FCoV	O
antibody	B-PROC
levels	O
,	O
the	O
Coronase	O
test	O
and	O
the	O
7B	O
Feline	O
Infectious	O
Peritonitis	O
(	O
FIP	O
)	O
test	O
,	O
were	O
recorded	O
over	O
a	O
2	O
-	O
year	O
period	O
,	O
with	O
patient	O
signalment	O
,	O
history	O
,	O
presenting	O
complaint	O
and	O
the	O
reason	O
for	O
ordering	O
the	O
test	O
(	O
as	O
available	O
).	O

There	O
were	O
significant	O
differences	O
in	O
median	O
Coronase	O
antibody	B-PROC
titres	O
between	O
breeds	B-PROC
of	O
cats	O
(	O
P	O
<	O
0	O
.	O
0005	O
).	O

ABSTRACT	O
:	O
Rapid	O
differentiation	B-PROC
of	O
vaccine	O
strains	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
from	O
wild	O
type	O
strains	O
would	O
enhance	O
investigations	O
of	O
disease	O
outbreaks	O
.	O

This	O
study	O
aimed	O
to	O
develop	O
a	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
to	O
differentiate	O
between	O
Australian	O
vaccine	O
strains	O
of	O
IBV	O
and	O
field	O
isolates	O
.	O

Viral	O
suppression	B-PROC
and	O
clinical	O
improvement	O
was	O
achieved	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
expression	B-PROC
of	O
clones	O
with	O
six	O
,	O
seven	O
and	O
eight	O
Ts	O
,	O
respectively	O
,	O
showed	O
the	O
detection	O
of	O
the	O
full	O
-	O
length	O
3a	O
protein	O
.	O

Taken	O
together	O
,	O
this	O
study	O
identifies	O
the	O
hepta	O
-	O
and	O
octo	O
-	O
uridine	O
stretches	O
that	O
function	O
as	O
sole	O
elements	O
for	O
efficient	O
+	O
1	O
and	O
-	O
1	O
ribosomal	B-PROC
frameshift	I-PROC
events	O
.	O

In	O
in	O
vitro	O
study	O
,	O
we	O
showed	O
that	O
the	O
A549	O
and	O
THP	O
-	O
1	O
cell	O
lines	O
were	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
.	O
A549	O
cells	O
produced	O
CCL2	O
/	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP	O
-	O
1	O
)	O
and	O
CXCL8	O
/	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
after	O
interaction	O
with	O
SARS	O
-	O
CoV	O
and	O
expressed	B-PROC
P	O
-	O
selectin	B-PROC
and	O
VCAM	O
-	O
1	O
.	O

RESULTS	O
:	O
Serum	O
IgG	O
antibody	B-PROC
against	O
SARS	O
coronavirus	O
was	O
detected	O
in	O
all	O
the	O
19	O
SARS	O
patients	O
,	O
and	O
among	O
the	O
200	O
staff	O
members	O
,	O
20	O
(	O
10	O
%)	O
were	O
found	O
positive	O
for	O
the	O
antibody	B-PROC
but	O
with	O
no	O
obvious	O
or	O
only	O
mild	O
symptoms	O
.	O

To	O
examine	O
the	O
anti	O
-	O
viral	O
and	O
/	O
or	O
regulatory	O
role	O
of	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
signaling	B-PROC
in	O
the	O
cell	O
that	O
synthesizes	O
and	O
maintains	O
the	O
myelin	O
sheath	O
,	O
we	O
analyzed	O
JHMV	O
pathogenesis	B-PROC
in	O
transgenic	O
mice	O
expressing	O
a	O
dominant	O
-	O
negative	O
IFN	O
-	O
gamma	O
receptor	O
on	O
oligodendroglia	O
.	O

TITLE	O
:	O
Identification	O
of	O
critical	O
determinants	O
on	O
ACE2	O
for	O
SARS	O
-	O
CoV	O
entry	O
and	O
development	B-PROC
of	O
a	O
potent	O
entry	O
inhibitor	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	O
pathogenesis	B-PROC
in	O
the	O
central	O
nervous	O
system	O
is	O
independent	O
of	O
IL	O
-	O
15	O
and	O
natural	O
killer	O
cells	O
.	O

TITLE	O
:	O
Deciphering	O
the	O
biosynthetic	B-PROC
codes	O
for	O
the	O
potent	O
anti	O
-	O
SARS	O
-	O
CoV	O
cyclodepsipeptide	O
valinomycin	O
in	O
Streptomyces	O
tsusimaensis	O
ATCC	O
15141	O
.	O

Progress	O
has	O
been	O
made	O
in	O
development	B-PROC
of	O
possible	O
specific	O
interventions	O
for	O
influenza	O
and	O
possibly	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
but	O
effective	O
antivirals	O
and	O
vaccines	O
for	O
most	O
other	O
respiratory	O
viruses	O
are	O
currently	O
lacking	O
.	O

TITLE	O
:	O
A	O
human	O
neutralizing	O
antibody	B-PROC
against	O
a	O
conformational	O
epitope	O
shared	O
by	O
oligomeric	O
SARS	O
S1	O
protein	O
.	O

This	O
effect	O
on	O
the	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
activity	O
by	O
the	O
S	O
glycoprotein	O
is	O
not	O
,	O
however	O
,	O
reflected	O
in	O
the	O
infectivity	O
of	O
pseudotyped	O
lentiviruses	O
bearing	O
the	O
cleaved	O
glycoprotein	O
.	O

ABSTRACT	O
:	O
To	O
review	O
the	O
involvement	O
of	O
coagulation	B-PROC
and	O
fibrinolysis	B-PROC
in	O
the	O
pathogenesis	B-PROC
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
pulmonary	O
infection	O
,	O
and	O
ventilator	O
-	O
induced	O
lung	O
injury	O
(	O
VILI	O
).	O

The	O
mechanisms	O
that	O
contribute	O
to	O
disturbed	O
alveolar	O
fibrin	O
turnover	O
are	O
localized	O
tissue	O
factor	O
-	O
mediated	O
thrombin	O
generation	O
and	O
depression	O
of	O
bronchoalveolar	O
urokinase	O
plasminogen	O
activator	O
-	O
mediated	O
fibrinolysis	B-PROC
,	O
caused	O
by	O
the	O
increase	O
of	O
plasminogen	O
activator	O
inhibitors	O
.	O

Diagnostic	O
criteria	O
'	O
s	O
besides	O
anamnesis	B-PROC
was	O
detailed	O
neurological	O
exam	O
,	O
blood	O
tests	O
,	O
analysis	O
of	O
the	O
cerebrospinal	O
liquor	O
,	O
EMG	O
,	O
ECG	O
and	O
cardiac	O
tests	O
.	O

ABSTRACT	O
:	O
This	O
article	O
summarizes	O
key	O
aspects	O
of	O
progress	O
made	O
during	O
2004	O
toward	O
the	O
design	O
,	O
discovery	O
and	O
development	B-PROC
of	O
antiviral	O
agents	O
for	O
clinical	O
use	O
.	O

Important	O
developments	O
in	O
the	O
identification	O
,	O
characterization	O
and	O
clinical	O
utility	O
of	O
inhibitors	O
of	O
human	O
immunodeficiency	O
virus	O
;	O
the	O
hepatitis	O
viruses	O
,	O
hepatitis	O
B	O
,	O
hepatitis	O
C	O
;	O
the	O
herpes	O
family	O
of	O
viruses	O
,	O
herpes	O
simplex	O
viruses	O
1	O
and	O
2	O
,	O
varicella	O
zoster	O
virus	O
,	O
Epstein	O
-	O
Barr	O
virus	O
and	O
human	O
cytomegalovirus	O
;	O
the	O
respiratory	O
viruses	O
,	O
influenza	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
picornaviruses	O
,	O
measles	O
and	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
;	O
human	O
papilloma	O
virus	O
;	O
rotavirus	O
;	O
Ebola	O
virus	O
and	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
are	O
reviewed	O
.	O

The	O
correlation	O
of	O
preoperative	O
pulmonary	B-PROC
function	I-PROC
of	O
esophageal	O
cancer	O
to	O
postoperative	O
ARDS	O
has	O
seldom	O
been	O
reported	O
.	O

The	O
correlations	O
of	O
postoperative	O
ARDS	O
to	O
3	O
traditional	O
parameters	O
in	O
pulmonary	B-PROC
function	I-PROC
test	O
,	O
including	O
forced	B-PROC
expiratory	I-PROC
volume	I-PROC
in	O
the	O
first	O
one	O
second	O
(	O
FEV1	O
%),	O
the	O
ratio	O
of	O
FEV1	O
to	O
forced	B-PROC
vital	I-PROC
capacity	I-PROC
[(	O
FEV1	O
/	O
FVC	B-PROC
)%]	O
and	O
maximal	O
voluntary	O
ventilation	O
(	O
MVV	O
%),	O
and	O
other	O
factors	O
,	O
such	O
as	O
age	O
,	O
sex	O
,	O
operation	O
pattern	O
,	O
preoperative	O
cardiac	B-PROC
function	I-PROC
,	O
early	O
postoperative	O
intensive	O
care	O
,	O
were	O
analyzed	O
.	O

These	O
data	O
are	O
the	O
first	O
direct	O
measure	O
of	O
virus	O
-	O
cell	B-PROC
fusion	I-PROC
for	O
any	O
coronavirus	O
and	O
demonstrate	O
that	O
the	O
coronavirus	O
IBV	O
employs	O
a	O
direct	O
,	O
low	O
-	O
pH	O
-	O
dependent	O
virus	O
-	O
cell	B-PROC
fusion	I-PROC
activation	O
reaction	O
.	O

TITLE	O
:	O
Novel	O
bifunctional	O
quinolonyl	O
diketo	O
acid	O
derivatives	O
as	O
HIV	O
-	O
1	O
integrase	B-PROC
inhibitors	I-PROC
:	O
design	O
,	O
synthesis	B-PROC
,	O
biological	O
activities	O
,	O
and	O
mechanism	B-PROC
of	I-PROC
action	I-PROC
.	O

Oxygenation	B-PROC
improvement	O
,	O
carbon	O
dioxide	O
elimination	B-PROC
,	O
hemodynamic	B-PROC
variables	O
,	O
and	O
the	O
amount	O
of	O
vasopressor	O
substitution	O
were	O
reported	O
before	O
,	O
2	O
hrs	O
after	O
,	O
and	O
24	O
hrs	O
after	O
implementation	O
of	O
the	O
system	O
.	O

To	O
evaluate	O
the	O
molecular	O
mechanisms	O
behind	O
this	O
event	O
,	O
we	O
investigated	O
the	O
roles	O
of	O
SARS	O
-	O
CoV	O
proteins	O
in	O
regulation	B-PROC
of	O
the	O
proinflammatory	O
factor	O
,	O
cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
).	O

ABSTRACT	O
:	O
Replication	O
of	O
the	O
giant	O
RNA	O
genome	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
and	O
synthesis	B-PROC
of	O
as	O
many	O
as	O
eight	O
subgenomic	O
(	O
sg	O
)	O
mRNAs	O
are	O
mediated	O
by	O
a	O
viral	O
replicase	O
-	O
transcriptase	B-PROC
of	O
outstanding	O
complexity	O
that	O
includes	O
an	O
essential	O
endoribonuclease	O
activity	O
.	O

Characterization	O
of	O
human	O
CoV	O
229E	O
ExoN	O
active	O
-	O
site	O
mutants	O
revealed	O
severe	O
defects	O
in	O
viral	O
RNA	B-PROC
synthesis	I-PROC
,	O
and	O
no	O
viable	O
virus	O
could	O
be	O
recovered	O
.	O

The	O
development	B-PROC
of	O
an	O
ELISA	O
based	O
on	O
CRCoV	O
antigen	O
and	O
immunofluorescence	O
assay	O
are	O
described	O
here	O
.	O

Following	O
that	O
,	O
each	O
of	O
the	O
patient	O
'	O
s	O
other	O
organ	O
systems	O
at	O
risk	O
needs	O
to	O
be	O
addressed	O
:	O
Renal	O
/	O
metabolic	B-PROC
,	O
gastrointestinal	O
,	O
hematological	O
,	O
and	O
endocrine	O
.	O

RESULTS	O
:	O
Under	O
the	O
conditions	O
of	O
infection	O
dose	O
(	O
MOI	O
of	O
50	O
)	O
and	O
expression	B-PROC
time	O
(	O
48	O
h	O
),	O
the	O
high	O
-	O
level	O
expression	B-PROC
of	O
S	O
-	O
protein	O
was	O
obtained	O
.	O

TITLE	O
:	O
Nurses	O
'	O
perceptions	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
:	O
relationship	O
between	O
commitment	O
and	O
intention	O
to	O
leave	O
nursing	B-PROC
.	O

ABSTRACT	O
:	O
This	O
paper	O
reports	O
a	O
study	O
which	O
aimed	O
to	O
:	O
(	O
1	O
)	O
investigate	O
the	O
relationship	O
between	O
nurses	O
'	O
commitment	O
to	O
the	O
nursing	B-PROC
profession	O
and	O
organization	O
and	O
their	O
intention	O
to	O
leave	O
;	O
(	O
2	O
)	O
investigate	O
nurses	O
'	O
perceptions	O
of	O
the	O
possibility	O
of	O
acquiring	O
severe	O
acute	O
respiratory	O
syndrome	O
infection	O
and	O
its	O
moderation	O
of	O
their	O
commitment	O
to	O
the	O
nursing	B-PROC
profession	O
and	O
the	O
organization	O
and	O
their	O
consequent	O
intentions	O
to	O
leave	O
the	O
profession	O
and	O
the	O
organization	O
following	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
outbreak	O
.	O

The	O
high	O
risk	O
of	O
infection	O
and	O
death	B-PROC
associated	O
with	O
caring	O
for	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
had	O
a	O
great	O
impact	O
on	O
nurse	O
retention	B-PROC
in	O
hospitals	O
.	O

Perceived	O
risk	O
to	O
life	O
from	O
infection	O
has	O
a	O
possible	O
influence	O
on	O
the	O
commitment	O
/	O
intention	O
-	O
to	O
-	O
leave	O
model	O
in	O
hospital	O
nurses	O
caring	O
for	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
and	O
this	O
information	O
can	O
inform	O
hospital	O
and	O
nursing	B-PROC
managers	O
about	O
nurse	O
retention	B-PROC
following	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
outbreak	O
and	O
the	O
management	O
of	O
commitment	O
in	O
the	O
context	O
of	O
nursing	B-PROC
human	O
resources	O
management	O
.	O

Recently	O
,	O
SARS	O
-	O
CoV	O
has	O
been	O
demonstrated	O
to	O
induce	O
cell	O
apoptosis	B-PROC
in	O
Vero	O
-	O
E6	O
cells	O
.	O

Since	O
the	O
Hajj	O
is	O
dictated	O
by	O
the	O
lunar	O
calendar	O
,	O
which	O
is	O
shorter	O
than	O
the	O
Gregorian	O
calendar	O
,	O
it	O
presents	O
public	O
-	O
health	O
policy	O
planners	O
with	O
a	O
moving	B-PROC
target	O
,	O
demanding	O
constant	O
preparedness	O
.	O

The	O
molecular	B-PROC
dynamics	I-PROC
simulations	O
show	O
that	O
the	O
monomers	O
are	O
always	O
inactive	O
,	O
that	O
the	O
two	O
protomers	O
in	O
the	O
dimer	O
are	O
asymmetric	O
,	O
and	O
that	O
only	O
one	O
protomer	O
is	O
active	O
at	O
a	O
time	O
.	O

Expression	B-PROC
of	O
recombinant	O
human	O
ALX	O
in	O
A549	O
airway	O
epithelial	O
cells	O
uncovered	O
ALX	O
-	O
dependent	O
inhibition	B-PROC
of	O
cytokine	O
release	O
by	O
LXA	O
(	O
4	O
).	O

ABSTRACT	O
:	O
The	O
Vaccine	O
Research	O
Center	O
has	O
developed	O
a	O
number	O
of	O
vaccine	O
candidates	O
for	O
different	O
diseases	O
/	O
infectious	O
agents	O
(	O
HIV	O
-	O
1	O
,	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
virus	O
,	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
and	O
Ebola	O
virus	O
,	O
plus	O
a	O
plasmid	O
cytokine	O
adjuvant	O
-	O
IL	O
-	O
2	O
/	O
Ig	O
)	O
based	O
on	O
a	O
DNA	O
plasmid	O
vaccine	O
platform	O
.	O

The	O
compound	O
inhibited	O
an	O
epidemic	O
strain	O
of	O
WN	O
virus	O
without	O
detectable	O
cytotoxicity	O
(	O
a	O
50	O
%	O
effective	O
concentration	O
of	O
28	O
microM	O
and	O
a	O
compound	O
concentration	O
of	O
>	O
or	O
=	O
300	O
microM	O
required	O
to	O
reduce	O
50	O
%	O
cell	B-PROC
viability	I-PROC
).	O

Besides	O
WN	O
virus	O
,	O
the	O
compound	O
also	O
inhibited	O
other	O
flaviviruses	O
(	O
dengue	O
,	O
yellow	O
fever	B-PROC
,	O
and	O
St	O
.	O
Louis	O
encephalitis	O
viruses	O
),	O
an	O
alphavirus	O
(	O
Western	O
equine	O
encephalitis	O
virus	O
),	O
a	O
coronavirus	O
(	O
mouse	O
hepatitis	O
virus	O
),	O
and	O
a	O
rhabdovirus	O
(	O
vesicular	O
stomatitis	O
virus	O
).	O

ABSTRACT	O
:	O
Antithymocyte	O
globulin	O
(	O
ATG	O
)	O
has	O
been	O
shown	O
to	O
be	O
effective	O
as	O
a	O
pretreatment	O
immunosuppressive	O
agent	O
in	O
liver	O
transplantation	O
because	O
of	O
the	O
ability	O
to	O
wean	B-PROC
tacrolimus	O
monotherapy	O
after	O
4	O
months	O
in	O
pretreated	O
recipients	O
.	O

ABSTRACT	O
:	O
Induction	O
of	O
mucosal	B-PROC
immunity	I-PROC
may	O
be	O
important	O
for	O
preventing	O
SARS	O
-	O
CoV	O
infections	O
.	O

TITLE	O
:	O
Cell	B-PROC
cycle	I-PROC
perturbations	O
induced	O
by	O
infection	O
with	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
and	O
their	O
effect	O
on	O
virus	B-PROC
replication	I-PROC
.	O

We	O
have	O
shown	O
that	O
infection	O
of	O
asynchronously	O
replicating	O
and	O
synchronized	O
replicating	O
cells	O
with	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
a	O
positive	O
-	O
strand	O
RNA	O
virus	O
,	O
resulted	O
in	O
the	O
accumulation	O
of	O
infected	O
cells	O
in	O
the	O
G2	O
/	O
M	B-PROC
phase	I-PROC
of	O
the	O
cell	B-PROC
cycle	I-PROC
.	O

Our	O
data	O
suggested	O
that	O
IBV	O
induces	O
a	O
G2	O
/	O
M	B-PROC
phase	I-PROC
arrest	I-PROC
in	O
infected	O
cells	O
to	O
promote	O
favorable	O
conditions	O
for	O
viral	B-PROC
replication	I-PROC
.	O

Comparative	O
sequence	O
analysis	O
of	O
polyprotein	O
1a	O
of	O
equine	O
torovirus	O
(	O
EToV	O
)	O
strain	O
Berne	O
,	O
identified	O
a	O
serine	O
proteinase	B-PROC
domain	O
,	O
flanked	O
by	O
hydrophobic	O
regions	O
.	O

TGEV	O
does	O
not	O
contain	O
a	O
receptor	O
-	O
destroying	O
enzyme	O
and	O
does	O
not	O
depend	O
on	O
the	O
sialic	O
acid	O
binding	B-PROC
activity	I-PROC
for	O
infection	O
of	O
cultured	O
cells	O
.	O

They	O
come	O
in	O
a	O
large	O
variety	O
and	O
are	O
differentially	O
expressed	B-PROC
in	O
cells	O
and	O
tissues	O
.	O

TITLE	O
:	O
Analysis	O
of	O
genetic	B-PROC
mutations	I-PROC
in	O
the	O
7a7b	O
open	O
reading	O
frame	O
of	O
coronavirus	O
of	O
cheetahs	O
(	O
Acinonyx	O
jubatus	O
).	O

In	O
contrast	O
,	O
an	O
intact	O
7b	O
gene	O
may	O
be	O
necessary	O
for	O
in	O
vivo	O
virus	B-PROC
infection	I-PROC
and	O
replication	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	O
-	O
like	O
protease	O
:	O
structure	O
of	O
a	O
viral	O
deubiquitinating	B-PROC
enzyme	I-PROC
.	O

Direct	O
exposure	O
,	O
fever	B-PROC
on	O
the	O
first	O
day	O
of	O
illness	O
,	O
and	O
elevated	B-PROC
temperature	I-PROC
,	O
pulmonary	O
infiltrates	O
,	O
lymphopenia	O
and	O
thrombocytopenia	O
at	O
admission	O
were	O
associated	O
with	O
confirmed	O
cases	O
.	O

TITLE	O
:	O
Anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
immune	B-PROC
responses	I-PROC
:	O
the	O
role	O
played	O
by	O
V	O
gamma	O
9V	O
delta	O
2	O
T	O
cells	O
.	O

Analyses	O
of	O
T	O
cell	O
repertoires	O
in	O
health	O
care	O
workers	O
who	O
survived	O
SARS	O
-	O
CoV	O
infection	O
during	O
the	O
2003	O
outbreak	O
revealed	O
that	O
their	O
effector	O
memory	B-PROC
V	O
gamma	O
9V	O
delta	O
2	O
T	O
cell	O
populations	O
were	O
selectively	O
expanded	O
~	O
3	O
months	O
after	O
the	O
onset	O
of	O
disease	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
give	O
some	O
examples	O
of	O
the	O
employment	O
of	O
antisense	O
oligonucleotides	O
,	O
ribozymes	O
,	O
and	O
RNA	B-PROC
interference	I-PROC
strategies	O
for	O
antiviral	O
purposes	O
.	O

TITLE	O
:	O
Structure	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
receptor	O
-	O
binding	O
domain	O
complexed	O
with	O
neutralizing	O
antibody	B-PROC
.	O

By	O
mimicking	O
immune	B-PROC
responses	I-PROC
with	O
the	O
use	O
of	O
RBD	O
as	O
an	O
antigen	O
to	O
screen	O
a	O
large	O
human	O
antibody	B-PROC
library	O
derived	O
from	O
healthy	O
volunteers	O
,	O
we	O
identified	O
a	O
novel	O
potent	O
cross	B-PROC
-	I-PROC
reactive	I-PROC
SCV	O
-	O
neutralizing	O
monoclonal	O
antibody	B-PROC
,	O
m396	O
,	O
which	O
competes	O
with	O
ACE2	O
for	O
binding	O
to	O
RBD	O
,	O
and	O
determined	O
the	O
crystal	O
structure	O
of	O
the	O
RBD	O
-	O
antibody	B-PROC
complex	O
at	O
2	O
.	O
3	O
-	O
A	O
resolution	O
.	O

Inhaled	B-PROC
nitric	O
oxide	O
(	O
NO	O
)	O
dilates	O
pulmonary	O
blood	O
vessels	O
and	O
has	O
been	O
used	O
to	O
reduce	O
pulmonary	B-PROC
vascular	I-PROC
resistance	I-PROC
in	O
patients	O
with	O
chronic	O
thromboembolic	O
pulmonary	O
hypertension	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Each	O
received	O
inhaled	B-PROC
NO	O
(	O
20	O
-	O
25	O
ppm	O
)	O
via	O
the	O
inspiratory	B-PROC
side	O
of	O
the	O
breathing	B-PROC
circuit	O
of	O
the	O
ventilator	O
.	O

The	O
pathophysiology	O
and	O
therapeutic	O
strategy	O
of	O
this	O
special	O
type	O
of	O
permanent	O
olfactory	B-PROC
dysfunction	O
deserve	O
further	O
investigation	O
.	O

Two	O
days	O
after	O
presentation	O
he	O
developed	O
rhabdomyolysis	O
,	O
most	O
probably	O
as	O
a	O
result	O
of	O
multiple	O
factors	O
(	O
hyperthermia	B-PROC
,	O
hypovolemia	O
/	O
dehydration	O
,	O
hypernatremia	O
,	O
metabolic	B-PROC
acidosis	O
),	O
followed	O
by	O
severe	O
complications	O
including	O
acute	O
renal	O
failure	O
,	O
hepatic	O
dysfunction	O
and	O
disseminated	O
intravascular	O
coagulation	B-PROC
.	O

Four	O
patients	O
with	O
DSS	O
died	B-PROC
of	O
severe	O
complications	O
.	O

While	O
effective	O
vaccines	O
have	O
been	O
developed	O
for	O
some	O
,	O
such	O
as	O
poliovirus	O
and	O
hepatitis	O
A	O
,	O
others	O
such	O
as	O
coxsackievirus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
have	O
no	O
accredited	O
drug	O
treatments	O
.	O

Antisense	O
technologies	O
,	O
which	O
encompass	O
small	O
interfering	O
RNA	O
,	O
antisense	O
oligonucleotides	O
,	O
ribozymes	O
and	O
their	O
chemically	O
modified	O
analogs	O
,	O
involve	O
small	O
sequence	O
-	O
specific	O
nucleic	O
-	O
acid	O
-	O
based	O
molecules	O
that	O
inhibit	O
viral	B-PROC
replication	I-PROC
at	O
the	O
level	O
of	O
translation	B-PROC
.	O

By	O
not	O
inhibiting	O
viral	B-PROC
replication	I-PROC
in	O
the	O
lungs	O
of	O
infected	O
mice	O
,	O
ribavirin	O
treatment	O
may	O
have	O
provided	O
a	O
continual	O
source	O
of	O
stimulation	O
for	O
the	O
inflammatory	B-PROC
response	I-PROC
thought	O
to	O
contribute	O
to	O
the	O
pathogenesis	B-PROC
of	O
the	O
infection	O
.	O

TITLE	O
:	O
Immunization	O
with	O
SARS	O
-	O
CoV	O
S	O
DNA	O
vaccine	O
generates	O
memory	B-PROC
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cell	O
immune	B-PROC
responses	I-PROC
.	O

with	O
SARS	O
-	O
CoV	O
S	O
DNA	O
vaccine	O
,	O
and	O
three	O
different	O
methods	O
(	O
ELISA	O
,	O
ELISPOT	O
and	O
FACS	O
)	O
were	O
used	O
to	O
evaluate	O
the	O
immune	B-PROC
responses	I-PROC
when	O
the	O
cells	O
were	O
stimulated	O
in	O
vitro	O
with	O
a	O
pool	O
of	O
peptides	O
overlapping	O
entire	O
SARS	O
spike	O
protein	O
.	O

RESULTS	O
:	O
Microscopically	O
,	O
all	O
lungs	O
from	O
4	O
cases	O
showed	O
edema	O
,	O
erythrocyte	O
and	O
fibrin	O
exudates	O
in	O
the	O
alveoli	O
,	O
hyperplasia	O
of	O
alveolar	O
epithelium	O
,	O
necrosis	B-PROC
,	O
hyaline	O
membrane	O
formation	B-PROC
and	O
fibroblast	O
foci	O
.	O

The	O
results	O
revealed	O
that	O
partial	O
ventilatory	O
support	O
was	O
superior	O
to	O
PCV	O
in	O
maintaining	O
adequate	O
oxygenation	B-PROC
and	O
hemodynamic	B-PROC
function	O
with	O
reduced	O
sedation	O
.	O

PSV	O
affected	O
the	O
pattern	O
of	O
breathing	B-PROC
and	O
deadspace	O
to	O
a	O
greater	O
degree	O
than	O
did	O
P	O
-	O
ACV	O
.	O

ABSTRACT	O
:	O
The	O
immunogenicity	O
of	O
HLA	O
-	O
A	O
*	O
0201	O
-	O
restricted	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
peptide	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nuclear	O
capsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
proteins	O
was	O
determined	O
by	O
testing	O
the	O
proteins	O
'	O
ability	O
to	O
elicit	O
a	O
specific	O
cellular	B-PROC
immune	I-PROC
response	I-PROC
after	O
immunization	O
of	O
HLA	O
-	O
A2	O
.	O
1	O
transgenic	O
mice	O
and	O
in	O
vitro	O
vaccination	O
of	O
HLA	O
-	O
A2	O
.	O
1	O
positive	O
human	O
peripheral	O
blood	O
mononuclearcytes	O
(	O
PBMCs	O
).	O

First	O
,	O
we	O
screened	O
SARS	O
N	O
and	O
S	O
amino	O
acid	O
sequences	O
for	O
allele	O
-	O
specific	O
motif	O
matching	O
those	O
in	O
human	O
HLA	O
-	O
A2	O
.	O
1	O
MHC	B-PROC
-	O
I	O
molecules	O
.	O

Here	O
we	O
combined	O
screening	O
of	O
phage	O
display	O
random	O
peptide	O
libraries	O
with	O
a	O
unique	O
computer	O
algorithm	O
""""	O
Mapitope	O
""""	O
to	O
identify	O
the	O
discontinuous	O
epitope	O
of	O
80R	O
,	O
a	O
potent	O
neutralizing	O
human	O
anti	O
-	O
SARS	O
monoclonal	O
antibody	B-PROC
against	O
the	O
spike	O
protein	O
.	O

TITLE	O
:	O
Kinetics	O
and	O
synergistic	O
effects	O
of	O
siRNAs	O
targeting	B-PROC
structural	O
and	O
replicase	O
genes	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

TITLE	O
:	O
Design	O
and	O
synthesis	B-PROC
of	O
hydroxyferroquine	O
derivatives	O
with	O
antimalarial	O
and	O
antiviral	O
activities	O
.	O

Whereas	O
these	O
organometallic	O
compounds	O
provide	O
the	O
expected	O
reduced	O
cytotoxic	O
effects	O
compared	O
to	O
FQ	O
,	O
they	O
inhibit	O
in	O
vitro	O
growth	B-PROC
of	O
Plasmodium	O
falciparum	O
far	O
better	O
than	O
chloroquine	O
(	O
CQ	O
).	O

It	O
was	O
further	O
revealed	O
that	O
wt	O
JHMV	O
S1	O
,	O
but	O
not	O
srr7	O
,	O
was	O
released	O
from	O
the	O
cell	O
surface	O
when	O
S	O
protein	O
was	O
expressed	B-PROC
on	O
cells	O
.	O

Despite	O
treatment	O
with	O
a	O
large	O
amount	O
of	O
saline	O
,	O
high	O
-	O
doses	O
of	O
catecholamines	O
,	O
and	O
blood	O
transfusion	O
,	O
the	O
patient	O
died	B-PROC
on	O
day	O
28	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
2	O
-	O
D	O
DIGE	O
and	O
MS	O
to	O
analyze	O
the	O
protein	O
profiles	O
of	O
plasma	O
from	O
SARS	O
patients	O
,	O
in	O
the	O
search	O
for	O
proteomic	O
alterations	O
associated	O
with	O
the	O
disease	O
progression	O
,	O
which	O
could	O
provide	O
some	O
clues	O
to	O
the	O
pathogenesis	B-PROC
.	O

Titers	O
of	O
SARS	O
-	O
CoV	O
shed	O
in	O
nasopharyngeal	O
specimens	O
varied	O
widely	O
,	O
ranging	O
from	O
nondetectable	O
to	O
10	O
(	O
8	O
)	O
SARS	O
-	O
CoV	O
RNA	O
copies	O
/	O
mL	O
,	O
and	O
they	O
were	O
correlated	O
positively	O
with	O
a	O
high	O
mortality	O
rate	O
(	O
P	O
<.	O
0001	O
,	O
by	O
trend	O
test	O
)	O
and	O
with	O
early	O
death	B-PROC
(	O
i	O
.	O
e	O
.,	O
death	B-PROC
occurring	O
within	O
2	O
weeks	O
of	O
the	O
onset	O
of	O
illness	O
)	O
(	O
P	O
=.	O
0015	O
,	O
by	O
trend	O
test	O
).	O

TITLE	O
:	O
Cross	O
-	O
neutralization	O
of	O
human	O
and	O
palm	O
civet	O
severe	O
acute	O
respiratory	O
syndrome	O
coronaviruses	O
by	O
antibodies	O
targeting	B-PROC
the	O
receptor	O
-	O
binding	O
domain	O
of	O
spike	O
protein	O
.	O

Some	O
cases	O
of	O
SARS	O
were	O
diagnosed	O
after	O
the	O
patients	O
had	O
died	B-PROC
.	O

The	O
polymorphisms	B-PROC
of	O
IL	O
-	O
10	O
and	O
TNF	O
-	O
alpha	O
were	O
not	O
associated	O
with	O
SARS	O
susceptibility	O
.	O

HRV	O
represent	O
the	O
single	O
most	O
important	O
etiological	O
agents	O
of	O
the	O
common	O
cold	B-PROC
[	O
Arruda	O
,	O
E	O
.,	O
Pitkaranta	O
,	O
A	O
.,	O
Witek	O
Jr	O
.,	O
T	O
.	O
J	O
.,	O
Doyle	O
,	O
C	O
.	O
A	O
.,	O
Hayden	O
,	O
F	O
.	O
G	O
.,	O
1997	O
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
feline	O
(	O
FIPV	O
)	O
and	O
human	O
(	O
SARS	O
)	O
coronavirus	O
by	O
semisynthetic	O
derivatives	O
of	O
glycopeptide	O
antibiotics	O
.	O

Major	O
nasal	O
airway	O
obstruction	O
is	O
probably	O
often	O
overlooked	O
when	O
acute	O
desaturation	O
of	O
the	O
neonate	O
requires	O
reanimation	O
procedures	O
,	O
although	O
it	O
is	O
well	O
established	O
that	O
the	O
baby	O
is	O
an	O
obligate	O
nose	O
breather	O
at	O
birth	B-PROC
.	O

RESULTS	O
:	O
All	O
patients	O
presented	O
fever	B-PROC
,	O
headache	O
,	O
sore	O
throat	O
,	O
hoarseness	O
,	O
muscular	O
ache	O
,	O
and	O
dry	O
cough	O
.	O

The	O
epidemic	O
spread	O
rapidly	O
within	O
China	O
and	O
internationally	O
,	O
with	O
8454	O
recorded	O
infections	O
and	O
792	O
deaths	B-PROC
by	O
June	O
15	O
,	O
2003	O
.	O

Thus	O
,	O
without	O
knowing	O
which	O
strain	O
may	O
lead	O
to	O
a	O
pandemic	O
,	O
development	B-PROC
and	O
manufacturing	O
of	O
a	O
vaccine	O
is	O
delayed	O
.	O

The	O
library	O
was	O
screened	O
for	O
the	O
production	O
of	O
Fab	O
antibody	B-PROC
fragments	O
to	O
a	O
recombinant	O
spike	O
protein	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Another	O
approach	O
is	O
an	O
arterio	O
-	O
venous	O
pumpless	O
interventional	O
lung	O
assist	O
(	O
ILA	O
)	O
with	O
a	O
low	O
resistance	B-PROC
oxygenator	O
.	O

Could	O
current	O
nursing	B-PROC
practices	O
support	O
the	O
care	O
of	O
SARS	O
or	O
SARS	O
-	O
like	O
patients	O
in	O
the	O
future	O
?	O

The	O
presence	O
of	O
two	O
distinct	O
membrane	O
topologies	O
of	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	O
may	O
provide	O
a	O
useful	O
clue	O
to	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
-	O
CoV	O
.	O

In	O
the	O
HV	O
group	O
,	O
the	O
expression	B-PROC
of	O
NF	O
-	O
ê	O
B	O
activation	O
at	O
6	O
h	O
,	O
12	O
h	O
and	O
24	O
h	O
was	O
lower	O
than	O
in	O
the	O
control	O
and	O
LV	O
groups	O
respectively	O
.	O

This	O
study	O
aims	O
to	O
characterize	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
caused	O
by	O
chlorine	O
gas	O
(	O
Cl2	O
)	O
inhalation	B-PROC
in	O
a	O
large	O
-	O
animal	O
model	O
.	O

This	O
process	O
is	O
indispensable	O
in	O
the	O
replication	O
of	O
numerous	O
viral	O
pathogens	O
,	O
including	O
HIV	O
and	O
the	O
coronavirus	O
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
and	O
is	O
also	O
exploited	O
in	O
the	O
expression	B-PROC
of	O
several	O
cellular	O
genes	O
.	O

TITLE	O
:	O
An	O
efficient	O
method	O
for	O
the	O
synthesis	B-PROC
of	O
peptide	O
aldehyde	O
libraries	O
employed	O
in	O
the	O
discovery	O
of	O
reversible	O
SARS	O
coronavirus	O
main	O
protease	O
(	O
SARS	O
-	O
CoV	O
Mpro	O
)	O
inhibitors	O
.	O

ABSTRACT	O
:	O
These	O
studies	O
attempt	O
to	O
understand	O
more	O
fully	O
the	O
host	B-PROC
response	I-PROC
and	O
pathogenesis	B-PROC
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
by	O
monitoring	O
gene	B-PROC
expression	I-PROC
using	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
pulmonary	O
autopsy	O
tissues	O
.	O

The	O
results	O
indicated	O
that	O
human	O
memory	B-PROC
T	O
-	O
cell	O
responses	O
specific	O
for	O
SARS	O
-	O
CoV	O
N	O
protein	O
could	O
persist	O
for	O
2	O
years	O
in	O
the	O
absence	O
of	O
antigen	O
,	O
which	O
would	O
be	O
a	O
valuable	O
for	O
the	O
design	O
of	O
effective	O
vaccines	O
against	O
SARS	O
-	O
CoV	O
and	O
for	O
basic	O
studies	O
of	O
human	O
T	O
-	O
cell	O
memory	B-PROC
.	O

Sense	B-PROC
-	O
antisense	O
base	O
-	O
pairing	O
interactions	O
between	O
short	O
conserved	O
sequences	O
play	O
a	O
key	O
regulatory	O
role	O
in	O
this	O
process	O
.	O

Upon	O
addition	O
of	O
FCoV	O
-	O
specific	O
antibodies	O
,	O
surface	O
-	O
expressed	B-PROC
viral	O
proteins	O
were	O
internalized	O
through	O
a	O
highly	O
efficient	O
process	O
,	O
resulting	O
in	O
cells	O
without	O
visually	O
detectable	O
viral	O
proteins	O
on	O
their	O
plasma	O
membrane	O
.	O

A	O
similarity	O
search	O
using	O
SARS	O
M	O
(	O
pro	O
)	O
protease	O
subpockets	O
as	O
queries	O
retrieved	O
ligands	O
and	O
ligand	B-PROC
fragments	O
accommodated	O
in	O
a	O
physicochemical	O
environment	O
similar	O
to	O
that	O
of	O
the	O
query	O
.	O

ABSTRACT	O
:	O
Reproductive	B-PROC
losses	O
in	O
camelids	O
are	O
due	O
to	O
infertility	O
,	O
pregnancy	O
loss	O
,	O
udder	O
diseases	O
and	O
neonatal	O
mortality	O
caused	O
by	O
a	O
variety	O
of	O
infectious	O
diseases	O
.	O

When	O
considered	O
together	O
,	O
the	O
structural	O
and	O
thermodynamic	O
features	O
of	O
the	O
four	O
domains	O
suggest	O
a	O
possible	O
mechanism	O
whereby	O
the	O
HR	O
regions	O
,	O
initially	O
sequestered	O
in	O
the	O
native	O
S	O
glycoprotein	O
spike	O
,	O
are	O
released	O
and	O
refold	O
sequentially	O
to	O
promote	O
membrane	B-PROC
fusion	I-PROC
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
responsible	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
contains	O
a	O
small	O
envelope	O
protein	O
,	O
E	O
,	O
with	O
putative	O
involvement	O
in	O
host	O
apoptosis	B-PROC
and	O
virus	O
morphogenesis	B-PROC
.	O

Over	O
the	O
last	O
20	O
years	O
,	O
substantial	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
alveolar	O
epithelium	O
have	O
provided	O
major	O
new	O
insights	O
into	O
how	O
molecular	O
and	O
cellular	O
mechanisms	O
regulate	O
the	O
active	B-PROC
transport	B-PROC
of	O
solutes	O
and	O
fluid	O
across	O
the	O
alveolar	O
epithelium	O
under	O
both	O
normal	O
and	O
pathological	O
conditions	O
.	O

Although	O
there	O
is	O
still	O
much	O
to	O
learn	B-PROC
about	O
the	O
mechanisms	O
that	O
impair	O
normal	O
alveolar	O
fluid	O
clearance	O
under	O
pathological	O
conditions	O
,	O
the	O
compelling	O
experimental	O
findings	O
presented	O
in	O
this	O
symposium	O
raise	O
the	O
prospect	O
that	O
we	O
are	O
now	O
poised	O
to	O
test	O
and	O
develop	O
therapeutic	O
strategies	O
to	O
improve	O
outcome	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Ertumaxomab	O
is	O
an	O
intact	O
bispecific	O
antibody	B-PROC
targeting	B-PROC
HER2	O
/	O
neu	O
and	O
CD3	O
with	O
selective	O
binding	O
to	O
activatory	O
Fcgamma	O
type	O
I	O
/	O
III	O
receptors	O
,	O
resulting	O
in	O
the	O
formation	B-PROC
of	O
a	O
tri	O
-	O
cell	O
complex	O
between	O
tumor	O
cells	O
,	O
T	O
cells	O
,	O
and	O
accessory	O
cells	O
.	O

TITLE	O
:	O
[	O
High	O
molecular	O
weight	O
kininogen	O
in	O
inflammation	O
and	O
angiogenesis	B-PROC
:	O
a	O
review	O
of	O
its	O
properties	O
and	O
therapeutic	O
applications	O
].	O

This	O
study	O
evaluated	O
the	O
impact	O
of	O
preexisting	O
immunity	B-PROC
to	O
human	O
adenovirus	O
on	O
the	O
efficacy	O
of	O
adenovirus	O
-	O
based	O
vaccines	O
against	O
the	O
coronavirus	O
that	O
causes	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
).	O

Viral	B-PROC
infections	I-PROC
were	O
diagnosed	O
by	O
either	O
immunological	O
(	O
monoclonal	O
antibodies	O
)	O
or	O
molecular	O
(	O
RT	O
-	O
PCR	O
)	O
methods	O
.	O

On	O
the	O
other	O
hand	O
,	O
all	O
hCoV	O
strains	O
could	O
be	O
detected	O
by	O
using	O
type	O
-	O
specific	O
primers	O
targeting	B-PROC
genes	O
1ab	O
and	O
N	O
.	O
The	O
HuH	O
-	O
7	O
cell	O
line	O
was	O
found	O
to	O
be	O
susceptible	O
to	O
isolation	O
and	O
identification	O
of	O
OC43	O
-	O
and	O
229E	O
-	O
like	O
strains	O
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
human	O
coronavirus	O
NL63	O
infection	O
at	O
early	O
stages	O
of	O
the	O
replication	O
cycle	O
.	O

To	O
achieve	O
a	O
PRV	O
genome	O
-	O
based	O
virus	O
live	O
vector	O
,	O
aiming	O
at	O
further	O
TGEV	O
/	O
PRV	O
bivalent	O
vaccine	O
development	B-PROC
,	O
a	O
recombinant	O
plasmid	O
pUG	O
was	O
constructed	O
via	O
inserting	O
partial	O
PK	O
and	O
full	O
-	O
length	O
gG	O
genes	O
of	O
PRV	O
strain	O
Bartha	O
K	O
-	O
61	O
amplified	O
into	O
pUC119	O
vector	O
.	O

The	O
continuous	O
region	O
containing	O
S1fragment	O
,	O
SV40	O
polyA	O
and	O
four	O
single	O
restriction	O
enzyme	O
sites	O
digested	B-PROC
from	O
pHS	O
was	O
subcloned	O
into	O
the	O
downstream	O
of	O
gG	O
promoter	O
of	O
pUG	O
.	O

The	O
3	O
emerging	O
infectious	O
diseases	O
pose	O
very	O
different	O
threats	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
is	O
a	O
newly	O
identified	O
pathogen	O
that	O
caused	O
an	O
international	O
pandemic	O
;	O
the	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
investigation	O
involved	O
an	O
old	O
pathogen	O
that	O
was	O
identified	O
in	O
a	O
new	O
location	O
;	O
and	O
the	O
anthrax	O
attacks	O
involved	O
the	O
intentional	O
introduction	O
of	O
a	O
pathogen	O
.	O

In	O
this	O
study	O
,	O
we	O
immunized	O
mice	O
with	O
full	O
-	O
length	O
S	O
protein	O
(	O
FL	O
-	O
S	O
)	O
or	O
its	O
extracellular	O
domain	O
(	O
EC	O
-	O
S	O
)	O
expressed	B-PROC
by	O
recombinant	O
baculoviruses	O
in	O
insect	O
cells	O
.	O

Inhibitors	O
of	O
the	O
endosomal	O
cysteine	O
proteases	O
cathepsin	O
B	O
and	O
cathepsin	O
L	O
greatly	O
reduce	O
MHV	O
-	O
2	O
spike	O
-	O
mediated	O
entry	O
,	O
while	O
they	O
have	O
little	O
effect	O
on	O
A59	O
entry	O
,	O
suggesting	O
that	O
there	O
is	O
a	O
proteolytic	B-PROC
step	O
in	O
MHV	O
-	O
2	O
entry	O
.	O

Finally	O
,	O
a	O
recombinant	O
virus	O
expressing	O
a	O
cleaved	O
MHV	O
-	O
2	O
spike	O
has	O
the	O
ability	O
to	O
induce	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
at	O
neutral	O
pH	O
values	O
and	O
does	O
not	O
require	O
low	O
pH	O
and	O
endosomal	O
cathepsins	O
during	O
infection	O
.	O

Here	O
,	O
using	O
a	O
panel	O
of	O
replicase	O
-	O
specific	O
antisera	O
,	O
we	O
have	O
analyzed	O
the	O
earlier	O
stages	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
in	O
Vero	O
E6	O
cells	O
,	O
in	O
particular	O
focusing	O
on	O
the	O
subcellular	O
localization	B-PROC
of	O
the	O
replicase	O
and	O
the	O
ultrastructure	O
of	O
the	O
associated	O
membranes	O
.	O

T	O
-	O
lymphocyte	O
subsets	O
including	O
CD4	O
+	O
T	O
cells	O
,	O
CD8	O
+	O
T	O
cells	O
,	O
and	O
naive	O
and	O
memory	B-PROC
CD4	O
+	O
T	O
cells	O
were	O
detected	O
by	O
flow	O
cytometry	O
.	O

Studying	O
nucleolar	O
trafficking	B-PROC
signals	O
is	O
problematic	O
as	O
many	O
nucleolar	O
retention	B-PROC
signals	O
(	O
NoRSs	O
)	O
are	O
part	O
of	O
classical	O
nuclear	O
localization	B-PROC
signals	O
(	O
NLSs	O
).	O

Additionally	O
,	O
a	O
classical	O
nuclear	B-PROC
export	I-PROC
signal	O
(	O
NES	O
)	O
functioned	O
to	O
direct	O
N	O
protein	O
to	O
the	O
cytoplasm	O
.	O

In	O
an	O
uncontrollable	O
state	O
of	O
diffuse	O
bleeding	O
,	O
36	O
hours	O
post	O
-	O
operation	O
,	O
the	O
patient	O
died	B-PROC
.	O

TITLE	O
:	O
Steroid	O
-	O
induced	O
osteonecrosis	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
:	O
a	O
retrospective	O
analysis	O
of	O
biochemical	O
markers	O
of	O
bone	B-PROC
metabolism	B-PROC
and	O
corticosteroid	O
therapy	O
.	O

Biochemical	O
markers	O
of	O
bone	B-PROC
metabolism	B-PROC
showed	O
significant	O
bone	B-PROC
resorption	B-PROC
as	O
evidenced	O
by	O
a	O
marked	O
increase	O
in	O
serum	O
C	O
-	O
terminal	O
telopeptide	O
concentration	O
(	O
CTx	O
)	O
from	O
Day	O
28	O
-	O
44	O
after	O
the	O
onset	O
of	O
fever	B-PROC
.	O

ABSTRACT	O
:	O
Serum	O
antibody	B-PROC
responses	I-PROC
and	O
haemolytic	O
complement	B-PROC
activity	I-PROC
were	O
evaluated	O
in	O
White	O
Leghorn	O
(	O
WLH	O
)	O
and	O
Rhode	O
Island	O
Red	O
(	O
RIR	O
)	O
chickens	O
that	O
were	O
vaccinated	O
with	O
live	O
-	O
attenuated	O
vaccines	O
of	O
Newcastle	O
disease	O
virus	O
,	O
or	O
infectious	O
bronchitis	O
virus	O
,	O
or	O
infectious	O
bursal	O
disease	O
virus	O
by	O
means	O
of	O
ocular	B-PROC
challenge	O
at	O
10	O
times	O
the	O
normal	O
vaccination	O
dose	O
.	O

The	O
siRNA	O
and	O
shRNA	O
for	O
one	O
of	O
the	O
siRNA	O
sites	O
of	O
the	O
RDRP	O
gene	O
were	O
also	O
tested	O
,	O
and	O
it	O
was	O
found	O
that	O
both	O
inhibited	O
exogenous	O
RDRP	O
expression	B-PROC
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

This	O
intermediate	O
phase	O
may	O
be	O
a	O
critical	O
stage	O
for	O
virus	O
evolution	B-PROC
and	O
disease	O
prevention	O
.	O

TITLE	O
:	O
Effect	O
of	O
various	O
pyrimidines	O
possessing	O
the	O
1	O
-[(	O
2	O
-	O
hydroxy	O
-	O
1	O
-(	O
hydroxymethyl	O
)	O
ethoxy	O
)	O
methyl	O
]	O
moiety	O
,	O
able	O
to	O
mimic	O
natural	O
2	O
'-	O
deoxyribose	O
,	O
on	O
wild	O
-	O
type	O
and	O
mutant	O
hepatitis	O
B	O
virus	B-PROC
replication	I-PROC
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
relationships	O
between	O
a	O
known	O
history	O
of	O
diabetes	O
and	O
ambient	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
)	O
levels	O
with	O
death	B-PROC
and	O
morbidity	O
rates	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Immature	O
DCs	O
were	O
activated	O
by	O
SARS	O
-	O
CoV	O
infection	O
and	O
by	O
UV	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
.	O
Infected	O
DCs	O
were	O
still	O
viable	O
on	O
day	O
6	O
post	O
-	O
infection	O
,	O
but	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
class	O
I	O
upregulation	B-PROC
was	O
missing	O
,	O
indicating	O
that	O
DC	O
function	O
was	O
impaired	O
.	O

The	O
data	O
was	O
divided	O
into	O
three	O
periods	B-PROC
:	O
(	O
1	O
)	O
before	O
PPE	O
was	O
instituted	O
from	O
1	O
November	O
2002	O
to	O
31	O
March	O
2003	O
;	O
(	O
2	O
)	O
during	O
SARS	O
(	O
when	O
PPE	O
use	O
was	O
mandatory	O
)	O
from	O
1	O
April	O
to	O
31	O
July	O
2003	O
;	O
(	O
3	O
)	O
post	O
-	O
SARs	O
(	O
when	O
PPE	O
use	O
was	O
non	O
-	O
mandatory	O
but	O
encouraged	O
)	O
from	O
1	O
August	O
to	O
31	O
March	O
2004	O
.	O

ABSTRACT	O
:	O
In	O
this	O
work	O
,	O
a	O
gold	O
complex	O
is	O
used	O
as	O
electroactive	O
label	O
for	O
monitoring	O
hybridization	B-PROC
assays	O
on	O
glassy	O
carbon	O
electrodes	O
.	O

The	O
DNA	O
hybridization	B-PROC
sensor	O
is	O
designed	O
immobilizing	O
the	O
complementary	O
probe	O
on	O
the	O
pre	O
-	O
treated	O
electrode	O
surface	O
and	O
,	O
then	O
,	O
the	O
hybridization	B-PROC
reaction	O
takes	O
place	O
with	O
the	O
gold	O
labeled	O
strand	O
.	O

Reduced	O
lung	B-PROC
volumes	I-PROC
and	O
severe	O
ventilation	O
maldistribution	O
are	O
found	O
in	O
the	O
acute	O
phase	O
but	O
may	O
persist	O
during	O
childhood	O
.	O

These	O
observations	O
imply	O
the	O
possible	O
involvement	O
of	O
lung	O
stem	O
/	O
progenitor	O
cells	O
,	O
in	O
addition	O
to	O
pneumocytes	O
,	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
,	O
accounting	O
for	O
the	O
continued	O
deterioration	O
of	O
lung	O
tissues	O
and	O
apparent	O
loss	O
of	O
capacity	O
for	O
lung	O
repair	B-PROC
.	O

A	O
dose	O
-	O
dependent	O
inhibitory	O
effect	O
on	O
mfgl2	O
expression	B-PROC
by	O
mfgl2	O
antisense	O
plasmid	O
was	O
observed	O
in	O
interferon	O
-	O
gamma	O
-	O
treated	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

Corticosteroid	O
pulse	B-PROC
-	O
therapy	O
resulted	O
in	O
prompt	O
improvement	O
of	O
chest	O
infiltrates	O
and	O
his	O
symptoms	O
.	O

All	O
the	O
409	O
serum	O
specimens	O
were	O
tested	O
for	O
specific	O
antibodies	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
by	O
different	O
methods	O
including	O
ELISA	O
for	O
specific	O
IgM	O
and	O
IgG	O
,	O
whole	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
,	O
IFA	O
for	O
specific	O
IgM	O
and	O
IgG	O
against	O
SARS	O
-	O
CoV	O
,	O
and	O
Western	O
-	O
blot	O
for	O
IgG	O
to	O
expressed	B-PROC
N	O
protein	O
from	O
SARS	O
-	O
CoV	O
.	O
The	O
positive	O
rates	O
of	O
specific	O
IgG	O
and	O
whole	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
ranged	O
from	O
39	O
.	O
1	O
%	O
to	O
43	O
.	O
5	O
%	O
in	O
the	O
children	O
who	O
had	O
been	O
clinically	O
diagnosed	O
as	O
SARS	O
,	O
zero	O
in	O
children	O
and	O
6	O
.	O
0	O
%	O
to	O
9	O
.	O
0	O
%	O
in	O
adults	O
who	O
had	O
closely	O
contacted	O
with	O
the	O
clinically	O
diagnosed	O
SARS	O
children	O
.	O

However	O
,	O
the	O
majority	O
of	O
memory	B-PROC
CD8	O
(+)	O
T	O
cells	O
revealed	O
effector	O
memory	B-PROC
phenotype	O
expressing	O
CD45RO	O
(-)	O
CCR7	O
(-)	O
CD62L	O
(-).	O

These	O
data	O
may	O
have	O
an	O
important	O
implication	O
in	O
the	O
possibility	O
of	O
designing	O
effective	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
infection	O
,	O
specifically	O
in	O
defining	O
T	O
-	O
cell	O
populations	O
that	O
are	O
implicated	O
in	O
protective	O
immunity	B-PROC
.	O

TITLE	O
:	O
Complement	B-PROC
inhibitors	I-PROC
selectively	O
attenuate	O
injury	O
following	O
administration	O
of	O
cobra	O
venom	O
factor	O
to	O
rats	O
.	O

Histopathological	O
changes	O
were	O
observed	O
under	O
light	O
microscope	O
,	O
diffuse	O
alveolar	O
damage	O
(	O
DAD	O
)	O
scores	O
was	O
estimated	O
,	O
and	O
polymorphonuclear	O
leucocytes	O
(	O
PMN	B-PROC
)	O
count	O
was	O
done	O
.	O

CONCLUSIONS	O
:	O
Large	O
tidal	O
volumes	O
with	O
high	O
inspiratory	B-PROC
flow	O
and	O
high	O
respiratory	O
rate	O
may	O
cause	O
severe	O
ventilator	O
induced	O
lung	O
injury	O
(	O
VILI	O
).	O

However	O
,	O
karyotypic	O
examination	O
of	O
bone	O
marrow	O
cells	O
revealed	O
that	O
chromosomal	O
translocation	B-PROC
with	O
t	O
(	O
4	O
;	O
10	O
)(	O
q12	O
;	O
p11	O
)	O
had	O
occurred	O
in	O
2000	O
,	O
and	O
chronic	O
eosinophilic	O
leukemia	O
was	O
diagnosed	O
.	O

Interestingly	O
,	O
both	O
saikosaponins	O
A	O
(	O
50	O
%	O
cellular	B-PROC
cytotoxicity	I-PROC
(	O
CC50	B-PROC
)	O
concentration	O
=	O
228	O
.	O
1	O
+/-	O

Twenty	O
-	O
seven	O
pregnancies	B-PROC
with	O
Stage	O
II	O
-	O
IV	O
TTTS	O
treated	O
with	O
amnioreduction	O
were	O
identified	O
(	O
amnioreduction	O
group	O
).	O

ABSTRACT	O
:	O
Development	B-PROC
of	O
an	O
effective	O
vaccine	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
remains	O
to	O
be	O
a	O
priority	O
to	O
prevent	O
possible	O
re	O
-	O
emergence	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

TITLE	O
:	O
Accelerated	O
induction	B-PROC
of	I-PROC
apoptosis	I-PROC
in	O
insect	O
cells	O
by	O
baculovirus	O
-	O
expressed	B-PROC
SARS	O
-	O
CoV	O
membrane	O
protein	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
):	O
development	B-PROC
of	O
diagnostics	O
and	O
antivirals	O
.	O

TITLE	O
:	O
Vascular	B-PROC
endothelial	I-PROC
growth	B-PROC
factor	I-PROC
(	O
VEGF	O
)	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
):	O
paradox	O
or	O
paradigm	O
?	O

It	O
is	O
characterised	O
by	O
alveolar	O
injury	O
and	O
increased	O
pulmonary	O
vascular	B-PROC
permeability	I-PROC
.	O

In	O
the	O
context	O
of	O
the	O
armed	O
forces	O
,	O
aggressive	B-PROC
containment	O
measures	O
are	O
essential	O
to	O
prevent	O
an	O
outbreak	O
.	O

In	O
the	O
early	O
recovery	O
period	O
,	O
potential	O
problems	O
during	O
diving	O
are	O
caused	O
by	O
inadequate	O
lung	O
ventilation	O
in	O
relation	O
to	O
exercise	O
level	O
and	O
increased	O
breathing	B-PROC
resistance	B-PROC
attributable	O
to	O
weak	O
respiratory	O
muscles	O
,	O
with	O
corresponding	O
risk	O
of	O
hypoxia	O
and	O
hypercapnia	O
,	O
as	O
well	O
as	O
decreased	O
ability	O
to	O
respond	O
to	O
nonrespiratory	O
problems	O
during	O
diving	O
.	O

Among	O
the	O
signaling	B-PROC
pathways	B-PROC
in	O
persistently	O
infected	O
cells	O
,	O
Akt	O
and	O
JNK	O
were	O
phosphorylated	O
in	O
SARS	O
-	O
CoV	O
-	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
-	O
expressing	O
Vero	O
E6	O
cells	O
using	O
vaccinia	O
viral	O
vector	O
(	O
DIs	O
),	O
strongly	O
suggesting	O
that	O
N	O
protein	O
-	O
induced	O
phosphorylation	B-PROC
of	O
Akt	O
and	O
JNK	O
are	O
necessary	O
to	O
establish	O
persistence	O
.	O

TITLE	O
:	O
Comparative	O
analysis	O
of	O
22	O
coronavirus	O
HKU1	O
genomes	O
reveals	O
a	O
novel	O
genotype	O
and	O
evidence	O
of	O
natural	O
recombination	B-PROC
in	O
coronavirus	O
HKU1	O
.	O

All	O
10	O
CoV	O
HKU1	O
strains	O
with	O
incomplete	O
imperfect	O
repeats	O
(	O
1	O
.	O
4	O
and	O
4	O
.	O
4	O
)	O
belonged	O
to	O
genotype	O
A	O
.	O
The	O
present	O
study	O
represents	O
the	O
first	O
evidence	O
for	O
natural	O
recombination	B-PROC
in	O
coronavirus	O
associated	O
with	O
human	O
infection	O
.	O

After	O
the	O
mice	O
had	O
been	O
immunized	O
intramuscularly	O
and	O
/	O
or	O
intraperitoneally	O
with	O
pcDNA3	O
.	O
1	O
-	O
N	O
and	O
rAd	O
-	O
N	O
in	O
prime	O
-	O
triple	O
boost	O
immunization	O
,	O
humoral	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
were	O
detected	O
.	O

ABSTRACT	O
:	O
All	O
coronaviruses	O
encode	O
a	O
small	O
hydrophobic	O
envelope	O
(	O
E	O
)	O
protein	O
,	O
which	O
mediates	O
viral	B-PROC
assembly	I-PROC
and	O
morphogenesis	B-PROC
by	O
an	O
unknown	O
mechanism	O
.	O

Taken	O
together	O
,	O
the	O
data	O
provide	O
evidence	O
of	O
a	O
link	O
between	O
inhibition	B-PROC
of	O
E	O
protein	O
ion	O
channel	O
activity	O
and	O
the	O
antiviral	O
activity	O
of	O
HMA	O
.	O

ABSTRACT	O
:	O
Acute	O
viral	O
encephalitis	O
is	O
believed	O
to	O
result	O
from	O
direct	O
virus	O
destruction	O
of	O
infected	O
cells	O
and	O
from	O
virus	O
-	O
induced	O
host	O
immune	B-PROC
response	I-PROC
,	O
but	O
the	O
relative	O
contribution	O
of	O
each	O
remains	O
largely	O
unknown	O
.	O

The	O
decrease	O
in	O
disease	O
severity	O
was	O
not	O
due	O
to	O
a	O
switch	O
from	O
Th1	O
to	O
Th2	O
predominance	O
in	O
rJ	O
.	O
M	O
(	O
Y135Q	O
)-	O
infected	O
mice	O
,	O
an	O
effect	O
on	O
CD8	O
T	O
-	O
cell	B-PROC
function	I-PROC
,	O
or	O
differential	O
expression	B-PROC
of	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
by	O
JHMV	O
-	O
specific	O
CD4	O
T	O
cells	O
.	O

No	O
positive	O
results	O
for	O
antibody	B-PROC
to	O
SARS	O
-	O
CoV	O
were	O
detected	O
in	O
the	O
25	O
healthy	O
persons	O
.	O

No	O
positive	O
results	O
for	O
antibody	B-PROC
to	O
SARS	O
-	O
CoV	O
were	O
detected	O
in	O
the	O
25	O
healthy	O
persons	O
.	O

ABSTRACT	O
:	O
The	O
nucleolus	O
is	O
a	O
dynamic	O
subnuclear	O
structure	O
involved	O
in	O
ribosome	O
subunit	O
biogenesis	B-PROC
,	O
cell	B-PROC
cycle	I-PROC
control	I-PROC
and	O
mediating	O
responses	O
to	O
cell	O
stress	O
,	O
among	O
other	O
functions	O
.	O

ABSTRACT	O
:	O
Host	O
genetic	O
factors	O
may	O
play	O
a	O
role	O
in	O
susceptibility	O
and	O
resistance	B-PROC
to	O
SARS	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
.	O

The	O
expression	B-PROC
of	O
pulmonary	O
surfactant	O
associated	O
protein	O
A	O
was	O
significantly	O
decreased	O
in	O
PQ	O
group	O
13	O
.	O
22	O
%	O
+/-	O

TITLE	O
:	O
RNA	O
recognition	O
and	O
cleavage	B-PROC
by	O
the	O
SARS	O
coronavirus	O
endoribonuclease	O
.	O

We	O
used	O
several	O
RNAs	O
,	O
including	O
some	O
with	O
nucleotide	O
analogs	O
,	O
and	O
mass	O
spectrometry	O
to	O
determine	O
that	O
Nsp15	O
cleaves	O
only	O
3	O
'	O
of	O
the	O
recognition	O
uridylate	O
,	O
with	O
some	O
cleavage	B-PROC
3	O
'	O
of	O
cytidylate	O
.	O

During	O
the	O
period	O
between	O
March	O
and	O
May	O
2003	O
,	O
238	O
probable	O
SARS	O
cases	O
,	O
including	O
8	O
imported	O
cases	O
and	O
33	O
deaths	B-PROC
,	O
were	O
reported	O
.	O

In	O
Singapore	O
,	O
there	O
were	O
238	O
cases	O
of	O
SARS	O
with	O
33	O
deaths	B-PROC
.	O

At	O
presentation	O
,	O
the	O
common	O
symptoms	O
were	O
fever	B-PROC
,	O
myalgia	O
,	O
cough	O
and	O
headache	O
;	O
rhinorrhoea	O
was	O
uncommon	O
.	O

Chest	O
radiographs	O
of	O
children	O
admitted	O
with	O
suspected	O
or	O
probable	O
SARS	O
as	O
well	O
as	O
other	O
febrile	B-PROC
illness	O
during	O
this	O
period	O
were	O
retrospectively	O
and	O
independently	O
reviewed	O
by	O
3	O
radiologists	O
.	O

RESULTS	O
:	O
The	O
levels	O
of	O
inactivation	O
expressed	B-PROC
as	O
log	O
-	O
reduction	O
were	O
as	O
follows	O
:	O
cell	O
-	O
free	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
),	O
greater	O
than	O
6	O
.	O
8	O
;	O
cell	O
-	O
associated	O
HIV	O
-	O
1	O
,	O
greater	O
than	O
6	O
.	O
4	O
;	O
human	O
T	O
-	O
lymphotropic	O
virus	O
-	O
I	O
(	O
HTLV	O
-	O
I	O
),	O
4	O
.	O
5	O
;	O
HTLV	O
-	O
II	O
,	O
greater	O
than	O
5	O
.	O
7	O
;	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
and	O
hepatitis	O
C	O
virus	O
,	O
greater	O
than	O
4	O
.	O
5	O
;	O
duck	O
HBV	O
,	O
4	O
.	O
4	O
to	O
4	O
.	O
5	O
;	O
bovine	O
viral	O
diarrhea	O
virus	O
,	O
6	O
.	O
0	O
;	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
5	O
.	O
5	O
;	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
6	O
.	O
8	O
;	O
bluetongue	O
virus	O
,	O
5	O
.	O
1	O
;	O
human	O
adenovirus	O
5	O
,	O
6	O
.	O
8	O
;	O
Klebsiella	O
pneumoniae	O
,	O
greater	O
than	O
7	O
.	O
4	O
;	O
Staphylococcus	O
epidermidis	O
and	O
Yersinia	O
enterocolitica	O
,	O
greater	O
than	O
7	O
.	O
3	O
;	O
Treponema	O
pallidum	O
,	O
greater	O
than	O
5	O
.	O
9	O
;	O
Borrelia	O
burgdorferi	O
,	O
greater	O
than	O
10	O
.	O
6	O
;	O
Plasmodium	O
falciparum	O
,	O
6	O
.	O
9	O
;	O
Trypanosoma	O
cruzi	O
,	O
greater	O
than	O
5	O
.	O
0	O
;	O
and	O
Babesia	O
microti	O
,	O
greater	O
than	O
5	O
.	O
3	O
.	O

Analysis	O
of	O
SCoV	O
particles	O
that	O
were	O
purified	O
by	O
either	O
sucrose	O
gradient	O
equilibrium	B-PROC
centrifugation	O
or	O
a	O
virus	O
capture	O
assay	O
,	O
in	O
which	O
intact	O
SCoV	O
particles	O
were	O
specifically	O
immunoprecipitated	O
by	O
anti	O
-	O
S	O
protein	O
monoclonal	O
antibody	B-PROC
,	O
demonstrated	O
that	O
7a	O
protein	O
was	O
associated	O
with	O
purified	O
SCoV	O
particles	O
.	O

In	O
this	O
review	O
,	O
we	O
have	O
discussed	O
currently	O
available	O
strategies	O
for	O
antiviral	O
drug	O
discovery	O
and	O
how	O
these	O
technologies	O
have	O
been	O
utilized	O
to	O
identify	O
potential	O
antiviral	O
agents	O
for	O
the	O
inhibition	B-PROC
of	O
SARS	O
-	O
CoV	O
replication	O
.	O

Subsequently	O
,	O
all	O
samples	O
were	O
divided	O
to	O
evaluate	O
alternative	O
processing	O
protocols	O
:	O
one	O
part	O
of	O
the	O
sample	O
was	O
OsO4	O
-	O
postfixed	O
,	O
ethanol	O
-	O
dehydrated	O
,	O
Epon	O
-	O
infiltrated	O
(	O
overnight	O
)	O
in	O
an	O
automated	O
tissue	O
processor	O
(	O
LYNX	O
,	O
Leica	O
),	O
and	O
polymerized	O
at	O
60	O
degrees	O
C	O
for	O
48	O
h	O
;	O
in	O
parallel	O
the	O
other	O
part	O
was	O
microwave	O
-	O
assisted	O
processed	O
in	O
the	O
bench	O
microwave	O
device	O
(	O
REM	B-PROC
,	O
Milestone	O
),	O
including	O
post	O
-	O
osmication	O
and	O
the	O
resin	O
block	O
polymerization	O
.	O

ABSTRACT	O
:	O
To	O
achieve	O
the	O
greatest	O
output	O
from	O
their	O
limited	O
genomes	O
,	O
viruses	O
frequently	O
make	O
use	O
of	O
alternative	O
open	O
reading	O
frames	O
,	O
in	O
which	O
translation	B-PROC
is	O
initiated	O
from	O
a	O
start	O
codon	O
within	O
an	O
existing	O
gene	O
and	O
,	O
being	O
out	O
of	O
frame	O
,	O
gives	O
rise	O
to	O
a	O
distinct	O
protein	O
product	O
.	O

TITLE	O
:	O
Perspectives	O
on	O
the	O
basic	O
reproductive	B-PROC
ratio	O
.	O

We	O
analyzed	O
pulmonary	O
surfactant	O
composition	O
and	O
function	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
from	O
ventilated	O
and	O
spontaneously	O
breathing	B-PROC
HIV	O
-	O
positive	O
patients	O
with	O
PCP	O
.	O

Although	O
statistical	O
significant	O
difference	O
was	O
found	O
in	O
the	O
practice	O
of	O
identified	O
preventive	O
measures	O
before	O
and	O
after	O
intervention	O
,	O
influence	O
on	O
behavioral	B-PROC
changes	O
needed	O
further	O
exploration	O
.	O

Oxygenation	B-PROC
parameters	O
(	O
oxygenation	B-PROC
index	O
,	O
OI	O
;	O
Pao	B-PROC
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
ratio	O
,	O
P	O
/	O
F	O
)	O
and	O
mean	O
airway	O
pressures	O
(	O
mPaw	O
)	O
were	O
recorded	O
at	O
baseline	O
and	O
at	O
1	O
to	O
4	O
,	O
8	O
to	O
12	O
,	O
and	O
12	O
to	O
24	O
hours	O
after	O
initiation	O
of	O
HFPV	O
.	O

TITLE	O
:	O
An	O
episulfide	O
cation	O
(	O
thiiranium	O
ring	O
)	O
trapped	O
in	O
the	O
active	O
site	O
of	O
HAV	O
3C	O
proteinase	B-PROC
inactivated	O
by	O
peptide	O
-	O
based	O
ketone	O
inhibitors	O
.	O

These	O
findings	O
suggest	O
that	O
IL	O
-	O
4	O
and	O
IFN	O
-	O
gamma	O
inhibit	O
SARS	O
-	O
CoV	O
replication	O
partly	O
through	O
downregulation	B-PROC
of	O
ACE2	O
.	O

Using	O
a	O
self	O
-	O
report	O
questionnaire	O
,	O
we	O
surveyed	O
all	O
eligible	O
young	O
women	O
(	O
n	O
=	O
464	O
)	O
enrolled	O
in	O
the	O
medical	O
,	O
nursing	B-PROC
and	O
medical	O
technology	O
/	O
respiratory	O
therapy	O
educational	O
programs	O
at	O
a	O
university	O
in	O
Dammam	O
.	O

Premenstrual	O
symptom	O
frequency	O
was	O
significantly	O
associated	O
with	O
a	O
maternal	O
history	O
of	O
premenstrual	O
syndrome	O
,	O
self	O
-	O
perception	O
of	O
mental	O
stress	O
,	O
physical	O
activity	O
,	O
consumption	O
of	O
sweet	B-PROC
-	O
tasting	B-PROC
foods	O
,	O
and	O
coffee	O
,	O
but	O
these	O
factors	O
only	O
explained	O
14	O
%	O
of	O
the	O
variability	O
in	O
the	O
multiple	O
regression	O
model	O
.	O

Moreover	O
,	O
women	O
with	O
PMS	O
might	O
eliminate	O
sweet	B-PROC
-	O
tasting	B-PROC
food	O
and	O
caffeine	O
-	O
containing	O
beverages	O
,	O
particularly	O
coffee	O
,	O
from	O
their	O
diet	O
.	O

The	O
first	O
open	O
reading	O
frame	O
encodes	O
replicase	O
polyproteins	O
1a	O
and	O
1ab	O
,	O
which	O
are	O
cleaved	O
to	O
generate	O
16	O
""""	O
nonstructural	O
""""	O
proteins	O
,	O
nsp1	O
to	O
nsp16	O
,	O
involved	O
in	O
viral	B-PROC
replication	I-PROC
and	O
/	O
or	O
RNA	B-PROC
processing	I-PROC
.	O

TITLE	O
:	O
The	O
human	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
8b	O
protein	O
is	O
distinct	O
from	O
its	O
counterpart	O
in	O
animal	O
SARS	O
-	O
CoV	O
and	O
down	O
-	O
regulates	O
the	O
expression	B-PROC
of	O
the	O
envelope	O
protein	O
in	O
infected	O
cells	O
.	O

Progress	O
in	O
the	O
investigation	O
of	O
these	O
processes	O
has	O
been	O
enhanced	O
by	O
the	O
development	B-PROC
of	O
reverse	O
genetic	O
systems	O
,	O
an	O
advance	O
that	O
was	O
heretofore	O
obstructed	O
by	O
the	O
enormous	O
size	O
of	O
the	O
coronavirus	O
genome	O
.	O

Plasma	O
levels	O
of	O
BNP	O
on	O
day	O
2	O
in	O
patients	O
with	O
septic	O
shock	O
significantly	O
correlated	O
with	O
right	O
atrial	O
pressure	O
(	O
r	O
=	O
0	O
.	O
744	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
mean	O
pulmonary	O
arterial	B-PROC
pressure	I-PROC
(	O
r	O
=	O
0	O
.	O
670	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
pulmonary	O
arterial	B-PROC
wedge	I-PROC
pressure	I-PROC
(	O
r	O
=	O
0	O
.	O
709	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
left	O
ventricular	O
stroke	O
work	O
index	O
(	O
r	O
=	O
-	O
0	O
.	O
552	O
,	O
P	O
<	O
0	O
.	O
05	O
),	O
Acute	O
Physiological	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
(	O
r	O
=	O
0	O
.	O
581	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
poor	O
prognosis	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
contrast	O
,	O
AR	O
calves	O
had	O
low	O
antibody	B-PROC
titers	O
against	O
BCV	O
at	O
arrival	O
(	O
GMT	O
,	O
102	O
)	O
and	O
64	O
%	O
shed	O
BCV	O
in	O
nasal	O
secretions	O
and	O
65	O
%	O
in	O
feces	O
.	O

The	O
crystal	O
structure	O
of	O
TG	O
-	O
0205221	O
(	O
resolution	O
=	O
1	O
.	O
93	O
A	O
)	O
has	O
revealed	O
a	O
unique	O
binding	O
mode	O
comprising	O
a	O
covalent	B-PROC
bond	O
,	O
hydrogen	O
bonds	O
,	O
and	O
numerous	O
hydrophobic	B-PROC
interactions	I-PROC
.	O

This	O
information	O
may	O
be	O
applied	O
toward	O
the	O
design	O
of	O
other	O
3CL	O
protease	B-PROC
inhibitors	I-PROC
.	O

RESULTS	O
:	O
In	O
the	O
pediatric	O
study	O
of	O
zanamivir	O
,	O
as	O
in	O
the	O
adult	O
zanamivir	O
study	O
,	O
cough	O
and	O
fever	B-PROC
were	O
the	O
best	O
predictors	O
of	O
influenza	O
virus	B-PROC
infection	I-PROC
;	O
a	O
temperature	O
>	O
or	O
=	O
38	O
.	O
2	O
degrees	O
C	O
plus	O
cough	O
predicted	O
83	O
%	O
(	O
95	O
%	O
CI	O
,	O
79	O
%-	O
88	O
%)	O
of	O
illnesses	O
that	O
were	O
determined	O
to	O
be	O
influenza	O
virus	O
positive	O
.	O

The	O
age	O
distributions	O
of	O
patients	O
with	O
viral	B-PROC
infections	I-PROC
differed	O
;	O
notably	O
,	O
RSV	O
was	O
responsible	O
for	O
77	O
%	O
of	O
LRTIs	O
that	O
occurred	O
in	O
infants	O
<	O
or	O
=	O
3	O
months	O
old	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
)	O
as	O
the	O
cause	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
catalyzed	O
the	O
development	B-PROC
of	O
rapid	O
diagnostic	O
tests	O
.	O

The	O
evolution	B-PROC
of	O
the	O
Simian	O
virus	O
(	O
SIV	O
)	O
into	O
a	O
human	O
virus	O
(	O
HIV	O
)	O
is	O
regarded	O
as	O
an	O
artifact	O
.	O

Real	O
-	O
time	O
fluorescence	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
also	O
proved	O
the	O
neutralizing	O
capacity	O
of	O
M1A	O
.	O

In	O
this	O
study	O
we	O
confirmed	O
the	O
3a	O
protein	B-PROC
expression	B-PROC
and	O
investigated	O
its	O
localization	B-PROC
at	O
the	O
surface	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
or	O
3a	O
-	O
cDNA	O
-	O
transfected	O
cells	O
.	O

After	O
FRhK	O
-	O
4	O
cells	O
were	O
transfected	O
with	O
an	O
siRNA	O
,	O
which	O
is	O
known	O
to	O
suppress	O
3a	O
expression	B-PROC
,	O
followed	O
by	O
infection	O
with	O
SARS	O
-	O
CoV	O
,	O
the	O
released	O
virus	O
was	O
significantly	O
decreased	O
,	O
whereas	O
the	O
replication	O
of	O
the	O
virus	O
in	O
the	O
infected	O
cells	O
was	O
not	O
changed	O
.	O

ABSTRACT	O
:	O
Aggressive	B-PROC
behaviours	I-PROC
represent	O
major	O
obstacles	O
to	O
the	O
integration	B-PROC
into	O
society	O
of	O
individuals	O
with	O
intellectual	O
disability	O
(	O
ID	O
)	O
and	O
pose	O
significant	O
management	O
issues	O
for	O
carers	O
.	O

TITLE	O
:	O
Maternal	O
antibody	B-PROC
transfer	O
from	O
dams	O
to	O
their	O
egg	O
yolks	O
,	O
egg	O
whites	O
,	O
and	O
chicks	O
in	O
meat	O
lines	O
of	O
chickens	O
.	O

Entering	O
the	O
index	O
patient	O
'	O
s	O
room	O
and	O
having	O
seen	O
(	O
viewed	O
)	O
the	O
patient	O
were	O
the	O
behaviors	B-PROC
associated	O
with	O
highest	O
risk	O
for	O
infection	O
by	O
univariate	O
analysis	O
(	O
odds	O
ratios	O
20	O
.	O
0	O
,	O
14	O
.	O
0	O
;	O
95	O
%	O
confidence	O
intervals	O
4	O
.	O
1	O
-	O
97	O
.	O
1	O
,	O
3	O
.	O
6	O
-	O
55	O
.	O
3	O
,	O
respectively	O
).	O

We	O
found	O
that	O
the	O
expression	B-PROC
of	O
Egr	O
-	O
1	O
was	O
dramatically	O
increased	O
following	O
virus	B-PROC
infection	I-PROC
.	O

Documentation	O
of	O
the	O
clinical	O
course	O
occurring	O
over	O
the	O
30	O
days	O
after	O
infusion	O
offers	O
insight	O
into	O
the	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
in	O
the	O
absence	O
of	O
contaminating	O
pathogens	O
,	O
endotoxin	O
,	O
or	O
underlying	O
disease	O
.	O

The	O
future	O
of	O
surfactant	O
therapy	O
may	O
well	O
take	O
advantage	O
of	O
the	O
recently	O
described	O
host	B-PROC
defense	I-PROC
functions	O
of	O
this	O
material	O
.	O

ECLS	O
is	O
capable	O
of	O
providing	O
full	O
respiratory	O
and	O
cardiac	O
support	O
,	O
allowing	O
time	O
for	O
the	O
patient	O
to	O
recover	B-PROC
from	O
the	O
underlying	O
disease	O
process	O
.	O

Expression	B-PROC
of	O
nsp1	O
,	O
the	O
most	O
N	O
-	O
terminal	O
gene	O
1	O
protein	O
,	O
prevented	O
Sendai	O
virus	O
-	O
induced	O
endogenous	O
IFN	O
-	O
beta	O
mRNA	O
accumulation	O
without	O
inhibiting	O
dimerization	O
of	O
IFN	O
regulatory	O
factor	O
3	O
,	O
a	O
protein	O
that	O
is	O
essential	O
for	O
activation	O
of	O
the	O
IFN	O
-	O
beta	O
promoter	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)),	O
a	O
protein	O
required	O
for	O
the	O
maturation	B-PROC
of	O
SARS	O
-	O
CoV	O
,	O
is	O
vital	O
for	O
its	O
life	O
cycle	O
,	O
making	O
it	O
an	O
attractive	O
target	O
for	O
structure	O
-	O
based	O
drug	O
design	O
of	O
anti	O
-	O
SARS	O
drugs	O
.	O

Arterial	O
blood	B-PROC
gas	I-PROC
,	O
white	O
blood	O
cell	O
count	O
in	O
bronchial	O
alveolar	O
lavage	O
fluid	O
,	O
and	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
and	O
interleukin	O
-	O
6	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
and	O
serum	O
were	O
measured	O
at	O
the	O
indicated	O
time	O
points	O
.	O

The	O
SCoV	O
5	O
'	O
UTR	O
was	O
predicted	O
to	O
contain	O
a	O
fourth	O
stem	O
-	O
loop	O
,	O
named	O
SL3	O
,	O
in	O
which	O
the	O
leader	O
transcriptional	B-PROC
regulatory	O
sequence	O
(	O
TRS	O
)	O
is	O
folded	O
into	O
a	O
hairpin	O
loop	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
the	O
TRS	O
in	O
the	O
replication	O
of	O
minus	O
-	O
sense	B-PROC
genomic	O
RNA	O
in	O
addition	O
to	O
its	O
known	O
function	O
in	O
subgenomic	O
RNA	B-PROC
synthesis	I-PROC
.	O

Herein	O
,	O
we	O
screened	O
12	O
,	O
000	O
people	O
in	O
a	O
community	O
stricken	O
by	O
SARS	O
10	O
months	O
previously	O
and	O
found	O
53	O
individuals	O
(	O
0	O
.	O
44	O
%)	O
who	O
had	O
immunoglobulin	B-PROC
G	O
antibodies	O
to	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
produced	O
in	O
bacteria	O
.	O

A	O
comparison	O
with	O
M	O
,	O
E	O
,	O
and	O
NSP6	O
proteins	O
indicates	O
that	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
sufficiently	O
induces	O
transcriptional	B-PROC
activation	I-PROC
of	O
several	O
UPR	O
effectors	O
,	O
including	O
glucose	O
-	O
regulated	O
protein	O
78	O
(	O
GRP78	O
),	O
GRP94	O
,	O
and	O
C	O
/	O
EBP	O
homologous	O
protein	O
.	O

Renal	O
expression	B-PROC
of	O
the	O
sodium	O
/	O
hydrogen	O
exchanger	B-PROC
isoform	O
3	O
and	O
of	O
aquaporin	B-PROC
2	O
was	O
lower	O
in	O
infected	O
animals	O
,	O
whereas	O
that	O
of	O
the	O
Na	O
-	O
K	O
-	O
2Cl	O
cotransporter	O
NKCC2	O
was	O
higher	O
.	O

Leptospirosis	O
-	O
induced	O
lesions	O
,	O
predominantly	O
in	O
the	O
proximal	O
tubule	O
,	O
were	O
responsible	O
for	O
the	O
polyuria	O
and	O
natriuresis	B-PROC
observed	O
.	O

There	O
was	O
no	O
clear	O
relationship	O
between	O
the	O
presence	O
of	O
the	O
L386del	O
variant	O
and	O
SARS	O
clinical	O
severity	O
as	O
defined	O
either	O
by	O
the	O
need	O
for	O
intensive	O
-	O
care	O
therapy	O
and	O
/	O
or	O
ventilation	O
or	O
by	O
death	B-PROC
.	O

To	O
take	O
the	O
growth	B-PROC
and	O
seasonal	O
trends	O
of	O
monthly	O
PE	O
into	O
consideration	O
,	O
Box	O
and	O
Tiao	O
'	O
s	O
time	O
-	O
series	O
event	O
intervention	O
analysis	O
based	O
on	O
the	O
Box	O
-	O
Jenkins	O
auto	O
-	O
regressive	O
integrated	O
moving	B-PROC
-	O
average	O
model	O
was	O
applied	O
to	O
evaluate	O
the	O
impact	O
of	O
various	O
cost	O
containment	O
strategies	O
on	O
total	O
and	O
subsector	O
(	O
outpatient	O
,	O
inpatient	O
,	O
clinic	O
and	O
hospital	O
sectors	O
)	O
PE	O
.	O

This	O
is	O
particularly	O
true	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
(	O
WNV	O
)	O
disease	O
,	O
Toscana	O
virus	O
(	O
TOSV	O
)	O
disease	O
,	O
and	O
potentially	O
for	O
avian	O
influenza	O
virus	O
(	O
H5N1	O
).	O

In	O
stable	O
transgenic	O
tobacco	O
plants	O
and	O
lettuce	O
plants	O
generated	O
by	O
Agrobacterium	O
-	O
mediated	O
transformation	B-PROC
,	O
tobacco	O
and	O
lettuce	O
leaves	O
were	O
observed	O
to	O
express	O
the	O
S1	O
at	O
high	O
levels	O
from	O
the	O
Cauliflower	O
Mosaic	O
Virus	O
35S	O
promoter	O
with	O
Northern	O
blot	O
analysis	O
.	O

When	O
the	O
S1	O
was	O
expressed	B-PROC
in	O
transplastomic	O
tobacco	O
,	O
S1	O
messenger	O
RNA	O
and	O
its	O
corresponding	O
protein	O
were	O
detected	O
on	O
Northern	O
and	O
Western	O
blot	O
analyses	O
,	O
respectively	O
.	O

During	O
the	O
process	O
of	O
docking	B-PROC
the	O
octapeptides	O
to	O
the	O
SARS	O
enzyme	O
,	O
the	O
residues	O
of	O
the	O
catalytic	O
dyad	O
,	O
i	O
.	O
e	O
.,	O
His	O
-	O
41	O
and	O
Cys	O
-	O
145	O
are	O
actively	O
involved	O
in	O
forming	O
the	O
hydrogen	O
bonds	O
,	O
so	O
is	O
the	O
center	O
residue	O
(	O
Gln	O
)	O
of	O
all	O
the	O
three	O
octapeptides	O
.	O

Here	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
the	O
S1	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
complex	O
with	O
a	O
neutralizing	O
antibody	B-PROC
,	O
80R	O
,	O
at	O
2	O
.	O
3	O
A	O
resolution	O
,	O
as	O
well	O
as	O
the	O
structure	O
of	O
the	O
uncomplexed	O
S1	O
RBD	O
at	O
2	O
.	O
2	O
A	O
resolution	O
.	O

We	O
further	O
show	O
that	O
the	O
RBD	O
of	O
S1	O
forms	O
dimers	O
via	O
an	O
extensive	O
interface	O
that	O
is	O
disrupted	O
in	O
receptor	O
-	O
and	O
antibody	B-PROC
-	O
bound	O
crystal	O
structures	O
,	O
and	O
we	O
propose	O
a	O
role	O
for	O
the	O
dimer	O
in	O
virus	O
stability	O
and	O
infectivity	O
.	O

Infectious	O
complication	O
was	O
the	O
most	O
common	O
cause	O
of	O
death	B-PROC
in	O
our	O
patients	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
process	O
of	O
spike	O
(	O
S	O
)-	O
receptor	O
interaction	O
during	O
coronavirus	O
entry	O
,	O
we	O
evaluated	O
the	O
contributions	O
of	O
mutations	O
in	O
different	O
regions	O
of	O
the	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
S	O
protein	O
to	O
natural	O
receptor	O
murine	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	B-PROC
adhesion	I-PROC
molecule	O
1a	O
(	O
CEACAM1a	O
)	O
dependence	O
and	O
to	O
the	O
acquisition	O
of	O
extended	O
host	O
range	O
.	O

In	O
addition	O
,	O
these	O
viruses	O
showed	O
a	O
decreased	O
binding	O
to	O
and	O
inhibition	B-PROC
by	O
soluble	O
CEACAM1a	O
.	O

TITLE	O
:	O
Exercise	O
capacity	O
and	O
pulmonary	B-PROC
function	I-PROC
in	O
hospital	O
workers	O
recovered	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Airflow	B-PROC
was	O
marked	O
with	O
intrapulmonary	O
smoke	O
for	O
visualization	O
.	O

Due	O
to	O
the	O
small	O
number	O
of	O
ferret	O
suppliers	O
,	O
animals	O
are	O
often	O
shipped	O
long	O
distances	O
,	O
requiring	O
air	O
transport	B-PROC
and	O
intermediate	O
handlers	O
.	O

The	O
animals	O
have	O
specific	O
dietary	O
requirements	O
,	O
and	O
proper	O
nutrition	B-PROC
is	O
key	O
.	O

No	O
significant	O
differences	O
were	O
found	O
between	O
children	O
representing	O
viral	B-PROC
infection	I-PROC
alone	O
,	O
combined	O
viral	O
and	O
bacterial	O
infection	O
,	O
bacterial	O
infection	O
alone	O
,	O
and	O
neither	O
viral	O
nor	O
bacterial	O
infection	O
,	O
regarding	O
clinical	O
cure	O
,	O
relapse	O
and	O
reinfection	O
rates	O
.	O

At	O
postchallenge	O
day	O
7	O
,	O
serum	O
IgG	O
and	O
fecal	O
IgA	O
antibody	B-PROC
titers	O
remained	O
the	O
same	O
or	O
increased	O
only	O
twofold	O
compared	O
to	O
prechallenge	O
titers	O
.	O

Pigs	O
were	O
ventilated	O
at	O
random	O
conventionally	O
with	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
2	O
-	O
3	O
cm	O
H2O	O
and	O
tidal	O
volume	O
10	O
-	O
12	O
mL	O
/	O
kg	O
(	O
control	O
),	O
with	O
CLPV	O
(	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
10	O
cm	O
H2O	O
,	O
tidal	O
volume	O
6	O
mL	O
/	O
kg	O
),	O
or	O
with	O
HFOV	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
N	O
protein	O
was	O
an	O
RNA	B-PROC
chaperone	I-PROC
.	O

During	O
construction	O
of	O
an	O
infectious	O
clone	O
from	O
a	O
Vero	O
cell	O
-	O
adapted	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
we	O
found	O
that	O
a	O
G	O
-	O
C	O
point	B-PROC
mutation	I-PROC
at	O
nucleotide	O
position	O
15526	O
,	O
causing	O
Arg	O
-	O
to	O
-	O
Pro	O
mutation	O
at	O
amino	O
acid	O
position	O
132	O
of	O
the	O
helicase	O
protein	O
,	O
is	O
lethal	O
to	O
the	O
infectivity	O
of	O
IBV	O
on	O
Vero	O
cells	O
.	O

CD4	O
+	O
and	O
CD8	O
+	O
spleen	O
T	O
lymphocytes	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
(	O
FCM	O
)	O
to	O
evaluate	O
T	O
cell	O
-	O
mediated	O
immune	B-PROC
responses	I-PROC
,	O
the	O
antigen	O
-	O
specific	O
responses	O
of	O
T	O
cells	O
were	O
evaluated	O
by	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
assay	O
,	O
and	O
the	O
level	O
of	O
IgG	O
in	O
antisera	O
from	O
immunized	O
mice	O
was	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Protection	O
based	O
criteria	O
were	O
:	O
virus	O
re	O
-	O
isolation	O
attempts	O
from	O
trachea	O
,	O
tracheal	O
and	O
renal	O
histopathology	O
as	O
well	O
as	O
IBV	O
antigens	O
detection	O
by	O
immunofluorescent	O
antibody	B-PROC
technique	O
in	O
kidney	O
sections	O
.	O

Protection	O
based	O
criteria	O
were	O
:	O
virus	O
re	O
-	O
isolation	O
attempts	O
from	O
trachea	O
,	O
tracheal	O
and	O
renal	O
histopathology	O
as	O
well	O
as	O
IBV	O
antigens	O
detection	O
by	O
immunofluorescent	O
antibody	B-PROC
technique	O
in	O
kidney	O
sections	O
.	O

The	O
study	O
adds	O
to	O
the	O
amazing	O
diversity	O
of	O
nidoviruses	O
and	O
appeals	O
for	O
a	O
more	O
extensive	O
characterization	O
of	O
nonmammalian	O
nidoviruses	O
to	O
better	O
understand	O
the	O
evolution	B-PROC
of	O
these	O
largest	O
known	O
RNA	O
viruses	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
,	O
the	O
cause	O
of	O
SARS	O
,	O
utilizes	O
ACE2	O
as	O
an	O
essential	O
receptor	O
for	O
cell	B-PROC
fusion	I-PROC
and	O
in	O
vivo	O
infections	O
in	O
mice	O
.	O

To	O
explore	O
the	O
relationship	O
between	O
S	O
and	O
COX	O
-	O
2	O
,	O
we	O
constructed	O
a	O
series	O
of	O
plasmids	O
containing	O
truncated	O
N	O
-	O
terminal	O
fragments	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
gene	O
(	O
designated	O
from	O
Sa	O
to	O
Si	O
),	O
which	O
encoded	O
truncated	O
S	O
proteins	O
,	O
and	O
investigated	O
whether	O
these	O
truncated	O
proteins	O
could	O
induce	O
effective	O
expression	B-PROC
of	O
COX	O
-	O
2	O
in	O
293T	O
cells	O
.	O

Our	O
results	O
showed	O
that	O
S	O
(	O
d	O
)	O
that	O
encoded	O
a	O
truncated	O
S	O
protein	O
with	O
422	O
amino	O
acid	O
residues	O
(	O
from	O
1	O
to	O
422	O
aa	O
),	O
a	O
part	O
of	O
672	O
amino	O
-	O
acid	O
S1	O
subunit	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
COX	O
-	O
2	O
expression	B-PROC
.	O

Immunofluorescence	O
examinations	O
also	O
give	O
the	O
evidence	O
that	O
these	O
N	O
terminal	O
422	O
amino	O
acids	O
of	O
the	O
S	O
protein	O
were	O
also	O
required	O
for	O
the	O
correct	O
localization	B-PROC
of	O
the	O
protein	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
binds	O
to	O
hUbc9	O
,	O
a	O
ubiquitin	B-PROC
conjugating	O
enzyme	O
of	O
the	O
sumoylation	B-PROC
system	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
explored	O
experiences	O
caring	O
for	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
with	O
a	O
focus	O
on	O
the	O
suffering	O
between	O
the	O
""""	O
private	O
""""	O
and	O
""""	O
professional	O
""""	O
selves	O
,	O
in	O
order	O
to	O
describe	O
the	O
psychological	O
impact	O
and	O
ethical	O
practice	O
of	O
SARS	O
events	O
as	O
related	O
to	O
nursing	B-PROC
professionals	O
.	O

TITLE	O
:	O
Use	O
of	O
virus	O
vectors	O
for	O
the	O
expression	B-PROC
in	O
plants	O
of	O
active	O
full	O
-	O
length	O
and	O
single	O
chain	O
anti	O
-	O
coronavirus	O
antibodies	O
.	O

ABSTRACT	O
:	O
To	O
extend	O
the	O
potential	O
of	O
antibodies	O
and	O
their	O
derivatives	O
to	O
provide	O
passive	O
protection	O
against	O
enteric	O
infections	O
when	O
supplied	O
orally	O
in	O
crude	O
plant	O
extracts	O
,	O
we	O
have	O
expressed	B-PROC
both	O
a	O
small	O
immune	O
protein	O
(	O
SIP	O
)	O
and	O
a	O
full	O
-	O
length	O
antibody	B-PROC
in	O
plants	O
using	O
two	O
different	O
plant	O
virus	O
vectors	O
based	O
on	O
potato	O
virus	O
X	O
(	O
PVX	O
)	O
and	O
cowpea	O
mosaic	O
virus	O
(	O
CPMV	O
).	O

Western	O
blot	O
analysis	O
revealed	O
the	O
efficient	O
expression	B-PROC
of	O
both	O
the	O
SIP	O
and	O
IgA	O
molecules	O
.	O

ABSTRACT	O
:	O
The	O
incidence	O
of	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
and	O
vancomycin	O
-	O
resistant	O
Enterococcus	O
(	O
VRE	O
)	O
infections	O
continues	O
to	O
rise	O
in	O
National	O
Nosocomial	O
Infections	O
Surveillance	O
system	O
hospitals	O
,	O
and	O
these	O
pathogens	O
are	O
reportedly	O
causing	O
more	O
than	O
100	O
,	O
000	O
infections	O
and	O
many	O
deaths	B-PROC
each	O
year	O
in	O
US	O
healthcare	O
facilities	O
.	O

To	O
better	O
understand	O
the	O
genomic	O
mechanisms	O
for	O
viral	O
attenuation	O
,	O
we	O
sequenced	O
the	O
complete	O
genomes	O
of	O
two	O
virulent	O
TGEV	O
strains	O
and	O
their	O
attenuated	O
counterparts	O
:	O
virulent	O
TGEV	O
Miller	O
M6	O
and	O
attenuated	O
TGEV	O
Miller	O
M60	O
and	O
virulent	O
TGEV	O
Purdue	O
and	O
attenuated	O
TGEV	O
Purdue	O
P115	O
,	O
together	O
with	O
the	O
ISU	O
-	O
1	O
strain	O
of	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
-	O
ISU	O
-	O
1	O
),	O
a	O
naturally	O
occurring	O
TGEV	O
deletion	O
mutant	O
with	O
an	O
altered	O
respiratory	O
tropism	B-PROC
and	O
reduced	O
virulence	B-PROC
.	O

ABSTRACT	O
:	O
The	O
observations	O
that	O
Lymphopenia	O
is	O
common	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
and	O
that	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
PBMC	O
)	O
could	O
be	O
infected	O
by	O
SARS	O
-	O
CoV	O
indicate	O
that	O
PBMC	O
could	O
be	O
useful	O
in	O
identifying	O
the	O
gene	B-PROC
expression	I-PROC
profile	O
in	O
convalescent	O
patients	O
and	O
tracing	O
the	O
host	B-PROC
response	I-PROC
to	O
SARS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Expression	B-PROC
of	O
elevated	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
ACE2	O
+	O
cells	O
in	O
SARS	O
patients	O
:	O
relation	O
to	O
the	O
acute	O
lung	O
injury	O
and	O
pathogenesis	B-PROC
of	O
SARS	O
.	O

In	O
the	O
present	O
study	O
,	O
immunohistochemistry	O
(	O
IHC	O
)	O
and	O
in	O
situ	O
hybridization	B-PROC
(	O
ISH	O
)	O
assays	O
were	O
used	O
to	O
analyse	O
the	O
expression	B-PROC
of	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
,	O
and	O
some	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
PICs	O
)	O
including	O
MCP	O
-	O
1	O
,	O
TGF	O
-	O
beta1	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
and	O
IL	O
-	O
6	O
in	O
autopsy	O
tissues	O
from	O
four	O
patients	O
who	O
died	B-PROC
of	O
SARS	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
oxygenation	B-PROC
index	O
after	O
24	O
hours	O
of	O
HFOV	O
support	O
.	O

There	O
was	O
no	O
significant	O
change	O
in	O
blood	B-PROC
pressure	I-PROC
associated	O
with	O
initiation	O
and	O
administration	O
of	O
HFOV	O
.	O

High	O
-	O
frequency	O
oscillatory	O
ventilation	O
was	O
effective	O
and	O
safe	O
in	O
correcting	O
oxygenation	B-PROC
failure	O
associated	O
with	O
ARDS	O
in	O
surgical	O
patients	O
.	O

Since	O
its	O
associated	O
morbidity	O
and	O
mortality	O
have	O
been	O
postulated	O
to	O
be	O
due	O
to	O
immune	O
dysregulation	O
,	O
we	O
investigated	O
which	O
of	O
the	O
viral	O
proteins	O
is	O
responsible	O
for	O
chemokine	O
overexpression	B-PROC
.	O

Interestingly	O
,	O
mutagenesis	B-PROC
of	O
Tyr414	O
showed	O
that	O
while	O
this	O
residue	O
can	O
tolerate	O
a	O
number	O
of	O
substitutions	O
,	O
it	O
was	O
intolerant	O
of	O
Lysine	O
or	O
deletion	O
.	O

Importantly	O
,	O
the	O
viruses	O
produced	O
in	O
this	O
study	O
provide	O
a	O
system	O
by	O
which	O
the	O
role	O
of	O
the	O
nsp2	O
protein	O
in	O
viral	B-PROC
infection	I-PROC
can	O
be	O
characterized	O
.	O

The	O
GBP	O
-	O
fused	O
SCVme	O
bound	O
to	O
gold	O
nanoparticles	O
successfully	O
interacted	O
with	O
its	O
antibody	B-PROC
and	O
showed	O
changes	O
in	O
absorbance	O
and	O
color	O
,	O
allowing	O
efficient	O
diagnosis	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
fusion	O
proteins	O
could	O
be	O
successfully	O
immobilized	O
on	O
the	O
gold	O
surface	O
by	O
nanopatterning	O
and	O
microcontact	O
printing	O
as	O
examined	O
by	O
atomic	O
force	O
microscopy	O
and	O
surface	O
plasmon	O
resonance	O
analysis	O
.	O

The	O
poly	O
(	O
dimethylsiloxane	O
)	O
microfluidic	O
channels	O
were	O
created	O
on	O
the	O
gold	O
surface	O
and	O
were	O
used	O
for	O
antigen	O
-	O
antibody	B-PROC
and	O
DNA	O
-	O
DNA	O
interaction	O
studies	O
.	O

These	O
include	O
other	O
acute	O
emerging	O
or	O
re	O
-	O
emerging	O
viral	B-PROC
diseases	I-PROC
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
West	O
-	O
Nile	O
virus	O
,	O
Ebola	O
virus	O
,	O
monkeypox	O
,	O
as	O
well	O
as	O
the	O
more	O
inapparent	O
insidious	O
slow	O
viral	O
and	O
prion	O
diseases	O
.	O

We	O
also	O
noted	O
that	O
MAb	O
SIb4	O
exerted	B-PROC
a	O
neutralizing	O
effect	O
against	O
HKU39849	O
;	O
its	O
reactive	O
epitope	O
was	O
mapped	O
to	O
aa	O
residues	O
435	O
to	O
439	O
of	O
the	O
S	O
protein	O
.	O

We	O
offer	O
the	O
data	O
to	O
facilitate	O
the	O
development	B-PROC
of	O
therapeutic	O
agents	O
and	O
preventive	O
vaccines	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

These	O
animals	O
died	B-PROC
with	O
a	O
shorter	O
survival	O
time	O
than	O
A	O
/	O
J	O
mice	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
TNF	O
-	O
alpha	O
,	O
produced	O
by	O
virus	O
-	O
infected	O
macrophages	O
,	O
is	O
responsible	O
for	O
induction	B-PROC
of	I-PROC
apoptosis	I-PROC
in	O
uninfected	O
T	O
cells	O
,	O
primarily	O
CD8	O
+	O
T	O
cells	O
.	O

The	O
elevation	O
of	O
IP	O
-	O
10	O
and	O
IL	O
-	O
2	O
antedated	O
the	O
development	B-PROC
of	O
chest	O
involvement	O
and	O
reached	O
peak	O
levels	O
earlier	O
than	O
the	O
radiographic	O
scores	O
.	O

Respiratory	B-PROC
mechanics	I-PROC
and	O
arterial	O
blood	B-PROC
gases	I-PROC
were	O
assessed	O
on	O
days	O
1	O
and	O
day	O
5	O
of	O
mechanical	O
ventilation	O
.	O

2	O
.	O
2	O
cmH	O
(	O
2	O
)	O
O	O
/	O
l	O
per	O
second	O
,	O
respectively	O
);	O
on	O
day	O
5	O
static	O
elastance	O
and	O
iso	O
-	O
CO	O
(	O
2	O
)	O
minimal	O
resistance	B-PROC
values	O
were	O
higher	O
than	O
on	O
day	O
1	O
(	O
21	O
.	O
2	O
+/-	O

On	O
day	O
5	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
PaO	B-PROC
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
in	O
both	O
groups	O
.	O

Such	O
reframing	O
may	O
lead	O
to	O
short	O
-	O
term	O
improvements	O
in	O
vaccination	O
rates	O
to	O
the	O
detriment	O
of	O
long	O
-	O
term	O
SARS	O
vaccination	O
development	B-PROC
.	O

The	O
combined	O
impact	O
of	O
the	O
two	O
levels	O
of	O
quarantine	O
had	O
reduced	O
the	O
case	O
number	O
and	O
deaths	B-PROC
by	O
almost	O
a	O
half	O
.	O

The	O
inspiratory	B-PROC
pressure	O
was	O
25	O
cm	O
H2O	O
and	O
PEEP	O
17	O
cm	O
H2O	O
.	O

The	O
endothelial	O
cell	O
is	O
the	O
target	O
of	O
the	O
systemic	O
phlogistic	O
reaction	O
;	O
its	O
stimulation	O
is	O
followed	O
by	O
the	O
production	O
of	O
many	O
vasoactive	O
paracrine	B-PROC
and	O
systemic	O
agents	O
.	O

Previous	O
work	O
has	O
pointed	O
to	O
the	O
immune	O
system	O
,	O
telomeres	O
and	O
DNA	B-PROC
repair	I-PROC
pathways	B-PROC
as	O
important	O
and	O
distinct	O
determinants	O
of	O
a	O
normal	O
healthy	O
lifespan	O
.	O

We	O
performed	O
autopsies	O
on	O
six	O
confirmed	O
SARS	O
cases	O
,	O
with	O
six	O
normal	O
subjects	O
as	O
controls	O
;	O
spleen	O
samples	O
from	O
these	O
autopsies	O
were	O
examined	O
with	O
hematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
)	O
sections	O
,	O
in	O
situ	O
hybridization	B-PROC
for	O
SARS	O
virus	O
genomic	O
sequences	O
,	O
and	O
immunohistochemistry	O
with	O
seven	O
monoclonal	O
antibodies	O
to	O
five	O
cell	O
types	O
.	O

TITLE	O
:	O
Baculovirus	O
expression	B-PROC
of	O
HCoV	O
-	O
OC43	O
nucleocapsid	O
protein	O
and	O
development	B-PROC
of	O
a	O
Western	O
blot	O
assay	O
for	O
detection	O
of	O
human	O
antibodies	O
against	O
HCoV	O
-	O
OC43	O
.	O

Here	O
we	O
show	O
that	O
inhibition	B-PROC
of	O
the	O
Raf	O
/	O
MEK	O
/	O
ERK	O
signaling	B-PROC
pathway	I-PROC
by	O
the	O
MEK	O
inhibitor	O
UO126	O
significantly	O
impaired	O
MHV	O
progeny	O
production	O
(	O
a	O
reduction	O
of	O
95	O
to	O
99	O
%	O
in	O
virus	O
titer	O
),	O
which	O
correlated	O
with	O
the	O
phosphorylation	B-PROC
status	O
of	O
ERK1	O
/	O
2	O
.	O

However	O
,	O
synthesis	B-PROC
of	O
viral	O
genomic	O
and	O
subgenomic	O
RNAs	O
was	O
severely	O
suppressed	O
by	O
UO126	O
treatment	O
,	O
as	O
demonstrated	O
by	O
a	O
reduced	O
incorporation	O
of	O
[	O
3H	O
]	O
uridine	O
and	O
a	O
decrease	O
in	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
activity	O
in	O
a	O
defective	O
-	O
interfering	O
RNA	O
-	O
CAT	O
reporter	O
assay	O
.	O

Furthermore	O
,	O
to	O
determine	O
whether	O
these	O
features	O
resulted	O
in	O
differences	O
in	O
total	O
TCR	B-PROC
diversity	O
in	O
the	O
NP366	O
+	O
and	O
PA224	O
+	O
responses	O
,	O
we	O
quantified	O
the	O
number	O
of	O
different	O
CD8	O
T	O
clonotypes	O
responding	O
to	O
each	O
epitope	O
.	O

To	O
investigate	O
it	O
,	O
two	O
molecular	B-PROC
dynamics	I-PROC
(	O
MD	O
)	O
simulations	O
in	O
water	O
for	O
dimer	O
and	O
monomer	O
models	O
have	O
been	O
carried	O
out	O
,	O
using	O
the	O
crystal	O
structure	O
of	O
protomer	O
A	O
of	O
the	O
dimer	O
as	O
the	O
starting	O
structure	O
for	O
the	O
monomer	O
.	O

CONCLUSIONS	O
:	O
CBP	O
was	O
effective	O
in	O
treatment	O
of	O
pediatric	O
septic	O
shock	O
by	O
improving	O
the	O
oxygenation	B-PROC
,	O
correcting	O
metabolic	B-PROC
acidosis	O
,	O
stabilizing	O
BP	O
,	O
increasing	O
the	O
tissue	O
perfusion	O
and	O
eliminating	O
the	O
medium	O
molecule	O
substances	O
.	O

Women	O
in	O
the	O
SARS	O
cohort	O
adopted	O
behavioral	B-PROC
strategies	O
to	O
mitigate	O
their	O
risk	O
of	O
contracting	O
infection	O
.	O

No	O
viral	B-PROC
infections	I-PROC
were	O
detected	O
in	O
six	O
herds	O
,	O
while	O
16	O
-	O
21	O
herds	O
had	O
RSV	O
,	O
BCV	O
,	O
BAV	O
or	O
PIV3	O
.	O

Forty	O
years	O
of	O
clinical	O
and	O
basic	O
science	O
research	O
have	O
elaborated	O
many	O
of	O
the	O
pathophysiologic	O
mechanisms	O
that	O
link	O
initiating	O
insults	O
to	O
the	O
development	B-PROC
of	O
alveolar	O
membrane	O
failure	O
.	O

ABSTRACT	O
:	O
Acute	O
necrotizing	O
pancreatitis	O
leads	O
to	O
a	O
systemic	O
inflammatory	B-PROC
response	I-PROC
characterized	O
by	O
widespread	O
leukocyte	B-PROC
activation	I-PROC
and	O
,	O
as	O
a	O
consequence	O
,	O
distant	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
Hochu	O
-	O
ekki	O
-	O
to	O
(	O
TJ	O
-	O
41	O
),	O
a	O
Japanese	O
herbal	O
medicine	O
,	O
on	O
the	O
development	B-PROC
of	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
in	O
mice	O
.	O

TITLE	O
:	O
Clinical	O
features	O
,	O
complications	O
and	O
atypical	O
manifestations	O
of	O
children	O
with	O
severe	O
forms	O
of	O
dengue	O
hemorrhagic	O
fever	B-PROC
in	O
South	O
India	O
.	O

RESULTS	O
:	O
Of	O
858	O
patients	O
with	O
dengue	O
fever	B-PROC
/	O
DHF	O
admitted	O
to	O
the	O
hospital	O
during	O
the	O
study	O
period	O
,	O
109	O
cases	O
with	O
severe	O
forms	O
of	O
disease	O
required	O
PICU	O
admission	O
,	O
of	O
which	O
9	O
patients	O
died	B-PROC
.	O

Acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHEII	O
)	O
scores	O
,	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
evaluation	O
scores	O
and	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
were	O
observed	O
before	O
and	O
after	O
HVHF	O
.	O

The	O
culture	O
of	O
CRCoV	O
will	O
enable	O
analysis	O
of	O
the	O
expression	B-PROC
and	O
function	O
of	O
this	O
and	O
other	O
CRCoV	O
proteins	O
as	O
well	O
as	O
allowing	O
the	O
study	O
of	O
the	O
role	O
of	O
CRCoV	O
in	O
the	O
aetiology	O
of	O
canine	O
infectious	O
respiratory	O
disease	O
.	O

The	O
enzymatic	O
inhibition	B-PROC
activities	O
of	O
these	O
52	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
binders	O
were	O
further	O
applied	O
to	O
FRET	O
-	O
based	O
assay	O
,	O
and	O
IC	O
(	O
50	O
)	O
values	O
were	O
determined	O
.	O

TITLE	O
:	O
A	O
hypervariable	O
region	O
within	O
the	O
3	O
'	O
cis	O
-	O
acting	O
element	O
of	O
the	O
murine	O
coronavirus	O
genome	O
is	O
nonessential	O
for	O
RNA	B-PROC
synthesis	I-PROC
but	O
affects	O
pathogenesis	B-PROC
.	O

Our	O
results	O
show	O
that	O
neither	O
the	O
HVR	O
nor	O
oct	O
is	O
essential	O
for	O
the	O
basic	O
mechanism	O
of	O
MHV	O
RNA	B-PROC
synthesis	I-PROC
in	O
tissue	O
culture	O
.	O

ABSTRACT	O
:	O
To	O
address	O
lung	O
recruitment	O
according	O
to	O
pressure	O
/	O
volume	O
curves	O
,	O
along	O
with	O
regional	O
recruitment	O
versus	O
hyperinflation	O
evidence	O
from	O
computed	O
tomography	O
and	O
electrical	B-PROC
impedance	I-PROC
tomography	O
.	O

Both	O
computed	O
tomography	O
and	O
electrical	B-PROC
impedance	I-PROC
tomography	O
can	O
help	O
titrate	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
in	O
these	O
regions	O
,	O
thereby	O
assuring	O
an	O
'	O
open	O
lung	O
'	O
ventilatory	O
pattern	O
.	O

This	O
study	O
shows	O
the	O
high	O
incidence	O
of	O
cytokine	O
-	O
related	O
disease	O
as	O
the	O
cause	O
of	O
death	B-PROC
in	O
children	O
with	O
perinatal	O
HIE	O
sequelae	O
.	O

Development	B-PROC
and	O
high	O
-	O
throughput	O
screening	O
of	O
efficacious	O
drugs	O
is	O
therefore	O
critical	O
.	O

If	O
enhanced	O
engineering	O
controls	O
could	O
reduce	O
the	O
basic	O
reproductive	B-PROC
number	O
(	O
R0	O
)	O
below	O
1	O
.	O
60	O
for	O
chickenpox	O
and	O
3	O
for	O
measles	O
,	O
our	O
simulations	O
show	O
that	O
in	O
such	O
a	O
prepared	O
response	O
with	O
public	O
health	O
interventions	O
would	O
have	O
a	O
high	O
probability	O
of	O
containing	O
the	O
indoor	O
airborne	O
infections	O
.	O

Pathologic	O
examination	O
suggests	O
that	O
the	O
extensive	O
involvement	O
of	O
the	O
central	O
nervous	O
system	O
likely	O
contributed	O
to	O
the	O
death	B-PROC
of	O
Tg	O
+	O
mice	O
,	O
even	O
though	O
viral	O
pneumonia	O
was	O
present	O
.	O

All	O
three	O
proteins	O
inhibit	O
the	O
expression	B-PROC
of	O
beta	O
interferon	O
(	O
IFN	O
-	O
beta	O
),	O
and	O
further	O
examination	O
revealed	O
that	O
these	O
SARS	O
-	O
CoV	O
proteins	O
inhibit	O
a	O
key	O
protein	O
necessary	O
for	O
the	O
expression	B-PROC
of	O
IFN	O
-	O
beta	O
,	O
IRF	O
-	O
3	O
.	O

The	O
recovered	O
deletion	O
mutant	O
grew	O
in	O
Vero	O
E6	O
,	O
Huh	O
-	O
7	O
,	O
and	O
CaCo	O
-	O
2	O
cells	O
to	O
titers	O
20	O
-,	O
200	O
-,	O
and	O
200	O
-	O
fold	O
lower	O
than	O
the	O
recombinant	O
wild	O
-	O
type	O
virus	O
,	O
respectively	O
,	O
indicating	O
that	O
although	O
the	O
E	O
protein	O
has	O
an	O
effect	O
on	O
growth	B-PROC
,	O
it	O
is	O
not	O
essential	O
for	O
virus	B-PROC
replication	I-PROC
.	O

Over	O
the	O
course	O
of	O
a	O
7	O
-	O
month	O
period	O
,	O
nasopharyngeal	O
-	O
wash	O
samples	O
from	O
2	O
(	O
7	O
.	O
7	O
%)	O
of	O
26	O
consecutive	O
children	O
with	O
KS	O
and	O
4	O
(	O
7	O
.	O
7	O
%)	O
of	O
52	O
matched	O
control	O
subjects	O
tested	O
positive	O
for	O
HCoV	O
-	O
NL63	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
.	O

TITLE	O
:	O
The	O
STAT4	O
and	O
STAT6	O
pathways	B-PROC
in	O
pancreatitis	O
-	O
associated	O
lung	O
injury	O
.	O

We	O
hypothesized	O
that	O
a	O
modified	O
organ	O
expression	B-PROC
of	O
cytokines	O
and	O
chemokines	O
that	O
occurs	O
in	O
transgenic	O
mice	O
may	O
affect	O
the	O
systemic	O
response	O
to	O
severe	O
acute	O
pancreatitis	O
.	O

The	O
genetic	O
susceptibility	O
factors	O
depend	O
on	O
the	O
degree	O
of	O
prematurity	O
at	O
birth	B-PROC
,	O
consistent	O
with	O
sequential	O
differentiation	B-PROC
of	O
the	O
lung	O
and	O
gestation	B-PROC
-	O
dependent	O
differences	O
in	O
clinical	O
presentation	O
.	O

Spike	O
glycoprotein	O
of	O
SARS	O
-	O
CoV	O
was	O
recombined	O
by	O
using	O
insect	O
-	O
baculovirus	O
expression	B-PROC
system	O
and	O
Nickel	O
affinity	O
Magnet	O
Beads	O
,	O
and	O
then	O
used	O
to	O
stimulate	O
cultured	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
).	O

The	O
hope	O
is	O
that	O
future	O
management	O
of	O
acute	O
pancreatitis	O
with	O
a	O
better	O
understanding	O
of	O
the	O
pathogenesis	B-PROC
of	O
lung	O
injury	O
will	O
be	O
directed	O
against	O
the	O
production	O
of	O
noxious	O
cytokines	O
.	O

TITLE	O
:	O
[	O
Emerging	O
viral	B-PROC
diseases	I-PROC
].	O

Numerous	O
pathogens	O
,	O
including	O
viruses	O
like	O
West	O
Nile	O
,	O
Chikungunya	O
and	O
Japanese	O
encephalitis	O
on	O
the	O
one	O
hand	O
,	O
and	O
hemorrhagic	O
fever	B-PROC
viruses	O
like	O
Ebola	O
and	O
Maburg	O
,	O
are	O
particular	O
concerns	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
characterized	O
by	O
rapidly	O
progressing	O
respiratory	O
failure	O
resembling	O
acute	O
/	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
associated	O
with	O
uncontrolled	O
inflammatory	B-PROC
responses	I-PROC
.	O

Our	O
results	O
suggest	O
potential	O
involvement	O
of	O
3a	O
/	O
X1	O
and	O
7a	O
/	O
X4	O
proteins	O
in	O
the	O
pathological	O
inflammatory	B-PROC
responses	I-PROC
in	O
SARS	O
.	O

Here	O
we	O
review	O
the	O
progress	O
of	O
studies	O
on	O
the	O
pathogenesis	B-PROC
of	O
the	O
disease	O
,	O
in	O
particular	O
,	O
studies	O
on	O
the	O
molecular	O
level	O
.	O

The	O
""""	O
progressive	O
docking	B-PROC
""""	O
has	O
been	O
tested	O
on	O
drug	O
-	O
like	O
substances	O
from	O
the	O
NCI	O
database	O
that	O
have	O
been	O
docked	O
into	O
several	O
unrelated	O
targets	O
,	O
including	O
human	O
sex	O
hormone	O
binding	O
globulin	O
(	O
SHBG	O
),	O
carbonic	O
anhydrase	O
,	O
corticosteroid	O
-	O
binding	O
globulin	O
,	O
SARS	O
3C	O
-	O
like	O
protease	O
,	O
and	O
HIV1	O
reverse	O
transcriptase	B-PROC
.	O

Malaria	O
must	O
always	O
be	O
suspected	O
in	O
a	O
returning	O
traveler	O
or	O
a	O
visitor	O
from	O
a	O
malaria	O
-	O
endemic	O
country	O
with	O
an	O
acute	O
febrile	B-PROC
illness	O
.	O

The	O
microarray	O
-	O
in	O
-	O
a	O
-	O
tube	O
system	O
is	O
a	O
rapid	O
,	O
labor	B-PROC
-	O
saving	O
tool	O
for	O
multiple	O
virus	O
detection	O
with	O
several	O
advantages	O
,	O
such	O
as	O
convenience	O
,	O
prevention	O
of	O
cross	O
-	O
contamination	O
of	O
the	O
PCR	O
products	O
,	O
and	O
potential	O
for	O
multiple	O
-	O
gene	O
detection	O
.	O

Second	O
,	O
HCoV	O
229E	O
structural	O
genes	O
can	O
be	O
replaced	O
by	O
multiple	O
transcriptional	B-PROC
units	O
encoding	O
various	O
antigens	O
.	O

Arterial	O
blood	B-PROC
gases	I-PROC
were	O
measured	O
immediately	O
before	O
treatment	O
,	O
and	O
again	O
at	O
3	O
and	O
6	O
hours	O
post	O
-	O
treatment	O
.	O

Accumulation	O
of	O
the	O
viral	O
envelope	O
proteins	O
at	O
this	O
compartment	O
is	O
a	O
prerequisite	O
for	O
virus	B-PROC
assembly	I-PROC
.	O

The	O
dibasic	O
motif	O
bound	O
the	O
coatomer	O
complex	O
I	O
(	O
COPI	O
)	O
in	O
an	O
in	O
vitro	O
binding	O
assay	O
,	O
suggesting	O
that	O
ER	O
retrieval	O
may	O
contribute	O
to	O
the	O
accumulation	O
of	O
SARS	O
CoV	O
S	O
protein	O
near	O
the	O
virus	B-PROC
assembly	I-PROC
site	O
for	O
interaction	O
with	O
other	O
viral	O
structural	O
proteins	O
.	O

No	O
efficacious	O
therapy	O
is	O
currently	O
available	O
,	O
and	O
vaccines	O
and	O
drugs	O
are	O
under	O
development	B-PROC
to	O
prevent	O
SARS	O
-	O
CoV	O
infection	O
in	O
many	O
countries	O
.	O

Expression	B-PROC
of	O
both	O
the	O
MisL	O
-	O
and	O
987P	O
subunit	O
FasA	O
-	O
fusions	O
to	O
the	O
TGEV	O
epitopes	O
were	O
under	O
the	O
control	O
of	O
in	O
vivo	O
-	O
induced	O
promoters	O
.	O

Expression	B-PROC
of	O
the	O
TGEV	O
epitopes	O
from	O
the	O
Salmonella	O
typhimurium	O
CS4552	O
(	O
crp	O
cya	O
asd	O
pgtE	O
)	O
vaccine	O
strain	O
was	O
greater	O
when	O
the	O
epitopes	O
were	O
fused	O
to	O
MisL	O
than	O
when	O
they	O
were	O
fused	O
to	O
the	O
987P	O
FasA	O
subunit	O
.	O

TITLE	O
:	O
Recombinant	O
dimeric	O
small	O
immunoproteins	O
neutralize	O
transmissible	O
gastroenteritis	O
virus	O
infectivity	O
efficiently	O
in	O
vitro	O
and	O
confer	O
passive	B-PROC
immunity	I-PROC
in	O
vivo	O
.	O

To	O
investigate	O
the	O
potential	O
of	O
these	O
molecules	O
to	O
provide	O
protection	O
against	O
enteric	O
infections	O
when	O
supplied	O
orally	O
,	O
SIPs	B-PROC
were	O
generated	O
against	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
a	O
highly	O
pathogenic	O
porcine	O
virus	O
.	O

Transfected	O
cells	O
secreted	B-PROC
these	O
recombinant	O
mini	O
-	O
antibodies	O
efficiently	O
,	O
mainly	O
as	O
dimers	O
stabilized	O
covalently	O
by	O
inter	O
-	O
chain	O
disulphide	O
bridges	O
.	O

This	O
viral	O
entry	O
process	O
is	O
a	O
primary	O
target	O
for	O
vaccine	O
and	O
drug	O
development	B-PROC
.	O

HCoV	O
-	O
NL63	O
S	O
is	O
expressed	B-PROC
as	O
a	O
single	O
-	O
chain	O
glycoprotein	O
and	O
consists	O
of	O
an	O
N	O
-	O
terminal	O
receptor	O
-	O
binding	O
domain	O
(	O
S1	O
)	O
and	O
a	O
C	O
-	O
terminal	O
transmembrane	O
fusion	O
domain	O
(	O
S2	O
).	O

TITLE	O
:	O
[	O
Survival	O
by	O
a	O
young	O
woman	O
with	O
malnutrition	O
due	O
to	O
alcoholism	O
and	O
eating	B-PROC
disorders	O
and	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
severe	O
pneumonia	O
who	O
showed	O
increased	O
serum	O
neutrophil	O
elastase	O
activity	O
].	O

Buffered	O
300	O
-	O
500	O
mM	O
NaCl	O
was	O
selected	O
after	O
comparison	O
of	O
several	O
buffers	O
previously	O
reported	O
for	O
similar	O
types	O
of	O
assays	O
,	O
and	O
200	O
-	O
500	O
mM	O
NaCl	O
was	O
found	O
to	O
be	O
the	O
optimal	O
ionic	O
strength	O
for	O
the	O
hybridization	B-PROC
temperatures	O
(	O
25	O
and	O
50	O
degrees	O
C	O
)	O
and	O
probe	O
designs	O
used	O
here	O
.	O

These	O
findings	O
suggest	O
that	O
E	O
protein	O
facilitates	O
viral	B-PROC
assembly	I-PROC
in	O
a	O
manner	O
that	O
does	O
not	O
require	O
E	O
protein	O
to	O
make	O
sequence	O
-	O
specific	O
contacts	O
with	O
M	O
protein	O
.	O

We	O
consider	O
isolation	O
of	O
symptomatic	O
infecteds	O
as	O
the	O
basic	O
scenario	O
,	O
and	O
express	O
effectiveness	O
as	O
the	O
proportion	O
of	O
contacts	O
that	O
need	O
to	O
be	O
traced	O
for	O
a	O
reproduction	B-PROC
ratio	O
smaller	O
than	O
1	O
.	O

TITLE	O
:	O
Expression	B-PROC
,	O
purification	O
and	O
characterization	O
of	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
non	O
-	O
structural	O
protein	O
1	O
.	O

Many	O
of	O
these	O
nsps	O
have	O
essential	O
roles	O
in	O
viral	B-PROC
replication	I-PROC
,	O
but	O
several	O
have	O
no	O
assigned	O
function	O
and	O
possess	O
amino	O
acid	O
sequences	O
that	O
are	O
unique	O
to	O
the	O
CoV	O
family	O
.	O

In	O
order	O
to	O
initiate	O
structural	O
and	O
biophysical	O
studies	O
of	O
SARS	O
-	O
CoV	O
nsp1	O
,	O
a	O
recombinant	O
expression	B-PROC
system	O
and	O
a	O
purification	O
protocol	O
have	O
been	O
developed	O
,	O
yielding	O
milligram	O
quantities	O
of	O
highly	O
purified	O
SARS	O
-	O
CoV	O
nsp1	O
.	O

No	O
surface	O
expression	B-PROC
of	O
viral	O
antigens	O
was	O
detected	O
on	O
FIPV	O
positive	O
cells	O
.	O

MHC	B-PROC
I	O
molecules	O
were	O
present	O
on	O
all	O
the	O
FIPV	O
positive	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
viral	O
proteases	O
have	O
proven	O
to	O
be	O
the	O
most	O
selective	O
and	O
useful	O
for	O
removing	O
the	O
fusion	O
tags	O
in	O
fusion	O
protein	B-PROC
expression	B-PROC
systems	O
.	O

Also	O
,	O
history	O
of	O
contacting	O
SARS	O
patients	O
within	O
2	O
weeks	O
prior	O
to	O
the	O
onset	O
of	O
illness	O
,	O
health	O
occupation	O
,	O
and	O
inferior	O
hospital	O
ranking	O
as	O
well	O
as	O
longer	O
interval	O
of	O
clinic	O
consulting	O
(	O
longer	O
than	O
1	O
day	O
)	O
were	O
the	O
risk	O
factors	O
for	O
SARS	O
-	O
related	O
deaths	B-PROC
.	O

To	O
determine	O
whether	O
primary	O
HCoV	O
-	O
229E	O
isolates	O
exhibit	O
this	O
unusual	O
genome	O
organization	O
,	O
we	O
analyzed	O
the	O
ORF4a	O
/	O
b	O
region	O
of	O
five	O
current	O
clinical	O
isolates	O
from	O
The	O
Netherlands	O
and	O
three	O
early	O
isolates	O
collected	O
at	O
the	O
Common	O
Cold	B-PROC
Unit	O
(	O
CCU	O
)	O
in	O
Salisbury	O
,	O
UK	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
acute	O
and	O
repeated	O
pulmonary	O
damage	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
caused	O
by	O
the	O
inhalation	B-PROC
of	O
3	O
-	O
methoxybutyl	O
chloroformate	O
(	O
3	O
-	O
MBCF	O
)	O
using	O
computed	O
tomography	O
(	O
CT	O
),	O
and	O
to	O
correlate	O
these	O
results	O
with	O
those	O
obtained	O
from	O
a	O
pathological	O
study	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
main	O
peptidase	O
(	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
))	O
plays	O
an	O
essential	O
role	O
in	O
the	O
life	O
-	O
cycle	O
of	O
the	O
virus	O
and	O
is	O
a	O
primary	O
target	O
for	O
the	O
development	B-PROC
of	O
anti	O
-	O
SARS	O
agents	O
.	O

The	O
most	O
worrying	O
factors	O
were	O
the	O
severity	O
of	O
consciousness	O
disorders	O
,	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
the	O
metabolic	B-PROC
acidosis	O
,	O
and	O
the	O
refractory	O
shock	O
.	O

ABSTRACT	O
:	O
This	O
prospective	O
large	O
-	O
animal	O
study	O
was	O
performed	O
to	O
evaluate	O
the	O
contribution	O
of	O
arterio	O
-	O
venous	O
extracorporeal	O
lung	O
assist	O
(	O
AV	O
-	O
ECLA	O
)	O
to	O
pulmonary	B-PROC
gas	I-PROC
exchange	I-PROC
in	O
a	O
porcine	O
lavage	O
-	O
induced	O
acute	O
lung	O
injury	O
model	O
.	O

Under	O
apnoeic	O
oxygenation	B-PROC
,	O
variations	O
of	O
sweep	O
-	O
gas	O
flow	O
were	O
performed	O
every	O
20	O
min	O
in	O
order	O
to	O
evaluate	O
the	O
membrane	O
lung	O
'	O
s	O
efficacy	O
,	O
in	O
terms	O
of	O
carbon	O
dioxide	O
(	O
CO2	O
)	O
removal	O
and	O
oxygen	O
(	O
O2	O
)	O
uptake	O
.	O

AV	O
-	O
ECLA	O
'	O
s	O
contribution	O
to	O
oxygenation	B-PROC
during	O
severe	O
hypoxemia	O
was	O
antagonized	O
by	O
a	O
significant	O
increase	O
in	O
the	O
pulmonary	O
shunt	O
fraction	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
mechanistic	O
basis	O
of	O
local	O
innate	O
and	O
adaptive	O
immunity	B-PROC
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
at	O
the	O
molecular	O
level	O
,	O
we	O
examined	O
the	O
gene	B-PROC
transcription	I-PROC
profile	O
of	O
tracheal	O
epithelial	O
layers	O
3	O
d	O
after	O
infection	O
of	O
chickens	O
with	O
an	O
attenuated	O
IBV	O
-	O
Massachusetts	O
strain	O
.	O

Using	O
serial	O
serum	O
samples	O
collected	O
from	O
SARS	O
patients	O
,	O
the	O
times	O
to	O
seroconversion	O
were	O
determined	O
by	O
IgM	O
antibody	B-PROC
detection	O
after	O
SARS	O
-	O
CoV	O
infection	O
.	O

Oxygen	O
deficiency	O
metabolic	B-PROC
variables	O
tended	O
to	O
deteriorate	O
in	O
the	O
non	O
survival	O
group	O
.	O

Dynamic	O
monitorings	O
of	O
metabolic	B-PROC
status	O
of	O
tissue	O
and	O
cell	O
are	O
valuable	O
in	O
predicting	O
the	O
development	B-PROC
of	O
MODS	O
after	O
severe	O
trauma	O
.	O

Using	O
EM	O
techniques	O
,	O
we	O
found	O
that	O
these	O
putative	O
viral	B-PROC
replication	I-PROC
sites	O
were	O
associated	O
with	O
characteristic	O
membrane	O
tubules	O
and	O
double	O
membrane	O
vesicles	O
that	O
most	O
probably	O
originated	O
from	O
ER	O
cisternae	O
.	O

RT	O
-	O
PCR	O
targeting	B-PROC
the	O
S	O
-	O
gene	O
of	O
CRCoV	O
was	O
carried	O
out	O
on	O
109	O
lung	O
samples	O
collected	O
from	O
carcasses	O
of	O
dogs	O
submitted	O
for	O
diagnostic	O
investigations	O
.	O

Abundant	O
viral	O
antigen	O
is	O
extensively	O
distributed	O
in	O
bronchial	O
epithelial	O
cells	O
and	O
alveolar	O
pneumocytes	O
,	O
and	O
necrotic	B-PROC
cellular	O
debris	O
is	O
present	O
in	O
airways	O
and	O
alveoli	O
,	O
with	O
only	O
mild	O
and	O
focal	O
pneumonitis	O
.	O

The	O
nsps	O
assemble	O
with	O
membranes	O
to	O
generate	O
double	O
membrane	O
vesicles	O
,	O
which	O
are	O
the	O
sites	O
of	O
viral	O
RNA	B-PROC
synthesis	I-PROC
.	O

One	O
of	O
them	O
,	O
a	O
54	O
-	O
year	O
-	O
old	O
woman	O
,	O
had	O
difficulty	O
breathing	B-PROC
and	O
lost	O
consciousness	O
.	O

Overall	O
the	O
results	O
indicate	O
that	O
the	O
transmembrane	O
domain	O
plays	O
a	O
crucial	O
role	O
during	O
biogenesis	B-PROC
of	O
virions	O
.	O

Tests	O
for	O
detection	O
of	O
SARS	O
coronavirus	O
antibody	B-PROC
were	O
performed	O
for	O
HCWs	O
at	O
these	O
2	O
time	O
points	O
and	O
for	O
control	O
subjects	O
during	O
the	O
SARS	O
epidemic	O
.	O

The	O
spko	O
mutant	O
(	O
mutate	B-PROC
a	O
.	O
a	O
.	O

120	O
-	O
150	O
)	O
with	O
the	O
E	O
.	O
R	O
.-	O
associated	O
domain	O
(	O
a	O
.	O
a	O
.	O
1	O
-	O
50	O
)	O
of	O
SARS	O
-	O
CoV	O
membrane	O
protein	O
results	O
in	O
the	O
failure	O
of	O
cleavage	B-PROC
of	O
this	O
recombinant	O
protein	O
by	O
SPP	O
,	O
though	O
this	O
protein	O
still	O
is	O
E	O
.	O
R	O
.-	O
associated	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
both	O
sequences	O
of	O
the	O
signal	O
peptide	O
and	O
the	O
E	O
.	O
R	O
.-	O
associated	O
domain	O
are	O
important	O
for	O
the	O
signal	O
peptide	O
cleavage	B-PROC
of	O
HCV	O
core	O
protein	O
by	O
SPP	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
performed	O
double	O
labeling	O
combining	O
in	O
situ	O
hybridization	B-PROC
with	O
immunohistochemistry	O
and	O
alternating	O
each	O
of	O
these	O
techniques	O
separately	O
in	O
consecutive	O
sections	O
to	O
evaluate	O
the	O
viral	O
distribution	O
on	O
various	O
cell	O
types	O
in	O
the	O
lungs	O
of	O
seven	O
patients	O
affected	O
with	O
SARS	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
investigate	O
immunogenicity	O
in	O
the	O
induction	O
of	O
humoral	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
,	O
severe	O
acute	O
respiratory	O
syndrome	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)-	O
N	O
gene	O
recombinant	O
replication	O
-	O
defective	O
adenoviral	O
vector	O
,	O
rAd	O
-	O
N	O
,	O
was	O
generated	O
and	O
immunized	O
BALB	O
/	O
c	O
mice	O
in	O
a	O
pcDNA3	O
.	O
1	O
-	O
N	O
prime	O
-	O
rAd	O
-	O
N	O
boost	O
regimen	O
.	O

The	O
heterogeneous	O
combinations	O
were	O
all	O
higher	O
than	O
those	O
of	O
the	O
homologous	O
combinations	O
in	O
the	O
induction	O
of	O
anti	O
-	O
N	O
antibody	B-PROC
response	I-PROC
.	O

Our	O
healthcare	O
systems	O
are	O
very	O
vulnerable	O
to	O
viruses	O
with	O
a	O
particular	O
tropism	B-PROC
for	O
hospital	O
personnel	O
.	O

Both	O
,	O
S	O
-	O
containing	O
exosomes	O
and	O
the	O
adenoviral	O
vector	O
vaccine	O
induced	O
neutralizing	O
antibody	B-PROC
titers	O
.	O

However	O
,	O
with	O
improvements	O
in	O
siRNA	O
design	O
and	O
delivery	O
methods	O
,	O
RNA	B-PROC
interference	I-PROC
has	O
the	O
potential	O
to	O
become	O
another	O
major	O
weapon	O
for	O
combating	O
dangerous	O
infections	O
due	O
to	O
viruses	O
such	O
as	O
SARS	O
-	O
CoV	O
.	O

PKC	O
epsilon	O
-	O
specific	O
siRNA	O
also	O
attenuated	O
the	O
phosphorylation	B-PROC
of	O
JNK	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
characterises	O
a	O
virulent	O
strain	O
(	O
CB	O
/	O
05	O
)	O
of	O
canine	O
coronavirus	O
(	O
CCoV	O
)	O
isolated	O
from	O
the	O
internal	O
organs	O
of	O
pups	O
that	O
had	O
died	B-PROC
of	O
a	O
systemic	O
disease	O
without	O
evidence	O
of	O
other	O
common	O
canine	O
pathogens	O
.	O

TITLE	O
:	O
Perceptions	O
related	O
to	O
human	O
avian	O
influenza	O
and	O
their	O
associations	O
with	O
anticipated	O
psychological	O
and	O
behavioral	B-PROC
responses	O
at	O
the	O
onset	O
of	O
outbreak	O
in	O
the	O
Hong	O
Kong	O
Chinese	O
general	O
population	O
.	O

Sharing	O
the	O
""""	O
lessons	O
learned	B-PROC
""""	O
in	O
different	O
regions	O
during	O
a	O
SARS	O
outbreak	O
will	O
help	O
prepare	O
for	O
the	O
next	O
epidemic	O
.	O

However	O
,	O
under	O
certain	O
experimental	O
conditions	O
,	O
such	O
as	O
intestinal	O
ischemia	O
-	O
reperfusion	O
,	O
high	O
volume	O
mechanical	O
ventilation	O
,	O
or	O
severe	O
bacterial	O
infection	O
,	O
increased	O
expression	B-PROC
of	O
PTX3	O
is	O
associated	O
with	O
more	O
severe	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Causative	O
viruses	O
of	O
postviral	O
olfactory	B-PROC
dysfunction	O
(	O
PVOD	O
)	O
have	O
not	O
yet	O
been	O
identified	O
.	O

We	O
investigated	O
the	O
presence	O
of	O
10	O
viruses	O
in	O
nasal	O
discharge	O
and	O
examined	O
the	O
time	O
course	O
,	O
with	O
regard	O
to	O
changes	O
in	O
olfactory	B-PROC
dysfunction	O
and	O
nasal	O
obstruction	O
in	O
patients	O
with	O
PVOD	O
,	O
using	O
questionnaires	O
,	O
acoustic	O
rhinometry	O
,	O
and	O
olfactory	B-PROC
tests	O
.	O

These	O
results	O
indicated	O
that	O
M	O
.	O
fermentans	O
enhances	O
apoptosis	B-PROC
in	O
surviving	O
cells	O
that	O
have	O
escaped	O
from	O
SARS	O
-	O
CoV	O
-	O
induced	O
apoptosis	B-PROC
.	O

These	O
observations	O
may	O
be	O
relevant	O
in	O
disease	O
pathogenesis	B-PROC
.	O

The	O
precision	O
of	O
the	O
system	O
can	O
reach	B-PROC
0	O
.	O
1	O
&#	O
176	O
;	O
C	O
and	O
the	O
machine	O
can	O
work	O
well	O
in	O
megathermal	O
environment	O
<	O
sup	O
>*</	O
sup	O
>.	O

The	O
etiologic	O
agent	O
of	O
this	O
disease	O
was	O
found	O
to	O
be	O
a	O
previously	O
unknown	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
detailed	O
pathology	O
of	O
SARS	O
-	O
CoV	O
infection	O
and	O
the	O
host	B-PROC
response	I-PROC
to	O
the	O
viral	B-PROC
infection	I-PROC
are	O
still	O
not	O
known	O
.	O

TITLE	O
:	O
[	O
Expression	B-PROC
of	O
predicted	O
B	O
cell	O
epitope	O
peptide	O
in	O
S2	O
subunit	O
of	O
SARS	O
coronavirus	O
spike	O
protein	O
in	O
E	O
.	O
coli	O
and	O
identification	O
of	O
its	O
mimic	O
antigenicity	O
].	O

TITLE	O
:	O
Effective	O
inhibition	B-PROC
of	O
porcine	O
transmissible	O
gastroenteritis	O
virus	B-PROC
replication	I-PROC
in	O
ST	O
cells	O
by	O
shRNAs	O
targeting	B-PROC
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
gene	O
.	O

The	O
newly	O
developed	O
cytokine	O
assays	O
strengthen	O
and	O
expand	O
the	O
ferret	O
model	O
not	O
only	O
for	O
Morbillivirus	O
pathogenesis	B-PROC
studies	O
but	O
also	O
for	O
several	O
other	O
human	O
respiratory	O
viruses	O
including	O
influenza	O
and	O
SARS	O
.	O

A	O
sustained	O
increase	O
of	O
adhesion	O
molecules	O
occurs	O
during	O
acute	O
stress	O
in	O
children	O
which	O
may	O
contribute	O
to	O
morbidity	O
in	O
patients	O
with	O
sepsis	O
(	O
sE	O
-	O
Selectin	B-PROC
)	O
or	O
traumatic	O
brain	O
injury	O
(	O
sICAM	O
-	O
1	O
).	O

Interestingly	O
breeds	B-PROC
of	O
chicken	O
vary	O
with	O
respect	O
to	O
the	O
severity	O
of	O
infection	O
with	O
IBV	O
,	O
which	O
may	O
be	O
related	O
to	O
the	O
immune	B-PROC
response	I-PROC
.	O

Severely	O
obese	O
patients	O
were	O
more	O
likely	O
to	O
be	O
discharged	O
to	O
a	O
rehabilitation	O
or	O
skilled	O
nursing	B-PROC
facility	O
than	O
to	O
home	O
.	O

Altogether	O
,	O
our	O
data	O
show	O
that	O
SARS	O
-	O
CoV	O
M	O
protein	O
induces	O
apoptosis	B-PROC
through	O
the	O
modulation	O
of	O
the	O
cellular	O
Akt	O
pro	B-PROC
-	I-PROC
survival	I-PROC
pathway	B-PROC
and	O
mitochondrial	O
cytochrome	B-PROC
c	I-PROC
release	O
.	O

The	O
cause	O
of	O
death	B-PROC
was	O
multi	O
-	O
organ	O
failure	O
,	O
with	O
the	O
first	O
sign	O
of	O
poor	O
prognosis	O
being	O
rapidly	O
progressing	O
renal	O
failure	O
resistant	O
to	O
treatment	O
in	O
three	O
men	O
;	O
in	O
one	O
case	O
death	B-PROC
resulted	O
from	O
cerebral	O
malaria	O
.	O

Furthermore	O
,	O
MHV	O
and	O
SARS	O
-	O
CoV	O
infection	O
could	O
not	O
prevent	O
IFN	O
induction	O
by	O
poly	O
(	O
I	O
:	O
C	O
)	O
or	O
Sendai	O
virus	O
,	O
suggesting	O
that	O
these	O
CoVs	O
do	O
not	O
inactivate	O
IRF3	O
-	O
mediated	O
transcription	B-PROC
regulation	I-PROC
,	O
but	O
apparently	O
prevent	O
detection	O
of	O
replicative	O
RNA	O
by	O
cellular	O
sensory	O
molecules	O
.	O

TITLE	O
:	O
Platelet	B-PROC
aggregation	I-PROC
and	O
aspirin	O
non	O
-	O
responsiveness	O
increase	O
when	O
an	O
acute	O
coronary	O
syndrome	O
is	O
complicated	O
by	O
an	O
infection	O
.	O

Platelet	B-PROC
aggregation	I-PROC
was	O
more	O
pronounced	O
during	O
an	O
infectious	O
complication	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

An	O
infectious	O
complication	O
during	O
the	O
course	O
of	O
an	O
acute	O
coronary	O
syndrome	O
leads	O
to	O
more	O
pronounced	O
platelet	B-PROC
aggregation	I-PROC
.	O

CRP	O
is	O
an	O
independent	O
predictor	O
of	O
platelet	B-PROC
aggregation	I-PROC
and	O
aspirin	O
non	O
-	O
responsiveness	O
in	O
the	O
setting	O
of	O
an	O
acute	O
coronary	O
syndrome	O
.	O

The	O
CRP	O
levels	O
were	O
independently	O
associated	O
with	O
platelet	B-PROC
aggregation	I-PROC
and	O
aspirin	O
non	O
-	O
responsiveness	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
respectively	O
).	O

Alfacell	O
is	O
conducting	B-PROC
a	O
confirmatory	O
phase	O
IIIb	O
registration	O
trial	O
of	O
ranpirnase	O
plus	O
doxorubicin	O
versus	O
doxorubicin	O
alone	O
in	O
more	O
than	O
360	O
patients	O
with	O
unresectable	O
malignant	O
mesothelioma	O
,	O
and	O
will	O
assess	O
survival	O
as	O
the	O
primary	O
endpoint	O
.	O

Development	B-PROC
for	O
these	O
indications	O
has	O
been	O
discontinued	O
.	O

Following	O
infusion	O
of	O
LPS	O
,	O
plasma	O
nitrate	O
/	O
nitrite	O
,	O
methyl	O
guanidine	O
,	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
tumour	O
necrosis	B-PROC
factor	O
-	O
alpha	O
and	O
interleukin	O
-	O
1beta	O
)	O
were	O
markedly	O
elevated	O
.	O

We	O
also	O
show	O
that	O
BHK	O
-	O
21	O
cells	O
are	O
slightly	O
susceptible	O
to	O
certain	O
IBV	O
strains	O
,	O
including	O
Ark99	O
,	O
Ark_DPI	O
,	O
CA99	O
,	O
and	O
Iowa97	O
(<	O
0	O
.	O
01	O
%	O
efficiency	O
),	O
but	O
this	O
level	O
of	O
infection	O
is	O
not	O
increased	O
by	O
fAPN	O
expression	B-PROC
.	O

The	O
potential	O
of	O
Myt1	O
to	O
play	O
a	O
role	O
in	O
OP	O
responses	O
leading	O
to	O
remyelination	B-PROC
was	O
examined	O
using	O
murine	O
hepatitis	O
virus	O
strain	O
A59	O
(	O
MHV	O
)	O
to	O
induce	O
spinal	O
cord	O
demyelination	O
and	O
potential	O
relevance	O
to	O
human	O
pathology	O
was	O
evaluated	O
in	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
lesions	O
.	O

MS	O
lesions	O
demonstrated	O
increased	O
Myt1	O
expression	B-PROC
in	O
both	O
the	O
periplaque	O
white	O
matter	O
adjacent	O
to	O
lesions	O
and	O
within	O
early	O
remyelinating	O
lesions	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
efficient	O
expression	B-PROC
of	O
S	O
from	O
the	O
wild	O
-	O
type	O
spike	O
gene	O
in	O
cultured	O
cells	O
required	O
the	O
use	O
of	O
improved	O
plasmid	O
vectors	O
containing	O
donor	O
and	O
acceptor	O
splice	O
sites	O
,	O
as	O
well	O
as	O
heterologous	O
viral	O
RNA	O
export	O
elements	O
,	O
such	O
as	O
the	O
CTE	O
of	O
Mazon	O
-	O
Pfizer	O
monkey	O
virus	O
or	O
the	O
PRE	O
of	O
Woodchuck	O
hepatitis	O
virus	O
(	O
WPRE	O
).	O

In	O
order	O
to	O
verify	O
the	O
pathogenic	O
role	O
of	O
these	O
purified	O
antibodies	O
,	O
we	O
injected	O
patient	O
IgG	O
intrathecally	O
into	O
cisterna	O
magna	O
of	O
C57BL	O
/	O
6	O
mice	O
pre	O
-	O
implanted	O
with	O
EEG	O
electrodes	O
and	O
we	O
observed	O
severe	O
ataxia	O
followed	O
by	O
breathing	B-PROC
depression	O
and	O
total	O
suppression	B-PROC
of	O
slow	B-PROC
wave	I-PROC
sleep	B-PROC
,	O
as	O
evidenced	O
by	O
EEG	O
recording	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Hemagglutination	B-PROC
assays	O
,	O
receptor	O
-	O
destroying	O
enzyme	O
activity	O
,	O
hemagglutination	B-PROC
inhibition	B-PROC
,	O
and	O
fluorescence	O
focus	O
neutralization	O
tests	O
revealed	O
close	O
biological	O
and	O
antigenic	O
relationships	O
between	O
the	O
GiCoV	O
-	O
OH3	O
isolate	O
and	O
selected	O
respiratory	O
and	O
enteric	O
bovine	O
CoV	O
(	O
BCoV	O
)	O
strains	O
.	O

Transfer	O
of	O
soiled	O
bedding	O
between	O
mice	O
in	O
static	O
cages	O
induced	O
seroconversion	O
of	O
sentinel	O
mice	O
most	O
reliably	O
during	O
peak	O
viral	B-PROC
shedding	I-PROC
(	O
1	O
wk	O
PI	O
for	O
MPV	O
and	O
3	O
d	O
PI	O
for	O
MHV	O
).	O

ABSTRACT	O
:	O
Fragments	O
within	O
S1	O
genes	O
((	O
poly100	O
)	O
S1	O
)	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strains	O
ZJ971	O
,	O
M41	O
and	O
SC021202	O
(	O
SC	O
)	O
were	O
subcloned	O
into	O
a	O
prokaryotic	O
expression	B-PROC
vector	O
and	O
expressed	B-PROC
in	O
Escherichia	O
coli	O
.	O

On	O
logistic	O
regression	O
analysis	O
,	O
the	O
development	B-PROC
of	O
respiratory	O
failure	O
and	O
other	O
organ	O
dysfunctions	O
were	O
independent	O
risk	O
factors	O
for	O
mortality	O
.	O

The	O
public	O
in	O
Hong	O
Kong	O
is	O
likely	O
to	O
adopt	O
self	O
-	O
protective	O
behaviors	B-PROC
(	O
e	O
.	O
g	O
.,	O
wearing	O
face	O
mask	O
in	O
public	O
venues	O
(	O
73	O
.	O
8	O
%),	O
increasing	O
the	O
frequency	O
of	O
handwashing	O
(	O
86	O
.	O
7	O
%))	O
and	O
behaviors	B-PROC
that	O
protect	O
others	O
(	O
e	O
.	O
g	O
.,	O
wearing	O
face	O
masks	O
when	O
experiencing	O
influenza	O
-	O
like	O
illness	O
(	O
ILI	O
,	O
92	O
.	O
4	O
%),	O
immediately	O
seeking	O
medical	O
consultation	O
(	O
94	O
.	O
2	O
%),	O
making	O
declarations	O
when	O
crossing	O
the	O
border	O
with	O
ILI	O
(	O
87	O
.	O
1	O
%),	O
complying	O
to	O
quarantine	O
policies	O
(	O
88	O
.	O
3	O
%)).	O

Similar	O
analyses	O
showed	O
that	O
education	O
level	O
,	O
variables	O
related	O
to	O
perceived	O
efficacy	O
,	O
perceived	O
major	O
local	O
outbreak	O
and	O
such	O
were	O
significantly	O
associated	O
with	O
various	O
behaviors	B-PROC
directed	O
towards	O
protecting	O
others	O
.	O

Clinical	O
and	O
oxymetric	O
evolution	B-PROC
was	O
favourable	O
,	O
with	O
resolution	O
of	O
the	O
radiological	O
infiltrates	O
.	O

The	O
authors	O
discuss	O
possible	O
mechanisms	O
of	O
ALI	O
development	B-PROC
by	O
multiple	O
defibrillation	O
shocks	O
.	O

At	O
the	O
time	O
G3139	O
was	O
conceived	O
as	O
an	O
anti	O
-	O
cancer	O
drug	O
candidate	O
,	O
it	O
was	O
viewed	O
optimistically	O
because	O
Bcl	O
-	O
2	O
was	O
widely	O
believed	O
to	O
be	O
the	O
most	O
important	O
protein	O
blocking	O
p53	O
-	O
dependent	O
apoptosis	B-PROC
caused	O
by	O
internal	O
stress	O
.	O

Since	O
that	O
time	O
,	O
we	O
have	O
learnt	O
that	O
Bcl	O
-	O
2	O
is	O
not	O
the	O
only	O
protein	O
that	O
inhibits	O
apoptosis	B-PROC
and	O
that	O
p53	O
itself	O
is	O
frequently	O
malfunctioning	O
in	O
tumors	O
.	O

Specifically	O
,	O
the	O
unmethylated	O
CpG	O
ODN	O
(	O
and	O
/	O
or	O
the	O
phosphorothioate	O
group	O
)	O
activates	O
the	O
immune	O
system	O
,	O
but	O
this	O
potentially	O
important	O
anti	O
-	O
cancer	O
effect	O
is	O
lost	O
when	O
the	O
immune	O
cells	O
undergo	O
premature	O
apoptosis	B-PROC
apparently	O
because	O
their	O
Bcl	O
-	O
2	O
levels	O
have	O
been	O
lowered	O
by	O
the	O
antisense	O
effect	O
of	O
G3139	O
.	O

Drak2	O
-	O
deficient	O
T	O
cells	O
possessed	O
no	O
obvious	O
defects	O
in	O
trafficking	B-PROC
into	O
the	O
CNS	O
following	O
MHV	O
infection	O
.	O

Moreover	O
,	O
Drak2	O
-	O
deficient	O
T	B-PROC
cell	I-PROC
activation	I-PROC
,	O
expansion	O
and	O
cytokine	B-PROC
production	I-PROC
were	O
unimpaired	O
in	O
response	O
to	O
acute	O
MHV	O
infection	O
.	O

ABSTRACT	O
:	O
Attenuated	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
vaccines	O
are	O
available	O
but	O
the	O
relationship	O
between	O
sequence	O
and	O
virulence	B-PROC
is	O
not	O
clear	O
.	O

None	O
or	O
one	O
amino	O
acid	O
substitution	O
was	O
found	O
in	O
the	O
small	O
membrane	O
protein	O
,	O
and	O
one	O
or	O
three	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
were	O
found	O
in	O
the	O
membrane	O
protein	O
.	O

The	O
protein	O
also	O
plays	O
roles	O
in	O
viral	O
RNA	O
transcription	B-PROC
and	O
/	O
or	O
replication	O
and	O
possibly	O
viral	O
mRNA	B-PROC
translation	B-PROC
.	O

Inhaled	B-PROC
nitric	O
oxide	O
should	O
be	O
used	O
early	O
in	O
severe	O
hypoxic	O
respiratory	O
failure	O
with	O
persistent	O
pulmonary	O
hypertension	O
of	O
newborn	O
and	O
can	O
improve	O
survival	O
rates	O
without	O
any	O
major	O
immediate	O
side	O
effects	O
.	O

CONCLUSIONS	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
should	O
be	O
used	O
early	O
in	O
severe	O
hypoxic	O
respiratory	O
failure	O
with	O
persistent	O
pulmonary	O
hypertension	O
of	O
newborn	O
and	O
can	O
improve	O
survival	O
rates	O
without	O
any	O
major	O
immediate	O
side	O
effects	O
.	O

Surfactant	O
replacement	O
was	O
well	O
tolerated	O
in	O
patients	O
with	O
lung	O
contusions	O
and	O
severe	O
hypoxemia	O
and	O
resulted	O
in	O
improved	O
oxygenation	B-PROC
and	O
compliance	O
.	O

Interactions	O
between	O
residues	O
248	O
-	O
280	O
and	O
the	O
rest	O
of	O
the	O
molecule	O
also	O
stabilize	O
the	O
formation	B-PROC
of	O
an	O
octamer	O
in	O
the	O
asymmetric	O
unit	O
.	O

ABSTRACT	O
:	O
At	O
the	O
beginning	O
of	O
the	O
20th	O
century	O
,	O
observations	O
of	O
apoplectic	O
adrenal	O
glands	O
in	O
fatal	O
meningococcemia	O
underlined	O
their	O
key	O
role	O
in	O
host	B-PROC
defence	I-PROC
against	O
infection	O
.	O

A	O
MEDLINE	O
search	O
was	O
performed	O
with	O
the	O
terms	O
""""	O
acute	O
pancreatitis	O
","""	O
""""	O
lung	O
injury	O
","""	O
""""	O
inflammatory	B-PROC
response	I-PROC
","""	O
""""	O
SIRS	O
","""	O
and	O
""""	O
multi	O
-	O
organ	O
dysfunction	O
.	O

ABSTRACT	O
:	O
Mediterranean	O
spotted	O
fever	B-PROC
is	O
a	O
rickettsiosis	O
caused	O
by	O
Rickettsia	O
conorii	O
.	O

First	O
cases	O
of	O
SARS	O
,	O
induced	O
by	O
a	O
new	O
strain	O
of	O
coronavirus	O
,	O
were	O
described	O
in	O
China	O
in	O
2002	O
and	O
by	O
May	O
2003	O
8360	O
cases	O
and	O
764	O
deaths	B-PROC
were	O
reported	O
by	O
the	O
World	O
Health	O
Organization	O
.	O

The	O
pathogenesis	B-PROC
of	O
SARS	O
is	O
highly	O
complex	O
,	O
with	O
multiple	O
factors	O
leading	O
to	O
severe	O
injury	O
in	O
the	O
lungs	O
and	O
dissemination	O
of	O
the	O
virus	O
to	O
several	O
other	O
organs	O
.	O

Furthermore	O
,	O
by	O
using	O
K48	O
-	O
linked	O
hexa	O
-	O
ubiquitin	B-PROC
substrate	O
and	O
ubiquitin	B-PROC
-	O
vinylsulfone	O
inhibitor	O
specific	O
for	O
deubiquitinating	B-PROC
enzymes	O
(	O
DUBs	O
),	O
we	O
confirmed	O
that	O
,	O
like	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
CoV	O
PLpro	O
,	O
HCoV	O
-	O
NL63	O
PLP2	O
has	O
DUB	O
activity	O
.	O

HIV	O
and	O
influenza	O
,	O
two	O
clear	O
threats	O
to	O
human	O
health	O
,	O
have	O
been	O
shown	O
to	O
rely	O
on	O
expression	B-PROC
of	O
specific	O
oligosaccharides	O
to	O
evade	O
detection	O
by	O
the	O
host	O
immune	O
system	O
.	O

Stigmatization	O
of	O
and	O
discrimination	O
against	O
the	O
chronically	O
ill	O
and	O
the	O
sense	B-PROC
of	O
searching	O
coping	O
strategy	O
during	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
outbreak	O
further	O
motivated	O
their	O
practice	O
.	O

As	O
a	O
result	O
,	O
increases	O
in	O
BCoV	O
-	O
neutralizing	O
antibody	B-PROC
titers	O
were	O
confirmed	O
in	O
all	O
pups	O
in	O
the	O
challenged	O
and	O
control	O
groups	O
.	O

The	O
reduction	O
of	O
cyclin	O
D3	O
level	O
and	O
phosphorylation	B-PROC
of	O
Rb	O
were	O
further	O
confirmed	O
in	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
cells	O
.	O

In	O
healthy	O
volunteers	O
,	O
S100A12	O
was	O
elevated	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
after	O
lipopolysaccharide	O
inhalation	B-PROC
.	O

HFOV	O
(	O
8	O
-	O
10	O
Hz	O
)	O
was	O
started	O
using	O
a	O
recruitment	O
strategy	O
and	O
oxygenation	B-PROC
improved	O
within	O
2	O
h	O
.	O
After	O
5	O
days	O
,	O
the	O
patient	O
was	O
switched	O
back	O
to	O
CV	O
uneventfully	O
and	O
av	O
-	O
ECLA	O
was	O
removed	O
after	O
8	O
days	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
7a	O
protein	O
,	O
which	O
is	O
not	O
expressed	B-PROC
by	O
other	O
known	O
coronaviruses	O
,	O
can	O
induce	O
apoptosis	B-PROC
in	O
various	O
cell	O
lines	O
.	O

Multivariable	O
logistic	O
regression	O
showed	O
that	O
the	O
strongest	O
predictors	O
of	O
SARS	O
were	O
abnormal	O
chest	O
x	O
-	O
ray	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
17	O
.	O
4	O
),	O
subjective	O
fever	B-PROC
(	O
OR	O
=	O
9	O
.	O
7	O
),	O
temperature	O
degrees	O
>	O
38	O
degrees	O
C	O
(	O
OR	O
=	O
6	O
.	O
4	O
),	O
myalgias	O
(	O
OR	O
=	O
5	O
.	O
5	O
),	O
chills	O
and	O
rigors	O
(	O
OR	O
=	O
4	O
.	O
0	O
)	O
and	O
contact	O
exposure	O
(	O
OR	O
=	O
2	O
.	O
6	O
).	O

The	O
current	O
SARS	O
outbreak	O
may	O
be	O
merely	O
a	O
taste	B-PROC
of	O
things	O
to	O
come	O
.	O

TITLE	O
:	O
Quasispecies	O
of	O
bovine	O
enteric	O
and	O
respiratory	O
coronaviruses	O
based	O
on	O
complete	O
genome	O
sequences	O
and	O
genetic	O
changes	O
after	O
tissue	O
culture	O
adaptation	B-PROC
.	O

The	O
recombinant	O
Salmonella	O
SL7207	O
(	O
pVAX1	O
-	O
S1	O
)	O
could	O
induce	O
significant	O
humoral	B-PROC
immune	I-PROC
response	I-PROC
in	O
mice	O
compared	O
with	O
the	O
control	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
0	O
.	O
01	O
)	O
at	O
2	O
w	O
post	O
-	O
boosting	O
and	O
2	O
w	O
post	O
-	O
three	O
immunization	O
.	O

Two	O
days	O
later	O
,	O
she	O
developed	O
quadriplegia	O
,	O
respiratory	O
arrest	O
and	O
died	B-PROC
.	O

Most	O
of	O
the	O
cases	O
of	O
NMO	O
in	O
Cuba	O
are	O
of	O
the	O
relapsing	O
form	O
,	O
but	O
this	O
case	O
report	O
is	O
the	O
first	O
one	O
with	O
monophasic	O
NMO	O
and	O
DS	O
with	O
a	O
very	O
aggressive	B-PROC
course	O
.	O

Gas	O
exchange	O
and	O
hemodynamics	B-PROC
were	O
determined	O
before	O
,	O
during	O
,	O
and	O
after	O
HFO	O
sessions	O
.	O

ABSTRACT	O
:	O
Tumor	O
necrosis	B-PROC
factor	O
(	O
TNF	O
)	O
is	O
critically	O
involved	O
in	O
biological	O
responses	O
against	O
various	O
insults	O
.	O

The	O
detection	O
of	O
increases	O
in	O
plasma	O
levels	O
of	O
soluble	O
E	O
-	O
selectin	B-PROC
in	O
patients	O
with	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
predicts	O
the	O
imminent	O
onset	O
of	O
acute	O
respiratory	O
syndrome	O
.	O

The	O
association	O
of	O
TB	O
with	O
AIDS	O
,	O
and	O
the	O
increasing	O
incidence	O
of	O
multiple	O
drug	B-PROC
resistance	B-PROC
has	O
further	O
compounded	O
the	O
problem	O
.	O

It	O
was	O
also	O
discontinued	O
in	O
29	O
patients	O
with	O
multiorgan	O
failure	O
,	O
in	O
22	O
patients	O
that	O
died	B-PROC
with	O
no	O
further	O
specification	O
,	O
and	O
in	O
7	O
patients	O
for	O
other	O
reasons	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
the	O
highly	O
pathogenic	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
has	O
reignited	O
interest	O
in	O
coronavirus	O
biology	O
and	O
pathogenesis	B-PROC
.	O

We	O
summarize	O
by	O
identifying	O
future	O
points	O
of	O
consideration	O
that	O
will	O
contribute	O
greatly	O
to	O
our	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
governing	O
coronavirus	O
pathogenesis	B-PROC
and	O
virulence	B-PROC
,	O
and	O
the	O
development	B-PROC
of	O
severe	O
disease	O
in	O
humans	O
and	O
animals	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
replication	O
and	O
pathogenesis	B-PROC
in	O
an	O
in	O
vitro	O
model	O
of	O
the	O
human	O
conducting	B-PROC
airway	O
epithelium	O
.	O

Experimental	O
results	O
using	O
these	O
lung	O
epithelial	O
cell	O
models	O
demonstrate	O
that	O
in	O
contrast	O
to	O
the	O
pathology	O
reported	O
in	O
late	O
stage	O
cases	O
SARS	O
-	O
CoV	O
replicates	O
to	O
high	O
titers	O
in	O
epithelial	O
cells	O
of	O
the	O
conducting	B-PROC
airway	O
.	O

Aspiration	O
resulted	O
from	O
the	O
patient	O
'	O
s	O
father	O
inducing	O
emesis	B-PROC
by	O
digital	O
stimulation	O
of	O
the	O
boy	O
'	O
s	O
throat	O
after	O
the	O
patient	O
had	O
ingested	O
an	O
unknown	O
amount	O
of	O
lamp	O
oil	O
.	O

This	O
study	O
demonstrates	O
the	O
importance	O
of	O
systematic	O
virological	O
surveillance	O
in	O
market	O
animals	O
for	O
understanding	O
the	O
evolution	B-PROC
and	O
emergence	O
of	O
viruses	O
with	O
infectious	O
potential	O
.	O

ABSTRACT	O
:	O
The	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strain	O
Beaudette	O
is	O
an	O
embryo	O
-	O
adapted	O
virus	O
that	O
has	O
extended	O
species	O
tropism	B-PROC
in	O
cell	O
culture	O
.	O

First	O
,	O
potential	O
compounds	O
were	O
extracted	O
from	O
protein	O
-	O
ligand	B-PROC
complexes	O
selected	O
from	O
Protein	O
Data	O
Bank	O
database	O
based	O
on	O
structural	O
similarity	O
to	O
the	O
target	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
renin	O
-	O
angiotensin	O
-	O
aldosterone	O
system	O
(	O
RAAS	O
)	O
is	O
a	O
key	O
regulator	O
of	O
systemic	O
blood	B-PROC
pressure	I-PROC
and	O
renal	B-PROC
function	I-PROC
and	O
a	O
key	O
player	O
in	O
renal	O
and	O
cardiovascular	O
disease	O
.	O

TITLE	O
:	O
Insertion	O
/	O
deletion	O
polymorphism	B-PROC
in	O
the	O
promoter	O
of	O
NFKB1	O
influences	O
severity	O
but	O
not	O
mortality	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

In	O
the	O
seven	O
unvaccinated	O
groups	O
,	O
CDV	O
titers	O
were	O
low	O
and	O
occurred	O
in	O
20	O
-	O
100	O
%	O
of	O
the	O
animals	O
;	O
antibody	B-PROC
titers	O
against	O
CPV	O
were	O
found	O
in	O
seven	O
of	O
eight	O
areas	O
.	O

The	O
viral	O
genome	O
and	O
its	O
expression	B-PROC
within	O
the	O
host	O
cell	O
undergoes	O
extensive	O
translational	B-PROC
and	O
enzymatic	O
processing	O
to	O
form	O
the	O
4	O
structural	O
,	O
8	O
accessory	O
and	O
16	O
nonstructural	O
proteins	O
.	O

It	O
has	O
been	O
our	O
effort	B-PROC
to	O
consolidate	O
all	O
information	O
known	O
to	O
date	O
about	O
the	O
molecular	O
mechanisms	O
of	O
the	O
SARS	O
-	O
CoV	O
into	O
this	O
chapter	O
to	O
update	O
our	O
readership	O
on	O
the	O
current	O
status	O
of	O
research	O
.	O

In	O
these	O
patients	O
,	O
one	O
-	O
year	O
survival	O
rate	O
is	O
67	O
%	O
and	O
5	O
%	O
for	O
kidney	B-PROC
function	I-PROC
.	O

ABSTRACT	O
:	O
The	O
truncated	O
fragment	O
M	O
'	O
gene	O
,	O
encoding	O
the	O
exterior	O
of	O
the	O
viral	O
envelope	O
protein	O
of	O
PEDV	O
,	O
was	O
subcloned	O
into	O
prokaryotic	O
expression	B-PROC
vector	O
pGEX	O
-	O
6p	O
-	O
1	O
.	O

For	O
Canada	O
,	O
a	O
similar	O
catalyst	O
stemmed	O
from	O
the	O
lessons	O
learned	B-PROC
during	O
the	O
2003	O
severe	O
acute	O
respiratory	O
syndrome	O
outbreak	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
26	O
blood	O
samples	O
were	O
collected	O
from	O
25	O
healthy	O
cats	O
and	O
one	O
cat	O
with	O
clinical	O
signs	O
suggestive	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
),	O
namely	O
,	O
fever	B-PROC
,	O
weight	O
loss	O
,	O
enlarged	O
abdomen	O
,	O
and	O
ascites	O
.	O

ABSTRACT	O
:	O
More	O
than	O
four	O
years	O
have	O
passed	O
since	O
the	O
outbreak	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
epidemic	O
,	O
and	O
still	O
very	O
little	O
is	O
known	O
about	O
the	O
molecular	O
biology	O
and	O
pathogenesis	B-PROC
of	O
this	O
deadly	O
virus	O
.	O

They	O
were	O
weaned	B-PROC
from	O
ECMO	O
after	O
a	O
mean	O
of	O
114	O
+/-	O

Spontaneous	O
pneumomediastinum	O
usually	O
only	O
requires	O
rest	O
,	O
analgesia	B-PROC
and	O
management	O
of	O
the	O
underlying	O
condition	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
coronavirus	O
replication	O
induces	O
host	O
translational	B-PROC
shutoff	O
and	O
mRNA	B-PROC
decay	I-PROC
,	O
with	O
concomitant	O
formation	B-PROC
of	O
stress	O
granules	O
and	O
processing	O
bodies	O
.	O

This	O
downregulation	B-PROC
,	O
which	O
is	O
reminiscent	O
of	O
a	O
cellular	O
stress	O
response	O
,	O
was	O
dependent	O
on	O
viral	B-PROC
replication	I-PROC
and	O
caused	O
by	O
mRNA	B-PROC
decay	I-PROC
.	O

We	O
also	O
showed	O
that	O
N	O
protein	O
activated	O
IL	O
-	O
6	O
expression	B-PROC
through	O
NF	O
-	O
kappaB	O
by	O
facilitating	O
the	O
translocation	B-PROC
of	O
NF	O
-	O
kappaB	O
from	O
cytosol	O
to	O
nucleus	O
.	O

ABSTRACT	O
:	O
DNA	O
vaccines	O
induce	O
humoral	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
in	O
animal	O
models	O
and	O
humans	O
.	O

The	O
cellular	O
and	O
humoral	B-PROC
immune	I-PROC
responses	I-PROC
were	O
assessed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
,	O
lymphocyte	B-PROC
proliferation	I-PROC
assays	O
,	O
enzyme	O
-	O
linked	O
immunospot	O
assays	O
,	O
and	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
analyses	O
.	O

We	O
evaluated	O
two	O
multiplex	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
products	O
coupled	O
with	O
microarray	O
-	O
based	O
systems	O
for	O
simultaneous	O
detection	O
of	O
common	O
respiratory	O
tract	O
viral	O
pathogens	O
.	O

Advancements	O
in	O
the	O
development	B-PROC
of	O
synthetic	O
surfactants	O
are	O
promising	O
,	O
yet	O
to	O
date	O
none	O
has	O
been	O
shown	O
to	O
be	O
superior	O
to	O
natural	O
preparations	O
.	O

Research	O
around	O
surfactant	O
is	O
evolving	O
and	O
recent	O
developments	O
include	O
further	O
evolution	B-PROC
of	O
synthetic	O
surfactants	O
,	O
evaluation	O
of	O
surfactant	O
as	O
a	O
therapeutic	O
option	O
in	O
lung	O
diseases	O
other	O
than	O
RDS	O
and	O
the	O
discovery	O
of	O
genetic	O
disorders	O
of	O
surfactant	O
metabolism	B-PROC
.	O

In	O
order	O
to	O
gain	O
more	O
insight	O
into	O
functions	O
and	O
modes	O
of	O
action	O
and	O
interaction	O
of	O
the	O
different	O
proteins	O
,	O
we	O
cloned	O
the	O
viral	O
ORFeome	O
and	O
performed	O
a	O
genome	O
-	O
wide	O
analysis	O
for	O
intraviral	O
protein	O
interactions	O
and	O
for	O
intracellular	B-PROC
localization	I-PROC
.	O

We	O
show	O
that	O
also	O
accessory	O
protein	O
ORF9b	O
does	O
not	O
play	O
a	O
pivotal	O
role	O
for	O
viral	B-PROC
replication	I-PROC
,	O
as	O
it	O
can	O
be	O
deleted	O
from	O
the	O
virus	O
displaying	O
normal	O
plaque	O
sizes	O
and	O
growth	B-PROC
characteristics	O
in	O
Vero	O
cells	O
.	O

Differential	O
inhibition	B-PROC
of	O
intracellular	O
signaling	B-PROC
steps	O
suggested	O
significant	O
contribution	O
of	O
phosphatidylcholine	O
-	O
specific	O
phospholipase	O
C	O
and	O
protein	O
kinase	O
C	O
and	O
of	O
the	O
Rho	O
/	O
Rho	O
-	O
kinase	O
pathway	B-PROC
to	O
PLY	O
-	O
induced	O
pulmonary	O
vasoconstriction	B-PROC
.	O

In	O
this	O
latter	O
respect	O
control	O
may	O
in	O
part	O
be	O
achieved	O
through	O
the	O
sub	O
-	O
cellular	B-PROC
localisation	I-PROC
of	O
the	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
is	O
undertaken	O
to	O
investigate	O
the	O
immune	B-PROC
response	I-PROC
that	O
was	O
induced	O
by	O
the	O
recombinant	O
spike	O
(	O
S	O
)	O
protein	O
from	O
swine	O
-	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
expressed	B-PROC
in	O
mouse	O
mammary	O
cells	O
.	O

This	O
article	O
reviews	O
recent	O
advancements	O
in	O
understanding	O
the	O
pathogenesis	B-PROC
,	O
immunology	O
,	O
and	O
genetics	O
of	O
severe	O
acute	O
pancreatitis	O
,	O
and	O
the	O
literature	O
on	O
laboratory	O
-	O
based	O
markers	O
,	O
which	O
predict	O
a	O
severe	O
clinical	O
course	O
and	O
pancreatic	O
necrosis	B-PROC
.	O

This	O
resulted	O
in	O
excessive	O
anticoagulation	B-PROC
and	O
severe	O
bleeding	O
.	O

In	O
addition	O
,	O
the	O
requirements	O
for	O
initiation	O
of	O
RNA	B-PROC
synthesis	I-PROC
from	O
the	O
3	O
'	O
end	O
of	O
the	O
viral	O
genome	O
were	O
studied	O
in	O
vivo	O
using	O
a	O
reverse	O
genetics	O
approach	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
3	O
'-	O
terminal	O
nucleotides	O
of	O
the	O
EAV	O
genome	O
play	O
a	O
critical	O
role	O
in	O
viral	O
RNA	B-PROC
synthesis	I-PROC
.	O

CONCLUSIONS	O
:	O
RANTES	O
-	O
28	O
G	O
allele	O
plays	O
a	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
.	O

The	O
role	O
and	O
regulation	B-PROC
of	O
the	O
neprilysin	O
(	O
NEP	O
)	O
family	O
of	O
metalloproteinases	O
is	O
highlighted	O
in	O
particular	O
in	O
the	O
context	O
of	O
proteolytic	B-PROC
events	O
underlying	O
the	O
pathology	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

The	O
application	O
of	O
functional	O
genomics	O
approaches	O
to	O
the	O
discovery	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
-	O
2	O
(	O
ACE2	O
)	O
as	O
a	O
counterbalance	O
to	O
the	O
well	O
known	O
hypertensive	O
target	O
ACE	O
will	O
be	O
highlighted	O
and	O
their	O
differential	O
cellular	B-PROC
targeting	I-PROC
and	O
enzymology	O
addressed	O
.	O

The	O
majority	O
of	O
cases	O
of	O
pulmonary	O
-	O
renal	O
syndrome	O
are	O
associated	O
with	O
ANCAs	O
,	O
either	O
c	O
-	O
ANCA	O
or	O
p	O
-	O
ANCA	O
,	O
due	O
to	O
autoantibodies	O
against	O
the	O
target	O
antigens	O
proteinase	B-PROC
-	O
3	O
and	O
myeloperoxidase	O
respectively	O
.	O

Lastly	O
,	O
we	O
found	O
that	O
expression	B-PROC
of	O
the	O
SDF	O
-	O
1	O
receptor	O
CXCR4	O
rises	O
in	O
a	O
similar	O
temporal	O
pattern	O
on	O
neutrophils	O
in	O
both	O
the	O
blood	O
and	O
airspace	O
of	O
LPS	O
-	O
injured	O
mice	O
and	O
that	O
Ab	O
-	O
mediated	O
SDF	O
-	O
1	O
blockade	O
significantly	O
attenuates	O
late	O
but	O
not	O
early	O
pulmonary	O
neutrophilia	O
in	O
this	O
model	O
.	O

The	O
coagulation	B-PROC
profile	O
was	O
associated	O
with	O
clinical	O
,	O
epidemiological	O
and	O
CT	O
findings	O
.	O

Lactococcus	O
lactis	O
was	O
selected	O
as	O
a	O
bacterial	O
carrier	O
for	O
the	O
expression	B-PROC
of	O
TGEV	O
spike	O
glycoprotein	O
.	O

Intriguingly	O
,	O
the	O
SARS	O
coronavirus	O
,	O
the	O
cause	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
utilizes	O
ACE2	O
as	O
an	O
essential	O
receptor	O
for	O
cell	B-PROC
fusion	I-PROC
and	O
in	O
vivo	O
infections	O
.	O

TITLE	O
:	O
Adenovirus	O
-	O
based	O
vaccine	O
prevents	O
pneumonia	O
in	O
ferrets	O
challenged	O
with	O
the	O
SARS	O
coronavirus	O
and	O
stimulates	O
robust	O
immune	B-PROC
responses	I-PROC
in	O
macaques	O
.	O

These	O
results	O
show	O
that	O
the	O
WD	O
-	O
BCoV	O
has	O
dual	O
tropism	B-PROC
and	O
induces	O
pathological	O
changes	O
in	O
both	O
the	O
digestive	B-PROC
and	O
respiratory	O
tracts	O
of	O
calves	O
.	O

CPAP	O
significantly	O
improved	O
rapid	B-PROC
eye	I-PROC
movement	I-PROC
(	O
REM	B-PROC
)	O
duration	O
(	O
p	O
<	O
0	O
.	O
005	O
),	O
AHI	O
(	O
p	O
<	O
0	O
.	O
005	O
),	O
arousal	O
indexes	O
(	O
p	O
<	O
0	O
.	O
005	O
),	O
and	O
percentage	O
of	O
total	O
sleep	B-PROC
time	O
(	O
TST	O
)	O
with	O
oxygen	O
saturation	O
(	O
SpO2	O
)	O
<	O
90	O
%	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
in	O
both	O
groups	O
.	O

Extremely	O
severe	O
obese	O
subjects	O
(	O
BMI	O
>	O
or	O
=	O
50	O
kg	O
/	O
m2	O
)	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
OSA	O
plus	O
OHS	O
exhibit	O
severe	O
oxygen	O
desaturation	O
but	O
similar	O
severities	O
of	O
AHI	O
,	O
arousal	O
indexes	O
,	O
and	O
sleep	B-PROC
architecture	O
abnormalities	O
when	O
compared	O
to	O
matched	O
subjects	O
without	O
OHS	O
.	O

The	O
expression	B-PROC
of	O
ACE2	O
receptor	O
was	O
the	O
highest	O
in	O
the	O
human	O
lung	O
microvascular	O
endothelial	O
cells	O
,	O
and	O
lowest	O
in	O
the	O
lymphatic	O
endothelial	O
cells	O
.	O

The	O
organ	O
derived	O
microvascular	O
endothelial	O
cells	O
are	O
the	O
important	O
target	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
pathological	O
injury	O
of	O
lung	O
and	O
lymph	O
system	O
induced	O
by	O
SARS	O
-	O
CoV	O
may	O
be	O
mediated	O
respectively	O
by	O
different	O
receptors	O
of	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
Both	O
SARS	O
-	O
CoV	O
receptors	O
of	O
ACE2	O
and	O
CD209L	O
were	O
expressed	B-PROC
in	O
the	O
8	O
organ	O
/	O
tissue	O
-	O
derived	O
endothelial	O
cells	O
.	O

Multicopy	O
expression	B-PROC
plasmids	O
encoding	O
essential	O
MOB1	O
or	O
CDC28	O
genes	O
are	O
absolutely	O
necessary	O
for	O
the	O
viability	O
of	O
host	O
cells	O
with	O
mob1	O
or	O
cdc28	O
deletions	O
in	O
their	O
genomes	O
.	O

However	O
,	O
for	O
other	O
pathogens	O
which	O
are	O
not	O
exposed	O
to	O
such	O
environmental	O
stress	O
,	O
activation	O
of	O
fusogenicity	O
can	O
result	O
from	O
precise	O
thiol	O
/	O
disulfide	O
rearrangements	O
mediated	O
by	O
either	O
an	O
endogenous	O
redox	B-PROC
autocatalytic	O
isomerase	O
or	O
a	O
cell	O
-	O
associated	O
oxidoreductase	O
.	O

Phospholipase	O
C	O
treatment	O
of	O
the	O
lung	O
and	O
tracheal	O
tissue	O
homogenates	O
from	O
IBV	O
-	O
positive	O
chickens	O
increased	O
the	O
detection	O
limit	O
for	O
M	O
-	O
41	O
strain	O
from	O
1	O
.	O
3	O
%	O
positive	O
samples	O
in	O
simple	O
hemagglutination	B-PROC
assay	O
to	O
30	O
.	O
6	O
%	O
positivity	O
when	O
the	O
same	O
samples	O
were	O
treated	O
with	O
phospholipase	O
C	O
.	O
Similarly	O
,	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
was	O
a	O
much	O
better	O
M	O
-	O
41	O
detection	O
tool	O
as	O
compared	O
with	O
the	O
classical	O
agar	O
gel	O
precipitation	B-PROC
assay	O
utilized	O
to	O
screen	O
tissue	O
homogenates	O
from	O
IBV	O
-	O
positive	O
chickens	O
.	O

In	O
addition	O
,	O
in	O
the	O
case	O
of	O
hypercytokinaemia	O
induced	O
by	O
potent	O
viruses	O
,	O
such	O
as	O
H5N1	O
,	O
systemic	O
inflammation	O
-	O
induced	O
,	O
acquired	O
glucocorticoid	O
resistance	B-PROC
is	O
likely	O
to	O
be	O
present	O
.	O

TITLE	O
:	O
[	O
Ligand	B-PROC
screening	O
in	O
affinity	O
chromatography	O
and	O
its	O
applications	O
].	O

To	O
date	O
,	O
however	O
,	O
it	O
remains	O
unknown	O
what	O
the	O
minimal	O
level	O
of	O
Nab	O
is	O
required	O
to	O
achieve	O
sterile	O
immunity	B-PROC
in	O
humans	O
.	O

Exogenous	O
leptin	O
attenuates	O
inflamma	O
-	O
tory	O
changes	O
,	O
and	O
reduces	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
nitric	O
oxide	O
levels	O
,	O
and	O
CD40	O
expression	B-PROC
in	O
cerulein	O
-	O
induced	O
AP	O
and	O
may	O
be	O
protective	O
in	O
AP	O
associated	O
ALI	O
.	O

CONCLUSIONS	O
:	O
Exogenous	O
leptin	O
attenuates	O
inflamma	O
-	O
tory	O
changes	O
,	O
and	O
reduces	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
nitric	O
oxide	O
levels	O
,	O
and	O
CD40	O
expression	B-PROC
in	O
cerulein	O
-	O
induced	O
AP	O
and	O
may	O
be	O
protective	O
in	O
AP	O
associated	O
ALI	O
.	O

TITLE	O
:	O
siRNAs	O
targeting	B-PROC
terminal	O
sequences	O
of	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
membrane	O
gene	O
inhibit	O
M	O
protein	B-PROC
expression	B-PROC
through	O
degradation	O
of	O
M	O
mRNA	O
.	O

ABSTRACT	O
:	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SCoV	O
)	O
M	O
protein	O
plays	O
a	O
key	O
role	O
in	O
viral	B-PROC
assembly	I-PROC
and	O
budding	B-PROC
.	O

Using	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
as	O
a	O
model	O
,	O
we	O
demonstrate	O
that	O
SARS	O
-	O
COV	O
ORF6	O
protein	O
is	O
localized	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)/	O
Golgi	O
membrane	O
in	O
infected	O
cells	O
,	O
where	O
it	O
binds	O
to	O
and	O
disrupts	O
nuclear	B-PROC
import	I-PROC
complex	O
formation	B-PROC
by	O
tethering	O
karyopherin	O
alpha	O
2	O
and	O
karyopherin	O
beta	O
1	O
to	O
the	O
membrane	O
.	O

We	O
mapped	O
the	O
region	O
of	O
ORF6	O
,	O
which	O
binds	O
karyopherin	O
alpha	O
2	O
,	O
to	O
the	O
C	O
terminus	O
of	O
ORF6	O
and	O
show	O
that	O
mutations	O
in	O
the	O
C	O
terminus	O
no	O
longer	O
bind	O
karyopherin	O
alpha	O
2	O
or	O
block	O
the	O
nuclear	B-PROC
import	I-PROC
of	O
STAT1	O
.	O

ABSTRACT	O
:	O
Virology	O
laboratories	O
historically	O
have	O
used	O
direct	O
fluorescent	O
-	O
antibody	B-PROC
assay	O
(	O
DFA	O
)	O
and	O
culture	O
to	O
detect	O
six	O
or	O
seven	O
respiratory	O
viruses	O
.	O

Results	O
showed	O
that	O
the	O
intranasal	O
route	O
caused	O
the	O
highest	O
production	O
of	O
specific	O
immunoglobulin	B-PROC
G	O
(	O
IgG	O
),	O
IgG2a	O
,	O
and	O
secretory	B-PROC
IgA	O
,	O
where	O
IgG2a	O
was	O
imprinted	O
as	O
a	O
Th1	O
cell	O
bias	O
.	O

TITLE	O
:	O
Open	O
reading	O
frame	O
8a	O
of	O
the	O
human	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
not	O
only	O
promotes	O
viral	B-PROC
replication	I-PROC
but	O
also	O
induces	O
apoptosis	B-PROC
.	O

Western	O
-	O
blot	O
and	O
immunofluorescent	O
antibody	B-PROC
assays	O
were	O
used	O
to	O
detect	O
anti	O
-	O
ORF8a	O
antibody	B-PROC
.	O

Supplemental	O
corticosteroids	O
may	O
restore	O
the	O
balance	B-PROC
between	O
the	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
mediators	O
in	O
patients	O
with	O
severe	O
sepsis	O
,	O
septic	O
shock	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
thereby	O
improve	O
the	O
outcome	O
of	O
patients	O
with	O
these	O
conditions	O
.	O

TITLE	O
:	O
Distinct	O
regulation	B-PROC
of	O
MHC	B-PROC
molecule	O
expression	B-PROC
on	O
astrocytes	O
and	O
microglia	O
during	O
viral	O
encephalomyelitis	O
.	O

Various	O
approaches	O
are	O
being	O
pursued	O
for	O
the	O
development	B-PROC
of	O
efficacious	O
therapeutics	O
.	O

These	O
data	O
provide	O
the	O
foundation	O
for	O
a	O
rational	O
small	O
-	O
molecule	O
inhibitor	O
design	O
effort	B-PROC
based	O
upon	O
the	O
inhibitor	O
scaffold	O
identified	O
,	O
the	O
crystal	O
structure	O
of	O
the	O
complex	O
,	O
and	O
a	O
more	O
complete	O
understanding	O
of	O
P1	O
-	O
P4	O
substrate	O
specificity	O
.	O

Mild	O
limb	O
weakness	O
with	O
severe	O
muscle	B-PROC
atrophy	I-PROC
and	O
diffuse	O
muscle	O
twitches	O
were	O
observed	O
.	O

ABSTRACT	O
:	O
Severe	O
sepsis	O
is	O
the	O
leading	O
cause	O
of	O
death	B-PROC
for	O
patients	O
in	O
intensive	O
care	O
units	O
.	O

ABSTRACT	O
:	O
Using	O
the	O
recombinant	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
expressing	O
the	O
T	O
cell	O
-	O
chemoattractant	O
CXCL10	O
(	O
MHV	O
-	O
CXCL10	O
),	O
we	O
demonstrate	O
a	O
potent	O
antiviral	O
role	O
for	O
CXCL10	O
in	O
host	B-PROC
defense	I-PROC
.	O

Trypsin	O
was	O
not	O
the	O
determinant	O
for	O
the	O
viral	B-PROC
replication	I-PROC
,	O
suggesting	O
that	O
the	O
restriction	O
of	O
IBV	O
replication	O
in	O
HeLa	O
cells	O
is	O
the	O
result	O
of	O
intracellular	O
events	O
rather	O
than	O
the	O
binding	O
to	O
or	O
fusion	O
with	O
host	O
cells	O
.	O

Sequence	O
analysis	O
and	O
mutagenesis	B-PROC
data	O
show	O
that	O
m396	O
might	O
neutralize	O
all	O
zoonotic	O
and	O
epidemic	O
SARS	O
-	O
CoV	O
isolates	O
with	O
known	O
sequences	O
,	O
except	O
strains	O
derived	O
from	O
bats	O
.	O

Trauma	O
-	O
induced	O
lung	O
injury	O
was	O
also	O
associated	O
with	O
dramatic	O
changes	O
in	O
neutrophil	O
function	O
,	O
namely	O
early	O
enhanced	O
chemotaxis	B-PROC
and	O
phagocytosis	B-PROC
,	O
followed	O
by	O
prolonged	O
functional	O
defects	O
-	O
all	O
of	O
which	O
were	O
ameliorated	O
by	O
anti	O
-	O
C5a	O
treatment	O
.	O

TITLE	O
:	O
Intratracheally	O
administered	O
pathogen	O
-	O
associated	O
molecular	O
patterns	O
affect	O
antibody	B-PROC
responses	I-PROC
of	O
poultry	O
.	O

We	O
also	O
confirmed	O
the	O
presence	O
of	O
a	O
second	O
cleavage	B-PROC
site	O
between	O
nsp7	O
and	O
nsp8	O
.	O

ABSTRACT	O
:	O
The	O
cellular	O
uptake	O
of	O
PMOs	O
(	O
phosphorodiamidate	O
morpholino	O
oligomers	O
)	O
can	O
be	O
enhanced	O
by	O
their	O
conjugation	B-PROC
to	O
arginine	O
-	O
rich	O
CPPs	O
(	O
cell	O
-	O
penetrating	O
peptides	O
).	O

ABSTRACT	O
:	O
Here	O
we	O
report	O
a	O
case	O
of	O
leptospirosis	O
without	O
fever	B-PROC
during	O
the	O
late	O
stage	O
of	O
pregnancy	O
in	O
which	O
the	O
initial	O
clinical	O
presentation	O
was	O
more	O
suggestive	O
of	O
a	O
pregnancy	O
-	O
related	O
liver	O
dysfunction	O
rather	O
than	O
an	O
infectious	O
disease	O
.	O

On	O
clinical	O
suspicion	O
of	O
pregnancy	O
-	O
related	O
liver	O
dysfunction	O
such	O
as	O
HELLP	O
syndrome	O
(	O
hemolysis	B-PROC
,	O
elevated	O
liver	O
enzyme	O
levels	O
,	O
low	O
platelet	O
count	O
)	O
or	O
acute	O
fatty	O
liver	O
of	O
pregnancy	O
(	O
AFLP	O
),	O
emergency	O
caesarean	O
section	O
was	O
performed	O
and	O
a	O
healthy	O
baby	O
was	O
delivered	O
.	O

Totally	O
,	O
131	O
patients	O
(	O
2	O
.	O
5	O
%)	O
developed	O
ARDS	O
,	O
among	O
whom	O
,	O
12	O
patients	O
were	O
excluded	O
from	O
this	O
study	O
because	O
they	O
died	B-PROC
within	O
24	O
hours	O
and	O
other	O
4	O
patients	O
were	O
also	O
excluded	O
for	O
their	O
incomplete	O
information	O
.	O

The	O
main	O
cause	O
of	O
death	B-PROC
is	O
multiple	O
organ	O
failure	O
.	O

Careful	O
attention	O
to	O
experimental	O
design	O
,	O
sample	O
handling	O
and	O
storage	B-PROC
,	O
and	O
the	O
use	O
of	O
appropriate	O
internal	O
controls	O
is	O
crucial	O
to	O
success	O
.	O

By	O
virus	O
isolation	O
and	O
RT	O
-	O
PCR	O
targeting	B-PROC
the	O
S	O
gene	O
,	O
BCoV	O
was	O
identified	O
as	O
the	O
etiological	O
agent	O
of	O
the	O
outbreak	O
,	O
whereas	O
bacteriological	O
,	O
parasitological	O
and	O
toxicological	O
investigations	O
failed	O
to	O
detect	O
other	O
causes	O
of	O
disease	O
.	O

TITLE	O
:	O
The	O
coronavirus	O
spike	O
protein	O
induces	O
endoplasmic	O
reticulum	O
stress	O
and	O
upregulation	B-PROC
of	O
intracellular	O
chemokine	O
mRNA	O
concentrations	O
.	O

Despite	O
significant	O
increases	O
in	O
levels	O
of	O
Cxcl2	O
mRNA	O
and	O
functional	O
nucleus	O
-	O
to	O
-	O
cytoplasm	O
RNA	B-PROC
transport	B-PROC
,	O
no	O
CXCL2	O
protein	O
was	O
released	O
into	O
the	O
medium	O
from	O
MHV	O
-	O
infected	O
cells	O
.	O

However	O
,	O
at	O
that	O
point	O
in	O
infection	O
,	O
translation	B-PROC
of	O
host	O
mRNA	O
is	O
already	O
severely	O
reduced	O
in	O
infected	O
cells	O
,	O
preventing	O
the	O
synthesis	B-PROC
of	O
CXCL2	O
and	O
ER	O
stress	O
proteins	O
despite	O
their	O
increased	O
mRNA	O
concentrations	O
.	O

This	O
decision	O
was	O
totally	O
justified	O
by	O
the	O
unfeasible	O
CPB	O
weaning	B-PROC
off	O
.	O

Here	O
,	O
we	O
used	O
SDS	O
-	O
PAGE	O
and	O
fluorescence	O
-	O
based	O
assays	O
to	O
demonstrate	O
that	O
ISG15	O
derivatives	O
are	O
the	O
preferred	O
substrates	O
for	O
the	O
deubiquitinating	B-PROC
activity	O
of	O
the	O
PLpro	O
.	O

Nevertheless	O
,	O
full	O
virion	O
maturation	B-PROC
was	O
blocked	O
.	O

Therefore	O
,	O
the	O
absence	O
of	O
E	O
protein	O
in	O
TGEV	O
resulted	O
in	O
two	O
actions	O
,	O
a	O
blockade	O
of	O
virus	O
trafficking	B-PROC
in	O
the	O
membranes	O
of	O
the	O
secretory	B-PROC
pathway	I-PROC
,	O
and	O
prevention	O
of	O
full	O
virus	B-PROC
maturation	B-PROC
.	O

In	O
either	O
clinical	O
presentation	O
,	O
vascular	B-PROC
permeability	I-PROC
is	O
a	O
major	O
component	O
of	O
the	O
pathologic	O
process	O
.	O

The	O
abnormalities	O
were	O
manifested	O
both	O
as	O
discontinuous	O
immunofluorescence	O
staining	O
of	O
the	O
junctional	O
proteins	O
ZO	O
-	O
1	O
,	O
claudin	O
5	O
,	O
and	O
VE	O
-	O
cadherin	O
and	O
the	O
formation	B-PROC
of	O
interendothelial	O
gaps	O
in	O
monolayers	O
.	O

ABSTRACT	O
:	O
Attenuated	O
viral	O
vaccines	O
can	O
be	O
generated	O
by	O
targeting	B-PROC
essential	O
pathogenicity	O
factors	O
.	O

Our	O
studies	O
emphasize	O
that	O
the	O
induction	O
of	O
early	O
IFN	O
signaling	B-PROC
may	O
be	O
critical	O
to	O
confer	O
protection	O
against	O
SARS	O
-	O
CoV	O
infection	O
and	O
highlight	O
the	O
strength	O
of	O
combining	O
functional	O
genomics	O
with	O
immunohistochemistry	O
to	O
further	O
unravel	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
are	O
major	O
etiological	O
agents	O
of	O
diarrhea	O
and	O
death	B-PROC
in	O
piglets	O
.	O

Age	O
,	O
gender	O
,	O
AKI	O
severity	O
,	O
APACHE	O
score	O
,	O
serum	O
urea	O
,	O
and	O
time	O
to	O
recovery	O
of	O
renal	B-PROC
function	I-PROC
were	O
assessed	O
.	O

Of	O
the	O
PaDD	O
group	O
patients	O
,	O
three	O
(	O
16	O
.	O
7	O
%)	O
died	B-PROC
,	O
compared	O
with	O
10	O
(	O
66	O
.	O
7	O
%)	O
of	O
the	O
DAdD	O
group	O
patients	O
.	O

Three	O
key	O
areas	O
for	O
retention	B-PROC
of	O
subjects	O
are	O
identified	O
from	O
the	O
literature	O
:	O
(	O
a	O
)	O
respect	O
for	O
patients	O
:	O
respect	O
for	O
their	O
ideas	O
and	O
their	O
time	O
commitment	O
to	O
the	O
research	O
project	O
;	O
(	O
b	O
)	O
tracking	O
:	O
collect	O
information	O
on	O
many	O
patient	O
contacts	O
at	O
the	O
initiation	O
of	O
the	O
study	O
and	O
outline	O
tracking	O
procedures	O
for	O
subjects	O
lost	O
to	O
follow	O
-	O
up	O
;	O
and	O
(	O
c	O
)	O
study	O
personnel	O
:	O
interpersonal	O
skills	O
must	O
be	O
reinforced	O
,	O
flexible	O
working	O
hours	O
mandated	O
,	O
and	O
support	O
offered	O
.	O

These	O
glycoproteins	O
are	O
key	O
to	O
the	O
infection	O
process	O
as	O
they	O
are	O
mediators	O
of	O
the	O
receptor	O
binding	O
and	O
membrane	B-PROC
fusion	I-PROC
of	O
the	O
virion	O
with	O
the	O
host	O
cell	O
.	O

Inhibition	B-PROC
of	O
mannosidases	O
in	O
host	O
cells	O
rendered	O
the	O
progeny	O
viruses	O
more	O
sensitive	O
to	O
the	O
mannose	O
-	O
binding	O
agents	O
and	O
even	O
to	O
the	O
N	O
-	O
acetylglucosamine	O
-	O
binding	O
UDA	O
.	O

In	O
addition	O
,	O
inhibition	B-PROC
of	O
coronaviruses	O
was	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
cell	O
-	O
type	O
used	O
to	O
grow	O
the	O
virus	O
stocks	O
.	O

The	O
carboxyl	O
terminal	O
of	O
M	O
protein	O
was	O
sufficient	O
for	O
the	O
M	O
protein	B-PROC
function	I-PROC
.	O

Identification	O
of	O
functional	O
dominant	O
epitopes	O
in	O
SARS	O
CoV	O
S	O
protein	O
for	O
T	O
cells	O
is	O
crucial	O
for	O
further	O
understanding	O
of	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
elicited	O
by	O
SARS	O
CoV	O
S	O
DNA	O
vaccine	O
.	O

We	O
propose	O
that	O
,	O
in	O
the	O
disease	O
-	O
resistant	O
SIV	O
-	O
infected	O
SMs	O
,	O
evolutionary	O
adaptation	B-PROC
to	O
both	O
preserve	O
immune	B-PROC
function	I-PROC
with	O
fewer	O
mucosal	O
CD4	O
+	O
T	O
cells	O
and	O
attenuate	O
the	O
immune	O
activation	O
that	O
follows	O
acute	O
viral	B-PROC
infection	I-PROC
protect	O
these	O
animals	O
from	O
progressing	O
to	O
AIDS	O
.	O

Viral	O
proteins	O
that	O
can	O
regulate	O
apoptosis	B-PROC
have	O
been	O
identified	O
,	O
and	O
many	O
of	O
these	O
also	O
have	O
the	O
abilities	O
to	O
interfere	O
with	O
cellular	O
functions	O
.	O

Occurrence	O
of	O
cell	B-PROC
death	I-PROC
in	O
host	O
cells	O
during	O
infection	O
by	O
other	O
coronaviruses	O
,	O
such	O
as	O
the	O
mouse	O
hepatitis	O
virus	O
and	O
transmissible	O
porcine	O
gastroenteritis	O
virus	O
,	O
has	O
also	O
being	O
extensively	O
studied	O
.	O

Continuing	O
research	O
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
regulation	B-PROC
of	I-PROC
cell	B-PROC
death	I-PROC
during	O
viral	B-PROC
infection	I-PROC
and	O
the	O
identification	O
of	O
novel	O
antiviral	O
targets	O
.	O

We	O
show	O
that	O
expression	B-PROC
of	O
nsp1	O
significantly	O
inhibited	O
IFN	O
-	O
dependent	O
signaling	B-PROC
by	O
decreasing	O
the	O
phosphorylation	B-PROC
levels	O
of	O
STAT1	O
while	O
having	O
little	O
effect	O
on	O
those	O
of	O
STAT2	O
,	O
JAK1	O
,	O
and	O
TYK2	O
.	O

TITLE	O
:	O
Acute	O
pancreatitis	O
presenting	O
as	O
sudden	O
,	O
unexpected	O
death	B-PROC
:	O
an	O
autopsy	O
-	O
based	O
study	O
of	O
27	O
cases	O
.	O

To	O
better	O
describe	O
outpatient	O
fatalities	O
due	O
to	O
acute	O
pancreatitis	O
that	O
present	O
as	O
sudden	O
,	O
unexpected	O
death	B-PROC
,	O
we	O
retrospectively	O
reviewed	O
the	O
autopsy	O
files	O
at	O
the	O
Institute	O
of	O
Legal	O
Medicine	O
,	O
University	O
of	O
Hamburg	O
,	O
Germany	O
,	O
from	O
2000	O
-	O
2004	O
.	O

Individual	O
cases	O
were	O
analyzed	O
for	O
sex	O
,	O
age	O
,	O
race	O
,	O
circumstances	O
of	O
death	B-PROC
,	O
social	O
background	O
of	O
the	O
deceased	B-PROC
and	O
previous	O
medical	O
history	O
,	O
seasonal	O
occurrence	O
of	O
the	O
disease	O
,	O
blood	O
alcohol	O
concentration	O
at	O
the	O
time	O
of	O
death	B-PROC
,	O
body	O
mass	O
index	O
,	O
autopsy	O
findings	O
,	O
histopathology	O
,	O
and	O
etiology	O
of	O
acute	O
pancreatitis	O
.	O

Among	O
the	O
6178	O
autopsies	O
carried	O
out	O
during	O
the	O
5	O
-	O
year	O
period	O
evaluated	O
,	O
there	O
were	O
27	O
cases	O
of	O
acute	O
pancreatitis	O
that	O
presented	O
as	O
sudden	O
,	O
unexpected	O
death	B-PROC
.	O

Conversely	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
majority	O
of	O
affected	O
individuals	O
died	B-PROC
during	O
the	O
very	O
early	O
phase	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
Cultivation	O
of	O
bovine	O
coronavirus	O
at	O
34	O
degrees	O
C	O
showed	O
the	O
relationship	O
of	O
the	O
degree	O
of	O
its	O
reproduction	B-PROC
to	O
the	O
cellular	O
system	O
.	O

The	O
acute	O
severe	O
asthma	O
was	O
induced	O
by	O
a	O
respiratory	O
viral	B-PROC
infection	I-PROC
in	O
80	O
%	O
of	O
cases	O
.	O

This	O
complication	O
typically	O
presents	O
as	O
shortness	O
of	O
breath	O
,	O
hypoxemia	O
,	O
hypotension	O
,	O
fever	B-PROC
and	O
noncardiogeneic	O
pulmonary	O
edema	O
,	O
all	O
occurring	O
during	O
or	O
within	O
6	O
h	O
after	O
transfusion	O
.	O

We	O
found	O
that	O
a	O
history	O
of	O
breastfeeding	B-PROC
was	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
risk	O
of	O
acute	O
otitis	O
media	O
,	O
non	O
-	O
specific	O
gastroenteritis	O
,	O
severe	O
lower	O
respiratory	O
tract	O
infections	O
,	O
atopic	O
dermatitis	O
,	O
asthma	O
(	O
young	O
children	O
),	O
obesity	O
,	O
type	O
1	O
and	O
2	O
diabetes	O
,	O
childhood	O
leukemia	O
,	O
sudden	O
infant	O
death	B-PROC
syndrome	O
(	O
SIDS	O
),	O
and	O
necrotizing	O
enterocolitis	O
.	O

The	O
effect	O
of	O
breastfeeding	B-PROC
in	O
mothers	O
on	O
return	O
-	O
to	O
-	O
pre	O
-	O
pregnancy	O
weight	O
was	O
negligible	O
,	O
and	O
the	O
effect	O
of	O
breastfeeding	B-PROC
on	O
postpartum	O
weight	O
loss	O
was	O
unclear	O
.	O

Seizure	O
patterns	O
were	O
determined	O
and	O
it	O
was	O
attempted	O
to	O
relate	O
occurrence	O
of	O
seizures	O
with	O
age	O
,	O
breed	B-PROC
,	O
sex	O
and	O
neuropathological	O
features	O
.	O

TITLE	O
:	O
Viral	O
epizootic	O
reveals	O
inbreeding	B-PROC
depression	O
in	O
a	O
habitually	O
inbreeding	B-PROC
mammal	O
.	O

We	O
demonstrate	O
that	O
,	O
contrary	O
to	O
common	O
assertions	O
,	O
strong	O
inbreeding	B-PROC
depression	O
is	O
evident	O
in	O
this	O
species	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
FEV1	O
/	O
FVC	B-PROC
,	O
total	O
lung	B-PROC
capacity	I-PROC
(	O
TLC	O
),	O
diffusing	O
capacity	O
of	O
the	O
lung	O
for	O
carbon	O
monoxide	O
(	O
DLCO	O
)	O
between	O
the	O
two	O
groups	O
(	O
all	O
P	O
>	O
0	O
.	O
05	O
).	O

The	O
PCR	O
detection	O
results	O
obtained	O
for	O
other	O
viruses	O
revealed	O
the	O
following	O
:	O
61	O
.	O
5	O
%	O
were	O
positive	O
for	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
,	O
30	O
.	O
8	O
%	O
for	O
swine	O
influenza	O
virus	O
,	O
15	O
.	O
4	O
%	O
for	O
porcine	O
parvovirus	O
,	O
69	O
.	O
2	O
%	O
for	O
swine	O
torque	O
teno	O
virus	O
(	O
swTTV	O
),	O
38	O
.	O
5	O
%	O
for	O
swine	O
hepatitis	O
E	O
virus	O
(	O
swHEV	O
)	O
and	O
84	O
.	O
6	O
%	O
for	O
Mycoplasma	O
hyorhinis	O
;	O
transmissible	O
gastroenteritis	O
virus	O
and	O
porcine	O
respiratory	O
coronavirus	O
(	O
TGEV	O
/	O
PRCV	O
)	O
was	O
not	O
detected	O
.	O

While	O
its	O
clinical	O
manifestations	O
have	O
been	O
extensively	O
studied	O
,	O
its	O
pathogenesis	B-PROC
is	O
not	O
yet	O
fully	O
understood	O
.	O

During	O
in	O
vitro	O
translation	B-PROC
in	O
rabbit	O
reticulocyte	O
lysate	O
,	O
we	O
observed	O
that	O
incorporation	O
of	O
the	O
pseudoknot	O
into	O
the	O
mRNA	O
resulted	O
in	O
production	O
of	O
a	O
translational	B-PROC
intermediate	O
that	O
corresponded	O
to	O
the	O
expected	O
size	O
for	O
ribosomal	O
arrest	O
at	O
the	O
pseudoknot	O
.	O

The	O
SARS	O
-	O
CoV	O
specific	O
antibody	B-PROC
was	O
detected	O
for	O
all	O
of	O
them	O
by	O
ELISA	O
and	O
neutralized	O
test	O
simultaneously	O
.	O

Results	O
showed	O
that	O
despite	O
the	O
fact	O
that	O
the	O
positive	O
rates	O
of	O
ELISA	O
antibody	B-PROC
were	O
100	O
%,	O
82	O
.	O
4	O
%	O
and	O
84	O
.	O
6	O
%	O
respectively	O
,	O
the	O
neutralizing	O
antibody	B-PROC
was	O
still	O
positive	O
for	O
all	O
the	O
samples	O
.	O

On	O
the	O
35th	O
month	O
after	O
the	O
onset	O
,	O
30	O
.	O
8	O
%	O
(	O
4	O
/	O
13	O
)	O
of	O
the	O
patients	O
were	O
still	O
having	O
the	O
neutralizing	O
antibody	B-PROC
level	O
of	O
above	O
1	O
:	O
36	O
,	O
but	O
the	O
neutralizing	O
antibody	B-PROC
level	O
in	O
another	O
30	O
.	O
8	O
%	O
(	O
4	O
/	O
13	O
)	O
of	O
the	O
patients	O
had	O
decreased	O
to	O
as	O
low	O
as	O
1	O
:	O
10	O
,	O
when	O
the	O
cut	O
-	O
off	O
level	O
was	O
set	O
as	O
1	O
:	O
8	O
.	O

Further	O
follow	O
-	O
up	O
study	O
was	O
worthwhile	O
to	O
observe	O
the	O
long	O
-	O
lasting	O
profile	O
of	O
antibody	B-PROC
existence	O
on	O
SARS	O
cases	O
.	O

A	O
42	O
-	O
year	O
-	O
old	O
kidney	O
transplant	O
recipient	O
experienced	O
on	O
postoperative	O
day	O
10	O
a	O
dehiscence	B-PROC
of	O
the	O
ureterovesical	O
anastomosis	O
,	O
associated	O
with	O
a	O
7	O
-	O
cm	O
longitudinal	O
tear	O
graft	O
on	O
the	O
lower	O
pole	O
of	O
the	O
kidney	O
and	O
an	O
ureteral	O
ischemia	O
.	O

Two	O
days	O
later	O
the	O
patient	O
presented	O
with	O
fever	B-PROC
(	O
39	O
.	O
5	O
degrees	O
C	O
),	O
diffuse	O
abdominal	O
pain	O
with	O
tenderness	O
and	O
bloody	O
diarrhea	O
,	O
and	O
diagnosis	O
of	O
CMV	O
colitis	O
was	O
achieved	O
;	O
rectal	O
samples	O
were	O
taken	O
for	O
histologic	O
examination	O
,	O
and	O
Clostridium	O
difficile	O
toxin	O
was	O
isolated	O
.	O

As	O
a	O
first	O
step	O
to	O
getting	O
more	O
insight	O
into	O
the	O
formation	B-PROC
of	O
the	O
coronavirus	O
replication	O
complex	O
,	O
the	O
membrane	O
topology	O
,	O
processing	O
,	O
and	O
subcellular	O
localization	B-PROC
of	O
nsp4	O
of	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
elucidated	O
in	O
this	O
study	O
.	O

The	O
COQ2	O
gene	O
encodes	O
the	O
para	O
-	O
hydroxybenzoate	O
-	O
polyprenyl	O
-	O
transferase	O
enzyme	O
of	O
the	O
CoQ	O
(	O
10	O
)	O
synthesis	B-PROC
pathway	B-PROC
.	O

All	O
four	O
immunodominant	O
peptides	O
could	O
elicit	O
cellular	B-PROC
immunity	I-PROC
with	O
a	O
predominance	O
of	O
CD8	O
+	O
T	O
-	O
cell	O
response	O
.	O

From	O
103	O
consecutive	O
patients	O
the	O
study	O
included	O
20	O
undergoing	O
NPPV	O
and	O
20	O
CMV	O
,	O
matched	O
for	O
age	O
,	O
simplified	O
acute	O
physiology	O
score	O
II	O
,	O
and	O
baseline	O
arterial	O
blood	B-PROC
gases	I-PROC
.	O

This	O
system	O
can	O
be	O
induced	O
effectively	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
direct	O
application	O
of	O
small	O
interfering	O
RNAs	O
(	O
siRNAs	O
),	O
or	O
by	O
expression	B-PROC
of	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
with	O
non	O
-	O
viral	O
and	O
viral	O
vectors	O
.	O

In	O
addition	O
,	O
many	O
reports	O
also	O
suggest	O
that	O
this	O
protein	O
interferes	O
with	O
different	O
cellular	O
pathways	B-PROC
,	O
thus	O
implying	O
it	O
to	O
be	O
a	O
key	O
regulatory	O
component	O
of	O
the	O
virus	O
too	O
.	O

The	O
expression	B-PROC
of	O
full	O
length	O
recombinant	O
SARS	O
spike	O
protein	O
(	O
rSS	O
)	O
in	O
HeLa	O
cells	O
possessing	O
specific	O
reaction	O
ability	O
to	O
chicken	O
anti	O
-	O
sera	O
was	O
confirmed	O
by	O
SDS	O
-	O
PAGE	O
and	O
Western	O
-	O
blot	O
(	O
190	O
kD	O
).	O

ABSTRACT	O
:	O
An	O
outbreak	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
occurred	O
in	O
Hong	O
Kong	O
in	O
late	O
February	O
2003	O
,	O
resulting	O
in	O
8	O
,	O
096	O
cumulative	O
cases	O
with	O
774	O
deaths	B-PROC
.	O

Proper	O
treatment	O
,	O
however	O
,	O
depends	O
on	O
correct	O
identification	O
of	O
the	O
pathogen	O
involved	O
as	O
antibiotics	O
provide	O
little	O
or	O
no	O
benefit	O
with	O
viral	B-PROC
infections	I-PROC
.	O

Because	O
ECD	O
uses	O
an	O
enzymatic	B-PROC
reaction	I-PROC
to	O
create	O
electrical	O
signals	O
that	O
can	O
be	O
read	O
directly	O
from	O
the	O
array	O
,	O
there	O
is	O
no	O
need	O
for	O
image	O
analysis	O
or	O
for	O
expensive	O
and	O
delicate	O
optical	O
scanning	O
equipment	O
.	O

Mice	O
were	O
subcutaneously	O
and	O
intraperitoneally	O
injected	O
with	O
recombinant	O
baculovirus	O
,	O
and	O
both	O
humoral	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
were	O
induced	O
in	O
the	O
vaccinated	O
groups	O
.	O

Additionally	O
,	O
a	O
marked	O
increase	O
of	O
CD4	O
T	O
cell	O
immune	B-PROC
responses	I-PROC
and	O
high	O
levels	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
humoral	O
responses	O
were	O
also	O
detected	O
in	O
the	O
vAc	O
-	O
N	O
or	O
vAc	O
-	O
S	O
immunized	O
groups	O
.	O

In	O
general	O
,	O
swaddled	O
infants	O
arouse	O
less	O
and	O
sleep	B-PROC
longer	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
whether	O
genetic	O
factors	O
of	O
innate	B-PROC
immunity	B-PROC
might	O
influence	O
susceptibility	O
and	O
/	O
or	O
progression	O
in	O
individuals	O
infected	O
with	O
SARS	O
,	O
we	O
evaluated	O
the	O
CD14	O
gene	B-PROC
polymorphism	I-PROC
in	O
198	O
Hong	O
Kong	O
blood	O
donors	O
and	O
152	O
Hong	O
Kong	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
who	O
were	O
previously	O
genotyped	O
for	O
FcgammaRIIA	O
polymorphisms	B-PROC
.	O

ABSTRACT	O
:	O
Infection	O
of	O
mice	O
with	O
variants	O
of	O
mouse	O
hepatitis	O
virus	O
,	O
strain	O
JHM	O
(	O
MHV	O
-	O
JHM	O
),	O
provide	O
models	O
of	O
acute	O
and	O
chronic	O
viral	B-PROC
infection	I-PROC
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
).	O

Using	O
multicolor	O
colocalization	O
techniques	O
,	O
we	O
previously	O
reported	O
that	O
SARS	O
(+)	O
cells	O
in	O
the	O
lung	O
of	O
fatally	O
infected	O
patients	O
expressed	B-PROC
the	O
only	O
known	O
functional	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
and	O
also	O
a	O
binding	O
receptor	O
,	O
liver	O
/	O
lymph	O
node	O
-	O
specific	O
ICAM	O
-	O
3	O
-	O
grabbing	O
non	O
-	O
integrin	O
(	O
CD209L	O
).	O

A	O
19	O
year	O
old	O
man	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
for	O
acute	O
respiratory	O
distress	O
with	O
fever	B-PROC
(	O
400C	O
),	O
lymph	O
node	O
enlargement	O
,	O
hepatomegaly	O
,	O
splenomegaly	O
and	O
eosinophilia	O
(	O
1640	O
/	O
mm3	O
).	O

ABSTRACT	O
:	O
Neurotropic	O
coronavirus	O
infection	O
induces	O
expression	B-PROC
of	O
both	O
beta	O
interferon	O
(	O
IFN	O
-	O
beta	O
)	O
RNA	O
and	O
protein	O
in	O
the	O
infected	O
rodent	O
central	O
nervous	O
system	O
(	O
CNS	O
).	O

A	O
soluble	O
,	O
unmodified	O
and	O
monomeric	O
8b	O
protein	O
was	O
now	O
expressed	B-PROC
in	O
the	O
cytoplasm	O
,	O
which	O
was	O
highly	O
unstable	O
and	O
rapidly	O
degraded	O
.	O

Clearly	O
,	O
the	O
29	O
-	O
nucleotide	O
deletion	O
disrupts	O
the	O
proper	O
expression	B-PROC
of	O
the	O
SARS	O
-	O
CoV	O
ORF8	O
,	O
the	O
implications	O
of	O
which	O
are	O
discussed	O
.	O

TITLE	O
:	O
Role	O
of	O
phosphorylation	B-PROC
clusters	O
in	O
the	O
biology	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
nucleocapsid	O
protein	O
.	O

Kinetic	O
analysis	O
of	O
RNA	O
binding	O
indicated	O
that	O
the	O
C	O
-	O
terminal	O
phosphorylation	B-PROC
cluster	O
was	O
involved	O
in	O
the	O
recognition	O
of	O
viral	O
RNA	O
from	O
non	O
-	O
viral	O
RNA	O
.	O

TITLE	O
:	O
Molecular	O
docking	B-PROC
identifies	O
the	O
binding	O
of	O
3	O
-	O
chloropyridine	O
moieties	O
specifically	O
to	O
the	O
S1	O
pocket	O
of	O
SARS	O
-	O
CoV	O
Mpro	O
.	O

Previously	O
,	O
it	O
was	O
thought	O
that	O
direct	O
transmission	B-PROC
of	I-PROC
virus	I-PROC
from	O
bird	O
to	O
human	O
could	O
not	O
take	O
place	O
,	O
but	O
it	O
came	O
to	O
be	O
true	O
in	O
1997	O
,	O
in	O
Hong	O
Kong	O
.	O

In	O
severe	O
cases	O
death	B-PROC
occurs	O
due	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
multiple	O
organ	O
involvement	O
.	O

Further	O
development	B-PROC
of	O
the	O
attenuated	O
CK	O
/	O
CH	O
/	O
LDL	O
/	O
97I	O
strain	O
may	O
provide	O
a	O
valuable	O
contribution	O
towards	O
this	O
goal	O
.	O

Trauma	O
-	O
associated	O
lung	O
injury	O
patients	O
had	O
a	O
significantly	O
lower	O
odds	O
of	O
death	B-PROC
at	O
90	O
days	O
,	O
even	O
after	O
adjusting	O
for	O
baseline	O
clinical	O
factors	O
including	O
age	O
,	O
gender	O
,	O
ethnicity	O
,	O
comorbidities	O
,	O
and	O
severity	O
of	O
illness	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
44	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
24	O
-	O
0	O
.	O
82	O
;	O
p	O
=	O
.	O
01	O
).	O

From	O
142	O
patients	O
enrolled	O
over	O
a	O
6	O
-	O
month	O
period	O
,	O
24	O
(	O
17	O
%)	O
died	B-PROC
in	O
the	O
intensive	O
care	O
unit	O
,	O
38	O
(	O
27	O
%)	O
in	O
the	O
hospital	O
,	O
and	O
55	O
(	O
39	O
%)	O
by	O
the	O
end	O
of	O
the	O
6	O
-	O
month	O
follow	O
-	O
up	O
.	O

TITLE	O
:	O
VII	O
International	O
Symposium	O
on	O
Respiratory	O
Viral	B-PROC
Infections	I-PROC
.	O

Other	O
talks	O
covered	O
the	O
live	O
,	O
attenuated	O
intranasal	O
influenza	O
vaccine	O
,	O
monoclonals	O
for	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
mechanisms	O
of	O
antiviral	O
resistance	B-PROC
in	O
influenza	O
B	O
,	O
and	O
novel	O
inhibitors	O
for	O
influenza	O
,	O
RSV	O
and	O
rhinovirus	O
infections	O
.	O

Our	O
effort	B-PROC
is	O
to	O
draft	O
our	O
guidelines	O
of	O
combining	O
traditional	O
Chinese	O
medicine	O
and	O
western	O
medicine	O
as	O
a	O
supplement	O
to	O
SSC	O
guidelines	O
.	O

Five	O
key	O
themes	O
emerged	O
from	O
this	O
research	O
:	O
(	O
1	O
)	O
during	O
times	O
of	O
crisis	O
,	O
pharmacies	O
become	O
frontline	O
health	O
care	O
facilities	O
,	O
(	O
2	O
)	O
a	O
vacuity	O
of	O
leadership	O
/	O
lack	O
of	O
utility	O
of	O
emergency	O
preparedness	O
guidelines	O
and	O
policies	O
,	O
(	O
3	O
)	O
role	O
of	O
and	O
reliance	O
on	O
experience	O
and	O
professional	O
judgment	O
,	O
(	O
4	O
)	O
importance	O
of	O
documentation	O
,	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
""""	O
teamness	O
""""	O
in	O
enabling	O
successful	O
adaptation	B-PROC
during	O
times	O
of	O
crisis	O
.	O

RESULTS	O
:	O
Five	O
key	O
themes	O
emerged	O
from	O
this	O
research	O
:	O
(	O
1	O
)	O
during	O
times	O
of	O
crisis	O
,	O
pharmacies	O
become	O
frontline	O
health	O
care	O
facilities	O
,	O
(	O
2	O
)	O
a	O
vacuity	O
of	O
leadership	O
/	O
lack	O
of	O
utility	O
of	O
emergency	O
preparedness	O
guidelines	O
and	O
policies	O
,	O
(	O
3	O
)	O
role	O
of	O
and	O
reliance	O
on	O
experience	O
and	O
professional	O
judgment	O
,	O
(	O
4	O
)	O
importance	O
of	O
documentation	O
,	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
""""	O
teamness	O
""""	O
in	O
enabling	O
successful	O
adaptation	B-PROC
during	O
times	O
of	O
crisis	O
.	O

Here	O
,	O
the	O
expression	B-PROC
of	O
the	O
3a	O
protein	O
in	O
various	O
in	O
vitro	O
systems	O
is	O
shown	O
,	O
it	O
has	O
been	O
localized	O
to	O
the	O
Golgi	O
region	O
and	O
its	O
membrane	O
topology	O
in	O
transfected	O
cells	O
has	O
been	O
confirmed	O
.	O

Studies	O
have	O
shown	O
potential	O
for	O
benefit	O
of	O
inhaled	B-PROC
nitric	O
oxide	O
in	O
newborns	O
with	O
hypoxemic	O
respiratory	O
failure	O
and	O
pulmonary	O
hypertension	O
,	O
surfactant	O
in	O
respiratory	O
distress	O
syndrome	O
in	O
preterm	O
neonates	O
and	O
heliox	O
in	O
severe	O
upper	O
airway	O
obstruction	O
.	O

One	O
month	O
after	O
the	O
first	O
examination	O
,	O
the	O
cat	O
died	B-PROC
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
twofold	O
:	O
to	O
determine	O
if	O
reduced	O
fertility	B-PROC
following	O
vaccination	O
with	O
live	O
attenuated	O
virus	O
was	O
the	O
result	O
of	O
reduced	O
sperm	O
concentration	O
or	O
reduced	O
sperm	O
quality	O
and	O
to	O
determine	O
if	O
vaccination	O
with	O
a	O
killed	O
strain	O
of	O
virus	O
caused	O
a	O
similar	O
reduction	O
in	O
sperm	O
function	O
in	O
vivo	O
.	O

There	O
were	O
no	O
differences	O
across	O
treatment	O
groups	O
in	O
sperm	B-PROC
mobility	I-PROC
through	O
Accudenz	O
or	O
in	O
numbers	O
of	O
sperm	O
holes	O
in	O
perivitelline	O
membranes	O
of	O
eggs	O
following	O
insemination	B-PROC
with	O
semen	O
from	O
27	O
-	O
week	O
-	O
old	O
cockerels	O
.	O

In	O
conclusion	O
,	O
pre	O
-	O
pubertal	O
vaccination	O
against	O
AIBV	O
and	O
subsequent	O
epididymal	O
stone	O
formation	B-PROC
had	O
a	O
limited	O
effect	O
on	O
sperm	O
concentration	O
,	O
sperm	O
quality	O
and	O
plasma	O
testosterone	O
concentrations	O
.	O

ABSTRACT	O
:	O
Rhabdomyolysis	O
is	O
a	O
clinical	O
syndrome	O
characterized	O
by	O
the	O
breakdown	B-PROC
and	O
later	O
necrosis	B-PROC
of	O
skeletal	O
muscle	O
,	O
leading	O
to	O
the	O
release	O
of	O
various	O
intracellular	O
components	O
into	O
the	O
blood	O
stream	O
.	O

TITLE	O
:	O
Conformational	O
reorganization	O
of	O
the	O
SARS	O
coronavirus	O
spike	O
following	O
receptor	O
binding	O
:	O
implications	O
for	O
membrane	B-PROC
fusion	I-PROC
.	O

This	O
study	O
is	O
expected	O
to	O
extend	O
our	O
understanding	O
on	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
at	O
a	O
molecular	O
level	O
.	O

ABSTRACT	O
:	O
The	O
contribution	O
of	O
DRAK2	O
[	O
death	B-PROC
-	O
associated	O
protein	O
kinase	O
(	O
DAPK	O
)-	O
related	O
apoptosis	B-PROC
-	O
inducing	O
kinase	O
2	O
]	O
to	O
anti	O
-	O
viral	O
memory	B-PROC
T	O
cell	O
responses	O
following	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
was	O
examined	O
.	O

ABSTRACT	O
:	O
The	O
worldwide	O
epidemic	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
2003	O
was	O
caused	O
by	O
a	O
novel	O
coronavirus	O
called	O
SARS	O
-	O
CoV	O
.	O
We	O
report	O
the	O
use	O
of	O
DNAzyme	O
(	O
catalytic	O
DNA	O
)	O
to	O
target	O
the	O
5	O
'-	O
untranslated	O
region	O
(	O
5	O
'	O
UTR	O
)	O
of	O
a	O
highly	O
conserved	O
fragment	O
in	O
the	O
SARS	O
genome	O
as	O
an	O
approach	O
to	O
suppression	B-PROC
of	O
SARS	O
-	O
CoV	O
replication	O
.	O

In	O
vitro	O
cleavage	B-PROC
was	O
performed	O
using	O
an	O
in	O
vitro	O
transcribed	O
5	O
'	O
UTR	O
RNA	O
substrate	O
.	O

A	O
vector	O
containing	O
a	O
fused	O
5	O
'	O
UTR	O
and	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
eGFP	O
)	O
was	O
co	O
-	O
transfected	O
with	O
the	O
DNAzyme	O
into	O
E6	O
cells	O
and	O
the	O
cells	O
expressing	O
eGFP	O
were	O
visualized	O
with	O
fluorescence	O
microscopy	O
and	O
analyzed	O
by	O
fluorescence	O
-	O
activated	O
cell	O
sorting	B-PROC
(	O
FACS	O
).	O

TITLE	O
:	O
Continuous	O
negative	O
extrathoracic	O
pressure	O
combined	O
with	O
high	O
-	O
frequency	O
oscillation	O
improves	O
oxygenation	B-PROC
with	O
less	O
impact	O
on	O
blood	B-PROC
pressure	I-PROC
than	O
high	O
-	O
frequency	O
oscillation	O
alone	O
in	O
a	O
rabbit	O
model	O
of	O
surfactant	O
depletion	O
.	O

The	O
effects	O
of	O
CNEP	O
combined	O
with	O
HFO	O
on	O
pulmonary	B-PROC
gas	I-PROC
exchange	I-PROC
and	O
circulation	B-PROC
were	O
examined	O
in	O
a	O
surfactant	O
-	O
depleted	O
rabbit	O
model	O
.	O

In	O
alveolar	O
epithelial	O
cells	O
exposed	O
to	O
severe	O
hypoxia	O
,	O
we	O
have	O
reported	O
that	O
increased	O
production	O
of	O
mitochondrial	O
reactive	O
oxygen	O
species	O
leads	O
to	O
Na	O
,	O
K	O
-	O
ATPase	O
endocytosis	B-PROC
and	O
degradation	O
.	O

We	O
found	O
that	O
this	O
regulated	O
process	O
follows	O
what	O
is	O
referred	O
as	O
the	O
Phosphorylation	B-PROC
-	O
Ubiquitination	B-PROC
-	O
Recognition	O
-	O
Endocytosis	B-PROC
-	O
Degradation	O
(	O
PURED	O
)	O
pathway	B-PROC
.	O

Dot	O
blot	O
analysis	O
showed	O
that	O
SARS	O
-	O
CoV	O
spike	O
protein	O
,	O
which	O
was	O
expressed	B-PROC
and	O
purified	O
from	O
mammal	O
cells	O
,	O
can	O
be	O
detected	O
by	O
anti	O
-	O
Z	O
sera	O
from	O
rabbit	O
.	O

TITLE	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
in	O
the	O
management	O
of	O
preterm	O
infants	O
with	O
severe	O
respiratory	O
failure	O
.	O

ABSTRACT	O
:	O
Elevated	O
pulmonary	B-PROC
vascular	I-PROC
resistance	I-PROC
and	O
poor	O
ventilation	O
-	O
perfusion	O
matching	O
are	O
commonly	O
found	O
in	O
preterm	O
infants	O
with	O
severe	O
respiratory	O
distress	O
syndrome	O
(	O
RDS	O
)	O
and	O
respiratory	O
failure	O
.	O

We	O
conclude	O
that	O
iNO	O
therapy	O
leads	O
to	O
an	O
improvement	O
in	O
oxygenation	B-PROC
without	O
short	O
-	O
term	O
side	O
effects	O
(	O
such	O
as	O
pulmonary	O
hemorrhage	O
,	O
intracranial	O
hemorrhage	O
,	O
pneumothorax	O
or	O
acute	O
deterioration	O
)	O
in	O
premature	O
infants	O
with	O
severe	O
RDS	O
and	O
respiratory	O
failure	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
iNO	O
therapy	O
leads	O
to	O
an	O
improvement	O
in	O
oxygenation	B-PROC
without	O
short	O
-	O
term	O
side	O
effects	O
(	O
such	O
as	O
pulmonary	O
hemorrhage	O
,	O
intracranial	O
hemorrhage	O
,	O
pneumothorax	O
or	O
acute	O
deterioration	O
)	O
in	O
premature	O
infants	O
with	O
severe	O
RDS	O
and	O
respiratory	O
failure	O
.	O

The	O
samples	O
were	O
screened	O
for	O
astrovirus	O
,	O
rotavirus	O
,	O
reovirus	O
,	O
and	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
by	O
a	O
reverse	O
transcriptase	B-PROC
and	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
for	O
groups	O
1	O
and	O
2	O
adenovirus	O
by	O
PCR	O
.	O

ABSTRACT	O
:	O
Infectious	O
bronchitis	O
(	O
IB	O
)	O
disease	O
progression	O
in	O
vaccinated	O
chickens	O
after	O
challenge	O
was	O
evaluated	O
in	O
a	O
single	O
commercial	O
line	O
of	O
layer	O
chickens	O
presenting	O
two	O
different	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
(	O
MHC	B-PROC
)	O
B	O
complex	O
genotypes	O
.	O

While	O
CXCL9	O
,	O
CXCL10	O
and	O
CXCL11	O
share	O
the	O
same	O
receptor	O
and	O
have	O
overlapping	O
functions	O
,	O
each	O
can	O
also	O
have	O
unique	O
activity	O
in	O
host	B-PROC
defense	I-PROC
.	O

In	O
order	O
to	O
gain	O
new	O
insight	O
into	O
the	O
protein	O
membrane	O
alteration	O
leading	O
to	O
the	O
viral	O
fusion	O
mechanism	O
,	O
a	O
peptide	O
pertaining	O
to	O
the	O
putative	O
pre	O
-	O
transmembrane	O
domain	O
(	O
PTM	B-PROC
)	O
of	O
the	O
S	O
glycoprotein	O
has	O
been	O
studied	O
by	O
infrared	O
and	O
fluorescence	O
spectroscopies	O
regarding	O
its	O
structure	O
,	O
its	O
ability	O
to	O
induce	O
membrane	O
leakage	O
,	O
aggregation	O
,	O
and	O
fusion	O
,	O
as	O
well	O
as	O
its	O
affinity	O
toward	O
specific	O
phospholipids	O
.	O

It	O
is	O
described	O
to	O
be	O
expressed	B-PROC
during	O
infection	O
and	O
to	O
be	O
a	O
component	O
of	O
the	O
virus	O
particle	O
surface	O
.	O

One	O
cell	O
type	O
was	O
type	O
II	O
cells	O
,	O
which	O
were	O
positive	O
for	O
SP	O
-	O
A	O
,	O
SP	O
-	O
C	O
,	O
cytokeratin	O
,	O
a	O
type	O
II	O
cell	O
-	O
specific	O
monoclonal	O
antibody	B-PROC
,	O
and	O
Ep	O
-	O
CAM	O
.	O

In	O
this	O
report	O
,	O
recombinant	O
PPV	O
(	O
plum	O
pox	O
virus	O
)	O
NIa	O
protease	O
was	O
employed	O
to	O
process	O
fusion	O
proteins	O
with	O
artificial	O
cleavage	B-PROC
site	O
in	O
vitro	O
.	O

Characteristics	O
such	O
as	O
catalytic	O
ability	O
and	O
affecting	O
factors	O
(	O
salt	O
,	O
temperature	O
,	O
protease	B-PROC
inhibitors	I-PROC
,	O
detergents	O
,	O
and	O
denaturing	O
reagents	O
)	O
were	O
investigated	O
.	O

The	O
patient	O
'	O
s	O
insulin	O
resistance	B-PROC
responded	O
to	O
glucocorticoids	O
and	O
plasmapheresis	O
.	O

Aggressive	B-PROC
management	O
was	O
practiced	O
with	O
continuous	O
transfusion	O
of	O
blood	O
products	O
and	O
administration	O
of	O
vasocopressors	O
.	O

ABSTRACT	O
:	O
Recent	O
experience	O
with	O
the	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
Canada	O
and	O
the	O
global	O
threat	O
of	O
the	O
H5N1	O
virus	O
(	O
avian	O
""""	O
flu	O
""")"	O
have	O
increased	O
the	O
appetite	B-PROC
for	O
and	O
urgency	O
of	O
pandemic	O
planning	O
as	O
a	O
policy	O
issue	O
.	O

The	O
level	O
of	O
predictability	O
offered	O
by	O
the	O
model	O
can	O
be	O
quantitatively	O
analyzed	O
and	O
related	O
to	O
the	O
appearance	O
of	O
robust	O
epidemic	O
pathways	B-PROC
that	O
represent	O
the	O
most	O
probable	O
routes	O
for	O
the	O
spread	O
of	O
the	O
disease	O
.	O

The	O
outbreak	O
likelihood	O
for	O
specific	O
countries	O
is	O
evaluated	O
along	O
with	O
the	O
emerging	O
epidemic	O
pathways	B-PROC
.	O

The	O
sensitivity	O
of	O
our	O
novel	O
SARS	O
CLEIA	O
was	O
significantly	O
higher	O
than	O
the	O
previous	O
EIA	O
and	O
comparable	O
to	O
the	O
other	O
methods	O
using	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
.	O

It	O
has	O
multiple	O
important	O
physiological	O
functions	O
,	O
one	O
of	O
which	O
is	O
to	O
act	O
as	O
an	O
immune	O
mechanism	O
against	O
intracellular	O
microbes	O
.(	O
1	O
,	O
2	O
)	O
Bacteria	O
and	O
viruses	O
targeted	B-PROC
for	O
destruction	O
are	O
sequestered	O
into	O
large	O
double	O
-	O
membrane	O
vesicles	O
called	O
autophagosomes	O
and	O
subsequently	O
delivered	O
to	O
the	O
lysosomes	O
where	O
they	O
are	O
consumed	O
by	O
resident	O
hydrolases	O
.	O

Unfortunately	O
,	O
conserved	O
cellular	O
pathways	B-PROC
are	O
often	O
exploited	O
by	O
pathogens	O
to	O
facilitate	O
their	O
entry	O
or	O
replication	O
,	O
and	O
autophagy	B-PROC
is	O
no	O
exception	O
.	O

Cimicifuga	O
rhizoma	O
,	O
Meliae	O
cortex	O
,	O
Coptidis	O
rhizoma	O
,	O
Phellodendron	O
cortex	O
and	O
Sophora	O
subprostrata	O
radix	O
decreased	O
the	O
MHV	O
production	O
and	O
the	O
intracellular	O
viral	O
RNA	O
and	O
protein	B-PROC
expression	B-PROC
with	O
EC50	O
values	O
ranging	O
from	O
2	O
.	O
0	O
to	O
27	O
.	O
5	O
microg	O
/	O
ml	O
.	O

Conversely	O
,	O
the	O
prolonged	O
administration	O
of	O
beta	O
-	O
adrenergic	B-PROC
antagonists	I-PROC
during	O
the	O
recovery	O
phase	O
after	O
cardiac	O
surgery	O
resulted	O
in	O
a	O
lower	O
number	O
of	O
traumatic	O
memories	O
and	O
a	O
lower	O
incidence	O
of	O
stress	O
symptoms	O
at	O
6	O
months	O
after	O
surgery	O
.	O

Moreover	O
,	O
elevated	O
levels	O
of	O
CXCL9	O
and	O
CXCL10	O
gene	B-PROC
expression	I-PROC
were	O
detected	O
in	O
retinal	O
tissue	O
.	O

Hyperthermia	B-PROC
develops	O
when	O
discord	O
occurs	O
between	O
metabolic	B-PROC
heat	B-PROC
production	I-PROC
and	O
heat	B-PROC
dissipation	I-PROC
.	O

Alanine	O
substitution	O
of	O
several	O
residues	O
in	O
the	O
RNA	O
-	O
contacting	O
portion	O
of	O
Nsp15	O
did	O
not	O
affect	O
hexamer	O
formation	B-PROC
but	O
decreased	O
the	O
affinity	O
of	O
RNA	O
binding	O
and	O
reduced	O
endonuclease	O
activity	O
.	O

TITLE	O
:	O
Novel	O
3	O
-	O
sulphonamido	O
-	O
quinazolin	O
-	O
4	O
(	O
3H	O
)-	O
one	O
derivatives	O
:	O
microwave	O
-	O
assisted	O
synthesis	B-PROC
and	O
evaluation	O
of	O
antiviral	O
activities	O
against	O
respiratory	O
and	O
biodefense	O
viruses	O
.	O

Three	O
of	O
those	O
genes	O
,	O
called	O
X4	O
,	O
X5	O
and	O
ORF10	O
,	O
were	O
synthesized	O
and	O
introduced	O
into	O
E	O
.	O
coli	O
to	O
induce	O
expression	B-PROC
.	O

We	O
treated	O
her	O
with	O
antituberculosis	O
chemotherapy	O
,	O
corticosteroid	O
,	O
sivelestat	O
sodium	O
hydrate	O
,	O
direct	O
hemoperfusion	O
using	O
a	O
polymyxin	O
B	O
immobilized	O
column	O
,	O
and	O
mechanical	O
ventilation	O
,	O
but	O
she	O
died	B-PROC
due	O
to	O
respiratory	O
failure	O
.	O

Recombinant	O
fusion	O
proteins	O
comprised	O
of	O
pgsA	O
and	O
neucleocapsid	O
protein	O
of	O
PEDV	O
were	O
stably	O
expressed	B-PROC
in	O
Lactobacillus	O
casei	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
nucleocapsid	O
protein	O
interacts	O
with	O
Smad3	O
and	O
modulates	O
transforming	O
growth	B-PROC
factor	O
-	O
beta	O
signaling	B-PROC
.	O

These	O
findings	O
provide	O
evidence	O
of	O
a	O
novel	O
mechanism	O
whereby	O
N	O
protein	O
modulates	O
TGF	O
-	O
beta	O
signaling	B-PROC
to	O
block	O
apoptosis	B-PROC
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
host	O
cells	O
and	O
meanwhile	O
promote	O
tissue	O
fibrosis	O
.	O

This	O
method	O
,	O
which	O
has	O
been	O
successfully	O
applied	O
to	O
isolate	O
broadly	O
neutralizing	O
antibodies	O
against	O
SARS	O
and	O
H5N1	O
influenza	O
viruses	O
,	O
is	O
expected	O
to	O
accelerate	O
the	O
development	B-PROC
of	O
therapeutics	O
in	O
the	O
field	O
of	O
infectious	O
diseases	O
not	O
only	O
by	O
providing	O
neutralizing	O
antibodies	O
for	O
passive	O
serotherapy	O
,	O
but	O
also	O
by	O
generating	O
relevant	O
information	O
for	O
vaccine	O
design	O
.	O

The	O
clinical	O
manifestations	O
of	O
IMS	O
typically	O
occur	O
within	O
24	O
to	O
96	O
hours	O
,	O
affecting	O
conscious	O
patients	O
without	O
cholinergic	O
signs	O
,	O
and	O
involve	O
the	O
muscles	O
of	O
respiration	B-PROC
,	O
proximal	O
limb	O
muscles	O
,	O
neck	O
flexors	O
,	O
and	O
muscles	O
innervated	O
by	O
motor	O
cranial	O
nerves	O
.	O

With	O
appropriate	O
therapy	O
that	O
commonly	O
includes	O
artificial	O
respiration	B-PROC
,	O
complete	O
recovery	O
develops	O
5	O
-	O
18	O
days	O
later	O
.	O

carboxy	O
-	O
terminal	O
portion	O
of	O
the	O
spike	O
protein	O
(	O
S	O
-	O
CT24	O
)	O
elicited	O
a	O
strong	O
antibody	B-PROC
response	I-PROC
in	O
BALB	O
/	O
c	O
mice	O
that	O
had	O
specific	O
reactivity	O
against	O
the	O
S	O
-	O
CT24	O
and	O
PEDV	O
.	O

Cardiopulmonary	O
hemodynamics	B-PROC
were	O
monitored	O
during	O
a	O
48	O
-	O
hr	O
experimental	O
time	O
period	O
.	O

To	O
identify	O
the	O
most	O
important	O
antigenic	O
region	O
of	O
S1	O
,	O
the	O
truncated	O
S1	O
-	O
GST	O
fusion	O
proteins	O
were	O
examined	O
for	O
their	O
ability	O
to	O
react	O
with	O
immune	O
serum	O
against	O
PEDV	O
and	O
to	O
elicit	O
the	O
formation	B-PROC
of	O
neutralization	O
antibodies	O
in	O
immunized	O
animals	O
.	O

ABSTRACT	O
:	O
Acute	O
poisoning	O
with	O
pesticides	O
is	O
a	O
global	O
public	O
health	O
problem	O
and	O
accounts	O
for	O
as	O
many	O
as	O
300	O
,	O
000	O
deaths	B-PROC
worldwide	O
every	O
year	O
.	O

Management	O
consists	O
of	O
proper	O
oxygenation	B-PROC
,	O
atropine	O
in	O
escalating	O
doses	O
and	O
pralidoxime	O
in	O
high	O
doses	O
.	O

The	O
pseudo	O
-	O
typed	O
lentiviral	O
particles	O
were	O
used	O
to	O
develop	O
an	O
in	O
vitro	O
microneutralization	O
assay	O
that	O
was	O
both	O
sensitive	O
and	O
specific	O
for	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-PROC
.	O

With	O
respect	O
to	O
the	O
former	O
,	O
considerations	O
should	O
be	O
given	O
to	O
minimize	O
the	O
inter	O
-	O
flat	O
airflow	B-PROC
via	O
windows	O
flush	O
with	O
façade	O
for	O
high	O
-	O
rise	O
buildings	O
with	O
natural	O
ventilation	O
;	O
and	O
with	O
respect	O
to	O
the	O
latter	O
,	O
more	O
targeted	B-PROC
and	O
earlier	O
intervention	O
can	O
be	O
implemented	O
in	O
case	O
of	O
any	O
highly	O
infectious	O
disease	O
outbreaks	O
.	O

The	O
coronavirus	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)),	O
which	O
plays	O
a	O
pivotal	O
role	O
in	O
viral	O
gene	B-PROC
expression	I-PROC
and	O
replication	O
through	O
the	O
proteolytic	B-PROC
processing	I-PROC
of	O
replicase	O
polyproteins	O
,	O
is	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
CoV	O
drug	O
design	O
.	O

Deletion	O
of	O
a	O
dilysine	O
motif	O
that	O
has	O
previously	O
been	O
suggested	O
to	O
function	O
as	O
a	O
retrieval	O
signal	O
did	O
not	O
abolish	O
intracellular	B-PROC
retention	I-PROC
.	O

Although	O
the	O
antiviral	O
effector	O
mechanism	O
is	O
initially	O
independent	O
of	O
IFN	B-PROC
-	I-PROC
gamma	I-PROC
secretion	I-PROC
,	O
sustained	O
control	O
of	O
CNS	O
virus	B-PROC
replication	I-PROC
by	O
CD4	O
(+)	O
T	O
cells	O
requires	O
IFN	O
-	O
gamma	O
.	O

Indications	O
were	O
severe	O
postresectional	O
and	O
unresponsive	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
hemodynamic	B-PROC
stability	O
,	O
and	O
no	O
significant	O
peripheral	O
arterial	O
occlusive	O
disease	O
or	O
heparin	O
-	O
induced	O
thrombocytopenia	O
.	O

In	O
addition	O
,	O
our	O
studies	O
indicate	O
that	O
the	O
nuclear	O
localization	B-PROC
of	O
N	O
is	O
essential	O
for	O
its	O
caspase	O
-	O
6	O
-	O
mediated	O
cleavage	B-PROC
.	O

ABSTRACT	O
:	O
Febrile	B-PROC
respiratory	O
illnesses	O
with	O
respiratory	O
failure	O
are	O
one	O
of	O
the	O
most	O
common	O
reasons	O
for	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
.	O

All	O
five	O
patients	O
who	O
required	O
invasive	O
ventilation	O
and	O
all	O
four	O
patients	O
who	O
died	B-PROC
during	O
the	O
immediate	O
hospital	O
course	O
had	O
jet	O
velocity	O
values	O
of	O
3	O
m	O
/	O
second	O
or	O
greater	O
.	O

At	O
the	O
first	O
ARI	O
with	O
cough	O
or	O
wheeze	O
,	O
we	O
analyzed	O
nasal	O
swabs	O
by	O
sensitive	O
individual	O
real	O
time	O
polymerase	O
chain	O
reaction	O
assays	O
targeting	B-PROC
16	O
different	O
respiratory	O
viruses	O
.	O

vaccination	O
,	O
but	O
the	O
local	O
humoral	B-PROC
immune	I-PROC
response	I-PROC
was	O
much	O
stronger	O
;	O
2	O
)	O
the	O
i	O
.	O
n	O
.	O

By	O
using	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
BCoV	O
RNA	O
was	O
detected	O
in	O
all	O
outbreaks	O
without	O
evidence	O
of	O
concurrent	O
viral	O
pathogens	O
(	O
i	O
.	O
e	O
.,	O
bovine	O
respiratory	O
syncytial	O
virus	O
,	O
bovine	O
herpesvirus	O
type	O
1	O
,	O
bovine	O
viral	O
diarrhea	O
virus	O
,	O
bovine	O
parainfluenza	O
virus	O
).	O

SPEF	O
contains	O
condition	O
-	O
specific	O
nutrients	O
to	O
modulate	O
the	O
inflammatory	B-PROC
response	I-PROC
.	O

To	O
understand	O
the	O
role	O
of	O
the	O
conserved	O
residues	O
and	O
the	O
necessity	O
of	O
palmitoylation	B-PROC
,	O
three	O
cysteines	O
at	O
positions	O
40	O
,	O
44	O
,	O
and	O
47	O
were	O
changed	O
singly	O
and	O
in	O
various	O
combinations	O
to	O
alanine	O
.	O

Single	O
-	O
substitution	O
viruses	O
exhibited	O
growth	B-PROC
characteristics	O
virtually	O
identical	O
to	O
those	O
of	O
the	O
wild	O
-	O
type	O
virus	O
,	O
while	O
the	O
double	O
-	O
substitution	O
mutations	O
gave	O
rise	O
to	O
viruses	O
with	O
less	O
robust	O
growth	B-PROC
phenotypes	O
indicated	O
by	O
smaller	O
plaques	O
and	O
decreased	O
virus	O
yields	O
.	O

Studies	O
in	O
the	O
populations	O
of	O
Hong	O
Kong	O
and	O
Taiwan	O
showed	O
an	O
association	O
of	O
human	O
leucocyte	O
antigen	O
(	O
HLA	O
)	O
polymorphisms	B-PROC
with	O
the	O
development	B-PROC
and	O
/	O
or	O
severity	O
of	O
SARS	O
,	O
respectively	O
.	O

The	O
same	O
groups	O
of	O
mice	O
had	O
high	O
levels	O
of	O
SCoV	O
-	O
specific	O
neutralizing	O
antibodies	O
,	O
while	O
mice	O
in	O
the	O
negative	O
control	O
groups	O
,	O
which	O
were	O
not	O
immunized	O
with	O
chimeric	O
VLPs	O
,	O
failed	O
to	O
manifest	O
neutralizing	O
antibodies	O
,	O
suggesting	O
that	O
SCoV	O
-	O
specific	O
neutralizing	O
antibodies	O
are	O
important	O
for	O
the	O
suppression	B-PROC
of	O
viral	B-PROC
replication	I-PROC
within	O
the	O
lungs	O
.	O

When	O
the	O
patient	O
was	O
re	O
-	O
exposed	O
to	O
amoxapine	O
(	O
52	O
.	O
5	O
mg	O
total	O
dose	O
),	O
high	O
fever	B-PROC
,	O
reduced	O
SaO	O
(	O
2	O
)	O
and	O
pulmonary	O
infiltrates	O
reappeared	O
.	O

Seventy	O
percent	O
of	O
these	O
patients	O
had	O
transient	O
impairment	O
of	O
liver	B-PROC
function	I-PROC
,	O
which	O
did	O
not	O
correlate	O
to	O
disease	O
severity	O
.	O

CONCLUSIONS	O
:	O
A	O
proper	O
ventilation	O
strategy	O
,	O
early	O
pharmacologic	O
therapy	O
including	O
glucocorticoids	O
,	O
and	O
complication	O
prevention	O
may	O
contribute	O
to	O
good	O
treatment	O
outcomes	O
after	O
white	O
smoke	O
inhalation	B-PROC
.	O

ABSTRACT	O
:	O
Two	O
years	O
after	O
the	O
SARS	O
outbreak	O
in	O
Hong	O
Kong	O
,	O
128	O
healthcare	O
workers	O
continued	O
to	O
present	O
with	O
musculoskeletal	O
complaints	O
and	O
38	O
workers	O
were	O
diagnosed	O
with	O
avascular	O
necrosis	B-PROC
(	O
AVN	O
)	O
in	O
different	O
joints	O
.	O

Both	O
S227	O
.	O
14	O
and	O
S230	O
.	O
15	O
completely	O
protected	O
young	O
and	O
old	O
mice	O
from	O
weight	O
loss	O
and	O
virus	B-PROC
replication	I-PROC
in	O
the	O
lungs	O
for	O
all	O
viruses	O
tested	O
,	O
while	O
S109	O
.	O
8	O
completely	O
protected	O
mice	O
from	O
weight	O
loss	O
and	O
clinical	O
signs	O
in	O
the	O
presence	O
of	O
viral	O
titers	O
.	O

A	O
reporter	O
gene	O
encoding	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
was	O
inserted	O
into	O
one	O
segment	O
,	O
and	O
a	O
red	O
fluorescent	O
protein	O
dsRed	O
gene	O
was	O
inserted	O
into	O
the	O
other	O
segment	O
in	O
order	O
to	O
easily	O
detect	O
the	O
replication	O
and	O
transcription	B-PROC
of	O
segments	O
in	O
infected	O
cells	O
.	O

Expression	B-PROC
of	O
Class	O
I	O
on	O
microglia	O
,	O
but	O
not	O
oligodendroglia	O
,	O
in	O
infected	O
IFN	O
gamma	O
deficient	O
mice	O
supported	O
distinct	O
IFN	O
requirements	O
for	O
Class	O
I	O
presentation	O
.	O

TITLE	O
:	O
Molecular	O
epidemiology	O
and	O
evolution	B-PROC
of	O
avian	O
infectious	O
bronchitis	O
virus	O
in	O
Spain	O
over	O
a	O
fourteen	O
-	O
year	O
period	O
.	O

The	O
aetiological	O
agent	O
was	O
originally	O
defined	O
as	O
a	O
novel	O
coronavirus	O
and	O
later	O
designated	O
as	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
which	O
appears	O
similar	O
to	O
other	O
coronaviruses	O
in	O
both	O
virion	O
structure	O
and	O
genome	O
organization	O
with	O
a	O
single	O
-	O
stranded	O
,	O
plus	O
-	O
sense	B-PROC
RNA	O
.	O

However	O
,	O
the	O
epidemiology	O
and	O
pathogenesis	B-PROC
of	O
SARS	O
remain	O
poorly	O
understood	O
and	O
there	O
is	O
currently	O
no	O
effective	O
treatment	O
.	O

The	O
best	O
available	O
evidence	O
comes	O
from	O
large	O
retrospective	O
or	O
observational	O
studies	O
which	O
suggest	O
a	O
causal	O
relation	O
between	O
the	O
use	O
of	O
large	O
tidal	O
volumes	O
and	O
the	O
development	B-PROC
of	O
lung	O
injury	O
.	O

It	O
was	O
noted	O
that	O
in	O
cells	O
infected	O
with	O
coronavirus	O
,	O
transcription	B-PROC
and	O
translation	B-PROC
of	O
some	O
of	O
these	O
genes	O
were	O
differentially	O
induced	O
.	O

However	O
,	O
induction	O
of	O
the	O
same	O
genes	O
at	O
the	O
translational	B-PROC
level	O
was	O
usually	O
found	O
to	O
be	O
minimal	O
to	O
moderate	O
.	O

Five	O
infants	O
(	O
21	O
.	O
7	O
%)	O
improved	O
their	O
oxygenation	B-PROC
parameters	O
under	O
conventional	O
mechanical	O
ventilation	O
(	O
CMV	O
)	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
p	O
=	O
0	O
.	O
002	O
et	O
p	O
=	O
0	O
.	O
003	O
respectively	O
for	O
D	O
(	O
A	O
-	O
a	O
)	O
O2	O
,	O
OI	O
and	O
PaO2	O
/	O
FiO2	O
).	O

This	O
is	O
because	O
the	O
post	O
-	O
translation	B-PROC
modification	O
is	O
a	O
host	O
function	O
.	O

TITLE	O
:	O
Equine	O
coronavirus	O
induces	O
apoptosis	B-PROC
in	O
cultured	O
cells	O
.	O

Although	O
IBV	O
has	O
been	O
indicated	O
as	O
a	O
possible	O
cause	O
of	O
the	O
formation	B-PROC
of	O
calcium	O
stones	O
in	O
the	O
epididymus	O
of	O
roosters	O
,	O
a	O
definitive	O
association	O
has	O
not	O
been	O
confirmed	O
.	O

ABSTRACT	O
:	O
The	O
potential	O
for	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
)	O
replication	O
interference	O
was	O
evaluated	O
using	O
quantitative	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
).	O

In	O
contrast	O
,	O
the	O
replication	O
of	O
IBV	O
strains	O
Mass	O
and	O
Ark	O
interfered	O
with	O
the	O
growth	B-PROC
of	O
NDV	O
strains	O
B1	O
,	O
VG	O
/	O
GA	O
,	O
and	O
C2	O
as	O
measured	O
by	O
qRT	O
-	O
PCR	O
.	O

Some	O
regional	O
differences	O
were	O
noted	O
;	O
Europeans	O
were	O
more	O
likely	O
than	O
Asians	O
to	O
avoid	O
places	O
of	O
entertainment	O
,	O
and	O
Asians	O
were	O
more	O
likely	O
to	O
avoid	O
seeing	B-PROC
physicians	O
.	O

TITLE	O
:	O
The	O
SARS	O
-	O
Coronavirus	O
PLnc	O
domain	O
of	O
nsp3	O
as	O
a	O
replication	O
/	O
transcription	B-PROC
scaffolding	O
protein	O
.	O

The	O
coronavirus	O
replication	O
/	O
transcription	B-PROC
complex	O
is	O
an	O
assembly	O
of	O
viral	O
and	O
,	O
most	O
probably	O
,	O
cellular	O
proteins	O
that	O
mediate	O
the	O
synthesis	B-PROC
of	O
both	O
the	O
unusually	O
large	O
(	O
approximately	O
30	O
kb	O
)	O
RNA	O
genome	O
and	O
an	O
extensive	O
set	O
of	O
subgenomic	O
mRNAs	O
.	O

The	O
MLPA	O
reaction	O
is	O
preceded	O
by	O
a	O
preamplification	O
step	O
which	O
ensures	O
the	O
detection	O
of	O
both	O
RNA	O
and	O
DNA	O
viruses	O
with	O
the	O
same	O
specificity	O
and	O
sensitivity	O
as	O
individual	O
monoplex	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
-	O
PCRs	O
.	O

We	O
examined	O
the	O
evolutionary	O
relationships	O
between	O
bat	O
CoVs	O
and	O
their	O
hosts	O
by	O
using	O
sequence	O
data	O
of	O
the	O
virus	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
gene	O
and	O
the	O
bat	O
cytochrome	B-PROC
b	O
gene	O
.	O

These	O
shifts	O
may	O
be	O
due	O
to	O
either	O
virus	O
biologic	O
traits	O
or	O
host	O
behavioral	B-PROC
traits	O
.	O

TITLE	O
:	O
Duration	O
of	O
antibody	B-PROC
responses	I-PROC
after	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
Among	O
176	O
patients	O
who	O
had	O
had	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
SARS	O
-	O
specific	O
antibodies	O
were	O
maintained	O
for	O
an	O
average	O
of	O
2	O
years	O
,	O
and	O
significant	O
reduction	O
of	O
immunoglobulin	B-PROC
G	O
-	O
positive	O
percentage	O
and	O
titers	O
occurred	O
in	O
the	O
third	O
year	O
.	O

The	O
emergence	O
of	O
antimicrobial	O
drug	B-PROC
resistance	B-PROC
among	O
bacterial	O
pathogens	O
,	O
the	O
reemergence	O
of	O
tuberculosis	O
,	O
the	O
entrance	O
of	O
HIV	O
into	O
Arctic	O
communities	O
,	O
and	O
the	O
spectre	O
of	O
pandemic	O
influenza	O
or	O
the	O
sudden	O
emergence	O
and	O
introduction	O
of	O
new	O
viral	O
pathogens	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
are	O
of	O
increasing	O
concern	O
to	O
residents	O
,	O
governments	O
,	O
and	O
public	O
health	O
authorities	O
.	O

In	O
this	O
review	O
,	O
the	O
significance	O
of	O
the	O
latter	O
findings	O
are	O
explored	O
,	O
and	O
the	O
possible	O
involvement	O
of	O
anti	O
-	O
IL	O
-	O
8	O
autoantibody	O
:	O
IL	O
-	O
8	O
immune	O
complexes	O
in	O
pathogenesis	B-PROC
of	O
ALI	O
/	O
ARDS	O
is	O
discussed	O
.	O

Severity	O
of	O
lymphocytic	O
bronchiolitis	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
BOS	O
and	O
death	B-PROC
after	O
lung	O
transplantation	O
independent	O
of	O
acute	O
vascular	O
rejection	O
.	O

In	O
patients	O
who	O
survive	O
the	O
acute	O
injury	O
the	O
process	O
of	O
repair	B-PROC
and	O
remodelling	O
may	O
be	O
an	O
independent	O
risk	O
factor	O
determining	O
morbidity	O
and	O
mortality	O
.	O

Viral	O
gene	B-PROC
expression	I-PROC
and	O
viral	O
particle	O
production	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)-	O
deficient	O
and	O
G6PD	O
-	O
knockdown	O
cells	O
were	O
much	O
higher	O
than	O
their	O
counterparts	O
when	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
229E	O
was	O
applied	O
at	O
0	O
.	O
1	O
multiplicity	O
of	O
infection	O
.	O

Use	O
of	O
inhaled	B-PROC
nitric	O
oxide	O
in	O
patients	O
with	O
severe	O
traumatic	O
brain	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
will	O
show	O
a	O
benefit	O
through	O
improved	O
physiological	O
parameters	O
,	O
a	O
decrease	O
in	O
biochemical	O
markers	O
of	O
inflammation	O
and	O
brain	O
injury	O
,	O
thus	O
leading	O
to	O
better	O
outcomes	O
.	O

Inhaled	B-PROC
nitric	O
oxide	O
therapy	O
in	O
traumatic	O
brain	O
injury	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
could	O
result	O
in	O
increased	O
numbers	O
of	O
lives	O
saved	O
,	O
decreased	O
patient	O
morbidity	O
,	O
decreased	O
hospital	O
costs	O
,	O
decreased	O
insurance	O
carrier	O
and	O
government	O
rehabilitation	O
costs	O
,	O
increased	O
tax	O
revenue	O
secondary	O
to	O
occupational	O
rehabilitation	O
,	O
and	O
families	O
could	O
still	O
have	O
their	O
loved	O
ones	O
among	O
them	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
(	O
CoV	O
)	O
transcription	B-PROC
includes	O
a	O
discontinuous	O
mechanism	O
during	O
the	O
synthesis	B-PROC
of	O
sub	O
-	O
genome	O
-	O
length	O
minus	O
-	O
strand	O
RNAs	O
leading	O
to	O
a	O
collection	O
of	O
mRNAs	O
in	O
which	O
the	O
5	O
'	O
terminal	O
leader	O
sequence	O
is	O
fused	O
to	O
contiguous	O
genome	O
sequences	O
.	O

Base	O
pairing	O
between	O
the	O
leader	O
TRS	O
(	O
TRS	O
-	O
L	O
)	O
and	O
the	O
complement	O
of	O
the	O
body	O
TRS	O
(	O
cTRS	O
-	O
B	O
)	O
in	O
the	O
nascent	O
RNA	O
is	O
a	O
determinant	O
factor	O
during	O
CoV	O
transcription	B-PROC
.	O

We	O
postulated	O
that	O
additional	O
factors	O
should	O
regulate	O
transcription	B-PROC
of	O
sg	O
mRNA	O
N	O
.	O
In	O
this	O
report	O
,	O
we	O
have	O
described	O
a	O
novel	O
transcription	B-PROC
regulation	I-PROC
mechanism	O
operating	O
in	O
CoV	O
by	O
which	O
a	O
9	O
-	O
nucleotide	O
(	O
nt	O
)	O
sequence	O
located	O
449	O
nt	O
upstream	O
of	O
the	O
N	O
gene	O
TRS	O
core	O
sequence	O
(	O
CS	O
-	O
N	O
)	O
interacts	O
with	O
a	O
complementary	O
sequence	O
just	O
upstream	O
of	O
CS	O
-	O
N	O
,	O
specifically	O
increasing	O
the	O
accumulation	O
of	O
sg	O
mRNA	O
N	O
.	O
Alteration	O
of	O
this	O
complementarity	O
in	O
mutant	O
replicon	O
genomes	O
showed	O
a	O
correlation	O
between	O
the	O
predicted	O
stability	O
of	O
the	O
base	O
pairing	O
between	O
9	O
-	O
nt	O
sequences	O
and	O
the	O
accumulation	O
of	O
sg	O
mRNA	O
N	O
.	O
This	O
interaction	O
is	O
exclusively	O
conserved	O
in	O
group	O
1a	O
CoVs	O
,	O
the	O
only	O
CoV	O
subgroup	O
in	O
which	O
the	O
N	O
gene	O
is	O
not	O
the	O
most	O
3	O
'	O
gene	O
in	O
the	O
viral	O
genome	O
.	O

We	O
found	O
that	O
the	O
diverging	O
political	O
interests	O
and	O
entrenched	O
administrative	O
practices	O
accounted	O
for	O
the	O
poor	O
coordination	B-PROC
between	O
and	O
within	O
these	O
players	O
.	O

A	O
Logistic	O
regression	O
model	O
was	O
applied	O
to	O
investigate	O
the	O
outcome	O
variables	O
:	O
death	B-PROC
,	O
complications	O
,	O
subsequent	O
lung	O
infection	O
and	O
other	O
infections	O
and	O
COX	O
regression	O
was	O
made	O
.	O

While	O
the	O
upper	O
region	O
of	O
SL1	O
is	O
required	O
to	O
be	O
paired	O
,	O
we	O
observe	O
strong	O
genetic	B-PROC
selection	I-PROC
against	O
viruses	O
that	O
contain	O
a	O
deletion	O
of	O
A35	O
,	O
an	O
extrahelical	O
nucleotide	O
that	O
destabilizes	O
SL1	O
,	O
in	O
favor	O
of	O
genomes	O
that	O
contain	O
a	O
diverse	O
panel	O
of	O
destabilizing	O
second	O
-	O
site	O
mutations	O
,	O
due	O
to	O
introduction	O
of	O
a	O
noncanonical	O
base	O
pair	O
near	O
A35	O
.	O

ABSTRACT	O
:	O
Development	B-PROC
of	O
vaccines	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
crucial	O
in	O
the	O
prevention	O
of	O
SARS	O
reemergence	O
.	O

The	O
data	O
highlight	O
that	O
(	O
i	O
)	O
RSV	O
has	O
a	O
central	O
role	O
as	O
a	O
respiratory	O
pathogen	O
of	O
infants	O
,	O
(	O
ii	O
)	O
the	O
wide	O
circulation	B-PROC
of	O
recently	O
identified	O
viruses	O
does	O
not	O
reduce	O
the	O
clinical	O
and	O
epidemiological	O
importance	O
of	O
RSV	O
,	O
and	O
that	O
(	O
iii	O
)	O
recently	O
identified	O
agents	O
(	O
hMPVs	O
,	O
hBoVs	O
,	O
and	O
hCoVs	O
)	O
act	O
as	O
primary	O
pathogens	O
or	O
co	O
-	O
pathogens	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
implicates	O
viral	B-PROC
infections	I-PROC
as	O
a	O
major	O
risk	O
factor	O
for	O
exacerbations	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

Rhinovirus	O
,	O
the	O
organism	O
most	O
often	O
responsible	O
for	O
causing	O
the	O
common	O
cold	B-PROC
,	O
is	O
also	O
the	O
most	O
common	O
infectious	O
cause	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
exacerbations	O
.	O

The	O
use	O
of	O
biomarkers	O
represents	O
an	O
exciting	O
new	O
potential	O
diagnostic	O
tool	O
that	O
may	O
lend	O
new	O
insights	O
into	O
the	O
pathogenesis	B-PROC
of	O
viral	B-PROC
infections	I-PROC
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

ABSTRACT	O
:	O
During	O
coronavirus	O
replication	O
,	O
viral	O
proteins	O
induce	O
the	O
formation	B-PROC
of	O
endoplasmic	O
reticulum	O
(	O
ER	O
)-	O
derived	O
double	O
-	O
membrane	O
vesicles	O
for	O
RNA	B-PROC
synthesis	I-PROC
,	O
and	O
viral	O
structural	O
proteins	O
assemble	O
virions	O
at	O
the	O
ER	O
-	O
Golgi	O
intermediate	O
compartment	O
.	O

We	O
hypothesized	O
that	O
the	O
association	O
and	O
intense	O
utilization	O
of	O
the	O
ER	O
during	O
viral	B-PROC
replication	I-PROC
would	O
induce	O
the	O
cellular	O
unfolded	O
protein	O
response	O
(	O
UPR	O
),	O
a	O
signal	B-PROC
transduction	I-PROC
cascade	O
that	O
acts	O
to	O
modulate	O
translation	B-PROC
,	O
membrane	O
biosynthesis	B-PROC
,	O
and	O
the	O
levels	O
of	O
ER	O
chaperones	O
.	O

Armored	O
L	O
-	O
RNA	O
is	O
a	O
complex	O
of	O
MS2	O
bacteriophage	O
coat	O
protein	O
and	O
RNA	O
produced	O
in	O
Escherichia	O
coli	O
by	O
the	O
induction	O
of	O
a	O
two	O
-	O
plasmid	O
coexpression	O
system	O
in	O
which	O
the	O
coat	O
protein	O
and	O
maturase	O
are	O
expressed	B-PROC
from	O
one	O
plasmid	O
and	O
the	O
target	O
RNA	O
sequence	O
with	O
modified	O
MS2	O
stem	O
-	O
loop	O
(	O
pac	O
site	O
)	O
is	O
transcribed	O
from	O
another	O
plasmid	O
.	O

A	O
3V	O
armored	O
L	O
-	O
RNA	O
of	O
2	O
,	O
248	O
bases	O
containing	O
six	O
gene	O
fragments	O
-	O
hepatitis	O
C	O
virus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV1	O
,	O
SARS	O
-	O
CoV2	O
,	O
and	O
SARS	O
-	O
CoV3	O
),	O
avian	O
influenza	O
virus	O
matrix	O
gene	O
(	O
M300	O
),	O
and	O
H5N1	O
avian	O
influenza	O
virus	O
(	O
HA300	O
)-	O
was	O
successfully	O
expressed	B-PROC
by	O
the	O
two	O
-	O
plasmid	O
coexpression	O
system	O
and	O
was	O
demonstrated	O
to	O
have	O
all	O
of	O
the	O
characteristics	O
of	O
armored	O
RNA	O
.	O

In	O
conclusion	O
,	O
the	O
approach	O
we	O
used	O
for	O
armored	O
L	O
-	O
RNA	O
preparation	O
is	O
practical	O
and	O
could	O
reduce	O
the	O
labor	B-PROC
and	O
cost	O
of	O
quality	O
control	O
in	O
multiplex	O
RNA	O
virus	O
assays	O
.	O

Six	O
days	O
before	O
the	O
operation	O
,	O
he	O
had	O
a	O
high	O
-	O
grade	O
fever	B-PROC
,	O
and	O
elevated	O
leukocyte	O
count	O
and	O
C	O
-	O
reactive	O
protein	O
concentration	O
,	O
but	O
this	O
was	O
resolved	O
by	O
an	O
intravenous	O
antibiotic	O
.	O

The	O
association	O
between	O
genetic	B-PROC
polymorphisms	I-PROC
of	O
TNF	O
-	O
alpha	O
gene	O
and	O
susceptibility	O
to	O
severe	O
acute	O
respiratory	O
syndromes	O
(	O
SARS	O
)	O
was	O
conducted	O
in	O
a	O
hospital	O
-	O
based	O
case	O
-	O
control	O
study	O
including	O
75	O
SARS	O
patients	O
,	O
41	O
health	O
care	O
workers	O
and	O
92	O
healthy	O
controls	O
.	O

PCR	O
sequencing	O
based	O
typing	O
(	O
PCR	O
-	O
SBT	O
)	O
method	O
was	O
used	O
to	O
determine	O
the	O
polymorphisms	B-PROC
of	O
TNF	O
-	O
alpha	O
gene	O
in	O
locus	O
of	O
the	O
promoter	O
region	O
and	O
univariate	O
logistic	O
analysis	O
was	O
conducted	O
in	O
analyzing	O
the	O
collected	O
data	O
.	O

Also	O
,	O
TT	O
genotype	O
,	O
CT	O
and	O
CC	O
were	O
found	O
associated	O
with	O
a	O
risk	O
effect	O
on	O
femoral	O
head	O
necrosis	B-PROC
with	O
ORs	O
(	O
95	O
%	O
CI	O
)	O
of	O
5	O
.	O
33	O
(	O
1	O
.	O
39	O
-	O
20	O
.	O
45	O
)	O
and	O
5	O
.	O
67	O
(	O
2	O
.	O
74	O
-	O
11	O
.	O
71	O
),	O
respectively	O
and	O
the	O
glucocorticoid	O
adjusted	O
OR	O
of	O
CT	O
was	O
5	O
.	O
25	O
(	O
95	O
%	O
CI	O
1	O
.	O
18	O
-	O
23	O
.	O
46	O
)	O
and	O
the	O
combined	O
(	O
CT	O
and	O
CC	O
)	O
genotype	O
OR	O
was	O
6	O
.	O
0	O
(	O
95	O
%	O
CI	O
1	O
.	O
60	O
-	O
22	O
.	O
55	O
)	O
at	O
-	O
1031	O
site	O
of	O
TNF	O
-	O
alpha	O
gene	O
.	O

However	O
,	O
the	O
-	O
1031CT	O
/	O
CC	O
and	O
-	O
863	O
AC	O
genotypes	O
may	O
be	O
risk	O
factors	O
of	O
femoral	O
head	O
necrosis	B-PROC
in	O
discharged	O
SARS	O
patients	O
.	O

ABSTRACT	O
:	O
Amiodarone	O
interferes	O
with	O
the	O
endocytic	O
pathway	B-PROC
,	O
inhibits	O
proteolysis	B-PROC
,	O
and	O
causes	O
the	O
formation	B-PROC
of	O
vacuoles	O
,	O
but	O
uptake	O
and	O
intracellular	O
distribution	O
of	O
the	O
drug	O
,	O
origin	O
of	O
vacuoles	O
,	O
and	O
functional	O
consequences	O
of	O
amiodarone	O
accumulation	O
remain	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
hypothesized	O
that	O
a	O
parenteral	O
formulation	O
of	O
H2S	O
would	O
reduce	O
the	O
lung	O
injury	O
induced	O
by	O
burn	O
and	O
smoke	O
inhalation	B-PROC
in	O
a	O
novel	O
murine	O
model	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
suggest	O
that	O
H2S	O
exerts	B-PROC
protective	O
effects	O
in	O
acute	O
lung	O
injury	O
,	O
at	O
least	O
in	O
part	O
through	O
the	O
activation	O
of	O
anti	O
-	O
inflammatory	O
and	O
antioxidant	O
pathways	B-PROC
.	O

ABSTRACT	O
:	O
Molecular	B-PROC
mimicry	I-PROC
,	O
defined	O
as	O
similar	O
structures	O
shared	O
by	O
molecules	O
from	O
dissimilar	O
genes	O
or	O
proteins	O
,	O
is	O
a	O
general	O
strategy	O
used	O
by	O
pathogens	O
to	O
infect	O
host	O
cells	O
.	O

However	O
,	O
repetitive	O
administration	O
of	O
endotoxin	O
can	O
cause	O
tolerance	B-PROC
.	O

ABSTRACT	O
:	O
Ovarian	O
hyperstimulation	O
syndrome	O
(	O
OHSS	O
)	O
is	O
an	O
iatrogenic	O
complication	O
,	O
the	O
basis	O
for	O
which	O
is	O
a	O
hyperergic	O
uncontrolled	O
ovarian	O
response	O
to	O
gonadotropins	O
in	O
the	O
ovulation	B-PROC
stimulation	O
cycles	O
and	O
assisted	O
procreation	B-PROC
programs	O
.	O

Therapies	O
in	O
patients	O
with	O
sepsis	O
have	O
specifically	O
focused	O
on	O
coagulation	B-PROC
disturbances	O
.	O

Evidence	O
from	O
preclinical	O
and	O
clinical	O
investigations	O
suggests	O
pharmacologically	O
targeting	B-PROC
pulmonary	O
""""	O
coagulopathy	O
""""	O
could	O
be	O
of	O
benefit	O
to	O
patients	O
with	O
ALI	O
/	O
ARDS	O
as	O
well	O
.	O

NK	O
cells	O
are	O
recruited	O
normally	O
in	O
the	O
liver	O
and	O
produce	O
interferon	O
(	O
IFN	O
)-	O
gamma	O
to	O
control	O
viral	B-PROC
replication	I-PROC
.	O

ABSTRACT	O
:	O
During	O
several	O
months	O
of	O
2002	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
caused	O
by	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spread	O
rapidly	O
from	O
China	O
throughout	O
the	O
world	O
causing	O
more	O
than	O
800	O
deaths	B-PROC
due	O
to	O
the	O
development	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ACE	O
cleaves	O
angiotensin	O
I	O
to	O
generate	O
angiotensin	O
II	O
that	O
is	O
a	O
key	O
effector	O
peptide	O
of	O
the	O
system	O
and	O
exerts	B-PROC
multiple	O
biological	O
functions	O
,	O
whereas	O
ACE2	O
reduces	O
angiotensin	O
II	O
levels	O
and	O
thus	O
is	O
a	O
negative	O
regulator	O
of	O
the	O
system	O
.	O

TITLE	O
:	O
Na	O
,	O
K	O
-	O
ATPase	O
expression	B-PROC
is	O
increased	O
in	O
the	O
lungs	O
of	O
alcohol	O
-	O
fed	O
rats	O
.	O

TITLE	O
:	O
Structural	O
,	O
biochemical	O
,	O
and	O
in	O
vivo	O
characterization	O
of	O
the	O
first	O
virally	O
encoded	O
cyclophilin	B-PROC
from	O
the	O
Mimivirus	O
.	O

To	O
help	O
elucidate	O
these	O
roles	O
,	O
we	O
have	O
characterized	O
the	O
first	O
virally	O
encoded	O
cyclophilin	B-PROC
(	O
mimicyp	O
)	O
derived	O
from	O
the	O
largest	O
virus	O
discovered	O
to	O
date	O
(	O
the	O
Mimivirus	O
)	O
that	O
is	O
also	O
a	O
causative	O
agent	O
of	O
pneumonia	O
in	O
humans	O
.	O

No	O
significant	O
temporal	O
trends	O
in	O
IL	O
-	O
10	O
,	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
,	O
transforming	O
growth	B-PROC
factor	O
-	O
beta1	O
,	O
sFasL	O
,	O
or	O
complement	O
factor	O
5a	O
were	O
found	O
.	O

TITLE	O
:	O
Effects	O
of	O
different	O
immunization	O
protocols	O
and	O
adjuvant	O
on	O
antibody	B-PROC
responses	I-PROC
to	O
inactivated	O
SARS	O
-	O
CoV	O
vaccine	O
.	O

L	O
.	O
nobilis	O
oil	O
exerted	B-PROC
an	O
interesting	O
activity	O
against	O
SARS	O
-	O
CoV	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
120	O
microg	O
/	O
ml	O
and	O
a	O
selectivity	O
index	O
(	O
SI	O
)	O
of	O
4	O
.	O
16	O
.	O

Lower	O
levels	O
of	O
protein	O
C	O
were	O
independently	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	B-PROC
(	O
odds	O
ratio	O
=	O
0	O
.	O
5	O
),	O
a	O
result	O
that	O
nearly	O
reached	O
statistical	O
significance	O
(	O
P	O
=	O
0	O
.	O
06	O
).	O

TITLE	O
:	O
[	O
Detection	O
of	O
the	O
mRNA	B-PROC
expression	B-PROC
of	O
human	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
as	O
a	O
SARS	O
coronavirus	O
functional	O
receptor	O
in	O
human	O
femoral	O
head	O
].	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
mRNA	B-PROC
expression	B-PROC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
COV	O
)	O
functional	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
in	O
human	O
femoral	O
head	O
and	O
conjunctiva	O
,	O
and	O
explore	O
the	O
possible	O
entry	O
route	O
of	O
SARS	O
-	O
COV	O
in	O
human	O
femoral	O
head	O
.	O

The	O
mRNA	O
of	O
human	O
ACE2	O
was	O
expressed	B-PROC
efficiently	O
in	O
the	O
normal	O
lung	O
tissue	O
,	O
but	O
not	O
in	O
the	O
cartilage	O
and	O
cancellous	O
bone	O
under	O
the	O
weight	O
-	O
bearing	O
area	O
of	O
the	O
femoral	O
head	O
.	O

The	O
mRNA	O
of	O
human	O
ACE2	O
was	O
expressed	B-PROC
efficiently	O
in	O
the	O
normal	O
lung	O
tissue	O
,	O
but	O
not	O
in	O
the	O
cartilage	O
and	O
cancellous	O
bone	O
under	O
the	O
weight	O
-	O
bearing	O
area	O
of	O
the	O
femoral	O
head	O
.	O

A	O
nasal	O
swab	O
was	O
taken	O
for	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
PCR	O
for	O
hMPV	O
,	O
HCoV	O
NL63	O
and	O
HBoV	O
;	O
when	O
positive	O
,	O
the	O
genes	O
were	O
sequenced	O
.	O

In	O
addition	O
to	O
the	O
toxicities	O
of	O
carbon	O
monoxide	O
,	O
concomitant	O
inhalation	B-PROC
of	O
formic	O
acid	O
fumes	O
can	O
cause	O
severe	O
lung	O
injury	O
,	O
which	O
may	O
complicate	O
the	O
management	O
of	O
carbon	O
monoxide	O
poisoning	O
.	O

This	O
results	O
in	O
a	O
positive	O
skin	O
test	O
and	O
,	O
with	O
rare	O
exception	O
,	O
lifelong	O
immunity	B-PROC
.	O

TITLE	O
:	O
Predicting	O
ribosomal	B-PROC
frameshifting	I-PROC
efficiency	O
.	O

Here	O
we	O
investigate	O
the	O
free	O
energy	O
landscape	O
for	O
a	O
minimal	O
-	O
1	O
programmed	O
ribosomal	B-PROC
frameshifting	I-PROC
machinery	O
,	O
including	O
the	O
codon	O
-	O
anticodon	O
base	O
pairs	O
at	O
the	O
slippery	O
site	O
,	O
the	O
downstream	O
messenger	O
RNA	O
structure	O
and	O
the	O
spacer	O
between	O
the	O
slippery	O
site	O
and	O
the	O
downstream	O
structure	O
.	O

The	O
free	O
energy	O
landscape	O
analysis	O
leads	O
to	O
a	O
quantitative	O
relationship	O
between	O
the	O
frameshifting	O
efficiency	O
and	O
the	O
tension	O
force	O
generated	O
during	O
the	O
movement	B-PROC
of	O
codon	O
-	O
anticodon	O
complexes	O
,	O
which	O
may	O
occur	O
in	O
the	O
A	O
/	O
T	O
to	O
A	O
/	O
A	O
accommodation	O
process	O
or	O
the	O
translocation	B-PROC
process	O
.	O

The	O
study	O
also	O
illustrates	O
the	O
capability	O
of	O
siRNA	O
to	O
enable	O
a	O
massive	O
reduction	O
in	O
development	B-PROC
time	O
for	O
novel	O
targeted	B-PROC
therapeutic	O
agents	O
.	O

Lessons	O
learned	B-PROC
from	O
the	O
emergence	O
of	O
and	O
response	O
to	O
agents	O
like	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
H5N1	O
avian	O
influenza	O
,	O
SARS	O
and	O
bovine	O
spongiform	O
encephalopathy	O
,	O
the	O
cause	O
of	O
new	O
-	O
variant	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
in	O
humans	O
,	O
must	O
be	O
used	O
to	O
create	O
better	O
plans	O
for	O
response	O
and	O
meet	O
the	O
challenge	O
for	O
public	O
health	O
and	O
biodefense	O
.	O

Oleic	O
acid	O
caused	O
systemic	O
hypotension	O
and	O
severe	O
ALI	O
as	O
evidenced	O
by	O
the	O
increases	O
in	O
the	O
extent	O
of	O
ALI	O
,	O
impairment	O
of	O
pulmonary	B-PROC
functions	I-PROC
(	O
blood	B-PROC
gas	I-PROC
variables	O
),	O
and	O
lung	O
pathology	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	B-PROC
and	O
screening	O
of	O
antisense	O
peptide	O
based	O
combinatorial	O
peptide	O
libraries	O
towards	O
an	O
aromatic	O
region	O
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
A	O
combination	O
of	O
high	O
-	O
performance	O
affinity	O
chromatography	O
and	O
antisense	O
peptide	O
based	O
combinatorial	O
peptide	O
libraries	O
was	O
used	O
to	O
screen	O
a	O
potential	O
inhibitor	O
for	O
SARS	O
-	O
CoV	O
.	O
An	O
aromatic	O
-	O
amino	O
acid	O
-	O
rich	O
region	O
within	O
the	O
transmembrane	O
domain	O
at	O
the	O
C	O
terminal	O
of	O
spike	O
(	O
S	O
)	O
protein	O
identified	O
as	O
a	O
membrane	O
-	O
active	O
region	O
was	O
chosen	O
as	O
the	O
target	O
sense	B-PROC
peptide	O
(	O
SP	O
)	O
and	O
immobilized	O
as	O
affinity	O
ligand	B-PROC
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
etiology	O
of	O
the	O
viral	O
bronchiolites	O
in	O
children	O
by	O
using	O
direct	O
immunofluorescence	O
test	O
and	O
3	O
RT	O
-	O
PCR	O
Multiplex	O
(	O
S	O
.	O
Bellau	O
-	O
Pujol	O
)	O
The	O
study	O
was	O
performed	O
on	O
122	O
nasal	O
inspirations	B-PROC
collected	O
from	O
3	O
weeks	O
-	O
6	O
month	O
old	O
children	O
hospitalizated	O
in	O
the	O
pediatrics	O
service	O
of	O
CH	O
Rouen	O
.	O

Luciferase	O
assay	O
showed	O
that	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
could	O
activate	O
the	O
transcription	B-PROC
of	O
hfgl2	O
promoter	O
compared	O
with	O
the	O
pcDNA3	O
.	O
1	O
empty	O
vector	O
.	O

The	O
results	O
showed	O
that	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
induced	O
hfgl2	O
gene	B-PROC
transcription	I-PROC
dependent	O
on	O
the	O
transcription	B-PROC
factor	O
C	O
/	O
EBP	O
alpha	O
,	O
which	O
maybe	O
contribute	O
to	O
the	O
development	B-PROC
of	O
thrombosis	O
in	O
SARS	O
.	O

ABSTRACT	O
:	O
Real	O
time	O
reverse	O
transcriptase	B-PROC
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
is	O
now	O
used	O
commonly	O
for	O
the	O
detection	O
of	O
viral	O
pathogens	O
in	O
respiratory	O
samples	O
.	O

These	O
results	O
should	O
be	O
important	O
for	O
the	O
study	O
of	O
SARS	O
-	O
CoV	O
morphogenesis	B-PROC
.	O

Neither	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
nor	O
swine	O
influenza	O
virus	O
(	O
SIV	O
)	O
was	O
detected	O
,	O
and	O
no	O
bacteria	O
could	O
be	O
cultured	O
in	O
any	O
of	O
the	O
cases	O
.	O

In	O
one	O
case	O
,	O
obliterating	O
thrombi	O
in	O
the	O
lymph	O
and	O
blood	O
vessels	O
were	O
directly	O
connected	O
to	O
areas	O
of	O
tissue	O
necrosis	B-PROC
and	O
were	O
associated	O
with	O
abundant	O
PCV2	O
antigen	O
.	O

The	O
results	O
further	O
suggest	O
the	O
causative	O
role	O
of	O
PCV2	O
infection	O
in	O
PNP	O
,	O
and	O
the	O
importance	O
of	O
the	O
vascular	O
system	O
in	O
the	O
pathogenesis	B-PROC
of	O
PCV2	O
-	O
associated	O
diseases	O
of	O
swine	O
.	O

These	O
findings	O
support	O
the	O
hypothesis	O
that	O
there	O
is	O
a	O
strong	O
,	O
'	O
systemic	O
'	O
cell	B-PROC
mediated	I-PROC
immune	I-PROC
response	I-PROC
in	O
clinically	O
normal	O
,	O
FCoV	O
-	O
infected	O
cats	O
and	O
that	O
a	O
similar	O
process	O
,	O
albeit	O
at	O
a	O
tissue	O
level	O
,	O
is	O
involved	O
in	O
the	O
pathogenesis	B-PROC
of	O
FIP	O
.	O

RESULTS	O
:	O
Virus	B-PROC
infection	I-PROC
was	O
documented	O
in	O
80	O
%	O
of	O
patients	O
with	O
croup	O
and	O
71	O
%	O
of	O
control	O
subjects	O
.	O

Long	O
-	O
standing	B-PROC
mechanical	O
ventilation	O
should	O
be	O
constrained	O
because	O
it	O
is	O
likely	O
to	O
cause	O
severe	O
refractory	O
complications	O
.	O

RESULTS	O
:	O
Of	O
the	O
22	O
patients	O
with	O
ARDS	O
caused	O
by	O
CAP	O
and	O
enrolled	O
in	O
the	O
study	O
,	O
17	O
(	O
77	O
.	O
3	O
%)	O
were	O
alive	O
14	O
days	O
after	O
admission	O
and	O
five	O
(	O
22	O
.	O
7	O
%)	O
had	O
died	B-PROC
.	O

We	O
show	O
that	O
TLR4	O
-	O
TRIF	O
-	O
TRAF6	O
signaling	B-PROC
is	O
a	O
key	O
disease	O
pathway	B-PROC
that	O
controls	O
the	O
severity	O
of	O
ALI	O
.	O

Herein	O
is	O
described	O
a	O
readily	O
quantifiable	O
novel	O
isopeptidase	O
assay	O
platform	O
consisting	O
of	O
Ub	O
or	O
UBL	O
fused	O
to	O
the	O
reporter	O
enzyme	O
phospholipase	B-PROC
A	I-PROC
(	O
2	O
)	O
(	O
PLA	O
(	O
2	O
)).	O

However	O
,	O
a	O
sustained	O
improvement	O
in	O
oxygenation	B-PROC
may	O
support	O
the	O
use	O
of	O
prone	O
positioning	O
in	O
patients	O
with	O
very	O
severe	O
hypoxemia	O
,	O
who	O
have	O
not	O
been	O
well	O
-	O
studied	O
to	O
date	O
.	O

The	O
main	O
purpose	O
of	O
this	O
review	O
is	O
to	O
summarize	O
the	O
current	O
research	O
(	O
2006	O
-	O
2007	O
)	O
concerning	O
the	O
development	B-PROC
of	O
novel	O
anticoronaviral	O
strategies	O
and	O
compounds	O
.	O

The	O
protein	O
was	O
named	O
human	O
embryo	O
lung	O
cellular	O
protein	O
interacting	O
with	O
SARS	O
-	O
CoV	O
nsp	O
-	O
10	O
(	O
HEPIS	O
),	O
and	O
it	O
is	O
composed	O
of	O
147	O
amino	O
acids	O
with	O
several	O
CK	O
II	O
phosphorylation	B-PROC
sites	O
.	O

This	O
is	O
useful	O
when	O
comparing	O
different	O
strategies	O
to	O
treat	O
severe	O
respiratory	O
insufficiency	O
,	O
optimizing	O
conventional	O
ventilation	O
,	O
improving	O
oxygenation	B-PROC
and	O
reducing	O
lung	O
injury	O
.	O

Among	O
the	O
three	O
types	O
of	O
incinerators	O
,	O
two	O
medium	O
-	O
scale	O
incinerators	O
generated	O
relatively	O
high	O
levels	O
of	O
PAHs	O
(	O
mean	O
summation	B-PROC
PAH	O
22	O
.	O
50	O
and	O
198	O
.	O
92	O
mg	O
kg	O
(-	O
1	O
))	O
compared	O
to	O
small	O
-	O
scale	O
and	O
large	O
-	O
scale	O
incinerators	O
(	O
mean	O
summation	B-PROC
PAH	O
4	O
.	O
16	O
and	O
16	O
.	O
43	O
mg	O
kg	O
(-	O
1	O
)).	O

Humoral	O
(	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
ELISA	O
)	O
and	O
cellular	O
(	O
by	O
cell	B-PROC
proliferation	I-PROC
and	O
CD4	O
(+):	O
CD8	O
(+)	O
assay	O
)	O
immunity	B-PROC
was	O
detected	O
by	O
using	O
recombinant	O
N1	O
and	O
N3	O
specific	O
antigen	O
.	O

Specific	O
humoral	O
and	O
cellular	B-PROC
immunity	I-PROC
in	O
mice	O
could	O
be	O
induced	O
significantly	O
by	O
inoculating	O
SARS	O
-	O
CoV	O
N1	O
and	O
N3	O
DNA	O
vaccine	O
.	O

In	O
a	O
parallel	O
experiment	O
,	O
we	O
employed	O
a	O
HIV	O
-	O
luc	O
/	O
SARS	O
pseudotyped	O
virus	O
entry	O
inhibition	B-PROC
assay	O
to	O
screen	O
for	O
potent	O
inhibitory	O
activities	O
on	O
HR	O
peptides	O
derived	O
from	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
HR	O
regions	O
and	O
a	O
series	O
of	O
other	O
small	O
-	O
molecule	O
drugs	O
.	O

ADS	O
-	O
J1	O
,	O
which	O
has	O
been	O
used	O
to	O
interfere	O
with	O
the	O
fusogenesis	O
of	O
HIV	O
-	O
1	O
onto	O
CD4	O
+	O
cells	O
,	O
demonstrated	O
the	O
highest	O
HIV	O
-	O
luc	O
/	O
SARS	O
pseudotyped	O
virus	O
-	O
entry	O
inhibition	B-PROC
activity	O
among	O
the	O
other	O
small	O
-	O
molecule	O
drugs	O
.	O

Increasingly	O
,	O
however	O
,	O
it	O
is	O
becoming	O
apparent	O
that	O
certain	O
pyruvate	O
esters	O
,	O
including	O
ethyl	O
pyruvate	O
,	O
have	O
pharmacological	O
effects	O
,	O
such	O
as	O
suppression	B-PROC
of	O
inflammation	O
,	O
which	O
are	O
distinct	O
from	O
those	O
exerted	B-PROC
by	O
pyruvate	O
anion	O
.	O

RESULTS	O
:	O
We	O
identified	O
92	O
patients	O
with	O
Nipah	O
virus	B-PROC
infection	I-PROC
,	O
67	O
(	O
73	O
%)	O
of	O
whom	O
died	B-PROC
.	O

Uncertainty	O
will	O
also	O
be	O
expressed	B-PROC
in	O
analysis	O
of	O
individual	O
patient	O
data	O
.	O

Protein	O
6	O
with	O
C	O
-	O
terminal	O
deletion	B-PROC
mutations	I-PROC
no	O
longer	O
interfered	O
with	O
nuclear	B-PROC
import	I-PROC
processes	O
but	O
still	O
retained	O
much	O
of	O
the	O
capacity	O
to	O
augment	O
MHV	O
infections	O
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
cleaves	O
angiotensin	O
I	O
to	O
generate	O
angiotensin	O
II	O
,	O
which	O
is	O
a	O
key	O
effector	O
peptide	O
of	O
the	O
system	O
and	O
exerts	B-PROC
multiple	O
biological	O
functions	O
,	O
whereas	O
ACE2	O
reduces	O
angiotensin	O
II	O
levels	O
.	O

TITLE	O
:	O
[	O
Late	O
respiratory	B-PROC
function	I-PROC
complications	O
following	O
burns	O
].	O

They	O
comprise	O
obstructive	O
ventilatory	O
defects	O
due	O
to	O
the	O
inhalation	B-PROC
syndrome	O
and	O
restrictive	O
defects	O
secondary	O
to	O
ARDS	O
or	O
to	O
dermal	O
injury	O
.	O

All	O
the	O
patients	O
were	O
divided	O
into	O
2	O
groups	O
,	O
the	O
death	B-PROC
group	O
and	O
the	O
survival	O
group	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
four	O
cases	O
(	O
24	O
.	O
1	O
%)	O
among	O
the	O
141	O
patients	O
died	B-PROC
.	O

Toward	O
this	O
end	O
,	O
lessons	O
learned	B-PROC
from	O
previous	O
outbreaks	O
merit	O
consideration	O
and	O
may	O
inform	O
future	O
epidemics	O
.	O

Multiplex	O
reverse	O
transcriptase	B-PROC
-	O
PCR	O
method	O
using	O
Seeplex	O
RV	O
Detection	O
kit	O
is	O
a	O
reliable	O
test	O
to	O
detect	O
rhinovirus	O
,	O
hMPV	O
,	O
and	O
coronavirus	O
.	O

A	O
novel	O
coronavirus	O
,	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
with	O
a	O
single	O
-	O
stranded	O
plus	O
sense	B-PROC
RNA	O
genome	O
,	O
was	O
promptly	O
implicated	O
as	O
the	O
causative	O
agent	O
and	O
subsequently	O
fulfilled	O
Koch	O
'	O
s	O
postulates	O
.	O

Clinical	O
and	O
general	O
laboratory	O
manifestations	O
included	O
fever	B-PROC
,	O
chills	O
,	O
rigor	O
,	O
myalgia	O
,	O
malaise	O
,	O
diarrhoea	O
,	O
cough	O
,	O
dyspnoea	O
,	O
pneumonia	O
,	O
lymphopenia	O
,	O
neutrophilia	O
,	O
thrombocytopenia	O
,	O
and	O
elevated	O
serum	O
lactate	O
dehydrogenase	O
(	O
LD	O
),	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
creatine	O
kinase	O
(	O
CK	O
)	O
activities	O
.	O

Measurement	O
of	O
biochemical	O
markers	O
of	O
bone	B-PROC
metabolism	B-PROC
demonstrated	O
significant	O
but	O
transient	O
increase	O
in	O
bone	B-PROC
resorption	B-PROC
from	O
Day	O
28	O
-	O
44	O
after	O
onset	O
of	O
fever	B-PROC
,	O
when	O
pulse	B-PROC
steroid	O
was	O
most	O
frequently	O
given	O
.	O

With	O
tapering	O
down	O
of	O
steroid	O
therapy	O
,	O
there	O
was	O
a	O
decrease	O
in	O
bone	B-PROC
resorption	B-PROC
marker	O
together	O
with	O
an	O
increase	O
in	O
bone	B-PROC
formation	I-PROC
markers	O
round	O
Day	O
50	O
,	O
suggesting	O
that	O
some	O
of	O
the	O
bone	O
loss	O
might	O
be	O
reversed	O
.	O

Although	O
SARS	O
is	O
etiologically	O
linked	O
to	O
a	O
new	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
functional	O
cell	O
receptor	O
has	O
been	O
identified	O
,	O
the	O
pathogenesis	B-PROC
of	O
the	O
virus	B-PROC
infection	I-PROC
is	O
largely	O
unclear	O
.	O

Human	O
long	O
interspersed	O
nuclear	O
element	O
1	O
(	O
LINE1	O
)	O
gene	O
endonuclease	O
(	O
EN	O
)	O
domain	O
protein	O
was	O
one	O
of	O
the	O
target	O
autoantigens	O
and	O
it	O
was	O
aberrantly	O
expressed	B-PROC
in	O
the	O
lung	O
tissue	O
of	O
SARS	O
patients	O
.	O

We	O
examined	O
whether	O
polymorphisms	B-PROC
of	O
interleukin	O
(	O
IL	O
)-	O
12	O
receptor	O
B1	O
(	O
IL	O
-	O
12RB1	O
)	O
affect	O
the	O
susceptibility	O
to	O
and	O
outcome	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

TITLE	O
:	O
[	O
Emerging	O
viral	B-PROC
infections	I-PROC
in	O
Belgium	O
and	O
abroad	O
].	O

Many	O
factors	O
,	O
some	O
changing	O
others	O
more	O
persistent	O
,	O
may	O
explain	O
the	O
high	O
appearance	O
rate	O
of	O
new	O
viral	B-PROC
infections	I-PROC
:	O
increasing	O
intercontinental	O
travel	O
,	O
globalization	O
of	O
transportation	O
,	O
increased	O
contacts	O
of	O
man	O
with	O
new	O
ecological	O
niches	O
,	O
great	O
variability	O
and	O
adaptability	O
of	O
viruses	O
,	O
climate	O
changes	O
,	O
increasing	O
density	O
of	O
populations	O
and	O
urbanisation	O
,	O
changing	O
human	O
behaviour	B-PROC
(	O
more	O
sexual	O
freedom	O
,	O
use	O
of	O
intravenous	O
drugs	O
,	O
etc	O
...),	O
changing	O
social	O
and	O
economic	O
conditions	O
,	O
which	O
influence	O
housing	O
,	O
nutrition	B-PROC
,	O
access	O
to	O
water	O
,	O
etc	O
...).	O

TITLE	O
:	O
Improved	O
microarray	O
gene	B-PROC
expression	I-PROC
profiling	O
of	O
virus	O
-	O
infected	O
cells	O
after	O
removal	O
of	O
viral	O
RNA	O
.	O

Yet	O
,	O
this	O
effect	O
has	O
not	O
been	O
investigated	O
despite	O
the	O
many	O
reports	O
that	O
describe	O
gene	B-PROC
expression	I-PROC
profiling	O
of	O
virus	O
-	O
infected	O
cells	O
using	O
microarrays	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
report	O
on	O
moderate	O
to	O
severe	O
respiratory	O
dysfunction	O
after	O
normal	O
oral	O
doses	O
of	O
quetiapine	O
in	O
two	O
obese	O
patients	O
with	O
sleep	B-PROC
apnea	O
syndrome	O
(	O
SAS	O
).	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
shown	O
that	O
the	O
brain	O
is	O
a	O
target	O
of	O
persistent	O
infection	O
with	O
bovine	O
viral	O
diarrhea	O
virus	O
(	O
BVDV	O
)	O
and	O
have	O
demonstrated	O
viral	O
tropism	B-PROC
for	O
neurons	O
as	O
well	O
as	O
other	O
endogenous	O
cell	O
types	O
in	O
diverse	O
brain	O
areas	O
.	O

Remarkably	O
,	O
the	O
virus	O
induces	O
minimal	O
cellular	B-PROC
infiltration	I-PROC
in	O
the	O
brain	O
.	O

In	O
examinations	O
of	O
the	O
longitudinal	O
serum	O
samples	O
we	O
observed	O
that	O
all	O
of	O
the	O
children	O
had	O
maternal	O
anti	O
-	O
NL63	O
and	O
anti	O
-	O
229E	O
antibodies	O
at	O
birth	B-PROC
that	O
disappeared	O
within	O
3	O
months	O
.	O

CONCLUSIONS	O
:	O
The	O
SARS	O
epidemic	O
was	O
associated	O
with	O
an	O
increase	O
in	O
older	O
adults	O
'	O
suicide	O
rate	O
in	O
April	O
2003	O
and	O
some	O
suicide	O
deaths	B-PROC
in	O
June	O
2003	O
might	O
have	O
been	O
brought	O
forward	O
.	O

Early	O
findings	O
from	O
infection	O
studies	O
and	O
use	O
of	O
inefficient	O
detection	O
methods	O
have	O
shaped	O
the	O
way	O
we	O
think	O
of	O
'	O
common	O
cold	B-PROC
'	O
viruses	O
today	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
feasibility	O
,	O
safety	O
,	O
and	O
efficacy	O
on	O
PaO	B-PROC
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
ratio	O
of	O
prone	O
positioning	O
(	O
PP	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
after	O
cardiac	O
surgery	O
.	O

PP	O
to	O
improve	O
oxygenation	B-PROC
.	O

TITLE	O
:	O
[	O
Role	O
of	O
AQP	O
-	O
4	O
in	O
pulmonary	O
water	O
metabolism	B-PROC
in	O
rats	O
in	O
early	O
stage	O
of	O
oleic	O
acid	O
-	O
induced	O
acute	O
lung	O
injury	O
].	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
capacity	O
of	O
alveolar	O
type	O
II	O
(	O
AT	O
II	O
)	O
cells	O
for	O
water	O
and	O
sodium	B-PROC
transport	B-PROC
in	O
rats	O
with	O
early	O
-	O
stage	O
oleic	O
acid	O
-	O
induced	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Microscopic	O
examination	O
and	O
blood	B-PROC
gas	I-PROC
analysis	O
indicated	O
severe	O
injury	O
of	O
the	O
lung	O
tissues	O
in	O
ALI	O
group	O
.	O

A	O
commercial	O
ELISA	O
kit	O
for	O
detecting	O
SARS	O
-	O
CoV	O
antibody	B-PROC
was	O
modified	O
for	O
detecting	O
coronavirus	O
antibodies	O
in	O
bat	O
serum	O
samples	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	B-PROC
infection	I-PROC
of	O
the	O
CNS	O
:	O
a	O
model	O
for	O
defense	O
,	O
disease	O
,	O
and	O
repair	B-PROC
.	O

A	O
programmed	O
-	O
1	O
ribosomal	B-PROC
frameshift	I-PROC
is	O
required	O
by	O
coronaviruses	O
for	O
the	O
production	O
of	O
the	O
RNA	O
dependent	O
RNA	O
polymerase	O
which	O
in	O
turn	O
is	O
essential	O
for	O
viral	B-PROC
replication	I-PROC
.	O

TITLE	O
:	O
[	O
Severe	O
case	O
of	O
Tsutsugamushi	O
disease	O
with	O
disseminated	O
intravascular	O
coagulation	B-PROC
and	O
acute	O
respiratory	O
distress	O
syndrome	O
].	O

ABSTRACT	O
:	O
Epitope	O
-	O
based	O
vaccines	O
designed	O
to	O
induce	O
antibody	B-PROC
responses	I-PROC
specific	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
are	O
being	O
developed	O
as	O
a	O
means	O
for	O
increasing	O
vaccine	O
potency	O
.	O

FECV	O
shedding	O
remained	O
at	O
high	O
levels	O
for	O
2	O
-	O
10	O
months	O
before	O
eventually	O
evolving	O
into	O
one	O
of	O
three	O
excretion	B-PROC
patterns	O
.	O

Eleven	O
cats	O
appeared	O
to	O
have	O
periods	B-PROC
of	O
virus	O
shedding	O
interlaced	O
with	O
periods	B-PROC
of	O
non	O
-	O
shedding	O
(	O
intermittent	O
or	O
recurrent	O
shedders	O
),	O
and	O
seven	O
cats	O
ceased	O
shedding	O
after	O
5	O
-	O
19	O
months	O
(	O
average	O
12	O
months	O
).	O

Compared	O
with	O
CMV	O
or	O
CMV	O
+	O
PS	O
,	O
HFOV	O
or	O
HFOV	O
+	O
PS	O
can	O
decrease	O
the	O
concentration	O
of	O
caspase	O
-	O
3	O
and	O
p73	O
,	O
reduce	O
the	O
mRNA	B-PROC
expression	B-PROC
of	O
caspase	O
-	O
3	O
and	O
p73	O
in	O
the	O
lung	O
homogenates	O
,	O
as	O
a	O
result	O
lung	O
tissue	O
apoptosis	B-PROC
in	O
inhalation	B-PROC
injury	O
may	O
be	O
suppressed	O
.	O

CONCLUSIONS	O
:	O
Compared	O
with	O
CMV	O
or	O
CMV	O
+	O
PS	O
,	O
HFOV	O
or	O
HFOV	O
+	O
PS	O
can	O
decrease	O
the	O
concentration	O
of	O
caspase	O
-	O
3	O
and	O
p73	O
,	O
reduce	O
the	O
mRNA	B-PROC
expression	B-PROC
of	O
caspase	O
-	O
3	O
and	O
p73	O
in	O
the	O
lung	O
homogenates	O
,	O
as	O
a	O
result	O
lung	O
tissue	O
apoptosis	B-PROC
in	O
inhalation	B-PROC
injury	O
may	O
be	O
suppressed	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	O
type	O
2	O
enters	O
cells	O
through	O
a	O
clathrin	O
-	O
mediated	O
endocytic	O
pathway	B-PROC
independent	O
of	O
Eps15	O
.	O

Whereas	O
the	O
structural	O
design	O
of	O
the	O
RDE	O
-	O
acetylesterase	O
domain	O
remained	O
unaltered	O
,	O
the	O
HE	O
receptor	O
-	O
binding	O
domain	O
underwent	O
remodeling	O
to	O
such	O
extent	O
that	O
the	O
ligand	B-PROC
is	O
now	O
bound	O
in	O
opposite	O
orientation	O
.	O

This	O
is	O
surprising	O
,	O
because	O
the	O
architecture	O
of	O
the	O
HEF	O
site	O
was	O
preserved	O
in	O
influenza	O
A	O
HA	O
over	O
a	O
much	O
larger	O
evolutionary	O
distance	O
,	O
a	O
switch	O
in	O
receptor	O
specificity	O
and	O
extensive	O
antigenic	B-PROC
variation	I-PROC
notwithstanding	O
.	O

Not	O
much	O
is	O
known	O
about	O
the	O
formation	B-PROC
of	O
these	O
vesicles	O
,	O
although	O
recent	O
observations	O
indicate	O
an	O
important	O
role	O
for	O
the	O
endoplasmic	O
reticulum	O
in	O
the	O
formation	B-PROC
of	O
the	O
mouse	O
hepatitis	O
coronavirus	O
(	O
MHV	O
)	O
replication	O
complexes	O
(	O
RCs	O
).	O

Immunofluorescence	O
analysis	O
and	O
quantitative	O
electron	O
microscopy	O
demonstrated	O
that	O
BFA	O
did	O
not	O
block	O
the	O
formation	B-PROC
of	O
RCs	O
per	O
se	O
,	O
but	O
rather	O
reduced	O
their	O
number	O
.	O

MHV	O
RNA	B-PROC
replication	I-PROC
was	O
not	O
sensitive	O
to	O
BFA	O
in	O
MDCK	O
cells	O
,	O
which	O
are	O
known	O
to	O
express	O
the	O
BFA	O
-	O
resistant	O
guanine	O
nucleotide	O
exchange	O
factor	O
GBF1	O
.	O

ARF1	O
,	O
the	O
cellular	O
effector	O
of	O
GBF1	O
,	O
also	O
appeared	O
to	O
be	O
involved	O
in	O
MHV	O
replication	O
,	O
as	O
siRNAs	O
targeting	B-PROC
this	O
small	O
GTPase	O
inhibited	O
MHV	O
infection	O
significantly	O
.	O

Collectively	O
,	O
our	O
results	O
demonstrate	O
that	O
GBF1	O
-	O
mediated	O
ARF1	O
activation	O
is	O
required	O
for	O
efficient	O
MHV	O
RNA	B-PROC
replication	I-PROC
and	O
reveal	O
that	O
the	O
early	O
secretory	B-PROC
pathway	I-PROC
and	O
MHV	O
replication	O
complex	O
formation	B-PROC
are	O
closely	O
connected	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
fully	O
integrated	O
microfluidic	O
system	O
for	O
sensing	O
infectious	O
viral	B-PROC
disease	I-PROC
.	O

A	O
complete	O
analytical	O
microfluidic	O
system	O
was	O
developed	O
by	O
integrating	O
various	O
functional	O
modules	O
into	O
a	O
single	O
chip	O
,	O
thus	O
allowing	O
cell	O
lysis	B-PROC
,	O
sample	O
preparation	O
,	O
purification	O
of	O
intracellular	O
molecules	O
,	O
and	O
subsequent	O
analysis	O
.	O

The	O
GBP	O
-	O
fusion	O
method	O
allows	O
immobilization	O
of	O
proteins	O
in	O
bioactive	O
forms	O
onto	O
the	O
gold	O
surface	O
without	O
surface	O
modification	O
suitable	O
for	O
studying	O
antigen	B-PROC
-	I-PROC
antibody	I-PROC
interaction	I-PROC
.	O

The	O
CoV	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)),	O
which	O
is	O
a	O
key	O
enzyme	O
in	O
viral	B-PROC
replication	I-PROC
via	O
the	O
proteolytic	B-PROC
processing	I-PROC
of	O
the	O
replicase	O
polyproteins	O
,	O
has	O
been	O
recognized	O
as	O
an	O
attractive	O
target	O
for	O
rational	O
drug	O
design	O
.	O

Combined	O
with	O
structural	O
data	O
from	O
other	O
CoV	O
M	O
(	O
pro	O
)	O
s	O
,	O
the	O
HCoV	O
-	O
HKU1	O
M	O
(	O
pro	O
)	O
structure	O
reported	O
here	O
provides	O
insights	O
into	O
both	O
substrate	O
preference	O
and	O
the	O
design	O
of	O
antivirals	O
targeting	B-PROC
CoVs	O
.	O

TITLE	O
:	O
Are	O
serum	O
cytokines	O
early	O
predictors	O
for	O
the	O
outcome	O
of	O
burn	O
patients	O
with	O
inhalation	B-PROC
injuries	O
who	O
do	O
not	O
survive	O
?	O

Cytokine	O
levels	O
were	O
profiled	O
using	O
multiplex	O
antibody	B-PROC
coated	O
beads	O
.	O

Significantly	O
altered	O
levels	O
of	O
IL	O
-	O
4	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
7	O
,	O
IL	O
-	O
10	O
,	O
and	O
IL	O
-	O
13	O
were	O
detected	O
within	O
the	O
first	O
7	O
days	O
after	O
admission	O
in	O
serum	O
from	O
burn	O
pediatric	O
patients	O
with	O
concomitant	O
inhalation	B-PROC
injury	O
who	O
did	O
not	O
survive	O
when	O
compared	O
with	O
similar	O
patients	O
who	O
did	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
vitro	O
,	O
distinct	O
signature	O
profiles	O
of	O
SeV	O
and	O
MHV	O
-	O
1	O
-	O
inducible	O
gene	B-PROC
expression	I-PROC
for	O
IFN	O
-	O
alpha2	O
,	O
IFN	O
-	O
alpha4	O
and	O
IFN	O
-	O
alpha5	O
subtypes	O
in	O
L2	O
and	O
L929	O
mouse	O
fibroblast	O
cells	O
,	O
in	O
relation	O
to	O
the	O
extent	O
and	O
kinetics	O
of	O
their	O
induction	O
,	O
were	O
identified	O
.	O

RESULTS	O
:	O
In	O
vitro	O
,	O
distinct	O
signature	O
profiles	O
of	O
SeV	O
and	O
MHV	O
-	O
1	O
-	O
inducible	O
gene	B-PROC
expression	I-PROC
for	O
IFN	O
-	O
alpha2	O
,	O
IFN	O
-	O
alpha4	O
and	O
IFN	O
-	O
alpha5	O
subtypes	O
in	O
L2	O
and	O
L929	O
mouse	O
fibroblast	O
cells	O
,	O
in	O
relation	O
to	O
the	O
extent	O
and	O
kinetics	O
of	O
their	O
induction	O
,	O
were	O
identified	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
develop	O
and	O
apply	O
the	O
direct	O
immunohistochemistry	O
(	O
D	O
-	O
IHC	O
)	O
assay	O
to	O
search	O
for	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
antigens	O
in	O
formalin	O
-	O
fixed	O
embedded	O
-	O
paraffin	O
tissues	O
by	O
the	O
use	O
of	O
biotin	O
-	O
labeled	O
polyclonal	O
antibody	B-PROC
.	O

Constraint	O
in	O
care	O
seeking	O
,	O
mainly	O
by	O
an	O
Israeli	O
checkpoint	B-PROC
,	O
occurred	O
in	O
8	O
%	O
and	O
10	O
%,	O
respectively	O
,	O
of	O
112	O
pregnancies	B-PROC
and	O
labours	O
and	O
31	O
%	O
of	O
16	O
neonates	O
prior	O
to	O
perinatal	O
or	O
late	O
neonatal	O
death	B-PROC
.	O

Poor	O
quality	O
care	O
for	O
a	O
complication	O
associated	O
with	O
the	O
death	B-PROC
was	O
identified	O
among	O
40	O
%	O
and	O
20	O
%,	O
respectively	O
,	O
of	O
112	O
pregnancies	B-PROC
and	O
labour	B-PROC
/	O
deliveries	O
and	O
43	O
%	O
of	O
68	O
neonates	O
.	O

Interventions	O
to	O
lower	O
stillbirths	O
and	O
neonatal	O
deaths	B-PROC
should	O
focus	O
on	O
improving	O
the	O
quality	O
of	O
medical	O
care	O
for	O
important	O
obstetric	O
complications	O
and	O
newborn	O
illnesses	O
.	O

Two	O
hundred	O
and	O
twenty	O
clinical	O
specimens	O
(	O
92	O
rectal	O
,	O
82	O
nasal	O
and	O
46	O
ocular	B-PROC
swabs	O
)	O
were	O
subjected	O
to	O
gel	O
-	O
based	O
and	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

TITLE	O
:	O
Pathways	B-PROC
of	O
cross	O
-	O
species	O
transmission	O
of	O
synthetically	O
reconstructed	O
zoonotic	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Virus	O
sequence	O
data	O
suggest	O
that	O
the	O
palm	O
civet	O
served	O
as	O
an	O
amplification	O
host	O
in	O
which	O
civet	O
and	O
human	O
interaction	O
fostered	O
the	O
evolution	B-PROC
of	O
the	O
epidemic	O
SARS	O
Urbani	O
strain	O
.	O

In	O
a	O
sub	O
-	O
group	O
analysis	O
we	O
identified	O
9	O
LTRs	O
who	O
developed	O
early	O
bronchiolitis	O
obliterans	O
syndrome	O
(	O
BOS	O
)	O
in	O
the	O
absence	O
of	O
acute	B-PROC
cellular	I-PROC
rejection	I-PROC
or	O
cytomegalovirus	O
reactivation	O
,	O
but	O
they	O
had	O
significant	O
lung	O
allograft	O
C3d	O
/	O
C4d	O
deposition	O
along	O
with	O
corroborative	O
light	O
-	O
microscopic	O
features	O
suggestive	O
of	O
AMR	O
.	O

MBL	O
and	O
MASP	O
-	O
2	O
serum	O
levels	O
,	O
as	O
well	O
as	O
lectin	O
pathway	B-PROC
activity	O
with	O
regard	O
to	O
MBL2	O
and	O
MASP2	O
genotypes	O
,	O
were	O
measured	O
in	O
healthy	O
control	O
subjects	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
has	O
been	O
identified	O
as	O
a	O
novel	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
development	B-PROC
of	O
rapid	O
screening	O
assays	O
is	O
essential	O
for	O
antiviral	O
drug	O
discovery	O
.	O

Pulse	B-PROC
therapy	O
with	O
cyclophosphamide	O
and	O
methylprednisolone	O
may	O
be	O
effective	O
in	O
preventing	O
respiratory	O
failure	O
and	O
reducing	O
mortality	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
paraquat	O
poisoning	O
.	O

CONCLUSIONS	O
:	O
Pulse	B-PROC
therapy	O
with	O
cyclophosphamide	O
and	O
methylprednisolone	O
may	O
be	O
effective	O
in	O
preventing	O
respiratory	O
failure	O
and	O
reducing	O
mortality	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
paraquat	O
poisoning	O
.	O

TITLE	O
:	O
[	O
Role	O
of	O
coagulation	B-PROC
in	O
acute	O
pulmonary	O
lesion	O
physiopathology	O
.	O

In	O
the	O
presence	O
of	O
each	O
neutralizing	O
antibody	B-PROC
,	O
double	O
mutants	O
with	O
substitutions	O
in	O
both	O
domains	O
exhibited	O
a	O
greater	O
growth	B-PROC
advantage	O
than	O
those	O
with	O
only	O
one	O
substitution	O
.	O

The	O
ability	O
of	O
the	O
ribosome	O
to	O
change	O
translational	B-PROC
reading	O
frames	O
in	O
the	O
-	O
1	O
direction	O
(-	O
1	O
PRF	O
)	O
is	O
employed	O
by	O
many	O
positive	O
strand	O
RNA	O
viruses	O
,	O
including	O
economically	O
important	O
plant	O
viruses	O
and	O
many	O
human	O
pathogens	O
,	O
such	O
as	O
retroviruses	O
,	O
e	O
.	O
g	O
.,	O
HIV	O
-	O
1	O
,	O
and	O
coronaviruses	O
,	O
e	O
.	O
g	O
.,	O
the	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
in	O
order	O
to	O
properly	O
express	O
their	O
genomes	O
.	O

ABSTRACT	O
:	O
The	O
pathogenesis	B-PROC
of	O
SARS	O
coronavirus	O
(	O
CoV	O
)	O
remains	O
poorly	O
understood	O
.	O

TITLE	O
:	O
Phosphorylation	B-PROC
of	O
the	O
arginine	O
/	O
serine	O
dipeptide	O
-	O
rich	O
motif	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	O
modulates	O
its	O
multimerization	O
,	O
translation	B-PROC
inhibitory	O
activity	O
and	O
cellular	B-PROC
localization	I-PROC
.	O

Taken	O
together	O
,	O
phosphorylation	B-PROC
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
CoV	O
nucleocapsid	O
protein	O
modulates	O
its	O
activity	O
in	O
translation	B-PROC
control	O
and	O
also	O
interferes	O
with	O
its	O
oligomerization	O
and	O
aggregation	O
in	O
stress	O
granules	O
.	O

TITLE	O
:	O
The	O
transmembrane	O
domain	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
ORF7b	O
protein	O
is	O
necessary	O
and	O
sufficient	O
for	O
its	O
retention	B-PROC
in	O
the	O
Golgi	O
complex	O
.	O

This	O
paper	O
is	O
a	O
review	O
of	O
the	O
current	O
literature	O
on	O
the	O
recent	O
genetic	O
evolution	B-PROC
of	O
CCoV	O
and	O
emergence	O
of	O
new	O
CoVs	O
in	O
the	O
dog	O
.	O

TITLE	O
:	O
Tachyphylaxis	B-PROC
to	O
cisatracurium	O
--	O
case	O
reports	O
and	O
literature	O
review	O
.	O

We	O
report	O
three	O
cases	O
of	O
tachyphylaxis	B-PROC
to	O
cisatracurium	O
in	O
a	O
surgical	O
intensive	O
care	O
unit	O
(	O
SICU	O
):	O
one	O
in	O
patient	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
the	O
other	O
two	O
with	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
).	O

Successful	O
weaning	B-PROC
and	O
survival	O
to	O
hospital	O
discharge	O
was	O
achieved	O
in	O
33	O
.	O
1	O
%	O
of	O
patients	O
after	O
a	O
mean	O
PECLA	O
support	O
of	O
8	O
.	O
5	O
+/-	O

Recent	O
reports	O
have	O
suggested	O
that	O
direct	O
hemoperfusion	O
with	O
a	O
polymyxin	O
B	O
-	O
immobilized	O
fiber	O
column	O
(	O
DHP	O
-	O
PMX	O
)	O
may	O
improve	O
the	O
oxygenation	B-PROC
in	O
patients	O
with	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

These	O
changes	O
were	O
accompanied	O
by	O
increased	O
BAL	O
levels	O
of	O
PMN	B-PROC
chemoattractants	O
(	O
KC	O
and	O
MIP	O
-	O
2	O
)	O
and	O
modest	O
increases	O
in	O
lung	O
vascular	O
and	O
alveolar	O
permeability	O
.	O

These	O
studies	O
implicate	O
PBEF	O
as	O
a	O
key	O
inflammatory	O
mediator	O
intimately	O
involved	O
in	O
both	O
the	O
development	B-PROC
and	O
severity	O
of	O
ventilator	O
-	O
induced	O
ALI	O
.	O

ABSTRACT	O
:	O
Macrophage	B-PROC
activation	I-PROC
syndrome	O
(	O
MAS	O
)	O
is	O
a	O
severe	O
,	O
potentially	O
life	O
-	O
threatening	O
condition	O
induced	O
by	O
chronic	O
rheumatic	O
diseases	O
,	O
especially	O
systemic	O
-	O
onset	O
juvenile	O
idiopathic	O
arthritis	O
(	O
SoJIA	O
)	O
in	O
childhood	O
.	O

ABSTRACT	O
:	O
Emerging	O
viral	B-PROC
diseases	I-PROC
are	O
nothing	O
new	O
.	O

The	O
second	O
half	O
of	O
the	O
20th	O
century	O
saw	O
the	O
emergence	O
of	O
HIV	O
/	O
AIDS	O
(	O
1981	O
),	O
among	O
other	O
viral	B-PROC
diseases	I-PROC
.	O

These	O
findings	O
suggest	O
that	O
secretion	B-PROC
of	O
IFN	O
-	O
beta	O
by	O
macrophages	O
and	O
microglia	O
plays	O
a	O
role	O
in	O
protecting	O
the	O
host	O
from	O
MHV	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
.	O

In	O
addition	O
,	O
an	O
experimental	O
study	O
showed	O
that	O
glucocorticosteroids	O
decrease	O
lung	O
inflammatory	B-PROC
response	I-PROC
and	O
lung	O
bacterial	O
burden	O
,	O
confirming	O
the	O
results	O
obtained	O
through	O
in	O
vitro	O
investigations	O
.	O

The	O
results	O
showed	O
that	O
HBs	O
DNA	O
positive	O
bands	O
were	O
detected	O
in	O
the	O
embryos	O
with	O
green	O
fluorescence	O
(	O
PCR	O
and	O
RT	O
-	O
PCR	O
)	O
and	O
positive	O
control	O
(	O
PCR	O
)	O
indicating	O
expression	B-PROC
of	O
pIRES2	O
-	O
EGFP	O
-	O
HBs	O
,	O
and	O
not	O
observed	O
in	O
the	O
embryos	O
without	O
green	O
fluorescence	O
and	O
negative	O
controls	O
(	O
PCR	O
and	O
RT	O
-	O
PCR	O
)	O
indicating	O
no	O
pIRES2	O
-	O
EGFP	O
-	O
HBs	O
in	O
the	O
cells	O
.	O

TITLE	O
:	O
Bench	O
-	O
to	O
-	O
bedside	O
review	O
:	O
rare	O
and	O
common	O
viral	B-PROC
infections	I-PROC
in	O
the	O
intensive	O
care	O
unit	O
--	O
linking	O
pathophysiology	O
to	O
clinical	O
presentation	O
.	O

Suspicious	O
necrosis	B-PROC
was	O
found	O
at	O
42	O
femoral	O
heads	O
of	O
23	O
patients	O
,	O
67	O
%	O
of	O
which	O
were	O
MRI	O
negative	O
.	O

RESULTS	O
:	O
Typical	O
avascular	O
necrosis	B-PROC
at	O
different	O
stages	O
and	O
severities	O
was	O
found	O
on	O
bone	O
scintigraphy	O
at	O
31	O
femoral	O
heads	O
of	O
16	O
SARS	O
patients	O
,	O
97	O
%	O
of	O
which	O
were	O
MRI	O
positive	O
.	O

rSP	O
-	O
C	O
surfactant	O
improved	O
oxygenation	B-PROC
in	O
patients	O
with	O
ARDS	O
irrespective	O
of	O
the	O
predisposition	O
.	O

This	O
is	O
a	O
potentially	O
important	O
physiological	B-PROC
phenomenon	I-PROC
not	O
previously	O
described	O
for	O
this	O
group	O
of	O
inhibitors	O
.	O

Variations	O
of	O
AGP	O
sialylation	O
were	O
recorded	O
only	O
in	O
cats	O
from	O
group	O
C	O
,	O
on	O
which	O
viral	B-PROC
shedding	I-PROC
peaked	O
before	O
the	O
occurrence	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
in	O
the	O
cattery	O
,	O
and	O
decreased	O
1	O
month	O
later	O
,	O
when	O
serum	O
AGP	O
had	O
an	O
increase	O
of	O
alpha	O
(	O
2	O
,	O
3	O
)-	O
linked	O
sialic	O
acid	O
.	O

These	O
results	O
indicate	O
that	O
immunostimulatory	O
BV	O
of	O
ApNPV	O
can	O
stimulate	O
the	O
innate	O
immune	O
activities	O
and	O
enhance	O
the	O
resistance	B-PROC
to	O
infectious	O
virus	O
of	O
neonatal	O
chickens	O
.	O

TITLE	O
:	O
A	O
SARS	O
-	O
CoV	O
protein	O
,	O
ORF	O
-	O
6	O
,	O
induces	O
caspase	O
-	O
3	O
mediated	O
,	O
ER	O
stress	O
and	O
JNK	O
-	O
dependent	O
apoptosis	B-PROC
.	O

Previous	O
reports	O
show	O
that	O
overexpression	B-PROC
of	O
ORF	O
-	O
3a	O
,	O
ORF	O
-	O
3b	O
and	O
ORF	O
-	O
7a	O
induce	O
apoptosis	B-PROC
.	O

Cockayne	O
syndrome	O
A	O
(	O
CSA	O
)	O
and	O
B	O
(	O
CSB	O
)	O
play	O
essential	O
roles	O
in	O
integrating	O
the	O
recognition	O
of	O
damage	O
,	O
chromatin	B-PROC
remodeling	I-PROC
,	O
and	O
the	O
core	O
nucleotide	B-PROC
excision	B-PROC
repair	I-PROC
proteins	O
.	O

TITLE	O
:	O
Expression	B-PROC
and	O
functional	O
characterisation	O
of	O
the	O
putative	O
SARS	O
coronavirus	O
non	O
-	O
structural	O
proteins	O
X1	O
-	O
X5	O
.	O

The	O
adenovirus	O
-	O
mediated	O
overexpression	B-PROC
of	O
SARS	O
-	O
CoV	O
N	O
-	O
terminal	O
domain	O
(	O
S1	O
)	O
and	O
other	O
structural	O
proteins	O
,	O
including	O
E	O
,	O
M	O
and	O
N	O
protein	O
,	O
do	O
not	O
induce	O
apoptosis	B-PROC
.	O

Genetic	O
-	O
association	O
studies	O
for	O
single	O
nucleotide	O
polymorphisms	B-PROC
of	O
the	O
inflammatory	B-PROC
response	I-PROC
genes	O
,	O
namely	O
TNF	O
-	O
alpha	O
,	O
INF	O
-	O
alpha	O
,	O
INF	O
-	O
beta	O
,	O
INF	O
-	O
gamma	O
,	O
IL1	O
-	O
alpha	O
,	O
IL1	O
-	O
beta	O
,	O
IL	O
-	O
4	O
,	O
IL	O
-	O
6	O
and	O
iNOS	O
,	O
failed	O
to	O
show	O
a	O
significant	O
association	O
with	O
SARS	O
clinical	O
outcomes	O
or	O
susceptibility	O
.	O

We	O
have	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
the	O
helicase	O
of	O
a	O
ribonucleic	O
acid	O
virus	O
,	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
is	O
a	O
valid	O
target	O
for	O
drug	O
development	B-PROC
.	O

Additional	O
doses	O
of	O
vaccine	O
increased	O
the	O
production	O
of	O
neutralising	O
antibody	B-PROC
5	O
-	O
fold	O
compared	O
with	O
a	O
single	O
dose	O
.	O

ABSTRACT	O
:	O
31	O
samples	O
of	O
blood	O
serum	O
of	O
pregnant	O
women	O
with	O
acute	O
respiratory	O
virus	B-PROC
infection	I-PROC
and	O
pneumonia	O
symptoms	O
who	O
had	O
been	O
administered	O
into	O
hospital	O
were	O
analyzed	O
.	O

More	O
sevenre	O
course	O
with	O
great	O
risk	O
of	O
myocardial	O
infarction	O
with	O
Q	O
wave	O
(	O
twice	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
prolongation	O
of	O
painless	O
ischemia	O
(	O
62	O
.	O
4	O
+/-	O
11	O
.	O
5	O
min	O
/	O
day	O
vs	O
.	O
22	O
.	O
8	O
+/-	O
11	O
.	O
1	O
min	O
/	O
day	O
),	O
inclination	O
to	O
complicated	O
rhythm	B-PROC
disturbances	O
(	O
38	O
vs	O
.	O
21	O
.	O
9	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
earlier	O
clinical	O
manifestations	O
of	O
heart	O
failure	O
(	O
4	O
.	O
3	O
+/-	O
0	O
.	O
6	O
years	O
earlier	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
is	O
typical	O
for	O
CHD	O
with	O
COPD	O
vs	O
.	O
patients	O
without	O
pulmonary	O
pathology	O
.	O

Finally	O
,	O
convergent	O
observations	O
indicate	O
that	O
the	O
molecules	O
encoded	O
by	O
the	O
2	O
'-	O
5	O
'	O
OAS	O
cluster	O
might	O
be	O
involved	O
in	O
other	O
fundamental	O
cellular	O
functions	O
such	O
as	O
cell	B-PROC
growth	B-PROC
and	O
differentiation	B-PROC
,	O
gene	B-PROC
regulation	I-PROC
,	O
and	O
apoptosis	B-PROC
.	O

TITLE	O
:	O
The	O
M	O
,	O
E	O
,	O
and	O
N	O
structural	O
proteins	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
are	O
required	O
for	O
efficient	O
assembly	O
,	O
trafficking	B-PROC
,	O
and	O
release	O
of	O
virus	O
-	O
like	O
particles	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
SARS	O
-	O
CoV	O
VLP	O
formation	B-PROC
depends	O
on	O
either	O
M	O
and	O
E	O
proteins	O
or	O
M	O
and	O
N	O
proteins	O
.	O

Interestingly	O
,	O
when	O
a	O
fluorescent	O
protein	O
tag	O
is	O
added	O
to	O
the	O
C	O
-	O
terminal	O
end	O
of	O
N	O
or	O
S	O
protein	O
,	O
but	O
not	O
M	O
protein	O
,	O
the	O
chimeric	O
viral	O
proteins	O
can	O
be	O
assembled	O
within	O
VLPs	O
and	O
allow	O
visualization	O
of	O
VLP	O
production	O
and	O
trafficking	B-PROC
in	O
living	O
cells	O
by	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
imaging	O
technologies	O
.	O

Both	O
the	O
whole	O
killed	O
SARS	O
-	O
CoV	O
vaccine	O
(	O
with	O
and	O
without	O
alum	O
)	O
and	O
adenovirus	O
-	O
based	O
vectors	O
encoding	O
the	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
protein	O
induced	O
neutralizing	O
antibody	B-PROC
responses	I-PROC
and	O
reduced	O
viral	B-PROC
replication	I-PROC
and	O
shedding	O
in	O
the	O
upper	O
respiratory	O
tract	O
and	O
progression	O
of	O
virus	O
to	O
the	O
lower	O
respiratory	O
tract	O
.	O

In	O
this	O
study	O
,	O
the	O
pathway	B-PROC
of	O
internalization	O
is	O
characterized	O
by	O
evaluating	O
the	O
effect	O
of	O
chemical	O
inhibitors	O
and	O
/	O
or	O
expression	B-PROC
of	O
dominant	O
-	O
negative	O
(	O
DN	O
)	O
proteins	O
on	O
the	O
percentage	O
of	O
internalized	O
virions	O
per	O
cell	O
and	O
infection	O
.	O

Arbidol	O
and	O
arbidol	O
mesylate	O
were	O
shown	O
to	O
have	O
a	O
direct	O
antiviral	O
effect	O
in	O
early	O
viral	B-PROC
replication	I-PROC
in	O
the	O
cultured	O
cells	O
.	O

TITLE	O
:	O
Adaptive	O
modeling	O
of	O
viral	B-PROC
diseases	I-PROC
in	O
bats	O
with	O
a	O
focus	O
on	O
rabies	O
.	O

The	O
7b	O
gene	O
from	O
a	O
virulent	O
strain	O
of	O
FCoV	O
was	O
cloned	O
into	O
a	O
protein	B-PROC
expression	B-PROC
vector	O
.	O

ABSTRACT	O
:	O
Avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
encodes	O
15	O
nonstructural	O
proteins	O
(	O
nsps	O
)	O
which	O
play	O
crucial	O
roles	O
in	O
RNA	O
transcription	B-PROC
and	O
genome	O
replication	O
.	O

TITLE	O
:	O
Viral	O
nucleolar	O
localisation	B-PROC
signals	O
determine	O
dynamic	O
trafficking	B-PROC
within	O
the	O
nucleolus	O
.	O

By	O
analysing	O
the	O
sub	O
-	O
cellular	B-PROC
localisation	I-PROC
and	O
trafficking	B-PROC
of	O
these	O
viral	O
proteins	O
and	O
their	O
chimeras	O
within	O
and	O
between	O
nucleoli	O
using	O
confocal	O
microscopy	O
and	O
photo	O
-	O
bleaching	O
we	O
show	O
that	O
NoLSs	O
are	O
responsible	O
for	O
different	O
nucleolar	O
localisations	O
and	O
trafficking	B-PROC
rates	O
.	O

ABSTRACT	O
:	O
Pathogens	O
causing	O
significant	O
respiratory	O
disease	O
in	O
growing	O
pigs	O
include	O
Porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
,	O
Porcine	O
circovirus	O
2	O
,	O
swine	O
influenza	O
virus	O
,	O
porcine	O
respiratory	O
coronavirus	O
,	O
Mycoplasma	O
hyopneumoniae	O
,	O
and	O
Bordetella	O
bronchiseptica	O
.	O

It	O
died	B-PROC
2	O
months	O
later	O
.	O

In	O
addition	O
to	O
the	O
granulomatous	O
host	B-PROC
response	I-PROC
,	O
necrosis	B-PROC
,	O
digestion	B-PROC
chambers	O
,	O
Gitter	O
cells	O
,	O
spheroids	O
and	O
lymphocytic	O
perivascular	O
cuffs	O
were	O
features	O
of	O
the	O
malacic	O
areas	O
.	O

TITLE	O
:	O
Lentivirus	O
display	O
:	O
stable	O
expression	B-PROC
of	O
human	O
antibodies	O
on	O
the	O
surface	O
of	O
human	O
cells	O
and	O
virus	O
particles	O
.	O

The	O
addition	O
of	O
an	O
eight	O
amino	O
acid	O
HIV	O
-	O
1	O
gp41	O
envelope	O
incorporation	O
motif	O
further	O
increased	O
scFvFc	O
expression	B-PROC
on	O
human	O
cells	O
and	O
incorporation	O
into	O
lentiviral	O
particles	O
.	O

High	O
level	O
scFvFc	O
expression	B-PROC
and	O
stable	O
integration	B-PROC
was	O
achieved	O
in	O
human	O
cells	O
following	O
transduction	B-PROC
with	O
IRES	O
containing	O
bicistronic	O
SIN	B-PROC
lentivectors	O
encoding	O
ZsGreen	O
when	O
scFvFc	O
fusion	O
proteins	O
were	O
expressed	B-PROC
from	O
the	O
first	O
cassette	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
structural	O
proteins	O
(	O
S	O
,	O
E	O
,	O
M	O
,	O
and	O
NC	O
)	O
localize	O
in	O
different	O
subcellular	O
positions	O
when	O
expressed	B-PROC
individually	O
.	O

This	O
can	O
potentially	O
be	O
turned	O
into	O
opportunities	O
of	O
promoting	O
desirable	O
public	O
health	O
behaviors	B-PROC
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	B-PROC
and	O
antiviral	O
efficacy	O
of	O
a	O
series	O
of	O
potent	O
chloropyridyl	O
ester	O
-	O
derived	O
SARS	O
-	O
CoV	O
3CLpro	O
inhibitors	O
.	O

We	O
showed	O
that	O
entry	O
of	O
the	O
serotype	O
II	O
feline	O
coronavirus	O
strains	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
WSU	O
79	O
-	O
1146	O
and	O
DF2	O
into	O
nonpermissive	O
mouse	O
3T3	O
cells	O
can	O
be	O
rescued	O
by	O
the	O
expression	B-PROC
of	O
human	O
DC	O
-	O
SIGN	O
(	O
hDC	O
-	O
SIGN	O
)	O
and	O
that	O
infection	O
of	O
a	O
permissive	O
feline	O
cell	O
line	O
(	O
Crandall	O
-	O
Reese	O
feline	O
kidney	O
)	O
was	O
markedly	O
enhanced	O
by	O
the	O
overexpression	B-PROC
of	O
hDC	O
-	O
SIGN	O
.	O

Proteinuria	O
and	O
decreased	O
glomerular	B-PROC
filtration	I-PROC
rate	O
are	O
usually	O
mild	O
.	O

Alternate	O
encoding	O
or	O
duplication	O
of	O
the	O
nsp2	O
gene	O
sequence	O
resulted	O
in	O
differences	O
in	O
nsp2	O
expression	B-PROC
,	O
processing	O
,	O
and	O
localization	B-PROC
,	O
was	O
neutral	O
or	O
detrimental	O
to	O
replication	O
,	O
and	O
did	O
not	O
complement	O
an	O
ORF1a	O
Deltansp2	O
replication	O
defect	O
.	O

Nine	O
subjects	O
completed	O
the	O
3	O
dose	O
vaccination	O
schedule	O
and	O
were	O
evaluated	O
for	O
vaccine	O
safety	O
and	O
immune	B-PROC
responses	I-PROC
.	O

ABSTRACT	O
:	O
Single	O
nucleotide	O
polymorphisms	B-PROC
in	O
the	O
myosin	O
light	O
chain	O
kinase	O
(	O
MYLK	O
)	O
gene	O
have	O
been	O
implicated	O
in	O
the	O
risk	O
of	O
sepsis	O
-	O
related	O
acute	O
lung	O
injury	O
and	O
asthma	O
.	O

A	O
total	O
of	O
17	O
tagging	O
single	O
nucleotide	O
polymorphisms	B-PROC
in	O
MYLK	O
were	O
genotyped	O
.	O

Conventional	O
herds	O
had	O
a	O
significantly	O
higher	O
mean	O
antibody	B-PROC
prevalence	O
to	O
BCV	O
and	O
BRSV	O
than	O
the	O
organically	O
managed	O
herds	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Animal	O
age	O
was	O
significantly	O
associated	O
with	O
increased	O
antibody	B-PROC
prevalence	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

The	O
results	O
indicate	O
that	O
among	O
the	O
six	O
viral	B-PROC
diseases	I-PROC
,	O
BHV	O
-	O
1	O
infection	O
is	O
quite	O
prevalent	O
,	O
while	O
BCoV	O
infection	O
is	O
less	O
prevalent	O
on	O
domestic	O
goat	O
farms	O
in	O
Gyeongsang	O
and	O
Jeonla	O
Provinces	O
.	O

Oxides	O
of	O
nitrogen	O
liberated	O
as	O
nitric	O
acid	O
interact	O
with	O
the	O
environment	O
to	O
cause	O
inhalation	B-PROC
injuries	O
.	O

A	O
66	O
-	O
year	O
-	O
old	O
man	O
developed	O
delayed	O
-	O
onset	O
pulmonary	O
edema	O
,	O
ARDS	O
,	O
and	O
fatal	O
circulatory	B-PROC
collapse	O
53	O
h	O
after	O
occupational	O
exposure	O
to	O
HNO	O
(	O
3	O
).	O

TITLE	O
:	O
Topology	O
and	O
membrane	O
anchoring	B-PROC
of	O
the	O
coronavirus	O
replication	O
complex	O
:	O
not	O
all	O
hydrophobic	O
domains	O
of	O
nsp3	O
and	O
nsp6	O
are	O
membrane	O
spanning	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
express	O
two	O
very	O
large	O
replicase	O
polyproteins	O
,	O
the	O
16	O
autoproteolytic	O
cleavage	B-PROC
products	O
of	O
which	O
collectively	O
form	O
the	O
membrane	O
-	O
anchored	O
replication	O
complexes	O
.	O

All	O
three	O
donor	O
CD4	O
(+)	O
T	O
-	O
cell	O
populations	O
controlled	O
CNS	O
virus	B-PROC
replication	I-PROC
at	O
8	O
days	O
postinfection	O
,	O
indicating	O
IFN	O
-	O
gamma	O
-	O
and	O
perforin	O
-	O
independent	O
antiviral	O
function	O
.	O

The	O
apoD	O
upregulation	B-PROC
coincides	O
with	O
glial	O
activation	O
,	O
and	O
its	O
expression	B-PROC
returns	O
to	O
normal	O
levels	O
when	O
the	O
virus	O
is	O
cleared	O
,	O
concomitantly	O
to	O
a	O
resolved	O
glial	O
reactivity	O
.	O

ABSTRACT	O
:	O
Acute	O
rhabdomyolysis	O
is	O
a	O
syndrome	O
characterized	O
by	O
the	O
lesion	O
of	O
skeletal	O
muscle	O
resulting	O
in	O
subsequent	O
release	O
of	O
intracellular	O
contents	O
into	O
the	O
circulatory	B-PROC
system	O
,	O
which	O
can	O
cause	O
potentially	O
lethal	O
complications	O
.	O

Arterial	O
blood	B-PROC
gases	I-PROC
revealed	O
metabolic	B-PROC
and	O
respiratory	O
acidosis	O
.	O

S1	O
was	O
secreted	B-PROC
into	O
the	O
medium	O
.	O

The	O
resulting	O
compound	O
,	O
GRL0617	O
,	O
inhibited	O
SARS	O
-	O
CoV	O
viral	B-PROC
replication	I-PROC
in	O
Vero	O
E6	O
cells	O
with	O
an	O
EC	O
(	O
50	O
)	O
of	O
15	O
microM	O
and	O
had	O
no	O
associated	O
cytotoxicity	O
.	O

Management	O
of	O
excessive	O
inflammation	O
may	O
be	O
possible	O
through	O
control	O
of	O
key	O
inflammatory	O
pathways	B-PROC
such	O
as	O
those	O
mediated	O
by	O
the	O
important	O
interleukin	O
-	O
1	O
receptor	O
associated	O
kinase	O
-	O
1	O
(	O
IRAK	O
-	O
1	O
).	O

Following	O
LPS	O
stimulation	O
,	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
ASODN	O
against	O
the	O
IRAK	O
-	O
1	O
gene	B-PROC
expression	I-PROC
is	O
evidenced	O
by	O
the	O
lower	O
expression	B-PROC
of	O
inflammatory	O
chemokines	O
,	O
cytokines	O
and	O
acute	O
-	O
phase	O
proteins	O
compared	O
to	O
control	O
cells	O
.	O

However	O
,	O
the	O
duration	O
of	O
antiviral	O
therapy	O
in	O
immunosuppressed	O
hosts	O
depends	O
on	O
clinical	O
and	O
radiological	O
resolution	O
,	O
the	O
degree	O
and	O
duration	O
of	O
immunosuppression	B-PROC
,	O
and	O
therefore	O
maintenance	O
therapy	O
is	O
sometimes	O
needed	O
after	O
the	O
initial	O
response	O
.	O

Virus	O
infections	O
of	O
the	O
upper	O
respiratory	O
tract	O
in	O
children	O
are	O
proved	O
in	O
77	O
.	O
4	O
%,	O
viral	O
bronchitis	O
in	O
58	O
.	O
6	O
%,	O
viral	O
pneumonia	O
in	O
47	O
.	O
6	O
%	O
and	O
febrile	B-PROC
conditions	O
with	O
lymphadenopathy	O
in	O
44	O
.	O
1	O
%	O
patients	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
effect	O
of	O
combining	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
with	O
prone	O
position	O
during	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
its	O
mechanism	O
.	O

The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
the	O
coronavirus	O
responsible	O
for	O
this	O
disease	O
plays	O
a	O
critical	O
role	O
in	O
viral	B-PROC
assembly	I-PROC
and	O
maturation	B-PROC
and	O
is	O
of	O
particular	O
interest	O
because	O
of	O
its	O
potential	O
as	O
an	O
antiviral	O
target	O
or	O
vaccine	O
candidate	O
.	O

Mass	O
spectroscopy	O
(	O
MALDI	O
,	O
SELDI	O
,	O
and	O
LC	O
/	O
MS	O
)	O
confirmed	O
that	O
the	O
bands	O
are	O
proteolytic	B-PROC
products	O
of	O
N	O
-	O
protein	O
and	O
the	O
cleavage	B-PROC
sites	O
are	O
four	O
SR	O
motifs	O
in	O
the	O
serine	O
-	O
arginine	O
-	O
rich	O
region	O
-	O
sites	O
not	O
suggestive	O
of	O
any	O
known	O
protease	O
.	O

Internalization	O
occurred	O
through	O
a	O
clathrin	O
-	O
and	O
caveolae	O
-	O
independent	O
pathway	B-PROC
that	O
did	O
not	O
require	O
dynamin	O
,	O
rafts	O
,	O
actin	O
or	O
rho	O
-	O
GTPases	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
viral	O
antigen	O
-	O
antibody	B-PROC
complexes	O
were	O
not	O
internalized	O
through	O
any	O
of	O
the	O
previously	O
described	O
pathways	B-PROC
.	O

ABSTRACT	O
:	O
Human	O
PP11	O
(	O
placental	O
protein	O
11	O
)	O
was	O
previously	O
described	O
as	O
a	O
serine	O
protease	O
specifically	O
expressed	B-PROC
in	O
the	O
syncytiotrophoblast	O
and	O
in	O
numerous	O
tumor	O
tissues	O
.	O

There	O
appears	O
to	O
be	O
widespread	O
support	O
for	O
bird	O
flu	O
control	O
measures	O
initiated	O
by	O
the	O
federal	O
government	O
,	O
although	O
less	O
agreement	O
regarding	O
personal	O
protective	O
behaviors	B-PROC
.	O

Gastric	O
juice	O
from	O
an	O
intensive	O
care	O
unit	O
patient	O
supporting	O
high	O
proinflammatory	O
activity	O
in	O
vitro	O
also	O
induced	O
a	O
more	O
severe	O
and	O
persistent	O
drop	O
in	O
PaO2	O
/	O
FIO2	O
and	O
respiratory	O
system	O
compliance	O
in	O
ventilated	O
rabbits	O
,	O
a	O
worse	O
histologic	O
score	O
,	O
higher	O
lung	O
lavage	O
concentrations	O
of	O
inflammatory	O
cells	O
,	O
interleukin	O
-	O
8	O
(	O
p	O
<	O
0	O
.	O
01	O
),	O
and	O
growth	B-PROC
-	O
related	O
oncogene	O
-	O
alpha	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
than	O
one	O
fluid	O
with	O
low	O
proinflammatory	O
activity	O
.	O

At	O
day	O
of	O
hatch	B-PROC
(	O
n	O
=	O
30	O
)	O
or	O
at	O
15	O
days	O
of	O
age	O
(	O
n	O
=	O
20	O
),	O
half	O
of	O
each	O
group	O
was	O
inoculated	O
with	O
either	O
IBV	O
H120	O
vaccine	O
(	O
H120	O
group	O
),	O
virulent	O
IBV	O
M41	O
(	O
M41	O
group	O
),	O
or	O
were	O
mock	O
-	O
infected	O
,	O
thereby	O
contact	O
-	O
exposing	O
the	O
other	O
half	O
of	O
each	O
group	O
.	O

It	O
also	O
implies	O
that	O
,	O
even	O
if	O
not	O
all	O
birds	O
received	O
vaccine	O
during	O
spray	O
application	O
,	O
due	O
to	O
the	O
ability	O
of	O
the	O
vaccine	O
to	O
spread	O
in	O
the	O
flock	O
,	O
they	O
will	O
most	O
likely	O
be	O
protected	O
against	O
clinical	O
signs	O
after	O
a	O
subsequent	O
field	O
virus	B-PROC
infection	I-PROC
.	O

These	O
results	O
suggest	O
that	O
an	O
excessive	O
host	O
immune	B-PROC
response	I-PROC
against	O
the	O
nucleocapsid	O
protein	O
of	O
SARS	O
-	O
CoV	O
is	O
involved	O
in	O
severe	O
pneumonia	O
caused	O
by	O
SARS	O
-	O
CoV	O
infection	O
.	O

Docking	B-PROC
simulations	O
helped	O
to	O
rationalize	O
the	O
SARs	O
.	O

ABSTRACT	O
:	O
Infections	O
by	O
coronaviruses	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SCoV	O
)	O
and	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
result	O
in	O
very	O
little	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
production	O
by	O
host	O
cells	O
,	O
which	O
is	O
potentially	O
responsible	O
for	O
the	O
rapid	O
viral	O
growth	B-PROC
and	O
severe	O
immunopathology	O
associated	O
with	O
SARS	O
.	O

Taken	O
together	O
,	O
pure	O
and	O
biological	O
active	O
RBD	O
of	O
the	O
S	O
protein	O
could	O
be	O
expressed	B-PROC
in	O
P	O
.	O
pastoris	O
,	O
and	O
the	O
P	O
.	O
pastoris	O
expression	B-PROC
platform	O
will	O
be	O
a	O
good	O
alternative	O
for	O
the	O
expression	B-PROC
of	O
viral	O
proteins	O
,	O
in	O
particular	O
,	O
the	O
highly	O
glycosylated	O
surface	O
proteins	O
that	O
mediate	O
the	O
tissue	B-PROC
tropism	B-PROC
and	O
viral	O
entry	O
.	O

Postoperatively	O
mediastinum	O
-	O
pleural	O
and	O
cervical	O
irrigation	B-PROC
with	O
iodopovidone	O
2	O
per	O
thousand	O
was	O
performed	O
until	O
a	O
culture	O
of	O
pleural	O
effusion	O
become	O
negative	O
.	O

In	O
this	O
review	O
,	O
the	O
technical	O
aspects	O
of	O
ECMO	O
cannulation	O
,	O
maintenance	O
and	O
weaning	B-PROC
are	O
outlined	O
.	O

We	O
found	O
that	O
HeLa	O
cells	O
infected	O
with	O
229E	O
via	O
APN	O
formed	O
syncytia	O
when	O
treated	O
with	O
trypsin	O
or	O
other	O
proteases	O
but	O
not	O
in	O
a	O
low	O
-	O
pH	O
environment	O
,	O
a	O
finding	O
consistent	O
with	O
syncytium	B-PROC
formation	I-PROC
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

These	O
findings	O
suggest	O
that	O
229E	O
takes	O
an	O
endosomal	O
pathway	B-PROC
for	O
cell	O
entry	O
and	O
that	O
proteases	O
like	O
CPL	O
are	O
involved	O
in	O
this	O
mode	O
of	O
entry	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
evaluation	O
of	O
a	O
leadership	O
training	O
program	O
for	O
public	O
health	O
emergency	O
response	O
:	O
results	O
from	O
a	O
Chinese	O
study	O
.	O

TITLE	O
:	O
Course	O
of	O
infection	O
and	O
immune	B-PROC
responses	I-PROC
in	O
the	O
respiratory	O
tract	O
of	O
IBV	O
infected	O
broilers	O
after	O
superinfection	O
with	O
E	O
.	O
coli	O
.	O

The	O
presence	O
of	O
high	O
numbers	O
of	O
T	O
cells	O
and	O
macrophages	O
in	O
IBV	O
infected	O
birds	O
most	O
likely	O
induced	O
an	O
altered	O
immune	B-PROC
response	I-PROC
,	O
which	O
is	O
responsible	O
for	O
the	O
enhanced	O
clinical	O
signs	O
of	O
colibacillosis	O
.	O

However	O
some	O
viruses	O
,	O
including	O
the	O
group	O
2	O
coronaviruses	O
,	O
have	O
evolved	O
mechanisms	O
to	O
overcome	O
or	O
circumvent	O
the	O
host	O
antiviral	B-PROC
response	I-PROC
.	O

Individual	O
point	B-PROC
mutations	I-PROC
in	O
MDO1	O
abolished	O
monomeric	O
ADP	B-PROC
-	I-PROC
ribose	I-PROC
binding	I-PROC
,	O
but	O
not	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
binding	O
;	O
in	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
binding	O
assays	O
,	O
the	O
monomer	O
did	O
not	O
compete	O
against	O
polymer	O
binding	O
.	O

Here	O
we	O
generated	O
two	O
monoclonal	O
antibodies	O
(	O
mAbs	O
),	O
targeting	B-PROC
RBD	O
,	O
with	O
marked	O
virus	O
neutralizing	O
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
the	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
class	O
I	O
C	O
molecule	O
(	O
HLA	O
-	O
C	O
)	O
as	O
an	O
attachment	O
factor	O
in	O
facilitating	O
HCoV	O
-	O
HKU1	O
spike	O
(	O
S	O
)-	O
mediated	O
infection	O
.	O

Transduced	O
cells	O
that	O
bind	O
soluble	O
HCoV	O
-	O
HKU1	O
S	O
(	O
1	O
-	O
600	O
)	O
glycoprotein	O
with	O
C	O
-	O
terminal	O
FLAG	O
were	O
sorted	B-PROC
.	O

When	O
HLA	O
-	O
C	O
was	O
constitutively	O
expressed	B-PROC
in	O
another	O
nonpermissive	O
cell	O
line	O
,	O
NIH	O
-	O
3T3	O
,	O
quantitative	O
PCR	O
showed	O
that	O
the	O
binding	O
of	O
HCoV	O
-	O
HKU1	O
S	O
pseudotyped	O
virus	O
to	O
cell	O
surfaces	O
was	O
increased	O
by	O
200	O
-	O
fold	O
,	O
but	O
the	O
cells	O
remained	O
nonsusceptible	O
to	O
HCoV	O
-	O
HKU1	O
S	O
pseudotyped	O
virus	B-PROC
infection	I-PROC
.	O

Strategies	O
to	O
block	O
this	O
nAb	O
escape	O
/	O
naturally	O
occurring	O
evolution	B-PROC
pathway	B-PROC
by	O
generating	O
broad	O
nAbs	O
(	O
BnAbs	O
)	O
with	O
activity	O
against	O
80R	O
escape	O
mutants	O
and	O
both	O
2002	O
/	O
03	O
and	O
2003	O
/	O
04	O
strains	O
were	O
explored	O
.	O

Structure	O
-	O
based	O
amino	O
acid	O
changes	O
in	O
an	O
activation	O
-	O
induced	O
cytidine	O
deaminase	O
(	O
AID	O
)	O
""""	O
hot	O
spot	O
""""	O
in	O
a	O
light	O
chain	O
CDR	O
(	O
complementarity	O
determining	O
region	O
)	O
alone	O
,	O
introduced	O
through	O
shuffling	O
of	O
naturally	O
occurring	O
non	O
-	O
immune	O
human	O
VL	O
chain	O
repertoire	O
or	O
by	O
targeted	B-PROC
mutagenesis	B-PROC
,	O
were	O
successful	O
in	O
generating	O
these	O
BnAbs	O
.	O

This	O
study	O
demonstrates	O
that	O
if	O
a	O
hospital	O
is	O
completely	O
shut	O
down	O
due	O
to	O
SARS	O
or	O
a	O
similar	O
disease	O
,	O
the	O
impact	O
is	O
longer	O
than	O
previous	O
reported	O
and	O
different	O
departments	O
may	O
experience	O
different	O
recover	B-PROC
periods	B-PROC
.	O

This	O
takes	O
place	O
via	O
formation	B-PROC
of	O
a	O
coiled	O
coil	O
6	O
-	O
helix	O
bundle	O
involving	O
N	O
and	O
C	O
-	O
terminal	O
heptad	O
repeat	O
domains	O
(	O
HR	O
-	O
N	O
and	O
HR	O
-	O
C	O
)	O
of	O
S2	O
.	O

Moreover	O
,	O
a	O
preceding	O
infection	O
with	O
vaccine	O
or	O
virulent	O
IBV	O
does	O
not	O
seem	O
to	O
impair	O
the	O
clearance	O
of	O
E	O
.	O
coli	O
in	O
the	O
respiratory	O
tract	O
of	O
broilers	O
,	O
but	O
rather	O
induces	O
an	O
exaggerated	O
inflammatory	B-PROC
response	I-PROC
in	O
the	O
airsacs	O
only	O
,	O
which	O
seems	O
to	O
be	O
the	O
mechanism	O
behind	O
the	O
pattern	O
of	O
airsacculitis	O
in	O
commercial	O
poultry	O
in	O
the	O
field	O
.	O

Although	O
SARS	O
likely	O
stems	O
from	O
overexuberant	O
host	O
inflammatory	B-PROC
responses	I-PROC
,	O
the	O
exact	O
mechanism	O
leading	O
to	O
the	O
detrimental	O
outcome	O
in	O
patients	O
remains	O
unknown	O
.	O

Such	O
strategic	O
locations	O
of	O
these	O
cells	O
within	O
the	O
airways	O
make	O
it	O
relevant	O
to	O
investigate	O
their	O
likely	O
impact	O
on	O
SARS	O
pathogenesis	B-PROC
subsequent	O
to	O
their	O
interaction	O
with	O
infected	O
lung	O
epithelial	O
cells	O
.	O

ABSTRACT	O
:	O
Examples	O
of	O
vaccine	O
-	O
induced	O
enhancement	O
of	O
susceptibility	O
to	O
virus	B-PROC
infection	I-PROC
or	O
of	O
aberrant	O
viral	O
pathogenesis	B-PROC
have	O
been	O
documented	O
for	O
infections	O
by	O
members	O
of	O
different	O
virus	O
families	O
.	O

No	O
divalent	O
metal	O
ion	O
was	O
required	O
for	O
in	O
vitro	O
enzymatic	B-PROC
activity	I-PROC
of	O
the	O
TCoV	O
nsp15	O
.	O

Donor	O
-	O
transmitted	O
viral	B-PROC
infections	I-PROC
are	O
uncommon	O
but	O
in	O
recent	O
years	O
have	O
brought	O
to	O
light	O
the	O
clinical	O
manifestations	O
of	O
rabies	O
,	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
and	O
lymphocytic	O
choriomeningitis	O
virus	O
in	O
the	O
early	O
posttransplant	O
period	O
.	O

Four	O
(	O
9	O
%)	O
of	O
the	O
43	O
patients	O
died	B-PROC
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

After	O
the	O
initial	O
surgery	O
,	O
2	O
died	B-PROC
within	O
6	O
months	O
,	O
and	O
the	O
remaining	O
2	O
within	O
1	O
year	O
.	O

There	O
were	O
differentially	O
expressed	B-PROC
serum	O
proteins	O
in	O
three	O
groups	O
.	O

cDNA	O
fragments	O
covering	O
the	O
complete	O
genome	O
were	O
amplified	O
by	O
the	O
long	O
reverse	B-PROC
transcription	B-PROC
PCR	O
.	O

Medical	O
records	O
and	O
autopsy	O
reports	O
were	O
reviewed	O
to	O
describe	O
the	O
clinical	O
presentation	O
,	O
hospital	O
course	O
,	O
and	O
pathology	O
observed	O
in	O
persons	O
hospitalized	O
or	O
deceased	B-PROC
as	O
a	O
result	O
of	O
chlorine	O
gas	O
exposure	O
.	O

Hypoxia	O
on	O
room	O
air	O
and	O
PO2	B-PROC
/	O
FiO2	O
ratio	O
predicted	O
severity	O
of	O
outcome	O
as	O
assessed	O
by	O
the	O
duration	O
of	O
hospitalization	O
and	O
the	O
need	O
for	O
intensive	O
care	O
support	O
.	O

Five	O
days	O
after	O
discharge	O
,	O
she	O
was	O
given	O
a	O
second	O
emergency	O
admission	O
,	O
because	O
of	O
fever	B-PROC
and	O
difficulty	O
in	O
walking	O
.	O

The	O
use	O
of	O
cross	O
-	O
foster	O
rederivation	O
alone	O
was	O
unsuccessful	O
for	O
the	O
elimination	B-PROC
of	O
Syphacia	O
obvelata	O
.	O

These	O
studies	O
are	O
revealing	O
a	O
rich	O
set	O
of	O
novel	O
viral	O
proteins	O
that	O
engage	O
,	O
modify	O
,	O
and	O
/	O
or	O
disrupt	O
host	O
cell	B-PROC
signaling	I-PROC
and	O
nuclear	B-PROC
import	I-PROC
machinery	O
for	O
the	O
benefit	O
of	O
virus	B-PROC
replication	I-PROC
.	O

In	O
this	O
chapter	O
,	O
we	O
discuss	O
the	O
details	O
of	O
the	O
method	O
to	O
assemble	O
a	O
full	O
-	O
length	O
infectious	O
clone	O
of	O
MHV	O
and	O
then	O
engineer	O
a	O
specific	O
mutation	O
into	O
the	O
clone	O
to	O
demonstrate	O
the	O
power	O
of	O
this	O
unique	O
site	O
-	O
directed	O
""""	O
No	O
See	O
'	O
m	O
""""	O
mutagenesis	B-PROC
approach	O
.	O

TITLE	O
:	O
Detection	O
of	O
group	O
1	O
coronaviruses	O
in	O
bats	O
using	O
universal	O
coronavirus	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reactions	O
.	O

In	O
the	O
second	O
step	O
this	O
chimeric	O
virus	O
is	O
used	O
as	O
the	O
recipient	O
for	O
recombination	B-PROC
with	O
synthetic	O
donor	O
RNA	O
carrying	O
the	O
original	O
spike	O
gene	O
.	O

In	O
order	O
to	O
develop	O
an	O
effective	O
vaccine	O
and	O
diagnostic	O
tools	O
,	O
we	O
prepared	O
UV	O
-	O
inactivated	O
SARS	O
coronavirus	O
on	O
a	O
large	O
scale	O
under	O
the	O
strict	O
Biosafety	O
Level	O
3	O
(	O
BSL3	O
)	O
regulation	B-PROC
.	O

This	O
study	O
demonstrates	O
that	O
glial	O
cells	O
derived	O
from	O
neural	O
progenitor	O
cells	O
are	O
susceptible	O
to	O
JHMV	O
infection	O
and	O
that	O
treatment	O
of	O
infected	O
cells	O
with	O
IFN	O
-	O
gamma	O
inhibits	O
viral	B-PROC
replication	I-PROC
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Although	O
type	B-PROC
I	I-PROC
IFN	I-PROC
production	I-PROC
is	O
muted	O
in	O
JHMV	O
-	O
infected	O
glial	O
cultures	O
,	O
IFN	O
-	O
beta	O
is	O
produced	O
following	O
IFN	O
-	O
gamma	O
-	O
treatment	O
of	O
JHMV	O
-	O
infected	O
cells	O
.	O

Also	O
,	O
direct	O
treatment	O
of	O
infected	O
glial	O
cultures	O
with	O
recombinant	O
mouse	O
IFN	O
-	O
alpha	O
or	O
IFN	O
-	O
beta	O
inhibits	O
viral	B-PROC
replication	I-PROC
.	O

This	O
study	O
investigated	O
the	O
effects	O
of	O
glutamine	O
(	O
Gln	O
)	O
on	O
neutrophil	B-PROC
recruitment	I-PROC
in	O
a	O
model	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
ALI	O
.	O

There	O
were	O
19	O
patients	O
with	O
burn	O
+	O
inhalation	B-PROC
injury	O
and	O
30	O
patients	O
with	O
burn	O
only	O
.	O

Burned	O
patients	O
with	O
ARDS	O
but	O
without	O
inhalation	B-PROC
injury	O
had	O
significant	O
temporal	O
improvement	O
in	O
the	O
oxygenation	B-PROC
index	O
from	O
27	O
+/-	O

In	O
chronically	O
malnourished	O
patients	O
undergoing	O
nutritional	O
support	O
,	O
even	O
hypocaloric	O
feeding	O
should	O
be	O
considered	O
a	O
risk	O
factor	O
for	O
developing	O
refeeding	O
syndrome	O
leading	O
to	O
severe	O
and	O
acute	O
electrolyte	O
fluid	O
-	O
balance	B-PROC
and	O
metabolic	B-PROC
abnormalities	O
.	O

We	O
analyzed	O
data	O
from	O
children	O
between	O
6	O
and	O
60	O
mo	O
of	O
age	O
,	O
comprising	O
13	O
,	O
307	O
admissions	O
,	O
674	O
deaths	B-PROC
,	O
3068	O
admissions	O
with	O
severe	O
disease	O
,	O
and	O
562	O
community	O
controls	O
by	O
logistic	O
regression	O
,	O
using	O
anthropometric	O
z	O
scores	O
as	O
the	O
independent	O
variable	O
and	O
admission	O
or	O
death	B-PROC
as	O
the	O
outcome	O
,	O
to	O
calculate	O
the	O
probability	O
of	O
admission	O
as	O
a	O
result	O
of	O
""""	O
true	O
malnutrition	O
""""	O
for	O
individual	O
cases	O
.	O

They	O
can	O
be	O
targeted	B-PROC
bysmall	O
molecule	O
inhibitors	O
,	O
peptides	O
and	O
peptidomimetics	O
,	O
which	O
represent	O
an	O
alternative	O
to	O
protein	O
therapeutics	O
that	O
carry	O
many	O
disadvantages	O
.	O

Application	O
of	O
this	O
model	O
to	O
platelet	O
collagen	O
receptor	B-PROC
signaling	B-PROC
has	O
already	O
led	O
to	O
the	O
development	B-PROC
of	O
a	O
novel	O
concept	O
of	O
platelet	O
inhibition	B-PROC
and	O
the	O
invention	O
of	O
new	O
platelet	O
inhibitors	O
,	O
thus	O
proving	O
the	O
suggested	O
hypothesis	O
and	O
highlighting	O
the	O
importance	O
and	O
broad	O
perspectives	O
of	O
the	O
SCHOOL	O
model	O
in	O
the	O
development	B-PROC
of	O
new	O
targeting	B-PROC
strategies	O
.	O

Breathing	B-PROC
room	O
air	O
arterial	O
blood	B-PROC
gases	I-PROC
,	O
revealed	O
severe	O
hypoxemia	O
(	O
P	O
/	O
F	O
ratio	O
185	O
mmHg	O
)	O
and	O
Chest	O
CT	O
showed	O
diffuse	O
ground	O
glass	O
opacities	O
in	O
both	O
lung	O
fields	O
.	O

Here	O
,	O
we	O
reconcile	O
these	O
apparently	O
conflicting	O
results	O
by	O
showing	O
that	O
p6	O
enhances	O
SARS	O
-	O
CoV	O
replication	O
to	O
nearly	O
the	O
same	O
extent	O
as	O
when	O
expressed	B-PROC
in	O
the	O
context	O
of	O
MHV	O
if	O
cells	O
are	O
infected	O
at	O
a	O
low	O
MOI	O
and	O
accelerates	O
disease	O
in	O
mice	O
transgenic	O
for	O
the	O
human	O
SARS	O
-	O
CoV	O
receptor	O
.	O

ABSTRACT	O
:	O
Borrelia	O
hermsii	O
causes	O
tick	O
-	O
borne	O
relapsing	O
fever	B-PROC
(	O
TBRF	O
)	O
in	O
the	O
Pacific	O
Northwest	O
.	O

Sequence	O
analyses	O
were	O
performed	O
to	O
detect	O
any	O
recombination	B-PROC
event	O
among	O
IBVs	O
.	O

Possible	O
recombination	B-PROC
sites	O
were	O
found	O
at	O
the	O
intergenic	O
region	O
of	O
spike	O
gene	O
,	O
3	O
'	O
end	O
of	O
S1	O
and	O
3a	O
gene	O
.	O

Viral	B-PROC
infection	I-PROC
of	O
epithelia	O
can	O
damage	O
or	O
disrupt	O
the	O
epithelial	O
barrier	O
that	O
protects	O
underlying	O
tissues	O
.	O

Similar	O
numbers	O
of	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	O
were	O
retained	O
in	O
the	O
CNS	O
of	O
IL	O
-	O
15	O
(-/-)	O
and	O
wt	O
mice	O
,	O
consistent	O
with	O
loss	O
of	O
IL	O
-	O
2	O
/	O
15	O
receptor	O
(	O
CD122	O
)	O
expression	B-PROC
.	O

Furthermore	O
,	O
CD8	O
(+)	O
T	O
cell	B-PROC
division	I-PROC
in	O
the	O
CNS	O
was	O
reduced	O
compared	O
to	O
spleen	O
.	O

Our	O
results	O
indicate	O
that	O
GSK	O
-	O
3	O
is	O
critical	O
for	O
CoV	O
N	O
protein	B-PROC
phosphorylation	I-PROC
and	O
suggest	O
that	O
it	O
plays	O
a	O
role	O
in	O
regulating	O
the	O
viral	B-PROC
life	I-PROC
cycle	I-PROC
.	O

Surprisingly	O
,	O
the	O
knockdown	O
of	O
PKR	O
neither	O
enhanced	O
SARS	O
-	O
CoV	O
replication	O
nor	O
abrogated	O
SARS	O
-	O
CoV	O
-	O
induced	O
eIF2alpha	O
phosphorylation	B-PROC
.	O

Pretreatment	O
of	O
cells	O
with	O
beta	O
interferon	O
prior	O
to	O
SARS	O
-	O
CoV	O
infection	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
PERK	O
activation	O
,	O
eIF2alpha	O
phosphorylation	B-PROC
,	O
and	O
SARS	O
-	O
CoV	O
replication	O
.	O

The	O
various	O
effects	O
of	O
beta	O
interferon	O
treatment	O
were	O
found	O
to	O
function	O
independently	O
on	O
the	O
expression	B-PROC
of	O
PKR	O
.	O

Moreover	O
,	O
knockdown	O
of	O
PU	O
.	O
1	O
through	O
the	O
use	O
of	O
small	O
interfering	O
RNA	O
led	O
to	O
a	O
decrease	O
in	O
LSECtin	O
mRNA	O
levels	O
in	O
THP	O
-	O
1	O
and	O
monocyte	O
-	O
derived	O
dendritic	O
cells	O
,	O
thus	O
confirming	O
the	O
involvement	O
of	O
PU	O
.	O
1	O
in	O
the	O
myeloid	O
expression	B-PROC
of	O
the	O
lectin	O
.	O

TITLE	O
:	O
[	O
Extracorporeal	O
membranous	O
oxygenation	B-PROC
in	O
severe	O
infant	O
pertussis	O
:	O
a	O
case	O
report	O
].	O

In	O
3	O
of	O
these	O
8	O
children	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
was	O
also	O
detected	O
by	O
reverse	O
-	O
transcription	B-PROC
polymerase	O
chain	O
reaction	O
in	O
the	O
stool	O
.	O

When	O
all	O
four	O
expression	B-PROC
vectors	O
were	O
co	O
-	O
transfected	O
VLP	O
formed	O
,	O
as	O
confirmed	O
using	O
electron	O
microscopy	O
.	O

IRF3	O
knockdown	O
and	O
p38	O
kinase	O
inhibition	B-PROC
separately	O
and	O
in	O
combination	O
led	O
to	O
a	O
substantial	O
reduction	O
of	O
IFN	O
-	O
beta	O
,	O
IFN	O
-	O
lambda1	O
,	O
and	O
MCP	O
-	O
1	O
but	O
only	O
to	O
a	O
partial	O
reduction	O
of	O
TNF	O
-	O
alpha	O
.	O

These	O
effects	O
can	O
be	O
due	O
to	O
direct	O
infection	O
of	O
the	O
gut	O
mucosa	O
,	O
but	O
can	O
also	O
be	O
because	O
of	O
decreased	O
antibacterial	O
defenses	O
,	O
increased	O
mucosal	O
permeability	O
,	O
bacterial	B-PROC
translocation	B-PROC
,	O
and	O
systemic	O
leak	O
of	O
endotoxin	O
.	O

At	O
presentation	O
,	O
all	O
patients	O
but	O
two	O
had	O
a	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
<	O
300	O
,	O
while	O
ARDS	O
was	O
present	O
in	O
17	O
and	O
acute	O
lung	O
injury	O
in	O
15	O
cases	O
.	O

The	O
""""	O
initial	O
""""	O
reproduction	B-PROC
number	O
for	O
the	O
outbreak	O
is	O
estimated	O
to	O
be	O
~	O
1	O
.	O
89	O
-	O
2	O
.	O
23	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
15	O
-	O
3	O
.	O
00	O
).	O

TITLE	O
:	O
Structural	O
basis	O
of	O
inhibition	B-PROC
specificities	O
of	O
3C	O
and	O
3C	O
-	O
like	O
proteases	O
by	O
zinc	O
-	O
coordinating	O
and	O
peptidomimetic	O
compounds	O
.	O

In	O
picornavirus	O
,	O
a	O
chymotrypsin	O
-	O
like	O
protease	O
(	O
3C	O
(	O
pro	O
))	O
is	O
required	O
for	O
viral	B-PROC
replication	I-PROC
by	O
processing	O
the	O
polyproteins	O
,	O
and	O
thus	O
it	O
is	O
regarded	O
as	O
an	O
antiviral	O
drug	O
target	O
.	O

Although	O
the	O
severity	O
of	O
a	O
pandemic	O
is	O
unpredictable	O
,	O
this	O
effort	B-PROC
is	O
not	O
likely	O
to	O
be	O
wasted	O
because	O
it	O
will	O
also	O
support	O
the	O
health	O
of	O
both	O
patients	O
and	O
staff	O
in	O
normal	O
times	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nsp9	O
dimerization	O
is	O
essential	O
for	O
efficient	O
viral	O
growth	B-PROC
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
dimerization	O
of	O
SARS	O
-	O
CoV	O
nsp9	O
at	O
the	O
GXXXG	O
motif	O
is	O
not	O
critical	O
for	O
RNA	O
binding	O
but	O
is	O
necessary	O
for	O
viral	B-PROC
replication	I-PROC
.	O

For	O
rhinovirus	O
,	O
new	O
OM	O
occurred	O
in	O
50	O
%	O
of	O
children	O
with	O
and	O
32	O
%	O
without	O
a	O
concurrent	O
CLI	O
(	O
P	O
=	O
.	O
15	O
),	O
and	O
OM	O
risk	O
was	O
predicted	O
by	O
OM	O
and	O
breastfeeding	B-PROC
histories	O
and	O
by	O
daily	O
environment	O
outside	O
the	O
home	O
.	O

ABSTRACT	O
:	O
Worldwide	O
pandemics	O
of	O
influenza	O
virus	O
caused	O
extensive	O
morbidity	O
and	O
mortality	O
around	O
the	O
world	O
and	O
influenza	O
vaccination	O
is	O
the	O
most	O
effective	O
method	O
for	O
preventing	O
influenza	O
virus	B-PROC
infection	I-PROC
and	O
its	O
potentially	O
severe	O
complications	O
.	O

We	O
identified	O
a	O
reference	O
data	O
set	O
of	O
624	O
mechanically	O
-	O
ventilated	O
patients	O
in	O
the	O
MIMIC	O
-	O
II	O
intensive	O
care	O
database	O
with	O
and	O
without	O
low	O
PaO	B-PROC
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratios	O
(	O
termed	O
respiratory	O
instability	O
),	O
and	O
developed	O
prediction	O
algorithms	O
for	O
distinguishing	O
these	O
patients	O
prior	O
to	O
the	O
critical	O
event	O
.	O

Equipment	O
availability	O
and	O
vision	B-PROC
impairment	O
were	O
often	O
cited	O
as	O
impediments	O
to	O
personal	O
protective	O
equipment	O
use	O
.	O

Various	O
vaccines	O
and	O
protocols	O
to	O
control	O
this	O
viral	B-PROC
disease	I-PROC
have	O
been	O
developed	O
,	O
although	O
the	O
severity	O
of	O
the	O
disease	O
varies	O
from	O
place	O
to	O
place	O
and	O
flock	O
to	O
flock	O
.	O

Initiation	O
of	O
iLA	O
resulted	O
in	O
a	O
marked	O
removal	O
in	O
arterial	O
carbon	O
dioxide	O
allowing	O
a	O
rapid	O
reduction	O
in	O
tidal	O
volume	O
(<	O
or	O
=	O
6	O
ml	O
/	O
kg	O
)	O
and	O
inspiratory	B-PROC
plateau	O
pressure	O
.	O

We	O
report	O
the	O
effects	O
of	O
extracorporeal	O
CO	O
(	O
2	O
)	O
removal	O
by	O
means	O
of	O
a	O
novel	O
pumpless	O
extracorporeal	O
lung	O
assist	O
(	O
p	O
-	O
ECLA	O
)	O
on	O
tidal	O
volumes	O
,	O
airway	O
pressures	O
,	O
breathing	B-PROC
patterns	O
and	O
sedation	O
management	O
in	O
pneumonia	O
patients	O
during	O
late	O
-	O
phase	O
ARDS	O
.	O

Elimination	B-PROC
of	O
CO	O
(	O
2	O
)	O
by	O
p	O
-	O
ECLA	O
therapy	O
allowed	O
reduction	O
of	O
ventilator	O
-	O
induced	O
shear	O
stress	O
through	O
ventilation	O
with	O
tidal	O
volumes	O
below	O
4	O
ml	O
/	O
kg	O
predicted	O
body	O
weight	O
in	O
pneumonia	O
patients	O
with	O
severely	O
impaired	O
pulmonary	O
compliance	O
during	O
late	O
-	O
phase	O
ARDS	O
.	O

TITLE	O
:	O
SARS	O
knowledge	O
,	O
perceptions	O
,	O
and	O
behaviors	B-PROC
:	O
a	O
comparison	O
between	O
Finns	O
and	O
the	O
Dutch	O
during	O
the	O
SARS	O
outbreak	O
in	O
2003	O
.	O

Multiple	O
logistic	O
regression	O
analyses	O
were	O
used	O
to	O
calculate	O
odds	O
ratios	O
(	O
with	O
95	O
%	O
confidence	O
intervals	O
)	O
to	O
compare	O
Finns	O
with	O
the	O
Dutch	O
for	O
various	O
levels	O
of	O
perceptions	O
and	O
behaviors	B-PROC
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
spike	O
protein	O
-	O
induced	O
innate	B-PROC
immune	I-PROC
response	I-PROC
occurs	O
via	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	B-PROC
in	O
human	O
monocyte	O
macrophages	O
in	O
vitro	O
.	O

Activation	O
and	O
translocation	B-PROC
of	O
NF	O
-	O
kappaB	O
was	O
shown	O
to	O
occur	O
rapidly	O
following	O
exposure	O
of	O
PBMC	O
or	O
THP	O
-	O
1	O
cells	O
to	O
S	O
protein	O
using	O
a	O
highly	O
sensitive	O
assay	O
for	O
active	O
nuclear	O
NF	O
-	O
kappaB	O
p65	O
transcription	B-PROC
factor	O
.	O

The	O
results	O
further	O
suggested	O
that	O
released	O
or	O
secreted	B-PROC
S	O
protein	O
could	O
activate	O
blood	O
monocytes	O
through	O
recognition	O
by	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
2	O
ligand	B-PROC
.	O

The	O
comparison	O
between	O
the	O
three	O
vaccination	O
routes	O
indicated	O
that	O
immunization	O
intramuscularly	O
induced	O
a	O
moderate	O
T	O
cell	O
response	O
and	O
antibody	B-PROC
response	I-PROC
.	O

These	O
results	O
indicated	O
that	O
the	O
distinct	O
types	O
of	O
immune	B-PROC
responses	I-PROC
were	O
generated	O
by	O
the	O
different	O
routes	O
of	O
DNA	O
immunization	O
.	O

Hypoxemia	O
and	O
facilitation	B-PROC
of	O
mechanical	O
ventilation	O
are	O
the	O
main	O
indications	O
of	O
NMBAs	O
.	O

Recent	O
studies	O
suggest	O
a	O
beneficial	O
effect	O
of	O
early	O
use	O
of	O
NMBAs	O
on	O
oxygenation	B-PROC
and	O
inflammation	O
.	O

Anti	O
-	O
coagulation	B-PROC
and	O
pro	O
-	O
fibrinolysis	B-PROC
activity	O
may	O
be	O
two	O
of	O
the	O
possible	O
mechanisms	O
by	O
which	O
activated	O
protein	O
C	O
attenuated	O
endotoxin	O
-	O
induced	O
ALI	O
.	O

CONCLUSIONS	O
:	O
Anti	O
-	O
coagulation	B-PROC
and	O
pro	O
-	O
fibrinolysis	B-PROC
activity	O
may	O
be	O
two	O
of	O
the	O
possible	O
mechanisms	O
by	O
which	O
activated	O
protein	O
C	O
attenuated	O
endotoxin	O
-	O
induced	O
ALI	O
.	O

Mortality	O
,	O
morbidity	O
,	O
and	O
psychosocial	O
impacts	O
resulting	O
from	O
other	O
major	O
events	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
(	O
WNV	O
),	O
and	O
the	O
U	O
.	O
S	O
.-	O
Iraq	O
war	O
made	O
the	O
theoretical	O
risks	O
of	O
BSE	O
and	O
vCJD	O
a	O
lower	O
priority	O
,	O
reducing	O
its	O
concern	O
as	O
a	O
risk	O
issue	O
.	O

Follow	O
-	O
up	O
was	O
conducted	O
for	O
14	O
days	O
to	O
observe	O
the	O
clinical	O
manifestation	O
,	O
and	O
time	O
of	O
ventilatory	O
support	O
,	O
arterial	O
blood	B-PROC
gas	I-PROC
analysis	O
and	O
radiological	O
examination	O
of	O
chest	O
were	O
performed	O
.	O

ABSTRACT	O
:	O
Infectious	O
bronchitis	O
virus	O
primarily	O
induces	O
a	O
disease	O
of	O
the	O
respiratory	O
system	O
,	O
different	O
IBV	O
strains	O
may	O
show	O
variable	O
tissue	O
tropisms	B-PROC
and	O
also	O
affect	O
the	O
oviduct	O
and	O
the	O
kidneys	O
.	O

RESULTS	O
:	O
To	O
this	O
end	O
chicken	O
embryos	O
were	O
inoculated	O
in	O
the	O
allantoic	O
sac	B-PROC
with	O
10	O
(	O
3	O
)	O
EID	O
(	O
50	O
)	O
of	O
IBV	O
M41	O
at	O
10	O
days	O
of	O
age	O
.	O

TITLE	O
:	O
The	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
--	O
a	O
target	O
for	O
vaccine	O
and	O
therapeutic	O
development	B-PROC
.	O

The	O
S	O
protein	O
plays	O
key	O
parts	O
in	O
the	O
induction	O
of	O
neutralizing	O
-	O
antibody	B-PROC
and	O
T	O
-	O
cell	O
responses	O
,	O
as	O
well	O
as	O
protective	O
immunity	B-PROC
,	O
during	O
infection	O
with	O
SARS	O
-	O
CoV	O
.	O
In	O
this	O
Review	O
,	O
we	O
highlight	O
recent	O
advances	O
in	O
the	O
development	B-PROC
of	O
vaccines	O
and	O
therapeutics	O
based	O
on	O
the	O
S	O
protein	O
.	O

Despite	O
maximal	O
intensive	O
care	O
,	O
the	O
patient	O
died	B-PROC
four	O
weeks	O
after	O
surgery	O
from	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

To	O
prevent	O
deaths	B-PROC
in	O
the	O
future	O
,	O
early	O
diagnosis	O
and	O
therapy	O
of	O
this	O
infectious	O
disease	O
is	O
of	O
paramount	O
importance	O
.	O

The	O
genetically	O
engineered	O
attenuated	O
form	O
of	O
the	O
virus	O
or	O
viral	O
vector	O
vaccine	O
encoding	O
for	O
the	O
SARS	O
-	O
CoV	O
spike	O
glycoprotein	O
has	O
been	O
shown	O
to	O
elicit	O
protective	O
immunity	B-PROC
in	O
vaccinated	O
animals	O
.	O

Five	O
stages	O
arose	O
in	O
the	O
participants	O
'	O
involvement	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
over	O
12	O
weeks	O
:	O
facing	O
shock	O
and	O
chaos	O
;	O
searching	O
for	O
reliable	O
sources	O
to	O
clarify	O
myths	O
;	O
developing	O
and	O
adjusting	O
nursing	B-PROC
care	O
;	O
supporting	O
nurses	O
and	O
their	O
clients	O
;	O
and	O
rewarding	O
nurses	O
.	O

ABSTRACT	O
:	O
The	O
development	B-PROC
of	O
technologies	O
with	O
rapid	O
and	O
sensitive	O
detection	O
capabilities	O
and	O
increased	O
throughput	O
have	O
become	O
crucial	O
for	O
responding	O
to	O
greater	O
number	O
threats	O
posed	O
by	O
emerging	O
and	O
re	O
-	O
emerging	O
viruses	O
in	O
the	O
recent	O
past	O
.	O

Other	O
items	O
obtained	O
were	O
gender	O
,	O
range	O
of	O
activities	O
,	O
eating	B-PROC
restrictions	O
,	O
restrictions	O
in	O
going	O
out	O
,	O
disinfection	O
of	O
clothing	O
,	O
and	O
infection	O
control	O
,	O
with	O
odds	O
ratios	O
of	O
3	O
.	O
2	O
,	O
5	O
.	O
5	O
,	O
3	O
.	O
9	O
,	O
3	O
.	O
2	O
,	O
0	O
.	O
2	O
,	O
and	O
0	O
.	O
1	O
,	O
respectively	O
,	O
and	O
the	O
contribution	O
ratio	O
was	O
87	O
.	O
7	O
%.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
a	O
major	O
target	O
in	O
the	O
development	B-PROC
of	O
diagnostic	O
assays	O
and	O
vaccines	O
,	O
but	O
its	O
antigenic	O
and	O
immunogenic	O
properties	O
remain	O
unclear	O
.	O

The	O
one	O
patient	O
with	O
detection	O
of	O
hMPV	O
and	O
clinical	O
diagnosis	O
of	O
atypical	O
pneumonia	O
died	B-PROC
of	O
pulmonary	O
failure	O
.	O

After	O
intraperitoneal	O
inoculation	O
,	O
virus	B-PROC
replication	I-PROC
was	O
predominantly	O
observed	O
in	O
the	O
liver	O
and	O
occasionally	O
in	O
the	O
intestines	O
,	O
but	O
interestingly	O
also	O
in	O
the	O
tail	O
and	O
paws	O
.	O

Our	O
results	O
provide	O
new	O
insights	O
in	O
coronavirus	O
pathogenesis	B-PROC
and	O
demonstrate	O
the	O
potential	O
of	O
BLI	O
to	O
study	O
coronavirus	O
-	O
host	O
interactions	O
in	O
vivo	O
.	O

Three	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
or	O
dengue	O
fever	B-PROC
interventions	O
in	O
airports	O
were	O
excluded	O
because	O
of	O
insufficient	O
information	O
.	O

Six	O
fever	B-PROC
screening	O
studies	O
in	O
other	O
gathering	O
areas	O
,	O
mainly	O
hospitals	O
,	O
were	O
included	O
(	O
N	O
=	O
176	O
to	O
72	O
,	O
327	O
persons	O
;	O
fever	B-PROC
prevalence	O
=	O
1	O
.	O
2	O
%	O
to	O
16	O
.	O
9	O
%).	O

This	O
article	O
will	O
review	O
these	O
studies	O
to	O
date	O
,	O
summarizing	O
candidate	O
genes	O
associated	O
with	O
ALI	O
and	O
ARDS	O
,	O
acknowledging	O
those	O
that	O
have	O
been	O
replicated	O
in	O
independent	O
populations	O
,	O
with	O
a	O
special	O
focus	O
on	O
the	O
specific	O
pathways	B-PROC
for	O
which	O
candidate	O
genes	O
identified	O
so	O
far	O
can	O
be	O
clustered	O
.	O

ABSTRACT	O
:	O
Use	O
of	O
inhaled	B-PROC
nitric	O
oxide	O
in	O
humans	O
with	O
traumatic	O
brain	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
has	O
twice	O
previously	O
been	O
reported	O
to	O
be	O
beneficial	O
.	O

ABSTRACT	O
:	O
A	O
high	O
survival	O
rate	O
can	O
be	O
achieved	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
using	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O

Pulmonary	B-PROC
function	I-PROC
tests	O
revealed	O
good	O
restitution	O
with	O
mean	O
values	O
in	O
the	O
lower	O
normal	O
range	O
,	O
while	O
T	O
(	O
1	O
/	O
2	O
)	O
for	O
outwash	O
of	O
inhaled	B-PROC
isotope	O
was	O
abnormal	O
in	O
all	O
patients	O
consistent	O
with	O
subclinical	O
obstructivity	O
.	O

The	O
relative	O
immaturity	O
of	O
the	O
immune	O
system	O
in	O
weanlings	O
may	O
confer	O
benefit	O
leading	O
to	O
less	O
impairment	O
of	O
lung	B-PROC
function	I-PROC
.	O

Polyclonal	O
antibody	B-PROC
of	O
this	O
protein	O
was	O
obtained	O
,	O
and	O
Western	O
blotting	O
assay	O
indicated	O
that	O
the	O
X5	O
protein	O
has	O
the	O
strong	O
property	O
of	O
antigen	O
.	O

TITLE	O
:	O
Cocktail	O
therapy	O
for	O
hip	O
necrosis	B-PROC
in	O
SARS	O
patients	O
.	O

Cocktail	O
therapy	O
seems	O
promising	O
in	O
delaying	O
the	O
disease	O
progression	O
of	O
SARS	O
-	O
associated	O
femoral	O
head	O
necrosis	B-PROC
in	O
the	O
short	O
-	O
term	O
.	O

Dexamethasone	O
could	O
ameliorate	O
PaO2	O
and	O
lung	O
damage	O
evidently	O
,	O
which	O
were	O
paralleled	O
by	O
significant	O
decreases	O
in	O
the	O
production	O
of	O
NO	O
and	O
in	O
the	O
expression	B-PROC
of	O
iNOS	O
mRNA	O
.	O

More	O
recently	O
,	O
potent	O
fully	O
-	O
human	O
neutralizing	O
mAbs	O
have	O
been	O
developed	O
against	O
a	O
variety	O
of	O
important	O
human	O
viral	B-PROC
disease	I-PROC
agents	O
including	O
the	O
paramyxoviruses	O
Hendra	O
virus	O
and	O
Nipah	O
virus	O
,	O
and	O
human	O
or	O
humanized	O
mAbs	O
have	O
been	O
developed	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
),	O
and	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
among	O
others	O
.	O

The	O
ability	O
of	O
the	O
rAd	O
-	O
N	O
to	O
induce	O
anti	O
-	O
SARS	O
-	O
CoV	O
N	O
antibody	B-PROC
production	I-PROC
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
was	O
evaluated	O
in	O
an	O
HLA	O
-	O
A2	O
.	O
1	O
/	O
Kb	O
transgenic	O
mouse	O
model	O
.	O

The	O
polymorphisms	B-PROC
of	O
IL	O
-	O
10	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
12	O
,	O
IP	O
-	O
10	O
,	O
Mig	O
and	O
MCP	O
-	O
1	O
are	O
not	O
associated	O
with	O
SARS	O
susceptibility	O
.	O

CONCLUSIONS	O
:	O
This	O
extensive	O
evolutionary	O
analysis	O
revealed	O
the	O
stepwise	O
evolution	B-PROC
of	O
different	O
functional	O
proteins	O
of	O
SARS	O
-	O
CoVs	O
at	O
different	O
epidemic	O
stages	O
and	O
different	O
hosts	O
.	O

Network	O
perspectives	O
offer	O
new	O
ways	O
to	O
study	O
systems	O
to	O
care	O
for	O
critically	O
ill	O
patients	O
and	O
provide	O
additional	O
tools	O
for	O
addressing	O
pragmatic	O
problems	O
in	O
triage	O
and	O
bed	O
management	O
,	O
regionalization	B-PROC
,	O
quality	O
improvement	O
,	O
and	O
disaster	O
preparedness	O
.	O

ABSTRACT	O
:	O
Little	O
is	O
known	O
about	O
the	O
effects	O
of	O
hemodialysis	O
on	O
the	O
injured	O
brain	O
,	O
however	O
;	O
concern	O
exists	O
over	O
the	O
use	O
of	O
intermittent	O
hemodialysis	O
in	O
patients	O
with	O
acute	O
brain	O
injury	O
(	O
ABI	O
)	O
due	O
to	O
its	O
hemodynamic	B-PROC
effects	O
and	O
increased	O
intracranial	B-PROC
pressure	I-PROC
(	O
ICP	O
)	O
associated	O
with	O
therapy	O
.	O

None	O
of	O
the	O
patients	O
experienced	O
life	O
-	O
threatening	O
complications	O
or	O
hemodynamic	B-PROC
instability	O
during	O
the	O
procedure	O
.	O

RESULTS	O
:	O
The	O
elapsed	O
time	O
from	O
the	O
initiation	O
of	O
mechanical	O
ventilation	O
to	O
pronation	B-PROC
was	O
35	O
+/-	O

ABSTRACT	O
:	O
Coronavirus	O
M	O
protein	O
is	O
an	O
essential	O
component	O
of	O
virion	O
and	O
plays	O
pivotal	O
roles	O
in	O
virion	B-PROC
assembly	I-PROC
,	O
budding	B-PROC
and	O
maturation	B-PROC
.	O

We	O
derived	O
an	O
expression	B-PROC
for	O
Re	O
,	O
the	O
reproduction	B-PROC
number	O
,	O
took	O
its	O
partial	O
derivatives	O
with	O
respect	O
to	O
control	O
parameters	O
,	O
and	O
encoded	O
these	O
analytical	O
results	O
in	O
a	O
user	O
-	O
friendly	O
Mathematica	O
notebook	O
.	O

Vaccinated	O
mice	O
were	O
protected	O
from	O
severe	O
respiratory	O
disease	O
in	O
parallel	O
with	O
a	O
low	O
virus	O
titer	O
in	O
the	O
lungs	O
and	O
a	O
high	O
neutralizing	O
antibody	B-PROC
titer	O
in	O
the	O
plasma	O
.	O

The	O
formation	B-PROC
of	O
major	O
study	O
groups	O
and	O
competence	O
centres	O
during	O
the	O
last	O
decade	O
has	O
made	O
meaningful	O
prospective	O
interventional	O
studies	O
possible	O
that	O
,	O
in	O
turn	O
,	O
have	O
resulted	O
in	O
the	O
development	B-PROC
of	O
clinical	O
treatment	O
algorithms	O
.	O

TITLE	O
:	O
Transduction	B-PROC
of	O
nonhuman	O
primate	O
brain	O
with	O
adeno	O
-	O
associated	O
virus	O
serotype	O
1	O
:	O
vector	O
trafficking	B-PROC
and	O
immune	B-PROC
response	I-PROC
.	O

We	O
conclude	O
that	O
transduction	B-PROC
of	O
antigen	O
-	O
presenting	O
cells	O
within	O
the	O
CNS	O
is	O
a	O
likely	O
cause	O
of	O
this	O
response	O
and	O
that	O
caution	O
is	O
warranted	O
when	O
foreign	O
transgenes	O
are	O
used	O
as	O
reporters	O
in	O
gene	O
therapy	O
studies	O
with	O
vectors	O
with	O
broader	O
tropism	B-PROC
than	O
AAV2	O
.	O

Symptoms	O
did	O
not	O
improve	O
with	O
steroid	O
or	O
immunoglobulin	B-PROC
treatment	O
,	O
but	O
improvement	O
in	O
symptoms	O
was	O
observed	O
after	O
plasmapheresis	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
characterized	O
and	O
compared	O
the	O
pathogeneses	B-PROC
of	O
SARS	O
-	O
CoV	O
infection	O
in	O
two	O
of	O
the	O
most	O
stable	O
Tg	O
lineages	O
,	O
AC70	O
and	O
AC22	O
,	O
representing	O
those	O
susceptible	O
and	O
resistant	O
to	O
the	O
lethal	O
SARS	O
-	O
CoV	O
infection	O
,	O
respectively	O
.	O

We	O
found	O
that	O
while	O
both	O
lineages	O
were	O
permissive	O
to	O
SARS	O
-	O
CoV	O
infection	O
,	O
causing	O
elevated	O
secretion	B-PROC
of	O
many	O
inflammatory	O
mediators	O
within	O
the	O
lungs	O
and	O
brains	O
,	O
viral	B-PROC
infection	I-PROC
appeared	O
to	O
be	O
more	O
intense	O
in	O
AC70	O
than	O
in	O
AC22	O
mice	O
,	O
especially	O
in	O
the	O
brain	O
.	O

Of	O
these	O
,	O
a	O
conserved	O
endoribonuclease	O
(	O
NendoU	O
)	O
is	O
a	O
major	O
genetic	B-PROC
marker	I-PROC
that	O
is	O
unique	O
to	O
nidoviruses	O
.	O

TITLE	O
:	O
Intestinal	O
mucosal	B-PROC
immune	I-PROC
response	I-PROC
against	O
virulent	O
duck	O
enteritis	O
virus	B-PROC
infection	I-PROC
in	O
ducklings	O
.	O

ABSTRACT	O
:	O
Duck	O
virus	O
enteritis	O
(	O
DVE	O
)	O
is	O
an	O
acute	O
and	O
contagious	O
herpes	O
virus	B-PROC
infection	I-PROC
of	O
duck	O
,	O
geese	O
and	O
swans	O
with	O
high	O
morbidity	O
and	O
mortality	O
.	O

The	O
results	O
showed	O
that	O
a	O
continuous	O
increased	O
DEV	O
DNA	O
levels	O
were	O
observed	O
in	O
blood	O
and	O
various	O
organs	O
examined	O
of	O
orally	O
infected	O
ducklings	O
throughout	O
the	O
infection	O
,	O
which	O
was	O
accompanied	O
by	O
the	O
development	B-PROC
of	O
infection	O
in	O
ducklings	O
from	O
mild	O
progressed	O
to	O
severe	O
pathological	O
lesions	O
.	O

These	O
findings	O
suggest	O
that	O
8ab	O
could	O
modulate	O
the	O
UPR	O
by	O
activating	O
ATF6	O
to	O
facilitate	O
protein	B-PROC
folding	I-PROC
and	O
processing	O
.	O

Thus	O
,	O
the	O
loss	O
of	O
8ab	O
in	O
SARS	O
-	O
CoV	O
through	O
viral	O
evolution	B-PROC
in	O
animals	O
may	O
play	O
a	O
role	O
in	O
its	O
pathogenicity	O
.	O

When	O
incubated	O
with	O
Hela	O
cells	O
,	O
the	O
purified	O
protein	O
could	O
not	O
internalize	O
through	O
membrane	B-PROC
fusion	I-PROC
.	O

This	O
includes	O
potential	O
mechanisms	O
of	O
presynaptic	O
feedback	O
which	O
may	O
reduce	O
acetylcholine	O
release	O
and	O
postsynaptic	O
receptor	B-PROC
desensitization	I-PROC
and	O
provides	O
some	O
explanation	O
for	O
the	O
time	O
course	O
of	O
IMS	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
E	O
gene	O
fragment	O
was	O
cloned	O
and	O
expressed	B-PROC
as	O
a	O
recombinant	O
protein	O
fused	O
with	O
a	O
myc	O
tag	O
at	O
the	O
N	O
-	O
terminus	O
in	O
vitro	O
and	O
in	O
Vero	O
E6	O
cells	O
.	O

The	O
structure	O
reveals	O
that	O
the	O
RBD	O
surface	O
recognized	O
by	O
F26G19	O
overlaps	O
significantly	O
with	O
the	O
surface	O
recognized	O
by	O
ACE2	O
and	O
,	O
as	O
such	O
,	O
suggests	O
that	O
F26G19	O
likely	O
neutralizes	O
SARS	O
-	O
CoV	O
by	O
blocking	O
the	O
virus	O
-	O
host	O
cell	B-PROC
interaction	I-PROC
.	O

Significant	O
elevations	O
in	O
oxygen	O
saturation	O
,	O
serum	O
creatinine	O
,	O
lactate	O
dehydrogenase	O
,	O
creatine	O
kinase	O
MB	O
isoenzyme	O
,	O
and	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
),	O
but	O
not	O
in	O
alanine	O
transaminase	O
were	O
predictors	O
for	O
death	B-PROC
.	O

The	O
localization	B-PROC
of	O
ACE2	O
expression	B-PROC
in	O
the	O
endocrine	O
part	O
of	O
the	O
pancreas	O
suggests	O
that	O
SARS	O
coronavirus	O
enters	O
islets	O
using	O
ACE2	O
as	O
its	O
receptor	O
and	O
damages	O
islets	O
causing	O
acute	O
diabetes	O
.	O

In	O
addition	O
,	O
51	O
commercial	O
chicken	O
flocks	O
(	O
25	O
broilers	O
,	O
15	O
layers	O
,	O
and	O
11	O
broiler	O
breeders	O
)	O
suffering	O
from	O
respiratory	O
disease	O
were	O
tested	O
for	O
the	O
presence	O
of	O
IBV	O
,	O
using	O
the	O
reverse	O
-	O
transcription	B-PROC
polymerase	O
chain	O
reaction	O
.	O

It	O
was	O
previously	O
demonstrated	O
that	O
patients	O
with	O
activated	O
PMNs	O
in	O
the	O
lungs	O
have	O
PMNs	O
in	O
the	O
peripheral	O
circulation	B-PROC
with	O
a	O
reduced	O
active	O
FcgammaRII	O
up	O
-	O
regulating	O
capacity	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
arterial	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
VA	O
-	O
ECMO	O
)	O
is	O
a	O
cardio	O
-	O
pulmonary	O
bypass	O
technique	O
to	O
provide	O
life	O
support	O
in	O
acute	O
reversible	O
cardio	O
-	O
respiratory	O
failure	O
when	O
conventional	O
management	O
is	O
not	O
successful	O
.	O

In	O
five	O
-	O
year	O
-	O
old	O
children	O
who	O
underwent	O
VA	O
-	O
ECMO	O
therapy	O
as	O
neonates	O
,	O
we	O
assessed	O
motor	B-PROC
performance	I-PROC
related	O
to	O
growth	B-PROC
,	O
intelligence	O
and	O
behaviour	B-PROC
,	O
and	O
the	O
association	O
with	O
the	O
primary	O
diagnosis	O
.	O

ABSTRACT	O
:	O
An	O
87	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
because	O
of	O
high	O
fever	B-PROC
,	O
progressive	O
dyspnea	O
and	O
abnormal	O
shadows	O
on	O
chest	O
roentgenogram	O
.	O

It	O
is	O
usually	O
an	O
early	O
phenomenon	O
,	O
partly	O
related	O
to	O
the	O
effects	O
of	O
the	O
inflammatory	O
process	O
,	O
causing	O
retroperitoneal	O
edema	O
,	O
fluid	O
collections	O
,	O
ascites	O
,	O
and	O
ileus	O
,	O
and	O
partly	O
iatrogenic	O
,	O
resulting	O
from	O
aggressive	B-PROC
fluid	O
resuscitation	O
.	O

Toll	O
-	O
like	O
receptor	O
-	O
3	O
(	O
TLR	O
-	O
3	O
)	O
is	O
an	O
integral	O
part	O
of	O
the	O
host	O
'	O
s	O
innate	O
immune	O
system	O
and	O
serves	O
as	O
an	O
important	O
signaling	B-PROC
pathway	I-PROC
for	O
the	O
recognition	O
of	O
dsRNA	O
for	O
the	O
triggering	O
of	O
antiviral	O
and	O
inflammatory	B-PROC
responses	I-PROC
to	O
combat	O
viral	B-PROC
infections	I-PROC
.	O

The	O
United	O
States	O
TRANSCOM	O
Regulation	B-PROC
and	O
Command	O
/	O
Control	O
Evacuation	O
System	O
and	O
the	O
United	O
States	O
Army	O
Institute	O
of	O
Surgical	O
Research	O
Joint	O
Theater	O
Trauma	O
Registry	O
databases	O
were	O
reviewed	O
for	O
all	O
critical	O
patients	O
transported	O
out	O
of	O
theater	O
between	O
November	O
2005	O
and	O
March	O
2007	O
.	O

ALRT	O
patients	O
required	O
a	O
mean	O
positive	O
end	O
expiratory	B-PROC
pressure	O
of	O
19	O
.	O
0	O
cm	O
H2O	O
+/-	O

Patients	O
for	O
whom	O
ALRT	O
was	O
activated	O
had	O
significantly	O
higher	O
positive	O
end	O
expiratory	B-PROC
pressure	O
and	O
FIO2	O
than	O
those	O
transported	O
by	O
CCATT	O
.	O

HCoV	O
-	O
229E	O
is	O
a	O
proven	O
common	O
cold	B-PROC
virus	O
in	O
healthy	O
adults	O
,	O
so	O
it	O
is	O
probable	O
that	O
both	O
viruses	O
induce	O
comparable	O
symptoms	O
in	O
adults	O
,	O
even	O
though	O
their	O
mode	O
of	O
infection	O
differs	O
.	O

Using	O
a	O
novel	O
interferon	O
(	O
IFN	O
)	O
antagonism	O
screen	O
,	O
we	O
show	O
that	O
the	O
SARS	O
-	O
CoV	O
proteome	O
contains	O
several	O
replicase	O
,	O
structural	O
,	O
and	O
accessory	O
proteins	O
that	O
antagonize	O
the	O
IFN	O
pathway	B-PROC
.	O

The	O
specificity	O
of	O
the	O
SN	O
-	O
PCR	O
amplicons	O
was	O
evaluated	O
by	O
restriction	O
fragment	O
length	O
polymorphism	B-PROC
(	O
RFLP	O
)	O
analysis	O
.	O

ABSTRACT	O
:	O
In	O
the	O
search	O
for	O
effective	O
therapeutics	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
6	O
-	O
mercaptopurine	O
(	O
6MP	O
)	O
and	O
6	O
-	O
thioguanine	O
(	O
6TG	O
)	O
were	O
found	O
to	O
be	O
specific	O
inhibitors	O
for	O
the	O
SARS	O
-	O
coronavirus	O
(	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
),	O
a	O
cysteine	O
protease	O
with	O
deubiquitinating	B-PROC
and	O
deISGylating	O
activity	O
.	O

TITLE	O
:	O
Use	O
of	O
GFP	O
to	O
investigate	O
expression	B-PROC
of	O
plant	O
-	O
derived	O
vaccines	O
.	O

Such	O
analysis	O
using	O
GFP	O
that	O
precedes	O
stable	O
plant	O
transformation	B-PROC
will	O
enable	O
the	O
rapid	O
screening	O
of	O
multiple	O
constructs	O
to	O
attain	O
optimal	O
recombinant	O
protein	B-PROC
expression	B-PROC
.	O

Furthermore	O
,	O
this	O
approach	O
determines	O
the	O
subcellular	O
localization	B-PROC
of	O
the	O
recombinant	O
protein	O
in	O
plant	O
cells	O
,	O
providing	O
information	O
on	O
optimal	O
subcellular	O
targeting	B-PROC
for	O
production	O
in	O
plant	O
bioreactors	O
.	O

TITLE	O
:	O
Identification	O
of	O
viral	O
peptide	O
fragments	O
for	O
vaccine	O
development	B-PROC
.	O

Depending	O
on	O
the	O
localization	B-PROC
and	O
the	O
size	O
of	O
the	O
mediastinal	O
tumour	O
,	O
the	O
clinical	O
presentation	O
is	O
variable	O
ranging	O
from	O
a	O
complete	O
lack	O
of	O
symptoms	O
to	O
severe	O
cardiorespiratory	O
problems	O
.	O

Proper	O
anaesthetic	O
management	O
of	O
patients	O
with	O
mediastinal	O
mass	O
syndrome	O
begins	O
with	O
an	O
assessment	O
of	O
the	O
preoperative	O
status	O
,	O
directed	O
foremost	O
at	O
establishing	O
the	O
localization	B-PROC
of	O
the	O
tumour	O
and	O
on	O
the	O
basis	O
of	O
the	O
clinical	O
and	O
radiological	O
findings	O
,	O
discerning	O
whether	O
any	O
vital	O
mediastinal	O
structures	O
are	O
affected	O
.	O

We	O
report	O
the	O
first	O
antibody	B-PROC
-	O
mediated	O
Western	O
blot	O
detection	O
of	O
nsp6	O
from	O
MHV	O
-	O
infected	O
cells	O
.	O

In	O
a	O
systematic	O
review	O
of	O
the	O
literature	O
on	O
nine	O
respiratory	O
viral	B-PROC
infections	I-PROC
of	O
public	O
-	O
health	O
importance	O
,	O
we	O
identified	O
436	O
articles	O
with	O
statements	O
of	O
incubation	O
period	O
and	O
38	O
with	O
data	O
for	O
pooled	O
analysis	O
.	O

They	O
are	O
believed	O
to	O
play	O
roles	O
in	O
the	O
viral	B-PROC
life	I-PROC
cycle	I-PROC
and	O
may	O
contribute	O
to	O
the	O
pathogenesis	B-PROC
and	O
virulence	B-PROC
.	O

Despite	O
all	O
means	O
used	O
to	O
treat	O
her	O
,	O
she	O
died	B-PROC
5	O
weeks	O
after	O
rituximab	O
infusion	O
.	O

Although	O
for	O
the	O
majority	O
of	O
suggested	O
indications	O
no	O
data	O
from	O
randomized	O
controlled	O
trials	O
exist	O
,	O
a	O
surfactant	O
replacement	O
that	O
counterbalances	O
surfactant	O
inactivation	O
seems	O
to	O
improve	O
oxygenation	B-PROC
and	O
lung	B-PROC
function	I-PROC
in	O
many	O
babies	O
with	O
ARDS	O
without	O
any	O
apparent	O
negative	O
side	O
effects	O
.	O

Additionally	O
,	O
ORF	O
3b	O
contains	O
a	O
consensus	O
nuclear	B-PROC
export	I-PROC
sequence	O
,	O
and	O
we	O
demonstrate	O
that	O
nuclear	B-PROC
export	I-PROC
and	O
thus	O
mitochondrial	B-PROC
translocation	I-PROC
are	O
dependent	O
on	O
a	O
leptomycin	O
B	O
-	O
sensitive	O
nuclear	B-PROC
export	I-PROC
mechanism	O
.	O

We	O
further	O
show	O
that	O
ORF	O
3b	O
inhibits	O
induction	O
of	O
type	O
I	O
interferon	O
induced	O
by	O
retinoic	O
acid	O
-	O
induced	O
gene	O
1	O
and	O
the	O
mitochondrial	O
antiviral	O
signaling	B-PROC
protein	O
.	O

ABSTRACT	O
:	O
Host	O
responses	O
to	O
viral	B-PROC
infection	I-PROC
include	O
both	O
immune	O
activation	O
and	O
programmed	B-PROC
cell	B-PROC
death	I-PROC
.	O

Further	O
research	O
into	O
the	O
pathogenesis	B-PROC
of	O
this	O
devastating	O
condition	O
is	O
crucial	O
for	O
the	O
development	B-PROC
of	O
novel	O
and	O
specific	O
therapies	O
that	O
target	O
specific	O
disease	O
mechanisms	O
.	O

These	O
data	O
would	O
support	O
its	O
role	O
in	O
SARS	O
-	O
CoV	O
mediated	O
membrane	B-PROC
fusion	I-PROC
and	O
suggest	O
that	O
the	O
region	O
where	O
this	O
peptide	O
resides	O
could	O
be	O
involved	O
in	O
the	O
merging	O
of	O
the	O
viral	O
and	O
target	O
cell	O
membranes	O
.	O

Mice	O
that	O
died	B-PROC
also	O
showed	O
unique	O
transcriptional	B-PROC
profiles	O
of	O
immune	B-PROC
response	I-PROC
,	O
apoptosis	B-PROC
,	O
cell	B-PROC
cycle	I-PROC
control	I-PROC
,	O
and	O
stress	O
.	O

Ten	O
-	O
day	O
-	O
old	O
mice	O
pups	O
were	O
immunized	O
with	O
MAb	O
,	O
inoculated	O
with	O
the	O
10	O
(	O
5	O
)	O
tissue	O
culture	O
-	O
infective	O
dose	O
of	O
HEV	O
at	O
3	O
days	O
after	O
immunization	O
,	O
and	O
then	O
examined	O
to	O
determine	O
the	O
viral	O
inhibition	B-PROC
.	O

The	O
1	O
:	O
800	O
-	O
diluted	O
MAb120	O
inhibited	O
the	O
viral	B-PROC
infection	I-PROC
in	O
mice	O
pups	O
,	O
though	O
the	O
1	O
:	O
1	O
,	O
000	O
-	O
diluted	O
MAb120	O
failed	O
to	O
inhibit	O
the	O
viral	O
infectivity	O
.	O

To	O
confirm	O
its	O
activity	O
,	O
in	O
vitro	O
cleavage	B-PROC
reactions	O
were	O
performed	O
with	O
the	O
synthesized	O
ribozyme	O
.	O

ABSTRACT	O
:	O
Among	O
the	O
structural	O
and	O
nonstructural	O
proteins	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
plays	O
pivotal	O
roles	O
in	O
the	O
biology	O
and	O
pathogenesis	B-PROC
of	O
viral	B-PROC
infection	I-PROC
.	O

The	O
inhibition	B-PROC
on	O
pseudovirus	O
was	O
also	O
seen	O
in	O
cells	O
pretreated	O
with	O
the	O
CC	O
and	O
CC	O
/	O
Fr	O
.	O
2	O
(	O
IC	O
(	O
50S	O
),	O
283	O
.	O
4	O
+/-	O
16	O
.	O
3	O
and	O
149	O
.	O
5	O
+/-	O
13	O
.	O
5	O
microg	O
/	O
ml	O
,	O
respectively	O
),	O
however	O
the	O
highest	O
activities	O
on	O
wtSARS	O
-	O
CoV	O
were	O
observed	O
when	O
the	O
viruses	O
were	O
treated	O
by	O
the	O
extracts	O
before	O
challenging	O
(	O
IC	O
(	O
50S	O
),	O
43	O
.	O
1	O
+/-	O
2	O
.	O
8	O
and	O
7	O
.	O
8	O
+/-	O
0	O
.	O
3	O
microg	O
/	O
ml	O
;	O
SIs	O
,	O
8	O
.	O
4	O
and	O
23	O
.	O
1	O
,	O
respectively	O
).	O

The	O
pAPN	O
and	O
its	O
specific	O
antibody	B-PROC
blocked	O
transmissible	O
gastroenteritis	O
coronavirus	O
infection	O
in	O
vitro	O
.	O

TITLE	O
:	O
Coronaviruses	O
post	O
-	O
SARS	O
:	O
update	O
on	O
replication	O
and	O
pathogenesis	B-PROC
.	O

Previously	O
these	O
viruses	O
were	O
known	O
to	O
be	O
important	O
agents	O
of	O
respiratory	O
and	O
enteric	O
infections	O
of	O
domestic	O
and	O
companion	O
animals	O
and	O
to	O
cause	O
approximately	O
15	O
%	O
of	O
all	O
cases	O
of	O
the	O
common	O
cold	B-PROC
.	O

ABSTRACT	O
:	O
Since	O
the	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
2003	O
,	O
the	O
three	O
-	O
dimensional	O
structures	O
of	O
several	O
of	O
the	O
replicase	O
/	O
transcriptase	B-PROC
components	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
the	O
non	O
-	O
structural	O
proteins	O
(	O
Nsps	O
),	O
have	O
been	O
determined	O
.	O

Therefore	O
,	O
SUD	O
may	O
be	O
involved	O
in	O
controlling	O
the	O
host	O
cell	O
'	O
s	O
response	O
to	O
the	O
viral	B-PROC
infection	I-PROC
.	O

Here	O
,	O
we	O
investigated	O
whether	O
this	O
internal	O
cleavage	B-PROC
of	O
S2	O
exposes	O
a	O
viral	O
fusion	O
peptide	O
.	O

Biochemical	O
analyses	O
of	O
synthetic	O
peptides	O
corresponding	O
to	O
the	O
proposed	O
S2	O
fusion	O
peptide	O
also	O
showed	O
an	O
important	O
role	O
for	O
this	O
region	O
in	O
membrane	B-PROC
fusion	I-PROC
and	O
indicated	O
the	O
presence	O
of	O
alpha	O
-	O
helical	O
structure	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
conduct	B-PROC
fast	O
screening	O
of	O
passengers	O
with	O
infections	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
or	O
pandemic	O
influenza	O
at	O
a	O
quarantine	O
depot	O
,	O
we	O
developed	O
a	O
non	O
-	O
contact	O
screening	O
system	O
with	O
a	O
self	O
-	O
produced	O
program	O
to	O
conduct	B-PROC
a	O
human	O
screening	O
within	O
five	O
seconds	O
,	O
via	O
a	O
linear	O
discriminant	O
function	O
from	O
non	O
-	O
contact	O
derived	O
variables	O
,	O
i	O
.	O
e	O
.	O
palmer	O
pulse	B-PROC
derived	O
from	O
a	O
laser	O
Doppler	O
blood	O
-	O
flow	O
meter	O
,	O
respiration	B-PROC
rate	O
determined	O
by	O
a	O
10	O
-	O
GHz	O
microwave	O
radar	O
,	O
and	O
facial	O
temperature	O
measured	O
by	O
a	O
thermography	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
intestinal	O
mucosal	B-PROC
immune	I-PROC
responses	I-PROC
in	O
ducklings	O
orally	O
inoculated	O
with	O
attenuated	O
Duck	O
enteritis	O
virus	O
(	O
DEV	O
),	O
the	O
kinetics	O
of	O
the	O
viral	O
load	O
,	O
the	O
specific	O
humoral	B-PROC
immune	I-PROC
responses	I-PROC
,	O
and	O
the	O
distribution	O
of	O
immunoglobulin	B-PROC
(	O
Ig	O
)	O
A	O
-	O
secreting	B-PROC
cells	O
in	O
the	O
intestine	O
were	O
evaluated	O
.	O

ABSTRACT	O
:	O
Respiratory	O
tract	O
viral	B-PROC
infection	I-PROC
continues	O
to	O
be	O
among	O
the	O
most	O
common	O
reasons	O
for	O
emergency	O
department	O
visits	O
and	O
hospitalization	O
of	O
children	O
,	O
particularly	O
infants	O
younger	O
than	O
1	O
year	O
,	O
in	O
the	O
United	O
States	O
.	O

TITLE	O
:	O
Surveillance	O
of	O
human	O
papilloma	O
virus	B-PROC
infection	I-PROC
and	O
cervical	O
cancer	O
in	O
kidney	O
transplant	O
recipients	O
:	O
preliminary	O
data	O
.	O

TITLE	O
:	O
Community	O
-	O
acquired	O
respiratory	O
viral	B-PROC
infections	I-PROC
in	O
lung	O
transplant	O
recipients	O
:	O
a	O
single	O
season	O
cohort	O
study	O
.	O

ABSTRACT	O
:	O
Researchers	O
routinely	O
adopt	O
molecular	O
clock	O
assumptions	O
in	O
conducting	B-PROC
sequence	O
analyses	O
to	O
estimate	O
dates	O
for	O
viral	O
origins	O
in	O
humans	O
.	O

Patient	O
died	B-PROC
before	O
any	O
specific	O
investigation	O
of	O
malignant	O
hyperthermia	B-PROC
,	O
but	O
it	O
is	O
important	O
to	O
look	O
for	O
susceptibility	O
for	O
this	O
syndrome	O
within	O
the	O
family	O
to	O
avoid	O
potentially	O
life	O
-	O
threatening	O
anesthetic	O
events	O
.	O

Kittens	O
may	O
profit	O
from	O
vaccination	O
when	O
they	O
have	O
not	O
been	O
exposed	O
to	O
FCoV	O
(	O
eg	O
,	O
in	O
an	O
early	O
-	O
weaning	B-PROC
programme	O
),	O
particularly	O
if	O
they	O
enter	O
a	O
FCoV	O
-	O
endemic	O
environment	O
.	O

The	O
development	B-PROC
of	O
safe	O
and	O
effective	O
human	O
and	O
veterinary	O
vaccines	O
is	O
a	O
priority	O
.	O

We	O
expressed	B-PROC
results	O
quantitatively	O
as	O
antibody	B-PROC
levels	O
and	O
qualitatively	O
as	O
seroprevalence	O
relative	O
to	O
a	O
defined	O
seropositivity	O
cutoff	O
value	O
.	O

ABSTRACT	O
:	O
Severe	O
lung	O
injury	O
,	O
responsible	O
for	O
up	O
to	O
15	O
%	O
of	O
mortality	O
in	O
acute	O
necrotizing	O
pancreatitis	O
patients	O
,	O
is	O
promoted	O
by	O
neutrophil	O
(	O
PMN	B-PROC
)	O
migration	B-PROC
into	O
the	O
lung	O
.	O

Naphtol	O
-	O
AS	O
-	O
D	O
-	O
chloroacetate	O
esterase	O
staining	O
was	O
used	O
to	O
determine	O
pulmonary	O
PMN	B-PROC
infiltration	O
.	O

Upon	O
arrival	O
in	O
the	O
labour	B-PROC
triage	O
unit	O
,	O
pregnant	O
patients	O
with	O
suspected	O
and	O
probable	O
SARS	O
should	O
be	O
placed	O
in	O
a	O
negative	O
pressure	O
isolation	O
room	O
with	O
at	O
least	O
6	O
air	O
exchanges	O
per	O
hour	O
.	O

There	O
were	O
three	O
maternal	B-PROC
deaths	B-PROC
at	O
about	O
32	O
weeks	O
gestation	B-PROC
due	O
to	O
ARDS	O
.	O

This	O
study	O
examines	O
the	O
effect	O
of	O
shifting	O
childbirth	B-PROC
services	O
from	O
advanced	O
hospitals	O
(	O
i	O
.	O
e	O
.,	O
medical	O
centers	O
and	O
regional	O
hospitals	O
)	O
to	O
local	O
community	O
hospitals	O
(	O
i	O
.	O
e	O
.,	O
clinics	O
and	O
district	O
hospitals	O
).	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
impact	O
of	O
shifting	O
maternity	O
services	O
among	O
hospitals	O
of	O
different	O
levels	O
on	O
neonatal	O
mortality	O
and	O
maternal	B-PROC
deaths	B-PROC
.	O

RESULTS	O
:	O
The	O
resulting	O
database	O
contains	O
a	O
total	O
of	O
5327	O
probable	O
SARS	O
cases	O
,	O
of	O
whom	O
343	O
died	B-PROC
,	O
giving	O
a	O
case	O
fatality	O
ratio	O
(	O
CFR	O
)	O
of	O
6	O
.	O
4	O
%.	O

TITLE	O
:	O
Construction	O
of	O
plasmids	O
expressing	O
Sars	O
-	O
CoV	O
encoding	O
proteins	O
and	O
their	O
effects	O
on	O
transcription	B-PROC
of	O
hfgl2	O
prothrombinase	O
.	O

Moreover	O
,	O
studies	O
with	O
a	O
longer	O
dsDNA	O
,	O
an	O
expression	B-PROC
vector	O
involved	O
in	O
the	O
transitory	O
or	O
stable	O
expression	B-PROC
in	O
mammals	O
cells	O
,	O
pFLAG	O
-	O
CMV4	O
,	O
has	O
also	O
been	O
performed	O
.	O

During	O
steroid	O
treatment	O
,	O
a	O
gradual	O
vanishing	O
of	O
the	O
pathologic	O
laughter	O
and	O
improvement	O
of	O
the	O
motor	O
and	O
speech	B-PROC
functions	O
occurred	O
.	O

ABSTRACT	O
:	O
Vaccines	O
produced	O
in	O
plant	O
systems	O
are	O
safe	O
and	O
economical	O
;	O
however	O
,	O
the	O
extensive	O
application	O
of	O
plant	O
-	O
based	O
vaccines	O
is	O
mainly	O
hindered	O
by	O
low	O
expression	B-PROC
levels	O
of	O
heterologous	O
proteins	O
in	O
plant	O
systems	O
.	O

Prone	O
positioning	O
,	O
bronchodilators	O
,	O
inhaled	B-PROC
nitric	O
oxide	O
,	O
tight	O
glucose	O
control	O
,	O
and	O
high	O
-	O
flow	O
nasal	O
cannula	O
(	O
HFNC	O
)	O
oxygen	O
are	O
therapies	O
that	O
require	O
further	O
study	O
before	O
they	O
can	O
be	O
recommended	O
for	O
children	O
with	O
ALI	O
/	O
ARDS	O
.	O

Further	O
functional	O
analysis	O
of	O
truncated	O
M	O
proteins	O
showed	O
that	O
the	O
N	O
-	O
terminal	O
134	O
amino	O
acids	O
comprising	O
the	O
three	O
transmembrane	O
domains	O
are	O
sufficient	O
to	O
mediate	O
accumulation	O
of	O
M	O
in	O
the	O
Golgi	O
complex	O
and	O
to	O
enforce	O
recruitment	O
of	O
the	O
viral	O
spike	O
protein	O
S	O
to	O
the	O
sites	O
of	O
virus	B-PROC
assembly	I-PROC
and	O
budding	B-PROC
in	O
the	O
ERGIC	O
.	O

These	O
results	O
strongly	O
indicate	O
that	O
chGM	O
-	O
CSF	O
can	O
be	O
used	O
as	O
a	O
molecular	O
adjuvant	O
to	O
enhance	O
the	O
protective	O
immunity	B-PROC
induced	O
by	O
an	O
IBV	O
-	O
specific	O
DNA	O
vaccine	O
.	O

CONCLUSIONS	O
:	O
It	O
is	O
suggested	O
that	O
N	O
protein	O
may	O
be	O
related	O
to	O
the	O
excessive	O
secretion	B-PROC
of	O
proinflammatory	O
cytokines	O
during	O
SARS	O
-	O
CoV	O
infection	O
at	O
the	O
acute	O
phase	O
.	O

Detailed	O
time	O
course	O
experiments	O
showed	O
that	O
a	O
peptide	O
furin	O
inhibitor	O
,	O
decanoyl	O
-	O
Arg	O
-	O
Val	O
-	O
Lys	O
-	O
Arg	O
-	O
chloromethylketone	O
,	O
blocked	O
both	O
viral	O
entry	O
and	O
syncytium	B-PROC
formation	I-PROC
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
proteolysis	B-PROC
at	O
a	O
novel	O
XXXR	O
/	O
S	O
motif	O
in	O
the	O
S2	O
subunit	O
might	O
be	O
a	O
common	O
mechanism	O
for	O
the	O
entry	O
of	O
CoV	O
into	O
cells	O
.	O

Despite	O
the	O
identification	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
as	O
the	O
etiologic	O
agent	O
of	O
SARS	O
,	O
a	O
thorough	O
understanding	O
of	O
the	O
underlying	O
disease	O
pathogenesis	B-PROC
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
a	O
suitable	O
animal	O
model	O
that	O
recapitulates	O
the	O
human	O
disease	O
.	O

ABSTRACT	O
:	O
3	O
-	O
Chlorobenzofuran	O
-	O
2	O
-	O
carbaldehyde	O
was	O
condensed	B-PROC
with	O
substituted	O
acetophenone	O
by	O
using	O
the	O
Claisen	O
-	O
Schmidt	O
condensation	O
to	O
obtain	O
3	O
-(	O
3	O
-	O
chlorobenzofuran	O
-	O
2	O
-	O
yl	O
)-	O
1	O
-(	O
substituted	O
phenyl	O
)-	O
2	O
-	O
propen	O
-	O
1	O
-	O
one	O
(	O
2a	O
-	O
m	O
)	O
which	O
upon	O
further	O
treatment	O
with	O
hydrazine	O
hydrate	O
gave	O
2	O
-[	O
3	O
-(	O
substituted	O
phenyl	O
)-	O
4	O
,	O
5	O
-	O
dihydro	O
-	O
1H	O
-	O
5	O
-	O
pyrazolyl	O
)	O
benzofuran	O
-	O
3	O
-	O
yl	O
chloride	O
derivatives	O
(	O
3a	O
-	O
m	O
).	O

Clinical	O
illnesses	O
observed	O
in	O
this	O
study	O
were	O
lengthier	O
than	O
those	O
reported	O
16	O
-	O
20	O
years	O
ago	O
,	O
based	O
on	O
fatal	O
disease	O
onset	O
,	O
treatment	O
interval	O
,	O
and	O
day	O
of	O
death	B-PROC
.	O

Twelve	O
patients	O
required	O
mechanical	O
ventilation	O
,	O
and	O
seven	O
died	B-PROC
.	O

The	O
legs	O
were	O
intact	O
with	O
brisk	O
reflexes	B-PROC
.	O

Interestingly	O
,	O
when	O
the	O
genomic	O
RNAs	O
were	O
delivered	O
directly	O
into	O
the	O
cells	O
via	O
transfection	B-PROC
,	O
the	O
levels	O
of	O
gene	B-PROC
expression	I-PROC
for	O
these	O
viruses	O
were	O
similar	O
.	O

However	O
,	O
the	O
severity	O
of	O
MHV	O
-	O
1	O
-	O
induced	O
pulmonary	O
disease	O
varies	O
among	O
mouse	O
strains	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
differences	O
in	O
the	O
host	O
immune	B-PROC
response	I-PROC
might	O
account	O
for	O
this	O
variation	O
.	O

TITLE	O
:	O
Acquisition	O
of	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
activity	O
by	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
in	O
spike	O
protein	O
determines	O
the	O
infectivity	O
of	O
a	O
coronavirus	O
in	O
cultured	O
cells	O
.	O

By	O
construction	O
of	O
chimeric	O
S	O
constructs	O
and	O
site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
,	O
a	O
point	B-PROC
mutation	I-PROC
(	O
L857	O
-	O
F	O
)	O
at	O
amino	O
acid	O
position	O
857	O
in	O
the	O
heptad	O
repeat	O
1	O
region	O
of	O
S	O
protein	O
was	O
shown	O
to	O
be	O
responsible	O
for	O
its	O
acquisition	O
of	O
the	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
activity	O
.	O

ABSTRACT	O
:	O
Attenuated	O
Salmonella	O
typhimurium	O
was	O
selected	O
as	O
a	O
transgenic	O
vehicle	O
for	O
the	O
development	B-PROC
of	O
live	O
mucosal	O
vaccines	O
against	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
).	O

Moreover	O
,	O
the	O
immunogenicity	O
of	O
the	O
DNA	O
vaccine	O
was	O
highly	O
dependent	O
on	O
the	O
dosage	O
of	O
the	O
attenuated	O
bacteria	O
used	O
for	O
oral	O
administration	O
,	O
10	O
(	O
9	O
)	O
CFU	O
dosage	O
group	O
showed	O
higher	O
antibody	B-PROC
response	I-PROC
than	O
10	O
(	O
8	O
)	O
CFU	O
and	O
10	O
(	O
7	O
)	O
CFU	O
dosages	O
groups	O
during	O
week	O
4	O
-	O
8	O
post	O
-	O
immunization	O
.	O

TITLE	O
:	O
The	O
protective	O
immune	B-PROC
response	I-PROC
against	O
infectious	O
bronchitis	O
virus	O
induced	O
by	O
multi	O
-	O
epitope	O
based	O
peptide	O
vaccines	O
.	O

Mutations	O
,	O
insertions	O
,	O
deletions	O
and	O
recombination	B-PROC
of	O
the	O
S1	O
protein	O
gene	O
contribute	O
to	O
the	O
genetic	O
diversity	O
of	O
IBV	O
in	O
China	O
.	O

Cocirculation	O
of	O
multiple	O
types	O
of	O
IBV	O
in	O
field	O
conditions	O
in	O
China	O
renders	O
its	O
epidemiology	O
and	O
evolution	B-PROC
very	O
complicated	O
,	O
indicating	O
the	O
necessity	O
for	O
development	B-PROC
of	O
new	O
vaccines	O
or	O
vaccine	O
strategies	O
.	O

Outcome	O
measures	O
included	O
the	O
occurrence	O
of	O
postoperative	O
infectious	O
complications	O
,	O
failure	O
of	O
primary	O
abdominal	O
wall	O
fascial	O
closure	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
acute	O
renal	O
insufficiency	O
,	O
multiple	O
system	O
organ	O
failure	O
,	O
days	O
of	O
ventilator	O
support	O
,	O
hospital	O
length	O
of	O
stay	O
,	O
and	O
death	B-PROC
.	O

It	O
is	O
possible	O
that	O
the	O
improved	O
outcomes	O
seen	O
in	O
the	O
group	O
undergoing	O
splenectomy	O
were	O
due	O
to	O
favorable	O
modulation	O
of	O
the	O
human	O
innate	O
immune	O
inflammatory	B-PROC
response	I-PROC
after	O
trauma	O
.	O

Results	O
Clinical	O
diagnoses	O
of	O
10	O
cases	O
were	O
respiratory	O
tract	O
infection	O
(	O
n	O
=	O
6	O
),	O
septic	O
shock	O
(	O
n	O
=	O
2	O
),	O
acute	O
esophagitis	O
(	O
n	O
=	O
1	O
),	O
and	O
undefined	O
causes	O
(	O
n	O
=	O
1	O
),	O
and	O
the	O
quickly	O
aggravating	O
conditions	O
resulted	O
in	O
death	B-PROC
ultimately	O
.	O

Three	O
patients	O
died	B-PROC
.	O

To	O
date	O
there	O
is	O
no	O
treatment	O
targeted	B-PROC
directly	O
to	O
the	O
lung	O
microvasculature	B-PROC
.	O

Here	O
,	O
we	O
show	O
that	O
pretreatment	O
of	O
non	O
-	O
lymphatic	O
cells	O
with	O
small	O
amounts	O
of	O
IFN	O
-	O
alpha	O
(	O
IFN	O
priming	O
)	O
partially	O
overturns	O
the	O
block	O
in	O
IFN	O
induction	O
imposed	O
by	O
SARS	O
-	O
CoV	O
.	O
IFN	O
priming	O
combined	O
with	O
SARS	O
-	O
CoV	O
infection	O
substantially	O
induced	O
genes	O
for	O
IFN	O
induction	O
,	O
IFN	O
signalling	B-PROC
,	O
antiviral	O
effector	O
proteins	O
,	O
ubiquitination	B-PROC
and	O
ISGylation	O
,	O
antigen	B-PROC
presentation	I-PROC
and	O
other	O
cytokines	O
and	O
chemokines	O
,	O
whereas	O
each	O
individual	O
treatment	O
had	O
no	O
major	O
effect	O
.	O

A	O
HeLa	O
cell	O
line	O
stably	O
expressing	O
rdACE2	O
was	O
established	O
;	O
Western	O
blot	O
analyses	O
and	O
an	O
enzyme	O
-	O
activity	O
assay	O
indicated	O
that	O
the	O
cell	O
line	O
expressed	B-PROC
ACE2	O
at	O
a	O
similar	O
level	O
to	O
two	O
previously	O
established	O
cell	O
lines	O
that	O
express	O
ACE2	O
from	O
human	O
and	O
masked	O
palm	O
civet	O
,	O
respectively	O
.	O

Treatment	O
of	O
mice	O
with	O
anti	O
-	O
CXCL10	O
neutralizing	O
antibody	B-PROC
results	O
in	O
limited	O
CD4	O
+	O
T	O
cell	O
infiltration	O
into	O
the	O
CNS	O
accompanied	O
by	O
a	O
reduction	O
in	O
white	O
matter	O
damage	O
.	O

The	O
current	O
study	O
determines	O
the	O
antigen	O
-	O
specificity	O
of	O
the	O
T	O
lymphocytes	O
present	O
during	O
chronic	O
disease	O
and	O
evaluates	O
how	O
blocking	O
CXCL10	O
signaling	B-PROC
affects	O
retention	B-PROC
of	O
virus	O
-	O
specific	O
T	O
cells	O
within	O
the	O
CNS	O
.	O

ABSTRACT	O
:	O
The	O
understanding	O
of	O
innate	O
immune	B-PROC
modulation	I-PROC
by	O
pathogens	O
and	O
immune	O
-	O
modulating	O
agents	O
,	O
including	O
synthetic	O
oligodeoxynucleotides	O
(	O
CpG	O
ODNs	O
),	O
has	O
offered	O
several	O
new	O
approaches	O
to	O
improve	O
prophylactic	O
and	O
therapeutic	O
strategies	O
against	O
infectious	O
diseases	O
in	O
humans	O
and	O
animals	O
.	O

Mortality	O
rates	O
for	O
each	O
severe	O
complication	O
were	O
as	O
follows	O
:	O
acute	O
respiratory	O
distress	O
syndrome	O
27	O
.	O
3	O
%	O
(	O
3	O
of	O
11	O
);	O
renal	O
failure	O
33	O
.	O
3	O
%	O
(	O
2	O
of	O
6	O
);	O
disseminated	O
intravascular	O
coagulation	B-PROC
33	O
.	O
3	O
%	O
(	O
2	O
of	O
6	O
);	O
severe	O
sepsis	O
0	O
%	O
(	O
0	O
of	O
1	O
);	O
septic	O
shock	O
/	O
MODS	O
66	O
.	O
7	O
%	O
(	O
2	O
of	O
3	O
);	O
interstitial	O
pneumonia	O
/	O
pulmonary	O
fibrosis	O
50	O
%	O
(	O
2	O
of	O
4	O
).	O

During	O
treatment	O
,	O
sudden	O
fever	B-PROC
,	O
hypoxemia	O
and	O
chest	O
radiography	O
-	O
confirmed	O
interstitial	O
shadows	O
throughout	O
the	O
lung	O
fields	O
were	O
noted	O
,	O
and	O
the	O
patient	O
was	O
referred	O
to	O
the	O
Department	O
of	O
Internal	O
Medicine	O
.	O

TITLE	O
:	O
Simultaneous	O
detection	O
of	O
respiratory	O
viruses	O
in	O
children	O
with	O
acute	O
respiratory	O
infection	O
using	O
two	O
different	O
multiplex	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
assays	O
.	O

In	O
chronic	O
respiratory	O
disease	O
(	O
CRD	O
)	O
PH	O
is	O
""""	O
pre	O
-	O
capillary	O
","""	O
due	O
to	O
an	O
increase	O
of	O
pulmonary	B-PROC
vascular	I-PROC
resistance	I-PROC
(	O
PVR	O
).	O

It	O
was	O
also	O
shown	O
that	O
the	O
""""	O
open	O
-	O
lung	O
""""	O
strategy	O
chosen	O
was	O
associated	O
with	O
sustained	O
improvements	O
in	O
oxygenation	B-PROC
,	O
even	O
though	O
VTs	O
were	O
minimized	O
.	O

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
describe	O
the	O
clinical	O
signs	O
,	O
pathogenesis	B-PROC
,	O
diagnosis	O
and	O
treatment	O
of	O
the	O
different	O
NTPE	O
subtypes	O
.	O

The	O
complex	O
and	O
diverse	O
pathogenesis	B-PROC
of	O
different	O
subtypes	O
of	O
emboli	O
is	O
subject	O
to	O
continuing	O
speculation	O
and	O
is	O
certainly	O
far	O
more	O
complex	O
than	O
""""	O
simple	O
""""	O
mechanical	O
obstruction	O
after	O
embolisation	O
of	O
vascular	O
thrombi	O
.	O

The	O
gene	O
that	O
encodes	O
a	O
double	O
-	O
mutant	O
IBV	O
nsp2	O
N	O
-	O
terminal	O
domain	O
(	O
residues	O
9	O
-	O
393	O
of	O
the	O
polyprotein	O
,	O
with	O
mutations	O
Q132L	O
and	O
L270F	O
)	O
was	O
cloned	O
and	O
expressed	B-PROC
in	O
Escherichia	O
coli	O
and	O
the	O
protein	O
was	O
subjected	O
to	O
crystallization	O
trials	O
.	O

The	O
virus	B-PROC
neutralization	I-PROC
(	O
VN	O
)	O
activity	O
with	O
vaccine	O
immunized	O
serum	O
was	O
investigated	O
to	O
evaluate	O
the	O
protective	O
effects	O
of	O
vaccines	O
against	O
Japanese	O
field	O
isolates	O
.	O

We	O
compared	O
three	O
ventilatory	O
strategies	O
,	O
each	O
used	O
for	O
1	O
h	O
,	O
with	O
P	O
(	O
plat	O
)	O
at	O
22	O
(	O
20	O
-	O
25	O
)	O
cmH	O
(	O
2	O
)	O
O	O
:	O
low	O
PEEP	O
(	O
5	O
.	O
4	O
cmH	O
(	O
2	O
)	O
O	O
)	O
or	O
high	O
PEEP	O
(	O
11	O
.	O
0	O
cmH	O
(	O
2	O
)	O
O	O
)	O
with	O
compensation	B-PROC
of	O
the	O
tidal	O
volume	O
reduction	O
by	O
either	O
a	O
high	O
respiratory	O
rate	O
(	O
high	O
PEEP	O
/	O
high	O
rate	O
)	O
or	O
instrumental	O
dead	B-PROC
space	O
decrease	O
(	O
high	O
PEEP	O
/	O
low	O
rate	O
).	O

An	O
innate	O
immunosuppressive	O
respiratory	O
virus	B-PROC
infection	I-PROC
was	O
established	O
by	O
infecting	O
weaned	B-PROC
pigs	O
with	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
);	O
10	O
days	O
later	O
,	O
the	O
pigs	O
were	O
exposed	O
to	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
).	O

Significant	O
suppression	B-PROC
of	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
[	O
reduced	O
alpha	O
interferon	O
(	O
IFN	O
-	O
alpha	O
)	O
levels	O
in	O
the	O
lungs	O
and	O
reduced	O
blood	O
natural	O
killer	O
cell	O
cytotoxicity	O
]	O
by	O
the	O
ongoing	O
PRRSV	O
infection	O
was	O
observed	O
in	O
dual	O
-	O
infected	O
pigs	O
,	O
which	O
coincided	O
with	O
exacerbated	O
pneumonia	O
during	O
early	O
PRCV	O
infection	O
.	O

Multivariate	O
modeling	O
revealed	O
no	O
statistical	O
difference	O
in	O
elevated	O
antibody	B-PROC
titers	O
against	O
HEV	O
between	O
the	O
two	O
groups	O
.	O

This	O
review	O
is	O
focused	O
on	O
members	O
of	O
the	O
GBF	O
/	O
Gea	O
and	O
BIG	O
/	O
Sec7	O
subfamilies	O
of	O
Arf	O
GEFs	O
,	O
all	O
of	O
which	O
use	O
the	O
class	O
I	O
Arf	O
proteins	O
(	O
Arf1	O
-	O
3	O
)	O
as	O
substrates	O
,	O
and	O
play	O
a	O
fundamental	O
role	O
in	O
trafficking	B-PROC
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)-	O
Golgi	O
and	O
endosomal	O
membrane	O
systems	O
.	O

Case	O
2	O
received	O
albendazole	O
and	O
antibiotic	O
treatment	O
for	O
over	O
2	O
weeks	O
,	O
but	O
developed	O
refractory	O
aseptic	O
meningitis	O
and	O
died	B-PROC
of	O
septic	O
shock	O
.	O

This	O
VASP	O
repression	O
results	O
in	O
increased	O
paracellular	O
permeability	O
and	O
migration	B-PROC
of	O
neutrophils	O
in	O
vitro	O
.	O

The	O
mechanism	O
of	O
axonal	O
loss	O
and	O
demyelination	O
in	O
MHV	O
infection	O
is	O
dependent	O
on	O
successful	O
transport	B-PROC
of	O
virus	O
from	O
gray	O
matter	O
to	O
white	O
matter	O
using	O
the	O
MHV	O
host	O
attachment	O
spike	O
glycoprotein	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
20	O
-	O
year	O
-	O
old	O
male	O
who	O
suffered	O
smoke	O
inhalation	B-PROC
injury	O
and	O
burns	O
covering	O
26	O
%	O
of	O
his	O
TBSA	O
,	O
including	O
his	O
face	O
,	O
dorsal	O
chest	O
,	O
and	O
both	O
the	O
arms	O
.	O

ABSTRACT	O
:	O
The	O
extent	O
to	O
which	O
self	O
-	O
adopted	O
or	O
intervention	O
-	O
related	O
changes	O
in	O
behaviors	B-PROC
affect	O
the	O
course	O
of	O
epidemics	O
remains	O
a	O
key	O
issue	O
for	O
outbreak	O
control	O
.	O

In	O
particular	O
,	O
estimates	O
of	O
daily	O
reproduction	B-PROC
numbers	O
were	O
provided	O
for	O
each	O
subpopulation	O
.	O

This	O
observation	O
suggests	O
that	O
public	O
health	O
measures	O
and	O
possible	O
changes	O
in	O
individual	O
behaviors	B-PROC
effectively	O
reduced	O
transmission	O
,	O
especially	O
in	O
hospitals	O
.	O

Compared	O
to	O
traditional	O
in	O
-	O
class	O
continuing	O
education	O
,	O
a	O
web	O
-	O
based	O
learning	B-PROC
system	O
is	O
efficient	O
for	O
nurses	O
with	O
a	O
three	O
shift	O
-	O
working	O
schedule	O
and	O
is	O
timely	O
to	O
deliver	O
knowledge	O
about	O
newly	O
emerging	O
epidemics	O
such	O
as	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
.	O

The	O
research	O
results	O
show	O
that	O
all	O
indicators	O
of	O
the	O
instrument	O
provide	O
a	O
fit	O
to	O
the	O
quality	O
measurement	O
of	O
a	O
web	O
-	O
based	O
learning	B-PROC
system	O
and	O
have	O
high	O
reliability	O
and	O
validity	O
.	O

Liposome	O
-	O
binding	O
assays	O
indicate	O
that	O
the	O
receptor	O
-	O
bound	O
virions	O
are	O
associated	O
with	O
the	O
target	O
membrane	O
through	O
hydrophobic	B-PROC
interactions	I-PROC
.	O

ABSTRACT	O
:	O
There	O
is	O
a	O
need	O
for	O
biomarkers	O
insuring	O
identification	O
of	O
septic	O
patients	O
at	O
high	O
-	O
risk	O
for	O
death	B-PROC
.	O

ABSTRACT	O
:	O
Cats	O
infected	O
with	O
virulent	O
feline	O
coronavirus	O
which	O
causes	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
usually	O
succumb	O
to	O
disease	O
despite	O
high	O
antibody	B-PROC
concentrations	O
.	O

ADCML	O
consists	O
of	O
virus	O
-	O
specific	O
antibodies	O
that	O
bind	O
to	O
cell	O
surface	O
expressed	B-PROC
viral	O
proteins	O
which	O
result	O
in	O
complement	B-PROC
activation	I-PROC
and	O
cell	O
lysis	B-PROC
.	O

This	O
new	O
evasion	O
strategy	O
is	O
not	O
attributed	O
to	O
the	O
group	O
-	O
specific	O
proteins	O
since	O
lysis	B-PROC
of	O
cells	O
infected	O
with	O
FIPV	O
Delta	O
3abc	O
/	O
Delta	O
7ab	O
was	O
not	O
detected	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
ligand	B-PROC
and	O
substrate	O
recognition	O
by	O
torovirus	O
hemagglutinin	O
esterases	O
.	O

Stroke	O
volume	O
variation	O
and	O
pulse	B-PROC
pressure	I-PROC
variation	O
related	O
to	O
changes	O
in	O
stroke	O
volume	O
during	O
positive	O
pressure	O
ventilation	O
predict	O
fluid	O
responsiveness	O
and	O
represent	O
an	O
evolving	O
practice	O
for	O
volume	O
management	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
or	O
operating	O
room	O
.	O

After	O
hybridization	B-PROC
,	O
the	O
microarrays	O
were	O
scanned	O
,	O
and	O
the	O
hybridization	B-PROC
pattern	O
agreed	O
perfectly	O
with	O
the	O
known	O
location	O
of	O
each	O
probe	O
.	O

Carcinoembryonic	O
cell	B-PROC
adhesion	I-PROC
antigen	O
1a	O
(	O
CEACAM1a	O
)	O
is	O
the	O
specific	O
receptor	O
for	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
a	O
coronavirus	O
known	O
to	O
induce	O
acute	O
viral	O
hepatitis	O
in	O
mice	O
.	O

TITLE	O
:	O
A	O
synergistic	O
interferon	B-PROC
-	I-PROC
gamma	I-PROC
production	I-PROC
is	O
induced	O
by	O
mouse	O
hepatitis	O
virus	O
in	O
interleukin	O
-	O
12	O
(	O
IL	O
-	O
12	O
)/	O
IL	O
-	O
18	O
-	O
activated	O
natural	O
killer	O
cells	O
and	O
modulated	O
by	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	B-PROC
adhesion	I-PROC
molecules	O
(	O
CEACAM	O
)	O
1a	O
receptor	O
.	O

The	O
messages	O
give	O
voice	B-PROC
to	O
the	O
Chinese	O
nursing	B-PROC
experience	O
and	O
when	O
synthesised	O
with	O
reports	O
from	O
other	O
international	O
nurses	O
,	O
they	O
enable	O
specific	O
direction	O
to	O
enhance	O
potential	O
for	O
a	O
well	O
-	O
prepared	O
nursing	B-PROC
workforce	O
and	O
quality	O
patient	O
care	O
in	O
future	O
epidemics	O
.	O

These	O
data	O
strongly	O
suggest	O
that	O
a	O
mixture	O
containing	O
antibodies	O
recognizing	O
distinct	O
regions	O
and	O
targeting	B-PROC
more	O
than	O
one	O
step	O
in	O
viral	O
entry	O
is	O
likely	O
to	O
be	O
more	O
effective	O
in	O
neutralizing	O
the	O
virus	O
and	O
suppressing	O
the	O
generation	O
of	O
escape	O
mutants	O
,	O
and	O
thus	O
potentially	O
constitute	O
a	O
highly	O
effective	O
passive	O
immunotherapy	O
.	O

These	O
studies	O
suggest	O
that	O
SL2	O
functions	O
as	O
an	O
important	O
,	O
but	O
rather	O
plastic	O
,	O
structural	O
element	O
in	O
stimulating	O
subgenomic	O
RNA	B-PROC
synthesis	I-PROC
in	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
clinical	O
and	O
treatment	O
factors	O
for	O
patients	O
recorded	O
in	O
the	O
Extracorporeal	O
Life	O
Support	O
Organization	O
(	O
ELSO	O
)	O
registry	O
and	O
survival	O
of	O
adult	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
respiratory	O
failure	O
patients	O
.	O

Treatment	O
with	O
PCN	O
significantly	O
increased	O
survival	O
and	O
was	O
marked	O
by	O
enhanced	O
viral	O
clearance	O
,	O
accelerated	O
induction	O
of	O
viral	O
-	O
specific	O
antibody	B-PROC
production	I-PROC
,	O
and	O
significant	O
decreases	O
in	O
morbidity	O
and	O
lung	O
damage	O
.	O

Inhibition	B-PROC
of	O
the	O
PP1	O
activity	O
by	O
okadaic	O
acid	O
and	O
overexpression	B-PROC
of	O
GADD34	O
,	O
eIF	O
-	O
2alpha	O
,	O
and	O
PKR	O
,	O
as	O
well	O
as	O
their	O
mutant	O
constructs	O
in	O
virus	O
-	O
infected	O
cells	O
,	O
showed	O
that	O
these	O
viral	O
regulatory	O
strategies	O
played	O
a	O
synergistic	O
role	O
in	O
facilitating	O
coronavirus	O
replication	O
.	O

Further	O
efforts	O
targeting	B-PROC
prevention	O
of	O
these	O
complications	O
are	O
warranted	O
.	O

We	O
propose	O
that	O
the	O
helix	O
melting	O
activity	O
of	O
the	O
coronavirus	O
N	O
protein	O
NTD	O
plays	O
a	O
critical	O
accessory	O
role	O
in	O
subgenomic	O
RNA	B-PROC
synthesis	I-PROC
and	O
other	O
processes	O
requiring	O
RNA	O
remodeling	O
.	O

Four	O
patients	O
(	O
8	O
.	O
2	O
%)	O
in	O
the	O
conservative	O
therapy	O
group	O
died	B-PROC
,	O
five	O
patients	O
(	O
31	O
.	O
3	O
%)	O
in	O
surgery	O
group	O
with	O
a	O
CTSI	O
>	O
8	O
.	O
0	O
died	B-PROC
,	O
and	O
all	O
patients	O
in	O
the	O
PCD	B-PROC
group	O
survived	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
clinical	O
features	O
and	O
treatment	O
strategy	O
of	O
human	O
influenza	O
A	O
(	O
H5N1	O
)	O
virus	B-PROC
infection	I-PROC
.	O

A	O
/	O
H5N1	O
nucleic	O
acid	O
was	O
detected	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
reverse	O
-	O
transcription	B-PROC
polymerase	O
chain	O
reaction	O
in	O
a	O
nasopharyngeal	O
aspirate	O
.	O

The	O
prominent	O
clinical	O
features	O
included	O
fever	B-PROC
,	O
cough	O
and	O
dyspnea	O
.	O

ABSTRACT	O
:	O
Nitric	O
oxide	O
is	O
an	O
important	O
molecule	O
playing	O
a	O
key	O
role	O
in	O
a	O
broad	O
range	O
of	O
biological	B-PROC
process	I-PROC
such	O
as	O
neurotransmission	B-PROC
,	O
vasodilatation	B-PROC
and	O
immune	B-PROC
responses	I-PROC
.	O

Secondly	O
,	O
NO	O
or	O
its	O
derivatives	O
cause	O
a	O
reduction	O
in	O
viral	O
RNA	O
production	O
in	O
the	O
early	O
steps	O
of	O
viral	B-PROC
replication	I-PROC
,	O
and	O
this	O
could	O
possibly	O
be	O
due	O
to	O
an	O
effect	O
on	O
one	O
or	O
both	O
of	O
the	O
cysteine	O
proteases	O
encoded	O
in	O
Orf1a	O
of	O
SARS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
In	O
a	O
patient	O
with	O
acute	O
respiratory	O
illness	O
(	O
cough	O
,	O
sputum	B-PROC
production	I-PROC
,	O
chest	O
pain	O
,	O
and	O
/	O
or	O
dyspnea	O
),	O
the	O
need	O
for	O
chest	O
imaging	O
depends	O
on	O
the	O
severity	O
of	O
illness	O
,	O
age	O
of	O
the	O
patient	O
,	O
clinical	O
history	O
,	O
physical	O
and	O
laboratory	O
findings	O
,	O
and	O
other	O
risk	O
factors	O
.	O

To	O
obtain	O
additional	O
insights	O
into	O
the	O
S	O
-	O
mediated	O
membrane	B-PROC
fusion	I-PROC
process	O
,	O
we	O
focused	O
on	O
these	O
acylated	O
carboxyl	O
-	O
terminal	O
intravirion	O
tails	O
.	O

ABSTRACT	O
:	O
In	O
some	O
cases	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
hypoxemia	O
occurs	O
despite	O
optimized	O
conservative	O
therapy	O
;	O
however	O
,	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
can	O
assure	O
sufficient	O
gas	O
exchange	O
.	O

H5N1	O
virus	B-PROC
infection	I-PROC
was	O
also	O
associated	O
with	O
an	O
elevated	O
rate	O
of	O
cell	B-PROC
death	I-PROC
.	O

Reverse	O
genetics	O
analyses	O
demonstrated	O
a	O
major	O
role	O
for	O
the	O
viral	O
hemagglutinin	O
in	O
this	O
cell	O
tropism	B-PROC
.	O

In	O
all	O
three	O
hospitals	O
the	O
epidemics	O
were	O
rapidly	O
controlled	O
,	O
bringing	O
the	O
reproduction	B-PROC
number	O
below	O
one	O
within	O
25	O
,	O
10	O
and	O
5	O
days	O
respectively	O
.	O

Analysis	O
of	O
the	O
chimaeric	O
virus	O
showed	O
that	O
it	O
was	O
avirulent	O
indicating	O
that	O
none	O
of	O
the	O
structural	O
or	O
accessory	O
genes	O
derived	O
from	O
a	O
virulent	O
isolate	O
of	O
IBV	O
were	O
able	O
to	O
restore	O
virulence	B-PROC
and	O
that	O
therefore	O
,	O
the	O
loss	O
of	O
virulence	B-PROC
associated	O
with	O
the	O
Beaudette	O
strain	O
resides	O
in	O
the	O
replicase	O
gene	O
.	O

The	O
dynamic	O
properties	O
of	O
the	O
different	O
states	O
,	O
which	O
are	O
stabilized	O
under	O
different	O
experimental	O
conditions	O
,	O
extend	O
the	O
current	O
model	O
of	O
viral	O
membrane	B-PROC
fusion	I-PROC
and	O
give	O
insight	O
into	O
the	O
design	O
of	O
structure	O
-	O
based	O
antagonists	O
of	O
SARS	O
-	O
CoV	O
in	O
particular	O
,	O
as	O
well	O
as	O
other	O
enveloped	O
viruses	O
such	O
as	O
HIV	O
.	O

TITLE	O
:	O
Hemocompatibility	O
of	O
a	O
miniaturized	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
and	O
a	O
pumpless	O
interventional	O
lung	O
assist	O
in	O
experimental	O
lung	O
injury	O
.	O

By	O
60	O
days	O
,	O
24	O
patients	O
had	O
died	B-PROC
(	O
41	O
.	O
4	O
%;	O
95	O
%	O
confidence	O
interval	O
,	O
28	O
.	O
9	O
%-	O
55	O
.	O
0	O
%).	O

Patients	O
who	O
died	B-PROC
had	O
greater	O
initial	O
severity	O
of	O
illness	O
,	O
worse	O
hypoxemia	O
,	O
higher	O
creatine	O
kinase	O
levels	O
,	O
higher	O
creatinine	O
levels	O
,	O
and	O
ongoing	O
organ	O
dysfunction	O
.	O

After	O
adjusting	O
for	O
a	O
reduced	O
opportunity	O
of	O
patients	O
dying	B-PROC
early	O
to	O
receive	O
neuraminidase	B-PROC
inhibitors	I-PROC
,	O
neuraminidase	O
inhibitor	O
treatment	O
(	O
vs	O
no	O
treatment	O
)	O
was	O
associated	O
with	O
improved	O
survival	O
(	O
odds	O
ratio	O
,	O
8	O
.	O
5	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
2	O
-	O
62	O
.	O
8	O
).	O

TITLE	O
:	O
Early	O
extracorporeal	O
life	O
support	O
as	O
rescue	O
therapy	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
inhalation	B-PROC
injury	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
22	O
-	O
year	O
-	O
old	O
man	O
with	O
Down	O
syndrome	O
who	O
presented	O
with	O
isolated	O
fire	O
-	O
induced	O
smoke	O
inhalation	B-PROC
injury	O
.	O

There	O
were	O
insufficient	O
good	O
quality	O
data	O
to	O
address	O
the	O
relationship	O
between	O
breastfeeding	B-PROC
and	O
cardiovascular	O
diseases	O
and	O
infant	O
mortality	O
.	O

Early	O
cessation	O
of	O
breastfeeding	B-PROC
or	O
no	O
breastfeeding	B-PROC
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
maternal	O
postpartum	O
depression	O
.	O

Future	O
research	O
would	O
benefit	O
from	O
clearer	O
selection	O
criteria	O
,	O
definitions	O
of	O
breastfeeding	B-PROC
exposure	O
,	O
and	O
adjustment	O
for	O
potential	O
confounders	O
.	O

We	O
report	O
on	O
a	O
75	O
-	O
year	O
-	O
old	O
patient	O
with	O
long	O
-	O
lasting	O
hepatitis	O
C	O
virus	B-PROC
infection	I-PROC
[	O
18	O
years	O
],	O
a	O
long	O
-	O
lasting	O
cryoglobulinemia	O
[	O
7	O
years	O
]	O
resistant	O
to	O
common	O
antiviral	O
therapy	O
,	O
diabetes	O
mellitus	O
and	O
deep	O
skin	O
ulcers	O
,	O
successfully	O
treated	O
with	O
the	O
combination	O
therapy	O
of	O
Rituximab	O
and	O
plasma	O
exchange	O
.	O

Lowering	O
of	O
body	O
temperature	O
,	O
however	O
,	O
may	O
be	O
a	O
major	O
clinical	O
problem	O
because	O
hyperthermia	B-PROC
in	O
neuroleptic	O
malignant	O
syndrome	O
is	O
typically	O
unresponsive	O
to	O
antipyretic	O
agents	O
while	O
manual	O
cooling	O
proves	O
difficult	O
due	O
to	O
peripheral	O
vasoconstriction	B-PROC
.	O

The	O
prolonged	O
immunosuppression	B-PROC
following	O
specific	O
treatment	O
may	O
be	O
associated	O
with	O
a	O
high	O
risk	O
of	O
developing	O
severe	O
infections	O
.	O

While	O
still	O
on	O
steroid	O
therapy	O
,	O
the	O
patient	O
developed	O
an	O
interstitial	O
pneumonia	O
with	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
,	O
which	O
required	O
immediate	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
where	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
therapy	O
was	O
administered	O
continuously	O
for	O
37	O
days	O
.	O

This	O
case	O
shows	O
that	O
aggressive	B-PROC
combined	O
immunosuppressive	O
therapy	O
may	O
lead	O
to	O
a	O
sustained	O
complete	O
remission	O
in	O
children	O
with	O
refractory	O
autoimmune	O
hemolytic	O
anemia	O
.	O

However	O
,	O
the	O
severe	O
life	O
-	O
threatening	O
complication	O
presented	O
by	O
our	O
patient	O
indicates	O
that	O
strict	O
clinical	O
monitoring	O
must	O
be	O
vigilantly	O
performed	O
,	O
that	O
antimicrobial	O
prophylaxis	O
should	O
always	O
be	O
considered	O
and	O
that	O
experienced	O
medical	O
and	O
nursing	B-PROC
staff	O
must	O
be	O
available	O
,	O
to	O
deliver	O
highly	O
specialized	O
supportive	O
salvage	O
therapies	O
,	O
if	O
necessary	O
,	O
during	O
intensive	O
care	O
monitoring	O
.	O

Furthermore	O
,	O
we	O
focus	O
on	O
MAS	O
-	O
related	O
apoptotic	B-PROC
cell	B-PROC
death	I-PROC
,	O
causing	O
severe	O
acute	O
lung	O
injury	O
due	O
to	O
damage	O
and	O
detachment	O
of	O
lung	O
airway	O
and	O
alveolar	O
cells	O
.	O

TITLE	O
:	O
Reverse	B-PROC
transcription	B-PROC
loop	O
-	O
mediated	O
isothermal	O
amplification	O
for	O
the	O
rapid	O
detection	O
of	O
infectious	O
bronchitis	O
virus	O
in	O
infected	O
chicken	O
tissues	O
.	O

We	O
present	O
evidence	O
that	O
nsp1	O
uses	O
a	O
novel	O
,	O
two	O
-	O
pronged	O
strategy	O
to	O
inhibit	O
host	O
translation	B-PROC
and	O
gene	B-PROC
expression	I-PROC
.	O

Of	O
the	O
patients	O
4	O
died	B-PROC
due	O
to	O
other	O
injuries	O
.	O

Virus	B-PROC
replication	I-PROC
predominantly	O
occurs	O
on	O
the	O
rough	O
endoplasmic	O
reticulum	O
(	O
RER	O
),	O
both	O
perinuclear	O
and	O
cytoplasmic	O
,	O
and	O
the	O
Golgi	O
.	O

TITLE	O
:	O
Recombinant	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
improves	O
pulmonary	O
blood	B-PROC
flow	I-PROC
and	O
oxygenation	B-PROC
in	O
lipopolysaccharide	O
-	O
induced	O
lung	O
injury	O
in	O
piglets	O
.	O

In	O
addition	O
,	O
ventilation	O
-	O
perfusion	O
distribution	O
of	O
the	O
lung	O
tissue	O
was	O
assessed	O
by	O
the	O
multiple	O
inert	O
gas	O
elimination	B-PROC
technique	O
.	O

These	O
results	O
may	O
be	O
relevant	O
for	O
SARS	O
in	O
humans	O
,	O
which	O
is	O
also	O
characterized	O
by	O
prolonged	O
virus	O
persistence	O
and	O
delayed	O
development	B-PROC
of	O
a	O
SARS	O
-	O
CoV	O
-	O
specific	B-PROC
immune	B-PROC
response	I-PROC
in	O
individuals	O
with	O
severe	O
disease	O
.	O

Given	O
that	O
15E2	O
showed	O
reactivity	O
with	O
the	O
(	O
199	O
)	O
FATFVYAK	O
(	O
206	O
)	O
motif	O
,	O
expressed	B-PROC
as	O
a	O
GST	O
fusion	O
protein	O
,	O
in	O
both	O
western	O
blotting	O
and	O
in	O
an	O
ELISA	O
,	O
we	O
proposed	O
that	O
this	O
motif	O
represented	O
a	O
linear	O
B	O
-	O
cell	O
epitope	O
of	O
the	O
M	O
protein	O
.	O

Strain	O
v2163	O
increased	O
IL	O
-	O
1alpha	O
,	O
IL	O
-	O
6	O
,	O
MIP	O
-	O
1alpha	O
,	O
MCP	O
-	O
1	O
,	O
and	O
RANTES	O
in	O
mice	O
,	O
and	O
high	O
IL	O
-	O
6	O
expression	B-PROC
correlated	O
with	O
mortality	O
.	O

TITLE	O
:	O
The	O
application	O
of	O
genomics	O
to	O
emerging	O
zoonotic	O
viral	B-PROC
diseases	I-PROC
.	O

Equivalent	O
antibody	B-PROC
responses	I-PROC
were	O
elicited	O
in	O
response	O
to	O
virulent	O
and	O
attenuated	O
viruses	O
,	O
indicating	O
that	O
the	O
antigenic	O
mass	O
necessary	O
for	O
an	O
immune	B-PROC
response	I-PROC
is	O
produced	O
at	O
a	O
low	O
level	O
of	O
infection	O
,	O
and	O
is	O
not	O
predicted	O
by	O
viremic	O
status	O
.	O

Thus	O
,	O
viral	B-PROC
replication	I-PROC
was	O
occurring	O
in	O
lung	O
or	O
lymphoid	O
tissues	O
even	O
though	O
viremia	O
was	O
not	O
always	O
observed	O
.	O

TITLE	O
:	O
Antibody	B-PROC
-	O
mediated	O
synergy	O
and	O
interference	O
in	O
the	O
neutralization	O
of	O
SARS	O
-	O
CoV	O
at	O
an	O
epitope	O
cluster	O
on	O
the	O
spike	O
protein	O
.	O

While	O
mAb	O
341C	O
binds	O
to	O
a	O
mostly	O
linear	O
epitope	O
composed	O
of	O
residues	O
(	O
507	O
)	O
PAT	B-PROC
(	O
509	O
)	O
and	O
V	O
(	O
349	O
),	O
mAb	O
240C	O
binds	O
to	O
an	O
epitope	O
that	O
partially	O
overlaps	O
the	O
former	O
by	O
at	O
least	O
two	O
residues	O
(	O
P	O
(	O
507	O
)	O
and	O
A	O
(	O
508	O
)).	O

Whether	O
NL63	O
-	O
S	O
exerts	B-PROC
a	O
similar	O
activity	O
is	O
yet	O
unknown	O
.	O

Finally	O
,	O
SARS	O
-	O
CoV	O
but	O
not	O
NL63	O
replicated	O
efficiently	O
in	O
ACE2	O
-	O
positive	O
Vero	O
cells	O
and	O
reduced	O
ACE2	O
expression	B-PROC
,	O
indicating	O
robust	O
receptor	O
interference	O
in	O
the	O
context	O
of	O
SARS	O
-	O
CoV	O
but	O
not	O
NL63	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
unscramble	O
the	O
relationship	O
between	O
protein	B-PROC
function	I-PROC
and	O
protein	O
structure	O
,	O
it	O
is	O
essential	O
to	O
assess	O
the	O
protein	O
similarity	O
from	O
different	O
aspects	O
.	O

The	O
5	O
'	O
fragment	O
of	O
the	O
S	O
protein	O
(	O
S	O
')	O
of	O
a	O
TGEV	O
-	O
like	O
canine	O
coronavirus	O
(	O
CCoV	O
),	O
strain	O
174	O
/	O
06	O
,	O
was	O
expressed	B-PROC
in	O
an	O
Escherichia	O
coli	O
cell	O
-	O
free	O
system	O
.	O

Furthermore	O
,	O
nuclear	B-PROC
translocation	B-PROC
of	O
activated	O
STAT1	O
and	O
a	O
range	O
of	O
interferon	O
-	O
stimulated	O
genes	O
could	O
be	O
demonstrated	O
in	O
the	O
lungs	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
macaques	O
.	O

Given	O
the	O
pivotal	O
role	O
of	O
interferons	O
during	O
viral	B-PROC
infections	I-PROC
,	O
(	O
differential	O
)	O
induction	O
of	O
interferons	O
may	O
affect	O
the	O
outcome	O
of	O
the	O
infection	O
.	O

Patients	O
with	O
cirrhosis	O
are	O
prone	O
to	O
develop	O
sepsis	O
,	O
sepsis	O
-	O
induced	O
organ	O
failure	O
,	O
and	O
death	B-PROC
.	O

In	O
this	O
study	O
,	O
evidence	O
is	O
provided	O
that	O
immunity	B-PROC
induced	O
by	O
natural	O
exposure	O
to	O
enteric	O
CCoV	O
is	O
not	O
fully	O
protective	O
against	O
strain	O
CB	O
/	O
05	O
.	O

We	O
investigated	O
the	O
functions	O
of	O
the	O
largest	O
of	O
the	O
accessory	O
proteins	O
,	O
the	O
ORF	O
3a	O
protein	O
,	O
using	O
a	O
3a	O
-	O
deficient	O
strain	O
of	O
SARS	O
-	O
CoV	O
.	O
Cell	B-PROC
death	I-PROC
of	O
Vero	O
cells	O
after	O
infection	O
with	O
SARS	O
-	O
CoV	O
was	O
reduced	O
upon	O
deletion	O
of	O
ORF	O
3a	O
.	O

Finally	O
,	O
overexpression	B-PROC
of	O
ADP	O
-	O
ribosylation	O
factor	O
1	O
(	O
Arf1	O
),	O
a	O
small	O
GTPase	O
essential	O
for	O
the	O
maintenance	O
of	O
the	O
Golgi	O
apparatus	O
,	O
restored	O
Golgi	O
morphology	O
during	O
infection	O
.	O

ABSTRACT	O
:	O
In	O
marked	O
contrast	O
to	O
their	O
historical	O
classification	O
as	O
relatively	O
harmless	O
,	O
common	O
cold	B-PROC
-	O
causing	O
,	O
respiratory	O
pathogens	O
,	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
are	O
associated	O
with	O
more	O
severe	O
clinical	O
complications	O
,	O
as	O
emphasized	O
by	O
the	O
discovery	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
CoV	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
2003	O
.	O

Treatment	O
of	O
JHMV	O
-	O
infected	O
mice	O
with	O
anti	O
-	O
CXCR2	O
blocking	O
antibody	B-PROC
reduced	O
PMN	B-PROC
trafficking	B-PROC
into	O
the	O
CNS	O
by	O
>	O
95	O
%,	O
dampened	O
MMP	B-PROC
-	I-PROC
9	I-PROC
activity	I-PROC
,	O
and	O
abrogated	O
blood	O
-	O
brain	O
-	O
barrier	O
(	O
BBB	O
)	O
breakdown	B-PROC
.	O

Collectively	O
,	O
these	O
findings	O
highlight	O
a	O
previously	O
unappreciated	O
role	O
for	O
ELR	O
-	O
positive	O
chemokines	O
in	O
enhancing	O
host	B-PROC
defense	I-PROC
during	O
acute	O
viral	B-PROC
infections	I-PROC
of	O
the	O
CNS	O
.	O

For	O
each	O
outcome	O
,	O
we	O
used	O
Grading	O
of	O
Recommendations	O
Assessments	O
,	O
Development	B-PROC
and	O
Evaluation	O
(	O
GRADE	O
)	O
criteria	O
to	O
evaluate	O
the	O
quality	O
of	O
the	O
underlying	O
evidence	O
.	O

These	O
results	O
provide	O
a	O
structural	O
basis	O
for	O
understanding	O
viral	O
evolution	B-PROC
and	O
virus	O
-	O
receptor	B-PROC
interactions	I-PROC
.	O

A	O
strong	O
antiviral	B-PROC
response	I-PROC
to	O
the	O
viral	O
surface	O
glycoprotein	O
(	O
SU	O
)	O
was	O
noted	O
in	O
both	O
natural	O
and	O
experimental	O
infections	O
.	O

Enhanced	O
production	O
of	O
cytokines	O
(	O
tumor	O
necrosis	B-PROC
factor	O
alpha	O
[	O
TNF	O
-	O
alpha	O
]	O
and	O
interleukin	O
-	O
6	O
[	O
IL	O
-	O
6	O
])	O
and	O
chemokines	O
(	O
CXCL10	O
,	O
CCL2	O
,	O
CCL3	O
,	O
and	O
CCL5	O
)	O
correlated	O
with	O
migration	B-PROC
of	O
NK	O
cells	O
,	O
macrophages	O
,	O
and	O
plasmacytoid	O
dendritic	O
cells	O
(	O
pDC	O
)	O
into	O
the	O
lungs	O
.	O

ABSTRACT	O
:	O
Over	O
the	O
past	O
30	O
years	O
,	O
several	O
cross	O
-	O
species	O
transmission	O
events	O
,	O
as	O
well	O
as	O
changes	O
in	O
virus	O
tropism	B-PROC
,	O
have	O
mediated	O
significant	O
animal	O
and	O
human	O
diseases	O
.	O

ABSTRACT	O
:	O
As	O
one	O
of	O
the	O
most	O
important	O
endogenous	O
chemotactic	O
factors	O
for	O
neutrophils	O
,	O
the	O
chemokine	O
CXCL8	O
(	O
IL	O
-	O
8	O
)	O
is	O
involved	O
in	O
the	O
pathogenesis	B-PROC
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
characterized	O
by	O
massive	O
neutrophil	O
infiltration	O
in	O
the	O
lung	O
.	O

This	O
work	O
encompasses	O
miRNA	O
array	O
data	O
analysis	O
,	O
target	O
prediction	O
,	O
and	O
miRNA	O
-	O
mRNA	O
enrichment	O
analysis	O
and	O
develops	O
a	O
complex	O
interaction	O
map	O
among	O
disease	O
-	O
related	O
factors	O
,	O
miRNAs	O
,	O
and	O
BASCs	O
in	O
SARS	O
pathway	B-PROC
,	O
which	O
will	O
provide	O
some	O
clues	O
for	O
diagnostic	O
markers	O
to	O
view	O
an	O
overall	O
interplay	O
leading	O
to	O
disease	O
progression	O
.	O

The	O
fluorogenic	O
probe	O
labeled	O
with	O
a	O
reporter	O
dye	O
(	O
FAM	O
,	O
6	O
-	O
carboxytetramethylrhodamin	O
)	O
and	O
a	O
quencher	O
dye	O
(	O
AbsoluteQuencher	O
)	O
was	O
designed	O
to	O
bind	O
to	O
a	O
186	O
base	O
-	O
pair	O
fragment	O
flanked	O
by	O
the	O
two	O
PCR	O
primers	O
targeting	B-PROC
the	O
3	O
'	O
end	O
of	O
spike	O
gene	O
of	O
TCoV	O
.	O
The	O
assay	O
was	O
performed	O
on	O
different	O
avian	O
viruses	O
and	O
bacteria	O
to	O
determine	O
the	O
specificity	O
as	O
well	O
as	O
serial	O
dilutions	O
of	O
TCoV	O
for	O
the	O
sensitivity	O
.	O

ABSTRACT	O
:	O
To	O
survey	O
the	O
dose	O
of	O
glucocorticosteroids	O
administered	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
assess	O
the	O
effect	O
of	O
glucocorticosteroid	O
doses	O
in	O
improving	O
the	O
patients	O
'	O
lung	B-PROC
function	I-PROC
.	O

For	O
SARS	O
treatment	O
,	O
Glucocorticosteroids	O
can	O
effectively	O
ameliorate	O
the	O
SARS	O
patients	O
'	O
lung	O
symptoms	O
and	O
improve	O
the	O
lung	B-PROC
function	I-PROC
.	O

TITLE	O
:	O
Cleavage	B-PROC
of	O
the	O
SARS	O
coronavirus	O
spike	O
glycoprotein	O
by	O
airway	O
proteases	O
enhances	O
virus	O
entry	O
into	O
human	O
bronchial	O
epithelial	O
cells	O
in	O
vitro	O
.	O

These	O
results	O
suggest	O
that	O
SARS	O
S	O
-	O
protein	O
is	O
susceptible	O
to	O
airway	O
protease	O
cleavage	B-PROC
and	O
,	O
furthermore	O
,	O
that	O
protease	O
mediated	O
enhancement	O
of	O
virus	O
entry	O
depends	O
on	O
specific	O
conformation	O
of	O
SARS	O
S	O
-	O
protein	O
upon	O
ACE2	O
binding	O
.	O

H1N1	O
influenza	O
was	O
confirmed	O
with	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
chain	O
reaction	O
assay	O
in	O
eight	O
patients	O
.	O

TITLE	O
:	O
[	O
Fulminant	O
,	O
life	O
-	O
threatening	O
influenza	O
A	O
/	O
H1N1	O
virus	B-PROC
infection	I-PROC
].	O

Severe	O
kidney	O
damage	O
and	O
dilatation	O
of	O
the	O
oviduct	O
were	O
the	O
prominent	O
lesions	O
that	O
could	O
be	O
related	O
to	O
the	O
QX	O
-	O
like	O
IBV	O
strains	O
,	O
although	O
neither	O
marked	O
virus	B-PROC
replication	I-PROC
nor	O
histopathological	O
lesions	O
were	O
detected	O
in	O
the	O
oviduct	O
.	O

Moreover	O
,	O
whereas	O
pDCs	O
exposed	O
to	O
TGEV	O
or	O
the	O
TLR9	O
agonist	O
rapidly	O
increased	O
IRF	O
-	O
7	O
production	O
and	O
morphed	O
into	O
DCs	O
with	O
enhanced	O
CD80	O
/	O
86	O
expression	B-PROC
,	O
similar	O
alterations	O
were	O
not	O
observed	O
during	O
incubation	O
with	O
PRRSV	O
.	O

Despite	O
advances	O
in	O
the	O
management	O
of	O
ARDS	O
,	O
mortality	O
remains	O
high	O
(	O
40	O
%)	O
and	O
autopsies	O
show	O
extended	O
pulmonary	O
fibrosis	O
in	O
55	O
%	O
of	O
patients	O
,	O
suggesting	O
the	O
importance	O
of	O
deregulated	O
repair	B-PROC
in	O
the	O
morbidity	O
and	O
mortality	O
of	O
these	O
patients	O
.	O

TITLE	O
:	O
Antibody	B-PROC
binding	O
site	O
mapping	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
receptor	O
-	O
binding	O
domain	O
by	O
a	O
combination	O
of	O
yeast	O
surface	O
display	O
and	O
phage	O
peptide	O
library	O
screening	O
.	O

In	O
this	O
study	O
,	O
three	O
hybridoma	O
cell	O
lines	O
secreting	B-PROC
specific	O
monoclonal	O
antibodies	O
against	O
the	O
RBD	O
of	O
the	O
S	O
protein	O
were	O
generated	O
and	O
their	O
exact	O
binding	O
sites	O
were	O
identified	O
.	O

The	O
volume	O
of	O
blood	O
being	O
lost	O
can	O
be	O
reduced	O
by	O
direct	O
methods	O
where	O
possible	O
(	O
i	O
.	O
e	O
.,	O
hemostasis	B-PROC
at	O
the	O
point	O
of	O
bleeding	O
),	O
or	O
by	O
improving	O
the	O
coagulation	B-PROC
profile	O
of	O
the	O
patient	O
,	O
thereby	O
improving	O
the	O
extrinsic	O
coagulation	B-PROC
.	O

Interestingly	O
,	O
N	O
protein	O
and	O
its	O
deletion	O
mutants	O
with	O
RNA	O
chaperone	B-PROC
activity	I-PROC
enhanced	O
template	O
switching	O
in	O
a	O
retrovirus	O
-	O
derived	O
heterologous	O
system	O
,	O
reinforcing	O
the	O
concept	O
that	O
TGEV	O
N	O
protein	O
is	O
an	O
RNA	B-PROC
chaperone	I-PROC
that	O
could	O
be	O
involved	O
in	O
template	O
switching	O
.	O

There	O
was	O
no	O
clinical	O
or	O
pathological	O
evidence	O
of	O
infectious	O
diseases	O
in	O
living	O
or	O
dead	B-PROC
cheetahs	O
.	O

To	O
set	O
PEEP	O
in	O
each	O
individual	O
patient	O
,	O
the	O
use	O
of	O
the	O
expiratory	B-PROC
limb	O
of	O
the	O
pressure	O
-	O
volume	O
curve	O
has	O
been	O
suggested	O
.	O

Bovine	O
immunology	O
research	O
has	O
provided	O
more	O
specific	O
information	O
on	O
immune	B-PROC
responses	I-PROC
,	O
T	O
cell	O
subsets	O
and	O
cytokines	O
.	O

Specific	O
parameters	O
assessed	O
in	O
the	O
innate	O
pulmonary	O
inflammatory	B-PROC
response	I-PROC
were	O
leukocytes	O
,	O
macrophages	O
,	O
and	O
polymorphonuclear	O
neutrophils	O
(	O
PMNs	O
)	O
in	O
BAL	O
;	O
whole	O
lung	O
myeloperoxidase	O
activity	O
;	O
and	O
a	O
series	O
of	O
cytokines	O
or	O
chemokines	O
present	O
in	O
BAL	O
at	O
5	O
or	O
24	O
hours	O
after	O
injury	O
:	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
interferon	O
-	O
gamma	O
,	O
IL	O
-	O
10	O
,	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
,	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
-	O
1	O
,	O
and	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
.	O

Rats	O
with	O
LC	O
,	O
CASP	O
,	O
LC	O
+	O
CASP	O
all	O
had	O
severe	O
lung	O
injury	O
compared	O
with	O
uninjured	O
controls	O
based	O
on	O
decreased	O
arterial	O
oxygenation	B-PROC
or	O
increased	O
BAL	O
albumin	O
at	O
5	O
or	O
24	O
hours	O
postinsult	O
.	O

RESULTS	O
:	O
Rats	O
with	O
LC	O
,	O
CASP	O
,	O
LC	O
+	O
CASP	O
all	O
had	O
severe	O
lung	O
injury	O
compared	O
with	O
uninjured	O
controls	O
based	O
on	O
decreased	O
arterial	O
oxygenation	B-PROC
or	O
increased	O
BAL	O
albumin	O
at	O
5	O
or	O
24	O
hours	O
postinsult	O
.	O

During	O
the	O
2006	O
-	O
2007	O
outbreak	O
in	O
Rome	O
,	O
Italy	O
,	O
a	O
young	O
infant	O
presented	O
with	O
ARDS	O
/	O
spontaneous	O
air	O
-	O
leak	O
and	O
needed	O
aggressive	B-PROC
ventilatory	O
management	O
and	O
haemodynamic	O
support	O
.	O

There	O
has	O
been	O
significant	O
progress	O
in	O
the	O
understanding	O
of	O
pathogenesis	B-PROC
of	O
severe	O
malaria	O
over	O
the	O
last	O
decade	O
.	O

ABSTRACT	O
:	O
The	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
reported	O
to	O
cause	O
apoptosis	B-PROC
of	O
infected	O
cells	O
and	O
several	O
of	O
its	O
proteins	O
including	O
the	O
3a	O
accessory	O
protein	O
,	O
are	O
pro	O
-	O
apoptotic	O
.	O

TITLE	O
:	O
Emergence	O
of	O
a	O
group	O
3	O
coronavirus	O
through	O
recombination	B-PROC
.	O

Comparative	O
genomics	O
revealed	O
two	O
recombination	B-PROC
sites	O
that	O
replaced	O
the	O
spike	O
gene	O
in	O
IBV	O
with	O
an	O
unidentified	O
sequence	O
likely	O
from	O
another	O
coronavirus	O
,	O
resulting	O
in	O
cross	O
-	O
species	O
transmission	O
and	O
a	O
pathogenicity	O
shift	O
.	O

In	O
the	O
ARDS	O
model	O
,	O
vitamin	O
K3	O
also	O
suppressed	O
the	O
LPS	O
-	O
induced	O
increase	O
in	O
the	O
serum	O
TNF	O
-	O
alpha	O
level	O
and	O
inhibited	O
the	O
LPS	O
-	O
evoked	O
nuclear	B-PROC
translocation	B-PROC
of	O
NF	O
-	O
kappaB	O
in	O
lung	O
tissue	O
.	O

Most	O
of	O
the	O
knowledge	O
about	O
the	O
pathogenesis	B-PROC
of	O
MS	O
has	O
been	O
derived	O
from	O
murine	O
models	O
,	O
such	O
as	O
experimental	O
autoimmune	O
encephalomyelitis	O
and	O
viral	O
encephalomyelitis	O
.	O

TITLE	O
:	O
Gamma	O
interferon	O
signaling	B-PROC
in	O
oligodendrocytes	O
is	O
critical	O
for	O
protection	O
from	O
neurotropic	O
coronavirus	O
infection	O
.	O

Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
was	O
given	O
as	O
support	O
.	O

The	O
patient	O
was	O
successfully	O
weaned	B-PROC
from	O
ECMO	O
after	O
24	O
days	O
,	O
extubated	O
at	O
6	O
weeks	O
,	O
and	O
continues	O
to	O
make	O
steady	O
rehabilitative	O
progress	O
.	O

Paradoxically	O
,	O
prolonged	O
administration	O
of	O
immunosuppressive	O
agents	O
because	O
of	O
acute	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
had	O
a	O
protective	O
effect	O
on	O
the	O
development	B-PROC
of	O
allo	O
-	O
LS	O
(	O
P	O
=	O
.	O
004	O
).	O

In	O
contrast	O
,	O
in	O
the	O
engineered	O
stable	O
cell	O
lines	O
,	O
a	O
high	O
level	O
of	O
recombinant	O
pAPN	O
expression	B-PROC
was	O
demonstrated	O
.	O

The	O
enzymatic	O
active	O
motif	O
-	O
null	O
mutant	O
pAPN	O
still	O
retained	O
the	O
ability	O
to	O
exert	B-PROC
its	O
receptor	O
activity	O
and	O
consequently	O
,	O
to	O
cause	O
infectious	O
virus	O
production	O
.	O

However	O
,	O
with	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
),	O
40	O
cases	O
(	O
93	O
%)	O
were	O
positive	O
for	O
rotavirus	O
,	O
36	O
(	O
84	O
%)	O
for	O
TAstV	O
-	O
2	O
,	O
and	O
17	O
(	O
40	O
%)	O
for	O
reovirus	O
.	O

Her	O
pregnancy	O
got	O
complicated	O
with	O
a	O
severe	O
preeclampsia	O
,	O
enough	O
reason	O
for	O
interrumpting	O
the	O
pregnancy	O
at	O
29	O
.	O
1	O
weeks	O
of	O
gestation	B-PROC
.	O

By	O
in	O
-	O
vitro	O
translation	B-PROC
analysis	O
and	O
subsequent	O
endoglycosidase	O
H	O
digestion	B-PROC
we	O
showed	O
that	O
ORF	O
3	O
protein	O
is	O
N	O
-	O
glycosylated	O
at	O
the	O
N	O
-	O
terminus	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
diagnostic	O
performance	O
and	O
clinical	O
use	O
of	O
a	O
novel	O
multiplex	O
PCR	O
method	O
in	O
adults	O
with	O
community	O
-	O
acquired	O
respiratory	O
viral	B-PROC
infection	I-PROC
,	O
and	O
the	O
impact	O
of	O
duration	O
of	O
symptoms	O
on	O
detection	O
rates	O
.	O

The	O
two	O
deaths	B-PROC
were	O
due	O
to	O
multiorgan	O
failure	O
,	O
which	O
occurred	O
while	O
the	O
patients	O
were	O
on	O
ECLS	O
.	O

TITLE	O
:	O
Dynamic	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
of	O
human	O
bronchial	O
epithelial	O
cells	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
infection	O
.	O

At	O
autopsy	O
,	O
both	O
lungs	O
were	O
voluminous	O
and	O
microscopic	O
examination	O
revealed	O
acute	O
-	O
stage	O
,	O
severe	O
diffuse	O
alveolar	O
damage	O
with	O
remarkable	O
mononuclear	O
cell	O
infiltration	O
and	O
hyaline	O
membrane	O
formation	B-PROC
in	O
the	O
lungs	O
.	O

Six	O
third	O
-	O
trimester	O
maternal	B-PROC
deaths	B-PROC
with	O
severe	O
H1N1	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
is	O
an	O
effective	O
rescue	O
tool	O
to	O
treat	O
cardiopulmonary	O
failure	O
.	O

Anticoagulation	B-PROC
,	O
hemodynamic	B-PROC
,	O
and	O
respiratory	O
variables	O
were	O
analyzed	O
.	O

43	O
mm	O
Hg	O
(	O
mean	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
,	O
70	O
+/-	O

32	O
mm	O
Hg	O
despite	O
maximal	O
(	O
ventilatory	O
)	O
conservative	O
therapy	O
(	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
,	O
0	O
.	O
98	O
+/-	O
0	O
.	O
08	O
).	O

After	O
24	O
hours	O
an	O
improvement	O
in	O
oxygenation	B-PROC
and	O
a	O
decrease	O
in	O
carbon	O
dioxide	O
was	O
achieved	O
with	O
a	O
mean	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
of	O
40	O
+/-	O

3	O
days	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
,	O
patients	O
were	O
hemodynamically	O
stabilized	O
.	O

Inhaled	B-PROC
nitric	O
oxide	O
(	O
INO	O
)	O
and	O
aerosolized	O
prostacyclins	O
are	O
currently	O
the	O
most	O
frequently	O
used	O
inhaled	B-PROC
vasodilators	O
.	O

We	O
report	O
the	O
following	O
case	O
:	O
a	O
23	O
-	O
year	O
-	O
old	O
female	O
patient	O
with	O
no	O
prior	O
medical	O
history	O
presented	O
a	O
severe	O
respiratory	O
distress	O
that	O
required	O
high	O
frequency	O
oscillation	O
ventilation	O
and	O
finally	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
(	O
ECMO	O
).	O

TITLE	O
:	O
The	O
N	O
-	O
terminal	O
region	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
protein	O
6	O
induces	O
membrane	O
rearrangement	B-PROC
and	O
enhances	O
virus	B-PROC
replication	I-PROC
.	O

ABSTRACT	O
:	O
Most	O
emerging	O
infectious	O
diseases	O
today	O
,	O
such	O
as	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
and	O
sudden	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
SARS	O
),	O
arise	O
from	O
zoonotic	O
reservoirs	O
and	O
many	O
are	O
transmitted	O
by	O
arthropod	O
vectors	O
.	O

Today	O
,	O
ticks	O
transmit	O
the	O
most	O
common	O
arthropod	O
-	O
borne	O
infectious	O
disease	O
in	O
the	O
United	O
States	O
(	O
US	O
),	O
Lyme	O
disease	O
(	O
LD	O
);	O
and	O
the	O
most	O
lethal	O
arthropod	O
-	O
borne	O
infectious	O
disease	O
in	O
the	O
US	O
,	O
Rocky	O
Mountain	O
spotted	O
fever	B-PROC
(	O
RMSF	O
).	O

There	O
is	O
also	O
evidence	O
that	O
greater	O
levels	O
of	O
state	O
anxiety	O
and	O
greater	O
trust	O
in	O
authorities	O
are	O
associated	O
with	O
behaviour	B-PROC
.	O

TITLE	O
:	O
Delayed	O
clearance	O
of	O
viral	O
load	O
and	O
marked	O
cytokine	B-PROC
activation	I-PROC
in	O
severe	O
cases	O
of	O
pandemic	O
H1N1	O
2009	O
influenza	O
virus	B-PROC
infection	I-PROC
.	O

ABSTRACT	O
:	O
A	O
typical	O
feature	O
of	O
Parkinson	O
'	O
s	O
disease	O
is	O
the	O
progressive	O
loss	O
of	O
dopaminergic	O
neurons	O
in	O
the	O
substantia	O
nigra	O
,	O
in	O
which	O
inhibition	B-PROC
of	O
mitochondrial	O
complex	O
I	O
activity	O
may	O
play	O
an	O
important	O
role	O
.	O

The	O
first	O
patient	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
required	O
intubation	O
,	O
and	O
eventually	O
died	B-PROC
.	O

Thyroid	B-PROC
function	I-PROC
(	O
thyroid	O
-	O
stimulating	O
hormone	O
,	O
T	O
(	O
4	O
),	O
free	O
T	O
(	O
4	O
)	O
[	O
fT	O
(	O
4	O
)],	O
and	O
free	O
triiodothyronine	O
)	O
and	O
cortisol	O
levels	O
were	O
collected	O
at	O
four	O
specified	O
intervals	O
(	O
birth	B-PROC
,	O
day	O
2	O
,	O
day	O
3	O
,	O
and	O
day	O
5	O
of	O
life	O
).	O

Infant	O
with	O
SNAP	O
>	O
or	O
=	O
10	O
had	O
a	O
diminished	O
thyroid	O
-	O
stimulating	O
hormone	O
at	O
birth	B-PROC
.	O

Fusion	O
proteins	O
containing	O
M	O
amino	O
-	O
terminal	O
50	O
residues	O
encompassing	O
the	O
first	O
transmembrane	O
domain	O
were	O
found	O
to	O
be	O
sufficient	O
for	O
membrane	O
binding	O
,	O
multimerization	O
,	O
and	O
Golgi	O
retention	B-PROC
.	O

Surprisingly	O
,	O
we	O
found	O
that	O
fusion	O
proteins	O
lacking	O
all	O
three	O
transmembrane	O
domains	O
were	O
still	O
capable	O
of	O
membrane	O
binding	O
,	O
Golgi	O
retention	B-PROC
,	O
and	O
interacting	O
with	O
M	O
.	O
The	O
data	O
suggest	O
that	O
multiple	O
SARS	O
-	O
CoV	O
M	O
regions	O
are	O
involved	O
in	O
M	O
self	O
-	O
assembly	O
and	O
subcellular	O
localization	B-PROC
.	O

Plasma	O
levels	O
of	O
surfactant	O
protein	O
D	O
(	O
SP	O
-	O
D	O
),	O
Clara	O
Cell	O
protein	O
(	O
CC16	O
),	O
KL	O
-	O
6	O
and	O
soluble	O
receptor	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
(	O
sRAGE	O
)	O
were	O
measured	O
in	O
plasma	O
samples	O
obtained	O
from	O
36	O
patients	O
-	O
16	O
patients	O
who	O
were	O
intubated	O
and	O
mechanically	O
ventilated	O
because	O
of	O
ALI	O
/	O
ARDS	O
and	O
20	O
patients	O
without	O
lung	O
injury	O
at	O
the	O
onset	O
of	O
mechanical	O
ventilation	O
and	O
during	O
conduct	B-PROC
of	O
the	O
study	O
.	O

TITLE	O
:	O
Adult	O
Respiratory	O
Distress	O
Syndrome	O
and	O
alveolar	O
epithelium	O
apoptosis	B-PROC
:	O
an	O
histopathological	O
and	O
immunohistochemical	O
study	O
.	O

He	O
died	B-PROC
on	O
the	O
seventh	O
day	O
as	O
a	O
consequence	O
of	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
Achieving	O
a	O
golden	O
mean	O
:	O
mechanisms	O
by	O
which	O
coronaviruses	O
ensure	O
synthesis	B-PROC
of	O
the	O
correct	O
stoichiometric	O
ratios	O
of	O
viral	O
proteins	O
.	O

ABSTRACT	O
:	O
The	O
occurrence	O
of	O
life	O
-	O
threatening	O
viral	B-PROC
infections	I-PROC
and	O
the	O
establishment	O
of	O
appropriate	O
defense	O
strategies	O
exhibit	O
major	O
challenges	O
to	O
the	O
disease	O
management	O
in	O
our	O
society	O
.	O

In	O
the	O
present	O
contribution	O
,	O
functional	O
aspects	O
of	O
the	O
target	O
proteases	O
,	O
their	O
structural	O
properties	O
,	O
drug	O
design	O
strategies	O
,	O
resulting	O
inhibitors	O
,	O
and	O
resistance	B-PROC
management	O
are	O
reviewed	O
and	O
discussed	O
by	O
means	O
of	O
the	O
four	O
essential	O
representative	O
cases	O
of	O
HIV	O
,	O
HCV	O
,	O
SARS	O
coronavirus	O
,	O
and	O
the	O
flaviviruses	O
Dengue	O
and	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
.	O

ABSTRACT	O
:	O
Neutralizing	O
antibody	B-PROC
responses	I-PROC
to	O
the	O
surface	O
glycoproteins	O
of	O
enveloped	O
viruses	O
play	O
an	O
important	O
role	O
in	O
immunity	B-PROC
.	O

TITLE	O
:	O
Bronchiolitis	O
obliterans	O
syndrome	O
development	B-PROC
in	O
lung	O
transplantation	O
patients	O
.	O

The	O
presence	O
of	O
acute	B-PROC
cellular	I-PROC
rejection	I-PROC
episodes	O
,	O
CMV	O
disease	O
,	O
and	O
GERD	O
were	O
factors	O
associated	O
with	O
chronic	O
lung	O
rejection	O
.	O

These	O
results	O
indicated	O
that	O
SIAMP	O
can	O
inhibit	O
virus	B-PROC
replication	I-PROC
and	O
reduce	O
tissue	O
injury	O
caused	O
by	O
IBV	O
.	O

The	O
patient	O
responded	O
to	O
pulse	B-PROC
steroid	O
therapy	O
and	O
recovered	O
from	O
severe	O
respiratory	O
failure	O
.	O

The	O
coefficients	O
describe	O
the	O
binding	O
affinity	O
between	O
the	O
virus	O
and	O
the	O
induced	O
antibody	B-PROC
and	O
that	O
between	O
the	O
virus	O
and	O
its	O
receptor	O
.	O

Indirect	O
data	O
suggest	O
,	O
that	O
the	O
critical	O
number	O
for	O
the	O
oxygen	B-PROC
content	I-PROC
is	O
rather	O
low	O
and	O
is	O
estimated	O
to	O
be	O
somewhere	O
around	O
33	O
%	O
of	O
the	O
normal	O
value	O
.	O

Although	O
immunoreactivity	B-PROC
for	O
surfactant	O
protein	O
SP	O
-	O
A	O
and	O
ABCA3	O
was	O
diminished	O
,	O
that	O
for	O
SP	O
-	O
B	O
and	O
proSP	O
-	O
C	O
was	O
robust	O
,	O
although	O
irregularly	O
distributed	O
,	O
corresponding	O
to	O
the	O
distribution	O
of	O
type	O
II	O
pneumocytes	O
.	O

Cow	O
'	O
s	O
milk	O
allergy	B-PROC
should	O
be	O
suspected	O
in	O
children	O
who	O
have	O
immediate	O
symptoms	O
such	O
as	O
acute	O
urticaria	O
/	O
angioedema	O
,	O
wheezing	O
,	O
rhinitis	O
,	O
dry	O
cough	O
,	O
vomiting	O
,	O
laryngeal	O
edema	O
,	O
acute	O
asthma	O
with	O
severe	O
respiratory	O
distress	O
,	O
anaphylaxis	O
.	O

Because	O
myelin	O
destruction	O
is	O
a	O
consequence	O
of	O
the	O
inflammatory	B-PROC
response	I-PROC
associated	O
with	O
virus	O
clearance	O
,	O
we	O
reasoned	O
that	O
decreasing	O
the	O
amount	O
of	O
inflammation	O
would	O
diminish	O
clinical	O
disease	O
and	O
demyelination	O
.	O

On	O
testing	O
of	O
263	O
VN	O
antibody	B-PROC
-	O
positive	O
sera	O
from	O
27	O
farms	O
with	O
a	O
commercial	O
blocking	O
ELISA	O
to	O
distinguish	O
TGEV	O
and	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
antibodies	O
,	O
78	O
.	O
3	O
%	O
were	O
positive	O
for	O
PRCV	O
antibody	B-PROC
only	O
,	O
while	O
12	O
.	O
5	O
%	O
were	O
positive	O
for	O
TGEV	O
antibody	B-PROC
only	O
or	O
both	O
TGEV	O
and	O
PRCV	O
antibodies	O
.	O

TITLE	O
:	O
Trypsin	O
-	O
induced	O
hemagglutination	B-PROC
activity	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

An	O
equal	O
level	O
of	O
anti	O
-	O
MNV	O
-	O
S7	O
antibody	B-PROC
response	I-PROC
was	O
observed	O
in	O
BALB	O
/	O
cAJcl	O
,	O
C57BL	O
/	O
6JJcl	O
,	O
DBA	O
/	O
2JJcl	O
,	O
and	O
Jcl	O
:	O
ICR	O
mice	O
;	O
whereas	O
,	O
C3H	O
/	O
HeJJcl	O
mice	O
demonstrated	O
slightly	O
lower	O
antibody	B-PROC
production	I-PROC
4	O
weeks	O
after	O
infection	O
.	O

We	O
then	O
used	O
the	O
two	O
-	O
antibody	B-PROC
sandwich	O
ELISA	O
method	O
to	O
detect	O
IFN	O
-	O
gamma	O
-	O
inducible	O
protein	O
10	O
(	O
IP	O
-	O
10	O
).	O

It	O
is	O
already	O
common	O
sense	B-PROC
that	O
the	O
prevention	O
of	O
acute	O
life	O
-	O
threatening	O
hypoxemia	O
usually	O
outweighs	O
the	O
risks	O
of	O
this	O
technique	O
.	O

In	O
the	O
present	O
study	O
,	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chickens	O
were	O
immunized	O
intramuscularly	O
with	O
a	O
DNA	O
vaccine	O
carrying	O
the	O
main	O
IBV	O
structural	O
genes	O
(	O
pVAX1	O
-	O
S1	O
,	O
pVAX1	O
-	O
M	O
,	O
and	O
pVAX1	O
-	O
N	O
,	O
respectively	O
)	O
and	O
boosted	O
with	O
the	O
IBV	O
M41	O
strain	O
inactivated	O
vaccine	O
to	O
assess	O
whether	O
such	O
a	O
new	O
strategy	O
could	O
enhance	O
the	O
immune	B-PROC
responses	I-PROC
against	O
IBV	O
.	O

TITLE	O
:	O
Understanding	O
stress	O
-	O
induced	O
immunosuppression	B-PROC
:	O
exploration	O
of	O
cytokine	O
and	O
chemokine	O
gene	O
profiles	O
in	O
chicken	O
peripheral	O
leukocytes	O
.	O

Translation	B-PROC
in	O
mammalian	O
cells	O
expressing	O
2B	O
protein	O
is	O
inhibited	O
by	O
hygromycin	O
B	O
(	O
HB	O
)	O
but	O
remains	O
unaffected	O
in	O
mock	O
cells	O
,	O
which	O
are	O
not	O
permeable	O
to	O
the	O
inhibitor	O
.	O

Expression	B-PROC
of	O
2B	O
induced	O
permeabilization	O
of	O
neighbouring	O
cell	O
lines	O
other	O
than	O
BHK	O
.	O

Finally	O
,	O
inhibition	B-PROC
of	O
HB	O
entry	O
to	O
neighbouring	O
cells	O
was	O
observed	O
with	O
18alpha	O
-	O
glycyrrhethinic	O
acid	O
,	O
an	O
inhibitor	O
of	O
gap	O
junctions	O
.	O

While	O
increased	O
avidity	O
offered	O
by	O
multivalent	O
targeting	B-PROC
is	O
attractive	O
,	O
it	O
can	O
also	O
promote	O
nonspecific	O
receptor	O
interaction	O
in	O
nontarget	O
tissues	O
,	O
reducing	O
the	O
effectiveness	O
of	O
multivalent	O
targeting	B-PROC
.	O

Two	O
early	O
postoperative	O
death	B-PROC
occurred	O
in	O
this	O
group	O
due	O
to	O
severe	O
low	O
cardiac	O
output	O
syndrome	O
,	O
with	O
the	O
mortality	O
rate	O
of	O
1	O
.	O
57	O
%.	O

TITLE	O
:	O
Lambda	O
interferon	O
renders	O
epithelial	O
cells	O
of	O
the	O
respiratory	O
and	O
gastrointestinal	O
tracts	O
resistant	O
to	O
viral	B-PROC
infections	I-PROC
.	O

Samples	O
collected	O
from	O
the	O
asymptomatic	O
contactors	O
were	O
all	O
negative	O
for	O
SARS	O
-	O
CoV	O
antibody	B-PROC
.	O

ABSTRACT	O
:	O
Airway	O
pressure	O
release	O
ventilation	O
(	O
APRV	O
)	O
is	O
a	O
ventilatory	O
mode	O
that	O
allows	O
unsupported	O
spontaneous	O
breathing	B-PROC
at	O
any	O
phase	O
of	O
the	O
ventilatory	O
cycle	O
with	O
high	O
mean	O
airway	O
pressures	O
.	O

Here	O
,	O
we	O
provide	O
our	O
perspective	O
on	O
the	O
role	O
of	O
systems	O
biology	O
in	O
deepening	O
our	O
understanding	O
of	O
virus	O
-	O
host	O
interactions	O
and	O
in	O
improving	O
drug	O
and	O
vaccine	O
development	B-PROC
.	O

Injured	O
animals	O
developed	O
hypotension	O
(	O
mean	O
arterial	B-PROC
pressure	I-PROC
;	O
40	O
.	O
8	O
+/-	O

0	O
.	O
40	O
l	O
/	O
min	O
)	O
and	O
decreased	O
systemic	B-PROC
vascular	I-PROC
resistance	I-PROC
(	O
8	O
.	O
48	O
+/-	O
2	O
.	O
75	O
vs	O
16	O
.	O
2	O
+/-	O

Our	O
laboratory	O
reported	O
a	O
total	O
of	O
14	O
subjects	O
associated	O
with	O
FES	O
and	O
died	B-PROC
of	O
ARDS	O
.	O

Metabolic	B-PROC
acidosis	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
6	O
.	O
1	O
),	O
ARDS	O
(	O
OR	O
3	O
.	O
6	O
),	O
altered	O
sensorium	O
(	O
OR	O
3	O
.	O
6	O
)	O
and	O
shock	O
(	O
OR	O
3	O
.	O
1	O
)	O
were	O
independent	O
predictors	O
of	O
mortality	O
.	O

Clinical	O
manifestations	O
from	O
HCoV	O
-	O
HKU1	O
positive	O
patients	O
included	O
diarrhea	O
,	O
emesis	B-PROC
and	O
respiratory	O
complaints	O
.	O

TITLE	O
:	O
Use	O
of	O
phylogenetics	O
in	O
the	O
molecular	O
epidemiology	O
and	O
evolutionary	O
studies	O
of	O
viral	B-PROC
infections	I-PROC
.	O

Whereas	O
all	O
deceased	B-PROC
patients	O
received	O
vasopressors	O
,	O
only	O
4	O
survivors	O
required	O
vasopressor	O
support	O
(	O
100	O
.	O
0	O
%	O
vs	O
.	O
36	O
.	O
4	O
%,	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
MHV	O
receptor	O
is	O
a	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	B-PROC
adhesion	I-PROC
molecule	O
,	O
CEACAM1a	O
;	O
paradoxically	O
,	O
CEACAM1a	O
is	O
poorly	O
expressed	B-PROC
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
),	O
leading	O
to	O
speculation	O
of	O
an	O
additional	O
receptor	O
.	O

Controlled	O
artificial	O
respiration	B-PROC
(	O
for	O
10	O
weeks	O
),	O
total	O
parenteral	O
alimentation	O
(	O
TPN	O
),	O
antihypertensive	O
treatment	O
and	O
diuretics	O
(	O
furosemide	O
,	O
dopamine	O
)	O
were	O
introduced	O
.	O

TITLE	O
:	O
Plasmapheresis	O
treatment	O
in	O
Guillain	O
-	O
Barré	O
syndrome	O
:	O
potential	O
benefit	O
over	O
intravenous	O
immunoglobulin	B-PROC
.	O

A	O
five	O
-	O
day	O
course	O
of	O
daily	O
immunoglobulin	B-PROC
(	O
0	O
.	O
4	O
g	O
/	O
kg	O
/	O
day	O
)	O
was	O
commenced	O
without	O
benefit	O
and	O
progressive	O
clinical	O
deterioration	O
.	O

Also	O
,	O
the	O
key	O
features	O
of	O
ligand	B-PROC
recognition	O
against	O
these	O
targets	O
are	O
accentuated	O
.	O

ABSTRACT	O
:	O
The	O
maturation	B-PROC
of	O
SARS	O
coronavirus	O
involves	O
the	O
autocleavage	O
of	O
polyproteins	O
1a	O
and	O
1ab	O
by	O
the	O
main	O
protease	O
(	O
Mpro	O
)	O
and	O
a	O
papain	O
-	O
like	O
protease	O
;	O
these	O
represent	O
attractive	O
targets	O
for	O
the	O
development	B-PROC
of	O
anti	O
-	O
SARS	O
drugs	O
.	O

Current	O
thinking	O
in	O
this	O
area	O
is	O
that	O
Mpro	O
dimerization	O
is	O
essential	O
for	O
catalysis	O
,	O
although	O
the	O
influence	O
of	O
the	O
substrate	O
binding	O
on	O
the	O
dimer	O
formation	B-PROC
has	O
never	O
been	O
explored	O
.	O

We	O
conclude	O
that	O
protein	O
-	O
ligand	B-PROC
and	O
protein	O
-	O
protein	O
interactions	O
are	O
closely	O
correlated	O
in	O
Mpro	O
.	O

Moreover	O
,	O
more	O
than	O
90	O
%	O
of	O
participants	O
reported	O
that	O
this	O
training	O
provided	O
a	O
valuable	O
learning	B-PROC
experience	O
and	O
reinforced	O
the	O
importance	O
of	O
emergency	O
preparedness	O
.	O

Prior	O
to	O
ECMO	O
median	O
oxygenation	B-PROC
ratio	O
(	O
OR	O
)	O
was	O
47	O
(	O
36	O
-	O
90	O
)	O
mmHg	O
,	O
median	O
paCO	O
(	O
2	O
)	O
was	O
67	O
(	O
36	O
-	O
89	O
)	O
mmHg	O
and	O
median	O
norepinephrine	O
demand	O
was	O
3	O
.	O
0	O
(	O
1	O
.	O
0	O
-	O
13	O
.	O
5	O
)	O
mg	O
/	O
h	O
.	O

We	O
sought	O
to	O
describe	O
the	O
ventilation	O
strategies	O
in	O
anesthetized	O
patients	O
with	O
varying	O
degrees	O
of	O
hypoxemia	O
as	O
defined	O
by	O
the	O
Pao	B-PROC
(	O
2	O
)	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
Fio	O
(	O
2	O
))	O
(	O
P	O
/	O
F	O
)	O
ratio	O
.	O

These	O
findings	O
demonstrated	O
that	O
SARS	O
-	O
CoV	O
pathogenesis	B-PROC
is	O
regulated	O
by	O
a	O
STAT1	O
dependent	O
but	O
type	O
I	O
,	O
II	O
and	O
III	O
interferon	O
receptor	O
independent	O
,	O
mechanism	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
SARS	O
-	O
CoV	O
antibody	B-PROC
in	O
all	O
Hong	O
Kong	O
patient	O
contacts	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
case	O
of	O
41	O
-	O
yr	O
.-	O
old	O
multigravida	O
at	O
35	O
weeks	O
gestation	B-PROC
,	O
with	O
a	O
diagnosis	O
of	O
Eisenmenger	O
syndrome	O
,	O
requiring	O
urgent	O
Cesarean	O
section	O
.	O

A	O
general	O
anesthetic	O
consisting	O
of	O
ketamine	O
and	O
etomidate	O
and	O
an	O
intravenous	O
infusion	O
of	O
remifentanil	O
were	O
used	O
to	O
provide	O
stable	O
anesthesia	O
and	O
analgesia	B-PROC
for	O
a	O
successful	O
delivery	O
.	O

This	O
is	O
of	O
interest	O
for	O
the	O
mechanisms	O
of	O
inhibition	B-PROC
of	O
the	O
SARS	O
coronavirus	O
main	O
protease	O
(	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
))	O
by	O
etacrynic	O
acid	O
derivatives	O
as	O
well	O
as	O
for	O
the	O
excess	O
toxicity	O
of	O
substituted	O
alpha	O
,	O
beta	O
-	O
unsaturated	O
carbonyl	O
compounds	O
.	O

Phenyl	O
and	O
methyl	O
substituents	O
at	O
the	O
Michael	O
system	O
decrease	O
the	O
reactivity	O
of	O
the	O
electrophilic	O
compound	O
,	O
but	O
chlorophenyl	O
substituents	O
partly	O
recover	B-PROC
the	O
reactivity	O
.	O

Computations	O
also	O
indicate	O
that	O
electron	O
-	O
pushing	B-PROC
substituents	O
lead	O
to	O
a	O
change	O
in	O
the	O
reaction	O
mechanism	O
.	O

Several	O
viral	O
and	O
cell	O
proteins	O
including	O
spike	O
,	O
membrane	O
,	O
non	O
-	O
structural	O
protein	O
3	O
(	O
nsp3	O
),	O
dynein	B-PROC
heavy	O
chain	O
,	O
fatty	O
acid	O
synthase	O
and	O
transmembrane	O
protein	O
43	O
bound	O
E	O
protein	O
.	O

It	O
was	O
shown	O
that	O
E	O
protein	O
was	O
ubiquitinated	O
in	O
vitro	O
and	O
in	O
cell	O
culture	O
,	O
suggesting	O
that	O
the	O
interaction	O
between	O
nsp3	O
and	O
E	O
protein	O
may	O
play	O
a	O
role	O
in	O
the	O
E	O
protein	B-PROC
ubiquitination	B-PROC
status	O
and	O
therefore	O
on	O
its	O
turnover	O
.	O

Pulmonary	O
epithelial	O
cell	O
necrosis	B-PROC
induced	O
by	O
PRCV	O
coincided	O
with	O
increased	O
NO	O
.	O

Our	O
study	O
suggests	O
that	O
unlike	O
PRRSV	O
which	O
induces	O
apoptosis	B-PROC
in	O
AMs	O
,	O
respiratory	O
CoVs	O
such	O
as	O
PRCV	O
that	O
infect	O
pulmonary	O
epithelial	O
cells	O
and	O
cause	O
cytolysis	B-PROC
,	O
induce	O
NO	O
production	O
in	O
the	O
respiratory	O
tract	O
.	O

Thus	O
,	O
cB61ba	O
mice	O
are	O
apparently	O
completely	O
resistant	O
to	O
MHV	O
-	O
A59	O
infection	O
,	O
while	O
SJL	O
mice	O
permit	O
low	O
levels	O
of	O
MHV	O
-	O
A59	O
virus	B-PROC
replication	I-PROC
during	O
self	O
-	O
limited	O
,	O
asymptomatic	O
infection	O
.	O

Tourism	O
constitutes	O
a	O
small	O
fraction	O
of	O
overall	O
movements	B-PROC
of	O
humans	O
but	O
a	O
point	O
worthy	O
of	O
note	O
is	O
the	O
number	O
of	O
international	O
travellers	O
has	O
increased	O
by	O
more	O
than	O
1	O
300	O
%	O
over	O
the	O
last	O
50	O
years	O
.	O

We	O
undertook	O
a	O
comparative	O
examination	O
of	O
cis	O
-	O
regulatory	O
sequences	O
involved	O
in	O
the	O
coordinated	O
expression	B-PROC
of	O
CS	O
-	O
responsive	O
genes	O
using	O
microarray	O
analysis	O
.	O

Analysis	O
of	O
stretched	O
versus	O
nonstretched	O
cells	O
identified	O
significant	O
enrichment	O
for	O
genes	O
containing	O
putative	O
binding	O
sites	O
for	O
the	O
transcription	B-PROC
factor	O
activating	O
transcription	B-PROC
factor	O
3	O
(	O
ATF3	O
).	O

This	O
RFLP	O
pattern	O
of	O
the	O
N	O
gene	O
differentiated	B-PROC
the	O
Chinese	O
vaccine	O
strain	O
from	O
its	O
parental	O
strain	O
,	O
the	O
11	O
TGEVs	O
studied	O
and	O
the	O
other	O
reported	O
TGEVs	O
in	O
the	O
GenBank	O
.	O

The	O
coronavirus	O
main	O
protease	O
,	O
3CL	O
(	O
pro	O
),	O
is	O
a	O
key	O
target	O
for	O
broad	O
-	O
spectrum	O
antiviral	O
development	B-PROC
because	O
of	O
its	O
critical	O
role	O
in	O
viral	B-PROC
maturation	B-PROC
and	O
high	O
degree	O
of	O
structural	O
conservation	O
among	O
coronaviruses	O
.	O

Characterization	O
of	O
these	O
dimerization	O
mechanisms	O
is	O
important	O
for	O
the	O
structure	O
-	O
based	O
design	O
of	O
new	O
treatments	O
targeting	B-PROC
coronavirus	O
-	O
based	O
infections	O
.	O

Hospitalized	O
patients	O
who	O
died	B-PROC
were	O
less	O
likely	O
to	O
have	O
received	O
oseltamivir	O
within	O
2	O
days	O
of	O
hospitalization	O
than	O
hospitalized	O
patients	O
who	O
survived	O
(	O
61	O
%	O
vs	O
96	O
%;	O
P	O
<	O
.	O
01	O
).	O

ABSTRACT	O
:	O
We	O
report	O
a	O
complicated	O
case	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
from	O
severe	O
sepsis	O
,	O
in	O
which	O
we	O
measured	O
the	O
ratio	O
of	O
physiologic	O
dead	B-PROC
space	O
to	O
tidal	O
volume	O
(	O
V	O
(	O
D	O
)/	O
V	O
(	O
T	O
))	O
with	O
volumetric	O
capnography	O
prior	O
to	O
,	O
during	O
,	O
and	O
after	O
therapy	O
with	O
human	O
recombinant	O
activated	O
protein	O
C	O
.	O
Previous	O
studies	O
hypothesized	O
that	O
early	O
in	O
ARDS	O
,	O
elevated	O
V	O
(	O
D	O
)/	O
V	O
(	O
T	O
)	O
primarily	O
reflects	O
increased	O
alveolar	O
V	O
(	O
D	O
),	O
probably	O
caused	O
by	O
pronounced	O
thrombi	O
formation	B-PROC
in	O
the	O
pulmonary	O
microvasculature	B-PROC
.	O

Over	O
the	O
course	O
of	O
activated	O
protein	O
C	O
therapy	O
there	O
was	O
a	O
persistent	O
decrease	O
in	O
alveolar	O
V	O
(	O
D	O
)	O
and	O
increase	O
in	O
alveolar	O
V	O
(	O
T	O
),	O
even	O
while	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
was	O
reduced	O
and	O
respiratory	O
-	O
system	O
compliance	O
decreased	O
.	O

TITLE	O
:	O
In	O
vitro	O
reconstitution	O
of	O
SARS	O
-	O
coronavirus	O
mRNA	O
cap	O
methylation	B-PROC
.	O

Most	O
examples	O
involve	O
emerging	O
zoonotic	O
diseases	B-PROC
caused	I-PROC
by	I-PROC
viruses	I-PROC
and	O
prions	O
and	O
transmitted	O
to	O
humans	O
by	O
a	O
bite	B-PROC
,	O
close	O
contact	O
with	O
affected	O
live	O
animals	O
or	O
carcasses	O
,	O
or	O
through	O
the	O
consumption	O
of	O
their	O
tissues	O
.	O

These	O
outbreaks	O
vary	O
from	O
very	O
small	O
and	O
localised	O
clusters	O
of	O
individual	O
cases	O
to	O
millions	O
of	O
deaths	B-PROC
,	O
as	O
reported	O
during	O
the	O
past	O
influenza	O
pandemics	O
.	O

Twenty	O
-	O
nine	O
patients	O
required	O
mechanical	O
ventilation	O
(	O
96	O
.	O
6	O
%);	O
only	O
one	O
required	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
;	O
and	O
19	O
(	O
63	O
%)	O
had	O
respiratory	O
complications	O
.	O

ABSTRACT	O
:	O
A	O
multiplex	O
reverse	B-PROC
transcription	B-PROC
-	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
nPCR	O
)	O
method	O
was	O
developed	O
for	O
the	O
detection	O
and	O
differentiation	B-PROC
of	O
wild	O
-	O
type	O
and	O
vaccine	O
strains	O
of	O
canine	O
distemper	O
virus	O
(	O
CDV	O
).	O

TITLE	O
:	O
Upper	O
-	O
respiratory	O
viral	B-PROC
infection	I-PROC
,	O
biomarkers	O
,	O
and	O
COPD	O
exacerbations	O
.	O

Fish	O
oil	O
-	O
containing	O
lipid	O
emulsions	O
have	O
been	O
used	O
in	O
parenteral	O
nutrition	B-PROC
in	O
adult	O
patients	O
post	O
-	O
surgery	O
(	O
mainly	O
gastrointestinal	O
).	O

TITLE	O
:	O
Functional	O
and	O
genetic	O
studies	O
of	O
the	O
substrate	O
specificity	O
of	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
3C	O
-	O
like	O
proteinase	B-PROC
.	O

Here	O
,	O
we	O
investigate	O
the	O
effects	O
of	O
amino	O
acid	O
substitution	O
at	O
the	O
P1	O
position	O
of	O
3CLpro	O
cleavage	B-PROC
sites	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
on	O
the	O
cleavage	B-PROC
efficiency	O
and	O
viral	B-PROC
replication	I-PROC
by	O
in	O
vitro	O
cleavage	B-PROC
assays	O
and	O
reverse	O
genetic	O
approaches	O
.	O

All	O
patients	O
were	O
on	O
mechanical	O
ventilation	O
and	O
inhaled	B-PROC
nitric	O
oxide	O
,	O
and	O
one	O
patient	O
was	O
on	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

This	O
suggests	O
that	O
-	O
123C	O
>	O
A	O
plays	O
a	O
more	O
important	O
role	O
in	O
modulating	O
basal	O
MxA	O
expression	B-PROC
,	O
thus	O
contributing	O
more	O
significantly	O
to	O
innate	B-PROC
immune	I-PROC
response	I-PROC
against	O
viral	B-PROC
infections	I-PROC
that	O
suppress	O
endogenous	O
IFN	O
-	O
alpha	O
and	O
IFN	O
-	O
beta	O
induction	O
such	O
as	O
SARS	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Most	O
RNA	O
viruses	O
lack	O
the	O
mechanisms	O
to	O
recognize	O
and	O
correct	O
mutations	O
that	O
arise	O
during	O
genome	O
replication	O
,	O
resulting	O
in	O
quasispecies	O
diversity	O
that	O
is	O
required	O
for	O
pathogenesis	B-PROC
and	O
adaptation	B-PROC
.	O

We	O
report	O
here	O
the	O
engineering	O
and	O
recovery	O
of	O
nsp14	O
-	O
ExoN	O
mutant	O
viruses	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
that	O
have	O
stable	O
growth	B-PROC
defects	O
and	O
demonstrate	O
a	O
21	O
-	O
fold	O
increase	O
in	O
mutation	O
frequency	O
during	O
replication	O
in	O
culture	O
.	O

TITLE	O
:	O
A	O
small	O
-	O
molecule	O
oxocarbazate	O
inhibitor	O
of	O
human	O
cathepsin	O
L	O
blocks	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
ebola	O
pseudotype	O
virus	B-PROC
infection	I-PROC
into	O
human	O
embryonic	O
kidney	O
293T	O
cells	O
.	O

Fractionation	O
of	O
cells	O
into	O
cytoplasmic	O
,	O
nuclear	O
,	O
and	O
nucleolar	O
extracts	O
was	O
used	O
to	O
reduce	O
sample	O
complexity	O
and	O
provide	O
information	O
on	O
the	O
trafficking	B-PROC
of	O
proteins	O
between	O
the	O
different	O
compartments	O
.	O

ABSTRACT	O
:	O
The	O
term	O
pulmonary	O
renal	O
vasculitis	O
syndrome	O
describes	O
a	O
clinical	O
syndrome	O
of	O
diffuse	O
alveolar	O
haemorrhage	O
(	O
DAH	O
)	O
complicating	O
acute	O
glomerulonephritis	O
that	O
often	O
heralds	O
severe	O
,	O
life	O
-	O
threatening	O
systemic	O
vasculitis	O
requiring	O
urgent	O
,	O
aggressive	B-PROC
therapy	O
.	O

After	O
adjusting	O
for	O
age	O
,	O
education	O
,	O
preexisting	O
cognitive	O
function	O
,	O
severity	O
of	O
illness	O
,	O
severe	O
sepsis	O
,	O
and	O
exposure	O
to	O
sedative	O
medications	O
in	O
the	O
intensive	O
care	O
unit	O
,	O
increasing	O
duration	O
of	O
delirium	O
was	O
an	O
independent	O
predictor	O
of	O
worse	O
cognitive	O
performance	O
-	O
determined	O
by	O
averaging	O
age	O
-	O
adjusted	O
and	O
education	O
-	O
adjusted	O
T	O
-	O
scores	O
from	O
nine	O
tests	O
measuring	O
seven	O
domains	O
of	O
cognition	B-PROC
-	O
at	O
3	O
-	O
mo	O
(	O
p	O
=.	O
02	O
)	O
and	O
12	O
-	O
mo	O
follow	O
-	O
up	O
(	O
p	O
=.	O
03	O
).	O

We	O
also	O
discuss	O
the	O
key	O
learning	B-PROC
points	O
from	O
this	O
experience	O
.	O

Alcohol	O
abuse	O
independently	O
increases	O
the	O
risk	O
approximately	O
two	O
-	O
to	O
fourfold	O
and	O
,	O
therefore	O
,	O
causes	O
tens	O
of	O
thousands	O
of	O
excess	O
deaths	B-PROC
annually	O
.	O

TITLE	O
:	O
Interactions	O
of	O
SARS	O
coronavirus	O
nucleocapsid	O
protein	O
with	O
the	O
host	O
cell	O
proteasome	B-PROC
subunit	O
p42	O
.	O

CONCLUSIONS	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
that	O
SARS	O
-	O
CoV	O
NP	O
interacts	O
with	O
the	O
proteasome	B-PROC
subunit	O
p42	O
within	O
host	O
cells	O
.	O

Exposure	O
of	O
NSCLC	O
cells	O
to	O
TSL	O
-	O
1	O
caused	O
cell	O
-	O
cycle	O
arrest	O
in	O
subG1	O
phase	O
and	O
caused	O
apoptosis	B-PROC
.	O

Taken	O
together	O
both	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
revealed	O
that	O
TSL	O
-	O
1	O
is	O
a	O
potent	O
inhibitor	O
against	O
NSCLC	O
growth	B-PROC
and	O
our	O
provoking	O
result	O
suggest	O
that	O
TSL	O
-	O
1	O
can	O
be	O
a	O
better	O
nutriceutical	O
as	O
a	O
singlet	O
or	O
along	O
with	O
doublet	O
agents	O
(	O
taxane	O
,	O
vinorelbine	O
,	O
and	O
gemcitabine	O
)	O
for	O
treating	O
NSCLC	O
.	O

Improving	O
alveolar	O
ventilation	O
and	O
oxygenation	B-PROC
may	O
improve	O
the	O
outcome	O
of	O
acute	O
chest	O
syndrome	O
(	O
ACS	O
).	O

TITLE	O
:	O
Upregulation	B-PROC
of	O
the	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-PROC
2	O
via	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
-	O
ACE2	O
signaling	B-PROC
pathway	I-PROC
.	O

To	O
understand	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
-	O
CoV	O
,	O
human	O
type	O
II	O
pneumocyte	O
(	O
A549	O
)	O
cells	O
were	O
incubated	O
with	O
the	O
viral	O
spike	O
protein	O
or	O
with	O
SARS	O
-	O
CoV	O
virus	O
-	O
like	O
particles	O
containing	O
the	O
viral	O
spike	O
protein	O
to	O
examine	O
cytokine	O
modulation	O
in	O
lung	O
cells	O
.	O

Furthermore	O
,	O
ACE2	O
receptor	O
was	O
activated	O
by	O
casein	O
kinase	O
II	O
-	O
mediated	O
phosphorylation	B-PROC
in	O
cells	O
pretreated	O
with	O
the	O
virus	O
-	O
like	O
particles	O
containing	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
ubiquitin	B-PROC
-	O
proteasome	B-PROC
system	O
(	O
UPS	O
)	O
is	O
a	O
key	O
player	O
in	O
regulating	O
the	O
intracellular	O
sorting	B-PROC
and	O
degradation	O
of	O
proteins	O
.	O

The	O
inhibitory	O
effect	O
on	O
CoV	O
protein	B-PROC
expression	B-PROC
did	O
not	O
appear	O
to	O
result	O
from	O
a	O
general	O
inhibition	B-PROC
of	O
translation	B-PROC
due	O
to	O
induction	O
of	O
a	O
cellular	O
stress	O
response	O
by	O
the	O
inhibitors	O
.	O

TITLE	O
:	O
Feline	O
lectin	B-PROC
activity	I-PROC
is	O
critical	O
for	O
the	O
cellular	O
entry	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
.	O

ABSTRACT	O
:	O
Many	O
viruses	O
,	O
including	O
coronaviruses	O
(	O
CoVs	O
),	O
depend	O
on	O
a	O
functional	O
cellular	O
proteasome	B-PROC
for	O
efficient	O
infection	O
in	O
vitro	O
.	O

We	O
constructed	O
a	O
large	O
protein	O
containing	O
the	O
cyan	O
fluorescent	O
protein	O
(	O
C	O
),	O
the	O
N	O
-	O
terminal	O
flanking	O
substrate	O
peptide	O
of	O
SARS	O
3CL	O
(	O
pro	O
)	O
(	O
XX	O
),	O
SARS	O
3CL	O
(	O
pro	O
)	O
(	O
3CLP	O
),	O
and	O
the	O
yellow	O
fluorescent	O
protein	O
(	O
Y	O
)	O
to	O
study	O
the	O
autoprocessing	O
of	O
3CL	O
(	O
pro	O
)	O
using	O
fluorescence	O
resonance	O
energy	B-PROC
transfer	I-PROC
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
2	O
-(	O
benzylthio	O
)-	O
6	O
-	O
oxo	O
-	O
4	O
-	O
phenyl	O
-	O
1	O
,	O
6	O
-	O
dihydropyrimidine	O
as	O
SARS	O
-	O
CoV	O
3CL	O
protease	B-PROC
inhibitors	I-PROC
were	O
developed	O
and	O
their	O
potency	O
was	O
evaluated	O
by	O
in	O
vitro	O
protease	O
inhibitory	O
assays	O
.	O

Two	O
candidates	O
had	O
encouraging	O
results	O
for	O
the	O
development	B-PROC
of	O
new	O
anti	O
-	O
SARS	O
compounds	O
.	O

We	O
observed	O
also	O
10	O
infections	O
A	O
/	O
H1N1	O
influenza	O
during	O
pregnancy	O
,	O
with	O
good	O
oseltamivir	O
tolerance	B-PROC
and	O
without	O
recent	O
perinathal	O
complications	O
.	O

We	O
observed	O
also	O
10	O
infections	O
A	O
/	O
H1N1	O
influenza	O
during	O
pregnancy	O
,	O
with	O
good	O
oseltamivir	O
tolerance	B-PROC
and	O
without	O
recent	O
perinathal	O
complications	O
.	O

We	O
propose	O
a	O
novel	O
mechanism	O
whereby	O
SARS	O
-	O
CoV	O
fusion	O
protein	B-PROC
function	I-PROC
can	O
be	O
controlled	O
by	O
spatial	O
regulation	B-PROC
of	O
the	O
proteolytic	B-PROC
priming	O
site	O
,	O
with	O
important	O
implications	O
for	O
viral	O
pathogenesis	B-PROC
.	O

This	O
study	O
examined	O
the	O
prevalence	O
of	O
the	O
avoidance	O
behaviors	B-PROC
(	O
i	O
.	O
e	O
.	O
avoiding	O
going	O
out	O
,	O
visiting	O
crowded	O
places	O
and	O
visiting	O
hospitals	O
)	O
and	O
negative	O
psychological	O
responses	O
of	O
the	O
general	O
population	O
in	O
Hong	O
Kong	O
at	O
the	O
initial	O
stage	O
of	O
the	O
H1N1	O
epidemic	O
.	O

Half	O
a	O
month	O
later	O
,	O
she	O
had	O
a	O
high	O
fever	B-PROC
and	O
abdominal	O
distension	O
.	O

H1N1	O
viral	B-PROC
infection	I-PROC
in	O
patients	O
with	O
cancer	O
can	O
cause	O
severe	O
illness	O
,	O
resulting	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
death	B-PROC
.	O

We	O
survey	O
particular	O
problems	O
associated	O
with	O
the	O
conduct	B-PROC
of	O
the	O
""""	O
pragmatic	O
""""	O
CESAR	O
trial	O
:	O
composite	O
endpoints	O
,	O
sample	O
size	O
estimation	O
under	O
uncertainty	O
of	O
baseline	O
mortality	O
rates	O
,	O
the	O
generation	O
of	O
unbiased	O
treatment	O
comparisons	O
,	O
the	O
impact	O
of	O
treatment	O
non	O
-	O
compliance	O
,	O
and	O
the	O
uncertainty	O
associated	O
with	O
cost	O
-	O
effectiveness	O
and	O
cost	O
-	O
utility	O
analysis	O
.	O

ABSTRACT	O
:	O
Influenza	O
infection	O
can	O
affect	O
cardiac	B-PROC
function	I-PROC
.	O

The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
one	O
of	O
the	O
structural	O
proteins	O
,	O
interacts	O
with	O
the	O
30	O
.	O
4	O
kb	O
virus	O
genomic	O
RNA	O
to	O
form	O
the	O
helical	O
nucleocapsid	O
and	O
associates	O
with	O
the	O
membrane	O
glycoprotein	O
via	O
its	O
C	O
-	O
terminus	O
to	O
stabilize	O
virion	B-PROC
assembly	I-PROC
.	O

Assumption	O
of	O
hemodynamic	B-PROC
stability	O
can	O
be	O
catastrophic	O
,	O
and	O
transferring	O
the	O
patient	O
to	O
a	O
second	O
facility	O
may	O
endanger	O
survival	O
,	O
when	O
operative	O
capacity	O
exists	O
at	O
the	O
initial	O
trauma	O
facility	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
these	O
infections	O
on	O
general	O
health	O
and	O
reproduction	B-PROC
parameters	O
measurable	O
on	O
herd	O
level	O
and	O
to	O
explore	O
the	O
association	O
between	O
antibody	B-PROC
status	O
and	O
some	O
herd	O
characteristics	O
.	O

Ten	O
herds	O
were	O
antibody	B-PROC
negative	O
to	O
both	O
viruses	O
and	O
were	O
compared	O
with	O
69	O
herds	O
positive	O
to	O
BCV	O
or	O
BRSV	O
or	O
both	O
.	O

The	O
medians	O
for	O
all	O
other	O
analyzed	O
health	O
and	O
reproductive	B-PROC
parameters	O
were	O
consistently	O
in	O
favour	O
of	O
the	O
herds	O
negative	O
to	O
both	O
viruses	O
although	O
the	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O

These	O
problems	O
suggest	O
deficiencies	O
in	O
recruiting	O
and	O
/	O
or	O
maturation	B-PROC
of	O
oligodendrocyte	O
progentior	O
cells	O
(	O
OPCs	O
)	O
and	O
highlight	O
cell	O
replacement	O
therapies	O
to	O
promote	O
remyelination	B-PROC
.	O

Treatment	O
with	O
anti	O
-	O
CXCL12	O
[	O
stromal	O
derived	O
factor	O
-	O
1alpha	O
,	O
(	O
SDF	O
-	O
1alpha	O
)]	O
blocking	O
serum	O
resulted	O
in	O
a	O
marked	O
impairment	O
in	O
migration	B-PROC
and	O
proliferation	O
of	O
engrafted	O
stem	O
cells	O
.	O

The	O
DMV	O
biogenesis	B-PROC
has	O
been	O
connected	O
with	O
the	O
early	O
secretory	B-PROC
pathway	I-PROC
.	O

We	O
show	O
that	O
MHV	O
co	O
-	O
opts	O
the	O
host	O
cell	O
machinery	O
for	O
COPII	O
-	O
independent	O
vesicular	O
ER	O
export	O
of	O
a	O
short	O
-	O
living	O
regulator	O
of	O
ER	O
-	O
associated	O
degradation	O
(	O
ERAD	B-PROC
),	O
EDEM1	O
,	O
to	O
derive	O
cellular	O
membranes	O
for	O
replication	O
.	O

We	O
previously	O
reported	O
that	O
the	O
adaptive	B-PROC
immune	I-PROC
response	I-PROC
plays	O
an	O
important	O
protective	O
role	O
in	O
MHV	O
-	O
1	O
-	O
infected	O
resistant	O
B6	O
mice	O
and	O
that	O
both	O
CD4	O
and	O
CD8	O
T	O
cells	O
play	O
a	O
significant	O
role	O
in	O
the	O
development	B-PROC
of	O
morbidity	O
and	O
lung	O
pathology	O
following	O
intranasal	O
MHV	O
-	O
1	O
infection	O
of	O
susceptible	O
C3H	O
/	O
HeJ	O
and	O
A	O
/	O
J	O
mice	O
.	O

Thus	O
,	O
it	O
is	O
important	O
to	O
explore	O
the	O
mechanism	O
(	O
s	O
)	O
controlling	O
alternative	B-PROC
splicing	B-PROC
of	O
CD200	O
.	O

A	O
total	O
of	O
501	O
patients	O
who	O
received	O
a	O
PA	O
catheter	O
were	O
evaluated	O
for	O
associations	O
between	O
increases	O
in	O
transpulmonary	O
gradient	O
(	O
TPG	O
)	O
(	O
PA	O
mean	O
pressure	O
-	O
PA	O
occlusion	B-PROC
pressure	O
)	O
or	O
pulmonary	B-PROC
vascular	I-PROC
resistance	I-PROC
index	O
(	O
PVRi	O
)	O
and	O
60	O
-	O
day	O
mortality	O
,	O
ventilator	O
-,	O
intensive	O
care	O
unit	O
(	O
ICU	O
)-,	O
and	O
cardiovascular	O
-	O
free	O
days	O
(	O
days	O
with	O
mean	O
arterial	B-PROC
pressure	I-PROC
≥	O
60	O
mm	O
Hg	O
off	O
vasopressor	O
support	O
).	O

During	O
virus	B-PROC
replication	I-PROC
,	O
a	O
3	O
'	O
coterminal	O
nested	O
set	O
of	O
five	O
to	O
eight	O
subgenomic	O
(	O
sg	O
)	O
mRNAs	O
are	O
made	O
that	O
are	O
also	O
5	O
'	O
coterminal	O
with	O
the	O
genome	O
,	O
because	O
they	O
carry	O
the	O
genomic	O
leader	O
as	O
the	O
result	O
of	O
discontinuous	O
transcription	B-PROC
at	O
intergenic	O
donor	O
signals	O
during	O
(-)-	O
strand	O
synthesis	B-PROC
when	O
templates	O
for	O
sgmRNA	O
synthesis	B-PROC
are	O
made	O
.	O

Here	O
,	O
using	O
RT	O
-	O
PCR	O
and	O
sequence	O
analyses	O
of	O
head	O
-	O
to	O
-	O
tail	O
-	O
ligated	O
(-)	O
strands	O
,	O
we	O
show	O
that	O
after	O
transfection	B-PROC
of	O
an	O
in	O
vitro	O
-	O
generated	O
marked	O
sgmRNA	O
into	O
virus	O
-	O
infected	O
cells	O
,	O
the	O
sgmRNA	O
,	O
like	O
the	O
genome	O
,	O
can	O
function	O
as	O
a	O
template	O
for	O
(-)-	O
strand	O
synthesis	B-PROC
.	O

Furthermore	O
,	O
when	O
the	O
transfected	O
sgmRNA	O
contains	O
an	O
internally	O
placed	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
template	O
-	O
switching	O
donor	O
signal	O
,	O
discontinuous	O
transcription	B-PROC
occurs	O
at	O
this	O
site	O
,	O
and	O
a	O
shorter	O
,	O
3	O
'	O
terminally	O
nested	O
leader	O
-	O
containing	O
sgmRNA	O
is	O
made	O
,	O
as	O
evidenced	O
by	O
its	O
leader	O
-	O
body	O
junction	O
and	O
by	O
the	O
expression	B-PROC
of	O
a	O
GFP	O
gene	O
.	O

To	O
improve	O
nursing	B-PROC
students	O
'	O
capacity	O
in	O
responding	O
to	O
infectious	O
epidemics	O
,	O
an	O
educational	O
programme	O
that	O
integrates	O
the	O
theme	O
of	O
infection	O
precautions	O
,	O
learning	B-PROC
theory	O
and	O
teaching	O
strategies	O
is	O
recommended	O
for	O
all	O
nursing	B-PROC
institutes	O
.	O

For	O
coronaviruses	O
,	O
it	O
was	O
long	O
speculated	O
that	O
replication	O
of	O
the	O
giant	O
RNA	O
genome	O
and	O
transcription	B-PROC
of	O
multiple	O
subgenomic	O
mRNA	O
species	O
by	O
a	O
unique	O
discontinuous	O
transcription	B-PROC
mechanism	O
may	O
require	O
host	O
cofactors	O
.	O

TITLE	O
:	O
Naturally	O
occurring	O
recombination	B-PROC
between	O
distant	O
strains	O
of	O
infectious	O
bronchitis	O
virus	O
.	O

This	O
contrasts	O
with	O
the	O
requirement	O
for	O
palmitoylation	B-PROC
of	O
mouse	O
hepatitis	O
virus	O
S	O
protein	O
for	O
interaction	O
with	O
M	O
protein	O
and	O
may	O
point	O
to	O
important	O
differences	O
in	O
assembly	O
and	O
infectivity	O
of	O
these	O
two	O
coronaviruses	O
.	O

TITLE	O
:	O
Monitoring	O
of	O
perceptions	O
,	O
anticipated	O
behavioral	B-PROC
,	O
and	O
psychological	O
responses	O
related	O
to	O
H5N1	O
influenza	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
monitor	O
changes	O
in	O
behavioral	B-PROC
and	O
emotional	O
responses	O
to	O
human	O
H5N1	O
in	O
the	O
community	O
over	O
a	O
28	O
-	O
month	O
period	O
(	O
from	O
November	O
2005	O
to	O
February	O
2008	O
).	O

Given	O
a	O
hypothetical	O
scenario	O
that	O
two	O
to	O
three	O
new	O
human	O
-	O
to	O
-	O
human	O
H5N1	O
cases	O
had	O
been	O
reported	O
in	O
Hong	O
Kong	O
,	O
the	O
trends	O
of	O
the	O
respondents	O
in	O
various	O
H5N1	O
-	O
related	O
risk	O
perceptions	O
,	O
anticipated	O
personal	O
psychological	O
responses	O
,	O
and	O
anticipated	O
personal	O
preventive	O
behaviors	B-PROC
were	O
investigated	O
.	O

We	O
sought	O
to	O
determine	O
the	O
effects	O
of	O
telbivudine	O
on	O
the	O
immune	O
system	O
,	O
particularly	O
on	O
cytokine	B-PROC
production	I-PROC
and	O
T	O
-	O
cell	O
response	O
,	O
using	O
an	O
animal	O
model	O
with	O
mouse	O
hepatitis	O
virus	O
strain	O
3	O
(	O
MHV	O
-	O
3	O
)-	O
induced	O
hepatitis	O
.	O

However	O
,	O
our	O
ability	O
to	O
make	O
sense	B-PROC
of	O
sequence	O
data	O
lags	O
behind	O
our	O
ability	O
to	O
acquire	O
the	O
data	O
.	O

Inhibiting	O
CXCR2	O
signaling	B-PROC
with	O
neutralizing	O
antiserum	O
significantly	O
(	O
p	O
<	O
0	O
.	O
03	O
)	O
delayed	O
clinical	O
recovery	O
.	O

It	O
was	O
shown	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
that	O
virulent	O
virus	O
present	O
in	O
the	O
quasispecies	O
did	O
not	O
emerge	O
from	O
the	O
""""	O
avirulent	O
background	O
""""	O
unless	O
a	O
direct	O
selection	O
pressure	O
was	O
placed	O
on	O
the	O
quasispecies	O
,	O
either	O
by	O
growth	B-PROC
conditions	O
or	O
by	O
transient	O
immunosuppression	B-PROC
.	O

Expectant	O
women	O
experienced	O
unexpected	O
social	O
disruption	O
and	O
isolation	O
within	O
their	O
day	O
-	O
to	O
-	O
day	O
life	O
that	O
have	O
not	O
been	O
described	O
in	O
their	O
own	O
voice	B-PROC
.	O

ABSTRACT	O
:	O
The	O
N	O
-	O
terminal	O
domain	O
of	O
nucleocapsid	O
protein	O
from	O
human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
N	O
-	O
NTD	O
)	O
mostly	O
contains	O
positively	O
charged	O
residues	O
and	O
has	O
been	O
identified	O
as	O
being	O
responsible	O
for	O
RNA	O
binding	O
during	O
ribonucleocapsid	O
formation	B-PROC
in	O
the	O
coronavirus	O
.	O

We	O
hypothesized	O
that	O
during	O
host	B-PROC
invasion	I-PROC
,	O
the	O
replicating	O
IBV	O
population	O
further	O
changes	O
as	O
it	O
confronts	O
the	O
distinct	O
environments	O
of	O
different	O
tissues	O
,	O
leading	O
to	O
selection	O
of	O
the	O
most	O
fit	O
population	O
.	O

At	O
present	O
,	O
there	O
are	O
no	O
BCoV	O
vaccines	O
to	O
prevent	O
respiratory	O
BCoV	O
infections	O
in	O
cattle	O
,	O
and	O
the	O
correlates	O
of	O
immunity	B-PROC
to	O
respiratory	O
BCoV	O
infections	O
are	O
unknown	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
panel	O
of	O
multiplex	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
assays	O
for	O
simultaneous	O
detection	O
of	O
major	O
agents	O
causing	O
calf	O
diarrhea	O
in	O
feces	O
.	O

TITLE	O
:	O
Cell	O
replacement	O
therapies	O
to	O
promote	O
remyelination	B-PROC
in	O
a	O
viral	O
model	O
of	O
demyelination	O
.	O

Challenge	O
studies	O
in	O
mice	O
demonstrated	O
that	O
expression	B-PROC
of	O
the	O
MHV	O
-	O
1	O
S	O
gene	O
within	O
the	O
MHV	O
-	O
A59	O
background	O
(	O
rA59	O
/	O
S	O
(	O
MHV	O
-	O
1	O
))	O
increased	O
the	O
pneumovirulence	O
of	O
MHV	O
-	O
A59	O
,	O
and	O
mice	O
infected	O
with	O
this	O
recombinant	O
virus	O
developed	O
pulmonary	O
lesions	O
that	O
were	O
similar	O
to	O
those	O
observed	O
with	O
MHV	O
-	O
1	O
,	O
although	O
rA59	O
/	O
S	O
(	O
MHV	O
-	O
1	O
)	O
was	O
significantly	O
less	O
virulent	O
.	O

The	O
combination	O
of	O
experimental	O
X	O
-	O
ray	O
structural	O
information	O
and	O
aspherical	O
atomic	O
electron	O
density	O
data	O
from	O
theoretical	O
calculations	O
resulted	O
in	O
properties	O
like	O
the	O
electrostatic	O
potential	O
and	O
the	O
Hirshfeld	O
surface	O
which	O
allowed	O
a	O
study	O
of	O
electronic	O
complementarity	O
and	O
the	O
identification	O
of	O
sites	O
and	O
strengths	O
of	O
drug	O
-	O
receptor	B-PROC
interactions	I-PROC
.	O

The	O
pathogenesis	B-PROC
of	O
aseptic	O
pneumonitis	O
is	O
unknown	O
,	O
but	O
various	O
proinflammatory	O
cytokines	O
have	O
been	O
implicated	O
,	O
especially	O
tumor	O
necrosis	B-PROC
factor	O
-	O
alpha	O
,	O
which	O
could	O
play	O
a	O
role	O
in	O
the	O
recruitment	O
of	O
leukocytes	O
to	O
the	O
lung	O
.	O

A	O
new	O
ensemble	O
of	O
20	O
conformers	O
representing	O
the	O
NMR	O
structure	O
of	O
the	O
NAB	O
,	O
which	O
was	O
calculated	O
with	O
an	O
input	O
containing	O
backbone	O
torsion	B-PROC
angle	O
constraints	O
derived	O
from	O
the	O
theoretical	O
(	O
13	O
)	O
C	O
(	O
alpha	O
)	O
chemical	O
shifts	O
as	O
supplementary	O
data	O
to	O
the	O
NOE	O
distance	O
constraints	O
,	O
exhibits	O
very	O
similar	O
topology	O
and	O
comparable	O
agreement	O
with	O
the	O
NOE	O
constraints	O
as	O
the	O
published	O
NMR	O
structure	O
.	O

TITLE	O
:	O
Complete	O
genome	O
sequence	O
and	O
recombination	B-PROC
analysis	O
of	O
infectious	O
bronchitis	O
virus	O
attenuated	O
vaccine	O
strain	O
H120	O
.	O

Of	O
the	O
9	O
ARDS	O
patients	O
,	O
3	O
died	B-PROC
of	O
ventilator	O
-	O
associated	O
pneumonia	O
caused	O
by	O
multidrug	O
-	O
resistant	O
Acinetobacter	O
baumannii	O
.	O

The	O
efficiency	O
of	O
RMs	O
may	O
be	O
affected	O
by	O
different	O
factors	O
,	O
including	O
the	O
nature	O
and	O
extent	O
of	O
lung	O
injury	O
,	O
capability	O
of	O
increasing	O
inspiratory	B-PROC
transpulmonary	O
pressures	O
,	O
patient	O
positioning	O
and	O
cardiac	O
preload	O
.	O

Our	O
genetic	O
results	O
were	O
corroborated	O
by	O
the	O
demonstration	O
that	O
the	O
expressed	B-PROC
amino	O
-	O
terminal	O
segment	O
of	O
nsp3	O
bound	O
selectively	O
to	O
N	O
protein	O
from	O
infected	O
cells	O
,	O
and	O
this	O
interaction	O
was	O
RNA	O
independent	O
.	O

During	O
a	O
vascular	O
occlusion	B-PROC
test	O
,	O
the	O
microcirculation	B-PROC
was	O
moderately	O
to	O
severely	O
compromised	O
with	O
a	O
NIRS	O
ascending	O
slope	O
of	O
2	O
.	O
39	O
%·	O
sec	O
(-	O
1	O
)	O

Korean	O
students	O
increased	O
their	O
frequency	O
of	O
hand	O
hygiene	O
practices	O
during	O
the	O
pandemic	O
,	O
with	O
significant	O
gender	O
differences	O
existing	O
in	O
the	O
attitudes	O
and	O
behaviors	B-PROC
related	O
to	O
the	O
use	O
of	O
hand	O
hygiene	O
as	O
a	O
means	O
of	O
disease	O
prevention	O
.	O

It	O
seems	O
that	O
adaptation	B-PROC
of	O
the	O
virus	O
within	O
the	O
host	O
animal	O
and	O
the	O
subsequent	O
abnormal	O
immune	B-PROC
responses	I-PROC
may	O
be	O
key	O
factors	O
in	O
the	O
pathogenesis	B-PROC
of	O
this	O
new	O
and	O
fatal	O
respiratory	O
disease	O
.	O

MHV	O
-	O
Brts31	O
has	O
near	O
-	O
normal	O
levels	O
of	O
RNA	B-PROC
synthesis	I-PROC
at	O
the	O
permissive	O
temperature	O
of	O
33	O
degrees	O
C	O
but	O
is	O
unable	O
to	O
synthesize	O
viral	O
RNA	O
when	O
the	O
infection	O
is	O
initiated	O
and	O
maintained	O
at	O
the	O
nonpermissive	O
temperature	O
of	O
39	O
.	O
5	O
degrees	O
C	O
.	O
Sequence	O
analysis	O
of	O
MHV	O
-	O
Brts31	O
RNA	O
indicated	O
that	O
a	O
single	O
G	O
-	O
to	O
-	O
A	O
transition	O
at	O
codon	O
1307	O
in	O
open	O
reading	O
frame	O
1a	O
,	O
which	O
results	O
in	O
a	O
replacement	O
of	O
methionine	O
-	O
475	O
with	O
isoleucine	O
in	O
nonstructural	O
protein	O
3	O
(	O
nsp3	O
),	O
was	O
responsible	O
for	O
the	O
ts	O
phenotype	O
.	O

TITLE	O
:	O
Papain	O
-	O
like	O
protease	O
1	O
from	O
transmissible	O
gastroenteritis	O
virus	O
:	O
crystal	O
structure	O
and	O
enzymatic	B-PROC
activity	I-PROC
toward	O
viral	O
and	O
cellular	O
substrates	O
.	O

International	O
cooperation	O
is	O
the	O
only	O
way	O
to	O
minimize	O
the	O
health	O
risks	O
associated	O
with	O
the	O
growth	B-PROC
in	O
global	O
air	O
travel	O
.	O

TITLE	O
:	O
Synthesis	B-PROC
,	O
activity	O
,	O
and	O
pharmacokinetic	O
properties	O
of	O
a	O
series	O
of	O
conformationally	O
-	O
restricted	O
thiourea	O
analogs	O
as	O
novel	O
hepatitis	O
C	O
virus	O
inhibitors	O
.	O

This	O
review	O
summarizes	O
recent	O
findings	O
of	O
human	O
coronavirus	O
HCoV	O
-	O
NL63	O
infections	O
,	O
including	O
isolation	O
and	O
identification	O
,	O
phylogeny	O
and	O
taxonomy	O
,	O
genome	O
structure	O
and	O
transcriptional	B-PROC
regulation	I-PROC
,	O
transmission	O
and	O
pathogenesis	B-PROC
,	O
and	O
detection	O
and	O
diagnosis	O
.	O

Such	O
unique	O
phenomena	O
,	O
and	O
the	O
unusual	O
instability	O
of	O
ORF7a	O
,	O
are	O
likely	O
due	O
to	O
recombination	B-PROC
which	O
may	O
have	O
been	O
facilitated	O
by	O
the	O
dense	O
roosting	O
behavior	O
and	O
long	O
foraging	O
range	O
of	O
Leschenault	O
'	O
s	O
rousette	O
.	O

Several	O
human	O
HLA	O
-	O
A	O
*	O
0201	O
restricted	O
CTL	O
epitopes	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
spike	O
(	O
S	O
)	O
protein	O
have	O
been	O
identified	O
in	O
HLA	O
-	O
A	O
*	O
0201	O
transgenic	O
(	O
Tg	O
)	O
mice	O
,	O
but	O
the	O
mechanisms	O
and	O
properties	O
of	O
immune	B-PROC
responses	I-PROC
are	O
still	O
not	O
well	O
understood	O
.	O

Three	O
different	O
methods	O
(	O
ELISA	O
,	O
ELISPOT	O
and	O
FACS	O
)	O
were	O
used	O
to	O
evaluate	O
the	O
immune	B-PROC
responses	I-PROC
during	O
short	O
and	O
long	O
periods	B-PROC
of	O
time	O
after	O
immunization	O
.	O

The	O
present	O
study	O
includes	O
data	O
on	O
conformational	O
equilibria	O
and	O
intramolecular	O
rate	O
processes	O
in	O
nsp7	O
in	O
solution	O
at	O
pH	O
6	O
.	O
5	O
,	O
which	O
provide	O
further	O
insights	O
into	O
the	O
polymorphisms	B-PROC
implicated	O
by	O
a	O
comparison	O
of	O
the	O
three	O
presently	O
available	O
nsp7	O
structures	O
.	O

On	O
review	O
of	O
our	O
database	O
held	O
from	O
September	O
1989	O
until	O
date	O
,	O
there	O
were	O
four	O
patients	O
with	O
sputum	O
-	O
confirmed	O
Panton	O
-	O
Valentine	O
leukocidin	O
expressing	O
S	O
.	O
aureus	O
pneumonia	O
managed	O
with	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

ABSTRACT	O
:	O
Culturing	O
newly	O
identified	O
human	O
lung	O
pathogens	O
from	O
clinical	O
sample	O
isolates	O
can	O
represent	O
a	O
daunting	O
task	O
,	O
with	O
problems	O
ranging	O
from	O
low	O
levels	O
of	O
pathogens	O
to	O
the	O
presence	O
of	O
growth	B-PROC
suppressive	O
factors	O
in	O
the	O
specimens	O
,	O
compounded	O
by	O
the	O
lack	O
of	O
a	O
suitable	O
tissue	O
culture	O
system	O
.	O

Multiplex	O
reverse	O
-	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
was	O
conducted	O
for	O
detection	O
of	O
11	O
respiratory	O
viruses	O
,	O
and	O
medical	O
records	O
were	O
reviewed	O
.	O

Two	O
patients	O
admitted	O
to	O
ICU	O
for	O
respiratory	O
insufficiency	O
and	O
a	O
diagnosis	O
of	O
severe	O
acute	O
pancreatitis	O
developed	O
pancreatic	O
necrosis	B-PROC
and	O
were	O
treated	O
by	O
necrosectomy	O
,	O
lesser	O
sac	B-PROC
marsupialisation	O
and	O
posterior	O
lumbotomic	O
opening	O
.	O

Reproductive	B-PROC
data	O
were	O
collected	O
during	O
a	O
period	O
from	O
January	O
2007	O
to	O
July	O
2008	O
and	O
were	O
retrospectively	O
evaluated	O
.	O

The	O
impacts	O
of	O
PEDV	O
infection	O
on	O
subsequent	O
reproductive	B-PROC
performance	O
were	O
more	O
severe	O
in	O
the	O
pregnant	O
gilts	O
than	O
the	O
pregnant	O
sows	O
.	O

The	O
results	O
of	O
molecular	O
modeling	O
and	O
docking	B-PROC
within	O
the	O
RT	O
non	O
-	O
nucleoside	O
binding	O
site	O
using	O
AutoDock	O
confirmed	O
that	O
the	O
3	O
series	O
,	O
similar	O
to	O
other	O
non	B-PROC
-	I-PROC
nucleoside	I-PROC
reverse	I-PROC
transcriptase	I-PROC
inhibitors	I-PROC
such	O
as	O
N	O
-(	O
5	O
-	O
chloro	O
-	O
2	O
-	O
pyridinyl	O
)-	O
N	O
'-[	O
2	O
-(	O
4	O
-	O
ethoxy	O
-	O
3	O
-	O
fluoro	O
-	O
2	O
-	O
pyridinyl	O
)	O
ethyl	O
]-	O
thiourea	O
(	O
PETT	O
),	O
was	O
assumed	O
in	O
a	O
butterfly	O
-	O
like	O
conformation	O
and	O
helped	O
to	O
rationalize	O
some	O
SARs	O
and	O
the	O
biological	O
activity	O
data	O
.	O

A	O
rapid	O
development	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
significant	O
hypoxemia	O
and	O
hypercapnia	O
with	O
the	O
low	O
efficiency	O
of	O
various	O
therapeutic	O
measures	O
and	O
hence	O
progressive	O
organ	O
dysfunction	O
determine	O
the	O
essence	O
of	O
the	O
severe	O
course	O
of	O
the	O
disease	O
.	O

No	O
specific	O
single	O
or	O
mixed	O
viral	B-PROC
infections	I-PROC
appeared	O
to	O
be	O
associated	O
significantly	O
with	O
secondary	O
hospitalization	O
in	O
infectious	O
disease	O
or	O
intensive	O
care	O
departments	O
during	O
the	O
study	O
period	O
(	O
P	O
>	O
0	O
.	O
5	O
).	O

In	O
order	O
to	O
investigate	O
whether	O
CEACAM1a	O
is	O
also	O
expressed	B-PROC
in	O
other	O
cell	O
types	O
,	O
ceacam1a	O
mRNA	B-PROC
expression	B-PROC
was	O
quantified	O
in	O
murine	O
tissues	O
and	O
primary	O
cells	O
.	O

As	O
expected	O
,	O
among	O
CNS	O
cell	O
types	O
,	O
microglia	O
expressed	B-PROC
the	O
highest	O
levels	O
of	O
ceacam1a	O
,	O
but	O
lower	O
levels	O
were	O
also	O
detected	O
in	O
oligodendrocytes	O
,	O
astrocytes	O
,	O
and	O
neurons	O
.	O

With	O
aggressive	B-PROC
hydration	O
her	O
renal	B-PROC
function	I-PROC
remained	O
normal	O
throughout	O
the	O
entire	O
disease	O
course	O
,	O
and	O
she	O
steadily	O
improved	O
clinically	O
.	O

This	O
interference	O
with	O
nuclear	B-PROC
import	I-PROC
requires	O
interaction	O
between	O
protein	O
6	O
and	O
cellular	O
karyopherins	O
,	O
a	O
process	O
that	O
typically	O
involves	O
nuclear	O
localization	B-PROC
signal	O
(	O
NLS	O
)	O
motifs	O
.	O

It	O
also	O
helped	O
reduce	O
the	O
amount	O
of	O
sclerosant	O
,	O
an	O
issue	O
that	O
is	O
associated	O
with	O
severe	O
complications	O
,	O
such	O
as	O
hemolysis	B-PROC
,	O
allergy	B-PROC
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
others	O
.	O

TITLE	O
:	O
Growth	B-PROC
hormone	O
releasing	O
peptide	O
-	O
2	O
,	O
a	O
ghrelin	O
agonist	O
,	O
attenuates	O
lipopolysaccharide	O
-	O
induced	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

We	O
therefore	O
explored	O
whether	O
GHRP	O
-	O
2	O
possesses	O
anti	O
-	O
inflammatory	O
properties	O
in	O
the	O
pathogenesis	B-PROC
of	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
ALI	O
.	O

Painful	O
and	O
repetitive	O
spasms	O
interfere	O
with	O
respiration	B-PROC
and	O
may	O
cause	O
metabolic	B-PROC
disturbances	O
such	O
as	O
hyperpyrexia	O
,	O
dehydration	O
,	O
respiratory	O
insufficiency	O
,	O
and	O
acute	O
renal	O
failure	O
secondary	O
to	O
rhabdomyolysis	O
.	O

TITLE	O
:	O
Generating	O
stable	O
Chinese	O
hamster	O
ovary	O
cell	O
clones	O
to	O
produce	O
a	O
truncated	O
SARS	O
-	O
CoV	O
spike	O
protein	O
for	O
vaccine	O
development	B-PROC
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
important	O
for	O
vaccine	O
development	B-PROC
.	O

To	O
establish	O
stable	O
expressing	O
cell	O
clones	O
,	O
we	O
transfected	O
CHO	O
/	O
dhFr	B-PROC
-	O
cells	O
with	O
the	O
amplifiable	O
vectors	O
ISID	O
(	O
IRES	O
-	O
driven	O
dhfr	B-PROC
)	O
and	O
ISIZ	O
(	O
SV40	O
-	O
driven	O
dhfr	B-PROC
)	O
to	O
select	O
stepwise	O
MTX	O
,	O
and	O
observed	O
enhanced	O
∼	O
115	O
kDa	O
glycoform	O
generation	O
through	O
gene	B-PROC
amplification	I-PROC
.	O

Following	O
stepwise	O
MTX	O
selection	O
,	O
we	O
compared	O
gene	B-PROC
amplification	I-PROC
levels	O
between	O
two	O
vectors	O
in	O
engineered	O
CHO	O
cell	O
chromosomes	O
.	O

These	O
results	O
confirm	O
that	O
the	O
IRES	O
-	O
driven	O
dhfr	B-PROC
promoter	O
generates	O
greater	O
gene	B-PROC
amplification	I-PROC
,	O
which	O
in	O
turn	O
enhances	O
S	O
(	O
TR2	O
)	O
expression	B-PROC
.	O

ABSTRACT	O
:	O
As	O
protein	B-PROC
folding	I-PROC
is	O
an	O
imperfect	O
process	O
,	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
contains	O
folding	O
as	O
well	O
as	O
ER	O
-	O
associated	O
degradation	O
(	O
ERAD	B-PROC
)	O
machineries	O
.	O

TITLE	O
:	O
Antioxidative	O
and	O
antiviral	O
properties	O
of	O
flowering	B-PROC
cherry	O
fruits	O
(	O
Prunus	O
serrulata	O
L	O
.	O
var	O
.	O

This	O
suggests	O
that	O
the	O
deaths	B-PROC
of	O
fellow	O
healthcare	O
workers	O
from	O
an	O
occupational	O
acquired	O
infection	O
had	O
an	O
overwhelming	O
effect	O
on	O
their	O
compliance	O
with	O
infection	O
control	O
measures	O
.	O

Using	O
multiplex	O
PCR	O
/	O
RT	O
-	O
PCR	O
methods	O
for	O
the	O
detection	O
of	O
18	O
respiratory	O
viruses	O
,	O
the	O
circulation	B-PROC
of	O
those	O
viruses	O
during	O
3	O
consecutive	O
dry	O
seasons	O
in	O
Cambodia	O
was	O
described	O
.	O

Among	O
patients	O
who	O
developed	O
ALI	O
/	O
ARDS	O
,	O
there	O
was	O
no	O
evidence	O
to	O
support	O
a	O
difference	O
in	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
in	O
arterial	O
blood	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
Pao	B-PROC
(	O
2	O
)/	O
Fio	O
(	O
2	O
))	O
(	O
P	O
=	O
.	O
33	O
),	O
lung	O
injury	O
score	O
(	O
P	O
=	O
.	O
67	O
),	O
or	O
mortality	O
(	O
P	O
=	O
.	O
78	O
)	O
by	O
race	O
.	O

Among	O
patients	O
who	O
developed	O
ALI	O
/	O
ARDS	O
,	O
there	O
was	O
no	O
evidence	O
to	O
support	O
a	O
difference	O
in	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
in	O
arterial	O
blood	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
Pao	B-PROC
(	O
2	O
)/	O
Fio	O
(	O
2	O
))	O
(	O
P	O
=	O
.	O
33	O
),	O
lung	O
injury	O
score	O
(	O
P	O
=	O
.	O
67	O
),	O
or	O
mortality	O
(	O
P	O
=	O
.	O
78	O
)	O
by	O
race	O
.	O

TITLE	O
:	O
Impaired	O
immune	B-PROC
responses	I-PROC
following	O
spinal	O
cord	O
injury	O
lead	O
to	O
reduced	O
ability	O
to	O
control	O
viral	B-PROC
infection	I-PROC
.	O

The	O
co	O
-	O
circulation	B-PROC
of	O
multiple	O
IBV	O
types	O
and	O
the	O
ongoing	O
emergence	O
of	O
IBV	O
variants	O
are	O
the	O
epidemiological	O
challenges	O
in	O
China	O
.	O

TITLE	O
:	O
[	O
Consecutive	O
five	O
-	O
year	O
follow	O
-	O
up	O
analysis	O
of	O
specific	O
IgG	O
antibody	B-PROC
of	O
22	O
cases	O
of	O
SARS	O
patients	O
after	O
recovery	O
].	O

These	O
data	O
provide	O
a	O
useful	O
reference	O
for	O
diagnosis	O
and	O
control	O
of	O
SARS	O
infection	O
,	O
the	O
evaluation	O
of	O
immune	B-PROC
response	I-PROC
and	O
vaccine	O
efficacy	O
.	O

TITLE	O
:	O
Muscarinic	O
receptor	O
antagonist	B-PROC
therapy	O
improves	O
acute	O
pulmonary	O
dysfunction	O
after	O
smoke	O
inhalation	B-PROC
injury	O
in	O
sheep	O
.	O

(	O
Funded	O
by	O
Assistance	O
Publique	O
-	O
Hôpitaux	O
de	O
Marseille	O
and	O
the	O
Programme	O
Hospitalier	O
de	O
Recherche	O
Clinique	O
Régional	O
2004	O
-	O
26	O
of	O
the	O
French	O
Ministry	O
of	O
Health	O
;	O
ClinicalTrials	O
.	O
gov	O
number	O
,	O
NCT00299650	O
.)	O
RESULTS	O
:	O
The	O
hazard	O
ratio	O
for	O
death	B-PROC
at	O
90	O
days	O
in	O
the	O
cisatracurium	O
group	O
,	O
as	O
compared	O
with	O
the	O
placebo	O
group	O
,	O
was	O
0	O
.	O
68	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
0	O
.	O
48	O
to	O
0	O
.	O
98	O
;	O
P	O
=	O
0	O
.	O
04	O
),	O
after	O
adjustment	O
for	O
both	O
the	O
baseline	O
PaO2	O
:	O
FIO2	O
and	O
plateau	O
pressure	O
and	O
the	O
Simplified	O
Acute	O
Physiology	O
II	O
score	O
.	O

Compared	O
with	O
SO	O
group	O
,	O
the	O
levels	O
of	O
arterial	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
(	O
PaO	B-PROC
(	O
2	O
))	O
and	O
pH	O
value	O
in	O
model	O
group	O
were	O
significantly	O
decreased	O
[	O
PaO	B-PROC
(	O
2	O
)	O
(	O
mm	O
Hg	O
,	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
):	O
79	O
.	O
24	O
±	O
5	O
.	O
84	O
vs	O
.	O
96	O
.	O
78	O
±	O
3	O
.	O
81	O
,	O
pH	O
value	O
:	O
7	O
.	O
269	O
±	O
0	O
.	O
054	O
vs	O
.	O
7	O
.	O
391	O
±	O
0	O
.	O
054	O
],	O
arterial	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
(	O
PaCO	O
(	O
2	O
)),	O
the	O
serum	O
levels	O
of	O
AMY	O
,	O
W	O
/	O
D	O
ratio	O
and	O
the	O
serum	O
levels	O
of	O
sPLA	O
(	O
2	O
)	O
were	O
significantly	O
increased	O
[	O
PaCO	O
(	O
2	O
)	O
(	O
mm	O
Hg	O
):	O
47	O
.	O
57	O
±	O
2	O
.	O
55	O
vs	O
.	O
27	O
.	O
69	O
±	O
1	O
.	O
02	O
,	O
AMY	O
(	O
U	O
/	O
L	O
):	O
7	O
144	O
.	O
19	O
±	O
727	O
.	O
91	O
vs	O
.	O
1	O
193	O
.	O
41	O
±	O
192	O
.	O
54	O
,	O
W	O
/	O
D	O
ratio	O
:	O
8	O
.	O
57	O
±	O
2	O
.	O
45	O
vs	O
.	O
3	O
.	O
70	O
±	O
0	O
.	O
90	O
,	O
sPLA	O
(	O
2	O
)	O
(	O
nmol	O
×	O
min	O
(-	O
1	O
)	O
×	O
ml	O
(-	O
1	O
)):	O
45	O
.	O
13	O
±	O
6	O
.	O
05	O
vs	O
.	O
29	O
.	O
94	O
±	O
6	O
.	O
39	O
],	O
the	O
expression	B-PROC
of	O
sPLA	O
(	O
2	O
)-	O
II	O
mRNA	O
(	O
1	O
.	O
28	O
±	O
0	O
.	O
21	O
vs	O
.	O
0	O
.	O
80	O
±	O
0	O
.	O
08	O
)	O
and	O
protein	O
were	O
significantly	O
increased	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
higher	O
expression	B-PROC
of	O
sPLA	O
(	O
2	O
)-	O
IIin	O
lung	O
may	O
be	O
one	O
of	O
pathogenetic	O
factors	O
in	O
ALI	O
induced	O
by	O
SAP	O
.	O

Recognition	O
of	O
this	O
complication	O
is	O
critical	O
,	O
as	O
it	O
has	O
to	O
be	O
differentiated	B-PROC
from	O
other	O
life	O
threatening	O
ones	O
including	O
oesophageal	O
rupture	O
,	O
Boerhave	O
'	O
s	O
syndrome	O
,	O
acute	O
coronary	O
syndrome	O
and	O
pulmonary	O
embolism	O
.	O

We	O
found	O
that	O
a	O
soluble	O
form	O
of	O
anti	O
-	O
NCAM	O
antibody	B-PROC
blocked	O
association	O
of	O
the	O
PHE	O
-	O
CoV	O
with	O
N2a	O
cells	O
.	O

RESULTS	O
:	O
We	O
identified	O
Neural	O
Cell	B-PROC
Adhesion	I-PROC
Molecule	O
(	O
NCAM	O
)	O
as	O
a	O
novel	O
interacting	O
partner	O
of	O
the	O
PHE	O
-	O
CoV	O
S	O
protein	O
.	O

ABSTRACT	O
:	O
Local	O
prevalences	O
of	O
individual	O
diseases	O
influence	O
the	O
prioritization	O
of	O
the	O
differential	O
diagnoses	O
of	O
a	O
clinical	O
syndrome	O
of	O
acute	O
undifferentiated	O
febrile	B-PROC
illness	O
(	O
AFI	O
).	O

ABSTRACT	O
:	O
The	O
T	O
cell	O
inhibitory	O
ligand	B-PROC
B7	O
-	O
H1	O
hinders	O
T	O
cell	O
-	O
mediated	O
virus	O
control	O
,	O
but	O
also	O
ameliorates	O
clinical	O
disease	O
during	O
autoimmune	O
and	O
virus	O
-	O
induced	O
CNS	O
disease	O
.	O

In	O
mice	O
infected	O
with	O
gliatropic	O
demyelinating	O
coronavirus	O
,	O
B7	O
-	O
H1	O
expression	B-PROC
on	O
oligodendroglia	O
delays	O
virus	O
control	O
,	O
but	O
also	O
dampens	O
clinical	O
disease	O
.	O

B7	O
-	O
H1	O
deficiency	O
did	O
not	O
affect	O
peripheral	O
T	O
or	O
B	B-PROC
cell	I-PROC
activation	I-PROC
or	O
alter	O
the	O
magnitude	O
or	O
composition	O
of	O
CNS	O
-	O
infiltrating	O
cells	O
.	O

Since	O
2003	O
,	O
there	O
have	O
been	O
a	O
total	O
of	O
436	O
cases	O
and	O
262	O
deaths	B-PROC
due	O
to	O
H5N1	O
infections	O
.	O

These	O
emerging	O
sublineages	O
display	O
varying	O
levels	O
of	O
drug	B-PROC
resistance	B-PROC
and	O
in	O
some	O
cases	O
an	O
increased	O
preference	O
for	O
binding	O
to	O
human	O
α2	O
,	O
6	O
-	O
linked	O
sialic	O
acid	O
cellular	O
receptors	O
.	O

There	O
was	O
only	O
one	O
death	B-PROC
in	O
2003	O
.	O

These	O
results	O
show	O
that	O
in	O
early	O
phase	O
,	O
the	O
inflammatory	O
cytokines	O
in	O
plasma	O
might	O
affect	O
iNOS	O
expression	B-PROC
and	O
cytokines	O
.	O

ABSTRACT	O
:	O
The	O
distribution	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
receptor	O
,	O
an	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
does	O
not	O
strictly	O
correlate	O
with	O
SARS	O
-	O
CoV	O
cell	O
tropism	B-PROC
in	O
lungs	O
;	O
therefore	O
,	O
other	O
cellular	O
factors	O
have	O
been	O
predicted	O
to	O
be	O
required	O
for	O
activation	O
of	O
virus	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Evaluation	O
of	O
prognosis	O
in	O
patients	O
with	O
respiratory	O
failure	O
requiring	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O

TITLE	O
:	O
Biflavonoids	O
from	O
Torreya	O
nucifera	O
displaying	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
inhibition	B-PROC
.	O

Following	O
bioactivity	O
-	O
guided	O
fractionation	O
,	O
eight	O
diterpenoids	O
(	O
1	O
-	O
8	O
)	O
and	O
four	O
biflavonoids	O
(	O
9	O
-	O
12	O
)	O
were	O
isolated	O
and	O
evaluated	O
for	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
inhibition	B-PROC
using	O
fluorescence	O
resonance	O
energy	B-PROC
transfer	I-PROC
analysis	O
.	O

However	O
,	O
the	O
only	O
therapeutic	O
measure	O
that	O
has	O
systematically	O
shown	O
to	O
be	O
able	O
to	O
improve	O
survival	O
is	O
that	O
of	O
low	O
volume	B-PROC
lung	I-PROC
protective	O
ventilation	O
.	O

We	O
utilized	O
a	O
highly	O
sensitive	O
antibody	B-PROC
profiling	O
technology	O
to	O
study	O
autoantibodies	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
severe	O
sepsis	O
,	O
conditions	O
characterized	O
by	O
intensive	O
immune	O
activation	O
leading	O
to	O
multiple	O
organ	O
dysfunction	O
.	O

The	O
relative	O
cleavage	B-PROC
rate	O
for	O
different	O
substrate	O
sequences	O
was	O
correlated	O
with	O
various	O
structural	O
properties	O
.	O

Rabbitpox	O
(	O
rabbitpox	O
virus	B-PROC
infection	I-PROC
in	O
rabbits	O
)	O
is	O
a	O
severe	O
and	O
often	O
lethal	O
infection	O
that	O
has	O
been	O
identified	O
as	O
an	O
ideal	O
disease	O
model	O
for	O
the	O
study	O
of	O
poxviruses	O
in	O
a	O
non	O
-	O
rodent	O
species	O
.	O

The	O
membrane	O
(	O
M	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
highly	O
abundant	O
during	O
viral	B-PROC
infections	I-PROC
and	O
is	O
a	O
critical	O
element	O
for	O
viral	B-PROC
assembly	I-PROC
.	O

The	O
results	O
demonstrated	O
that	O
both	O
siRNAs	O
effectively	O
and	O
specifically	O
blocked	O
the	O
targeted	B-PROC
gene	B-PROC
expression	I-PROC
.	O

The	O
co	O
-	O
localization	B-PROC
of	O
SARS	O
-	O
CoVN	O
and	O
CXCL16	O
in	O
the	O
cytoplasm	O
of	O
HEK293FT	O
cells	O
was	O
also	O
shown	O
using	O
confocal	O
laser	O
scanning	O
microscopy	O
.	O

Our	O
results	O
showed	O
that	O
immunized	O
mice	O
generated	O
strong	O
humoral	B-PROC
immune	I-PROC
responses	I-PROC
against	O
the	O
SL	O
-	O
CoV	O
S	O
protein	O
.	O

The	O
expression	B-PROC
of	O
mTNFR1	O
was	O
detected	O
by	O
Real	O
-	O
time	O
PCR	O
,	O
immunohistochemistry	O
staining	O
.	O

This	O
study	O
was	O
designed	O
to	O
explore	O
the	O
opportunity	O
of	O
RNA	B-PROC
interference	I-PROC
technique	O
in	O
inhibiting	O
TNFR1	O
expression	B-PROC
,	O
which	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
the	O
development	B-PROC
of	O
a	O
variety	O
of	O
diseases	O
including	O
fulminant	O
viral	O
hepatitis	O
and	O
severe	O
chronic	O
hepatitis	O
B	O
.	O

ABSTRACT	O
:	O
In	O
late	O
March	O
2009	O
,	O
an	O
outbreak	O
of	O
influenza	O
A	O
virus	B-PROC
infection	I-PROC
was	O
detected	O
in	O
Mexico	O
with	O
subsequent	O
cases	O
observed	O
in	O
many	O
other	O
countries	O
.	O

IFN	O
production	O
in	O
infected	O
BMM	O
was	O
nearly	O
completely	O
dependent	O
on	O
signaling	B-PROC
through	O
the	O
alpha	O
/	O
beta	O
interferon	O
(	O
IFN	O
-	O
α	O
/	O
β	O
)	O
receptor	O
(	O
IFNAR	O
).	O

Several	O
IFN	O
-	O
dependent	O
cytokines	O
and	O
chemokines	O
showed	O
the	O
same	O
expression	B-PROC
pattern	O
,	O
with	O
enhanced	O
production	O
in	O
BMM	O
compared	O
to	O
BMDC	O
and	O
dependence	O
upon	O
signaling	B-PROC
through	O
the	O
IFNAR	O
.	O

TITLE	O
:	O
Unique	O
signatures	O
of	O
long	O
noncoding	O
RNA	B-PROC
expression	I-PROC
in	O
response	B-PROC
to	I-PROC
virus	I-PROC
infection	O
and	O
altered	O
innate	O
immune	O
signaling	B-PROC
.	O

This	O
study	O
was	O
to	O
investigate	O
the	O
pathogenesis	B-PROC
,	O
clinical	O
characteristics	O
and	O
management	O
strategies	O
of	O
RDS	O
in	O
full	O
-	O
term	O
neonates	O
,	O
with	O
the	O
aim	O
of	O
developing	O
a	O
working	O
protocol	O
for	O
improving	O
the	O
outcome	O
in	O
full	O
-	O
term	O
neonates	O
with	O
RDS	O
.	O

ABSTRACT	O
:	O
Type	O
I	O
interferons	O
(	O
IFNs	O
)	O
are	O
essential	O
to	O
the	O
clearance	O
of	O
viral	B-PROC
diseases	I-PROC
,	O
however	O
,	O
a	O
clear	O
distinction	O
between	O
genes	O
upregulated	O
by	O
direct	O
virus	O
-	O
cell	B-PROC
interactions	I-PROC
and	O
genes	O
upregulated	O
by	O
secondary	O
IFN	O
production	O
has	O
not	O
been	O
made	O
.	O

Here	O
,	O
we	O
investigated	O
differential	O
gene	B-PROC
regulation	I-PROC
in	O
ferrets	O
upon	O
subcutaneous	O
administration	O
of	O
IFN	O
-	O
α2b	O
and	O
during	O
SARS	O
-	O
CoV	O
infection	O
.	O

These	O
signatures	O
can	O
be	O
useful	O
markers	O
to	O
evaluate	O
the	O
status	O
of	O
IFN	O
responses	O
during	O
a	O
viral	B-PROC
infection	I-PROC
and	O
specific	O
features	O
of	O
different	O
viruses	O
.	O

Interestingly	O
,	O
while	O
viral	O
genomic	O
RNAs	O
persisted	O
in	O
infected	O
cells	O
over	O
14	O
subsequent	O
passages	O
with	O
concomitant	O
synthesis	B-PROC
of	O
viral	O
subgenomic	O
mRNAs	O
and	O
structural	O
proteins	O
,	O
no	O
infectious	O
virus	O
was	O
isolated	O
beyond	O
passage	O
2	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
8b	O
negatively	O
modulates	O
virus	B-PROC
replication	I-PROC
by	O
down	O
-	O
regulating	O
E	O
via	O
an	O
ubiquitin	B-PROC
-	O
independent	O
proteasome	B-PROC
pathway	I-PROC
.	O

Based	O
on	O
WNv	O
screening	O
of	O
kidney	O
tissue	O
,	O
IHC	O
and	O
RT	O
-	O
PCR	O
were	O
in	O
agreement	O
with	O
95	O
.	O
45	O
%	O
(	O
21	O
/	O
22	O
)	O
for	O
positive	O
dead	B-PROC
birds	O
and	O
were	O
in	O
100	O
%	O
(	O
22	O
/	O
22	O
)	O
agreement	O
when	O
multi	O
-	O
organ	O
screening	O
by	O
IHC	O
was	O
performed	O
.	O

TGEV	O
nsp1	O
also	O
suppressed	O
protein	B-PROC
translation	B-PROC
in	O
cell	O
-	O
free	O
HeLa	O
cell	O
extract	O
;	O
however	O
,	O
it	O
did	O
not	O
affect	O
translation	B-PROC
in	O
rabbit	O
reticulocyte	O
lysate	O
(	O
RRL	O
).	O

Genetic	O
variations	O
,	O
including	O
whole	O
-	O
gene	B-PROC
deletions	I-PROC
,	O
are	O
key	O
to	O
IBV	O
evolution	B-PROC
.	O

Of	O
these	O
,	O
however	O
,	O
genes	O
3b	O
and	O
5b	O
were	O
found	O
to	O
be	O
present	O
but	O
contained	O
various	O
mutations	O
that	O
may	O
affect	O
transcription	B-PROC
.	O

TITLE	O
:	O
Evaluation	O
of	O
commercial	O
ResPlex	O
II	O
v2	O
.	O
0	O
,	O
MultiCode	O
-	O
PLx	O
,	O
and	O
xTAG	O
respiratory	O
viral	O
panels	O
for	O
the	O
diagnosis	O
of	O
respiratory	O
viral	B-PROC
infections	I-PROC
in	O
adults	O
.	O

Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
belongs	O
to	O
gamma	O
-	O
coronaviruses	O
and	O
causes	O
a	O
costly	O
respiratory	O
viral	B-PROC
disease	I-PROC
in	O
chickens	O
.	O

When	O
comparing	O
viral	O
ARDS	O
with	O
bacterial	O
ARDS	O
,	O
the	O
level	O
of	O
IL	O
-	O
8	O
,	O
IL	B-PROC
-	I-PROC
17	I-PROC
and	O
TNFα	O
was	O
significantly	O
higher	O
in	O
bacterial	O
ARDS	O
and	O
IL	O
-	O
12	O
was	O
increased	O
only	O
in	O
viral	O
ARDS	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
underlines	O
that	O
diseases	O
such	O
as	O
malaria	O
,	O
viral	O
hepatitis	O
and	O
enteric	O
fever	B-PROC
occur	O
in	O
Singapore	O
mainly	O
because	O
of	O
importation	O
.	O

The	O
multi	O
-	O
zone	O
airflow	B-PROC
model	O
was	O
evaluated	O
by	O
our	O
experimental	O
data	O
.	O

ABSTRACT	O
:	O
Spike	O
(	O
S	O
)	O
proteins	O
,	O
the	O
defining	O
projections	O
of	O
the	O
enveloped	O
coronaviruses	O
(	O
CoVs	O
),	O
mediate	O
cell	O
entry	O
by	O
connecting	O
viruses	O
to	O
plasma	O
membrane	O
receptors	O
and	O
by	O
catalyzing	O
subsequent	O
virus	O
-	O
cell	O
membrane	B-PROC
fusions	I-PROC
.	O

Taken	O
together	O
,	O
this	O
treatment	O
strategy	O
is	O
not	O
a	O
single	O
mediator	O
approach	O
,	O
but	O
it	O
rather	O
provides	O
protection	O
by	O
modulating	O
multiple	O
levels	O
of	O
early	O
signaling	B-PROC
pathways	B-PROC
involved	O
in	O
apoptosis	B-PROC
,	O
inflammation	O
,	O
and	O
peroxidation	O
,	O
potentially	O
restoring	O
overall	O
homeostasis	B-PROC
.	O

Furthermore	O
,	O
EPO	O
appears	O
to	O
confer	O
vascular	O
protection	O
by	O
promoting	O
angiogenesis	B-PROC
.	O

Lung	O
injury	O
,	O
neutrophil	O
infiltration	O
,	O
cell	B-PROC
death	I-PROC
,	O
fibrin	O
deposition	O
,	O
and	O
tissue	O
factor	O
expression	B-PROC
in	O
the	O
lung	O
were	O
determined	O
.	O

Local	O
and	O
systemic	O
inflammatory	B-PROC
responses	I-PROC
were	O
assessed	O
by	O
measuring	O
cytokines	O
in	O
the	O
lung	O
and	O
plasma	O
.	O

TITLE	O
:	O
Differentiation	B-PROC
between	O
human	O
coronaviruses	O
NL63	O
and	O
229E	O
using	O
a	O
novel	O
double	O
-	O
antibody	B-PROC
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
based	O
on	O
specific	O
monoclonal	O
antibodies	O
.	O

Thus	O
,	O
differentiation	B-PROC
between	O
the	O
two	O
viruses	O
is	O
relevant	O
for	O
epidemiology	O
studies	O
.	O

Sheep	O
treated	O
with	O
TLV	O
maintained	O
normal	O
blood	B-PROC
gases	I-PROC
with	O
statistically	O
greater	O
PO2	B-PROC
(	O
p	O
<	O
10	O
(-	O
9	O
))	O
and	O
lower	O
PCO2	O
(	O
p	O
<	O
10	O
(-	O
3	O
))	O
than	O
the	O
CMV	O
group	O
.	O

There	O
are	O
multiple	O
factors	O
in	O
the	O
pathogenesis	B-PROC
of	O
Acute	O
decompression	O
syndrome	O
(	O
Caisson	O
'	O
s	O
disease	O
)	O
such	O
as	O
health	O
problems	O
in	O
divers	O
(	O
respiratory	O
problems	O
or	O
congenital	O
heart	O
diseases	O
like	O
atrial	O
septal	O
defect	O
,	O
patent	O
ductus	O
arteriosus	O
etc	O
),	O
speed	O
of	O
ascent	O
from	O
the	O
depth	O
and	O
habits	O
like	O
smoking	O
that	O
render	O
divers	O
susceptible	O
for	O
such	O
neurological	O
emergency	O
.	O

Subsequently	O
,	O
pGEX	O
-	O
SARS	O
-	O
S1	O
was	O
transformed	O
into	O
host	O
cells	O
BL21	O
(	O
DE3	O
)	O
pLysS	O
,	O
and	O
the	O
expression	B-PROC
of	O
the	O
S1	O
protein	O
was	O
induced	O
by	O
isopropyl	O
β	O
-	O
D	O
-	O
thiogalactoside	O
(	O
IPTG	O
).	O

The	O
reactivity	O
of	O
the	O
antibody	B-PROC
to	O
the	O
SARS	O
-	O
CoV	O
S1	O
protein	O
was	O
confirmed	O
by	O
Western	O
blot	O
analysis	O
.	O

The	O
expression	B-PROC
of	O
NF	O
-	O
κB	O
and	O
CD4	O
(+)/	O
CD8	O
(+)	O
ratio	O
in	O
the	O
virus	O
and	O
model	O
groups	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
damp	O
-	O
heat	O
and	O
control	O
groups	O
,	O
while	O
the	O
expression	B-PROC
of	O
AQP4	O
was	O
significantly	O
higher	O
in	O
the	O
model	O
and	O
damp	O
-	O
heat	O
groups	O
than	O
in	O
the	O
other	O
groups	O
.	O

ABSTRACT	O
:	O
Neutral	O
endopeptidase	O
(	O
NEP	O
),	O
an	O
enzyme	O
that	O
cleaves	O
inflammatory	O
bioactive	O
peptides	O
,	O
may	O
play	O
a	O
protective	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Immuno	O
-	O
histochemical	O
and	O
Western	O
immunoblot	O
studies	O
in	O
mice	O
confirmed	O
a	O
)	O
the	O
presence	O
of	O
NEP	O
in	O
the	O
alveolar	O
wall	O
,	O
a	O
critical	O
target	O
in	O
ALI	O
/	O
ARDS	O
,	O
and	O
b	O
)	O
a	O
decrease	O
in	O
its	O
expression	B-PROC
in	O
HCl	O
-	O
and	O
LPS	O
-	O
induced	O
ALI	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
oxygenation	B-PROC
as	O
measured	O
by	O
the	O
PaO₂	O
/	O
FiO₂	O
ratio	O
and	O
the	O
oxygenation	B-PROC
index	O
,	O
but	O
there	O
was	O
a	O
transient	O
but	O
significant	O
increase	O
in	O
PaCO₂	O
intraoperatively	O
.	O

Sodium	O
bicarbonate	O
(	O
50	O
ml	O
8	O
.	O
4	O
%)	O
only	O
for	O
excessive	O
hyperkaliemia	O
,	O
metabolic	B-PROC
acidosis	O
,	O
or	O
intoxication	O
with	O
tricyclic	O
antidepressants	O
.	O

Defibrillation	O
(	O
4	O
J	O
/	O
kgBW	O
;	O
monophasic	O
or	O
biphasic	O
)	O
followed	O
by	O
2	O
min	O
CPR	O
,	O
then	O
ECG	O
and	O
pulse	B-PROC
check	O
.	O

Aggressive	B-PROC
fluid	O
resuscitation	O
,	O
hyperventilation	O
and	O
excessive	O
ventilation	O
pressure	O
may	O
impair	O
outcome	O
in	O
patients	O
with	O
severe	O
hemorrhagic	O
shock	O
.	O

Three	O
pairs	O
of	O
primers	O
targeting	B-PROC
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
TGEV	O
were	O
synthesized	O
and	O
used	O
in	O
the	O
RT	O
-	O
LAMP	O
.	O

A	O
retrospective	O
analysis	O
of	O
preterm	O
infants	O
≤	O
28	O
weeks	O
'	O
gestational	O
age	O
(	O
GA	O
)	O
admitted	O
to	O
neonatal	O
intensive	O
care	O
units	O
in	O
the	O
Canadian	O
Neonatal	O
Network	O
was	O
conducted	O
comparing	O
infants	O
on	O
the	O
basis	O
of	O
receipt	O
of	O
opioid	O
infusion	O
during	O
day	O
1	O
and	O
day	O
3	O
after	O
birth	B-PROC
.	O

ABSTRACT	O
:	O
These	O
studies	O
detail	O
the	O
altered	O
structure	O
-	O
function	O
relationships	O
caused	O
by	O
oxidation	B-PROC
of	O
surfactant	O
protein	O
B	O
(	O
SP	O
-	O
B	O
),	O
a	O
mode	O
of	O
damage	O
thought	O
to	O
be	O
important	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
a	O
common	O
and	O
frequently	O
fatal	O
condition	O
.	O

Forced	B-PROC
vital	I-PROC
capacity	I-PROC
values	O
were	O
persistently	O
less	O
than	O
1	O
L	O
.	O
The	O
patient	O
developed	O
respiratory	O
failure	O
and	O
required	O
endotracheal	O
intubation	O
.	O

The	O
predominant	O
cause	O
of	O
death	B-PROC
in	O
ARDS	O
is	O
not	O
severe	O
hypoxemia	O
,	O
which	O
is	O
one	O
of	O
the	O
defining	O
criteria	O
of	O
ARDS	O
,	O
but	O
multiple	O
organ	O
failure	O
(	O
MOF	O
).	O

Several	O
techniques	O
are	O
available	O
to	O
improve	O
oxygenation	B-PROC
in	O
severely	O
hypoxemic	O
patients	O
.	O

TITLE	O
:	O
[	O
Study	O
on	O
the	O
changing	O
regularity	O
of	O
special	O
antibody	B-PROC
and	O
expression	B-PROC
of	O
stomach	O
and	O
enteric	O
involvement	O
on	O
SARS	O
-	O
coronavirus	O
infection	O
in	O
the	O
recovery	O
period	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

The	O
nucleocapsid	O
antibody	B-PROC
titer	O
was	O
between	O
1	O
/	O
156	O
and	O
1	O
/	O
210	O
in	O
3	O
cases	O
,	O
and	O
2	O
cases	O
were	O
normal	O
.	O

The	O
nucleocapsid	O
antibody	B-PROC
titer	O
was	O
related	O
to	O
pathogenetic	O
condition	O
.	O

In	O
the	O
past	O
few	O
decades	O
,	O
there	O
has	O
been	O
a	O
consistent	O
scientific	O
and	O
technologic	O
effort	B-PROC
to	O
develop	O
alternative	O
strategies	O
to	O
avoid	O
the	O
need	O
for	O
mechanical	O
ventilation	O
.	O

Therefore	O
,	O
further	O
development	B-PROC
in	O
this	O
direction	O
will	O
occur	O
only	O
with	O
a	O
permanent	O
integration	B-PROC
and	O
exchange	O
of	O
knowledge	O
among	O
industry	O
,	O
clinicians	O
,	O
and	O
scientific	O
investigators	O
.	O

The	O
present	O
authors	O
have	O
previously	O
demonstrated	O
that	O
antigens	O
chemically	O
coupled	O
to	O
the	O
surface	O
of	O
liposomes	O
made	O
using	O
unsaturated	O
fatty	O
acids	O
are	O
cross	O
-	O
presented	O
by	O
APCs	O
via	O
MHC	B-PROC
class	O
I	O
to	O
CD8	O
(+)	O
T	O
cells	O
and	O
induce	O
antigen	O
-	O
specific	O
CTLs	O
.	O

The	O
sequence	O
analysis	O
showed	O
two	O
amino	O
acid	O
deletions	O
and	O
loss	O
of	O
an	O
N	O
-	O
glycosylation	B-PROC
site	O
in	O
transmissible	O
gastroenteritis	O
virus	O
S	O
protein	O
after	O
passages	O
in	O
piglets	O
.	O

Suppression	B-PROC
occurred	O
independently	O
of	O
virus	O
viability	O
and	O
acidification	B-PROC
of	O
pDC	O
early	O
endosomes	O
but	O
correlated	O
with	O
diminished	O
levels	O
of	O
IFN	O
-	O
α	O
mRNA	O
.	O

Moreover	O
,	O
an	O
augmented	O
phosphorylation	B-PROC
of	O
NF	O
-	O
κB	O
seen	O
in	O
activated	O
pDC	O
was	O
not	O
only	O
unaffected	O
by	O
PRRSV	O
but	O
actually	O
occurred	O
in	O
its	O
presence	O
.	O

Thus	O
,	O
as	O
supported	O
by	O
a	O
demonstrated	O
resilience	O
of	O
pDC	O
to	O
PRRSV	O
infection	O
,	O
this	O
pathogen	O
may	O
interact	O
with	O
a	O
cell	O
surface	O
protein	O
(	O
s	O
)	O
to	O
selectively	O
impede	O
the	O
completion	O
of	O
cascades	O
involved	O
in	O
cytokine	B-PROC
production	I-PROC
by	O
stimulated	O
pDC	O
.	O

ABSTRACT	O
:	O
Central	O
nervous	O
system	O
(	O
CNS	O
)	O
infections	O
and	O
autoimmune	O
inflammatory	O
disorders	O
are	O
often	O
associated	O
with	O
retention	B-PROC
of	O
antibody	B-PROC
-	O
secreting	B-PROC
cells	O
(	O
ASC	O
).	O

Similarly	O
,	O
CD4	O
T	O
cell	O
-	O
secreted	B-PROC
interleukin	O
-	O
21	O
,	O
a	O
critical	O
regulator	O
of	O
both	O
peripheral	O
activated	O
B	O
cells	O
and	O
CD8	O
T	O
cells	O
,	O
was	O
sustained	O
during	O
viral	O
persistence	O
.	O

Last	O
,	O
the	O
expression	B-PROC
kinetics	O
of	O
the	O
APRIL	O
and	O
BAFF	O
receptors	O
coincided	O
with	O
CNS	O
accumulation	O
of	O
ASC	O
.	O

TITLE	O
:	O
Interferon	O
-	O
gamma	O
negatively	O
regulates	O
Th17	O
-	O
mediated	O
immunopathology	O
during	O
mouse	O
hepatitis	O
virus	B-PROC
infection	I-PROC
.	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
produces	O
a	O
series	O
of	O
subgenomic	O
RNAs	O
for	O
viral	O
protein	B-PROC
expression	B-PROC
.	O

CONCLUSIONS	O
:	O
These	O
results	O
showed	O
that	O
intranasal	O
immunization	O
with	O
PEI	O
/	O
pci	O
-	O
S	O
nanoparticles	O
induce	O
antigen	O
specific	O
humoral	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
.	O

Transmission	O
pathway	B-PROC
of	O
aerosols	O
of	O
Fluorescein	O
-	O
KCl	O
solution	O
through	O
facemasks	O
and	O
protective	O
efficiency	O
of	O
facemasks	O
were	O
examined	O
by	O
using	O
normal	O
surgical	O
facemasks	O
and	O
two	O
facemasks	O
with	O
exhaust	O
valves	O
(	O
Facemask	O
A	O
)	O
and	O
exhaust	O
holes	O
(	O
Facemask	O
B	O
)	O
covered	O
with	O
the	O
same	O
surgical	O
filters	O
situated	O
at	O
the	O
back	O
of	O
the	O
facemasks	O
.	O

The	O
main	O
protease	O
(	O
M	O
(	O
pro	O
))	O
of	O
SARS	O
-	O
CoV	O
is	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
SARS	O
drug	O
development	B-PROC
as	O
it	O
is	O
essential	O
for	O
the	O
polyprotein	O
processing	O
.	O

The	O
discovery	O
of	O
AOM	O
(	O
pro	O
)	O
provides	O
new	O
insights	O
about	O
the	O
functional	O
mechanism	O
of	O
M	O
(	O
pro	O
)	O
and	O
its	O
maturation	B-PROC
process	O
.	O

This	O
specific	O
proteolysis	B-PROC
may	O
indicate	O
one	O
possible	O
mechanism	O
by	O
which	O
coronaviruses	O
to	O
switch	O
from	O
viral	B-PROC
infection	I-PROC
to	O
genome	O
replication	O
and	O
viral	B-PROC
assembly	I-PROC
stages	O
.	O

ABSTRACT	O
:	O
The	O
main	O
protease	O
(	O
M	O
(	O
pro	O
))	O
plays	O
a	O
vital	O
role	O
in	O
proteolytic	B-PROC
processing	I-PROC
of	O
the	O
polyproteins	O
in	O
the	O
replicative	O
cycle	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

In	O
conclusion	O
,	O
an	O
auto	O
-	O
release	O
model	O
of	O
M	O
(	O
pro	O
)	O
from	O
the	O
polyproteins	O
is	O
proposed	O
,	O
which	O
will	O
help	O
understand	O
the	O
auto	O
-	O
processing	O
mechanism	O
and	O
the	O
difference	O
between	O
the	O
autocleavage	O
and	O
trans	O
-	O
cleavage	B-PROC
proteolytic	B-PROC
activities	O
of	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
).	O

However	O
,	O
which	O
clinical	O
parameters	O
and	O
inflammatory	O
biomarkers	O
including	O
sRAGE	O
are	O
associated	O
with	O
death	B-PROC
in	O
ARDS	O
patients	O
remain	O
unknown	O
.	O

TITLE	O
:	O
Mutation	O
of	O
neutralizing	O
/	O
antibody	B-PROC
-	O
dependent	O
enhancing	O
epitope	O
on	O
spike	O
protein	O
and	O
7b	O
gene	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
:	O
influences	O
of	O
viral	B-PROC
replication	I-PROC
in	O
monocytes	O
/	O
macrophages	O
and	O
virulence	B-PROC
in	O
cats	O
.	O

We	O
also	O
discovered	O
that	O
amino	O
acid	O
mutation	O
in	O
the	O
neutralizing	O
epitope	O
reduced	O
viral	B-PROC
replication	I-PROC
in	O
monocytes	O
/	O
macrophages	O
.	O

TITLE	O
:	O
Screening	O
and	O
identification	O
of	O
T	O
helper	O
1	O
and	O
linear	O
immunodominant	O
antibody	B-PROC
-	O
binding	O
epitopes	O
in	O
the	O
spike	O
2	O
domain	O
and	O
the	O
nucleocapsid	O
protein	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
.	O

In	O
the	O
S2	O
domain	O
of	O
type	O
II	O
FIPV	O
,	O
4	O
peptides	O
containing	O
linear	O
immunodominant	O
antibody	B-PROC
-	O
binding	O
epitopes	O
were	O
identified	O
in	O
the	O
HR2	O
region	O
.	O

In	O
N	O
protein	O
,	O
4	O
peptides	O
containing	O
linear	O
immunodominant	O
antibody	B-PROC
-	O
binding	O
epitopes	O
were	O
identified	O
,	O
and	O
2	O
peptides	O
derived	O
from	O
residues	O
345	O
to	O
372	O
showed	O
strong	O
reactivity	O
with	O
plasma	O
of	O
type	O
I	O
FIPV	O
-	O
and	O
type	O
II	O
FIPV	O
-	O
infected	O
cats	O
.	O

Highly	O
significant	O
decreases	O
in	O
haematocrit	O
and	O
albumin	O
levels	O
and	O
an	O
increase	O
in	O
total	O
bilirubin	O
level	O
were	O
noted	O
in	O
both	O
effusive	O
and	O
non	O
-	O
effusive	O
FIP	O
,	O
at	O
first	O
presentation	O
and	O
before	O
death	B-PROC
.	O

However	O
,	O
a	O
defined	O
biological	O
role	O
for	O
2	O
'-	O
O	O
-	O
methylation	B-PROC
of	O
mRNA	O
remains	O
elusive	O
.	O

We	O
demonstrate	O
that	O
human	O
and	O
mouse	O
coronavirus	O
mutants	O
lacking	O
2	O
'-	O
O	O
-	O
methyltransferase	O
activity	O
induced	O
higher	O
expression	B-PROC
of	O
type	O
I	O
interferon	O
and	O
were	O
highly	O
sensitive	O
to	O
type	O
I	O
interferon	O
.	O

ABSTRACT	O
:	O
Emerging	O
infectious	O
diseases	O
have	O
caused	O
a	O
global	O
effort	B-PROC
for	O
development	B-PROC
of	O
fast	O
and	O
accurate	O
detection	O
techniques	O
.	O

The	O
most	O
N	O
-	O
terminal	O
portion	O
of	O
the	O
S1	O
region	O
,	O
which	O
comprises	O
antigenic	O
sites	O
C	O
and	O
B	O
,	O
is	O
needed	O
for	O
the	O
enteric	O
tropism	B-PROC
of	O
TGEV	O
,	O
whereas	O
the	O
major	O
antigenic	O
site	O
A	O
at	O
the	O
C	O
-	O
terminal	O
moiety	O
is	O
required	O
for	O
both	O
respiratory	O
and	O
enteric	O
cell	O
tropism	B-PROC
,	O
and	O
is	O
engaged	O
in	O
recognition	O
of	O
the	O
aminopeptidase	O
N	O
(	O
APN	O
)	O
receptor	O
.	O

ABSTRACT	O
:	O
The	O
main	O
cause	O
of	O
death	B-PROC
from	O
novel	O
(	O
swine	O
origin	O
)	O
influenza	O
A	O
/	O
H1N1	O
infection	O
is	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Two	O
patients	O
most	O
likely	O
had	O
pre	O
-	O
existent	O
cardiac	O
pathologies	O
,	O
and	O
three	O
required	O
catecholamine	O
therapy	O
to	O
maintain	O
hemodynamic	B-PROC
function	O
.	O

Symptoms	O
,	O
virus	B-PROC
replication	I-PROC
,	O
and	O
antibody	B-PROC
-	O
titres	O
were	O
monitored	O
.	O

Common	O
cold	B-PROC
symptoms	O
and	O
incidence	O
of	O
seroconversion	O
were	O
unaffected	O
.	O

TITLE	O
:	O
Controlling	O
epidemic	O
viral	B-PROC
infection	I-PROC
.	O

The	O
herd	O
status	O
regarding	O
the	O
calves	O
'	O
passive	O
transfer	O
(	O
total	O
protein	O
),	O
levels	O
of	O
α	O
-	O
tocopherol	O
,	O
β	O
-	O
carotene	O
and	O
retinol	O
,	O
and	O
excretion	B-PROC
of	O
faecal	O
pathogens	O
(	O
Cryptosporidium	O
spp	O
.,	O
Escherichia	O
coli	O
F5	O
,	O
rota	O
and	O
corona	O
virus	O
)	O
was	O
evaluated	O
based	O
on	O
targeted	B-PROC
sampling	O
of	O
high	O
risk	O
calf	O
groups	O
;	O
in	O
each	O
herd	O
,	O
blood	O
and	O
faecal	O
samples	O
were	O
collected	O
from	O
calves	O
1	O
-	O
7	O
and	O
1	O
-	O
14	O
days	O
old	O
,	O
respectively	O
.	O

LM	O
and	O
HM	O
herds	O
were	O
compared	O
using	O
five	O
logistic	O
regression	O
models	O
,	O
covering	O
potential	O
risk	O
factors	O
within	O
different	O
areas	O
:	O
""""	O
Disease	O
susceptibility	O
""","	O
""""	O
Factors	O
affecting	O
the	O
gastrointestinal	O
tract	O
""","	O
""""	O
Factors	O
related	O
to	O
transmission	O
of	O
infectious	O
disease	O
""","	O
""""	O
Hygiene	O
""""	O
and	O
""""	O
Labour	B-PROC
management	O
"""."	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
),	O
a	O
deubiquitinating	B-PROC
enzyme	I-PROC
,	O
reportedly	O
blocks	O
poly	O
I	O
:	O
C	O
-	O
induced	O
activation	O
of	O
interferon	O
regulatory	O
factor	O
3	O
and	O
nuclear	O
factor	O
kappa	O
B	O
,	O
reducing	O
interferon	O
(	O
IFN	O
)	O
induction	O
.	O

In	O
this	O
study	O
,	O
a	O
killed	O
vaccine	O
against	O
TGEV	O
-	O
like	O
CCoV	O
strains	O
,	O
included	O
in	O
the	O
new	O
subtype	O
CCoV	O
-	O
IIb	O
,	O
was	O
developed	O
through	O
inactivation	O
with	O
betapropiolactone	O
and	O
emulsification	B-PROC
with	O
MF59	O
™	O
adjuvant	O
.	O

ABSTRACT	O
:	O
The	O
shedding	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
into	O
saliva	O
droplets	O
plays	O
a	O
critical	O
role	O
in	O
viral	B-PROC
transmission	I-PROC
.	O

In	O
a	O
test	O
case	O
,	O
it	O
also	O
enabled	O
automated	O
model	O
building	O
when	O
>	O
50	O
%	O
of	O
an	O
antigen	O
-	O
antibody	B-PROC
complex	O
was	O
absent	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
anti	O
-	O
viral	O
agents	O
using	O
molecular	O
modeling	O
and	O
virtual	O
screening	O
techniques	O
.	O

Thirty	O
-	O
day	O
mortality	O
was	O
53	O
%	O
(	O
n	O
=	O
16	O
)	O
for	O
all	O
comers	O
:	O
63	O
%	O
(	O
n	O
=	O
7	O
)	O
died	B-PROC
in	O
the	O
vv	O
-	O
group	O
,	O
75	O
%	O
(	O
n	O
=	O
6	O
)	O
in	O
the	O
va	O
-	O
group	O
and	O
27	O
%	O
(	O
n	O
=	O
3	O
)	O
in	O
the	O
vva	O
-	O
group	O
.	O

In	O
DAI	O
patients	O
,	O
bad	O
outcome	O
is	O
predicted	O
by	O
age	O
,	O
bilateral	O
absence	O
of	O
pupillary	O
light	O
reflexes	B-PROC
,	O
multiplicity	O
of	O
CCL	O
,	O
and	O
BSL	O
on	O
MRI	O
.	O

To	O
examine	O
whether	O
GABA	O
deficits	O
contributed	O
to	O
breathing	B-PROC
defects	O
of	O
Mecp2	O
(-/	O
y	O
)	O
mice	O
,	O
mice	O
were	O
subjected	O
to	O
acute	O
administration	O
of	O
Midazolam	O
,	O
a	O
benzodiazepine	O
of	O
clinical	O
use	O
known	O
to	O
enhance	O
GABA	B-PROC
effects	I-PROC
.	O

For	O
the	O
first	O
time	O
,	O
we	O
showed	O
that	O
Midazolam	O
abolished	O
,	O
although	O
transiently	O
,	O
the	O
breathing	B-PROC
defects	O
of	O
Mecp2	O
(-/	O
y	O
)	O
mice	O
,	O
confirming	O
a	O
crucial	O
role	O
of	O
GABA	O
deficits	O
in	O
their	O
breathing	B-PROC
defects	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
can	O
achieve	O
sufficient	O
gas	O
exchange	O
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
plasmatic	O
coagulation	B-PROC
was	O
only	O
mildly	O
activated	O
without	O
significant	O
platelet	O
consumption	O
.	O

We	O
show	O
that	O
these	O
siRNAs	O
could	O
effectively	O
and	O
specifically	O
block	O
the	O
isolated	O
N	O
gene	B-PROC
expression	I-PROC
in	O
mammal	O
cells	O
.	O

Earlier	O
research	O
determined	O
metabolic	B-PROC
oxidative	O
stress	O
in	O
hosts	O
deficient	O
in	O
antioxidant	O
selenium	O
(	O
Se	O
)	O
(<	O
1	O
μMol	O
Se	O
/	O
L	O
of	O
blood	O
)	O
induces	O
both	O
impaired	O
human	O
host	O
immunocompetence	B-PROC
and	O
rapidly	O
mutated	O
benign	O
variants	O
of	O
RNA	O
viruses	O
to	O
virulence	B-PROC
.	O

This	O
study	O
investigated	O
how	O
the	O
3CLpro	O
affected	O
the	O
secretion	B-PROC
of	O
cytokines	O
in	O
the	O
gene	O
-	O
transfected	O
cells	O
.	O

Because	O
African	O
green	O
monkeys	O
developed	O
more	O
severe	O
ALI	O
than	O
macaques	O
,	O
with	O
hyaline	O
membrane	O
formation	B-PROC
,	O
some	O
of	O
these	O
differentially	O
expressed	B-PROC
proinflammatory	O
genes	O
may	O
be	O
critically	O
involved	O
in	O
development	B-PROC
of	O
the	O
observed	O
pathological	O
changes	O
.	O

In	O
contrast	O
,	O
it	O
is	O
largely	O
unknown	O
whether	O
host	O
cell	O
proteases	O
located	O
in	O
the	O
secretory	B-PROC
pathway	I-PROC
of	O
infected	O
cells	O
and	O
/	O
or	O
on	O
the	O
surface	O
of	O
target	O
cells	O
can	O
cleave	O
SARS	O
S	O
.	O
We	O
along	O
with	O
others	O
could	O
previously	O
show	O
that	O
the	O
type	O
II	O
transmembrane	O
protease	O
TMPRSS2	O
activates	O
the	O
influenza	O
virus	O
hemagglutinin	O
and	O
the	O
human	O
metapneumovirus	O
F	O
protein	O
by	O
cleavage	B-PROC
.	O

cis	O
-	O
cleavage	B-PROC
resulted	O
in	O
release	O
of	O
SARS	O
S	O
fragments	O
into	O
the	O
cellular	O
supernatant	O
and	O
in	O
inhibition	B-PROC
of	O
antibody	B-PROC
-	I-PROC
mediated	I-PROC
neutralization	I-PROC
,	O
most	O
likely	O
because	O
SARS	O
S	O
fragments	O
function	O
as	O
antibody	B-PROC
decoys	O
.	O

trans	O
-	O
cleavage	B-PROC
activated	O
SARS	O
S	O
on	O
effector	O
cells	O
for	O
fusion	O
with	O
target	O
cells	O
and	O
allowed	O
efficient	O
SARS	O
S	O
-	O
driven	O
viral	O
entry	O
into	O
targets	O
treated	O
with	O
a	O
lysosomotropic	O
agent	O
or	O
a	O
cathepsin	O
inhibitor	O
.	O

ABSTRACT	O
:	O
Understanding	O
the	O
mechanisms	O
of	O
augmented	O
bacterial	O
pathogenicity	O
in	O
post	O
-	O
viral	B-PROC
infections	I-PROC
is	O
the	O
first	O
step	O
in	O
the	O
development	B-PROC
of	O
an	O
effective	O
therapy	O
.	O

Passage	O
level	O
80	O
was	O
investigated	O
for	O
safety	O
for	O
the	O
reproductive	B-PROC
tract	O
in	O
1	O
-	O
day	O
-	O
old	O
and	O
7	O
-	O
day	O
-	O
old	O
SPF	O
chickens	O
.	O

Historically	O
,	O
the	O
term	O
""""	O
disuse	O
atrophy	O
""""	O
has	O
described	O
a	O
situation	O
wherein	O
sustained	O
inactivity	O
of	O
the	O
respiratory	O
muscles	O
(	O
ie	O
,	O
passive	B-PROC
ventilation	I-PROC
)	O
results	O
in	O
deconditioning	O
and	O
weakness	O
.	O

One	O
plausible	O
explanation	O
is	O
that	O
spontaneous	O
breathing	B-PROC
is	O
superimposed	O
upon	O
the	O
mechanical	O
ventilation	O
pattern	O
.	O

Thus	O
a	O
variety	O
of	O
""""	O
breathing	B-PROC
environments	O
""""	O
exist	O
during	O
APRV	O
/	O
BIPAP	O
that	O
affect	O
patient	O
WOB	O
and	O
respiratory	O
drive	O
differently	O
and	O
perhaps	O
unpredictably	O
.	O

Rescue	O
therapies	O
are	O
utilized	O
in	O
younger	O
patients	O
with	O
more	O
severe	O
oxygenation	B-PROC
deficits	O
.	O

Demographic	O
,	O
clinical	O
,	O
biological	O
and	O
electrophysiologic	O
data	O
,	O
results	O
of	O
sequential	O
spirometry	O
,	O
and	O
times	O
of	O
endotracheal	O
intubation	O
,	O
tracheotomy	O
,	O
and	O
MV	O
weaning	B-PROC
were	O
prospectively	O
collected	O
for	O
all	O
patients	O
.	O

The	O
lack	O
of	O
foot	O
flexion	B-PROC
ability	O
at	O
ICU	O
admission	O
and	O
at	O
the	O
end	O
of	O
immunotherapy	O
was	O
significantly	O
associated	O
with	O
MV	O
length	O
>	O
15	O
days	O
(	O
positive	O
predictive	O
value	O
:	O
82	O
%;	O
odds	O
ratio	O
:	O
5	O
.	O
4	O
[	O
1	O
.	O
2	O
-	O
23	O
.	O
8	O
]	O
and	O
82	O
%;	O
6	O
.	O
4	O
[	O
1	O
.	O
4	O
-	O
28	O
.	O
8	O
],	O
respectively	O
).	O

The	O
association	O
of	O
a	O
sciatic	O
nerve	O
motor	O
conduction	B-PROC
block	O
with	O
the	O
lack	O
of	O
foot	O
flexion	B-PROC
at	O
the	O
end	O
of	O
immunotherapy	O
was	O
associated	O
with	O
prolonged	O
MV	O
with	O
a	O
100	O
%	O
positive	O
predictive	O
value	O
.	O

In	O
patients	O
admitted	O
to	O
ICU	O
with	O
Guillain	O
-	O
Barré	O
syndrome	O
and	O
acute	O
respiratory	O
failure	O
,	O
the	O
lack	O
of	O
foot	O
flexion	B-PROC
ability	O
at	O
the	O
end	O
of	O
immune	O
therapy	O
predicts	O
a	O
prolonged	O
duration	O
of	O
MV	O
.	O

The	O
identification	O
of	O
CCoV	O
into	O
the	O
basolateral	O
medium	O
could	O
play	O
an	O
important	O
role	O
in	O
the	O
viral	O
pathogenesis	B-PROC
.	O

TITLE	O
:	O
Alizarine	O
derivatives	O
as	O
new	O
dual	O
inhibitors	O
of	O
the	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-PROC
-	O
associated	O
DNA	O
polymerase	O
and	O
RNase	O
H	O
activities	O
effective	O
also	O
on	O
the	O
RNase	O
H	O
activity	O
of	O
non	O
-	O
nucleoside	O
resistant	O
reverse	O
transcriptases	O
.	O

The	O
efficacy	O
of	O
this	O
vaccine	O
is	O
highly	O
dose	O
dependent	O
and	O
the	O
flock	O
antibody	B-PROC
response	I-PROC
is	O
weak	O
.	O

Attrition	O
was	O
associated	O
with	O
preferential	O
loss	O
of	O
effector	O
memory	B-PROC
CD8	O
T	O
cells	O
and	O
reduced	O
immunity	B-PROC
to	O
P	O
.	O
berghei	O
sporozoite	O
challenge	O
.	O

Two	O
other	O
patients	O
died	B-PROC
after	O
referral	O
but	O
before	O
ECMO	O
support	O
could	O
be	O
established	O
.	O

TITLE	O
:	O
PLP2	O
of	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
targets	O
TBK1	O
to	O
negatively	O
regulate	O
cellular	O
type	O
I	O
interferon	O
signaling	B-PROC
pathway	I-PROC
.	O

Here	O
we	O
provide	O
further	O
evidence	O
that	O
PLP2	O
may	O
also	O
target	O
TANK	O
-	O
binding	O
kinase	O
-	O
1	O
(	O
TBK1	O
),	O
the	O
upstream	O
kinase	O
of	O
IRF3	O
in	O
the	O
IFN	O
signaling	B-PROC
pathway	I-PROC
.	O

Identification	O
of	O
the	O
conserved	O
DUB	O
activity	O
of	O
PLP2	O
in	O
suppression	B-PROC
of	O
IFN	O
signaling	B-PROC
would	O
provide	O
a	O
useful	O
clue	O
to	O
the	O
development	B-PROC
of	O
therapeutics	O
against	O
coronaviruses	O
infection	O
.	O

The	O
60	O
-	O
day	O
mortality	O
was	O
19	O
%	O
and	O
death	B-PROC
occurred	O
after	O
12	O
±	O
5	O
days	O
.	O

In	O
this	O
study	O
we	O
sequentially	O
followed	O
up	O
19	O
recovered	O
SARS	O
patients	O
over	O
a	O
3	O
-	O
y	O
period	O
in	O
order	O
to	O
characterize	O
the	O
dynamic	O
changes	O
in	O
antibody	B-PROC
responses	I-PROC
against	O
viral	O
components	O
in	O
detail	O
.	O

Secondary	O
outcome	O
variables	O
included	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
support	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
and	O
duration	O
of	O
viral	B-PROC
shedding	I-PROC
.	O

An	O
additional	O
17	O
patients	O
(	O
68	O
%)	O
required	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
a	O
median	O
of	O
10	O
days	O
(	O
IQR	O
,	O
6	O
to	O
19	O
days	O
).	O

RT	O
-	O
PCR	O
expression	B-PROC
of	O
IFN	O
-	O
γ	O
mRNA	O
was	O
also	O
evaluated	O
after	O
incubation	O
of	O
the	O
peptides	O
or	O
a	O
sham	O
solution	O
with	O
whole	O
blood	O
from	O
4	O
clinically	O
healthy	O
cats	O
.	O

Many	O
cellular	O
proteins	O
interacting	O
with	O
regulatory	O
CoV	O
RNA	O
sequences	O
are	O
members	O
of	O
the	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
(	O
hnRNP	O
)	O
family	O
of	O
RNA	O
-	O
binding	O
proteins	O
,	O
involved	O
in	O
mRNA	B-PROC
processing	I-PROC
and	O
transport	B-PROC
,	O
which	O
shuttle	O
between	O
the	O
nucleus	O
and	O
the	O
cytoplasm	O
.	O

Organs	O
and	O
tissues	O
from	O
deceased	B-PROC
patients	O
were	O
histologically	O
studied	O
;	O
chest	O
computed	O
tomography	O
,	O
body	O
plethysmography	O
,	O
fibrobronchoscopy	O
,	O
breath	O
test	O
,	O
and	O
6	O
-	O
minute	O
walk	O
test	O
were	O
performed	O
in	O
the	O
late	O
period	O
.	O

CONCLUSIONS	O
:	O
The	O
severity	O
of	O
pandemic	O
influenza	O
A	O
/	O
H1N1	O
/	O
2009	O
was	O
determined	O
by	O
massive	O
bilateral	O
pneumonia	O
,	O
interstitial	O
(	O
alveolar	O
)	O
pulmonary	O
edema	O
,	O
formation	B-PROC
of	O
diffuse	O
bilateral	O
lung	O
fibrosis	O
at	O
the	O
outcome	O
of	O
severe	O
virus	O
pneumonia	O
(	O
acute	O
respiratory	O
distress	O
syndrome	O
)	O
with	O
a	O
decrease	O
in	O
vital	O
and	O
diffusing	O
capacities	O
,	O
thereby	O
generating	O
a	O
need	O
to	O
follow	O
up	O
this	O
patient	O
category	O
and	O
,	O
possibly	O
,	O
to	O
elaborate	O
special	O
rehabilitation	O
programs	O
.	O

While	O
rhinovirus	O
and	O
adenovirus	O
infections	O
occurred	O
year	O
round	O
,	O
RSV	O
,	O
influenza	O
virus	O
A	O
and	O
coronavirus	O
OC43	O
had	O
defined	O
period	O
of	O
circulation	B-PROC
.	O

Colloidal	O
gold	O
-	O
labeled	O
rabbit	O
anti	O
-	O
pig	O
immunoglobulin	B-PROC
G	O
(	O
IgG	O
)	O
was	O
used	O
as	O
the	O
detection	O
reagent	O
,	O
and	O
the	O
PHEV	O
recombinant	O
antigens	O
and	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
were	O
coated	O
on	O
the	O
prototype	O
strip	O
and	O
the	O
control	O
lines	O
,	O
respectively	O
.	O

Treatment	O
is	O
mainly	O
supportive	O
combining	O
oxygen	O
supplementation	O
adequate	O
hydration	O
analgesia	B-PROC
and	O
sedation	O
.	O

Other	O
respiratory	O
complications	O
such	O
as	O
sleep	B-PROC
disorders	O
and	O
nocturnal	O
hypoxemia	O
,	O
infiltrative	O
lung	O
disease	O
and	O
exertional	O
dyspnea	O
are	O
described	O
and	O
should	O
be	O
considered	O
.	O

A	O
temporal	O
regulation	B-PROC
of	O
PTB	O
cytoplasmic	O
levels	O
was	O
observed	O
during	O
infection	O
,	O
with	O
a	O
significant	O
increase	O
from	O
7	O
to	O
16	O
h	O
postinfection	O
being	O
inversely	O
associated	O
with	O
a	O
decrease	O
in	O
viral	B-PROC
replication	I-PROC
and	O
transcription	B-PROC
.	O

The	O
extremely	O
short	O
incubation	O
period	O
compared	O
with	O
other	O
experimental	O
models	O
of	O
infectious	O
spongiform	O
degeneration	O
in	O
the	O
brain	O
would	O
provide	O
a	O
superior	O
experimental	O
model	O
to	O
investigate	O
the	O
mechanism	O
of	O
spongiotic	O
lesions	O
formation	B-PROC
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
SYBR	O
Green	O
I	O
based	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
for	O
detection	O
and	O
quantification	O
of	O
bovine	O
coronavirus	O
.	O

Therefore	O
,	O
via	O
regulation	B-PROC
of	O
target	O
genes	O
in	O
these	O
biological	B-PROC
processes	I-PROC
and	O
pathways	B-PROC
,	O
miRNAs	O
potentially	O
contribute	O
to	O
the	O
development	B-PROC
of	O
ALI	O
.	O

TITLE	O
:	O
Inhaled	B-PROC
ribavirin	O
therapy	O
in	O
adult	O
respiratory	O
syncytial	O
virus	O
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Inhaled	B-PROC
ribavirin	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
hospitalized	O
infants	O
and	O
young	O
children	O
with	O
severe	O
lower	O
respiratory	O
tract	O
infections	O
due	O
to	O
RSV	O
.	O

Immunohistochemistry	O
demonstrated	O
that	O
in	O
birds	O
infected	O
with	O
the	O
pathogenic	O
strain	O
of	O
virus	O
,	O
IBV	O
spike	O
protein	O
is	O
detected	O
first	O
in	O
the	O
ciliated	O
cells	O
lining	O
the	O
air	O
sac	B-PROC
.	O

Ten	O
key	O
themes	O
emerged	O
from	O
our	O
qualitative	O
analysis	O
of	O
written	O
comments	O
,	O
including	O
family	O
-	O
work	O
balance	B-PROC
,	O
antiviral	O
prophylaxis	O
,	O
and	O
mistrust	O
or	O
fear	O
towards	O
health	O
care	O
workers	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
RNA	O
-	O
synthesizing	O
activity	O
of	O
coronavirus	O
replication	O
structures	O
in	O
the	O
absence	O
of	O
protein	B-PROC
synthesis	I-PROC
.	O

Both	O
inhibitors	O
prevented	O
the	O
usual	O
exponential	O
increase	O
in	O
viral	O
RNA	B-PROC
synthesis	I-PROC
,	O
with	O
immunofluorescence	O
and	O
electron	O
microscopy	O
indicating	O
that	O
RVN	O
development	B-PROC
came	O
to	O
a	O
standstill	O
.	O

The	O
MFI	O
was	O
evaluated	O
for	O
its	O
diagnostic	O
power	O
,	O
with	O
panels	O
of	O
mouse	O
sera	O
classified	O
as	O
positive	O
or	O
negative	O
for	O
anti	O
-	O
MHV	O
antibodies	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
MHV	O
virion	O
antigen	O
and	O
indirect	O
fluorescent	O
antibody	B-PROC
assay	O
.	O

Real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
was	O
used	O
for	O
detection	O
of	O
H1N1	O
virus	O
in	O
the	O
respiratory	O
specimens	O
.	O

In	O
this	O
study	O
,	O
variable	O
learning	B-PROC
rate	O
has	O
been	O
demonstrated	O
for	O
training	O
artificial	O
neural	B-PROC
network	I-PROC
and	O
predicting	O
BNB	O
for	O
small	O
datasets	O
.	O

The	O
evolution	B-PROC
of	O
a	O
given	O
social	O
network	O
was	O
represented	O
like	O
an	O
evolution	B-PROC
of	O
the	O
algebraic	O
complexity	O
of	O
the	O
corresponding	O
Tutte	O
polynomial	O
.	O

ABSTRACT	O
:	O
The	O
long	O
term	O
adverse	O
effects	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
),	O
a	O
viral	B-PROC
disease	I-PROC
,	O
are	O
poorly	O
understood	O
.	O

RESULTS	O
:	O
Chronic	O
post	O
-	O
SARS	O
is	O
characterized	O
by	O
persistent	O
fatigue	O
,	O
diffuse	O
myalgia	O
,	O
weakness	O
,	O
depression	O
,	O
and	O
nonrestorative	O
sleep	B-PROC
with	O
associated	O
REM	B-PROC
-	O
related	O
apneas	O
/	O
hypopneas	O
,	O
an	O
elevated	O
sleep	B-PROC
EEG	O
cyclical	O
alternating	O
pattern	O
,	O
and	O
alpha	O
EEG	O
sleep	B-PROC
anomaly	O
.	O

Mutation	O
T760R	O
,	O
which	O
optimizes	O
the	O
minimal	O
furin	O
consensus	O
motif	O
758	O
-	O
RXXR	O
-	O
762	O
,	O
and	O
furin	O
overexpression	B-PROC
augmented	O
SARS	O
-	O
S	O
activity	O
,	O
but	O
did	O
not	O
result	O
in	O
detectable	O
SARS	O
-	O
S	O
cleavage	B-PROC
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
two	O
bacterial	O
pathogens	O
(	O
Fusobacterium	O
necrophorum	O
and	O
Acinetobacter	O
baumannii	O
)	O
causing	O
sepsis	O
were	O
detected	O
by	O
DNA	O
-	O
probe	O
hybridization	B-PROC
and	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
was	O
detected	O
by	O
antigen	B-PROC
-	I-PROC
antibody	I-PROC
interaction	I-PROC
using	O
the	O
functional	O
PCs	O
.	O

Equid	O
herpesvirus	O
1	O
and	O
equine	O
rhinitis	O
A	O
virus	O
were	O
prevalent	O
,	O
and	O
equine	O
arteritis	O
virus	O
and	O
equid	O
herpesvirus	O
3	O
were	O
detected	O
over	O
a	O
wide	O
area	O
though	O
their	O
rates	O
of	O
antibody	B-PROC
-	O
positivity	O
were	O
not	O
high	O
.	O

One	O
hundred	O
and	O
fourteen	O
children	O
aged	O
6	O
-	O
14	O
years	O
with	O
chronic	O
stable	O
asthma	O
and	O
on	O
regular	O
inhaled	B-PROC
steroid	O
were	O
monitored	O
for	O
respiratory	O
symptoms	O
over	O
a	O
full	O
calendar	O
year	O
from	O
recruitment	O
.	O

Through	O
site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
,	O
we	O
demonstrate	O
that	O
a	O
predicted	O
beta	O
-	O
hairpin	O
structural	O
motif	O
in	O
the	O
tail	O
is	O
sufficient	O
for	O
Golgi	O
complex	O
localization	B-PROC
of	O
a	O
reporter	O
protein	O
.	O

Dissecting	O
the	O
mechanism	O
of	O
targeting	B-PROC
of	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	O
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
its	O
role	O
in	O
the	O
assembly	O
and	O
release	O
of	O
virions	O
.	O

Notably	O
,	O
the	O
patient	O
had	O
fever	B-PROC
,	O
severe	O
abdominal	O
pain	O
,	O
hematuria	O
,	O
arthritis	O
,	O
and	O
purpuric	O
manifestations	O
associated	O
with	O
a	O
normal	O
platelet	O
count	O
.	O

Recombinant	O
plasmids	O
were	O
digested	B-PROC
by	O
the	O
restriction	O
enzyme	O
Bsa	O
I	O
,	O
and	O
all	O
the	O
cDNA	O
fragments	O
were	O
recovered	O
.	O

Four	O
of	O
forty	O
-	O
three	O
patients	O
with	O
acute	O
exacerbation	O
of	O
idiopathic	O
pulmonary	O
fibrosis	O
had	O
evidence	O
of	O
common	O
respiratory	O
viral	B-PROC
infection	I-PROC
(	O
parainfluenza	O
[	O
n	O
=	O
1	O
],	O
rhinovirus	O
[	O
n	O
=	O
2	O
],	O
coronavirus	O
[	O
n	O
=	O
1	O
]);	O
no	O
viruses	O
were	O
detected	O
in	O
the	O
bronchoalveolar	O
lavage	O
from	O
stable	O
patients	O
.	O

Factors	O
significantly	O
associated	O
with	O
mortality	O
were	O
PaO2	O
/	O
FiO2	O
on	O
day	O
3	O
,	O
pH	O
and	O
SOFA	O
score	O
;	O
and	O
SOFA	O
score	O
of	O
13	O
or	O
above	O
was	O
predictive	O
of	O
death	B-PROC
.	O

ABSTRACT	O
:	O
During	O
the	O
co	O
-	O
evolution	B-PROC
of	O
viruses	O
and	O
their	O
hosts	O
,	O
the	O
latter	O
have	O
equipped	O
themselves	O
with	O
an	O
elaborate	O
immune	O
system	O
to	O
defend	O
themselves	O
from	O
the	O
invading	O
viruses	O
.	O

We	O
report	O
an	O
unusual	O
clinical	O
manifestation	O
of	O
neuralgic	O
amyotrophy	B-PROC
,	O
namely	O
bilateral	O
phrenic	O
nerve	O
palsy	O
with	O
concomitant	O
laryngeal	O
paresis	O
.	O

An	O
electromyography	O
of	O
the	O
upper	O
limb	O
muscles	O
and	O
nerve	B-PROC
conduction	B-PROC
studies	O
did	O
not	O
reveal	O
signs	O
of	O
denervation	O
.	O

This	O
suggested	O
that	O
different	O
recombination	B-PROC
events	O
could	O
have	O
played	O
a	O
role	O
in	O
the	O
evolution	B-PROC
of	O
the	O
NA	O
and	O
Fr	O
TCoV	O
.	O
The	O
present	O
results	O
provide	O
the	O
first	O
S	O
sequence	O
for	O
a	O
European	O
TCoV	O
.	O
They	O
reveal	O
extensive	O
genetic	O
variation	O
in	O
TCoV	O
and	O
suggest	O
different	O
evolutionary	O
pathways	B-PROC
in	O
North	O
America	O
and	O
Europe	O
.	O

The	O
common	O
clinical	O
manifestations	O
of	O
HBoV	O
-	O
infected	O
patients	O
included	O
frequent	O
coughing	O
,	O
wheezing	O
and	O
fever	B-PROC
.	O

Similar	O
T	O
cell	O
CNS	O
recruitment	O
and	O
local	O
T	O
cell	O
-	O
dependent	O
antiviral	O
activity	O
further	O
indicated	O
that	O
the	O
ASC	O
migration	B-PROC
defect	O
was	O
T	O
cell	O
independent	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
RNA	B-PROC
synthesis	I-PROC
is	O
a	O
sophisticated	O
process	O
performed	O
by	O
a	O
viral	O
multienzymatic	O
replicase	O
complex	O
,	O
together	O
with	O
cellular	O
factors	O
.	O

The	O
availability	O
of	O
TGEV	O
RdRp	O
mAbs	O
will	O
be	O
instrumental	O
to	O
study	O
coronavirus	O
replication	O
and	O
to	O
analyze	O
the	O
function	O
of	O
RdRp	O
in	O
pathogenesis	B-PROC
.	O

TITLE	O
:	O
A	O
case	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
associated	O
with	O
novel	O
H1N1	O
treated	O
with	O
intravenous	O
immunoglobulin	B-PROC
G	O
.	O
ABSTRACT	O
:	O
Influenza	O
A	O
""""	O
novel	O
H1N1	O
""""	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
serious	O
illness	O
that	O
poses	O
a	O
challenge	O
to	O
clinicians	O
managing	O
such	O
cases	O
.	O

The	O
relevance	O
of	O
these	O
activities	O
in	O
the	O
viral	B-PROC
life	I-PROC
cycle	I-PROC
has	O
not	O
yet	O
been	O
resolved	O
.	O

The	O
polyclonal	O
antibody	B-PROC
against	O
PRRSV	O
N	O
protein	O
used	O
as	O
a	O
diagnostic	O
agent	O
was	O
capable	O
of	O
differentiating	O
PRRSV	O
from	O
the	O
other	O
viruses	O
.	O

Herein	O
,	O
we	O
explore	O
whether	O
inflammation	O
induced	O
via	O
viral	B-PROC
infection	I-PROC
,	O
compared	O
with	O
inflammation	O
induced	O
via	O
bacterial	O
lipopolysaccharide	O
,	O
modulates	O
AD	O
-	O
like	O
pathological	O
features	O
in	O
the	O
3xTg	O
-	O
AD	O
mouse	O
model	O
and	O
provide	O
evidence	O
to	O
support	O
the	O
hypothesis	O
that	O
infectious	O
agents	O
may	O
act	O
as	O
a	O
comorbidity	O
for	O
AD	O
.	O

The	O
primary	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
value	O
of	O
adding	O
baseline	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
and	O
Fio₂	O
to	O
PaO₂	O
/	O
Fio₂	O
for	O
predicting	O
mortality	O
of	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
enrolled	O
in	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Network	O
clinical	O
trials	O
.	O

Only	O
1	O
.	O
3	O
%	O
of	O
patients	O
enrolled	O
in	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Network	O
trials	O
had	O
baseline	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
<	O
5	O
cm	O
H₂O	O
,	O
and	O
50	O
%	O
had	O
baseline	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
≥	O
10	O
cm	O
H₂O	O
.	O
Baseline	O
PaO₂	O
/	O
Fio₂	O
predicted	O
mortality	O
,	O
but	O
after	O
controlling	O
for	O
PaO₂	O
/	O
Fio₂	O
,	O
baseline	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
did	O
not	O
predict	O
mortality	O
.	O

At	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Network	O
hospitals	O
,	O
the	O
addition	O
of	O
baseline	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
would	O
not	O
have	O
increased	O
the	O
value	O
of	O
PaO₂	O
/	O
Fio₂	O
for	O
predicting	O
mortality	O
of	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
.	O

CONCLUSIONS	O
:	O
At	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Network	O
hospitals	O
,	O
the	O
addition	O
of	O
baseline	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
would	O
not	O
have	O
increased	O
the	O
value	O
of	O
PaO₂	O
/	O
Fio₂	O
for	O
predicting	O
mortality	O
of	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
epidemic	O
was	O
characterized	O
by	O
increased	O
pathogenicity	O
in	O
the	O
elderly	O
due	O
to	O
an	O
early	O
exacerbated	O
innate	O
host	B-PROC
response	I-PROC
.	O

TITLE	O
:	O
LocaPep	O
:	O
localization	B-PROC
of	O
epitopes	O
on	O
protein	O
surfaces	O
using	O
peptides	O
from	O
phage	O
display	O
libraries	O
.	O

Molecular	B-PROC
dynamics	I-PROC
simulations	O
for	O
20	O
ns	O
are	O
performed	O
as	O
a	O
short	O
equilibration	O
to	O
assess	O
the	O
bundle	O
stability	O
in	O
a	O
lipid	O
environment	O
.	O

ABSTRACT	O
:	O
The	O
programmed	O
-	O
1	O
ribosomal	B-PROC
frameshifting	I-PROC
(-	O
1	O
PRF	O
)	O
utilized	O
by	O
eukaryotic	O
RNA	O
viruses	O
plays	O
a	O
crucial	O
role	O
for	O
the	O
controlled	O
,	O
limited	O
synthesis	B-PROC
of	O
viral	O
RNA	O
replicase	O
polyproteins	O
required	O
for	O
genome	O
replication	O
.	O

Four	O
air	O
-	O
handling	O
units	O
were	O
selected	O
from	O
each	O
building	O
,	O
and	O
a	O
total	O
of	O
64	O
prefilters	O
and	O
final	O
filters	O
were	O
tested	O
for	O
the	O
presence	O
of	O
influenza	O
A	O
,	O
influenza	O
B	O
,	O
respiratory	O
syncytial	O
,	O
corona	O
,	O
parainfluenza	O
1	O
-	O
3	O
,	O
adeno	O
,	O
orthopox	O
,	O
entero	O
,	O
Ebola	O
,	O
Marburg	O
,	O
Lassa	O
fever	B-PROC
,	O
Machupo	O
,	O
eastern	O
equine	O
encephalitis	O
,	O
western	O
equine	O
encephalitis	O
,	O
and	O
Venezuelan	O
equine	O
encephalitis	O
viruses	O
.	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
have	O
reported	O
that	O
a	O
serial	O
passage	O
of	O
83P	O
-	O
5	O
strain	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
in	O
Vero	O
cells	O
resulted	O
in	O
a	O
growth	B-PROC
adaptation	B-PROC
of	O
the	O
virus	O
in	O
cultured	O
cells	O
at	O
the	O
22nd	O
passage	O
.	O

In	O
this	O
work	O
,	O
we	O
studied	O
the	O
effect	O
of	O
3b	O
on	O
the	O
transcriptional	B-PROC
activity	O
of	O
AP	O
-	O
1	O
.	O

The	O
inhibition	B-PROC
of	O
TGEV	O
infection	O
in	O
vitro	O
by	O
LiCl	O
was	O
observed	O
at	O
different	O
virus	O
doses	O
and	O
with	O
different	O
cell	O
lines	O
.	O

These	O
higher	O
values	O
of	O
PEEP	O
resulted	O
in	O
improved	O
lung	O
mechanics	O
,	O
reduced	O
driving	O
pressure	O
,	O
improved	O
oxygenation	B-PROC
,	O
with	O
a	O
trend	O
for	O
higher	O
PaCO2	O
and	O
lower	O
systemic	O
and	O
pulmonary	O
pressure	O
.	O

It	O
is	O
critical	O
to	O
find	O
out	O
whether	O
a	O
potential	O
anamnestic	B-PROC
response	I-PROC
,	O
as	O
seen	O
with	O
other	O
viral	B-PROC
infections	I-PROC
,	O
exists	O
to	O
protect	O
a	O
person	O
from	O
reinfection	O
in	O
case	O
of	O
another	O
SARS	O
outbreak	O
.	O

5H10	O
,	O
which	O
recognized	O
the	O
same	O
epitope	O
that	O
is	O
also	O
a	O
cleavage	B-PROC
site	O
critical	O
for	O
the	O
entry	O
of	O
SARS	O
-	O
CoV	O
into	O
host	O
cells	O
,	O
inhibited	O
propagation	O
of	O
the	O
virus	O
and	O
pathological	O
changes	O
found	O
in	O
Rhesus	O
macaques	O
infected	O
with	O
the	O
virus	O
through	O
the	O
nasal	O
route	O
.	O

RESULTS	O
:	O
5H10	O
,	O
which	O
recognized	O
the	O
same	O
epitope	O
that	O
is	O
also	O
a	O
cleavage	B-PROC
site	O
critical	O
for	O
the	O
entry	O
of	O
SARS	O
-	O
CoV	O
into	O
host	O
cells	O
,	O
inhibited	O
propagation	O
of	O
the	O
virus	O
and	O
pathological	O
changes	O
found	O
in	O
Rhesus	O
macaques	O
infected	O
with	O
the	O
virus	O
through	O
the	O
nasal	O
route	O
.	O

TITLE	O
:	O
Virally	O
expressed	B-PROC
interleukin	O
-	O
10	O
ameliorates	O
acute	O
encephalomyelitis	O
and	O
chronic	O
demyelination	O
in	O
coronavirus	O
-	O
infected	O
mice	O
.	O

TITLE	O
:	O
Oral	O
and	O
nasal	O
DNA	O
vaccines	O
delivered	O
by	O
attenuated	O
Salmonella	O
enterica	O
serovar	O
Typhimurium	O
induce	O
a	O
protective	O
immune	B-PROC
response	I-PROC
against	O
infectious	O
bronchitis	O
in	O
chickens	O
.	O

ABSTRACT	O
:	O
Several	O
studies	O
have	O
reported	O
that	O
intramuscular	O
injection	O
of	O
DNA	O
vaccines	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
induces	O
protective	O
immune	B-PROC
responses	I-PROC
.	O

TITLE	O
:	O
Effect	O
of	O
Da	O
-	O
Cheng	O
-	O
Qi	O
decoction	O
on	O
pancreatitis	O
-	O
associated	O
lung	O
injury	O
in	O
patients	O
and	O
anti	O
-	O
inflammatory	B-PROC
responses	I-PROC
in	O
rat	O
models	O
.	O

TITLE	O
:	O
Inhibitors	O
of	O
SARS	O
-	O
3CLpro	O
:	O
virtual	O
screening	O
,	O
biological	O
evaluation	O
,	O
and	O
molecular	B-PROC
dynamics	I-PROC
simulation	O
studies	O
.	O

Cumulative	O
analysis	O
of	O
the	O
evaluated	O
compounds	O
and	O
the	O
simulation	O
studies	O
led	O
to	O
the	O
identification	O
of	O
certain	O
protein	O
-	O
ligand	B-PROC
interaction	O
patterns	O
which	O
would	O
be	O
useful	O
in	O
further	O
structure	O
based	O
design	O
efforts	O
.	O

ABSTRACT	O
:	O
Pneumonia	O
is	O
still	O
one	O
of	O
the	O
most	O
frequent	O
causes	O
of	O
death	B-PROC
in	O
the	O
elderly	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
pulmonary	O
tuberculosis	O
and	O
severe	O
ARDS	O
(	O
PaO2	O
/	O
FiO2	O
<	O
100	O
mmHg	O
)	O
who	O
was	O
initially	O
managed	O
with	O
advanced	O
up	O
-	O
to	O
-	O
date	O
treatments	O
(	O
protective	O
ventilation	O
and	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
,	O
ECMO	O
)	O
but	O
failed	O
to	O
improve	O
.	O

In	O
addition	O
,	O
functional	O
genomics	O
approaches	O
using	O
a	O
gene	O
array	O
methodology	O
to	O
measure	O
lung	O
gene	B-PROC
expression	I-PROC
have	O
identified	O
differential	O
patterns	O
of	O
gene	B-PROC
expression	I-PROC
in	O
animal	O
models	O
of	O
VILI	O
,	O
similar	O
to	O
those	O
gene	O
pathways	B-PROC
activated	O
during	O
experimental	O
and	O
clinical	O
sepsis	O
.	O

This	O
report	O
provides	O
evidence	O
that	O
host	B-PROC
defense	I-PROC
peptides	O
from	O
scorpion	O
venom	O
can	O
be	O
modified	O
for	O
antiviral	O
activity	O
by	O
rational	O
design	O
and	O
represents	O
a	O
practical	O
approach	O
for	O
developing	O
broad	O
-	O
spectrum	O
antiviral	O
agents	O
,	O
especially	O
against	O
RNA	O
viruses	O
.	O

Seven	O
patients	O
did	O
not	O
reach	B-PROC
the	O
350	O
-	O
mmHg	O
PaO	B-PROC
(	O
2	O
)	O
target	O
.	O

Although	O
stepwise	O
-	O
RM	O
improves	O
oxygenation	B-PROC
,	O
it	O
has	O
a	O
heterogeneous	O
impact	O
on	O
respiratory	B-PROC
mechanics	I-PROC
and	O
may	O
cause	O
adverse	O
hemodynamic	B-PROC
effects	O
and	O
transient	O
hypoxemia	O
.	O

Approximately	O
7	O
hours	O
after	O
aspiration	O
,	O
she	O
required	O
mechanical	O
ventilation	O
and	O
had	O
an	O
oxygenation	B-PROC
index	O
(	O
OI	O
)	O
of	O
13	O
.	O
2	O
.	O

A	O
marked	O
decline	O
in	O
pulmonary	O
oxygenation	B-PROC
was	O
observed	O
during	O
the	O
surgery	O
,	O
which	O
led	O
to	O
a	O
diagnosis	O
of	O
ARDS	O
.	O

Inhaled	B-PROC
nitric	O
oxide	O
(	O
NO	O
10	O
ppm	O
)	O
was	O
administered	O
to	O
the	O
patient	O
as	O
a	O
rescue	O
treatment	O
,	O
resulting	O
in	O
a	O
gradual	O
but	O
dramatic	O
improvement	O
in	O
pulmonary	O
oxygenation	B-PROC
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
9b	O
protein	O
diffuses	O
into	O
nucleus	O
,	O
undergoes	O
active	O
Crm1	O
mediated	O
nucleocytoplasmic	O
export	O
and	O
triggers	O
apoptosis	B-PROC
when	O
retained	O
in	O
the	O
nucleus	O
.	O

9b	O
is	O
known	O
to	O
localize	O
in	O
the	O
extra	O
-	O
nuclear	O
region	O
and	O
has	O
been	O
postulated	O
to	O
possess	O
a	O
nuclear	B-PROC
export	I-PROC
signal	O
(	O
NES	O
),	O
however	O
the	O
role	O
of	O
NES	O
in	O
9b	O
functioning	O
is	O
not	O
well	O
understood	O
.	O

Pathologically	O
ARDS	O
is	O
characterised	O
by	O
diffuse	O
alveolar	O
damage	O
,	O
alveolar	O
capillary	O
leakage	O
,	O
and	O
protein	O
rich	O
pulmonary	O
oedema	O
leading	O
to	O
the	O
clinical	O
manifestation	O
of	O
poor	O
lung	B-PROC
compliance	I-PROC
,	O
severe	O
hypoxaemia	O
,	O
and	O
bilateral	O
infiltrates	O
on	O
chest	O
radiograph	O
.	O

Several	O
aetiological	O
factors	O
associated	O
with	O
the	O
development	B-PROC
of	O
ARDS	O
are	O
identified	O
with	O
sepsis	O
,	O
pneumonia	O
,	O
and	O
trauma	O
with	O
multiple	O
transfusions	O
accounting	O
for	O
most	O
cases	O
.	O

Pharmacotherapies	O
remain	O
experimental	O
and	O
recent	O
advances	O
in	O
the	O
modulation	O
of	O
inflammation	O
and	O
novel	O
cellular	O
based	O
therapies	O
,	O
such	O
as	O
mesenchymal	O
stem	O
cells	O
,	O
may	O
reduce	O
lung	O
injury	O
and	O
facilitate	O
repair	B-PROC
.	O

We	O
propose	O
that	O
life	O
history	O
patterns	O
of	O
many	O
species	O
of	O
temperate	O
-	O
zone	O
bats	O
,	O
coupled	O
with	O
sufficiently	O
long	O
incubation	O
periods	B-PROC
,	O
allows	O
for	O
rabies	O
virus	O
maintenance	O
.	O

Secondary	O
outcomes	O
included	O
the	O
development	B-PROC
of	O
individual	O
organ	O
failure	O
,	O
increased	O
ICU	O
and	O
hospital	O
length	O
of	O
stay	O
,	O
need	O
for	O
mechanical	O
ventilation	O
and	O
28	O
-	O
day	O
all	O
-	O
cause	O
mortality	O
.	O

Asthma	O
and	O
wheezing	O
may	O
represent	O
more	O
significant	O
risk	O
factors	O
for	O
the	O
development	B-PROC
of	O
ACS	O
in	O
children	O
with	O
hemoglobin	O
SC	O
disease	O
.	O

TITLE	O
:	O
Reversible	O
cerebral	O
vasoconstriction	B-PROC
syndrome	O
with	O
increased	O
intracranial	B-PROC
pressure	I-PROC
,	O
probably	O
related	O
to	O
altitude	O
changes	O
and	O
windy	O
winter	O
travelling	O
.	O

ABSTRACT	O
:	O
Reversible	O
cerebral	O
vasoconstriction	B-PROC
syndrome	O
(	O
RCVS	O
)	O
has	O
reversible	O
multifocal	O
narrowing	O
of	O
the	O
cerebral	O
arteries	O
.	O

Blood	O
tests	O
,	O
including	O
complete	O
blood	O
count	O
,	O
protein	O
C	O
,	O
protein	O
S	O
,	O
antithrombin	O
III	O
,	O
high	O
-	O
sensitivity	O
C	O
-	O
reactive	O
protein	O
,	O
immunologic	O
and	O
antibody	B-PROC
profiles	O
were	O
normal	O
.	O

Tachypnoea	O
,	O
low	O
grade	O
fever	B-PROC
,	O
clubbed	O
fingers	O
,	O
palmar	O
erythaema	O
,	O
spider	O
angioma	O
,	O
wheezing	O
and	O
severe	O
hypoxaemia	O
were	O
found	O
.	O

ABSTRACT	O
:	O
Antiviral	O
antisepsis	O
and	O
disinfection	O
are	O
crucial	O
for	O
preventing	O
the	O
environmental	O
spread	O
of	O
viral	B-PROC
infections	I-PROC
.	O

We	O
postulated	O
that	O
TGEV	O
protein	O
7	O
may	O
counteract	O
host	O
antiviral	B-PROC
response	I-PROC
by	O
its	O
association	O
with	O
PP1c	O
.	O

This	O
brief	O
article	O
is	O
based	O
on	O
the	O
hypothesis	O
that	O
neonatal	O
RDS	O
has	O
a	O
complex	O
and	O
multifactorial	O
pathogenesis	B-PROC
characterized	O
by	O
an	O
injurious	O
inflammatory	O
sequence	O
in	O
the	O
immature	O
lung	O
.	O

DAD	O
with	O
alveolar	O
collapse	O
was	O
observed	O
in	O
all	O
dead	B-PROC
mice	O
.	O

However	O
,	O
in	O
the	O
surviving	O
mice	O
,	O
instead	O
of	O
DAD	O
,	O
glandular	O
metaplasia	B-PROC
was	O
broadly	O
observed	O
in	O
their	O
lungs	O
.	O

TITLE	O
:	O
Beyond	O
the	O
black	O
box	O
:	O
drug	O
-	O
and	O
device	O
-	O
associated	O
hypersensitivity	B-PROC
events	O
.	O

CONCLUSIONS	O
:	O
Improvements	O
are	O
needed	O
in	O
pharmacovigilance	O
and	O
subsequent	O
dissemination	O
of	O
safety	O
advisories	O
for	O
drug	O
/	O
device	O
-	O
associated	O
hypersensitivity	B-PROC
reactions	I-PROC
.	O

Furthermore	O
,	O
the	O
truncated	O
rS	O
-	O
AD	O
peptide	O
was	O
able	O
to	O
bind	O
to	O
the	O
surface	O
of	O
cells	O
from	O
swine	O
testes	O
in	O
a	O
competitive	O
manner	O
and	O
completely	O
inhibit	O
viral	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Effectiveness	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
when	O
conventional	O
ventilation	O
fails	O
:	O
valuable	O
option	O
or	O
vague	O
remedy	O
?	O

We	O
compared	O
the	O
effects	O
of	O
airway	O
pressure	O
release	O
ventilation	O
and	O
conventional	O
mechanical	O
ventilation	O
on	O
oxygenation	B-PROC
in	O
a	O
porcine	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
induced	O
by	O
wood	O
smoke	O
inhalation	B-PROC
.	O

ABSTRACT	O
:	O
TNF	O
-	O
α	O
and	O
its	O
two	O
receptors	O
(	O
TNFR1	O
and	O
2	O
)	O
are	O
known	O
to	O
stimulate	O
dendritic	O
cell	O
(	O
DC	O
)	O
maturation	B-PROC
and	O
T	O
cell	O
response	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
in	O
response	O
to	O
an	O
attenuated	O
mouse	O
hepatitis	O
virus	B-PROC
infection	I-PROC
,	O
DCs	O
fail	O
to	O
mobilize	O
and	O
up	O
-	O
regulate	O
CD40	O
,	O
CD80	O
,	O
CD86	O
,	O
and	O
MHC	B-PROC
class	O
I	O
in	O
TNFR1	O
(-/-)	O
mice	O
as	O
compared	O
with	O
the	O
wild	O
-	O
type	O
and	O
TNFR2	O
(-/-)	O
mice	O
.	O

Interestingly	O
,	O
adoptive	O
transfer	O
of	O
TNFR1	O
-	O
expressing	O
naive	O
T	O
cells	O
also	O
restores	O
DC	O
mobilization	O
and	O
maturation	B-PROC
and	O
endogenous	O
CD8	O
T	O
cell	O
response	O
.	O

If	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
develops	O
,	O
miniaturised	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
might	O
provide	O
a	O
unique	O
and	O
efficacious	O
possibility	O
to	O
prolong	O
the	O
time	O
frame	O
for	O
diagnosis	O
and	O
the	O
beginning	O
of	O
treatment	O
.	O

An	O
active	O
domain	O
,	O
a	O
novel	O
essential	O
component	O
of	O
the	O
transcription	B-PROC
-	O
regulating	O
motif	O
,	O
has	O
been	O
identified	O
.	O

ABSTRACT	O
:	O
The	O
management	O
of	O
bronchial	O
fistula	O
associated	O
with	O
acute	O
lung	O
injury	O
raises	O
two	O
major	O
concerns	O
:	O
(	O
1	O
)	O
high	O
ventilation	O
pressures	O
are	O
necessary	O
for	O
lung	O
recruitment	O
but	O
detrimental	O
for	O
fistula	O
healing	B-PROC
,	O
and	O
(	O
2	O
)	O
adequate	O
lung	O
recruitment	O
is	O
prevented	O
by	O
large	O
air	O
leak	O
.	O

Arteriovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
was	O
initiated	O
by	O
femorofemoral	O
cannulation	O
.	O

In	O
Hluhluwe	O
-	O
iMfolozi	O
Park	O
(	O
HiP	O
),	O
a	O
small	O
,	O
enclosed	O
reserve	O
in	O
South	O
Africa	O
,	O
a	O
large	O
lion	O
(	O
Panthera	O
leo	O
)	O
population	O
arose	O
from	O
a	O
small	O
founder	O
group	O
in	O
the	O
1960s	O
and	O
started	O
showing	O
conspicuous	O
signs	O
of	O
inbreeding	B-PROC
.	O

More	O
than	O
30	O
%	O
of	O
the	O
native	O
lion	O
population	O
died	B-PROC
from	O
bTB	O
or	O
malnutrition	O
compared	O
with	O
<	O
2	O
%	O
of	O
the	O
translocated	O
lions	O
and	O
their	O
offspring	O
.	O

Nine	O
days	O
later	O
,	O
she	O
emergently	O
presented	O
with	O
respiratory	O
distress	O
,	O
and	O
circulatory	B-PROC
collapse	O
rapidly	O
developed	O
.	O

Despite	O
resuscitative	O
efforts	O
,	O
the	O
child	O
died	B-PROC
.	O

Histologic	O
analysis	O
disclosed	O
acute	O
necrosis	B-PROC
in	O
the	O
cardiac	O
apex	O
and	O
interventricular	O
septum	O
,	O
and	O
focal	O
chronic	O
inflammatory	O
and	O
granulation	O
tissue	O
in	O
the	O
aortic	O
wall	O
.	O

This	O
study	O
was	O
performed	O
to	O
evaluate	O
the	O
incidence	O
and	O
outcomes	O
of	O
RVD	B-PROC
in	O
septic	O
shock	O
patients	O
.	O

The	O
significant	O
factors	O
associated	O
with	O
RVD	B-PROC
include	O
low	O
tidal	O
volume	O
and	O
high	O
peak	O
airway	O
pressure	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
septic	O
shock	O
,	O
the	O
incidence	O
of	O
RVD	B-PROC
is	O
substantial	O
.	O

TITLE	O
:	O
The	O
invasion	O
of	O
tobacco	O
mosaic	O
virus	O
RNA	O
induces	O
endoplasmic	O
reticulum	O
stress	O
-	O
related	O
autophagy	B-PROC
in	O
HeLa	O
cells	O
.	O

Other	O
Gag	O
proteins	O
,	O
including	O
those	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
),	O
murine	O
leukemia	O
virus	O
(	O
MLV	O
),	O
foamy	O
virus	O
and	O
retrotransposons	O
in	O
Schizosaccharomyces	O
pombe	O
and	O
Drosophila	O
,	O
have	O
also	O
been	O
detected	O
in	O
the	O
nucleus	O
,	O
suggesting	O
that	O
nuclear	O
trafficking	B-PROC
of	O
Gag	O
proteins	O
is	O
a	O
common	O
property	O
of	O
retroviruses	O
and	O
retrotransposons	O
.	O

Although	O
her	O
respiratory	O
symptoms	O
responded	O
well	O
to	O
antibiotic	O
treatment	O
,	O
her	O
renal	B-PROC
function	I-PROC
worsened	O
,	O
with	O
severe	O
proteinuria	O
and	O
edema	O
.	O

At	O
presentation	O
,	O
34	O
patients	O
(	O
54	O
.	O
8	O
%)	O
had	O
comorbidities	O
such	O
as	O
smoking	O
(	O
29	O
.	O
0	O
%),	O
hypertension	O
(	O
29	O
.	O
0	O
%)	O
and	O
hepatitis	O
B	O
virus	B-PROC
infection	I-PROC
(	O
9	O
.	O
7	O
%).	O

The	O
pathogenesis	B-PROC
is	O
still	O
unknown	O
.	O

ABSTRACT	O
:	O
The	O
prone	O
position	O
has	O
been	O
used	O
to	O
improve	O
oxygenation	B-PROC
in	O
patients	O
with	O
severe	O
hypoxemia	O
and	O
acute	O
respiratory	O
failure	O
since	O
1974	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
in	O
supporting	O
adult	O
refractory	O
respiratory	O
failure	O
continues	O
to	O
evolve	O
.	O

TITLE	O
:	O
Cerebral	O
edema	O
and	O
a	O
transtentorial	O
brain	O
herniation	O
syndrome	O
associated	O
with	O
pandemic	O
swine	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	B-PROC
infection	I-PROC
.	O

However	O
,	O
identifying	O
pathogen	O
-	O
specific	O
epitopes	O
targeted	B-PROC
by	O
these	O
cells	O
has	O
been	O
elusive	O
.	O

Identification	O
of	O
T	O
reg	O
cell	O
target	O
epitopes	O
by	O
cytokine	B-PROC
production	I-PROC
is	O
also	O
applicable	O
in	O
autoimmune	O
disease	O
because	O
myelin	O
oligodendrocyte	O
glycoprotein	O
-	O
specific	O
Foxp3	O
(+)	O
T	O
reg	O
cells	O
express	O
IL	O
-	O
10	O
and	O
IL	B-PROC
-	I-PROC
17	I-PROC
at	O
the	O
peak	O
of	O
disease	O
in	O
mice	O
with	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
24	O
-	O
year	O
gravida	O
4	O
para	O
2	O
with	O
singleton	O
pregnancy	O
admitted	O
to	O
obstetrical	O
unit	O
for	O
fever	B-PROC
up	O
to	O
38	O
°	O
C	O
during	O
the	O
20th	O
week	O
of	O
a	O
so	O
far	O
uncomplicated	O
pregnancy	O
.	O

ABSTRACT	O
:	O
Low	O
micromolar	O
,	O
non	O
-	O
cytotoxic	O
concentrations	O
of	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
strongly	O
affected	O
the	O
replication	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
human	O
coronavirus	O
229E	O
and	O
mouse	O
hepatitis	O
virus	O
in	O
cell	O
culture	O
,	O
as	O
was	O
evident	O
from	O
the	O
strong	O
inhibition	B-PROC
of	O
GFP	O
reporter	O
gene	B-PROC
expression	I-PROC
and	O
a	O
reduction	O
of	O
up	O
to	O
4	O
logs	O
in	O
progeny	O
titres	O
.	O

TITLE	O
:	O
Local	O
renin	O
-	O
angiotensin	O
II	O
systems	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
and	O
its	O
homologue	O
ACE2	O
:	O
their	O
potential	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
chronic	O
obstructive	O
pulmonary	O
diseases	O
,	O
pulmonary	O
hypertension	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
review	O
data	O
from	O
studies	O
of	O
the	O
past	O
decade	O
that	O
implicate	O
AngII	O
and	O
functional	O
polymorphisms	B-PROC
of	O
the	O
ACE	O
gene	O
that	O
increase	O
ACE	O
activity	O
with	O
increased	O
susceptibility	O
for	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
and	O
for	O
pulmonary	O
hypertension	O
.	O

We	O
report	O
a	O
case	O
of	O
an	O
80	O
-	O
year	O
-	O
old	O
woman	O
who	O
presented	O
with	O
fever	B-PROC
,	O
lung	O
infiltrates	O
,	O
peripheral	O
blood	O
eosinophilia	O
and	O
acute	O
respiratory	O
failure	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
eight	O
of	O
189	O
patients	O
died	B-PROC
in	O
hospital	O
.	O

In	O
addition	O
,	O
compounds	O
that	O
have	O
been	O
tested	O
in	O
various	O
animal	O
models	O
and	O
were	O
found	O
to	O
reduce	O
virus	O
lung	O
titers	O
and	O
/	O
or	O
were	O
protective	O
against	O
death	B-PROC
in	O
lethal	O
models	O
of	O
disease	O
,	O
or	O
otherwise	O
have	O
been	O
shown	O
to	O
ameliorate	O
the	O
effects	O
of	O
viral	B-PROC
infection	I-PROC
,	O
are	O
also	O
reported	O
.	O

Four	O
fragments	O
coding	O
spike	O
proteins	O
(	O
S1	O
,	O
S2	O
,	O
RL	O
and	O
RS	O
)	O
from	O
HCoV	O
-	O
NL63	O
were	O
amplified	O
and	O
cloned	O
into	O
the	O
expression	B-PROC
vector	O
derived	O
from	O
vaccinia	O
virus	O
(	O
Tiantan	O
strain	O
),	O
and	O
recombinant	O
vaccinia	O
viruses	O
expressing	O
four	O
segments	O
of	O
spike	O
proteins	O
were	O
generated	O
(	O
vJSC1175	O
-	O
S1	O
;	O
vJSC1175	O
-	O
S2	O
;	O
vJSC1175	O
-	O
RL	O
;	O
vJSC1175	O
-	O
RS	O
),	O
respectively	O
.	O

The	O
inhibition	B-PROC
or	O
perturbation	O
of	O
the	O
function	O
of	O
cellular	O
PDZ	O
proteins	O
appears	O
to	O
be	O
a	O
widely	O
used	O
strategy	O
for	O
viruses	O
to	O
enhance	O
their	O
replication	O
,	O
disseminate	O
in	O
the	O
host	O
,	O
and	O
transmit	O
to	O
new	O
hosts	O
.	O

Recently	O
,	O
the	O
combination	O
of	O
cell	O
and	O
gene	O
therapy	O
which	O
has	O
been	O
demonstrated	O
to	O
provide	O
additive	O
benefit	O
has	O
opened	O
up	O
a	O
new	O
chapter	O
in	O
therapeutic	O
strategy	O
and	O
provides	O
a	O
basis	O
for	O
the	O
development	B-PROC
of	O
an	O
innovative	O
approach	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
ALI	O
/	O
ARDS	O
.	O

Our	O
results	O
support	O
previous	O
findings	O
which	O
suggest	O
that	O
high	O
levels	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
in	O
serum	O
somehow	O
participate	O
in	O
the	O
inflammatory	B-PROC
response	I-PROC
in	O
severe	O
cases	O
of	O
pandemic	O
influenza	O
pneumonia	O
.	O

For	O
these	O
purposes	O
,	O
we	O
first	O
identified	O
an	O
entry	O
-	O
efficient	O
S	O
gene	B-PROC
template	I-PROC
from	O
a	O
pool	O
of	O
gene	O
variants	O
and	O
used	O
it	O
as	O
a	O
backbone	O
to	O
generate	O
a	O
series	O
of	O
cytoplasmic	O
tail	O
deletion	O
and	O
single	O
residue	O
substitution	O
mutants	O
.	O

Degradation	O
through	O
autophagy	B-PROC
can	O
provide	O
an	O
innate	O
defence	O
against	O
virus	B-PROC
infection	I-PROC
,	O
or	O
conversely	O
autophagosomes	O
can	O
promote	O
infection	O
by	O
facilitating	O
assembly	O
of	O
replicase	O
proteins	O
.	O

This	O
property	O
was	O
shared	O
with	O
nsp6	O
of	O
mammalian	O
coronaviruses	O
Mouse	O
Hepatitis	O
Virus	O
,	O
and	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Virus	O
,	O
and	O
the	O
equivalent	O
nsp5	O
-	O
7	O
of	O
the	O
arterivirus	O
Porcine	O
Reproductive	B-PROC
and	O
Respiratory	O
Syndrome	O
Virus	O
.	O

The	O
vesicles	O
recruited	O
double	O
FYVE	O
-	O
domain	O
containing	O
protein	O
(	O
DFCP	O
)	O
indicating	O
localised	O
concentration	O
of	O
phosphatidylinositol	O
3	O
phosphate	O
,	O
and	O
therefore	O
shared	O
many	O
features	O
with	O
omegasomes	O
formed	O
from	O
the	O
ER	O
in	O
response	B-PROC
to	I-PROC
starvation	I-PROC
.	O

ABSTRACT	O
:	O
Expression	B-PROC
of	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
),	O
especially	O
MMP9	O
correlates	O
with	O
blood	B-PROC
-	I-PROC
brain	I-PROC
barrier	I-PROC
(	O
BBB	O
)	O
disruption	O
during	O
many	O
neuroinflammatory	O
diseases	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
will	O
help	O
to	O
identify	O
the	O
nucleolar	O
localization	B-PROC
signals	O
in	O
PEDV	O
N	O
protein	O
and	O
to	O
elucidate	O
the	O
mechanism	O
of	O
N	O
protein	O
located	O
in	O
nucleus	O
.	O

The	O
type	O
of	O
respiratory	O
failure	O
was	O
oxygenation	B-PROC
failure	O
.	O

Fat	O
embolism	O
syndrome	O
(	O
FES	O
)	O
is	O
an	O
infrequent	O
clinical	O
outcome	O
of	O
FE	O
and	O
is	O
triggered	O
by	O
systemic	O
biochemical	O
and	O
mechanical	O
responses	O
to	O
fat	O
in	O
circulation	B-PROC
.	O

Despite	O
extensive	O
replacement	O
of	O
coagulation	B-PROC
factors	O
,	O
severe	O
vaginal	O
bleeding	O
persisted	O
after	O
weaning	B-PROC
from	O
extracorporal	O
bypass	O
,	O
and	O
the	O
bleeding	O
stopped	O
only	O
after	O
a	O
hysterectomy	O
was	O
performed	O
.	O

Further	O
,	O
an	O
increase	O
in	O
the	O
rate	O
of	O
spontaneous	B-PROC
recovery	I-PROC
of	O
liver	B-PROC
function	I-PROC
has	O
been	O
described	O
.	O

In	O
order	O
to	O
better	O
understand	O
the	O
pathogenesis	B-PROC
of	O
infection	O
caused	O
by	O
this	O
infectious	O
bronchitis	O
variant	O
and	O
to	O
be	O
able	O
to	O
support	O
the	O
poultry	O
industry	O
with	O
substantiated	O
advice	O
to	O
prevent	O
or	O
decrease	O
the	O
damage	O
caused	O
by	O
the	O
D388	O
strain	O
,	O
several	O
vaccination	O
and	O
challenge	O
experiments	O
were	O
performed	O
in	O
young	O
specific	O
pathogen	O
free	O
layers	O
,	O
young	O
layers	O
with	O
maternally	O
derived	O
antibodies	O
against	O
the	O
D388	O
strain	O
and	O
young	O
commercial	O
broiler	O
breeders	O
.	O

ABSTRACT	O
:	O
Integrase	O
(	O
IN	O
)	O
represents	O
a	O
clinically	O
validated	O
target	O
for	O
the	O
development	B-PROC
of	O
antivirals	O
against	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
).	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
),	O
herein	O
we	O
report	O
the	O
design	O
and	O
microwave	O
-	O
assisted	O
synthesis	B-PROC
of	O
a	O
novel	O
series	O
of	O
1	O
-	O
H	O
-	O
benzylindole	O
derivatives	O
.	O

We	O
expressed	B-PROC
and	O
compared	O
the	O
fusion	O
activity	O
of	O
MK	O
-	O
p10	O
S	O
,	O
S	O
with	O
the	O
H1381R	O
mutation	O
,	O
S	O
with	O
the	O
three	O
other	O
mutations	O
that	O
were	O
not	O
thought	O
to	O
be	O
involved	O
in	O
high	O
fusion	O
activity	O
,	O
and	O
the	O
original	O
S	O
protein	O
.	O

ABSTRACT	O
:	O
As	O
part	O
of	O
our	O
ongoing	O
surveillance	O
program	O
,	O
40	O
field	O
strains	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
were	O
isolated	O
from	O
dead	B-PROC
or	O
diseased	O
chicken	O
flocks	O
in	O
different	O
areas	O
of	O
China	O
between	O
2009	O
and	O
2010	O
.	O

In	O
turn	O
,	O
stigmatization	O
during	O
the	O
SARS	O
crisis	O
facilitated	O
a	O
moral	O
panic	O
of	O
sorts	B-PROC
in	O
which	O
racism	O
at	O
a	O
cultural	O
level	O
was	O
expressed	B-PROC
and	O
rationalized	O
on	O
the	O
basis	O
of	O
a	O
rhetoric	O
of	O
the	O
new	O
public	O
health	O
and	O
anti	O
-	O
globalization	O
sentiments	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
HC	O
on	O
cell	O
infection	O
by	O
IBV	O
was	O
determined	O
using	O
plaque	O
assay	O
and	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
.	O

These	O
patients	O
had	O
severe	O
,	O
hypoxemic	O
respiratory	O
failure	O
compatible	O
with	O
ARDS	O
that	O
persisted	O
over	O
time	O
,	O
frequently	O
requiring	O
rescue	O
therapies	O
to	O
support	O
oxygenation	B-PROC
.	O

ABSTRACT	O
:	O
A	O
shotgun	O
proteomics	O
approach	O
was	O
used	O
to	O
characterize	O
and	O
compare	O
the	O
proteins	O
that	O
lead	O
to	O
the	O
formation	B-PROC
of	O
a	O
rich	O
""""	O
protein	O
corona	O
""""	O
adsorbed	O
onto	O
the	O
surfaces	O
of	O
cationic	O
liposomes	O
(	O
CLs	O
),	O
lipoplexes	O
,	O
and	O
lipid	O
/	O
polycation	O
/	O
DNA	O
(	O
LPD	O
)	O
complexes	O
,	O
when	O
they	O
come	O
into	O
contact	O
with	O
plasma	O
.	O

TITLE	O
:	O
Complementary	O
roles	O
of	O
Fas	O
-	O
associated	O
death	B-PROC
domain	O
(	O
FADD	O
)	O
and	O
receptor	O
interacting	O
protein	O
kinase	O
-	O
3	O
(	O
RIPK3	O
)	O
in	O
T	B-PROC
-	I-PROC
cell	I-PROC
homeostasis	I-PROC
and	O
antiviral	O
immunity	B-PROC
.	O

A	O
61	O
-	O
year	O
-	O
old	O
female	O
on	O
multiple	O
medications	O
,	O
including	O
several	O
antipsychotics	O
,	O
rapidly	O
deteriorated	O
,	O
with	O
fever	B-PROC
,	O
lead	O
-	O
pipe	O
rigidity	O
,	O
and	O
decreased	O
level	O
of	O
consciousness	O
.	O

The	O
complex	B-PROC
II	I-PROC
and	O
complex	O
IV	O
,	O
on	O
the	O
other	O
hand	O
,	O
revealed	O
unaltered	O
activity	O
.	O

Among	O
the	O
currently	O
available	O
techniques	O
,	O
the	O
negative	O
expiratory	B-PROC
pressure	O
has	O
been	O
validated	O
in	O
a	O
wide	O
variety	O
of	O
settings	O
and	O
disorders	O
.	O

ABSTRACT	O
:	O
In	O
May	O
2011	O
,	O
an	O
outbreak	O
of	O
Shiga	O
toxin	O
-	O
producing	O
enterohaemorrhagic	O
E	O
coli	O
O104	O
:	O
H4	O
in	O
northern	O
Germany	O
led	O
to	O
a	O
high	O
proportion	O
of	O
patients	O
developing	O
post	O
-	O
enteritis	O
haemolytic	O
uraemic	O
syndrome	O
and	O
thrombotic	O
microangiopathy	O
that	O
were	O
unresponsive	O
to	O
therapeutic	O
plasma	O
exchange	O
or	O
complement	O
-	O
blocking	O
antibody	B-PROC
(	O
eculizumab	O
).	O

TITLE	O
:	O
Drastic	O
changes	O
in	O
the	O
tissue	O
-	O
specific	O
expression	B-PROC
of	O
secreted	B-PROC
phospholipases	O
A2	O
in	O
chicken	O
pulmonary	O
disease	O
.	O

TITLE	O
:	O
Objective	O
assessment	O
of	O
increase	O
in	O
breathing	B-PROC
resistance	B-PROC
of	O
N95	O
respirators	O
on	O
human	O
subjects	O
.	O

ABSTRACT	O
:	O
Genetic	O
background	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
SARS	O
-	O
CoV	O
infection	O
and	O
SARS	O
development	B-PROC
.	O

Further	O
,	O
the	O
SNP	O
rs2248690	O
affected	O
the	O
transcriptional	B-PROC
activity	O
of	O
the	O
AHSG	O
promoter	O
and	O
thus	O
regulated	O
the	O
AHSG	O
serum	O
level	O
.	O

The	O
predefined	O
composite	O
endpoint	O
was	O
the	O
occurrence	O
of	O
any	O
of	O
the	O
following	O
:	O
death	B-PROC
(	O
any	O
cause	O
),	O
cardiac	O
dysfunction	O
(	O
myocardial	O
infarction	O
or	O
congestive	O
heart	O
failure	O
),	O
cerebral	O
dysfunction	O
(	O
stroke	O
or	O
encephalopathy	O
),	O
renal	O
dysfunction	O
(	O
dysfunction	O
or	O
failure	O
),	O
or	O
pulmonary	O
dysfunction	O
(	O
acute	O
respiratory	O
distress	O
syndrome	O
).	O

PAC	O
patients	O
received	O
inotropic	O
drugs	O
more	O
frequently	O
(	O
57	O
.	O
8	O
%	O
vs	O
50	O
.	O
0	O
%;	O
P	O
<	O
0	O
.	O
001	O
),	O
had	O
a	O
larger	O
positive	O
IV	O
fluid	B-PROC
balance	I-PROC
after	O
surgery	O
(	O
3220	O
mL	O
vs	O
3022	O
mL	O
;	O
P	O
=	O
0	O
.	O
003	O
),	O
and	O
experienced	O
longer	O
time	O
to	O
tracheal	O
extubation	O
(	O
15	O
.	O
40	O
hours	O
[	O
11	O
.	O
28	O
/	O
20	O
.	O
80	O
]	O
versus	O
13	O
.	O
18	O
hours	O
[	O
9	O
.	O
58	O
/	O
19	O
.	O
33	O
],	O
median	O
plus	O
Q1	O
/	O
Q3	O
interquartile	O
range	O
;	O
P	O
<	O
0	O
.	O
0001	O
).	O

TITLE	O
:	O
Coronavirus	O
infection	O
induces	O
DNA	B-PROC
replication	I-PROC
stress	O
partly	O
through	O
interaction	O
of	O
its	O
nonstructural	O
protein	O
13	O
with	O
the	O
p125	O
subunit	O
of	O
DNA	O
polymerase	O
δ	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
activation	O
of	O
cellular	B-PROC
DNA	I-PROC
damage	I-PROC
response	I-PROC
is	O
one	O
of	O
the	O
mechanisms	O
exploited	O
by	O
Coronavirus	O
to	O
induce	O
cell	B-PROC
cycle	I-PROC
arrest	I-PROC
.	O

Suppression	B-PROC
of	O
the	O
ATR	O
kinase	O
activity	O
by	O
chemical	O
inhibitors	O
and	O
siRNA	O
-	O
mediated	O
knockdown	O
of	O
ATR	O
reduced	O
the	O
IBV	O
-	O
induced	O
ATR	O
signaling	B-PROC
and	O
inhibited	O
the	O
replication	O
of	O
IBV	O
.	O

Western	O
blot	O
analysis	O
further	O
demonstrated	O
that	O
this	O
ssDNA	O
aptamer	O
could	O
be	O
used	O
to	O
efficiently	O
detect	O
the	O
SARS	O
CoV	O
nucleocapsid	O
protein	O
when	O
compared	O
with	O
a	O
nucleocapsid	O
antibody	B-PROC
.	O

Prompt	O
relief	O
in	O
some	O
conditions	O
,	O
such	O
as	O
croup	O
,	O
may	O
be	O
related	O
to	O
airway	O
mucosal	O
vasoconstriction	B-PROC
through	O
a	O
nongenomic	O
mechanism	O
.	O

New	O
drug	O
regimens	O
,	O
including	O
the	O
more	O
flexible	O
use	O
of	O
inhaled	B-PROC
corticosteroids	O
and	O
long	O
-	O
acting	O
β	O
-	O
agonists	O
in	O
asthma	O
,	O
the	O
lack	O
of	O
efficacy	O
of	O
oral	O
corticosteroids	O
in	O
preschool	O
children	O
with	O
acute	O
wheeze	O
,	O
the	O
severe	O
complications	O
of	O
systemic	O
dexamethasone	O
used	O
to	O
prevent	O
bronchopulmonary	O
dysplasia	O
and	O
thus	O
more	O
restricted	O
use	O
,	O
and	O
the	O
beneficial	O
effect	O
of	O
pulse	B-PROC
high	O
-	O
dose	O
intravenous	O
methylprednisolone	O
in	O
patients	O
with	O
allergic	O
bronchopulmonary	O
aspergillosis	O
or	O
cystic	O
fibrosis	O
are	O
among	O
the	O
major	O
recent	O
developments	O
.	O

Disturbances	O
of	O
lipid	B-PROC
metabolism	I-PROC
are	O
supposed	O
to	O
be	O
major	O
risk	O
factors	O
of	O
severe	O
influenza	O
and	O
its	O
fatal	O
outcome	O
that	O
may	O
be	O
related	O
to	O
obesity	O
through	O
common	O
pathogenetic	O
pathways	B-PROC
.	O

After	O
adjustment	O
for	O
age	O
,	O
%	O
TBSA	O
burn	O
,	O
and	O
full	O
-	O
thickness	O
component	O
,	O
severe	O
inhalation	B-PROC
injury	O
(	O
grades	O
2	O
and	O
3	O
)	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
at	O
24	O
and	O
72	O
hours	O
,	O
as	O
well	O
as	O
ventilator	O
days	O
>	O
21	O
days	O
,	O
and	O
a	O
trend	O
toward	O
multiple	O
organ	O
dysfunction	O
syndrome	O
and	O
mortality	O
.	O

It	O
manifests	O
itself	O
by	O
haemoptysis	O
and	O
intravascular	O
haemolysis	B-PROC
.	O

Indeed	O
,	O
the	O
use	O
intravenous	O
immunoglobulin	B-PROC
has	O
utterly	O
changed	O
prognosis	O
.	O

A	O
retrospective	O
study	O
was	O
performed	O
of	O
all	O
hospitalized	O
patients	O
at	O
the	O
peak	O
of	O
the	O
pH1N1	O
season	O
in	O
whom	O
a	O
single	O
respiratory	O
virus	O
was	O
detected	O
by	O
a	O
molecular	O
assay	O
targeting	B-PROC
18	O
viruses	O
/	O
subtypes	O
(	O
RVP	O
,	O
Luminex	O
xTAG	O
).	O

In	O
patients	O
with	O
cough	O
and	O
gastrointestinal	O
complaints	O
,	O
the	O
presence	O
of	O
subjective	O
fever	B-PROC
/	O
chills	O
independently	O
raised	O
the	O
likelihood	O
of	O
pH1N1	O
(	O
OR	O
10	O
).	O

TITLE	O
:	O
Houttuynia	O
cordata	O
blocks	O
HSV	O
infection	O
through	O
inhibition	B-PROC
of	O
NF	O
-	O
κB	O
activation	O
.	O

The	O
prevalence	O
of	O
FCoV	O
antigen	O
and	O
antibody	B-PROC
in	O
Korean	O
cats	O
are	O
expected	O
to	O
gradually	O
increase	O
due	O
to	O
the	O
rising	O
numbers	O
of	O
stray	O
and	O
companion	O
cats	O
.	O

TITLE	O
:	O
Cytokines	O
and	O
organ	O
failure	O
in	O
acute	O
pancreatitis	O
:	O
inflammatory	B-PROC
response	I-PROC
in	O
acute	O
pancreatitis	O
.	O

ABSTRACT	O
:	O
We	O
aimed	O
at	O
synchronously	O
examining	O
the	O
early	O
time	O
course	O
of	O
4	O
proinflammatory	O
cytokines	O
as	O
predictive	O
factors	O
for	O
development	B-PROC
of	O
organ	O
failure	O
in	O
patients	O
with	O
acute	O
pancreatitis	O
(	O
AP	O
).	O

Interleukin	O
6	O
and	O
IL	O
-	O
8	O
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
who	O
developed	O
renal	O
,	O
respiratory	O
,	O
and	O
circulatory	B-PROC
failure	O
,	O
as	O
was	O
the	O
case	O
for	O
patients	O
with	O
multiorgan	O
failure	O
.	O

Tumor	O
necrosis	B-PROC
factor	O
α	O
was	O
significantly	O
elevated	O
in	O
all	O
types	O
of	O
organ	O
failures	O
,	O
except	O
for	O
intestinal	O
failure	O
.	O

RESULTS	O
:	O
Interleukin	O
6	O
and	O
IL	O
-	O
8	O
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
who	O
developed	O
renal	O
,	O
respiratory	O
,	O
and	O
circulatory	B-PROC
failure	O
,	O
as	O
was	O
the	O
case	O
for	O
patients	O
with	O
multiorgan	O
failure	O
.	O

Finally	O
,	O
GYKI	O
-	O
52466	O
treatment	O
of	O
S	O
mutant	O
virus	O
-	O
infected	O
mice	O
led	O
to	O
reduced	O
microglial	O
activation	O
,	O
which	O
may	O
lead	O
to	O
improvement	O
in	O
the	O
regulation	B-PROC
of	O
CNS	O
glutamate	B-PROC
homeostasis	I-PROC
.	O

Taken	O
together	O
,	O
our	O
results	O
strongly	O
suggest	O
an	O
involvement	O
of	O
excitotoxicity	O
in	O
the	O
paralysis	O
-	O
associated	O
neuropathology	O
induced	O
by	O
an	O
HCoV	O
-	O
OC43	O
mutant	O
which	O
harbors	O
a	O
single	O
point	B-PROC
mutation	I-PROC
in	O
its	O
spike	O
protein	O
that	O
is	O
acquired	O
upon	O
persistent	O
virus	B-PROC
infection	I-PROC
.	O

The	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
,	O
by	O
controlling	O
gas	O
exchange	O
,	O
allowed	O
the	O
performing	O
of	O
a	O
successful	O
liver	O
transplantation	O
and	O
final	O
recovery	O
.	O

The	O
results	O
showed	O
that	O
IBV	O
infection	O
of	O
cultured	O
human	O
and	O
animal	O
cells	O
activated	O
the	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathway	B-PROC
and	O
induced	O
the	O
expression	B-PROC
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
.	O

The	O
average	O
PC	O
volume	O
percentage	O
was	O
21	O
.	O
86	O
%	O
±	O
13	O
.	O
90	O
%	O
(	O
range	O
,	O
5	O
.	O
6	O
%	O
to	O
61	O
.	O
0	O
%),	O
which	O
was	O
inconsistently	O
correlated	O
with	O
the	O
admission	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
ratio	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
083	O
).	O

The	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
ratio	O
,	O
the	O
needed	O
maximal	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
level	O
,	O
and	O
ARDS	O
incidence	O
between	O
the	O
severe	O
group	O
and	O
the	O
general	O
group	O
was	O
significantly	O
different	O
(	O
p	O
<.	O
05	O
).	O

The	O
fourth	O
was	O
complicated	O
with	O
eclampsia	O
,	O
adult	O
respiratory	O
distress	O
and	O
maternal	B-PROC
death	B-PROC
.	O

The	O
protease	O
cleavage	B-PROC
site	O
in	O
S	O
protein	O
is	O
thought	O
to	O
be	O
exposed	O
only	O
after	O
receptor	O
binding	O
.	O

The	O
causes	O
of	O
deaths	B-PROC
were	O
acute	O
renal	O
failure	O
(	O
24	O
cases	O
,	O
42	O
.	O
1	O
%),	O
septicaemia	O
(	O
18	O
cases	O
,	O
31	O
.	O
6	O
%),	O
acute	O
respiratory	O
syndrome	O
(	O
5	O
cases	O
,	O
8	O
.	O
7	O
%),	O
shock	O
(	O
4	O
cases	O
,	O
7	O
.	O
0	O
%),	O
and	O
upper	O
gastrointestinal	O
bleeding	O
due	O
to	O
peptic	O
ulcer	O
and	O
severe	O
anaemia	O
(	O
1	O
case	O
each	O
,	O
1	O
.	O
8	O
%).	O

There	O
were	O
acute	O
complications	O
,	O
consisting	O
of	O
infection	O
of	O
the	O
skin	O
areas	O
(	O
Candida	O
),	O
gastrointestinal	O
bleeding	O
,	O
pleural	O
effusion	O
,	O
and	O
severe	O
ocular	B-PROC
mucous	O
membrane	O
damage	O
.	O

Risk	O
factors	O
for	O
the	O
development	B-PROC
of	O
ocular	B-PROC
complications	O
are	O
not	O
known	O
.	O

Significant	O
genetic	B-PROC
drift	I-PROC
existed	O
between	O
isolates	O
from	O
geographically	O
distinct	O
regions	O
of	O
the	O
Western	O
US	O
.	O

Recombination	B-PROC
in	O
coronaviruses	O
was	O
most	O
notable	O
between	O
different	O
strains	O
of	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
between	O
different	O
strains	O
of	O
infectious	O
bronchitis	O
virus	O
,	O
between	O
MHV	O
and	O
bovine	O
coronavirus	O
,	O
between	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
type	O
I	O
and	O
canine	O
coronavirus	O
generating	O
FCoV	O
type	O
II	O
,	O
and	O
between	O
the	O
three	O
genotypes	O
of	O
human	O
coronavirus	O
HKU1	O
(	O
HCoV	O
-	O
HKU1	O
).	O

TITLE	O
:	O
Unconventional	O
use	O
of	O
LC3	O
by	O
coronaviruses	O
through	O
the	O
alleged	O
subversion	O
of	O
the	O
ERAD	B-PROC
tuning	O
pathway	B-PROC
.	O

The	O
FDA	O
-	O
cleared	O
version	O
includes	O
the	O
following	O
targets	O
:	O
adenovirus	O
,	O
coronaviruses	O
HKU1	O
and	O
NL63	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
influenza	O
A	O
virus	O
(	O
to	O
type	O
level	O
only	O
),	O
influenza	O
A	O
H1	O
seasonal	O
virus	O
,	O
influenza	O
A	O
H3	O
seasonal	O
virus	O
,	O
influenza	O
A	O
virus	O
H1	O
-	O
2009	O
,	O
influenza	O
B	O
virus	O
,	O
parainfluenza	O
viruses	O
1	O
to	O
4	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
and	O
RV	O
/	O
EV	O
(	O
no	O
differentiation	B-PROC
).	O

This	O
strong	O
selective	O
pressure	O
resulted	O
in	O
recombination	B-PROC
events	O
,	O
insertions	O
and	O
deletions	O
in	O
the	O
S	O
gene	O
.	O

Two	O
new	O
isolates	O
generated	O
from	O
recombination	B-PROC
were	O
found	O
with	O
nucleotide	O
sequence	O
diverging	O
1	O
.	O
7	O
-	O
2	O
.	O
4	O
%	O
from	O
the	O
D388	O
/	O
QX	O
-	O
like	O
branch	O
,	O
indicating	O
the	O
emergence	O
of	O
a	O
new	O
lineage	O
.	O

The	O
study	O
demonstrates	O
a	O
constant	O
evolution	B-PROC
of	O
IBV	O
that	O
might	O
be	O
in	O
relation	O
to	O
increased	O
poultry	O
farming	O
,	O
trade	O
and	O
vaccine	O
pressure	O
.	O

Filter	O
efficacy	O
was	O
tested	O
through	O
an	O
independent	O
laboratory	O
,	O
and	O
expiratory	B-PROC
resistance	B-PROC
measurements	O
were	O
taken	O
after	O
prolonged	O
use	O
with	O
humidification	O
.	O

TITLE	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
insertion	O
/	O
deletion	O
polymorphism	B-PROC
is	O
associated	O
with	O
severe	O
hypoxemia	O
in	O
pediatric	O
ARDS	O
.	O

Intravenous	O
administration	O
of	O
immunoglobulin	B-PROC
resolved	O
her	O
potentially	O
life	O
-	O
threatening	O
autonomic	O
instability	O
.	O

In	O
the	O
present	O
study	O
,	O
recombinant	O
SARS	O
-	O
CoV	O
N	O
protein	O
was	O
expressed	B-PROC
and	O
purified	O
and	O
nine	O
specific	O
MAbs	O
against	O
SARS	O
-	O
CoV	O
N	O
protein	O
were	O
obtained	O
successfully	O
.	O

We	O
review	O
several	O
approaches	O
referred	O
to	O
as	O
""""	O
rescue	O
""""	O
therapies	O
for	O
severe	O
hypoxemia	O
,	O
including	O
lung	O
-	O
recruitment	O
maneuvers	O
,	O
ventilation	O
modes	O
,	O
prone	O
positioning	O
,	O
inhaled	B-PROC
vasodilator	O
therapy	O
,	O
and	O
the	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

The	O
primary	O
IBV	O
infection	O
induced	O
changes	O
in	O
circulating	O
T	O
-	O
cell	O
populations	O
and	O
in	O
the	O
specific	O
antibody	B-PROC
responses	I-PROC
.	O

Total	O
lung	B-PROC
compliance	I-PROC
was	O
21	O
mL	O
cm	O
H2O	O
-	O
1	O
,	O
and	O
SAP	O
/	O
DAP	O
was	O
63	O
/	O
39	O
mm	O
Hg	O
).	O

NAVA	O
has	O
mainly	O
been	O
studied	O
in	O
children	O
who	O
underwent	O
cardiac	O
surgery	O
during	O
the	O
period	O
of	O
weaning	B-PROC
from	O
a	O
respirator	O
.	O

Establishment	O
of	O
NAVA	O
provided	O
synchronization	O
of	O
mechanical	O
ventilatory	O
support	O
with	O
the	O
breathing	B-PROC
efforts	O
of	O
the	O
children	O
.	O

Each	O
of	O
the	O
seven	O
strains	O
was	O
infective	O
to	O
the	O
test	O
chickens	O
and	O
could	O
induce	O
an	O
immune	B-PROC
response	I-PROC
.	O

Compared	O
to	O
H120	O
vaccine	O
strain	O
,	O
point	B-PROC
mutation	I-PROC
,	O
short	O
insertion	O
,	O
and	O
deletion	O
occurred	O
at	O
many	O
positions	O
in	O
the	O
S1	O
protein	O
of	O
the	O
seven	O
strains	O
.	O

ABSTRACT	O
:	O
Samples	O
collected	O
in	O
2008	O
and	O
2009	O
,	O
from	O
49	O
turkey	O
flocks	O
of	O
6	O
to	O
43	O
days	O
in	O
age	O
and	O
presenting	O
clinical	O
signs	O
of	O
enteric	O
disease	O
and	O
high	O
mortality	O
,	O
were	O
tested	O
by	O
polymerase	O
chain	O
reaction	O
and	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
for	O
the	O
presence	O
of	O
viruses	O
currently	O
associated	O
with	O
enteric	O
disease	O
(	O
ED	O
)	O
syndromes	O
:	O
astrovirus	O
,	O
reovirus	O
,	O
rotavirus	O
,	O
coronavirus	O
,	O
adenovirus	O
,	O
and	O
parvovirus	O
.	O

Twenty	O
-	O
five	O
percent	O
of	O
patients	O
(	O
5	O
/	O
20	O
)	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
which	O
progressed	O
to	O
predominantly	O
peripheral	O
pulmonary	O
fibrosis	O
in	O
10	O
%	O
(	O
2	O
/	O
20	O
;	O
one	O
died	B-PROC
and	O
one	O
had	O
late	O
-	O
onset	O
pulmonary	O
fibrosis	O
,	O
documented	O
on	O
day	O
68	O
).	O

TITLE	O
:	O
Biochemical	O
and	O
structural	O
insights	O
into	O
the	O
mechanisms	O
of	O
SARS	O
coronavirus	O
RNA	O
ribose	O
2	O
'-	O
O	O
-	O
methylation	B-PROC
by	O
nsp16	O
/	O
nsp10	O
protein	O
complex	O
.	O

Numerous	O
properties	O
of	O
ORF6	O
have	O
been	O
documented	O
and	O
this	O
study	O
focuses	O
on	O
two	O
of	O
these	O
,	O
namely	O
,	O
its	O
ability	O
to	O
suppress	O
the	O
expression	B-PROC
of	O
co	O
-	O
transfected	O
expression	B-PROC
constructs	O
and	O
its	O
subcellular	O
localization	B-PROC
to	O
vesicular	O
structures	O
.	O

Here	O
,	O
ORF6	O
was	O
observed	O
to	O
be	O
localized	O
to	O
similar	O
vesicular	O
structures	O
in	O
Vero	O
E6	O
cells	O
which	O
have	O
been	O
transiently	O
transfected	O
with	O
a	O
mammalian	O
expression	B-PROC
plasmid	O
encoding	O
for	O
untagged	O
ORF6	O
.	O

The	O
alanine	O
substitution	O
of	O
the	O
diacidic	O
cluster	O
motif	O
also	O
altered	O
the	O
subcellular	O
localization	B-PROC
of	O
the	O
ORF6	O
protein	O
,	O
indicating	O
a	O
potential	O
relationship	O
between	O
the	O
subcellular	O
localization	B-PROC
of	O
the	O
ORF6	O
protein	O
and	O
its	O
ability	O
to	O
suppress	O
the	O
expression	B-PROC
of	O
co	O
-	O
transfected	O
expression	B-PROC
constructs	O
.	O

The	O
indication	O
for	O
HFOV	O
was	O
severe	O
oxygenation	B-PROC
failure	O
(	O
PaO2	O
/	O
FiO2	O
<	O
120	O
mm	O
Hg	O
)	O
while	O
receiving	O
aggressive	B-PROC
CV	O
support	O
(	O
defined	O
by	O
either	O
PaO2	O
≤	O
65	O
mm	O
Hg	O
with	O
FiO2	O
≥	O
0	O
.	O
6	O
when	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressures	O
>	O
10	O
cmH2O	O
or	O
plateau	O
airway	O
pressure	O
≥	O
35	O
cm	O
H2O	O
).	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	O
protein	O
regulates	O
cell	O
stress	B-PROC
response	I-PROC
and	O
apoptosis	B-PROC
.	O

Twenty	O
-	O
five	O
stress	B-PROC
response	I-PROC
genes	O
were	O
preferentially	O
upregulated	O
during	O
infection	O
in	O
the	O
absence	O
of	O
the	O
E	O
gene	O
.	O

In	O
addition	O
,	O
genes	O
involved	O
in	O
signal	B-PROC
transduction	I-PROC
,	O
transcription	B-PROC
,	O
cell	O
metabolism	B-PROC
,	O
immunoregulation	B-PROC
,	O
inflammation	O
,	O
apoptosis	B-PROC
and	O
cell	B-PROC
cycle	I-PROC
and	O
differentiation	B-PROC
were	O
differentially	O
regulated	O
in	O
cells	O
infected	O
with	O
rSARS	O
-	O
CoV	O
with	O
or	O
without	O
the	O
E	O
gene	O
.	O

In	O
addition	O
,	O
SARS	O
-	O
CoV	O
E	O
protein	O
down	O
-	O
regulated	O
the	O
signaling	B-PROC
pathway	I-PROC
inositol	O
-	O
requiring	O
enzyme	O
1	O
(	O
IRE	O
-	O
1	O
)	O
of	O
the	O
unfolded	O
protein	O
response	O
,	O
but	O
not	O
the	O
PKR	O
-	O
like	O
ER	O
kinase	O
(	O
PERK	O
)	O
or	O
activating	O
transcription	B-PROC
factor	O
6	O
(	O
ATF	O
-	O
6	O
)	O
pathways	B-PROC
,	O
and	O
reduced	O
cell	O
apoptosis	B-PROC
.	O

The	O
primary	O
outcome	O
was	O
death	B-PROC
before	O
hospital	O
discharge	O
and	O
within	O
90	O
days	O
of	O
study	O
enrolment	O
.	O

The	O
authors	O
describe	O
3	O
challenging	O
cases	O
of	O
the	O
abrupt	O
onset	O
of	O
CM	O
-	O
I	O
/	O
syringomyelia	O
to	O
reveal	O
more	O
information	O
on	O
the	O
clinical	O
presentation	O
and	O
pathogenetic	O
mechanisms	O
of	O
this	O
sudden	O
and	O
potentially	O
severe	O
clinical	O
phenomenon	O
:	O
a	O
38	O
-	O
year	O
-	O
old	O
man	O
experienced	O
acute	O
respiratory	O
failure	O
requiring	O
intubation	O
following	O
acute	O
decompensation	O
of	O
hydrocephalus	O
associated	O
with	O
Noonan	O
syndrome	O
,	O
a	O
1	O
-	O
year	O
-	O
old	O
boy	O
had	O
sudden	O
hemiparesis	O
and	O
Horner	O
syndrome	O
after	O
a	O
minor	O
head	O
/	O
neck	O
injury	O
,	O
and	O
a	O
2	O
.	O
5	O
-	O
year	O
-	O
old	O
boy	O
presented	O
with	O
quickly	O
progressing	O
tetraplegia	O
and	O
dyspnea	O
after	O
a	O
mild	O
flexion	B-PROC
and	O
extension	O
neck	O
injury	O
a	O
few	O
hours	O
before	O
.	O

Overexpression	B-PROC
of	O
NSP1	O
and	O
infection	O
with	O
live	O
SARS	O
-	O
CoV	O
strongly	O
increased	O
signalling	B-PROC
through	O
the	O
Calcineurin	B-PROC
/	O
NFAT	B-PROC
pathway	I-PROC
and	O
enhanced	O
the	O
induction	O
of	O
interleukin	O
2	O
,	O
compatible	O
with	O
late	O
-	O
stage	O
immunopathogenicity	O
and	O
long	O
-	O
term	O
cytokine	O
dysregulation	O
as	O
observed	O
in	O
severe	O
SARS	O
cases	O
.	O

Several	O
lymphocyte	O
subsets	O
vary	O
naturally	O
with	O
aging	B-PROC
,	O
so	O
the	O
interpretation	O
of	O
results	O
using	O
animals	O
of	O
different	O
age	O
ranges	O
must	O
proceed	O
with	O
care	O
.	O

We	O
further	O
show	O
that	O
purified	O
human	O
effector	O
memory	B-PROC
CD8	O
(+)	O
T	O
lymphocytes	O
transmigrate	O
more	O
readily	O
across	O
blood	B-PROC
-	I-PROC
brain	I-PROC
barrier	I-PROC
-	O
endothelial	O
cells	O
than	O
non	O
-	O
effector	O
memory	B-PROC
CD8	O
(+)	O
T	O
lymphocytes	O
,	O
and	O
that	O
blood	B-PROC
-	I-PROC
brain	I-PROC
barrier	I-PROC
endothelium	O
promotes	O
the	O
selective	O
recruitment	O
of	O
effector	O
memory	B-PROC
CD8	O
(+)	O
T	O
lymphocytes	O
.	O

These	O
results	O
add	O
to	O
the	O
growing	O
evidence	O
supporting	O
the	O
clinical	O
and	O
research	O
value	O
of	O
measuring	O
pulmonary	B-PROC
dead	B-PROC
space	I-PROC
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
using	O
this	O
pulmonary	O
physiologic	O
end	O
-	O
point	O
as	O
one	O
indicator	O
of	O
a	O
favorable	O
response	O
to	O
therapy	O
.	O

Acknowledging	O
that	O
the	O
critical	O
care	O
needs	O
of	O
children	O
during	O
disasters	O
were	O
unaddressed	O
by	O
this	O
effort	B-PROC
,	O
a	O
17	O
-	O
member	O
Steering	O
Committee	O
,	O
assembled	O
by	O
the	O
Oak	O
Ridge	O
Institute	O
for	O
Science	O
and	O
Education	O
with	O
guidance	O
from	O
members	O
of	O
the	O
American	O
Academy	O
of	O
Pediatrics	O
,	O
convened	O
in	O
April	O
2009	O
to	O
determine	O
priority	O
topic	O
areas	O
for	O
pediatric	O
emergency	O
mass	O
critical	O
care	O
recommendations	O
.	O

The	O
molecular	O
basis	O
for	O
the	O
extreme	O
virulence	B-PROC
of	O
SARS	O
-	O
CoV	O
remains	O
elusive	O
.	O

Their	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
)),	O
which	O
catalyzes	O
the	O
proteolytic	B-PROC
processing	I-PROC
of	O
the	O
polyproteins	O
for	O
viral	B-PROC
replication	I-PROC
,	O
is	O
a	O
potential	O
target	O
for	O
anti	O
-	O
coronaviral	O
infection	O
.	O

The	O
adipose	O
COPD	O
-	O
patient	O
died	B-PROC
due	O
to	O
septic	O
shock	O
with	O
multiple	O
organ	O
failure	O
without	O
possibility	O
for	O
ECMO	O
support	O
.	O

Since	O
it	O
was	O
first	O
described	O
in	O
1976	O
,	O
prone	O
positioning	O
has	O
been	O
safely	O
employed	O
to	O
improve	O
oxygenation	B-PROC
in	O
many	O
patients	O
with	O
ARDS	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
levels	O
of	O
secreted	B-PROC
IgA	O
decreased	O
significantly	O
at	O
42	O
d	O
of	O
age	O
in	O
the	O
chickens	O
that	O
were	O
treated	O
with	O
LPS	O
or	O
CPM	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Virus	O
-	O
binding	B-PROC
activity	I-PROC
of	O
the	O
truncated	O
C	O
subunit	O
of	O
porcine	O
aminopeptidase	O
N	O
expressed	B-PROC
in	O
Escherichia	O
coli	O
.	O

Novel	O
insights	O
into	O
miRNA	O
expression	B-PROC
changes	O
,	O
including	O
the	O
association	O
with	O
pathogenic	O
outcomes	O
and	O
large	O
differences	O
between	O
in	O
vivo	O
and	O
in	O
vitro	O
experimental	O
systems	O
,	O
were	O
further	O
elucidated	O
by	O
a	O
survey	O
of	O
selected	O
miRNAs	O
across	O
diverse	O
virus	O
infections	O
.	O

Most	O
studies	O
examining	O
the	O
host	O
transcriptional	B-PROC
response	O
to	O
infection	O
focus	O
only	O
on	O
protein	O
-	O
coding	O
genes	O
.	O

Using	O
this	O
approach	O
,	O
we	O
recently	O
discovered	O
widespread	O
differential	O
expression	B-PROC
of	O
host	O
long	O
(>	O
200	O
nucleotide	O
[	O
nt	O
])	O
ncRNAs	O
in	O
response	B-PROC
to	I-PROC
virus	I-PROC
infection	O
.	O

ABSTRACT	O
:	O
n	O
our	O
previous	O
study	O
,	O
we	O
have	O
shown	O
that	O
canine	O
coronavirus	O
type	O
II	O
(	O
CCoV	O
-	O
II	O
)	O
activates	O
both	O
extrinsic	O
and	O
intrinsic	B-PROC
apoptotic	I-PROC
pathway	B-PROC
in	O
a	O
canine	O
fibrosarcoma	O
cell	O
line	O
(	O
A	O
-	O
72	O
cells	O
).	O

Fluorescent	O
antibody	B-PROC
staining	O
indicated	O
that	O
HCoV	O
-	O
229E	O
could	O
readily	O
infect	O
AMs	O
,	O
but	O
no	O
evidence	O
was	O
found	O
for	O
infection	O
in	O
differentiated	B-PROC
alveolar	O
epithelial	O
type	O
II	O
cells	O
and	O
only	O
a	O
very	O
low	O
level	O
of	O
infection	O
in	O
type	O
II	O
cells	O
transitioning	O
to	O
the	O
type	O
I	O
-	O
like	O
cell	O
phenotype	O
.	O

AMs	O
from	O
smokers	O
had	O
reduced	O
secretion	B-PROC
of	O
TNF	O
-	O
α	O
compared	O
with	O
non	O
-	O
smokers	O
in	O
response	O
to	O
HCoV	O
-	O
229E	O
infection	O
.	O

Nonstructural	O
proteins	O
include	O
the	O
small	O
accessory	O
proteins	O
that	O
are	O
not	O
at	O
all	O
conserved	O
between	O
MHV	O
and	O
SARS	O
-	O
CoV	O
and	O
the	O
16	O
conserved	O
proteins	O
encoded	O
in	O
the	O
replicase	O
locus	O
,	O
many	O
of	O
which	O
have	O
enzymatic	O
activities	O
in	O
RNA	B-PROC
metabolism	I-PROC
or	O
protein	B-PROC
processing	I-PROC
in	O
addition	O
to	O
functions	O
in	O
antagonizing	O
host	B-PROC
response	I-PROC
.	O

TITLE	O
:	O
The	O
impact	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
on	O
survival	O
in	O
pediatric	O
patients	O
with	O
respiratory	O
and	O
heart	O
failure	O
:	O
review	O
of	O
our	O
experience	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
widely	O
used	O
for	O
circulatory	B-PROC
support	O
in	O
pediatric	O
cardiac	O
patients	O
with	O
low	O
cardiac	O
output	O
and	O
hypoxemia	O
.	O

Ten	O
patients	O
(	O
71	O
%)	O
were	O
successfully	O
weaned	B-PROC
from	O
ECMO	O
,	O
and	O
eight	O
patients	O
(	O
57	O
%)	O
were	O
discharged	O
from	O
the	O
hospital	O
.	O

Blocking	O
PGD	O
(	O
2	O
)	O
function	O
with	O
small	O
-	O
molecule	O
antagonists	O
enhanced	O
rDC	O
migration	B-PROC
,	O
T	O
cell	O
responses	O
,	O
and	O
survival	O
.	O

This	O
effect	O
correlated	O
with	O
upregulation	B-PROC
on	O
rDCs	O
of	O
CCR7	O
,	O
a	O
chemokine	O
receptor	O
involved	O
in	O
DC	O
chemotaxis	B-PROC
.	O

We	O
describe	O
the	O
clinical	O
course	O
of	O
a	O
critically	O
ill	O
patient	O
with	O
diffuse	O
large	O
B	O
-	O
cell	O
lymphoma	O
nongerminal	O
center	O
B	O
-	O
cell	O
phenotype	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
caused	O
by	O
influenza	O
B	O
virus	B-PROC
infection	I-PROC
.	O

Administering	O
oxygen	O
via	O
the	O
respiratory	O
tract	O
is	O
,	O
however	O
,	O
limited	O
in	O
respiratory	O
diseases	O
such	O
as	O
pulmonary	O
fibrosis	O
,	O
pneumoconiosis	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
or	O
following	O
the	O
inhalation	B-PROC
of	O
asphyxiating	O
poisons	O
.	O

Treatment	O
was	O
changed	O
to	O
veno	O
-	O
arterial	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
on	O
the	O
third	O
day	O
.	O

In	O
vitro	O
experiments	O
showed	O
that	O
FXR	O
activation	O
blocked	O
TNFα	O
-	O
induced	O
expression	B-PROC
of	O
P	O
-	O
selectin	B-PROC
but	O
stimulated	O
proliferation	O
of	O
lung	O
microvascular	O
endothelial	O
cells	O
through	O
up	B-PROC
-	I-PROC
regulation	B-PROC
of	O
Foxm1b	O
.	O

Acute	O
chest	O
syndrome	O
is	O
defined	O
by	O
the	O
association	O
of	O
chest	O
pain	O
or	O
fever	B-PROC
and	O
recent	O
radiographic	O
infiltrates	O
,	O
in	O
patients	O
suffering	O
from	O
sickle	O
cell	O
disease	O
.	O

In	O
this	O
study	O
,	O
two	O
siRNA	O
expression	B-PROC
plasmids	O
(	O
shN1	O
and	O
shN2	O
)	O
were	O
generated	O
to	O
target	O
two	O
different	O
coding	O
regions	O
of	O
the	O
nucleocapsid	O
protein	O
(	O
N	O
)	O
of	O
PHEV	O
.	O

Maintaining	O
calorie	O
balance	B-PROC
alone	O
the	O
days	O
after	O
an	O
insult	O
does	O
not	O
clearly	O
lead	O
to	O
an	O
improved	O
clinical	O
outcome	O
.	O

Glutamine	O
(	O
0	O
.	O
2	O
-	O
0	O
.	O
4	O
g	O
/	O
kg	O
/	O
day	O
of	O
L	O
-	O
glutamine	O
)	O
should	O
be	O
added	O
to	O
enteral	O
nutrition	B-PROC
in	O
burn	O
and	O
trauma	O
patients	O
(	O
ESPEN	O
guidelines	O
2006	O
)	O
and	O
to	O
parenteral	O
nutrition	B-PROC
,	O
in	O
the	O
form	O
of	O
dipeptides	O
,	O
in	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
patients	O
in	O
general	O
(	O
ESPEN	O
guidelines	O
2009	O
).	O

We	O
have	O
developed	O
VIRsiRNAdb	O
,	O
a	O
manually	O
curated	O
database	O
having	O
comprehensive	O
details	O
of	O
1358	O
siRNA	O
/	O
shRNA	O
targeting	B-PROC
viral	O
genome	O
regions	O
.	O

A	O
yeast	O
-	O
based	O
assay	O
was	O
established	O
for	O
PLP	O
activity	O
that	O
relies	O
on	O
the	O
ability	O
of	O
PLP	O
to	O
induce	O
a	O
pronounced	O
slow	O
-	O
growth	B-PROC
phenotype	O
when	O
expressed	B-PROC
in	O
S	O
.	O
cerevisiae	O
.	O

The	O
detection	O
of	O
viral	O
nucleic	O
acid	O
in	O
gut	O
by	O
RT	O
-	O
PCR	O
was	O
consistent	O
and	O
more	O
persistent	O
viral	B-PROC
shedding	I-PROC
was	O
detected	O
in	O
faeces	O
than	O
in	O
nasal	O
exudates	O
.	O

The	O
escape	O
of	O
viral	O
mRNAs	O
from	O
nsp1	O
-	O
induced	O
RNA	O
cleavage	B-PROC
may	O
be	O
an	O
important	O
strategy	O
by	O
which	O
the	O
virus	O
circumvents	O
the	O
action	O
of	O
nsp1	O
leading	O
to	O
the	O
efficient	O
accumulation	O
of	O
viral	O
mRNAs	O
and	O
viral	O
proteins	O
during	O
infection	O
.	O

TITLE	O
:	O
The	O
dependence	O
of	O
viral	O
RNA	B-PROC
replication	I-PROC
on	O
co	O
-	O
opted	O
host	O
factors	O
.	O

To	O
facilitate	O
RNA	B-PROC
replication	I-PROC
,	O
(+)	O
RNA	O
viruses	O
interact	O
with	O
numerous	O
host	O
molecules	O
through	O
protein	O
-	O
protein	O
,	O
RNA	O
-	O
protein	O
and	O
protein	O
-	O
lipid	O
interactions	O
.	O

These	O
interactions	O
lead	O
to	O
the	O
formation	B-PROC
of	O
viral	B-PROC
replication	I-PROC
complexes	O
,	O
which	O
produce	O
new	O
viral	O
RNA	O
progeny	O
in	O
host	O
cells	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
interhospital	O
transfer	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
:	O
5	O
-	O
year	O
experience	O
.	O

Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
allows	O
safe	O
transport	B-PROC
of	O
these	O
patients	O
to	O
tertiary	O
care	O
institutions	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
respiratory	O
failure	O
in	O
adults	O
.	O

The	O
highest	O
-	O
performing	O
signature	O
was	O
expressed	B-PROC
as	O
a	O
continuum	O
in	O
low	O
-,	O
medium	O
-,	O
and	O
high	O
-	O
pathogenicity	O
samples	O
,	O
suggesting	O
a	O
direct	O
,	O
analog	O
relationship	O
between	O
expression	B-PROC
and	O
pathogenicity	O
.	O

This	O
increased	O
degree	O
of	O
expression	B-PROC
may	O
result	O
in	O
the	O
uncontrolled	O
co	O
-	O
localization	B-PROC
of	O
inflammatory	O
cell	O
types	O
and	O
lead	O
to	O
irreversible	O
host	O
damage	O
.	O

Despite	O
significant	O
morphological	O
differences	O
,	O
a	O
striking	O
parallel	O
between	O
the	O
two	O
virus	O
groups	O
,	O
and	O
possibly	O
all	O
members	O
of	O
the	O
order	O
Nidovirales	O
,	O
is	O
the	O
accumulation	O
in	O
the	O
DMV	O
interior	O
of	O
double	O
-	O
stranded	O
RNA	O
,	O
the	O
presumed	O
intermediate	O
of	O
viral	O
RNA	B-PROC
synthesis	I-PROC
.	O

This	O
potential	O
intermediate	O
in	O
nucleocapsid	O
formation	B-PROC
,	O
which	O
was	O
not	O
observed	O
in	O
coronavirus	O
-	O
infected	O
cells	O
,	O
suggests	O
that	O
arterivirus	O
RNA	B-PROC
synthesis	I-PROC
and	O
assembly	O
are	O
coordinated	O
in	O
intracellular	O
space	O
.	O

The	O
pathogenesis	B-PROC
of	O
ARDS	O
is	O
unknown	O
but	O
lung	O
inflammation	O
and	O
lung	O
oxidative	O
stress	O
are	O
likely	O
contributing	O
factors	O
.	O

TITLE	O
:	O
CD4	O
T	O
cells	O
promote	O
CD8	O
T	O
cell	O
immunity	B-PROC
at	O
the	O
priming	O
and	O
effector	O
site	O
during	O
viral	O
encephalitis	O
.	O

ABSTRACT	O
:	O
CD4	O
T	B-PROC
cell	I-PROC
activation	I-PROC
during	O
peripheral	O
infections	O
not	O
only	O
is	O
essential	O
in	O
inducing	O
protective	O
CD8	O
T	O
cell	O
memory	B-PROC
but	O
also	O
promotes	O
CD8	O
T	O
cell	B-PROC
function	I-PROC
and	O
survival	O
.	O

However	O
,	O
the	O
contributions	O
of	O
CD4	O
T	O
cell	O
help	O
to	O
antiviral	O
CD8	O
T	O
cell	O
immunity	B-PROC
during	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
infection	O
are	O
not	O
well	O
established	O
.	O

The	O
effects	O
of	O
an	O
ambient	O
airflow	B-PROC
,	O
as	O
an	O
infection	O
control	O
,	O
are	O
incorporated	O
leading	O
to	O
a	O
delay	O
equation	O
,	O
with	O
droplet	O
density	O
dependent	O
on	O
the	O
infectious	O
density	O
at	O
a	O
previous	O
time	O
.	O

A	O
threshold	O
air	O
velocity	O
is	O
derived	O
,	O
above	O
which	O
disease	O
transmission	O
is	O
impaired	O
even	O
when	O
the	O
basic	O
reproduction	B-PROC
number	O
R	O
(	O
0	O
)	O
exceeds	O
unity	O
.	O

We	O
discussed	O
the	O
potential	O
advantages	O
of	O
extracorporeal	O
oxygenation	B-PROC
as	O
the	O
main	O
support	O
in	O
this	O
particular	O
clinical	O
setting	O
.	O

MRS	O
guided	O
by	O
thoracic	O
computed	O
tomography	O
(	O
CT	O
)	O
included	O
two	O
parts	O
:	O
a	O
recruitment	O
phase	O
to	O
calculate	O
opening	O
pressures	O
(	O
incremental	O
steps	O
under	O
pressure	O
-	O
controlled	O
ventilation	O
up	O
to	O
maximum	O
inspiratory	B-PROC
pressures	O
of	O
60	O
cmH2O	O
,	O
at	O
constant	O
driving	O
-	O
pressures	O
of	O
15	O
cmH2O	O
);	O
and	O
a	O
PEEP	O
titration	O
phase	O
(	O
decremental	O
PEEP	O
steps	O
from	O
25	O
to	O
10	O
cmH2O	O
)	O
used	O
to	O
estimate	O
the	O
minimum	O
PEEP	O
to	O
keep	O
lungs	O
open	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
role	O
of	O
virus	O
and	O
bacteria	O
in	O
CD4	O
(+)	O
T	O
cell	O
-	O
derived	O
cytokine	B-PROC
production	I-PROC
in	O
newborns	O
.	O

We	O
compared	O
the	O
effects	O
of	O
five	O
bacteria	O
(	O
Staphlococcus	O
aureus	O
,	O
Escherichia	O
coli	O
,	O
Clostridium	O
difficile	O
,	O
Lactobacillus	O
rhamnosus	O
and	O
Bifidobacterium	O
bifidus	O
)	O
and	O
seven	O
virus	O
(	O
adenovirus	O
,	O
coronavirus	O
,	O
cytomegalovirus	O
,	O
herpes	O
simplex	O
virus	O
,	O
influenza	O
virus	O
,	O
morbillivirus	O
and	O
poliovirus	O
)	O
on	O
the	O
Th1	O
/	O
Th2	O
cytokine	B-PROC
production	I-PROC
in	O
mixed	O
lymphocyte	O
reactions	O
using	O
CD4	O
(+)	O
T	O
cells	O
from	O
cord	O
blood	O
cocultured	O
with	O
allogenic	O
myeloid	O
or	O
plasmacytoid	O
dendritic	O
cells	O
.	O

When	O
comparing	O
the	O
baseline	O
cytokine	B-PROC
production	I-PROC
prior	O
to	O
microbial	O
stimulation	O
,	O
we	O
observed	O
that	O
cord	O
plasmacytoid	O
DC	O
were	O
stronger	O
inducers	O
of	O
Th2	O
cytokines	O
(	O
IL	O
-	O
5	O
and	O
IL	O
-	O
13	O
)	O
compared	O
with	O
cord	O
myeloid	O
DC	O
and	O
to	O
adult	O
DC	O
.	O

Our	O
findings	O
suggest	O
that	O
M	O
-	O
S	O
co	O
-	O
localization	B-PROC
and	O
S	O
incorporation	O
occur	O
independently	O
of	O
one	O
another	O
in	O
SCoV	O
virion	B-PROC
assembly	I-PROC
.	O

Female	O
BLM	O
WT	O
mice	O
had	O
mild	O
fibrosis	O
and	O
displayed	O
a	O
possible	O
compensatory	O
upregulation	B-PROC
of	O
the	O
AT2	O
receptor	O
.	O

The	O
data	O
indicated	O
overexpression	B-PROC
of	O
the	O
viral	O
receptor	O
as	O
a	O
potential	O
mechanism	O
for	O
severe	O
disease	O
in	O
some	O
patients	O
.	O

Crucial	O
technical	O
innovations	O
and	O
ease	O
of	O
device	O
transport	B-PROC
and	O
implantation	B-PROC
allow	O
location	O
-	O
independent	O
stabilization	O
with	O
consecutive	O
inter	O
-	O
hospital	O
transfer	O
.	O

Recently	O
our	O
lab	O
uncovered	O
a	O
new	O
role	O
for	O
3b	O
in	O
upregulation	B-PROC
of	O
AP	O
-	O
1	O
transcriptional	B-PROC
activity	O
and	O
its	O
downstream	O
genes	O
.	O

Emphasis	O
is	O
placed	O
on	O
detecting	O
post	O
apnea	O
episodes	O
,	O
hence	O
the	O
apnea	O
periods	B-PROC
.	O

An	O
attempt	O
to	O
trace	O
FIPV	O
isolates	O
back	O
to	O
enteric	O
strains	O
existing	O
in	O
the	O
shelter	O
was	O
only	O
partially	O
successful	O
due	O
to	O
the	O
large	O
region	O
over	O
which	O
shelter	O
cats	O
and	O
kittens	O
originated	O
,	O
housing	O
conditions	O
prior	O
to	O
acquisition	O
,	O
and	O
rapid	O
movement	B-PROC
through	O
the	O
shelter	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
hemodynamic	B-PROC
and	O
respiratory	O
variables	O
before	O
and	O
after	O
the	O
procedure	O
.	O

TITLE	O
:	O
[	O
Guidelines	O
for	O
specialized	O
nutritional	O
and	O
metabolic	B-PROC
support	O
in	O
the	O
critically	O
-	O
ill	O
patient	O
.	O

These	O
patients	O
have	O
a	O
high	O
risk	O
of	O
malnutrition	O
due	O
to	O
the	O
underlying	O
disease	O
,	O
their	O
altered	O
catabolism	B-PROC
and	O
the	O
use	O
of	O
mechanical	O
ventilation	O
.	O

Although	O
CoV	O
-	O
HKU1	O
was	O
not	O
identified	O
in	O
any	O
of	O
the	O
studied	O
animals	O
,	O
a	O
coronavirus	O
closely	O
related	O
to	O
SARS	O
-	O
CoV	O
(	O
bat	O
-	O
SARS	O
-	O
CoV	O
)	O
was	O
identified	O
in	O
23	O
(	O
19	O
%)	O
of	O
118	O
wild	O
Chinese	O
horseshoe	O
bats	O
by	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Using	O
the	O
'	O
pancoronavirus	O
'	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
assay	O
,	O
detection	O
rates	O
were	O
0	O
.	O
6	O
%	O
for	O
HCoVNL63	O
,	O
1	O
.	O
2	O
%	O
for	O
HCoV	O
-	O
OC43	O
,	O
0	O
.	O
5	O
%	O
for	O
HCoV	O
-	O
HKU1	O
,	O
and	O
0	O
.	O
2	O
%	O
for	O
HCoV	O
-	O
229E	O
.	O

Antibody	B-PROC
-	O
mediated	O
enhancement	O
of	O
SARS	O
-	O
CoV	O
infection	O
with	O
anti	O
-	O
SARS	O
-	O
CoV	O
Spike	O
immune	O
-	O
serum	O
was	O
observed	O
in	O
vitro	O
.	O

TITLE	O
:	O
Virus	O
-	O
infected	O
alveolar	O
epithelial	O
cells	O
direct	O
neutrophil	B-PROC
chemotaxis	I-PROC
and	O
inhibit	O
their	O
apoptosis	B-PROC
.	O

ABSTRACT	O
:	O
Viruses	O
have	O
evolved	O
elaborate	O
mechanisms	O
to	O
evade	O
or	O
inactivate	O
the	O
complex	O
system	O
of	O
sensors	O
and	O
signaling	B-PROC
molecules	O
that	O
make	O
up	O
the	O
host	O
innate	B-PROC
immune	I-PROC
response	I-PROC
.	O

TITLE	O
:	O
Plasmacytoid	O
dendritic	O
cells	O
control	O
T	O
-	O
cell	O
response	O
to	O
chronic	O
viral	B-PROC
infection	I-PROC
.	O

These	O
data	O
suggest	O
that	O
pDCs	O
facilitate	O
CD4	O
(+)	O
helper	O
T	O
-	O
cell	O
responses	O
to	O
persistent	O
viruses	O
independently	O
of	O
direct	O
antigen	B-PROC
presentation	I-PROC
.	O

Oxygenation	B-PROC
status	O
,	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
level	O
,	O
and	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
[	O
FiO	O
(	O
2	O
)]	O
were	O
compared	O
before	O
and	O
after	O
treatment	O
with	O
ECMO	O
,	O
while	O
the	O
adverse	O
effects	O
of	O
ECMO	O
were	O
recorded	O
.	O

The	O
main	O
complications	O
were	O
bleeding	O
and	O
hemolysis	B-PROC
.	O

The	O
setting	O
of	O
ventilator	O
support	O
were	O
significantly	O
decreased	O
,	O
and	O
arterial	B-PROC
oxygen	I-PROC
saturation	I-PROC
[	O
SaO	O
(	O
2	O
)],	O
arterial	O
blood	O
carbon	O
dioxide	O
partial	O
pressure	O
[	O
PaCO	O
(	O
2	O
)]	O
and	O
blood	O
pH	O
value	O
were	O
improved	O
significantly	O
after	O
the	O
V	O
-	O
V	O
mode	O
ECMO	O
.	O

ECMO	O
has	O
a	O
rapid	O
effect	O
to	O
temporarily	O
support	O
heart	O
or	O
lung	B-PROC
function	I-PROC
(	O
partially	O
or	O
totally	O
)	O
during	O
cardiopulmonary	O
failure	O
,	O
leading	O
to	O
organ	O
recovery	O
.	O

Serum	O
sodium	O
ion	O
[	O
Na	O
(+),	O
mmol	O
/	O
L	O
:	O
140	O
.	O
61	O
±	O
6	O
.	O
69	O
vs	O
.	O
134	O
.	O
06	O
±	O
4	O
.	O
80	O
],	O
arterial	O
partial	O
pressure	O
of	O
oxygen	O
[	O
PO	O
(	O
2	O
),	O
mm	O
Hg	O
,	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
:	O
84	O
.	O
41	O
±	O
30	O
.	O
58	O
vs	O
.	O
59	O
.	O
88	O
±	O
15	O
.	O
19	O
]	O
and	O
pulse	B-PROC
oxygen	O
saturation	O
[	O
SpO	O
(	O
2	O
):	O
0	O
.	O
91	O
±	O
0	O
.	O
08	O
vs	O
.	O
0	O
.	O
78	O
±	O
0	O
.	O
15	O
]	O
were	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

Histopathologically	O
,	O
multifocal	O
granulomas	O
consisting	O
of	O
necrotic	B-PROC
foci	O
,	O
macrophages	O
,	O
fibroblasts	O
and	O
plentiful	O
fibrous	O
connective	O
tissues	O
were	O
observed	O
in	O
the	O
mesenteric	O
mass	O
.	O

TITLE	O
:	O
[	O
Synthesis	B-PROC
of	O
A	O
-	O
secomethylenamino	O
-	O
and	O
substituted	O
amidoximotriterpenoids	O
].	O

In	O
this	O
study	O
,	O
we	O
have	O
prepared	O
full	O
-	O
length	O
SARS	O
-	O
CoV	O
NP	O
expressed	B-PROC
in	O
Escherichia	O
coli	O
and	O
purified	O
.	O

pH	O
,	O
arterial	O
partial	O
pressure	O
of	O
O2	O
(	O
PaO2	O
),	O
PaO2	O
/	O
inspired	B-PROC
O2	O
fraction	O
(	O
FiO2	O
)	O
and	O
lung	B-PROC
compliance	I-PROC
decreased	O
,	O
while	O
PaCO2	O
and	O
airway	O
pressure	O
increased	O
in	O
comparison	O
with	O
baseline	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	B-PROC
infection	I-PROC
induces	O
apoptosis	B-PROC
through	O
FasL	O
-	O
and	O
mitochondria	O
-	O
mediated	O
pathways	B-PROC
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
initial	O
velocity	O
and	O
the	O
angle	O
of	O
the	O
exhaled	B-PROC
airflow	B-PROC
from	O
coughing	O
and	O
speaking	O
of	O
17	O
males	O
and	O
9	O
females	O
using	O
Particle	O
Image	O
Velocimetry	O
(	O
PIV	O
)	O
and	O
acrylic	O
indoor	O
chamber	O
.	O

Structural	O
features	O
imparting	O
strong	O
antiviral	O
activity	O
were	O
identified	O
through	O
iterative	O
cycles	O
of	O
synthesis	B-PROC
and	O
testing	O
.	O

Development	B-PROC
of	O
modified	O
θ	O
-	O
defensin	O
analogs	O
provides	O
an	O
approach	O
for	O
creating	O
novel	O
antiviral	O
agents	O
for	O
IAV	O
infections	O
.	O

The	O
new	O
assay	O
combines	O
the	O
M	O
gene	O
subgenomic	O
messenger	O
RNA	O
(	O
sg	O
-	O
mRNA	O
)	O
detection	O
and	O
the	O
quantitation	O
of	O
the	O
genome	O
copies	O
of	O
FCoV	O
.	O
In	O
order	O
to	O
detect	O
the	O
broadest	O
spectrum	O
of	O
potential	O
FCoV	O
variants	O
and	O
to	O
achieve	O
the	O
most	O
accurate	O
results	O
in	O
the	O
detection	O
ability	O
the	O
new	O
assay	O
is	O
applying	O
the	O
primer	O
-	O
probe	O
energy	B-PROC
transfer	I-PROC
(	O
PriProET	O
)	O
principle	O
.	O

However	O
,	O
this	O
case	O
also	O
suggests	O
that	O
the	O
early	O
administration	O
of	O
corticosteroid	O
therapy	O
as	O
immunomodulation	B-PROC
might	O
be	O
effective	O
in	O
selected	O
cases	O
,	O
and	O
that	O
cessation	O
of	O
such	O
therapy	O
during	O
the	O
early	O
phase	O
of	O
ARDS	O
may	O
cause	O
exacerbation	O
of	O
clinical	O
symptoms	O
.	O

TITLE	O
:	O
Impact	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
and	O
continuous	O
venovenous	O
hemodiafiltration	O
on	O
the	O
pharmacokinetics	B-PROC
of	O
oseltamivir	O
carboxylate	O
in	O
critically	O
ill	O
patients	O
with	O
pandemic	O
(	O
H1N1	O
)	O
influenza	O
.	O

In	O
rare	O
cases	O
,	O
some	O
patients	O
develop	O
influenza	O
-	O
associated	O
multiple	O
organ	O
failures	O
,	O
requiring	O
rescue	O
therapies	O
such	O
as	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
or	O
continuous	O
venovenous	O
hemodiafiltration	O
(	O
CVVHDF	O
).	O

The	O
pDNA	O
loaded	O
biotinylated	O
chitosan	O
nanoparticles	O
were	O
targeted	B-PROC
with	O
bifunctional	O
fusion	O
protein	O
(	O
bfFp	O
)	O
vector	O
for	O
achieving	O
DC	O
selective	O
targeting	B-PROC
.	O

TITLE	O
:	O
New	O
respiratory	O
viral	B-PROC
infections	I-PROC
.	O

Cases	O
were	O
observed	O
only	O
during	O
the	O
cold	B-PROC
months	O
.	O

Sixty	O
percent	O
recovered	O
and	O
40	O
%	O
died	B-PROC
.	O

The	O
Acute	O
Physiology	O
Age	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
,	O
Sequential	O
Organ	O
Failure	O
Assessment	O
(	O
SOFA	O
)	O
score	O
,	O
and	O
the	O
Acute	O
Tubular	O
Necrosis	B-PROC
-	O
Individual	O
Severity	O
Index	O
(	O
ATN	O
-	O
ISI	O
)	O
score	O
were	O
all	O
significantly	O
higher	O
in	O
the	O
expired	O
group	O
(	O
19	O
±	O
5	O
.	O
49	O
)	O
when	O
compared	O
to	O
the	O
survivor	O
group	O
(	O
14	O
.	O
4	O
±	O
3	O
.	O
15	O
)	O
(	O
P	O
=	O
0	O
.	O
014	O
).	O

Finally	O
,	O
extra	O
corporeal	O
oxygenation	B-PROC
methods	O
are	O
very	O
useful	O
as	O
rescue	O
therapy	O
in	O
patients	O
with	O
intractable	O
hypoxemia	O
,	O
even	O
though	O
a	O
survival	O
benefit	O
has	O
not	O
,	O
to	O
this	O
date	O
been	O
demonstrated	O
.	O

Extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
was	O
established	O
using	O
either	O
ELS	O
or	O
Cardiohelp	O
systems	O
(	O
Maquet	O
-	O
Cardiopulmonary	O
-	O
AG	O
,	O
Hirrlingen	O
,	O
Germany	O
).	O

Recombination	B-PROC
analysis	O
revealed	O
possible	O
recombination	B-PROC
events	O
during	O
the	O
evolution	B-PROC
of	O
RbCoV	O
HKU14	O
and	O
members	O
of	O
Betacoronavirus	O
1	O
,	O
which	O
may	O
have	O
occurred	O
during	O
cross	O
-	O
species	O
transmission	O
.	O

This	O
study	O
provides	O
further	O
evidence	O
that	O
FIP	O
is	O
a	O
disease	O
primarily	O
of	O
young	O
cats	O
and	O
that	O
significant	O
breed	B-PROC
and	O
sex	O
predilections	O
exist	O
in	O
Australia	O
.	O

Deoxynivalenol	O
(	O
DON	O
)	O
is	O
known	O
to	O
modulate	O
immune	B-PROC
function	I-PROC
,	O
but	O
only	O
a	O
few	O
studies	O
have	O
investigated	O
the	O
effect	O
of	O
DON	O
on	O
the	O
vaccinal	O
immune	B-PROC
response	I-PROC
.	O

An	O
overview	O
of	O
the	O
prevalence	O
and	O
pathogenesis	B-PROC
of	O
the	O
disorder	O
,	O
clinical	O
diagnosis	O
,	O
and	O
treatment	O
are	O
presented	O
.	O

Initial	O
metabolic	B-PROC
screening	O
was	O
normal	O
,	O
except	O
for	O
a	O
cyclic	O
neutropenia	O
.	O

The	O
reverse	O
genetic	O
system	O
was	O
finally	O
used	O
to	O
generate	O
a	O
recSARS	O
-	O
CoV	O
reporter	O
virus	O
expressing	O
Renilla	O
luciferase	O
in	O
order	O
to	O
facilitate	O
the	O
analysis	O
of	O
SARS	O
-	O
CoV	O
gene	B-PROC
expression	I-PROC
in	O
human	O
dendritic	O
cells	O
(	O
hDCs	O
).	O

The	O
treatment	O
has	O
relied	O
on	O
different	O
unspecific	O
treatment	O
modalities	O
based	O
on	O
a	O
mixture	O
of	O
treatment	O
of	O
the	O
underlying	O
disease	O
and	O
treatment	O
without	O
evidence	O
targeted	B-PROC
to	O
stop	O
the	O
alveolar	O
bleeding	O
.	O

The	O
expression	B-PROC
of	O
KCTD9	O
protein	O
was	O
mainly	O
evidenced	O
in	O
infiltrative	O
mononuclear	O
cells	O
of	O
liver	O
as	O
shown	O
by	O
immunohistochemistry	O
.	O

Basal	O
expression	B-PROC
was	O
also	O
investigated	O
and	O
showed	O
constitutive	O
expression	B-PROC
of	O
KCTD9	O
in	O
brain	O
,	O
thymus	O
and	O
other	O
organs	O
in	O
BALB	O
/	O
cJ	O
mice	O
.	O

CONCLUSIONS	O
:	O
A	O
novel	O
potassium	O
channel	O
gene	O
KCTD9	O
was	O
highly	O
expressed	B-PROC
in	O
hepatic	O
NK	O
cells	O
and	O
T	O
cells	O
of	O
fulminant	O
hepatitis	O
mice	O
induced	O
by	O
MHV	O
-	O
3	O
.	O

TITLE	O
:	O
Prolonged	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
combined	O
with	O
prone	O
positioning	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
invasive	O
Aspergillosis	O
.	O

These	O
results	O
demonstrate	O
the	O
feasibility	O
of	O
detecting	O
viral	O
RNA	B-PROC
synthesis	I-PROC
by	O
using	O
click	O
chemistry	O
and	O
indicate	O
that	O
dsRNA	O
dots	O
do	O
not	O
necessarily	O
correspond	O
with	O
sites	O
of	O
active	O
viral	O
RNA	B-PROC
synthesis	I-PROC
.	O

TITLE	O
:	O
Molecular	O
characterization	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
strain	O
DF	O
-	O
2	O
and	O
studies	O
of	O
the	O
role	O
of	O
ORF3abc	O
in	O
viral	O
cell	O
tropism	B-PROC
.	O

Transplantation	O
of	O
Olig1	O
-/-	O
and	O
Olig1	O
+/+	O
NPCs	O
into	O
JHMV	O
-	O
infected	O
mice	O
resulted	O
in	O
similar	O
cell	B-PROC
survival	I-PROC
,	O
proliferation	O
,	O
and	O
selective	O
migration	B-PROC
to	O
areas	O
of	O
demyelination	O
.	O

In	O
vivo	O
characterization	O
of	O
NPCs	O
revealed	O
that	O
Olig1	O
+/+	O
NPCs	O
preferentially	O
differentiated	B-PROC
into	O
NG2	O
-	O
positive	O
OPCs	O
and	O
formed	O
processes	O
expressing	O
myelin	O
basic	O
protein	O
that	O
encircled	O
axons	O
.	O

TITLE	O
:	O
Trends	O
in	O
and	O
perspectives	O
on	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
severe	O
adult	O
respiratory	O
failure	O
.	O

Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
has	O
been	O
aggressively	O
introduced	O
for	O
such	O
patients	O
,	O
although	O
in	O
only	O
a	O
few	O
institutions	O
.	O

TITLE	O
:	O
The	O
impact	O
of	O
Staphylococcus	O
aureus	O
concentration	O
on	O
the	O
development	B-PROC
of	O
pulmonary	O
lesions	O
and	O
cytokine	O
expression	B-PROC
after	O
intravenous	O
inoculation	O
of	O
pigs	O
.	O

This	O
could	O
potentially	O
create	O
a	O
risk	O
of	O
cytokine	O
spillover	O
to	O
the	O
circulation	B-PROC
,	O
leading	O
to	O
an	O
increased	O
systemic	O
response	O
.	O

The	O
mRNA	B-PROC
expression	B-PROC
of	O
local	O
pulmonary	O
inflammatory	O
markers	O
was	O
compared	O
to	O
protein	O
levels	O
of	O
systemic	O
inflammatory	O
markers	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
(	O
2	O
-	O
DE	O
)	O
and	O
two	O
-	O
dimensional	O
fluorescence	O
difference	O
gel	O
electrophoresis	O
(	O
2	O
-	O
DIGE	O
),	O
coupled	O
with	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	B-PROC
tandem	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
/	O
TOF	O
-	O
MS	O
),	O
to	O
explore	O
the	O
global	O
proteome	O
profiles	O
of	O
trachea	O
and	O
kidney	O
tissues	O
from	O
chicken	O
at	O
different	O
stages	O
infected	O
in	O
vivo	O
with	O
the	O
highly	O
virulent	O
ck	O
/	O
CH	O
/	O
LDL	O
/	O
97I	O
P5	O
strain	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
the	O
embryo	O
-	O
passaged	O
,	O
attenuated	O
ck	O
/	O
CH	O
/	O
LDL	O
/	O
97I	O
P115	O
strain	O
.	O

Results	O
demonstrated	O
that	O
some	O
proteins	O
which	O
had	O
functions	O
in	O
cytoskeleton	B-PROC
organization	I-PROC
,	O
anti	O
-	O
oxidative	O
stress	O
,	O
and	O
stress	B-PROC
response	I-PROC
,	O
showed	O
different	O
change	O
patterns	O
in	O
abundance	O
from	O
chicken	O
infected	O
with	O
the	O
highly	O
virulent	O
ck	O
/	O
CH	O
/	O
LDL	O
/	O
97I	O
P5	O
strain	O
and	O
those	O
given	O
the	O
embryo	O
-	O
passaged	O
,	O
attenuated	O
P115	O
stain	O
.	O

All	O
broilers	O
in	O
the	O
dexamethasone	O
group	O
died	B-PROC
.	O

Vitamin	O
D	O
levels	O
were	O
associated	O
with	O
pulmonary	B-PROC
function	I-PROC
(	O
forced	B-PROC
expiratory	I-PROC
volume	I-PROC
in	O
1	O
second	O
[	O
FEV	O
(	O
1	O
)]),	O
but	O
not	O
associated	O
with	O
either	O
rates	O
of	O
acute	O
pain	O
or	O
acute	O
chest	O
syndrome	O
episodes	O
.	O

(	O
2	O
)	O
Heme	O
up	O
-	O
regulates	O
HO	O
-	O
1	O
and	O
CXCL10	B-PROC
production	I-PROC
through	O
STAT3	O
pathway	B-PROC
,	O
and	O
regulates	O
CXCL10	O
at	O
the	O
transcriptional	B-PROC
level	O
in	O
vitro	O
.	O

(	O
3	O
)	O
HO	O
-	O
1	O
transcription	B-PROC
is	O
positively	O
regulated	O
by	O
CXCL10	O
.	O

The	O
VL	O
and	O
VH	O
amplicons	O
were	O
combined	O
randomly	O
by	O
a	O
12	O
amino	O
acid	O
flexible	O
linker	O
by	O
splicing	B-PROC
by	O
overlap	O
extension	O
PCR	O
(	O
SOE	O
-	O
PCR	O
),	O
which	O
produced	O
the	O
scFv	O
gene	O
repertoire	O
.	O

Similarly	O
,	O
the	O
mean	O
IBV	O
ELISA	O
antibody	B-PROC
titres	O
in	O
the	O
toxin	O
fed	O
groups	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
reduced	O
as	O
compared	O
with	O
the	O
IBV	O
ELISA	O
antibody	B-PROC
titres	O
of	O
IBV	O
infected	O
but	O
not	O
toxin	O
fed	O
group	O
,	O
at	O
all	O
intervals	O
.	O

TITLE	O
:	O
Two	O
years	O
after	O
pandemic	O
influenza	O
A	O
/	O
2009	O
/	O
H1N1	O
:	O
what	O
have	O
we	O
learned	B-PROC
?	O

This	O
efficient	O
inhibition	B-PROC
could	O
be	O
attributed	O
to	O
the	O
dual	O
blockade	O
of	O
entry	O
from	O
the	O
cell	O
surface	O
and	O
through	O
the	O
endosomal	O
pathway	B-PROC
.	O

The	O
IPV	O
induced	O
the	O
IgG1	O
subclass	O
of	O
serum	O
antibodies	O
and	O
expression	B-PROC
of	O
the	O
cytokine	O
interleukin	O
-	O
4	O
(	O
IL	O
-	O
4	O
),	O
suggesting	O
that	O
the	O
IPV	O
generated	O
a	O
predominantly	O
Th2	O
-	O
type	O
immune	B-PROC
response	I-PROC
.	O

TITLE	O
:	O
Validation	O
of	O
a	O
fecal	O
scoring	O
scale	O
in	O
puppies	O
during	O
the	O
weaning	B-PROC
period	O
.	O

After	O
adjustment	O
,	O
age	O
and	O
severity	O
at	O
baseline	O
,	O
but	O
not	O
VAP	O
,	O
were	O
associated	O
with	O
ICU	O
death	B-PROC
.	O

RESULTS	O
:	O
Ninety	O
-	O
eight	O
(	O
28	O
.	O
9	O
%)	O
patients	O
had	O
at	O
least	O
one	O
episode	O
of	O
microbiologically	O
documented	O
bacterial	O
VAP	O
,	O
including	O
41	O
(	O
41	O
.	O
8	O
%)	O
who	O
died	B-PROC
in	O
the	O
ICU	O
,	O
compared	O
with	O
74	O
(	O
30	O
.	O
7	O
%)	O
of	O
the	O
241	O
patients	O
without	O
VAP	O
(	O
P	O
=	O
0	O
.	O
05	O
).	O

Our	O
results	O
indicate	O
that	O
ARV	O
σC	O
protein	O
delivered	O
by	O
LAB	O
via	O
the	O
IN	O
route	O
elicits	O
strong	O
mucosal	B-PROC
immunity	I-PROC
.	O

on	O
day	O
0	O
and	O
28	O
and	O
sacrificed	O
for	O
serum	O
antibody	B-PROC
measurements	O
or	O
challenged	O
with	O
live	O
virus	O
on	O
day	O
56	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
genetic	O
and	O
biological	O
characterisation	O
of	O
a	O
novel	O
pantropic	O
canine	O
coronavirus	O
(	O
CCoV	O
),	O
strain	O
450	O
/	O
07	O
,	O
which	O
caused	O
the	O
death	B-PROC
of	O
a	O
60	O
-	O
day	O
-	O
old	O
miniature	O
pinscher	O
.	O

TITLE	O
:	O
Suppression	B-PROC
of	O
feline	O
coronavirus	O
replication	O
in	O
vitro	O
by	O
cyclosporin	O
A	O
.	O
ABSTRACT	O
:	O
The	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
is	O
a	O
member	O
of	O
the	O
feline	O
coronavirus	O
family	O
that	O
causes	O
FIP	O
,	O
which	O
is	O
incurable	O
and	O
fatal	O
in	O
cats	O
.	O

Neither	O
cell	B-PROC
growth	B-PROC
nor	O
viability	O
changed	O
in	O
the	O
presence	O
of	O
either	O
CsA	O
or	O
FK506	O
,	O
and	O
these	O
factors	O
did	O
not	O
affect	O
the	O
NF	O
-	O
AT	O
pathway	B-PROC
in	O
fcwf	O
-	O
4	O
cells	O
.	O

Therefore	O
,	O
CsA	O
does	O
not	O
seem	O
to	O
exert	B-PROC
inhibitory	O
effects	O
via	O
the	O
NF	O
-	O
AT	O
pathway	B-PROC
.	O

By	O
the	O
time	O
this	O
coronavirus	O
,	O
labeled	O
SCoV	O
,	O
apparently	O
receded	O
from	O
human	O
hosts	O
in	O
July	O
2003	O
,	O
nearly	O
10	O
percent	O
of	O
more	O
than	O
8	O
,	O
000	O
individuals	O
who	O
fit	O
the	O
probable	O
case	O
definition	O
had	O
died	B-PROC
of	O
the	O
disease	O
now	O
known	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
(	O
World	O
Health	O
Organization	O
[	O
WHO	O
],	O
2003a	O
).	O

In	O
sum	O
,	O
our	O
results	O
show	O
that	O
TMPRSS2	O
and	O
HAT	O
are	O
expressed	B-PROC
by	O
important	O
influenza	O
and	O
SARS	O
-	O
coronavirus	O
target	O
cells	O
and	O
could	O
thus	O
support	O
viral	O
spread	O
in	O
the	O
human	O
host	O
.	O

TITLE	O
:	O
Pathogenesis	B-PROC
and	O
tissue	O
distribution	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
isolate	O
IRFIBV32	O
(	O
793	O
/	O
B	O
serotype	O
)	O
in	O
experimentally	O
infected	O
broiler	O
chickens	O
.	O

The	O
infection	O
is	O
an	O
intrinsic	O
property	O
of	O
the	O
virions	O
,	O
and	O
the	O
biological	B-PROC
process	I-PROC
provides	O
a	O
good	O
model	O
for	O
studying	O
how	O
these	O
nanoparticles	O
enter	O
into	O
cells	O
.	O

The	O
bacteriophage	O
-	O
bacteria	O
interactions	O
are	O
also	O
introduced	O
to	O
elucidate	O
how	O
the	O
bacteriophage	O
conquers	O
the	O
barrier	O
of	O
cell	O
walls	O
in	O
the	O
prokaryotic	O
cells	O
to	O
transport	B-PROC
genome	O
into	O
the	O
host	O
.	O

The	O
hairpin	O
version	O
of	O
E	O
was	O
unable	O
to	O
disrupt	O
the	O
secretory	B-PROC
pathway	I-PROC
or	O
produce	O
particles	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
pathogenesis	B-PROC
:	O
host	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
and	O
viral	O
antagonism	O
of	O
interferon	O
.	O

Gene	B-PROC
transcription	I-PROC
signatures	O
unique	O
to	O
SARS	O
-	O
CoV	O
disease	O
states	O
have	O
been	O
identified	O
,	O
but	O
host	O
factors	O
that	O
regulate	O
exacerbated	O
disease	O
phenotypes	O
still	O
remain	O
largely	O
undetermined	O
.	O

While	O
none	O
of	O
the	O
compounds	O
,	O
examined	O
in	O
our	O
study	O
inhibited	O
the	O
DNA	B-PROC
unwinding	I-PROC
activity	O
or	O
ATPase	O
activity	O
of	O
human	O
HCV	O
helicase	O
protein	O
,	O
we	O
found	O
that	O
myricetin	O
and	O
scutellarein	O
potently	O
inhibit	O
the	O
SARS	O
-	O
CoV	O
helicase	O
protein	O
in	O
vitro	O
by	O
affecting	O
the	O
ATPase	O
activity	O
,	O
but	O
not	O
the	O
unwinding	O
activity	O
,	O
nsP13	O
.	O

In	O
this	O
article	O
we	O
focus	O
on	O
the	O
mechanisms	O
of	O
inhibition	B-PROC
of	O
viral	O
proteins	O
by	O
acylguanidines	O
.	O

In	O
response	O
to	O
infection	O
,	O
numerous	O
cytokines	O
/	O
chemokines	O
are	O
secreted	B-PROC
by	O
resident	O
cells	O
of	O
the	O
CNS	O
and	O
inflammatory	O
leukocytes	O
that	O
participate	O
in	O
both	O
host	B-PROC
defense	I-PROC
and	O
disease	O
.	O

Early	O
following	O
JHMV	O
infection	O
,	O
ELR	O
-	O
positive	O
chemokines	O
contribute	O
to	O
host	B-PROC
defense	I-PROC
by	O
attracting	O
CXCR2	O
-	O
expressing	O
cells	O
including	O
polymorphonuclear	O
cells	O
to	O
the	O
CNS	O
that	O
aid	O
in	O
host	B-PROC
defense	I-PROC
through	O
increasing	O
the	O
permeability	O
the	O
blood	O
-	O
brain	O
-	O
barrier	O
(	O
BBB	O
).	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
safety	O
and	O
efficacy	O
of	O
high	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
ventilation	O
strategy	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
after	O
traumatic	O
brain	O
injury	O
.	O

TITLE	O
:	O
Co	O
-	O
circulation	B-PROC
of	O
four	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
in	O
Queensland	O
children	O
with	O
acute	O
respiratory	O
tract	O
illnesses	O
in	O
2004	O
.	O

High	O
frequency	O
ventilation	O
and	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
are	O
used	O
as	O
rescue	O
modes	O
of	O
support	O
in	O
difficult	O
situations	O
.	O

Rapid	O
evolution	B-PROC
of	O
avian	O
coronavirus	O
IBV	O
makes	O
this	O
virus	O
extremely	O
difficult	O
to	O
diagnose	O
and	O
control	O
,	O
but	O
also	O
makes	O
it	O
an	O
excellent	O
model	O
system	O
to	O
study	O
viral	O
genetic	O
diversity	O
and	O
the	O
mechanisms	O
behind	O
the	O
emergence	O
of	O
coronaviruses	O
in	O
their	O
natural	O
host	O
.	O

The	O
reason	O
for	O
death	B-PROC
in	O
all	O
these	O
patients	O
was	O
low	O
cardiac	O
output	O
syndrome	O
with	O
subsequent	O
multi	O
-	O
organ	O
failure	O
.	O

In	O
influenza	O
A	O
virus	B-PROC
infection	I-PROC
we	O
show	O
that	O
viral	O
clearance	O
is	O
determined	O
by	O
sex	O
but	O
not	O
by	O
CD200R	O
signaling	B-PROC
.	O

Our	O
data	O
predict	O
a	O
sex	O
bias	O
in	O
both	O
beneficial	O
and	O
pathological	O
immune	B-PROC
responses	I-PROC
to	O
virus	B-PROC
infection	I-PROC
upon	O
therapeutic	O
targeting	B-PROC
of	O
CD200	O
-	O
CD200R	O
.	O

Our	O
data	O
provide	O
experimental	O
evidence	O
that	O
nsp13	O
and	O
nsp12	O
can	O
function	O
in	O
a	O
concerted	O
manner	O
to	O
improve	O
the	O
efficiency	O
of	O
viral	B-PROC
replication	I-PROC
and	O
enhance	O
our	O
understanding	O
of	O
nsp13	O
function	O
during	O
SARS	O
-	O
CoV	O
RNA	B-PROC
synthesis	I-PROC
.	O

ABSTRACT	O
:	O
Hundreds	O
of	O
million	O
people	O
worldwide	O
have	O
been	O
infected	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
the	O
rate	O
of	O
global	O
death	B-PROC
from	O
SARS	O
has	O
remarkably	O
increased	O
.	O

TITLE	O
:	O
Role	O
of	O
the	O
SEL1L	O
:	O
LC3	O
-	O
I	O
complex	O
as	O
an	O
ERAD	B-PROC
tuning	O
receptor	O
in	O
the	O
mammalian	O
ER	O
.	O

ABSTRACT	O
:	O
Several	O
regulators	O
of	O
endoplasmic	O
reticulum	O
(	O
ER	O
)-	O
associated	O
degradation	O
(	O
ERAD	B-PROC
)	O
have	O
a	O
shorter	O
half	O
-	O
life	O
compared	O
to	O
conventional	O
ER	O
chaperones	O
.	O

Here	O
we	O
identify	O
the	O
complex	O
comprising	O
the	O
type	O
-	O
I	O
transmembrane	O
protein	O
SEL1L	O
and	O
the	O
cytosolic	O
protein	O
LC3	O
-	O
I	O
as	O
an	O
ERAD	B-PROC
tuning	O
receptor	O
regulating	O
the	O
COPII	O
-	O
independent	O
,	O
vesicle	O
-	O
mediated	O
removal	O
of	O
the	O
lumenal	O
ERAD	B-PROC
regulators	O
EDEM1	O
and	O
OS	O
-	O
9	O
from	O
the	O
ER	O
.	O

This	O
raises	O
ERAD	B-PROC
activity	O
in	O
the	O
absence	O
of	O
UPR	O
-	O
induction	O
.	O

ABSTRACT	O
:	O
The	O
replication	O
/	O
transcription	B-PROC
complex	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
is	O
composed	O
of	O
at	O
least	O
16	O
nonstructural	O
proteins	O
(	O
nsp1	O
-	O
16	O
)	O
encoded	O
by	O
the	O
ORF	O
-	O
1a	O
/	O
1b	O
.	O

ABSTRACT	O
:	O
Fulminant	O
viral	O
hepatitis	O
(	O
FH	O
)	O
remains	O
a	O
serious	O
clinical	O
problem	O
for	O
which	O
the	O
underlying	O
pathogenesis	B-PROC
remains	O
unclear	O
.	O

The	O
early	O
loss	O
of	O
macrophages	O
resulted	O
in	O
reduced	O
pathogenic	O
tumour	O
necrosis	B-PROC
factor	O
α	O
(	O
TNFα	O
)	O
and	O
FGL2	O
levels	O
and	O
lower	O
viral	O
titres	O
.	O

Encephalitis	O
induced	O
by	O
a	O
gliatropic	O
murine	O
coronavirus	O
was	O
used	O
as	O
a	O
model	O
to	O
assess	O
the	O
direct	O
contributions	O
of	O
neutrophils	O
,	O
IFN	O
-	O
γ	O
and	O
IL	B-PROC
-	I-PROC
17	I-PROC
to	O
virus	O
-	O
induced	O
mortality	O
.	O

Furthermore	O
,	O
co	O
-	O
transfer	O
of	O
WT	O
and	O
GKO	O
CD4	O
+	O
T	O
cells	O
prolonged	O
survival	O
in	O
an	O
IFN	O
-	O
γ	O
dependent	O
manner	O
,	O
although	O
IL	B-PROC
-	I-PROC
17	I-PROC
transcription	B-PROC
was	O
not	O
reduced	O
.	O

Herein	O
,	O
we	O
generated	O
three	O
distinct	O
DNA	O
constructs	O
in	O
the	O
eukaryotic	O
expression	B-PROC
plasmid	O
pVAX1	O
;	O
one	O
encoding	O
the	O
S	O
protein	O
[	O
pVAX1	O
-(	O
PEDV	O
-	O
S	O
)],	O
the	O
second	O
encoding	O
the	O
N	O
-	O
terminal	O
fragment	O
(	O
S1	O
)	O
[	O
pVAX1	O
-(	O
PEDV	O
-	O
S1	O
)]	O
containing	O
potent	O
antigenic	O
sites	O
,	O
and	O
the	O
third	O
expressing	O
the	O
porcine	O
interleukin	O
-	O
18	O
(	O
pIL	O
-	O
18	O
)	O
[	O
pVAX1	O
-(	O
IL	O
-	O
18	O
)].	O

Immunofluorescence	O
assays	O
in	O
BHK	O
-	O
21	O
cells	O
demonstrated	O
successful	O
protein	B-PROC
expression	B-PROC
from	O
all	O
3	O
constructs	O
.	O

CONCLUSIONS	O
:	O
The	O
development	B-PROC
of	O
a	O
severe	O
and	O
acute	O
methemoglobinemia	O
following	O
the	O
administration	O
of	O
MCP	O
is	O
described	O
in	O
this	O
case	O
report	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
our	O
previous	O
structure	O
-	O
activity	O
relationship	O
and	O
antiviral	O
mechanism	O
studies	O
,	O
a	O
series	O
of	O
14	O
-	O
aminophenanthroindolizidines	O
(	O
1a	O
-	O
i	O
,	O
2	O
,	O
and	O
3	O
)	O
were	O
designed	O
,	O
targeting	B-PROC
tobacco	O
mosaic	O
virus	O
(	O
TMV	O
)	O
RNA	O
,	O
and	O
synthesized	O
and	O
systematically	O
evaluated	O
for	O
their	O
antiviral	O
activity	O
against	O
TMV	O
.	O

Most	O
of	O
the	O
skin	O
grafts	O
could	O
neither	O
survive	O
nor	O
spread	O
on	O
the	O
fresh	O
wound	O
after	O
removing	O
the	O
necrotic	B-PROC
tissue	O
.	O

To	O
describe	O
the	O
characteristics	O
of	O
ICU	O
patients	O
with	O
pH1N1	O
virus	B-PROC
infection	I-PROC
in	O
the	O
United	O
States	O
during	O
the	O
spring	O
and	O
fall	O
of	O
2009	O
and	O
to	O
describe	O
the	O
factors	O
associated	O
with	O
severe	O
complications	O
including	O
ARDS	O
and	O
death	B-PROC
.	O

Forty	O
-	O
eight	O
(	O
38	O
%)	O
patients	O
developed	O
ARDS	O
and	O
37	O
(	O
24	O
%)	O
died	B-PROC
.	O

ABSTRACT	O
:	O
Carcinoembryonic	O
antigen	O
-	O
related	O
cell	B-PROC
adhesion	I-PROC
molecule	O
1	O
(	O
CEACAM1	O
)	O
is	O
the	O
sole	O
known	O
receptor	O
of	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
A59	O
,	O
but	O
the	O
available	O
,	O
often	O
qualitative	O
,	O
data	O
about	O
CEACAM1	O
expression	B-PROC
does	O
not	O
explain	O
MHV	O
organ	O
tropism	B-PROC
.	O

Ceacam1	O
transcripts	O
undergo	O
alternative	B-PROC
splicing	B-PROC
resulting	O
in	O
multiple	O
isoforms	O
,	O
including	O
secreted	B-PROC
CEACAM1	O
isoforms	O
that	O
can	O
neutralize	O
the	O
virus	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
dengue	O
haemorrhagic	O
fever	B-PROC
complicated	O
with	O
acute	O
pancreatitis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
ability	O
of	O
A77	O
-	O
1726	O
to	O
improve	O
cardiopulmonary	O
function	O
in	O
influenza	O
-	O
infected	O
mice	O
and	O
to	O
reduce	O
the	O
severity	O
of	O
ongoing	O
acute	O
respiratory	O
distress	O
syndrome	O
late	O
in	O
infection	O
suggests	O
that	O
pyrimidine	O
synthesis	B-PROC
inhibitors	O
are	O
promising	O
therapeutic	O
candidates	O
for	O
the	O
management	O
of	O
severe	O
influenza	O
.	O

IBV	O
nsp2	O
is	O
one	O
of	O
the	O
first	O
replicase	O
proteins	O
to	O
be	O
translated	O
and	O
processed	O
in	O
the	O
viral	B-PROC
life	I-PROC
cycle	I-PROC
;	O
however	O
,	O
it	O
has	O
an	O
entirely	O
unknown	O
function	O
.	O

Four	O
patients	O
died	B-PROC
from	O
earthquake	O
-	O
related	O
injuries	O
and	O
three	O
from	O
other	O
illnesses	O
.	O

The	O
theoretical	O
benefits	O
of	O
administering	O
heparin	O
to	O
prevent	O
the	O
thrombosis	O
and	O
epsilon	O
-	O
aminocaproic	O
acid	O
to	O
enhance	O
lysis	B-PROC
have	O
not	O
proven	O
beneficial	O
.	O

TITLE	O
:	O
Antagonism	O
of	O
the	O
interferon	O
-	O
induced	O
OAS	O
-	O
RNase	O
L	O
pathway	B-PROC
by	O
murine	O
coronavirus	O
ns2	O
protein	O
is	O
required	O
for	O
virus	B-PROC
replication	I-PROC
and	O
liver	O
pathology	O
.	O

Ns2	O
cleaves	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
,	O
the	O
product	O
of	O
OAS	O
,	O
to	O
prevent	O
activation	O
of	O
the	O
cellular	O
endoribonuclease	O
RNase	O
L	O
and	O
consequently	O
block	O
viral	O
RNA	B-PROC
degradation	I-PROC
.	O

TITLE	O
:	O
Feline	O
infectious	O
peritonitis	O
virus	O
with	O
a	O
large	O
deletion	O
in	O
the	O
5	O
'-	O
terminal	O
region	O
of	O
the	O
spike	O
gene	O
retains	O
its	O
virulence	B-PROC
for	O
cats	O
.	O

Block	O
copolymers	O
facilitated	O
the	O
development	B-PROC
of	O
innovative	O
concepts	O
in	O
the	O
fields	O
of	O
drug	O
delivery	O
,	O
nanomedicine	O
,	O
organic	O
electronics	O
,	O
and	O
nanoscience	O
.	O

Washes	O
and	O
flocked	O
swabs	O
collected	O
from	O
children	O
<	O
3	O
years	O
old	O
hospitalized	O
with	O
a	O
lower	O
respiratory	O
tract	O
infection	O
were	O
tested	O
for	O
parainfluenza	O
virus	O
1	O
-	O
3	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	O
A	O
and	O
B	O
and	O
metapneumovirus	O
(	O
Group	O
1	O
)	O
and	O
adenovirus	O
,	O
rhinovirus	O
and	O
coronavirus	O
(	O
Group	O
2	O
)	O
using	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
PCR	O
(	O
rRT	O
-	O
PCR	O
).	O

In	O
PTX3	O
WT	O
mice	O
,	O
MHV	O
-	O
1	O
induced	O
PTX3	O
expression	B-PROC
in	O
the	O
lung	O
and	O
serum	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

Enzyme	O
kinetic	O
studies	O
on	O
the	O
mechanism	O
of	O
nsp13	O
inhibition	B-PROC
revealed	O
that	O
SSYA10	O
-	O
001	O
acts	O
as	O
a	O
noncompetitive	O
inhibitor	O
of	O
nsp13	O
with	O
respect	O
to	O
nucleic	O
acid	O
and	O
ATP	O
substrates	O
.	O

Moreover	O
,	O
SSYA10	O
-	O
001	O
does	O
not	O
affect	O
ATP	B-PROC
hydrolysis	I-PROC
or	O
nsp13	O
binding	O
to	O
the	O
nucleic	O
acid	O
substrate	O
.	O

All	O
patients	O
presented	O
with	O
fever	B-PROC
,	O
hemoptysis	O
,	O
bilateral	O
pulmonary	O
infiltrates	O
in	O
chest	O
radiographs	O
,	O
and	O
thrombocytopenia	O
and	O
had	O
compatible	O
epidemiological	O
history	O
with	O
leptospirosis	O
;	O
3	O
patients	O
had	O
anemia	O
,	O
3	O
had	O
renal	O
failure	O
,	O
2	O
had	O
increased	O
creatine	O
kinase	O
,	O
whereas	O
bilirubin	O
was	O
slightly	O
increased	O
in	O
only	O
1	O
patient	O
.	O

These	O
results	O
indicate	O
that	O
liver	O
TCRγδ	O
(+)	O
DN	O
T	O
cells	O
play	O
a	O
critical	O
role	O
in	O
the	O
liver	O
injury	O
in	O
MHV	O
-	O
3	O
-	O
induced	O
hepatitis	O
,	O
via	O
a	O
TNF	O
-	O
α	O
dependent	O
pathway	B-PROC
.	O

TITLE	O
:	O
Post	B-PROC
-	I-PROC
transcriptional	B-PROC
control	I-PROC
of	O
type	O
I	O
interferon	O
induction	O
by	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
in	O
its	O
natural	O
host	O
cells	O
.	O

The	O
purposes	O
of	O
this	O
review	O
are	O
to	O
summarize	O
the	O
key	O
findings	O
in	O
supporting	O
the	O
post	B-PROC
-	I-PROC
transcriptional	B-PROC
control	I-PROC
of	O
type	O
I	O
interferon	O
in	O
its	O
natural	O
host	O
cells	O
and	O
to	O
propose	O
the	O
possible	O
role	O
of	O
translational	B-PROC
control	O
in	O
the	O
regulation	B-PROC
of	O
type	O
I	O
interferon	O
induction	O
by	O
PRRSV	O
.	O

Atypical	O
T	O
(	O
regs	O
)	O
express	O
FoxP3	O
and	O
CD4	O
but	O
have	O
no	O
surface	O
expression	B-PROC
of	O
CD25	O
.	O

Twenty	O
were	O
unable	O
to	O
maintain	O
pulse	B-PROC
oxymetry	O
more	O
than	O
92	O
%	O
with	O
conventional	O
oxygen	O
administration	O
and	O
required	O
HFNC	O
O	O
(	O
2	O
)	O
therapy	O
,	O
which	O
was	O
successful	O
in	O
9	O
(	O
45	O
%).	O

Nine	O
(	O
11	O
.	O
1	O
%)	O
showed	O
development	B-PROC
of	O
severe	O
illnesses	O
such	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
2	O
patients	O
),	O
aseptic	O
meningitis	O
(	O
3	O
),	O
and	O
acute	O
renal	O
failure	O
(	O
4	O
).	O

By	O
modification	O
of	O
the	O
infectious	O
cDNA	O
of	O
the	O
genome	O
of	O
coronaviruse	O
,	O
it	O
has	O
led	O
to	O
an	O
efficient	O
(>	O
50	O
microg	O
/	O
10	O
(	O
6	O
)	O
cells	O
)	O
and	O
stable	O
(>	O
30	O
passages	O
)	O
expression	B-PROC
of	O
the	O
foreign	O
gene	O
.	O

Seventeen	O
of	O
these	O
19	O
deaths	B-PROC
were	O
fully	O
autopsied	O
.	O

This	O
process	O
is	O
accomplished	O
by	O
the	O
virus	O
-	O
coded	O
reverse	O
transcriptase	B-PROC
(	O
RT	O
)	O
protein	O
,	O
which	O
is	O
a	O
primary	O
target	O
in	O
the	O
current	O
treatments	O
for	O
HIV	O
-	O
1	O
infection	O
.	O

The	O
in	O
vitro	O
RdRp	O
assay	O
system	O
established	O
with	O
a	O
full	O
-	O
length	O
nsp12	O
will	O
be	O
useful	O
for	O
understanding	O
the	O
mechanisms	O
of	O
coronavirus	O
replication	O
and	O
for	O
the	O
development	B-PROC
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
agents	O
.	O

In	O
a	O
fibrotic	O
cell	O
model	O
with	O
transforming	O
growth	B-PROC
factor	O
beta	O
-	O
1	O
induction	O
,	O
the	O
human	O
lung	O
epithelial	O
A549	O
acquired	O
a	O
mesenchymal	O
phenotype	O
and	O
an	O
increase	O
of	O
vimentin	O
expression	B-PROC
with	O
a	O
concomitant	O
decrease	O
of	O
E	O
-	O
cadherin	O
.	O

RESULTS	O
:	O
Reduction	O
of	O
infiltration	O
of	O
inflammatory	O
cells	O
,	O
deposition	O
of	O
fibroblastic	O
loci	O
and	O
collagen	O
,	O
formation	B-PROC
of	O
reactive	O
oxygen	O
species	O
,	O
and	O
production	O
of	O
cytokines	O
,	O
as	O
well	O
as	O
recovery	O
from	O
imbalance	O
of	O
MMP	O
-	O
9	O
/	O
TIMP	O
-	O
1	O
,	O
were	O
observed	O
in	O
fibrotic	O
rats	O
after	O
treatment	O
with	O
Cordyceps	O
in	O
preventive	O
(	O
from	O
the	O
day	O
of	O
BLM	O
administration	O
)	O
and	O
therapeutic	O
(	O
from	O
14	O
days	O
after	O
BLM	O
)	O
regimens	O
.	O

TITLE	O
:	O
The	O
long	O
duration	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
a	O
child	O
with	O
acute	O
severe	O
hypoxic	O
respiratory	O
failure	O
treated	O
in	O
a	O
resource	O
-	O
limited	O
center	O
.	O

ABSTRACT	O
:	O
Animal	O
coronaviruses	O
,	O
such	O
as	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
and	O
arteriviruses	O
,	O
such	O
as	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
are	O
able	O
to	O
manifest	O
highly	O
contagious	O
infections	O
in	O
their	O
specific	O
native	O
hosts	O
,	O
thereby	O
arising	O
in	O
critical	O
economic	O
damage	O
to	O
animal	O
industries	O
.	O

This	O
review	O
discusses	O
recent	O
progress	O
in	O
studies	O
of	O
virus	O
-	O
host	O
interactions	O
during	O
animal	O
and	O
human	O
coronavirus	O
and	O
arterivirus	O
infections	O
,	O
with	O
emphasis	O
on	O
IBV	O
-	O
host	O
cell	B-PROC
interactions	I-PROC
.	O

We	O
describe	O
the	O
clinical	O
and	O
epidemiologic	O
features	O
of	O
hospitalized	O
patients	O
who	O
survived	O
and	O
patients	O
who	O
died	B-PROC
because	O
of	O
pandemic	O
2009	O
influenza	O
A	O
(	O
H1N1	O
)	O
infection	O
reported	O
in	O
Santa	O
Fe	O
,	O
Argentina	O
,	O
from	O
May	O
to	O
July	O
2009	O
.	O

Of	O
the	O
242	O
,	O
46	O
%	O
were	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
and	O
33	O
·	O
5	O
%	O
died	B-PROC
.	O

This	O
interaction	O
has	O
been	O
reinforced	O
by	O
co	O
-	O
localization	B-PROC
of	O
both	O
proteins	O
in	O
the	O
cytoplasm	O
of	O
SARS	O
-	O
CoV	O
infected	O
cells	O
.	O

Two	O
of	O
the	O
3	O
patients	O
who	O
died	B-PROC
had	O
very	O
long	O
run	O
lengths	O
(	O
28	O
.	O
8	O
and	O
24	O
.	O
7	O
days	O
,	O
respectively	O
),	O
whereas	O
1	O
patient	O
had	O
a	O
short	O
run	O
(	O
2	O
.	O
4	O
days	O
).	O

The	O
incidence	O
of	O
respiratory	O
viruses	O
was	O
compared	O
in	O
tracheal	O
secretion	B-PROC
(	O
TS	O
)	O
samples	O
(	O
n	O
=	O
100	O
)	O
of	O
mechanically	O
ventilated	O
patients	O
in	O
winter	O
(	O
n	O
=	O
50	O
)	O
and	O
summer	O
(	O
n	O
=	O
50	O
).	O

APRV	O
may	O
safely	O
be	O
applied	O
to	O
neurocritically	O
ill	O
patients	O
,	O
and	O
that	O
this	O
mode	O
of	O
ventilation	O
may	O
increase	O
cerebral	B-PROC
blood	I-PROC
flow	I-PROC
without	O
increasing	O
intracranial	B-PROC
pressure	I-PROC
.	O

To	O
understand	O
the	O
kinetics	O
and	O
relationships	O
between	O
the	O
humoral	O
(	O
Ab	O
)	O
and	O
antigen	O
specific	O
T	O
cell	O
immunity	B-PROC
as	O
well	O
as	O
pathological	O
changes	O
during	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
infection	O
and	O
immunization	O
,	O
one	O
-	O
week	O
-	O
old	O
SPF	O
chickens	O
were	O
vaccinated	O
with	O
live	O
IBV	O
H52	O
strain	O
and	O
challenged	O
with	O
IBV	O
M41	O
15	O
days	O
post	O
primary	O
infection	O
.	O

Chickens	O
were	O
sacrificed	O
every	O
3	O
days	O
to	O
monitor	O
antigen	O
specific	O
serum	O
IgG	O
and	O
IBV	O
nucleoprotein	O
-	O
specific	O
immune	B-PROC
responses	I-PROC
using	O
a	O
chicken	O
MHC	B-PROC
I	O
tetramer	O
developed	O
in	O
our	O
laboratory	O
.	O

Sequence	O
analysis	O
of	O
the	O
S1	O
and	O
sM	O
genes	O
showed	O
that	O
each	O
sample	O
had	O
unique	O
characteristics	O
,	O
and	O
the	O
sample	O
P55	O
may	O
be	O
differentiated	B-PROC
from	O
the	O
others	O
by	O
the	O
unique	O
deletions	O
and	O
insertions	O
of	O
sM	O
gene	O
.	O

Computer	O
simulation	O
optimizes	O
ventilation	O
and	O
limiting	O
of	O
dead	B-PROC
space	O
using	O
ASPIDS	O
.	O

Influenza	O
infection	O
of	O
mice	O
results	O
in	O
impairment	O
of	O
alveolar	O
gas	O
exchange	O
consistent	O
with	O
rapid	O
development	B-PROC
of	O
acute	O
lung	O
injury	O
and	O
progression	O
to	O
ARDS	O
.	O

Breast	O
-	O
feeding	O
is	O
clearly	O
associated	O
with	O
benefits	O
to	O
the	O
infant	O
,	O
including	O
significant	O
protective	O
effects	O
for	O
gastrointestinal	O
infections	O
(	O
64	O
%),	O
middle	O
ear	O
(	O
23	O
-	O
50	O
%),	O
severe	O
respiratory	O
infections	O
(	O
73	O
%)	O
and	O
for	O
acute	O
lymphocytic	O
leukemia	O
(	O
19	O
%)	O
and	O
sudden	O
death	B-PROC
syndrome	O
in	O
infants	O
(	O
36	O
%).	O

We	O
obtained	O
four	O
hybridoma	O
cell	O
lines	O
secreting	B-PROC
mAbs	O
against	O
recombinant	O
N	O
protein	O
.	O

High	O
plasma	O
IL	O
-	O
6	O
,	O
thrombomodulin	O
,	O
and	O
mini	O
-	O
BAL	O
protein	O
were	O
all	O
significantly	O
associated	O
with	O
fewer	O
ventilator	O
-	O
free	O
days	O
(	O
VFDs	O
)	O
(	O
P	O
=	O
0	O
.	O
01	O
,	O
0	O
.	O
01	O
,	O
and	O
0	O
.	O
05	O
,	O
respectively	O
);	O
no	O
markers	O
were	O
associated	O
with	O
mortality	O
,	O
but	O
we	O
hypothesized	O
that	O
this	O
was	O
due	O
to	O
the	O
small	O
size	O
of	O
our	O
cohort	O
and	O
the	O
low	O
death	B-PROC
rate	O
.	O

The	O
use	O
of	O
lung	O
-	O
protective	O
ventilation	O
has	O
helped	O
to	O
reduce	O
mortality	O
from	O
malaria	O
-	O
induced	O
ALI	O
/	O
ARDS	O
,	O
but	O
permissive	O
hypercapnia	O
in	O
unconscious	O
patients	O
is	O
not	O
recommended	O
because	O
increased	O
intracranial	B-PROC
pressure	I-PROC
and	O
cerebral	O
swelling	O
may	O
occur	O
in	O
cerebral	O
malaria	O
.	O

Two	O
British	O
siblings	O
in	O
the	O
mid	O
-	O
1980s	O
showed	O
nearly	O
constant	O
fecal	O
viral	B-PROC
shedding	I-PROC
.	O

TITLE	O
:	O
Origin	O
,	O
diversity	O
,	O
and	O
maturation	B-PROC
of	O
human	O
antiviral	O
antibodies	O
analyzed	O
by	O
high	O
-	O
throughput	O
sequencing	O
.	O

Analysis	O
of	O
immune	O
-	O
related	O
gene	B-PROC
expression	I-PROC
profiles	O
showed	O
that	O
at	O
24	O
h	O
after	O
SARS	O
-	O
CoV	O
infection	O
:	O
(	O
1	O
)	O
IFN	O
-	O
α	O
/	O
β	O
-	O
inducible	O
and	O
cathepsin	O
/	O
proteasome	B-PROC
genes	O
were	O
downregulated	O
;	O
(	O
2	O
)	O
hypoxia	O
/	O
hyperoxia	O
-	O
related	O
genes	O
were	O
upregulated	O
;	O
and	O
(	O
3	O
)	O
TLR	O
/	O
TLR	O
-	O
signaling	B-PROC
,	O
cytokine	O
/	O
cytokine	O
receptor	O
-	O
related	O
,	O
chemokine	O
/	O
chemokine	O
receptor	O
-	O
related	O
,	O
lysosome	O
-	O
related	O
,	O
MHC	B-PROC
/	O
chaperon	O
-	O
related	O
,	O
and	O
fibrosis	O
-	O
related	O
genes	O
were	O
differentially	O
regulated	O
.	O

These	O
results	O
elucidate	O
that	O
SARS	O
-	O
CoV	O
infection	O
regulates	O
immune	O
-	O
related	O
genes	O
in	O
monocytes	O
/	O
macrophages	O
,	O
which	O
may	O
be	O
important	O
to	O
the	O
pathogenesis	B-PROC
of	O
SARS	O
.	O

However	O
,	O
rosmariquinone	O
(	O
7	O
)	O
showed	O
a	O
different	O
kinetic	O
mechanism	O
through	O
mixed	O
-	O
type	O
simple	O
reversible	O
slow	O
-	O
binding	O
inhibition	B-PROC
.	O

The	O
analysis	O
reveals	O
that	O
p7	O
and	O
2B	O
TMDs	O
align	O
with	O
the	O
pore	O
-	O
facing	O
TMD	O
of	O
MscL	O
,	O
and	O
3a	O
-	O
TMDs	O
align	O
with	O
those	O
of	O
ligand	B-PROC
-	O
gated	O
ion	O
channels	O
.	O

ABSTRACT	O
:	O
Secretory	B-PROC
and	O
membrane	O
proteins	O
attain	O
their	O
native	O
structure	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
).	O

Enhanced	O
ERAD	B-PROC
activity	O
may	O
interfere	O
with	O
protein	O
biogenesis	B-PROC
by	O
inappropriately	O
targeting	B-PROC
not	O
-	O
yet	O
-	O
native	O
protein	B-PROC
folding	I-PROC
intermediates	O
for	O
disposal	O
.	O

This	O
sets	O
the	O
ERAD	B-PROC
activity	O
at	O
levels	O
that	O
do	O
not	O
interfere	O
with	O
completion	O
of	O
ongoing	O
folding	O
programs	O
.	O

These	O
results	O
indicate	O
that	O
selection	O
does	O
not	O
cease	O
in	O
immunodeficient	O
chickens	O
and	O
that	O
phenotype	O
C2	O
may	O
show	O
a	O
distinct	O
adaptation	B-PROC
to	O
this	O
environment	O
.	O

To	O
clarify	O
this	O
question	O
,	O
four	O
intragastric	O
infection	O
experiments	O
were	O
performed	O
on	O
a	O
total	O
of	O
95	O
conventional	O
weaned	B-PROC
pigs	O
.	O

The	O
isolated	O
strains	O
were	O
characterized	O
by	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
and	O
sequence	O
analysis	O
of	O
the	O
hypervariable	O
region	O
3	O
of	O
the	O
S1	O
spike	O
glycoprotein	O
gene	O
.	O

ABSTRACT	O
:	O
The	O
occurrence	O
of	O
avian	O
influenza	O
A	O
(	O
H5N1	O
)	O
in	O
Hong	O
Kong	O
in	O
1997	O
led	O
to	O
the	O
development	B-PROC
of	O
a	O
""""	O
One	O
-	O
Health	O
""""	O
approach	O
to	O
deal	O
with	O
emerging	O
infectious	O
diseases	O
that	O
has	O
been	O
applied	O
to	O
other	O
emergent	O
diseases	O
such	O
as	O
SARS	O
and	O
the	O
pandemic	O
H1N1	O
2009	O
.	O

Although	O
of	O
pivotal	O
importance	O
for	O
many	O
patients	O
suffering	O
from	O
respiratory	O
insufficiency	O
MV	O
itself	O
may	O
further	O
induce	O
pathophysiological	O
processes	O
due	O
to	O
the	O
mechanical	O
stress	O
exerted	B-PROC
on	O
the	O
lungs	O
.	O

ABSTRACT	O
:	O
After	O
repetitive	O
deep	O
dives	O
,	O
breath	O
-	O
hold	O
divers	O
are	O
often	O
affected	O
by	O
a	O
syndrome	O
characterized	O
by	O
typical	O
symptoms	O
such	O
as	O
cough	O
,	O
sensation	B-PROC
of	O
chest	O
constriction	O
,	O
blood	O
-	O
striated	O
expectorate	B-PROC
(	O
hemoptysis	O
)	O
and	O
,	O
rarely	O
,	O
an	O
overt	O
acute	O
pulmonary	O
edema	O
syndrome	O
,	O
often	O
together	O
with	O
various	O
degrees	O
of	O
dyspnea	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
performance	O
evaluation	O
of	O
calf	O
diarrhea	O
pathogen	O
nucleic	O
acid	O
purification	O
and	O
detection	O
workflow	O
.	O

ABSTRACT	O
:	O
Calf	O
diarrhea	O
(	O
scours	O
)	O
is	O
a	O
primary	O
cause	O
of	O
illness	O
and	O
death	B-PROC
in	O
young	O
calves	O
.	O

A	O
workflow	O
was	O
developed	O
consisting	O
of	O
an	O
optimized	O
fecal	O
nucleic	O
acid	O
purification	O
and	O
multiplex	O
reverse	B-PROC
transcription	B-PROC
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
for	O
single	O
tube	O
concurrent	O
detection	O
of	O
BCV	O
,	O
BRV	O
,	O
and	O
Cryptosporidium	O
spp	O
.,	O
and	O
an	O
internal	O
control	O
to	O
monitor	O
nucleic	O
acid	O
purification	O
efficacy	O
and	O
PCR	O
reagent	O
functionality	O
.	O

TITLE	O
:	O
Monitoring	O
of	O
S	O
protein	B-PROC
maturation	B-PROC
in	O
the	O
endoplasmic	O
reticulum	O
by	O
calnexin	O
is	O
important	O
for	O
the	O
infectivity	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

These	O
findings	O
demonstrated	O
that	O
calnexin	O
strictly	O
monitors	O
the	O
maturation	B-PROC
of	O
S	O
protein	O
by	O
its	O
direct	O
binding	O
,	O
resulting	O
in	O
conferring	O
infectivity	O
on	O
SARS	O
-	O
CoV	O
.	O

TITLE	O
:	O
One	O
hundred	O
ten	O
days	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
a	O
young	O
woman	O
with	O
postpartum	O
cerebral	O
venous	O
thrombosis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Western	O
-	O
Bolt	O
results	O
show	O
that	O
all	O
the	O
six	O
fragments	O
have	O
reacted	O
with	O
the	O
SARS	O
patient	O
convalescent	O
sera	O
,	O
but	O
the	O
PN360	O
and	O
PN301	O
showed	O
obvious	O
cross	B-PROC
-	I-PROC
reaction	I-PROC
with	O
sera	O
from	O
SARS	O
-	O
CoV	O
-	O
negative	O
normal	O
adults	O
;	O
sensitivity	O
analysis	O
using	O
an	O
ELISA	O
coating	O
with	O
PN199	O
,	O
PN185	O
,	O
PN155b	O
,	O
PN125	O
as	O
antigen	O
showed	O
that	O
the	O
PN185	O
and	O
PN155b	O
are	O
better	O
than	O
PN125	O
.	O

RESULTS	O
:	O
Western	O
-	O
Bolt	O
results	O
show	O
that	O
all	O
the	O
six	O
fragments	O
have	O
reacted	O
with	O
the	O
SARS	O
patient	O
convalescent	O
sera	O
,	O
but	O
the	O
PN360	O
and	O
PN301	O
showed	O
obvious	O
cross	B-PROC
-	I-PROC
reaction	I-PROC
with	O
sera	O
from	O
SARS	O
-	O
CoV	O
-	O
negative	O
normal	O
adults	O
;	O
sensitivity	O
analysis	O
using	O
an	O
ELISA	O
coating	O
with	O
PN199	O
,	O
PN185	O
,	O
PN155b	O
,	O
PN125	O
as	O
antigen	O
showed	O
that	O
the	O
PN185	O
and	O
PN155b	O
are	O
better	O
than	O
PN125	O
.	O

Storage	B-PROC
of	O
the	O
strips	O
at	O
room	O
temperature	O
for	O
6	O
months	O
or	O
at	O
4	O
°	O
C	O
for	O
12	O
months	O
did	O
not	O
change	O
their	O
sensitivity	O
or	O
specificity	O
.	O

The	O
results	O
of	O
this	O
experiment	O
indicate	O
that	O
the	O
number	O
of	O
total	O
cells	O
and	O
neutrophils	O
and	O
the	O
concentration	O
of	O
protein	O
exudation	B-PROC
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
significantly	O
decreased	O
in	O
the	O
MCR	O
-	O
LPS	O
group	O
.	O

Furthermore	O
,	O
leukocyte	O
infiltration	O
and	O
protein	O
exudation	B-PROC
in	O
the	O
alveolar	O
space	O
were	O
less	O
severe	O
in	O
the	O
MCR	O
-	O
LPS	O
group	O
than	O
in	O
the	O
LPS	O
group	O
.	O

In	O
the	O
reporter	O
assays	O
,	O
three	O
of	O
four	O
shRNA	O
expression	B-PROC
plasmids	O
were	O
able	O
to	O
inhibit	O
significantly	O
the	O
expression	B-PROC
of	O
ORF	O
7	O
gene	O
and	O
replication	O
of	O
TGEV	O
,	O
as	O
shown	O
by	O
real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
analysis	O
of	O
viral	O
ORF	O
7	O
and	O
N	O
genes	O
and	O
detection	B-PROC
of	I-PROC
virus	I-PROC
titers	O
(	O
TCID50	O
/	O
ml	O
).	O

Evolution	B-PROC
of	O
the	O
spike	O
protein	O
was	O
also	O
rapid	O
in	O
Hi	O
-	O
BatCoV	O
HKU10	O
strains	O
from	O
2005	O
to	O
2006	O
but	O
stabilized	O
thereafter	O
.	O

Proteasome	B-PROC
inhibitor	O
MG	O
-	O
132	O
significantly	O
reduced	O
expression	B-PROC
of	O
TGF	O
-	O
β1	O
and	O
vimentin	O
.	O

These	O
outbreaks	O
have	O
shown	O
that	O
animal	O
breeding	B-PROC
activities	O
can	O
pose	O
a	O
significant	O
public	O
health	O
risk	O
.	O

Rapid	O
administration	O
of	O
antibiotics	O
and	O
resuscitative	O
measures	O
in	O
case	O
of	O
sepsis	O
and	O
septic	O
shock	O
associated	O
with	O
protective	O
ventilatory	O
strategies	O
and	O
early	O
short	O
-	O
term	O
paralysis	O
associated	O
with	O
differential	O
ventilatory	O
techniques	O
(	O
recruitment	O
maneuvers	O
with	O
adequate	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
titration	O
,	O
prone	O
position	O
,	O
and	O
new	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
techniques	O
)	O
in	O
severe	O
ARDS	O
can	O
help	O
improve	O
its	O
prognosis	O
.	O

These	O
data	O
suggest	O
roles	O
for	O
ps20	O
in	O
regulating	O
expression	B-PROC
of	O
neutrophil	O
-	O
specific	O
chemotactic	O
factors	O
,	O
thereby	O
potentially	O
modulating	O
neutrophil	B-PROC
migration	I-PROC
,	O
and	O
in	O
modulating	O
neutrophil	O
susceptibility	O
to	O
MHV	O
-	O
1	O
infection	O
.	O

The	O
Respironics	O
V60	O
Ventilator	O
,	O
in	O
the	O
average	O
volume	O
-	O
assured	O
pressure	O
support	O
mode	O
,	O
was	O
attached	O
to	O
our	O
patient	O
and	O
improved	O
and	O
stabilized	O
his	O
sleep	B-PROC
-	O
related	O
hypoventilation	O
by	O
automatically	O
adjusting	O
force	O
to	O
within	O
an	O
acceptable	O
range	O
.	O

Polysomnography	O
performed	O
while	O
our	O
patient	O
was	O
on	O
noninvasive	O
positive	O
pressure	O
ventilation	O
revealed	O
obstructive	O
sleep	B-PROC
apnea	O
syndrome	O
(	O
apnea	O
-	O
hypopnea	O
index	O
=	O
14	O
),	O
suggesting	O
that	O
his	O
chronic	O
obstructive	O
pulmonary	O
disease	O
was	O
complicated	O
by	O
obstructive	O
sleep	B-PROC
apnea	O
syndrome	O
.	O

On	O
such	O
occasions	O
,	O
the	O
Respironics	O
V60	O
Ventilator	O
,	O
which	O
is	O
equipped	O
with	O
an	O
average	O
volume	O
-	O
assured	O
pressure	O
support	O
mode	O
,	O
may	O
be	O
useful	O
in	O
improving	O
gas	O
exchange	O
and	O
may	O
achieve	O
good	O
patient	O
compliance	O
,	O
because	O
that	O
mode	O
allows	O
ventilation	O
to	O
be	O
maintained	O
by	O
automatically	O
adjusting	O
the	O
inspiratory	B-PROC
force	I-PROC
to	O
within	O
an	O
acceptable	O
range	O
whenever	O
ventilation	O
falls	O
below	O
target	O
levels	O
.	O

Fluid	O
intake	O
,	O
fluid	O
output	O
,	O
fluid	B-PROC
balance	I-PROC
(	O
the	O
difference	O
between	O
fluid	O
intake	O
and	O
output	O
),	O
and	O
plasma	O
albumin	O
level	O
from	O
post	O
burn	O
day	O
(	O
PBD	O
)	O
3	O
to	O
10	O
,	O
pulmonary	O
oxygenation	B-PROC
index	O
on	O
PBD	O
3	O
,	O
5	O
,	O
7	O
,	O
10	O
,	O
and	O
14	O
,	O
occurrence	O
of	O
lung	O
and	O
blood	O
stream	O
infections	O
from	O
PBD	O
7	O
to	O
14	O
,	O
and	O
occurrence	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
occurrence	O
of	O
other	O
organ	O
complications	O
,	O
and	O
mortality	O
within	O
2	O
weeks	O
post	O
burn	O
(	O
PBW	O
)	O
were	O
recorded	O
and	O
compared	O
.	O

Fluid	B-PROC
balance	I-PROC
lowered	O
in	O
both	O
groups	O
,	O
and	O
it	O
was	O
the	O
lowest	O
on	O
PBD	O
10	O
in	O
control	O
group	O
and	O
PBD	O
6	O
in	O
treatment	O
group	O
.	O

Treatment	O
of	O
MHC	B-PROC
-	O
mismatched	O
mice	O
with	O
T	O
-	O
cell	O
subset	O
-	O
specific	O
depleting	O
antibodies	O
increased	O
survival	O
of	O
allogeneic	O
NPCs	O
without	O
affecting	O
commitment	O
to	O
an	O
oligodendrocyte	O
lineage	O
.	O

TITLE	O
:	O
High	O
incidence	O
of	O
multiple	O
viral	B-PROC
infections	I-PROC
identified	O
in	O
upper	O
respiratory	O
tract	O
infected	O
children	O
under	O
three	O
years	O
of	O
age	O
in	O
Shanghai	O
,	O
China	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
mRT	O
-	O
PCR	O
were	O
determined	O
by	O
comparing	O
it	O
to	O
a	O
rapid	O
antigen	O
test	O
(	O
RAT	O
)	O
or	O
immuno	O
-	O
chromatography	O
test	O
kit	O
and	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
in	O
the	O
detection	O
of	O
CDV	O
,	O
CRCoV	O
and	O
CIV	O
antigens	O
present	O
in	O
100	O
clinical	O
samples	O
(	O
nasal	O
swabs	O
and	O
whole	O
blood	O
samples	O
)	O
from	O
50	O
dogs	O
with	O
respiratory	O
disease	O
symptoms	O
.	O

Animals	O
treated	O
with	O
air	O
-	O
PS	O
for	O
20	O
minutes	O
had	O
significantly	O
improved	O
lung	B-PROC
function	I-PROC
,	O
reduced	O
pulmonary	O
edema	O
,	O
decreased	O
concentration	O
of	O
total	O
protein	O
and	O
proinflammatory	O
cytokines	O
in	O
BALF	O
,	O
ameliorated	O
lung	O
injury	O
,	O
and	O
improved	O
animal	O
survival	O
.	O

Inhalation	B-PROC
of	O
aerosolized	O
PS	O
generated	O
by	O
the	O
noninvasive	O
apparatus	O
could	O
significantly	O
reduce	O
lung	O
injury	O
,	O
while	O
using	O
oxygen	O
line	O
available	O
in	O
the	O
clinical	O
wards	O
to	O
generate	O
PS	O
aerosol	O
is	O
more	O
convenient	O
and	O
adds	O
further	O
benefits	O
.	O

CONCLUSIONS	O
:	O
Inhalation	B-PROC
of	O
aerosolized	O
PS	O
generated	O
by	O
the	O
noninvasive	O
apparatus	O
could	O
significantly	O
reduce	O
lung	O
injury	O
,	O
while	O
using	O
oxygen	O
line	O
available	O
in	O
the	O
clinical	O
wards	O
to	O
generate	O
PS	O
aerosol	O
is	O
more	O
convenient	O
and	O
adds	O
further	O
benefits	O
.	O

TITLE	O
:	O
Prolonged	O
period	O
of	O
acute	O
bronchitis	O
with	O
late	O
progression	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
as	O
possible	O
result	O
of	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	B-PROC
infection	I-PROC
.	O

The	O
susceptibility	O
,	O
immune	B-PROC
responses	I-PROC
,	O
pathogenesis	B-PROC
,	O
and	O
pharmacokinetics	B-PROC
may	O
differ	O
between	O
the	O
various	O
animal	O
models	O
.	O

As	O
a	O
consequence	O
,	O
the	O
thymus	O
begins	O
an	O
involution	B-PROC
process	O
,	O
producing	O
a	O
severe	O
impairment	O
in	O
cellular	O
and	O
humoral	B-PROC
immunity	I-PROC
.	O

TITLE	O
:	O
Prevalence	O
of	O
viral	B-PROC
infections	I-PROC
in	O
Norwegian	O
cats	O
with	O
and	O
without	O
feline	O
lower	O
urinary	O
tract	O
disease	O
.	O

The	O
spike	O
protein	O
plays	O
an	O
important	O
role	O
in	O
virus	O
entry	O
,	O
virus	O
receptor	B-PROC
interactions	I-PROC
,	O
and	O
virus	O
tropism	B-PROC
.	O

The	O
hybridomas	O
secreting	B-PROC
anti	O
-	O
S1	O
antibodies	O
,	O
F26G18	O
and	O
P136	O
.	O
8D12	O
,	O
were	O
fused	O
respectively	O
with	O
the	O
YP4	O
hybridoma	O
to	O
generate	O
quadromas	O
.	O

At	O
48	O
h	O
post	O
transfection	B-PROC
,	O
the	O
medium	O
to	O
culture	O
the	O
transfected	O
BHK	O
-	O
21	O
cells	O
was	O
harvested	O
and	O
inoculated	O
into	O
10	O
-	O
days	O
old	O
SPF	O
embryonated	O
chicken	O
eggs	O
(	O
ECE	O
)	O
to	O
replicate	O
the	O
rescued	O
virus	O
.	O

In	O
penehyclidine	O
hydrochloride	O
sequential	O
to	O
atropine	O
group	O
,	O
except	O
for	O
1	O
case	O
of	O
cancer	O
of	O
gastric	O
cardia	O
with	O
poisoning	O
after	O
operation	O
showing	O
intermediate	O
syndrome	O
of	O
poisoning	O
,	O
the	O
remaining	O
patients	O
did	O
not	O
have	O
any	O
complication	O
,	O
and	O
the	O
incidence	O
of	O
complications	O
was	O
1	O
.	O
67	O
％.	O
No	O
death	B-PROC
occurred	O
in	O
all	O
the	O
patients	O
,	O
and	O
the	O
cure	O
rate	O
was	O
100	O
.	O
00	O
％.	O
Time	O
of	O
recovery	O
from	O
ChE	O
activity	O
to	O
70	O
％	O
was	O

In	O
penehyclidine	O
hydrochloride	O
group	O
,	O
1	O
patient	O
was	O
found	O
to	O
have	O
respiratory	O
failure	O
,	O
1	O
case	O
suffered	O
from	O
pulmonary	O
edema	O
,	O
and	O
the	O
complication	O
rate	O
was	O
3	O
.	O
33	O
％.	O
Two	O
patients	O
died	B-PROC
,	O
the	O
mortality	O
rate	O
wan	O
3	O
.	O
33	O
％.	O
Fifty	O
-	O
eight	O
patients	O
were	O
cured	O
,	O
the	O
cure	O
rate	O
was	O
96	O
.	O
67	O
％.	O
The	O
time	O
of	O
ChE	O
activity	O
recovery	O
to	O
70	O
％	O
was	O
(	O
6	O
.	O
0	O
±	O
0	O
.	O
7	O
)	O
days	O
,	O
hospital	O
stay	O
was	O
(	O
9	O
.	O
0	O
±	O
1	O
.	O
5	O
)	O
days	O
,	O
and	O
hospital	O
expenses	O
were	O
(	O
7921	O
±	O
230	O
)	O
yuan	O
.	O

Progression	O
to	O
lower	O
respiratory	O
tract	O
infection	O
with	O
clinical	O
and	O
radiological	O
signs	O
of	O
pneumonia	O
and	O
respiratory	O
failure	O
appears	O
to	O
depend	O
on	O
the	O
intrinsic	O
virulence	B-PROC
of	O
the	O
specific	O
CARV	O
as	O
well	O
as	O
factors	O
specific	O
to	O
the	O
patient	O
,	O
the	O
underlying	O
disease	O
,	O
and	O
its	O
treatment	O
.	O

ABSTRACT	O
:	O
The	O
major	O
structural	O
protein	O
of	O
coronaviruses	O
,	O
the	O
membrane	O
(	O
M	O
)	O
protein	O
,	O
can	O
elicit	O
the	O
formation	B-PROC
of	O
protective	O
antibodies	O
,	O
but	O
little	O
information	O
is	O
available	O
about	O
the	O
M	O
protein	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
).	O

One	O
hybridoma	O
cell	O
line	O
secreting	B-PROC
anti	O
-	O
M	O
protein	O
monoclonal	O
antibody	B-PROC
(	O
McAb	O
)	O
was	O
generated	O
and	O
designated	O
4D4	O
.	O

SDS	O
-	O
PAGE	O
and	O
Western	O
blot	O
results	O
indicated	O
that	O
EpiC	O
was	O
successfully	O
expressed	B-PROC
and	O
had	O
good	O
immunoreactivity	B-PROC
with	O
chicken	O
anti	O
-	O
IBV	O
serum	O
.	O

We	O
employed	O
a	O
reverse	B-PROC
transcription	B-PROC
(	O
RT	O
)-	O
PCR	O
assay	O
and	O
CODEHOP	O
-	O
based	O
primers	O
(	O
CT12	O
-	O
mCODEHOP	O
)	O
previously	O
developed	O
to	O
recognize	O
known	O
and	O
unknown	O
corona	O
-	O
and	O
toroviruses	O
.	O

The	O
relevance	O
of	O
these	O
high	O
-	O
order	O
structures	O
for	O
virus	O
transcription	B-PROC
is	O
reinforced	O
by	O
the	O
phylogenetic	O
conservation	O
of	O
the	O
involved	O
RNA	O
motifs	O
in	O
CoVs	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
role	O
of	O
αB	O
-	O
crystallin	O
in	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
pathogenesis	B-PROC
and	O
inflammation	O
.	O

Tissue	O
detection	O
of	O
the	O
protein	O
showed	O
that	O
it	O
was	O
significantly	O
overexpressed	O
in	O
COPD	O
smokers	O
in	O
comparison	O
to	O
COPD	O
nonsmokers	O
and	O
was	O
only	O
slightly	O
expressed	B-PROC
in	O
patients	O
with	O
age	O
-	O
related	O
emphysema	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
inhaled	B-PROC
nitric	O
oxide	O
and	O
prone	O
position	O
in	O
an	O
ARDS	O
patient	O
with	O
severe	O
traumatic	O
brain	O
injury	O
during	O
spine	O
stabilization	O
.	O

The	O
objective	O
of	O
this	O
analysis	O
was	O
to	O
assess	O
the	O
effectiveness	O
,	O
safety	O
,	O
and	O
cost	O
-	O
effectiveness	O
of	O
extracorporeal	O
lung	O
support	O
technologies	O
in	O
the	O
improvement	O
of	O
pulmonary	B-PROC
gas	I-PROC
exchange	I-PROC
and	O
the	O
survival	O
of	O
adult	O
patients	O
with	O
acute	O
pulmonary	O
failure	O
and	O
those	O
with	O
end	O
-	O
stage	O
chronic	O
progressive	O
lung	O
disease	O
as	O
a	O
bridge	O
to	O
lung	O
transplantation	O
(	O
LTx	O
).	O

Because	O
droplet	O
nuclei	O
remain	O
airborne	O
for	O
longer	O
periods	B-PROC
than	O
do	O
droplets	O
,	O
they	O
are	O
more	O
amenable	O
to	O
engineering	O
infection	O
control	O
methods	O
than	O
are	O
droplets	O
.	O

At	O
least	O
one	O
underlying	O
medical	O
condition	O
was	O
reported	O
in	O
70	O
.	O
7	O
%	O
(	O
for	O
pandemic	O
influenza	O
strain	O
)	O
and	O
96	O
%	O
(	O
for	O
influenza	O
type	O
B	O
)	O
of	O
deaths	B-PROC
.	O

The	O
virus	O
(	O
called	O
HCoV	O
-	O
EMC	O
)	O
replicated	O
readily	O
in	O
cell	O
culture	O
,	O
producing	O
cytopathic	O
effects	O
of	O
rounding	O
,	O
detachment	O
,	O
and	O
syncytium	B-PROC
formation	I-PROC
.	O

Patients	O
with	O
septic	O
shock	O
had	O
significantly	O
higher	O
rates	O
of	O
disseminated	O
intravascular	O
coagulation	B-PROC
(	O
DIC	O
)	O
(	O
p	O
=	O
0	O
.	O
01	O
),	O
altered	O
mental	O
status	O
(	O
p	O
≤	O
0	O
.	O
001	O
),	O
total	O
bilirubin	O
>	O
4	O
mg	O
/	O
dl	O
(	O
p	O
=	O
0	O
.	O
04	O
),	O
failure	O
in	O
≥	O
3	O
organ	O
systems	O
(	O
70	O
%	O
vs	O
.	O
15	O
%,	O
p	O
=	O
0	O
.	O
005	O
),	O
and	O
maternal	B-PROC
death	B-PROC
(	O
30	O
%	O
vs	O
.	O
0	O
%,	O
p	O
=	O
0	O
.	O
03	O
).	O

Here	O
we	O
report	O
the	O
complete	O
genome	O
sequence	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
strain	O
LC	O
,	O
which	O
was	O
recently	O
isolated	O
from	O
sucking	B-PROC
piglets	O
that	O
suffered	O
from	O
severe	O
watery	O
diarrhea	O
in	O
Guangdong	O
.	O

These	O
results	O
suggest	O
a	O
successful	O
viral	O
evolution	B-PROC
strategy	O
in	O
which	O
coronaviruses	O
stole	O
a	O
galectin	O
from	O
hosts	O
,	O
incorporated	O
it	O
into	O
their	O
spike	O
protein	O
,	O
and	O
evolved	O
it	O
into	O
viral	O
receptor	O
-	O
binding	O
domains	O
with	O
altered	O
sugar	O
specificity	O
in	O
contemporary	O
BCoV	O
or	O
novel	O
protein	O
specificity	O
in	O
contemporary	O
MHV	O
.	O

Corticosteroids	O
decreased	O
the	O
prevalence	O
of	O
fever	B-PROC
,	O
lowered	O
visual	O
analog	O
pain	O
scores	O
,	O
and	O
improved	O
knee	O
motion	O
.	O

This	O
categorization	O
enables	O
quick	O
identification	O
of	O
viruses	O
with	O
similar	O
behaviors	B-PROC
in	O
transmission	O
,	O
regardless	O
of	O
genetic	O
proximity	O
.	O

ABSTRACT	O
:	O
Non	O
-	O
specific	O
symptoms	O
of	O
acute	O
respiratory	O
viral	B-PROC
infections	I-PROC
make	O
it	O
difficult	O
for	O
many	O
countries	O
without	O
ongoing	O
transmission	O
of	O
a	O
novel	O
coronavirus	O
to	O
rule	O
out	O
other	O
possibilities	O
including	O
influenza	O
before	O
isolating	O
imported	O
febrile	B-PROC
individuals	O
with	O
a	O
possible	O
exposure	O
history	O
.	O

Since	O
2003	O
the	O
H5N1	O
virus	O
has	O
caused	O
widespread	O
disease	O
and	O
death	B-PROC
in	O
poultry	O
,	O
mainly	O
in	O
south	O
East	O
Asia	O
and	O
Africa	O
.	O

The	O
list	O
of	O
potential	O
maternal	O
risks	O
and	O
complications	O
from	O
severe	O
impaired	O
glucose	B-PROC
tolerance	I-PROC
includes	O
,	O
for	O
example	O
,	O
increased	O
rate	O
of	O
Caesarean	O
sections	O
,	O
pre	O
-	O
eclampsia	O
and	O
injuries	O
during	O
delivery	O
.	O

The	O
list	O
of	O
risks	O
to	O
the	O
baby	O
includes	O
,	O
for	O
example	O
,	O
birth	B-PROC
trauma	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
metabolic	B-PROC
disorders	O
that	O
require	O
intervention	O
.	O

TITLE	O
:	O
Workforce	O
integration	B-PROC
of	O
new	O
graduate	O
nurses	O
:	O
evaluation	O
of	O
a	O
health	O
human	O
resources	O
employment	O
policy	O
.	O

The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
outbreak	O
in	O
2003	O
alerted	O
the	O
Ontario	O
government	O
to	O
the	O
issue	O
of	O
part	O
-	O
time	O
and	O
casual	O
nursing	B-PROC
.	O

Results	O
indicated	O
that	O
full	O
-	O
time	O
employment	O
of	O
new	O
graduate	O
nurses	O
increased	O
during	O
the	O
study	O
period	O
and	O
that	O
mentorship	O
facilitated	O
workforce	O
integration	B-PROC
of	O
new	O
graduate	O
nurses	O
.	O

TITLE	O
:	O
Reverse	B-PROC
transcription	B-PROC
-	O
loop	O
-	O
mediated	O
isothermal	O
amplification	O
for	O
the	O
detection	O
of	O
rodent	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
The	O
degradative	O
activity	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
reverse	O
transcriptase	B-PROC
(	O
RT	O
),	O
termed	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
),	O
which	O
hydrolyzes	O
the	O
RNA	O
component	O
of	O
the	O
heteroduplex	O
RNA	O
:	O
DNA	B-PROC
replication	I-PROC
intermediate	O
,	O
is	O
an	O
excellent	O
target	O
for	O
drug	O
discovery	O
.	O

TITLE	O
:	O
Biogenesis	B-PROC
of	O
the	O
vaccinia	O
virus	O
membrane	O
:	O
genetic	O
and	O
ultrastructural	O
analysis	O
of	O
the	O
contributions	O
of	O
the	O
A14	O
and	O
A17	O
proteins	O
.	O

A	O
variety	O
of	O
mutant	O
alleles	O
of	O
A14	O
and	O
A17	O
were	O
tested	O
for	O
their	O
ability	O
to	O
support	O
virion	B-PROC
assembly	I-PROC
.	O

For	O
A14	O
,	O
biologically	O
important	O
motifs	O
within	O
the	O
N	O
-	O
terminal	O
or	O
central	O
loop	O
region	O
affected	O
crescent	O
maturation	B-PROC
and	O
the	O
immature	O
virion	O
(	O
IV	O
)→	O
mature	O
virion	O
(	O
MV	O
)	O
transition	O
.	O

Precleavage	O
of	O
the	O
C	O
terminus	O
or	O
abrogation	O
of	O
its	O
phosphorylation	B-PROC
diminished	O
the	O
IV	O
→	O
MV	O
maturation	B-PROC
;	O
a	O
block	O
to	O
cleavage	B-PROC
spared	O
virion	O
maturation	B-PROC
but	O
compromised	O
the	O
yield	O
of	O
infectious	O
virus	O
.	O

The	O
ExoN	O
inactivation	O
genotype	O
and	O
mutator	O
phenotype	O
are	O
stable	O
and	O
do	O
not	O
revert	O
to	O
virulence	B-PROC
,	O
even	O
after	O
serial	O
passage	O
or	O
long	O
-	O
term	O
persistent	O
infection	O
in	O
vivo	O
.	O

By	O
multivariate	O
analysis	O
,	O
increasing	O
values	O
of	O
age	O
,	O
lactate	O
,	O
and	O
plateau	O
pressure	O
under	O
ECMO	O
were	O
associated	O
with	O
death	B-PROC
.	O

In	O
heroin	O
addicts	O
,	O
rhabdomyolysis	O
is	O
a	O
consequence	O
of	O
the	O
development	B-PROC
of	O
a	O
compartment	O
syndrome	O
due	O
to	O
immobilization	O
of	O
patients	O
in	O
the	O
state	O
of	O
unconsciousness	O
and	O
prolonged	O
compression	O
of	O
extremities	O
,	O
direct	O
heroin	O
toxicity	O
or	O
extremities	O
ischemia	O
caused	O
by	O
intraluminal	O
occlusion	B-PROC
of	O
blood	O
vessels	O
after	O
intraarterial	O
injection	O
of	O
heroin	O
.	O

Severe	O
hyperkalemia	O
and	O
the	O
development	B-PROC
of	O
acute	O
renal	O
failure	O
require	O
urgent	O
therapeutic	O
measures	O
,	O
which	O
imply	O
the	O
application	O
of	O
either	O
conventional	O
treatment	O
or	O
a	O
form	O
of	O
dialysis	O
.	O

Six	O
cases	O
had	O
bleeding	O
from	O
sutures	O
,	O
2	O
cases	O
with	O
severe	O
bleeding	O
underwent	O
thoracotomy	O
hemostasis	B-PROC
,	O
2	O
presented	O
with	O
acute	O
renal	O
failure	O
.	O

TITLE	O
:	O
Evolution	B-PROC
of	O
infectious	O
bronchitis	O
virus	O
in	O
Taiwan	O
:	O
positively	O
selected	O
sites	O
in	O
the	O
nucleocapsid	O
protein	O
and	O
their	O
effects	O
on	O
RNA	O
-	O
binding	B-PROC
activity	I-PROC
.	O

This	O
study	O
illustrates	O
that	O
the	O
N	O
protein	O
of	O
the	O
current	O
TW	O
IBV	O
variant	O
has	O
been	O
shaped	O
by	O
both	O
RNA	O
recombination	B-PROC
and	O
positive	O
selection	O
and	O
that	O
the	O
latter	O
may	O
promote	O
viral	O
survival	O
and	O
fitness	O
,	O
potentially	O
by	O
increasing	O
the	O
RNA	O
-	O
binding	O
capacity	O
of	O
the	O
N	O
protein	O
.	O

Some	O
sacrococcygeal	O
teratomas	O
can	O
hide	O
more	O
or	O
less	O
extensive	O
islands	O
of	O
immaturity	O
or	O
signs	O
of	O
malignant	O
transformation	B-PROC
that	O
are	O
clinically	O
evident	O
.	O

The	O
predictive	O
values	O
of	O
ΔPP	O
and	O
static	O
variables	O
[	O
right	O
atrial	O
pressure	O
(	O
RAP	O
)	O
and	O
pulmonary	O
artery	O
occlusion	B-PROC
pressure	O
(	O
PAOP	O
)]	O
were	O
evaluated	O
through	O
a	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
analysis	O
.	O

There	O
were	O
3	O
deaths	B-PROC
as	O
a	O
result	O
of	O
severe	O
malaria	O
.	O

We	O
report	O
here	O
the	O
complete	O
genome	O
sequence	O
of	O
SD	O
-	O
M	O
.	O
This	O
sequence	O
will	O
promote	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
pathogenesis	B-PROC
of	O
PEDV	O
.	O

Three	O
assays	O
were	O
conducted	O
:	O
inhibition	B-PROC
of	O
cancer	O
cell	B-PROC
proliferation	I-PROC
,	O
inhibition	B-PROC
of	O
TGEV	O
replication	O
for	O
anticoronavirus	O
activity	O
,	O
and	O
suppression	B-PROC
of	O
nitric	O
oxide	O
production	O
in	O
RAW264	O
.	O
7	O
cells	O
(	O
a	O
measure	O
of	O
anti	O
-	O
inflammation	O
).	O

Influenza	O
virus	O
circulation	B-PROC
peaked	O
during	O
June	O
-	O
August	O
in	O
both	O
years	O
and	O
A	O
(	O
H1N1	O
)	O
pdm09	O
occurred	O
at	O
the	O
end	O
of	O
the	O
influenza	O
season	O
in	O
2009	O
.	O

Influenza	O
virus	O
circulation	B-PROC
peaked	O
during	O
June	O
-	O
August	O
in	O
both	O
years	O
and	O
A	O
(	O
H1N1	O
)	O
pdm09	O
occurred	O
at	O
the	O
end	O
of	O
the	O
influenza	O
season	O
in	O
2009	O
.	O

This	O
report	O
describes	O
the	O
complete	O
genome	O
sequence	O
,	O
genome	O
organization	O
,	O
and	O
expression	B-PROC
strategy	O
of	O
HCoV	O
-	O
EMC	O
/	O
2012	O
and	O
its	O
relation	O
with	O
known	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
are	O
characterised	O
by	O
severe	O
hypoxemic	O
respiratory	O
failure	O
and	O
poor	O
lung	B-PROC
compliance	I-PROC
.	O

However	O
,	O
whilst	O
some	O
adult	O
studies	O
have	O
shown	O
improved	O
oxygenation	B-PROC
,	O
no	O
survival	O
benefit	O
has	O
been	O
demonstrated	O
to	O
date	O
.	O

ABSTRACT	O
:	O
A	O
virulent	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
was	O
isolated	O
from	O
30	O
-	O
day	O
-	O
old	O
broiler	O
chickens	O
that	O
exhibited	O
respiratory	O
symptoms	O
,	O
nephropathologic	O
lesions	O
,	O
and	O
a	O
high	O
proportion	O
of	O
deaths	B-PROC
in	O
the	O
People	O
'	O
s	O
Republic	O
of	O
China	O
during	O
2005	O
.	O

IBV	O
antigens	O
were	O
detected	O
by	O
immunohistochemical	O
analysis	O
in	O
the	O
trachea	O
,	O
lung	O
,	O
kidney	O
,	O
and	O
bursa	O
,	O
consistent	O
with	O
histopathologic	O
observations	O
,	O
virus	O
isolation	O
,	O
and	O
reverse	B-PROC
transcription	B-PROC
PCR	O
detection	O
.	O

This	O
study	O
may	O
assist	O
the	O
development	B-PROC
of	O
anti	O
-	O
viral	O
drugs	O
against	O
HCoV	O
.	O

This	O
recombination	B-PROC
event	O
took	O
place	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
N	O
gene	O
and	O
the	O
3	O
'	O
untranslated	O
region	O
may	O
account	O
for	O
differences	O
in	O
replication	O
efficiency	O
in	O
tissues	O
of	O
chickens	O
inoculated	O
by	O
the	O
two	O
viruses	O
.	O

TITLE	O
:	O
An	O
autophagy	B-PROC
-	O
independent	O
role	O
for	O
LC3	O
in	O
equine	O
arteritis	O
virus	B-PROC
replication	I-PROC
.	O

Increased	O
production	O
of	O
nitric	O
oxide	O
in	O
the	O
cells	O
treated	O
with	O
E	O
.	O
faecium	O
and	O
elevated	O
expression	B-PROC
of	O
interleukin	O
6	O
and	O
8	O
pointed	O
to	O
stimulated	O
cellular	O
defense	O
as	O
a	O
mechanism	O
to	O
fight	O
TGEV	O
infection	O
.	O

TITLE	O
:	O
Patient	O
-	O
ventilator	O
interaction	O
in	O
ARDS	O
patients	O
with	O
extremely	O
low	O
compliance	O
undergoing	O
ECMO	O
:	O
a	O
novel	O
approach	O
based	O
on	O
diaphragm	O
electrical	B-PROC
activity	I-PROC
.	O

As	O
a	O
consequence	O
,	O
they	O
are	O
at	O
high	O
risk	O
of	O
experiencing	O
poor	O
patient	O
-	O
ventilator	O
interaction	O
during	O
assisted	O
breathing	B-PROC
.	O

We	O
hypothesized	O
that	O
monitoring	O
of	O
diaphragm	O
electrical	B-PROC
activity	I-PROC
(	O
EAdi	O
)	O
may	O
enhance	O
asynchrony	O
assessment	O
and	O
that	O
neurally	O
adjusted	O
ventilatory	O
assist	O
(	O
NAVA	O
)	O
may	O
reduce	O
asynchrony	O
,	O
especially	O
in	O
more	O
severely	O
restricted	O
patients	O
.	O

We	O
lay	O
out	O
a	O
series	O
of	O
research	O
and	O
surveillance	O
opportunities	O
and	O
goals	O
that	O
could	O
help	O
to	O
overcome	O
these	O
challenges	O
and	O
move	B-PROC
the	O
global	O
pandemic	O
strategy	O
from	O
response	O
to	O
pre	O
-	O
emption	O
.	O

TITLE	O
:	O
Comparative	O
genomics	O
of	O
Korean	O
infectious	O
bronchitis	O
viruses	O
(	O
IBVs	O
)	O
and	O
an	O
animal	O
model	O
to	O
evaluate	O
pathogenicity	O
of	O
IBVs	O
to	O
the	O
reproductive	B-PROC
organs	O
.	O

A	O
recombination	B-PROC
analysis	O
revealed	O
that	O
SNU8067	O
was	O
a	O
recombinant	O
virus	O
with	O
a	O
KM91	O
-	O
like	O
backbone	O
except	O
S1	O
,	O
3a	O
,	O
and	O
3b	O
genes	O
which	O
might	O
be	O
from	O
an	O
unknown	O
virus	O
.	O

In	O
patients	O
with	O
BOS	O
,	O
we	O
identified	O
two	O
functional	O
phenotypes	O
:	O
a	O
typical	O
OLD	O
,	O
that	O
is	O
,	O
forced	B-PROC
expiratory	I-PROC
volume	I-PROC
in	O
1	O
s	O
(	O
FEV1	O
)/	O
forced	B-PROC
vital	I-PROC
capacity	I-PROC
(	O
FVC	B-PROC
)	O
ratio	O
<	O
0	O
.	O
7	O
(	O
n	O
=	O
53	O
),	O
and	O
an	O
atypical	O
OLD	O
with	O
a	O
concomitant	O
decrease	O
in	O
the	O
FEV1	O
<	O
80	O
%	O
and	O
FVC	B-PROC
<	O
80	O
%	O
predicted	O
with	O
a	O
normal	O
total	O
lung	B-PROC
capacity	I-PROC
(	O
n	O
=	O
24	O
).	O

The	O
mean	O
age	O
was	O
40	O
.	O
7	O
years	O
;	O
69	O
.	O
8	O
%	O
of	O
patients	O
had	O
≥	O
1	O
of	O
the	O
risk	O
factors	O
:	O
asthmatics	O
20	O
%,	O
obesity	O
23	O
.	O
8	O
%,	O
and	O
pregnancy	O
5	O
%;	O
and	O
72	O
.	O
5	O
%	O
had	O
acute	O
lung	O
injury	O
or	O
adult	O
respiratory	O
distress	O
syndrome	O
,	O
12	O
.	O
5	O
%	O
had	O
viral	O
pneumonia	O
,	O
42	O
.	O
5	O
%	O
had	O
secondary	O
bacterial	O
pneumonia	O
,	O
and	O
15	O
%	O
had	O
exacerbation	O
of	O
airflow	B-PROC
disease	O
.	O

We	O
found	O
a	O
relationship	O
between	O
arterial	B-PROC
oxygen	I-PROC
saturation	I-PROC
(	O
SaO	O
(	O
2	O
))	O
and	O
its	O
relevant	O
parameters	O
.	O

TITLE	O
:	O
Potent	O
inhibition	B-PROC
of	O
feline	O
coronaviruses	O
with	O
peptidyl	O
compounds	O
targeting	B-PROC
coronavirus	O
3C	O
-	O
like	O
protease	O
.	O

Currently	O
,	O
there	O
is	O
no	O
specific	O
treatment	O
approved	O
for	O
FIP	O
despite	O
the	O
importance	O
of	O
FIP	O
as	O
the	O
leading	O
infectious	O
cause	O
of	O
death	B-PROC
in	O
young	O
cats	O
.	O

Since	O
the	O
cleavages	O
of	O
viral	O
polyproteins	O
are	O
an	O
essential	O
step	O
for	O
virus	B-PROC
replication	I-PROC
,	O
blockage	O
of	O
viral	O
protease	O
is	O
an	O
attractive	O
target	O
for	O
therapeutic	O
intervention	O
.	O

Herein	O
we	O
report	O
that	O
our	O
compounds	O
behave	O
as	O
reversible	O
,	O
competitive	O
inhibitors	O
of	O
3CL	O
protease	O
,	O
potently	O
inhibited	O
the	O
replication	O
of	O
feline	O
coronaviruses	O
(	O
EC	O
(	O
50	O
)	O
in	O
a	O
nanomolar	O
range	O
)	O
and	O
,	O
furthermore	O
,	O
combination	O
of	O
cathepsin	O
B	O
and	O
3CL	O
protease	B-PROC
inhibitors	I-PROC
led	O
to	O
a	O
strong	O
synergistic	O
interaction	O
against	O
feline	O
coronaviruses	O
in	O
a	O
cell	O
culture	O
system	O
.	O

In	O
mouse	O
models	O
,	O
cytokines	O
and	O
markers	O
for	O
endothelial	O
damage	O
and	O
coagulation	B-PROC
activation	O
significantly	O
increased	O
immediately	O
after	O
trauma	O
or	O
histone	O
infusion	O
.	O

In	O
severe	O
sepsis	O
and	O
septic	O
shock	O
should	O
be	O
early	O
goal	O
-	O
directed	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
hrs	O
after	O
recognition	O
;	O
-	O
appropriate	O
diagnostic	O
studies	O
to	O
ascertain	O
causative	O
organisms	O
before	O
starting	O
antibiotics	O
;	O
-	O
early	O
administration	O
of	O
broad	O
-	O
spectrum	O
antibiotic	O
therapy	O
;	O
-	O
reassessment	O
of	O
antibiotic	O
therapy	O
with	O
microbiology	O
and	O
clinical	O
data	O
to	O
narrow	O
coverage	O
,	O
when	O
appropriate	O
;	O
-	O
a	O
usual	O
7	O
-	O
10	O
days	O
of	O
antibiotic	O
therapy	O
guided	O
by	O
clinical	O
response	O
;	O
-	O
source	O
control	O
with	O
attention	O
to	O
the	O
method	O
that	O
balances	O
risks	O
and	O
benefits	O
;	O
-	O
equivalence	O
of	O
crystalloid	O
and	O
colloid	O
resuscitation	O
;	O
aggressive	B-PROC
fluid	O
challenge	O
to	O
restore	O
mean	O
circulating	O
filling	O
pressure	O
;	O
-	O
vasopressor	O
preference	O
for	O
norepinephrine	O
and	O
dopamine	O
;	O
-	O
cautious	O
use	O
of	O
vasopressin	O
pending	O
further	O
studies	O
;	O
-	O
avoiding	O
low	O
-	O
dose	O
dopamine	O
administration	O
for	O
renal	O
protection	O
;	O
consideration	O
of	O
dobutamine	O
inotropic	O
therapy	O
in	O
some	O
clinical	O
situations	O
;	O
-	O
stress	O
-	O
dose	O
steroid	O
therapy	O
for	O
septic	O
shock	O
;	O
use	O
of	O
recombinant	O
activated	O
protein	O
C	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
high	O
risk	O
for	O
death	B-PROC
;	O
-	O
with	O
resolution	O
of	O
tissue	O
hypoperfusion	O
and	O
in	O
the	O
absence	O
of	O
coronary	O
artery	O
disease	O
or	O
acute	O
hemorrhage	O
,	O
targeting	B-PROC
a	O
hemoglobin	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
;	O
-	O
a	O
low	O
tidal	O
volume	O
and	O
limitation	O
of	O
inspiratory	B-PROC
plateau	O
pressure	O
strategy	O
for	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
-	O
application	O
of	O
a	O
minimal	O
amount	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
in	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
-	O
protocols	O
for	O
weaning	B-PROC
and	O
sedation	O
,	O
using	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
with	O
daily	O
interruptions	O
/	O
lightening	O
;	O
-	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
;	O
-	O
maintenance	O
of	O
blood	O
glucose	O
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
.	O

To	O
study	O
the	O
differences	O
of	O
dynamic	O
distribution	O
between	O
nephropathogenic	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strains	O
such	O
as	O
SAIBK	O
and	O
other	O
strains	O
(	O
the	O
M41	O
and	O
H120	O
strains	O
),	O
relative	O
quantitative	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
was	O
developed	O
by	O
housekeeping	O
gene	O
selection	O
.	O

Glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
and	O
Ubiquitin	B-PROC
were	O
chosen	O
for	O
normalization	O
in	O
this	O
experimental	O
set	O
.	O

Then	O
nine	O
tissues	O
,	O
the	O
trachea	O
,	O
thymus	O
,	O
liver	O
,	O
spleen	O
,	O
lungs	O
,	O
kidney	O
,	O
pancreas	O
,	O
proventriculus	O
,	O
and	O
bursa	O
of	O
Fabricius	O
,	O
were	O
analyzed	O
and	O
compared	O
to	O
determine	O
the	O
tropism	B-PROC
of	O
IBV	O
infection	O
.	O

ABSTRACT	O
:	O
A	O
multiplex	O
PCR	O
assay	O
was	O
developed	O
and	O
evaluated	O
for	O
its	O
ability	O
to	O
simultaneously	O
detect	O
three	O
viral	B-PROC
infections	I-PROC
of	O
swine	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
influenza	O
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
report	O
a	O
case	O
of	O
platypnea	O
-	O
orthodeoxia	O
syndrome	O
secondary	O
to	O
the	O
development	B-PROC
of	O
RLS	O
through	O
a	O
'	O
stretched	O
'	O
PFO	O
,	O
in	O
a	O
patient	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
with	O
severe	O
respiratory	O
failure	O
requiring	O
mechanical	O
ventilation	O
.	O

This	O
is	O
remarkable	O
,	O
as	O
human	O
CoVs	O
normally	O
cannot	O
replicate	O
in	O
bat	O
cells	O
as	O
a	O
consequence	O
of	O
host	O
adaptation	B-PROC
.	O

We	O
could	O
show	O
that	O
ketone	O
-	O
stabilized	O
1	O
-	O
adamantyl	O
singlet	O
nitrenes	O
are	O
versatile	O
synthons	O
for	O
the	O
synthesis	B-PROC
of	O
antiviral	O
drug	O
candidates	O
.	O

These	O
results	O
indicate	O
that	O
the	O
aromatic	O
-	O
aliphatic	O
ketone	O
-	O
stabilized	O
1	O
-	O
adamantyl	O
singlet	O
nitrenes	O
,	O
beyond	O
being	O
of	O
fundamental	O
interest	O
in	O
organic	O
chemistry	O
,	O
represent	O
versatile	O
synthons	O
for	O
the	O
synthesis	B-PROC
of	O
new	O
amantadine	O
-	O
related	O
potentially	O
antiviral	O
drugs	O
.	O

A	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
value	O
of	O
at	O
least	O
5	O
cm	O
H	O
(	O
2	O
)	O
O	O
became	O
required	O
for	O
the	O
diagnosis	O
of	O
ARDS	O
.	O

B7	O
-	O
H1	O
-	O
mediated	O
restraint	O
of	O
CD4	O
T	O
-	O
cell	O
activity	O
is	O
thus	O
crucial	O
to	O
dampen	O
both	O
CD8	O
T	O
-	O
cell	B-PROC
function	I-PROC
and	O
microglia	O
/	O
macrophage	B-PROC
activation	I-PROC
,	O
thereby	O
providing	O
protection	O
from	O
T	O
-	O
cell	O
-	O
mediated	O
bystander	O
damage	O
.	O

Daily	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
in	O
arterial	O
blood	O
(	O
P	O
(	O
a	O
)	O
O	O
(	O
2	O
)):	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
))	O
and	O
oxygenation	B-PROC
index	O
was	O
calculated	O
for	O
each	O
patient	O
.	O

Bootscan	O
analysis	O
revealed	O
that	O
NTU156	O
evolved	O
from	O
two	O
crossover	O
events	O
between	O
type	O
I	O
FCoV	O
and	O
canine	O
coronavirus	O
,	O
with	O
recombination	B-PROC
sites	O
located	O
in	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
and	O
M	O
genes	O
.	O

TITLE	O
:	O
Neuropathogenesis	O
of	O
a	O
mouse	O
-	O
adapted	O
porcine	O
epidemic	O
diarrhea	O
virus	B-PROC
infection	I-PROC
in	O
suckling	O
mice	O
.	O

The	O
wide	O
spectrum	O
of	O
initial	O
target	O
cells	O
following	O
MK	O
-	O
p10	O
infection	O
,	O
as	O
well	O
as	O
its	O
faster	O
spread	O
in	O
the	O
brain	O
,	O
may	O
be	O
evidence	O
of	O
enhanced	O
virulence	B-PROC
in	O
suckling	O
mice	O
.	O

Nonetheless	O
,	O
a	O
systematic	O
analysis	O
of	O
viral	B-PROC
infections	I-PROC
with	O
modern	O
available	O
techniques	O
as	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
in	O
the	O
context	O
of	O
petechial	O
rash	O
is	O
lacking	O
.	O

Gas	O
exchange	O
worsening	O
over	O
the	O
next	O
24	O
hr	O
resulted	O
in	O
HFOV	O
use	O
in	O
36	O
%	O
of	O
patients	O
,	O
while	O
the	O
remaining	O
subjects	O
sustained	O
improvements	O
in	O
oxygenation	B-PROC
at	O
12	O
and	O
24	O
hr	O
.	O

In	O
the	O
presence	O
of	O
alveolar	O
capillary	O
damage	O
,	O
which	O
occurs	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
intra	O
-	O
abdominal	O
hypertension	O
promotes	O
lung	O
injury	O
as	O
well	O
as	O
edema	O
,	O
impedes	O
the	O
pulmonary	O
lymphatic	O
drainage	O
,	O
and	O
increases	O
intra	O
-	O
thoracic	O
pressures	O
,	O
leading	O
to	O
atelectasis	O
,	O
airway	O
closure	O
,	O
and	O
deterioration	O
of	O
respiratory	B-PROC
mechanics	I-PROC
and	O
gas	O
exchange	O
.	O

When	O
ARDS	O
is	O
severe	O
,	O
high	O
-	O
inspired	B-PROC
oxygen	O
concentrations	O
are	O
frequently	O
required	O
to	O
minimise	O
hypoxaemia	O
.	O

In	O
situations	O
where	O
these	O
first	O
line	O
rescue	O
therapies	O
are	O
inadequate	O
extra	O
-	O
corporeal	O
membrane	O
oxygenation	B-PROC
has	O
emerged	O
as	O
a	O
lifesaving	O
second	O
line	O
rescue	O
therapy	O
.	O

Effective	O
,	O
reliable	O
measurement	O
of	O
tissue	B-PROC
oxygenation	B-PROC
along	O
with	O
the	O
use	O
of	O
selected	O
biomarkers	O
to	O
identify	O
suitable	O
candidates	O
and	O
monitor	O
harm	O
will	O
aid	O
the	O
development	B-PROC
of	O
permissive	O
hypoxemia	O
as	O
viable	O
clinical	O
strategy	O
.	O

RESULTS	O
:	O
Inadequate	O
tissue	B-PROC
oxygenation	B-PROC
and	O
excessive	O
oxygen	O
administration	O
can	O
be	O
detrimental	O
to	O
outcome	O
but	O
safety	O
thresholds	O
lack	O
definition	O
in	O
critically	O
ill	O
patients	O
.	O

Electrostatic	O
precipitation	B-PROC
has	O
been	O
used	O
as	O
an	O
inexpensive	O
approach	O
to	O
remove	O
large	O
particles	O
from	O
airflows	O
,	O
but	O
it	O
has	O
a	O
collection	O
efficiency	O
minimum	O
in	O
the	O
submicrometer	O
size	O
range	O
,	O
allowing	O
for	O
a	O
penetration	O
window	O
for	O
some	O
allergens	O
and	O
ultrafine	O
particles	O
.	O

These	O
results	O
indicate	O
antigenic	O
evolution	B-PROC
of	O
BCoV	O
between	O
the	O
genetic	O
groups	O
circulating	O
in	O
Japan	O
.	O

Further	O
,	O
macrophages	O
from	O
infected	O
CCL2	O
Tg	O
brains	O
relative	O
to	O
non	O
-	O
Tg	O
controls	O
were	O
less	O
activated	O
/	O
mature	O
,	O
expressing	O
lower	O
levels	O
of	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
class	O
II	O
(	O
MHC	B-PROC
-	O
II	O
),	O
CD86	O
,	O
and	O
CD40	O
.	O

However	O
,	O
comparisons	O
of	O
surface	O
electrostatics	O
,	O
shape	O
,	O
and	O
amino	O
acid	O
conservation	O
between	O
the	O
alpha	O
-	O
and	O
betacoronaviruses	O
lead	O
us	O
to	O
speculate	O
that	O
the	O
mechanism	O
for	O
nsp1	O
-	O
induced	O
suppression	B-PROC
of	O
host	O
gene	B-PROC
expression	I-PROC
might	O
be	O
different	O
in	O
these	O
two	O
genera	O
.	O

By	O
the	O
early	O
1970s	O
P	O
(	O
aO	O
(	O
2	O
))	O
had	O
become	O
the	O
gold	O
standard	O
for	O
clinically	O
assessing	O
oxygenation	B-PROC
in	O
the	O
body	O
.	O

Since	O
the	O
1980s	O
the	O
measurement	O
of	O
arterial	B-PROC
oxygen	I-PROC
saturation	I-PROC
by	O
pulse	B-PROC
oximetry	O
has	O
also	O
been	O
increasingly	O
used	O
as	O
an	O
adjunct	O
to	O
(	O
but	O
not	O
a	O
replacement	O
for	O
)	O
P	O
(	O
aO	O
(	O
2	O
)).	O

The	O
retrospective	O
observational	O
study	O
included	O
all	O
mechanically	O
ventilated	O
adult	O
patients	O
of	O
three	O
university	O
-	O
affiliated	O
hospitals	O
between	O
November	O
1	O
,	O
2009	O
and	O
March	O
1	O
2010	O
who	O
had	O
2009	O
H1N1	O
influenza	O
infection	O
confirmed	O
by	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
nasopharyngeal	O
swab	O
specimens	O
and	O
respiratory	O
secretions	O
.	O

ABSTRACT	O
:	O
Messenger	O
RNA	O
encoded	O
signals	O
that	O
are	O
involved	O
in	O
programmed	O
-	O
1	O
ribosomal	B-PROC
frameshifting	I-PROC
(-	O
1	O
PRF	O
)	O
are	O
typically	O
two	O
-	O
stemmed	O
hairpin	O
(	O
H	O
)-	O
type	O
pseudoknots	O
(	O
pks	O
).	O

These	O
results	O
suggest	O
that	O
the	O
homodimeric	O
RNA	O
complex	O
formed	O
by	O
the	O
SARS	O
pseudoknot	O
occurs	O
in	O
the	O
cellular	O
environment	O
and	O
that	O
loop	O
-	O
loop	O
kissing	O
interactions	O
involving	O
Stem	O
3	O
modulate	O
-	O
1	O
PRF	O
and	O
play	O
a	O
role	O
in	O
subgenomic	O
and	O
full	O
-	O
length	O
RNA	B-PROC
synthesis	I-PROC
.	O

In	O
these	O
patients	O
,	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
can	O
be	O
used	O
as	O
a	O
rescue	O
therapy	O
.	O

The	O
pathogenesis	B-PROC
of	O
five	O
geographically	O
unrelated	O
canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
)	O
isolates	O
was	O
investigated	O
.	O

Viral	B-PROC
shedding	I-PROC
was	O
readily	O
detected	O
from	O
the	O
oropharynx	O
up	O
to	O
10	O
days	O
post	O
infection	O
,	O
but	O
there	O
was	O
little	O
or	O
no	O
evidence	O
of	O
rectal	O
shedding	O
.	O

Children	O
with	O
multiple	O
viruses	O
detected	O
at	O
the	O
time	O
of	O
illness	O
onset	O
had	O
less	O
frequent	O
fever	B-PROC
(	O
odds	O
ratio	O
[	O
OR	O
],	O
0	O
.	O
56	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
0	O
.	O
35	O
,	O
0	O
.	O
90	O
),	O
however	O
,	O
these	O
children	O
more	O
often	O
had	O
illness	O
symptoms	O
lasting	O
over	O
7	O
days	O
(	O
OR	O
,	O
1	O
.	O
94	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
20	O
,	O
3	O
.	O
14	O
).	O

Three	O
patients	O
died	B-PROC
during	O
ECMO	O
,	O
while	O
another	O
3	O
patients	O
died	B-PROC
after	O
withdrawal	O
of	O
further	O
treatment	O
.	O

After	O
hemofiltration	O
,	O
the	O
clinical	O
symptoms	O
such	O
as	O
abdominal	O
pain	O
,	O
fever	B-PROC
,	O
tachycardia	O
and	O
respiratory	O
distress	O
in	O
hemofiltration	O
group	O
were	O
significantly	O
remitted	O
compared	O
to	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

vv	O
-	O
ECMO	O
blood	B-PROC
flow	I-PROC
and	O
FiO	O
(	O
2ECMO	O
)	O
determined	O
arterial	O
oxygenation	B-PROC
.	O

ABSTRACT	O
:	O
A	O
new	O
human	O
betacoronavirus	O
in	O
lineage	O
c	O
,	O
tentatively	O
called	O
HCoV	O
-	O
EMC	O
,	O
was	O
isolated	O
from	O
a	O
patient	O
from	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
who	O
died	B-PROC
from	O
acute	O
severe	O
pneumonia	O
and	O
renal	O
failure	O
.	O

There	O
was	O
also	O
no	O
evidence	O
for	O
dysregulation	O
of	O
chemokines	O
or	O
cytokines	O
involved	O
in	O
ASC	O
regulation	B-PROC
.	O

While	O
CXCL10	O
was	O
predominantly	O
expressed	B-PROC
by	O
astrocytes	O
,	O
CXCL9	O
expression	B-PROC
was	O
confined	O
to	O
the	O
vasculature	O
/	O
perivascular	O
spaces	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
are	O
positive	O
-	O
sense	B-PROC
,	O
single	O
-	O
stranded	O
,	O
enveloped	O
RNA	O
viruses	O
that	O
infect	O
a	O
variety	O
of	O
vertebrate	O
hosts	O
.	O

Risk	O
factors	O
for	O
the	O
syndrome	O
include	O
starvation	O
,	O
chronic	O
alcoholism	O
,	O
anorexia	O
nervosa	O
and	O
surgical	O
interventions	O
that	O
require	O
lengthy	O
periods	B-PROC
of	O
fasting	O
.	O

Refeeding	O
syndrome	O
was	O
a	O
rare	O
,	O
survivable	O
phenomenon	O
that	O
occurred	O
during	O
hypocaloric	O
nutrition	B-PROC
support	O
in	O
participants	O
identified	O
at	O
risk	O
.	O

RESULTS	O
:	O
Out	O
of	O
240	O
enrolled	O
patients	O
,	O
24	O
patients	O
(	O
10	O
%)	O
were	O
admitted	O
to	O
the	O
ICU	O
,	O
57	O
patients	O
(	O
24	O
.	O
3	O
%)	O
had	O
a	O
PLOS	O
of	O
>	O
9	O
days	O
and	O
12	O
patients	O
(	O
5	O
%)	O
died	B-PROC
.	O

We	O
hypothesised	O
that	O
there	O
is	O
an	O
increase	O
in	O
plasma	O
HBP	O
content	O
after	O
trauma	O
and	O
that	O
the	O
increased	O
levels	O
are	O
related	O
to	O
the	O
severity	O
of	O
the	O
trauma	O
or	O
later	O
development	B-PROC
of	O
severe	O
sepsis	O
and	O
organ	O
failure	O
(	O
ARDS	O
).	O

Further	O
research	O
is	O
required	O
to	O
confirm	O
a	O
casual	O
relationship	O
between	O
plasma	O
HBP	O
and	O
the	O
development	B-PROC
of	O
ARDS	O
.	O

We	O
found	O
,	O
however	O
,	O
a	O
correlation	O
between	O
HBP	O
levels	O
and	O
development	B-PROC
of	O
ARDS	O
(	O
P	O
=	O
0	O
.	O
026	O
,	O
n	O
=	O
47	O
),	O
but	O
not	O
to	O
severe	O
sepsis	O
.	O

Heat	B-PROC
shock	I-PROC
results	O
in	O
IRAK1	O
detergent	O
insolubility	O
and	O
a	O
disruption	O
of	O
Hsp90	O
binding	O
to	O
IRAK1	O
.	O

Remarkably	O
,	O
IL	O
-	O
1β	O
-	O
dependent	O
p38	O
activation	O
24	O
h	O
after	O
heat	B-PROC
shock	I-PROC
did	O
not	O
result	O
in	O
an	O
inhibition	B-PROC
of	O
αENaC	O
mRNA	B-PROC
expression	B-PROC
and	O
channel	O
function	O
.	O

Further	O
analysis	O
demonstrates	O
prolonged	O
preservation	O
of	O
αENaC	O
expression	B-PROC
by	O
the	O
activation	O
of	O
the	O
heat	B-PROC
shock	I-PROC
response	I-PROC
that	O
involves	O
inducible	O
Hsp70	O
.	O

Adenovirus	O
serotype	O
7	O
and	O
3	O
can	O
cause	O
severe	O
disease	O
-	O
even	O
death	B-PROC
-	O
in	O
children	O
,	O
especially	O
those	O
with	O
underlying	O
neurological	O
diseases	O
.	O

TITLE	O
:	O
Visualizing	O
the	O
autophagy	B-PROC
pathway	B-PROC
in	O
avian	O
cells	O
and	O
its	O
application	O
to	O
studying	O
infectious	O
bronchitis	O
virus	O
.	O

Although	O
autophagy	B-PROC
has	O
been	O
studied	O
in	O
many	O
animal	O
species	O
,	O
reagents	O
to	O
study	O
autophagy	B-PROC
in	O
avian	O
systems	O
are	O
lacking	O
.	O

IBV	O
induced	O
autophagic	O
signaling	B-PROC
in	O
mammalian	O
Vero	O
cells	O
but	O
not	O
primary	O
avian	O
chick	O
kidney	O
cells	O
or	O
the	O
avian	O
DF1	O
cell	O
line	O
.	O

Further	O
studies	O
show	O
that	O
PEDV	O
E	O
protein	O
induced	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
and	O
activated	O
NF	O
-	O
κB	O
which	O
is	O
responsible	O
for	O
the	O
up	B-PROC
-	I-PROC
regulation	B-PROC
of	O
IL	O
-	O
8	O
and	O
Bcl	O
-	O
2	O
expression	B-PROC
.	O

Consequently	O
,	O
we	O
here	O
examined	O
whether	O
IFNα	O
immobilized	O
on	O
nanoscale	O
ferromagnetic	O
R	O
-	O
Chitosan	O
carriers	O
is	O
capable	O
of	O
inducing	O
rapid	O
and	O
sustained	O
activation	O
of	O
STAT1	O
signaling	B-PROC
.	O

Employing	O
human	O
prostate	O
cancer	O
and	O
melanoma	O
cell	O
models	O
,	O
we	O
found	O
that	O
the	O
intensity	O
and	O
duration	O
of	O
STAT1	O
phosphorylation	B-PROC
as	O
well	O
as	O
the	O
downstream	O
activation	O
of	O
pathobiologically	O
relevant	O
genes	O
were	O
dose	O
and	O
particle	O
dependent	O
.	O

Coinfection	O
with	O
other	O
respiratory	O
viruses	O
was	O
associated	O
with	O
lower	O
respiratory	O
tract	O
infections	O
in	O
HCoV	O
-	O
OC43	O
-	O
infected	O
cases	O
,	O
but	O
did	O
not	O
lead	O
to	O
increased	O
rates	O
of	O
hospitalization	O
,	O
admission	O
to	O
intensive	O
care	O
unit	O
or	O
death	B-PROC
.	O

ABSTRACT	O
:	O
This	O
study	O
evaluates	O
the	O
effects	O
of	O
Sargassum	O
pallidum	O
polysaccharides	O
(	O
SPP	O
)	O
on	O
the	O
immune	B-PROC
responses	I-PROC
in	O
a	O
chicken	O
model	O
.	O

The	O
potential	O
effects	O
of	O
supplemental	O
oxygen	O
may	O
include	O
augmentation	O
of	O
lung	O
inflammation	O
by	O
inhibiting	O
anti	O
-	O
inflammatory	O
pathways	B-PROC
in	O
alveolar	O
macrophages	O
.	O

Recommendations	O
were	O
classified	O
into	O
three	O
groups	O
:	O
1	O
)	O
those	O
directly	O
targeting	B-PROC
severe	O
sepsis	O
;	O
2	O
)	O
those	O
targeting	B-PROC
general	O
care	O
of	O
the	O
critically	O
ill	O
patient	O
and	O
considered	O
high	O
priority	O
in	O
severe	O
sepsis	O
;	O
and	O
3	O
)	O
pediatric	O
considerations	O
.	O

Key	O
recommendations	O
and	O
suggestions	O
,	O
listed	O
by	O
category	O
,	O
include	O
:	O
early	O
quantitative	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
hrs	O
after	O
recognition	O
(	O
1C	O
);	O
blood	O
cultures	O
before	O
antibiotic	O
therapy	O
(	O
1C	O
);	O
imaging	O
studies	O
performed	O
promptly	O
to	O
confirm	O
a	O
potential	O
source	O
of	O
infection	O
(	O
UG	O
);	O
administration	O
of	O
broad	O
-	O
spectrum	O
antimicrobials	O
therapy	O
within	O
1	O
hr	O
of	O
recognition	O
of	O
septic	O
shock	O
(	O
1B	O
)	O
and	O
severe	O
sepsis	O
without	O
septic	O
shock	O
(	O
1C	O
)	O
as	O
the	O
goal	O
of	O
therapy	O
;	O
reassessment	O
of	O
antimicrobial	O
therapy	O
daily	O
for	O
de	O
-	O
escalation	O
,	O
when	O
appropriate	O
(	O
1B	O
);	O
infection	O
source	O
control	O
with	O
attention	O
to	O
the	O
balance	B-PROC
of	O
risks	O
and	O
benefits	O
of	O
the	O
chosen	O
method	O
within	O
12	O
hrs	O
of	O
diagnosis	O
(	O
1C	O
);	O
initial	O
fluid	O
resuscitation	O
with	O
crystalloid	O
(	O
1B	O
)	O
and	O
consideration	O
of	O
the	O
addition	O
of	O
albumin	O
in	O
patients	O
who	O
continue	O
to	O
require	O
substantial	O
amounts	O
of	O
crystalloid	O
to	O
maintain	O
adequate	O
mean	O
arterial	B-PROC
pressure	I-PROC
(	O
2C	O
)	O
and	O
the	O
avoidance	O
of	O
hetastarch	O
formulations	O
(	O
1C	O
);	O
initial	O
fluid	O
challenge	O
in	O
patients	O
with	O
sepsis	O
-	O
induced	O
tissue	O
hypoperfusion	O
and	O
suspicion	O
of	O
hypovolemia	O
to	O
achieve	O
a	O
minimum	O
of	O
30	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
more	O
rapid	O
administration	O
and	O
greater	O
amounts	O
of	O
fluid	O
may	O
be	O
needed	O
in	O
some	O
patients	O
)	O
(	O
1C	O
);	O
fluid	O
challenge	O
technique	O
continued	O
as	O
long	O
as	O
hemodynamic	B-PROC
improvement	O
,	O
as	O
based	O
on	O
either	O
dynamic	O
or	O
static	O
variables	O
(	O
UG	O
);	O
norepinephrine	O
as	O
the	O
first	O
-	O
choice	O
vasopressor	O
to	O
maintain	O
mean	O
arterial	B-PROC
pressure	I-PROC
≥	O
65	O
mm	O
Hg	O
(	O
1B	O
);	O
epinephrine	O
when	O
an	O
additional	O
agent	O
is	O
needed	O
to	O
maintain	O
adequate	O
blood	B-PROC
pressure	I-PROC
(	O
2B	O
);	O
vasopressin	O
(	O
0	O
.	O
03	O
U	O
/	O
min	O
)	O
can	O
be	O
added	O
to	O
norepinephrine	O
to	O
either	O
raise	O
mean	O
arterial	B-PROC
pressure	I-PROC
to	O
target	O
or	O
to	O
decrease	O
norepinephrine	O
dose	O
but	O
should	O
not	O
be	O
used	O
as	O
the	O
initial	O
vasopressor	O
(	O
UG	O
);	O
dopamine	O
is	O
not	O
recommended	O
except	O
in	O
highly	O
selected	O
circumstances	O
(	O
2C	O
);	O
dobutamine	O
infusion	O
administered	O
or	O
added	O
to	O
vasopressor	O
in	O
the	O
presence	O
of	O
a	O
)	O
myocardial	O
dysfunction	O
as	O
suggested	O
by	O
elevated	O
cardiac	O
filling	O
pressures	O
and	O
low	O
cardiac	O
output	O
,	O
or	O
b	O
)	O
ongoing	O
signs	O
of	O
hypoperfusion	O
despite	O
achieving	O
adequate	O
intravascular	O
volume	O
and	O
adequate	O
mean	O
arterial	B-PROC
pressure	I-PROC
(	O
1C	O
);	O
avoiding	O
use	O
of	O
intravenous	O
hydrocortisone	O
in	O
adult	O
septic	O
shock	O
patients	O
if	O
adequate	O
fluid	O
resuscitation	O
and	O
vasopressor	O
therapy	O
are	O
able	O
to	O
restore	O
hemodynamic	B-PROC
stability	O
(	O
2C	O
);	O
hemoglobin	O
target	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
in	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
ischemic	O
coronary	O
artery	O
disease	O
,	O
or	O
acute	O
hemorrhage	O
(	O
1B	O
);	O
low	O
tidal	O
volume	O
(	O
1A	O
)	O
and	O
limitation	O
of	O
inspiratory	B-PROC
plateau	O
pressure	O
(	O
1B	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
in	O
ARDS	O
(	O
1B	O
);	O
higher	O
rather	O
than	O
lower	O
level	O
of	O
PEEP	O
for	O
patients	O
with	O
sepsis	O
-	O
induced	O
moderate	O
or	O
severe	O
ARDS	O
(	O
2C	O
);	O
recruitment	O
maneuvers	O
in	O
sepsis	O
patients	O
with	O
severe	O
refractory	O
hypoxemia	O
due	O
to	O
ARDS	O
(	O
2C	O
);	O
prone	O
positioning	O
in	O
sepsis	O
-	O
induced	O
ARDS	O
patients	O
with	O
a	O
PaO2	O
/	O
FIO2	O
ratio	O
of	O
≤	O
100	O
mm	O
Hg	O
in	O
facilities	O
that	O
have	O
experience	O
with	O
such	O
practices	O
(	O
2C	O
);	O
head	O
-	O
of	O
-	O
bed	O
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ARDS	O
who	O
do	O
not	O
have	O
evidence	O
of	O
tissue	O
hypoperfusion	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	B-PROC
and	O
sedation	O
(	O
1A	O
);	O
minimizing	O
use	O
of	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
targeting	B-PROC
specific	O
titration	O
endpoints	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
if	O
possible	O
in	O
the	O
septic	O
patient	O
without	O
ARDS	O
(	O
1C	O
);	O
a	O
short	O
course	O
of	O
neuromuscular	O
blocker	O
(	O
no	O
longer	O
than	O
48	O
hrs	O
)	O
for	O
patients	O
with	O
early	O
ARDS	O
and	O
a	O
Pao2	O
/	O
Fio2	O
<	O
150	O
mm	O
Hg	O
(	O
2C	O
);	O
a	O
protocolized	O
approach	O
to	O
blood	O
glucose	O
management	O
commencing	O
insulin	O
dosing	O
when	O
two	O
consecutive	O
blood	O
glucose	O
levels	O
are	O
>	O
180	O
mg	O
/	O
dL	O
,	O
targeting	B-PROC
an	O
upper	O
blood	O
glucose	O
≤	O
180	O
mg	O
/	O
dL	O
(	O
1A	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
venous	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	O
vein	O
thrombosis	O
(	O
1B	O
);	O
use	O
of	O
stress	O
ulcer	O
prophylaxis	O
to	O
prevent	O
upper	O
gastrointestinal	O
bleeding	O
in	O
patients	O
with	O
bleeding	O
risk	O
factors	O
(	O
1B	O
);	O
oral	O
or	O
enteral	O
(	O
if	O
necessary	O
)	O
feedings	O
,	O
as	O
tolerated	O
,	O
rather	O
than	O
either	O
complete	O
fasting	O
or	O
provision	O
of	O
only	O
intravenous	O
glucose	O
within	O
the	O
first	O
48	O
hrs	O
after	O
a	O
diagnosis	O
of	O
severe	O
sepsis	O
/	O
septic	O
shock	O
(	O
2C	O
);	O
and	O
addressing	O
goals	O
of	O
care	O
,	O
including	O
treatment	O
plans	O
and	O
end	O
-	O
of	O
-	O
life	O
planning	O
(	O
as	O
appropriate	O
)	O
(	O
1B	O
),	O
as	O
early	O
as	O
feasible	O
,	O
but	O
within	O
72	O
hrs	O
of	O
intensive	O
care	O
unit	O
admission	O
(	O
2C	O
).	O

Recombination	B-PROC
analysis	O
showed	O
that	O
Sczy3	O
is	O
a	O
chimeric	O
strain	O
derived	O
from	O
LX4	O
(	O
major	O
parental	O
sequence	O
)	O
and	O
H120	O
(	O
minor	O
parental	O
sequence	O
)	O
suggesting	O
that	O
recombination	B-PROC
occurred	O
in	O
a	O
region	O
containing	O
the	O
3	O
'	O
terminal	O
5a	O
sequence	O
(	O
83	O
nt	O
),	O
the	O
5	O
'	O
terminal	O
5b	O
sequence	O
(	O
222	O
nt	O
),	O
and	O
the	O
5	O
'	O
terminal	O
nucleocapsid	O
protein	O
gene	O
sequence	O
(	O
132	O
nt	O
).	O

Recommendations	O
were	O
classified	O
into	O
three	O
groups	O
:	O
(	O
1	O
)	O
those	O
directly	O
targeting	B-PROC
severe	O
sepsis	O
;	O
(	O
2	O
)	O
those	O
targeting	B-PROC
general	O
care	O
of	O
the	O
critically	O
ill	O
patient	O
and	O
considered	O
high	O
priority	O
in	O
severe	O
sepsis	O
;	O
and	O
(	O
3	O
)	O
pediatric	O
considerations	O
.	O

By	O
bioinformatic	O
and	O
systems	O
biology	O
approaches	O
,	O
we	O
evaluated	O
the	O
impact	O
of	O
nuclear	B-PROC
import	I-PROC
antagonism	O
on	O
host	O
expression	B-PROC
networks	O
by	O
using	O
human	O
lung	O
epithelial	O
cells	O
infected	O
with	O
either	O
wild	O
-	O
type	O
virus	O
or	O
a	O
mutant	O
that	O
does	O
not	O
express	O
ORF6	O
protein	O
.	O

The	O
results	O
of	O
the	O
study	O
demonstrated	O
that	O
there	O
were	O
different	O
predominant	O
serotypes	O
and	O
multiple	O
serotypes	O
of	O
IBV	O
circulated	O
in	O
Guangxi	O
in	O
recent	O
years	O
,	O
antigenic	B-PROC
variation	I-PROC
existed	O
between	O
Guangxi	O
field	O
isolates	O
and	O
vaccine	O
strains	O
.	O

Among	O
patients	O
with	O
asthma	O
,	O
those	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
or	O
who	O
died	B-PROC
(	O
n	O
=	O
38	O
)	O
compared	O
with	O
survivors	O
not	O
admitted	O
to	O
an	O
ICU	O
(	O
n	O
=	O
99	O
)	O
were	O
more	O
likely	O
to	O
have	O
pneumonia	O
on	O
admission	O
(	O
60	O
%	O
vs	O
.	O
27	O
%,	O
p	O
<	O
0	O
.	O
01	O
)	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
24	O
%	O
vs	O
.	O
0	O
%,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
less	O
likely	O
to	O
receive	O
influenza	O
antiviral	O
agents	O
≤	O
2	O
days	O
of	O
admission	O
(	O
73	O
%	O
vs	O
.	O
92	O
%,	O
p	O
=	O
0	O
.	O
02	O
).	O

All	O
patients	O
who	O
died	B-PROC
and	O
had	O
a	O
clinical	O
autopsy	O
in	O
our	O
intensive	O
care	O
unit	O
over	O
a	O
20	O
-	O
year	O
period	O
(	O
1991	O
-	O
2010	O
)	O
were	O
included	O
.	O

TITLE	O
:	O
Breastfeeding	B-PROC
:	O
an	O
overview	O
of	O
oral	O
and	O
general	O
health	O
benefits	O
.	O

ABSTRACT	O
:	O
Breastfeeding	B-PROC
is	O
the	O
reference	O
against	O
which	O
alternative	O
infant	O
feeding	O
models	O
must	O
be	O
measured	O
with	O
regard	O
to	O
growth	B-PROC
,	O
development	B-PROC
and	O
other	O
health	O
outcomes	O
.	O

RESULTS	O
:	O
When	O
compared	O
with	O
health	O
outcomes	O
among	O
formula	O
-	O
fed	O
children	O
,	O
the	O
health	O
advantages	O
associated	O
with	O
breastfeeding	B-PROC
include	O
a	O
lower	O
risk	O
of	O
acute	O
otitis	O
media	O
,	O
gastroenteritis	O
and	O
diarrhea	O
,	O
severe	O
lower	O
respiratory	O
infections	O
,	O
asthma	O
,	O
sudden	O
infant	O
death	B-PROC
syndrome	O
,	O
obesity	O
and	O
other	O
childhood	O
diseases	O
and	O
conditions	O
.	O

During	O
2006	O
-	O
2011	O
,	O
74	O
.	O
0	O
%	O
(	O
94	O
/	O
127	O
)	O
of	O
samples	O
from	O
32	O
swine	O
-	O
raising	O
farms	O
in	O
15	O
provinces	O
were	O
positive	O
for	O
PEDV	O
by	O
reverse	B-PROC
transcription	B-PROC
nested	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
nested	O
PCR	O
).	O

The	O
number	O
of	O
potential	O
phosphorylation	B-PROC
sites	O
in	O
the	O
N	O
protein	O
varied	O
from	O
5	O
to	O
12	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
are	O
characterized	O
by	O
a	O
disruption	O
of	O
the	O
endothelium	O
and	O
alveolar	O
epithelial	O
barriers	O
involving	O
increased	O
microvascular	B-PROC
permeability	I-PROC
,	O
thus	O
resulting	O
in	O
the	O
set	O
of	O
protein	O
-	O
rich	O
pulmonary	O
edema	O
.	O

Angiogenic	B-PROC
factors	O
and	O
their	O
receptors	O
,	O
including	O
vascular	B-PROC
endothelial	I-PROC
growth	B-PROC
factor	I-PROC
(	O
VEGF	B-PROC
)/	O
VEGF	B-PROC
-	O
receptor	O
(	O
VEGFR	O
)	O
and	O
the	O
angiopoietin	O
(	O
Ang	O
)/	O
Tie2	O
signaling	B-PROC
pathways	B-PROC
,	O
play	O
pivotal	O
roles	O
in	O
both	O
angiogenesis	B-PROC
and	O
microvascular	B-PROC
permeability	I-PROC
.	O

aMPV	O
was	O
detected	O
by	O
reverse	B-PROC
transcription	B-PROC
(	O
RT	O
)-	O
PCR	O
,	O
and	O
blood	O
samples	O
were	O
collected	O
for	O
serology	O
by	O
aMPV	O
ELISA	O
.	O

PLP2	O
binds	O
ubiquitin	B-PROC
using	O
a	O
zinc	O
finger	O
that	O
is	O
uniquely	O
integrated	O
into	O
an	O
exceptionally	O
compact	O
OTU	O
-	O
domain	O
fold	O
that	O
represents	O
a	O
new	O
subclass	O
of	O
zinc	O
-	O
dependent	O
OTU	O
DUBs	O
.	O

Compared	O
with	O
WT	O
virus	B-PROC
infection	I-PROC
,	O
IFN	O
-	O
β	O
mRNA	O
levels	O
in	O
equine	O
cells	O
infected	O
with	O
PLP2	O
mutants	O
were	O
increased	O
by	O
nearly	O
an	O
order	O
of	O
magnitude	O
.	O

The	O
perfusion	O
of	O
the	O
small	O
and	O
large	O
intestine	O
is	O
impaired	O
due	O
to	O
reduced	O
arterial	B-PROC
pressure	I-PROC
,	O
increased	O
vascular	O
resistence	O
and	O
diminished	O
portal	O
blood	B-PROC
flow	I-PROC
.	O

Mechanical	O
failure	O
of	O
the	O
necrotic	B-PROC
segment	O
of	O
bone	O
principally	O
occurred	O
within	O
3	O
years	O
after	O
the	O
administration	O
of	O
steroids	O
.	O

The	O
structure	O
activity	O
relationships	O
(	O
SARs	O
)	O
were	O
discussed	O
and	O
rationalized	O
by	O
docking	B-PROC
simulations	O
.	O

Six	O
percent	O
of	O
subjects	O
died	B-PROC
,	O
and	O
of	O
those	O
,	O
54	O
%	O
had	O
no	O
pathogen	O
identified	O
.	O

Rhinovirus	O
was	O
the	O
most	O
common	O
pathogen	O
among	O
those	O
who	O
died	B-PROC
,	O
although	O
it	O
did	O
not	O
have	O
the	O
highest	O
case	O
fatality	O
rate	O
.	O

TITLE	O
:	O
Innate	B-PROC
immune	I-PROC
response	I-PROC
of	O
human	O
alveolar	O
type	O
II	O
cells	O
infected	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
.	O

Viral	O
antigens	O
were	O
detected	O
in	O
the	O
cytoplasm	O
of	O
infected	O
type	O
II	O
cells	O
,	O
electron	O
micrographs	O
demonstrated	O
secretory	B-PROC
vesicles	O
filled	O
with	O
virions	O
,	O
virus	O
RNA	O
concentrations	O
increased	O
with	O
time	O
,	O
and	O
infectious	O
virions	O
were	O
released	O
by	O
exocytosis	B-PROC
from	O
the	O
apical	O
surface	O
of	O
polarized	O
type	O
II	O
cells	O
.	O

In	O
conclusion	O
,	O
the	O
cultivation	O
of	O
alveolar	O
type	O
II	O
cells	O
at	O
an	O
air	O
-	O
liquid	O
interface	O
provides	O
primary	O
cultures	O
in	O
which	O
to	O
study	O
the	O
pulmonary	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
to	O
infection	O
with	O
SARS	O
-	O
CoV	O
,	O
and	O
to	O
explore	O
possible	O
therapeutic	O
approaches	O
to	O
modulating	O
these	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
.	O

Poor	O
prognostic	O
factors	O
were	O
delayed	O
diagnosis	O
,	O
anaemia	O
,	O
severe	O
AKI	O
,	O
shock	O
,	O
ARDS	O
,	O
need	O
for	O
ventilatory	O
support	O
,	O
raised	O
serum	O
transaminases	O
and	O
metabolic	B-PROC
acidosis	O
.	O

Here	O
,	O
we	O
detail	O
the	O
establishment	O
of	O
a	O
polarized	O
,	O
liquid	O
-	O
covered	O
culture	O
(	O
LCC	O
)	O
of	O
Calu	O
-	O
3	O
cells	O
,	O
focusing	O
on	O
the	O
technical	O
details	O
of	O
growing	O
and	O
culturing	O
Calu	O
-	O
3	O
cells	O
,	O
maintaining	O
cells	O
that	O
have	O
been	O
cultured	O
into	O
LCC	O
,	O
and	O
we	O
present	O
the	O
method	O
for	O
performing	O
respiratory	O
virus	B-PROC
infection	I-PROC
of	O
polarized	O
Calu	O
-	O
3	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
determine	O
immune	B-PROC
response	I-PROC
and	O
protection	O
efficacy	O
of	O
a	O
spike	O
(	O
S	O
)	O
protein	O
fragment	O
containing	O
neutralizing	O
epitopes	O
(	O
4F	O
/	O
4R	O
)	O
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
by	O
priming	O
with	O
DNA	O
vaccine	O
and	O
boosting	O
with	O
the	O
recombinant	O
protein	O
from	O
the	O
corresponding	O
DNA	O
vaccine	O
gene	O
segment	O
.	O

ABSTRACT	O
:	O
The	O
nucleotide	O
sequences	O
of	O
a	O
region	O
including	O
S1	O
,	O
S2	O
,	O
3a	O
,	O
3b	O
and	O
E	O
genes	O
of	O
twenty	O
-	O
seven	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
isolates	O
in	O
Korea	O
between	O
1990	O
-	O
2011	O
were	O
determined	O
and	O
phylogenetic	O
and	O
computational	O
recombination	B-PROC
analyses	O
were	O
conducted	O
.	O

Markers	O
with	O
complete	O
loss	O
after	O
light	O
exposure	O
also	O
had	O
reduced	O
immunoreactivity	B-PROC
when	O
stored	O
in	O
the	O
dark	O
,	O
as	O
early	O
as	O
day	O
3	O
.	O

ABSTRACT	O
:	O
In	O
September	O
2012	O
,	O
a	O
novel	O
coronavirus	O
was	O
isolated	O
from	O
a	O
patient	O
in	O
Saudi	O
Arabia	O
who	O
had	O
died	B-PROC
of	O
an	O
acute	O
respiratory	O
illness	O
and	O
renal	O
failure	O
.	O

The	O
dose	O
of	O
tranexamic	O
acid	O
was	O
reduced	O
to	O
1000	O
mg	O
every	O
12	O
hours	O
,	O
adjusting	O
for	O
renal	B-PROC
function	I-PROC
.	O

To	O
begin	O
to	O
understand	O
the	O
role	O
and	O
mechanism	B-PROC
of	I-PROC
action	I-PROC
of	O
the	O
MHV	O
PS	O
in	O
its	O
native	O
genomic	O
locus	O
,	O
we	O
constructed	O
viral	O
mutants	O
in	O
which	O
this	O
cis	O
-	O
acting	O
element	O
was	O
altered	O
,	O
deleted	O
,	O
or	O
transposed	O
.	O

The	O
data	O
indicate	O
that	O
the	O
pro	O
-	O
forms	O
of	O
the	O
enzyme	O
have	O
proteolytic	B-PROC
activity	O
,	O
and	O
are	O
stimulated	O
by	O
the	O
same	O
proteolytic	B-PROC
activity	O
.	O

Interestingly	O
,	O
a	O
novel	O
endocan	O
peptide	O
fragment	O
of	O
14	O
kDa	O
,	O
named	O
p14	O
,	O
was	O
identified	O
,	O
resulting	O
from	O
the	O
specific	O
cleavage	B-PROC
of	O
endocan	O
by	O
CG	O
,	O
corresponding	O
to	O
the	O
N	O
-	O
terminal	O
111	O
-	O
116	O
amino	O
acids	O
of	O
the	O
endocan	O
polypeptide	O
.	O

We	O
found	O
that	O
the	O
spike	O
protein	O
of	O
hCoV	O
-	O
EMC	O
(	O
EMC	O
-	O
S	O
)	O
is	O
incorporated	O
into	O
lentiviral	O
particles	O
and	O
mediates	O
transduction	B-PROC
of	O
human	O
cell	O
lines	O
derived	O
from	O
different	O
organs	O
,	O
including	O
the	O
lungs	O
,	O
kidneys	O
,	O
and	O
colon	O
,	O
as	O
well	O
as	O
primary	O
human	O
macrophages	O
.	O

Independent	O
of	O
T4	O
treatment	O
,	O
cold	B-PROC
exposure	O
was	O
generally	O
associated	O
with	O
decreased	O
immune	O
functions	O
at	O
early	O
stages	O
.	O

The	O
data	O
suggested	O
that	O
oral	O
exposure	O
of	O
broiler	O
breeder	O
hens	O
to	O
1	O
mg	O
/	O
L	O
of	O
T4	O
not	O
only	O
had	O
no	O
adverse	O
effect	O
on	O
immune	B-PROC
function	I-PROC
,	O
but	O
also	O
modulated	O
early	O
adaptive	B-PROC
immune	I-PROC
responses	I-PROC
in	O
progeny	O
chicks	O
for	O
which	O
the	O
causal	O
mechanisms	O
remain	O
to	O
be	O
unraveled	O
.	O

Studies	O
in	O
humans	O
and	O
animals	O
have	O
demonstrated	O
a	O
decrease	O
in	O
the	O
expression	B-PROC
of	O
proximal	O
sodium	O
(	O
NHE3	O
)	O
and	O
water	O
tubular	O
transporter	O
,	O
aquaporin	B-PROC
1	O
(	O
AQP1	O
)	O
together	O
with	O
higher	O
renal	O
expression	B-PROC
of	O
the	O
Na	O
-	O
K	O
-	O
2Cl	O
cotransporter	O
NKCC2	O
.	O

Reconstitution	O
of	O
the	O
peptides	O
as	O
TMD1	O
+	O
TMD3	O
as	O
well	O
as	O
TMD2	O
+	O
TMD3	O
in	O
a	O
1	O
:	O
1	O
mixture	O
induces	O
membrane	B-PROC
activity	I-PROC
for	O
both	O
mixtures	O
.	O

Five	O
patients	O
died	B-PROC
.	O

The	O
relationship	O
between	O
ethnicity	O
and	O
immunity	B-PROC
to	O
severe	O
disease	O
is	O
complex	O
.	O

We	O
used	O
logistic	O
regression	O
and	O
receiving	O
-	O
operator	O
characteristics	O
curve	O
to	O
test	O
associations	O
with	O
oxygenation	B-PROC
and	O
mortality	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
is	O
a	O
causative	O
agent	O
of	O
the	O
common	O
cold	B-PROC
.	O

Patient	O
died	B-PROC
98	O
hours	O
after	O
her	O
admission	O
to	O
the	O
hospital	O
unit	O
.	O

For	O
refractory	O
APCPF	O
,	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
one	O
of	O
the	O
last	O
resorts	O
.	O

In	O
the	O
end	O
,	O
2	O
patients	O
(	O
33	O
.	O
3	O
%)	O
died	B-PROC
from	O
multiple	O
-	O
organ	O
failure	O
,	O
despite	O
intensive	O
resuscitation	O
.	O

HCoV	O
-	O
EMC	O
was	O
found	O
to	O
infect	O
the	O
human	O
respiratory	O
tract	O
(	O
polarized	O
airway	O
epithelium	O
cell	O
line	O
Calu	O
-	O
3	O
,	O
embryonic	O
fibroblast	O
cell	O
line	O
HFL	O
,	O
and	O
lung	O
adenocarcinoma	O
cell	O
line	O
A549	O
),	O
kidney	O
(	O
embryonic	O
kidney	O
cell	O
line	O
HEK	O
),	O
intestinal	O
tract	O
(	O
colorectal	O
adenocarcinoma	O
cell	O
line	O
Caco	O
-	O
2	O
),	O
liver	O
cells	O
(	O
hepatocellular	O
carcinoma	O
cell	O
line	O
Huh	O
-	O
7	O
),	O
and	O
histiocytes	O
(	O
malignant	O
histiocytoma	O
cell	O
line	O
His	O
-	O
1	O
),	O
as	O
evident	O
by	O
detection	O
of	O
high	O
or	O
increasing	O
viral	O
load	O
in	O
culture	O
supernatants	O
,	O
detection	O
of	O
viral	O
nucleoprotein	O
expression	B-PROC
by	O
immunostaining	O
,	O
and	O
/	O
or	O
detection	O
of	O
cytopathic	O
effects	O
.	O

The	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Network	O
,	O
a	O
consortium	O
of	O
12	O
university	O
centers	O
(	O
44	O
hospitals	O
)	O
dedicated	O
to	O
the	O
conduct	B-PROC
of	O
multicenter	O
clinical	O
trials	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
.	O

Severe	O
but	O
not	O
mild	O
to	O
moderate	O
alcohol	O
misuse	O
is	O
independently	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	B-PROC
or	O
persistent	O
hospitalization	O
at	O
90	O
days	O
in	O
acute	O
lung	O
injury	O
patients	O
.	O

The	O
patient	O
was	O
weaned	B-PROC
from	O
mechanical	O
ventilation	O
and	O
has	O
done	O
well	O
without	O
recurrence	O
.	O

For	O
each	O
patient	O
we	O
recorded	O
anthropometric	O
and	O
anamnestic	O
data	O
,	O
smoking	O
habits	O
,	O
respiratory	B-PROC
function	I-PROC
,	O
GOLD	O
(	O
Global	O
initiative	O
for	O
chronic	O
Obstructive	O
Lung	O
Disease	O
)	O
severity	O
stage	O
,	O
Body	O
Mass	O
Index	O
(	O
BMI	O
),	O
number	O
of	O
acute	O
COPD	O
exacerbations	O
in	O
previous	O
years	O
,	O
presence	O
and	O
type	O
of	O
comorbidities	O
,	O
and	O
the	O
Charlson	O
Comorbidity	O
Index	O
(	O
CCI	O
).	O

Use	O
of	O
combination	O
of	O
bronchodilators	O
and	O
inhaled	B-PROC
corticosteroids	O
was	O
more	O
frequent	O
in	O
younger	O
patients	O
with	O
more	O
severe	O
airways	O
obstruction	O
and	O
lower	O
CCI	O
.	O

We	O
utilized	O
ex	O
vivo	O
cultures	O
of	O
human	O
bronchial	O
and	O
lung	O
tissue	O
specimens	O
to	O
investigate	O
the	O
tissue	B-PROC
tropism	B-PROC
and	O
virus	B-PROC
replication	I-PROC
kinetics	O
following	O
experimental	O
infection	O
with	O
HCoV	O
-	O
EMC	O
compared	O
with	O
those	O
following	O
infection	O
with	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Human	O
T	O
-	O
cell	O
Immunoglobulin	B-PROC
and	O
Mucin	O
-	O
domain	O
containing	O
proteins	O
(	O
TIM1	O
,	O
3	O
,	O
and	O
4	O
)	O
specifically	O
bind	O
phosphatidylserine	O
(	O
PS	O
).	O

All	O
interactions	O
between	O
TIM1	O
and	O
pseudoviruses	O
or	O
VLPs	O
were	O
PS	O
-	O
mediated	O
,	O
as	O
demonstrated	O
with	O
liposome	O
blocking	O
and	O
TIM1	O
mutagenesis	B-PROC
experiments	O
.	O

The	O
predictors	O
of	O
NIV	O
failure	O
were	O
the	O
severity	O
of	O
associated	O
organ	O
dysfunctions	O
(	O
OR	O
,	O
1	O
.	O
20	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
05	O
to	O
1	O
.	O
34	O
),	O
ARDS	O
(	O
OR	O
,	O
2	O
.	O
31	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
10	O
to	O
4	O
.	O
82	O
)	O
and	O
positive	O
fluid	B-PROC
balance	I-PROC
(	O
OR	O
,	O
2	O
.	O
09	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
02	O
to	O
4	O
.	O
30	O
).	O

TITLE	O
:	O
Is	O
there	O
a	O
place	O
for	O
pressure	O
-	O
support	O
ventilation	O
and	O
high	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
combined	O
to	O
alpha	O
-	O
2	O
agonists	O
early	O
in	O
severe	O
diffuse	O
acute	O
respiratory	O
distress	O
syndrome	O
?	O

The	O
virus	O
can	O
attack	O
many	O
organ	O
systems	O
and	O
causes	O
a	O
broad	O
range	O
of	O
signs	O
,	O
commonly	O
including	O
weight	O
loss	O
and	O
fever	B-PROC
.	O

The	O
nerve	B-PROC
conduction	B-PROC
study	O
was	O
consistent	O
with	O
GBS	O
.	O

Severe	O
pulmonary	O
dysfunction	O
may	O
preclude	O
their	O
use	O
,	O
leaving	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
as	O
the	O
most	O
frequently	O
used	O
option	O
for	O
combined	O
cardiac	O
and	O
respiratory	O
failure	O
.	O

We	O
previously	O
showed	O
that	O
recombinant	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
(	O
Urbani	O
strain	O
based	O
)	O
lacking	O
envelope	O
(	O
E	O
)	O
protein	B-PROC
expression	B-PROC
(	O
rU	O
-	O
ΔE	O
)	O
provided	O
good	O
but	O
not	O
perfect	O
protection	O
in	O
young	O
mice	O
against	O
challenge	O
with	O
virulent	O
mouse	O
-	O
adapted	O
SARS	O
-	O
CoV	O
(	O
MA15	O
).	O

The	O
clinical	O
signs	O
in	O
the	O
affected	O
birds	O
included	O
swelling	O
of	O
the	O
face	O
and	O
eyes	O
,	O
loss	O
of	O
condition	O
,	O
gasping	O
respirations	B-PROC
and	O
coughing	O
.	O

Exposure	O
to	O
other	O
intercurrent	O
factors	O
,	O
including	O
adverse	O
weather	O
conditions	O
and	O
internal	O
parasitism	B-PROC
,	O
may	O
also	O
have	O
exacerbated	O
the	O
severity	O
of	O
disease	O
.	O

Previous	O
studies	O
suggested	O
that	O
PEDV	O
does	O
not	O
elicit	O
a	O
robust	O
IFN	O
response	O
,	O
but	O
the	O
mechanism	O
(	O
s	O
)	O
used	O
to	O
evade	O
or	O
block	O
this	O
innate	B-PROC
immune	I-PROC
response	I-PROC
was	O
not	O
known	O
.	O

ABSTRACT	O
:	O
The	O
variable	O
regions	O
of	O
the	O
heavy	O
chain	O
(	O
VH	O
)	O
and	O
light	O
chain	O
(	O
VL	O
)	O
were	O
amplified	O
by	O
RT	O
-	O
PCR	O
from	O
the	O
hybridoma	O
6E6	O
,	O
which	O
secretes	O
the	O
monoclonal	O
antibody	B-PROC
against	O
PEDV	O
S	O
protein	O
.	O

The	O
recombinant	O
scFv	O
/	O
6E6	O
protein	O
was	O
successfully	O
expressed	B-PROC
in	O
recombinant	O
Escherichia	O
coli	O
by	O
IPTG	O
induction	O
.	O

These	O
findings	O
highlight	O
relevant	O
differences	O
between	O
these	O
distantly	O
related	O
zoonotic	O
CoVs	O
in	O
terms	O
of	O
their	O
interaction	O
with	O
and	O
evasion	O
of	O
the	O
cellular	O
innate	B-PROC
immune	I-PROC
response	I-PROC
.	O

However	O
,	O
essential	O
immune	O
functions	O
of	O
FRCs	B-PROC
,	O
including	O
homeostatic	B-PROC
chemokine	O
and	O
interleukin	O
-	O
7	O
expression	B-PROC
,	O
were	O
impaired	O
.	O

These	O
changes	O
in	O
T	O
cell	O
zone	O
reticular	O
cell	B-PROC
function	I-PROC
were	O
associated	O
with	O
increased	O
susceptibility	O
to	O
viral	B-PROC
infection	I-PROC
.	O

Later	O
in	O
infection	O
,	O
HCoV	O
-	O
EMC	O
induced	O
a	O
massive	O
dysregulation	O
of	O
the	O
host	O
transcriptome	O
,	O
to	O
a	O
much	O
greater	O
extent	O
than	O
SARS	O
-	O
CoV	O
.	O
Both	O
viruses	O
induced	O
a	O
similar	O
activation	O
of	O
pattern	O
recognition	O
receptors	O
and	O
the	O
interleukin	O
17	O
(	O
IL	B-PROC
-	I-PROC
17	I-PROC
)	O
pathway	B-PROC
,	O
but	O
HCoV	O
-	O
EMC	O
specifically	O
down	O
-	O
regulated	O
the	O
expression	B-PROC
of	O
several	O
genes	O
within	O
the	O
antigen	B-PROC
presentation	I-PROC
pathway	I-PROC
,	O
including	O
both	O
type	O
I	O
and	O
II	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
(	O
MHC	B-PROC
)	O
genes	O
.	O

Furthermore	O
,	O
lung	O
protective	O
mechanical	O
ventilation	O
must	O
be	O
applied	O
using	O
low	O
tidal	O
volumes	O
and	O
limiting	O
inspiratory	B-PROC
pressures	O
.	O

In	O
extreme	O
,	O
life	O
threatening	O
cases	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
can	O
stabilize	O
gas	O
exchange	O
and	O
serve	O
as	O
a	O
bridge	O
to	O
recovery	O
and	O
means	O
to	O
enable	O
lung	O
protective	O
ventilation	O
.	O

ABSTRACT	O
:	O
The	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
main	O
protease	O
(	O
M	O
(	O
pro	O
))	O
cleaves	O
two	O
virion	O
polyproteins	O
(	O
pp1a	O
and	O
pp1ab	O
);	O
this	O
essential	O
process	O
represents	O
an	O
attractive	O
target	O
for	O
the	O
development	B-PROC
of	O
anti	O
-	O
SARS	O
drugs	O
.	O

These	O
included	O
ribosomal	O
proteins	O
,	O
nucleolar	O
proteins	O
,	O
translation	B-PROC
initiation	I-PROC
factors	O
,	O
helicases	O
,	O
and	O
hnRNPs	O
.	O

Both	O
cell	O
types	O
had	O
increased	O
expression	B-PROC
of	O
IL	O
-	O
1β	O
mRNA	O
upon	O
viral	B-PROC
infection	I-PROC
,	O
though	O
at	O
different	O
levels	O
.	O

TITLE	O
:	O
Effect	O
of	O
chloroquine	O
on	O
feline	O
infectious	O
peritonitis	O
virus	B-PROC
infection	I-PROC
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
detection	O
of	O
these	O
cases	O
initiated	O
a	O
cascade	O
of	O
activities	O
in	O
China	O
,	O
including	O
diagnostic	O
test	O
development	B-PROC
,	O
enhanced	O
surveillance	O
for	O
new	O
cases	O
,	O
and	O
investigations	O
to	O
identify	O
the	O
source	O
(	O
s	O
)	O
of	O
infection	O
.	O

The	O
mean	O
duration	O
of	O
illness	O
prior	O
to	O
hospitalization	O
was	O
4	O
.	O
7	O
days	O
and	O
deaths	B-PROC
occurred	O
at	O
an	O
average	O
of	O
2	O
.	O
4	O
days	O
post	O
-	O
admission	O
.	O

During	O
the	O
hospitalization	O
,	O
she	O
required	O
emergency	O
transfer	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
because	O
of	O
progressive	O
deterioration	O
of	O
respiratory	O
muscle	B-PROC
function	I-PROC
,	O
severe	O
respiratory	O
acidosis	O
,	O
obtundation	O
and	O
hypotension	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
constitutes	O
a	O
spectrum	O
of	O
increasingly	O
severe	O
acute	O
respiratory	O
failure	O
and	O
is	O
the	O
leading	O
cause	O
of	O
death	B-PROC
and	O
disability	O
in	O
the	O
critically	O
ill	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
infection	O
induced	O
apoptosis	B-PROC
in	O
several	O
cell	O
lines	O
in	O
vitro	O
.	O

TITLE	O
:	O
Cytokine	O
release	O
syndrome	O
after	O
blinatumomab	O
treatment	O
related	O
to	O
abnormal	O
macrophage	B-PROC
activation	I-PROC
and	O
ameliorated	O
with	O
cytokine	O
-	O
directed	O
therapy	O
.	O

Studies	O
on	O
their	O
mechanisms	O
of	O
action	O
revealed	O
that	O
the	O
compounds	O
act	O
by	O
three	O
distinct	O
mechanisms	O
:	O
(	O
i	O
)	O
SSAA09E2	O
{	O
N	O
-[[	O
4	O
-(	O
4	O
-	O
methylpiperazin	O
-	O
1	O
-	O
yl	O
)	O
phenyl	O
]	O
methyl	O
]-	O
1	O
,	O
2	O
-	O
oxazole	O
-	O
5	O
-	O
carboxamide	O
}	O
acts	O
through	O
a	O
novel	O
mechanism	B-PROC
of	I-PROC
action	I-PROC
,	O
by	O
blocking	O
early	O
interactions	O
of	O
SARS	O
-	O
S	O
with	O
the	O
receptor	O
for	O
SARS	O
-	O
CoV	O
,	O
angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
);	O
(	O
ii	O
)	O
SSAA09E1	O
{[(	O
Z	O
)-	O
1	O
-	O
thiophen	O
-	O
2	O
-	O
ylethylideneamino	O
]	O
thiourea	O
}	O
acts	O
later	O
,	O
by	O
blocking	O
cathepsin	O
L	O
,	O
a	O
host	O
protease	O
required	O
for	O
processing	O
of	O
SARS	O
-	O
S	O
during	O
viral	O
entry	O
;	O
and	O
(	O
iii	O
)	O
SSAA09E3	O
[	O
N	O
-(	O
9	O
,	O
10	O
-	O
dioxo	O
-	O
9	O
,	O
10	O
-	O
dihydroanthracen	O
-	O
2	O
-	O
yl	O
)	O
benzamide	O
]	O
also	O
acts	O
later	O
and	O
does	O
not	O
affect	O
interactions	O
of	O
SARS	O
-	O
S	O
with	O
ACE2	O
or	O
the	O
enzymatic	O
functions	O
of	O
cathepsin	O
L	O
but	O
prevents	O
fusion	O
of	O
the	O
viral	O
membrane	O
with	O
the	O
host	O
cellular	O
membrane	O
.	O

Our	O
work	O
demonstrates	O
that	O
there	O
are	O
at	O
least	O
three	O
independent	O
strategies	O
for	O
blocking	O
SARS	O
-	O
CoV	O
entry	O
,	O
validates	O
these	O
mechanisms	O
of	O
inhibition	B-PROC
,	O
and	O
introduces	O
promising	O
leads	O
for	O
the	O
development	B-PROC
of	O
SARS	O
therapeutics	O
.	O

TITLE	O
:	O
Upregulation	B-PROC
of	O
CHOP	O
/	O
GADD153	O
during	O
coronavirus	O
infectious	O
bronchitis	O
virus	B-PROC
infection	I-PROC
modulates	O
apoptosis	B-PROC
by	O
restricting	O
activation	O
of	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
pathway	B-PROC
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
activation	O
of	O
the	O
protein	O
kinase	O
R	O
-	O
like	O
ER	O
kinase	O
(	O
PERK	O
)	O
pathway	B-PROC
of	O
UPR	O
in	O
cells	O
infected	O
with	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
its	O
relationship	O
with	O
IBV	O
-	O
induced	O
apoptosis	B-PROC
.	O

Both	O
combination	O
vaccines	O
gave	O
partial	O
protection	O
against	O
the	O
development	B-PROC
of	O
DMV	O
/	O
1639	O
/	O
11	O
-	O
induced	O
renal	O
lesions	O
.	O

For	O
comparison	O
purposes	O
,	O
the	O
survival	O
of	O
Ad2	O
,	O
CoV229E	O
,	O
and	O
PV1	O
was	O
determined	O
for	O
periods	B-PROC
up	O
to	O
10	O
days	O
on	O
produce	O
.	O

In	O
this	O
paper	O
,	O
we	O
review	O
evidence	O
that	O
lung	O
endothelial	O
activation	O
and	O
vascular	O
leak	O
are	O
a	O
""""	O
final	O
common	O
pathway	B-PROC
""""	O
in	O
severe	O
influenza	O
,	O
as	O
has	O
been	O
reported	O
in	O
bacterial	O
sepsis	O
,	O
and	O
that	O
enhancing	O
endothelial	O
barrier	O
function	O
may	O
improve	O
the	O
outcome	O
of	O
illness	O
.	O

Thus	O
,	O
it	O
is	O
likely	O
that	O
the	O
aggressive	B-PROC
treatment	O
of	O
this	O
child	O
with	O
hemodiafiltration	O
might	O
have	O
prevented	O
him	O
from	O
long	O
-	O
term	O
neurological	O
sequelae	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
:	O
beneficial	O
strategy	O
for	O
lung	O
transplant	O
recipients	O
.	O

The	O
sequestration	O
of	O
cerebral	O
vasculature	O
with	O
parasitized	O
red	O
blood	O
cells	O
is	O
one	O
of	O
the	O
proposed	O
mechanisms	O
for	O
the	O
development	B-PROC
of	O
cerebral	O
malaria	O
.	O

Common	O
respiratory	O
viruses	O
were	O
identified	O
by	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
.	O

Demographic	O
differences	O
were	O
observed	O
between	O
patients	O
with	O
different	O
viruses	O
,	O
suggesting	O
that	O
host	O
and	O
viral	O
factors	O
play	O
a	O
role	O
in	O
phenotypic	O
expression	B-PROC
of	O
viral	B-PROC
illness	I-PROC
.	O

Fever	B-PROC
and	O
cough	O
were	O
the	O
most	O
common	O
presenting	O
symptoms	O
.	O

The	O
median	O
times	O
from	O
the	O
onset	O
of	O
illness	O
and	O
from	O
the	O
initiation	O
of	O
antiviral	O
therapy	O
to	O
a	O
negative	O
viral	O
test	O
result	O
on	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-PROC
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
assay	O
were	O
11	O
days	O
(	O
interquartile	O
range	O
,	O
9	O
to	O
16	O
)	O
and	O
6	O
days	O
(	O
interquartile	O
range	O
,	O
4	O
to	O
7	O
),	O
respectively	O
.	O

Thus	O
,	O
RNase	O
L	O
activation	O
during	O
MHV	O
infection	O
is	O
cell	O
type	O
specific	O
and	O
correlates	O
with	O
relatively	O
high	O
levels	O
of	O
expression	B-PROC
of	O
OAS	O
genes	O
,	O
which	O
are	O
necessary	O
but	O
not	O
sufficient	O
for	O
induction	O
of	O
an	O
effective	O
RNase	O
L	O
antiviral	B-PROC
response	I-PROC
.	O

The	O
inhibition	B-PROC
of	O
calcineurin	B-PROC
blocks	O
the	O
translocation	B-PROC
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
from	O
the	O
cytosol	O
into	O
the	O
nucleus	O
,	O
thus	O
preventing	O
the	O
transcription	B-PROC
of	O
genes	O
encoding	O
cytokines	O
such	O
as	O
interleukin	O
-	O
2	O
.	O

A	O
systematic	O
study	O
of	O
the	O
oligomerization	O
behavior	O
revealed	O
that	O
altering	O
the	O
intermolecular	O
electrostatic	O
repulsion	O
through	O
changes	O
in	O
solution	O
salt	O
concentration	O
or	O
phosphorylation	B-PROC
-	O
mimicking	O
mutations	O
affects	O
oligomerization	O
propensity	O
.	O

TITLE	O
:	O
Experimental	O
study	O
on	O
histopathological	O
changes	O
and	O
tissue	B-PROC
tropism	B-PROC
of	O
Iranian	O
infectious	O
bronchitis	O
serotype	O
793	O
/	O
B	O
-	O
like	O
virus	O
in	O
SPF	O
chickens	O
.	O

Broad	O
-	O
spectrum	O
antibiotic	O
treatment	O
for	O
infectious	O
hepatitis	O
was	O
to	O
no	O
avail	O
;	O
the	O
cat	O
deteriorated	O
and	O
died	B-PROC
72	O
h	O
after	O
admission	O
.	O

Necropsy	O
revealed	O
mild	O
icterus	O
and	O
anaemia	O
,	O
severe	O
multifocal	O
hepatic	O
necrosis	B-PROC
,	O
serofibrinous	O
hydrothorax	O
,	O
pulmonary	O
oedema	O
and	O
interstitial	O
pneumonia	O
.	O

Substantial	O
advances	O
have	O
been	O
made	O
in	O
understanding	O
the	O
pathogenesis	B-PROC
of	O
these	O
forms	O
of	O
permeability	O
pulmonary	O
edema	O
,	O
including	O
Starling	O
forces	O
and	O
cellular	O
transport	B-PROC
mechanisms	O
involved	O
in	O
the	O
generation	O
and	O
resolution	O
of	O
this	O
form	O
of	O
lung	O
injury	O
.	O

In	O
this	O
article	O
,	O
we	O
review	O
the	O
history	O
of	O
the	O
pathophysiology	O
of	O
lung	O
fluid	O
and	O
solute	O
movement	B-PROC
and	O
the	O
seminal	O
clinical	O
observations	O
that	O
brought	O
that	O
history	O
to	O
clinical	O
relevance	O
.	O

We	O
review	O
the	O
relevant	O
lung	O
structure	O
and	O
function	O
and	O
the	O
dynamics	O
of	O
edema	O
formation	B-PROC
and	O
resolution	O
,	O
and	O
we	O
describe	O
the	O
related	O
clinical	O
syndromes	O
and	O
the	O
current	O
treatment	O
modalities	O
.	O

This	O
study	O
was	O
aimed	O
to	O
determine	O
whether	O
hyposialylated	O
fAGP	O
influences	O
phagocytosis	B-PROC
.	O

Several	O
events	O
have	O
since	O
stimulated	O
progress	O
in	O
public	O
health	O
emergency	O
planning	O
:	O
the	O
1997	O
avian	O
influenza	O
A	O
(	O
H5N1	O
)	O
outbreak	O
in	O
Hong	O
Kong	O
,	O
China	O
;	O
the	O
2001	O
anthrax	O
attacks	O
in	O
the	O
United	O
States	O
;	O
the	O
2003	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
;	O
and	O
the	O
2003	O
reemergence	O
of	O
influenza	O
A	O
(	O
H5N1	O
)	O
virus	B-PROC
infection	I-PROC
in	O
humans	O
.	O

Lessons	O
learned	B-PROC
from	O
the	O
global	O
SARS	O
outbreak	O
highlight	O
the	O
need	O
to	O
avoid	O
complacency	O
,	O
strengthen	O
efforts	O
to	O
improve	O
global	O
capacity	O
to	O
address	O
the	O
next	O
pandemic	O
using	O
all	O
available	O
21st	O
century	O
tools	O
,	O
and	O
support	O
research	O
to	O
develop	O
new	O
treatment	O
options	O
,	O
countermeasures	O
,	O
and	O
insights	O
while	O
striving	O
to	O
address	O
the	O
global	O
inequities	O
that	O
are	O
the	O
root	O
cause	O
of	O
many	O
of	O
these	O
challenges	O
.	O

Given	O
the	O
continued	O
scale	O
and	O
pace	O
of	O
change	O
in	O
East	O
and	O
Southeast	O
Asia	O
,	O
it	O
is	O
vital	O
that	O
capabilities	O
for	O
predicting	O
,	O
identifying	O
,	O
and	O
controlling	O
biologic	O
threats	O
do	O
not	O
stagnate	O
as	O
the	O
memory	B-PROC
of	O
SARS	O
fades	O
.	O

The	O
rates	O
of	O
severe	O
sepsis	O
/	O
septic	O
shock	O
(	O
70	O
.	O
0	O
%	O
vs	O
24	O
.	O
1	O
%,	O
P	O
<	O
0	O
.	O
01	O
),	O
pancreatic	O
encephalopathy	O
(	O
50	O
.	O
0	O
%	O
vs	O
17	O
.	O
2	O
%,	O
P	O
<	O
0	O
.	O
05	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
90	O
.	O
0	O
%	O
vs	O
41	O
.	O
4	O
%,	O
P	O
<	O
0	O
.	O
01	O
),	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
70	O
.	O
0	O
%	O
vs	O
24	O
.	O
1	O
%,	O
P	O
<	O
0	O
.	O
01	O
),	O
acute	O
renal	O
failure	O
(	O
40	O
.	O
0	O
%	O
vs	O
27	O
.	O
6	O
%,	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
death	B-PROC
(	O
40	O
.	O
0	O
%	O
vs	O
13	O
.	O
8	O
%,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
GC	O
than	O
in	O
those	O
without	O
GC	O
.	O

The	O
rates	O
of	O
severe	O
sepsis	O
/	O
septic	O
shock	O
(	O
70	O
.	O
0	O
%	O
vs	O
24	O
.	O
1	O
%,	O
P	O
<	O
0	O
.	O
01	O
),	O
pancreatic	O
encephalopathy	O
(	O
50	O
.	O
0	O
%	O
vs	O
17	O
.	O
2	O
%,	O
P	O
<	O
0	O
.	O
05	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
90	O
.	O
0	O
%	O
vs	O
41	O
.	O
4	O
%,	O
P	O
<	O
0	O
.	O
01	O
),	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
70	O
.	O
0	O
%	O
vs	O
24	O
.	O
1	O
%,	O
P	O
<	O
0	O
.	O
01	O
),	O
acute	O
renal	O
failure	O
(	O
40	O
.	O
0	O
%	O
vs	O
27	O
.	O
6	O
%,	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
death	B-PROC
(	O
40	O
.	O
0	O
%	O
vs	O
13	O
.	O
8	O
%,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
GC	O
than	O
in	O
those	O
without	O
GC	O
.	O

TITLE	O
:	O
Pathogenesis	B-PROC
of	O
malaria	O
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Common	O
manifestations	O
of	O
the	O
disease	O
are	O
weakness	O
and	O
muscle	B-PROC
fatigue	I-PROC
,	O
which	O
is	O
the	O
result	O
of	O
skeletal	O
muscles	O
inflammation	O
(	O
usually	O
the	O
proximal	O
group	O
of	O
muscles	O
,	O
bilaterally	O
and	O
symmetrical	O
).	O

Among	O
constitutional	O
(	O
general	O
)	O
symptoms	O
,	O
fever	B-PROC
,	O
malaise	O
and	O
weight	O
loss	O
are	O
usually	O
expressed	B-PROC
.	O

Cardiac	O
affection	O
is	O
usually	O
subclinical	O
,	O
but	O
can	O
also	O
be	O
expressed	B-PROC
as	O
heart	O
failure	O
,	O
acute	O
coronary	O
syndrome	O
or	O
conduction	B-PROC
disturbances	O
.	O

pulse	B-PROC
doses	O
of	O
1	O
g	O
/	O
day	O
.	O

In	O
vitro	O
antiviral	O
activity	O
was	O
tested	O
using	O
two	O
different	O
assay	O
strategies	O
:	O
(	O
1	O
)	O
blockage	O
of	O
the	O
binding	O
of	O
virus	O
to	O
cells	O
(	O
simultaneous	O
-	O
treatment	O
assay	O
)	O
and	O
(	O
2	O
)	O
inhibition	B-PROC
of	O
viral	B-PROC
replication	I-PROC
(	O
post	O
-	O
treatment	O
assay	O
).	O

These	O
low	O
-	O
molecular	O
weight	O
compounds	O
are	O
attractive	O
leads	O
for	O
the	O
further	O
development	B-PROC
of	O
potent	O
peptidomimetic	O
inhibitors	O
with	O
pharmaceutical	O
profiles	O
.	O

The	O
use	O
of	O
dexmedetomidine	O
to	O
wean	B-PROC
high	O
-	O
dose	O
benzodiazepines	O
and	O
opiates	O
also	O
permitted	O
successful	O
liberation	O
from	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
The	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
protein	O
of	O
HCoV	O
-	O
NL63	O
is	O
a	O
major	O
target	O
in	O
the	O
development	B-PROC
of	O
diagnostic	O
assay	O
and	O
vaccine	O
,	O
it	O
has	O
a	O
pivotal	O
role	O
in	O
receptor	O
attachment	O
,	O
viral	O
entry	O
and	O
membrane	B-PROC
fusion	I-PROC
.	O

The	O
RBD	O
(	O
RL	O
and	O
RS	O
)	O
of	O
HCoV	O
-	O
NL63	O
were	O
expressed	B-PROC
majorly	O
as	O
inclusion	O
body	O
when	O
expressed	B-PROC
in	O
E	O
.	O
coli	O
BL21pLys	O
S	O
under	O
different	O
conditions	O
.	O

In	O
conclusion	O
,	O
the	O
purified	O
recombinant	O
RBD	O
proteins	O
(	O
RL	O
and	O
RS	O
)	O
derived	O
from	O
E	O
.	O
coli	O
were	O
first	O
prepared	O
in	O
China	O
and	O
they	O
might	O
provide	O
a	O
basis	O
for	O
further	O
exploring	O
biological	O
role	O
and	O
vaccine	O
development	B-PROC
of	O
HCoV	O
-	O
NL63	O
.	O

TITLE	O
:	O
[	O
Nutrition	B-PROC
and	O
acute	O
respiratory	O
failure	O
].	O

These	O
insights	O
into	O
FIP	O
pathogenesis	B-PROC
may	O
be	O
useful	O
in	O
development	B-PROC
of	O
diagnostic	O
,	O
prevention	O
,	O
and	O
treatment	O
measures	O
against	O
coronaviruses	O
.	O

Replication	O
of	O
PHEV	O
in	O
a	O
porcine	O
kidney	O
-	O
derived	O
cell	O
line	O
(	O
PK	O
-	O
15	O
cells	O
)	O
caused	O
an	O
extensive	O
CPE	O
,	O
leading	O
to	O
the	O
destruction	O
of	O
the	O
entire	O
monolayer	O
and	O
the	O
death	B-PROC
of	O
the	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
As	O
exemplified	O
by	O
coronaviruses	O
and	O
influenza	O
viruses	O
,	O
bats	O
and	O
birds	O
are	O
natural	O
reservoirs	O
for	O
providing	O
viral	O
genes	O
during	O
evolution	B-PROC
of	O
new	O
virus	O
species	O
and	O
viruses	O
for	O
interspecies	O
transmission	O
.	O

ABSTRACT	O
:	O
Indoor	O
human	O
environments	O
,	O
including	O
homes	O
,	O
offices	O
,	O
schools	O
,	O
workplaces	O
,	O
transport	B-PROC
systems	O
and	O
other	O
settings	O
,	O
often	O
harbor	O
potentially	O
unsafe	O
microorganisms	O
.	O

Based	O
on	O
experimental	O
and	O
clinical	O
studies	O
,	O
progress	O
has	O
been	O
made	O
in	O
understanding	O
the	O
mechanisms	O
responsible	O
for	O
the	O
pathogenesis	B-PROC
and	O
the	O
resolution	O
of	O
lung	O
injury	O
.	O

Our	O
MIA	O
results	O
support	O
previous	O
studies	O
with	O
decreased	O
mortality	O
in	O
HRR	B-PROC
group	O
when	O
compared	O
with	O
LRR	O
.	O

The	O
evidence	O
for	O
the	O
role	O
of	O
vitamin	O
D	O
in	O
lung	O
disease	O
is	O
growing	O
-	O
deficiency	O
has	O
been	O
associated	O
with	O
impaired	O
pulmonary	B-PROC
function	I-PROC
,	O
increased	O
incidence	O
of	O
viral	O
and	O
bacterial	O
infections	O
and	O
inflammatory	O
disease	O
including	O
asthma	O
and	O
COPD	O
.	O

RESULTS	O
:	O
Overall	O
detection	O
in	O
356	O
enrolled	O
adults	O
were	O
92	O
(	O
26	O
%)	O
cases	O
of	O
a	O
single	O
bacterial	O
pathogen	O
,	O
80	O
(	O
22	O
%)	O
cases	O
of	O
a	O
single	O
viral	O
pathogen	O
,	O
60	O
(	O
17	O
%)	O
cases	O
with	O
mixed	O
bacterial	O
and	O
viral	B-PROC
infection	I-PROC
and	O
124	O
(	O
35	O
%)	O
cases	O
with	O
no	O
identified	O
pathogen	O
.	O

The	O
selection	O
pattern	O
along	O
the	O
S	O
glycoprotein	O
implies	O
adaptive	O
evolution	B-PROC
of	O
BCoVs	O
,	O
suggesting	O
a	O
successful	O
mechanism	O
for	O
BCoV	O
to	O
continuously	O
circulate	O
among	O
cattle	O
and	O
other	O
ruminants	O
without	O
disappearance	O
.	O

It	O
also	O
has	O
the	O
potential	O
to	O
cross	O
the	O
blood	B-PROC
-	I-PROC
brain	I-PROC
barrier	I-PROC
to	O
enter	O
the	O
avian	O
central	O
nervous	O
system	O
(	O
CNS	O
).	O

ABSTRACT	O
:	O
A	O
32	O
-	O
year	O
-	O
old	O
female	O
with	O
epilepsy	O
presented	O
at	O
our	O
hospital	O
with	O
high	O
-	O
grade	O
fever	B-PROC
,	O
seizures	O
,	O
and	O
unconsciousness	O
.	O

We	O
emphasize	O
the	O
importance	O
of	O
aggressive	B-PROC
workup	O
and	O
empirical	O
therapy	O
for	O
patients	O
with	O
Legionella	O
pneumonia	O
with	O
rapidly	O
worsening	O
symptoms	O
and	O
clinical	O
features	O
such	O
as	O
unconsciousness	O
,	O
epilepsy	O
,	O
and	O
hyponatremia	O
and	O
in	O
whom	O
fluoroquinolone	O
and	O
corticosteroid	O
therapy	O
are	O
effective	O
despite	O
the	O
presence	O
of	O
epilepsy	O
.	O

In	O
2003	O
,	O
World	O
Health	O
Organisation	B-PROC
(	O
WHO	O
)	O
coined	O
the	O
word	O
SARS	O
for	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
in	O
patients	O
with	O
a	O
relevant	O
travel	O
/	O
contact	O
history	O
and	O
sars	O
.	O

ABSTRACT	O
:	O
Among	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-PROC
(	O
RT	O
)-	O
associated	O
functions	O
,	O
DNA	O
polymerase	O
and	O
Ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
are	O
both	O
essential	O
for	O
HIV	O
replication	O
and	O
excellent	O
targets	O
for	O
drug	O
development	B-PROC
.	O

Liberal	O
and	O
conservative	O
fluid	O
strategies	O
therefore	O
are	O
complementary	O
and	O
should	O
ideally	O
follow	O
each	O
other	O
in	O
time	O
in	O
the	O
same	O
patient	O
whose	O
hemodynamic	B-PROC
state	O
progressively	O
stabilizes	O
.	O

We	O
hypothesized	O
that	O
this	O
increase	O
in	O
elderly	O
injured	O
patients	O
may	O
have	O
combined	O
with	O
recent	O
care	O
innovations	O
to	O
alter	O
the	O
causes	O
of	O
death	B-PROC
after	O
trauma	O
.	O

In	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
as	O
a	O
model	O
,	O
we	O
previously	O
reported	O
that	O
accessory	O
gene	O
7	O
counteracts	O
the	O
host	O
antiviral	B-PROC
response	I-PROC
by	O
associating	O
with	O
the	O
catalytic	O
subunit	O
of	O
protein	O
phosphatase	O
1	O
(	O
PP1c	O
).	O

TITLE	O
:	O
Bilateral	O
entry	O
and	O
release	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
induces	O
profound	O
apoptosis	B-PROC
of	O
human	O
bronchial	O
epithelial	O
cells	O
.	O

The	O
relative	O
effect	O
of	O
the	O
moving	B-PROC
human	O
figure	O
on	O
spreading	O
any	O
potential	O
contamination	O
was	O
greatest	O
with	O
the	O
sliding	O
doors	O
,	O
as	O
the	O
bulk	O
airflows	O
induced	O
were	O
large	O
relative	O
to	O
those	O
resulting	O
from	O
these	O
door	O
-	O
opening	O
motions	O
.	O

To	O
assess	O
the	O
interhuman	O
transmissibility	O
of	O
MERS	O
-	O
CoV	O
,	O
we	O
used	O
Bayesian	O
analysis	O
to	O
estimate	O
the	O
basic	O
reproduction	B-PROC
number	O
(	O
R0	O
)	O
and	O
compared	O
it	O
to	O
that	O
of	O
prepandemic	O
SARS	O
.	O

TITLE	O
:	O
Lactococcus	O
lactis	O
anchoring	B-PROC
avian	O
infectious	O
bronchitis	O
virus	O
multi	O
-	O
epitope	O
peptide	O
EpiC	O
induced	O
specific	O
immune	B-PROC
responses	I-PROC
in	O
chickens	O
.	O

In	O
four	O
western	O
Panama	O
clinics	O
,	O
we	O
tested	O
individuals	O
presenting	O
with	O
a	O
severe	O
febrile	B-PROC
prodrome	O
for	O
acute	O
hantavirus	O
(	O
HV	O
)	O
infection	O
by	O
immunoglobulin	B-PROC
M	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
as	O
well	O
as	O
clinically	O
similar	O
infections	O
,	O
such	O
as	O
dengue	O
and	O
leptospirosis	O
.	O

The	O
emergence	O
of	O
this	O
novel	O
coronavirus	O
prompts	O
the	O
need	O
for	O
a	O
small	O
animal	O
model	O
to	O
study	O
the	O
pathogenesis	B-PROC
of	O
this	O
virus	O
and	O
to	O
test	O
the	O
efficacy	O
of	O
potential	O
intervention	O
strategies	O
.	O

ABSTRACT	O
:	O
After	O
gastric	O
aspiration	O
events	O
,	O
patients	O
are	O
at	O
risk	O
of	O
pulmonary	O
dysfunction	O
and	O
the	O
development	B-PROC
of	O
severe	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
which	O
may	O
contribute	O
to	O
the	O
development	B-PROC
of	O
an	O
inflammatory	O
reaction	O
.	O

The	O
blood	B-PROC
flow	I-PROC
was	O
significantly	O
increased	O
to	O
these	O
regions	O
compared	O
with	O
the	O
blood	B-PROC
flow	I-PROC
to	O
uninjured	O
lungs	O
in	O
the	O
control	O
animals	O
(	O
middle	O
region	O
:	O
1	O
.	O
23	O
[	O
1	O
.	O
1	O
;	O
1	O
.	O
4	O
]	O
(	O
median	O
[	O
25	O
%;	O
75	O
%])	O
vs	O
.	O
1	O
.	O
04	O
[	O
1	O
.	O
0	O
;	O
1	O
.	O
1	O
]	O
and	O
basal	O
region	O
:	O
1	O
.	O
25	O
[	O
1	O
.	O
2	O
;	O
1	O
.	O
3	O
]	O
vs	O
.	O
1	O
.	O
02	O
[	O
1	O
.	O
0	O
;	O
1	O
.	O
05	O
],	O
respectively	O
).	O

HFOV	O
did	O
not	O
compromise	O
hemodynamics	B-PROC
,	O
and	O
a	O
reduction	O
in	O
heart	O
rate	O
was	O
observed	O
(	O
141	O
±	O
32	O
vs	O
.	O
119	O
±	O
22	O
beats	O
/	O
min	O
),	O
whereas	O
mean	O
arterial	B-PROC
pressure	I-PROC
(	O
66	O
±	O
20	O
vs	O
.	O
71	O
±	O
17	O
mmHg	O
)	O
and	O
inotropic	O
score	O
[	O
44	O
(	O
17	O
-	O
130	O
)	O
vs	O
.	O
20	O
(	O
16	O
-	O
75	O
)]	O
remained	O
stable	O
during	O
this	O
period	O
.	O

CONCLUSIONS	O
:	O
HFOV	O
improves	O
oxygenation	B-PROC
in	O
pediatric	O
patients	O
with	O
ARDS	O
and	O
severe	O
hypoxemia	O
refractory	O
to	O
conventional	O
ventilatory	O
support	O
.	O

ABSTRACT	O
:	O
Acute	O
generalized	O
exanthematous	O
pustulosis	O
(	O
AGEP	O
)	O
is	O
a	O
severe	O
cutaneous	O
adverse	O
reaction	O
characterized	O
by	O
rash	O
with	O
sterile	O
pustules	O
,	O
high	O
fever	B-PROC
and	O
elevated	O
circulating	O
neutrophil	O
counts	O
.	O

Information	O
remains	O
limited	O
about	O
the	O
comparative	O
protein	B-PROC
expression	B-PROC
of	O
host	O
cells	O
in	O
response	O
to	O
TGEV	O
infection	O
.	O

Through	O
modulations	O
of	O
rate	O
,	O
depth	O
,	O
and	O
patterning	O
of	O
breathing	B-PROC
,	O
the	O
ventilatory	O
control	O
system	O
maintains	O
numerous	O
critical	O
variables	O
within	O
their	O
homeostatic	B-PROC
ranges	O
.	O

A	O
dynamic	O
respiratory	O
control	O
system	O
is	O
critical	O
to	O
successful	O
adaptation	B-PROC
in	O
the	O
face	O
of	O
progressive	O
pulmonary	O
pathology	O
.	O

Over	O
time	O
,	O
adaptations	B-PROC
of	O
the	O
respiratory	O
control	O
system	O
to	O
this	O
disease	O
include	O
changes	O
in	O
the	O
intrinsic	O
properties	O
of	O
respiratory	O
muscles	O
,	O
chemoreceptor	O
signaling	B-PROC
,	O
and	O
central	O
respiratory	O
drive	O
which	O
increase	O
motor	O
output	O
to	O
the	O
respiratory	O
muscles	O
.	O

Fecal	O
shedding	O
of	O
this	O
type	O
II	O
virus	O
in	O
the	O
effusive	O
form	O
of	O
FIP	O
can	O
be	O
detected	O
up	O
to	O
six	O
days	O
before	O
death	B-PROC
.	O

If	O
the	O
basic	O
reproduction	B-PROC
number	O
is	O
below	O
unity	O
,	O
the	O
disease	O
-	O
free	O
equilibrium	B-PROC
is	O
locally	O
asymptotically	O
stable	O
.	O

There	O
exists	O
an	O
endemic	O
equilibrium	B-PROC
which	O
is	O
locally	O
asymptotically	O
stable	O
if	O
the	O
reproduction	B-PROC
number	O
is	O
larger	O
than	O
unity	O
.	O

Conventional	O
approaches	O
to	O
vaccine	O
development	B-PROC
,	O
production	O
,	O
clinical	O
testing	O
and	O
licensure	O
are	O
incompatible	O
with	O
the	O
prompt	O
deployment	O
needed	O
for	O
an	O
effective	O
public	O
health	O
response	O
.	O

We	O
previously	O
showed	O
that	O
murine	O
coronavirus	O
(	O
MHV	O
)	O
accessory	O
protein	O
ns2	O
,	O
a	O
2H	O
phosphoesterase	O
superfamily	O
member	O
,	O
is	O
a	O
phosphodiesterase	B-PROC
(	O
PDE	O
)	O
that	O
cleaves	O
2	O
-	O
5A	O
,	O
thereby	O
preventing	O
activation	O
of	O
RNase	O
L	O
.	O
The	O
PDE	O
activity	O
of	O
ns2	O
is	O
required	O
for	O
MHV	O
replication	O
in	O
macrophages	O
and	O
for	O
hepatitis	O
.	O

ABSTRACT	O
:	O
Total	O
internal	O
reflection	O
microscopy	O
combined	O
with	O
microfluidics	O
and	O
supported	O
bilayers	O
is	O
a	O
powerful	O
,	O
single	O
particle	O
tracking	O
(	O
SPT	O
)	O
platform	O
for	O
host	O
-	O
pathogen	O
membrane	B-PROC
fusion	I-PROC
studies	O
.	O

But	O
this	O
method	O
also	O
provides	O
quantitative	O
kinetic	O
rate	O
parameters	O
for	O
intermediate	O
steps	O
in	O
the	O
coronavirus	O
fusion	O
pathway	B-PROC
,	O
which	O
to	O
our	O
knowledge	O
have	O
not	O
been	O
obtained	O
before	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
HKU1	O
infection	O
of	O
primary	O
human	O
type	O
II	O
alveolar	O
epithelial	O
cells	O
:	O
cytopathic	O
effects	O
and	O
innate	B-PROC
immune	I-PROC
response	I-PROC
.	O

The	O
primary	O
outcome	O
was	O
the	O
development	B-PROC
of	O
ARDS	O
requiring	O
mechanical	O
ventilation	O
during	O
the	O
first	O
5	O
hospital	O
days	O
.	O

The	O
CD69	O
expression	B-PROC
in	O
NK	O
cells	O
in	O
the	O
liver	O
,	O
spleen	O
,	O
bone	O
marrow	O
and	O
peripheral	O
blood	O
was	O
detected	O
by	O
using	O
flow	O
cytometry	O
.	O

These	O
results	O
suggested	O
that	O
hepatic	O
CD69	O
+	O
NK	O
cells	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
FHF	O
by	O
enhancing	O
degranulation	O
and	O
cytotoxic	O
ability	O
of	O
NK	O
cells	O
and	O
increasing	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

Furthermore	O
,	O
viral	O
production	O
decreased	O
when	O
the	O
ORF4a	O
protein	B-PROC
expression	B-PROC
was	O
suppressed	O
by	O
siRNA	O
in	O
infected	O
cells	O
.	O

TITLE	O
:	O
The	O
replication	O
of	O
a	O
mouse	O
adapted	O
SARS	O
-	O
CoV	O
in	O
a	O
mouse	O
cell	O
line	O
stably	O
expressing	O
the	O
murine	O
SARS	O
-	O
CoV	O
receptor	O
mACE2	O
efficiently	O
induces	O
the	O
expression	B-PROC
of	O
proinflammatory	O
cytokines	O
.	O

Two	O
of	O
his	O
brothers	O
presented	O
later	O
to	O
another	O
hospital	O
with	O
respiratory	O
symptoms	O
and	O
fever	B-PROC
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
on	O
recruitment	O
,	O
cyclic	O
recruitment	O
and	O
derecruitment	O
and	O
strain	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
using	O
lung	O
computed	O
tomography	O
.	O

RESULTS	O
:	O
Increasing	O
levels	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
were	O
correlated	O
with	O
increased	O
recruitment	O
and	O
global	O
strain	O
(	O
p	O
<	O
0	O
.	O
01	O
),	O
which	O
was	O
significantly	O
correlated	O
with	O
plateau	O
pressure	O
(	O
r²	O
=	O
0	O
.	O
97	O
,	O
p	O
<	O
0	O
.	O
01	O
).	O

The	O
patient	O
was	O
weaned	B-PROC
successfully	O
from	O
vv	O
-	O
ECMO	O
after	O
5	O
additional	O
days	O
and	O
transferred	O
back	O
to	O
the	O
referring	O
hospital	O
for	O
weaning	B-PROC
from	O
the	O
ventilator	O
.	O

ABSTRACT	O
:	O
Two	O
deaths	B-PROC
involving	O
3	O
,	O
4	O
-	O
methylenedioxypyrovalerone	O
(	O
MDPV	O
)	O
are	O
reported	O
.	O

ABSTRACT	O
:	O
Systems	O
biology	O
offers	O
considerable	O
promise	O
in	O
uncovering	O
novel	O
pathways	B-PROC
by	O
which	O
viruses	O
and	O
other	O
microbial	O
pathogens	O
interact	O
with	O
host	O
signaling	B-PROC
and	O
expression	B-PROC
networks	O
to	O
mediate	O
disease	O
severity	O
.	O

Similar	O
transcriptional	B-PROC
signatures	O
were	O
noted	O
in	O
1918	O
and	O
2009	O
H1N1	O
influenza	O
virus	O
-	O
infected	O
mice	O
,	O
suggesting	O
a	O
common	O
,	O
potentially	O
treatable	O
mechanism	O
in	O
development	B-PROC
of	O
virus	O
-	O
induced	O
ALI	O
.	O

TITLE	O
:	O
Regulation	B-PROC
of	O
coronaviral	O
poly	O
(	O
A	O
)	O
tail	O
length	O
during	O
infection	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
increasingly	O
applied	O
in	O
adults	O
with	O
acute	O
refractory	O
respiratory	O
failure	O
that	O
is	O
deemed	O
reversible	O
.	O

The	O
patient	O
was	O
successfully	O
weaned	B-PROC
from	O
ECMO	O
,	O
extubated	O
,	O
and	O
discharged	O
home	O
.	O

TITLE	O
:	O
A	O
(	O
H1N1	O
)	O
pdm09	O
hemagglutinin	O
D222G	O
and	O
D222N	O
variants	O
are	O
frequently	O
harbored	O
by	O
patients	O
requiring	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
and	O
advanced	O
respiratory	O
assistance	O
for	O
severe	O
A	O
(	O
H1N1	O
)	O
pdm09	O
infection	O
.	O

These	O
data	O
emphasize	O
the	O
importance	O
of	O
monitoring	O
viral	O
evolution	B-PROC
for	O
understanding	O
virus	O
-	O
host	O
adaptation	B-PROC
aimed	O
at	O
the	O
surveillance	O
of	O
strain	O
circulation	B-PROC
and	O
the	O
study	O
of	O
viral	O
correlates	O
of	O
disease	O
severity	O
.	O

This	O
TCR	B-PROC
-	O
β	O
chain	O
was	O
introduced	O
into	O
bone	O
marrow	O
cells	O
with	O
a	O
lentivirus	O
vector	O
,	O
generating	O
TCR	B-PROC
-	O
β	O
retrogenic	O
mice	O
.	O

After	O
demonstrating	O
that	O
these	O
cells	O
were	O
functional	O
and	O
responded	O
to	O
epitope	O
M133	O
,	O
these	O
TCR	B-PROC
chains	O
were	O
used	O
to	O
generate	O
an	O
epitope	O
M133	O
-	O
specific	O
TCR	B-PROC
Tg	O
mouse	O
.	O

This	O
method	O
should	O
be	O
generally	O
useful	O
for	O
engineering	O
TCR	B-PROC
Tg	O
mice	O
without	O
introduction	O
of	O
bias	O
caused	O
by	O
in	O
vitro	O
manipulation	O
and	O
propagation	O
.	O

ABSTRACT	O
:	O
Acute	O
viral	O
pneumonia	O
is	O
an	O
important	O
cause	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
although	O
not	O
enough	O
is	O
known	O
about	O
the	O
exact	O
incidence	O
of	O
viral	B-PROC
infection	I-PROC
in	O
ALI	O
.	O

TITLE	O
:	O
Manipulation	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
genome	O
using	O
targeted	B-PROC
RNA	O
recombination	B-PROC
.	O

His	O
renal	B-PROC
function	I-PROC
was	O
restored	O
after	O
appropriate	O
therapy	O
for	O
rhabdomyolysis	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoV	O
),	O
like	O
other	O
positive	O
-	O
stranded	O
RNA	O
viruses	O
,	O
redirect	O
and	O
rearrange	O
host	O
cell	O
membranes	O
for	O
use	O
as	O
part	O
of	O
the	O
viral	B-PROC
genome	I-PROC
replication	I-PROC
and	O
transcription	B-PROC
machinery	O
.	O

Specifically	O
,	O
coronaviruses	O
induce	O
the	O
formation	B-PROC
of	O
double	O
-	O
membrane	O
vesicles	O
in	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
case	O
of	O
a	O
42	O
-	O
year	O
-	O
old	O
man	O
admitted	O
for	O
a	O
multi	O
-	O
organ	O
failure	O
with	O
a	O
coma	O
,	O
a	O
hemodynamic	B-PROC
instability	O
,	O
a	O
respiratory	O
distress	O
syndrome	O
,	O
an	O
acute	O
renal	O
failure	O
and	O
a	O
thrombocytopenia	O
.	O

Retrospective	O
study	O
of	O
hospitalized	O
patients	O
of	O
acute	O
febrile	B-PROC
illness	O
who	O
were	O
diagnosed	O
scrub	O
typhus	O
and	O
had	O
AKI	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
for	O
acute	O
respiratory	O
failure	O
is	O
still	O
a	O
matter	O
of	O
debate	O
.	O

CONCLUSIONS	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
benefit	O
on	O
hospital	O
mortality	O
is	O
unclear	O
.	O

In	O
addition	O
,	O
the	O
mRNA	O
levels	O
of	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
1β	O
,	O
and	O
lipopolysaccharide	O
-	O
induced	O
tumor	O
necrosis	B-PROC
factor	O
-	O
α	O
factor	O
and	O
the	O
serum	O
levels	O
of	O
α1	O
-	O
acid	O
glycoprotein	O
,	O
which	O
is	O
a	O
major	O
acute	O
phase	O
protein	O
,	O
were	O
measured	O
.	O

In	O
chickens	O
infected	O
with	O
this	O
isolate	O
,	O
simultaneous	O
peaks	O
in	O
the	O
viral	O
copy	O
number	O
and	O
cytokine	B-PROC
production	I-PROC
were	O
observed	O
at	O
7	O
dpi	O
in	O
the	O
trachea	O
and	O
9	O
d	O
postinoculation	O
in	O
the	O
kidney	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
chickens	O
infected	O
with	O
the	O
ChVI	O
genotype	O
(	O
Kr	O
/	O
ADL120003	O
/	O
2012	O
)	O
did	O
not	O
show	O
a	O
response	O
other	O
than	O
a	O
mild	O
upregulation	B-PROC
of	O
cytokines	O
at	O
1	O
d	O
postinoculation	O
,	O
which	O
appears	O
to	O
indicate	O
the	O
invasion	O
of	O
the	O
virus	O
.	O

In	O
this	O
study	O
,	O
long	O
-	O
term	O
feline	O
intestinal	O
epithelial	O
cell	O
cultures	O
were	O
established	O
from	O
primary	O
ileocytes	O
and	O
colonocytes	O
by	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
T	O
-	O
antigen	O
-	O
and	O
human	O
Telomerase	O
Reverse	O
Transcriptase	B-PROC
(	O
hTERT	O
)-	O
induced	O
immortalization	O
.	O

TGEV	O
RNA	O
sequences	O
identified	O
as	O
necessary	O
for	O
viral	B-PROC
genome	I-PROC
packaging	I-PROC
were	O
not	O
sufficient	O
to	O
direct	O
packaging	O
of	O
a	O
heterologous	O
sequence	O
derived	O
from	O
the	O
green	O
fluorescent	O
protein	O
gene	O
.	O

Ninety	O
percent	O
of	O
these	O
mutations	O
represented	O
A	O
:	O
G	O
and	O
U	O
:	O
C	O
transitions	O
,	O
consistent	O
with	O
5	O
-	O
FU	O
incorporation	O
during	O
RNA	B-PROC
synthesis	I-PROC
.	O

The	O
enzyme	O
arginase	O
,	O
the	O
activity	O
of	O
which	O
can	O
be	O
regulated	O
by	O
the	O
redox	B-PROC
status	O
of	O
the	O
cell	O
,	O
exists	O
in	O
two	O
isoforms	O
-	O
arginase	O
1	O
(	O
cytosolic	O
)	O
and	O
arginase	O
2	O
(	O
mitochondrial	O
)	O
-	O
both	O
of	O
which	O
can	O
be	O
expressed	B-PROC
in	O
lung	O
microvascular	O
endothelial	O
cells	O
.	O

Bigger	O
isolation	O
rooms	O
with	O
16	O
ACH	O
are	O
more	O
effective	O
than	O
smaller	O
isolation	O
rooms	O
with	O
12	O
ACH	O
in	O
removing	O
exhaled	B-PROC
air	O
and	O
preventing	O
room	O
contamination	O
but	O
at	O
the	O
expense	O
of	O
more	O
noise	O
and	O
electricity	O
consumption	O
.	O

This	O
review	O
will	O
discuss	O
key	O
advances	O
in	O
the	O
development	B-PROC
of	O
RBD	O
-	O
based	O
SARS	O
vaccines	O
and	O
the	O
possibility	O
of	O
using	O
a	O
similar	O
strategy	O
to	O
develop	O
vaccines	O
against	O
MERS	O
-	O
CoV	O
.	O

Microglial	O
activation	O
and	O
phagocytosis	B-PROC
are	O
recognized	O
to	O
be	O
critically	O
important	O
in	O
the	O
pathogenesis	B-PROC
of	O
demyelination	O
.	O

RESULTS	O
:	O
Median	O
duration	O
of	O
MCS	O
was	O
4	O
days	O
(	O
0	O
-	O
18	O
days	O
),	O
12	O
patients	O
(	O
75	O
%)	O
were	O
weaned	B-PROC
successfully	O
from	O
MCS	O
,	O
4	O
of	O
these	O
children	O
(	O
25	O
%)	O
died	B-PROC
after	O
weaning	B-PROC
,	O
with	O
a	O
median	O
survival	O
time	O
of	O
15	O
days	O
(	O
6	O
-	O
28	O
days	O
).	O

Among	O
the	O
5	O
pregnant	O
patients	O
,	O
the	O
course	O
of	O
measles	O
infection	O
was	O
uneventful	O
,	O
albeit	O
1	O
patient	O
underwent	O
emergent	O
cesarean	O
delivery	O
because	O
of	O
fetal	B-PROC
growth	B-PROC
restriction	O
.	O

TITLE	O
:	O
Combination	O
of	O
positioning	O
therapy	O
and	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
ARDS	O
patients	O
.	O

Vaccinated	O
mice	O
produced	O
high	O
levels	O
of	O
serum	O
antibodies	O
neutralizing	O
MERS	O
-	O
CoV	O
.	O
Thus	O
,	O
MVA	O
-	O
MERS	O
-	O
S	O
may	O
serve	O
for	O
further	O
development	B-PROC
of	O
an	O
emergency	O
vaccine	O
against	O
MERS	O
-	O
CoV	O
.	O

These	O
data	O
demonstrate	O
a	O
critical	O
role	O
of	O
IL	O
-	O
21	O
in	O
regulating	O
CNS	O
immunity	B-PROC
,	O
sustaining	O
viral	O
persistence	O
and	O
preventing	O
mortality	O
.	O

Responding	O
to	O
the	O
epidemic	O
provided	O
clinicians	O
with	O
extensive	O
experience	O
in	O
diagnosing	O
and	O
treating	O
a	O
novel	O
respiratory	O
viral	B-PROC
disease	I-PROC
.	O

Common	O
presenting	O
symptoms	O
included	O
fever	B-PROC
(	O
97	O
.	O
9	O
%)	O
and	O
cough	O
and	O
rhinitis	O
(	O
74	O
%).	O

The	O
clinical	O
picture	O
mimicked	O
bacterial	O
infection	O
for	O
its	O
prolonged	O
high	O
fever	B-PROC
and	O
neutrophilic	B-PROC
blood	O
picture	O
.	O

is	O
of	O
global	O
concern	O
:	O
the	O
virus	O
has	O
caused	O
severe	O
respiratory	O
illness	O
,	O
with	O
111	O
confirmed	O
cases	O
and	O
52	O
deaths	B-PROC
at	O
the	O
time	O
of	O
this	O
article	O
'	O
s	O
publication	O
.	O

TITLE	O
:	O
The	O
antiviral	O
activity	O
of	O
poly	O
-	O
γ	O
-	O
glutamic	O
acid	O
,	O
a	O
polypeptide	O
secreted	B-PROC
by	O
Bacillus	O
sp	O
.,	O
through	O
induction	O
of	O
CD14	O
-	O
dependent	O
type	O
I	O
interferon	O
responses	O
.	O

The	O
induction	O
required	O
both	O
myeloid	O
differentiation	B-PROC
factor	O
2	O
(	O
MD2	O
)	O
and	O
the	O
pattern	O
-	O
recognition	O
receptor	O
CD14	O
,	O
which	O
are	O
two	O
TLR4	O
-	O
associated	O
accessory	O
proteins	O
.	O

We	O
previously	O
showed	O
that	O
MERS	O
-	O
CoV	O
counteracts	O
parts	O
of	O
the	O
innate	B-PROC
immune	I-PROC
response	I-PROC
in	O
human	O
bronchiolar	O
cells	O
.	O

The	O
serine	O
protease	O
inhibitor	O
camostat	O
,	O
which	O
inhibits	O
TMPRSS2	O
activity	O
,	O
completely	O
blocked	O
syncytium	B-PROC
formation	I-PROC
but	O
only	O
partially	O
blocked	O
virus	O
entry	O
into	O
Vero	O
-	O
TMPRSS2	O
cells	O
.	O

ABSTRACT	O
:	O
In	O
lung	O
transplant	O
recipients	O
(	O
LTRs	O
),	O
severe	O
clinical	O
complications	O
,	O
such	O
as	O
microbial	O
infections	O
of	O
the	O
lung	O
or	O
transplant	B-PROC
rejection	I-PROC
,	O
may	O
occur	O
.	O

PMN	B-PROC
hypotonic	O
challenge	O
resulted	O
in	O
a	O
transient	O
increase	O
of	O
the	O
relative	O
cell	O
volume	O
,	O
which	O
returned	O
to	O
baseline	O
after	O
600	O
seconds	O
,	O
while	O
incubation	O
in	O
the	O
presence	O
of	O
LPS	O
resulted	O
in	O
persistently	O
increased	O
cell	O
volume	O
.	O

Aquaporin	B-PROC
-	O
1	O
is	O
induced	O
in	O
leukocytes	O
of	O
patients	O
with	O
ICU	O
-	O
acquired	O
sepsis	O
and	O
exhibits	O
higher	O
expression	B-PROC
in	O
septic	O
shock	O
.	O

It	O
was	O
concluded	O
that	O
this	O
assay	O
can	O
be	O
used	O
as	O
a	O
rapid	O
tool	O
for	O
BCoV	O
genotypes	O
differentiation	B-PROC
.	O

The	O
preoperative	O
evaluation	O
showed	O
a	O
severe	O
alteration	O
of	O
diffusion	O
(	O
pO2	B-PROC
68	O
mm	O
Hg	O
),	O
without	O
hepatopulmonary	O
syndrome	O
or	O
portopulmonary	O
hypertension	O
(	O
PPH	O
)	O
upon	O
basal	O
and	O
dobutamine	O
stress	O
echocardiography	O
.	O

At	O
the	O
beginning	O
of	O
the	O
OLT	O
the	O
hemodynamic	B-PROC
profile	O
showed	O
mean	O
pulmonary	O
artery	O
pressure	O
(	O
mPAP	O
)	O
38	O
mm	O
Hg	O
,	O
wedge	O
pressure	O
(	O
WP	O
)	O
19	O
mm	O
Hg	O
,	O
cardiac	O
output	O
(	O
CO	O
)	O
9	O
.	O
1	O
L	O
/	O
min	O
,	O
pulmonary	B-PROC
vascular	I-PROC
resistance	I-PROC
(	O
PVR	O
)	O
166	O
dyne	O
s	O
/	O
cm	O
(	O
5	O
),	O
transpulmonary	O
gradient	O
(	O
TPG	O
)	O
19	O
mm	O
Hg	O
,	O
which	O
lead	O
us	O
to	O
promptly	O
initiate	O
inhaled	B-PROC
nitric	O
oxide	O
(	O
iNO	O
)	O
and	O
intravenous	O
epoprostenol	O
2	O
to	O
5	O
ng	O
/	O
kg	O
/	O
min	O
.	O

Realizing	O
a	O
sustainable	O
,	O
global	O
impact	O
on	O
death	B-PROC
and	O
suffering	O
due	O
to	O
severe	O
influenza	O
and	O
other	O
severe	O
illness	O
necessitates	O
an	O
ongoing	O
and	O
concerted	O
international	O
effort	B-PROC
to	O
iteratively	O
generate	O
,	O
implement	O
,	O
and	O
evaluate	O
best	O
-	O
practice	O
management	O
guidelines	O
for	O
use	O
in	O
resource	O
-	O
limited	O
settings	O
.	O

ABSTRACT	O
:	O
Endothelial	O
cell	O
(	O
EC	O
)	O
inflammation	O
is	O
a	O
central	O
event	O
in	O
the	O
pathogenesis	B-PROC
of	O
many	O
pulmonary	O
diseases	O
such	O
as	O
acute	O
lung	O
injury	O
and	O
its	O
more	O
severe	O
form	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Similar	O
symptoms	O
hinder	O
the	O
differentiation	B-PROC
of	O
infection	O
with	O
the	O
two	O
viruses	O
by	O
standard	O
veterinary	O
procedures	O
like	O
clinical	O
examination	O
or	O
necropsy	O
.	O

Both	O
S	O
-	O
IgG	O
and	O
S	O
-	O
IgM	O
antibodies	O
were	O
detectable	O
among	O
children	O
and	O
increased	O
with	O
age	O
,	O
reaching	B-PROC
a	O
plateau	O
at	O
6	O
years	O
of	O
age	O
.	O

In	O
addition	O
,	O
TRT	O
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
bone	O
mineral	O
density	O
in	O
men	O
with	O
osteoporosis	O
,	O
with	O
an	O
improvement	O
in	O
lean	O
body	O
mass	O
in	O
subjects	O
with	O
human	O
immunodeficiency	O
virus	B-PROC
infection	I-PROC
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
as	O
well	O
as	O
with	O
peripheral	O
oxygenation	B-PROC
in	O
patients	O
with	O
chronic	O
kidney	O
diseases	O
.	O

The	O
following	O
characteristics	O
(	O
or	O
predictors	O
)	O
were	O
compared	O
between	O
the	O
groups	O
:	O
age	O
,	O
sex	O
,	O
calculated	O
amount	O
of	O
glufosinate	O
(	O
volume	O
of	O
ingested	O
poison	O
(	O
glufosinate	O
-	O
containing	O
herbicide	O
)	O
×	O
glufosinate	O
concentration	O
of	O
the	O
product	O
),	O
time	O
duration	O
from	O
poison	O
ingestion	O
to	O
arrival	O
at	O
our	O
hospital	O
,	O
use	O
of	O
gastric	O
lavage	O
,	O
use	O
of	O
whole	O
bowel	O
irrigation	B-PROC
,	O
Glasgow	O
Coma	O
Scale	O
,	O
laboratory	O
parameters	O
,	O
PaO₂	O
/	O
FiO₂	O
ratio	O
(	O
P	O
/	O
F	O
ratio	O
),	O
shock	O
index	O
,	O
and	O
presence	O
or	O
absence	O
of	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
SIRS	O
)	O
on	O
arrival	O
.	O

TITLE	O
:	O
3C	O
protein	O
of	O
feline	O
coronavirus	O
inhibits	O
viral	B-PROC
replication	I-PROC
independently	O
of	O
the	O
autophagy	B-PROC
pathway	B-PROC
.	O

We	O
experimentally	O
demonstrate	O
that	O
the	O
predictive	O
power	O
of	O
algorithms	O
defining	O
peptide	O
-	O
MHC	B-PROC
interaction	I-PROC
directly	O
correlates	O
with	O
the	O
amount	O
of	O
training	O
data	O
on	O
which	O
the	O
predictive	O
algorithm	O
has	O
been	O
constructed	O
.	O

The	O
hepatocyte	O
-	O
specific	O
IL	O
-	O
33	O
expression	B-PROC
was	O
down	O
-	O
regulated	O
in	O
NK	O
-	O
depleted	O
poly	O
(	O
I	O
:	O
C	O
)	O
treated	O
mice	O
suggesting	O
a	O
partial	O
regulation	B-PROC
of	O
IL	O
-	O
33	O
by	O
NK	O
cells	O
.	O

We	O
found	O
evidence	O
that	O
a	O
Th1	O
-	O
biased	O
cytokine	O
/	O
chemokine	O
response	O
and	O
eicosanoid	O
-	O
derived	O
inflammation	O
accompany	O
persistent	O
MHV	O
infection	O
and	O
that	O
antigen	B-PROC
presentation	I-PROC
is	O
ongoing	O
.	O

TITLE	O
:	O
Active	O
replication	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
and	O
aberrant	O
induction	O
of	O
inflammatory	O
cytokines	O
and	O
chemokines	O
in	O
human	O
macrophages	O
:	O
implications	O
for	O
pathogenesis	B-PROC
.	O

Notably	O
,	O
MERS	O
-	O
CoV	O
induced	O
significantly	O
higher	O
expression	B-PROC
levels	O
of	O
interleukin	O
12	O
,	O
IFN	O
-	O
γ	O
,	O
and	O
chemokines	O
(	O
IP	O
-	O
10	O
/	O
CXCL	O
-	O
10	O
,	O
MCP	O
-	O
1	O
/	O
CCL	O
-	O
2	O
,	O
MIP	O
-	O
1α	O
/	O
CCL	O
-	O
3	O
,	O
RANTES	O
/	O
CCL	O
-	O
5	O
,	O
and	O
interleukin	O
8	O
)	O
than	O
SARS	O
-	O
CoV	O
.	O
The	O
expression	B-PROC
of	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
class	O
I	O
and	O
costimulatory	O
molecules	O
were	O
significantly	O
higher	O
in	O
MERS	O
-	O
CoV	O
-	O
infected	O
MDMs	O
than	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
Two	O
studies	O
were	O
conducted	O
to	O
determine	O
the	O
role	O
of	O
enteric	O
viruses	O
in	O
Light	O
Turkey	O
Syndrome	O
(	O
LTS	O
),	O
which	O
is	O
characterized	O
by	O
lower	O
weight	O
in	O
market	O
age	O
turkeys	O
than	O
their	O
standard	O
breed	B-PROC
character	O
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
by	O
anti	O
-	O
CD26	O
monoclonal	O
antibody	B-PROC
.	O

It	O
is	O
known	O
that	O
the	O
surface	O
spike	O
(	O
S	O
)	O
proteins	O
of	O
coronaviruses	O
mediate	O
receptor	O
recognition	O
and	O
membrane	B-PROC
fusion	I-PROC
,	O
thereby	O
playing	O
an	O
indispensable	O
role	O
in	O
initiating	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
earliest	O
definition	O
of	O
transfusion	O
-	O
related	O
acute	O
lung	O
injury	O
(	O
TRALI	O
)	O
included	O
all	O
patients	O
who	O
developed	O
acute	O
respiratory	O
distress	O
,	O
moderate	O
to	O
severe	O
hypoxemia	O
,	O
rapid	O
onset	O
of	O
pulmonary	O
edema	O
,	O
mild	O
to	O
moderate	O
hypotension	O
,	O
and	O
fever	B-PROC
within	O
6	O
hours	O
of	O
receiving	O
a	O
plasma	O
containing	O
blood	O
transfusion	O
.	O

ABSTRACT	O
:	O
Diarrhea	O
is	O
the	O
leading	O
cause	O
of	O
death	B-PROC
in	O
neonatal	O
calves	O
and	O
contributes	O
to	O
major	O
economic	O
losses	O
.	O

Initially	O
,	O
severe	O
bronchiolar	O
epithelial	O
necrosis	B-PROC
and	O
acute	O
respiratory	O
distress	O
was	O
observed	O
,	O
followed	O
by	O
marked	O
bronchiolar	O
epithelial	O
hyperplasia	O
.	O

All	O
patients	O
met	O
the	O
inclusion	O
criteria	O
of	O
hemodynamic	B-PROC
instability	O
with	O
high	O
catecholamine	O
infusion	O
requirement	O
and	O
100	O
%	O
oxygen	O
demand	O
in	O
ventilation	O
and	O
ECMO	O
flow	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
codon	O
evolution	B-PROC
in	O
virus	O
-	O
host	O
systems	O
,	O
Avian	O
coronavirus	O
and	O
its	O
natural	O
host	O
Gallus	O
gallus	O
were	O
used	O
as	O
a	O
model	O
.	O

The	O
codon	O
adaptation	B-PROC
index	O
(	O
CAI	O
)	O
showed	O
a	O
lower	O
adaptation	B-PROC
of	O
S	O
to	O
G	O
.	O
gallus	O
compared	O
to	O
NSP2	O
,	O
PL	O
(	O
pro	O
)	O
and	O
N	O
.	O
The	O
effective	O
number	O
of	O
codons	O
(	O
Nc	O
)	O
and	O
GC3	O
%	O
revealed	O
that	O
natural	O
selection	O
and	O
genetic	B-PROC
drift	I-PROC
are	O
the	O
evolutionary	O
forces	O
driving	O
the	O
codon	O
usage	O
evolution	B-PROC
of	O
both	O
A	O
.	O
coronavirus	O
and	O
G	O
.	O
gallus	O
regardless	O
of	O
the	O
gene	O
being	O
considered	O
.	O

TGEV	O
infection	O
promoted	O
p21	O
accumulation	O
,	O
down	O
-	O
regulated	O
cell	B-PROC
cycle	I-PROC
-	O
regulatory	O
proteins	O
cyclins	O
B1	O
,	O
cdc2	O
,	O
cdk2	O
and	O
PCNA	O
.	O

Chronic	O
bronchitis	O
,	O
pulmonary	O
emphysema	O
,	O
and	O
bronchial	O
asthma	O
may	O
all	O
be	O
associated	O
with	O
airflow	B-PROC
limitation	O
;	O
therefore	O
,	O
exacerbation	O
of	O
asthma	O
may	O
be	O
associated	O
with	O
the	O
pathophysiology	O
of	O
COPD	O
.	O

A	O
secondary	O
aim	O
was	O
reaching	B-PROC
a	O
consensus	O
on	O
clinical	O
tools	O
(	O
risk	O
factors	O
list	O
and	O
illustrative	O
radiographs	O
)	O
to	O
help	O
the	O
application	O
of	O
BD	O
.	O

TITLE	O
:	O
Generation	O
of	O
a	O
monoclonal	O
antibody	B-PROC
to	O
S1	O
protein	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

In	O
the	O
Cox	O
proportional	O
hazard	O
regression	O
analysis	O
ARDS	O
stage	O
was	O
not	O
significantly	O
associated	O
with	O
patient	O
death	B-PROC
at	O
day	O
28	O
.	O

Here	O
,	O
we	O
will	O
review	O
the	O
proteolytic	B-PROC
systems	O
hijacked	O
by	O
SARS	O
-	O
CoV	O
for	O
S	O
protein	B-PROC
activation	I-PROC
,	O
we	O
will	O
discuss	O
their	O
contribution	O
to	O
viral	O
spread	O
in	O
the	O
host	O
and	O
we	O
will	O
outline	O
antiviral	O
strategies	O
targeting	B-PROC
these	O
enzymes	O
.	O

Only	O
little	O
information	O
on	O
the	O
influence	O
of	O
sample	O
storage	B-PROC
and	O
reaction	O
conditions	O
on	O
test	O
results	O
is	O
available	O
,	O
and	O
diagnostic	O
sensitivity	O
and	O
specificity	O
to	O
diagnose	O
FIP	O
vary	O
considerably	O
between	O
few	O
available	O
studies	O
.	O

RESULTS	O
:	O
Even	O
after	O
storage	B-PROC
for	O
21	O
days	O
,	O
test	O
results	O
were	O
comparable	O
.	O

ECMO	O
support	O
allowed	O
adequate	O
oxygenation	B-PROC
and	O
correction	O
of	O
hypercapnia	O
under	O
lung	O
protective	O
ventilation	O
,	O
therefore	O
reducing	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

In	O
light	O
of	O
recent	O
functional	O
,	O
biochemical	O
and	O
structural	O
findings	O
,	O
we	O
review	O
the	O
inhibition	B-PROC
mechanisms	O
of	O
RLRs	O
recognition	O
of	O
dsRNA	O
displayed	O
by	O
a	O
number	O
of	O
highly	O
pathogenic	O
RNA	O
viruses	O
with	O
different	O
disease	O
phenotypes	O
such	O
as	O
haemorrhagic	O
fever	B-PROC
(	O
Ebola	O
,	O
Marburg	O
,	O
Lassa	O
fever	B-PROC
,	O
Lujo	O
,	O
Machupo	O
,	O
Junin	O
,	O
Guanarito	O
,	O
Crimean	O
-	O
Congo	O
,	O
Rift	O
Valley	O
fever	B-PROC
,	O
dengue	O
),	O
severe	O
respiratory	O
disease	O
(	O
influenza	O
,	O
SARS	O
,	O
Hendra	O
,	O
Hantaan	O
,	O
Sin	B-PROC
Nombre	O
,	O
Andes	O
)	O
and	O
encephalitis	O
(	O
Nipah	O
,	O
West	O
Nile	O
).	O

TITLE	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
does	O
not	O
reduce	O
mortality	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
regardless	O
of	O
severity	O
:	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

These	O
data	O
may	O
help	O
explain	O
why	O
some	O
sudden	O
infant	O
death	B-PROC
syndrome	O
cases	O
die	O
from	O
what	O
appears	O
to	O
be	O
cardiovascular	O
collapse	O
during	O
apparent	O
severe	O
hypoxia	O
.	O

Among	O
trauma	O
and	O
surgical	O
patients	O
,	O
large	O
volume	O
crystalloid	O
resuscitation	O
and	O
markers	O
of	O
shock	O
/	O
hypotension	O
and	O
metabolic	B-PROC
derangement	O
/	O
organ	O
failure	O
were	O
risk	O
factors	O
for	O
IAH	O
and	O
ACS	O
while	O
increased	O
disease	O
severity	O
scores	O
and	O
elevated	O
creatinine	O
were	O
risk	O
factors	O
for	O
ACS	O
in	O
severe	O
acute	O
pancreatitis	O
patients	O
.	O

The	O
specimens	O
were	O
subjected	O
to	O
a	O
previously	O
described	O
multiplex	O
reverse	B-PROC
transcription	B-PROC
PCR	O
assay	O
to	O
detect	O
the	O
following	O
microorganisms	O
:	O
enterovirus	O
,	O
influenza	O
virus	O
types	O
A	O
and	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenzavirus	O
types	O
1	O
-	O
4	O
,	O
adenovirus	O
,	O
Mycoplasma	O
pneumoniae	O
,	O
Chlamydophila	O
pneumoniae	O
,	O
rhinovirus	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
coronavirus	O
OC43	O
and	O
229E	O
,	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
,	O
Bordetella	O
pertussis	O
,	O
Bordetella	O
parapertussis	O
,	O
and	O
Legionella	O
pneumophila	O
.	O

As	O
MMPs	O
(	O
matrix	O
metalloproteinases	O
)	O
facilitate	O
migration	B-PROC
across	O
the	O
glia	O
limitans	O
,	O
specific	O
expression	B-PROC
of	O
the	O
TIMP	O
(	O
tissue	O
inhibitor	O
of	O
MMPs	O
)-	O
1	O
by	O
CD4	O
⁺	O
T	O
cells	O
present	O
in	O
the	O
perivascular	O
cuffs	O
suggested	O
that	O
TIMP	O
-	O
1	O
is	O
responsible	O
for	O
stalling	O
CD4	O
⁺	O
T	B-PROC
cell	I-PROC
migration	B-PROC
into	O
the	O
CNS	O
parenchyma	O
.	O

Coryza	O
,	O
cough	O
and	O
fever	B-PROC
were	O
the	O
most	O
common	O
symptoms	O
at	O
presentation	O
of	O
positive	O
cases	O
and	O
wheezing	O
,	O
a	O
lower	O
respiratory	O
tract	O
infection	O
symptom	O
was	O
reported	O
by	O
12	O
%	O
of	O
the	O
total	O
,	O
and	O
27	O
%	O
of	O
high	O
at	O
-	O
risk	O
patients	O
.	O

Patients	O
with	O
necrotic	B-PROC
collections	O
have	O
a	O
poor	O
prognosis	O
,	O
especially	O
if	O
associated	O
with	O
infection	O
.	O

Our	O
patient	O
'	O
s	O
respiratory	O
failure	O
was	O
refractory	O
to	O
multiple	O
therapies	O
that	O
have	O
shown	O
benefit	O
in	O
pediatric	O
hypoxemic	O
respiratory	O
failure	O
,	O
including	O
open	O
lung	O
strategies	O
,	O
prone	O
positioning	O
,	O
intratracheal	O
surfactant	O
,	O
and	O
inhaled	B-PROC
nitric	O
oxide	O
.	O

RESULTS	O
:	O
IBV	O
infection	O
contributed	O
to	O
differential	O
expression	B-PROC
of	O
1777	O
genes	O
,	O
of	O
which	O
876	O
were	O
up	O
-	O
regulated	O
and	O
901	O
down	O
-	O
regulated	O
in	O
the	O
kidney	O
compared	O
to	O
those	O
of	O
control	O
chickens	O
and	O
103	O
associated	O
with	O
immune	O
and	O
inflammatory	B-PROC
responses	I-PROC
may	O
play	O
important	O
roles	O
in	O
the	O
host	B-PROC
defense	B-PROC
response	I-PROC
during	O
IBV	O
infection	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
are	O
candidates	O
for	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
therapy	O
.	O

Preliminary	O
in	O
vitro	O
testing	O
indicates	O
that	O
WIV1	O
also	O
has	O
a	O
broad	O
species	O
tropism	B-PROC
.	O

They	O
also	O
highlight	O
the	O
importance	O
of	O
pathogen	O
-	O
discovery	O
programs	O
targeting	B-PROC
high	O
-	O
risk	O
wildlife	O
groups	O
in	O
emerging	O
disease	O
hotspots	O
as	O
a	O
strategy	O
for	O
pandemic	O
preparedness	O
.	O

Both	O
,	O
viral	O
and	O
cellular	O
factors	O
cooperatively	O
generate	O
distinct	O
organelle	O
-	O
like	O
structures	O
,	O
designated	O
viral	B-PROC
replication	I-PROC
factories	O
.	O

Electron	O
tomography	O
studies	O
conducted	O
during	O
the	O
last	O
couple	O
of	O
years	O
revealed	O
the	O
three	O
dimensional	O
structure	O
of	O
numerous	O
plus	O
-	O
strand	O
RNA	O
virus	B-PROC
replication	I-PROC
compartments	O
and	O
highlight	O
morphological	O
analogies	O
between	O
different	O
virus	O
families	O
.	O

We	O
then	O
conduct	B-PROC
a	O
comprehensive	O
phylogenetic	O
analysis	O
of	O
the	O
genera	O
Alpha	O
-	O
and	O
Betacoronavirus	O
,	O
to	O
show	O
that	O
bats	O
harbour	O
more	O
CoV	O
diversity	O
than	O
other	O
mammalian	O
hosts	O
and	O
are	O
widely	O
represented	O
in	O
most	O
,	O
but	O
not	O
all	O
parts	O
of	O
the	O
tree	O
of	O
mammalian	O
CoVs	O
.	O

Therefore	O
,	O
candidiasis	O
was	O
selected	O
as	O
a	O
model	O
,	O
and	O
application	O
of	O
the	O
secretory	B-PROC
protease	O
of	O
Candida	O
albicans	O
was	O
examined	O
for	O
the	O
development	B-PROC
of	O
novel	O
drugs	O
.	O

Positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
levels	O
selected	O
by	O
the	O
ExPress	O
,	O
stress	O
index	O
,	O
and	O
absolute	O
esophageal	O
pressures	O
methods	O
were	O
unrelated	O
with	O
lung	O
recruitability	O
,	O
whereas	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
levels	O
selected	O
by	O
the	O
lung	O
open	O
ventilation	O
method	O
showed	O
a	O
weak	O
relationship	O
with	O
lung	O
recruitability	O
(	O
r	O
=	O
0	O
.	O
29	O
;	O
p	O
<	O
0	O
.	O
0001	O
).	O

Bedside	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
selection	O
methods	O
based	O
on	O
lung	O
mechanics	O
or	O
absolute	O
esophageal	O
pressures	O
provide	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
levels	O
unrelated	O
to	O
lung	O
recruitability	O
and	O
similar	O
in	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
whereas	O
the	O
oxygenation	B-PROC
-	O
based	O
method	O
provided	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
levels	O
related	O
with	O
lung	O
recruitability	O
progressively	O
increasing	O
from	O
mild	O
to	O
moderate	O
and	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
patient	O
was	O
in	O
a	O
fair	O
condition	O
during	O
30	O
hours	O
of	O
hospitalization	O
until	O
he	O
suddenly	O
developed	O
respiratory	O
distress	O
and	O
unfortunately	O
died	B-PROC
with	O
cardiopulmonary	O
arrest	O
.	O

Obtaining	O
a	O
U	O
.	O
S	O
.	O
PEDV	O
isolate	O
that	O
can	O
grow	O
efficiently	O
in	O
cell	O
culture	O
is	O
critical	O
for	O
investigating	O
pathogenesis	B-PROC
and	O
developing	O
diagnostic	O
assays	O
and	O
for	O
vaccine	O
development	B-PROC
.	O

These	O
data	O
indicated	O
that	O
activation	O
of	O
the	O
NF	O
-	O
κB	O
signaling	B-PROC
pathway	I-PROC
represents	O
a	O
major	O
contribution	O
to	O
the	O
inflammation	O
induced	O
after	O
SARS	O
-	O
CoV	O
infection	O
and	O
that	O
NF	O
-	O
κB	O
inhibitors	O
are	O
promising	O
antivirals	O
in	O
infections	O
caused	O
by	O
SARS	O
-	O
CoV	O
and	O
potentially	O
other	O
pathogenic	O
human	O
coronaviruses	O
.	O

Collectively	O
,	O
the	O
data	O
implicate	O
Ifit2	O
as	O
a	O
positive	O
regulator	O
of	O
IFN	O
-	O
α	O
/	O
β	O
expression	B-PROC
,	O
rather	O
than	O
direct	O
antiviral	O
mediator	O
,	O
during	O
MHV	O
-	O
induced	O
encephalitis	O
.	O

Most	O
genes	O
were	O
closely	O
clustered	O
together	O
,	O
suggesting	O
a	O
homogeneous	O
expression	B-PROC
.	O

Heart	O
rate	O
(	O
P	O
<	O
.	O
001	O
)	O
and	O
mean	O
arterial	B-PROC
pressure	I-PROC
(	O
P	O
<	O
.	O
001	O
)	O
increased	O
less	O
during	O
NAVA	O
than	O
during	O
PSV	O
.	O

ABSTRACT	O
:	O
The	O
influence	O
of	O
CD25	O
(+)	O
CD4	O
(+)	O
regulatory	O
T	O
cells	O
(	O
Treg	O
)	O
on	O
acute	O
and	O
chronic	O
viral	B-PROC
infection	I-PROC
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
was	O
examined	O
using	O
a	O
glial	O
tropic	O
murine	O
coronavirus	O
.	O

In	O
this	O
Review	O
,	O
we	O
describe	O
the	O
emergence	O
and	O
identification	O
of	O
novel	O
human	O
coronaviruses	O
over	O
the	O
past	O
10	O
years	O
,	O
discuss	O
their	O
key	O
biological	O
features	O
,	O
including	O
tropism	B-PROC
and	O
receptor	O
use	O
,	O
and	O
summarize	O
approaches	O
for	O
developing	O
broadly	O
effective	O
vaccines	O
.	O

The	O
lung	O
expression	B-PROC
of	O
adhesion	O
molecules	O
(	O
intercellular	O
adhesion	O
molecule	O
1	O
,	O
platelet	O
endothelial	O
cell	B-PROC
adhesion	I-PROC
molecule	O
1	O
,	O
and	O
vascular	O
cell	B-PROC
adhesion	I-PROC
molecule	O
[	O
VCAM	O
])	O
was	O
evaluated	O
by	O
immunohistochemistry	O
.	O

In	O
contrast	O
,	O
ACE2	O
cleavage	B-PROC
was	O
dispensable	O
for	O
activation	O
of	O
the	O
viral	O
S	O
protein	O
.	O

Finally	O
,	O
TMPRSS2	O
was	O
found	O
to	O
compete	O
with	O
the	O
metalloprotease	O
ADAM17	O
for	O
ACE2	O
processing	O
,	O
but	O
only	O
cleavage	B-PROC
by	O
TMPRSS2	O
resulted	O
in	O
augmented	O
SARS	O
-	O
S	O
-	O
driven	O
entry	O
.	O

Collectively	O
,	O
our	O
results	O
in	O
conjunction	O
with	O
those	O
of	O
previous	O
studies	O
indicate	O
that	O
TMPRSS2	O
and	O
potentially	O
related	O
proteases	O
promote	O
SARS	O
-	O
CoV	O
entry	O
by	O
two	O
separate	O
mechanisms	O
:	O
ACE2	O
cleavage	B-PROC
,	O
which	O
might	O
promote	O
viral	O
uptake	O
,	O
and	O
SARS	O
-	O
S	O
cleavage	B-PROC
,	O
which	O
activates	O
the	O
S	O
protein	O
for	O
membrane	B-PROC
fusion	I-PROC
.	O

The	O
PARP	O
inhibition	B-PROC
attenuated	O
lung	O
-	O
kidney	O
crosstalk	B-PROC
induced	O
by	O
intratracheal	O
LPS	O
instillation	O
,	O
partly	O
via	O
an	O
inhibition	B-PROC
of	O
NF	O
-	O
κB	O
dependent	O
proinflammatory	O
cytokines	O
.	O

TITLE	O
:	O
Apnea	O
testing	O
for	O
brain	O
death	B-PROC
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
possible	O
solution	O
.	O

ABSTRACT	O
:	O
Ten	O
years	O
have	O
elapsed	O
since	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
outbreak	O
,	O
which	O
resulted	O
in	O
more	O
than	O
8000	O
cases	O
worldwide	O
with	O
more	O
than	O
700	O
deaths	B-PROC
.	O

Based	O
on	O
the	O
IgG	O
antibody	B-PROC
positivity	O
of	O
the	O
serum	O
samples	O
,	O
the	O
patient	O
was	O
diagnosed	O
as	O
having	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
in	O
the	O
past	O
.	O

Here	O
we	O
show	O
the	O
resistance	B-PROC
of	O
ferrets	O
to	O
MERS	O
-	O
CoV	O
infection	O
and	O
inability	O
of	O
ferret	O
DDP4	O
to	O
bind	O
MERS	O
-	O
CoV	O
.	O
Site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
of	O
amino	O
acids	O
variable	O
in	O
ferret	O
DPP4	O
thus	O
revealed	O
the	O
functional	O
human	O
DPP4	O
virus	O
binding	O
site	O
.	O

This	O
review	O
summarizes	O
current	O
progress	O
towards	O
development	B-PROC
of	O
both	O
active	O
site	O
and	O
allosteric	O
RNaseH	O
inhibitors	O
.	O

TITLE	O
:	O
Lung	B-PROC
function	I-PROC
in	O
sickle	O
cell	O
disease	O
.	O

Prominent	O
among	O
them	O
is	O
the	O
effect	O
that	O
the	O
disease	O
has	O
on	O
lung	B-PROC
growth	B-PROC
and	O
function	O
.	O

The	O
RTC	O
directs	O
and	O
coordinates	O
processes	O
in	O
order	O
to	O
replicate	O
and	O
transcribe	O
the	O
coronavirus	O
genome	O
,	O
a	O
single	O
-	O
stranded	O
,	O
positive	O
-	O
sense	B-PROC
RNA	O
of	O
outstanding	O
length	O
(∼	O
27	O
-	O
32kilobases	O
).	O

An	O
important	O
step	O
in	O
antiviral	O
drug	O
development	B-PROC
is	O
the	O
screening	O
of	O
potential	O
inhibitors	O
in	O
cell	O
-	O
based	O
systems	O
.	O

Of	O
245	O
hospitalized	O
children	O
,	O
respiratory	O
viruses	O
were	O
detected	O
among	O
98	O
(	O
40	O
%),	O
of	O
whom	O
92	O
(	O
94	O
%)	O
had	O
fever	B-PROC
or	O
respiratory	O
symptoms	O
.	O

We	O
detail	O
outcomes	O
of	O
clinical	O
examination	O
,	O
pulmonary	B-PROC
function	I-PROC
testing	O
,	O
quality	O
of	O
life	O
assessment	O
and	O
radiographic	O
appearance	O
on	O
CT	O
Thorax	O
at	O
follow	O
-	O
up	O
at	O
6	O
months	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
assessed	O
the	O
possible	O
effect	O
of	O
TCoV	O
on	O
the	O
reproductive	B-PROC
performance	O
of	O
experimentally	O
infected	O
turkey	O
hens	O
.	O

Cloacal	O
swabs	O
and	O
intestinal	O
and	O
reproductive	B-PROC
tissues	O
were	O
collected	O
and	O
standard	O
reverse	O
-	O
transcription	B-PROC
PCR	O
was	O
conducted	O
to	O
detect	O
TCoV	O
RNA	O
.	O

In	O
both	O
models	O
,	O
results	O
demonstrated	O
two	O
phases	O
of	O
neutrophil	O
chemotactic	O
factor	O
expression	B-PROC
;	O
first	O
,	O
an	O
early	O
phase	O
characterized	O
by	O
high	O
levels	O
of	O
CXCL1	O
/	O
keratinocyte	O
-	O
derived	O
chemokine	O
,	O
CXCL2	O
/	O
monocyte	O
-	O
inhibitory	O
protein	O
-	O
2	O
,	O
and	O
CXCL5	O
/	O
LPS	O
-	O
induced	O
chemokine	O
expression	B-PROC
,	O
and	O
second	O
,	O
a	O
late	O
phase	O
distinguished	O
by	O
increases	O
in	O
extracellular	O
ATP	O
.	O

Aptamer	O
technology	O
has	O
high	O
target	O
specificity	O
and	O
versatility	O
,	O
i	O
.	O
e	O
.,	O
any	O
viral	O
proteins	O
could	O
potentially	O
be	O
targeted	B-PROC
.	O

The	O
aptamer	O
selection	O
process	O
will	O
be	O
described	O
,	O
followed	O
by	O
an	O
explanation	O
of	O
the	O
potential	O
for	O
treating	O
virus	B-PROC
infection	I-PROC
by	O
aptamers	O
.	O

In	O
Vero	O
cells	O
,	O
the	O
virus	O
proliferates	O
as	O
its	O
parental	O
virus	O
and	O
can	O
cause	O
syncytium	B-PROC
formation	I-PROC
.	O

The	O
peak	O
titer	O
would	O
reach	B-PROC
10	O
(	O
5	O
.	O
9	O
)	O
50	O
%	O
(	O
median	O
)	O
tissue	O
culture	O
infective	O
dose	O
/	O
mL	O
at	O
24	O
h	O
post	O
-	O
infection	O
.	O

Conversely	O
,	O
many	O
viruses	O
co	O
-	O
opt	O
nucleocytoplasmic	O
trafficking	B-PROC
to	O
facilitate	O
transport	B-PROC
of	O
viral	O
RNAs	O
.	O

It	O
is	O
therefore	O
necessary	O
to	O
conduct	B-PROC
studies	O
of	O
sufficient	O
sample	O
size	O
to	O
compare	O
the	O
treatment	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
using	O
a	O
protective	O
ventilation	O
strategy	O
with	O
high	O
PEEP	O
guided	O
by	O
the	O
characteristics	O
of	O
lung	O
mechanics	O
and	O
ventilation	O
with	O
the	O
protocol	O
proposed	O
by	O
the	O
ARDS	O
Network	O
.	O

Overall	O
28	O
day	O
mortality	O
was	O
17	O
.	O
1	O
%	O
(	O
51	O
deaths	B-PROC
)	O
in	O
the	O
placebo	O
arm	O
and	O
18	O
.	O
5	O
%	O
(	O
56	O
deaths	B-PROC
)	O
in	O
the	O
clarithromycin	O
arm	O
(	O
P	O
=	O
0	O
.	O
671	O
).	O

There	O
are	O
still	O
over	O
2	O
million	O
deaths	B-PROC
annually	O
from	O
tuberculosis	O
,	O
with	O
most	O
of	O
these	O
occurring	O
in	O
the	O
developing	O
world	O
.	O

Autoimmune	O
diseases	O
of	O
the	O
lung	O
pose	O
a	O
different	O
set	O
of	O
challenges	O
,	O
including	O
the	O
development	B-PROC
of	O
biomarkers	O
to	O
diagnose	O
and	O
monitor	O
the	O
disease	O
and	O
biological	O
modulators	O
to	O
treat	O
the	O
disease	O
.	O

The	O
patients	O
in	O
the	O
treatment	O
group	O
were	O
administered	O
with	O
CQCQD	O
by	O
gastric	O
perfusion	O
(	O
50	O
mL	O
/	O
2	O
h	O
)	O
and	O
retention	B-PROC
enema	O
(	O
200	O
mL	O
/	O
6	O
h	O
)	O
for	O
7	O
days	O
.	O

They	O
presented	O
with	O
fever	B-PROC
and	O
rapidly	O
progressive	O
pneumonia	O
that	O
did	O
not	O
respond	O
to	O
antibiotics	O
.	O

Here	O
,	O
we	O
assessed	O
antitumor	O
immunity	B-PROC
induced	O
by	O
attenuated	O
coronavirus	O
vectors	O
which	O
exclusively	O
target	O
DCs	O
in	O
vivo	O
and	O
express	O
either	O
lymphocyte	O
-	O
or	O
DC	O
-	O
activating	O
cytokines	O
in	O
combination	O
with	O
a	O
GFP	O
-	O
tagged	O
model	O
antigen	O
.	O

Of	O
all	O
the	O
IFNs	O
tested	O
,	O
IFN	O
-	O
β	O
showed	O
the	O
strongst	O
inhibition	B-PROC
of	O
MERS	O
-	O
CoV	O
in	O
vitro	O
,	O
with	O
an	O
IC₅₀	O
of	O
1	O
.	O
37	O
U	O
ml	O
(-	O
1	O
),	O
41	O
times	O
lower	O
than	O
the	O
previously	O
reported	O
IC₅₀	O
(	O
56	O
.	O
08	O
U	O
ml	O
(-	O
1	O
))	O
of	O
IFN	O
-	O
α2b	O
.	O

ABSTRACT	O
:	O
Polymorphonuclear	O
neutrophils	O
(	O
PMN	B-PROC
)	O
infiltrate	O
the	O
respiratory	O
tract	O
early	O
after	O
viral	B-PROC
infection	I-PROC
and	O
can	O
contribute	O
to	O
both	O
host	B-PROC
defence	I-PROC
and	O
pathology	O
.	O

These	O
findings	O
indicate	O
that	O
this	O
truncated	O
RBD	O
protein	O
shows	O
promise	O
for	O
further	O
development	B-PROC
as	O
an	O
effective	O
and	O
safe	O
vaccine	O
for	O
the	O
prevention	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

Herein	O
,	O
we	O
report	O
a	O
case	O
of	O
vivax	O
malaria	O
complicated	O
by	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
that	O
was	O
successfully	O
managed	O
with	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O

A	O
59	O
-	O
year	O
-	O
old	O
man	O
presented	O
at	O
our	O
hospital	O
with	O
fever	B-PROC
and	O
abdominal	O
pain	O
,	O
which	O
had	O
persisted	O
for	O
10	O
days	O
.	O

IFN	O
-	O
λ	O
is	O
expressed	B-PROC
at	O
higher	O
levels	O
in	O
organs	O
with	O
high	O
epithelial	O
cell	O
content	O
such	O
as	O
the	O
respiratory	O
and	O
gastrointestinal	O
tracts	O
.	O

TITLE	O
:	O
Identification	O
of	O
novel	O
drug	O
scaffolds	O
for	O
inhibition	B-PROC
of	O
SARS	O
-	O
CoV	O
3	O
-	O
Chymotrypsin	O
-	O
like	O
protease	O
using	O
virtual	O
and	O
high	O
-	O
throughput	O
screenings	O
.	O

The	O
genes	O
in	O
the	O
1	O
-	O
Mb	O
windows	O
surrounding	O
each	O
single	O
nucleotide	O
polymorphism	B-PROC
with	O
significant	O
effect	O
for	O
the	O
antibody	B-PROC
level	O
against	O
IBV	O
were	O
associated	O
with	O
many	O
biological	B-PROC
processes	I-PROC
or	O
pathways	B-PROC
related	O
to	O
immunity	B-PROC
,	O
such	O
as	O
the	O
defense	B-PROC
response	I-PROC
and	O
mTOR	B-PROC
signaling	B-PROC
pathway	I-PROC
.	O

In	O
addition	O
,	O
the	O
major	O
loci	O
significantly	O
associated	O
with	O
the	O
antibody	B-PROC
level	O
against	O
IBV	O
on	O
GGA1	O
and	O
GGA5	O
could	O
explain	O
about	O
12	O
%	O
and	O
13	O
%	O
of	O
the	O
phenotypic	O
variation	O
,	O
respectively	O
.	O

Hemodynamics	B-PROC
did	O
not	O
change	O
with	O
exception	O
of	O
increased	O
mean	O
pulmonary	O
arterial	B-PROC
pressure	I-PROC
during	O
PrP	O
and	O
decrease	O
after	O
PrP	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
while	O
norepinephrine	O
dosage	O
decreased	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
(	O
MANOVA	O
).	O

In	O
previous	O
work	O
,	O
we	O
generated	O
the	O
BacMam	O
virus	O
Ac	O
-	O
CMV	O
-	O
S1	O
,	O
which	O
expressed	B-PROC
the	O
S1	O
glycoprotein	O
of	O
IBV	O
-	O
M41	O
.	O

BV	O
-	O
Dual	O
-	O
S1	O
elicited	O
stronger	O
humoral	O
and	O
cell	O
-	O
mediated	O
immune	B-PROC
responses	I-PROC
,	O
and	O
showed	O
greater	O
capacity	O
for	O
induction	O
of	O
cytotoxic	O
T	O
lymphocyte	O
responses	O
,	O
compared	O
with	O
Ac	O
-	O
CMV	O
-	O
S1	O
in	O
specific	O
pathogen	O
-	O
free	O
chickens	O
.	O

In	O
this	O
climate	O
,	O
Maier	O
et	O
al	O
.	O
(	O
H	O
.	O
J	O
.	O
Maier	O
,	O
P	O
.	O
C	O
.	O
Hawes	O
,	O
E	O
.	O
M	O
.	O
Cottam	O
,	O
J	O
.	O
Mantell	O
,	O
P	O
.	O
Verkade	O
,	O
et	O
al	O
.,	O
mBio	O
4	O
:	O
e00801	O
-	O
13	O
,	O
2013	O
)	O
explored	O
the	O
replicative	O
structures	O
formed	O
by	O
an	O
avian	O
coronavirus	O
that	O
appears	O
to	O
have	O
diverged	O
at	O
an	O
early	O
point	O
in	O
coronavirus	O
evolution	B-PROC
and	O
shed	O
light	O
on	O
controversial	O
aspects	O
of	O
viral	O
biology	O
.	O

Structures	O
that	O
shed	O
light	O
on	O
the	O
function	O
and	O
biological	O
roles	O
of	O
the	O
proteins	O
in	O
viral	B-PROC
replication	I-PROC
and	O
pathogenesis	B-PROC
are	O
highlighted	O
.	O

TITLE	O
:	O
Yeast	O
-	O
expressed	B-PROC
recombinant	O
protein	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
in	O
SARS	O
-	O
CoV	O
spike	O
protein	O
with	O
deglycosylated	O
forms	O
as	O
a	O
SARS	O
vaccine	O
candidate	O
.	O

This	O
review	O
describes	O
our	O
current	O
knowledge	O
of	O
VEGF	O
biology	O
and	O
summarises	O
the	O
literature	O
investigating	O
the	O
potential	O
role	O
VEGF	O
may	O
play	O
in	O
normal	O
lung	O
maintenance	O
and	O
in	O
the	O
development	B-PROC
of	O
lung	O
injury	O
.	O

Another	O
study	O
reported	O
higher	O
rates	O
of	O
dysfunction	O
for	O
pulmonary	O
(	O
non	O
-	O
ARDS	O
and	O
ARDS	O
),	O
hepatic	O
and	O
renal	O
but	O
similar	O
rates	O
for	O
central	O
nervous	O
system	O
and	O
disseminated	O
intravascular	O
coagulation	B-PROC
when	O
compared	O
to	O
the	O
first	O
two	O
studies	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
MERS	O
-	O
CoV	O
PLpro	O
,	O
which	O
is	O
a	O
protease	O
and	O
can	O
recognize	O
and	O
process	O
the	O
cleavage	B-PROC
sites	O
(	O
CS	O
)	O
of	O
nsp1	O
-	O
2	O
,	O
nsp2	O
-	O
3	O
and	O
nsp3	O
-	O
4	O
.	O

Its	O
surface	O
receptor	O
glycoproteins	O
,	O
hemagglutinin	O
(	O
HA	O
)	O
and	O
neuraminidase	O
(	O
NA	O
),	O
are	O
characterized	O
by	O
high	O
antigenic	B-PROC
variation	I-PROC
,	O
thus	O
a	O
host	O
organism	O
cannot	O
develop	O
permanent	O
resistance	B-PROC
.	O

Together	O
with	O
the	O
findings	O
that	O
early	O
renal	B-PROC
function	I-PROC
,	O
incidence	O
of	O
ARDS	O
,	O
length	O
of	O
stay	O
,	O
and	O
mortality	O
were	O
not	O
negatively	O
influenced	O
by	O
HES	O
in	O
this	O
setting	O
,	O
balanced	O
HES	O
130	O
/	O
0	O
.	O
4	O
(	O
6	O
%)	O
plus	O
lactated	O
Ringer	O
'	O
s	O
solution	O
could	O
not	O
be	O
considered	O
superior	O
to	O
lactated	O
Ringer	O
'	O
s	O
solution	O
alone	O
.	O

Each	O
OSA	O
subject	O
was	O
assigned	O
to	O
CPAP	O
or	O
APAP	O
treatment	O
and	O
underwent	O
a	O
sleep	B-PROC
study	O
after	O
1	O
week	O
of	O
treatment	O
.	O

In	O
CPAP	O
and	O
CON	O
,	O
LFnu	O
and	O
LF	O
/	O
HF	O
,	O
markers	O
of	O
sympathetic	O
modulation	O
,	O
decreased	O
from	O
N2	O
to	O
N3	O
and	O
increased	O
during	O
REM	B-PROC
sleep	B-PROC
(	O
p	O
<	O
0	O
.	O
001	O
),	O
while	O
in	O
APAP	O
group	O
,	O
sympathetic	O
modulation	O
was	O
significantly	O
higher	O
compared	O
with	O
those	O
of	O
CPAP	O
and	O
CON	O
during	O
all	O
sleep	B-PROC
stages	I-PROC
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
provide	O
insights	O
into	O
the	O
effects	O
of	O
pentacyclic	O
triterpenes	O
on	O
lung	O
inflammatory	O
actions	O
through	O
reversible	O
inhibition	B-PROC
of	O
HNE	O
activity	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
FJU	O
-	O
C4	O
compound	O
may	O
act	O
as	O
a	O
promising	O
therapeutic	O
agent	O
against	O
inflammatory	O
diseases	O
by	O
inhibiting	O
the	O
p38MAPK	O
and	O
NF	O
-	O
κB	O
signaling	B-PROC
pathway	I-PROC
.	O

Finally	O
,	O
the	O
chimeric	O
VLPs	O
induced	O
significantly	O
higher	O
IL	B-PROC
-	I-PROC
4	I-PROC
production	I-PROC
in	O
mice	O
.	O

The	O
patient	O
,	O
after	O
6	O
days	O
of	O
ECMO	O
,	O
recovered	O
completely	O
and	O
was	O
successfully	O
weaned	B-PROC
from	O
the	O
mechanical	O
ventilator	O
on	O
the	O
9th	O
day	O
after	O
admission	O
.	O

TITLE	O
:	O
Aerobic	O
and	O
strength	O
training	O
in	O
concomitant	O
metabolic	B-PROC
syndrome	O
and	O
type	O
2	O
diabetes	O
.	O

The	O
observed	O
decrease	O
in	O
metabolic	B-PROC
syndrome	O
was	O
mediated	O
by	O
significant	O
improvements	O
in	O
exercise	O
efficiency	O
for	O
the	O
AER	O
and	O
AER	O
+	O
RES	O
training	O
groups	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
which	O
was	O
more	O
strongly	O
related	O
to	O
TTE	O
(	O
25	O
%-	O
30	O
%;	O
r	O
=	O
-	O
0	O
.	O
38	O
,	O
95	O
%	O
CI	O
=	O
-	O
0	O
.	O
55	O
to	O
-	O
0	O
.	O
19	O
)	O
than	O
VO2peak	O
(	O
5	O
%-	O
6	O
%;	O
r	O
=	O
-	O
0	O
.	O
24	O
,	O
95	O
%	O
CI	O
=	O
-	O
0	O
.	O
45	O
to	O
-	O
0	O
.	O
01	O
).	O

It	O
is	O
vital	O
to	O
collect	O
the	O
information	O
of	O
the	O
incubation	O
period	O
upon	O
emergence	O
of	O
a	O
novel	O
infectious	O
disease	O
,	O
and	O
moreover	O
,	O
in	O
our	O
model	O
,	O
the	O
fundamental	O
transmission	O
dynamics	O
including	O
the	O
initial	O
growth	B-PROC
rate	O
has	O
to	O
be	O
explored	O
to	O
differentiate	O
the	O
disease	O
diagnoses	O
with	O
non	O
-	O
specific	O
symptoms	O
.	O

In	O
contrast	O
,	O
the	O
relatively	O
high	O
percentage	O
of	O
cats	O
negative	O
for	O
all	O
8	O
enteropathogens	O
tested	O
could	O
indicate	O
an	O
innate	O
resistance	B-PROC
to	O
infection	O
.	O

TITLE	O
:	O
The	O
effects	O
of	O
Nigella	O
sativa	O
(	O
Ns	O
),	O
Anthemis	O
hyalina	O
(	O
Ah	O
)	O
and	O
Citrus	O
sinensis	O
(	O
Cs	O
)	O
extracts	O
on	O
the	O
replication	O
of	O
coronavirus	O
and	O
the	O
expression	B-PROC
of	O
TRP	O
genes	O
family	O
.	O

JHMV	O
infection	O
leads	O
to	O
increased	O
cell	B-PROC
death	I-PROC
and	O
dampens	O
IFN	O
-	O
γ	O
-	O
induced	O
MHC	B-PROC
class	O
II	O
expression	B-PROC
.	O

We	O
have	O
developed	O
the	O
methods	O
needed	O
to	O
explore	O
whether	O
a	O
relationship	O
exists	O
between	O
co	O
-	O
expression	B-PROC
network	O
models	O
built	O
from	O
transcriptomic	O
and	O
proteomic	O
data	O
types	O
,	O
and	O
whether	O
this	O
relationship	O
can	O
be	O
used	O
to	O
improve	O
the	O
disease	O
signature	O
discovery	O
process	O
.	O

Using	O
publicly	O
available	O
infectious	O
disease	O
time	O
series	O
data	O
,	O
we	O
analyzed	O
the	O
related	O
co	O
-	O
expression	B-PROC
structure	O
of	O
the	O
transcriptome	O
and	O
proteome	O
in	O
response	O
to	O
SARS	O
-	O
CoV	O
infection	O
in	O
mice	O
.	O

Transcript	O
and	O
peptide	O
expression	B-PROC
data	O
was	O
filtered	O
using	O
quality	O
scores	O
and	O
subset	O
by	O
taking	O
the	O
intersection	O
on	O
mapped	O
Entrez	O
IDs	O
.	O

The	O
effects	O
of	O
multiple	O
pathogens	O
on	O
the	O
disease	O
outcomes	O
remain	O
unclear	O
because	O
the	O
rate	O
of	O
death	B-PROC
and	O
the	O
duration	O
of	O
diarrhea	O
did	O
not	O
seem	O
to	O
be	O
affected	O
by	O
these	O
factors	O
.	O

No	O
statistical	O
difference	O
(	O
P	O
=	O
0	O
.	O
8374	O
)	O
was	O
observed	O
in	O
the	O
duration	O
of	O
diarrhea	O
or	O
the	O
number	O
of	O
deaths	B-PROC
(	O
P	O
=	O
0	O
.	O
5722	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
single	O
or	O
co	O
-	O
infections	O
.	O

Peritoneal	O
ventilation	O
has	O
long	O
been	O
desired	O
for	O
extrapulmonary	O
oxygenation	B-PROC
owing	O
to	O
easy	O
access	O
of	O
the	O
peritoneal	O
cavity	O
for	O
catheterization	O
and	O
the	O
relative	O
safety	O
compared	O
to	O
an	O
extracorporeal	O
circuit	O
.	O

In	O
contrast	O
to	O
the	O
inhibited	O
inflammatory	O
lung	O
injury	O
in	O
Cav1	O
(-/-)	O
mice	O
,	O
we	O
observed	O
severe	O
lung	O
inflammation	O
and	O
markedly	O
increased	O
lung	O
vascular	B-PROC
permeability	I-PROC
in	O
DKO	O
mice	O
in	O
response	B-PROC
to	I-PROC
LPS	I-PROC
challenge	O
.	O

A	O
hallmark	O
of	O
highly	O
pathogenic	O
respiratory	O
viruses	O
is	O
their	O
ability	O
to	O
evade	O
the	O
innate	B-PROC
immune	I-PROC
response	I-PROC
of	O
the	O
host	O
.	O

This	O
is	O
a	O
retrospective	O
cohort	O
study	O
of	O
14	O
patients	O
with	O
HMs	O
(	O
aggressive	B-PROC
non	O
-	O
Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
n	O
=	O
5	O
;	O
highly	O
aggressive	B-PROC
NHL	O
,	O
that	O
is	O
acute	O
lymphoblastic	O
leukemia	O
or	O
Burkitt	O
lymphoma	O
,	O
n	O
=	O
5	O
;	O
Hodgkin	O
lymphoma	O
,	O
n	O
=	O
2	O
;	O
acute	O
myeloid	O
leukemia	O
,	O
n	O
=	O
1	O
;	O
multiple	O
myeloma	O
,	O
n	O
=	O
1	O
)	O
receiving	O
ECMO	O
support	O
because	O
of	O
ARF	O
(	O
all	O
data	O
as	O
medians	O
and	O
interquartile	O
ranges	O
;	O
age	O
,	O
32	O
years	O
(	O
22	O
to	O
51	O
years	O
);	O
simplified	O
acute	O
physiology	O
score	O
II	O
(	O
SAPS	O
II	O
):	O
51	O
(	O
42	O
to	O
65	O
)).	O

Echocardiography	O
at	O
36	O
h	O
post	O
ingestion	O
showed	O
a	O
left	B-PROC
ventricular	I-PROC
ejection	I-PROC
fraction	O
(	O
LVEF	O
)	O
of	O
<	O
20	O
%.	O

Using	O
single	O
-	O
molecule	O
force	O
spectroscopy	O
to	O
unfold	O
pseudoknots	O
mechanically	O
,	O
we	O
found	O
that	O
the	O
ligand	B-PROC
binding	I-PROC
effectively	O
abolished	O
the	O
formation	B-PROC
of	O
alternate	O
conformers	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
values	O
of	O
factors	O
based	O
on	O
PIRO	O
conception	B-PROC
in	O
predicting	O
the	O
prognosis	O
of	O
critical	O
patients	O
.	O

In	O
contrast	O
,	O
in	O
cl	O
-	O
2	O
infection	O
,	O
10	O
-	O
20	O
%	O
of	O
the	O
infected	O
mice	O
exhibited	O
apoptosis	B-PROC
in	O
the	O
hippocampus	O
,	O
which	O
was	O
primarily	O
observed	O
in	O
the	O
CA1	O
subregion	O
.	O

Here	O
we	O
analyze	O
charge	O
regulation	B-PROC
effects	O
in	O
different	O
protein	O
-	O
lipid	O
conformations	O
,	O
stressing	O
how	O
important	O
is	O
the	O
role	O
of	O
electrostatic	O
interactions	O
in	O
the	O
ion	O
channel	O
function	O
that	O
traditionally	O
has	O
been	O
rationalized	O
paying	O
attention	O
mainly	O
to	O
changes	O
in	O
pore	O
size	O
.	O

Therefore	O
,	O
interactions	O
of	O
MERS	O
-	O
CoV	O
at	O
the	O
human	O
-	O
animal	O
interface	O
may	O
have	O
been	O
ongoing	O
for	O
several	O
,	O
perhaps	O
many	O
,	O
years	O
and	O
by	O
inference	O
,	O
a	O
widespread	O
pandemic	O
may	O
be	O
less	O
likely	O
unless	O
significant	O
evolution	B-PROC
of	O
the	O
virus	O
allow	O
accelerated	O
infection	O
and	O
spread	O
potential	O
in	O
the	O
human	O
population	O
.	O

We	O
suggest	O
that	O
viral	O
ion	O
channels	O
,	O
in	O
general	O
,	O
may	O
be	O
a	O
good	O
target	O
for	O
the	O
development	B-PROC
of	O
antiviral	O
agents	O
,	O
and	O
that	O
,	O
in	O
particular	O
,	O
kaempferol	O
glycosides	O
are	O
good	O
candidates	O
for	O
3a	O
channel	O
proteins	O
of	O
coronaviruses	O
.	O

Although	O
androgens	O
are	O
involved	O
in	O
prostate	O
growth	B-PROC
during	O
developmental	O
age	O
,	O
their	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
BPH	O
/	O
LUTS	O
is	O
debated	O
.	O

Using	O
a	O
novel	O
visual	O
analogue	O
scale	O
(	O
VAS	O
),	O
we	O
sought	O
to	O
undertake	O
a	O
systematic	O
exploration	O
of	O
the	O
symptomatology	O
of	O
AMS	O
using	O
an	O
unbiased	O
,	O
data	O
-	O
driven	O
approach	O
originally	O
designed	O
for	O
analysis	O
of	O
gene	B-PROC
expression	I-PROC
.	O

Although	O
fatigue	O
is	O
a	O
ubiquitous	O
finding	O
,	O
sleep	B-PROC
disturbance	O
and	O
headache	O
are	O
each	O
commonly	O
reported	O
without	O
the	O
other	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	B-PROC
,	O
antiviral	O
activity	O
,	O
and	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
two	O
types	O
of	O
structurally	O
novel	O
phenanthroindo	O
/	O
quinolizidine	O
analogues	O
.	O

Five	O
of	O
the	O
six	O
patients	O
in	O
the	O
ICU	O
who	O
did	O
not	O
receive	O
lung	O
transplantation	O
died	B-PROC
.	O

Lessons	O
learned	B-PROC
included	O
awareness	O
that	O
integrated	O
functions	O
within	O
the	O
health	O
system	O
for	O
GHS	O
require	O
careful	O
planning	O
,	O
stakeholder	O
buy	O
-	O
in	O
,	O
and	O
intradepartmental	O
and	O
interdepartmental	O
coordination	B-PROC
and	O
communication	O
.	O

In	O
addition	O
,	O
we	O
describe	O
novel	O
treatment	O
avenues	O
that	O
exploit	O
this	O
pathway	B-PROC
and	O
could	O
potentially	O
be	O
used	O
against	O
a	O
diverse	O
range	O
of	O
viral	O
pathogens	O
that	O
utilize	O
2	O
'-	O
O	O
-	O
MTase	O
activity	O
to	O
subvert	O
the	O
immune	O
system	O
.	O

TITLE	O
:	O
Synthesis	B-PROC
and	O
biological	O
evaluation	O
of	O
2	O
-	O
oxonicotinonitriles	O
and	O
2	O
-	O
oxonicotinonitrile	O
based	O
nucleoside	O
analogues	O
.	O

We	O
focused	O
on	O
2	O
-	O
oxonicotinonitrile	O
(	O
2	O
-	O
ONN	O
)	O
as	O
derivative	O
of	O
the	O
natural	O
product	O
2	O
-	O
pyridinone	O
.(	O
1	O
)	O
Herein	O
,	O
we	O
describe	O
the	O
synthesis	B-PROC
of	O
2	O
-	O
ONNs	O
bearing	O
two	O
aryl	O
groups	O
,	O
which	O
we	O
coupled	O
with	O
organohalides	O
,	O
including	O
three	O
glycosyl	O
bromides	O
,	O
to	O
prepare	O
the	O
nucleoside	O
analogues	O
.	O

Many	O
viruses	O
have	O
evolved	O
various	O
mechanisms	O
to	O
develop	O
their	O
own	O
capping	B-PROC
enzymes	O
(	O
e	O
.	O
g	O
.	O
flavivirus	O
and	O
coronavirus	O
)	O
or	O
to	O
'	O
steal	O
'	O
caps	O
from	O
host	O
mRNAs	O
(	O
e	O
.	O
g	O
.	O
influenza	O
virus	O
).	O

In	O
this	O
study	O
we	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
intravenous	O
infusion	O
of	O
PFC	O
emulsion	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induced	O
ALI	O
in	O
rats	O
and	O
elucidate	O
its	O
mechanism	B-PROC
of	I-PROC
action	I-PROC
.	O

By	O
analyzing	O
pulmonary	O
pathology	O
,	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
in	O
the	O
blood	O
(	O
PaO2	O
)	O
and	O
lung	O
wet	O
-	O
dry	O
weight	O
ratio	O
(	O
W	O
/	O
D	O
)	O
of	O
each	O
rat	O
,	O
we	O
found	O
that	O
intravenous	O
infusion	O
of	O
PFC	O
significantly	O
alleviated	O
acute	O
lung	O
injury	O
induced	O
by	O
LPS	O
.	O

MSCs	O
appear	O
to	O
restore	O
epithelial	O
and	O
endothelial	O
function	O
,	O
via	O
both	O
paracrine	B-PROC
and	O
cell	O
contact	O
dependent	O
effects	O
.	O

Multiplex	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
was	O
undertaken	O
on	O
archived	O
nasopharyngeal	O
aspirates	O
from	O
HIV	O
-	O
infected	O
and	O
-	O
uninfected	O
children	O
(<	O
2	O
years	O
age	O
)	O
hospitalized	O
for	O
LRTI	O
,	O
who	O
had	O
been	O
previously	O
investigated	O
for	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
parainfluenza	O
I	O
-	O
III	O
,	O
adenovirus	O
and	O
influenza	O
A	O
/	O
B	O
.	O
At	O
least	O
one	O
of	O
these	O
viruses	O
were	O
identified	O
in	O
274	O
(	O
53	O
.	O
0	O
%)	O
of	O
517	O
and	O
in	O
509	O
(	O
54	O
.	O
0	O
%)	O
of	O
943	O
LRTI	O
-	O
episodes	O
in	O
HIV	O
-	O
infected	O
and	O
-	O
uninfected	O
children	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
the	O
Hendra	O
and	O
Nipah	O
virus	O
fusion	O
glycoproteins	O
were	O
not	O
cleaved	O
in	O
the	O
presence	O
of	O
the	O
small	O
molecule	O
in	O
a	O
cell	O
-	O
based	O
cleavage	B-PROC
assay	O
.	O

Parameters	O
of	O
mechanical	O
ventilation	O
and	O
pulmonary	B-PROC
function	I-PROC
were	O
analyzed	O
on	O
day	O
of	O
admission	O
and	O
over	O
the	O
consecutive	O
10	O
days	O
using	O
a	O
nonparametric	O
analysis	O
of	O
longitudinal	O
data	O
in	O
a	O
2	O
-	O
factorial	O
design	O
.	O

ABSTRACT	O
:	O
Hantavirus	O
(	O
Bunyaviridae	O
)	O
cardiopulmonary	O
syndrome	O
(	O
HCPS	O
)	O
is	O
an	O
emerging	O
health	O
problem	O
in	O
South	O
America	O
due	O
to	O
urban	O
growth	B-PROC
and	O
to	O
the	O
expansion	O
of	O
agriculture	O
and	O
cattle	O
-	O
raising	O
areas	O
into	O
ecosystems	O
containing	O
most	O
of	O
the	O
species	O
of	O
Sigmodontinae	O
rodents	O
that	O
act	O
as	O
hantavirus	O
reservoirs	O
.	O

TITLE	O
:	O
Myosins	O
1	O
and	O
6	O
,	O
myosin	O
light	O
chain	O
kinase	O
,	O
actin	O
and	O
microtubules	O
cooperate	O
during	O
antibody	B-PROC
-	O
mediated	O
internalisation	O
and	O
trafficking	B-PROC
of	O
membrane	O
-	O
expressed	B-PROC
viral	O
antigens	O
in	O
feline	O
infectious	O
peritonitis	O
virus	O
infected	O
monocytes	O
.	O

With	O
co	O
-	O
localisation	B-PROC
stainings	O
,	O
it	O
was	O
found	O
that	O
MLCK	O
and	O
myosin	O
1	O
co	O
-	O
localise	O
with	O
antigens	O
even	O
before	O
internalisation	O
started	O
.	O

Intracellular	O
trafficking	B-PROC
over	O
microtubules	O
was	O
mediated	O
by	O
MLCK	O
,	O
myosin	O
1	O
and	O
a	O
small	O
actin	O
tail	O
.	O

The	O
most	O
commonly	O
diagnosed	O
cause	O
of	O
death	B-PROC
was	O
respiratory	O
disease	O
(	O
107	O
/	O
180	O
,	O
59	O
.	O
4	O
%),	O
followed	O
by	O
lameness	O
(	O
n	O
=	O
22	O
,	O
12	O
.	O
2	O
%),	O
ketosis	O
(	O
n	O
=	O
12	O
,	O
6	O
.	O
7	O
%),	O
septicemia	O
(	O
n	O
=	O
11	O
,	O
6	O
.	O
1	O
%),	O
and	O
enteric	O
disease	O
(	O
n	O
=	O
10	O
,	O
5	O
.	O
6	O
%).	O

In	O
this	O
study	O
,	O
site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
and	O
thermal	O
stability	O
experiments	O
on	O
electrostatic	O
,	O
hydrophobic	O
,	O
and	O
polar	O
residues	O
to	O
dissect	O
their	O
roles	O
in	O
stabilizing	O
the	O
S2	O
postfusion	O
conformation	O
was	O
performed	O
.	O

Expression	B-PROC
of	O
MERS	O
-	O
CoV	O
4a	O
protein	O
suppressed	O
the	O
interferon	B-PROC
production	I-PROC
induced	O
by	O
poly	O
(	O
I	O
·	O
C	O
)	O
or	O
Sendai	O
virus	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
a	O
new	O
mechanism	O
through	O
which	O
MERS	O
-	O
CoV	O
employs	O
a	O
viral	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	O
protein	O
to	O
circumvent	O
the	O
innate	O
antiviral	B-PROC
response	I-PROC
by	O
perturbing	O
the	O
function	O
of	O
cellular	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	O
protein	O
PACT	O
.	O

Fifty	O
-	O
four	O
patients	O
with	O
ARDS	O
who	O
received	O
pulse	B-PROC
index	O
continuous	O
cardiac	O
output	O
(	O
PiCCO	O
)	O
monitoring	O
were	O
analyzed	O
retrospectively	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
catalysis	O
and	O
ubiquitin	B-PROC
recognition	O
by	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	O
-	O
like	O
protease	O
.	O

Here	O
,	O
the	O
crystal	O
structure	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
C112S	O
mutant	O
in	O
complex	O
with	O
ubiquitin	B-PROC
(	O
Ub	O
)	O
is	O
reported	O
at	O
1	O
.	O
4	O
Å	O
resolution	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
N	O
-	O
glycosylation	B-PROC
of	O
the	O
Fc	O
-	O
portion	O
of	O
serum	O
IgG	O
was	O
investigated	O
in	O
patients	O
with	O
GBS	O
before	O
and	O
after	O
treatment	O
with	O
IVIg	O
in	O
relation	O
to	O
clinical	O
course	O
and	O
outcome	O
.	O

Moreover	O
,	O
the	O
expression	B-PROC
of	O
TGEV	O
N	O
gene	O
promoted	O
translocation	B-PROC
of	O
Bax	O
to	O
mitochondria	O
,	O
which	O
in	O
turn	O
caused	O
the	O
release	O
of	O
cytochrome	B-PROC
c	I-PROC
,	O
followed	O
by	O
activation	O
of	O
caspase	O
-	O
3	O
,	O
resulting	O
in	O
cell	O
apoptosis	B-PROC
in	O
the	O
transfected	O
PK	O
-	O
15	O
cells	O
following	O
cell	B-PROC
cycle	I-PROC
arrest	I-PROC
.	O

Finally	O
,	O
we	O
confirm	O
previous	O
in	O
vitro	O
findings	O
that	O
MERS	O
-	O
CoV	O
can	O
drive	O
IL	B-PROC
-	I-PROC
17	I-PROC
production	I-PROC
in	O
humans	O
.	O

We	O
used	O
a	O
prototype	O
coronavirus	O
--	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)--	O
to	O
develop	O
a	O
conditional	O
biotinylation	O
assay	O
that	O
enables	O
the	O
specific	O
identification	O
and	O
biochemical	O
characterization	O
of	O
viral	O
S	O
proteins	O
on	O
virions	O
that	O
mediated	O
membrane	B-PROC
fusion	I-PROC
with	O
the	O
target	O
cell	O
.	O

We	O
demonstrate	O
that	O
MHV	O
S	O
proteins	O
are	O
indeed	O
cleaved	O
upon	O
virus	O
endocytosis	B-PROC
,	O
and	O
we	O
identify	O
a	O
novel	O
processing	O
product	O
S2	O
*	O
with	O
characteristics	O
of	O
a	O
fusion	O
-	O
active	O
subunit	O
.	O

Virus	O
entry	O
determines	O
the	O
tropism	B-PROC
and	O
is	O
a	O
crucial	O
step	O
in	O
the	O
virus	O
life	O
cycle	O
.	O

Therefore	O
,	O
development	B-PROC
of	O
effective	O
vaccines	O
is	O
crucial	O
for	O
preventing	O
its	O
further	O
spread	O
and	O
future	O
pandemic	O
.	O

By	O
targeting	B-PROC
this	O
pocket	O
,	O
we	O
identified	O
and	O
developed	O
a	O
new	O
coronavirus	O
N	O
protein	O
inhibitor	O
,	O
N	O
-(	O
6	O
-	O
oxo	O
-	O
5	O
,	O
6	O
-	O
dihydrophenanthridin	O
-	O
2	O
-	O
yl	O
)(	O
N	O
,	O
N	O
-	O
dimethylamino	O
)	O
acetamide	O
hydrochloride	O
(	O
PJ34	O
),	O
using	O
virtual	O
screening	O
;	O
this	O
inhibitor	O
reduced	O
the	O
N	O
protein	O
'	O
s	O
RNA	O
-	O
binding	O
affinity	O
and	O
hindered	O
viral	B-PROC
replication	I-PROC
.	O

On	O
admission	O
,	O
his	O
clinical	O
status	O
was	O
severe	O
,	O
with	O
high	O
fever	B-PROC
of	O
41ºC	O
,	O
preceded	O
by	O
chills	O
,	O
bleeding	O
from	O
the	O
gums	O
and	O
oral	O
mucosa	O
,	O
haemorrhages	O
at	O
the	O
sites	O
of	O
venipuncture	O
,	O
numerous	O
ecchymoses	O
,	O
fine	O
-	O
spotted	O
skin	O
rash	O
,	O
tachycardia	O
,	O
hepatosplenomegaly	O
,	O
dehydration	O
,	O
jaundice	O
,	O
dyspnoea	O
,	O
hypoxaemia	O
,	O
generalised	O
oedema	O
and	O
oliguria	O
.	O

A	O
severe	O
clinical	O
course	O
of	O
acute	O
rhodesiense	O
trypanosomiasis	O
with	O
renal	O
failure	O
,	O
respiratory	O
distress	O
,	O
disseminated	O
intravascular	O
coagulation	B-PROC
syndrome	O
,	O
haemolysis	B-PROC
,	O
liver	O
insufficiency	O
and	O
myocarditis	O
was	O
confirmed	O
.	O

CONCLUSIONS	O
:	O
Sleeping	B-PROC
sickness	O
should	O
always	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
fever	B-PROC
in	O
people	O
returning	O
from	O
safari	O
trips	O
to	O
the	O
national	O
parks	O
or	O
nature	O
reserves	O
of	O
sub	O
-	O
Saharan	O
Africa	O
.	O

Tonsillar	O
tissue	O
from	O
patients	O
with	O
OSA	O
and	O
RI	O
was	O
subjected	O
to	O
multiplex	O
quantitative	O
real	O
time	O
reverse	B-PROC
transcription	B-PROC
PCR	O
(	O
mqRTPCR	O
),	O
analyzed	O
for	O
the	O
presence	O
of	O
common	O
respiratory	O
viruses	O
'	O
genetic	O
material	O
.	O

The	O
unique	O
mutation	O
PA	O
L336M	O
may	O
enhance	O
viral	B-PROC
replication	I-PROC
and	O
therefore	O
disease	O
severity	O
.	O

Over	O
a	O
year	O
after	O
the	O
emergence	O
of	O
this	O
novel	O
coronavirus	O
--	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)--	O
it	O
has	O
caused	O
178	O
laboratory	O
-	O
confirmed	O
cases	O
and	O
76	O
deaths	B-PROC
.	O

The	O
patient	O
received	O
no	O
systemic	O
anticoagulation	B-PROC
for	O
25	O
of	O
26	O
ECMO	O
days	O
(	O
20	O
days	O
consecutively	O
)	O
and	O
suffered	O
no	O
coagulation	B-PROC
-	O
related	O
adverse	O
events	O
.	O

This	O
procedure	O
utilized	O
primers	O
composed	O
of	O
20	O
bases	O
of	O
known	O
sequence	O
with	O
8	O
random	O
bases	O
at	O
the	O
3	O
'-	O
end	O
that	O
also	O
served	O
as	O
an	O
identifying	O
barcode	O
that	O
allowed	O
the	O
differentiation	B-PROC
each	O
viral	O
library	O
following	O
pooling	O
and	O
sequencing	O
.	O

The	O
Scientific	O
Development	B-PROC
Committee	O
of	O
the	O
Healthcare	O
Infection	O
HealtSociety	O
established	O
a	O
working	O
group	O
to	O
develop	O
guidance	O
addressing	O
this	O
issue	O
.	O

The	O
contemporary	O
occurrence	O
of	O
ARF	O
and	O
SS	O
was	O
associated	O
with	O
age	O
(	O
p	O
=	O
0	O
.	O
002	O
),	O
residency	O
in	O
nursing	B-PROC
home	O
(	O
p	O
=	O
0	O
.	O
007	O
),	O
COPD	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
multilobar	O
involvement	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
renal	O
disease	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Our	O
results	O
demonstrate	O
that	O
recently	O
emerged	O
H7N9	O
as	O
well	O
as	O
seasonal	O
IAVs	O
mainly	O
use	O
the	O
specific	O
protease	O
TMPRSS2	O
for	O
HA	O
cleavage	B-PROC
in	O
vivo	O
and	O
,	O
thus	O
,	O
that	O
TMPRSS2	O
expression	B-PROC
is	O
essential	O
for	O
IAV	O
replication	O
in	O
vivo	O
.	O

Stridor	O
was	O
auscultated	O
but	O
breathing	B-PROC
was	O
not	O
labored	O
.	O

In	O
the	O
context	O
of	O
the	O
S	O
protein	O
of	O
TGEV	O
(	O
1440YEPI1443	O
),	O
this	O
motif	O
acts	O
as	O
a	O
retention	B-PROC
signal	O
,	O
preventing	O
surface	O
expression	B-PROC
of	O
the	O
protein	O
.	O

TITLE	O
:	O
C5a	O
/	O
C5aR	O
pathway	B-PROC
is	O
essential	O
for	O
the	O
pathogenesis	B-PROC
of	O
murine	O
viral	O
fulminant	O
hepatitis	O
by	O
way	O
of	O
potentiating	O
Fgl2	O
/	O
fibroleukin	O
expression	B-PROC
.	O

Inferring	O
from	O
a	O
correlation	O
observed	O
between	O
the	O
genetic	O
differences	O
in	O
the	O
complement	O
component	O
5	O
(	O
C5	O
)	O
and	O
the	O
susceptibility	O
of	O
mouse	O
strains	O
to	O
murine	O
hepatitis	O
virus	O
strain	O
-	O
3	O
(	O
MHV	O
-	O
3	O
)	O
infections	O
,	O
we	O
propose	O
that	O
excessive	O
complement	B-PROC
activation	I-PROC
plays	O
a	O
critical	O
role	O
in	O
the	O
development	B-PROC
of	O
FH	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
provide	O
evidence	O
that	O
mouse	O
susceptibility	O
to	O
MHV	O
-	O
3	O
-	O
induced	O
FH	O
may	O
rely	O
on	O
C5a	O
/	O
C5aR	O
interactions	O
,	O
for	O
which	O
ERK1	O
/	O
2	O
and	O
p38	O
pathways	B-PROC
participate	O
in	O
up	O
-	O
regulating	O
Fgl2	O
expression	B-PROC
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
severe	O
cancer	O
cachexia	O
disrupts	O
the	O
acute	O
contraction	O
-	O
induced	O
response	O
to	O
low	O
-	O
frequency	O
muscle	B-PROC
contraction	I-PROC
[	O
low	O
-	O
frequency	O
stimulation	O
(	O
LoFS	O
)].	O

However	O
,	O
in	O
Min	O
mice	O
,	O
LoFS	O
was	O
not	O
able	O
to	O
induce	O
muscle	O
proliferator	O
-	O
activated	O
receptor	O
-	O
α	O
coactivator	O
-	O
1	O
targets	O
nuclear	O
respiratory	O
factor	O
-	O
1	O
and	O
mitochondrial	B-PROC
transcription	I-PROC
factor	O
A	O
mRNA	O
.	O

To	O
better	O
understand	O
the	O
replication	O
features	O
of	O
these	O
viruses	O
in	O
their	O
target	O
organs	O
and	O
molecular	O
pathogenesis	B-PROC
of	O
these	O
different	O
viruses	O
,	O
comparative	O
proteomic	O
analysis	O
was	O
performed	O
to	O
investigate	O
the	O
proteome	O
changes	O
of	O
primary	O
target	O
organ	O
during	O
IBV	O
,	O
NDV	O
,	O
and	O
AIV	O
H9	O
infections	O
,	O
using	O
2D	O
-	O
DIGE	O
followed	O
MALDI	O
-	O
TOF	O
/	O
TOF	O
-	O
MS	O
.	O

The	O
changes	O
in	O
the	O
expression	B-PROC
of	O
genes	O
related	O
to	O
eggshell	B-PROC
formation	I-PROC
(	O
collagen	O
types	O
I	O
and	O
V	O
,	O
and	O
CaBP	O
-	O
D28K	O
),	O
densities	O
of	O
cytotoxic	O
cells	O
(	O
CD8	O
(+)	O
and	O
TCR	B-PROC
-	O
γδ	O
(+)	O
T	O
cells	O
),	O
and	O
gene	B-PROC
expression	I-PROC
of	O
molecules	O
related	O
to	O
cytotoxic	O
immunoreaction	B-PROC
(	O
B	O
-	O
NK	O
,	O
perforin	O
,	O
granzyme	O
,	O
and	O
IL	O
-	O
2	O
)	O
and	O
proinflammatory	O
cytokines	O
(	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
6	O
and	O
IFN	O
-	O
γ	O
)	O
were	O
examined	O
by	O
quantitative	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
or	O
immunohistochemistry	O
in	O
the	O
isthmus	O
and	O
uterus	O
.	O

The	O
frequencies	O
of	O
CD8	O
(+)	O
cells	O
and	O
TCR	B-PROC
-	O
γδ	O
(+)	O
T	O
cells	O
in	O
the	O
isthmus	O
and	O
uterus	O
were	O
significantly	O
higher	O
in	O
the	O
aIBV	O
group	O
than	O
in	O
the	O
control	O
group	O
.	O

ABSTRACT	O
:	O
Recombination	B-PROC
among	O
infectious	O
bronchitis	O
viruses	O
(	O
IBVs	O
),	O
coupled	O
with	O
point	B-PROC
mutations	I-PROC
,	O
insertions	O
,	O
and	O
deletions	O
that	O
occur	O
in	O
the	O
genome	O
,	O
is	O
thought	O
to	O
contribute	O
to	O
the	O
emergence	O
of	O
new	O
IBV	O
variants	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
S1	O
subunit	O
sequence	O
confirmed	O
that	O
strain	O
ck	O
/	O
CH	O
/	O
LJL	O
/	O
111054	O
is	O
of	O
the	O
Connecticut	O
-	O
type	O
;	O
however	O
,	O
further	O
extensive	O
full	O
-	O
length	O
genomic	O
analysis	O
identified	O
the	O
occurrence	O
of	O
recombination	B-PROC
events	O
.	O

Acute	O
and	O
chronic	O
CD4	O
(+)	O
T	O
cell	O
-	O
mediated	O
experimental	O
autoimmune	O
encephalomyelitis	O
lesions	O
showed	O
transient	O
expression	B-PROC
of	O
p22phox	O
and	O
iNOS	O
associated	O
with	O
inflammation	O
.	O

Macrophages	O
in	O
chronic	O
lesions	O
of	O
antibody	B-PROC
-	O
mediated	O
demyelinating	O
encephalomyelitis	O
showed	O
lysosomal	O
activity	O
but	O
very	O
little	O
p22phox	O
or	O
iNOS	O
expressions	O
.	O

Active	O
inflammatory	O
demyelinating	O
lesions	O
induced	O
by	O
CD8	O
(+)	O
T	O
cells	O
or	O
by	O
innate	B-PROC
immunity	B-PROC
showed	O
macrophage	O
and	O
microglial	O
activation	O
together	O
with	O
the	O
expression	B-PROC
of	O
p22phox	O
,	O
but	O
low	O
or	O
absent	O
iNOS	O
reactivity	O
.	O

We	O
corroborated	O
the	O
differences	O
between	O
acute	O
CD4	O
(+)	O
T	O
cell	O
-	O
mediated	O
experimental	O
autoimmune	O
encephalomyelitis	O
and	O
acute	O
MS	O
lesions	O
via	O
gene	B-PROC
expression	I-PROC
studies	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
papain	O
-	O
like	O
protease	O
inhibits	O
the	O
type	O
I	O
interferon	O
signaling	B-PROC
pathway	I-PROC
through	O
interaction	O
with	O
the	O
STING	O
-	O
TRAF3	O
-	O
TBK1	O
complex	O
.	O

These	O
results	O
collectively	O
point	O
to	O
a	O
new	O
mechanism	O
used	O
by	O
SARS	O
-	O
CoV	O
through	O
which	O
PLpro	O
negatively	O
regulates	O
IRF3	O
activation	O
by	O
interaction	O
with	O
STING	O
-	O
TRAF3	O
-	O
TBK1	O
complex	O
,	O
yielding	O
a	O
SARS	O
-	O
CoV	O
countermeasure	O
against	O
host	O
innate	B-PROC
immunity	B-PROC
.	O

The	O
results	O
show	O
that	O
the	O
replicase	O
gene	O
has	O
flexibility	O
to	O
accommodate	O
a	O
foreign	O
gene	O
addition	O
and	O
can	O
be	O
used	O
directly	O
to	O
study	O
replicase	O
complex	O
formation	B-PROC
and	O
evolution	B-PROC
during	O
infection	O
as	O
well	O
as	O
to	O
provide	O
highly	O
sensitive	O
and	O
specific	O
markers	O
for	O
protein	B-PROC
translation	B-PROC
and	O
genome	O
replication	O
.	O

Coronaviruses	O
are	O
a	O
family	O
of	O
enveloped	O
,	O
positive	O
-	O
sense	B-PROC
RNA	O
viruses	O
that	O
are	O
important	O
agents	O
of	O
disease	O
,	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

TITLE	O
:	O
Molecular	O
characterizations	O
of	O
subcellular	O
localization	B-PROC
signals	O
in	O
the	O
nucleocapsid	O
protein	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Furthermore	O
,	O
by	O
utilizing	O
fusion	O
proteins	O
with	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
),	O
deletion	B-PROC
mutations	I-PROC
or	O
site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
of	O
PEDV	O
N	O
protein	O
,	O
coupled	O
with	O
live	O
cell	O
imaging	O
and	O
confocal	O
microscopy	O
,	O
it	O
was	O
revealed	O
that	O
,	O
a	O
region	O
spanning	O
amino	O
acids	O
(	O
aa	O
),	O
71	O
-	O
90	O
in	O
region	O
1	O
of	O
the	O
N	O
protein	O
was	O
sufficient	O
for	O
nucleolar	O
localization	B-PROC
and	O
R87	O
and	O
R89	O
were	O
critical	O
for	O
its	O
function	O
.	O

We	O
also	O
identified	O
two	O
nuclear	B-PROC
export	I-PROC
signals	O
(	O
NES	O
,	O
aa221	O
-	O
236	O
,	O
and	O
325	O
-	O
364	O
),	O
however	O
,	O
only	O
the	O
nuclear	B-PROC
export	I-PROC
signal	O
(	O
aa325	O
-	O
364	O
)	O
was	O
found	O
to	O
be	O
functional	O
in	O
the	O
context	O
of	O
the	O
full	O
-	O
length	O
N	O
protein	O
.	O

This	O
study	O
provides	O
unique	O
insight	O
into	O
how	O
several	O
parameters	O
of	O
the	O
systemic	O
and	O
mucosal	B-PROC
immune	I-PROC
response	I-PROC
to	O
SARS	O
-	O
CoV	O
infection	O
are	O
significantly	O
modulated	O
by	O
age	O
.	O

These	O
immune	O
differences	O
may	O
contribute	O
to	O
deficient	O
immune	B-PROC
function	I-PROC
and	O
the	O
observed	O
trend	O
of	O
higher	O
SARS	O
-	O
CoV	O
replication	O
in	O
aged	O
nonhuman	O
primates	O
.	O

ABSTRACT	O
:	O
Double	O
-	O
stranded	O
RNA	O
-	O
dependent	O
protein	O
kinase	O
(	O
PKR	O
)	O
regulates	O
antiviral	O
activity	O
,	O
immune	B-PROC
responses	I-PROC
,	O
apoptosis	B-PROC
and	O
neurotoxicity	O
.	O

However	O
,	O
in	O
situations	O
where	O
there	O
is	O
severe	O
decrease	O
in	O
lung	B-PROC
compliance	I-PROC
,	O
an	O
ICU	O
ventilator	O
may	O
be	O
superior	O
in	O
its	O
ability	O
to	O
regulate	O
inspiratory	B-PROC
flow	O
improving	O
both	O
ventilation	O
and	O
oxygenation	B-PROC
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
co	O
-	O
infection	O
induced	O
chlamydial	O
persistence	O
/	O
stress	O
does	O
not	O
require	O
viral	B-PROC
replication	I-PROC
.	O

Synthetic	O
-	O
genome	O
platforms	O
capable	O
of	O
reconstituting	O
emerging	O
zoonotic	O
viral	O
pathogens	O
or	O
their	O
phylogenetic	O
relatives	O
provide	O
new	O
strategies	O
for	O
identifying	O
broad	O
-	O
based	O
therapeutics	O
,	O
evaluating	O
vaccine	O
outcomes	O
,	O
and	O
studying	O
viral	O
pathogenesis	B-PROC
.	O

ABSTRACT	O
:	O
Zinc	O
(	O
Zn	O
)	O
supplementation	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
incidence	O
of	O
diarrhea	O
and	O
to	O
protect	O
animals	O
from	O
intestinal	O
diseases	O
,	O
but	O
the	O
mechanisms	O
of	O
this	O
protective	O
effect	O
against	O
virus	B-PROC
infection	I-PROC
in	O
vivo	O
have	O
not	O
yet	O
been	O
elucidated	O
.	O

Fecal	O
consistency	O
was	O
improved	O
and	O
body	O
weights	O
increased	O
in	O
the	O
Znhigh	O
group	O
when	O
compared	O
to	O
the	O
other	O
groups	O
,	O
but	O
no	O
direct	O
effect	O
of	O
Zn	O
concentrations	O
in	O
the	O
diet	O
on	O
fecal	O
TGEV	O
shedding	O
and	O
mucosal	B-PROC
immune	I-PROC
responses	I-PROC
was	O
detectable	O
.	O

Finally	O
,	O
in	O
the	O
Znhigh	O
group	O
,	O
we	O
documented	O
an	O
earlier	O
and	O
higher	O
systemic	O
TGEV	O
-	O
specific	O
serum	O
antibody	B-PROC
response	I-PROC
.	O

ABSTRACT	O
:	O
Few	O
studies	O
have	O
investigated	O
associations	O
between	O
psychological	O
and	O
behavioral	B-PROC
indices	O
throughout	O
a	O
major	O
epidemic	O
.	O

This	O
study	O
was	O
aimed	O
to	O
compare	O
the	O
strength	O
of	O
associations	O
between	O
different	O
cognitive	O
and	O
affective	O
measures	O
of	O
risk	O
and	O
self	O
-	O
reported	O
protective	O
behaviors	B-PROC
in	O
a	O
series	O
of	O
ten	O
cross	O
-	O
sectional	O
surveys	O
conducted	O
throughout	O
the	O
first	O
wave	O
of	O
influenza	O
A	O
/	O
H1N1	O
pandemic	O
.	O

Molecular	O
docking	B-PROC
of	O
compound	O
Ih	O
with	O
wt	O
HIV	O
-	O
1	O
RT	O
was	O
performed	O
to	O
understand	O
the	O
binding	O
mode	O
between	O
these	O
inhibitors	O
and	O
the	O
wt	O
HIV	O
-	O
1	O
RT	O
and	O
to	O
rationalize	O
some	O
SARs	O
.	O

Based	O
on	O
the	O
data	O
presented	O
in	O
this	O
paper	O
,	O
it	O
can	O
be	O
concluded	O
that	O
genetic	O
changes	O
due	O
to	O
adaptive	O
evolution	B-PROC
and	O
recombination	B-PROC
both	O
contributed	O
to	O
the	O
origin	O
of	O
strain	O
ck	O
/	O
CH	O
/	O
IBTZ	O
/	O
2012	O
,	O
which	O
belongs	O
to	O
a	O
new	O
genotype	O
.	O

ABSTRACT	O
:	O
The	O
relationships	O
between	O
tonsillar	O
immune	B-PROC
responses	I-PROC
,	O
and	O
viral	B-PROC
infection	I-PROC
and	O
allergy	B-PROC
are	O
incompletely	O
known	O
.	O

To	O
study	O
intratonsillar	O
/	O
nasopharyngeal	O
virus	O
detections	O
and	O
in	O
vivo	O
expressions	O
of	O
T	O
-	O
cell	O
-	O
and	O
innate	B-PROC
immune	I-PROC
response	I-PROC
-	O
specific	O
cytokines	O
,	O
transcription	B-PROC
factors	O
,	O
and	O
type	O
I	O
/	O
II	O
/	O
III	O
interferons	O
in	O
human	O
tonsils	O
.	O

The	O
mRNA	B-PROC
expression	B-PROC
levels	O
of	O
IFN	O
-	O
α	O
,	O
IFN	O
-	O
β	O
,	O
IFN	O
-	O
γ	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
13	O
,	O
IL	B-PROC
-	I-PROC
17	I-PROC
,	O
IL	O
-	O
28	O
,	O
IL	O
-	O
29	O
,	O
IL	O
-	O
37	O
,	O
TGF	O
-	O
β	O
,	O
FOXP3	O
,	O
GATA3	O
,	O
RORC2	O
,	O
and	O
Tbet	O
were	O
directly	O
analyzed	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O

Network	O
analyses	O
demonstrated	O
strongly	O
polarized	O
clusters	O
of	O
immune	O
regulatory	O
(	O
IL	O
-	O
10	O
,	O
IL	B-PROC
-	I-PROC
17	I-PROC
,	O
TGF	O
-	O
β	O
,	O
FOXP3	O
,	O
GATA3	O
,	O
RORC2	O
,	O
Tbet	O
)	O
and	O
antiviral	O
(	O
IFN	O
-	O
α	O
,	O
IFN	O
-	O
β	O
,	O
IL	O
-	O
28	O
,	O
IL	O
-	O
29	O
)	O
genes	O
.	O

TITLE	O
:	O
Spectrum	O
of	O
viral	B-PROC
infections	I-PROC
in	O
patients	O
with	O
cystic	O
fibrosis	O
.	O

We	O
also	O
found	O
that	O
the	O
amount	O
of	O
Ark	O
vaccine	O
virus	O
was	O
low	O
or	O
undetectable	O
in	O
choanal	O
swabs	O
out	O
to	O
35	O
days	O
postvaccination	O
when	O
vaccine	O
was	O
administered	O
by	O
eyedrop	O
or	O
drinking	B-PROC
water	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
detection	O
of	O
IBV	O
vaccine	O
virus	O
early	O
after	O
administration	O
,	O
regardless	O
of	O
strain	O
or	O
route	O
,	O
correlated	O
with	O
protection	O
against	O
homologous	O
challenge	O
and	O
may	O
thus	O
be	O
a	O
good	O
indicator	O
of	O
vaccine	O
efficacy	O
in	O
the	O
field	O
because	O
humoral	O
antibody	B-PROC
titers	O
are	O
typically	O
low	O
or	O
undetectable	O
after	O
vaccination	O
.	O

TITLE	O
:	O
An	O
Avian	O
coronavirus	O
in	O
quail	O
with	O
respiratory	O
and	O
reproductive	B-PROC
signs	O
.	O

JMML	O
are	O
all	O
stem	O
cell	O
diseases	O
the	O
common	O
denominator	O
of	O
which	O
is	O
RAS	O
pathway	B-PROC
dysregulation	O
,	O
due	O
to	O
mutations	O
in	O
RAS	O
(	O
NRAS	O
,	O
KRAS	O
)	O
or	O
RAS	O
regulatory	O
components	O
(	O
PTPN11	O
,	O
NF1	O
or	O
CBL	O
).	O

TITLE	O
:	O
Predicting	O
survival	O
after	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
severe	O
acute	O
respiratory	O
failure	O
.	O

No	O
cross	B-PROC
reactivity	I-PROC
was	O
observed	O
for	O
both	O
panels	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
first	O
described	O
in	O
September	O
2012	O
and	O
to	O
date	O
86	O
deaths	B-PROC
from	O
a	O
total	O
of	O
206	O
cases	O
of	O
MERS	O
-	O
CoV	O
infection	O
have	O
been	O
reported	O
to	O
the	O
WHO	O
.	O

Further	O
,	O
we	O
show	O
that	O
this	O
physiological	O
depriming	O
mechanism	O
may	O
fail	O
in	O
patients	O
with	O
ARDS	O
,	O
resulting	O
in	O
increased	O
numbers	O
of	O
primed	O
neutrophils	O
within	O
the	O
systemic	O
circulation	B-PROC
.	O

TITLE	O
:	O
Dramatic	O
differences	O
in	O
the	O
response	O
of	O
macrophages	O
from	O
B2	O
and	O
B19	O
MHC	B-PROC
-	O
defined	O
haplotypes	O
to	O
interferon	O
gamma	O
and	O
polyinosinic	O
:	O
polycytidylic	O
acid	O
stimulation	O
.	O

Peripheral	O
blood	O
-	O
derived	O
macrophages	O
were	O
stimulated	O
with	O
poly	O
I	O
:	O
C	O
,	O
simulating	O
an	O
RNA	O
virus	O
,	O
or	O
IFNγ	O
,	O
a	O
cytokine	O
at	O
the	O
interface	O
of	O
innate	O
and	O
adaptive	O
immunity	B-PROC
.	O

Many	O
commercial	O
herbal	O
medicines	O
containing	O
one	O
or	O
more	O
compounds	O
have	O
been	O
successfully	O
applied	O
to	O
prevent	O
and	O
treat	O
viral	B-PROC
infections	I-PROC
of	O
respiratory	O
tract	O
clinically	O
.	O

Many	O
commercial	O
herbal	O
medicines	O
containing	O
one	O
or	O
more	O
compounds	O
have	O
been	O
successfully	O
applied	O
to	O
prevent	O
and	O
treat	O
viral	B-PROC
infections	I-PROC
of	O
respiratory	O
tract	O
clinically	O
.	O

Our	O
findings	O
suggest	O
that	O
these	O
six	O
herbal	O
extracts	O
may	O
have	O
potential	O
as	O
candidates	O
for	O
future	O
development	B-PROC
of	O
anti	O
-	O
SARS	O
therapeutics	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
vvECMO	O
)	O
can	O
be	O
a	O
life	O
-	O
saving	O
therapy	O
in	O
patients	O
with	O
severe	O
acute	O
lung	O
failure	O
refractory	O
to	O
conventional	O
therapy	O
.	O

Acute	O
respiratory	O
syndrome	O
(	O
ARDS	O
)	O
has	O
been	O
found	O
to	O
be	O
the	O
most	O
severe	O
form	O
of	O
acute	O
lung	O
injury	O
caused	O
by	O
H5N1	O
virus	B-PROC
infection	I-PROC
while	O
cytokine	O
dysregulation	O
and	O
viral	B-PROC
replication	I-PROC
are	O
thought	O
to	O
contribute	O
to	O
its	O
pathogenesis	B-PROC
.	O

Specifically	O
,	O
when	O
given	O
to	O
a	O
person	O
(	O
e	O
.	O
g	O
.,	O
a	O
patient	O
'	O
s	O
family	O
member	O
or	O
a	O
health	O
care	O
worker	O
)	O
either	O
before	O
or	O
after	O
exposure	O
to	O
MERS	O
-	O
CoV	O
,	O
the	O
humanized	O
antibody	B-PROC
may	O
prevent	O
or	O
inhibit	O
MERS	O
-	O
CoV	O
infection	O
,	O
thereby	O
stopping	O
the	O
spread	O
of	O
MERS	O
-	O
CoV	O
in	O
humans	O
.	O

Macrolide	O
resistance	B-PROC
genotypes	O
have	O
been	O
detected	O
.	O

An	O
internal	O
amplification	O
control	O
was	O
included	O
into	O
the	O
RT	O
-	O
PCR	O
assays	O
targeting	B-PROC
the	O
genomic	O
region	O
upstream	O
of	O
the	O
Envelope	O
gene	O
(	O
upE	O
)	O
and	O
within	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1A	O
.	O

ABSTRACT	O
:	O
Cytokine	O
storm	O
defines	O
a	O
dysregulation	O
of	O
and	O
an	O
excessively	O
exaggerated	O
immune	B-PROC
response	I-PROC
most	O
often	O
accompanying	O
selected	O
viral	B-PROC
infections	I-PROC
and	O
several	O
autoimmune	O
diseases	O
.	O

It	O
provides	O
the	O
compelling	O
evidence	O
that	O
illuminates	O
cytokine	O
storm	O
in	O
influenza	O
pathogenesis	B-PROC
and	O
the	O
clear	O
findings	O
that	O
cytokine	O
storm	O
is	O
chemically	O
tractable	O
by	O
therapy	O
directed	O
toward	O
sphingosine	O
-	O
1	O
-	O
phosphate	O
receptor	O
(	O
S1PR	O
)	O
modulation	O
,	O
specifically	O
S1P1R	O
agonist	O
therapy	O
.	O

Our	O
data	O
suggest	O
that	O
neutrophil	O
elastase	O
inhibitor	O
attenuates	O
high	O
-	O
tidal	O
-	O
volume	O
mechanical	O
ventilation	O
-	O
induced	O
neutrophil	O
influx	O
,	O
oxidative	O
stress	O
,	O
and	O
production	O
of	O
MIP	O
-	O
2	O
,	O
at	O
least	O
partly	O
,	O
through	O
inhibition	B-PROC
of	O
NF	O
-	O
κB	O
/	O
NRF	O
pathway	B-PROC
.	O

SimPlot	O
analysis	O
of	O
the	O
7	O
.	O
2	O
-	O
kb	O
3	O
'	O
end	O
of	O
the	O
N1	O
/	O
08	O
genome	O
with	O
the	O
same	O
region	O
for	O
other	O
Australian	O
reference	O
strains	O
identified	O
the	O
sites	O
of	O
recombination	B-PROC
as	O
immediately	O
upstream	O
and	O
downstream	O
of	O
the	O
S1	O
gene	O
.	O

RESULTS	O
:	O
In	O
pneumococcal	O
pneumonia	O
,	O
MV	O
increased	O
lung	O
permeability	O
,	O
and	O
worsened	O
lung	O
mechanics	O
and	O
oxygenation	B-PROC
failure	O
.	O

TITLE	O
:	O
Long	O
-	O
term	O
survival	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
rescue	O
therapies	O
for	O
refractory	O
hypoxemia	O
*.	O
ABSTRACT	O
:	O
To	O
describe	O
long	O
-	O
term	O
survival	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
assess	O
differences	O
in	O
patient	O
characteristics	O
and	O
outcomes	O
among	O
those	O
who	O
receive	O
rescue	O
therapies	O
(	O
prone	O
position	O
ventilation	O
,	O
inhaled	B-PROC
nitric	O
oxide	O
,	O
or	O
inhaled	B-PROC
epoprostenol	O
)	O
versus	O
conventional	O
treatment	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	B-PROC
,	O
anti	O
-	O
tobacco	O
mosaic	O
virus	O
(	O
TMV	O
)	O
activity	O
,	O
and	O
SARs	O
of	O
7	O
-	O
methoxycryptopleurine	O
derivatives	O
.	O

Not	O
surprisingly	O
,	O
viruses	O
have	O
adapted	O
to	O
encode	O
virulence	B-PROC
factors	O
to	O
cope	O
with	O
the	O
IFN	O
response	O
.	O

TITLE	O
:	O
Comparison	O
of	O
vaccine	O
subpopulation	O
selection	O
,	O
viral	O
loads	O
,	O
vaccine	O
virus	O
persistence	O
in	O
trachea	O
and	O
cloaca	O
,	O
and	O
mucosal	O
antibody	B-PROC
responses	I-PROC
after	O
vaccination	O
with	O
two	O
different	O
Arkansas	O
Delmarva	O
Poultry	O
Industry	O
-	O
derived	O
infectious	O
bronchitis	O
virus	O
vaccines	O
.	O

Immunofluorescence	O
assays	O
detected	O
no	O
difference	O
in	O
HCoV	O
-	O
NL63	O
antibody	B-PROC
positivity	O
between	O
the	O
patients	O
with	O
Kawasaki	O
disease	O
and	O
controls	O
,	O
whereas	O
the	O
rate	O
of	O
HCoV	O
-	O
229E	O
antibody	B-PROC
positivity	O
was	O
higher	O
in	O
the	O
patients	O
with	O
Kawasaki	O
disease	O
than	O
that	O
in	O
controls	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
3a	O
protein	O
functions	O
as	O
an	O
ion	O
channel	O
,	O
induces	O
apoptosis	B-PROC
and	O
is	O
important	O
for	O
viral	O
pathogenesis	B-PROC
.	O

Although	O
the	O
catalytic	O
activity	O
of	O
the	O
ACE2	O
,	O
APN	O
,	O
and	O
DPP4	O
peptidases	O
is	O
not	O
required	O
for	O
virus	O
entry	O
,	O
co	O
-	O
expression	B-PROC
of	O
other	O
host	O
proteases	O
allows	O
efficient	O
viral	O
entry	O
.	O

All	O
the	O
patients	O
in	O
the	O
NIV	O
failure	O
group	O
died	B-PROC
within	O
20	O
.	O
2	O
±	O
15	O
.	O
3	O
days	O
of	O
intubation	O
.	O

The	O
use	O
of	O
NIV	O
was	O
,	O
nevertheless	O
,	O
found	O
to	O
be	O
associated	O
with	O
clinical	O
benefits	O
in	O
selected	O
IPF	O
patients	O
,	O
preventing	O
the	O
need	O
for	O
intubation	O
and	O
reducing	O
the	O
rate	O
of	O
complications	O
/	O
death	B-PROC
.	O

TITLE	O
:	O
Act	O
fast	O
and	O
ventilate	O
soft	O
:	O
the	O
Düsseldorf	O
hands	O
-	O
on	O
translation	B-PROC
of	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
Berlin	O
definition	O
.	O

We	O
here	O
present	O
an	O
integrated	O
""""	O
Düsseldorf	O
hands	O
-	O
on	O
translation	B-PROC
""""	O
in	O
the	O
form	O
of	O
a	O
""""	O
one	O
-	O
page	O
""""	O
standard	O
operating	O
procedure	O
in	O
order	O
to	O
fasten	O
and	O
standardize	O
both	O
diagnosis	O
and	O
therapeutic	O
algorithms	O
on	O
an	O
intensive	O
care	O
unit	O
.	O

Nonhuman	O
primates	O
(	O
NHP	O
)	O
are	O
considered	O
the	O
gold	O
standard	O
model	O
for	O
studying	O
the	O
underlying	O
immune	O
activation	O
/	O
suppression	B-PROC
associated	O
with	O
immunopathogenic	O
viruses	O
such	O
as	O
hantaviruses	O
;	O
however	O
,	O
to	O
date	O
an	O
NHP	O
model	O
for	O
HPS	O
has	O
not	O
been	O
described	O
.	O

MERS	O
-	O
4	O
also	O
showed	O
inhibitory	O
activity	O
against	O
syncytia	O
formation	B-PROC
mediated	O
by	O
interaction	O
between	O
MERS	O
-	O
CoV	O
spike	O
glycoprotein	O
and	O
DPP4	O
.	O

Interestingly	O
,	O
mice	O
infected	O
with	O
viruses	O
displaying	O
E	O
protein	O
IC	O
activity	O
,	O
either	O
with	O
the	O
wild	O
-	O
type	O
E	O
protein	O
sequence	O
or	O
with	O
the	O
revertants	O
that	O
restored	O
ion	B-PROC
transport	B-PROC
,	O
rapidly	O
lost	O
weight	O
and	O
died	B-PROC
.	O

We	O
identified	O
three	O
human	O
monoclonal	O
antibodies	O
(	O
MAbs	O
),	O
m336	O
,	O
m337	O
,	O
and	O
m338	O
,	O
targeting	B-PROC
the	O
receptor	O
(	O
CD26	O
/	O
DPP4	O
)	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
glycoprotein	O
from	O
a	O
very	O
large	O
naïve	O
-	O
antibody	B-PROC
library	O
(	O
containing	O
∼	O
10	O
(	O
11	O
)	O
antibodies	O
).	O

We	O
report	O
here	O
the	O
identification	O
of	O
human	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
from	O
a	O
large	O
nonimmune	O
antibody	B-PROC
library	O
that	O
target	O
MERS	O
-	O
CoV	O
.	O
One	O
of	O
the	O
antibodies	O
,	O
m336	O
,	O
neutralized	O
the	O
virus	O
with	O
exceptional	O
potency	O
.	O

These	O
new	O
tools	O
will	O
allow	O
a	O
more	O
comprehensive	O
analysis	O
of	O
the	O
ferret	O
immune	B-PROC
responses	I-PROC
following	O
infection	O
or	O
in	O
other	O
disease	O
states	O
.	O

A	O
51	O
-	O
year	O
-	O
old	O
man	O
,	O
who	O
had	O
undergone	O
a	O
TLPG	O
at	O
a	O
referring	O
hospital	O
,	O
was	O
referred	O
for	O
fever	B-PROC
,	O
elevated	O
inflammation	O
markers	O
,	O
and	O
pleural	O
effusion	O
on	O
postoperative	O
day	O
3	O
.	O

The	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHEII	O
)	O
score	O
,	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
),	O
arterial	O
oxygenation	B-PROC
index	O
(	O
PaO2	O
/	O
FiO2	O
),	O
central	O
venous	B-PROC
oxygen	I-PROC
saturation	I-PROC
(	O
ScvO2	O
),	O
arterial	O
blood	O
lactate	O
(	O
Lac	O
),	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
levels	O
of	O
two	O
groups	O
were	O
compared	O
before	O
treatment	O
and	O
48	O
hours	O
after	O
treatment	O
,	O
and	O
21	O
-	O
day	O
mortality	O
rate	O
was	O
finally	O
compared	O
.	O

The	O
oxygenation	B-PROC
index	O
(	O
OI	O
),	O
peak	O
inspiratory	B-PROC
pressure	O
(	O
PIP	O
),	O
plat	O
pressure	O
(	O
Pplat	O
)	O
and	O
central	O
venous	B-PROC
pressure	I-PROC
(	O
CVP	B-PROC
)	O
were	O
markedly	O
elevated	O
(	O
OI	O
:	O
324	O
.	O
7	O
±	O
117	O
.	O
2	O
mmHg	O
vs	O
.	O
173	O
.	O
4	O
±	O
95	O
.	O
8	O
mmHg	O
,	O
t	O
=	O
5	O
.	O
913	O
,	O
P	O
=	O
0	O
.	O
000	O
;	O
PIP	O
:	O
34	O
.	O
7	O
±	O
9	O
.	O
1	O
cmH2O	O
vs	O
.	O
26	O
.	O
1	O
±	O
7	O
.	O
9	O
cmH2O	O
,	O
t	O
=	O
4	O
.	O
222	O
,	O
P	O
=	O
0	O
.	O
000	O
;	O
Pplat	O
:	O
30	O
.	O
5	O
±	O
8	O
.	O
4	O
cmH2O	O
vs	O
.	O
22	O
.	O
2	O
±	O
7	O
.	O
1	O
cmH2O	O
,	O
t	O
=	O
4	O
.	O
465	O
,	O
P	O
=	O
0	O
.	O
000	O
;	O
CVP	B-PROC
:	O
12	O
.	O
1	O
±	O
3	O
.	O
5	O
mmHg	O
vs	O
.	O
8	O
.	O
8	O
±	O
2	O
.	O
2	O
mmHg	O
,	O
t	O
=	O
4	O
.	O
723	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
when	O
PEEP	O
was	O
increased	O
from	O
(	O
6	O
.	O
4	O
±	O
1	O
.	O
0	O
)	O
cmH2O	O
to	O
(	O
14	O
.	O
5	O
±	O
2	O
.	O
0	O
)	O
cmH2O	O
(	O
1	O
cmH2O	O
=	O
0	O
.	O
098	O
kPa	O
).	O

However	O
,	O
independent	O
of	O
preexisting	O
cerebral	O
autoregulation	B-PROC
may	O
not	O
further	O
be	O
impaired	O
when	O
a	O
high	O
PEEP	O
was	O
chosen	O
.	O

(	O
2	O
)	O
The	O
areas	O
under	O
the	O
ROC	O
curve	O
of	O
0	O
h	O
blood	O
lactate	O
,	O
6	O
h	O
lactate	O
clearance	O
rate	O
and	O
APACHE	O
II	O
score	O
for	O
predicting	O
death	B-PROC
were	O
0	O
.	O
699	O
±	O
0	O
.	O
083	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
567	O
∼	O
0	O
.	O
892	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
0	O
.	O
871	O
±	O
0	O
.	O
119	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
724	O
∼	O
0	O
.	O
980	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
0	O
.	O
836	O
±	O
0	O
.	O
063	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
713	O
∼	O
0	O
.	O
958	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

ABSTRACT	O
:	O
In	O
April	O
2012	O
,	O
the	O
Jordan	O
Ministry	O
of	O
Health	O
investigated	O
an	O
outbreak	O
of	O
lower	O
respiratory	O
illnesses	O
at	O
a	O
hospital	O
in	O
Jordan	O
;	O
2	O
fatal	O
cases	O
were	O
retrospectively	O
confirmed	O
by	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
to	O
be	O
the	O
first	O
detected	O
cases	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Influenza	O
A	O
viruses	O
recruit	O
components	O
of	O
the	O
nuclear	B-PROC
import	I-PROC
pathway	B-PROC
to	O
enter	O
the	O
host	O
cell	O
nucleus	O
and	O
promote	O
viral	B-PROC
replication	I-PROC
.	O

In	O
WT	O
mice	O
,	O
influenza	O
virus	B-PROC
replication	I-PROC
in	O
the	O
bronchial	O
and	O
alveolar	O
epithelium	O
already	O
occurred	O
a	O
few	O
days	O
after	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
evidence	O
saying	O
that	O
the	O
rate	O
of	O
Systemic	O
Inflammatory	B-PROC
Response	I-PROC
Syndrome	O
(	O
SIRS	O
)	O
is	O
high	O
in	O
patients	O
with	O
advanced	O
cirrhosis	O
and	O
portal	O
hypertension	O
,	O
this	O
could	O
have	O
negative	O
outcome	O
on	O
patients	O
prognosis	O
.	O

SIRS	O
was	O
correlated	O
with	O
death	B-PROC
(	O
p	O
<	O
0	O
.	O
00	O
)	O
on	O
multivariate	O
analysis	O
,	O
SIRS	O
was	O
independently	O
associated	O
with	O
hospital	O
death	B-PROC
.	O

TITLE	O
:	O
T	O
cell	B-PROC
-	I-PROC
mediated	I-PROC
immune	I-PROC
response	I-PROC
to	O
respiratory	O
coronaviruses	O
.	O

Notably	O
,	O
influenza	O
A	O
virus	O
NS1	O
appears	O
to	O
play	O
a	O
central	O
role	O
in	O
this	O
histone	O
-	O
mediated	O
downregulation	B-PROC
in	O
highly	O
pathogenic	O
influenza	O
strains	O
.	O

The	O
use	O
of	O
vv	O
-	O
ECMO	O
was	O
performed	O
without	O
anticoagulation	B-PROC
because	O
of	O
his	O
traumatic	O
brain	O
injury	O
and	O
severe	O
spinal	O
cord	O
injury	O
.	O

TITLE	O
:	O
Sonographic	O
dynamic	O
assessment	O
of	O
lung	O
injury	O
in	O
a	O
child	O
with	O
hypoplastic	O
left	O
heart	O
syndrome	O
undergoing	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

No	O
effect	O
of	O
treatment	O
was	O
found	O
for	O
clinical	O
scores	O
,	O
levels	O
of	O
the	O
5	O
most	O
common	O
pathogens	O
in	O
feces	O
,	O
or	O
in	O
development	B-PROC
of	O
serum	O
antibodies	O
against	O
the	O
3	O
most	O
common	O
respiratory	O
pathogens	O
.	O

Analysis	O
of	O
the	O
whole	O
human	O
-	O
derived	O
virus	O
and	O
15	O
%	O
of	O
the	O
camel	O
-	O
derived	O
virus	O
sequence	O
yielded	O
nucleotide	O
polymorphism	B-PROC
signatures	O
suggestive	O
of	O
cross	O
-	O
species	O
transmission	O
.	O

TITLE	O
:	O
Major	O
emerging	O
and	O
re	O
-	O
emerging	O
zoonoses	O
in	O
China	O
:	O
a	O
matter	O
of	O
global	O
health	O
and	O
socioeconomic	O
development	B-PROC
for	O
1	O
.	O
3	O
billion	O
.	O

Using	O
a	O
glia	O
-	O
tropic	O
coronavirus	O
model	O
,	O
we	O
demonstrate	O
that	O
the	O
accumulation	O
of	O
B	O
cells	O
ranging	O
from	O
early	O
-	O
activated	O
to	O
isotype	O
-	O
switched	O
differentiation	B-PROC
stages	O
is	O
both	O
temporally	O
and	O
spatially	O
orchestrated	O
.	O

ABSTRACT	O
:	O
Genomes	O
of	O
positive	O
(+)-	O
strand	O
RNA	O
viruses	O
use	O
cis	O
-	O
acting	O
signals	O
to	O
direct	O
both	O
translation	B-PROC
and	O
replication	O
.	O

We	O
postulate	O
that	O
the	O
higher	O
-	O
order	O
structure	O
promotes	O
(+)-	O
strand	O
synthesis	B-PROC
.	O

Previous	O
studies	O
have	O
shown	O
that	O
PEDV	O
infection	O
inhibits	O
the	O
synthesis	B-PROC
of	O
type	O
I	O
interferon	O
(	O
IFN	O
),	O
and	O
viral	O
papain	O
-	O
like	O
protease	O
2	O
has	O
been	O
identified	O
as	O
an	O
IFN	O
antagonist	B-PROC
.	O

Specifically	O
,	O
the	O
formation	B-PROC
of	O
double	O
membrane	O
vesicles	O
(	O
DMVs	O
),	O
a	O
hallmark	O
of	O
coronavirus	O
replication	O
,	O
was	O
greatly	O
impaired	O
upon	O
K22	O
treatment	O
accompanied	O
by	O
near	O
-	O
complete	O
inhibition	B-PROC
of	O
viral	O
RNA	B-PROC
synthesis	I-PROC
.	O

However	O
,	O
in	O
the	O
1980s	O
several	O
investigators	O
provided	O
novel	O
evidence	O
that	O
the	O
primary	O
mechanism	O
for	O
removal	O
of	O
alveolar	O
edema	O
fluid	O
depended	O
on	O
active	B-PROC
ion	B-PROC
transport	I-PROC
across	O
the	O
alveolar	O
epithelium	O
.	O

Fluorescence	O
microscopy	O
and	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
were	O
utilized	O
to	O
assess	O
occurrence	O
and	O
consequences	O
of	O
infection	O
.	O

For	O
the	O
identification	O
of	O
these	O
three	O
FIP	O
-	O
related	O
SNP	O
,	O
genotyping	O
methods	O
were	O
established	O
using	O
amplification	O
refractory	O
mutation	O
system	O
PCR	O
(	O
ARMS	O
-	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphisms	B-PROC
(	O
RFLP	O
),	O
and	O
the	O
different	O
genotypes	O
could	O
easily	O
be	O
identified	O
without	O
sequencing	O
.	O

However	O
,	O
it	O
is	O
uncertain	O
whether	O
the	O
beneficial	O
effects	O
of	O
PP	O
are	O
associated	O
with	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
levels	O
and	O
long	O
durations	O
of	O
PP	O
.	O

Secondary	O
outcomes	O
will	O
include	O
the	O
four	O
key	O
features	O
of	O
preclinical	O
acute	O
lung	O
injury	O
as	O
defined	O
by	O
the	O
American	O
Thoracic	O
Society	O
consensus	O
conference	O
(	O
histologic	O
evidence	O
of	O
lung	O
injury	O
,	O
altered	O
alveolar	O
capillary	O
barrier	O
,	O
lung	O
inflammatory	B-PROC
response	I-PROC
,	O
and	O
physiological	O
dysfunction	O
)	O
and	O
pathogen	O
clearance	O
for	O
acute	O
lung	O
injury	O
models	O
that	O
are	O
caused	O
by	O
infection	O
.	O

Immunofluoresence	O
assays	O
indicated	O
that	O
inhibition	B-PROC
of	O
PEDV	O
infection	O
by	O
peptide	O
H	O
was	O
independent	O
of	O
pAPN	O
.	O

The	O
absence	O
of	O
IL	O
-	O
27	O
signaling	B-PROC
accelerated	O
virus	O
control	O
within	O
the	O
CNS	O
associated	O
with	O
increased	O
IFN	O
-	O
γ	O
secreting	B-PROC
virus	O
-	O
specific	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
.	O

Human	O
MSCs	O
were	O
well	O
tolerated	O
and	O
improved	O
oxygenation	B-PROC
and	O
decreased	O
pulmonary	O
oedema	O
in	O
a	O
sheep	O
model	O
of	O
severe	O
ARDS	O
.	O

ABSTRACT	O
:	O
Avian	O
infectious	O
bronchitis	O
is	O
a	O
highly	O
contagious	O
viral	B-PROC
disease	I-PROC
with	O
economic	O
effects	O
on	O
poultry	O
agribusiness	O
.	O

In	O
the	O
present	O
study	O
,	O
MERS	O
-	O
CoV	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
is	O
expressed	B-PROC
,	O
and	O
its	O
structural	O
and	O
functional	O
consequences	O
are	O
elucidated	O
.	O

Expression	B-PROC
of	O
the	O
DPP4s	O
of	O
these	O
species	O
on	O
BHK	O
cells	O
supported	O
MERS	O
-	O
CoV	O
replication	O
.	O

TITLE	O
:	O
Genomic	O
profiling	O
of	O
collaborative	O
cross	O
founder	O
mice	O
infected	O
with	O
respiratory	O
viruses	O
reveals	O
novel	O
transcripts	O
and	O
infection	O
-	O
related	O
strain	O
-	O
specific	O
gene	O
and	O
isoform	O
expression	B-PROC
.	O

Recently	O
,	O
it	O
has	O
been	O
reported	O
that	O
GAPDH	O
has	O
other	O
physiological	O
functions	O
,	O
such	O
as	O
apoptosis	B-PROC
,	O
DNA	B-PROC
repair	I-PROC
and	O
autophagy	B-PROC
.	O

TITLE	O
:	O
Syndrome	O
of	O
inappropriate	O
antidiuretic	O
hormone	B-PROC
secretion	I-PROC
related	O
to	O
Guillain	O
-	O
Barré	O
syndrome	O
after	O
laparoscopic	O
cholecystectomy	O
.	O

This	O
molecular	B-PROC
mimicry	I-PROC
of	O
FcγRII	O
by	O
the	O
MHV	O
S	O
protein	O
is	O
also	O
exhibited	O
by	O
other	O
lineage	O
2a	O
betacoronaviruses	O
,	O
with	O
the	O
exception	O
of	O
the	O
human	O
coronavirus	O
HCoV	O
-	O
OC43	O
.	O

In	O
this	O
work	O
we	O
undertook	O
a	O
mutational	O
analysis	O
to	O
attempt	O
to	O
identify	O
specific	O
amino	O
acid	O
sequences	O
within	O
the	O
spike	O
glycoprotein	O
crucial	O
for	O
molecular	B-PROC
mimicry	I-PROC
of	O
FcγRII	O
.	O

ABSTRACT	O
:	O
The	O
management	O
of	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	O
(	O
CAP	O
)	O
is	O
largely	O
influenced	O
by	O
the	O
development	B-PROC
of	O
new	O
molecular	O
diagnostic	O
tests	O
that	O
allow	O
the	O
simultaneous	O
detection	O
of	O
a	O
wide	O
range	O
of	O
pathogens	O
.	O

Here	O
,	O
we	O
report	O
4	O
IPEX	O
patients	O
,	O
3	O
of	O
which	O
died	B-PROC
from	O
severe	O
pulmonary	O
disease	O
.	O

FOXP3	O
expression	B-PROC
and	O
T	O
reg	O
activity	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
Patient	O
I	O
(	O
PI	O
)	O
presented	O
with	O
nephrotic	O
syndrome	O
at	O
3	O
years	O
of	O
age	O
and	O
then	O
developed	O
autoimmune	O
hepatitis	O
without	O
eczema	O
,	O
enteropathy	O
or	O
high	O
IgE	O
and	O
died	B-PROC
at	O
9	O
years	O
of	O
age	O
due	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
Previous	O
trials	O
of	O
higher	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
failed	O
to	O
demonstrate	O
mortality	O
benefit	O
,	O
possibly	O
because	O
of	O
differences	O
in	O
lung	O
recruitability	O
among	O
patients	O
with	O
ARDS	O
.	O

We	O
performed	O
total	O
RNA	O
-	O
Seq	O
on	O
viral	O
-	O
infected	O
lungs	O
from	O
eight	O
mouse	O
strains	O
,	O
yielding	O
a	O
large	O
data	O
set	O
of	O
transcriptional	B-PROC
responses	O
.	O

Altogether	O
,	O
these	O
results	O
provide	O
a	O
broad	O
categorization	O
of	O
potential	O
lncRNA	O
functions	O
and	O
identify	O
subsets	O
of	O
lncRNAs	O
with	O
likely	O
key	O
roles	O
in	O
respiratory	O
virus	O
pathogenesis	B-PROC
.	O

The	O
large	O
size	O
of	O
the	O
CoV	O
genome	O
and	O
the	O
instability	O
of	O
some	O
CoV	O
replicase	O
gene	O
sequences	O
during	O
its	O
propagation	O
in	O
bacteria	O
,	O
represent	O
serious	O
obstacles	O
for	O
the	O
development	B-PROC
of	O
reverse	O
genetic	O
systems	O
similar	O
to	O
those	O
used	O
for	O
smaller	O
positive	O
sense	B-PROC
RNA	O
viruses	O
.	O

Knowledge	O
related	O
to	O
the	O
structure	O
and	O
function	O
of	O
the	O
surfactant	O
proteins	O
and	O
their	O
roles	O
in	O
alveolar	O
homeostasis	B-PROC
has	O
provided	O
new	O
diagnostic	O
,	O
prognostic	O
and	O
therapeutic	O
tools	O
to	O
advance	O
our	O
understanding	O
of	O
the	O
causes	O
and	O
treatments	O
of	O
acute	O
and	O
chronic	O
lung	O
diseases	O
.	O

Mutations	O
in	O
genes	O
encoding	O
the	O
surfactant	O
proteins	O
,	O
transcription	B-PROC
factors	O
critical	O
for	O
alveolar	O
morphogenesis	B-PROC
and	O
surfactant	O
clearance	O
,	O
are	O
now	O
known	O
to	O
play	O
important	O
roles	O
in	O
the	O
pathogenesis	B-PROC
of	O
chronic	O
lung	O
diseases	O
.	O

These	O
catalytic	O
improvements	O
translated	O
into	O
superior	O
performance	O
of	O
the	O
biocatalysts	O
for	O
the	O
precipitation	B-PROC
of	O
calcium	O
carbonate	O
from	O
solution	O
which	O
is	O
an	O
attractive	O
strategy	O
for	O
long	O
-	O
term	O
sequestration	O
of	O
captured	O
carbon	O
dioxide	O
.	O

TITLE	O
:	O
SOCS3	O
expression	B-PROC
correlates	O
with	O
severity	O
of	O
inflammation	O
in	O
mouse	O
hepatitis	O
virus	O
strain	O
3	O
-	O
induced	O
acute	O
liver	O
failure	O
and	O
HBV	O
-	O
ACLF	O
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
role	O
of	O
SOCS3	O
in	O
the	O
development	B-PROC
of	O
mouse	O
hepatitis	O
virus	O
strain	O
3	O
(	O
MHV	O
-	O
3	O
)-	O
induced	O
acute	O
liver	O
failure	O
and	O
its	O
expression	B-PROC
in	O
liver	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
of	O
patients	O
with	O
HBV	O
-	O
ACLF	O
.	O

These	O
data	O
suggested	O
that	O
SOCS3	O
may	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
MHV	O
-	O
3	O
-	O
induced	O
acute	O
liver	O
failure	O
and	O
HBV	O
-	O
ACLF	O
.	O

ABSTRACT	O
:	O
To	O
present	O
the	O
3	O
-	O
year	O
experience	O
of	O
using	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
patients	O
with	O
severe	O
respiratory	O
failure	O
in	O
a	O
single	O
centre	O
in	O
Hong	O
Kong	O
.	O

TITLE	O
:	O
Synthesis	B-PROC
and	O
biological	O
evaluation	O
of	O
2	O
-	O
oxo	O
-	O
pyrazine	O
-	O
3	O
-	O
carboxamide	O
-	O
yl	O
nucleoside	O
analogues	O
and	O
their	O
epimers	O
as	O
inhibitors	O
of	O
influenza	O
A	O
viruses	O
.	O

The	O
complete	O
genome	O
sequences	O
of	O
the	O
strains	O
were	O
identical	O
or	O
almost	O
identical	O
(	O
one	O
synonymous	O
single	O
-	O
nucleotide	O
polymorphism	B-PROC
(	O
SNP	O
)	O
in	O
the	O
ORF1a	O
/	O
1b	O
genomic	O
sequence	O
).	O

Of	O
9	O
,	O
419	O
SARI	O
patients	O
,	O
2	O
.	O
7	O
%	O
died	B-PROC
;	O
the	O
median	O
length	O
of	O
hospitalization	O
was	O
4	O
days	O
.	O

These	O
RNA	O
-	O
dependent	O
functions	O
are	O
necessary	O
for	O
replication	O
of	O
many	O
human	O
disease	O
-	O
causing	O
viruses	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
,	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
and	O
HIV	O
-	O
1	O
.	O

Oxygenation	B-PROC
,	O
plateau	O
pressure	O
and	O
pH	O
goals	O
were	O
controlled	O
during	O
the	O
automatic	O
ventilation	O
therapy	O
using	O
autoARDSNet	O
.	O

Preexisting	O
neutralizing	O
antibody	B-PROC
did	O
not	O
appear	O
to	O
protect	O
against	O
infection	O
.	O

For	O
FCoV	O
screening	O
,	O
speed	O
and	O
sensitivity	O
are	O
important	O
,	O
and	O
for	O
FCoV	O
elimination	B-PROC
antibody	B-PROC
titre	O
is	O
essential	O
.	O

Severe	O
complications	O
like	O
significant	O
hepatomegaly	O
,	O
thrombocytopenia	O
,	O
acute	O
renal	O
failure	O
,	O
severe	O
anaemia	O
,	O
leucopoenia	O
,	O
electrolyte	O
disturbance	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
cerebral	O
malaria	O
,	O
multiorgan	O
dysfunction	O
,	O
hepatic	O
dysfunction	O
,	O
pancytopenia	O
,	O
and	O
death	B-PROC
seen	O
in	O
21	O
.	O
57	O
%,	O
18	O
.	O
63	O
%,	O
11	O
.	O
76	O
%,	O
8	O
.	O
82	O
%,	O
5	O
.	O
88	O
%,	O
5	O
.	O
88	O
%,	O
3	O
.	O
92	O
%,	O
2	O
.	O
94	O
%,	O
1	O
.	O
96	O
%,	O
1	O
.	O
96	O
%,	O
0	O
.	O
98	O
%,	O
1	O
.	O
96	O
%	O
patients	O
respectively	O
.	O

TITLE	O
:	O
EDs	O
on	O
heightened	O
alert	O
for	O
MERS	O
-	O
CoV	O
as	O
first	O
cases	O
reach	B-PROC
the	O
US	O
.	O

The	O
World	O
Health	O
Organization	O
reports	O
that	O
roughly	O
one	O
-	O
quarter	O
of	O
514	O
people	O
who	O
have	O
tested	O
positive	O
for	O
the	O
virus	O
have	O
died	B-PROC
.	O

Public	O
health	O
officials	O
urge	O
emergency	O
personnel	O
to	O
pay	O
strict	O
attention	O
to	O
infection	O
control	O
practices	O
,	O
and	O
to	O
query	O
patients	O
who	O
present	O
with	O
fever	B-PROC
and	O
respiratory	O
distress	O
about	O
recent	O
travel	O
to	O
the	O
Arabian	O
Peninsula	O
and	O
/	O
or	O
close	O
contact	O
with	O
a	O
person	O
who	O
has	O
a	O
confirmed	O
or	O
probable	O
case	O
of	O
MERS	O
-	O
CoV	O
.	O

The	O
differential	O
expression	B-PROC
of	O
these	O
genes	O
suggests	O
a	O
strong	O
antiviral	O
host	B-PROC
response	I-PROC
,	O
but	O
may	O
also	O
contribute	O
to	O
the	O
pathogenesis	B-PROC
of	O
PHEV	O
resulting	O
in	O
encephalomyelitis	O
.	O

Consistently	O
,	O
conservative	O
strategies	O
lead	O
to	O
better	O
oxygenation	B-PROC
and	O
reduce	O
the	O
length	O
of	O
mechanical	O
ventilation	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
a	O
survey	O
of	O
these	O
techniques	O
and	O
their	O
applications	O
in	O
the	O
development	B-PROC
of	O
promising	O
anti	O
-	O
SARS	O
agents	O
.:	O

Viroporins	O
,	O
encoded	O
by	O
all	O
common	O
respiratory	O
viruses	O
,	O
are	O
responsible	O
for	O
the	O
changes	O
in	O
intracellular	O
ion	B-PROC
homeostasis	I-PROC
that	O
modulate	O
inflammasome	O
activation	O
.	O

Recently	O
,	O
our	O
laboratories	O
reported	O
a	O
novel	O
mode	O
of	O
regulation	B-PROC
of	O
the	O
IFN	O
antiviral	B-PROC
response	I-PROC
.	O

ER	O
stress	O
and	O
UPR	O
activation	O
may	O
therefore	O
contribute	O
significantly	O
to	O
the	O
viral	B-PROC
replication	I-PROC
and	O
pathogenesis	B-PROC
during	O
coronavirus	O
infection	O
.	O

The	O
prevalence	O
of	O
HCoV	O
-	O
OC43	O
infection	O
among	O
these	O
patients	O
was	O
assessed	O
using	O
two	O
different	O
OneStep	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
.	O

The	O
molecule	O
consists	O
of	O
a	O
ubiquitin	B-PROC
-	O
like	O
domain	O
and	O
a	O
catalytic	O
core	O
domain	O
.	O

This	O
article	O
assesses	O
pandemic	O
preparedness	O
in	O
Taipei	O
in	O
the	O
wake	B-PROC
of	O
recent	O
pandemic	O
experiences	O
in	O
order	O
to	O
draw	O
lessons	O
relevant	O
to	O
the	O
broader	O
international	O
public	O
health	O
community	O
.	O

These	O
new	O
strategies	O
for	O
pandemic	O
response	O
and	O
control	O
have	O
been	O
largely	O
effective	O
at	O
providing	O
interim	O
pandemic	O
containment	O
and	O
control	O
,	O
while	O
development	B-PROC
and	O
implementation	O
of	O
an	O
effective	O
vaccination	O
programme	O
is	O
underway	O
.	O

A	O
62	O
-	O
year	O
-	O
old	O
Caucasian	O
female	O
was	O
admitted	O
with	O
septic	O
shock	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
acute	O
renal	O
failure	O
,	O
metabolic	B-PROC
acidosis	O
and	O
disseminated	O
intravascular	O
coagulation	B-PROC
after	O
suffering	O
two	O
small	O
bites	O
from	O
her	O
dog	O
.	O

The	O
prophylactic	O
application	O
of	O
antibiotics	O
after	O
a	O
dog	O
bite	B-PROC
should	O
be	O
considered	O
in	O
high	O
-	O
risk	O
individuals	O
with	O
immune	O
deficiency	O
in	O
order	O
to	O
prevent	O
both	O
Capnocytophyga	O
canimorsus	O
sepsis	O
and	O
serious	O
nosocomial	O
complications	O
.	O

Further	O
analysis	O
showed	O
that	O
recombination	B-PROC
events	O
formed	O
a	O
new	O
subgroup	O
.	O

Our	O
findings	O
strongly	O
demonstrated	O
that	O
enforced	O
expression	B-PROC
of	O
miR	O
-	O
125b	O
could	O
effectively	O
ameliorate	O
the	O
LPS	O
-	O
induced	O
ALI	O
,	O
suggesting	O
a	O
potential	O
application	O
for	O
miR	O
-	O
125b	O
-	O
based	O
therapy	O
to	O
treat	O
clinical	O
ARDS	O
.	O

He	O
was	O
in	O
severe	O
respiratory	O
distress	O
with	O
use	O
of	O
accessory	O
muscles	O
of	O
respiration	B-PROC
.	O

On	O
pulse	B-PROC
oximetry	O
,	O
oxygen	O
saturation	O
was	O
28	O
%	O
on	O
room	O
air	O
,	O
which	O
increased	O
up	O
to	O
36	O
%	O
with	O
the	O
help	O
of	O
4	O
L	O
oxygen	O
via	O
nasal	O
prongs	O
.	O

Our	O
results	O
provide	O
direct	O
evidence	O
showing	O
that	O
coronavirus	O
-	O
induced	O
demyelination	O
of	O
the	O
central	O
nervous	O
system	O
causes	O
the	O
development	B-PROC
of	O
a	O
neurogenic	O
bladder	O
that	O
is	O
comparable	O
with	O
neurogenic	O
detrusor	O
overactivity	O
observed	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
sought	O
to	O
investigate	O
whether	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
induces	O
apoptosis	B-PROC
and	O
to	O
elucidate	O
the	O
mechanisms	O
associated	O
with	O
apoptotic	B-PROC
cell	B-PROC
death	I-PROC
after	O
PEDV	O
infection	O
.	O

Our	O
data	O
showed	O
significant	O
differential	O
up	B-PROC
-	I-PROC
regulation	B-PROC
of	O
IFN	O
-	O
γ	O
,	O
IL	O
-	O
8	O
(	O
CXCLi2	O
)	O
and	O
MIP	O
-	O
1β	O
genes	O
and	O
suppression	B-PROC
of	O
IL	O
-	O
6	O
gene	B-PROC
expression	I-PROC
being	O
associated	O
with	O
inhibition	B-PROC
of	O
IBV	O
replication	O
in	O
lungs	O
tissue	O
retrieved	O
from	O
embryos	O
pre	O
-	O
treated	O
with	O
CpG	O
ODN	O
.	O

It	O
is	O
expected	O
that	O
understanding	O
of	O
the	O
innate	O
immune	B-PROC
modulation	I-PROC
of	O
target	O
tissues	O
by	O
the	O
virus	O
and	O
innate	O
immune	O
stimulants	O
will	O
be	O
helpful	O
in	O
identification	O
of	O
valuable	O
targets	O
for	O
development	B-PROC
of	O
novel	O
,	O
safe	O
,	O
effective	O
and	O
economical	O
control	O
strategies	O
against	O
IBV	O
infection	O
in	O
chickens	O
.	O

TITLE	O
:	O
Microorganisms	O
in	O
respiratory	O
tract	O
of	O
patients	O
diagnosed	O
with	O
atypical	O
pneumonia	O
:	O
results	O
of	O
a	O
research	O
based	O
on	O
the	O
use	O
of	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
DNA	O
microarray	O
method	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

TITLE	O
:	O
The	O
effectiveness	O
of	O
convalescent	O
plasma	O
and	O
hyperimmune	O
immunoglobulin	B-PROC
for	O
the	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
infections	O
of	O
viral	O
etiology	O
:	O
a	O
systematic	O
review	O
and	O
exploratory	O
meta	O
-	O
analysis	O
.	O

Extracorporeal	O
carbon	O
dioxide	O
removal	O
(	O
ECCO₂R	O
)	O
devices	O
allow	O
uncoupling	O
of	O
ventilation	O
from	O
oxygenation	B-PROC
,	O
thereby	O
removing	O
carbon	O
dioxide	O
and	O
facilitating	O
lower	O
tidal	O
volume	O
ventilation	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
demonstrated	O
that	O
the	O
length	O
of	O
the	O
poly	O
(	O
A	O
)	O
tail	O
in	O
the	O
bovine	O
coronavirus	O
(	O
BCoV	O
),	O
which	O
belongs	O
to	O
genus	O
betacoronaviruses	O
,	O
is	O
regulated	O
throughout	O
infection	O
in	O
human	O
rectal	O
tumor	O
-	O
18	O
(	O
HRT	O
-	O
18	O
)	O
cells	O
,	O
and	O
the	O
length	O
of	O
the	O
poly	O
(	O
A	O
)	O
tail	O
is	O
associated	O
with	O
the	O
efficiency	O
of	O
virus	O
translation	B-PROC
.	O

The	O
much	O
longer	O
persistence	O
of	O
MERS	O
-	O
CoV	O
in	O
the	O
population	O
,	O
with	O
a	O
lower	O
reproductive	B-PROC
number	O
,	O
some	O
evidence	O
of	O
human	O
-	O
to	O
-	O
human	O
transmission	O
but	O
an	O
otherwise	O
sporadic	O
pattern	O
,	O
is	O
difficult	O
to	O
explain	O
.	O

Furthermore	O
,	O
MERS	O
-	O
CoV	O
is	O
occurring	O
in	O
a	O
region	O
that	O
is	O
a	O
major	O
global	O
transport	B-PROC
hub	O
and	O
hosts	O
significant	O
mass	O
gatherings	O
,	O
making	O
it	O
imperative	O
to	O
understand	O
the	O
source	O
and	O
means	O
of	O
the	O
yet	O
unexplained	O
and	O
puzzling	O
ongoing	O
persistence	O
of	O
the	O
virus	O
in	O
the	O
human	O
population	O
.	O

TITLE	O
:	O
Effects	O
of	O
therapeutic	O
approach	O
on	O
the	O
neonatal	O
evolution	B-PROC
of	O
very	O
low	O
birth	B-PROC
weight	O
infants	O
with	O
patent	O
ductus	O
arteriosus	O
.	O

TITLE	O
:	O
S1	O
of	O
distinct	O
IBV	O
population	O
expressed	B-PROC
from	O
recombinant	O
adenovirus	O
confers	O
protection	O
against	O
challenge	O
.	O

In	O
addition	O
,	O
IBV	O
Ark	O
-	O
type	O
vaccines	O
may	O
induce	O
suboptimal	O
mucosal	B-PROC
immune	I-PROC
responses	I-PROC
,	O
contributing	O
to	O
the	O
prevalence	O
and	O
persistence	O
of	O
the	O
Ark	O
serotype	O
.	O

Interestingly	O
,	O
the	O
peak	O
IgA	O
SFC	O
response	O
occurred	O
2	O
days	O
earlier	O
in	O
spleen	O
than	O
in	O
the	O
head	O
-	O
associated	O
lymphoid	O
tissues	O
despite	O
ocular	B-PROC
vaccination	O
.	O

ABSTRACT	O
:	O
Periodic	O
monitoring	O
of	O
poultry	O
flocks	O
in	O
the	O
United	O
States	O
via	O
molecular	O
diagnostic	O
methods	O
has	O
revealed	O
a	O
number	O
of	O
potential	O
enteric	O
viral	O
pathogens	O
in	O
continuous	O
circulation	B-PROC
in	O
turkeys	O
and	O
chickens	O
.	O

Recently	O
turkey	O
integrators	O
in	O
the	O
Southeastern	O
United	O
States	O
and	O
Arkansas	O
experienced	O
an	O
outbreak	O
of	O
moderate	O
to	O
severe	O
enteritis	O
associated	O
with	O
turkey	O
enteric	O
coronavirus	O
(	O
TCoV	O
),	O
and	O
numerous	O
enteric	O
samples	O
collected	O
from	O
turkey	O
flocks	O
in	O
these	O
areas	O
tested	O
positive	O
for	O
TCoV	O
via	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-PROC
PCR	O
(	O
RRT	O
-	O
PCR	O
).	O

A	O
dose	O
of	O
OA	O
(	O
30	O
-	O
90	O
microL	O
;	O
iv	O
)	O
was	O
injected	O
in	O
each	O
animal	O
and	O
changes	O
in	O
respiratory	O
frequency	O
(	O
RF	O
),	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
mean	O
arterial	B-PROC
pressure	I-PROC
(	O
MAP	O
)	O
were	O
recorded	O
.	O

At	O
all	O
doses	O
of	O
OA	O
,	O
there	O
was	O
immediate	O
decrease	O
followed	O
by	O
increase	O
in	O
RF	O
,	O
however	O
at	O
75	O
and	O
90	O
microL	O
of	O
OA	O
,	O
RF	O
decreased	O
abruptly	O
and	O
the	O
animals	O
died	B-PROC
by	O
63	O
+/-	O

In	O
this	O
study	O
,	O
we	O
have	O
developed	O
a	O
chimeric	O
virus	O
-	O
like	O
particle	O
(	O
VLP	O
)	O
vaccine	O
candidate	O
for	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
and	O
H3N2	O
influenza	O
virus	O
and	O
investigated	O
its	O
immunogenicity	O
in	O
mice	O
.	O

This	O
review	O
focuses	O
on	O
complications	O
allied	O
to	O
commercially	O
available	O
dual	O
-	O
lumen	O
,	O
single	O
,	O
venovenous	O
cannula	O
implantation	B-PROC
,	O
pointing	O
out	O
the	O
critical	O
segments	O
of	O
the	O
implantation	B-PROC
process	O
and	O
analyzing	O
the	O
structure	O
of	O
the	O
device	O
.	O

TITLE	O
:	O
Antibody	B-PROC
-	O
dependent	O
SARS	O
coronavirus	O
infection	O
is	O
mediated	O
by	O
antibodies	O
against	O
spike	O
proteins	O
.	O

Describe	O
the	O
kinetics	O
and	O
pattern	O
of	O
viral	O
excretion	B-PROC
in	O
two	O
infected	O
patients	O
.	O

These	O
experiments	O
imply	O
that	O
the	O
nsp10	O
surface	O
that	O
interacts	O
with	O
nsp14	O
and	O
nsp16	O
and	O
possibly	O
other	O
subunits	O
of	O
the	O
viral	B-PROC
replication	I-PROC
complex	O
may	O
be	O
a	O
target	O
for	O
the	O
development	B-PROC
of	O
antiviral	O
compounds	O
against	O
pathogenic	O
coronaviruses	O
.	O

Therefore	O
,	O
the	O
objective	O
of	O
this	O
paper	O
is	O
to	O
describe	O
the	O
cases	O
and	O
deaths	B-PROC
caused	O
by	O
the	O
new	O
coronavirus	O
.	O

RESULTS	O
:	O
There	O
are	O
17	O
confirmed	O
cases	O
and	O
11	O
deaths	B-PROC
in	O
several	O
countries	O
in	O
Asia	O
and	O
Europe	O
;	O
men	O
predominated	O
.	O

People	O
who	O
died	B-PROC
took	O
five	O
days	O
to	O
hospitalize	O
after	O
the	O
first	O
symptoms	O
.	O

The	O
phenotypic	O
differences	O
in	O
pathology	O
among	O
different	O
strains	O
of	O
IAPV	O
found	O
globally	O
may	O
be	O
due	O
to	O
high	O
levels	O
of	O
standing	B-PROC
genetic	O
variation	O
.	O

TITLE	O
:	O
Identification	O
of	O
cis	O
-	O
acting	O
elements	O
on	O
positive	O
-	O
strand	O
subgenomic	O
mRNA	O
required	O
for	O
the	O
synthesis	B-PROC
of	O
negative	O
-	O
strand	O
counterpart	O
in	O
bovine	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
NL63	O
mainly	O
infects	O
younger	O
children	O
and	O
causes	O
cough	O
,	O
fever	B-PROC
,	O
rhinorrhoea	O
,	O
bronchiolitis	O
and	O
croup	O
.	O

TITLE	O
:	O
[	O
Chikungunya	O
fever	B-PROC
-	O
A	O
new	O
global	O
threat	O
].	O

TITLE	O
:	O
An	O
evaluation	O
of	O
contaminated	O
complete	O
feed	O
as	O
a	O
vehicle	O
for	O
porcine	O
epidemic	O
diarrhea	O
virus	B-PROC
infection	I-PROC
of	O
naïve	O
pigs	O
following	O
consumption	O
via	O
natural	O
feeding	B-PROC
behavior	I-PROC
:	O
proof	O
of	O
concept	O
.	O

These	O
data	O
provide	O
proof	O
of	O
concept	O
that	O
contaminated	O
complete	O
feed	O
can	O
serve	O
as	O
a	O
vehicle	O
for	O
PEDV	O
infection	O
of	O
naïve	O
pigs	O
using	O
natural	O
feeding	B-PROC
behavior	I-PROC
.	O

Age	O
,	O
female	O
sex	O
,	O
and	O
higher	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
were	O
associated	O
with	O
complications	O
.	O

Key	O
CoV	O
proteins	O
involved	O
in	O
the	O
regulation	B-PROC
of	O
these	O
pathways	B-PROC
and	O
the	O
proinflammatory	O
immune	B-PROC
response	I-PROC
are	O
revisited	O
in	O
this	O
manuscript	O
.	O

ABSTRACT	O
:	O
Acute	O
febrile	B-PROC
neutrophilic	B-PROC
dermatosis	O
or	O
Sweet	B-PROC
'	O
s	O
syndrome	O
(	O
SS	O
)	O
is	O
characterized	O
by	O
painful	O
,	O
erythematous	O
plaques	O
of	O
rapid	O
onset	O
accompanied	O
by	O
fever	B-PROC
.	O

Histopathological	O
examination	O
suggested	O
perivascular	O
neutrophilic	B-PROC
infiltration	O
with	O
scattered	O
eosinophils	O
.	O

ABSTRACT	O
:	O
To	O
combat	O
emerging	O
coronaviruses	O
,	O
developing	O
safe	O
and	O
efficient	O
platforms	O
to	O
evaluate	O
viral	O
protease	O
activities	O
and	O
the	O
efficacy	O
of	O
protease	B-PROC
inhibitors	I-PROC
is	O
a	O
high	O
priority	O
.	O

This	O
system	O
provides	O
an	O
important	O
tool	O
to	O
rapidly	O
assess	O
the	O
efficacy	O
of	O
protease	B-PROC
inhibitors	I-PROC
targeting	B-PROC
existing	O
and	O
emerging	O
human	O
pathogens	O
,	O
as	O
well	O
as	O
other	O
enzymes	O
capable	O
of	O
removing	O
ISG15	O
from	O
cellular	O
proteins	O
.	O

TITLE	O
:	O
Detection	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
using	O
reverse	B-PROC
transcription	B-PROC
loop	O
-	O
mediated	O
isothermal	O
amplification	O
(	O
RT	O
-	O
LAMP	O
).	O

The	O
RT	O
-	O
LAMP	O
assay	O
was	O
capable	O
of	O
detecting	O
as	O
few	O
as	O
3	O
.	O
4	O
copies	O
of	O
MERS	O
-	O
CoV	O
RNA	O
,	O
and	O
was	O
highly	O
specific	O
,	O
with	O
no	O
cross	B-PROC
-	I-PROC
reaction	I-PROC
to	O
other	O
respiratory	O
viruses	O
.	O

The	O
main	O
features	O
are	O
bacterial	O
and	O
fungal	O
infections	O
predominantly	O
in	O
the	O
skin	O
and	O
mucosal	O
surfaces	O
,	O
impaired	O
wound	B-PROC
healing	I-PROC
and	O
delayed	O
umbilical	O
cord	O
separation	O
.	O

A	O
Phase	O
2b	O
/	O
3	O
clinical	O
trial	O
recently	O
published	O
in	O
The	O
Lancet	O
Infectious	O
Diseases	O
found	O
that	O
oral	O
administration	O
of	O
nitazoxanide	O
600mg	O
twice	O
daily	O
for	O
five	O
days	O
reduced	O
the	O
duration	O
of	O
clinical	O
symptoms	O
and	O
reduced	O
viral	B-PROC
shedding	I-PROC
compared	O
to	O
placebo	O
in	O
persons	O
with	O
laboratory	O
-	O
confirmed	O
influenza	O
.	O

The	O
same	O
study	O
also	O
suggested	O
a	O
potential	O
benefit	O
for	O
subjects	O
with	O
influenza	O
-	O
like	O
illness	O
who	O
did	O
not	O
have	O
influenza	O
or	O
other	O
documented	O
respiratory	O
viral	B-PROC
infection	I-PROC
.	O

ABSTRACT	O
:	O
Current	O
teaching	O
and	O
guidelines	O
suggest	O
that	O
aggressive	B-PROC
fluid	O
resuscitation	O
is	O
the	O
best	O
initial	O
approach	O
to	O
the	O
patient	O
with	O
hemodynamic	B-PROC
instability	O
.	O

EGDT	O
and	O
the	O
Surviving	O
Sepsis	O
Campaign	O
Guidelines	O
recommend	O
targeting	B-PROC
a	O
central	O
venous	B-PROC
pressure	I-PROC
(	O
CVP	O
)	O
>	O
8	O
mmHg	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
and	O
extracorporeal	O
CO	O
(	O
2	O
)	O
removal	O
(	O
ECCO	O
(	O
2	O
)	O
R	O
)	O
techniques	O
have	O
increasingly	O
been	O
applied	O
in	O
patients	O
with	O
severe	O
acute	O
lung	O
injury	O
refractory	O
to	O
conventional	O
mechanical	O
ventilatory	O
support	O
.	O

Four	O
(	O
80	O
%)	O
of	O
the	O
five	O
patients	O
died	B-PROC
despite	O
receiving	O
appropriate	O
respiratory	O
support	O
.	O

Here	O
,	O
we	O
expressed	B-PROC
and	O
purified	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
3a	O
protein	O
,	O
called	O
Cyto3a	O
,	O
as	O
a	O
recombinant	O
His	O
-	O
tagged	O
protein	O
in	O
the	O
E	O
.	O
coli	O
.	O

The	O
calcium	B-PROC
binding	I-PROC
nature	O
was	O
established	O
by	O
performing	O
various	O
staining	O
methods	O
such	O
as	O
ruthenium	O
red	O
and	O
stains	O
-	O
all	O
.	O

The	O
aim	O
of	O
our	O
study	O
is	O
to	O
describe	O
the	O
epidemiology	O
of	O
pediatric	O
ARDS	O
in	O
Singapore	O
and	O
compare	O
the	O
outcomes	O
of	O
ARDS	O
using	O
the	O
following	O
respiratory	O
indices	O
:	O
PaO2	O
/	O
FiO2	O
ratio	O
(	O
P	O
/	O
F	O
ratio	O
),	O
SpO2	O
/	O
FiO2	O
ratio	O
(	O
S	O
/	O
F	O
ratio	O
),	O
oxygenation	B-PROC
index	O
(	O
OI	O
),	O
and	O
oxygen	O
saturation	O
index	O
(	O
OSI	O
).	O

Active	O
p38	O
MAPK	O
was	O
reduced	O
in	O
lungs	O
of	O
mice	O
infected	O
with	O
SARS	O
-	O
CoVs	O
lacking	O
E	O
protein	O
PBM	O
as	O
compared	O
with	O
the	O
parental	O
virus	O
,	O
leading	O
to	O
a	O
decreased	O
expression	B-PROC
of	O
inflammatory	O
cytokines	O
and	O
to	O
virus	O
attenuation	O
.	O

Therefore	O
,	O
the	O
E	O
protein	O
PBM	O
is	O
a	O
virulence	B-PROC
domain	O
that	O
activates	O
immunopathology	O
most	O
likely	O
by	O
using	O
syntenin	O
as	O
a	O
mediator	O
of	O
p38	O
MAPK	O
induced	O
inflammation	O
.	O

Here	O
,	O
we	O
analyzed	O
TTSPs	O
,	O
reported	O
to	O
be	O
expressed	B-PROC
in	O
the	O
respiratory	O
system	O
,	O
for	O
the	O
ability	O
to	O
activate	O
influenza	O
viruses	O
and	O
coronaviruses	O
.	O

An	O
immunofluorescence	O
assay	O
based	O
on	O
cells	O
infected	O
with	O
the	O
recombinant	O
viruses	O
that	O
was	O
capable	O
of	O
distinguishing	O
between	O
the	O
two	O
types	O
of	O
viral	B-PROC
infection	I-PROC
was	O
established	O
.	O

Moreover	O
,	O
most	O
of	O
the	O
cats	O
(	O
84	O
.	O
6	O
%,	O
22	O
/	O
26	O
)	O
infected	O
with	O
a	O
genotypic	O
untypable	O
virus	O
bearing	O
a	O
type	O
I	O
FCoV	O
antibody	B-PROC
.	O

However	O
,	O
understanding	O
of	O
FIP	O
pathogenesis	B-PROC
is	O
still	O
incomplete	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
adults	O
for	O
severe	O
acute	O
respiratory	O
failure	O
.	O

The	O
goal	O
of	O
ECMO	O
is	O
to	O
maintain	O
a	O
safe	O
level	O
of	O
oxygenation	B-PROC
and	O
controlled	O
respiratory	O
acidosis	O
under	O
protective	O
ventilation	O
.	O

TITLE	O
:	O
SARS	O
-	O
coronavirus	O
open	O
reading	O
frame	O
-	O
9b	O
suppresses	O
innate	B-PROC
immunity	B-PROC
by	O
targeting	B-PROC
mitochondria	O
and	O
the	O
MAVS	O
/	O
TRAF3	O
/	O
TRAF6	O
signalosome	O
.	O

In	O
this	O
study	O
,	O
we	O
inoculated	O
three	O
Japanese	O
draft	O
horses	O
with	O
an	O
ECoV	O
-	O
positive	O
diarrheic	O
fecal	O
sample	O
to	O
confirm	O
infection	O
after	O
inoculation	O
and	O
to	O
investigate	O
the	O
clinical	O
course	O
and	O
virus	O
shedding	O
patterns	O
of	O
ECoV	O
.	O
Virus	B-PROC
neutralization	I-PROC
tests	O
showed	O
that	O
all	O
three	O
horses	O
became	O
infected	O
with	O
ECoV	O
.	O
Two	O
of	O
the	O
three	O
horses	O
developed	O
clinical	O
signs	O
similar	O
to	O
those	O
observed	O
during	O
ECoV	O
outbreaks	O
,	O
including	O
fever	B-PROC
,	O
anorexia	O
,	O
and	O
gastrointestinal	O
dysfunction	O
.	O

MERS	O
-	O
CoV	O
PLpro	O
constructs	O
with	O
and	O
without	O
the	O
putative	O
ubiquitin	B-PROC
-	O
like	O
(	O
UBL	O
)	O
domain	O
at	O
the	O
N	O
terminus	O
were	O
found	O
to	O
possess	O
protease	O
,	O
deubiquitinating	B-PROC
,	O
deISGylating	O
,	O
and	O
interferon	O
antagonism	O
activities	O
in	O
transfected	O
HEK293T	O
cells	O
.	O

TITLE	O
:	O
The	O
endoplasmic	O
reticulum	O
stress	O
sensor	O
IRE1α	O
protects	O
cells	O
from	O
apoptosis	B-PROC
induced	O
by	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

UPR	O
resolves	O
ER	O
stress	O
by	O
activating	O
a	O
cascade	O
of	O
cellular	O
responses	O
,	O
including	O
the	O
induction	O
of	O
molecular	O
chaperones	O
,	O
translational	B-PROC
attenuation	I-PROC
,	O
ER	O
-	O
associated	O
degradation	O
,	O
and	O
other	O
mechanisms	O
.	O

Knockdown	O
and	O
overexpression	B-PROC
experiments	O
demonstrated	O
that	O
IRE1α	O
protects	O
infected	O
cells	O
from	O
IBV	O
-	O
induced	O
apoptosis	B-PROC
,	O
which	O
required	O
both	O
its	O
kinase	O
and	O
RNase	O
activities	O
.	O

Moreover	O
,	O
IRE1α	O
antagonized	O
IBV	O
-	O
induced	O
apoptosis	B-PROC
by	O
modulating	O
the	O
phosphorylation	B-PROC
status	O
of	O
the	O
proapoptotic	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
and	O
the	O
prosurvival	O
RAC	O
-	O
alpha	O
serine	O
/	O
threonine	O
-	O
protein	O
kinase	O
(	O
Akt	O
).	O

ABSTRACT	O
:	O
The	O
availability	O
of	O
a	O
robust	O
disease	O
model	O
is	O
essential	O
for	O
the	O
development	B-PROC
of	O
countermeasures	O
for	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

The	O
value	O
of	O
the	O
TUS	O
approach	O
was	O
particularly	O
important	O
to	O
disambiguate	O
cases	O
of	O
hemodynamic	B-PROC
pulmonary	O
edema	O
and	O
pneumonia	O
.	O

The	O
oxygenation	B-PROC
index	O
recorded	O
in	O
the	O
supine	O
position	O
was	O
significantly	O
higher	O
in	O
the	O
intervention	O
group	O
than	O
in	O
the	O
control	O
group	O
since	O
day	O
3	O
,	O
whereas	O
the	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
and	O
fraction	O
of	O
inspired	B-PROC
O2	O
were	O
significantly	O
lower	O
in	O
the	O
intervention	O
group	O
.	O

With	O
more	O
than	O
24	O
months	O
of	O
follow	O
-	O
up	O
,	O
renal	B-PROC
function	I-PROC
remains	O
normal	O
.	O

Part	O
16	O
:	O
Structure	O
-	O
based	O
bioisosterism	O
design	O
,	O
synthesis	B-PROC
and	O
biological	O
evaluation	O
of	O
novel	O
pyrimidinylthioacetanilides	O
as	O
potent	O
HIV	O
-	O
1	O
inhibitors	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
novel	O
pyrimidinylthioacetanilides	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
for	O
their	O
biological	O
activity	O
as	O
potent	O
HIV	O
-	O
1	O
non	B-PROC
-	I-PROC
nucleoside	I-PROC
reverse	I-PROC
transcriptase	I-PROC
inhibitors	I-PROC
(	O
NNRTIs	O
).	O

Tested	O
combinations	O
targeted	B-PROC
the	O
FCoV	O
leader	O
and	O
3	O
'	O
untranslated	O
region	O
,	O
FCoV	O
leader	O
region	O
and	O
nucleocapsid	O
gene	O
,	O
and	O
FCoV	O
leader	O
region	O
,	O
3	O
'	O
untranslated	O
region	O
,	O
and	O
nucleocapsid	O
gene	O
.	O

ABSTRACT	O
:	O
Viral	B-PROC
infection	I-PROC
converts	O
the	O
normal	O
constitution	O
of	O
a	O
cell	O
to	O
optimise	O
viral	O
entry	O
,	O
replication	O
,	O
and	O
virion	O
production	O
.	O

In	O
addition	O
,	O
they	O
also	O
could	O
affect	O
the	O
microfilaments	O
remodelling	O
of	O
IPEC	O
-	O
J2	O
cells	O
,	O
and	O
the	O
drug	O
-	O
interfered	O
microfilaments	O
could	O
inhibit	O
viral	B-PROC
replication	I-PROC
and	O
release	O
.	O

We	O
assessed	O
viral	B-PROC
replication	I-PROC
kinetics	O
and	O
competence	O
in	O
Vero	O
-	O
E6	O
cells	O
(	O
rhesus	O
monkey	O
),	O
tissue	B-PROC
tropism	B-PROC
in	O
cultures	O
of	O
ex	O
-	O
vivo	O
human	O
bronchial	O
and	O
lung	O
tissues	O
,	O
and	O
cytokine	O
and	O
chemokine	O
induction	O
,	O
gene	B-PROC
expression	I-PROC
,	O
and	O
quantification	O
of	O
viral	O
RNA	O
in	O
Calu	O
-	O
3	O
cells	O
(	O
human	O
respiratory	O
tract	O
).	O

The	O
epitope	O
was	O
further	O
tested	O
for	O
binding	O
against	O
the	O
HLA	O
molecules	O
,	O
using	O
in	O
silico	O
docking	B-PROC
techniques	O
,	O
to	O
verify	O
the	O
binding	O
cleft	O
epitope	O
interaction	O
.	O

ABSTRACT	O
:	O
The	O
impact	O
of	O
anesthetic	O
equipment	O
on	O
clinical	O
practice	O
parameters	O
associated	O
with	O
development	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
has	O
not	O
been	O
extensively	O
studied	O
.	O

Traditional	O
Chinese	O
medicine	O
(	O
TCM	O
)	O
is	O
one	O
of	O
the	O
mainstreams	O
of	O
complementary	O
and	O
alternative	O
medicine	O
,	O
and	O
serves	O
as	O
rich	O
resources	O
for	O
new	O
drug	O
development	B-PROC
.	O

All	O
the	O
vaccinated	O
animals	O
had	O
antibody	B-PROC
responses	I-PROC
against	O
spike	O
protein	O
,	O
which	O
neutralized	O
MERS	O
-	O
CoV	O
in	O
vitro	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
conduct	B-PROC
an	O
epidemiological	O
and	O
laboratory	O
surveillance	O
of	O
Influenza	O
-	O
Like	O
Illnesses	O
(	O
ILI	O
)	O
in	O
Polish	O
Armed	O
Forces	O
,	O
civilian	O
military	O
personnel	O
and	O
their	O
families	O
in	O
2011	O
/	O
2012	O
epidemic	O
season	O
,	O
under	O
the	O
United	O
States	O
Department	O
of	O
Defense	O
-	O
Global	O
Emerging	O
Infections	O
Surveillance	O
and	O
Response	O
System	O
(	O
DoD	O
-	O
GEIS	O
).	O

In	O
this	O
study	O
,	O
reverse	B-PROC
transcription	B-PROC
iiPCR	O
(	O
RT	O
-	O
iiPCR	O
)	O
was	O
developed	O
to	O
facilitate	O
point	O
-	O
of	O
-	O
need	O
diagnosis	O
of	O
CDV	O
infection	O
.	O

TITLE	O
:	O
C5aR	O
,	O
TNF	O
-	O
α	O
,	O
and	O
FGL2	O
contribute	O
to	O
coagulation	B-PROC
and	O
complement	B-PROC
activation	I-PROC
in	O
virus	O
-	O
induced	O
fulminant	O
hepatitis	O
.	O

C5b	O
-	O
9	O
,	O
C5aR	O
,	O
FGL2	O
,	O
CD31	O
,	O
CD11b	O
,	O
fibrin	O
,	O
TNF	O
-	O
α	O
,	O
and	O
complement	O
C3	O
cleavage	B-PROC
products	O
were	O
detected	O
by	O
immunohistochemistry	O
,	O
immunofluorescence	O
,	O
or	O
ELISA	O
.	O

Sorted	B-PROC
liver	O
sinusoidal	O
endothelial	O
cells	O
(	O
LSECs	O
)	O
or	O
myeloid	O
-	O
derived	O
(	O
CD11b	O
(+))	O
cells	O
were	O
stimulated	O
with	O
C5a	O
,	O
TNF	O
-	O
α	O
or	O
MHV	O
-	O
3	O
in	O
vitro	O
.	O

Immunoglobulin	B-PROC
neutralize	O
virus	O
invasion	O
and	O
suppress	O
viremia	O
,	O
acting	O
synergistically	O
with	O
acyclovir	O
.	O

Agents	O
were	O
prioritized	O
relative	O
to	O
their	O
scientific	O
/	O
epidemiologic	O
threat	O
and	O
their	O
perceived	O
threat	O
to	O
the	O
community	O
including	O
concerns	O
expressed	B-PROC
by	O
the	O
regulators	O
of	O
blood	O
.	O

Western	O
blot	O
showed	O
expression	B-PROC
of	O
the	O
recombinant	O
fusion	O
protein	O
mostly	O
in	O
soluble	O
monomeric	O
form	O
.	O

TITLE	O
:	O
Expression	B-PROC
patterns	O
of	O
plasma	O
von	O
Willebrand	O
factor	O
and	O
serum	O
interleukin	O
-	O
8	O
in	O
patients	O
with	O
early	O
-	O
stage	O
severe	O
pulmonary	O
contusion	O
.	O

Since	O
then	O
the	O
virus	O
has	O
spread	O
rapidly	O
nationwide	O
and	O
to	O
Canada	O
and	O
Mexico	O
causing	O
high	O
mortality	O
among	O
nursing	B-PROC
piglets	O
and	O
significant	O
economic	O
losses	O
.	O

The	O
paper	O
ends	O
with	O
the	O
notion	O
of	O
panorama	O
,	O
as	O
defined	O
by	O
Bruno	O
Latour	O
:	O
a	O
suggestion	O
to	O
describe	O
the	O
common	O
denominator	O
of	O
the	O
aforementioned	O
operators	O
,	O
and	O
a	O
means	O
to	O
foresee	O
the	O
development	B-PROC
of	O
global	O
scales	O
for	O
certain	O
health	O
alerts	O
.	O

Following	O
sequence	O
alignment	O
of	O
IBV	O
strains	O
,	O
a	O
combination	O
of	O
selective	O
primer	O
sets	O
was	O
designed	O
to	O
individually	O
amplify	O
the	O
IBV	O
wild	O
-	O
type	O
and	O
vaccine	O
strains	O
using	O
a	O
multiplex	O
amplification	O
refractory	O
mutation	O
system	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
ARMS	O
RT	O
-	O
PCR	O
)	O
approach	O
.	O

Although	O
a	O
large	O
number	O
of	O
neutralizing	O
antibodies	O
(	O
nAbs	O
)	O
have	O
been	O
developed	O
,	O
it	O
remains	O
unclear	O
if	O
a	O
single	O
RBD	O
-	O
targeting	B-PROC
nAb	O
or	O
two	O
in	O
combination	O
can	O
prevent	O
neutralization	O
escape	O
and	O
,	O
if	O
not	O
,	O
attenuate	O
viral	O
virulence	B-PROC
in	O
vivo	O
.	O

Interestingly	O
,	O
in	O
mice	O
the	O
neutralization	O
escape	O
mutant	O
viruses	O
showed	O
either	O
attenuation	O
(	O
Urbani	O
background	O
)	O
or	O
increased	O
virulence	B-PROC
(	O
GD03	O
background	O
)	O
consistent	O
with	O
the	O
different	O
binding	O
affinities	O
between	O
their	O
RBDs	O
and	O
the	O
mouse	O
ACE2	O
.	O

In	O
the	O
context	O
of	O
viral	B-PROC
infections	I-PROC
,	O
expression	B-PROC
of	O
these	O
enzymes	O
can	O
result	O
in	O
a	O
variety	O
of	O
outcomes	O
for	O
the	O
host	O
.	O

Clearly	O
,	O
monocyte	O
/	O
macrophage	B-PROC
activation	I-PROC
and	O
arginine	B-PROC
metabolism	I-PROC
will	O
continue	O
to	O
be	O
important	O
areas	O
of	O
investigation	O
in	O
the	O
context	O
of	O
viral	B-PROC
infections	I-PROC
.	O

Plasma	O
samples	O
of	O
77	O
patients	O
with	O
severe	O
multiple	O
trauma	O
as	O
defined	O
by	O
an	O
Injury	O
Severity	O
Score	O
(	O
ISS	O
)	O
16	O
or	O
greater	O
were	O
obtained	O
from	O
a	O
local	O
repository	O
and	O
levels	O
of	O
soluble	O
RAGE	O
,	O
endogenous	O
secretory	B-PROC
RAGE	O
,	O
cytokeratin	O
18	O
,	O
cleaved	O
cytokeratin	O
18	O
,	O
and	O
interleukin	O
6	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

TITLE	O
:	O
Detection	O
of	O
Influenza	O
and	O
Other	O
Respiratory	O
Viruses	O
Carried	O
Out	O
in	O
the	O
Influenza	O
Project	O
-	O
Monitoring	O
Vaccine	O
Effectiveness	O
(	O
I	O
-	O
MOVE	B-PROC
).	O

ABSTRACT	O
:	O
The	O
project	O
Influenza	O
Vaccine	O
Effectiveness	O
-	O
Monitoring	O
(	O
I	O
-	O
MOVE	B-PROC
)	O
is	O
part	O
of	O
the	O
European	O
research	O
carried	O
out	O
by	O
the	O
ECDC	O
(	O
European	O
Center	O
for	O
Disease	O
Prevention	O
and	O
Control	O
),	O
aimed	O
at	O
monitoring	O
the	O
effectiveness	O
of	O
vaccination	O
in	O
Europe	O
during	O
the	O
growing	O
incidence	O
of	O
flu	O
and	O
influenza	O
-	O
like	O
illnesses	O
in	O
the	O
coming	O
epidemic	O
seasons	O
.	O

Furthermore	O
,	O
TRIM56	O
was	O
revealed	O
to	O
impair	O
YFV	O
and	O
DENV2	O
propagation	O
by	O
suppressing	O
intracellular	O
viral	O
RNA	O
accumulation	O
but	O
to	O
compromise	O
HCoV	O
-	O
OC43	O
infection	O
at	O
a	O
later	O
step	O
in	O
the	O
viral	B-PROC
life	I-PROC
cycle	I-PROC
,	O
suggesting	O
that	O
distinct	O
TRIM56	O
domains	O
accommodate	O
differing	O
antiviral	O
mechanisms	O
.	O

The	O
N	O
-	O
terminus	O
RBD	O
(	O
S367	O
-	O
S606	O
)	O
of	O
S	O
glycoprotein	O
was	O
found	O
to	O
be	O
conserved	O
among	O
all	O
the	O
available	O
strains	O
of	O
MERS	O
-	O
CoV	O
.	O
Based	O
on	O
the	O
lower	O
IC50	O
value	O
,	O
a	O
total	O
of	O
eight	O
potential	O
T	O
-	O
cell	O
epitopes	O
and	O
19	O
major	B-PROC
histocompatibility	I-PROC
complex	I-PROC
(	O
MHC	B-PROC
)	O
class	O
-	O
I	O
alleles	O
were	O
identified	O
for	O
this	O
conserved	O
region	O
.	O

The	O
causes	O
of	O
death	B-PROC
were	O
relapse	O
(	O
n	O
=	O
2	O
),	O
infection	O
(	O
n	O
=	O
2	O
),	O
bleeding	O
(	O
n	O
=	O
1	O
),	O
thrombotic	O
microangiopathy	O
(	O
n	O
=	O
1	O
),	O
and	O
chronic	O
GVHD	O
(	O
n	O
=	O
1	O
).	O

The	O
data	O
revealed	O
that	O
during	O
ALI	O
,	O
insulin	O
stimulates	O
alveolar	O
fluid	O
clearance	O
by	O
upregulating	O
the	O
expression	B-PROC
of	O
α	O
-,	O
β	O
-,	O
and	O
γ	O
-	O
ENaC	O
at	O
the	O
cell	O
surface	O
,	O
which	O
was	O
,	O
at	O
least	O
,	O
partially	O
through	O
activating	O
mTROC2	O
/	O
SGK1	O
signaling	B-PROC
pathway	I-PROC
.	O

Viral	O
clearance	O
and	O
subsequent	O
recovery	O
from	O
infection	O
require	O
activation	O
of	O
an	O
effective	O
host	O
immune	B-PROC
response	I-PROC
;	O
however	O
,	O
many	O
immune	O
effector	O
cells	O
may	O
also	O
cause	O
injury	O
to	O
host	O
tissues	O
.	O

This	O
interaction	O
disrupted	O
the	O
association	O
between	O
PDK1	O
and	O
PKB	O
/	O
Akt	O
,	O
and	O
led	O
to	O
down	B-PROC
-	I-PROC
regulation	B-PROC
of	O
PKB	O
/	O
Akt	O
activity	O
.	O

This	O
subsequently	O
reduced	O
the	O
level	O
of	O
the	O
phosphorylated	O
forkhead	O
transcription	B-PROC
factor	O
FKHRL1	O
and	O
ASK	O
(	O
apoptosis	B-PROC
signal	O
-	O
regulating	O
kinase	O
),	O
and	O
led	O
to	O
the	O
activation	O
of	O
caspases	O
8	O
and	O
9	O
.	O

Our	O
work	O
highlights	O
that	O
the	O
SARS	O
-	O
CoV	O
M	O
protein	O
is	O
highly	O
pro	O
-	O
apoptotic	O
and	O
is	O
capable	O
of	O
simultaneously	O
inducing	O
apoptosis	B-PROC
via	O
initiating	O
caspases	O
8	O
and	O
9	O
.	O

Here	O
,	O
we	O
focused	O
on	O
the	O
role	O
of	O
Sprouty	O
-	O
related	O
EVH1	O
-	O
domain	O
-	O
containing	O
protein	O
(	O
Spred	O
)-	O
2	O
,	O
a	O
negative	O
regulator	O
of	O
the	O
Ras	O
-	O
Raf	O
-	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)-	O
MAPK	O
pathway	B-PROC
,	O
in	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
acute	O
lung	O
inflammation	O
.	O

After	O
LPS	O
-	O
injection	O
,	O
the	O
lungs	O
were	O
harvested	O
to	O
assess	O
leukocyte	O
infiltration	O
,	O
cytokine	O
and	O
chemokine	B-PROC
production	I-PROC
,	O
ERK	O
-	O
MAPK	B-PROC
activation	I-PROC
and	O
immunopathology	O
.	O

Specific	O
knock	O
down	O
of	O
Spred	O
-	O
2	O
augmented	O
LPS	O
-	O
induced	O
cytokine	O
and	O
chemokine	O
responses	O
in	O
RAW264	O
.	O
7	O
cells	O
and	O
MLE	O
-	O
12	O
cells	O
,	O
whereas	O
Spred	O
-	O
2	O
overexpression	B-PROC
decreased	O
this	O
response	O
in	O
RAW264	O
.	O
7	O
cells	O
.	O

A	O
Cox	O
proportional	O
hazards	O
model	O
adjusted	O
for	O
age	O
,	O
sex	O
and	O
frailty	O
,	O
determined	O
the	O
relationship	O
between	O
immune	O
phenotypes	O
and	O
time	O
to	O
viral	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
The	O
economic	O
effect	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
to	O
support	O
adults	O
with	O
severe	O
respiratory	O
failure	O
in	O
Brazil	O
:	O
a	O
hypothetical	O
analysis	O
.	O

Thus	O
,	O
coronaviruses	O
employ	O
a	O
unique	O
strategy	O
for	O
the	O
transition	O
from	O
discontinuous	O
to	O
continuous	O
transcription	B-PROC
to	O
ensure	O
balanced	O
sgmRNAs	O
and	O
full	O
-	O
length	O
gRNA	O
synthesis	B-PROC
.	O

The	O
polysaccharide	O
exhibited	O
potent	O
antiviral	O
activity	O
against	O
PEDV	O
reducing	O
the	O
formation	B-PROC
of	O
a	O
visible	O
CPE	O
[	O
a	O
50	O
%	O
inhibitory	O
concentration	O
(	O
IC50	O
)=	O
1	O
.	O
7	O
±	O
1	O
.	O
3μg	O
/	O
mL	O
],	O
compared	O
to	O
positive	O
control	O
,	O
ribavirin	O
and	O
it	O
did	O
not	O
show	O
cytotoxicity	O
at	O
100μg	O
/	O
mL	O
[	O
a	O
50	O
%	O
cytotoxicity	O
concentration	O
(	O
CC50	O
)=	O
100μg	O
/	O
mL	O
].	O

UPR	O
is	O
mediated	O
by	O
three	O
ER	O
transmembrane	O
sensors	O
,	O
namely	O
the	O
PKR	O
-	O
like	O
ER	O
protein	O
kinase	O
(	O
PERK	O
),	O
the	O
inositol	O
-	O
requiring	O
protein	O
1	O
(	O
IRE1	O
)	O
and	O
the	O
activating	O
transcriptional	B-PROC
factor	O
6	O
(	O
ATF6	O
).	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
efficacy	O
of	O
negative	O
fluid	B-PROC
balance	I-PROC
in	O
hypoxemic	O
patients	O
with	O
an	O
elevated	O
extravascular	O
lung	O
water	O
index	O
(	O
EVLWI	O
).	O

The	O
protocol	O
dictates	O
a	O
negative	O
fluid	B-PROC
balance	I-PROC
between	O
500	O
and	O
1500ml	O
/	O
day	O
.	O

These	O
gene	O
variations	O
may	O
influence	O
the	O
inflammatory	B-PROC
response	I-PROC
mediators	O
'	O
expression	B-PROC
,	O
directly	O
affecting	O
the	O
susceptibility	O
to	O
acute	O
lung	O
injury	O
,	O
the	O
intensity	O
of	O
lung	O
parenchyma	O
inflammation	O
,	O
the	O
development	B-PROC
clinical	O
course	O
and	O
outcome	O
.	O

He	O
developed	O
multiple	O
organ	O
dysfunction	O
syndromes	O
(	O
pulmonary	O
,	O
renal	O
,	O
coagulation	B-PROC
,	O
cardiovascular	O
and	O
metabolic	B-PROC
).	O

The	O
goal	O
of	O
this	O
article	O
is	O
to	O
review	O
the	O
key	O
role	O
of	O
corticosteroids	O
in	O
the	O
host	O
response	B-PROC
to	I-PROC
stress	I-PROC
and	O
will	O
update	O
the	O
reader	O
with	O
the	O
new	O
validated	O
indications	O
of	O
corticosteroids	O
treatment	O
in	O
the	O
ICU	O
.	O

TITLE	O
:	O
[	O
Inhaled	B-PROC
nitric	O
oxide	O
for	O
children	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
].	O

Inhaled	B-PROC
nitric	O
oxide	O
as	O
the	O
first	O
vasodilator	O
to	O
produce	O
selective	O
pulmonary	O
vasodilation	B-PROC
has	O
beneficial	O
effects	O
on	O
gas	O
exchange	O
and	O
ventilation	O
,	O
improving	O
outcome	O
in	O
children	O
with	O
severe	O
hypoxia	O
.	O

Although	O
the	O
mortality	O
rate	O
from	O
sepsis	O
in	O
children	O
has	O
steadily	O
decreased	O
in	O
the	O
last	O
decades	O
,	O
the	O
mortality	O
rate	O
in	O
newborns	O
remains	O
high	O
(	O
20	O
%	O
to	O
40	O
%)	O
despite	O
the	O
development	B-PROC
in	O
intensive	O
care	O
.	O

He	O
presented	O
to	O
the	O
emergency	O
room	O
complaining	O
of	O
diarrhea	O
and	O
dyspnea	O
,	O
and	O
then	O
transferred	O
to	O
the	O
ICU	O
after	O
development	B-PROC
of	O
hypoxemic	O
acute	O
respiratory	O
failure	O
and	O
refractory	O
septic	O
shock	O
,	O
and	O
despite	O
treatment	O
the	O
patient	O
died	B-PROC
.	O

Strongyloides	O
stercoralis	O
infection	O
symptoms	O
are	O
usually	O
mild	O
,	O
but	O
in	O
the	O
setting	O
of	O
impaired	O
host	O
immunity	B-PROC
,	O
a	O
disseminated	O
and	O
severe	O
illness	O
may	O
occur	O
.	O

Virulence	B-PROC
factors	O
of	O
Escherichia	O
coli	O
were	O
identified	O
in	O
103	O
strains	O
:	O
eae	O
(	O
7	O
),	O
K99	O
/	O
STa	O
(	O
7	O
),	O
Stx1	O
(	O
7	O
),	O
Stx1	O
/	O
eae	O
(	O
36	O
),	O
Stx1	O
/	O
Stx2	O
/	O
eae	O
(	O
2	O
),	O
Stx2	O
(	O
43	O
),	O
and	O
Stx2	O
/	O
eae	O
(	O
1	O
).	O

The	O
complete	O
spike	O
gene	O
of	O
Indian	O
AIB	O
vaccine	O
strain	O
was	O
amplified	O
and	O
sequenced	O
using	O
a	O
conventional	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
and	O
is	O
submitted	O
to	O
the	O
GenBank	O
(	O
accession	O
no	O
KF188436	O
).	O

Finally	O
,	O
knockdown	O
of	O
Beclin1	O
partially	O
reverses	O
PLP2	O
-	O
TM	O
'	O
s	O
inhibitory	O
effect	O
on	O
innate	B-PROC
immunity	B-PROC
which	O
resulting	O
in	O
decreased	O
coronavirus	O
replication	O
.	O

Twenty	O
-	O
three	O
pathogenic	O
respiratory	O
agents	O
,	O
18	O
respiratory	O
viruses	O
and	O
five	O
bacteria	O
were	O
investigated	O
using	O
multiplex	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
indirect	O
immunofluorescence	O
assay	O
(	O
IIF	O
).	O

RESULTS	O
:	O
In	O
EcoV	O
positive	O
horses	O
,	O
27	O
%	O
(	O
4	O
/	O
15	O
)	O
of	O
the	O
animals	O
died	B-PROC
or	O
were	O
euthanized	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
bound	O
to	O
ubiquitin	B-PROC
facilitates	O
targeted	B-PROC
disruption	O
of	O
deubiquitinating	B-PROC
activity	O
to	O
demonstrate	O
its	O
role	O
in	O
innate	O
immune	O
suppression	B-PROC
.	O

In	O
addition	O
to	O
this	O
replicative	O
function	O
,	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	O
)	O
was	O
recently	O
shown	O
to	O
be	O
a	O
deubiquitinating	B-PROC
enzyme	I-PROC
(	O
DUB	O
)	O
and	O
to	O
possess	O
deISGylating	O
activity	O
,	O
as	O
previously	O
reported	O
for	O
other	O
coronaviral	O
PL	O
(	O
pro	O
)	O
domains	O
,	O
including	O
that	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

To	O
understand	O
the	O
molecular	O
basis	O
for	O
ubiquitin	B-PROC
(	O
Ub	B-PROC
)	O
recognition	O
and	O
deconjugation	O
by	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	O
),	O
we	O
determined	O
its	O
crystal	O
structure	O
in	O
complex	O
with	O
Ub	B-PROC
.	O

Having	O
developed	O
a	O
strategy	O
to	O
selectively	O
disable	O
PL	O
(	O
pro	O
)	O
DUB	O
activity	O
,	O
we	O
were	O
able	O
to	O
specifically	O
examine	O
the	O
effects	O
of	O
this	O
activity	O
on	O
the	O
innate	B-PROC
immune	I-PROC
response	I-PROC
.	O

These	O
findings	O
directly	O
implicate	O
the	O
DUB	O
function	O
of	O
PL	O
(	O
pro	O
),	O
and	O
not	O
its	O
proteolytic	B-PROC
activity	O
per	O
se	O
,	O
in	O
the	O
inhibition	B-PROC
of	O
IFN	O
-	O
β	O
promoter	O
activity	O
.	O

ABSTRACT	O
:	O
Toxic	O
epidermal	O
necrosis	B-PROC
is	O
a	O
severe	O
mucocutaneous	O
disease	O
with	O
a	O
high	O
mortality	O
rate	O
.	O

Here	O
,	O
we	O
report	O
the	O
case	O
of	O
a	O
child	O
(	O
German	O
,	O
male	O
)	O
with	O
H1N1	O
-	O
associated	O
fulminate	O
respiratory	O
and	O
secondary	O
hemodynamic	B-PROC
deterioration	O
who	O
was	O
rescued	O
by	O
initial	O
emergent	O
ECMO	O
established	O
through	O
a	O
dialysis	O
catheter	O
and	O
subsequent	O
switch	O
to	O
central	O
cannulation	O
following	O
median	O
sternotomy	O
.	O

Necroptosis	B-PROC
and	O
subsequent	O
danger	O
signal	B-PROC
release	I-PROC
is	O
a	O
novel	O
mechanism	O
of	O
injury	O
following	O
transfusion	O
that	O
may	O
account	O
for	O
the	O
increased	O
risk	O
of	O
ARDS	O
in	O
critically	O
ill	O
transfused	O
patients	O
.	O

The	O
results	O
showed	O
that	O
the	O
4	O
-	O
plex	O
iTRAQ	O
-	O
based	O
quantitative	O
approach	O
identified	O
4	O
,	O
112	O
proteins	O
,	O
146	O
of	O
which	O
showed	O
significant	O
changes	O
in	O
expression	B-PROC
48	O
h	O
after	O
infection	O
.	O

Changes	O
in	O
the	O
expression	B-PROC
levels	O
of	O
transforming	O
growth	B-PROC
factor	O
beta	O
1	O
(	O
TGF	O
-	O
β1	O
),	O
caspase	O
-	O
8	O
,	O
and	O
heat	B-PROC
shock	I-PROC
protein	O
90	O
alpha	O
(	O
HSP90α	O
)	O
were	O
also	O
verified	O
by	O
western	O
blot	O
analysis	O
.	O

Our	O
data	O
indicates	O
that	O
emodin	O
potently	O
inhibits	O
LPS	O
-	O
induced	O
pulmonary	O
inflammation	O
,	O
pulmonary	O
edema	O
and	O
MCP	O
-	O
1	O
and	O
E	O
-	O
selectin	B-PROC
expression	B-PROC
,	O
and	O
that	O
these	O
effects	O
were	O
very	O
likely	O
mediated	O
by	O
inactivation	O
of	O
NF	O
-	O
κB	O
in	O
mice	O
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
endoplasmic	O
reticulum	O
-	O
resident	O
glucosidases	O
impairs	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
human	O
coronavirus	O
NL63	O
spike	O
protein	O
-	O
mediated	O
entry	O
by	O
altering	O
the	O
glycan	O
processing	O
of	O
angiotensin	O
I	O
-	O
converting	O
enzyme	O
2	O
.	O

Because	O
most	O
of	O
the	O
viral	O
envelope	O
glycoproteins	O
contain	O
N	O
-	O
linked	O
glycans	O
,	O
inhibition	B-PROC
of	O
ER	O
glucosidases	O
with	O
derivatives	O
of	O
1	O
-	O
deoxynojirimycin	O
,	O
i	O
.	O
e	O
.,	O
iminosugars	O
,	O
efficiently	O
disrupts	O
the	O
morphogenesis	B-PROC
of	O
a	O
broad	O
spectrum	O
of	O
enveloped	O
viruses	O
.	O

RecV	O
and	O
inspiratory	B-PROC
capacity	O
(	O
IC	O
)	O
were	O
determined	O
in	O
12	O
LH	O
and	O
in	O
25	O
ARDS	O
patients	O
during	O
incremental	O
PEEP	O
(	O
steps	O
of	O
2	O
cmH2	O
O	O
).	O

In	O
this	O
study	O
,	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
coupled	O
to	O
isobaric	O
tags	O
for	O
relative	O
and	O
absolute	O
quantification	O
labeling	O
was	O
used	O
to	O
quantitatively	O
identify	O
differentially	O
expressed	B-PROC
cellular	O
proteins	O
after	O
TGEV	O
infection	O
in	O
PK	O
-	O
15	O
cells	O
.	O

Affymetrix	O
Microarray	O
analysis	O
for	O
mRNA	B-PROC
expression	B-PROC
data	O
reveals	O
expression	B-PROC
of	O
inflammatory	O
mediators	O
that	O
are	O
known	O
to	O
be	O
released	O
by	O
activated	O
microglia	O
.	O

Effects	O
that	O
arise	O
long	O
after	O
the	O
primary	O
infection	O
can	O
also	O
increase	O
the	O
propensity	O
for	O
chronic	O
conditions	O
or	O
lead	O
to	O
the	O
development	B-PROC
of	O
cancer	O
.	O

The	O
authors	O
found	O
that	O
:	O
(	O
1	O
)	O
UP	O
-	O
MVcontr	O
reduced	O
diffuse	O
alveolar	O
damage	O
score	O
in	O
dorsal	O
lung	O
zones	O
(	O
median	O
[	O
interquartile	O
])	O
(	O
12	O
.	O
0	O
[	O
7	O
.	O
0	O
to	O
16	O
.	O
8	O
]	O
vs	O
.	O
22	O
.	O
5	O
[	O
13	O
.	O
8	O
to	O
40	O
.	O
8	O
]),	O
but	O
worsened	O
oxygenation	B-PROC
and	O
intrapulmonary	O
shunt	O
,	O
compared	O
to	O
P	O
-	O
MVcontr	O
;	O
(	O
2	O
)	O
UP	O
-	O
MVspont	O
and	O
UP	O
-	O
MVPS	O
improved	O
oxygenation	B-PROC
and	O
intrapulmonary	O
shunt	O
,	O
and	O
redistributed	O
ventilation	O
towards	O
dorsal	O
areas	O
,	O
as	O
compared	O
to	O
UP	O
-	O
MVcontr	O
;	O
(	O
3	O
)	O
compared	O
to	O
P	O
-	O
MVcontr	O
,	O
UP	O
-	O
MVcontr	O
and	O
UP	O
-	O
MVspont	O
,	O
UP	O
-	O
MVPS	O
yielded	O
higher	O
levels	O
of	O
tumor	O
necrosis	B-PROC
factor	O
-	O
α	O
(	O
6	O
.	O
9	O
[	O
6	O
.	O
5	O
to	O
10	O
.	O
1	O
]	O
vs	O
.	O
2	O
.	O
8	O
[	O
2	O
.	O
2	O
to	O
3	O
.	O
0	O
],	O
3	O
.	O
6	O
[	O
3	O
.	O
0	O
to	O
4	O
.	O
7	O
]	O
and	O
4	O
.	O
0	O
[	O
2	O
.	O
8	O
to	O
4	O
.	O
4	O
]	O
pg	O
/	O
mg	O
,	O
respectively	O
)	O
and	O
interleukin	O
-	O
8	O
(	O
216	O
.	O
8	O
[	O
113	O
.	O
5	O
to	O
343	O
.	O
5	O
]	O
vs	O
.	O
59	O
.	O
8	O
[	O
45	O
.	O
3	O
to	O
66	O
.	O
7	O
],	O
37	O
.	O
6	O
[	O
18	O
.	O
8	O
to	O
52	O
.	O
0	O
],	O
and	O
59	O
.	O
5	O
[	O
36	O
.	O
1	O
to	O
79	O
.	O
7	O
]	O
pg	O
/	O
mg	O
,	O
respectively	O
)	O
in	O
dorsal	O
lung	O
zones	O
.	O

Thus	O
,	O
this	O
method	O
may	O
provide	O
an	O
insight	O
for	O
the	O
chemical	O
synthesis	B-PROC
of	O
antiviral	O
RNA	O
molecule	O
for	O
the	O
treatment	O
of	O
MERS	O
-	O
CoV	O
,	O
at	O
genomic	O
level	O
.	O

Specific	O
cues	O
in	O
the	O
endosomal	O
microenvironment	O
induce	O
conformational	O
changes	O
in	O
the	O
viral	O
fusion	O
proteins	O
leading	O
to	O
viral	O
and	O
host	O
membrane	B-PROC
fusion	I-PROC
.	O

Molecular	O
specificity	O
of	O
newly	O
synthesised	O
PC	O
fraction	O
showed	O
time	O
course	O
variation	O
,	O
with	O
lower	O
PC16	O
:	O
0	O
/	O
16	O
:	O
0	O
composition	O
at	O
earlier	O
time	O
points	O
,	O
but	O
achieved	O
near	O
equilibrium	B-PROC
with	O
endogenous	O
composition	O
at	O
48	O
hours	O
after	O
methyl	O
-	O
D9	O
-	O
choline	O
infusion	O
.	O

We	O
concluded	O
that	O
plasmoblastic	O
/	O
plasmocytoid	O
-	O
like	O
type	O
II	O
pneumocytes	O
might	O
represent	O
a	O
morphologic	O
marker	O
of	O
A	O
/	O
H1N1	O
influenza	O
virus	B-PROC
infection	I-PROC
as	O
well	O
as	O
reparative	O
cellular	O
activation	O
after	O
diffuse	O
alveolar	O
damage	O
.	O

Possible	O
mechanisms	O
of	O
death	B-PROC
include	O
respiratory	O
depression	O
,	O
central	B-PROC
nervous	I-PROC
system	I-PROC
depression	I-PROC
,	O
and	O
serotonin	O
syndrome	O
.	O

Subsequently	O
,	O
in	O
weaned	B-PROC
animals	O
,	O
oral	O
vaccines	O
incorporating	O
novel	O
mucosal	O
adjuvants	O
(	O
e	O
.	O
g	O
.,	O
vitamin	O
A	O
,	O
probiotics	O
)	O
may	O
provide	O
active	O
protection	O
when	O
maternal	O
immunity	B-PROC
wanes	O
.	O

Transmission	O
of	O
viruses	O
from	O
bats	O
to	O
humans	O
requires	O
a	O
hierarchy	O
of	O
enabling	O
conditions	O
that	O
connect	O
the	O
distribution	O
of	O
reservoir	O
hosts	O
,	O
viral	B-PROC
infection	I-PROC
within	O
these	O
hosts	O
,	O
and	O
exposure	O
and	O
susceptibility	O
of	O
recipient	O
hosts	O
.	O

Focusing	O
on	O
Hendra	O
virus	O
,	O
but	O
also	O
addressing	O
Nipah	O
virus	O
,	O
Ebola	O
virus	O
,	O
Marburg	O
virus	O
and	O
coronaviruses	O
,	O
we	O
delineate	O
this	O
cross	O
-	O
species	O
spillover	O
dynamic	O
from	O
the	O
within	O
-	O
host	O
processes	O
that	O
drive	O
virus	O
excretion	B-PROC
to	O
land	O
-	O
use	O
changes	O
that	O
increase	O
interaction	O
among	O
species	O
.	O

TITLE	O
:	O
[	O
Risk	O
factors	O
of	O
the	O
occurence	O
and	O
death	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
prospective	O
multicenter	O
cohort	O
study	O
].	O

There	O
was	O
no	O
significant	O
difference	O
between	O
observation	O
group	O
and	O
control	O
group	O
in	O
acute	O
pathologic	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHEII	O
)	O
score	O
,	O
Murray	O
score	O
,	O
oxygenation	B-PROC
index	O
(	O
PaO2	O
/	O
FiO2	O
)	O
before	O
transportation	O
,	O
transit	O
time	O
,	O
and	O
transit	O
distance	O
[	O
APACHEII	O
score	O
:	O
36	O
(	O
33	O
,	O
39	O
)	O
vs	O
.	O
27	O
(	O
23	O
,	O
35	O
),	O
Z	O
=-	O
1	O
.	O
830	O
,	O
P	O
=	O
0	O
.	O
067	O
;	O
Murray	O
score	O
:	O
3	O
.	O
5	O
±	O
0	O
.	O
3	O
vs	O
.	O
3	O
.	O
4	O
±	O
0	O
.	O
2	O
,	O
t	O
=	O
0	O
.	O
667	O
,	O
P	O
=	O
0	O
.	O
524	O
;	O
PaO₂	O
/	O
FiO₂	O
(	O
mmHg	O
,	O
1	O
mmHg	O
=	O
0	O
.	O
133	O
kPa	O
):	O
61	O
±	O
14	O
vs	O
.	O
63	O
±	O
14	O
,	O
t	O
=	O
-	O
0	O
.	O
249	O
,	O
P	O
=	O
0	O
.	O
809	O
;	O
transit	O
time	O
(	O
minutes	O
):	O
24	O
(	O
18	O
,	O
74	O
)	O
vs	O
.	O
79	O
(	O
41	O
,	O
86	O
),	O
Z	O
=-	O
1	O
.	O
654	O
,	O
P	O
=	O
0	O
.	O
098	O
;	O
transit	O
distance	O
(	O
km	O
):	O
12	O
.	O
9	O
(	O
8	O
.	O
3	O
,	O
71	O
.	O
8	O
)	O
vs	O
.	O
72	O
.	O
4	O
(	O
39	O
.	O
5	O
,	O
86	O
.	O
8	O
),	O
Z	O
=	O
-	O
1	O
.	O
651	O
,	O
P	O
=	O
0	O
.	O
099	O
].	O

Four	O
patients	O
were	O
survived	O
in	O
observation	O
group	O
,	O
and	O
one	O
died	B-PROC
from	O
the	O
shortage	O
of	O
oxygen	O
induced	O
lung	O
injury	O
deterioration	O
during	O
transportation	O
.	O

Three	O
patients	O
died	B-PROC
in	O
control	O
group	O
,	O
which	O
was	O
directly	O
associated	O
with	O
lung	O
injury	O
deterioration	O
.	O

Absence	O
of	O
ATF3	O
in	O
myeloid	O
-	O
derived	O
cells	O
caused	O
increased	O
pulmonary	O
cellular	B-PROC
infiltration	I-PROC
.	O

ABSTRACT	O
:	O
The	O
development	B-PROC
of	O
an	O
effective	O
vaccine	O
is	O
critical	O
for	O
prevention	O
of	O
a	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
pandemic	O
.	O

The	O
immune	B-PROC
responses	I-PROC
of	O
mice	O
vaccinated	O
with	O
RBD	O
,	O
incomplete	O
Freund	O
'	O
s	O
adjuvant	O
(	O
IFA	O
)	O
and	O
CpG	O
ODN	O
by	O
a	O
subcutaneous	O
(	O
s	O
.	O
c	O
.	O

Finally	O
,	O
sequential	O
passage	O
of	O
MERS	O
-	O
CoV	O
in	O
permissive	O
bat	O
cells	O
established	O
persistent	O
infection	O
with	O
concomitant	O
downregulation	B-PROC
of	O
CD26	O
/	O
DPP4	O
surface	O
expression	B-PROC
.	O

TITLE	O
:	O
Carrageenan	O
nasal	O
spray	O
in	O
virus	O
confirmed	O
common	O
cold	B-PROC
:	O
individual	O
patient	O
data	O
analysis	O
of	O
two	O
randomized	O
controlled	O
trials	O
.	O

ABSTRACT	O
:	O
Clinical	O
trials	O
applying	O
iota	O
-	O
carrageenan	O
nasal	O
spray	O
have	O
previously	O
shown	O
to	O
reduce	O
duration	O
of	O
virus	O
-	O
confirmed	O
common	O
cold	B-PROC
.	O

Prevalence	O
of	O
viral	B-PROC
infections	I-PROC
,	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
assay	O
,	O
is	O
higher	O
in	O
cases	O
of	O
bronchiectasis	O
exacerbations	O
than	O
in	O
steady	O
-	O
state	O
bronchiectasis	O
,	O
suggesting	O
that	O
respiratory	O
viruses	O
play	O
crucial	O
roles	O
in	O
triggering	O
bronchiectasis	O
exacerbations	O
.	O

For	O
prokaryotic	O
expression	B-PROC
of	O
partial	O
fragments	O
of	O
spike	O
protein	O
the	O
size	O
and	O
location	O
of	O
S1	O
,	O
S2	O
,	O
and	O
S3	O
,	O
and	O
full	O
nucleocapsid	O
protein	O
,	O
polymerase	O
chain	O
reaction	O
was	O
performed	O
using	O
specific	O
primers	O
.	O

Neurological	O
examination	O
revealed	O
distal	O
weakness	O
and	O
loss	O
of	O
deep	O
tendon	O
reflexes	B-PROC
in	O
lower	O
extremities	O
.	O

TITLE	O
:	O
Experience	O
and	O
results	O
with	O
VV	O
-	O
ECMO	O
for	O
severe	O
acute	O
respiratory	O
failure	O
:	O
weaning	B-PROC
versus	O
nonweaning	O
.	O

In	O
a	O
univariate	O
analysis	O
median	O
platelet	O
(	O
PLT	O
)	O
count	O
at	O
ICU	O
admission	O
(	O
162	O
vs	O
.	O
97	O
×	O
10	O
/	O
L	O
;	O
p	O
=	O
0	O
.	O
046	O
)	O
and	O
pre	O
-	O
day	O
1	O
(	O
118	O
.	O
5	O
vs	O
.	O
62	O
.	O
5	O
×	O
10	O
/	O
L	O
;	O
p	O
=	O
0	O
.	O
046	O
)	O
was	O
higher	O
in	O
the	O
ECMO	O
-	O
weaned	B-PROC
group	O
than	O
those	O
in	O
the	O
weaning	B-PROC
failure	O
group	O
.	O

We	O
identified	O
MERS	O
-	O
CoV	O
neutralizing	O
antibodies	O
in	O
81	O
.	O
0	O
%	O
of	O
samples	O
from	O
the	O
main	O
camel	O
-	O
exporting	O
countries	O
,	O
Sudan	O
and	O
Somalia	O
,	O
suggesting	O
long	O
-	O
term	O
virus	O
circulation	B-PROC
in	O
these	O
animals	O
.	O

A	O
third	O
calf	O
from	O
another	O
herd	O
died	B-PROC
and	O
was	O
necropsied	O
.	O

Before	O
combining	O
lung	O
recruitment	O
maneuver	O
,	O
24	O
h	O
after	O
combining	O
lung	O
recruitment	O
maneuver	O
,	O
and	O
at	O
the	O
end	O
of	O
combining	O
lung	O
recruitment	O
maneuver	O
,	O
variables	O
of	O
blood	B-PROC
gas	I-PROC
analysis	O
(	O
pH	O
,	O
PaO2	O
,	O
and	O
PaCO2	O
)	O
were	O
obtained	O
by	O
blood	B-PROC
gas	I-PROC
analyzer	O
,	O
and	O
the	O
OI	O
values	O
were	O
calculated	O
;	O
hemodynamic	B-PROC
parameters	O
including	O
heart	O
rate	O
,	O
mean	O
arterial	B-PROC
pressure	I-PROC
(	O
MAP	O
),	O
central	O
venous	B-PROC
pressure	I-PROC
(	O
CVP	O
)	O
of	O
all	O
patients	O
and	O
the	O
cardiac	O
output	O
(	O
CO	O
),	O
extravascular	O
lung	O
water	O
index	O
(	O
EVLWI	O
)	O
of	O
4	O
patients	O
who	O
received	O
pulse	B-PROC
contour	O
cardiac	O
output	O
(	O
PiCCO	O
)	O
monitoring	O
were	O
monitored	O
.	O

None	O
of	O
the	O
children	O
with	O
asthma	O
syndrome	O
died	B-PROC
.	O

ABSTRACT	O
:	O
The	O
recent	O
emergence	O
of	O
two	O
highly	O
pathogenic	O
human	O
coronaviruses	O
(	O
CoVs	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
CoV	O
,	O
has	O
ignited	O
a	O
strong	O
interest	O
in	O
the	O
identification	O
of	O
viral	O
factors	O
that	O
determine	O
the	O
virulence	B-PROC
and	O
pathogenesis	B-PROC
of	O
CoVs	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
can	O
be	O
used	O
as	O
a	O
salvage	O
therapy	O
,	O
but	O
the	O
effectiveness	O
is	O
controversial	O
.	O

Type	O
II	O
epithelial	B-PROC
cell	I-PROC
proliferation	I-PROC
was	O
significantly	O
more	O
common	O
in	O
cases	O
with	O
a	O
longer	O
time	O
between	O
burn	O
and	O
admission	O
(	O
p	O
<	O
0	O
.	O
02	O
).	O

Various	O
models	O
have	O
successfully	O
been	O
developed	O
to	O
elucidate	O
the	O
contribution	O
of	O
the	O
spike	O
in	O
binding	O
of	O
the	O
virus	O
to	O
cells	O
,	O
entry	O
of	O
cell	O
culture	O
cells	O
and	O
organ	O
explants	O
,	O
and	O
the	O
in	O
vivo	O
tropism	B-PROC
and	O
pathogenesis	B-PROC
.	O

With	O
this	O
,	O
we	O
aim	O
to	O
summarize	O
the	O
current	O
understanding	O
on	O
the	O
avian	O
coronavirus	O
spike	O
'	O
s	O
contribution	O
to	O
host	O
and	O
tissue	O
predilections	O
,	O
pathogenesis	B-PROC
,	O
as	O
well	O
as	O
its	O
role	O
in	O
therapeutic	O
and	O
protective	O
interventions	O
.	O

Receptor	O
-	O
binding	O
domains	O
(	O
RBD	O
)	O
have	O
been	O
identified	O
in	O
the	O
S	O
of	O
diverse	O
CoV	O
;	O
they	O
usually	O
contain	O
antigenic	O
determinants	O
targeted	B-PROC
by	O
antibodies	O
that	O
neutralize	O
CoV	O
infections	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
has	O
led	O
to	O
more	O
than	O
800	O
laboratory	O
-	O
confirmed	O
MERS	O
cases	O
with	O
a	O
high	O
case	O
fatality	O
rate	O
(∼	O
35	O
%),	O
posing	O
a	O
serious	O
threat	O
to	O
global	O
public	O
health	O
and	O
calling	O
for	O
the	O
development	B-PROC
of	O
effective	O
and	O
safe	O
therapeutic	O
and	O
prophylactic	O
strategies	O
to	O
treat	O
and	O
prevent	O
MERS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Simian	O
hemorrhagic	O
fever	B-PROC
virus	O
:	O
Recent	O
advances	O
.	O

In	O
contrast	O
,	O
similar	O
percentages	O
of	O
myeloid	O
dendritic	O
cells	O
were	O
infected	O
but	O
virus	B-PROC
replication	I-PROC
was	O
efficient	O
in	O
the	O
macaque	O
cells	O
but	O
inefficient	O
in	O
the	O
baboon	O
cells	O
.	O

Coronaviruses	O
encode	O
16	O
nonstructural	O
proteins	O
(	O
nsps	O
),	O
three	O
of	O
which	O
,	O
nsp3	O
,	O
nsp4	O
,	O
and	O
nsp6	O
,	O
are	O
necessary	O
and	O
sufficient	O
for	O
DMV	O
formation	B-PROC
.	O

Mutations	O
that	O
altered	O
DMV	O
morphology	O
but	O
not	O
glycosylation	B-PROC
did	O
not	O
affect	O
virus	O
fitness	O
while	O
viruses	O
lacking	O
nsp4	O
glycosylation	B-PROC
exhibited	O
a	O
loss	O
in	O
fitness	O
.	O

The	O
N	O
-	O
terminal	O
fusion	O
peptide	O
(	O
FP	O
,	O
residues	O
770	O
-	O
788	O
),	O
an	O
internal	O
fusion	O
peptide	O
(	O
IFP	O
,	O
residues	O
873	O
-	O
888	O
)	O
and	O
the	O
pre	O
-	O
transmembrane	O
region	O
(	O
PTM	B-PROC
,	O
residues	O
1185	O
-	O
1202	O
)	O
demonstrated	O
interactions	O
with	O
model	O
lipid	O
membranes	O
and	O
potentially	O
involved	O
in	O
the	O
fusion	O
process	O
.	O

When	O
P34	O
and	O
EAV	O
were	O
incubated	O
for	O
6	O
h	O
at	O
37	O
°	O
C	O
the	O
viral	O
titer	O
reduced	O
from	O
10	O
(	O
4	O
.	O
5	O
)	O
TCID50	O
to	O
10	O
(	O
2	O
.	O
75	O
)	O
TCID50	O
,	O
showing	O
a	O
percent	O
of	O
inhibition	B-PROC
of	O
98	O
.	O
6	O
%.	O

Our	O
results	O
could	O
help	O
evaluate	O
the	O
progression	O
of	O
MERS	O
-	O
CoV	O
in	O
recent	O
months	O
in	O
response	O
to	O
changes	O
in	O
disease	O
surveillance	O
,	O
control	O
interventions	O
,	O
or	O
viral	O
adaptation	B-PROC
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
SARS	O
-	O
CoV	O
Papain	O
-	O
like	O
Protease	O
(	O
PLpro	O
)	O
inhibits	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
by	O
inhibiting	O
IRF3	O
phosphorylation	B-PROC
thereby	O
blocking	O
downstream	O
Interferon	O
induction	O
.	O

However	O
,	O
inhibition	B-PROC
of	O
PLpro	O
'	O
s	O
DUB	O
activity	O
by	O
mutagenesis	B-PROC
blocked	O
the	O
IRF3	O
inhibition	B-PROC
activity	O
of	O
PLpro	O
,	O
suggesting	O
a	O
role	O
for	O
IRF3	O
ubiquitination	B-PROC
in	O
induction	O
of	O
a	O
type	O
I	O
IFN	O
innate	B-PROC
immune	I-PROC
response	I-PROC
.	O

ABSTRACT	O
:	O
The	O
spike	O
protein	O
S	O
of	O
transmissible	O
gastroenteritis	O
virus	O
,	O
an	O
Alphacoronavirus	O
,	O
contains	O
a	O
tyrosine	O
-	O
based	O
sorting	B-PROC
signal	O
that	O
is	O
responsible	O
for	O
ERGIC	O
retention	B-PROC
and	O
may	O
be	O
important	O
for	O
a	O
correct	O
viral	B-PROC
assembly	I-PROC
process	O
.	O

This	O
requires	O
a	O
more	O
detailed	O
understanding	O
of	O
virus	O
-	O
host	O
cell	B-PROC
interactions	I-PROC
to	O
identify	O
candidates	O
for	O
targeted	B-PROC
virus	O
attenuation	O
.	O

We	O
identified	O
structures	O
novel	O
to	O
the	O
coronavirus	O
family	O
,	O
which	O
strongly	O
resemble	O
replication	O
sites	O
of	O
other	O
positive	O
sense	B-PROC
RNA	O
viruses	O
.	O

The	O
virus	O
in	O
the	O
harvest	O
can	O
be	O
used	O
to	O
characterize	O
the	O
viral	O
genome	O
sequence	O
and	O
cell	O
tropism	B-PROC
,	O
but	O
also	O
provides	O
progeny	O
virus	O
to	O
initiate	O
experiments	O
to	O
fulfill	O
the	O
Koch	O
'	O
s	O
postulates	O
.	O

As	O
a	O
member	O
of	O
the	O
genus	O
Alphacoronavirus	O
,	O
FIPV	O
encodes	O
two	O
polyprotein	O
precursors	O
required	O
for	O
genome	O
replication	O
and	O
transcription	B-PROC
.	O

Recent	O
work	O
adds	O
new	O
information	O
on	O
the	O
physiological	B-PROC
effects	I-PROC
of	O
neurally	O
adjusted	O
ventilatory	O
assist	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
ERK	O
/	O
MAPK	O
and	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
signaling	B-PROC
responses	O
play	O
important	O
roles	O
in	O
MERS	O
-	O
CoV	O
infection	O
and	O
may	O
represent	O
novel	O
drug	O
targets	O
for	O
therapeutic	O
intervention	O
strategies	O
.	O

Six	O
required	O
salvage	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
with	O
one	O
survivor	O
.	O

Predictors	O
included	O
higher	O
ISS	O
,	O
renal	O
failure	O
,	O
continuous	O
renal	O
replacement	O
therapy	O
,	O
and	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

ECMO	O
was	O
weaned	B-PROC
at	O
a	O
mean	O
duration	O
of	O
188	O
(	O
range	O
,	O
43	O
-	O
672	O
)	O
h	O
in	O
all	O
patients	O
.	O

The	O
SF1	O
helicase	O
protein	O
of	O
viruses	O
classified	O
in	O
the	O
order	O
Nidovirales	O
is	O
encoded	O
in	O
replicase	O
open	O
reading	O
frame	O
1b	O
(	O
ORF1b	O
),	O
which	O
is	O
translated	O
to	O
give	O
rise	O
to	O
a	O
large	O
polyprotein	O
following	O
a	O
ribosomal	B-PROC
frameshift	I-PROC
from	O
the	O
upstream	O
ORF1a	O
.	O

In	O
the	O
context	O
of	O
our	O
knowledge	O
of	O
related	O
helicases	O
of	O
cellular	O
and	O
viral	O
origin	O
,	O
it	O
discusses	O
the	O
implications	O
of	O
these	O
results	O
for	O
the	O
protein	O
'	O
s	O
emerging	O
critical	O
function	O
(	O
s	O
)	O
in	O
nidovirus	O
evolution	B-PROC
,	O
genome	O
replication	O
and	O
expression	B-PROC
,	O
virion	O
biogenesis	B-PROC
,	O
and	O
possibly	O
also	O
post	O
-	O
transcriptional	B-PROC
processing	O
of	O
viral	O
RNAs	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
of	O
this	O
inhibition	B-PROC
remains	O
unclear	O
.	O

By	O
promoting	O
p53	O
degradation	O
,	O
PLP2	O
inhibits	O
the	O
p53	O
-	O
mediated	O
antiviral	B-PROC
response	I-PROC
and	O
apoptosis	B-PROC
to	O
ensure	O
viral	O
growth	B-PROC
in	O
infected	O
cells	O
.	O

At	O
clinical	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
11	O
±	O
3	O
cm	O
H2O	O
),	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
had	O
a	O
greater	O
lung	O
tissue	O
weight	O
and	O
recruitability	O
than	O
patients	O
with	O
mild	O
or	O
moderate	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

The	O
practice	O
of	O
ASA	O
challenge	O
and	O
desensitization	B-PROC
in	O
Canada	O
is	O
infrequently	O
utilized	O
,	O
which	O
may	O
explain	O
its	O
omission	O
as	O
a	O
viable	O
therapeutic	O
option	O
in	O
the	O
latest	O
Canadian	O
clinical	O
practice	O
guidelines	O
for	O
acute	O
and	O
chronic	O
rhinosinusitis	O
(	O
AACI	O
7	O
:	O
1	O
-	O
38	O
,	O
2011	O
).	O

TITLE	O
:	O
Balancing	B-PROC
neuromuscular	B-PROC
blockade	I-PROC
versus	O
preserved	O
muscle	O
activity	O
.	O

In	O
the	O
less	O
severe	O
patients	O
(	O
mild	O
ARDS	O
),	O
however	O
,	O
a	O
few	O
studies	O
have	O
demonstrated	O
the	O
benefits	O
of	O
preserving	O
spontaneous	O
breathing	B-PROC
with	O
an	O
improvement	O
in	O
oxygenation	B-PROC
and	O
a	O
decrease	O
in	O
the	O
length	O
of	O
mechanical	O
ventilation	O
.	O

While	O
all	O
vaccines	O
protected	O
against	O
lethal	O
infection	O
,	O
addition	O
of	O
adjuvant	O
significantly	O
increased	O
serum	O
neutralizing	O
-	O
antibody	B-PROC
titers	O
and	O
reduced	O
lung	O
virus	O
titers	O
on	O
day	O
3	O
postchallenge	O
.	O

Therefore	O
,	O
early	O
recognition	O
of	O
ARDS	O
modified	O
risk	O
factors	O
and	O
the	O
avoidance	O
of	O
aggravating	O
factors	O
during	O
the	O
patient	O
'	O
s	O
hospital	O
stay	O
can	O
help	O
decrease	O
its	O
development	B-PROC
.	O

Family	O
members	O
,	O
clinicians	O
,	O
and	O
experts	O
identified	O
specific	O
communication	O
behaviors	B-PROC
that	O
clinicians	O
should	O
use	O
to	O
discuss	O
prognosis	O
in	O
the	O
critical	O
care	O
setting	O
.	O

Using	O
topological	O
techniques	O
,	O
including	O
persistence	O
homology	O
and	O
filtered	O
clustering	O
,	O
we	O
performed	O
a	O
comparative	O
transcriptional	B-PROC
analysis	O
of	O
human	O
Calu	O
-	O
3	O
cell	O
host	O
responses	O
to	O
the	O
different	O
MERS	O
-	O
CoV	O
strains	O
,	O
with	O
MERS	O
-	O
CoV	O
Eng	O
1	O
inducing	O
early	O
kinetic	O
changes	O
,	O
between	O
3	O
and	O
12	O
hours	O
post	O
infection	O
,	O
compared	O
to	O
MERS	O
-	O
CoV	O
SA	O
1	O
.	O

Combining	O
statistical	O
analysis	O
of	O
infection	O
and	O
cytokine	O
-	O
stimulated	O
Calu	O
-	O
3	O
transcriptomics	O
,	O
we	O
identified	O
differential	O
innate	O
responses	O
,	O
including	O
up	B-PROC
-	I-PROC
regulation	B-PROC
of	O
extracellular	O
remodeling	O
genes	O
following	O
MERS	O
-	O
CoV	O
Eng	O
1	O
infection	O
and	O
differential	O
pro	O
-	O
inflammatory	B-PROC
responses	I-PROC
.	O

Foreign	O
children	O
were	O
diagnosed	O
and	O
treated	O
with	O
steroids	O
in	O
1	O
-	O
2	O
weeks	O
,	O
and	O
10	O
cases	O
were	O
cured	O
,	O
and	O
2	O
cases	O
died	B-PROC
.	O

In	O
May	O
2011	O
,	O
the	O
MOH	O
replaced	O
paper	O
-	O
based	O
collection	O
with	O
an	O
electronic	O
data	O
collection	O
system	O
using	O
Field	O
Adapted	O
Survey	O
Toolkit	O
(	O
FAST	O
)	O
on	O
HTC	O
Touch	B-PROC
Pro2	O
smartphones	O
at	O
four	O
sentinel	O
sites	O
.	O

TITLE	O
:	O
Selecting	O
the	O
'	O
right	O
'	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
level	O
.	O

Increasing	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
in	O
patients	O
with	O
severe	O
hypoxemia	O
is	O
associated	O
with	O
better	O
outcome	O
if	O
the	O
oxygenation	B-PROC
response	O
is	O
greater	O
and	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
tests	O
may	O
be	O
performed	O
in	O
a	O
few	O
minutes	O
.	O

If	O
,	O
after	O
recruitment	O
maneuver	O
,	O
the	O
recruitment	O
is	O
not	O
sustained	O
by	O
sufficient	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
,	O
the	O
lung	O
will	O
unavoidably	O
collapse	O
.	O

Under	O
hyperoxic	O
conditions	O
,	O
the	O
lungs	O
of	O
NLRP3	O
(-/-)	O
mice	O
exhibited	O
reduced	O
inflammatory	B-PROC
responses	I-PROC
,	O
such	O
as	O
inflammatory	O
cell	O
infiltration	O
and	O
cytokine	O
expression	B-PROC
,	O
as	O
well	O
as	O
increased	O
and	O
decreased	O
expression	B-PROC
of	O
MMP	O
-	O
9	O
and	O
Bcl	O
-	O
2	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
The	O
replication	O
of	O
coronaviruses	O
,	O
as	O
in	O
other	O
positive	O
-	O
strand	O
RNA	O
viruses	O
,	O
is	O
closely	O
tied	O
to	O
the	O
formation	B-PROC
of	O
membrane	O
-	O
bound	O
replicative	O
organelles	O
inside	O
infected	O
cells	O
.	O

There	O
were	O
5327	O
SARS	O
cases	O
from	O
November	O
2002	O
to	O
May	O
2003	O
in	O
Mainland	O
China	O
,	O
which	O
involved	O
29	O
provinces	O
,	O
resulted	O
in	O
349	O
deaths	B-PROC
,	O
and	O
directly	O
caused	O
economic	O
losses	O
of	O
$	O
18	O
.	O
3	O
billion	O
.	O

TITLE	O
:	O
Ebola	O
virus	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
display	O
late	O
cell	O
entry	O
kinetics	O
:	O
evidence	O
that	O
transport	B-PROC
to	O
NPC1	O
+	O
endolysosomes	O
is	O
a	O
rate	O
-	O
defining	O
step	O
.	O

For	O
EBOV	O
,	O
the	O
long	O
lag	O
is	O
not	O
due	O
to	O
the	O
large	O
size	O
or	O
unusual	O
shape	O
of	O
EBOV	O
filaments	O
,	O
the	O
need	O
to	O
prime	O
EBOV	O
GP	O
to	O
the	O
19	O
-	O
kDa	O
receptor	O
-	O
binding	O
species	O
,	O
or	O
a	O
need	O
for	O
unusually	O
low	O
endosomal	O
pH	O
.	O
In	O
contrast	O
,	O
since	O
we	O
observed	O
that	O
EBOV	O
entry	O
occurs	O
upon	O
arrival	O
in	O
Niemann	O
-	O
Pick	O
C1	O
(	O
NPC1	O
)-	O
positive	O
endolysosomes	O
(	O
LE	O
/	O
Lys	O
),	O
we	O
propose	O
that	O
trafficking	B-PROC
to	O
LE	O
/	O
Lys	O
is	O
a	O
key	O
rate	O
-	O
defining	O
step	O
.	O

Its	O
unique	O
putative	O
cleavage	B-PROC
sites	O
between	O
nonstructural	O
proteins	O
1	O
and	O
2	O
and	O
in	O
the	O
spike	O
(	O
S	O
)	O
protein	O
and	O
low	O
sequence	O
identities	O
to	O
other	O
lineage	O
A	O
betacoronaviruses	O
(	O
βCoVs	O
)	O
in	O
conserved	O
replicase	O
domains	O
support	O
ChRCoV	O
HKU24	O
as	O
a	O
separate	O
species	O
.	O

Despite	O
the	O
fact	O
that	O
the	O
SARS	O
-	O
CoV	O
pandemic	O
infected	O
over	O
8500	O
individuals	O
,	O
claimed	O
over	O
800	O
lives	O
and	O
cost	O
billions	O
of	O
dollars	O
in	O
economic	O
loss	O
worldwide	O
,	O
there	O
still	O
are	O
no	O
clinically	O
approved	O
antiviral	O
drugs	O
,	O
vaccines	O
or	O
monoclonal	O
antibody	B-PROC
therapies	O
to	O
treat	O
SARS	O
-	O
CoV	O
infections	O
.	O

RESULTS	O
:	O
LiCl	O
significantly	O
suppressed	O
the	O
synthesis	B-PROC
of	O
viral	O
RNA	O
and	O
protein	O
;	O
however	O
,	O
it	O
did	O
not	O
block	O
PRRSV	O
binding	O
and	O
entry	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
ICU	O
deaths	B-PROC
.	O

For	O
these	O
patients	O
,	O
tailored	O
use	O
of	O
ventilator	O
settings	O
should	O
be	O
considered	O
,	O
including	O
:	O
further	O
reduction	O
of	O
tidal	O
volumes	O
,	O
administration	O
of	O
neuromuscular	O
blocking	O
agents	O
if	O
the	O
patient	O
'	O
s	O
spontaneous	O
breathing	B-PROC
is	O
incompatible	O
with	O
mechanical	O
ventilation	O
,	O
and	O
adjusting	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
settings	O
based	O
on	O
transpulmonary	O
pressure	O
levels	O
.	O

The	O
present	O
study	O
suggested	O
the	O
potential	O
of	O
compounds	O
6	O
,	O
9	O
,	O
11	O
,	O
and	O
13	O
as	O
promising	O
scaffolds	O
for	O
treating	O
PEDV	O
infection	O
via	O
inhibiting	O
viral	B-PROC
replication	I-PROC
.	O

ABSTRACT	O
:	O
To	O
compare	O
the	O
laboratory	O
course	O
of	O
HELLP	O
syndrome	O
between	O
patients	O
who	O
recover	B-PROC
and	O
those	O
who	O
progress	O
to	O
postpartum	O
thrombotic	O
microangiopathic	O
syndrome	O
(	O
PTMS	O
)	O
and	O
require	O
postpartum	O
plasma	O
exchange	O
(	O
PPEX	O
)	O
and	O
to	O
describe	O
maternal	O
characteristics	O
and	O
morbidity	O
in	O
women	O
with	O
PTMS	O
.	O

This	O
lecture	O
first	O
discussed	O
whether	O
respiratory	O
viral	B-PROC
infections	I-PROC
are	O
airborne	O
with	O
reference	O
to	O
published	O
reviews	O
of	O
studies	O
before	O
2008	O
,	O
comparative	O
trials	O
of	O
surgical	O
masks	O
and	O
N95	O
respirators	O
,	O
and	O
relevant	O
new	O
experimental	O
studies	O
.	O

Social	O
species	O
have	O
evolved	O
various	O
behavioral	B-PROC
strategies	O
reducing	O
the	O
probability	O
of	O
pathogen	O
exposure	O
.	O

The	O
antibody	B-PROC
status	O
regarding	O
BRSV	O
and	O
BoCV	O
was	O
analysed	O
with	O
commercial	O
indirect	O
ELISAs	O
.	O

Herd	O
-	O
level	O
data	O
on	O
production	O
,	O
health	O
and	O
reproduction	B-PROC
were	O
retrieved	O
from	O
VÄXA	O
Sweden	O
and	O
the	O
study	O
herds	O
were	O
representative	O
of	O
the	O
source	O
population	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
,	O
immunoblotting	O
using	O
monoclonal	O
antibodies	O
and	O
Escherichia	O
coli	O
-	O
expressed	B-PROC
recombinant	O
PEDV	O
and	O
TGEV	O
nucleocapsid	O
(	O
N	O
)	O
proteins	O
,	O
and	O
sequence	O
analysis	O
suggested	O
at	O
least	O
one	O
epitope	O
on	O
the	O
N	O
-	O
terminal	O
region	O
of	O
PEDV	O
/	O
TGEV	O
N	O
protein	O
that	O
contributed	O
to	O
this	O
cross	O
-	O
reactivity	O
.	O

Attenuated	O
IB	O
virus	O
(	O
aIBV	O
group	O
)	O
or	O
its	O
vehicle	O
(	O
control	O
group	O
)	O
was	O
introduced	O
to	O
the	O
oviductal	O
magnum	O
lumen	O
of	O
White	O
Leghorn	O
hens	O
in	O
the	O
laying	O
and	O
molting	B-PROC
phase	O
,	O
as	O
well	O
as	O
molting	B-PROC
hens	O
injected	O
with	O
estradiol	O
benzoate	O
(	O
M	O
-	O
EB	O
hens	O
)	O
or	O
corn	O
oil	O
(	O
M	O
-	O
oil	O
hens	O
).	O

The	O
expression	B-PROC
of	O
the	O
genes	O
of	O
toll	O
-	O
like	O
receptor	O
7	O
(	O
TLR7	O
),	O
natural	O
killer	O
cell	O
receptor	O
(	O
BNK	O
),	O
cytotoxic	O
substances	O
(	O
granzyme	O
,	O
perforin	O
),	O
and	O
cytokines	O
(	O
CXCL12	O
,	O
CX3CL1	O
,	O
and	O
IFNγ	O
)	O
were	O
examined	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

TITLE	O
:	O
The	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
from	O
mechanism	O
to	O
translation	B-PROC
.	O

A	O
major	O
challenge	O
facing	O
the	O
development	B-PROC
of	O
any	O
antiviral	O
strategy	O
is	O
that	O
of	O
resistance	B-PROC
,	O
a	O
problem	O
which	O
is	O
particularly	O
acute	O
for	O
RNAi	B-PROC
based	O
therapeutics	O
due	O
to	O
the	O
exquisite	O
sequence	O
specificity	O
of	O
the	O
targeting	B-PROC
mechanism	O
.	O

Combined	O
,	O
these	O
data	O
inform	O
the	O
potential	O
therapeutic	O
application	O
of	O
antiviral	O
RNAi	B-PROC
against	O
FIPV	O
.	O

These	O
mechanisms	O
are	O
usually	O
mediated	O
by	O
antiviral	O
proteins	O
whose	O
expression	B-PROC
and	O
activities	O
can	O
be	O
constitutive	O
but	O
are	O
frequently	O
amplified	O
by	O
interferon	O
induction	O
.	O

These	O
activities	O
limit	O
infection	O
in	O
cultured	O
cells	O
by	O
many	O
viruses	O
,	O
including	O
dengue	O
virus	O
,	O
Ebola	O
virus	O
,	O
influenza	O
A	O
virus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
and	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
.	O

The	O
findings	O
indicated	O
that	O
durable	O
lactogenic	O
immunity	B-PROC
was	O
present	O
in	O
sows	O
previously	O
exposed	O
to	O
a	O
mild	O
strain	O
of	O
PEDv	O
and	O
this	O
immunity	B-PROC
induced	O
cross	O
-	O
protection	O
to	O
representative	O
virulent	O
PEDv	O
.	O

However	O
,	O
unlike	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
PLpro	O
that	O
lacks	O
blocking	O
loop	O
(	O
BL	O
)	O
1	O
of	O
deubiquitinating	B-PROC
enzymes	O
,	O
the	O
IBV	O
PLpro	O
has	O
a	O
short	O
BL1	O
-	O
like	O
loop	O
.	O

A	O
model	O
of	O
ubiquitin	B-PROC
-	O
bound	O
IBV	O
CoV	O
PLpro	O
brings	O
out	O
key	O
differences	O
in	O
substrate	O
binding	O
sites	O
of	O
PLpros	O
.	O

TITLE	O
:	O
Ear	O
necrosis	B-PROC
syndrome	O
in	O
weaning	B-PROC
pigs	O
associated	O
with	O
PCV2	O
infection	O
:	O
A	O
case	O
report	O
.	O

ABSTRACT	O
:	O
Porcine	O
necrotic	B-PROC
ear	O
syndrome	O
(	O
PNES	O
)	O
in	O
pigs	O
has	O
been	O
reported	O
as	O
an	O
increasing	O
health	O
problem	O
in	O
many	O
countries	O
with	O
intensive	O
pig	O
farming	O
.	O

Approximately	O
35	O
%	O
of	O
weaners	O
(	O
1	O
-	O
3	O
weeks	O
after	O
weaning	B-PROC
)	O
presented	O
clinical	O
symptoms	O
similar	O
to	O
Post	O
-	O
weaning	B-PROC
Multisystemic	O
Wasting	O
Syndrome	O
(	O
PMWS	O
).	O

TITLE	O
:	O
Fused	O
-	O
ring	O
structure	O
of	O
decahydroisoquinolin	O
as	O
a	O
novel	O
scaffold	O
for	O
SARS	O
3CL	O
protease	B-PROC
inhibitors	I-PROC
.	O

Focusing	O
on	O
hydrophobic	B-PROC
interactions	I-PROC
at	O
the	O
S2	O
site	O
,	O
the	O
decahydroisoquinolin	O
scaffold	O
was	O
designed	O
by	O
connecting	O
the	O
P2	O
site	O
cyclohexyl	O
group	O
of	O
the	O
substrate	O
-	O
based	O
inhibitor	O
to	O
the	O
main	O
-	O
chain	O
at	O
the	O
α	O
-	O
nitrogen	O
atom	O
of	O
the	O
P2	O
position	O
via	O
a	O
methylene	O
linker	O
.	O

RESULTS	O
:	O
All	O
patients	O
required	O
respiratory	O
support	O
before	O
ExT	O
.	O
After	O
ExT	O
,	O
respiration	B-PROC
status	O
improved	O
in	O
all	O
five	O
patients	O
:	O
WBC	O
count	O
(	O
mean	O
)	O
decreased	O
by	O
85	O
%	O
from	O
143	O
×	O
10	O
(	O
9	O
)	O
/	O
L	O
to	O
21	O
×	O
10	O
(	O
9	O
)	O
/	O
L	O
.	O

CONCLUSIONS	O
:	O
ExT	O
was	O
very	O
effective	O
in	O
improving	O
hyperleukocytosis	O
and	O
may	O
have	O
had	O
favorable	O
effects	O
on	O
respiration	B-PROC
.	O

From	O
HIV	O
to	O
hepatotropic	O
viruses	O
to	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
,	O
humanized	O
mice	O
have	O
led	O
to	O
the	O
identification	O
of	O
factors	O
crucial	O
to	O
the	O
viral	B-PROC
life	I-PROC
cycle	I-PROC
,	O
served	O
as	O
an	O
outlet	O
for	O
testing	O
candidate	O
therapies	O
,	O
and	O
improved	O
our	O
abilities	O
to	O
analyze	O
human	O
immune	B-PROC
responses	I-PROC
to	O
infection	O
.	O

These	O
studies	O
have	O
provided	O
the	O
framework	O
for	O
understanding	O
the	O
structure	O
and	O
function	O
of	O
pulmonary	O
surfactant	O
,	O
which	O
has	O
informed	O
understanding	O
of	O
the	O
pathogenesis	B-PROC
of	O
diverse	O
pulmonary	O
disorders	O
previously	O
considered	O
idiopathic	O
.	O

This	O
review	O
considers	O
the	O
pulmonary	O
surfactant	O
system	O
and	O
the	O
genetic	O
causes	O
of	O
acute	O
and	O
chronic	O
lung	O
disease	O
caused	O
by	O
disruption	O
of	O
alveolar	O
homeostasis	B-PROC
.	O

These	O
changes	O
were	O
interpreted	O
as	O
the	O
transition	O
from	O
an	O
acute	O
disease	O
with	O
a	O
primary	O
respiratory	O
manifestation	O
into	O
a	O
chronic	O
condition	O
where	O
renal	O
amyloidosis	O
led	O
to	O
chronic	O
renal	O
failure	O
and	O
death	B-PROC
.	O

ABSTRACT	O
:	O
A	O
10	O
-	O
mo	O
-	O
old	O
female	O
fennec	O
fox	O
(	O
Vulpes	O
zerda	O
)	O
with	O
drooling	O
suddenly	O
died	B-PROC
and	O
was	O
examined	O
postmortem	O
.	O

Prespecified	O
ancillary	O
outcomes	O
included	O
time	O
to	O
hemostasis	B-PROC
,	O
blood	O
product	O
volumes	O
transfused	O
,	O
complications	O
,	O
incidence	O
of	O
surgical	O
procedures	O
,	O
and	O
functional	O
status	O
.	O

More	O
patients	O
in	O
the	O
1	O
:	O
1	O
:	O
1	O
group	O
achieved	O
hemostasis	B-PROC
than	O
in	O
the	O
1	O
:	O
1	O
:	O
2	O
group	O
(	O
86	O
%	O
vs	O
78	O
%,	O
respectively	O
;	O
P	O
=	O
.	O
006	O
).	O

Consistently	O
,	O
nanomolar	O
concentrations	O
of	O
the	O
cardiotonic	O
steroids	O
ouabain	O
and	O
bufalin	O
,	O
which	O
are	O
known	O
not	O
to	O
affect	O
the	O
transport	B-PROC
function	O
of	O
Na	O
(+),	O
K	O
(+)-	O
ATPase	O
,	O
inhibited	O
infection	O
of	O
cells	O
with	O
MHV	O
,	O
FIPV	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
CoV	O
,	O
and	O
VSV	O
,	O
but	O
not	O
IAV	O
,	O
when	O
the	O
compounds	O
were	O
present	O
during	O
virus	O
inoculation	O
.	O

None	O
of	O
the	O
gp3	O
proteins	O
modulate	O
the	O
viral	B-PROC
replication	I-PROC
cycle	I-PROC
of	O
heterologous	O
genotype	O
II	O
CCoV	O
in	O
canine	O
cell	O
line	O
,	O
leading	O
to	O
the	O
conclusion	O
that	O
the	O
gp3	O
proteins	O
are	O
probably	O
advantageous	O
only	O
for	O
CCoV	O
-	O
I	O
and	O
atypical	O
FCoV	O
strains	O
.	O

Furthermore	O
,	O
of	O
the	O
signs	O
of	O
positive	O
selection	O
in	O
the	O
S	O
protein	O
,	O
the	O
conservative	O
substitutions	O
were	O
more	O
frequent	O
than	O
radical	O
substitutions	O
in	O
PEDVs	O
,	O
suggesting	O
that	O
the	O
evolution	B-PROC
of	O
Korean	O
strains	O
has	O
been	O
slow	O
.	O

The	O
hemodynamics	B-PROC
were	O
monitored	O
by	O
pulse	B-PROC
-	O
indicated	O
continuous	O
cardiac	O
output	O
(	O
PiCCO	O
)	O
and	O
the	O
airway	O
pressure	O
changes	O
and	O
blood	B-PROC
gas	I-PROC
analysis	O
indexes	O
were	O
recorded	O
at	O
different	O
time	O
points	O
.	O

PaO2	O
and	O
oxygenation	B-PROC
indexes	O
in	O
the	O
small	O
VT	O
group	O
showed	O
the	O
most	O
obvious	O
increase	O
after	O
ventilation	O
for	O
2	O
hours	O
and	O
were	O
much	O
higher	O
than	O
the	O
other	O
two	O
groups	O
after	O
ventilation	O
for	O
6	O
hours	O
.	O

Small	O
tidal	O
volume	O
ventilation	O
combined	O
with	O
PEEP	O
could	O
alleviate	O
the	O
acute	O
lung	O
injury	O
induced	O
by	O
paraquat	O
and	O
improve	O
oxygenation	B-PROC
.	O

Presepsin	O
is	O
another	O
biomarker	O
that	O
was	O
recently	O
evaluated	O
and	O
is	O
elevated	O
in	O
patients	O
with	O
severe	O
sepsis	O
patients	O
at	O
risk	O
of	O
dying	B-PROC
.	O

This	O
is	O
the	O
first	O
report	O
of	O
FIP	O
in	O
an	O
African	O
lion	O
and	O
the	O
first	O
report	O
of	O
ocular	B-PROC
FIP	O
in	O
a	O
non	O
-	O
domestic	O
felid	O
.	O

Then	O
,	O
we	O
treated	O
different	O
bat	O
cells	O
,	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEF	O
)	O
and	O
splenocytes	O
with	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
(	O
polyI	O
:	O
C	O
)	O
and	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
to	O
assess	O
and	O
compare	O
antiviral	O
immune	B-PROC
responses	I-PROC
between	O
bats	O
and	O
mice	O
.	O

The	O
patient	O
'	O
s	O
clinical	O
course	O
continued	O
for	O
2	O
months	O
and	O
was	O
complicated	O
by	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
pneumonia	O
,	O
septic	O
shock	O
,	O
poor	O
skin	O
graft	O
adherence	O
,	O
renal	O
failure	O
requiring	O
continuous	O
renal	O
replacement	O
therapy	O
,	O
cutaneous	O
mucormycosis	O
,	O
and	O
ultimately	O
,	O
withdrawal	O
of	O
care	O
and	O
death	B-PROC
.	O

Many	O
current	O
studies	O
have	O
reported	O
possible	O
application	O
of	O
aptamers	O
as	O
a	O
treatment	O
or	O
diagnostic	O
tool	O
in	O
viral	B-PROC
infections	I-PROC
,	O
e	O
.	O
g	O
.,	O
HIV	O
(	O
Human	O
Immunodeficiency	O
Virus	O
),	O
HBV	O
(	O
Hepatitis	O
B	O
Virus	O
),	O
HCV	O
(	O
Hepatitis	O
C	O
Virus	O
),	O
SARS	O
(	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
),	O
H5N1	O
avian	O
influenza	O
and	O
recently	O
spread	O
Ebola	O
.	O

The	O
syndrome	O
is	O
thought	O
to	O
result	O
from	O
occlusion	B-PROC
of	O
the	O
artery	O
of	O
Percheron	O
,	O
which	O
arises	O
as	O
a	O
common	O
trunk	O
from	O
one	O
of	O
the	O
posterior	O
cerebral	O
arteries	O
to	O
supply	O
both	O
paramedian	O
thalamic	O
regions	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
has	O
become	O
pandemic	O
in	O
the	O
Asian	O
pig	O
-	O
breeding	B-PROC
industry	O
,	O
causing	O
significant	O
economic	O
loss	O
.	O

Overall	O
,	O
our	O
study	O
provides	O
the	O
first	O
insight	O
into	O
a	O
structural	O
platform	O
for	O
anti	O
-	O
FIPV	O
and	O
anti	O
-	O
FCV	O
drug	O
development	B-PROC
.	O

TITLE	O
:	O
Managing	O
hypercapnia	O
in	O
patients	O
with	O
severe	O
ARDS	O
and	O
low	O
respiratory	O
system	O
compliance	O
:	O
the	O
role	O
of	O
esophageal	B-PROC
pressure	I-PROC
monitoring	O
--	O
a	O
case	O
cohort	O
study	O
.	O

Spontaneous	O
circulation	B-PROC
had	O
earlier	O
resumed	O
after	O
brief	O
application	O
of	O
cardiopulmonary	O
resuscitation	O
.	O

TITLE	O
:	O
Analysis	O
of	O
cathepsin	O
and	O
furin	O
proteolytic	B-PROC
enzymes	O
involved	O
in	O
viral	O
fusion	O
protein	B-PROC
activation	I-PROC
in	O
cells	O
of	O
the	O
bat	O
reservoir	O
host	O
.	O

To	O
determine	O
whether	O
the	O
utilization	O
of	O
cathepsins	O
by	O
bat	O
-	O
borne	O
viruses	O
is	O
related	O
to	O
the	O
nature	O
of	O
proteases	O
in	O
their	O
natural	O
hosts	O
,	O
we	O
examined	O
proteolytic	B-PROC
processing	I-PROC
of	O
several	O
viral	O
fusion	O
proteins	O
in	O
cells	O
derived	O
from	O
two	O
fruit	O
bat	O
species	O
,	O
Pteropus	O
alecto	O
and	O
Rousettus	O
aegyptiacus	O
.	O

RESULTS	O
:	O
Calves	O
with	O
initial	O
antibody	B-PROC
titers	O
against	O
BRSV	O
<	O
1	O
:	O
64	O
that	O
were	O
treated	O
for	O
BRD	O
had	O
a	O
slower	O
rate	O
of	O
anti	O
-	O
BRSV	O
antibody	B-PROC
decay	O
than	O
did	O
similar	O
calves	O
that	O
were	O
not	O
treated	O
for	O
BRD	O
.	O

Of	O
255	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
MERS	O
-	O
CoV	O
infection	O
,	O
93	O
died	B-PROC
(	O
case	O
fatality	O
rate	O
,	O
36	O
.	O
5	O
%).	O

The	O
first	O
patient	O
presented	O
with	O
progressive	O
respiratory	O
symptoms	O
,	O
acute	O
renal	O
failure	O
and	O
died	B-PROC
.	O

TITLE	O
:	O
Characterization	O
of	O
human	O
coronaviruses	O
on	O
well	O
-	O
differentiated	B-PROC
human	O
airway	O
epithelial	O
cell	O
cultures	O
.	O

Infectious	O
recombinant	O
IBVs	O
are	O
generated	O
in	O
situ	O
following	O
the	O
transfection	B-PROC
of	O
vaccinia	O
virus	O
DNA	O
,	O
containing	O
the	O
modified	O
IBV	O
cDNA	O
,	O
into	O
cells	O
infected	O
with	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
T7	O
DNA	O
-	O
dependent	O
RNA	O
polymerase	O
.	O

ABSTRACT	O
:	O
The	O
large	O
size	O
of	O
the	O
coronavirus	O
(	O
CoV	O
)	O
genome	O
(	O
around	O
30	O
kb	O
)	O
and	O
the	O
instability	O
in	O
bacteria	O
of	O
plasmids	O
carrying	O
CoV	O
replicase	O
sequences	O
represent	O
serious	O
restrictions	O
for	O
the	O
development	B-PROC
of	O
CoV	O
infectious	O
clones	O
using	O
reverse	O
genetic	O
systems	O
similar	O
to	O
those	O
used	O
for	O
smaller	O
positive	O
sense	B-PROC
RNA	O
viruses	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
viral	B-PROC
replication	I-PROC
and	O
pathogenesis	B-PROC
,	O
it	O
is	O
necessary	O
to	O
establish	O
the	O
virus	O
-	O
host	O
protein	B-PROC
interaction	I-PROC
networks	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
hybridoma	O
cell	O
line	O
secreting	B-PROC
monoclonal	O
antibody	B-PROC
against	O
S	O
protein	O
of	O
a	O
Chinese	O
variant	O
of	O
PEDV	O
.	O

TITLE	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
to	O
improve	O
oxygenation	B-PROC
for	O
safe	O
critical	O
care	O
transport	B-PROC
of	O
adults	O
with	O
severe	O
hypoxemia	O
.	O

RESULTS	O
:	O
Patients	O
treated	O
with	O
iNO	O
had	O
significant	O
improvement	O
in	O
oxygenation	B-PROC
:	O
mean	O
(	O
SD	O
)	O
for	O
PaO2	O
increased	O
from	O
60	O
.	O
7	O
(	O
20	O
.	O
2	O
)	O
to	O
72	O
.	O
3	O
(	O
40	O
.	O
6	O
)	O
mm	O
Hg	O
(	O
P	O
=.	O
008	O
),	O
and	O
mean	O
(	O
SD	O
)	O
for	O
ratio	O
of	O
PaO2	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
(	O
P	O
:	O
F	O
)	O
increased	O
from	O
62	O
.	O
4	O
(	O
26	O
.	O
1	O
)	O
to	O
73	O
.	O
1	O
(	O
42	O
.	O
6	O
)	O
(	O
P	O
=	O
.	O
03	O
).	O

RT	O
-	O
PCR	O
assays	O
targeting	B-PROC
these	O
regions	O
were	O
designed	O
and	O
optimized	O
.	O

Our	O
results	O
have	O
revealed	O
the	O
role	O
of	O
cellular	O
VHL	O
in	O
the	O
regulation	B-PROC
of	O
SARS	O
-	O
CoV	O
replication	O
.	O

ABSTRACT	O
:	O
Breastfeeding	B-PROC
is	O
vital	O
for	O
child	O
survival	O
,	O
health	O
,	O
and	O
development	B-PROC
.	O

The	O
costs	O
presented	O
in	O
this	O
article	O
provide	O
the	O
minimum	O
amount	O
that	O
the	O
country	O
should	O
invest	O
to	O
achieve	O
better	O
breastfeeding	B-PROC
practices	O
.	O

Patients	O
classified	O
as	O
having	O
severe	O
illness	O
were	O
further	O
classified	O
according	O
to	O
outcome	O
(	O
survival	O
versus	O
death	B-PROC
)	O
and	O
clinical	O
syndrome	O
.	O

The	O
sensitivity	O
of	O
the	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
of	O
CSF	O
in	O
cats	O
with	O
neurological	O
and	O
/	O
or	O
ocular	B-PROC
signs	O
was	O
85	O
.	O
7	O
%.	O

TITLE	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
CO2	O
removal	O
improves	O
pulmonary	O
hemodynamics	B-PROC
in	O
a	O
porcine	O
ARDS	O
model	O
.	O

We	O
investigated	O
if	O
extracorporeal	O
veno	O
-	O
venous	O
CO2	O
removal	O
therapy	O
could	O
have	O
beneficial	O
effects	O
on	O
pulmonary	B-PROC
circulation	B-PROC
and	O
RV	O
function	O
.	O

A	O
number	O
of	O
host	O
RNA	O
proteins	O
have	O
been	O
shown	O
to	O
bind	O
to	O
the	O
5	O
'	O
and	O
3	O
'	O
cis	O
-	O
acting	O
regions	O
,	O
but	O
the	O
significance	O
of	O
these	O
in	O
viral	B-PROC
replication	I-PROC
is	O
not	O
clear	O
.	O

We	O
purified	O
6	O
lignans	O
from	O
Schisandra	O
chinensis	O
fruits	O
and	O
assayed	O
their	O
effects	O
on	O
HIV	O
-	O
1	O
RT	O
and	O
viral	B-PROC
replication	I-PROC
.	O

Out	O
of	O
eight	O
patients	O
with	O
respiratory	O
distress	O
(	O
20	O
%),	O
five	O
required	O
respiratory	O
support	O
(	O
12	O
.	O
5	O
%)	O
of	O
which	O
three	O
of	O
them	O
had	O
speech	B-PROC
impairment	O
as	O
well	O
.	O

TITLE	O
:	O
Successful	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
a	O
human	O
immunodeficiency	O
virus	O
infected	O
patient	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

A	O
25	O
year	O
old	O
male	O
with	O
no	O
significant	O
past	O
medical	O
history	O
had	O
been	O
admitted	O
to	O
a	O
local	O
hospital	O
due	O
to	O
dyspnea	O
and	O
fever	B-PROC
.	O

His	O
pulmonary	B-PROC
function	I-PROC
subsequently	O
failed	O
necessitating	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
and	O
introduction	O
of	O
ECMO	O
support	O
.	O

Of	O
the	O
322	O
sera	O
from	O
the	O
field	O
,	O
101	O
were	O
positive	O
for	O
TCoV	O
by	O
immunofluorescent	O
antibody	B-PROC
assay	O
(	O
IFA	O
).	O

In	O
addition	O
,	O
inhibitory	O
activity	O
of	O
this	O
compound	O
was	O
selective	O
for	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
PLpro	O
enzymes	O
over	O
two	O
human	O
homologues	O
,	O
the	O
ubiquitin	B-PROC
C	O
-	O
terminal	O
hydrolases	O
1	O
and	O
3	O
(	O
hUCH	O
-	O
L1	O
and	O
hUCH	O
-	O
L3	O
).	O

ABSTRACT	O
:	O
PET	O
with	O
[	O
18F	O
]	O
fluoro	O
-	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
can	O
be	O
used	O
to	O
image	O
cellular	B-PROC
metabolism	I-PROC
,	O
which	O
during	O
lung	O
inflammation	O
mainly	O
reflects	O
neutrophil	O
activity	O
,	O
allowing	O
the	O
study	O
of	O
regional	O
lung	O
inflammation	O
in	O
vivo	O
.	O

Lung	O
injury	O
was	O
induced	O
by	O
lung	O
lavages	O
and	O
210	O
minutes	O
of	O
injurious	O
mechanical	O
ventilation	O
using	O
low	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
and	O
high	O
inspiratory	B-PROC
pressures	O
.	O

The	O
origin	O
and	O
virulence	B-PROC
of	O
this	O
novel	O
porcine	O
coronavirus	O
are	O
not	O
known	O
.	O

The	O
GAIT	O
element	O
is	O
involved	O
in	O
the	O
translation	B-PROC
silencing	O
of	O
these	O
mRNAs	O
through	O
its	O
interaction	O
with	O
the	O
GAIT	O
complex	O
(	O
EPRS	O
,	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
Q	O
,	O
ribosomal	B-PROC
protein	I-PROC
L13a	O
,	O
and	O
glyceraldehyde	O
3	O
-	O
phosphate	O
dehydrogenase	O
)	O
to	O
favor	O
the	O
resolution	O
of	O
inflammation	O
.	O

Interestingly	O
,	O
we	O
showed	O
that	O
the	O
viral	O
RNA	O
motif	O
bound	O
the	O
GAIT	O
complex	O
and	O
inhibited	O
the	O
in	O
vitro	O
translation	B-PROC
of	O
a	O
chimeric	O
mRNA	O
containing	O
this	O
RNA	O
motif	O
.	O

Mutations	O
of	O
the	O
GAIT	O
-	O
like	O
RNA	O
motif	O
did	O
not	O
affect	O
virus	O
growth	B-PROC
in	O
cell	O
cultures	O
.	O

All	O
together	O
,	O
these	O
data	O
strongly	O
suggested	O
that	O
the	O
viral	O
GAIT	O
-	O
like	O
RNA	O
motif	O
modulates	O
the	O
host	O
innate	B-PROC
immune	I-PROC
response	I-PROC
.	O

Following	O
convection	O
enhanced	O
delivery	O
(	O
CED	O
),	O
conventional	O
gene	O
vectors	O
are	O
confined	O
to	O
the	O
injection	O
site	O
,	O
presumably	O
by	O
adhesive	O
interactions	O
with	O
the	O
brain	O
ECM	O
and	O
do	O
not	O
provide	O
gene	B-PROC
expression	I-PROC
beyond	O
the	O
point	O
of	O
administration	O
.	O

Norovirus	O
3C	O
-	O
like	O
protease	O
is	O
essential	O
for	O
viral	B-PROC
replication	I-PROC
,	O
consequently	O
,	O
inhibition	B-PROC
of	O
this	O
enzyme	O
is	O
a	O
fruitful	O
avenue	O
of	O
investigation	O
that	O
may	O
lead	O
to	O
the	O
emergence	O
of	O
antinorovirus	O
therapeutics	O
.	O

To	O
analyse	O
circumstances	O
resulting	O
in	O
toxic	O
exposure	O
to	O
phosphine	O
in	O
the	O
sea	O
transport	B-PROC
sector	O
.	O

TITLE	O
:	O
Emerging	O
respiratory	O
tract	O
viral	B-PROC
infections	I-PROC
.	O

Our	O
results	O
demonstrate	O
a	O
poorer	O
performance	O
of	O
growing	O
pigs	O
weaned	B-PROC
after	O
a	O
PEDv	O
outbreak	O
compared	O
with	O
those	O
weaned	B-PROC
within	O
the	O
previous	O
14	O
-	O
120	O
days	O
,	O
suggesting	O
that	O
in	O
addition	O
to	O
the	O
mortality	O
induced	O
by	O
PEDv	O
in	O
suckling	O
pigs	O
,	O
the	O
disease	O
also	O
impairs	O
the	O
performance	O
of	O
surviving	O
pig	O
.	O

This	O
review	O
focuses	O
on	O
the	O
discovery	O
and	O
development	B-PROC
of	O
indole	O
inhibitors	O
targeting	B-PROC
on	O
NS5B	O
thumb	O
site	O
I	O
.	O
Five	O
fundamental	O
principles	O
,	O
the	O
general	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
model	O
of	O
indole	O
scaffold	O
,	O
were	O
summarized	O
,	O
which	O
could	O
pave	O
the	O
way	O
for	O
further	O
structural	O
optimization	O
of	O
indole	O
-	O
based	O
anti	O
-	O
HCV	O
agents	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
pancreatitis	O
(	O
SAP	O
)	O
is	O
a	O
critical	O
illness	O
in	O
clinical	O
practice	O
,	O
which	O
is	O
characterized	O
by	O
intensive	O
inflammatory	B-PROC
response	I-PROC
in	O
the	O
early	O
phase	O
and	O
infected	O
pancreatic	O
necrosis	B-PROC
in	O
the	O
later	O
phase	O
.	O

TITLE	O
:	O
The	O
causes	O
and	O
consequences	O
of	O
changes	O
in	O
virulence	B-PROC
following	O
pathogen	O
host	O
shifts	O
.	O

Virulence	B-PROC
--	O
the	O
harm	O
a	O
pathogen	O
does	O
to	O
its	O
host	O
-	O
can	O
be	O
extremely	O
high	O
following	O
a	O
host	O
shift	O
(	O
for	O
example	O
Ebola	O
,	O
HIV	O
,	O
and	O
SARs	O
),	O
while	O
other	O
host	O
shifts	O
may	O
go	O
undetected	O
as	O
they	O
cause	O
few	O
symptoms	O
in	O
the	O
new	O
host	O
.	O

Here	O
we	O
examine	O
how	O
virulence	B-PROC
varies	O
across	O
host	O
species	O
by	O
carrying	O
out	O
a	O
large	O
cross	O
infection	O
experiment	O
using	O
48	O
species	O
of	O
Drosophilidae	O
and	O
an	O
RNA	O
virus	O
.	O

ABSTRACT	O
:	O
Community	O
-	O
acquired	O
pneumonia	O
(	O
CAP	O
)	O
is	O
the	O
most	O
common	O
infectious	O
disease	O
cause	O
of	O
death	B-PROC
.	O

The	O
risk	O
of	O
CLD	O
in	O
survivors	O
at	O
term	O
equivalent	O
gestational	O
age	O
was	O
significantly	O
reduced	O
with	O
the	O
use	O
of	O
HFOV	O
but	O
this	O
effect	O
was	O
inconsistent	O
across	O
studies	O
,	O
even	O
after	O
the	O
meta	O
-	O
analysis	O
was	O
restricted	O
to	O
studies	O
that	O
applied	O
a	O
high	O
lung	B-PROC
volume	I-PROC
strategy	O
with	O
HFOV	O
.	O

In	O
contrast	O
,	O
nearly	O
all	O
camels	O
in	O
the	O
Middle	O
East	O
have	O
been	O
infected	O
with	O
MERS	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
show	O
that	O
sera	O
obtained	O
from	O
MERS	O
-	O
immune	O
camels	O
augment	O
the	O
kinetics	O
of	O
MERS	O
-	O
CoV	O
clearance	O
and	O
reduce	O
the	O
severity	O
of	O
pathological	O
changes	O
in	O
infected	O
lungs	O
,	O
with	O
efficacy	O
proportional	O
to	O
the	O
titer	O
of	O
MERS	O
-	O
CoV	O
-	O
neutralizing	O
serum	O
antibody	B-PROC
.	O

ABSTRACT	O
:	O
The	O
basic	O
reproductive	B-PROC
number	O
(	O
R₀	O
)	O
and	O
the	O
distribution	O
of	O
the	O
serial	O
interval	O
(	O
SI	O
)	O
are	O
often	O
used	O
to	O
quantify	O
transmission	O
during	O
an	O
infectious	O
disease	O
outbreak	O
.	O

In	O
addition	O
,	O
current	O
academic	O
and	O
training	O
programs	O
for	O
PHC	O
and	O
PH	O
should	O
be	O
revisited	O
in	O
the	O
light	O
of	O
national	O
vision	B-PROC
and	O
strategy	O
that	O
aim	O
for	O
high	O
quality	O
products	O
that	O
protect	O
and	O
promote	O
healthy	O
nation	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	B-PROC
infection	I-PROC
induces	O
NF	O
-	O
κB	O
activation	O
through	O
the	O
TLR2	O
,	O
TLR3	O
and	O
TLR9	O
pathways	B-PROC
in	O
porcine	O
intestinal	O
epithelial	O
cells	O
.	O

They	O
were	O
more	O
likely	O
to	O
have	O
complications	O
such	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
liver	O
and	O
renal	O
dysfunctions	O
,	O
and	O
had	O
a	O
significantly	O
higher	O
risk	O
of	O
death	B-PROC
.	O

This	O
review	O
summarizes	O
recent	O
gains	O
in	O
our	O
knowledge	O
of	O
how	O
cytoplasmic	O
RNA	O
viruses	O
use	O
these	O
co	O
-	O
opted	O
host	O
nuclear	O
factors	O
in	O
new	O
functional	O
roles	O
supporting	O
virus	O
translation	B-PROC
and	O
virus	O
RNA	B-PROC
replication	I-PROC
and	O
common	O
themes	O
employed	O
between	O
different	O
virus	O
groups	O
.	O

However	O
,	O
the	O
role	O
of	O
recruitment	O
maneuver	O
remains	O
controversial	O
in	O
routine	O
practice	O
owing	O
to	O
concerns	O
regarding	O
complications	O
,	O
especially	O
its	O
effects	O
on	O
hemodynamics	B-PROC
.	O

Three	O
out	O
of	O
6	O
patients	O
who	O
had	O
comorbid	O
conditions	O
died	B-PROC
during	O
the	O
study	O
period	O
,	O
while	O
3	O
had	O
suc	O
.	O
cessful	O
outcomes	O
.	O

We	O
report	O
a	O
new	O
case	O
of	O
MERS	O
-	O
CoV	O
infection	O
in	O
a	O
9	O
-	O
month	O
-	O
old	O
child	O
complicated	O
by	O
severe	O
respiratory	O
symptoms	O
,	O
multi	O
-	O
organ	O
dysfunction	O
,	O
and	O
death	B-PROC
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
multi	O
-	O
epitope	O
antigen	O
of	O
S	O
protein	O
-	O
based	O
ELISA	O
for	O
antibodies	O
detection	O
against	O
infectious	O
bronchitis	O
virus	O
.	O

TITLE	O
:	O
Coronavirus	O
and	O
influenza	O
virus	O
proteolytic	B-PROC
priming	O
takes	O
place	O
in	O
tetraspanin	O
-	O
enriched	O
membrane	O
microdomains	O
.	O

Among	O
these	O
priming	O
components	O
are	O
proteases	O
,	O
which	O
cleave	O
viral	O
surface	O
glycoproteins	O
,	O
unleashing	O
them	O
to	O
refold	O
in	O
ways	O
that	O
catalyze	O
virus	O
-	O
cell	O
membrane	B-PROC
fusions	I-PROC
.	O

TITLE	O
:	O
Emerging	O
Viral	B-PROC
Diseases	I-PROC
:	O
The	O
One	O
Health	O
Connection	O
:	O
Workshop	O
Summary	O
ABSTRACT	O
:	O
In	O
the	O
past	O
half	O
century	O
,	O
deadly	O
disease	O
outbreaks	O
caused	O
by	O
novel	O
viruses	O
of	O
animal	O
origin	O
—	O
Nipah	O
virus	O
in	O
Malaysia	O
,	O
Hendra	O
virus	O
in	O
Australia	O
,	O
Hantavirus	O
in	O
the	O
United	O
States	O
,	O
Ebola	O
virus	O
in	O
Africa	O
,	O
along	O
with	O
HIV	O
(	O
human	O
immunodeficiency	O
virus	O
),	O
several	O
influenza	O
subtypes	O
,	O
and	O
the	O
SARS	O
(	O
sudden	O
acute	O
respiratory	O
syndrome	O
)	O
and	O
MERS	O
(	O
Middle	O
East	O
respiratory	O
syndrome	O
)	O
coronaviruses	O
—	O
have	O
underscored	O
the	O
urgency	O
of	O
understanding	O
factors	O
influencing	O
viral	B-PROC
disease	I-PROC
emergence	O
and	O
spread	O
.	O

A	O
QX	O
-	O
like	O
strain	O
was	O
analysed	O
by	O
high	O
-	O
throughput	O
Illumina	O
sequencing	O
and	O
genetic	O
variation	O
across	O
the	O
entire	O
viral	O
genome	O
was	O
explored	O
at	O
the	O
sub	O
-	O
consensus	O
level	O
by	O
single	O
nucleotide	O
polymorphism	B-PROC
(	O
SNP	O
)	O
analysis	O
.	O

Given	O
the	O
lack	O
of	O
diversity	O
observed	O
at	O
the	O
sub	O
-	O
consensus	O
level	O
,	O
the	O
tenet	O
that	O
the	O
HVRs	O
in	O
the	O
S1	O
subunit	O
are	O
very	O
tolerant	O
of	O
amino	O
acid	O
changes	O
produced	O
by	O
genetic	B-PROC
drift	I-PROC
is	O
questioned	O
.	O

Moreover	O
,	O
the	O
docking	B-PROC
study	O
of	O
all	O
synthesized	O
compounds	O
inside	O
the	O
HLA	O
-	O
A	O
protein	O
(	O
PDB	O
ID	O
:	O
3OX8	O
)	O
active	O
site	O
were	O
carried	O
out	O
to	O
explore	O
the	O
molecular	O
interactions	O
and	O
a	O
molecular	O
target	O
for	O
activity	O
of	O
phenylpropanoid	O
derivatives	O
with	O
the	O
protein	O
using	O
a	O
moe	O
-	O
docking	B-PROC
technique	O
.	O

ABSTRACT	O
:	O
Influenza	O
A	O
H1N1	O
virus	O
strain	O
was	O
associated	O
with	O
the	O
pandemic	O
outbreak	O
of	O
febrile	B-PROC
respiratory	O
infections	O
worldwide	O
in	O
2009	O
,	O
however	O
in	O
August	O
2010	O
,	O
the	O
WHO	O
announced	O
that	O
the	O
world	O
had	O
entered	O
the	O
postpandemic	O
period	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
protein	O
mimics	O
for	O
intracellular	O
delivery	O
.	O

Being	O
able	O
to	O
incorporate	O
the	O
key	O
features	O
of	O
these	O
proteins	O
that	O
enable	O
cell	O
entry	O
into	O
simpler	O
scaffolds	O
opens	O
up	O
a	O
wide	O
range	O
of	O
opportunities	O
for	O
the	O
development	B-PROC
of	O
new	O
delivery	O
reagents	O
with	O
improved	O
performance	O
.	O

This	O
finding	O
was	O
associated	O
with	O
a	O
hyperdynamic	O
and	O
septic	O
state	O
,	O
but	O
did	O
not	O
influence	O
oxygenation	B-PROC
.	O

Extracorporeal	O
membrane	O
oxygenation	B-PROC
may	O
be	O
a	O
useful	O
tool	O
in	O
non	O
-	O
operative	O
management	O
of	O
tracheal	O
injury	O
in	O
the	O
setting	O
of	O
severe	O
respiratory	O
failure	O
and	O
need	O
for	O
prolonged	O
intubation	O
.	O

This	O
patient	O
was	O
successfully	O
managed	O
by	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
,	O
high	O
frequency	O
oscillator	O
ventilation	O
,	O
proning	O
position	O
and	O
tube	O
thoracostomy	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
:	O
obstacles	O
and	O
prospects	O
for	O
vaccine	O
development	B-PROC
.	O

ABSTRACT	O
:	O
The	O
recent	O
emergence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
highlights	O
the	O
need	O
to	O
engineer	O
new	O
methods	O
for	O
expediting	O
vaccine	O
development	B-PROC
against	O
emerging	O
diseases	O
.	O

Then	O
,	O
the	O
transcription	B-PROC
product	O
was	O
transfected	O
into	O
Vero	O
cells	O
by	O
electroporation	O
.	O

Western	O
blot	O
analysis	O
of	O
rBeau	O
-	O
H120	O
(	O
S1	O
)-	O
infected	O
Vero	O
cell	O
lysates	O
demonstrated	O
that	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
was	O
expressed	B-PROC
,	O
which	O
implied	O
that	O
rBeau	O
-	O
H120	O
(	O
S1	O
)	O
could	O
propagate	O
in	O
Vero	O
cells	O
.	O

Laryngitis	O
needed	O
long	O
time	O
to	O
cure	O
and	O
had	O
weaning	B-PROC
difficulties	O
,	O
and	O
the	O
case	O
associated	O
with	O
pleural	O
effusion	O
or	O
bronchopleural	O
fistula	O
must	O
be	O
treated	O
with	O
surgery	O
,	O
and	O
the	O
patients	O
easily	O
develop	O
secondary	O
bacterial	O
infection	O
.	O

Among	O
24	O
Scrub	O
typhus	O
patients	O
with	O
ARDS	O
,	O
22	O
patients	O
recovered	O
,	O
and	O
2	O
patients	O
died	B-PROC
.	O

Scrub	O
typhus	O
is	O
an	O
important	O
differential	O
diagnosis	O
in	O
a	O
patients	O
having	O
fever	B-PROC
with	O
thrombocytopenia	O
.	O

Within	O
a	O
short	O
time	O
period	O
,	O
confirmed	O
disease	O
was	O
present	O
on	O
multiple	O
sites	O
within	O
and	O
across	O
breeding	B-PROC
and	O
post	O
weaning	B-PROC
production	O
flows	O
of	O
the	O
operation	O
and	O
mortality	O
approached	O
100	O
%	O
in	O
neonatal	O
piglets	O
.	O

The	O
results	O
highlight	O
the	O
critical	O
need	O
for	O
surveillance	O
of	O
feed	O
and	O
feed	O
components	O
to	O
further	O
define	O
transmission	O
avenues	O
in	O
an	O
effort	B-PROC
to	O
limit	O
the	O
spread	O
of	O
PEDV	O
throughout	O
the	O
U	O
.	O
S	O
.	O
swine	O
industry	O
.	O

Therefore	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
humoral	B-PROC
immune	I-PROC
response	I-PROC
to	O
the	O
selected	O
inactivated	O
PEDV	O
vaccine	O
candidate	O
in	O
a	O
dose	O
-	O
titration	O
manner	O
.	O

TITLE	O
:	O
Recruitment	O
maneuvers	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
during	O
general	B-PROC
anesthesia	I-PROC
.	O

Samples	O
collected	O
(	O
either	O
fresh	O
feces	O
or	O
rectal	O
swabs	O
)	O
were	O
placed	O
directly	O
into	O
RNA	B-PROC
stabilization	I-PROC
reagent	O
,	O
transported	O
on	O
ice	O
within	O
24	O
hours	O
and	O
preserved	O
at	O
-	O
80	O
°	O
C	O
until	O
further	O
analysis	O
.	O

Her	O
condition	O
was	O
complicated	O
by	O
development	B-PROC
of	O
a	O
pneumothorax	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)-	O
associated	O
acute	O
cor	O
pulmonale	O
and	O
patent	O
foramen	O
ovale	O
:	O
a	O
multicenter	O
noninvasive	O
hemodynamic	B-PROC
study	O
.	O

In	O
this	O
study	O
,	O
a	O
nanoparticle	O
-	O
assisted	O
polymerase	O
chain	O
reaction	O
(	O
nanoPCR	O
)	O
assay	O
targeting	B-PROC
the	O
N	O
gene	O
of	O
PEDV	O
was	O
developed	O
and	O
the	O
sensitivity	O
and	O
specificity	O
were	O
investigated	O
.	O

In	O
101	O
critically	O
ill	O
patients	O
,	O
with	O
or	O
at	O
risk	O
for	O
ARDS	O
after	O
new	O
onset	O
fever	B-PROC
,	O
data	O
were	O
collected	O
on	O
days	O
(	O
D	O
)	O
0	O
,	O
1	O
,	O
2	O
,	O
and	O
7	O
after	O
inclusion	O
.	O

HEV	O
and	O
PCV2	O
co	O
-	O
infection	O
in	O
piglets	O
was	O
detected	O
in	O
four	O
out	O
of	O
seven	O
dead	B-PROC
pigs	O
from	O
two	O
pig	O
farms	O
in	O
Hebei	O
,	O
China	O
,	O
producing	O
severe	O
pathological	O
changes	O
.	O

Meanwhile	O
,	O
compound	O
c26	O
reduced	O
the	O
LPS	O
-	O
induced	O
inflammatory	O
gene	B-PROC
expression	I-PROC
in	O
human	O
pulmonary	O
epithelial	O
cells	O
.	O

The	O
detailed	O
analysis	O
of	O
the	O
genetic	O
variation	O
of	O
TGEVs	O
in	O
China	O
provides	O
essential	O
information	O
for	O
further	O
understanding	O
the	O
evolution	B-PROC
of	O
TGEVs	O
.	O

ABSTRACT	O
:	O
To	O
define	O
the	O
molecular	O
epidemiology	O
of	O
respiratory	O
viral	B-PROC
infections	I-PROC
in	O
adult	O
patients	O
.	O

Ninety	O
percent	O
(	O
9	O
/	O
10	O
)	O
of	O
patients	O
with	O
positive	O
plasma	O
MERS	O
-	O
CoV	O
PCR	O
died	B-PROC
compared	O
with	O
44	O
%	O
(	O
4	O
/	O
9	O
)	O
of	O
those	O
with	O
negative	O
plasma	O
MERS	O
-	O
CoV	O
PCR	O
.	O

These	O
results	O
indicate	O
that	O
dietary	O
DON	O
altered	O
the	O
humoral	B-PROC
immune	I-PROC
response	I-PROC
to	O
viral	O
vaccine	O
and	O
affected	O
the	O
serum	O
clinical	O
biochemistry	O
.	O

As	O
compared	O
with	O
the	O
historic	O
PEDVs	O
and	O
CV777	O
-	O
based	O
vaccine	O
strains	O
,	O
the	O
nine	O
Taiwan	O
PEDV	O
variants	O
shared	O
almost	O
the	O
same	O
genetic	O
signatures	O
as	O
the	O
global	O
non	O
-	O
S	O
INDEL	B-PROC
strains	O
,	O
including	O
a	O
series	O
of	O
insertions	O
,	O
deletions	O
and	O
mutations	O
in	O
the	O
amino	O
terminal	O
as	O
well	O
as	O
identical	O
mutations	O
in	O
the	O
neutralizing	O
epitopes	O
of	O
the	O
S	O
gene	O
.	O

There	O
are	O
28	O
faculty	O
staff	O
,	O
84	O
support	O
staff	O
and	O
480	O
students	O
in	O
the	O
College	O
of	O
Nursing	B-PROC
.	O

ABSTRACT	O
:	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
(	O
WNV	O
)	O
and	O
Dengue	O
virus	O
(	O
DENV	O
)	O
are	O
important	O
human	O
pathogens	O
for	O
which	O
there	O
are	O
presently	O
no	O
vaccine	O
or	O
specific	O
antivirals	O
.	O

Further	O
synthesis	B-PROC
of	O
various	O
triazole	O
bioisosteres	O
demonstrated	O
clear	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
in	O
which	O
the	O
antiviral	O
activity	O
against	O
WNV	O
and	O
DENV	O
hinges	O
largely	O
on	O
both	O
the	O
5	O
'-	O
silyl	O
group	O
and	O
the	O
substituent	O
of	O
3	O
'-	O
triazole	O
or	O
its	O
bioisosteres	O
.	O

Life	O
-	O
threatening	O
acute	O
respiratory	O
failure	O
associated	O
with	O
tumor	O
lysis	B-PROC
syndrome	O
is	O
rare	O
.	O

In	O
addition	O
,	O
results	O
indicate	O
the	O
existence	O
of	O
age	O
-	O
dependent	O
changes	O
in	O
key	O
components	O
of	O
the	O
intracellular	O
signaling	B-PROC
pathways	B-PROC
involved	O
in	O
the	O
inflammatory	B-PROC
response	I-PROC
.	O

Except	O
for	O
a	O
higher	O
,	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
score	O
in	O
the	O
ECMO	O
group	O
(	O
12	O
[	O
9	O
-	O
15	O
]	O
vs	O
.	O
11	O
[	O
7	O
-	O
14	O
],	O
P	O
=	O
0	O
.	O
007	O
),	O
a	O
better	O
oxygenation	B-PROC
,	O
and	O
a	O
lower	O
dosage	O
of	O
vasopressors	O
in	O
the	O
iLA	O
patients	O
,	O
both	O
groups	O
had	O
similar	O
baseline	O
characteristics	O
.	O

Many	O
aspects	O
of	O
respiration	B-PROC
can	O
be	O
measured	O
using	O
devices	O
known	O
as	O
plethysmographs	O
that	O
can	O
measure	O
thoracic	O
movement	B-PROC
.	O

The	O
patient	O
remained	O
in	O
a	O
comatose	O
state	O
with	O
no	O
signs	O
of	O
neurologic	O
recovery	O
until	O
he	O
died	B-PROC
few	O
weeks	O
later	O
following	O
an	O
increase	O
in	O
the	O
brain	O
edema	O
and	O
herniation	O
.	O

At	O
present	O
it	O
is	O
unknown	O
whether	O
the	O
risk	O
for	O
respiratory	O
disease	O
(	O
BRD	O
)	O
or	O
neonatal	O
calf	O
diarrhea	O
(	O
NCD	O
)	O
in	O
the	O
veal	O
herd	O
is	O
associated	O
with	O
total	O
immunoglobulin	B-PROC
(	O
Ig	O
)	O
and	O
/	O
or	O
on	O
the	O
serostatus	O
for	O
respiratory	O
pathogens	O
measured	O
at	O
arrival	O
.	O

To	O
accelerate	O
the	O
development	B-PROC
of	O
3	O
CL	O
(	O
pro	O
)	O
inhibitors	O
,	O
three	O
crystal	O
structures	O
of	O
a	O
catalytically	O
inactive	O
variant	O
(	O
C148A	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
3	O
CL	O
(	O
pro	O
)	O
enzyme	O
were	O
determined	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
effects	O
of	O
open	O
endotracheal	O
suctioning	O
on	O
gas	O
exchange	O
and	O
respiratory	B-PROC
mechanics	I-PROC
in	O
ARF	O
patients	O
under	O
the	O
modes	O
of	O
PCV	O
or	O
VCV	O
.	O

Summarily	O
,	O
endotracheal	O
suctioning	O
may	O
impair	O
gas	O
exchange	O
and	O
decrease	O
lung	B-PROC
compliance	I-PROC
in	O
ARF	O
patients	O
receiving	O
mechanical	O
ventilation	O
under	O
both	O
PCV	O
and	O
VCV	O
modes	O
,	O
but	O
endotracheal	O
suctioning	O
effects	O
on	O
gas	O
exchange	O
were	O
more	O
severe	O
and	O
longer	O
-	O
lasting	O
under	O
PCV	O
mode	O
than	O
VCV	O
.	O

TITLE	O
:	O
Progress	O
and	O
challenges	O
toward	O
the	O
development	B-PROC
of	O
vaccines	O
against	O
avian	O
infectious	O
bronchitis	O
.	O

The	O
presence	O
of	O
hemodynamic	B-PROC
instability	O
was	O
not	O
different	O
in	O
both	O
groups	O
.	O

The	O
use	O
of	O
fluid	O
resuscitation	O
is	O
an	O
important	O
treatment	O
for	O
sepsis	O
,	O
but	O
positive	O
fluid	B-PROC
balance	I-PROC
may	O
induce	O
pulmonary	O
injury	O
.	O

Focal	B-PROC
adhesion	I-PROC
kinase	O
(	O
FAK	O
)	O
activation	O
was	O
reduced	O
in	O
HS	O
group	O
as	O
well	O
as	O
neutrophil	O
infiltration	O
,	O
NOS2	O
expression	B-PROC
and	O
NO	O
content	O
.	O

ABSTRACT	O
:	O
The	O
emerging	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
requires	O
trypsin	O
supplementation	O
to	O
activate	O
its	O
S	O
protein	O
for	O
membrane	B-PROC
fusion	I-PROC
and	O
virus	O
propagation	O
in	O
cell	O
culture	O
.	O

In	O
contrast	O
to	O
NDV	O
infection	O
,	O
HeV	O
and	O
NiV	O
infection	O
of	O
PVK	O
cells	O
failed	O
to	O
induce	O
these	O
innate	B-PROC
immune	I-PROC
response	I-PROC
genes	O
.	O

Here	O
,	O
we	O
engineered	O
VeroE6	O
cells	O
to	O
stably	O
express	O
porcine	O
aminopeptidase	O
N	O
(	O
pAPN	O
)	O
and	O
used	O
them	O
as	O
a	O
platform	O
to	O
obtain	O
a	O
high	O
-	O
growth	B-PROC
variant	O
of	O
PEDV	O
,	O
termed	O
PEDVAVCT12	O
.	O

Among	O
the	O
351	O
(	O
47	O
.	O
8	O
%)	O
patients	O
diagnosed	O
with	O
viral	O
infections	B-PROC
,	I-PROC
viral	I-PROC
mixed	O
detection	O
was	O
identified	O
in	O
49	O
patients	O
(	O
14	O
%),	O
with	O
human	O
rhinovirus	O
(	O
HRV	O
)	O
being	O
the	O
most	O
common	O
virus	O
associated	O
with	O
viral	O
mixed	O
detection	O
(	O
7	O
.	O
1	O
%),	O
followed	O
by	O
adenovirus	O
(	O
AdV	O
)	O
(	O
4	O
%)	O
and	O
human	O
coronavirus	O
-	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
(	O
3	O
.	O
7	O
%).	O

It	O
is	O
possible	O
that	O
extracellular	O
histones	O
were	O
derived	O
from	O
formation	B-PROC
of	O
neutrophil	O
extracellular	O
traps	O
(	O
NETs	O
)	O
in	O
lung	O
after	O
PMN	B-PROC
contact	O
with	O
C5a	O
.	O

These	O
3D	O
systems	O
have	O
numerous	O
applications	O
including	O
drug	O
testing	O
,	O
maintenance	O
of	O
large	O
tissue	O
explants	O
,	O
monitoring	O
migration	B-PROC
of	O
human	O
lymphocytes	O
in	O
tissues	O
,	O
analysis	O
of	O
human	O
organ	O
tissue	B-PROC
development	B-PROC
and	O
investigation	O
of	O
virus	O
-	O
host	O
interactions	O
including	O
viral	B-PROC
latency	I-PROC
.	O

Different	O
approaches	O
were	O
used	O
to	O
manage	O
contact	O
tracing	O
for	O
each	O
flight	B-PROC
due	O
to	O
variations	O
in	O
the	O
quality	O
and	O
timeliness	O
of	O
the	O
passenger	O
contact	O
information	O
provided	O
by	O
the	O
airlines	O
involved	O
.	O

Her	O
cranial	O
nerves	O
and	O
respiratory	B-PROC
function	I-PROC
remained	O
intact	O
.	O

Other	O
hemorrhagic	O
fever	B-PROC
disease	O
-	O
viruses	O
occur	O
in	O
distinct	O
regions	O
in	O
South	O
America	O
.	O

The	O
present	O
findings	O
indicate	O
that	O
dietary	O
genistein	O
supplementation	O
at	O
the	O
levels	O
of	O
20	O
to	O
80	O
mg	O
/	O
kg	O
not	O
only	O
improves	O
growth	B-PROC
performance	O
,	O
but	O
also	O
could	O
beneficially	O
affect	O
immunological	O
responses	O
in	O
broiler	O
chicks	O
.	O

The	O
pain	O
was	O
severe	O
enough	O
to	O
impair	O
tidal	O
breathing	B-PROC
.	O

Identification	O
of	O
these	O
recombinant	O
viruses	O
,	O
together	O
with	O
temporal	O
analysis	O
and	O
tMRCA	O
estimation	O
,	O
provides	O
important	O
information	O
for	O
understanding	O
the	O
dynamics	O
of	O
the	O
evolution	B-PROC
of	O
these	O
epidemic	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
are	O
sensors	O
that	O
recognize	O
molecular	O
patterns	O
from	O
viruses	O
,	O
bacteria	O
,	O
and	O
fungi	O
to	O
initiate	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
to	O
invading	O
pathogens	O
.	O

High	O
fever	B-PROC
and	O
severe	O
SIRS	O
are	O
two	O
early	O
predictors	O
of	O
stroke	O
patients	O
with	O
SE	O
,	O
and	O
survival	O
rates	O
were	O
worse	O
in	O
stroke	O
patients	O
with	O
SE	O
than	O
those	O
without	O
SE	O
.	O

RESULTS	O
:	O
In	O
February	O
-	O
March	O
2013	O
the	O
number	O
of	O
children	O
protected	O
by	O
antibodies	O
against	O
influenza	O
decreased	O
,	O
and	O
circulation	B-PROC
of	O
influenza	O
viruses	O
A	O
/	O
H3N2	O
and	O
A	O
/	O
H1N1	O
/	O
pdm09	O
was	O
detected	O
.	O

Supine	O
and	O
upright	O
vital	B-PROC
capacities	I-PROC
were	O
not	O
different	O
(	O
P	O
=	O
0	O
.	O
76	O
),	O
suggesting	O
absence	O
of	O
diaphragmatic	O
dysfunction	O
.	O

Respiratory	B-PROC
function	I-PROC
and	O
cough	O
effectiveness	O
should	O
especially	O
be	O
monitored	O
in	O
patients	O
with	O
severe	O
motor	O
impairment	O
and	O
high	O
body	O
mass	O
index	O
.	O

ABSTRACT	O
:	O
Tissue	O
factor	O
(	O
TF	O
)	O
and	O
tissue	O
factor	O
pathway	B-PROC
inhibitor	O
(	O
TFPI	O
)	O
play	O
a	O
central	O
role	O
in	O
the	O
endothelial	O
permeability	O
regulation	B-PROC
and	O
dysfunction	O
,	O
which	O
is	O
associated	O
with	O
the	O
development	B-PROC
of	O
sepsis	O
and	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ALI	O
/	O
ARDS	O
).	O

The	O
effects	O
of	O
SHED	O
-	O
CM	O
on	O
macrophage	B-PROC
differentiation	I-PROC
in	O
vitro	O
were	O
also	O
assessed	O
.	O

TITLE	O
:	O
Influenza	O
induces	O
IL	O
-	O
8	O
and	O
GM	O
-	O
CSF	B-PROC
secretion	I-PROC
by	O
human	O
alveolar	O
epithelial	O
cells	O
through	O
HGF	O
/	O
c	O
-	O
Met	O
and	O
TGF	O
-	O
α	O
/	O
EGFR	O
signaling	B-PROC
.	O

There	O
was	O
weak	O
agreement	O
on	O
recommendations	O
concerning	O
approach	O
to	O
tidal	O
volume	O
and	O
inspiratory	B-PROC
pressure	O
limitation	O
(	O
88	O
%	O
to	O
72	O
%	O
agreement	O
,	O
respectively	O
),	O
whereas	O
strong	O
agreement	O
could	O
be	O
achieved	O
for	O
accepting	O
permissive	O
hypercapnia	O
.	O

Overall	O
,	O
the	O
routine	O
use	O
of	O
surfactant	O
,	O
inhaled	B-PROC
nitric	O
oxide	O
,	O
glucocorticoids	O
,	O
prone	O
positioning	O
,	O
endotracheal	O
suctioning	O
,	O
and	O
chest	O
physiotherapy	O
cannot	O
be	O
recommended	O
.	O

The	O
attachment	O
pattern	O
of	O
the	O
hemagglutinin	O
protein	O
was	O
in	O
line	O
with	O
the	O
reported	O
tropism	B-PROC
of	O
influenza	O
virus	O
H5N1	O
,	O
confirming	O
the	O
validity	O
of	O
TMAs	O
in	O
profiling	O
the	O
initial	O
virus	B-PROC
-	I-PROC
host	I-PROC
interaction	I-PROC
.	O

By	O
applying	O
this	O
method	O
to	O
MERS	O
-	O
CoV	O
,	O
the	O
11	O
canonical	O
cleavage	B-PROC
sites	O
were	O
readily	O
identified	O
and	O
verified	O
by	O
the	O
biochemical	O
assays	O
.	O

Interestingly	O
,	O
nine	O
putative	O
non	O
-	O
canonical	O
cleavage	B-PROC
sites	O
were	O
predicted	O
and	O
three	O
of	O
them	O
could	O
be	O
cleaved	O
by	O
MERS	O
-	O
CoV	O
nsp5	O
.	O

In	O
this	O
review	O
,	O
we	O
highlight	O
some	O
key	O
advances	O
in	O
the	O
development	B-PROC
of	O
antiviral	O
vaccines	O
targeting	B-PROC
the	O
RBDs	O
of	O
spike	O
proteins	O
of	O
emerging	O
and	O
re	O
-	O
emerging	O
viruses	O
,	O
using	O
SARS	O
-	O
CoV	O
,	O
influenza	O
virus	O
,	O
Hendra	O
virus	O
(	O
HeV	O
)	O
and	O
Nipah	O
virus	O
(	O
NiV	O
)	O
as	O
examples	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
host	O
factors	O
relevant	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
replication	O
,	O
we	O
performed	O
a	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
library	O
screen	O
targeting	B-PROC
the	O
human	O
kinome	O
.	O

Pathway	B-PROC
analysis	O
grouped	O
subsets	O
of	O
these	O
factors	O
in	O
specific	O
cellular	O
processes	O
,	O
including	O
the	O
innate	B-PROC
immune	I-PROC
response	I-PROC
and	O
the	O
metabolism	B-PROC
of	O
complex	O
lipids	O
,	O
which	O
appear	O
to	O
play	O
a	O
role	O
in	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
cells	O
depleted	O
for	O
the	O
β2	O
subunit	O
of	O
the	O
coatomer	O
protein	O
complex	O
(	O
COPB2	O
),	O
the	O
strongest	O
proviral	O
hit	O
,	O
we	O
observed	O
reduced	O
SARS	O
-	O
CoV	O
protein	B-PROC
expression	B-PROC
and	O
a	O
>	O
2	O
-	O
log	O
reduction	O
in	O
virus	O
yield	O
.	O

Knockdown	O
of	O
the	O
COPB2	O
-	O
related	O
proteins	O
COPB1	O
and	O
Golgi	O
-	O
specific	O
brefeldin	O
A	O
-	O
resistant	O
guanine	O
nucleotide	O
exchange	O
factor	O
1	O
(	O
GBF1	O
)	O
also	O
suggested	O
that	O
COPI	O
-	O
coated	O
vesicles	O
and	O
/	O
or	O
the	O
early	O
secretory	B-PROC
pathway	I-PROC
are	O
important	O
for	O
SARS	O
-	O
CoV	O
replication	O
.	O

To	O
study	O
the	O
role	O
of	O
host	O
proteins	O
in	O
SARS	O
-	O
CoV	O
infection	O
,	O
we	O
set	O
out	O
to	O
systematically	O
identify	O
kinase	O
-	O
regulated	O
processes	O
that	O
influence	O
virus	B-PROC
replication	I-PROC
.	O

Interestingly	O
,	O
the	O
peptide	O
TP29	O
exerted	B-PROC
robust	O
inhibitory	O
effects	O
in	O
vivo	O
in	O
MHV	O
-	O
infected	O
mice	O
by	O
impairing	O
MHV	O
virulence	B-PROC
and	O
pathogenesis	B-PROC
through	O
suppressing	O
virus	B-PROC
replication	I-PROC
and	O
enhancing	O
type	B-PROC
I	I-PROC
interferon	B-PROC
production	I-PROC
at	O
an	O
early	O
stage	O
of	O
infection	O
.	O

SARS	O
-	O
CoV	O
encodes	O
the	O
2	O
'-	O
O	O
-	O
MTase	O
that	O
is	O
composed	O
of	O
the	O
catalytic	O
subunit	O
nsp16	O
and	O
the	O
stimulatory	O
subunit	O
nsp10	O
and	O
plays	O
an	O
important	O
role	O
in	O
virus	O
genome	O
replication	O
and	O
evasion	O
from	O
innate	B-PROC
immunity	B-PROC
.	O

We	O
demonstrate	O
that	O
a	O
peptide	O
derived	O
from	O
the	O
nsp16	O
-	O
interacting	O
domain	O
of	O
MHV	O
nsp10	O
could	O
inhibit	O
2	O
'-	O
O	O
-	O
MTase	O
activity	O
of	O
different	O
coronaviruses	O
in	O
vitro	O
and	O
viral	B-PROC
replication	I-PROC
of	O
MHV	O
and	O
SARS	O
-	O
CoV	O
replicon	O
in	O
cell	O
culture	O
,	O
and	O
it	O
could	O
strongly	O
inhibit	O
virus	B-PROC
replication	I-PROC
and	O
pathogenesis	B-PROC
in	O
MHV	O
-	O
infected	O
mice	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	B-PROC
and	O
evaluation	O
of	O
a	O
series	O
of	O
acyclic	O
fleximer	O
nucleoside	O
analogues	O
with	O
anti	O
-	O
coronavirus	O
activity	O
.	O

However	O
,	O
the	O
virus	O
could	O
mutate	B-PROC
to	O
have	O
increased	O
interhuman	O
transmissibility	O
,	O
increasing	O
its	O
pandemic	O
potential	O
.	O

Ventilation	O
impairment	O
may	O
be	O
due	O
to	O
either	O
neurologic	O
compromise	O
such	O
as	O
cervical	O
intervertebral	O
disk	O
disease	O
or	O
severe	O
parenchymal	O
disease	O
,	O
while	O
oxygenation	B-PROC
failure	O
may	O
result	O
from	O
either	O
the	O
underlying	O
disease	O
or	O
severe	O
complications	O
such	O
as	O
aspiration	O
pneumonia	O
,	O
volume	O
overload	O
,	O
pulmonary	O
thromboembolism	O
,	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
All	O
coronaviruses	O
,	O
including	O
the	O
recently	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
from	O
the	O
β	O
-	O
CoV	O
subgroup	O
,	O
require	O
the	O
proteolytic	B-PROC
activity	O
of	O
the	O
nsp5	O
protease	O
(	O
also	O
known	O
as	O
3C	O
-	O
like	O
protease	O
,	O
3CL	O
(	O
pro	O
))	O
during	O
virus	B-PROC
replication	I-PROC
,	O
making	O
it	O
a	O
high	O
value	O
target	O
for	O
the	O
development	B-PROC
of	O
anti	O
-	O
coronavirus	O
therapeutics	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
C5a	O
in	O
acute	O
lung	O
injury	O
induced	O
by	O
highly	O
pathogenic	O
viral	B-PROC
infections	I-PROC
.	O

A	O
comprehensive	O
understanding	O
of	O
the	O
tropism	B-PROC
and	O
pathogenicity	O
of	O
these	O
viruses	O
explained	O
by	O
their	O
receptor	O
specificity	O
and	O
receptor	B-PROC
expression	B-PROC
on	O
tissues	O
was	O
therefore	O
needed	O
.	O

A	O
novel	O
variant	O
PEDV	O
strain	O
FL2013	O
with	O
reduced	O
virulence	B-PROC
,	O
as	O
determined	O
by	O
the	O
pathological	O
study	O
,	O
was	O
identified	O
from	O
east	O
China	O
.	O

However	O
,	O
the	O
necessity	O
of	O
renal	O
replacement	O
therapy	O
during	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
was	O
not	O
an	O
independent	O
risk	O
factor	O
for	O
mortality	O
in	O
these	O
patients	O
(	O
p	O
=	O
0	O
.	O
37	O
).	O

Vascular	O
cell	B-PROC
adhesion	I-PROC
molecule	O
-	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
is	O
one	O
kind	O
of	O
adhesion	O
molecules	O
participating	O
in	O
the	O
process	O
of	O
polymorphonuclear	O
leukocyte	O
transmigration	O
and	O
regulating	O
the	O
occurrence	O
and	O
amplification	O
of	O
tissue	O
inflammation	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
ET	O
-	O
1	O
-	O
mediated	O
expression	B-PROC
of	O
VCAM	O
-	O
1	O
on	O
human	O
tracheal	O
smooth	O
muscle	O
cells	O
(	O
HTSMCs	O
)	O
were	O
largely	O
unknown	O
.	O

RESULTS	O
:	O
After	O
multiple	O
testing	O
adjustments	O
,	O
our	O
analysis	O
revealed	O
10	O
non	O
-	O
coding	O
SNPs	O
in	O
tight	O
linkage	B-PROC
disequilibrium	O
(	O
0	O
.	O
75	O
≤	O
r	O
(	O
2	O
)	O
≤	O
1	O
)	O
that	O
were	O
associated	O
with	O
ARDS	O
susceptibility	O
as	O
a	O
single	O
association	O
signal	O
.	O

Influenza	O
virus	O
type	O
A	O
and	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
adenovirus	O
and	O
parainfluenza	O
virus	O
type	O
1	O
-	O
3	O
were	O
investigated	O
using	O
shell	O
-	O
vial	O
cell	O
culture	O
method	O
and	O
direct	O
fluorescent	O
antibody	B-PROC
test	O
and	O
/	O
or	O
multiplex	O
PCR	O
test	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
has	O
recently	O
attracted	O
interest	O
as	O
a	O
treatment	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
temporal	O
dynamics	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
in	O
dromedary	O
camels	O
,	O
specimens	O
were	O
collected	O
at	O
1	O
-	O
2	O
month	O
intervals	O
from	O
2	O
independent	O
groups	O
of	O
animals	O
during	O
April	O
2013	O
-	O
May	O
2014	O
in	O
Al	O
-	O
Ahsa	O
Province	O
,	O
Saudi	O
Arabia	O
,	O
and	O
tested	O
for	O
MERS	O
-	O
CoV	O
RNA	O
by	O
reverse	B-PROC
transcription	B-PROC
PCR	O
.	O

Hydroxyurea	O
decreases	O
sickling	O
,	O
improves	O
red	O
cell	B-PROC
survival	I-PROC
,	O
and	O
reduces	O
the	O
frequency	O
of	O
vasoocclusive	O
crises	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
RNAi	B-PROC
is	O
a	O
part	O
of	O
the	O
antiviral	O
immunity	B-PROC
responses	O
in	O
mammalian	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
coronaviruses	O
encode	O
a	O
VSR	O
that	O
functions	O
in	O
the	O
replication	O
cycle	O
and	O
provide	O
further	O
evidence	O
to	O
support	O
that	O
RNAi	B-PROC
-	O
mediated	O
antiviral	B-PROC
response	I-PROC
exists	O
in	O
mammalian	O
cells	O
.	O

Despite	O
intensive	O
therapy	O
,	O
the	O
patient	O
died	B-PROC
on	O
day	O
18	O
.	O

Neutralization	O
tests	O
showed	O
that	O
ZL	O
.	O
10	O
,	O
which	O
bound	O
the	O
S1	O
protein	O
in	O
western	O
blots	O
,	O
inhibited	O
the	O
formation	B-PROC
of	O
syncytia	O
in	O
Vero	O
cells	O
48	O
h	O
post	O
IBV	O
infection	O
and	O
decreased	O
the	O
transcriptional	B-PROC
level	O
of	O
nucleoprotein	O
mRNA	O
to	O
17	O
.	O
2	O
%,	O
while	O
the	O
other	O
five	O
scFvs	O
,	O
including	O
ZL	O
.	O
78	O
and	O
ZL	O
.	O
256	O
,	O
that	O
bound	O
the	O
N	O
protein	O
did	O
not	O
.	O

All	O
piglets	O
orally	O
inoculated	O
developed	O
severe	O
watery	O
diarrhea	O
and	O
vomiting	O
within	O
24	O
hours	O
post	O
-	O
inoculation	O
(	O
hpi	O
)	O
and	O
died	B-PROC
within	O
72	O
hpi	O
.	O

According	O
to	O
the	O
results	O
of	O
high	O
-	O
resolution	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
,	O
a	O
total	O
of	O
43	O
protein	O
spots	O
were	O
initially	O
found	O
to	O
be	O
differentially	O
expressed	B-PROC
in	O
PK	O
-	O
PDCoV	O
-	O
N	O
cells	O
in	O
comparison	O
with	O
control	O
PK	O
cells	O
.	O

In	O
contrast	O
,	O
treatment	O
of	O
cells	O
with	O
methiothepin	O
mesylate	O
,	O
a	O
serotonin	O
antagonist	B-PROC
,	O
enhanced	O
infection	O
by	O
reovirus	O
.	O

5	O
-	O
NT	O
did	O
not	O
alter	O
cell	O
surface	O
expression	B-PROC
of	O
JAM	O
-	O
A	O
or	O
attachment	O
of	O
reovirus	O
to	O
cells	O
.	O

This	O
study	O
compared	O
the	O
clinical	O
characteristics	O
of	O
HRV	O
to	O
other	O
common	O
viral	B-PROC
infections	I-PROC
and	O
investigated	O
the	O
molecular	O
epidemiology	O
of	O
HRV	O
in	O
hospitalized	O
children	O
with	O
acute	O
respiratory	O
infections	O
(	O
ARIs	O
)	O
in	O
Vietnam	O
.	O

TITLE	O
:	O
New	O
Metrics	O
for	O
Evaluating	O
Viral	O
Respiratory	O
Pathogenesis	B-PROC
.	O

Here	O
,	O
whole	O
-	O
body	O
plethysmography	O
was	O
used	O
to	O
directly	O
measure	O
changes	O
in	O
pulmonary	B-PROC
function	I-PROC
during	O
two	O
respiratory	O
viral	B-PROC
infections	I-PROC
.	O

ABSTRACT	O
:	O
Respiratory	O
viral	B-PROC
infections	I-PROC
(	O
RVI	O
)	O
are	O
important	O
in	O
hematopoietic	O
stem	O
cell	O
transplantations	O
(	O
HSCT	O
)	O
and	O
knowledge	O
regarding	O
incidence	O
,	O
morbidity	O
,	O
mortality	O
,	O
and	O
long	O
-	O
term	O
pulmonary	O
complications	O
is	O
limited	O
.	O

When	O
screening	O
for	O
causes	O
of	O
death	B-PROC
in	O
the	O
first	O
year	O
after	O
HSCT	O
in	O
the	O
844	O
patients	O
,	O
we	O
found	O
that	O
RVI	O
as	O
a	O
cause	O
of	O
death	B-PROC
was	O
only	O
evident	O
in	O
the	O
first	O
100	O
days	O
after	O
HSCT	O
.	O

Most	O
of	O
the	O
recent	O
major	O
losses	O
of	O
managed	O
honey	O
bee	O
colonies	O
occur	O
during	O
the	O
winter	O
,	O
suggesting	O
that	O
winter	O
bees	O
may	O
have	O
compromised	O
immune	B-PROC
function	I-PROC
and	O
higher	O
susceptibility	O
to	O
diseases	O
.	O

This	O
expression	B-PROC
pattern	O
could	O
reflect	O
evolutionary	O
adaptations	B-PROC
to	O
resist	O
bacterial	O
pathogens	O
and	O
economize	O
energy	O
during	O
the	O
winter	O
under	O
a	O
pathogen	O
landscape	O
with	O
reduced	O
risk	O
of	O
pathogenic	O
viral	B-PROC
infections	I-PROC
.	O

After	O
NPPV	O
treatment	O
,	O
systolic	O
pressure	O
,	O
heart	O
rate	O
,	O
respiratory	O
rate	O
,	O
and	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
decreased	O
,	O
whereas	O
oxygen	O
saturation	O
increased	O
significantly	O
in	O
the	O
NPPV	O
success	O
group	O
compared	O
with	O
the	O
failed	O
group	O
.	O

Impaired	O
muscle	B-PROC
function	I-PROC
in	O
ARDS	O
is	O
associated	O
with	O
increased	O
mortality	O
,	O
increased	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
and	O
functional	O
disability	O
in	O
survivors	O
.	O

The	O
early	O
phase	O
occurs	O
temporally	O
with	O
the	O
onset	O
of	O
lung	O
injury	O
,	O
is	O
driven	O
by	O
inflammation	O
and	O
disuse	O
,	O
and	O
is	O
marked	O
predominantly	O
by	O
muscle	B-PROC
atrophy	I-PROC
from	O
increased	O
protein	B-PROC
degradation	I-PROC
.	O

In	O
the	O
setting	O
of	O
Berlin	O
defined	O
mild	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
ARDSNet	O
protocol	O
and	O
optimal	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
were	O
the	O
top	O
ventilator	O
choices	O
,	O
along	O
with	O
fluid	O
restriction	O
/	O
diuresis	B-PROC
as	O
a	O
nonventilator	O
adjunct	O
.	O

CoV	O
E	O
has	O
a	O
single	O
hydrophobic	O
domain	O
(	O
HD	O
),	O
is	O
targeted	B-PROC
to	O
Golgi	O
complex	O
membranes	O
,	O
and	O
has	O
cation	O
channel	O
activity	O
in	O
vitro	O
.	O

A	O
high	O
-	O
order	O
oligomer	O
of	O
IBV	O
E	O
is	O
required	O
for	O
the	O
production	O
of	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
),	O
implicating	O
this	O
form	O
of	O
the	O
protein	O
in	O
virion	B-PROC
assembly	I-PROC
.	O

Additionally	O
,	O
disruption	O
of	O
the	O
secretory	B-PROC
pathway	I-PROC
by	O
IBV	O
E	O
correlates	O
with	O
a	O
form	O
that	O
is	O
likely	O
monomeric	O
,	O
suggesting	O
that	O
the	O
effects	O
on	O
the	O
secretory	B-PROC
pathway	I-PROC
are	O
independent	O
of	O
E	O
ion	O
channel	O
activity	O
.	O

We	O
previously	O
reported	O
that	O
the	O
hydrophobic	O
domain	O
of	O
the	O
IBV	O
E	O
protein	O
,	O
a	O
putative	O
viroporin	O
,	O
causes	O
disruption	O
of	O
the	O
mammalian	O
secretory	B-PROC
pathway	I-PROC
when	O
exogenously	O
expressed	B-PROC
in	O
cells	O
.	O

During	O
the	O
period	O
of	O
hospitalization	O
in	O
ICU	O
,	O
171	O
patients	O
survived	O
and	O
35	O
died	B-PROC
,	O
and	O
the	O
mortality	O
rate	O
was	O
16	O
.	O
99	O
%.	O

The	O
risk	O
factors	O
of	O
the	O
two	O
groups	O
were	O
analyzed	O
by	O
variable	O
analysis	O
,	O
and	O
it	O
was	O
shown	O
that	O
compared	O
with	O
those	O
in	O
survival	O
group	O
,	O
the	O
age	O
(	O
years	O
:	O
57	O
.	O
26	O
±	O
16	O
.	O
23	O
vs	O
.	O
48	O
.	O
07	O
±	O
13	O
.	O
48	O
,	O
t	O
=	O
3	O
.	O
544	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
APACHEII	O
score	O
(	O
20	O
.	O
83	O
±	O
9	O
.	O
73	O
vs	O
.	O
12	O
.	O
61	O
±	O
6	O
.	O
63	O
,	O
t	O
=	O
4	O
.	O
777	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
the	O
length	O
of	O
invasive	O
mechanical	O
ventilation	O
(	O
days	O
:	O
10	O
.	O
97	O
±	O
7	O
.	O
71	O
vs	O
.	O
6	O
.	O
91	O
±	O
2	O
.	O
48	O
,	O
t	O
=	O
2	O
.	O
555	O
,	O
P	O
=	O
0	O
.	O
015	O
)	O
and	O
the	O
number	O
of	O
dysfunction	O
organs	O
(	O
3	O
.	O
11	O
±	O
1	O
.	O
21	O
vs	O
.	O
1	O
.	O
60	O
±	O
1	O
.	O
34	O
,	O
t	O
=	O
6	O
.	O
222	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
in	O
death	B-PROC
group	O
were	O
significantly	O
higher	O
.	O

Univariate	O
analysis	O
showed	O
that	O
age	O
(	O
t	O
=-	O
2	O
.	O
134	O
,	O
P	O
=	O
0	O
.	O
035	O
),	O
oxygenation	B-PROC
index	O
(	O
t	O
=-	O
4	O
.	O
245	O
,	O
P	O
=	O
0	O
.	O
001	O
),	O
arterial	O
lactate	O
(	O
Lac	O
,	O
t	O
=	O
6	O
.	O
245	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
drugs	O
for	O
vascular	O
diseases	O
(	O
χ2	O
=	O
4	O
.	O
261	O
,	O
P	O
=	O
0	O
.	O
026	O
),	O
shock	O
(	O
χ2	O
=	O
4	O
.	O
386	O
,	O
P	O
=	O
0	O
.	O
021	O
),	O
MEDS	O
(	O
t	O
=	O
4	O
.	O
021	O
,	O
P	O
=	O
0	O
.	O
045	O
),	O
LIPS	O
(	O
t	O
=	O
5	O
.	O
569	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
lung	O
infections	O
(	O
χ2	O
=	O
4	O
.	O
289	O
,	O
P	O
=	O
0	O
.	O
025	O
),	O
and	O
mechanical	O
ventilation	O
(	O
χ2	O
=	O
6	O
.	O
245	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
were	O
related	O
to	O
ARDS	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
value	O
of	O
lung	O
ultrasound	O
score	O
(	O
LUS	O
)	O
on	O
assessing	O
the	O
severity	O
and	O
prognosis	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
to	O
investigate	O
its	O
correlation	O
with	O
oxygenation	B-PROC
index	O
,	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluationII	O
(	O
APACHEII	O
)	O
score	O
,	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
score	O
,	O
and	O
clinical	O
pulmonary	O
infection	O
score	O
(	O
CPIS	O
),	O
and	O
other	O
traditional	O
parameters	O
.	O

LUS	O
was	O
24	O
.	O
3	O
±	O
3	O
.	O
8	O
in	O
the	O
death	B-PROC
group	O
,	O
and	O
12	O
.	O
7	O
±	O
2	O
.	O
9	O
in	O
the	O
survival	O
group	O
.	O

Compared	O
with	O
control	O
group	O
,	O
oxygenation	B-PROC
index	O
in	O
bundle	O
treatment	O
group	O
was	O
significantly	O
improved	O
[	O
mmHg	O
(	O
1	O
mmHg	O
=	O
0	O
.	O
133	O
kPa	O
):	O
135	O
.	O
4	O
±	O
34	O
.	O
5	O
vs	O
.	O
117	O
.	O
1	O
±	O
34	O
.	O
2	O
,	O
t	O
=-	O
2	O
.	O
273	O
,	O
P	O
=	O
0	O
.	O
026	O
),	O
the	O
duration	O
of	O
mechanical	O
ventilation	O
was	O
obviously	O
reduced	O
(	O
days	O
:	O
8	O
.	O
70	O
±	O
2	O
.	O
50	O
vs	O
.	O
10	O
.	O
10	O
±	O
2	O
.	O
67	O
,	O
t	O
=	O
2	O
.	O
308	O
,	O
P	O
=	O
0	O
.	O
024	O
),	O
incidence	O
of	O
VAP	O
was	O
significantly	O
lower	O
[	O
18	O
.	O
2	O
%	O
(	O
6	O
/	O
33	O
)	O
vs	O
.	O
32	O
.	O
5	O
%	O
(	O
13	O
/	O
40	O
),	O
χ2	O
=	O
5	O
.	O
027	O
,	O
P	O
=	O
0	O
.	O
025	O
],	O
and	O
28	O
-	O
day	O
mortality	O
rate	O
was	O
obviously	O
lowered	O
[	O
24	O
.	O
2	O
%	O
(	O
8	O
/	O
33	O
)	O
vs	O
.	O
37	O
.	O
5	O
%	O
(	O
15	O
/	O
40	O
),	O
χ2	O
=	O
4	O
.	O
372	O
,	O
P	O
=	O
0	O
.	O
037	O
],	O
the	O
length	O
of	O
ICU	O
stay	O
shown	O
no	O
statistical	O
difference	O
(	O
days	O
:	O
10	O
.	O
40	O
±	O
1	O
.	O
94	O
vs	O
.	O
11	O
.	O
30	O
±	O
2	O
.	O
34	O
,	O
t	O
=	O
1	O
.	O
620	O
,	O
P	O
=	O
0	O
.	O
110	O
).	O

Compared	O
with	O
control	O
group	O
,	O
oxygenation	B-PROC
index	O
in	O
bundle	O
treatment	O
group	O
was	O
significantly	O
improved	O
[	O
mmHg	O
(	O
1	O
mmHg	O
=	O
0	O
.	O
133	O
kPa	O
):	O
135	O
.	O
4	O
±	O
34	O
.	O
5	O
vs	O
.	O
117	O
.	O
1	O
±	O
34	O
.	O
2	O
,	O
t	O
=-	O
2	O
.	O
273	O
,	O
P	O
=	O
0	O
.	O
026	O
),	O
the	O
duration	O
of	O
mechanical	O
ventilation	O
was	O
obviously	O
reduced	O
(	O
days	O
:	O
8	O
.	O
70	O
±	O
2	O
.	O
50	O
vs	O
.	O
10	O
.	O
10	O
±	O
2	O
.	O
67	O
,	O
t	O
=	O
2	O
.	O
308	O
,	O
P	O
=	O
0	O
.	O
024	O
),	O
incidence	O
of	O
VAP	O
was	O
significantly	O
lower	O
[	O
18	O
.	O
2	O
%	O
(	O
6	O
/	O
33	O
)	O
vs	O
.	O
32	O
.	O
5	O
%	O
(	O
13	O
/	O
40	O
),	O
χ2	O
=	O
5	O
.	O
027	O
,	O
P	O
=	O
0	O
.	O
025	O
],	O
and	O
28	O
-	O
day	O
mortality	O
rate	O
was	O
obviously	O
lowered	O
[	O
24	O
.	O
2	O
%	O
(	O
8	O
/	O
33	O
)	O
vs	O
.	O
37	O
.	O
5	O
%	O
(	O
15	O
/	O
40	O
),	O
χ2	O
=	O
4	O
.	O
372	O
,	O
P	O
=	O
0	O
.	O
037	O
],	O
the	O
length	O
of	O
ICU	O
stay	O
shown	O
no	O
statistical	O
difference	O
(	O
days	O
:	O
10	O
.	O
40	O
±	O
1	O
.	O
94	O
vs	O
.	O
11	O
.	O
30	O
±	O
2	O
.	O
34	O
,	O
t	O
=	O
1	O
.	O
620	O
,	O
P	O
=	O
0	O
.	O
110	O
).	O

TITLE	O
:	O
Lessons	O
to	O
learn	B-PROC
from	O
MERS	O
-	O
CoV	O
outbreak	O
in	O
South	O
Korea	O
.	O

Although	O
the	O
mean	O
arterial	B-PROC
pressure	I-PROC
was	O
similar	O
between	O
these	O
two	O
groups	O
,	O
the	O
median	O
pH	O
and	O
the	O
bicarbonate	O
ion	O
(	O
HCO	O
(	O
3	O
)(-))	O
were	O
significantly	O
lower	O
in	O
the	O
NPE	O
group	O
than	O
in	O
the	O
non	O
-	O
NPE	O
group	O
(	O
pH	O
:	O
7	O
.	O
32	O
vs	O
.	O
7	O
.	O
39	O
,	O
P	O
=	O
0	O
.	O
002	O
;	O
HCO	O
(	O
3	O
)(-),	O
20	O
.	O
6	O
mmol	O
/	O
L	O
vs	O
.	O
22	O
.	O
7	O
mmol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
01	O
).	O

The	O
results	O
showed	O
that	O
high	O
concentrations	O
of	O
PQ	O
resulted	O
in	O
toxicity	O
,	O
as	O
indicated	O
by	O
a	O
decrease	O
in	O
cell	B-PROC
viability	I-PROC
.	O

Polymorphisms	B-PROC
at	O
OAS1	O
have	O
been	O
shown	O
to	O
correlate	O
with	O
differential	O
susceptibility	O
to	O
several	O
infections	O
of	O
great	O
public	O
health	O
significance	O
,	O
including	O
hepatitis	O
C	O
virus	O
,	O
SARS	O
coronavirus	O
,	O
and	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
.	O

Interestingly	O
,	O
we	O
found	O
that	O
a	O
number	O
of	O
polymorphisms	B-PROC
involved	O
in	O
RNA	O
-	O
binding	O
were	O
shared	O
between	O
macaques	O
and	O
chimpanzees	O
.	O

This	O
represents	O
an	O
unusual	O
case	O
of	O
convergent	O
polymorphism	B-PROC
.	O

So	O
far	O
,	O
no	O
empirical	O
virus	O
isolation	O
study	O
has	O
been	O
done	O
to	O
elucidate	O
infectious	O
virus	O
secretion	B-PROC
or	O
serotype	O
variability	O
.	O

Our	O
key	O
finding	O
is	O
that	O
TGEV	O
selectively	O
manipulates	O
the	O
expression	B-PROC
of	O
some	O
cellular	O
miRNAs	O
to	O
regulate	O
its	O
subgenomic	O
transcription	B-PROC
.	O

Serious	O
maternal	O
complications	O
were	O
defined	O
as	O
:	O
hemorrhage	O
(	O
blood	O
loss	O
≥	O
1500	O
mL	O
,	O
blood	O
transfusion	O
,	O
or	O
hysterectomy	O
for	O
hemorrhage	O
),	O
infection	O
(	O
endometritis	O
,	O
wound	O
dehiscence	B-PROC
,	O
or	O
wound	O
infection	O
requiring	O
antibiotics	O
,	O
reopening	O
,	O
or	O
unexpected	O
procedure	O
),	O
intensive	O
care	O
unit	O
admission	O
,	O
or	O
death	B-PROC
.	O

Association	O
of	O
delivery	O
route	O
with	O
complications	O
was	O
estimated	O
using	O
multivariable	O
regression	O
models	O
yielding	O
adjusted	O
relative	O
risks	O
(	O
aRR	O
)	O
controlling	O
for	O
maternal	O
age	O
,	O
race	O
,	O
body	O
mass	O
index	O
,	O
hypertension	O
,	O
diabetes	O
,	O
preterm	O
premature	O
rupture	O
of	O
membranes	O
,	O
preterm	O
labor	B-PROC
,	O
GA	O
,	O
and	O
hospital	O
of	O
delivery	O
.	O

We	O
hypothesized	O
that	O
a	O
pneumotropic	O
and	O
highly	O
pathogenic	O
HAdV	O
type	O
infects	O
differentiated	B-PROC
human	O
bronchial	O
epithelial	O
cells	O
efficiently	O
from	O
the	O
apical	O
surface	O
and	O
also	O
induces	O
proinflammatory	O
cytokines	O
in	O
order	O
to	O
establish	O
ARDS	O
and	O
pneumonia	O
.	O

TITLE	O
:	O
Emerging	O
and	O
changing	O
viral	B-PROC
diseases	I-PROC
in	O
the	O
new	O
millennium	O
.	O

However	O
,	O
the	O
apparent	O
benignity	O
may	O
be	O
illusory	O
as	O
some	O
viral	B-PROC
infections	I-PROC
have	O
unexpected	O
consequences	O
-	O
such	O
as	O
the	O
oncogenicity	O
of	O
some	O
herpesviruses	O
and	O
human	O
papillomaviruses	O
.	O

An	O
attractive	O
target	O
for	O
the	O
development	B-PROC
of	O
anti	O
-	O
coronaviral	O
therapeutics	O
is	O
the	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
)),	O
which	O
is	O
essential	O
for	O
the	O
progression	O
of	O
the	O
coronaviral	O
life	O
cycle	O
.	O

Sepsis	O
can	O
be	O
averted	O
experimentally	O
by	O
endothelial	O
cytoprotection	B-PROC
through	O
targeting	B-PROC
nuclear	O
signaling	B-PROC
that	O
mediates	O
inflammation	O
and	O
deranged	O
metabolism	B-PROC
.	O

Physiologic	O
'	O
extinguishers	O
'	O
(	O
e	O
.	O
g	O
.	O
suppressor	O
of	O
cytokine	B-PROC
signaling	B-PROC
3	O
)	O
can	O
be	O
replenished	O
through	O
intracellular	O
protein	O
therapy	O
.	O

We	O
show	O
that	O
,	O
whenever	O
optimism	O
prevails	O
in	O
the	O
risk	O
behaviour	B-PROC
response	O
,	O
the	O
fate	O
of	O
an	O
epidemic	O
may	O
change	O
from	O
disease	O
clearance	O
to	O
disease	O
persistence	O
.	O

Five	O
cases	O
were	O
died	B-PROC
after	O
4	O
to	O
15	O
hours	O
into	O
hospital	O
(	O
3	O
cases	O
died	B-PROC
for	O
severe	O
trauma	O
-	O
hemorrhagic	O
shock	O
and	O
2	O
cases	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
).	O

Similarly	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
open	O
-	O
lung	O
and	O
stress	O
-	O
index	O
guided	O
PEEPs	O
in	O
terms	O
of	O
oxygenation	B-PROC
index	O
(	O
P	O
=	O
0	O
.	O
95	O
)	O
and	O
PaCO2	O
(	O
P	O
=	O
0	O
.	O
42	O
).	O

Ocular	B-PROC
and	O
oronasal	O
swabs	O
from	O
asymptomatic	O
dogs	O
(	O
n	O
=	O
503	O
)	O
were	O
tested	O
using	O
qPCR	O
assay	O
for	O
Bordetella	O
bronchiseptica	O
,	O
canine	O
adenovirus	O
type	O
2	O
(	O
CAV	O
-	O
2	O
),	O
canine	O
distemper	O
virus	O
(	O
CDV	O
),	O
canine	O
herpesvirus	O
type	O
1	O
(	O
CHV	O
),	O
canine	O
influenza	O
virus	O
(	O
CIV	O
),	O
canine	O
parainfluenza	O
virus	O
(	O
CPIV	O
),	O
canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
),	O
Mycoplasma	O
cynos	O
and	O
Streptococcus	O
equi	O
subsp	O
zooepidemicus	O
.	O

TITLE	O
:	O
Silencing	O
of	O
Tumor	O
Necrosis	B-PROC
Factor	O
Receptor	O
-	O
1	O
in	O
Human	O
Lung	O
Microvascular	O
Endothelial	O
Cells	O
Using	O
Particle	O
Platforms	O
for	O
siRNA	O
Delivery	O
.	O

To	O
determine	O
the	O
relevance	O
of	O
TNF	O
-	O
α	O
in	O
disrupting	O
bronchial	O
endothelial	O
cell	B-PROC
function	I-PROC
,	O
we	O
stimulated	O
human	O
THP	O
-	O
1	O
macrophages	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
used	O
the	O
resulting	O
cytokine	O
-	O
supplemented	O
media	O
to	O
disrupt	O
normal	O
endothelial	O
cell	B-PROC
functions	I-PROC
.	O

Endothelial	O
tube	B-PROC
formation	I-PROC
was	O
disrupted	O
in	O
the	O
presence	O
of	O
LPS	O
-	O
activated	O
THP	O
-	O
1	O
conditioned	O
media	O
,	O
with	O
reversal	O
of	O
the	O
effect	O
occurring	O
in	O
the	O
presence	O
of	O
0	O
.	O
1µg	O
/	O
ml	O
Enbrel	O
,	O
indicating	O
that	O
TNF	O
-	O
α	O
was	O
the	O
major	O
serum	O
component	O
inhibiting	O
endothelial	O
tube	B-PROC
formation	I-PROC
.	O

We	O
provide	O
evidence	O
that	O
production	O
of	O
IFN	O
-	O
β	O
by	O
BMECs	O
during	O
CoV	O
infection	O
may	O
prevent	O
BBB	O
breakdown	B-PROC
and	O
brain	O
viral	O
invasion	O
.	O

The	O
objectives	O
of	O
the	O
present	O
study	O
were	O
to	O
assess	O
the	O
mucosal	O
,	O
cellular	O
,	O
and	O
humoral	B-PROC
immune	I-PROC
responses	I-PROC
induced	O
by	O
two	O
different	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
vaccination	O
regimes	O
and	O
their	O
efficacy	O
against	O
challenge	O
by	O
a	O
variant	O
IBV	O
Q1	O
.	O

The	O
clinical	O
evolution	B-PROC
is	O
gradual	O
:	O
from	O
mild	O
non	O
-	O
specific	O
manifestations	O
of	O
acute	O
tracheobronchitis	O
to	O
severe	O
acute	O
respiratory	O
insufficiency	O
determined	O
by	O
a	O
bronchial	O
obstruction	O
syndrome	O
.	O

Design	O
and	O
synthesis	B-PROC
of	O
quinoxalin	O
-	O
2	O
(	O
1H	O
)-	O
one	O
derivatives	O
as	O
new	O
non	O
-	O
nucleoside	O
small	O
-	O
molecule	O
HCV	O
inhibitors	O
.	O

The	O
antibody	B-PROC
,	O
named	O
LCA60	O
,	O
binds	O
to	O
a	O
novel	O
site	O
on	O
the	O
spike	O
protein	O
and	O
potently	O
neutralizes	O
infection	O
of	O
multiple	O
MERS	O
-	O
CoV	O
isolates	O
by	O
interfering	O
with	O
the	O
binding	O
to	O
the	O
cellular	O
receptor	O
CD26	O
.	O

The	O
fact	O
that	O
it	O
took	O
only	O
4	O
mo	O
from	O
the	O
initial	O
screening	O
of	O
B	O
cells	O
derived	O
from	O
a	O
convalescent	O
patient	O
for	O
the	O
development	B-PROC
of	O
a	O
stable	O
chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cell	O
line	O
producing	O
neutralizing	O
antibodies	O
at	O
more	O
than	O
5	O
g	O
/	O
L	O
provides	O
an	O
example	O
of	O
a	O
rapid	O
pathway	B-PROC
toward	O
the	O
generation	O
of	O
effective	O
antiviral	O
therapies	O
against	O
emerging	O
viruses	O
.	O

Immunization	O
of	O
rhesus	O
macaques	O
confers	O
protection	O
against	O
MERS	O
-	O
CoV	O
-	O
induced	O
radiographic	O
pneumonia	O
,	O
as	O
assessed	O
using	O
computerized	O
tomography	O
,	O
supporting	O
this	O
strategy	O
as	O
a	O
promising	O
approach	O
for	O
MERS	O
-	O
CoV	O
vaccine	O
development	B-PROC
.	O

Wnt3a	O
signaling	B-PROC
has	O
been	O
implicated	O
in	O
anti	O
-	O
inflammatory	O
effects	O
,	O
whereas	O
Wnt5a	O
signaling	B-PROC
has	O
been	O
postulated	O
to	O
have	O
pro	O
-	O
inflammatory	O
properties	O
.	O

However	O
,	O
the	O
balance	B-PROC
between	O
Wnt3a	O
and	O
Wnt5a	O
signaling	B-PROC
pathway	I-PROC
in	O
the	O
lung	O
of	O
rats	O
with	O
endotoxic	O
shock	O
has	O
not	O
been	O
determined	O
.	O

Thus	O
,	O
we	O
investigated	O
the	O
major	O
components	O
of	O
Wnt3a	O
and	O
Wnt5a	O
signaling	B-PROC
pathway	I-PROC
in	O
the	O
lung	O
of	O
endotoxemic	O
rats	O
.	O

Huge	O
challenges	O
for	O
an	O
efficient	O
protection	O
against	O
virulent	O
IBVs	O
and	O
chicken	O
production	O
are	O
posed	O
by	O
co	O
-	O
circulating793B	O
,	O
Mass	O
and	O
D274	O
viruses	O
with	O
less	O
than	O
99	O
%	O
homology	O
to	O
the	O
respective	O
vaccine	O
strains	O
,	O
along	O
with	O
the	O
recently	O
emerged	O
variant	O
IBVs	O
,	O
despite	O
active	O
IBV	O
vaccination	O
strategies	O
in	O
the	O
Middle	O
East	O
,	O
continuous	O
surveillance	O
of	O
IBV	O
genotypes	O
is	O
essential	O
in	O
formulating	O
optimal	O
control	O
strategies	O
,	O
including	O
the	O
choice	O
and	O
development	B-PROC
of	O
new	O
vaccine	O
strains	O
and	O
formulation	O
of	O
vaccination	O
programmes	O
.	O

Planet	O
Biotechnology	O
has	O
specialized	O
in	O
developing	O
anti	O
-	O
infective	O
immunoadhesins	O
using	O
plant	O
expression	B-PROC
systems	O
.	O

Through	O
a	O
systematic	O
political	O
and	O
socio	O
-	O
economic	O
analysis	O
,	O
it	O
identifies	O
seven	O
major	O
drivers	O
for	O
China	O
'	O
s	O
success	O
,	O
including	O
(	O
1	O
)	O
the	O
SARS	O
outbreak	O
as	O
a	O
wake	B-PROC
-	O
up	O
call	O
,	O
(	O
2	O
)	O
strong	O
public	O
support	O
for	O
government	O
intervention	O
in	O
health	O
care	O
,	O
(	O
3	O
)	O
renewed	O
political	O
commitment	O
from	O
top	O
leaders	O
,	O
(	O
4	O
)	O
heavy	O
government	O
subsidies	O
,	O
(	O
5	O
)	O
fiscal	O
capacity	O
backed	O
by	O
China	O
'	O
s	O
economic	O
power	O
,	O
(	O
6	O
)	O
financial	O
and	O
political	O
responsibilities	O
delegated	O
to	O
local	O
governments	O
and	O
(	O
7	O
)	O
programmatic	O
implementation	O
strategy	O
.	O

No	O
cross	B-PROC
-	I-PROC
reaction	I-PROC
was	O
detected	O
for	O
the	O
developed	O
ELISA	O
with	O
other	O
coronaviruses	O
or	O
other	O
common	O
pig	O
pathogens	O
.	O

He	O
had	O
a	O
sustaining	O
fever	B-PROC
for	O
1	O
week	O
with	O
the	O
maximum	O
temperature	O
of	O
39	O
.	O
5	O
centigrade	O
,	O
then	O
the	O
body	O
temperature	O
returned	O
to	O
normal	O
.	O

According	O
to	O
phylogenetic	O
analysis	O
of	O
the	O
full	O
-	O
length	O
genome	O
,	O
replicase	O
transcriptase	B-PROC
complex	O
,	O
spike	O
protein	O
,	O
partial	O
S1	O
gene	O
and	O
M	O
protein	O
,	O
B1648	O
strain	O
clustered	O
with	O
the	O
non	O
-	O
Massachusetts	O
type	O
strains	O
NGA	O
/	O
A116E7	O
/	O
2006	O
,	O
UKr	O
27	O
-	O
11	O
,	O
QX	O
-	O
like	O
ITA	O
/	O
90254	O
/	O
2005	O
,	O
QX	O
-	O
like	O
CK	O
/	O
SWE	O
/	O
0658946	O
/	O
10	O
,	O
TN20	O
/	O
00	O
,	O
RF	O
-	O
27	O
/	O
99	O
,	O
RF	O
/	O
06	O
/	O
2007	O
and	O
SLO	O
/	O
266	O
/	O
05	O
.	O

Hereby	O
,	O
we	O
report	O
a	O
case	O
of	O
30	O
-	O
year	O
-	O
old	O
man	O
,	O
who	O
presented	O
with	O
fever	B-PROC
with	O
chills	O
and	O
diminution	O
of	O
vision	B-PROC
.	O

TITLE	O
:	O
Hemodynamic	B-PROC
monitoring	O
using	O
a	O
single	O
-	O
use	O
indwelling	O
transesophageal	O
echocardiography	O
probe	O
in	O
an	O
unstable	O
patient	O
after	O
open	O
-	O
heart	O
surgery	O
.	O

ABSTRACT	O
:	O
Hemodynamic	B-PROC
monitoring	O
is	O
frequently	O
needed	O
in	O
ventilated	O
patients	O
with	O
unstable	O
hemodynamics	B-PROC
after	O
open	O
-	O
heart	O
surgery	O
.	O

The	O
multi	O
-	O
fragment	O
antigen	O
(	O
BE	O
)	O
may	O
represent	O
a	O
promising	O
alternative	O
to	O
the	O
whole	O
virus	O
without	O
safety	O
problems	O
,	O
and	O
this	O
newly	O
established	O
ELISA	O
provides	O
an	O
effective	O
method	O
for	O
anti	O
-	O
IBV	O
antibody	B-PROC
detection	O
.	O

We	O
report	O
a	O
28	O
-	O
year	O
-	O
old	O
pregnant	O
woman	O
(	O
26	O
weeks	O
gestation	B-PROC
)	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
whom	O
ECMO	O
support	O
was	O
necessary	O
for	O
survival	O
,	O
and	O
she	O
was	O
transported	O
to	O
another	O
facility	O
1	O
,	O
155	O
km	O
away	O
with	O
the	O
aid	O
of	O
the	O
portable	O
ECMO	O
system	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
the	O
neutralization	O
of	O
MERS	O
-	O
CoV	O
by	O
a	O
human	O
monoclonal	O
antibody	B-PROC
MERS	O
-	O
27	O
.	O

The	O
envelope	O
spike	O
glycoprotein	O
on	O
the	O
surface	O
of	O
MERS	O
-	O
CoV	O
mediates	O
receptor	O
binding	O
,	O
membrane	B-PROC
fusion	I-PROC
,	O
and	O
viral	O
entry	O
.	O

Limited	O
reports	O
showed	O
that	O
PEDV	O
could	O
inhibit	O
type	B-PROC
I	I-PROC
interferon	B-PROC
production	I-PROC
.	O

As	O
the	O
key	O
IFN	O
-	O
β	O
transcription	B-PROC
factors	O
,	O
we	O
found	O
that	O
dsRNA	O
-	O
induced	O
activation	O
of	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF	O
-	O
3	O
)	O
was	O
inhibited	O
after	O
PEDV	O
infection	O
,	O
but	O
not	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
κB	O
).	O

Notable	O
members	O
include	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
Dengue	O
virus	O
,	O
Chikungunya	O
,	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
Coronavirus	O
and	O
enteroviruses	O
of	O
the	O
Picornaviridae	O
family	O
.	O

This	O
review	O
summarizes	O
current	O
knowledge	O
of	O
critical	O
host	O
factors	O
recruited	O
to	O
or	O
demonstrated	O
to	O
be	O
involved	O
in	O
the	O
biogenesis	B-PROC
and	O
stabilization	O
of	O
+	O
RNA	O
virus	O
VRCs	O
.	O

TITLE	O
:	O
A	O
synthetic	O
consensus	O
anti	O
-	O
spike	O
protein	O
DNA	O
vaccine	O
induces	O
protective	O
immunity	B-PROC
against	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
in	O
nonhuman	O
primates	O
.	O

TITLE	O
:	O
Effects	O
of	O
Adaptation	B-PROC
of	O
Infectious	O
Bronchitis	O
Virus	O
Arkansas	O
Attenuated	O
Vaccine	O
to	O
Embryonic	O
Kidney	O
Cells	O
.	O

One	O
patient	O
died	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
treatment	O
with	O
ethanolamine	O
oleate	O
.	O

TITLE	O
:	O
Construction	O
of	O
an	O
oral	O
vaccine	O
for	O
transmissible	O
gastroenteritis	O
virus	O
based	O
on	O
the	O
TGEV	O
N	O
gene	O
expressed	B-PROC
in	O
an	O
attenuated	O
Salmonella	O
typhimurium	O
vector	O
.	O

Humoral	O
(	O
neutralization	O
titer	O
and	O
specific	O
IgG	O
),	O
cellular	O
(	O
interleukin	O
-	O
4	O
,	O
γ	O
-	O
interferon	O
,	O
and	O
peripheral	O
lymphocyte	B-PROC
proliferation	I-PROC
),	O
and	O
mucosal	O
(	O
sIgA	O
)	O
immune	B-PROC
responses	I-PROC
were	O
detected	O
and	O
evaluated	O
.	O

In	O
conclusion	O
,	O
the	O
oral	O
vaccine	O
was	O
developed	O
successfully	O
,	O
and	O
the	O
vaccine	O
could	O
significantly	O
induce	O
humoral	O
,	O
cellular	O
,	O
and	O
mucosal	B-PROC
immune	I-PROC
responses	I-PROC
in	O
piglets	O
.	O

TITLE	O
:	O
Immune	B-PROC
Responses	I-PROC
to	O
Virulent	O
and	O
Vaccine	O
Strains	O
of	O
Infectious	O
Bronchitis	O
Viruses	O
in	O
Chickens	O
.	O

Multiple	O
interlinking	O
immune	B-PROC
responses	I-PROC
are	O
essential	O
for	O
protection	O
against	O
virulent	O
IBVs	O
,	O
including	O
passive	O
,	O
innate	O
,	O
adaptive	O
,	O
and	O
effector	O
T	O
cells	O
active	O
at	O
mucosal	O
surfaces	O
.	O

ABSTRACT	O
:	O
A	O
domestic	O
ferret	O
from	O
Lima	O
,	O
Peru	O
,	O
died	B-PROC
after	O
ten	O
days	O
of	O
non	O
-	O
specific	O
clinical	O
signs	O
.	O

ABSTRACT	O
:	O
After	O
severe	O
blunt	O
chest	O
trauma	O
,	O
the	O
development	B-PROC
of	O
an	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
often	O
associated	O
with	O
severe	O
or	O
even	O
lethal	O
complications	O
.	O

Taken	O
together	O
,	O
the	O
provided	O
global	O
perspective	O
of	O
the	O
inflammatory	B-PROC
response	I-PROC
following	O
blunt	O
chest	O
trauma	O
could	O
provide	O
a	O
molecular	O
framework	O
for	O
future	O
research	O
in	O
trauma	O
pathophysiology	O
.	O

RESULTS	O
:	O
The	O
results	O
suggest	O
an	O
activation	O
of	O
a	O
highly	O
complex	O
transcriptional	B-PROC
program	O
in	O
response	O
to	O
chest	O
trauma	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
has	O
been	O
available	O
for	O
decades	O
,	O
with	O
its	O
use	O
steadily	O
expanding	O
in	O
the	O
setting	O
of	O
advances	O
in	O
technology	O
.	O

Bioinformatics	O
analysis	O
of	O
this	O
non	O
-	O
structural	O
protein	O
has	O
now	O
revealed	O
a	O
nidoviral	O
signature	O
domain	O
(	O
genetic	B-PROC
marker	I-PROC
)	O
that	O
is	O
N	O
-	O
terminally	O
adjacent	O
to	O
the	O
RdRp	O
and	O
has	O
no	O
apparent	O
homologs	O
elsewhere	O
.	O

Potential	O
functions	O
supported	O
by	O
NiRAN	O
may	O
include	O
nucleic	O
acid	O
ligation	O
,	O
mRNA	B-PROC
capping	B-PROC
and	O
protein	O
-	O
primed	O
RNA	B-PROC
synthesis	I-PROC
,	O
possibilities	O
that	O
remain	O
to	O
be	O
explored	O
in	O
future	O
studies	O
.	O

Both	O
groups	O
had	O
the	O
same	O
frequency	O
of	O
upper	O
respiratory	O
and	O
gastrointestinal	O
symptoms	O
and	O
had	O
the	O
same	O
incidence	O
of	O
admission	O
to	O
the	O
PICU	O
,	O
intravenous	O
immunoglobulin	B-PROC
-	O
resistant	O
disease	O
,	O
and	O
coronary	O
artery	O
lesions	O
.	O

Twenty	O
traumatic	O
brain	O
injury	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
were	O
submitted	O
to	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
levels	O
of	O
5	O
,	O
10	O
,	O
and	O
15	O
cm	O
H2O	O
progressively	O
.	O

RESULTS	O
:	O
Brain	O
tissue	O
oxygen	O
pressure	O
and	O
oxygen	O
saturation	O
increased	O
significantly	O
with	O
increasing	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
from	O
5	O
to	O
10	O
and	O
from	O
10	O
to	O
15	O
cm	O
H2O	O
(	O
P	O
=.	O
0001	O
and	O
P	O
=.	O
0001	O
respectively	O
).	O

TITLE	O
:	O
Development	B-PROC
of	O
an	O
indirect	O
ELISA	O
based	O
on	O
a	O
truncated	O
S	O
protein	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Thirty	O
of	O
these	O
hits	O
can	O
be	O
placed	O
in	O
a	O
network	O
of	O
interactions	O
with	O
viral	O
proteins	O
and	O
are	O
involved	O
in	O
RNA	B-PROC
splicing	I-PROC
,	O
membrane	O
trafficking	B-PROC
,	O
and	O
ubiquitin	B-PROC
conjugation	B-PROC
.	O

Despite	O
these	O
functional	O
similarities	O
,	O
MERS	O
-	O
CoV	O
nsp1	O
used	O
a	O
strikingly	O
different	O
strategy	O
that	O
selectively	O
targeted	B-PROC
translationally	O
competent	O
host	O
mRNAs	O
for	O
inhibition	B-PROC
.	O

The	O
present	O
study	O
represents	O
a	O
meaningful	O
step	O
toward	O
a	O
better	O
understanding	O
of	O
the	O
factors	O
and	O
molecular	O
mechanisms	O
governing	O
the	O
virulence	B-PROC
and	O
pathogenesis	B-PROC
of	O
MERS	O
-	O
CoV	O
.	O

The	O
benefits	O
of	O
regional	O
analgesia	B-PROC
are	O
likely	O
most	O
influential	O
when	O
it	O
is	O
initiated	O
as	O
early	O
as	O
possible	O
,	O
and	O
the	O
performance	O
of	O
nerve	O
blocks	O
both	O
in	O
the	O
emergency	O
room	O
and	O
in	O
the	O
field	O
has	O
been	O
shown	O
to	O
provide	O
quality	O
pain	O
relief	O
with	O
an	O
excellent	O
safety	O
profile	O
.	O

After	O
treatment	O
with	O
35	O
PPV	O
sessions	O
,	O
the	O
oxygenation	B-PROC
index	O
(	O
OI	O
)	O
values	O
of	O
the	O
six	O
patients	O
when	O
measured	O
post	O
-	O
PPV	O
and	O
post	O
-	O
supine	O
position	O
ventilation	O
(	O
SPV	O
)	O
were	O
significantly	O
higher	O
than	O
those	O
measured	O
pre	O
-	O
PPV	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O
The	O
six	O
patients	O
showed	O
no	O
significant	O
differences	O
in	O
their	O
values	O
for	O
respiratory	O
rate	O
(	O
RR	O
),	O
peak	O
inspiratory	B-PROC
pressure	O
(	O
PIP	O
),	O
tidal	O
volume	O
(	O
TV	O
)	O
or	O
arterial	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
(	O
PaCO2	O
)	O
when	O
compared	O
pre	O
-	O
PPV	O
,	O
post	O
-	O
PPV	O
,	O
and	O
post	O
-	O
SPV	O
.	O

Additionally	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
mean	O
values	O
for	O
arterial	B-PROC
pressure	I-PROC
(	O
MAP	O
),	O
cardiac	O
index	O
(	O
CI	O
),	O
central	O
venous	B-PROC
pressure	I-PROC
(	O
CVP	O
),	O
heart	O
rate	O
(	O
HR	O
),	O
lactic	O
acid	O
(	O
LAC	O
)	O
levels	O
or	O
the	O
doses	O
of	O
norepinephrine	O
(	O
NE	O
)	O
administered	O
when	O
compared	O
pre	O
-	O
PPV	O
,	O
post	O
-	O
PPV	O
,	O
and	O
post	O
-	O
SPV	O
.	O

TITLE	O
:	O
Genetic	O
deficiency	O
and	O
polymorphisms	B-PROC
of	O
cyclophilin	B-PROC
A	O
reveal	O
its	O
essential	O
role	O
for	O
Human	O
Coronavirus	O
229E	O
replication	O
.	O

Here	O
,	O
we	O
summarize	O
present	O
knowledge	O
on	O
the	O
role	O
of	O
cyclophilin	B-PROC
A	O
during	O
coronavirus	O
replication	O
.	O

Pv	O
infection	O
is	O
associated	O
with	O
ARDS	O
and	O
other	O
complications	O
such	O
as	O
sepsis	O
and	O
multi	O
-	O
organ	O
dysfunction	O
syndrome	O
;	O
this	O
enhanced	O
severity	O
of	O
Pv	O
infection	O
,	O
if	O
unrecognized	O
,	O
can	O
lead	O
to	O
more	O
deaths	B-PROC
in	O
malaria	O
-	O
endemic	O
areas	O
.	O

ABSTRACT	O
:	O
Dysregulation	O
of	O
the	O
innate	O
immune	O
system	O
drives	O
lung	O
injury	O
and	O
its	O
systemic	O
sequelae	O
due	O
to	O
breakdown	B-PROC
of	O
vascular	O
barrier	O
function	O
,	O
harmful	O
hyperinflammation	O
and	O
microcirculatory	O
failure	O
,	O
which	O
contribute	O
to	O
the	O
unfavourable	O
outcome	O
of	O
patients	O
with	O
severe	O
pneumonia	O
.	O

Combining	O
SpO2	O
/	O
FiO2	O
with	O
ultrasound	O
to	O
determine	O
oxygenation	B-PROC
and	O
radiographic	O
criteria	O
for	O
ARDS	O
,	O
the	O
sensitivity	O
was	O
83	O
%	O
(	O
95	O
%	O
CI	O
52	O
-	O
98	O
)	O
and	O
specificity	O
was	O
62	O
%	O
(	O
95	O
%	O
CI	O
38	O
-	O
82	O
).	O

TITLE	O
:	O
Effective	O
inhibition	B-PROC
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
by	O
RNA	B-PROC
interference	I-PROC
in	O
vitro	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
E	O
protein	B-PROC
transports	I-PROC
calcium	O
ions	O
and	O
activates	O
the	O
NLRP3	O
inflammasome	O
.	O

We	O
describe	O
a	O
Siglec	O
-	O
targeting	B-PROC
platform	O
consisting	O
of	O
poly	O
(	O
lactic	O
-	O
co	O
-	O
glycolic	O
acid	O
)	O
nanoparticles	O
decorated	O
with	O
a	O
natural	O
Siglec	O
ligand	B-PROC
,	O
di	O
(	O
α2	O
→	O
8	O
)	O
N	O
-	O
acetylneuraminic	O
acid	O
(	O
α2	O
,	O
8	O
NANA	O
-	O
NP	O
).	O

In	O
rare	O
cases	O
,	O
ventilator	O
therapy	O
proves	O
insufficient	O
,	O
and	O
only	O
the	O
option	O
of	O
employing	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
V	O
-	O
V	O
)	O
remains	O
.	O

There	O
,	O
he	O
underwent	O
ECMO	O
V	O
-	O
V	O
therapy	O
lasting	O
22	O
days	O
,	O
which	O
resulted	O
in	O
the	O
improvement	O
of	O
his	O
arterial	O
blood	B-PROC
gas	I-PROC
parameters	O
and	O
clinical	O
condition	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
the	O
case	O
of	O
a	O
55	O
-	O
year	O
-	O
old	O
male	O
who	O
died	B-PROC
of	O
a	O
severe	O
febrile	B-PROC
neutropenia	O
during	O
adjuvant	O
chemotherapy	O
.	O

Complement	B-PROC
activation	I-PROC
products	O
may	O
contribute	O
to	O
the	O
fibroproliferative	O
response	O
,	O
suggesting	O
that	O
complement	B-PROC
inhibitors	I-PROC
are	O
potential	O
therapeutic	O
agents	O
.	O

Specific	O
inhibition	B-PROC
of	O
complement	O
with	O
compstatin	O
down	O
-	O
regulated	O
sepsis	O
-	O
induced	O
fibrosis	O
genes	O
,	O
including	O
transforming	O
growth	B-PROC
factor	O
-	O
beta	O
(	O
TGF	O
-	O
β	O
),	O
connective	O
tissue	B-PROC
growth	B-PROC
factor	O
(	O
CTGF	O
),	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
1	O
(	O
TIMP1	O
),	O
various	O
collagens	O
and	O
chemokines	O
responsible	O
for	O
fibrocyte	O
recruitment	O
(	O
e	O
.	O
g	O
.	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-PROC
2	O
(	O
CCL2	O
)	O
and	O
12	O
(	O
CCL12	O
)).	O

HCoV	O
-	O
OC43	O
was	O
isolated	O
in	O
the	O
1960s	O
and	O
is	O
a	O
major	O
agent	O
of	O
the	O
common	O
cold	B-PROC
.	O

Therefore	O
,	O
our	O
findings	O
revealed	O
that	O
the	O
ns12	O
.	O
9	O
viroporin	O
facilitates	O
virion	O
morphogenesis	B-PROC
to	O
enhance	O
viral	O
production	O
,	O
and	O
these	O
results	O
provided	O
a	O
deeper	O
understanding	O
of	O
HCoV	O
-	O
OC43	O
pathogenesis	B-PROC
.	O

Recent	O
report	O
on	O
the	O
prognostic	O
value	O
of	O
eicosanoids	O
in	O
patients	O
with	O
ARDS	O
suggests	O
that	O
modulating	O
the	O
inflammatory	B-PROC
response	I-PROC
through	O
the	O
use	O
of	O
polyunsaturated	O
fatty	O
acids	O
may	O
be	O
a	O
useful	O
strategy	O
for	O
ARDS	O
treatment	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
causes	O
acute	O
diarrhea	O
and	O
dehydration	O
in	O
sucking	B-PROC
piglets	O
and	O
has	O
a	O
high	O
mortality	O
rate	O
.	O

ABSTRACT	O
:	O
During	O
attempts	O
to	O
clone	O
retroviral	O
determinants	O
associated	O
with	O
a	O
mouse	O
model	O
of	O
Langerhans	O
cell	O
histiocytosis	O
(	O
LCH	O
),	O
suppression	B-PROC
subtractive	O
hybridization	B-PROC
(	O
SSH	O
)	O
was	O
used	O
to	O
identify	O
unique	O
viruses	O
in	O
the	O
liver	O
of	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
mice	O
transplanted	O
with	O
LCH	O
tissues	O
.	O

Degenerate	O
PCR	O
targeting	B-PROC
of	O
type	O
D	O
retrovirus	O
and	O
5	O
'-	O
RACE	O
targeting	B-PROC
of	O
other	O
types	O
of	O
retroviruses	O
confirmed	O
the	O
absence	O
of	O
any	O
retroviral	O
association	O
with	O
the	O
LCH	O
xenografted	O
SCID	O
mice	O
.	O

Replication	O
-	O
competent	O
recombinant	O
measles	O
virus	O
(	O
MV	O
)	O
expressing	O
foreign	O
antigens	O
constitutes	O
a	O
promising	O
tool	O
to	O
induce	O
protective	O
immunity	B-PROC
against	O
corresponding	O
pathogens	O
.	O

Additionally	O
,	O
induction	O
of	O
specific	O
T	O
cells	O
was	O
demonstrated	O
by	O
T	B-PROC
cell	I-PROC
proliferation	I-PROC
,	O
antigen	O
-	O
specific	O
T	O
cell	O
cytotoxicity	O
,	O
and	O
gamma	O
interferon	B-PROC
secretion	I-PROC
after	O
stimulation	O
of	O
splenocytes	O
with	O
MERS	O
-	O
CoV	O
-	O
S	O
presented	O
by	O
murine	O
dendritic	O
cells	O
.	O

Therefore	O
,	O
the	O
development	B-PROC
of	O
a	O
vaccine	O
is	O
mandatory	O
.	O

The	O
present	O
study	O
shows	O
that	O
a	O
recombinant	O
MV	O
expressing	O
MERS	O
-	O
S	O
is	O
genetically	O
stable	O
and	O
induces	O
strong	O
humoral	O
and	O
cellular	B-PROC
immunity	I-PROC
against	O
MERS	O
-	O
CoV	O
in	O
vaccinated	O
mice	O
.	O

TITLE	O
:	O
[	O
ASSESSMENT	O
OF	O
PULMONARY	B-PROC
VENTILATION	I-PROC
FUNCTION	O
AT	O
INTENSIVE	O
CARE	O
UNIT	O
PATIENTS	O
].	O

When	O
divided	O
according	O
to	O
outcome	O
,	O
the	O
BNP	O
level	O
in	O
the	O
death	B-PROC
group	O
(	O
267	O
.	O
07	O
±	O
45	O
.	O
06	O
pg	O
/	O
ml	O
)	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
survival	O
group	O
(	O
128	O
.	O
99	O
±	O
45	O
.	O
42	O
pg	O
/	O
ml	O
).	O

ABSTRACT	O
:	O
Patients	O
with	O
severe	O
sepsis	O
and	O
septic	O
shock	O
are	O
at	O
high	O
risk	O
for	O
development	B-PROC
of	O
pulmonary	O
complications	O
,	O
including	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Index	O
cases	O
were	O
patients	O
with	O
influenza	O
-	O
like	O
-	O
illness	O
(	O
cough	O
and	O
self	O
-	O
reported	O
or	O
measured	O
fever	B-PROC
(≥	O
38	O
°	O
C	O
))	O
with	O
onset	O
in	O
the	O
last	O
3	O
days	O
and	O
no	O
sick	O
household	O
contacts	O
,	O
at	O
clinics	O
in	O
South	O
Africa	O
.	O

Our	O
results	O
also	O
have	O
important	O
implications	O
for	O
development	B-PROC
of	O
vaccine	O
immunogens	O
based	O
on	O
the	O
newly	O
identified	O
m336	O
epitope	O
as	O
well	O
as	O
for	O
elucidation	O
of	O
mechanisms	O
of	O
neutralization	O
by	O
m336	O
-	O
like	O
antibodies	O
and	O
their	O
elicitation	O
in	O
vivo	O
.	O

Finally	O
,	O
we	O
also	O
show	O
that	O
SARS	O
-	O
CoV	O
ORF7a	O
blocks	O
the	O
restriction	O
activity	O
of	O
BST	O
-	O
2	O
by	O
blocking	O
the	O
glycosylation	B-PROC
of	O
BST	O
-	O
2	O
.	O

TITLE	O
:	O
TMPRSS2	O
Isoform	O
1	O
Activates	O
Respiratory	O
Viruses	O
and	O
Is	O
Expressed	B-PROC
in	O
Viral	O
Target	O
Cells	O
.	O

In	O
this	O
prospective	O
study	O
,	O
we	O
measured	O
the	O
dynamic	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
lung	B-PROC
volume	I-PROC
changes	O
(	O
ΔEELV	O
)	O
during	O
an	O
increase	O
and	O
decrease	O
in	O
PEEP	O
to	O
determine	O
the	O
optimal	O
duration	O
for	O
each	O
step	O
.	O

The	O
dynamic	O
of	O
ΔEELV	O
was	O
measured	O
by	O
direct	O
spirometry	O
as	O
the	O
difference	O
between	O
inspiratory	B-PROC
and	O
expiratory	B-PROC
tidal	O
volumes	O
over	O
2	O
.	O
5	O
minutes	O
following	O
each	O
increase	O
and	O
decrease	O
in	O
PEEP	O
.	O

TITLE	O
:	O
Apoptosis	B-PROC
transcriptional	B-PROC
mechanism	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
infected	O
cells	O
.	O

TITLE	O
:	O
A	O
humanized	O
neutralizing	O
antibody	B-PROC
against	O
MERS	O
-	O
CoV	O
targeting	B-PROC
the	O
receptor	O
-	O
binding	O
domain	O
of	O
the	O
spike	O
protein	O
.	O

To	O
maintain	O
lung	O
homeostasis	B-PROC
,	O
chronic	O
inflammation	O
is	O
countered	O
by	O
enhanced	O
expression	B-PROC
of	O
proresolving	O
/	O
antiinflammatory	O
factors	O
.	O

Strikingly	O
,	O
infection	O
of	O
mice	O
lacking	O
PLA2G2D	O
expression	B-PROC
(	O
Pla2g2d	O
(-/-)	O
mice	O
)	O
converted	O
a	O
uniformly	O
lethal	O
infection	O
to	O
a	O
nonlethal	O
one	O
(>	O
80	O
%	O
survival	O
),	O
subsequent	O
to	O
development	B-PROC
of	O
enhanced	O
respiratory	O
DC	O
migration	B-PROC
to	O
the	O
draining	O
lymph	O
nodes	O
,	O
augmented	O
antivirus	O
T	O
cell	O
responses	O
,	O
and	O
diminished	O
lung	O
damage	O
.	O

Furthermore	O
,	O
oxidative	O
stress	O
,	O
probably	O
via	O
lipid	B-PROC
peroxidation	I-PROC
,	O
was	O
found	O
to	O
induce	O
PLA2G2D	O
expression	B-PROC
in	O
mice	O
and	O
in	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

APRV	O
provides	O
increased	O
airway	O
pressure	O
as	O
a	O
potential	O
recruitment	O
mechanism	O
and	O
allows	O
spontaneous	O
breathing	B-PROC
,	O
with	O
the	O
potential	O
benefits	O
of	O
decreased	O
sedation	O
,	O
shorter	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
and	O
improvement	O
in	O
cardiac	O
performance	O
.	O

CONCLUSIONS	O
:	O
Although	O
ischemic	O
complications	O
associated	O
with	O
VA	O
-	O
ECMO	O
are	O
accepted	O
by	O
intensivists	O
under	O
the	O
slogan	O
""""	O
leg	O
for	O
life	O
""","	O
for	O
the	O
repair	B-PROC
of	O
the	O
femoral	O
artery	O
in	O
the	O
presence	O
of	O
groin	O
infection	O
the	O
sartorius	O
muscle	O
remains	O
an	O
efficient	O
solution	O
for	O
limb	O
salvage	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
first	O
case	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
was	O
reported	O
in	O
2012	O
,	O
the	O
virus	O
has	O
infected	O
more	O
than	O
1300	O
individuals	O
in	O
26	O
countries	O
,	O
and	O
caused	O
more	O
than	O
480	O
deaths	B-PROC
.	O

We	O
employ	O
this	O
approach	O
to	O
(	O
1	O
)	O
quantify	O
the	O
risks	O
of	O
death	B-PROC
and	O
(	O
2	O
)	O
characterize	O
the	O
temporal	O
evolution	B-PROC
of	O
the	O
case	O
fatality	O
ratio	O
(	O
CFR	O
)	O
as	O
case	O
ascertainment	O
greatly	O
improved	O
during	O
the	O
course	O
of	O
the	O
outbreak	O
.	O

48	O
(	O
4	O
.	O
11	O
%)	O
deaths	B-PROC
were	O
attributed	O
to	O
GBS	O
.	O

Conduction	B-PROC
block	O
is	O
the	O
major	O
abnormality	O
noted	O
in	O
electrophysiological	O
studies	O
and	O
proximal	O
nerve	O
segment	O
assessing	O
with	O
Erb	O
'	O
s	O
point	O
stimulation	O
has	O
high	O
predictive	O
value	O
.	O

No	O
difference	O
in	O
complications	O
and	O
outcome	O
is	O
found	O
in	O
treatment	O
regimens	O
of	O
intravenous	O
immunoglobulin	B-PROC
(	O
IVIG	O
)	O
and	O
plasma	O
exchange	O
.	O

One	O
such	O
sensor	O
,	O
MDA5	O
,	O
detects	O
viral	O
RNA	O
and	O
triggers	O
induction	O
of	O
type	O
I	O
interferons	O
,	O
chemical	O
messengers	O
that	O
induce	O
inflammation	O
and	O
help	O
regulate	O
the	O
immune	B-PROC
responses	I-PROC
.	O

Viral	B-PROC
replication	I-PROC
in	O
the	O
liver	O
was	O
similar	O
in	O
mice	O
with	O
and	O
without	O
MDA5	O
,	O
but	O
liver	O
damage	O
was	O
increased	O
in	O
MDA5	O
(-/-)	O
mice	O
,	O
suggesting	O
that	O
the	O
immune	B-PROC
response	I-PROC
is	O
causing	O
the	O
damage	O
.	O

Although	O
they	O
are	O
both	O
autoimmune	O
conditions	O
that	O
benefit	O
from	O
the	O
administration	O
of	O
plasma	O
exchange	O
or	O
IV	O
immunoglobulin	B-PROC
(	O
IVIg	O
),	O
they	O
are	O
otherwise	O
very	O
different	O
disorders	O
with	O
unique	O
features	O
and	O
distinct	O
complications	O
.	O

In	O
ferrets	O
,	O
we	O
also	O
measured	O
H7	O
-	O
specific	O
cell	B-PROC
-	I-PROC
mediated	I-PROC
immunity	I-PROC
.	O

Studies	O
are	O
currently	O
ongoing	O
to	O
better	O
characterize	O
the	O
immune	B-PROC
response	I-PROC
elicited	O
by	O
the	O
plant	O
-	O
derived	O
VLP	O
vaccines	O
.	O

Strikingly	O
,	O
PEDV	O
infected	O
suckling	O
pigs	O
had	O
significantly	O
lower	O
NK	O
cell	O
frequencies	O
,	O
undetectable	O
NK	O
cell	O
activity	O
and	O
lower	O
IFNγ	O
producing	O
NK	O
cells	O
in	O
blood	O
and	O
ileum	O
compared	O
to	O
PEDV	O
infected	O
weaned	B-PROC
pigs	O
.	O

Pro	O
-	O
inflammatory	O
cytokine	O
profiles	O
of	O
PEDV	O
infected	O
suckling	O
pigs	O
differed	O
from	O
those	O
of	O
PEDV	O
infected	O
weaned	B-PROC
pigs	O
and	O
coincided	O
with	O
onset	O
of	O
fecal	O
PEDV	O
RNA	O
shedding	O
and	O
serum	O
PEDV	O
RNA	O
titers	O
.	O

This	O
study	O
demonstrated	O
for	O
the	O
first	O
time	O
the	O
association	O
of	O
ST3GAL1	O
gene	O
haplotypes	O
on	O
the	O
risk	O
of	O
more	O
severe	O
disease	O
and	O
death	B-PROC
in	O
patients	O
infected	O
with	O
Influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
virus	O
.	O

Multivariate	O
analysis	O
associated	O
hospital	O
mortality	O
with	O
age	O
and	O
Pao	B-PROC
CONCLUSIONS	O
:	O
The	O
overall	O
hospital	O
mortality	O
(	O
38	O
%)	O
was	O
similar	O
to	O
that	O
of	O
other	O
studies	O
and	O
according	O
to	O
the	O
presence	O
of	O
ARDS	O
(	O
Pao	B-PROC

The	O
main	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
oral	O
minimum	O
infectious	O
dose	O
of	O
PEDV	O
in	O
naïve	O
conventional	O
neonatal	O
piglets	O
and	O
weaned	B-PROC
pigs	O
.	O

As	O
outcomes	O
of	O
MERS	O
-	O
CoV	O
infection	O
in	O
patients	O
differ	O
greatly	O
,	O
ranging	O
from	O
asymptomatic	O
to	O
overwhelming	O
disease	O
and	O
death	B-PROC
,	O
having	O
available	O
both	O
an	O
infection	O
model	O
and	O
a	O
lethal	O
model	O
makes	O
this	O
transgenic	O
mouse	O
model	O
relevant	O
for	O
advancing	O
MERS	O
research	O
.	O

TITLE	O
:	O
Genetic	O
Predisposition	O
to	O
Stevens	O
-	O
Johnson	O
Syndrome	O
With	O
Severe	O
Ocular	B-PROC
Surface	O
Complications	O
.	O

ABSTRACT	O
:	O
Stevens	O
-	O
Johnson	O
syndrome	O
(	O
SJS	O
)	O
is	O
an	O
acute	O
inflammatory	O
vesiculobullous	O
reaction	O
of	O
the	O
skin	O
and	O
mucosa	O
,	O
including	O
the	O
ocular	B-PROC
surface	O
,	O
oral	O
cavity	O
,	O
and	O
genitals	O
.	O

Integrating	O
phenotypic	O
and	O
genetic	O
data	O
narrowed	O
this	O
region	O
to	O
a	O
single	O
gene	O
,	O
Trim55	O
,	O
an	O
E3	O
ubiquitin	B-PROC
ligase	O
with	O
a	O
role	O
in	O
muscle	B-PROC
fiber	I-PROC
maintenance	I-PROC
.	O

The	O
host	O
innate	B-PROC
immune	I-PROC
response	I-PROC
was	O
evaluated	O
over	O
these	O
3	O
days	O
and	O
differences	O
between	O
the	O
susceptible	O
and	O
resistant	O
lines	O
examined	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
new	O
portable	O
air	O
sampler	O
based	O
on	O
electrostatic	O
precipitation	B-PROC
.	O

Of	O
the	O
2	O
studies	O
that	O
reported	O
hemodynamic	B-PROC
instability	O
during	O
the	O
prone	O
positioning	O
maneuvers	O
,	O
very	O
few	O
adverse	O
hemodynamic	B-PROC
episodes	O
were	O
reported	O
.	O

ABSTRACT	O
:	O
A	O
simple	O
,	O
rapid	O
and	O
sensitive	O
colorimetric	O
reverse	O
-	O
transcription	B-PROC
loop	O
-	O
mediated	O
isothermal	O
amplification	O
(	O
RT	O
-	O
LAMP	O
)	O
was	O
developed	O
for	O
rapid	O
detection	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
in	O
the	O
Republic	O
of	O
Korea	O
started	O
from	O
the	O
index	O
case	O
who	O
developed	O
fever	B-PROC
after	O
returning	O
from	O
the	O
Middle	O
East	O
.	O

However	O
,	O
under	O
this	O
condition	O
,	O
adoptive	O
transfer	O
of	O
the	O
DN	O
T	O
cells	O
accelerated	O
the	O
disease	O
progression	O
and	O
reversed	O
the	O
benefit	O
from	O
mfgl2	O
gene	O
silence	O
,	O
leading	O
to	O
a	O
100	O
%	O
death	B-PROC
rate	O
.	O

These	O
findings	O
support	O
the	O
idea	O
that	O
echocardiographic	O
assessment	O
of	O
pulmonary	O
artery	O
pressure	O
in	O
patients	O
with	O
refractory	O
ARDS	O
before	O
VV	O
-	O
ECMO	O
implantation	B-PROC
may	O
have	O
value	O
for	O
risk	O
-	O
stratification	O
.	O

We	O
report	O
the	O
case	O
of	O
5	O
-	O
month	O
-	O
old	O
infant	O
who	O
presented	O
a	O
normal	O
development	B-PROC
until	O
the	O
age	O
of	O
4	O
months	O
when	O
a	O
respiratory	O
infection	O
caused	O
an	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
a	O
fatal	O
outcome	O
.	O

However	O
,	O
concerns	O
about	O
the	O
overall	O
ineffectiveness	O
,	O
toxicity	O
of	O
certain	O
ingredients	O
of	O
disinfectants	O
,	O
pollution	O
of	O
the	O
environment	O
,	O
and	O
the	O
short	O
duration	O
of	O
antimicrobial	O
activity	O
of	O
alcohol	O
have	O
not	O
been	O
addressed	O
,	O
and	O
the	O
epidemiology	O
of	O
certain	O
major	O
viral	B-PROC
infections	I-PROC
are	O
not	O
correlated	O
inversely	O
with	O
the	O
current	O
measures	O
of	O
viral	O
prevention	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
first	O
report	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
in	O
2012	O
in	O
Saudi	O
Arabia	O
,	O
no	O
standard	O
treatment	O
guideline	O
has	O
been	O
set	O
despite	O
the	O
virulence	B-PROC
of	O
MERS	O
-	O
coronavirus	O
(	O
CoV	O
)	O
and	O
the	O
high	O
case	O
-	O
fatality	O
rate	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
truncated	O
S1	O
gene	O
,	O
encoding	O
the	O
exterior	O
of	O
the	O
viral	O
spike	O
protein	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
was	O
subcloned	O
into	O
prokaryotic	O
expression	B-PROC
vector	O
pET32a	O
(+)	O
and	O
expressed	B-PROC
as	O
a	O
recombinant	O
protein	O
in	O
Escherichia	O
coli	O
BL21	O
(	O
DE3	O
).	O

Maximal	O
oxygenation	B-PROC
improvement	O
occurs	O
over	O
a	O
wide	O
time	O
frame	O
ranging	O
from	O
several	O
hours	O
to	O
several	O
days	O
.	O

A	O
29	O
-	O
year	O
-	O
old	O
man	O
living	O
in	O
Pyeongtaek	O
presented	O
on	O
June	O
16	O
with	O
a	O
febrile	B-PROC
sensation	B-PROC
,	O
chills	O
,	O
and	O
myalgia	O
.	O

We	O
suggest	O
that	O
governmental	O
authorities	O
in	O
Korea	O
enforce	O
preventive	O
policies	O
,	O
foster	O
the	O
development	B-PROC
of	O
highly	O
qualified	O
personnel	O
,	O
and	O
increase	O
investment	O
in	O
the	O
public	O
health	O
domain	O
of	O
infectious	O
disease	O
prevention	O
.	O

We	O
queried	O
PubMed	O
(	O
R	O
),	O
for	O
citations	O
to	O
the	O
following	O
:	O
MRSA	O
,	O
HIV	O
/	O
AIDS	O
,	O
Staphylococcus	O
aureus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
Lyme	O
disease	O
,	O
avian	O
influenza	O
,	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
Chikungunya	O
,	O
Ebola	O
virus	O
and	O
Middle	O
Eastern	O
respiratory	O
syndrome	O
.	O

Primary	O
repair	B-PROC
was	O
performed	O
in	O
36	O
patients	O
(	O
51	O
.	O
4	O
%),	O
while	O
damage	O
control	O
with	O
perihepatic	O
packing	O
was	O
done	O
in	O
34	O
(	O
48	O
.	O
6	O
%).	O

The	O
nucleotides	O
sequences	O
of	O
non	O
-	O
structural	O
protein	O
(	O
NSP	O
)	O
2	O
,	O
NSP4	O
-	O
7	O
,	O
NSP10	O
,	O
NSP12	O
and	O
NSP13	O
genes	O
did	O
not	O
change	O
during	O
the	O
Vero	O
cell	O
adaptation	B-PROC
process	O
.	O

The	O
development	B-PROC
of	O
a	O
human	O
HeV	O
vaccine	O
is	O
essential	O
for	O
the	O
biosecurity	O
of	O
Australia	O
,	O
as	O
part	O
of	O
a	O
multipronged	O
strategy	O
to	O
control	O
HeV	O
in	O
Australia	O
.	O

TITLE	O
:	O
Respiratory	O
syncytial	O
virus	B-PROC
infection	I-PROC
in	O
infants	O
with	O
acute	O
leukemia	O
:	O
a	O
retrospective	O
survey	O
of	O
the	O
Japanese	O
Pediatric	O
Leukemia	O
/	O
Lymphoma	O
Study	O
Group	O
.	O

In	O
this	O
paper	O
,	O
we	O
also	O
report	O
the	O
results	O
of	O
the	O
preparation	O
of	O
newly	O
targeted	B-PROC
TAZ	O
derivatives	O
and	O
the	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
these	O
trialkoxy	O
-	O
substituted	O
TAZ	O
derivatives	O
and	O
related	O
compounds	O
.	O

One	O
single	O
-	O
nucleotide	O
polymorphism	B-PROC
from	O
IL4	O
gene	O
was	O
significant	O
for	O
pooled	O
respiratory	O
infections	O
(	O
rs2070874	O
;	O
1	O
.	O
66	O
[	O
1	O
.	O
29	O
-	O
2	O
.	O
14	O
]).	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
demonstrate	O
non	O
-	O
invasive	O
detection	O
of	O
lung	O
inflammation	O
using	O
integrin	O
receptor	O
targeted	B-PROC
fluorescence	O
liposomes	O
.	O

We	O
categorized	O
81	O
eligible	O
patients	O
into	O
bacterial	O
infection	O
,	O
viral	B-PROC
infection	I-PROC
,	O
coinfection	O
,	O
and	O
non	O
-	O
infectious	O
groups	O
.	O

Thus	O
far	O
,	O
only	O
the	O
α	O
-	O
amylase	O
inhibition	B-PROC
activity	O
has	O
been	O
described	O
for	O
members	O
of	O
this	O
family	O
.	O

Here	O
,	O
we	O
show	O
that	O
cystine	O
knot	O
α	O
-	O
amylase	B-PROC
inhibitors	I-PROC
named	O
alstotides	O
discovered	O
from	O
the	O
Alstonia	O
scholaris	O
plant	O
of	O
the	O
Apocynaceae	O
family	O
display	O
antiviral	O
activity	O
.	O

Taken	O
together	O
,	O
our	O
results	O
expand	O
membership	O
of	O
cystine	O
knot	O
α	O
-	O
amylase	B-PROC
inhibitors	I-PROC
in	O
the	O
Apocynaceae	O
family	O
and	O
their	O
bioactivity	O
,	O
functional	O
promiscuity	O
that	O
could	O
be	O
exploited	O
as	O
leads	O
in	O
developing	O
therapeutics	O
.	O

ABSTRACT	O
:	O
The	O
evolution	B-PROC
of	O
the	O
techniques	O
used	O
in	O
the	O
intensive	O
care	O
setting	O
over	O
the	O
past	O
decades	O
has	O
led	O
on	O
one	O
side	O
to	O
better	O
survival	O
rates	O
in	O
patients	O
with	O
acute	O
conditions	O
and	O
severely	O
impaired	O
vital	O
functions	O
.	O

The	O
envelope	O
spike	O
glycoprotein	O
on	O
the	O
surface	O
of	O
MERS	O
-	O
CoV	O
which	O
mediates	O
receptor	O
binding	O
,	O
membrane	B-PROC
fusion	I-PROC
and	O
viral	O
entry	O
is	O
thought	O
to	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
MERS	O
-	O
CoV	O
.	O
No	O
specific	O
and	O
effective	O
treatment	O
for	O
MERS	O
-	O
CoV	O
is	O
currently	O
recommended	O
,	O
although	O
supportive	O
treatment	O
has	O
played	O
an	O
important	O
role	O
.	O

TITLE	O
:	O
Human	O
Coronavirus	O
229E	O
Remains	O
Infectious	O
on	O
Common	O
Touch	B-PROC
Surface	O
Materials	O
.	O

Without	O
these	O
diagnostic	O
tools	O
,	O
the	O
geographical	O
spread	O
of	O
new	O
infections	O
,	O
follow	O
-	O
up	O
of	O
the	O
disease	O
outbreak	O
and	O
analysis	O
of	O
the	O
pathogenesis	B-PROC
of	O
the	O
disease	O
are	O
not	O
possible	O
.	O

Because	O
diffusion	O
-	O
weighted	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
findings	O
demonstrated	O
right	O
optic	O
neuritis	O
and	O
ventriculitis	O
,	O
enucleation	B-PROC
of	O
her	O
right	O
eye	O
was	O
performed	O
based	O
on	O
the	O
diagnosis	O
of	O
pyogenic	O
ventriculitis	O
via	O
the	O
optic	O
nerve	O
.	O

TITLE	O
:	O
Intra	O
-	O
abdominal	O
hypertension	O
complicating	O
pancreatitis	O
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
three	O
patients	O
on	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

In	O
some	O
of	O
these	O
patients	O
,	O
conventional	O
methods	O
of	O
ventilation	O
and	O
respiratory	O
support	O
will	O
fail	O
,	O
demanding	O
the	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O

A	O
microglial	O
response	O
was	O
present	O
only	O
in	O
severe	O
lesions	O
,	O
and	O
RCA	O
-	O
I	O
expression	B-PROC
was	O
detected	O
primarily	O
in	O
gitter	O
cells	O
and	O
resting	O
microglia	O
.	O

Delayed	O
antibody	B-PROC
responses	I-PROC
with	O
the	O
neutralization	O
test	O
were	O
associated	O
with	O
more	O
severe	O
disease	O
.	O

Sepsis	O
patients	O
with	O
multiorgan	O
dysfunction	O
syndrome	O
and	O
/	O
or	O
shock	O
(	O
original	O
study	O
)	O
were	O
regrouped	O
based	O
on	O
the	O
presence	O
or	O
the	O
absence	O
of	O
concurrent	O
hepatobiliary	O
dysfunction	O
and	O
disseminated	O
intravascular	O
coagulation	B-PROC
as	O
features	O
of	O
macrophage	B-PROC
activation	I-PROC
syndrome	O
.	O

This	O
protocol	O
is	O
optimised	O
for	O
transfection	B-PROC
in	O
a	O
100	O
mm	O
Petri	O
dish	O
with	O
7	O
ml	O
of	O
supernatant	O
harvested	O
,	O
however	O
it	O
can	O
be	O
readily	O
scaled	O
to	O
different	O
production	O
volumes	O
.	O

Patients	O
admitted	O
to	O
five	O
acute	O
care	O
hospitals	O
that	O
met	O
the	O
SARI	O
case	O
definition	O
(	O
temperature	O
≥	O
37	O
·	O
8	O
°	O
C	O
or	O
reported	O
fever	B-PROC
or	O
chills	O
with	O
history	O
of	O
cough	O
,	O
sore	O
throat	O
,	O
or	O
shortness	O
of	O
breath	O
in	O
a	O
hospitalized	O
person	O
)	O
were	O
enrolled	O
.	O

Staff	O
completed	O
a	O
standard	O
form	O
and	O
collected	O
a	O
nasopharyngeal	O
swab	O
which	O
was	O
tested	O
for	O
selected	O
respiratory	O
viruses	O
by	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
.	O

The	O
air	O
emitted	O
by	O
15	O
participants	O
with	O
laboratory	O
-	O
confirmed	O
influenza	O
virus	B-PROC
infection	I-PROC
was	O
sampled	O
.	O

It	O
is	O
especially	O
important	O
for	O
the	O
development	B-PROC
of	O
lightweight	O
,	O
point	O
-	O
of	O
-	O
care	O
devices	O
for	O
use	O
in	O
both	O
developing	O
and	O
developed	O
countries	O
.	O

TITLE	O
:	O
X	O
-	O
ray	O
structure	O
and	O
inhibition	B-PROC
of	O
the	O
feline	O
infectious	O
peritonitis	O
virus	O
3C	O
-	O
like	O
protease	O
:	O
Structural	O
implications	O
for	O
drug	O
design	O
.	O

However	O
,	O
clinically	O
relevant	O
trends	O
toward	O
worsened	O
oxygenation	B-PROC
over	O
postburn	O
days	O
0	O
to	O
3	O
,	O
longer	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
and	O
reduced	O
ventilator	O
-	O
free	O
days	O
in	O
association	O
with	O
more	O
severe	O
INH	O
were	O
identified	O
when	O
subjects	O
were	O
broadly	O
stratified	O
into	O
low	O
-	O
grade	O
(	O
grades	O
1and	O
2	O
)	O
INH	O
and	O
high	O
-	O
grade	O
(	O
grades	O
3	O
and	O
4	O
)	O
INH	O
.	O

Serial	O
magnetic	O
resonance	O
imaging	O
studies	O
,	O
done	O
from	O
the	O
initial	O
presentation	O
through	O
18	O
months	O
of	O
follow	O
-	O
up	O
,	O
showed	O
evolution	B-PROC
from	O
normal	O
imaging	O
to	O
severe	O
cerebral	O
atrophy	O
.	O

Febrile	B-PROC
infection	O
-	O
related	O
epilepsy	O
syndrome	O
is	O
a	O
devastating	O
epilepsy	O
syndrome	O
of	O
childhood	O
without	O
a	O
diagnostic	O
biologic	O
marker	O
.	O

Multivariate	O
analysis	O
was	O
performed	O
to	O
identify	O
factors	O
associated	O
with	O
ARDS	O
and	O
death	B-PROC
.	O

These	O
data	O
confirm	O
the	O
persistent	O
virulence	B-PROC
of	O
A	O
(	O
H1N1	O
)	O
pdm09	O
after	O
the	O
pandemic	O
and	O
the	O
heterogeneity	O
of	O
influenza	O
seasons	O
,	O
and	O
reinforce	O
the	O
need	O
for	O
surveillance	O
of	O
severe	O
influenza	O
cases	O
.	O

This	O
study	O
investigated	O
the	O
incidence	O
and	O
cause	O
of	O
pulmonary	O
edema	O
in	O
patients	O
with	O
SAH	O
by	O
using	O
hemodynamic	B-PROC
monitoring	O
with	O
PiCCO	O
-	O
plus	O
pulse	B-PROC
contour	O
analysis	O
.	O

In	O
the	O
early	O
phase	O
(	O
Days	O
1	O
-	O
5	O
after	O
SAH	O
),	O
the	O
daily	O
water	B-PROC
balance	I-PROC
of	O
the	O
PE	O
group	O
was	O
slightly	O
positive	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
after	O
2	O
days	O
of	O
initial	O
PBMC	O
/	O
EPO	O
application	O
,	O
lung	B-PROC
function	I-PROC
improved	O
and	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
support	O
was	O
reduced	O
.	O

Despite	O
improving	O
respiratory	B-PROC
function	I-PROC
,	O
the	O
patient	O
died	B-PROC
of	O
multisystem	O
organ	O
failure	O
on	O
day	O
38	O
of	O
ECMO	O
treatment	O
.	O

Imatinib	O
also	O
attenuated	O
systemic	O
cytokine	O
expression	B-PROC
after	O
intravenous	O
LPS	O
exposure	O
.	O

ABSTRACT	O
:	O
Influenza	O
virus	O
(	O
IFV	O
)	O
infection	O
is	O
a	O
common	O
cause	O
of	O
severe	O
viral	O
pneumonia	O
associated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
which	O
is	O
difficult	O
to	O
control	O
with	O
general	O
immunosuppressive	O
therapy	O
including	O
corticosteroids	O
due	O
to	O
the	O
unfavorable	O
effect	O
on	O
viral	B-PROC
replication	I-PROC
.	O

Syk	O
or	O
CARD9	O
-	O
deficient	O
DCs	O
but	O
not	O
macrophages	O
showed	O
impaired	O
cytokine	O
but	O
not	O
type	O
-	O
I	O
interferon	B-PROC
production	I-PROC
in	O
response	O
to	O
IFV	O
in	O
vitro	O
,	O
indicating	O
a	O
possible	O
role	O
for	O
the	O
Syk	O
-	O
CARD9	O
pathway	B-PROC
in	O
DCs	O
in	O
excessive	O
inflammation	O
of	O
IFV	O
-	O
infected	O
lungs	O
.	O

ABSTRACT	O
:	O
Development	B-PROC
an	O
effective	O
vaccine	O
against	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
urgent	O
and	O
limited	O
information	O
is	O
available	O
on	O
vaccination	O
in	O
nonhuman	O
primate	O
(	O
NHP	O
)	O
model	O
.	O

Robust	O
and	O
sustained	O
immunological	O
responses	O
(	O
including	O
neutralisation	O
antibody	B-PROC
)	O
were	O
elicited	O
by	O
the	O
rRBD	O
vaccination	O
.	O

These	O
data	O
in	O
NHP	O
paves	O
a	O
way	O
for	O
further	O
development	B-PROC
of	O
an	O
effective	O
human	O
vaccine	O
against	O
MERS	O
-	O
CoV	O
infection	O
.	O

The	O
existing	O
IBVs	O
continue	O
to	O
evolve	O
in	O
various	O
geographic	O
areas	O
in	O
Asia	O
,	O
which	O
results	O
in	O
the	O
recombination	B-PROC
and	O
co	O
-	O
circulation	B-PROC
between	O
IBV	O
types	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
MERS	O
-	O
CoV	O
ORF4b	O
antagonizes	O
the	O
early	O
antiviral	O
alpha	O
/	O
beta	O
interferon	O
(	O
IFN	O
-	O
α	O
/	O
β	O
)	O
response	O
,	O
which	O
may	O
significantly	O
contribute	O
to	O
MERS	O
-	O
CoV	O
pathogenesis	B-PROC
;	O
however	O
,	O
the	O
underlying	O
mechanism	O
is	O
poorly	O
understood	O
.	O

Topics	O
addressed	O
include	O
;	O
transformation	B-PROC
and	O
expression	B-PROC
systems	O
,	O
plant	O
bioreactors	O
,	O
safety	O
concerns	O
,	O
and	O
various	O
opportunities	O
to	O
produce	O
topical	O
applications	O
and	O
health	O
supplements	O
.	O

However	O
,	O
available	O
ECMO	O
systems	O
are	O
large	O
and	O
not	O
well	O
designed	O
for	O
fast	O
delivery	O
,	O
emergency	O
implantation	B-PROC
,	O
and	O
interhospital	O
transfer	O
.	O

The	O
B	O
-	O
and	O
T	O
-	O
cell	O
stimulation	O
potentials	O
of	O
the	O
screened	O
epitopes	O
is	O
to	O
be	O
further	O
validated	O
for	O
their	O
efficient	O
use	O
as	O
vaccines	O
against	O
MERS	O
-	O
CoV	O
.	O
Collectively	O
,	O
this	O
study	O
provides	O
novel	O
vaccine	O
target	O
candidates	O
and	O
may	O
prompt	O
further	O
development	B-PROC
of	O
vaccines	O
against	O
MERS	O
-	O
CoV	O
and	O
other	O
emerging	O
infectious	O
diseases	O
.	O

Within	O
one	O
week	O
,	O
the	O
patient	O
was	O
weaned	B-PROC
from	O
both	O
ECCO2R	O
and	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
is	O
a	O
rescue	O
therapy	O
for	O
patients	O
with	O
severe	O
lung	O
failure	O
.	O

Therefore	O
hemostasis	B-PROC
,	O
anticoagulation	B-PROC
,	O
hemolysis	B-PROC
,	O
and	O
inflammatory	O
parameters	O
were	O
monitored	O
.	O

During	O
the	O
first	O
5	O
days	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
therapy	O
,	O
prothrombin	O
fragment	O
1	O
.	O
2	O
(	O
F1	O
.	O
2	O
)	O
(	O
1	O
.	O
36	O
-	O
2	O
.	O
4	O
µM	O
),	O
thrombin	O
-	O
antithrombin	O
complex	O
(	O
14	O
.	O
5	O
-	O
50	O
µg	O
/	O
L	O
),	O
and	O
D	O
-	O
dimers	O
(	O
6	O
.	O
00	O
-	O
27	O
.	O
0	O
mg	O
/	O
L	O
)	O
increased	O
,	O
whereas	O
fibrinogen	O
values	O
dropped	O
from	O
5	O
.	O
8	O
to	O
4	O
.	O
1	O
g	O
/	O
L	O
.	O
The	O
three	O
different	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
systems	O
did	O
not	O
show	O
any	O
differences	O
with	O
regard	O
to	O
hemostasis	B-PROC
,	O
anticoagulation	B-PROC
,	O
hemolysis	B-PROC
,	O
and	O
inflammatory	O
parameters	O
within	O
the	O
first	O
5	O
days	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
therapy	O
.	O

Here	O
,	O
we	O
show	O
that	O
PEDV	O
-	O
encoded	O
3C	O
-	O
like	O
protease	O
,	O
nsp5	O
,	O
is	O
an	O
IFN	O
antagonist	B-PROC
that	O
proteolytically	O
cleaves	O
the	O
nuclear	O
transcription	B-PROC
factor	O
kappa	O
B	O
(	O
NF	O
-	O
κB	O
)	O
essential	O
modulator	O
(	O
NEMO	O
),	O
an	O
essential	O
adaptor	O
bridging	O
interferon	O
-	O
regulatory	O
factor	O
and	O
NF	O
-	O
κB	O
activation	O
.	O

Structural	O
analysis	O
suggests	O
that	O
several	O
key	O
residues	O
outside	O
the	O
catalytic	O
sites	O
of	O
PEDV	O
nsp5	O
probably	O
impact	O
NEMO	O
cleavage	B-PROC
by	O
modulating	O
potential	O
interactions	O
of	O
nsp5	O
with	O
their	O
substrates	O
.	O

The	O
continued	O
emergence	O
and	O
reemergence	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
underscore	O
the	O
importance	O
of	O
studying	O
how	O
this	O
virus	O
manipulates	O
the	O
immune	B-PROC
responses	I-PROC
of	O
its	O
hosts	O
.	O

The	O
clinical	O
effects	O
of	O
inhaling	B-PROC
powder	O
depend	O
on	O
the	O
powder	O
contents	O
,	O
degree	O
of	O
aspiration	O
,	O
and	O
the	O
child	O
'	O
s	O
underlying	O
systemic	O
response	O
.	O

ABSTRACT	O
:	O
Angiopoietin	O
-	O
2	O
(	O
Ang	O
-	O
2	O
)	O
is	O
a	O
key	O
mediator	O
of	O
pulmonary	O
vascular	B-PROC
permeability	I-PROC
.	O

For	O
a	O
fixed	O
sequence	O
of	O
stepwise	O
increases	O
in	O
the	O
respiratory	O
rate	O
,	O
corresponding	O
decreases	O
in	O
tidal	O
volume	O
to	O
keep	O
the	O
alveolar	O
minute	O
ventilation	O
and	O
inspiratory	B-PROC
flow	O
constant	O
were	O
calculated	O
according	O
to	O
standard	O
formulae	O
.	O

TITLE	O
:	O
Venovenous	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
for	O
Negative	O
Pressure	O
Pulmonary	O
Hemorrhage	O
in	O
an	O
Elderly	O
Patient	O
.	O

The	O
report	O
highlights	O
the	O
importance	O
of	O
early	O
diagnosis	O
and	O
aggressive	B-PROC
therapy	O
in	O
the	O
management	O
of	O
ARDS	O
,	O
and	O
summarizes	O
the	O
published	O
literature	O
on	O
this	O
rarely	O
reported	O
complication	O
of	O
pediatric	O
DKA	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
humoral	O
immune	B-PROC
status	I-PROC
in	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
infected	O
sows	O
under	O
field	O
conditions	O
.	O

Comprehensive	O
information	O
on	O
the	O
levels	O
and	O
duration	O
of	O
effector	O
/	O
memory	B-PROC
IgA	O
and	O
IgG	O
antibody	B-PROC
secreting	B-PROC
B	O
cell	O
response	O
in	O
the	O
intestines	O
and	O
lymphoid	O
organs	O
of	O
PEDV	O
-	O
infected	O
sows	O
,	O
and	O
their	O
association	O
with	O
specific	O
antibody	B-PROC
levels	O
in	O
clinical	O
samples	O
such	O
as	O
plasma	O
,	O
oral	O
fluid	O
,	O
and	O
feces	O
is	O
important	O
.	O

Paricalcitol	O
treatment	O
partially	O
inhibited	O
these	O
pathological	O
changes	O
in	O
WT	O
mice	O
by	O
maintaining	O
the	O
mRNA	O
and	O
protein	B-PROC
expression	B-PROC
levels	O
of	O
occludin	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
ZO	O
‑	O
1	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
addition	O
,	O
results	O
show	O
that	O
MHV	O
infection	O
impairs	O
Cx43	O
expression	B-PROC
in	O
addition	O
to	O
gap	O
junction	O
communication	O
in	O
primary	O
astrocytes	O
.	O

Here	O
we	O
show	O
that	O
a	O
modified	O
vaccinia	O
virus	O
Ankara	O
(	O
MVA	O
)	O
vaccine	O
expressing	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
confers	O
mucosal	B-PROC
immunity	I-PROC
in	O
dromedary	O
camels	O
.	O

TITLE	O
:	O
(+)-	O
Catechin	O
inhibition	B-PROC
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
in	O
swine	O
testicular	O
cells	O
is	O
involved	O
its	O
antioxidation	O
.	O

TITLE	O
:	O
Biodegradable	O
DNA	O
Nanoparticles	O
that	O
Provide	O
Widespread	O
Gene	B-PROC
Delivery	I-PROC
in	O
the	O
Brain	O
.	O

More	O
information	O
about	O
the	O
virus	O
and	O
the	O
disease	O
is	O
still	O
necessary	O
for	O
the	O
development	B-PROC
of	O
effective	O
vaccines	O
and	O
control	O
strategies	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
:	O
virus	O
-	O
host	O
cell	B-PROC
interactions	I-PROC
and	O
implications	O
on	O
pathogenesis	B-PROC
.	O

Currently	O
,	O
the	O
pathogenesis	B-PROC
of	O
human	O
MERS	O
-	O
CoV	O
infection	O
remains	O
poorly	O
understood	O
.	O

Human	O
respiratory	O
epithelial	O
cells	O
are	O
highly	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
and	O
can	O
support	O
productive	O
viral	B-PROC
replication	I-PROC
.	O

This	O
epidemic	O
had	O
caused	O
185	O
laboratory	O
-	O
confirmed	O
cases	O
and	O
36	O
deaths	B-PROC
in	O
the	O
Republic	O
of	O
Korea	O
until	O
September	O
2	O
,	O
2015	O
,	O
which	O
attracted	O
public	O
'	O
s	O
attention	O
.	O

ABSTRACT	O
:	O
WU	O
polyomavirus	O
(	O
WUPyV	O
)	O
was	O
detected	O
in	O
a	O
bone	O
marrow	O
transplant	O
recipient	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
who	O
died	B-PROC
in	O
2001	O
.	O

TITLE	O
:	O
Glucose	O
-	O
6	O
-	O
Phosphate	O
Dehydrogenase	O
Enhances	O
Antiviral	B-PROC
Response	I-PROC
through	O
Downregulation	B-PROC
of	O
NADPH	O
Sensor	O
HSCARG	O
and	O
Upregulation	B-PROC
of	O
NF	O
-	O
κB	O
Signaling	B-PROC
.	O

Molecular	O
analysis	O
revealed	O
that	O
the	O
promoter	O
activities	O
of	O
TNF	O
-	O
α	O
and	O
MX1	O
were	O
downregulated	O
in	O
G6PD	O
-	O
knockdown	O
cells	O
,	O
and	O
that	O
the	O
IκB	O
degradation	O
and	O
DNA	O
binding	B-PROC
activity	I-PROC
of	O
NF	O
-	O
κB	O
were	O
decreased	O
.	O

In	O
humans	O
,	O
MERS	O
is	O
mostly	O
known	O
as	O
a	O
lower	O
respiratory	O
tract	O
(	O
LRT	O
)	O
disease	O
involving	O
fever	B-PROC
,	O
cough	O
,	O
breathing	B-PROC
difficulties	O
and	O
pneumonia	O
that	O
may	O
progress	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
multiorgan	O
failure	O
and	O
death	B-PROC
in	O
20	O
%	O
to	O
40	O
%	O
of	O
those	O
infected	O
.	O

TITLE	O
:	O
Detection	O
of	O
feline	O
coronavirus	O
spike	O
gene	B-PROC
mutations	I-PROC
as	O
a	O
tool	O
to	O
diagnose	O
feline	O
infectious	O
peritonitis	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
lung	B-PROC
function	I-PROC
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
10	O
years	O
after	O
recovery	O
and	O
the	O
influencing	O
factors	O
.	O

Twenty	O
-	O
five	O
percent	O
of	O
patients	O
were	O
treated	O
with	O
neuromuscular	B-PROC
blockade	I-PROC
,	O
10	O
.	O
1	O
%	O
received	O
inhaled	B-PROC
pulmonary	O
vasodilators	O
,	O
and	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
was	O
initiated	O
in	O
2	O
.	O
6	O
%.	O

TITLE	O
:	O
Blockade	O
of	O
Interleukin	O
-	O
17	O
Restrains	O
the	O
Development	B-PROC
of	O
Acute	O
Lung	O
Injury	O
.	O

Here	O
,	O
we	O
explored	O
the	O
association	O
between	O
IL	B-PROC
-	I-PROC
17	I-PROC
and	O
development	B-PROC
of	O
ALI	O
using	O
LPS	O
-	O
induced	O
murine	O
model	O
.	O

Of	O
the	O
scenarios	O
,	O
flexible	O
intermediate	O
bulk	O
containers	O
"("""	O
feed	O
totes	O
""")"	O
used	O
to	O
transport	B-PROC
bulk	O
feed	O
serving	O
as	O
fomites	O
for	O
movement	B-PROC
of	O
PED	O
virus	O
provided	O
the	O
simplest	O
explanation	O
for	O
the	O
accumulated	O
findings	O
of	O
the	O
investigation	O
.	O

We	O
conducted	O
a	O
retrospective	O
analysis	O
of	O
the	O
serum	O
creatinine	O
(	O
SCr	O
),	O
estimated	O
glomerular	B-PROC
filtration	I-PROC
rate	O
(	O
eGFR	O
),	O
urine	O
dipstick	O
tests	O
,	O
urinary	O
protein	O
quantitation	O
(	O
ACR	O
or	O
PCR	O
),	O
and	O
other	O
clinical	O
parameters	O
in	O
all	O
patients	O
.	O

RESULTS	O
:	O
Between	O
May	O
20	O
and	O
July	O
13	O
,	O
2015	O
,	O
a	O
total	O
of	O
186	O
confirmed	O
MERS	O
cases	O
(	O
1	O
index	O
case	O
,	O
29	O
secondary	O
cases	O
,	O
125	O
third	O
generation	O
cases	O
,	O
25	O
fourth	O
generation	O
cases	O
and	O
6	O
cases	O
without	O
clear	O
generation	O
data	O
),	O
including	O
36	O
deaths	B-PROC
(	O
case	O
fatality	O
rate	O
:	O
19	O
%),	O
were	O
reported	O
in	O
Korea	O
.	O

TITLE	O
:	O
Prolonged	O
Venovenous	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
in	O
a	O
Patient	O
With	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

All	O
children	O
(	O
0	O
-	O
12	O
y	O
of	O
age	O
)	O
diagnosed	O
and	O
confirmed	O
as	O
dengue	O
fever	B-PROC
at	O
a	O
tertiary	O
care	O
hospital	O
at	O
Puducherry	O
,	O
between	O
the	O
1st	O
of	O
August	O
2012	O
and	O
January	O
31st	O
2015	O
were	O
reviewed	O
retrospectively	O
from	O
hospital	O
case	O
records	O
as	O
per	O
the	O
revised	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
guidelines	O
2011	O
for	O
dengue	O
fever	B-PROC
.	O

Although	O
these	O
four	O
strains	O
remained	O
monophyletic	O
in	O
the	O
entire	O
protein	O
-	O
coding	O
region	O
,	O
this	O
clade	O
showed	O
different	O
phylogenetic	O
relationships	O
across	O
the	O
genome	O
,	O
indicating	O
a	O
shared	O
unique	O
recombination	B-PROC
pattern	O
that	O
is	O
different	O
from	O
previously	O
reported	O
putative	O
recombination	B-PROC
strains	O
.	O

To	O
study	O
the	O
genetic	O
factors	O
that	O
regulate	O
pathogenesis	B-PROC
and	O
transmission	O
,	O
we	O
developed	O
a	O
molecular	O
clone	O
of	O
PEDV	O
strain	O
PC22A	O
.	O

Together	O
,	O
these	O
data	O
describe	O
the	O
development	B-PROC
of	O
a	O
robust	O
reverse	O
-	O
genetics	O
platform	O
for	O
identifying	O
genetic	O
factors	O
that	O
regulate	O
pathogenic	O
outcomes	O
and	O
transmission	O
efficiency	O
in	O
vivo	O
,	O
providing	O
key	O
infrastructural	O
developments	O
for	O
developing	O
and	O
evaluating	O
the	O
efficacy	O
of	O
live	O
attenuated	O
vaccines	O
and	O
therapeutics	O
in	O
a	O
clinical	O
setting	O
.	O

TITLE	O
:	O
Activation	O
of	O
RNase	O
L	O
by	O
Murine	O
Coronavirus	O
in	O
Myeloid	O
Cells	O
Is	O
Dependent	O
on	O
Basal	O
Oas	O
Gene	B-PROC
Expression	I-PROC
and	O
Independent	O
of	O
Virus	O
-	O
Induced	O
Interferon	O
.	O

However	O
,	O
ns2	O
(	O
H126R	O
)	O
failed	O
to	O
induce	O
RNase	O
L	O
activation	O
in	O
BMM	O
treated	O
with	O
IFNAR1	O
-	O
blocking	O
antibody	B-PROC
,	O
as	O
well	O
as	O
in	O
Ifnar1	O
(-/-)	O
BMM	O
,	O
both	O
expressing	O
low	O
basal	O
levels	O
of	O
Oas	O
genes	O
.	O

These	O
findings	O
challenge	O
the	O
notion	O
that	O
activation	O
of	O
the	O
OAS	O
-	O
RNase	O
L	O
pathway	B-PROC
requires	O
virus	O
to	O
induce	O
type	O
I	O
IFN	O
,	O
which	O
in	O
turn	O
upregulates	O
OAS	O
gene	B-PROC
expression	I-PROC
,	O
as	O
well	O
as	O
to	O
provide	O
dsRNA	O
to	O
activate	O
OAS	O
.	O

The	O
Mass2	O
+	O
793B2	O
group	O
showed	O
the	O
worst	O
clinical	O
signs	O
,	O
higher	O
mortality	O
and	O
severe	O
lesions	O
following	O
vaccination	O
,	O
but	O
had	O
the	O
highest	O
tracheal	O
immune	B-PROC
responses	I-PROC
and	O
demonstrated	O
the	O
best	O
protection	O
against	O
all	O
three	O
challenge	O
viruses	O
.	O

Respiratory	O
variables	O
,	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
volume	O
(	O
EELV	O
)	O
and	O
gas	O
exchange	O
were	O
assessed	O
during	O
mechanical	O
ventilation	O
.	O

Anticoagulation	B-PROC
is	O
a	O
major	O
concern	O
with	O
ECMO	O
,	O
and	O
the	O
evidence	O
is	O
evolving	O
with	O
respect	O
to	O
diagnostic	O
testing	O
and	O
use	O
of	O
anticoagulants	O
.	O

ABSTRACT	O
:	O
Prior	O
studies	O
have	O
demonstrated	O
that	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
A59	O
strain	O
ns2	O
protein	O
is	O
a	O
member	O
of	O
the	O
2H	O
phosphoesterase	O
family	O
and	O
exhibits	O
2	O
',	O
5	O
'-	O
phosphodiesterase	B-PROC
(	O
PDE	O
)	O
activity	O
.	O

ABSTRACT	O
:	O
The	O
truncated	O
spike	O
protein	O
(	O
S1	O
,	O
390	O
-	O
789aa	O
)	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
was	O
expressed	B-PROC
as	O
a	O
recombinant	O
protein	O
in	O
Baculorvirus	O
expression	B-PROC
system	O
.	O

TITLE	O
:	O
Inducible	O
Expression	B-PROC
of	O
CXCL1	O
within	O
the	O
Central	O
Nervous	O
System	O
Amplifies	O
Viral	O
-	O
Induced	O
Demyelination	O
.	O

Sustained	O
CXCL1	O
expression	B-PROC
within	O
the	O
CNS	O
resulted	O
in	O
increased	O
mortality	O
that	O
correlated	O
with	O
elevated	O
neutrophil	O
infiltration	O
,	O
diminished	O
numbers	O
of	O
mature	O
oligodendrocytes	O
,	O
and	O
an	O
increase	O
in	O
the	O
severity	O
of	O
demyelination	O
.	O

A	O
further	O
study	O
showed	O
that	O
the	O
CBP	O
degradation	O
by	O
nsp1	O
was	O
proteasome	B-PROC
-	O
dependent	O
.	O

In	O
recent	O
years	O
,	O
microRNAs	O
(	O
miRNAs	O
),	O
small	O
non	O
-	O
coding	O
molecules	O
have	O
emerged	O
as	O
a	O
major	O
area	O
of	O
biomedical	O
research	O
as	O
they	O
post	O
-	O
transcriptionally	O
regulate	O
gene	B-PROC
expression	I-PROC
in	O
diverse	O
biological	O
and	O
pathological	O
processes	O
,	O
including	O
ALI	O
/	O
ARDS	O
.	O

This	O
clearly	O
highlights	O
the	O
potential	O
for	O
coronavirus	O
host	O
shifting	O
and	O
the	O
relevance	O
of	O
understanding	O
the	O
molecular	O
events	O
underlying	O
the	O
adaptation	B-PROC
to	O
new	O
host	O
species	O
.	O

During	O
coronavirus	O
encephalomyelitis	O
CXCL13	O
deficiency	O
impaired	O
CNS	O
accumulation	O
of	O
memory	B-PROC
B	O
cells	O
and	O
antibody	B-PROC
-	O
secreting	B-PROC
cells	O
(	O
ASC	O
)	O
but	O
not	O
naïve	O
/	O
early	O
-	O
activated	O
B	O
cells	O
.	O

ABSTRACT	O
:	O
Viral	B-PROC
infections	I-PROC
have	O
been	O
implicated	O
as	O
the	O
cause	O
of	O
cardiomyopathy	O
in	O
several	O
mammalian	O
species	O
.	O

Mutagenesis	B-PROC
studies	O
showed	O
that	O
RT	O
RNase	O
H	O
domain	O
residues	O
Asn474	O
and	O
Tyr501	O
,	O
and	O
in	O
a	O
lesser	O
extent	O
Ala502	O
and	O
Ala508	O
,	O
are	O
critical	O
for	O
RMNC6	O
inhibition	B-PROC
of	O
the	O
endonuclease	O
activity	O
of	O
the	O
RT	O
,	O
without	O
affecting	O
its	O
DNA	O
polymerization	O
activity	O
.	O

None	O
of	O
the	O
patients	O
with	O
moderately	O
severe	O
AP	O
died	B-PROC
during	O
their	O
intensive	O
care	O
unit	O
stay	O
vs	O
.	O
29	O
.	O
5	O
%	O
with	O
severe	O
AP	O
(	O
p	O
=	O
0	O
.	O
049	O
).	O

Besides	O
,	O
4a	O
condensed	B-PROC
with	O
succinic	O
anhydride	O
and	O
with	O
phthalic	O
anhydride	O
,	O
yielding	O
the	O
pyrrolidine	O
-	O
2	O
,	O
5	O
-	O
dione	O
12	O
and	O
the	O
isoindoline	O
-	O
1	O
,	O
3	O
-	O
dione	O
13	O
,	O
respectively	O
.	O

Patients	O
were	O
classified	O
into	O
2	O
groups	O
(	O
responders	O
/	O
non	O
responders	O
)	O
according	O
their	O
oxygenation	B-PROC
response	O
to	O
PP	O
.	O

At	O
12	O
months	O
following	O
hematopoietic	O
stem	O
cell	O
transplantation	O
,	O
89	O
patients	O
(	O
66	O
.	O
9	O
%)	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
had	O
died	B-PROC
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
is	O
a	O
positive	O
-	O
sense	B-PROC
RNA	O
virus	O
that	O
causes	O
infectious	O
gastroenteritis	O
in	O
pigs	O
.	O

Compared	O
with	O
baseline	O
,	O
lung	B-PROC
compliance	I-PROC
(	O
CL	O
)	O
(	O
48	O
.	O
1	O
±	O
10	O
.	O
3	O
)	O
cmH2O	O
vs	O
(	O
25	O
.	O
7	O
±	O
6	O
.	O
4	O
)	O
cmH2O	O
and	O
oxygenation	B-PROC
index	O
(	O
PaO2	O
/	O
FiO2	O
)	O
(	O
235	O
±	O
48	O
)	O
mmHg	O
vs	O
(	O
160	O
±	O
35	O
)	O
mmHg	O
improved	O
obviously	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
dead	B-PROC
space	O
fraction	O
(	O
VD	O
/	O
VT	O
)	O
(	O
0	O
.	O
48	O
±	O
0	O
.	O
07	O
)	O
vs	O
(	O
0	O
.	O
59	O
±	O
0	O
.	O
06	O
)	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
but	O
Ccw	O
and	O
respiratory	O
compliance	O
(	O
Cr	O
)	O
didn	O
'	O
t	O
improve	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

Transpulmonary	O
pressure	O
-	O
directed	O
mechanical	O
ventilation	O
in	O
ARDS	O
secondary	O
to	O
severe	O
acute	O
pancreatitis	O
patient	O
with	O
intraabdominal	O
hypertension	O
could	O
not	O
only	O
recruit	O
the	O
collapsed	O
alveoli	O
,	O
improve	O
lung	B-PROC
compliance	I-PROC
,	O
increase	O
oxygenation	B-PROC
index	O
and	O
decrease	O
dead	B-PROC
space	O
ventilation	O
but	O
also	O
monitor	O
lung	O
stress	O
to	O
avoid	O
alveoli	O
overinflation	O
,	O
which	O
might	O
be	O
lung	O
protective	O
.	O

The	O
analysis	O
of	O
risk	O
factors	O
of	O
associative	O
pathology	O
development	B-PROC
,	O
roentgenographic	O
study	O
,	O
investigation	O
of	O
the	O
function	O
of	O
external	O
respiration	B-PROC
(	O
FER	O
)	O
(	O
peak	O
flowmetry	O
,	O
spirometry	O
),	O
intracavitary	O
pH	O
-	O
metry	O
,	O
esophagofibrogastroduodenoscopy	O
(	O
EFGDS	O
)	O
and	O
ultrasonic	O
investigation	O
(	O
USI	O
)	O
of	O
the	O
organs	O
of	O
the	O
gastro	O
-	O
intestinal	O
tract	O
(	O
GIT	O
)	O
were	O
carried	O
out	O
.	O

Functional	O
analysis	O
was	O
performed	O
using	O
Gene	O
Ontology	O
(	O
GO	O
)	O
Immune	B-PROC
System	I-PROC
Process	I-PROC
terms	O
specific	O
for	O
Gallus	O
gallus	O
.	O

RESULTS	O
:	O
Comparing	O
uninfected	O
L10H	O
and	O
L10L	O
birds	O
,	O
we	O
identified	O
1698	O
and	O
1424	O
differentially	O
expressed	B-PROC
(	O
DE	O
)	O
genes	O
at	O
weeks	O
1	O
and	O
3	O
,	O
respectively	O
.	O

TITLE	O
:	O
What	O
Is	O
the	O
Evidence	O
for	O
Harm	O
of	O
Neuromuscular	B-PROC
Blockade	I-PROC
and	O
Corticosteroid	O
Use	O
in	O
the	O
Intensive	O
Care	O
Unit	O
?	O

Neuromuscular	B-PROC
blockade	I-PROC
is	O
commonly	O
used	O
to	O
ease	O
tracheal	O
intubation	O
,	O
to	O
optimize	O
mechanical	O
ventilation	O
and	O
oxygenation	B-PROC
in	O
acute	O
respiratory	O
disorders	O
such	O
as	O
status	O
asthmaticus	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
to	O
prevent	O
shivering	O
during	O
therapeutic	O
hypothermia	O
,	O
and	O
also	O
in	O
patients	O
with	O
elevated	O
intracranial	B-PROC
pressure	I-PROC
.	O

ABSTRACT	O
:	O
A	O
total	O
of	O
1	O
,	O
320	O
tracheal	O
samples	O
from	O
66	O
broiler	O
flocks	O
sent	O
to	O
slaughterhouses	O
and	O
42	O
tracheal	O
samples	O
from	O
42	O
flocks	O
of	O
local	O
chickens	O
in	O
the	O
field	O
were	O
collected	O
for	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
gene	O
detection	O
by	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
using	O
nucleocapsid	O
-	O
specific	O
primers	O
and	O
spike	O
-	O
specific	O
primers	O
.	O

A	O
comprehensive	O
literature	O
search	O
was	O
obtained	O
from	O
MEDLINE	O
via	O
PubMed	O
.	O
gov	O
and	O
from	O
ScienceDirect	O
.	O
com	O
using	O
the	O
following	O
search	O
queries	O
:	O
ECLS	O
and	O
pregnancy	O
,	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	B-PROC
)	O
and	O
pregnancy	O
,	O
ECMO	B-PROC
and	O
H1N1	O
influenza	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
pregnancy	O
,	O
pregnancy	O
and	O
H1N1	O
influenza	O
,	O
and	O
Extracorporeal	O
Life	O
Support	O
Organization	O
registry	O
.	O

Evolution	B-PROC
analysis	O
showed	O
that	O
the	O
Kenyan	O
HCoV	O
-	O
OC43	O
and	O
HCoV	O
-	O
NL63	O
isolates	O
were	O
under	O
purifying	O
selection	O
.	O

TITLE	O
:	O
Small	O
interfering	O
RNA	B-PROC
expression	I-PROC
inhibits	O
avian	O
infectious	O
bronchitis	O
virus	B-PROC
replication	I-PROC
and	O
inflammatory	B-PROC
response	I-PROC
.	O

Inflammatory	B-PROC
responses	I-PROC
and	O
oxidative	O
damage	O
were	O
significantly	O
decreased	O
,	O
yielding	O
minimal	O
tissue	O
injury	O
.	O

We	O
measured	O
plasma	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
biomarkers	O
of	O
inflammation	O
and	O
lung	O
injury	O
in	O
smokers	O
and	O
non	O
-	O
smokers	O
in	O
two	O
distinct	O
cohorts	O
of	O
healthy	O
volunteers	O
,	O
one	O
unstimulated	O
(	O
n	O
=	O
20	O
)	O
and	O
one	O
undergoing	O
50	O
μg	O
LPS	O
inhalation	B-PROC
(	O
n	O
=	O
30	O
).	O

TITLE	O
:	O
Pathogenesis	B-PROC
comparison	O
between	O
the	O
United	O
States	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
prototype	O
and	O
S	O
-	O
INDEL	B-PROC
-	O
variant	O
strains	O
in	O
conventional	O
neonatal	O
piglets	O
.	O

ABSTRACT	O
:	O
At	O
least	O
two	O
genetically	O
different	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
strains	O
have	O
been	O
identified	O
in	O
the	O
USA	O
:	O
US	O
PEDV	O
prototype	O
and	O
S	O
-	O
INDEL	B-PROC
-	O
variant	O
strains	O
.	O

However	O
,	O
the	O
US	O
PEDV	O
prototype	O
and	O
the	O
S	O
-	O
INDEL	B-PROC
-	O
variant	O
strains	O
induced	O
similar	O
viraemia	O
levels	O
in	O
inoculated	O
pigs	O
.	O

Whole	O
genome	O
sequences	O
of	O
the	O
PEDV	O
prototype	O
and	O
S	O
-	O
INDEL	B-PROC
-	O
variant	O
strains	O
were	O
determined	O
,	O
but	O
the	O
molecular	O
basis	O
of	O
virulence	B-PROC
differences	O
between	O
these	O
PEDV	O
strains	O
remains	O
to	O
be	O
elucidated	O
using	O
a	O
reverse	O
genetics	O
approach	O
.	O

ABSTRACT	O
:	O
In	O
patients	O
who	O
developed	O
a	O
combined	O
situation	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
refractory	O
hypoxemia	O
and	O
acute	O
cardiac	O
failure	O
with	O
circulatory	B-PROC
collapse	O
,	O
traditional	O
veno	O
-	O
venous	O
or	O
veno	O
-	O
arterial	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
approach	O
alone	O
may	O
not	O
be	O
sufficient	O
enough	O
to	O
maintain	O
both	O
an	O
acceptable	O
range	O
of	O
gas	O
exchange	O
and	O
a	O
hemodynamic	B-PROC
stability	O
.	O

Many	O
viruses	O
have	O
evolved	O
mechanisms	O
for	O
generating	O
their	O
own	O
cap	O
structures	O
with	O
methylation	B-PROC
at	O
the	O
N7	O
position	O
of	O
the	O
capped	O
guanine	O
and	O
the	O
ribose	O
2	O
'-	O
Oposition	O
of	O
the	O
first	O
nucleotide	O
,	O
which	O
help	O
viral	O
RNAs	O
escape	O
recognition	O
by	O
the	O
host	O
innate	O
immune	O
system	O
.	O

Recent	O
theoretical	O
work	O
has	O
focused	O
on	O
making	O
best	O
use	O
of	O
data	O
from	O
the	O
initial	O
exponential	O
phase	O
of	O
growth	B-PROC
of	O
incidence	O
in	O
large	O
populations	O
.	O

TITLE	O
:	O
Biochemical	O
characterization	O
of	O
a	O
multi	O
-	O
drug	O
resistant	O
HIV	O
-	O
1	O
subtype	O
AG	O
reverse	O
transcriptase	B-PROC
:	O
antagonism	O
of	O
AZT	O
discrimination	O
and	O
excision	O
pathways	B-PROC
and	O
sensitivity	O
to	O
RNase	O
H	O
inhibitors	O
.	O

The	O
antiviral	O
activities	O
of	O
various	O
concentrations	O
of	O
the	O
EA	O
fraction	O
of	O
H	O
.	O
cordata	O
and	O
flavonoids	O
were	O
assessed	O
using	O
virus	B-PROC
neutralization	I-PROC
tests	O
against	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
DENV	O
type	O
2	O
(	O
DENV	O
-	O
2	O
).	O

H	O
.	O
cordata	O
has	O
much	O
potential	O
for	O
the	O
development	B-PROC
of	O
antiviral	O
agents	O
against	O
coronavirus	O
and	O
dengue	O
infections	O
.	O

We	O
speculate	O
that	O
glycosylation	B-PROC
of	O
7b	O
is	O
part	O
of	O
the	O
viral	O
evasion	O
strategy	O
to	O
prevent	O
an	O
immune	B-PROC
response	I-PROC
against	O
this	O
antigenic	O
site	O
.	O

TITLE	O
:	O
Fatal	O
outcome	O
of	O
human	O
coronavirus	O
NL63	O
infection	O
despite	O
successful	O
viral	O
elimination	B-PROC
by	O
IFN	O
-	O
alpha	O
in	O
a	O
patient	O
with	O
newly	O
diagnosed	O
ALL	O
.	O

Despite	O
immediate	O
initiation	O
of	O
treatment	O
and	O
elimination	B-PROC
of	O
virus	O
in	O
subsequent	O
tests	O
,	O
the	O
progressive	O
lung	O
failure	O
led	O
to	O
death	B-PROC
7	O
d	O
after	O
onset	O
of	O
fever	B-PROC
with	O
massive	O
lung	O
bleeding	O
as	O
a	O
consequence	O
of	O
diffuse	O
alveolar	O
hemorrhage	O
.	O

Pathogenesis	B-PROC
following	O
infection	O
with	O
these	O
viruses	O
is	O
characterized	O
by	O
a	O
marked	O
delay	O
in	O
the	O
induction	O
of	O
Type	O
I	O
interferon	O
(	O
IFN	O
I	O
)	O
and	O
,	O
subsequently	O
,	O
by	O
a	O
poor	O
adaptive	B-PROC
immune	I-PROC
response	I-PROC
.	O

M	O
protein	O
rather	O
than	O
M	O
mRNA	O
is	O
responsible	O
for	O
M	O
-	O
mediated	O
IFN	O
-	O
β	O
induction	O
that	O
is	O
preferentially	O
associated	O
with	O
the	O
activation	O
of	O
the	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
adaptor	O
proteins	O
MyD88	O
,	O
TIRAP	O
,	O
and	O
TICAM2	O
but	O
not	O
the	O
RIG	O
-	O
I	O
signaling	B-PROC
cascade	I-PROC
.	O

ABSTRACT	O
:	O
Dysregulated	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
I	O
)	O
expression	B-PROC
can	O
lead	O
to	O
severe	O
pathology	O
and	O
disease	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
in	O
contrast	O
to	O
HIV	O
,	O
HCV	O
resistance	B-PROC
to	O
CBAs	O
is	O
not	O
directly	O
conferred	O
by	O
mutations	O
in	O
the	O
envelope	O
protein	O
genes	O
but	O
could	O
occur	O
through	O
an	O
indirect	O
mechanism	O
involving	O
mutations	O
in	O
other	O
viral	O
proteins	O
.	O

With	O
emerging	O
resistance	B-PROC
to	O
the	O
drugs	O
currently	O
licensed	O
for	O
treatment	O
and	O
prophylaxis	O
of	O
influenza	O
viruses	O
,	O
primarily	O
the	O
neuraminidase	O
inhibitor	O
oseltamivir	O
phosphate	O
(	O
Tamiflu	O
)	O
and	O
the	O
M2	O
inhibitors	O
amantadine	O
and	O
rimantadine	O
,	O
and	O
the	O
lack	O
of	O
effective	O
interventions	O
against	O
other	O
respiratory	O
viruses	O
,	O
the	O
3	O
-	O
day	O
programme	O
focused	O
on	O
the	O
discovery	O
and	O
development	B-PROC
of	O
inhibitors	O
of	O
several	O
virus	O
targets	O
and	O
key	O
host	O
cell	O
factors	O
involved	O
in	O
virus	B-PROC
replication	I-PROC
or	O
mediating	O
the	O
inflammatory	B-PROC
response	I-PROC
.	O

Of	O
the	O
657	O
patients	O
aged	O
≥	O
40	O
years	O
,	O
377	O
(	O
57	O
.	O
3	O
%)	O
died	B-PROC
.	O

TITLE	O
:	O
Interactive	O
mechanism	O
between	O
avian	O
infectious	O
bronchitis	O
S1	O
protein	O
T	O
cell	O
peptide	O
and	O
avian	O
MHC	B-PROC
I	O
molecule	O
.	O

A	O
diagnosis	O
of	O
malaria	O
must	O
always	O
be	O
sought	O
in	O
a	O
feverish	B-PROC
or	O
sick	O
child	O
or	O
adult	O
who	O
has	O
visited	O
malaria	O
-	O
endemic	O
areas	O
.	O

They	O
may	O
require	O
haemodynamic	O
support	O
and	O
management	O
of	O
:	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
disseminated	O
intravascular	O
coagulation	B-PROC
,	O
acute	O
kidney	O
injury	O
,	O
seizures	O
,	O
and	O
severe	O
intercurrent	O
infections	O
including	O
Gram	O
-	O
negative	O
bacteraemia	O
/	O
septicaemia	O
.	O

An	O
oral	O
ACT	O
is	O
preferred	O
for	O
a	O
mixed	O
infection	O
,	O
if	O
there	O
is	O
uncertainty	O
about	O
the	O
infecting	O
species	O
,	O
or	O
for	O
P	O
.	O
vivax	O
infection	O
from	O
areas	O
where	O
chloroquine	O
resistance	B-PROC
is	O
common	O
(	O
Grade	O
1B	O
).	O

Primaquine	O
should	O
be	O
avoided	O
or	O
given	O
with	O
caution	O
under	O
expert	O
supervision	O
in	O
patients	O
with	O
Glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
deficiency	O
(	O
G6PD	O
),	O
in	O
whom	O
it	O
may	O
cause	O
severe	O
haemolysis	B-PROC
.	O

In	O
multivariable	O
analysis	O
,	O
older	O
age	O
,	O
greater	O
severity	O
scores	O
at	O
ICU	O
admission	O
,	O
and	O
hematologic	O
malignancy	O
or	O
liver	O
disease	O
were	O
independently	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
in	O
-	O
hospital	O
death	B-PROC
,	O
whereas	O
influenza	O
vaccination	O
prior	O
to	O
ICU	O
admission	O
and	O
adequate	O
antibiotic	O
administration	O
on	O
ICU	O
admission	O
were	O
associated	O
with	O
a	O
lower	O
risk	O
.	O

Common	O
genetic	O
variants	O
that	O
influence	O
TIE2	O
expression	B-PROC
were	O
then	O
sought	O
in	O
the	O
HapMap3	O
cohort	O
.	O

The	O
haplotype	O
associated	O
with	O
the	O
highest	O
TIE2	O
expression	B-PROC
conferred	O
a	O
28	O
%	O
reduction	O
in	O
the	O
risk	O
of	O
ARDS	O
independent	O
of	O
other	O
major	O
clinical	O
variables	O
,	O
including	O
disease	O
severity	O
.	O

The	O
records	O
of	O
178	O
patients	O
aged	O
above	O
2	O
years	O
who	O
presented	O
to	O
pediatric	O
emergency	O
outpatient	O
clinic	O
with	O
fever	B-PROC
and	O
respiratory	O
tract	O
infection	O
findings	O
between	O
December	O
2013	O
and	O
April	O
2014	O
were	O
examined	O
retrospectively	O
.	O

Lack	O
of	O
DPP4	O
expression	B-PROC
may	O
be	O
the	O
primary	O
cause	O
of	O
limited	O
MERS	O
-	O
CoV	O
replication	O
in	O
the	O
human	O
upper	O
respiratory	O
tract	O
and	O
hence	O
restrict	O
transmission	O
.	O

TITLE	O
:	O
The	O
C	O
-	O
Terminal	O
Tail	O
of	O
TRIM56	O
Dictates	O
Antiviral	O
Restriction	O
of	O
Influenza	O
A	O
and	O
B	O
Viruses	O
by	O
Impeding	O
Viral	O
RNA	B-PROC
Synthesis	I-PROC
.	O

After	O
24	O
hours	O
,	O
animals	O
were	O
weaned	B-PROC
from	O
treatment	O
for	O
recovery	O
in	O
the	O
ensuing	O
14	O
days	O
,	O
with	O
their	O
lungs	O
assessed	O
for	O
injury	O
and	O
reparation	O
.	O

More	O
PKH26	O
-	O
labeled	O
type	O
II	O
alveolar	O
epithelial	O
cells	O
were	O
detected	O
by	O
fluorescence	O
in	O
the	O
lungs	O
of	O
ALI	O
-	O
EC	O
-	O
T	O
than	O
in	O
CON	O
-	O
EC	O
-	O
T	O
as	O
further	O
verified	O
by	O
the	O
expression	B-PROC
of	O
messenger	O
RNA	O
of	O
sex	O
-	O
determining	O
region	O
of	O
Y	O
chromosome	O
.	O

Analysis	O
of	O
the	O
innate	O
gene	B-PROC
expression	I-PROC
in	O
the	O
lungs	O
showed	O
a	O
moderate	O
,	O
transient	O
induction	O
of	O
expression	B-PROC
.	O

We	O
investigated	O
Le	O
(	O
x	O
)	O
expression	B-PROC
using	O
CD11b	O
-	O
positive	O
peritoneal	O
exudate	O
cells	O
(	O
PECs	O
)	O
and	O
found	O
that	O
Le	O
(	O
x	O
)	O
is	O
inducible	O
in	O
Mo	O
/	O
Mas	O
after	O
infection	O
with	O
srr7	O
,	O
especially	O
in	O
the	O
syncytial	O
cells	O
during	O
the	O
late	O
phase	O
of	O
infection	O
.	O

In	O
acute	O
exacerbation	O
of	O
COPD	O
ventilator	O
settings	O
need	O
a	O
long	O
expiration	B-PROC
and	O
short	O
inspiration	B-PROC
time	O
to	O
avoid	O
further	O
hyperinflation	O
and	O
an	O
increase	O
in	O
intrinsic	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
).	O

Seven	O
patients	O
(	O
70	O
%)	O
were	O
weaned	B-PROC
from	O
ECMO	O
without	O
difficulty	O
;	O
one	O
patient	O
failed	O
to	O
maintain	O
awake	O
ECMO	O
,	O
was	O
re	O
-	O
intubated	O
after	O
2	O
days	O
of	O
awake	O
ECMO	O
,	O
and	O
was	O
re	O
-	O
tried	O
on	O
awake	O
ECMO	O
after	O
4	O
days	O
of	O
ventilator	O
care	O
.	O

We	O
weaned	B-PROC
a	O
total	O
of	O
eight	O
patients	O
(	O
80	O
%)	O
from	O
awake	O
ECMO	O
.	O

The	O
spike	O
(	O
S	O
)	O
protein	O
mediates	O
PEDV	O
entry	B-PROC
into	I-PROC
host	I-PROC
cells	O
.	O

The	O
time	O
-	O
dependent	O
reproduction	B-PROC
numbers	O
declined	O
substantially	O
below	O
the	O
value	O
of	O
1	O
on	O
and	O
after	O
13	O
June	O
2015	O
.	O

ABSTRACT	O
:	O
Porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
RNA	O
endoribonuclease	O
nsp11	O
belongs	O
to	O
the	O
XendoU	O
superfamily	O
and	O
plays	O
a	O
crucial	O
role	O
in	O
arterivirus	O
replication	O
.	O

Therefore	O
,	O
it	O
is	O
necessary	O
to	O
know	O
the	O
definition	O
of	O
the	O
interaction	O
mechanism	O
of	O
N	O
and	O
nsp3	O
protein	O
in	O
terms	O
of	O
the	O
CoV	O
replication	O
transcription	B-PROC
mechanism	O
.	O

Finally	O
,	O
protein	O
-	O
protein	O
docking	B-PROC
was	O
performed	O
to	O
prove	O
accuracy	O
of	O
model	O
structures	O
of	O
the	O
MHV	O
N	O
and	O
to	O
clarify	O
the	O
interaction	O
with	O
nsp3	O
.	O

There	O
are	O
other	O
areas	O
of	O
treatment	O
right	O
now	O
that	O
include	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
,	O
as	O
well	O
for	O
severe	O
refractory	O
hypoxemia	O
.	O

Endothelial	O
activation	O
biomarkers	O
(	O
soluble	O
vascular	O
cell	B-PROC
adhesion	I-PROC
molecule	O
-	O
1	O
[	O
sVCAM	O
-	O
1	O
],	O
soluble	O
endothelial	O
selectin	B-PROC
[	O
sESEL	O
],	O
angiopoietin	O
-	O
1	O
[	O
Ang	O
-	O
1	O
]	O
and	O
angiopoietin	O
-	O
2	O
[	O
Ang	O
-	O
2	O
])	O
were	O
measured	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

Our	O
findings	O
add	O
to	O
the	O
growing	O
evidence	O
supporting	O
the	O
concept	O
that	O
endothelial	O
activation	O
plays	O
an	O
important	O
mechanistic	O
role	O
in	O
the	O
pathogenesis	B-PROC
of	O
ARDS	O
.	O

Furthermore	O
,	O
coronavirus	O
co	O
-	O
infection	O
was	O
detected	O
in	O
all	O
six	O
bat	O
species	O
,	O
a	O
phenomenon	O
that	O
fosters	O
recombination	B-PROC
and	O
promotes	O
the	O
emergence	O
of	O
novel	O
virus	O
strains	O
.	O

Eight	O
of	O
12	O
centers	O
used	O
inhaled	B-PROC
ribavirin	O
(	O
RBV	O
)	O
in	O
some	O
patient	O
populations	O
.	O

In	O
terms	O
of	O
clinical	O
period	O
,	O
the	O
days	O
from	O
onset	O
to	O
death	B-PROC
[	O
13	O
(	O
4	O
~	O
17	O
)	O
vs	O
14	O
.	O
5	O
(	O
0	O
~	O
52	O
),	O
p	O
=	O
0	O
.	O
045	O
]	O
and	O
to	O
discharge	O
[	O
11	O
(	O
5	O
~	O
24	O
)	O
vs	O
24	O
(	O
0	O
~	O
74	O
),	O
p	O
=	O
0	O
.	O
010	O
]	O
and	O
be	O
hospitalized	O
days	O
[	O
9	O
.	O
5	O
(	O
3	O
~	O
22	O
)	O
vs	O
22	O
(	O
0	O
~	O
69	O
),	O
p	O
=	O
0	O
.	O
040	O
]	O
were	O
much	O
shorter	O
in	O
MERS	O
-	O
HCP	O
than	O
SARS	O
-	O
HCP	O
.	O

Public	O
health	O
programs	O
targeting	B-PROC
respiratory	O
disease	O
in	O
this	O
region	O
should	O
account	O
for	O
care	O
at	O
private	O
hospitals	O
and	O
clinics	O
,	O
as	O
well	O
as	O
illnesses	O
that	O
are	O
treated	O
at	O
home	O
,	O
in	O
order	O
to	O
capture	O
the	O
true	O
burden	O
of	O
illness	O
in	O
these	O
communities	O
.	O

We	O
isolated	O
13	O
new	O
viral	O
genomes	O
from	O
14	O
infected	O
patients	O
treated	O
at	O
a	O
hospital	O
and	O
found	O
that	O
12	O
of	O
these	O
genomes	O
possess	O
a	O
point	B-PROC
mutation	I-PROC
in	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
viral	O
spike	O
(	O
S	O
)	O
protein	O
.	O

Additionally	O
,	O
pseudotyped	O
virus	O
bearing	O
an	O
I529T	O
mutation	O
in	O
S	O
protein	O
showed	O
reduced	O
entry	B-PROC
into	I-PROC
host	I-PROC
cells	O
compared	O
to	O
virus	O
with	O
wild	O
-	O
type	O
S	O
protein	O
.	O

These	O
unexpected	O
findings	O
suggest	O
that	O
MERS	O
-	O
CoV	O
adaptation	B-PROC
during	O
human	O
-	O
to	O
-	O
human	O
spread	O
may	O
be	O
driven	O
by	O
host	O
immunological	O
pressure	O
such	O
as	O
neutralizing	O
antibodies	O
,	O
resulting	O
in	O
reduced	O
affinity	O
to	O
host	O
receptor	O
,	O
and	O
thereby	O
impairs	O
viral	O
fitness	O
and	O
virulence	B-PROC
,	O
rather	O
than	O
positive	O
selection	O
for	O
a	O
better	O
affinity	O
to	O
CD26	O
.	O

In	O
the	O
pre	O
-	O
fusion	O
conformation	O
,	O
the	O
receptor	O
-	O
binding	O
subunits	O
,	O
S1	O
,	O
rest	O
above	O
the	O
fusion	O
-	O
mediating	O
subunits	O
,	O
S2	O
,	O
preventing	O
their	O
conformational	O
rearrangement	B-PROC
.	O

1	O
-	O
179	O
of	O
the	O
N	O
protein	O
is	O
useful	O
for	O
detection	O
of	O
antibody	B-PROC
to	O
FRCoV	O
for	O
diagnosis	O
and	O
seroepidemiology	O
of	O
FRCoV	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
design	O
an	O
alternative	O
vaccine	O
for	O
control	O
of	O
infectious	O
bronchitis	O
in	O
chickens	O
,	O
three	O
recombinant	O
duck	O
enteritis	O
viruses	O
(	O
rDEVs	O
)	O
expressing	O
the	O
N	O
,	O
S	O
,	O
or	O
S1	O
protein	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
were	O
constructed	O
using	O
conventional	O
homologous	B-PROC
recombination	B-PROC
methods	O
,	O
and	O
were	O
designated	O
as	O
rDEV	O
-	O
N	O
,	O
rDEV	O
-	O
S	O
,	O
and	O
rDEV	O
-	O
S1	O
,	O
respectively	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
role	O
of	O
Zika	O
virus	O
and	O
dengue	O
virus	B-PROC
infection	I-PROC
in	O
developing	O
Guillain	O
-	O
Barré	O
syndrome	O
.	O

Controls	O
were	O
age	O
-	O
matched	O
,	O
sex	O
-	O
matched	O
,	O
and	O
residence	O
-	O
matched	O
patients	O
who	O
presented	O
at	O
the	O
hospital	O
with	O
a	O
non	O
-	O
febrile	B-PROC
illness	O
(	O
control	O
group	O
1	O
;	O
n	O
=	O
98	O
)	O
and	O
age	O
-	O
matched	O
patients	O
with	O
acute	O
Zika	O
virus	B-PROC
disease	I-PROC
and	O
no	O
neurological	O
symptoms	O
(	O
control	O
group	O
2	O
;	O
n	O
=	O
70	O
).	O

The	O
results	O
indicated	O
that	O
the	O
infected	O
mice	O
showed	O
typical	O
pneumonia	O
,	O
virus	B-PROC
replication	I-PROC
,	O
histological	O
lesions	O
,	O
and	O
neutralizing	O
antibody	B-PROC
production	I-PROC
.	O

Fourteen	O
days	O
after	O
infection	O
,	O
the	O
specific	O
antibody	B-PROC
to	O
virus	O
structural	O
protein	O
and	O
neutralizing	O
antibody	B-PROC
were	O
analyzed	O
,	O
the	O
high	O
dosage	O
group	O
induced	O
higher	O
level	O
antibody	B-PROC
.	O

Notably	O
,	O
given	O
that	O
teicoplanin	O
has	O
routinely	O
been	O
used	O
in	O
the	O
clinic	O
with	O
low	O
toxicity	O
,	O
our	O
work	O
provides	O
a	O
promising	O
prospect	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
Ebola	O
,	O
MERS	O
,	O
and	O
SARS	O
virus	B-PROC
infection	I-PROC
.	O

In	O
this	O
study	O
,	O
the	O
screening	O
for	O
the	O
presence	O
of	O
SARS	O
-	O
specific	O
T	O
cells	O
in	O
a	O
cohort	O
of	O
three	O
SARS	O
-	O
recovered	O
individuals	O
at	O
9	O
and	O
11	O
years	O
post	O
-	O
infection	O
was	O
carried	O
out	O
,	O
and	O
all	O
memory	B-PROC
T	O
cell	O
responses	O
detected	O
target	O
the	O
SARS	O
-	O
CoV	O
structural	O
proteins	O
.	O

Early	O
prone	O
combined	O
with	O
ACPC	O
-	O
IRV	B-PROC
in	O
H1N1	O
patients	O
having	O
severe	O
ARDS	O
can	O
be	O
used	O
as	O
a	O
rescue	O
therapy	O
and	O
it	O
should	O
be	O
confirmed	O
by	O
large	O
observational	O
studies	O
.	O

However	O
,	O
the	O
virus	O
is	O
able	O
to	O
evolve	O
through	O
genetic	B-PROC
mutations	I-PROC
,	O
which	O
is	O
why	O
vaccines	O
with	O
updated	O
composition	O
are	O
necessary	O
every	O
season	O
.	O

ABSTRACT	O
:	O
When	O
judged	O
by	O
ubiquity	O
,	O
adaptation	B-PROC
,	O
and	O
emergence	O
of	O
new	O
diseases	O
,	O
RNA	O
viruses	O
are	O
arguably	O
the	O
most	O
successful	O
biological	O
organisms	O
.	O

Transcription	B-PROC
includes	O
a	O
template	O
switch	O
during	O
the	O
synthesis	B-PROC
of	O
subgenomic	O
negative	O
-	O
strand	O
RNAs	O
to	O
add	O
a	O
copy	O
of	O
the	O
leader	O
sequence	O
.	O

Temperature	O
was	O
categorized	O
into	O
hypothermia	O
(<	O
36	O
.	O
0ºC	O
),	O
normothermia	O
(	O
36	O
.	O
0ºC	O
-	O
38	O
.	O
0ºC	O
)	O
and	O
fever	B-PROC
(>	O
38	O
.	O
0ºC	O
).	O

ABSTRACT	O
:	O
A	O
previous	O
study	O
demonstrated	O
the	O
existence	O
of	O
a	O
natural	O
resistance	B-PROC
to	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
among	O
36	O
%	O
of	O
randomly	O
bred	O
laboratory	O
cats	O
.	O

HAdV	O
should	O
be	O
tested	O
in	O
severe	O
CAP	O
patients	O
with	O
negative	O
bacterial	O
cultures	O
and	O
a	O
lack	O
of	O
response	B-PROC
to	I-PROC
antibiotic	I-PROC
treatment	O
,	O
even	O
if	O
radiologic	O
imaging	O
and	O
clinical	O
presentation	O
initially	O
suggest	O
bacterial	O
pneumonia	O
.	O

Batch	O
4	O
(	O
segments	O
1	O
-	O
4	O
)	O
represented	O
the	O
previous	O
events	O
,	O
including	O
transport	B-PROC
to	O
Des	O
Moines	O
,	O
IA	O
(	O
days	O
1	O
-	O
37	O
PC	O
).	O

ABSTRACT	O
:	O
A	O
66	O
-	O
year	O
-	O
old	O
woman	O
,	O
who	O
had	O
been	O
treated	O
with	O
systemic	O
corticosteroids	O
for	O
four	O
months	O
for	O
vasculitis	O
of	O
unknown	O
etiology	O
,	O
was	O
referred	O
to	O
our	O
department	O
due	O
to	O
a	O
fever	B-PROC
,	O
dyspnea	O
and	O
patchy	O
ground	O
-	O
glass	O
opacities	O
on	O
chest	O
computed	O
tomography	O
.	O

Antituberculous	O
drugs	O
were	O
administered	O
because	O
a	O
previous	O
blood	O
interferon	O
-	O
gamma	O
release	O
assay	O
was	O
positive	O
,	O
however	O
,	O
the	O
patient	O
died	B-PROC
of	O
severe	O
respiratory	O
failure	O
within	O
several	O
days	O
,	O
and	O
cultures	O
of	O
her	O
blood	O
,	O
urine	O
and	O
bone	O
marrow	O
posthumously	O
revealed	O
Mycobacterium	O
tuberculosis	O
.	O

An	O
autopsy	O
revealed	O
multiple	O
foci	O
of	O
air	O
-	O
space	O
pneumonia	O
containing	O
numerous	O
acid	O
-	O
fast	O
bacilli	O
without	O
granuloma	B-PROC
formation	I-PROC
,	O
accompanied	O
by	O
diffuse	O
alveolar	O
damage	O
.	O

This	O
review	O
summarizes	O
our	O
current	O
knowledge	O
on	O
AIV	O
epidemiology	O
,	O
disease	O
symptoms	O
,	O
inflammatory	O
processes	O
underlying	O
the	O
AIV	O
infection	O
in	O
humans	O
,	O
and	O
recent	O
studies	O
on	O
universal	O
pre	O
-	O
existing	O
CD8	O
(+)	O
T	O
cell	O
immunity	B-PROC
to	O
AIVs	O
.	O

Extracorporeal	O
membrane	O
oxygenation	B-PROC
is	O
used	O
in	O
specialized	O
centers	O
for	O
severe	O
cases	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	B-PROC
,	O
molecular	O
docking	B-PROC
studies	O
and	O
anti	O
-	O
HBV	O
activity	O
of	O
phenylpropanoid	O
derivatives	O
.	O

The	O
humoral	O
,	O
mucosal	O
,	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
induced	O
by	O
SL7207	O
(	O
pAXD	O
-	O
PS1	O
-	O
TS	O
)	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
PBS	O
and	O
SL7207	O
(	O
pVAXD	O
)	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
It	O
has	O
been	O
well	O
characterized	O
that	O
piglets	O
can	O
absorb	O
colostrum	O
IgG	O
across	O
the	O
intestine	O
to	O
neonatal	O
bloodstream	B-PROC
and	O
a	O
certain	O
level	O
of	O
IgG	O
has	O
been	O
found	O
in	O
the	O
mucosal	O
secretions	O
of	O
the	O
porcine	O
intestinal	O
tract	O
.	O

Although	O
CMV	O
was	O
superior	O
to	O
HFJV	O
at	O
1	O
h	O
of	O
ventilation	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
differences	O
in	O
lung	B-PROC
function	I-PROC
or	O
edema	O
formation	B-PROC
between	O
CMV	O
and	O
LAV	O
in	O
both	O
models	O
of	O
respiratory	O
insufficiency	O
at	O
4	O
h	O
of	O
ventilation	O
.	O

TITLE	O
:	O
Immune	B-PROC
responses	I-PROC
induced	O
by	O
recombinant	O
Bacillus	O
subtilis	O
expressing	O
the	O
spike	O
protein	O
of	O
transmissible	O
gastroenteritis	O
virus	O
in	O
pigs	O
.	O

Our	O
results	O
showed	O
that	O
the	O
recombinant	O
B	O
.	O
subtilis	O
had	O
the	O
ability	O
to	O
recruit	O
more	O
DCs	O
to	O
sample	O
B	O
.	O
subtilis	O
CotGSG	O
,	O
migrate	O
to	O
MLNs	O
,	O
and	O
induce	O
immune	B-PROC
responses	I-PROC
.	O

Novel	O
kinase	B-PROC
inhibitors	I-PROC
SB203580	O
(	O
MAPK	O
-	O
2	O
antagonist	B-PROC
)	O
and	O
LY294002	O
(	O
phosphoinositide	O
-	O
3	O
kinases	O
antagonist	B-PROC
)	O
exhibit	O
promising	O
anti	O
-	O
MERS	O
-	O
CoV	O
activity	O
.	O

The	O
animals	O
were	O
tested	O
for	O
the	O
prevalence	O
and	O
expression	B-PROC
of	O
porcine	O
endogenous	O
retroviruses	O
(	O
PERVs	O
)	O
and	O
the	O
presence	O
of	O
some	O
selected	O
microorganisms	O
,	O
among	O
them	O
HEV	O
,	O
PCMV	O
,	O
and	O
porcine	O
lymphotropic	O
herpesviruses	O
(	O
PLHVs	O
)	O
using	O
highly	O
sensitive	O
and	O
specific	O
PCR	O
and	O
RT	O
-	O
PCR	O
methods	O
.	O

The	O
animals	O
were	O
free	O
of	O
eight	O
other	O
microorganisms	O
tested	O
,	O
but	O
some	O
were	O
seropositive	O
for	O
porcine	O
circovirus	O
2	O
(	O
PCV2	O
),	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
and	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
).	O

The	O
animals	O
were	O
free	O
of	O
eight	O
other	O
microorganisms	O
tested	O
,	O
but	O
some	O
were	O
seropositive	O
for	O
porcine	O
circovirus	O
2	O
(	O
PCV2	O
),	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
and	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
).	O

In	O
this	O
issue	O
of	O
the	O
JCI	O
,	O
Peteranderl	O
and	O
colleagues	O
define	O
a	O
paracrine	B-PROC
communication	I-PROC
between	O
macrophages	O
and	O
type	O
II	O
alveolar	O
epithelial	O
cells	O
during	O
influenza	O
infection	O
where	O
IFNα	O
induces	O
macrophage	O
secretion	B-PROC
of	O
TRAIL	O
that	O
causes	O
endocytosis	B-PROC
of	O
Na	O
,	O
K	O
-	O
ATPase	O
by	O
the	O
alveolar	O
epithelium	O
.	O

The	O
authors	O
conducted	O
a	O
prospective	O
,	O
randomized	O
,	O
crossover	O
study	O
on	O
eight	O
spontaneously	O
breathing	B-PROC
ARDS	O
patients	O
undergoing	O
venovenous	O
ECMO	O
since	O
28	O
±	O
20	O
days	O
.	O

ABSTRACT	O
:	O
This	O
single	O
site	O
retrospective	O
observational	O
study	O
assessed	O
the	O
evolution	B-PROC
of	O
sedation	O
therapy	O
for	O
severe	O
alcohol	O
withdrawal	O
syndrome	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

The	O
aspiration	O
is	O
associated	O
with	O
possible	O
clinical	O
outcomes	O
,	O
ranging	O
from	O
mild	O
asymptomatic	O
limited	O
episodes	O
of	O
bronchial	O
injury	O
up	O
to	O
the	O
development	B-PROC
of	O
a	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Some	O
techniques	O
to	O
prevent	O
pulmonary	O
aspiration	O
entered	O
medical	O
practice	O
on	O
a	O
limited	O
evidence	O
base	O
,	O
but	O
with	O
common	O
sense	B-PROC
supporting	O
its	O
use	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
(	O
CoV	O
)	O
nonstructural	O
protein	O
14	O
(	O
nsp14	O
)	O
is	O
a	O
60	O
-	O
kDa	O
protein	O
encoded	O
by	O
the	O
replicase	O
gene	O
that	O
is	O
part	O
of	O
the	O
replication	O
-	O
transcription	B-PROC
complex	O
.	O

nsp14	O
N7	O
-	O
MTase	O
activity	O
is	O
required	O
for	O
viral	O
mRNA	O
cap	O
synthesis	B-PROC
and	O
prevents	O
the	O
recognition	O
of	O
viral	O
mRNAs	O
as	O
""""	O
non	O
-	O
self	O
""""	O
by	O
the	O
host	O
cell	O
.	O

The	O
introduction	O
of	O
a	O
mutation	O
in	O
zinc	O
finger	O
1	O
of	O
the	O
ExoN	O
domain	O
of	O
nsp14	O
led	O
to	O
production	O
of	O
a	O
virus	O
that	O
induced	O
a	O
weak	O
antiviral	B-PROC
response	I-PROC
,	O
most	O
likely	O
due	O
to	O
the	O
accumulation	O
of	O
lower	O
levels	O
of	O
dsRNA	O
in	O
the	O
late	O
phases	O
of	O
infection	O
.	O

These	O
observations	O
allowed	O
us	O
to	O
propose	O
a	O
novel	O
role	O
for	O
CoV	O
nsp14	O
ExoN	O
activity	O
in	O
counteracting	O
the	O
antiviral	B-PROC
response	I-PROC
,	O
which	O
could	O
serve	O
as	O
a	O
novel	O
target	O
for	O
the	O
design	O
of	O
antiviral	O
strategies	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
the	O
detection	O
and	O
identification	O
of	O
IBV	O
by	O
reverse	B-PROC
transcription	B-PROC
(	O
RT	O
)-	O
PCR	O
in	O
Iran	O
.	O

In	O
contrast	O
,	O
during	O
the	O
baseline	O
periods	B-PROC
,	O
there	O
was	O
no	O
difference	O
between	O
UpToDate	O
searches	O
for	O
MERS	O
in	O
the	O
affected	O
cities	O
compared	O
with	O
the	O
negative	O
control	O
cities	O
.	O

Like	O
many	O
coronaviruses	O
,	O
MERS	O
-	O
CoV	O
carries	O
genes	O
that	O
encode	O
multiple	O
accessory	O
proteins	O
that	O
are	O
not	O
required	O
for	O
replication	O
of	O
the	O
genome	O
but	O
are	O
likely	O
involved	O
in	O
pathogenesis	B-PROC
.	O

However	O
,	O
the	O
expression	B-PROC
level	O
of	O
cytoplasmic	O
MERS	O
-	O
CoV	O
NS4b	O
protein	O
is	O
sufficient	O
to	O
prevent	O
activation	O
of	O
RNase	O
L	O
.	O
Finally	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
RNase	O
L	O
antagonist	B-PROC
expressed	B-PROC
by	O
a	O
human	O
or	O
bat	O
coronavirus	O
and	O
provides	O
a	O
specific	O
mechanism	O
by	O
which	O
this	O
occurs	O
.	O

Like	O
murine	O
coronavirus	O
NS2	O
,	O
a	O
previously	O
characterized	O
PDE	O
,	O
MERS	O
NS4b	O
,	O
can	O
antagonize	O
activation	O
of	O
the	O
OAS	O
-	O
RNase	O
L	O
pathway	B-PROC
,	O
an	O
interferon	O
-	O
induced	O
potent	O
antiviral	O
activity	O
.	O

The	O
pathogenesis	B-PROC
of	O
FIP	O
is	O
intimately	O
associated	O
with	O
immune	B-PROC
responses	I-PROC
and	O
involves	O
depletion	O
of	O
T	O
cells	O
,	O
features	O
shared	O
by	O
some	O
other	O
coronaviruses	O
like	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
.	O

More	O
than	O
40	O
%	O
of	O
ALI	O
patients	O
had	O
neurological	O
,	O
cardiovascular	O
and	O
haematological	O
dysfunctions	O
or	O
disseminated	O
intravascular	O
coagulation	B-PROC
,	O
all	O
of	O
which	O
were	O
associated	O
with	O
higher	O
mortality	O
.	O

ABSTRACT	O
:	O
Autophagy	B-PROC
is	O
an	O
evolutionarily	O
ancient	O
pathway	B-PROC
that	O
has	O
been	O
shown	O
to	O
be	O
important	O
in	O
the	O
innate	O
immune	O
defense	O
against	O
several	O
viruses	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
TGEV	O
infection	O
increased	O
the	O
number	O
of	O
autophagosome	O
-	O
like	O
double	O
-	O
and	O
single	O
-	O
membrane	O
vesicles	O
in	O
the	O
cytoplasm	O
of	O
host	O
cells	O
,	O
a	O
phenomenon	O
that	O
is	O
known	O
to	O
be	O
related	O
to	O
autophagy	B-PROC
.	O

The	O
structures	O
and	O
identified	O
active	O
site	O
residues	O
may	O
facilitate	O
the	O
discovery	O
of	O
protease	B-PROC
inhibitors	I-PROC
with	O
antiviral	O
activity	O
.	O

ABSTRACT	O
:	O
The	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
in	O
the	O
trauma	O
population	O
has	O
been	O
reported	O
to	O
have	O
a	O
mortality	O
benefit	O
in	O
patients	O
with	O
severe	O
refractory	O
hypoxic	O
respiratory	O
failure	O
.	O

Over	O
time	O
,	O
he	O
started	O
to	O
show	O
signs	O
of	O
disseminated	O
intravascular	O
coagulation	B-PROC
,	O
such	O
as	O
multiple	O
organ	O
failure	O
and	O
thrombocytopenia	O
.	O

Moreover	O
,	O
populations	O
of	O
IgA	O
-	O
secreting	B-PROC
cells	O
,	O
CD3	O
+	O
T	O
lymphocytes	O
and	O
intraepithelial	O
lymphocytes	O
(	O
IELs	O
),	O
in	O
the	O
intestine	O
increased	O
significantly	O
after	O
immunization	O
with	O
ITGEV	O
plus	O
CpG	O
DNA	O
(	O
P	O
≤	O
0	O
.	O
05	O
).	O

Thus	O
,	O
we	O
expressed	B-PROC
and	O
produced	O
recombinant	O
S1	O
protein	O
to	O
protect	O
newborn	O
piglets	O
by	O
immunization	O
of	O
sows	O
.	O

PEDV	O
-	O
specific	O
immune	B-PROC
responses	I-PROC
in	O
sera	O
and	O
colostrum	O
of	O
the	O
sow	O
and	O
piglets	O
were	O
assayed	O
by	O
ELISA	O
and	O
virus	B-PROC
neutralization	I-PROC
assays	O
.	O

Our	O
result	O
revealed	O
that	O
RAGE	O
was	O
highly	O
expressed	B-PROC
on	O
the	O
alveolar	O
type	O
I	O
epithelial	O
cells	O
in	O
the	O
healthy	O
rat	O
lung	O
including	O
sRAGE	O
isoform	O
sized	O
45	O
kDa	O
.	O

On	O
Day	O
3	O
,	O
the	O
patient	O
developed	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
leading	O
to	O
death	B-PROC
on	O
Day	O
7	O
.	O

A	O
U	O
.	O
S	O
.	O
PEDV	O
S	O
-	O
INDEL	B-PROC
-	O
variant	O
strain	O
was	O
isolated	O
in	O
cell	O
culture	O
in	O
this	O
study	O
.	O

In	O
patients	O
receiving	O
ECLS	O
therapy	O
,	O
hemodynamic	B-PROC
monitoring	O
is	O
often	O
required	O
.	O

Hemodynamic	B-PROC
monitoring	O
was	O
performed	O
using	O
the	O
Pulse	B-PROC
index	O
Continuous	O
Cardiac	O
Output	O
system	O
.	O

Our	O
findings	O
support	O
the	O
virus	O
-	O
host	O
co	O
-	O
evolution	B-PROC
hypothesis	O
,	O
with	O
the	O
detection	O
of	O
Miniopterus	O
bat	O
coronavirus	O
HKU8	O
(	O
previously	O
reported	O
in	O
Miniopterus	O
species	O
in	O
China	O
,	O
Hong	O
Kong	O
and	O
Bulgaria	O
)	O
in	O
Australian	O
Miniopterus	O
species	O
.	O

Serum	O
,	O
colostrum	O
,	O
and	O
milk	O
were	O
tested	O
for	O
PEDV	O
IgG	O
,	O
IgA	O
,	O
and	O
virus	O
-	O
neutralizing	O
antibody	B-PROC
.	O

TITLE	O
:	O
Roles	O
of	O
neurally	O
adjusted	O
ventilatory	O
assist	O
in	O
improving	O
gas	O
exchange	O
in	O
a	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
patient	O
after	O
weaning	B-PROC
from	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
:	O
a	O
case	O
report	O
.	O

ABSTRACT	O
:	O
Patient	O
-	O
ventilator	O
asynchrony	O
is	O
a	O
major	O
cause	O
of	O
difficult	O
weaning	B-PROC
from	O
mechanical	O
ventilation	O
.	O

The	O
28	O
-	O
day	O
mortality	O
rate	O
was	O
49	O
.	O
1	O
%,	O
and	O
multivariate	O
analysis	O
identified	O
age	O
,	O
PaO2	O
/	O
FiO2	O
on	O
Day	O
1	O
,	O
number	O
of	O
organ	O
failures	O
,	O
and	O
positive	O
fluid	B-PROC
balance	I-PROC
within	O
5	O
days	O
as	O
significant	O
risk	O
factors	O
of	O
death	B-PROC
.	O

In	O
the	O
multivariate	O
analysis	O
,	O
age	O
≥	O
65	O
years	O
,	O
CAP	O
resulting	O
from	O
P	O
aeruginosa	O
,	O
chronic	O
liver	O
disease	O
,	O
neurologic	O
disease	O
,	O
nursing	B-PROC
home	O
,	O
criteria	O
of	O
ARDS	O
,	O
acute	O
renal	O
failure	O
,	O
ICU	O
admission	O
,	O
and	O
inappropriate	O
empiric	O
treatment	O
were	O
the	O
factors	O
associated	O
with	O
30	O
-	O
day	O
mortality	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
infected	O
over	O
1600	O
individuals	O
with	O
nearly	O
600	O
deaths	B-PROC
since	O
it	O
was	O
first	O
identified	O
in	O
human	O
populations	O
in	O
2012	O
.	O

Approaches	O
to	O
the	O
development	B-PROC
of	O
MERS	O
vaccines	O
are	O
discussed	O
herein	O
,	O
including	O
a	O
summary	O
of	O
previous	O
efforts	O
to	O
develop	O
vaccines	O
useful	O
against	O
human	O
and	O
non	O
-	O
human	O
coronaviruses	O
.	O

The	O
pathologic	O
responses	O
occurring	O
within	O
the	O
first	O
10	O
min	O
following	O
the	O
injection	O
of	O
the	O
anti	O
-	O
MHC	B-PROC
I	O
mAb	O
,	O
i	O
.	O
e	O
.	O
the	O
severity	O
of	O
lung	O
edema	O
and	O
the	O
drop	O
in	O
aortic	O
blood	O
oxygenation	B-PROC
,	O
were	O
similar	O
in	O
severely	O
thrombocytopenic	O
DT	O
-	O
iDTR	O
and	O
control	O
mice	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
impact	O
of	O
PRRS	O
virus	O
and	O
PED	O
virus	O
,	O
alone	O
or	O
in	O
combination	O
,	O
on	O
growth	B-PROC
performance	O
,	O
feed	O
efficiency	O
,	O
and	O
digestibility	O
in	O
grower	O
pigs	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
intestinal	O
function	O
and	O
integrity	O
is	O
altered	O
due	O
to	O
porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
(	O
PRRS	O
)	O
virus	O
and	O
porcine	O
epidemic	O
diarrhea	O
(	O
PED	O
)	O
virus	B-PROC
infection	I-PROC
in	O
growing	O
pigs	O
.	O

Interestingly	O
,	O
digestive	B-PROC
machinery	O
during	O
PED	O
challenge	O
remained	O
intact	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
increasingly	O
used	O
for	O
the	O
management	O
of	O
acute	O
severe	O
cardiac	O
and	O
respiratory	O
failure	O
.	O

ABSTRACT	O
:	O
Severe	O
sepsis	O
or	O
septic	O
shock	O
is	O
characterized	O
by	O
an	O
excessive	O
inflammatory	B-PROC
response	I-PROC
to	O
infectious	O
pathogens	O
.	O

TITLE	O
:	O
Biogenesis	B-PROC
and	O
architecture	O
of	O
arterivirus	O
replication	O
organelles	O
.	O

There	O
were	O
no	O
deaths	B-PROC
or	O
major	O
incidents	O
(	O
tube	O
dislodgement	O
or	O
line	O
displacement	O
)	O
during	O
patient	O
transport	B-PROC
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
SARS	O
Coronavirus	O
Vaccine	O
from	O
Recombinant	O
Spike	O
Protein	O
Plus	O
Delta	O
Inulin	O
Adjuvant	O
.	O

This	O
chapter	O
describes	O
the	O
use	O
of	O
an	O
insect	O
cell	O
expression	B-PROC
system	O
for	O
rapid	O
production	O
of	O
a	O
recombinant	O
vaccine	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
).	O

Detailed	O
methods	O
are	O
presented	O
for	O
expression	B-PROC
,	O
purification	O
,	O
and	O
release	O
testing	O
of	O
SARS	O
recombinant	O
spike	O
protein	O
antigen	O
,	O
followed	O
by	O
adjuvant	O
formulation	O
and	O
animal	O
testing	O
.	O

HFOV	O
combined	O
with	O
LVRM	O
in	O
severe	O
pediatric	O
ARDS	O
had	O
superior	O
oxygenation	B-PROC
and	O
tended	O
to	O
have	O
better	O
clinical	O
effect	O
over	O
CV	O
.	O

TITLE	O
:	O
Retinoic	O
acid	O
facilitates	O
inactivated	O
transmissible	O
gastroenteritis	O
virus	B-PROC
induction	I-PROC
of	O
CD8	O
(+)	O
T	B-PROC
-	I-PROC
cell	I-PROC
migration	B-PROC
to	O
the	O
porcine	O
gut	O
.	O

In	O
summary	O
,	O
CCoV	O
and	O
CRCoV	O
rNPs	O
were	O
successfully	O
expressed	B-PROC
in	O
E	O
.	O
coli	O
and	O
showed	O
antigenic	O
cross	O
-	O
reactivity	O
with	O
antisera	O
raised	O
against	O
human	O
coronaviruses	O
.	O

The	O
same	O
inflammatory	O
mechanism	O
also	O
may	O
harm	O
the	O
kidney	O
through	O
mediator	O
spillover	O
from	O
the	O
injured	O
lungs	O
into	O
the	O
bloodstream	B-PROC
.	O

Detection	O
of	O
amplification	O
products	O
based	O
on	O
labeled	O
probe	O
primers	O
was	O
conducted	O
with	O
strip	O
binding	O
antibody	B-PROC
of	O
labeled	O
markers	O
.	O

The	O
reverse	B-PROC
transcription	B-PROC
CPA	O
system	O
was	O
further	O
optimized	O
for	O
detecting	O
PEDV	O
RNA	O
in	O
clinical	O
specimens	O
.	O

None	O
of	O
the	O
included	O
studies	O
reported	O
a	O
standardised	O
classification	O
of	O
the	O
protective	O
properties	O
against	O
viral	B-PROC
penetration	I-PROC
of	O
the	O
PPE	O
,	O
and	O
only	O
one	O
reported	O
the	O
brand	O
of	O
PPE	O
used	O
.	O

TITLE	O
:	O
BCX4430	O
-	O
A	O
broad	O
-	O
spectrum	O
antiviral	O
adenosine	O
nucleoside	O
analog	O
under	O
development	B-PROC
for	O
the	O
treatment	O
of	O
Ebola	O
virus	B-PROC
disease	I-PROC
.	O

In	O
nonclinical	O
studies	O
involving	O
lethal	O
infections	O
with	O
Ebola	O
virus	O
,	O
Marburg	O
virus	O
,	O
Rift	O
Valley	O
fever	B-PROC
virus	O
,	O
and	O
Yellow	O
Fever	B-PROC
virus	O
,	O
BCX4430	O
has	O
demonstrated	O
pronounced	O
efficacy	O
.	O

Cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
is	O
a	O
key	O
mediator	O
in	O
the	O
regulation	B-PROC
of	O
viral	B-PROC
replication	I-PROC
and	O
inflammatory	B-PROC
response	I-PROC
.	O

In	O
the	O
current	O
study	O
,	O
the	O
role	O
of	O
G6PD	O
on	O
the	O
inflammatory	B-PROC
response	I-PROC
was	O
determined	O
in	O
both	O
scramble	O
control	O
and	O
G6PD	O
-	O
knockdown	O
(	O
G6PD	O
-	O
kd	O
)	O
A549	O
cells	O
upon	O
tumor	O
necrosis	B-PROC
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
stimulation	O
.	O

TITLE	O
:	O
Rapid	O
generation	O
of	O
a	O
human	O
monoclonal	O
antibody	B-PROC
to	O
combat	O
Middle	O
East	O
respiratory	O
syndrome	O
.	O

A	O
virus	O
inhibition	B-PROC
assay	O
was	O
used	O
to	O
identify	O
the	O
antiviral	O
activity	O
of	O
GO	O
and	O
GO	O
-	O
Ag	O
.	O

TITLE	O
:	O
Comparison	O
of	O
SYBR	O
green	O
I	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
with	O
conventional	O
agarose	O
gel	O
-	O
based	O
RT	O
-	O
PCR	O
for	O
the	O
diagnosis	O
of	O
infectious	O
bronchitis	O
virus	B-PROC
infection	I-PROC
in	O
chickens	O
in	O
Morocco	O
.	O

TITLE	O
:	O
Coronavirus	O
Infection	O
in	O
Ferrets	O
:	O
Antigen	O
Distribution	O
and	O
Inflammatory	B-PROC
Response	I-PROC
.	O

This	O
study	O
reveals	O
the	O
important	O
role	O
of	O
macrophages	O
in	O
the	O
inflammatory	B-PROC
response	I-PROC
of	O
ferrets	O
against	O
the	O
virus	O
and	O
the	O
variable	O
proportions	O
of	O
leukocytes	O
among	O
different	O
types	O
of	O
lesions	O
,	O
indicating	O
their	O
variable	O
age	O
.	O

Comparison	O
and	O
recombination	B-PROC
analyses	O
with	O
other	O
IBV	O
strains	O
revealed	O
that	O
SAIBK2	O
may	O
originate	O
from	O
recombination	B-PROC
events	O
among	O
a	O
YX10	O
-,	O
a	O
YN	O
-,	O
and	O
a	O
Mass	O
-	O
like	O
strain	O
.	O

We	O
determined	O
the	O
kinetics	O
of	O
antibody	B-PROC
(	O
IgG	O
and	O
IgM	O
)	O
and	O
neutralizing	O
antibodies	O
against	O
MERS	O
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
this	O
case	O
before	O
discharge	O
.	O

Our	O
results	O
strengthen	O
the	O
importance	O
to	O
integrate	O
the	O
circulatory	B-PROC
condition	O
in	O
the	O
analysis	O
of	O
the	O
state	O
of	O
the	O
respiratory	O
system	O
.	O

It	O
was	O
cloned	O
and	O
sub	O
-	O
cloned	O
into	O
pGH	O
and	O
pET32a	O
(+)	O
expression	B-PROC
vector	O
.	O

This	O
protein	O
was	O
expressed	B-PROC
by	O
induction	O
of	O
IPTG	O
at	O
concentration	O
of	O
1mM	O
and	O
it	O
was	O
confirmed	O
by	O
Ni	O
-	O
NTA	O
column	O
,	O
dot	O
-	O
blotting	O
analysis	O
and	O
SDS	O
-	O
PAGE	O
electrophoresis	O
.	O

TITLE	O
:	O
Factors	O
influencing	O
preventive	O
behavior	O
against	O
Middle	O
East	O
Respiratory	O
Syndrome	O
-	O
Coronavirus	O
among	O
nursing	B-PROC
students	O
in	O
South	O
Korea	O
.	O

During	O
caesarean	O
delivery	O
under	O
spinal	O
anaesthesia	O
a	O
previously	O
healthy	O
woman	O
became	O
hypotensive	O
,	O
requiring	O
ephedrine	O
to	O
maintain	O
her	O
blood	B-PROC
pressure	I-PROC
.	O

CONCLUSIONS	O
:	O
Although	O
the	O
application	O
of	O
ECMO	O
during	O
severe	O
ARDS	O
resulted	O
in	O
a	O
period	O
of	O
maximum	O
sedation	O
exposure	O
that	O
was	O
both	O
greater	O
and	O
took	O
longer	O
to	O
reach	B-PROC
,	O
factors	O
other	O
than	O
ECMO	O
,	O
particularly	O
high	O
-	O
dose	O
opioid	O
administration	O
,	O
appeared	O
more	O
likely	O
to	O
account	O
for	O
this	O
maximum	O
sedation	O
use	O
.	O

Vital	O
signs	O
and	O
saturation	O
of	O
pulse	B-PROC
oximetry	O
(	O
SpO2	O
)	O
were	O
monitored	O
continuously	O
.	O

Oxygenation	B-PROC
index	O
(	O
PaO2	O
/	O
FiO2	O
)	O
decreased	O
to	O
144	O
mmHg	O
(	O
1	O
mmHg	O
=	O
0	O
.	O
133	O
kPa	O
).	O

HFNC	O
could	O
improve	O
respiratory	B-PROC
function	I-PROC
of	O
the	O
patient	O
with	O
MERS	O
obviously	O
,	O
and	O
complication	O
ARDS	O
was	O
prevented	O
.	O

TITLE	O
:	O
[	O
A	O
new	O
score	O
system	O
for	O
prediction	O
of	O
death	B-PROC
in	O
patients	O
with	O
severe	O
trauma	O
:	O
the	O
value	O
of	O
death	B-PROC
warning	O
score	O
].	O

The	O
clinical	O
data	O
in	O
two	O
groups	O
were	O
recorded	O
as	O
following	O
:	O
gender	O
,	O
age	O
;	O
respiratory	O
rate	O
,	O
heart	O
rate	O
,	O
and	O
systolic	O
blood	B-PROC
pressure	I-PROC
at	O
admission	O
;	O
the	O
lowest	O
values	O
of	O
serum	O
creatinine	O
(	O
SCr	O
),	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
),	O
platelet	O
count	O
(	O
PLT	O
),	O
hematocrit	O
(	O
Hct	O
),	O
respectively	O
,	O
within	O
24	O
hours	O
after	O
admission	O
;	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
,	O
Glasgow	O
coma	O
scale	O
(	O
GCS	O
)	O
score	O
,	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
),	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
SIRS	O
)	O
score	O
,	O
injury	O
severity	O
score	O
(	O
ISS	O
)	O
within	O
24	O
hours	O
of	O
final	O
diagnosis	O
;	O
the	O
performance	O
of	O
emergency	O
operation	O
or	O
intubation	O
within	O
24	O
hours	O
;	O
incidence	O
of	O
sepsis	O
,	O
and	O
clinical	O
outcomes	O
.	O

Age	O
≥	O
65	O
years	O
,	O
APACHE	O
II	O
score	O
≥	O
21	O
,	O
GCS	O
<	O
6	O
,	O
severe	O
sepsis	O
or	O
septic	O
shock	O
were	O
the	O
risk	O
factors	O
of	O
death	B-PROC
in	O
patients	O
with	O
severe	O
trauma	O
,	O
and	O
they	O
can	O
be	O
considered	O
as	O
warning	O
score	O
of	O
death	B-PROC
in	O
patients	O
with	O
severe	O
trauma	O
.	O

When	O
the	O
cut	O
-	O
off	O
value	O
of	O
warning	O
score	O
of	O
death	B-PROC
was	O
1	O
.	O
5	O
,	O
the	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
predict	O
value	O
(+	O
PV	O
),	O
negative	O
predict	O
value	O
(-	O
PV	O
),	O
positive	O
likelihood	O
ratio	O
(+	O
LR	O
),	O
negative	O
likelihood	O
ratio	O
(-	O
LR	O
),	O
and	O
Youden	O
index	O
was	O
75	O
.	O
00	O
%,	O
85	O
.	O
40	O
%,	O
50	O
.	O
0	O
%,	O
94	O
.	O
6	O
%,	O
5	O
.	O
16	O
,	O
0	O
.	O
29	O
,	O
and	O
0	O
.	O
605	O
,	O
respectively	O
.	O

(	O
4	O
)	O
The	O
76	O
patients	O
of	O
late	O
group	O
were	O
subdivided	O
into	O
three	O
groups	O
,	O
namely	O
6	O
-	O
hour	O
reaching	B-PROC
standard	O
of	O
EGDT	O
group	O
(	O
n	O
=	O
22	O
),	O
24	O
-	O
hour	O
reaching	B-PROC
standard	O
of	O
EGDT	O
group	O
(	O
n	O
=	O
28	O
),	O
and	O
non	O
-	O
reaching	B-PROC
standard	O
of	O
EGDT	O
group	O
(	O
n	O
=	O
28	O
).	O

Patients	O
with	O
severe	O
hypoxaemia	O
can	O
be	O
managed	O
with	O
early	O
short	O
-	O
term	O
use	O
of	O
neuromuscular	B-PROC
blockade	I-PROC
,	O
prone	O
position	O
ventilation	O
,	O
or	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

In	O
conclusion	O
,	O
these	O
results	O
indicate	O
that	O
herpesviruses	O
lower	O
respiratory	O
tract	O
infection	O
,	O
which	O
occurs	O
more	O
frequently	O
following	O
influenza	O
virus	B-PROC
infection	I-PROC
,	O
can	O
be	O
a	O
negative	O
prognostic	O
marker	O
.	O

Finally	O
,	O
immunization	O
of	O
mice	O
with	O
10	O
μg	O
of	O
purified	O
proteins	O
elicited	O
highly	O
potent	O
serum	O
IgG	O
and	O
serum	O
neutralizing	O
antibody	B-PROC
titers	O
.	O

The	O
patients	O
developed	O
similar	O
clinical	O
symptoms	O
and	O
signs	O
,	O
such	O
as	O
fever	B-PROC
,	O
loss	O
of	O
consciousness	O
,	O
and	O
multiple	O
organ	O
dysfunction	O
.	O

While	O
the	O
virus	O
normally	O
causes	O
mild	O
to	O
moderate	O
disease	O
,	O
hospitalization	O
and	O
death	B-PROC
can	O
occur	O
in	O
many	O
cases	O
.	O

ABSTRACT	O
:	O
The	O
cytoplasmic	O
tails	O
of	O
some	O
coronavirus	O
(	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
proteins	O
contain	O
an	O
endoplasmic	O
reticulum	O
retrieval	O
signal	O
(	O
ERRS	O
)	O
that	O
can	O
retrieve	O
S	O
proteins	O
from	O
the	O
Golgi	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
);	O
this	O
process	O
is	O
thought	O
to	O
accumulate	O
S	O
proteins	O
at	O
the	O
CoV	O
budding	B-PROC
site	O
,	O
the	O
ER	O
-	O
Golgi	O
intermediate	O
compartment	O
(	O
ERGIC	O
),	O
and	O
to	O
facilitate	O
S	O
protein	O
incorporation	O
into	O
virions	O
.	O

Thus	O
,	O
the	O
precise	O
role	O
of	O
the	O
ERRS	O
in	O
virus	B-PROC
assembly	I-PROC
remains	O
unclear	O
.	O

The	O
specific	O
MAb	O
of	O
porcine	O
BST	O
-	O
2	O
provides	O
a	O
valuable	O
tool	O
for	O
further	O
studies	O
of	O
BST	O
-	O
2	O
to	O
restrict	O
virus	B-PROC
infection	I-PROC
.	O

This	O
isolation	O
process	O
constitutes	O
a	O
first	O
step	O
toward	O
vaccine	O
development	B-PROC
.	O

After	O
adjustment	O
for	O
the	O
severity	O
of	O
illness	O
and	O
the	O
degree	O
of	O
organ	O
dysfunction	O
,	O
the	O
need	O
for	O
vasopressors	O
was	O
an	O
independent	O
risk	O
factor	O
for	O
death	B-PROC
in	O
the	O
ICU	O
(	O
odds	O
ratio	O
=	O
18	O
.	O
33	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
11	O
-	O
302	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
04	O
).	O

The	O
results	O
revealed	O
that	O
the	O
antagonism	O
of	O
SARS	O
-	O
CoV	O
PLPro	O
on	O
TLR7	O
-	O
mediated	O
innate	B-PROC
immunity	B-PROC
was	O
associated	O
with	O
the	O
negative	O
regulation	B-PROC
of	O
TRAF3	O
/	O
6	O
-	O
TBK1	O
-	O
IRF3	O
/	O
NF	O
-	O
κB	O
/	O
AP1	O
signals	O
.	O

Meanwhile	O
,	O
the	O
results	O
of	O
the	O
virus	B-PROC
neutralization	I-PROC
test	O
indicated	O
that	O
the	O
strains	O
of	O
JX	O
/	O
99	O
/	O
01	O
,	O
GD	O
,	O
SAIBK	O
,	O
LDT3	O
showed	O
cross	O
-	O
reactivity	O
with	O
the	O
ZZ2004	O
isolate	O
,	O
and	O
hardly	O
any	O
cross	O
-	O
neutralization	O
of	O
IBV	O
ZZ2004	O
was	O
observed	O
with	O
the	O
strains	O
of	O
M41	O
,	O
H120	O
,	O
Gray	O
,	O
Holte	O
,	O
or	O
Aust	O
-	O
T	O
.	O
Phylogenetic	O
analysis	O
suggested	O
that	O
there	O
were	O
large	O
differences	O
between	O
ZZ2004	O
and	O
other	O
IBV	O
reference	O
strains	O
on	O
the	O
S1	O
subunit	O
.	O

His	O
arterial	O
blood	B-PROC
gas	I-PROC
revealed	O
type	O
1	O
respiratory	O
failure	O
(	O
PaO2	O
<	O
8	O
kPa	O
or	O
60	O
mm	O
Hg	O
with	O
normal	O
or	O
low	O
PaCO2	O
)	O
with	O
a	O
compensated	O
lactic	O
acidosis	O
.	O

MERS	O
-	O
CoV	O
presentation	O
varies	O
from	O
asymptomatic	O
infection	O
to	O
severe	O
respiratory	O
disease	O
causing	O
death	B-PROC
.	O

Oxygenation	B-PROC
significantly	O
improved	O
over	O
time	O
from	O
PaO2	O
/	O
FiO2	O
of	O
169	O
mmHg	O
at	O
day	O
1	O
to	O
199	O
mmHg	O
at	O
day	O
7	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

They	O
were	O
further	O
classified	O
into	O
those	O
with	O
long	O
PED	O
periods	B-PROC
(	O
L	O
-	O
PED	O
-	O
positive	O
;	O
n	O
=	O
28	O
)	O
and	O
those	O
with	O
short	O
PED	O
periods	B-PROC
(	O
S	O
-	O
PED	O
-	O
positive	O
;	O
n	O
=	O
10	O
).	O

A	O
virus	B-PROC
infection	I-PROC
assay	O
showed	O
that	O
rWIV1	O
-	O
ΔX	O
replicated	O
as	O
efficiently	O
as	O
rWIV1	O
in	O
Vero	O
E6	O
,	O
Calu	O
-	O
3	O
,	O
and	O
HeLa	O
-	O
hACE2	O
cells	O
.	O

In	O
a	O
mouse	O
model	O
with	O
a	O
direct	O
pulmonary	O
injection	O
,	O
PLpro	O
stimulated	O
macrophage	O
infiltration	O
into	O
lung	O
,	O
up	O
-	O
regulating	O
Egr	O
-	O
1	O
,	O
TSP	O
-	O
1	O
,	O
TGF	O
-	O
β1	O
and	O
vimentin	O
expression	B-PROC
in	O
lung	O
tissues	O
.	O

We	O
report	O
the	O
expression	B-PROC
,	O
purification	O
,	O
crystallization	O
and	O
2	O
.	O
10	O
Å	O
X	O
-	O
ray	O
structure	O
of	O
3CL	O
(	O
pro	O
)	O
from	O
PEDV	O
.	O

CLA	O
and	O
CGA	O
enhanced	O
the	O
actions	O
of	O
ATG	O
and	O
exhibited	O
synergistic	O
NF	O
-	O
κB	O
inactivation	O
effects	O
possibly	O
via	O
the	O
Ras	O
/	O
MAPK	B-PROC
signaling	B-PROC
pathway	I-PROC
.	O

The	O
present	O
study	O
provided	O
a	O
novel	O
strategy	O
for	O
the	O
treatment	O
of	O
ARDS	O
by	O
specifically	O
interfering	O
with	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
signaling	B-PROC
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
provided	O
a	O
novel	O
treatment	O
strategy	O
for	O
ARDS	O
by	O
modulating	O
the	O
balance	B-PROC
of	O
Treg	O
/	O
Th17	O
and	O
the	O
subsequent	O
immune	B-PROC
response	I-PROC
via	O
cAMP	B-PROC
signaling	I-PROC
,	O
which	O
requires	O
pre	O
-	O
clinical	O
and	O
clinical	O
validation	O
.	O

With	O
sustained	O
efforts	O
focusing	O
on	O
relevant	O
and	O
strategic	O
information	O
towards	O
control	O
and	O
elimination	B-PROC
of	O
infectious	O
diseases	O
,	O
Infectious	O
Diseases	O
of	O
Poverty	O
has	O
become	O
a	O
leading	O
journal	O
in	O
the	O
field	O
of	O
surveillance	O
and	O
response	O
systems	O
in	O
infectious	O
diseases	O
and	O
beyond	O
.	O

ABSTRACT	O
:	O
Massive	O
outbreaks	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
recurred	O
in	O
South	O
Korea	O
in	O
2013	O
-	O
2014	O
and	O
affected	O
approximately	O
40	O
%	O
of	O
the	O
swine	O
breeding	B-PROC
herds	O
across	O
the	O
country	O
,	O
incurring	O
a	O
tremendous	O
financial	O
impact	O
on	O
producers	O
and	O
consumers	O
.	O

Despite	O
the	O
nationwide	O
use	O
of	O
commercially	O
available	O
attenuated	O
and	O
inactivated	O
vaccines	O
in	O
South	O
Korea	O
,	O
PEDV	O
has	O
continued	O
to	O
plague	O
the	O
domestic	O
pork	O
industry	O
,	O
raising	O
concerns	O
regarding	O
their	O
protective	O
efficacies	O
and	O
the	O
need	O
for	O
new	O
vaccine	O
development	B-PROC
.	O

Among	O
CP	O
-	O
COPD	O
patients	O
,	O
in	O
-	O
hospital	O
mortality	O
of	O
patients	O
with	O
only	O
viral	B-PROC
infection	I-PROC
group	O
,	O
only	O
bacterial	O
infection	O
group	O
,	O
and	O
viral	O
-	O
bacterial	O
co	O
-	O
infection	O
were	O
2	O
.	O
6	O
%,	O
25	O
.	O
8	O
%,	O
and	O
17	O
.	O
5	O
%,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
01	O
).	O

Intestinal	O
content	O
samples	O
were	O
collected	O
from	O
101	O
broiler	O
flocks	O
from	O
several	O
regions	O
of	O
Jordan	O
to	O
detect	O
the	O
presence	O
of	O
astrovirus	O
,	O
coronavirus	O
,	O
reovirus	O
,	O
and	O
rotavirus	O
,	O
by	O
using	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Among	O
79	O
relatives	O
,	O
19	O
(	O
24	O
%)	O
were	O
MERS	O
-	O
CoV	O
positive	O
;	O
11	O
were	O
hospitalized	O
,	O
and	O
2	O
died	B-PROC
.	O

TITLE	O
:	O
Development	B-PROC
of	O
Medical	O
Countermeasures	O
to	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
.	O

Necroptosis	B-PROC
is	O
a	O
newly	O
identified	O
programmed	O
necrosis	B-PROC
that	O
is	O
mediated	O
by	O
receptor	O
interacting	O
protein	O
3	O
(	O
RIP3	O
).	O

However	O
,	O
the	O
potential	O
involvement	O
and	O
impact	O
of	O
necroptosis	B-PROC
in	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
ARDS	O
remains	O
unknown	O
.	O

Results	O
showed	O
that	O
in	O
high	O
dose	O
LPS	O
(	O
30mg	O
/	O
kg	O
and	O
40mg	O
/	O
kg	O
)	O
-	O
induced	O
severe	O
ARDS	O
,	O
RIP3	O
protein	O
was	O
increased	O
significantly	O
,	O
accompanied	O
by	O
increases	O
of	O
p	O
-	O
RIP3	O
and	O
MLKL	O
,	O
while	O
in	O
low	O
dose	O
LPS	O
(	O
10mg	O
/	O
kg	O
and	O
20mg	O
/	O
kg	O
)	O
-	O
induced	O
mild	O
ARDS	O
,	O
apoptosis	B-PROC
was	O
remarkably	O
increased	O
.	O

It	O
is	O
concluded	O
that	O
RIP3	O
-	O
mediated	O
necroptosis	B-PROC
is	O
a	O
major	O
mechanism	O
of	O
enhanced	O
inflammation	O
and	O
lung	O
tissue	O
injury	O
in	O
high	O
dose	O
LPS	O
-	O
induced	O
severe	O
ARDS	O
in	O
mice	O
.	O

They	O
may	O
account	O
for	O
a	O
small	O
proportion	O
of	O
SARI	O
diagnoses	O
,	O
increased	O
need	O
for	O
mechanical	O
ventilation	O
,	O
intensive	O
care	O
unit	O
admission	O
,	O
and	O
death	B-PROC
.	O

Japanese	O
spotted	O
fever	B-PROC
is	O
noted	O
to	O
occur	O
in	O
any	O
place	O
other	O
than	O
Kobe	O
City	O
.	O

It	O
has	O
Krebs	B-PROC
cycle	I-PROC
metabolism	B-PROC
,	O
rapid	O
clearance	O
,	O
relative	O
hydrophilicity	O
,	O
and	O
unique	O
drug	B-PROC
interactions	I-PROC
.	O

Acute	O
motor	O
axonal	O
neuropathy	O
,	O
a	O
subtype	O
of	O
GBS	O
,	O
was	O
diagnosed	O
by	O
cerebrospinal	O
fluid	O
and	O
nerve	O
conduction	B-PROC
velocity	I-PROC
testing	O
.	O

An	O
electroencephalogram	O
showed	O
that	O
the	O
patient	O
had	O
normal	O
,	O
appropriately	O
reactive	O
brain	B-PROC
function	I-PROC
.	O

ABSTRACT	O
:	O
In	O
this	O
Series	O
paper	O
,	O
we	O
review	O
the	O
current	O
evidence	O
for	O
the	O
use	O
of	O
high	O
-	O
flow	O
oxygen	O
therapy	O
,	O
inhaled	B-PROC
gases	O
,	O
and	O
aerosols	O
in	O
the	O
care	O
of	O
critically	O
ill	O
patients	O
.	O

Type	O
I	O
interferons	O
(	O
IFN	O
-	O
α	O
/	O
β	O
)	O
are	O
major	O
antiviral	O
cytokines	O
forming	O
host	O
innate	B-PROC
immunity	B-PROC
,	O
and	O
in	O
turn	O
,	O
these	O
enteric	O
coronaviruses	O
have	O
evolved	O
to	O
modulate	O
the	O
host	O
innate	O
immune	O
signaling	B-PROC
during	O
infection	O
.	O

Protecting	O
suckling	O
piglets	O
through	O
lactogenic	O
immunity	B-PROC
is	O
dependent	O
on	O
trafficking	B-PROC
of	O
pathogen	O
-	O
specific	O
IgA	O
plasmablasts	O
to	O
the	O
mammary	O
gland	O
and	O
accumulation	O
of	O
secretory	B-PROC
IgA	O
(	O
sIgA	O
)	O
antibodies	O
in	O
milk	O
,	O
defined	O
as	O
the	O
gut	O
-	O
mammary	O
-	O
sIgA	O
axis	O
.	O

Senecavirus	O
A	O
(	O
SV	O
-	O
A	O
)	O
formerly	O
known	O
as	O
Seneca	O
Valley	O
virus	O
was	O
detected	O
by	O
real	O
-	O
time	O
reverse	O
-	O
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
from	O
serum	O
,	O
skin	O
and	O
faeces	O
of	O
piglets	O
and	O
from	O
serum	O
and	O
faeces	O
of	O
sows	O
.	O

This	O
is	O
the	O
first	O
case	O
report	O
in	O
the	O
United	O
States	O
associating	O
SV	O
-	O
A	O
with	O
a	O
clinical	O
course	O
of	O
severe	O
but	O
transient	O
neonatal	O
morbidity	O
and	O
mortality	O
followed	O
by	O
vesicular	O
lesions	O
in	O
breeding	B-PROC
stock	O
animals	O
.	O

In	O
summary	O
,	O
our	O
data	O
demonstrated	O
critical	O
roles	O
of	O
the	O
p38	O
and	O
JNK1	O
/	O
2	O
signaling	B-PROC
pathways	B-PROC
in	O
facilitating	O
successful	O
viral	B-PROC
infection	I-PROC
during	O
the	O
post	O
-	O
entry	O
steps	O
of	O
the	O
PEDV	O
life	O
cycle	O
.	O

As	O
found	O
in	O
this	O
study	O
,	O
nurses	O
'	O
ethical	O
problems	O
were	O
influenced	O
most	O
by	O
cognitions	B-PROC
of	O
social	O
stigmatization	O
.	O

TITLE	O
:	O
Time	O
Course	O
of	O
MERS	O
-	O
CoV	O
Infection	O
and	O
Immunity	B-PROC
in	O
Dromedary	O
Camels	O
.	O

Recently	O
,	O
dengue	O
fever	B-PROC
,	O
Alkhumra	O
hemorrhagic	O
fever	B-PROC
,	O
and	O
Rift	O
Valley	O
fever	B-PROC
have	O
emerged	O
but	O
no	O
case	O
of	O
MERS	O
-	O
coronavirus	O
,	O
appeared	O
in	O
Saudi	O
Arabia	O
in	O
2012	O
,	O
have	O
yet	O
been	O
observed	O
during	O
the	O
2012	O
-	O
2014	O
Hajj	O
.	O

This	O
review	O
describes	O
the	O
synthesis	B-PROC
,	O
bioactivities	O
and	O
SARs	O
of	O
indole	O
-	O
based	O
agents	O
targeting	B-PROC
tubulin	O
polymerization	O
during	O
the	O
past	O
decade	O
.	O

Using	O
syndrome	O
definitions	O
to	O
screen	O
patients	O
for	O
laboratory	O
confirmation	O
of	O
infection	O
is	O
an	O
established	O
means	O
to	O
effectively	O
conduct	B-PROC
influenza	O
surveillance	O
.	O

In	O
order	O
to	O
assure	O
student	O
learning	B-PROC
,	O
medical	O
schools	O
may	O
consider	O
offering	O
distant	O
education	O
with	O
online	O
technology	O
.	O

Many	O
viruses	O
use	O
5	O
'	O
caps	O
or	O
other	O
mechanisms	O
to	O
mimic	O
a	O
cap	O
structure	O
to	O
limit	O
detection	O
of	O
viral	O
RNAs	O
by	O
intracellular	O
innate	O
sensors	O
and	O
to	O
direct	O
efficient	O
translation	B-PROC
of	O
viral	O
proteins	O
.	O

Here	O
,	O
we	O
engineered	O
mutations	O
in	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
nsp14	O
N7	O
-	O
MTase	O
at	O
residues	O
D330	O
and	O
G332	O
and	O
determined	O
the	O
effects	O
of	O
these	O
mutations	O
on	O
viral	B-PROC
replication	I-PROC
,	O
sensitivity	O
to	O
mutagen	O
,	O
inhibition	B-PROC
by	O
type	O
I	O
interferon	O
(	O
IFN	O
),	O
and	O
translation	B-PROC
efficiency	O
.	O

Since	O
specific	O
antiviral	O
therapies	O
are	O
not	O
available	O
for	O
the	O
treatment	O
of	O
human	O
coronavirus	O
infections	O
,	O
it	O
is	O
essential	O
to	O
understand	O
the	O
functions	O
of	O
conserved	O
CoV	O
proteins	O
in	O
viral	B-PROC
replication	I-PROC
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
characterized	O
by	O
a	O
noncardiogenic	O
pulmonary	O
edema	O
with	O
bilateral	O
chest	O
X	O
-	O
ray	O
opacities	O
and	O
reduction	O
in	O
lung	B-PROC
compliance	I-PROC
,	O
and	O
the	O
hallmark	O
of	O
the	O
syndrome	O
is	O
hypoxemia	O
refractory	O
to	O
oxygen	O
therapy	O
.	O

In	O
this	O
study	O
,	O
the	O
NTD	O
spanning	O
amino	O
acid	O
residues	O
25	O
-	O
229	O
(	O
S25	O
-	O
229	O
)	O
of	O
S1	O
domain	O
of	O
PEDV	O
variant	O
strain	O
was	O
expressed	B-PROC
in	O
Escherichia	O
coli	O
BL21	O
(	O
DE3	O
)	O
in	O
the	O
form	O
of	O
inclusion	O
bodies	O
(	O
IBs	O
).	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
:	O
Overview	O
of	O
infection	O
dynamics	O
,	O
diagnostic	O
methods	O
,	O
prevalence	O
and	O
genetic	O
evolution	B-PROC
.	O

ABSTRACT	O
:	O
Helicopter	O
emergency	O
medical	O
services	O
(	O
HEMS	O
)	O
extend	O
the	O
reach	B-PROC
of	O
a	O
tertiary	O
care	O
center	O
significantly	O
.	O

To	O
build	O
a	O
comprehensive	O
flow	O
diagram	O
for	O
management	O
of	O
hypoxemia	O
during	O
VV	O
-	O
ECMO	O
,	O
we	O
considered	O
(	O
1	O
)	O
relationship	O
between	O
O2	O
arterial	O
saturation	O
and	O
its	O
determinants	O
;	O
(	O
2	O
)	O
analysis	O
of	O
physiopathology	O
of	O
oxygenation	B-PROC
under	O
VV	O
-	O
ECMO	O
;	O
and	O
(	O
3	O
)	O
main	O
guidelines	O
and	O
recommendations	O
recapitulated	O
in	O
troubleshooting	O
charts	O
.	O

Second	O
,	O
if	O
hypoxemia	O
persists	O
,	O
algorithm	O
considers	O
multiple	O
reasons	O
for	O
inadequate	O
oxygenation	B-PROC
,	O
namely	O
:	O
(	O
1	O
)	O
excessive	O
recirculation	O
,	O
(	O
2	O
)	O
excessive	O
cardiac	O
output	O
(	O
decrease	O
of	O
ratio	O
pump	O
flow	O
/	O
cardiac	O
output	O
),	O
(	O
3	O
)	O
decrease	O
in	O
SvO2	B-PROC
(	O
oxygen	O
saturation	O
in	O
mixed	O
venous	O
blood	O
),	O
(	O
4	O
)	O
malfunction	O
of	O
oxygenator	O
,	O
and	O
(	O
5	O
)	O
deterioration	O
of	O
residual	O
lung	B-PROC
function	I-PROC
.	O

RESULTS	O
:	O
The	O
nucleoprotein	O
of	O
PDCoV	O
was	O
expressed	B-PROC
as	O
a	O
recombinant	O
protein	O
and	O
purified	O
for	O
use	O
as	O
an	O
antigen	O
to	O
immunize	O
mice	O
for	O
polyclonal	O
,	O
hyperimmune	O
sera	O
and	O
monoclonal	O
antibody	B-PROC
(	O
mAb	O
)	O
production	O
.	O

TITLE	O
:	O
Influence	O
of	O
Breed	B-PROC
Size	O
,	O
Age	O
,	O
Fecal	O
Quality	O
,	O
and	O
Enteropathogen	O
Shedding	O
on	O
Fecal	O
Calprotectin	O
and	O
Immunoglobulin	B-PROC
A	O
Concentrations	O
in	O
Puppies	O
During	O
the	O
Weaning	B-PROC
Period	O
.	O

For	O
nsp12	O
-	O
V553I	O
,	O
we	O
also	O
demonstrate	O
resistance	B-PROC
to	O
the	O
mutagen	O
5	O
-	O
azacytidine	O
(	O
5	O
-	O
AZC	O
)	O
and	O
decreased	O
accumulation	O
of	O
mutations	O
.	O

RNA	O
viruses	O
have	O
evolutionarily	O
fine	O
-	O
tuned	O
replication	O
fidelity	O
to	O
balance	B-PROC
requirements	O
for	O
genetic	O
stability	O
and	O
diversity	O
.	O

Coronaviruses	O
(	O
CoVs	O
)	O
are	O
the	O
only	O
known	O
RNA	O
viruses	O
to	O
encode	O
a	O
proofreading	O
exonuclease	O
(	O
nsp14	O
-	O
ExoN	O
),	O
as	O
well	O
as	O
other	O
replicase	O
proteins	O
involved	O
in	O
regulation	B-PROC
of	O
fidelity	O
.	O

As	O
such	O
,	O
our	O
study	O
is	O
a	O
significant	O
step	O
forward	O
in	O
the	O
understanding	O
of	O
coronavirus	O
biology	O
and	O
closes	O
a	O
gap	O
in	O
the	O
understanding	O
of	O
some	O
IBV	O
virulence	B-PROC
strategies	O
.	O

TITLE	O
:	O
Airway	O
Memory	B-PROC
CD4	O
(+)	O
T	O
Cells	O
Mediate	O
Protective	O
Immunity	B-PROC
against	O
Emerging	O
Respiratory	O
Coronaviruses	O
.	O

Here	O
,	O
we	O
showed	O
that	O
induction	O
of	O
airway	O
memory	B-PROC
CD4	O
(+)	O
T	O
cells	O
specific	O
for	O
a	O
conserved	O
epitope	O
shared	O
by	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
is	O
a	O
potential	O
strategy	O
for	O
developing	O
pan	O
-	O
coronavirus	O
vaccines	O
.	O

On	O
Site	O
Two	O
,	O
pen	O
oral	O
fluid	O
samples	O
and	O
individual	O
pig	O
serum	O
samples	O
were	O
negative	O
for	O
both	O
PEDV	O
antibody	B-PROC
and	O
nucleic	O
acid	O
.	O

The	O
highest	O
NA	O
was	O
observed	O
in	O
colostrum	O
on	O
day	O
1	O
,	O
and	O
decreased	O
rapidly	O
in	O
milk	O
at	O
day	O
3	O
,	O
then	O
gradually	O
declined	O
from	O
day	O
3	O
to	O
day	O
19	O
post	O
-	O
farrowing	B-PROC
.	O

ABSTRACT	O
:	O
Typhoid	O
fever	B-PROC
is	O
commonly	O
characterized	O
by	O
fever	B-PROC
and	O
abdominal	O
pain	O
.	O

Recombination	B-PROC
analyses	O
demonstrated	O
that	O
the	O
S1	O
gene	O
of	O
the	O
GX	O
-	O
NN130048	O
isolate	O
originated	O
from	O
recombination	B-PROC
events	O
between	O
vaccine	O
strain	O
4	O
/	O
91	O
and	O
a	O
LX4	O
-	O
like	O
isolate	O
.	O

We	O
showed	O
that	O
recombination	B-PROC
events	O
can	O
lead	O
to	O
the	O
emergence	O
of	O
new	O
serotypes	O
.	O

TITLE	O
:	O
[	O
Bioinformatics	O
-	O
based	O
Design	O
of	O
Peptide	O
Vaccine	O
Candidates	O
Targeting	B-PROC
Spike	O
Protein	O
of	O
MERS	O
-	O
CoV	O
and	O
Immunity	B-PROC
analysis	O
in	O
Mice	O
].	O

The	O
results	O
showed	O
that	O
an	O
individual	O
peptide	O
of	O
YVDVGPDSVKSACIEVDIQQTFFDKTWPRPIDVSKADGI	O
could	O
induce	O
the	O
highest	O
level	O
of	O
total	O
IgG	O
as	O
well	O
as	O
CMI	O
(	O
high	O
frequency	O
of	O
IFN	O
-	O
γ	O
secretion	B-PROC
)	O
against	O
MERS	O
-	O
CoV	O
antigen	O
in	O
mice	O
.	O

TITLE	O
:	O
Bovine	O
coronavirus	O
in	O
naturally	O
and	O
experimentally	O
exposed	O
calves	O
;	O
viral	B-PROC
shedding	I-PROC
and	O
the	O
potential	O
for	O
transmission	O
.	O

ABSTRACT	O
:	O
Numerous	O
viral	B-PROC
infections	I-PROC
have	O
arisen	O
and	O
affected	O
global	O
healthcare	O
facilities	O
.	O

Two	O
weeks	O
after	O
gene	O
transfer	O
,	O
animals	O
received	O
LPS	O
(	O
7	O
.	O
5	O
mg	O
/	O
Kg	O
)	O
injection	O
alone	O
or	O
in	O
combination	O
with	O
Mas	O
receptor	O
antagonist	B-PROC
A779	O
(	O
10	O
μg	O
/	O
Kg	O
)	O
or	O
ACE2	O
inhibitor	O
MLN	O
-	O
4760	O
(	O
1	O
mg	O
/	O
Kg	O
)	O
pretreatment	O
.	O

Our	O
observation	O
suggests	O
that	O
AEC2	O
attenuates	O
LPS	O
-	O
induced	O
ARDS	O
via	O
the	O
Ang	O
-(	O
1	O
-	O
7	O
)/	O
Mas	O
pathway	B-PROC
by	O
inhibiting	O
ERK	O
/	O
NF	O
-	O
κB	O
activation	O
.	O

At	O
least	O
one	O
respiratory	O
virus	O
was	O
detected	O
in	O
samples	O
from	O
39	O
of	O
87	O
episodes	O
of	O
febrile	B-PROC
neutropenia	O
(	O
45	O
%),	O
with	O
rhinoviruses	O
the	O
most	O
frequently	O
detected	O
.	O

The	O
frequency	O
of	O
respiratory	O
viral	B-PROC
infections	I-PROC
in	O
this	O
group	O
of	O
patients	O
suggests	O
an	O
etiologic	O
role	O
in	O
febrile	B-PROC
neutropenia	O
.	O

Since	O
the	O
therapeutic	O
potential	O
of	O
human	O
NPCs	O
may	O
differ	O
greatly	O
depending	O
on	O
the	O
method	O
of	O
derivation	O
and	O
culture	O
,	O
we	O
wanted	O
to	O
determine	O
whether	O
NPCs	O
differentiated	B-PROC
using	O
conventional	O
methods	O
would	O
be	O
similarly	O
effective	O
in	O
improving	O
clinical	O
outcome	O
under	O
neuroinflammatory	O
demyelinating	O
conditions	O
.	O

Here	O
,	O
we	O
generated	O
a	O
humanized	O
monoclonal	O
antibody	B-PROC
(	O
mAb	O
),	O
designated	O
hMS	O
-	O
1	O
,	O
which	O
targeted	B-PROC
the	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
with	O
high	O
affinity	O
.	O

Characterized	O
by	O
severe	O
inflammation	O
and	O
compromised	O
lung	B-PROC
function	I-PROC
,	O
ALI	O
/	O
ARDS	O
result	O
in	O
very	O
high	O
mortality	O
of	O
affected	O
individuals	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
the	O
strategy	O
of	O
concerted	O
activation	O
of	O
Nrf2	O
and	O
autophagy	B-PROC
as	O
a	O
preventive	O
and	O
therapeutic	O
intervention	O
to	O
ameliorate	O
ALI	O
/	O
ARDS	O
.	O

ABSTRACT	O
:	O
We	O
present	O
an	O
analysis	O
of	O
the	O
diagnostic	O
technologies	O
that	O
were	O
used	O
to	O
identify	O
historical	O
outbreaks	O
of	O
Ebola	O
virus	B-PROC
disease	I-PROC
and	O
consider	O
systematic	O
surveillance	O
strategies	O
that	O
may	O
greatly	O
reduce	O
the	O
peak	O
size	O
of	O
future	O
epidemics	O
.	O

Our	O
aim	O
was	O
to	O
predict	O
the	O
magnitude	O
of	O
oxygenation	B-PROC
response	O
after	O
PP	O
using	O
bedside	O
LUS	O
.	O

No	O
difference	O
in	O
PaCO2	O
change	O
was	O
found	O
according	O
to	O
oxygenation	B-PROC
response	O
or	O
lung	O
morphology	O
.	O

Serological	O
results	O
from	O
archived	O
camel	O
sera	O
provide	O
evidence	O
for	O
circulation	B-PROC
of	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
among	O
dromedary	O
camels	O
in	O
the	O
Greater	O
Horn	O
of	O
Africa	O
as	O
far	O
back	O
as	O
1983	O
and	O
in	O
Saudi	O
Arabia	O
as	O
far	O
back	O
as	O
1992	O
.	O

ABSTRACT	O
:	O
Over	O
the	O
past	O
decades	O
global	O
environmental	O
change	O
,	O
globalization	O
,	O
urbanization	O
,	O
and	O
the	O
rise	O
in	O
movement	B-PROC
of	O
people	O
have	O
increased	O
the	O
risk	O
for	O
pandemic	O
disease	O
outbreaks	O
.	O

The	O
most	O
prominent	O
neonatal	O
outcomes	O
associated	O
with	O
HELLP	O
syndrome	O
were	O
:	O
antenatal	O
fetal	O
death	B-PROC
,	O
intrauterine	O
growth	B-PROC
restriction	O
,	O
prematurity	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
how	O
long	O
antibodies	O
against	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
persist	O
,	O
we	O
measured	O
long	O
-	O
term	O
antibody	B-PROC
responses	I-PROC
among	O
persons	O
serologically	O
positive	O
or	O
indeterminate	O
after	O
a	O
2012	O
outbreak	O
in	O
Jordan	O
.	O

TITLE	O
:	O
Improvement	O
of	O
Oxygenation	B-PROC
in	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
With	O
High	O
-	O
Volume	O
Continuous	O
Veno	O
-	O
venous	O
Hemofiltration	O
.	O

Improvement	O
in	O
oxygenation	B-PROC
is	O
likely	O
related	O
to	O
both	O
restoration	O
of	O
fluid	B-PROC
balance	I-PROC
and	O
clearance	O
of	O
inflammatory	O
mediators	O
.	O

Among	O
the	O
20	O
patients	O
(	O
52	O
.	O
6	O
%)	O
who	O
were	O
successfully	O
weaned	B-PROC
from	O
ECMO	O
,	O
16	O
patients	O
(	O
42	O
.	O
1	O
%)	O
survived	O
to	O
hospital	O
discharge	O
.	O

Children	O
who	O
are	O
exposed	O
to	O
secondhand	O
smoke	O
are	O
at	O
increased	O
risk	O
for	O
sudden	O
infant	O
death	B-PROC
syndrome	O
,	O
acute	O
respiratory	O
infections	O
,	O
middle	O
ear	O
disease	O
,	O
more	O
severe	O
asthma	O
,	O
respiratory	O
symptoms	O
,	O
and	O
slowed	O
lung	B-PROC
growth	B-PROC
(	O
1	O
,	O
2	O
).	O

Previous	O
case	O
studies	O
have	O
demonstrated	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
as	O
a	O
life	O
-	O
saving	O
measure	O
for	O
pregnant	O
women	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
as	O
well	O
as	O
non	O
-	O
pregnant	O
patients	O
with	O
status	O
asthmaticus	O
.	O

Despite	O
rescue	O
therapies	O
such	O
as	O
pressure	O
control	O
ventilation	O
with	O
high	O
inspiratory	B-PROC
pressures	O
,	O
inhaled	B-PROC
beta2	O
agonists	O
and	O
antimuscarinic	O
drugs	O
,	O
intravenous	O
salbutamol	O
,	O
methylprednisolone	O
and	O
magnesium	O
sulfate	O
,	O
her	O
condition	O
gradually	O
deteriorated	O
.	O

This	O
family	O
includes	O
T	O
cell	O
receptor	O
(	O
TCR	B-PROC
)	O
that	O
is	O
critically	O
involved	O
in	O
immune	O
diseases	O
such	O
as	O
autoimmune	O
arthritis	O
.	O

Use	O
of	O
resources	O
such	O
as	O
HealthMap	O
can	O
aid	O
in	O
the	O
timely	O
assessment	O
of	O
risk	O
factors	O
,	O
vaccination	O
development	B-PROC
initiatives	O
,	O
prevention	O
strategies	O
and	O
measured	O
allocation	O
of	O
healthcare	O
resources	O
while	O
running	O
at	O
a	O
low	O
cost	O
with	O
greater	O
flexibility	O
and	O
increased	O
scalability	O
compared	O
to	O
isolated	O
diseases	O
surveillance	O
systems	O
.	O

Samples	O
from	O
camels	O
and	O
humans	O
underwent	O
real	O
-	O
time	O
reverse	O
-	O
transcription	B-PROC
quantitative	O
PCR	O
screening	O
to	O
detect	O
MERS	O
-	O
CoV	O
.	O
In	O
addition	O
,	O
sequencing	O
and	O
phylogenetic	O
analysis	O
of	O
partially	O
characterized	O
MERS	O
-	O
CoV	O
genome	O
fragments	O
obtained	O
from	O
camels	O
were	O
performed	O
.	O

Furthermore	O
,	O
the	O
results	O
of	O
SimPlot	O
analysis	O
indicated	O
that	O
FRCoV	O
(	O
MSU	O
-	O
2	O
strain	O
)	O
emerged	O
via	O
a	O
recombination	B-PROC
event	O
of	O
S	O
protein	O
between	O
the	O
MSU	O
-	O
1	O
and	O
Saitama	O
-	O
1	O
strains	O
.	O

This	O
information	O
will	O
be	O
useful	O
for	O
understanding	O
the	O
pathogenesis	B-PROC
of	O
FRCoV	O
in	O
ferrets	O
.	O

TITLE	O
:	O
Comparative	O
Evaluation	O
of	O
Three	O
Homogenization	O
Methods	O
for	O
Isolating	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Nucleic	O
Acids	O
From	O
Sputum	O
Samples	O
for	O
Real	O
-	O
Time	O
Reverse	B-PROC
Transcription	B-PROC
PCR	O
.	O

Pressure	O
-	O
controlled	O
IRV	B-PROC
was	O
used	O
for	O
13	O
patients	O
during	O
the	O
study	O
period	O
.	O

IRV	B-PROC
significantly	O
improved	O
the	O
PaO2	O
/	O
FiO2	O
from	O
76	O
±	O
27	O
to	O
208	O
±	O
91	O
mmHg	O
without	O
circulatory	B-PROC
impairment	O
.	O

We	O
showed	O
that	O
chloroquine	O
strongly	O
inhibited	O
HCoV	O
-	O
OC43	O
replication	O
in	O
vitro	O
,	O
with	O
a	O
50	O
%	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
of	O
0	O
.	O
33	O
μM	O
.	O
However	O
,	O
ribavirin	O
showed	O
inhibition	B-PROC
of	O
HCoV	O
-	O
OC43	O
replication	O
only	O
at	O
high	O
concentrations	O
which	O
may	O
not	O
be	O
applicable	O
to	O
humans	O
in	O
clinical	O
treatment	O
,	O
with	O
an	O
IC50	O
of	O
10	O
μM	O
.	O
Furthermore	O
,	O
using	O
a	O
luciferase	O
-	O
based	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
screening	O
assay	O
,	O
we	O
identified	O
double	O
-	O
stranded	O
-	O
RNA	O
-	O
activated	O
protein	O
kinase	O
(	O
PKR	O
)	O
and	O
DEAD	B-PROC
box	O
RNA	O
helicases	O
(	O
DDX3X	O
)	O
that	O
exhibited	O
antiviral	O
activities	O
,	O
which	O
were	O
further	O
verified	O
by	O
the	O
use	O
of	O
HCoV	O
-	O
OC43	O
-	O
WT	O
.	O

Factor	O
analysis	O
provided	O
a	O
questionnaire	O
of	O
23	O
items	O
on	O
5	O
dimensions	O
of	O
sleep	B-PROC
disturbance	O
in	O
coronary	O
patients	O
:	O
""""	O
sleep	B-PROC
onset	I-PROC
and	O
continuity	O
disorder	O
","""	O
""""	O
disorder	O
in	O
daytime	O
functioning	O
","""	O
""""	O
sleep	B-PROC
disturbance	O
caused	O
by	O
environmental	O
factors	O
","""	O
""""	O
sleep	B-PROC
disturbance	O
as	O
a	O
result	O
of	O
cardiac	O
diseases	O
","""	O
and	O
""""	O
respiratory	O
disorders	O
during	O
sleep	B-PROC
.	O

To	O
control	O
and	O
improve	O
the	O
sleep	B-PROC
quality	O
of	O
CCU	O
hospitalized	O
patients	O
,	O
we	O
need	O
to	O
identify	O
and	O
remove	O
predisposing	O
factors	O
.	O

In	O
the	O
first	O
group	O
(	O
APRV	O
)	O
the	O
airway	O
pressure	O
release	O
ventilation	O
was	O
used	O
;	O
the	O
second	O
group	O
(	O
SIMV	O
)	O
was	O
ventilated	O
using	O
synchronized	O
intermittent	O
mandatory	O
ventilation	O
mode	O
and	O
positive	O
end	O
expiratory	B-PROC
pressure	O
(	O
PEEP	O
).	O

Oxygenation	B-PROC
index	O
was	O
increased	O
,	O
airway	O
peak	O
pressure	O
(	O
Ppeak	O
)	O
was	O
reduced	O
,	O
the	O
lung	O
dynamic	O
compliance	O
improved	O
,	O
extravascular	O
lung	O
water	O
was	O
relieved	O
,	O
functional	B-PROC
residual	I-PROC
capacity	I-PROC
increased	O
and	O
Murray	O
score	O
was	O
improved	O
.	O

Viruses	O
have	O
evolved	O
the	O
capacity	O
to	O
overcome	O
the	O
protein	B-PROC
translation	B-PROC
shutoff	O
to	O
ensure	O
viral	O
protein	O
production	O
.	O

The	O
involvement	O
of	O
coronavirus	O
-	O
induced	O
stress	O
responses	O
and	O
translational	B-PROC
control	O
in	O
viral	O
pathogenesis	B-PROC
will	O
also	O
be	O
briefly	O
discussed	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
is	O
a	O
worldwide	O
-	O
distributed	O
alphacoronavirus	O
,	O
but	O
the	O
pathogenesis	B-PROC
of	O
PEDV	O
infection	O
is	O
not	O
fully	O
characterized	O
.	O

Since	O
PEDV	O
infection	O
-	O
induced	O
STAT1	O
degradation	O
was	O
evident	O
in	O
cells	O
pretreated	O
with	O
the	O
general	O
tyrosine	O
kinase	B-PROC
inhibitor	I-PROC
,	O
we	O
conclude	O
that	O
STAT1	O
degradation	O
is	O
independent	O
of	O
the	O
IFN	O
signaling	B-PROC
pathway	I-PROC
.	O

On	O
day	O
25	O
,	O
he	O
developed	O
fever	B-PROC
and	O
respiratory	O
distress	O
with	O
bilateral	O
pulmonary	O
infiltrates	O
,	O
suggesting	O
differentiation	B-PROC
syndrome	O
(	O
DS	O
)	O
caused	O
by	O
ATRA	O
.	O

The	O
use	O
of	O
thin	O
soft	O
silicone	O
foam	O
dressings	O
may	O
prevent	O
the	O
development	B-PROC
of	O
facial	O
deep	O
tissue	O
injuries	O
in	O
patients	O
receiving	O
prolonged	O
pronation	B-PROC
therapy	O
.	O

Results	O
suggest	O
that	O
the	O
demyelinating	O
strain	O
induced	O
an	O
innate	O
-	O
immune	B-PROC
response	I-PROC
during	O
acute	O
infection	O
that	O
may	O
promote	O
switching	O
of	O
Ig	O
isotype	O
genes	O
during	O
chronic	O
infection	O
,	O
potentially	O
playing	O
a	O
role	O
in	O
antibody	B-PROC
-	O
mediated	O
progressive	O
demyelination	O
even	O
after	O
viral	O
clearance	O
.	O

To	O
this	O
end	O
,	O
host	O
cell	B-PROC
signaling	I-PROC
pathways	B-PROC
influencing	O
porcine	O
CoV	O
virulence	B-PROC
should	O
be	O
identified	O
.	O

Similarly	O
,	O
the	O
identity	O
of	O
viral	O
proteins	O
involved	O
in	O
the	O
modulation	O
of	O
host	O
cell	O
pathways	B-PROC
influencing	O
CoV	O
pathogenesis	B-PROC
should	O
be	O
analyzed	O
.	O

In	O
addition	O
,	O
novel	O
antiviral	O
drugs	O
may	O
be	O
developed	O
once	O
the	O
host	O
cell	O
pathways	B-PROC
and	O
the	O
molecular	O
mechanism	O
affecting	O
porcine	O
CoV	O
replication	O
and	O
virulence	B-PROC
are	O
known	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
increasingly	O
being	O
used	O
to	O
treat	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Medically	O
critically	O
ill	O
patients	O
who	O
require	O
urgent	O
bedside	O
diagnostic	O
assessment	O
fall	O
into	O
2	O
categories	O
:	O
(	O
1	O
)	O
acute	O
respiratory	O
failure	O
and	O
(	O
2	O
)	O
hemodynamic	B-PROC
derangements	O
.	O

The	O
questionnaire	O
was	O
modified	O
for	O
this	O
study	O
to	O
include	O
26	O
items	O
that	O
were	O
divided	O
into	O
three	O
main	O
domains	O
of	O
interest	O
:	O
(	O
1	O
)	O
the	O
ability	O
to	O
care	O
for	O
critically	O
ill	O
MERS	O
-	O
CoV	O
patients	O
;	O
(	O
2	O
)	O
laboratory	O
capacity	O
to	O
diagnose	O
MERS	O
-	O
CoV	O
and	O
blood	O
bank	O
ability	O
to	O
prepare	O
convalescent	O
plasma	O
;	O
and	O
(	O
3	O
),	O
research	O
capacity	O
to	O
conduct	B-PROC
randomized	O
controlled	O
trials	O
.	O

Initial	O
resting	O
arterial	O
blood	B-PROC
gases	I-PROC
showed	O
mean	O
arterial	O
oxygen	B-PROC
tension	I-PROC
(	O
PaO2	O
)	O
61	O
mmHg	O
(	O
range	O
45	O
to	O
78	O
mmHg	O
),	O
mean	O
arterial	O
carbon	B-PROC
dioxide	I-PROC
tension	I-PROC
(	O
PaCO2	O
)	O
75	O
.	O
2	O
mmHg	O
(	O
range	O
32	O
to	O
127	O
mmHg	O
)	O
and	O
mean	O
arterial	O
pH	O
-	O
7	O
.	O
26	O
(	O
range	O
7	O
.	O
03	O
to	O
7	O
.	O
45	O
).	O

Mean	O
inspiratory	B-PROC
positive	O
airway	O
pressure	O
(	O
IPAP	O
)	O
was	O
14	O
cm	O
H2O	O
(	O
range	O
10	O
to	O
20	O
cm	O
H2O	O
).	O

MSCs	O
reduce	O
the	O
pro	O
-	O
inflammatory	B-PROC
response	I-PROC
to	O
injury	O
while	O
augmenting	O
the	O
host	B-PROC
response	I-PROC
to	O
bacterial	O
infection	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
can	O
be	O
a	O
lifesaving	O
therapy	O
in	O
patients	O
with	O
refractory	O
severe	O
respiratory	O
failure	O
or	O
cardiac	O
failure	O
.	O

We	O
report	O
on	O
a	O
-	O
48	O
-	O
year	O
-	O
old	O
man	O
with	O
ARDS	O
due	O
to	O
severe	O
pulmonary	O
tuberculosis	O
who	O
was	O
rescued	O
by	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O

Of	O
47	O
cases	O
,	O
22	O
were	O
given	O
oral	O
nutrition	B-PROC
,	O
28	O
were	O
fed	O
with	O
nasogastric	O
tube	O
and	O
4	O
with	O
nasojejunal	O
tube	O
feeding	O
,	O
2	O
with	O
percutaneous	O
endoscopic	O
gastrojejunostomy	O
tube	O
feeding	O
for	O
each	O
.	O

The	O
nutrition	B-PROC
indicators	O
before	O
and	O
after	O
EN	O
therapy	O
were	O
compared	O
by	O
paired	O
t	O
-	O
test	O
.	O

Both	O
are	O
based	O
on	O
an	O
older	O
concept	O
,	O
where	O
molecular	O
beacons	O
are	O
used	O
as	O
the	O
downstream	O
detection	O
of	O
viral	O
RNA	O
in	O
biological	O
mixtures	O
followed	O
by	O
reverse	B-PROC
transcription	B-PROC
PCR	O
amplification	O
.	O

Regulated	O
TRPV4	O
function	O
is	O
also	O
essential	O
for	O
healthy	O
cardiovascular	B-PROC
system	I-PROC
function	I-PROC
as	O
a	O
potent	O
agonist	O
compromises	O
endothelial	O
cell	B-PROC
function	I-PROC
,	O
leading	O
to	O
vascular	O
collapse	O
.	O

Due	O
to	O
its	O
wide	O
expression	B-PROC
profile	O
,	O
TRPV4	O
is	O
implicated	O
in	O
multiple	O
pathophysiological	O
states	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
the	O
first	O
time	O
determination	O
values	O
of	O
physiological	O
and	O
biochemical	O
indexes	O
after	O
admission	O
including	O
pH	O
value	O
,	O
base	O
excess	O
,	O
PaCO	O
(	O
2	O
),	O
PaO	B-PROC
(	O
2	O
),	O
hemoglobin	O
,	O
platelet	O
count	O
,	O
and	O
blood	O
sodium	O
of	O
patients	O
among	O
these	O
three	O
years	O
(	O
with	O
t	O
values	O
from	O
0	O
.	O
80	O
to	O
29	O
.	O
10	O
,	O
W	O
values	O
respectively	O
0	O
.	O
110	O
and	O
5	O
.	O
450	O
,	O
P	O
values	O
above	O
0	O
.	O
05	O
),	O
while	O
there	O
were	O
statistically	O
significant	O
differences	O
in	O
standard	O
bicarbonate	O
ion	O
,	O
leucocyte	O
count	O
,	O
neutrophile	O
granulocyte	O
,	O
albumin	O
,	O
urea	O
nitrogen	O
,	O
lactic	O
acid	O
,	O
and	O
blood	O
glucose	O
of	O
patients	O
among	O
these	O
three	O
years	O
(	O
with	O
t	O
values	O
from	O
1	O
542	O
.	O
00	O
to	O
500	O
000	O
.	O
00	O
,	O
W	O
values	O
from	O
637	O
.	O
000	O
to	O
500	O
000	O
.	O
000	O
,	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
trauma	O
integration	B-PROC
treatment	O
system	O
can	O
improve	O
the	O
treatment	O
quality	O
of	O
patients	O
with	O
severe	O
trauma	O
.	O

A	O
confirmed	O
case	O
was	O
defined	O
as	O
positive	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
test	O
for	O
MERS	O
-	O
CoV	O
.	O
RESULTS	O
Of	O
the	O
130	O
suspected	O
cases	O
,	O
81	O
(	O
62	O
%)	O
were	O
confirmed	O
and	O
49	O
(	O
38	O
%)	O
were	O
probable	O
.	O

Whole	O
exome	O
sequencing	O
revealed	O
biallelic	O
missense	B-PROC
mutations	I-PROC
in	O
the	O
NSMCE3	O
(	O
also	O
known	O
as	O
NDNL2	O
)	O
gene	O
,	O
which	O
encodes	O
a	O
subunit	O
of	O
the	O
SMC5	O
/	O
6	O
complex	O
that	O
is	O
essential	O
for	O
DNA	B-PROC
damage	I-PROC
response	I-PROC
and	O
chromosome	B-PROC
segregation	I-PROC
.	O

This	O
work	O
associates	O
missense	B-PROC
mutations	I-PROC
in	O
NSMCE3	O
with	O
an	O
autosomal	O
recessive	O
chromosome	B-PROC
breakage	I-PROC
syndrome	O
that	O
leads	O
to	O
defective	O
T	O
and	O
B	O
cell	B-PROC
function	I-PROC
and	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
early	O
childhood	O
.	O

Angiopoietin	O
-	O
2	O
and	O
IL	O
-	O
1	O
receptor	O
antagonist	B-PROC
concentrations	O
did	O
not	O
differ	O
between	O
groups	O
.	O

TITLE	O
:	O
Maternal	O
antibody	B-PROC
decay	O
and	O
antibody	B-PROC
-	O
mediated	O
immune	B-PROC
responses	I-PROC
in	O
chicken	O
pullets	O
fed	O
prebiotics	O
and	O
synbiotics	O
.	O

In	O
addition	O
,	O
specific	O
antibody	B-PROC
response	I-PROC
against	O
SRBC	O
and	O
BSA	O
was	O
not	O
affected	O
by	O
diets	O
.	O

The	O
incubation	O
periods	B-PROC
and	O
serial	O
intervals	O
were	O
estimated	O
.	O

Older	O
age	O
,	O
presence	O
of	O
coexisting	O
medical	O
conditions	O
including	O
diabetes	O
or	O
chronic	O
lung	O
disease	O
,	O
presence	O
of	O
dyspnea	O
,	O
hypotension	O
,	O
and	O
leukocytosis	O
at	O
admission	O
,	O
and	O
the	O
use	O
of	O
mechanical	O
ventilation	O
were	O
revealed	O
to	O
be	O
independent	O
predictors	O
of	O
death	B-PROC
.	O

We	O
describe	O
the	O
case	O
of	O
a	O
33	O
-	O
year	O
-	O
old	O
patient	O
who	O
developed	O
acute	O
cardiovascular	O
collapse	O
and	O
ARDS	O
secondary	O
to	O
superinfection	O
of	O
Panton	O
-	O
Valentine	O
leukocidin	O
-	O
positive	O
Staphylococcus	O
aureus	O
and	O
H1N1	O
pneumonia	O
who	O
underwent	O
successful	O
combination	O
therapy	O
for	O
severe	O
sepsis	O
-	O
related	O
cardiomyopathy	O
and	O
respiratory	O
failure	O
using	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
and	O
cytokine	O
adsorption	O
therapy	O
.	O

The	O
2	O
topics	O
may	O
converge	O
when	O
considering	O
the	O
intersection	O
of	O
autophagy	B-PROC
with	O
viral	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Severe	O
Thrombocytopenia	O
in	O
Adults	O
with	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
:	O
Impact	O
of	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
Use	O
.	O

However	O
,	O
the	O
patient	O
developed	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
on	O
the	O
2nd	O
day	O
,	O
and	O
as	O
a	O
result	O
,	O
she	O
underwent	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
).	O

She	O
was	O
weaned	B-PROC
from	O
ECMO	O
on	O
the	O
10th	O
day	O
,	O
as	O
her	O
respiratory	O
status	O
gradually	O
improved	O
.	O

Virus	B-PROC
replication	I-PROC
takes	O
place	O
within	O
the	O
host	O
cell	O
cytosol	O
,	O
whereas	O
assembly	O
and	O
budding	B-PROC
occur	O
at	O
the	O
endoplasmic	O
reticulum	O
-	O
Golgi	O
intermediate	O
compartment	O
.	O

ABSTRACT	O
:	O
Human	O
rhinovirus	O
(	O
HRV	O
)	O
and	O
coronavirus	O
(	O
HCoV	O
)	O
infections	O
are	O
associated	O
with	O
both	O
upper	O
respiratory	O
tract	O
illness	O
"("""	O
the	O
common	O
cold	B-PROC
""")"	O
and	O
lower	O
respiratory	O
tract	O
illness	O
(	O
pneumonia	O
).	O

TITLE	O
:	O
Antivirals	O
for	O
Respiratory	O
Viral	B-PROC
Infections	I-PROC
:	O
Problems	O
and	O
Prospects	O
.	O

Direct	O
bilirubin	O
and	O
the	O
arterial	O
oxygen	B-PROC
tension	I-PROC
/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
ratio	O
were	O
significantly	O
higher	O
in	O
the	O
SLED	O
group	O
.	O

We	O
identified	O
the	O
following	O
risk	O
factors	O
(	O
sensitivities	O
/	O
specificities	O
)	O
for	O
mortality	O
in	O
severe	O
leptospirosis	O
:	O
age	O
≥	O
55	O
years	O
(	O
67	O
%/	O
91	O
%);	O
serum	O
urea	O
≥	O
204	O
mg	O
/	O
dl	O
(	O
100	O
%/	O
70	O
%);	O
creatinine	O
≥	O
5	O
.	O
2	O
mg	O
/	O
dl	O
(	O
100	O
%/	O
58	O
%);	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
≥	O
39	O
.	O
5	O
(	O
67	O
%/	O
88	O
%);	O
Sequential	O
Organ	O
Failure	O
Assessment	O
score	O
≥	O
20	O
.	O
5	O
(	O
67	O
%/	O
85	O
%);	O
and	O
inspiratory	B-PROC
pressure	O
≥	O
31	O
mmHg	O
(	O
84	O
%/	O
85	O
%).	O

The	O
expressed	B-PROC
protein	O
was	O
purified	O
by	O
Ni	O
-	O
NTA	O
chromatography	O
column	O
.	O

TITLE	O
:	O
Mouse	O
Hepatitis	O
Virus	B-PROC
Infection	I-PROC
Induces	O
a	O
Toll	O
-	O
Like	O
Receptor	O
2	O
-	O
Dependent	O
Activation	O
of	O
Inflammatory	O
Functions	O
in	O
Liver	O
Sinusoidal	O
Endothelial	O
Cells	O
during	O
Acute	O
Hepatitis	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
proteins	O
of	O
coronaviruses	O
are	O
capable	O
of	O
binding	O
to	O
a	O
wide	O
range	O
of	O
cellular	O
targets	O
,	O
which	O
contributes	O
to	O
the	O
broad	O
species	O
tropism	B-PROC
of	O
coronaviruses	O
.	O

In	O
the	O
current	O
study	O
,	O
using	O
the	O
virus	O
overlay	O
protein	O
binding	O
assay	O
(	O
VOPBA	O
),	O
we	O
identified	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	B-PROC
adhesion	I-PROC
molecule	O
5	O
(	O
CEACAM5	O
)	O
as	O
a	O
novel	O
cell	O
surface	O
binding	O
target	O
of	O
MERS	O
-	O
CoV	O
.	O
CEACAM5	O
coimmunoprecipitated	O
with	O
the	O
spike	O
protein	O
of	O
MERS	O
-	O
CoV	O
in	O
both	O
overexpressed	O
and	O
endogenous	O
settings	O
.	O

Our	O
data	O
provide	O
evidence	O
that	O
PEDV	O
non	O
S	O
-	O
INDEL	B-PROC
strains	O
with	O
genetic	O
diversities	O
and	O
potential	O
recombination	B-PROC
circulate	O
in	O
seven	O
regions	O
of	O
China	O
in	O
2015	O
;	O
Chinese	O
PEDV	O
S	O
-	O
INDEL	B-PROC
strains	O
exhibit	O
genetic	O
diversity	O
and	O
co	O
-	O
circulate	O
with	O
non	O
S	O
-	O
INDEL	B-PROC
strains	O
.	O

PDCoV	O
was	O
detected	O
exclusively	O
from	O
nursing	B-PROC
piglets	O
with	O
an	O
overall	O
prevalence	O
of	O
approximate	O
1	O
.	O
28	O
%	O
(	O
5	O
/	O
390	O
),	O
not	O
in	O
suckling	O
and	O
fattening	O
piglets	O
.	O

On	O
histologic	O
analysis	O
,	O
left	O
pneumonectomy	O
followed	O
by	O
LPS	O
administration	O
induced	O
both	O
severe	O
inflammatory	O
cellular	B-PROC
infiltration	I-PROC
and	O
alveolar	O
wall	O
congestion	O
with	O
hemorrhage	O
.	O

rTM	O
may	O
have	O
the	O
potential	O
therapeutic	O
effect	O
for	O
surgical	O
ARDS	O
via	O
suppression	B-PROC
of	O
HMGB1	O
and	O
the	O
secretion	B-PROC
of	O
proinflammatory	O
cytokines	O
induced	O
by	O
the	O
administration	O
of	O
LPS	O
after	O
left	O
pneumonectomy	O
.	O

Poor	O
correlation	O
existed	O
between	O
TOF	O
and	O
oxygenation	B-PROC
index	O
(	O
OI	O
)	O
at	O
12	O
(	O
τ	O
=	O
0	O
.	O
03	O
),	O
24	O
(	O
τ	O
=	O
0	O
.	O
15	O
)	O
and	O
48	O
hours	O
(	O
τ	O
=	O
0	O
.	O
08	O
).	O

This	O
evaluation	O
demonstrates	O
that	O
the	O
use	O
of	O
TOF	O
monitoring	O
for	O
neuromuscular	B-PROC
blockade	I-PROC
does	O
not	O
correlate	O
with	O
gas	O
exchange	O
markers	O
in	O
moderate	O
to	O
severe	O
ARDS	O
.	O

General	O
strategies	O
to	O
design	O
specific	O
and	O
selective	O
drugs	O
targeting	B-PROC
helicase	O
for	O
the	O
treatment	O
of	O
viral	B-PROC
infections	I-PROC
could	O
act	O
via	O
one	O
or	O
more	O
of	O
the	O
following	O
mechanisms	O
:	O
inhibition	B-PROC
of	O
the	O
NTPase	O
activity	O
,	O
by	O
interferences	O
with	O
ATP	O
binding	O
and	O
therefore	O
by	O
limiting	O
the	O
energy	O
required	O
for	O
the	O
unwinding	O
and	O
translocation	B-PROC
,	O
or	O
by	O
allosteric	O
mechanism	O
and	O
therefore	O
by	O
stabilizing	O
the	O
conformation	O
of	O
the	O
enzyme	O
in	O
low	O
helicase	O
activity	O
state	O
;	O
inhibition	B-PROC
of	O
nucleic	O
acids	O
binding	O
to	O
the	O
helicase	O
;	O
inhibition	B-PROC
of	O
coupling	O
of	O
ATP	B-PROC
hydrolysis	I-PROC
to	O
unwinding	O
;	O
inhibition	B-PROC
of	O
unwinding	O
by	O
sterically	O
blocking	O
helicase	O
translocation	B-PROC
.	O

In	O
general	O
,	O
the	O
nucleotide	O
bias	O
was	O
the	O
major	O
determinant	O
of	O
the	O
virus	O
-	O
specific	O
codon	O
usages	O
,	O
thus	O
limiting	O
a	O
role	O
for	O
codon	O
selection	O
and	O
translational	B-PROC
control	O
.	O

TITLE	O
:	O
Predictive	O
factors	O
for	O
pneumonia	O
development	B-PROC
and	O
progression	O
to	O
respiratory	O
failure	O
in	O
MERS	O
-	O
CoV	O
infected	O
patients	O
.	O

The	O
identified	O
predictive	O
factors	O
for	O
pneumonia	O
development	B-PROC
included	O
age	O
≥	O
45	O
years	O
,	O
fever	B-PROC
≥	O
37	O
.	O
5	O
°	O
C	O
,	O
thrombocytopenia	O
,	O
lymphopenia	O
,	O
CRP	O
≥	O
2	O
mg	O
/	O
dL	O
,	O
and	O
a	O
threshold	O
cycle	O
value	O
of	O
PCR	O
less	O
than	O
28	O
.	O
5	O
.	O

In	O
vivo	O
phosphorylation	B-PROC
shows	O
that	O
SUD	O
does	O
not	O
regulate	O
phosphorylation	B-PROC
of	O
RCHY1	O
via	O
CAMK2D	O
.	O

The	O
%	O
FT	O
burn	O
predicted	O
the	O
development	B-PROC
of	O
moderate	O
to	O
severe	O
ARDS	O
[	O
OR	O
1	O
.	O
034	O
,	O
95	O
%	O
CI	O
(	O
1	O
.	O
013	O
-	O
1	O
.	O
055	O
),	O
p	O
=	O
0	O
.	O
001	O
].	O

TITLE	O
:	O
Rational	O
design	O
of	O
a	O
synthetic	O
mammalian	O
riboswitch	O
as	O
a	O
ligand	B-PROC
-	O
responsive	O
-	O
1	O
ribosomal	O
frame	O
-	O
shifting	O
stimulator	O
.	O

ABSTRACT	O
:	O
Metabolite	O
-	O
responsive	O
RNA	O
pseudoknots	O
derived	O
from	O
prokaryotic	O
riboswitches	O
have	O
been	O
shown	O
to	O
stimulate	O
-	O
1	O
programmed	O
ribosomal	B-PROC
frameshifting	I-PROC
(	O
PRF	B-PROC
),	O
suggesting	O
-	O
1	O
PRF	B-PROC
as	O
a	O
promising	O
gene	B-PROC
expression	I-PROC
platform	O
to	O
extend	O
riboswitch	O
applications	O
in	O
higher	O
eukaryotes	O
.	O

The	O
system	O
is	O
buttressed	O
by	O
three	O
fundamental	O
,	O
mutually	O
reinforcing	O
components	O
:	O
(	O
1	O
)	O
enduring	O
government	O
administration	O
reforms	O
,	O
including	O
legislation	O
establishing	O
a	O
unified	O
public	O
health	O
emergency	O
management	O
system	O
;	O
(	O
2	O
)	O
prioritized	O
funding	O
for	O
biotechnology	O
and	O
biomedicine	O
industrialization	O
,	O
especially	O
in	O
the	O
areas	O
of	O
pathogen	O
identification	O
,	O
drug	O
production	O
,	O
and	O
the	O
development	B-PROC
of	O
vaccines	O
and	O
diagnostics	O
;	O
and	O
(	O
3	O
)	O
increasing	O
investment	O
for	O
public	O
health	O
and	O
establishment	O
of	O
a	O
rapid	O
-	O
response	O
infectious	O
diseases	O
prevention	O
and	O
control	O
system	O
.	O

However	O
,	O
inefficient	O
replication	O
in	O
several	O
mucosa	O
-	O
derived	O
cell	O
lines	O
and	O
airway	O
epithelial	O
cultures	O
suggested	O
lack	O
of	O
adaptation	B-PROC
to	O
the	O
human	O
host	O
.	O

TITLE	O
:	O
Xanthine	O
Oxidase	O
-	O
Derived	O
ROS	O
Display	O
a	O
Biphasic	O
Effect	O
on	O
Endothelial	O
Cells	O
Adhesion	O
and	O
FAK	O
Phosphorylation	B-PROC
.	O

The	O
results	O
could	O
provide	O
a	O
reference	O
for	O
vaccine	O
development	B-PROC
and	O
the	O
prevention	O
of	O
infectious	O
bronchitis	O
in	O
southwestern	O
China	O
.	O

iNO	O
has	O
repeatedly	O
been	O
shown	O
to	O
transiently	O
improve	O
oxygenation	B-PROC
in	O
all	O
age	O
groups	O
,	O
and	O
yet	O
neonates	O
and	O
pediatric	O
patients	O
have	O
shown	O
improvement	O
in	O
other	O
outcomes	O
that	O
have	O
not	O
been	O
seen	O
in	O
adults	O
.	O

There	O
are	O
physiologic	O
studies	O
that	O
suggest	O
alternative	O
mechanisms	O
for	O
explaining	O
the	O
positive	O
effects	O
of	O
iNO	O
,	O
such	O
as	O
platelet	B-PROC
aggregation	I-PROC
inhibition	B-PROC
and	O
reduction	O
in	O
systemic	O
inflammation	O
.	O

Undertaking	O
clinical	O
trials	O
of	O
convalescent	O
plasma	O
for	O
passive	O
immunotherapy	O
of	O
MERS	O
-	O
CoV	O
infection	O
may	O
be	O
feasible	O
,	O
but	O
such	O
trials	O
would	O
be	O
challenging	O
because	O
of	O
the	O
small	O
pool	O
of	O
potential	O
donors	O
with	O
sufficiently	O
high	O
antibody	B-PROC
titers	O
.	O

Alternative	O
strategies	O
to	O
identify	O
convalescent	O
plasma	O
donors	O
with	O
adequate	O
antibody	B-PROC
titers	O
should	O
be	O
explored	O
,	O
including	O
the	O
sampling	O
of	O
serum	O
from	O
patients	O
with	O
more	O
severe	O
disease	O
and	O
sampling	O
at	O
earlier	O
points	O
during	O
illness	O
.	O

TITLE	O
:	O
Passive	O
Transfer	O
of	O
A	O
Germline	O
-	O
like	O
Neutralizing	O
Human	O
Monoclonal	O
Antibody	B-PROC
Protects	O
Transgenic	O
Mice	O
Against	O
Lethal	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
.	O

Several	O
neutralizing	O
human	O
monoclonal	O
antibodies	O
(	O
mAbs	O
),	O
including	O
m336	O
,	O
a	O
germline	O
-	O
like	O
human	O
mAb	O
,	O
have	O
been	O
chosen	O
as	O
promising	O
MCM	O
for	O
MERS	O
-	O
CoV	O
.	O
However	O
,	O
their	O
clinical	O
development	B-PROC
has	O
been	O
hindered	O
by	O
the	O
lack	O
of	O
a	O
robust	O
animal	O
model	O
that	O
recapitulate	O
the	O
morbidity	O
and	O
mortality	O
of	O
human	O
infections	O
.	O

TITLE	O
:	O
Upregulation	B-PROC
of	O
endothelial	O
cell	B-PROC
adhesion	I-PROC
molecules	O
characterizes	O
veins	O
close	O
to	O
granulomatous	O
infiltrates	O
in	O
the	O
renal	O
cortex	O
of	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
and	O
is	O
indirectly	O
triggered	O
by	O
feline	O
infectious	O
peritonitis	O
virus	O
-	O
infected	O
monocytes	O
in	O
vitro	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
Metastatic	O
Spinal	O
Tumor	O
Frailty	O
Index	O
(	O
MSTFI	O
)	O
Using	O
a	O
Nationwide	O
Database	O
and	O
Its	O
Association	O
with	O
Inpatient	O
Morbidity	O
,	O
Mortality	O
,	O
and	O
Length	O
of	O
Stay	O
After	O
Spine	O
Surgery	O
.	O

Twenty	O
-	O
two	O
percent	O
met	O
the	O
primary	O
outcome	O
,	O
21	O
%	O
died	B-PROC
,	O
and	O
57	O
%	O
developed	O
kidney	O
injury	O
.	O

MERS	O
-	O
CoV	O
is	O
an	O
enveloped	O
virus	O
,	O
and	O
its	O
envelope	O
protein	O
(	O
S	O
protein	O
)	O
mediates	O
membrane	B-PROC
fusion	I-PROC
at	O
the	O
plasma	O
membrane	O
or	O
endosomal	O
membrane	O
.	O

TMPRSS2	O
,	O
which	O
is	O
localized	O
to	O
the	O
plasma	O
membrane	O
,	O
is	O
a	O
serine	O
protease	O
responsible	O
for	O
the	O
proteolysis	B-PROC
of	O
S	O
in	O
the	O
post	O
-	O
receptor	O
-	O
binding	O
stage	O
.	O

ABSTRACT	O
:	O
The	O
ongoing	O
battle	O
against	O
current	O
and	O
rising	O
viral	O
infectious	O
threats	O
has	O
prompted	O
increasing	O
effort	B-PROC
in	O
the	O
development	B-PROC
of	O
vaccine	O
technology	O
.	O

TITLE	O
:	O
Frequency	O
of	O
electrophoretic	O
changes	O
consistent	O
with	O
feline	O
infectious	O
peritonitis	O
in	O
two	O
different	O
time	O
periods	B-PROC
(	O
2004	O
-	O
2009	O
vs	O
2013	O
-	O
2014	O
).	O

Transient	O
transfection	B-PROC
of	O
pFcRn	O
promoter	O
luciferase	O
report	O
plasmids	O
with	O
overexpression	B-PROC
of	O
NF	O
-	O
κB	O
p65	O
transcription	B-PROC
factor	O
enhanced	O
the	O
activation	O
of	O
the	O
luciferase	O
report	O
plasmids	O
.	O

TITLE	O
:	O
Influenza	O
-	O
like	O
illness	O
outbreaks	O
in	O
nursing	B-PROC
homes	O
in	O
Corsica	O
,	O
France	O
,	O
2014	O
-	O
2015	O
:	O
epidemiological	O
and	O
molecular	O
characterization	O
.	O

The	O
bundles	O
include	O
early	O
guideline	O
-	O
concordant	O
antibiotics	O
including	O
macrolides	O
,	O
early	O
haemodynamic	O
support	O
(	O
lactate	O
measurement	O
,	O
intravenous	O
fluids	O
,	O
and	O
vasopressors	O
),	O
and	O
early	O
respiratory	O
support	O
(	O
high	O
-	O
flow	O
nasal	O
cannulae	O
,	O
lung	O
-	O
protective	O
ventilation	O
,	O
prone	O
positioning	O
,	O
and	O
neuromuscular	B-PROC
blockade	I-PROC
for	O
acute	O
respiratory	O
distress	O
syndrome	O
).	O
While	O
the	O
proposed	O
interventions	O
appear	O
straightforward	O
,	O
multiple	O
barriers	O
to	O
their	O
implementation	O
exist	O
.	O

TITLE	O
:	O
MERS	O
coronavirus	O
induces	O
apoptosis	B-PROC
in	O
kidney	O
and	O
lung	O
by	O
upregulating	O
Smad7	O
and	O
FGF2	O
.	O

Smad7	O
and	O
FGF2	O
expression	B-PROC
were	O
elevated	O
in	O
the	O
lungs	O
and	O
kidneys	O
of	O
the	O
infected	O
animals	O
.	O

Our	O
results	O
provide	O
insights	O
into	O
the	O
pathogenesis	B-PROC
of	O
MERS	O
-	O
CoV	O
and	O
host	O
targets	O
for	O
treatment	O
.	O

An	O
esophageal	O
balloon	O
catheter	O
was	O
used	O
to	O
measure	O
esophageal	O
pressures	O
(	O
Pes	O
)	O
at	O
end	O
inspiration	B-PROC
and	O
end	O
expiration	B-PROC
and	O
to	O
calculate	O
P	O
L	O
.	O
Measurements	O
were	O
taken	O
during	O
ventilation	O
with	O
CMV	O
(	O
CMVpre	O
)	O
after	O
which	O
patients	O
were	O
switched	O
to	O
HFOV	O
with	O
three	O
1	O
-	O
h	O
different	O
levels	O
of	O
mPaw	O
set	O
at	O
+	O
5	O
,	O
+	O
10	O
and	O
+	O
15	O
cm	O
H2O	O
above	O
the	O
mean	O
airway	O
pressure	O
measured	O
during	O
CMV	O
.	O

We	O
observed	O
that	O
:	O
(	O
1	O
)	O
there	O
were	O
striking	O
differences	O
between	O
cases	O
and	O
controls	O
with	O
regard	O
to	O
three	O
biological	O
variables	O
:	O
post	O
-	O
exercise	O
M	O
-	O
wave	O
,	O
TBARS	O
variations	O
and	O
CD26	O
-	O
expression	B-PROC
at	O
rest	O
;	O
(	O
2	O
)	O
each	O
of	O
these	O
three	O
variables	O
correlated	O
with	O
the	O
other	O
two	O
;	O
(	O
3	O
)	O
abnormalities	O
in	O
the	O
biomarkers	O
associated	O
with	O
health	O
-	O
related	O
quality	O
of	O
life	O
:	O
the	O
LHS	O
score	O
was	O
negatively	O
correlated	O
with	O
the	O
exercise	O
-	O
induced	O
TBARS	O
increase	O
and	O
positively	O
correlated	O
with	O
CD26	O
-	O
expression	B-PROC
while	O
the	O
pain	O
component	O
of	O
SF	O
-	O
36	O
was	O
negatively	O
correlated	O
with	O
CD26	O
-	O
expression	B-PROC
;	O
(	O
4	O
)	O
the	O
TBARS	O
increase	O
and	O
the	O
M	O
-	O
wave	O
decrease	O
were	O
the	O
highest	O
,	O
and	O
the	O
CD26	O
-	O
expression	B-PROC
level	O
the	O
lowest	O
in	O
patients	O
who	O
had	O
been	O
submitted	O
to	O
infectious	O
stressors	O
.	O

RESULTS	O
:	O
We	O
observed	O
that	O
:	O
(	O
1	O
)	O
there	O
were	O
striking	O
differences	O
between	O
cases	O
and	O
controls	O
with	O
regard	O
to	O
three	O
biological	O
variables	O
:	O
post	O
-	O
exercise	O
M	O
-	O
wave	O
,	O
TBARS	O
variations	O
and	O
CD26	O
-	O
expression	B-PROC
at	O
rest	O
;	O
(	O
2	O
)	O
each	O
of	O
these	O
three	O
variables	O
correlated	O
with	O
the	O
other	O
two	O
;	O
(	O
3	O
)	O
abnormalities	O
in	O
the	O
biomarkers	O
associated	O
with	O
health	O
-	O
related	O
quality	O
of	O
life	O
:	O
the	O
LHS	O
score	O
was	O
negatively	O
correlated	O
with	O
the	O
exercise	O
-	O
induced	O
TBARS	O
increase	O
and	O
positively	O
correlated	O
with	O
CD26	O
-	O
expression	B-PROC
while	O
the	O
pain	O
component	O
of	O
SF	O
-	O
36	O
was	O
negatively	O
correlated	O
with	O
CD26	O
-	O
expression	B-PROC
;	O
(	O
4	O
)	O
the	O
TBARS	O
increase	O
and	O
the	O
M	O
-	O
wave	O
decrease	O
were	O
the	O
highest	O
,	O
and	O
the	O
CD26	O
-	O
expression	B-PROC
level	O
the	O
lowest	O
in	O
patients	O
who	O
had	O
been	O
submitted	O
to	O
infectious	O
stressors	O
.	O

Twelve	O
months	O
after	O
admission	O
,	O
her	O
neurological	O
symptoms	O
gradually	O
improved	O
and	O
she	O
was	O
weaned	B-PROC
off	O
of	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
Synbiotics	O
suppress	O
the	O
release	O
of	O
lactate	O
dehydrogenase	O
,	O
promote	O
non	B-PROC
-	I-PROC
specific	B-PROC
immunity	I-PROC
and	O
integrity	O
of	O
jejunum	O
mucosa	O
in	O
piglets	O
.	O

The	O
aim	O
of	O
our	O
experiment	O
was	O
to	O
study	O
how	O
synbiotics	O
are	O
able	O
to	O
deal	O
with	O
the	O
problems	O
of	O
post	O
-	O
weaning	B-PROC
piglets	O
.	O

Probiotics	O
and	O
flaxseed	O
applied	O
together	O
seem	O
to	O
be	O
a	O
good	O
source	O
of	O
nutrients	O
to	O
improve	O
the	O
immune	B-PROC
status	I-PROC
and	O
the	O
integrity	O
of	O
jejunum	O
mucosa	O
during	O
infection	O
.	O

ABSTRACT	O
:	O
On	O
the	O
basis	O
of	O
partial	O
sequencing	O
of	O
the	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
S1	O
gene	O
,	O
this	O
study	O
investigated	O
the	O
molecular	O
diversity	O
of	O
the	O
virus	O
in	O
two	O
life	O
periods	B-PROC
of	O
a	O
batch	O
of	O
breeding	B-PROC
hens	O
at	O
the	O
field	O
level	O
.	O

We	O
critically	O
review	O
the	O
literature	O
on	O
the	O
release	O
of	O
respiratory	O
droplets	O
,	O
their	O
transport	B-PROC
and	O
dispersion	O
in	O
the	O
indoor	O
environment	O
,	O
and	O
the	O
ultimate	O
exposure	O
of	O
a	O
susceptible	O
host	O
,	O
as	O
influenced	O
by	O
airflows	O
.	O

These	O
droplets	O
or	O
droplet	O
nuclei	O
are	O
transported	O
by	O
expired	O
airflows	O
,	O
which	O
are	O
sometimes	O
affected	O
by	O
the	O
human	O
body	O
plume	O
and	O
use	O
of	O
a	O
face	O
mask	O
,	O
as	O
well	O
as	O
room	O
airflow	B-PROC
.	O

Birds	O
of	O
LK	O
and	O
SN	O
varieties	O
also	O
indicated	O
maximum	O
antibody	B-PROC
titer	O
against	O
NDV	O
and	O
IBV	O
,	O
respectively	O
.	O

TITLE	O
:	O
[	O
Predictive	O
values	O
of	O
different	O
critical	O
scoring	O
systems	O
for	O
mortality	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
failure	O
supported	O
by	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
].	O

RESULTS	O
:	O
(	O
1	O
)	O
Positive	O
end	O
expiratory	B-PROC
pressure	O
(	O
PEEP	O
)	O
6	O
hours	O
prior	O
to	O
VV	O
-	O
ECMO	O
support	O
in	O
the	O
survivors	O
group	O
[(	O
9	O
.	O
7	O
±	O
5	O
.	O
0	O
)	O
cmH2O	O
,	O
(	O
1	O
cmH2O	O
=	O
0	O
.	O
098	O
kPa	O
)]	O
was	O
lower	O
than	O
that	O
in	O
the	O
nonsurvivors	O
group	O
[(	O
13	O
.	O
2	O
±	O
5	O
.	O
4	O
)	O
cmH2O	O
,	O
t	O
=-	O
2	O
.	O
134	O
,	O
P	O
=	O
0	O
.	O
039	O
].	O

TITLE	O
:	O
MicroRNA	O
-	O
155	O
enhances	O
T	O
cell	O
trafficking	B-PROC
and	O
antiviral	O
effector	O
function	O
in	O
a	O
model	O
of	O
coronavirus	O
-	O
induced	O
neurologic	O
disease	O
.	O

We	O
believe	O
that	O
addressing	O
beliefs	O
,	O
attitudes	O
,	O
capacity	O
,	O
and	O
supportive	O
infrastructures	O
to	O
sustain	O
hand	O
-	O
hygiene	O
routine	O
behaviors	B-PROC
are	O
important	O
components	O
of	O
an	O
implementation	O
strategy	O
in	O
enhancing	O
health	O
care	O
workers	O
'	O
KAP	O
of	O
hand	O
hygiene	O
.	O

Prespecified	O
outcomes	O
included	O
mortality	O
,	O
time	O
to	O
death	B-PROC
and	O
time	O
-	O
to	O
-	O
unassisted	O
breathing	B-PROC
.	O

Asplenic	O
patients	O
may	O
be	O
at	O
additional	O
increased	O
risk	O
of	O
intravascular	O
haemolysis	B-PROC
.	O

ABSTRACT	O
:	O
The	O
current	O
outbreaks	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
and	O
Ebolavirus	O
(	O
EboV	O
)	O
have	O
revealed	O
a	O
gap	O
in	O
the	O
development	B-PROC
and	O
availability	O
of	O
drugs	O
to	O
treat	O
these	O
infections	O
.	O

Among	O
the	O
261	O
confirmed	O
cases	O
of	O
dengue	O
fever	B-PROC
non	O
-	O
severe	O
and	O
severe	O
dengue	O
infection	O
was	O
seen	O
in	O
60	O
.	O
9	O
%	O
and	O
39	O
.	O
1	O
%,	O
respectively	O
.	O

There	O
were	O
six	O
deaths	B-PROC
(	O
2	O
.	O
3	O
%)	O
and	O
out	O
of	O
them	O
four	O
presented	O
with	O
impaired	O
consciousness	O
(	O
66	O
.	O
6	O
%).	O

There	O
has	O
been	O
a	O
resurgence	O
of	O
dengue	O
fever	B-PROC
with	O
a	O
change	O
in	O
the	O
pattern	O
of	O
presentation	O
during	O
the	O
recent	O
epidemics	O
.	O

TITLE	O
:	O
Selection	O
of	O
reference	O
genes	O
for	O
gene	B-PROC
expression	I-PROC
analysis	O
by	O
real	O
-	O
time	O
qPCR	O
in	O
avian	O
cells	O
infected	O
with	O
infectious	O
bronchitis	O
virus	O
.	O

In	O
1	O
case	O
,	O
they	O
started	O
cisatracurium	O
,	O
and	O
in	O
3	O
others	O
,	O
they	O
initiated	O
inhaled	B-PROC
epoprostenol	O
.	O

Thus	O
,	O
peptide	O
-	O
based	O
vaccines	O
against	O
SARS	O
-	O
CoV	O
could	O
be	O
engineered	O
to	O
avoid	O
ADE	O
via	O
elimination	B-PROC
of	O
the	O
S597	O
-	O
603	O
epitope	O
.	O

We	O
provide	O
herein	O
an	O
alternative	O
strategy	O
to	O
prepare	O
a	O
safe	O
and	O
effective	O
vaccine	O
for	O
ADE	O
of	O
viral	B-PROC
infection	I-PROC
by	O
identifying	O
and	O
eliminating	O
epitope	O
sequence	O
-	O
dependent	O
enhancement	O
of	O
viral	B-PROC
infection	I-PROC
.	O

This	O
review	O
highlights	O
recent	O
advances	O
in	O
the	O
development	B-PROC
of	O
biologically	O
active	O
spirooxindoles	O
for	O
their	O
antiviral	O
potential	O
,	O
primarily	O
focusing	O
on	O
the	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
and	O
modes	O
of	O
action	O
,	O
as	O
well	O
as	O
future	O
directions	O
to	O
achieve	O
more	O
potent	O
analogues	O
toward	O
a	O
viable	O
antiviral	O
therapy	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
application	O
of	O
multiplex	O
PCR	O
assays	O
for	O
detection	B-PROC
of	I-PROC
virus	I-PROC
-	O
induced	O
respiratory	O
disease	O
complex	O
in	O
dogs	O
.	O

Plasma	O
proinflammatory	O
markers	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
and	O
anti	O
-	O
inflammatory	O
marker	O
IL	O
-	O
10	O
were	O
associated	O
with	O
the	O
development	B-PROC
of	O
ARDS	O
(	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
1	O
.	O
55	O
,	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1	O
.	O
14	O
,	O
2	O
.	O
11	O
,	O
P	O
=	O
0	O
.	O
005	O
for	O
IL	O
-	O
6	O
;	O
adjusted	O
HR	O
=	O
1	O
.	O
32	O
,	O
CI	O
=	O
1	O
.	O
10	O
,	O
1	O
.	O
59	O
,	O
P	O
=	O
0	O
.	O
003	O
for	O
IL	O
-	O
8	O
).	O

Herein	O
,	O
we	O
report	O
the	O
first	O
bacterial	O
expression	B-PROC
,	O
enzyme	O
purification	O
,	O
and	O
biochemical	O
characterization	O
of	O
MERS	O
-	O
CoV	O
helicase	O
.	O

Chromatin	O
immunoprecipitation	O
,	O
dual	O
-	O
luciferase	O
reporter	O
gene	O
assay	O
,	O
and	O
co	O
-	O
immunoprecipitation	O
experiments	O
illustrated	O
that	O
PEDV	O
-	O
N	O
could	O
induce	O
HMGB1	O
transcription	B-PROC
by	O
interacting	O
with	O
C	O
/	O
EBP	O
-	O
β	O
,	O
which	O
could	O
bind	O
to	O
C	O
/	O
EBP	O
motif	O
in	O
HMGB1	O
promotor	O
region	O
.	O

Cell	O
clones	O
expressed	B-PROC
interferon	O
beta	O
in	O
response	O
to	O
poly	O
(	O
I	O
:	O
C	O
)	O
stimulation	O
and	O
supported	O
the	O
replication	O
of	O
four	O
different	O
viruses	O
,	O
namely	O
,	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
),	O
porcine	O
epidemic	O
diarrhea	O
coronavirus	O
(	O
PED	O
-	O
CoV	O
),	O
Middle	O
-	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
).	O

The	O
chance	O
of	O
catch	O
-	O
up	O
growth	B-PROC
may	O
decrease	O
the	O
number	O
of	O
pervious	O
""""	O
diagnosed	O
""""	O
microcephaly	O
.	O

The	O
Common	O
Vampire	O
Bat	O
(	O
Desmodus	O
rotundus	O
),	O
due	O
to	O
its	O
abundance	O
,	O
sanguivorous	O
feeding	O
habit	O
involving	O
humans	O
and	O
domestic	O
animals	O
,	O
and	O
highly	O
social	O
behavioral	B-PROC
ecology	O
,	O
may	O
have	O
an	O
unusually	O
high	O
potential	O
for	O
interspecies	O
disease	O
transmission	O
.	O

To	O
investigate	O
this	O
dichotomy	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
we	O
developed	O
a	O
transcriptional	B-PROC
network	I-PROC
model	O
of	O
SARS	O
-	O
CoV	O
infection	O
in	O
mice	O
and	O
used	O
the	O
model	O
to	O
prioritize	O
candidate	O
regulatory	O
targets	O
for	O
further	O
investigation	O
.	O

The	O
results	O
presented	O
here	O
suggest	O
the	O
role	O
of	O
Kepi	O
in	O
the	O
host	B-PROC
response	I-PROC
to	O
SARS	O
-	O
CoV	O
,	O
as	O
well	O
as	O
inflammatory	O
activity	O
driving	O
pathogenesis	B-PROC
through	O
TNFα	O
signaling	B-PROC
in	O
SARS	O
-	O
CoV	O
infections	O
.	O

by	O
reverse	O
line	O
blot	O
hybridization	B-PROC
assay	O
.	O

Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
typically	O
used	O
when	O
conventional	O
therapy	O
fails	O
.	O

The	O
accepted	O
definition	O
of	O
'	O
influenza	O
-	O
like	O
illness	O
'	O
includes	O
fever	B-PROC
and	O
may	O
be	O
insensitive	O
for	O
surveillance	O
when	O
high	O
case	O
-	O
finding	O
is	O
required	O
.	O

We	O
found	O
that	O
the	O
loss	O
of	O
G	O
-	O
CSF	O
recapitulated	O
the	O
neutrophil	O
response	O
of	O
Ly6G	O
-	O
treated	O
mice	O
and	O
was	O
associated	O
with	O
defective	O
alveolar	O
epithelial	O
repair	B-PROC
,	O
similar	O
to	O
neutrophil	O
-	O
depleted	O
mice	O
,	O
and	O
was	O
reversed	O
by	O
administration	O
of	O
exogenous	O
G	O
-	O
CSF	O
.	O

The	O
viruses	O
most	O
strongly	O
associated	O
with	O
febrile	B-PROC
seizures	O
were	O
influenza	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
parainfluenza	O
,	O
human	O
coronavirus	O
,	O
and	O
rotavirus	O
.	O

Antibody	B-PROC
titers	O
were	O
measurable	O
between	O
14	O
and	O
42	O
dpi	O
.	O

TITLE	O
:	O
Awareness	O
of	O
droplet	O
and	O
airborne	O
isolation	O
precautions	O
among	O
dental	O
health	O
professionals	O
during	O
the	O
outbreak	O
of	O
corona	O
virus	B-PROC
infection	I-PROC
in	O
Riyadh	O
city	O
,	O
Saudi	O
Arabia	O
.	O

Oxygen	B-PROC
content	I-PROC
was	O
significantly	O
different	O
between	O
PFC	O
post	O
-	O
OA	O
and	O
the	O
control	O
(	O
p	O
=	O
0	O
.	O
001	O
).	O

Commonest	O
symptoms	O
were	O
fever	B-PROC
(	O
84	O
.	O
2	O
%;	O
379	O
/	O
450	O
),	O
cough	O
(	O
97	O
.	O
8	O
%;	O
440	O
/	O
450	O
)	O
and	O
rhinorrhea	O
(	O
83	O
.	O
6	O
%;	O
376	O
/	O
450	O
).	O

IFITM3	O
knockdown	O
by	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
could	O
partially	O
rescue	O
H1N1	O
virus	B-PROC
infection	I-PROC
in	O
HULEC	O
,	O
suggesting	O
IFITM3	O
proteins	O
were	O
involved	O
in	O
blocking	O
human	O
influenza	O
virus	B-PROC
infection	I-PROC
in	O
endothelial	O
cells	O
.	O

Collectively	O
,	O
our	O
study	O
demonstrates	O
that	O
the	O
human	O
pulmonary	O
endothelium	O
possesses	O
intrinsic	O
immunity	B-PROC
to	O
human	O
influenza	O
viruses	O
,	O
in	O
part	O
due	O
to	O
the	O
constitutive	O
expression	B-PROC
of	O
IFITM3	O
proteins	O
.	O

Epitope	B-PROC
spreading	I-PROC
,	O
molecular	B-PROC
mimicry	I-PROC
,	O
cryptic	O
antigen	O
,	O
and	O
bystander	O
activation	O
have	O
been	O
implicated	O
as	O
mechanisms	O
responsible	O
for	O
activating	O
self	O
-	O
reactive	O
(	O
SR	O
)	O
immune	O
cells	O
,	O
ultimately	O
leading	O
to	O
organ	O
-	O
specific	O
autoimmune	O
disease	O
.	O

Genome	O
replication	O
and	O
transcription	B-PROC
is	O
mediated	O
by	O
a	O
multisubunit	O
protein	O
complex	O
comprised	O
of	O
more	O
than	O
a	O
dozen	O
virus	O
-	O
encoded	O
proteins	O
.	O

We	O
discuss	O
the	O
structural	O
and	O
functional	O
features	O
of	O
these	O
cis	O
-	O
acting	O
RNA	O
elements	O
and	O
their	O
specific	O
functions	O
in	O
coronavirus	O
RNA	B-PROC
synthesis	I-PROC
.	O

The	O
5	O
'-	O
terminal	O
two	O
-	O
thirds	O
of	O
the	O
genome	O
contain	O
two	O
open	O
reading	O
frames	O
(	O
ORFs	O
),	O
1a	O
and	O
1b	O
,	O
that	O
together	O
make	O
up	O
the	O
viral	O
replicase	O
gene	O
and	O
encode	O
two	O
large	O
polyproteins	O
that	O
are	O
processed	O
by	O
viral	O
proteases	O
into	O
15	O
-	O
16	O
nonstructural	O
proteins	O
,	O
most	O
of	O
them	O
being	O
involved	O
in	O
viral	O
RNA	B-PROC
synthesis	I-PROC
.	O

ABSTRACT	O
:	O
Virus	O
vaccines	O
have	O
to	O
be	O
immunogenic	O
,	O
sufficiently	O
stable	O
,	O
safe	O
,	O
and	O
suitable	O
to	O
induce	O
long	O
-	O
lasting	O
immunity	B-PROC
.	O

In	O
most	O
cases	O
,	O
the	O
latter	O
induce	O
long	O
-	O
lasting	O
immunity	B-PROC
but	O
they	O
may	O
require	O
special	O
safety	O
measures	O
to	O
prevent	O
reversion	O
to	O
highly	O
virulent	O
viruses	O
following	O
vaccination	O
.	O

Lung	O
inflammation	O
in	O
surviving	O
infected	O
mice	O
peaked	O
14	O
days	O
after	O
initial	O
infection	O
,	O
accompanied	O
marked	O
focal	O
distal	O
airway	O
bronchiolization	O
and	O
epithelial	O
metaplasia	B-PROC
followed	O
by	O
desquamation	O
and	O
fibrotic	O
interstitial	O
remodeling	O
,	O
and	O
persisted	O
for	O
at	O
least	O
6	O
weeks	O
.	O

Most	O
deaths	B-PROC
occurred	O
during	O
the	O
second	O
week	O
of	O
infection	O
in	O
both	O
groups	O
of	O
mice	O
.	O

Two	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
(	O
R642M	O
and	O
N714K	O
)	O
in	O
the	O
S	O
protein	O
of	O
HCoV	O
-	O
229E	O
clinical	O
isolates	O
altered	O
their	O
sensitivity	O
to	O
a	O
cathepsin	O
L	O
inhibitor	O
,	O
suggesting	O
that	O
these	O
amino	O
acids	O
were	O
responsible	O
for	O
cathepsin	O
L	O
use	O
.	O

These	O
results	O
suggest	O
that	O
the	O
endosomal	O
pathway	B-PROC
is	O
disadvantageous	O
for	O
HCoV	O
-	O
229E	O
infection	O
of	O
human	O
airway	O
epithelial	O
cells	O
;	O
therefore	O
,	O
clinical	O
isolates	O
are	O
less	O
able	O
to	O
use	O
cathepsin	O
.	O

In	O
particular	O
,	O
Rotavirus	O
is	O
the	O
cause	O
of	O
more	O
than	O
2	O
million	O
hospitalizations	O
and	O
over	O
half	O
a	O
million	O
deaths	B-PROC
from	O
acute	O
GE	O
in	O
infants	O
and	O
young	O
children	O
.	O

TITLE	O
:	O
Bioinformatics	O
and	O
functional	O
analyses	O
of	O
coronavirus	O
nonstructural	O
proteins	O
involved	O
in	O
the	O
formation	B-PROC
of	O
replicative	O
organelles	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
discuss	O
the	O
function	O
of	O
proteins	O
responsible	O
for	O
formation	B-PROC
of	O
the	O
coronavirus	O
replicative	O
organelle	O
.	O

Knowledge	O
about	O
the	O
pathways	B-PROC
and	O
mechanisms	O
of	O
transmission	O
from	O
animals	O
to	O
humans	O
is	O
limited	O
;	O
as	O
of	O
yet	O
,	O
transmission	O
risks	O
have	O
not	O
been	O
quantified	O
.	O

Overexpression	B-PROC
of	O
Nur77	O
markedly	O
decreased	O
basal	O
and	O
LPS	O
-	O
induced	O
ET	O
-	O
1	O
expression	B-PROC
in	O
A549	O
cells	O
,	O
whereas	O
knockdown	O
of	O
Nur77	O
increased	O
the	O
ET	O
-	O
1	O
expression	B-PROC
.	O

If	O
not	O
properly	O
accounted	O
for	O
,	O
recombination	B-PROC
can	O
compromise	O
many	O
evolutionary	O
analyses	O
.	O

Since	O
June	O
2012	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
caused	O
1	O
,	O
106	O
laboratory	O
-	O
confirmed	O
infections	O
,	O
with	O
421	O
MERS	O
-	O
CoV	O
-	O
associated	O
deaths	B-PROC
as	O
of	O
16	O
April	O
2015	O
.	O

In	O
this	O
article	O
,	O
we	O
use	O
phylogenetic	O
methods	O
and	O
simulations	O
to	O
show	O
that	O
MERS	O
-	O
CoV	O
genome	O
has	O
likely	O
undergone	O
numerous	O
recombinations	B-PROC
recently	O
.	O

ABSTRACT	O
:	O
The	O
incubation	O
period	O
is	O
an	O
important	O
epidemiologic	O
distribution	O
,	O
it	O
is	O
often	O
incorporated	O
in	O
case	O
definitions	O
,	O
used	O
to	O
determine	O
appropriate	O
quarantine	O
periods	B-PROC
,	O
and	O
is	O
an	O
input	O
to	O
mathematical	O
modeling	O
studies	O
.	O

Also	O
,	O
disuse	O
and	O
loss	O
of	O
peripheral	O
muscle	O
and	O
diaphragm	B-PROC
function	I-PROC
is	O
increasingly	O
recognized	O
,	O
and	O
thus	O
spontaneous	O
breathing	B-PROC
may	O
confer	O
additional	O
advantage	O
.	O

Notwithstanding	O
the	O
central	O
place	O
of	O
spontaneous	O
breathing	B-PROC
in	I-PROC
mechanical	O
ventilation	O
,	O
accumulating	O
evidence	O
indicates	O
that	O
it	O
may	O
cause	O
-	O
or	O
worsen	O
-	O
acute	O
lung	O
injury	O
,	O
especially	O
if	O
acute	O
respiratory	O
distress	O
syndrome	O
is	O
severe	O
and	O
spontaneous	O
effort	B-PROC
is	O
vigorous	O
.	O

Fusion	O
occurs	O
only	O
after	O
S	O
proteins	O
are	O
cleaved	O
sequentially	O
,	O
first	O
during	O
their	O
secretion	B-PROC
through	O
the	O
exocytic	O
organelles	O
of	O
virus	O
-	O
producing	O
cells	O
,	O
and	O
second	O
after	O
virus	O
binding	O
to	O
target	O
-	O
cell	O
receptors	O
.	O

PRRSV	O
,	O
a	O
leading	O
swine	O
pathogen	O
,	O
causes	O
reproductive	B-PROC
failure	O
in	O
breeding	B-PROC
stock	O
and	O
respiratory	O
tract	O
illness	O
in	O
young	O
pigs	O
.	O

WQ	O
-	O
IDL	O
and	O
MT	O
-	O
WQ	O
-	O
IDL	O
were	O
also	O
more	O
effective	O
than	O
WQ	O
in	O
blocking	O
HIV	O
-	O
1	O
Env	O
-	O
mediated	O
membrane	B-PROC
fusion	I-PROC
and	O
had	O
higher	O
levels	O
of	O
binding	O
affinity	O
with	O
NHR	O
peptide	O
N46	O
.	O

TITLE	O
:	O
Recombinant	O
Receptor	O
-	O
Binding	O
Domains	O
of	O
Multiple	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronaviruses	O
(	O
MERS	O
-	O
CoVs	O
)	O
Induce	O
Cross	O
-	O
Neutralizing	O
Antibodies	O
against	O
Divergent	O
Human	O
and	O
Camel	O
MERS	O
-	O
CoVs	O
and	O
Antibody	B-PROC
Escape	O
Mutants	O
.	O

ABSTRACT	O
:	O
Within	O
the	O
last	O
15	O
years	O
,	O
two	O
related	O
coronaviruses	O
(	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
[	O
SARS	O
]-	O
CoV	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
[	O
MERS	O
]-	O
CoV	O
)	O
expanded	O
their	O
host	O
range	O
to	O
include	O
humans	O
,	O
with	O
increased	O
virulence	B-PROC
in	O
their	O
new	O
host	O
.	O

Our	O
data	O
highlight	O
the	O
variety	O
of	O
presentations	O
that	O
may	O
be	O
seen	O
with	O
HCoV	O
-	O
NL63	O
,	O
and	O
underscore	O
the	O
apparent	O
ease	O
with	O
which	O
CoV	O
strains	O
move	B-PROC
among	O
countries	O
,	O
with	O
our	O
data	O
consistent	O
with	O
recurrent	O
introduction	O
of	O
strains	O
into	O
the	O
Caribbean	O
(	O
Haiti	O
and	O
Florida	O
)	O
from	O
Asia	O
.	O

The	O
mortality	O
trends	O
and	O
current	O
mortality	O
were	O
calculated	O
for	O
subgroups	O
consisting	O
of	O
in	O
-	O
hospital	O
,	O
ICU	O
,	O
28	O
/	O
30	O
-	O
d	O
,	O
and	O
60	O
-	O
d	O
mortality	O
over	O
3	O
time	O
periods	B-PROC
(	O
A	O
,	O
before	O
1995	O
;	O
B	O
,	O
1995	O
-	O
2000	O
;	O
C	O
,	O
after	O
2000	O
).	O

The	O
identification	O
of	O
the	O
3Cpro	O
cleavage	B-PROC
site	O
at	O
the	O
C	O
terminus	O
of	O
N	O
supported	O
previous	O
observations	O
that	O
PEDV	O
3Cpro	O
showed	O
a	O
substrate	O
requirement	O
slightly	O
different	O
from	O
that	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
3Cpro	O
and	O
revealed	O
a	O
greater	O
flexibility	O
in	O
its	O
substrate	O
recognition	O
site	O
.	O

Next	O
,	O
we	O
challenged	O
both	O
vaccinated	O
mice	O
and	O
control	O
mice	O
with	O
MERS	O
-	O
CoV	O
after	O
adenovirus	O
transduction	B-PROC
of	O
the	O
human	O
dipeptidyl	O
peptidase	O
4	O
(	O
hDPP4	O
)	O
receptor	O
and	O
then	O
analyzed	O
the	O
ability	O
of	O
mice	O
to	O
control	O
MERS	O
-	O
CoV	O
infection	O
.	O

Serial	O
blood	O
samples	O
were	O
obtained	O
every	O
2	O
days	O
until	O
extubation	O
or	O
death	B-PROC
(	O
from	O
1	O
to	O
9	O
samples	O
per	O
patient	O
).	O

Viral	O
growth	B-PROC
depends	O
on	O
many	O
host	O
factors	O
,	O
but	O
human	O
cells	O
may	O
not	O
provide	O
the	O
ideal	O
growth	B-PROC
conditions	O
for	O
viruses	O
invading	O
from	O
nonhuman	O
hosts	O
.	O

Cytoplasmic	O
GLTSCR2	O
was	O
able	O
to	O
interact	O
with	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
I	O
(	O
RIG	O
-	O
I	O
)	O
and	O
the	O
ubiquitin	B-PROC
-	O
specific	O
protease	O
15	O
(	O
USP15	O
),	O
and	O
the	O
triple	O
interaction	O
induced	O
USP15	O
activity	O
to	O
remove	O
K63	O
-	O
linked	O
ubiquitination	B-PROC
of	O
RIG	O
-	O
I	O
,	O
leading	O
to	O
attenuation	O
of	O
RIG	O
-	O
I	O
and	O
IFN	O
-	O
β	O
.	O

Secondary	O
outcomes	O
included	O
development	B-PROC
of	O
acute	O
kidney	O
injury	O
,	O
acute	O
decompensated	O
heart	O
failure	O
(	O
ADHF	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
stroke	O
,	O
and	O
severe	O
sepsis	O
in	O
the	O
ICU	O
.	O

TITLE	O
:	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
(	O
ECMO	O
)	O
for	O
Lung	O
Injury	O
in	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
):	O
Review	O
of	O
the	O
Literature	O
.	O

Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
a	O
modified	O
cardiopulmonary	O
bypass	O
circuit	O
that	O
serves	O
as	O
an	O
artificial	O
membrane	O
lung	O
and	O
blood	O
pump	O
to	O
provide	O
gas	O
exchange	O
and	O
systemic	O
perfusion	O
for	O
patients	O
when	O
their	O
own	O
heart	O
and	O
lungs	O
are	O
unable	O
to	O
function	O
adequately	O
.	O

Case	O
n	O
In	O
dermatomyositis	O
,	O
anti	O
-	O
MDA5	O
antibody	B-PROC
screening	O
is	O
essential	O
for	O
the	O
prognosis	O
since	O
the	O
disease	O
carries	O
a	O
risk	O
of	O
complication	O
with	O
severe	O
lung	O
disease	O
.	O

TITLE	O
:	O
T	O
-	O
cell	O
immunity	B-PROC
of	O
SARS	O
-	O
CoV	O
:	O
Implications	O
for	O
vaccine	O
development	B-PROC
against	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Over	O
12	O
years	O
have	O
elapsed	O
since	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
triggered	O
the	O
first	O
global	O
alert	O
for	O
coronavirus	O
infections	O
.	O

TITLE	O
:	O
Celastrol	O
inhibits	O
dengue	O
virus	B-PROC
replication	I-PROC
via	O
up	O
-	O
regulating	O
type	O
I	O
interferon	O
and	O
downstream	O
interferon	O
-	O
stimulated	O
responses	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
is	O
a	O
coronavirus	O
that	O
causes	O
villus	O
atrophy	O
,	O
followed	O
by	O
crypt	O
hyperplasia	O
,	O
reduces	O
the	O
activities	O
of	O
intestinal	O
digestive	B-PROC
enzymes	O
,	O
and	O
disrupts	O
the	O
absorption	O
of	O
intestinal	O
nutrients	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigate	O
the	O
different	O
effects	O
of	O
PEEP	O
on	O
the	O
pleural	O
pressure	O
and	O
ICP	O
in	O
different	O
respiratory	B-PROC
mechanics	I-PROC
.	O

There	O
has	O
been	O
no	O
evidence	O
of	O
viral	B-PROC
transmission	I-PROC
following	O
the	O
implantation	B-PROC
of	O
these	O
same	O
encapsulated	O
and	O
functional	O
porcine	O
islets	O
into	O
non	O
-	O
immunosuppressed	O
diabetic	O
cynomolgus	O
macaques	O
for	O
up	O
to	O
4	O
years	O
.	O

RESULTS	O
:	O
Influenza	O
A	O
virus	O
accounted	O
for	O
half	O
the	O
isolated	O
viruses	O
,	O
especially	O
subtype	O
A	O
(	O
H1N1	O
)	O
pdm09	O
among	O
patients	O
aged	O
20	O
-	O
59	O
years	O
old	O
,	O
and	O
subtype	O
A	O
(	O
H3N2	O
)	O
in	O
those	O
aged	O
60	O
or	O
over	O
;	O
the	O
most	O
frequently	O
identified	O
respiratory	O
virus	O
among	O
children	O
under	O
five	O
years	O
old	O
was	O
respiratory	O
syncytial	O
virus	O
(	O
65	O
.	O
6	O
%),	O
followed	O
by	O
influenza	O
A	O
virus	O
(	O
21	O
.	O
2	O
%);	O
influenza	O
virus	O
circulated	O
in	O
all	O
seasons	O
of	O
the	O
year	O
and	O
its	O
periods	B-PROC
of	O
greatest	O
incidence	O
were	O
interspersed	O
with	O
those	O
of	O
higher	O
Respiratory	O
Syncytial	O
Virus	O
activity	O
.	O

ABSTRACT	O
:	O
Systemic	O
complications	O
related	O
to	O
acute	O
pancreatitis	O
include	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
multiple	O
organ	O
dysfunction	O
syndrome	O
,	O
disseminated	O
intravascular	O
coagulation	B-PROC
,	O
hypocalcemia	O
,	O
hyperglycemia	O
,	O
and	O
insulin	O
dependent	O
diabetes	O
or	O
diabetic	O
ketoacidosis	O
.	O

Though	O
the	O
symptoms	O
were	O
rapidly	O
relieved	O
after	O
initiation	O
of	O
treatment	O
,	O
severe	O
hyperglycemia	O
(	O
575	O
mg	O
/	O
dL	O
),	O
severe	O
metabolic	B-PROC
acidosis	O
(	O
pH	O
6	O
.	O
9	O
),	O
and	O
ketonuria	O
developed	O
at	O
four	O
days	O
after	O
hospitalization	O
.	O

ABSTRACT	O
:	O
Viral	O
subunit	O
vaccines	O
often	O
contain	O
immunodominant	O
non	O
-	O
neutralizing	O
epitopes	O
that	O
divert	O
host	O
immune	B-PROC
responses	I-PROC
.	O

Because	O
no	O
cases	O
were	O
reported	O
in	O
the	O
United	O
States	O
during	O
2015	O
,	O
the	O
following	O
diseases	O
do	O
not	O
appear	O
in	O
this	O
early	O
release	O
table	O
:	O
anthrax	O
;	O
dengue	O
hemorrhagic	O
fever	B-PROC
;	O
diphtheria	O
;	O
eastern	O
equine	O
encephalitis	O
virus	B-PROC
disease	I-PROC
,	O
nonneuroinvasive	O
;	O
poliomyelitis	O
,	O
paralytic	O
;	O
poliovirus	O
infection	O
,	O
nonparalytic	O
;	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
disease	O
(	O
SARS	O
-	O
CoV	O
);	O
smallpox	O
;	O
western	O
equine	O
encephalitis	O
virus	B-PROC
disease	I-PROC
,	O
neuroinvasive	O
and	O
nonneuroinvasive	O
;	O
yellow	O
fever	B-PROC
;	O
and	O
viral	O
hemorrhagic	O
fevers	B-PROC
.	O

TITLE	O
:	O
IL	B-PROC
-	I-PROC
17	I-PROC
protein	O
levels	O
in	O
both	O
induced	O
sputum	O
and	O
plasma	O
are	O
increased	O
in	O
stable	O
but	O
not	O
acute	O
asthma	O
individuals	O
with	O
obesity	O
.	O

ABSTRACT	O
:	O
Viral	O
membrane	B-PROC
fusion	I-PROC
is	O
an	O
orchestrated	O
process	O
triggered	O
by	O
membrane	O
-	O
anchored	O
viral	O
fusion	O
glycoproteins	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
RNA	O
viral	B-PROC
infections	I-PROC
caused	O
by	O
respiratory	O
viruses	O
,	O
such	O
as	O
influenza	O
,	O
parainfluenza	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
coronavirus	O
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
and	O
Zika	O
virus	O
,	O
are	O
a	O
major	O
public	O
health	O
threats	O
in	O
the	O
world	O
.	O

Although	O
the	O
outcome	O
might	O
vary	O
with	O
different	O
rescue	O
procedures	O
,	O
most	O
of	O
them	O
will	O
improve	O
oxygenation	B-PROC
.	O

In	O
ICU	O
case	O
studies	O
,	O
the	O
expected	O
odds	O
ratios	O
(	O
OR	O
)	O
of	O
death	B-PROC
among	O
patients	O
with	O
underlying	O
heart	O
disease	O
or	O
renal	O
disease	O
to	O
patients	O
without	O
such	O
comorbidities	O
were	O
0	O
.	O
6	O
(	O
95	O
%	O
Confidence	O
Interval	O
(	O
CI	O
):	O
0	O
.	O
1	O
,	O
4	O
.	O
3	O
)	O
and	O
0	O
.	O
6	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
0	O
,	O
2	O
.	O
1	O
),	O
respectively	O
,	O
while	O
the	O
ORs	O
were	O
3	O
.	O
8	O
(	O
95	O
%	O
CI	O
:	O
3	O
.	O
4	O
,	O
4	O
.	O
2	O
)	O
and	O
2	O
.	O
4	O
(	O
95	O
%	O
CI	O
:	O
2	O
.	O
0	O
,	O
2	O
.	O
9	O
),	O
respectively	O
,	O
in	O
studies	O
with	O
other	O
types	O
of	O
designs	O
.	O

ABSTRACT	O
:	O
Inhaled	B-PROC
nitric	O
oxide	O
(	O
iNO	O
)	O
is	O
a	O
rescue	O
therapy	O
for	O
severe	O
hypoxemia	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

TITLE	O
:	O
Treatment	O
of	O
Adenoviral	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Using	O
Cidofovir	O
With	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
.	O

We	O
invite	O
the	O
attention	O
of	O
researchers	O
for	O
detailed	O
ethnopharmacological	O
and	O
phytochemical	O
studies	O
on	O
unexplored	O
plants	O
used	O
to	O
treat	O
bronchitis	O
for	O
the	O
development	B-PROC
of	O
novel	O
antiviral	O
drugs	O
.	O

ABSTRACT	O
:	O
In	O
this	O
paper	O
design	O
and	O
synthesis	B-PROC
of	O
a	O
scaffold	O
comprising	O
primaquine	O
(	O
PQ	O
)	O
motif	O
and	O
cinnamic	O
acid	O
derivatives	O
(	O
CADs	O
)	O
bound	O
directly	O
(	O
compounds	O

The	O
average	O
single	O
nucleotide	O
polymorphism	B-PROC
counts	O
of	O
swab	O
isolates	O
were	O
greater	O
than	O
those	O
found	O
in	O
tissue	O
samples	O
.	O

TITLE	O
:	O
Outcomes	O
and	O
survival	O
prediction	O
models	O
for	O
severe	O
adult	O
acute	O
respiratory	O
distress	O
syndrome	O
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
has	O
known	O
a	O
growing	O
interest	O
over	O
the	O
last	O
decades	O
with	O
promising	O
results	O
during	O
the	O
2009	O
A	O
(	O
H1N1	O
)	O
influenza	O
epidemic	O
.	O

ABSTRACT	O
:	O
The	O
occurrence	O
of	O
a	O
noninfectious	O
interstitial	O
lung	O
disease	O
is	O
a	O
rare	O
but	O
life	O
-	O
threatening	O
side	O
effect	O
of	O
infliximab	O
,	O
an	O
antitumor	O
necrosis	B-PROC
factor	O
alpha	O
antibody	B-PROC
.	O

These	O
life	O
-	O
threatening	O
syndromes	O
are	O
caused	O
by	O
increased	O
permeability	O
of	O
the	O
alveolar	O
and	O
airway	O
epithelium	O
and	O
exudate	O
formation	B-PROC
.	O

TITLE	O
:	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
in	O
Dengue	O
,	O
Malaria	O
,	O
and	O
Acute	O
Chagas	O
Disease	O
.	O

It	O
is	O
unknown	O
whether	O
the	O
cellular	O
innate	O
immune	O
system	O
can	O
detect	O
and	O
/	O
or	O
inhibit	O
the	O
formation	B-PROC
of	O
these	O
membrane	O
structures	O
,	O
which	O
could	O
be	O
an	O
effective	O
mechanism	O
to	O
delay	O
viral	O
RNA	B-PROC
replication	I-PROC
.	O

Herein	O
,	O
we	O
investigated	O
the	O
role	O
of	O
neutrophils	O
in	O
the	O
pathogenesis	B-PROC
of	O
malaria	O
-	O
associated	O
ALI	O
/	O
ARDS	O
.	O

The	O
depletion	O
of	O
neutrophils	O
,	O
treatment	O
with	O
AMD3100	O
(	O
a	O
CXCR4	O
antagonist	B-PROC
),	O
Pulmozyme	O
(	O
human	O
recombinant	O
DNase	O
)	O
or	O
Sivelestat	O
(	O
inhibitor	O
of	O
neutrophil	O
elastase	O
)	O
decreased	O
the	O
development	B-PROC
of	O
malaria	O
-	O
associated	O
ALI	O
/	O
ARDS	O
and	O
significantly	O
increased	O
mouse	O
survival	O
.	O

ABSTRACT	O
:	O
Community	O
-	O
acquired	O
pneumonia	O
is	O
a	O
leading	O
cause	O
of	O
death	B-PROC
.	O

After	O
recording	O
clinical	O
and	O
demographic	O
data	O
,	O
twin	O
swabs	O
(	O
nasopharyngeal	O
and	O
throat	O
)	O
were	O
collected	O
from	O
each	O
participant	O
,	O
pooled	O
in	O
viral	O
transport	B-PROC
media	O
and	O
tested	O
by	O
real	O
-	O
time	O
RT	O
PCR	O
for	O
MERS	O
-	O
CoV	O
and	O
influenza	O
A	O
and	O
B	O
viruses	O
and	O
their	O
subtypes	O
.	O

Lastly	O
,	O
we	O
will	O
address	O
how	O
increased	O
integration	B-PROC
of	O
clinical	O
and	O
basic	O
research	O
will	O
assist	O
treatment	O
and	O
prevention	O
efforts	O
for	O
emerging	O
pathogens	O
.	O

Bat	O
epithelial	O
or	O
fibroblast	O
cell	O
lines	O
were	O
previously	O
established	O
to	O
study	O
the	O
bat	O
immune	B-PROC
response	I-PROC
against	O
viral	B-PROC
infection	I-PROC
.	O

MERS	O
-	O
CoV	O
S	O
protein	O
represents	O
a	O
key	O
target	O
for	O
developing	O
therapeutics	O
to	O
block	O
viral	O
entry	O
and	O
inhibit	O
membrane	B-PROC
fusion	I-PROC
.	O

Areas	O
covered	O
:	O
In	O
this	O
review	O
,	O
we	O
provide	O
an	O
overview	O
of	O
the	O
progress	O
in	O
the	O
development	B-PROC
of	O
therapeutic	O
strategies	O
for	O
MERS	O
.	O

TITLE	O
:	O
Full	O
genome	O
analysis	O
of	O
Australian	O
infectious	O
bronchitis	O
viruses	O
suggests	O
frequent	O
recombination	B-PROC
events	O
between	O
vaccine	O
strains	O
and	O
multiple	O
phylogenetically	O
distant	O
avian	O
coronaviruses	O
of	O
unknown	O
origin	O
.	O

Group	O
3	O
-	O
2	O
PEDV	O
serum	O
antibody	B-PROC
-	O
negative	O
sows	O
and	O
22	O
piglets	O
,	O
provided	O
a	O
baseline	O
for	O
piglet	O
survivability	O
and	O
growth	B-PROC
rate	O
.	O

Piglets	O
on	O
sows	O
without	O
(	O
Group	O
1	O
)	O
or	O
with	O
(	O
Group	O
2	O
)	O
anti	O
-	O
PEDV	O
antibody	B-PROC
showed	O
significantly	O
different	O
responses	O
to	O
PEDV	O
infection	O
in	O
virus	O
shedding	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
thermoregulation	B-PROC
(	O
p	O
<	O
0	O
.	O
05	O
),	O
growth	B-PROC
rate	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
and	O
survivability	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

Viral	B-PROC
shedding	I-PROC
was	O
detected	O
in	O
rectal	O
swabs	O
until	O
14	O
DPI	O
in	O
challenged	O
5	O
-	O
day	O
-	O
old	O
pigs	O
and	O
until	O
18	O
DPI	O
in	O
challenged	O
21	O
-	O
day	O
-	O
old	O
pigs	O
.	O

Compared	O
with	O
non	O
-	O
influenza	O
patients	O
,	O
those	O
with	O
influenza	O
were	O
more	O
likely	O
to	O
have	O
fever	B-PROC
,	O
cough	O
,	O
sore	O
throat	O
,	O
and	O
fatigue	O
.	O

While	O
vaccines	O
for	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
have	O
been	O
available	O
to	O
producers	O
around	O
the	O
world	O
for	O
a	O
long	O
time	O
,	O
effective	O
vaccines	O
for	O
PEDV	O
and	O
deltacoronaviruses	O
were	O
only	O
recently	O
developed	O
or	O
are	O
still	O
in	O
development	B-PROC
.	O

Using	O
a	O
coinfection	O
assay	O
,	O
we	O
found	O
that	O
inclusion	O
of	O
mutant	O
virus	O
in	O
the	O
inoculum	O
protected	O
mice	O
from	O
an	O
otherwise	O
lethal	O
SARS	O
-	O
CoV	O
infection	O
without	O
reducing	O
virus	O
loads	O
,	O
indicating	O
that	O
the	O
changes	O
in	O
innate	B-PROC
immune	I-PROC
response	I-PROC
were	O
physiologically	O
significant	O
.	O

We	O
hypothesized	O
that	O
ARDS	O
development	B-PROC
might	O
be	O
associated	O
with	O
changes	O
in	O
plasma	O
coagulation	B-PROC
and	O
fibrinolysis	B-PROC
.	O

(	O
2	O
)	O
The	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
new	O
corona	O
virus	O
isolated	O
for	O
the	O
first	O
time	O
in	O
a	O
patients	O
who	O
died	B-PROC
of	O
severe	O
lower	O
respiratory	O
tract	O
infection	O
in	O
Jeddah	O
(	O
Saudi	O
Arabia	O
)	O
in	O
June	O
2012	O
(	O
Zaki	O
et	O
al	O
.	O
2012	O
).	O

RESULTS	O
:	O
After	O
5	O
days	O
of	O
treatment	O
,	O
the	O
low	O
-	O
and	O
high	O
-	O
dose	O
groups	O
had	O
significant	O
reductions	O
in	O
serum	O
levels	O
of	O
tumor	O
necrosis	B-PROC
factor	O
-	O
α	O
,	O
interleukin	O
-	O
6	O
,	O
and	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
reductions	O
of	O
these	O
markers	O
between	O
the	O
two	O
groups	O
.	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
nsp5	O
inhibits	O
interferon	O
-	O
β	O
production	O
through	O
the	O
cleavage	B-PROC
of	O
NEMO	O
.	O

Furthermore	O
,	O
this	O
cleavage	B-PROC
impaired	O
the	O
ability	O
of	O
NEMO	O
to	O
activate	O
the	O
IFN	O
response	O
and	O
downstream	O
signaling	B-PROC
.	O

Indirect	O
immunofluorescence	O
(	O
IFA	O
)	O
assays	O
confirmed	O
no	O
cross	B-PROC
-	I-PROC
reaction	I-PROC
between	O
these	O
two	O
MAbs	O
and	O
TGEV	O
.	O

CONCLUSIONS	O
:	O
These	O
respiratory	O
symptoms	O
might	O
be	O
related	O
to	O
anaphylactoid	O
or	O
hypersensitivity	B-PROC
reaction	I-PROC
.	O

Imbalance	O
between	O
coagulation	B-PROC
and	O
inflammation	O
is	O
a	O
predominant	O
characteristic	O
of	O
ARDS	O
,	O
leading	O
to	O
extreme	O
inflammatory	B-PROC
response	I-PROC
and	O
diffuse	O
fibrin	O
deposition	O
in	O
vascular	O
capillary	O
bed	O
and	O
alveoli	O
.	O

Our	O
data	O
support	O
a	O
polyphyletic	O
origin	O
of	O
MERS	O
-	O
CoV	O
in	O
dromedaries	O
and	O
the	O
co	O
-	O
circulation	B-PROC
of	O
diverse	O
MERS	O
-	O
CoVs	O
including	O
recombinant	O
strains	O
in	O
the	O
UAE	O
.	O

Overall	O
,	O
the	O
introduced	O
models	O
represent	O
meaningful	O
and	O
robust	O
methods	O
to	O
investigate	O
principles	O
of	O
pathogen	B-PROC
-	I-PROC
host	I-PROC
interaction	I-PROC
in	O
original	O
human	O
lung	O
tissue	O
.	O

Given	O
a	O
stabilized	O
early	O
severe	O
ARDS	O
,	O
as	O
soon	O
as	O
the	O
overall	O
clinical	O
situation	O
improves	O
,	O
spontaneous	O
ventilation	O
will	O
be	O
used	O
with	O
the	O
following	O
stringent	O
conditionalities	O
:	O
upfront	O
circulatory	B-PROC
optimization	O
,	O
upright	O
positioning	O
,	O
lowered	O
VO2	O
,	O
lowered	O
acidotic	O
and	O
hypercapnic	O
drives	O
,	O
sedation	O
without	O
ventilatory	O
depression	O
and	O
without	O
lowered	O
muscular	O
tone	O
,	O
as	O
well	O
as	O
high	O
PEEP	O
(	O
titrated	O
on	O
transpulmonary	O
pressure	O
,	O
or	O
as	O
a	O
second	O
best	O
:	O
""""	O
trial	O
"""-"	O
PEEP	O
)	O
with	O
spontaneous	O
ventilation	O
+	O
pressure	O
support	O
(	O
or	O
newer	O
modes	O
of	O
ventilation	O
).	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
severe	O
medical	O
condition	O
occurring	O
in	O
critically	O
ill	O
patients	O
and	O
with	O
mortality	O
of	O
33	O
-	O
52	O
%	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
death	B-PROC
in	O
critically	O
ill	O
patients	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
asthma	O
have	O
a	O
higher	O
incidence	O
of	O
obstructive	O
sleep	B-PROC
apnea	O
(	O
OSA	O
).	O

The	O
new	O
definition	O
of	O
ARDS	O
requires	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
to	O
assess	O
gas	O
exchange	O
and	O
has	O
better	O
predictive	O
validity	O
for	O
short	O
-	O
term	O
mortality	O
compared	O
with	O
the	O
previous	O
definition	O
.	O

Severity	O
of	O
ARDS	O
defined	O
by	O
the	O
partial	O
pressure	O
arterial	O
oxygen	O
and	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
ratio	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
2	O
.	O
20	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
15	O
-	O
4	O
.	O
19	O
),	O
pulmonary	O
infection	O
(	O
OR	O
,	O
1	O
.	O
81	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
08	O
-	O
3	O
.	O
03	O
),	O
and	O
modified	O
Sequential	O
Organ	O
Failure	O
Assessment	O
(	O
SOFA	O
)	O
score	O
(	O
OR	O
,	O
1	O
.	O
13	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
06	O
-	O
1	O
.	O
21	O
)	O
were	O
associated	O
with	O
NIV	O
failure	O
.	O

The	O
results	O
suggest	O
potential	O
linkages	O
among	O
viral	O
strategies	O
for	O
the	O
regulation	B-PROC
of	O
cell	B-PROC
survival	I-PROC
activities	O
,	O
possibly	O
through	O
an	O
interaction	O
of	O
N	O
protein	O
with	O
NPM1	O
which	O
prevents	O
its	O
proteolytic	B-PROC
cleavage	B-PROC
and	O
enhances	O
cell	B-PROC
survival	I-PROC
,	O
thus	O
ultimately	O
promoting	O
the	O
replication	O
of	O
PEDV	O
.	O

Phylogenetic	O
,	O
recombination	B-PROC
and	O
comparative	O
genomic	O
analyses	O
revealed	O
two	O
distinct	O
clusters	O
diverging	O
from	O
a	O
genotype	O
D	O
-	O
like	O
common	O
ancestor	O
through	O
recombination	B-PROC
with	O
a	O
putative	O
genotype	O
A	O
-	O
like	O
lineage	O
in	O
the	O
non	O
-	O
structural	O
protein	O
(	O
nsp	O
)	O
10	O
gene	O
.	O

Signature	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
and	O
a	O
glycine	O
residue	O
insertion	O
at	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
S1	O
subunit	O
of	O
the	O
spike	O
gene	O
,	O
among	O
others	O
,	O
exhibited	O
further	O
distinction	O
in	O
a	O
recombination	B-PROC
pattern	O
,	O
to	O
which	O
these	O
clusters	O
were	O
classified	O
as	O
genotypes	O
F	O
and	O
G	O
.	O
The	O
phylogeographic	O
mapping	O
of	O
the	O
global	O
spike	O
gene	O
indicated	O
that	O
the	O
genetically	O
similar	O
HCoV	O
-	O
OC43	O
genotypes	O
F	O
and	O
G	O
strains	O
were	O
potentially	O
circulating	O
in	O
China	O
,	O
Japan	O
,	O
Thailand	O
and	O
Europe	O
as	O
early	O
as	O
the	O
late	O
2000s	O
.	O

Locations	O
included	O
quarantines	O
,	O
markets	O
,	O
abattoirs	O
,	O
free	O
-	O
roaming	O
herds	O
and	O
farmed	O
breeding	B-PROC
herds	O
.	O

The	O
mention	O
of	O
eating	B-PROC
immunity	B-PROC
-	O
boosting	O
food	O
in	O
the	O
news	O
led	O
to	O
a	O
94	O
percent	O
chance	O
of	O
a	O
positive	O
MERS	O
emotion	O
and	O
that	O
such	O
a	O
chance	O
of	O
showing	O
a	O
positive	O
emotion	O
was	O
4	O
.	O
75	O
times	O
higher	O
than	O
that	O
without	O
such	O
a	O
mention	O
(	O
support	O
of	O
0	O
.	O
001	O
,	O
confidence	O
of	O
0	O
.	O
94	O
,	O
and	O
lift	O
of	O
4	O
.	O
75	O
).	O

There	O
was	O
a	O
difference	O
in	O
mortality	O
between	O
confirmed	O
MERS	O
-	O
CoV	O
cases	O
(	O
63	O
.	O
7	O
%	O
alive	O
versus	O
36	O
.	O
3	O
%	O
dead	B-PROC
cases	O
,	O
respectively	O
).	O

TITLE	O
:	O
Origin	O
and	O
evolution	B-PROC
of	O
LX4	O
genotype	O
infectious	O
bronchitis	O
coronavirus	O
in	O
China	O
.	O

TITLE	O
:	O
Widespread	O
Virus	B-PROC
Replication	I-PROC
in	O
Alveoli	O
Drives	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
in	O
Aerosolized	O
H5N1	O
Influenza	O
Infection	O
of	O
Macaques	O
.	O

As	O
in	O
autoimmune	O
disease	O
,	O
therapeutic	O
interventions	O
that	O
diminish	O
an	O
overactive	O
immune	B-PROC
response	I-PROC
would	O
be	O
useful	O
.	O

ABSTRACT	O
:	O
Respiratory	O
viruses	O
(	O
influenza	O
,	O
parainfluenza	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
coronavirus	O
,	O
human	O
metapneumovirus	O
,	O
and	O
rhinovirus	O
)	O
represent	O
the	O
most	O
common	O
causes	O
of	O
respiratory	O
viral	B-PROC
infections	I-PROC
in	O
immunocompromised	O
patients	O
.	O

Of	O
223	O
eligible	O
respondents	O
,	O
nurse	O
managers	O
from	O
136	O
(	O
61	O
%)	O
medical	O
,	O
surgical	O
,	O
mixed	O
medical	O
-	O
surgical	O
,	O
cardiac	O
,	O
and	O
specialty	O
ICUs	O
in	O
98	O
hospitals	O
completed	O
the	O
2014	O
survey	O
,	O
compared	O
with	O
124	O
of	O
164	O
(	O
76	O
%)	O
chief	O
nursing	B-PROC
officers	O
in	O
the	O
2005	O
survey	O
.	O

TITLE	O
:	O
X	O
-	O
ray	O
Structure	O
and	O
Enzymatic	B-PROC
Activity	I-PROC
Profile	O
of	O
a	O
Core	O
Papain	O
-	O
like	O
Protease	O
of	O
MERS	O
Coronavirus	O
with	O
utility	O
for	O
structure	O
-	O
based	O
drug	O
design	O
.	O

ABSTRACT	O
:	O
Ubiquitin	B-PROC
-	O
like	O
domain	O
2	O
(	O
Ubl2	O
)	O
is	O
immediately	O
adjacent	O
to	O
the	O
N	O
-	O
terminus	O
of	O
the	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
domain	O
in	O
coronavirus	O
polyproteins	O
,	O
and	O
it	O
may	O
play	O
a	O
critical	O
role	O
in	O
protease	O
regulation	B-PROC
and	O
stability	O
as	O
well	O
as	O
in	O
viral	B-PROC
infection	I-PROC
.	O

However	O
,	O
our	O
recent	O
cellular	O
studies	O
reveal	O
that	O
removing	O
the	O
Ubl2	O
domain	O
from	O
MERS	O
PLpro	O
has	O
no	O
effect	O
on	O
its	O
ability	O
to	O
process	O
the	O
viral	O
polyprotein	O
or	O
act	O
as	O
an	O
interferon	O
antagonist	B-PROC
,	O
which	O
involves	O
deubiquitinating	B-PROC
and	O
deISGylating	O
cellular	O
proteins	O
.	O

The	O
patient	O
reported	O
that	O
she	O
had	O
a	O
cough	O
and	O
runny	O
nose	O
one	O
week	O
prior	O
to	O
this	O
presentation	O
,	O
followed	O
by	O
a	O
sudden	O
sharp	O
pain	O
in	O
the	O
center	O
of	O
the	O
chest	O
8	O
/	O
10	O
in	O
intensity	O
on	O
the	O
visual	O
analog	O
scale	O
and	O
pleuritic	O
in	O
nature	O
,	O
which	O
aggravated	O
by	O
deep	O
breathing	B-PROC
and	O
lying	B-PROC
down	I-PROC
flat	O
.	O

This	O
effort	B-PROC
led	O
to	O
the	O
discovery	O
of	O
potent	O
analogues	O
within	O
this	O
series	O
that	O
demonstrated	O
sub	O
-	O
nanomolar	O
EC	O

ABSTRACT	O
:	O
BACKGROUND	O
Pulmonary	O
infections	O
are	O
a	O
major	O
cause	O
of	O
mortality	O
and	O
morbidity	O
in	O
patients	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
and	O
can	O
progress	O
rapidly	O
to	O
respiratory	O
failure	O
and	O
death	B-PROC
without	O
appropriate	O
therapy	O
.	O

The	O
expression	B-PROC
profiles	O
of	O
multiple	O
cytokines	O
were	O
determined	O
in	O
CoV	O
-	O
positive	O
patients	O
.	O

A	O
reverse	B-PROC
transcription	B-PROC
loop	O
mediated	O
isothermal	O
amplification	O
(	O
RT	O
-	O
LAMP	O
)	O
assay	O
was	O
developed	O
.	O

Antisera	O
against	O
vaccine	O
strains	O
H120	O
and	O
4	O
/	O
91	O
could	O
not	O
provide	O
effective	O
protection	O
against	O
CK	O
/	O
CH	O
/	O
2010	O
/	O
JT	O
-	O
1	O
in	O
virus	B-PROC
neutralization	I-PROC
assays	O
.	O

Briefly	O
,	O
IFN	O
-	O
β	O
expression	B-PROC
induced	O
by	O
TGEV	O
infection	O
is	O
delayed	O
with	O
respect	O
to	O
that	O
induced	O
by	O
poly	O
(	O
I	O
:	O
C	O
)	O
transfection	B-PROC
.	O

Significant	O
histopathology	O
of	O
FmoPV	O
RNA	O
-	O
positive	O
dead	B-PROC
cats	O
included	O
tubulointerstitial	O
nephritis	O
characterised	O
by	O
severe	O
granular	O
and	O
vacuolar	O
degeneration	O
of	O
the	O
epithelial	O
cells	O
of	O
the	O
cortical	O
and	O
medullary	O
tubules	O
as	O
well	O
as	O
mononuclear	O
cell	O
infiltrates	O
.	O

The	O
absence	O
of	O
pure	O
QX	O
-	O
like	O
viruses	O
before	O
the	O
appearance	O
of	O
the	O
early	O
viruses	O
suggests	O
that	O
the	O
viruses	O
were	O
introduced	O
from	O
other	O
countries	O
after	O
recombination	B-PROC
,	O
but	O
the	O
NC1	O
viruses	O
originated	O
in	O
Korea	O
.	O

The	O
recent	O
prevalence	O
of	O
recurrent	O
viruses	O
with	O
different	O
genomic	O
backgrounds	O
and	O
spike	O
genes	O
from	O
the	O
early	O
and	O
the	O
NC1	O
viruses	O
may	O
indicate	O
the	O
repeated	O
introduction	O
of	O
different	O
infectious	O
bronchitis	O
viruses	O
from	O
other	O
countries	O
and	O
their	O
successful	O
evasion	O
of	O
vaccine	O
immunity	B-PROC
in	O
the	O
field	O
.	O

Inhibition	B-PROC
of	O
DPP4	O
by	O
its	O
inhibitor	O
sitagliptin	O
or	O
siRNA	O
abrogated	O
the	O
effects	O
of	O
MERS	O
-	O
CoV	O
S	O
glycoprotein	O
on	O
IRAK	O
-	O
M	O
,	O
PPARγ	O
and	O
IL	O
-	O
10	O
,	O
confirming	O
that	O
its	O
immunosuppressive	O
effects	O
were	O
mediated	O
by	O
DPP4	O
receptor	O
.	O

No	O
patient	O
had	O
air	O
leak	O
syndrome	O
or	O
died	B-PROC
.	O

Among	O
people	O
with	O
CF	O
,	O
these	O
viruses	O
are	O
associated	O
with	O
prolonged	O
respiratory	O
illness	O
and	O
show	O
a	O
clear	O
association	O
with	O
pulmonary	O
exacerbations	O
which	O
in	O
turn	O
are	O
associated	O
with	O
lung	B-PROC
function	I-PROC
decline	O
and	O
risk	O
of	O
death	B-PROC
.	O

Of	O
the	O
79	O
patients	O
treated	O
with	O
NIV	O
,	O
44	O
(	O
56	O
%)	O
failed	O
NIV	O
and	O
required	O
ETI	O
,	O
7	O
(	O
9	O
%)	O
had	O
a	O
do	O
-	O
not	O
-	O
intubate	O
(	O
DNI	O
)	O
order	O
and	O
died	B-PROC
,	O
and	O
28	O
(	O
35	O
%)	O
avoided	O
ETI	O
.	O

Compared	O
with	O
patients	O
who	O
avoided	O
ETI	O
,	O
those	O
who	O
failed	O
NIV	O
or	O
had	O
a	O
DNI	O
order	O
and	O
died	B-PROC
were	O
more	O
likely	O
to	O
have	O
acute	O
leukemia	O
(	O
84	O
%	O
vs	O
61	O
%;	O
P	O
=	O
.	O
02	O
)	O
and	O
at	O
baseline	O
had	O
higher	O
Paco	O
CONCLUSIONS	O
:	O
Two	O
-	O
thirds	O
of	O
patients	O
with	O
HM	O
and	O
respiratory	O
failure	O
failed	O
NIV	O
and	O
required	O
ETI	O
,	O
and	O
had	O
high	O
subsequent	O
mortality	O
.	O

TITLE	O
:	O
In	O
Situ	O
Tagged	O
nsp15	O
Reveals	O
Interactions	O
with	O
Coronavirus	O
Replication	O
/	O
Transcription	B-PROC
Complex	O
-	O
Associated	O
Proteins	O
.	O

Our	O
data	O
calls	O
for	O
prompt	O
investigation	O
during	O
an	O
exacerbation	O
for	O
viruses	O
to	O
obviate	O
inappropriate	O
antibiotic	O
use	O
and	O
institute	O
antiviral	O
therapy	O
in	O
viral	B-PROC
disease	I-PROC
amenable	O
to	O
antiviral	O
therapy	O
.	O

Many	O
strains	O
of	O
the	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
have	O
distinct	O
,	O
S	O
-	O
dependent	O
organ	O
and	O
tissue	O
tropisms	B-PROC
despite	O
using	O
a	O
common	O
receptor	O
,	O
suggesting	O
that	O
they	O
employ	O
different	O
cellular	O
proteases	O
for	O
fusion	O
.	O

The	O
evaluation	O
of	O
the	O
effect	O
of	O
sesquiterpenoids	O
on	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
replication	O
showed	O
that	O
compounds	O
1	O
-	O
5	O
,	O
12	O
,	O
14	O
,	O
16	O
,	O
17	O
,	O
19	O
,	O
and	O
21	O
increased	O
cell	B-PROC
viability	I-PROC
against	O
cell	B-PROC
death	I-PROC
in	O
PEDV	O
-	O
injected	O
cells	O
.	O

A	O
refinement	O
in	O
the	O
approach	O
to	O
delivering	O
HFOV	O
is	O
warranted	O
,	O
with	O
more	O
attention	O
paid	O
to	O
its	O
adverse	O
hemodynamic	B-PROC
consequences	O
.	O

In	O
macrophages	O
we	O
found	O
immediate	O
induction	O
of	O
IFN	O
-	O
I	O
expression	B-PROC
and	O
RNase	O
L	O
-	O
mediated	O
breakdown	B-PROC
of	O
ribosomal	O
RNA	O
.	O

Generic	O
treatments	O
with	O
intravenous	O
immunoglobulin	B-PROC
,	O
ribavirin	O
,	O
and	O
interferons	O
may	O
benefit	O
select	O
severe	O
viral	O
pneumonia	O
patients	O
,	O
whereas	O
cidofovir	O
has	O
activity	O
for	O
severe	O
adenoviral	O
pneumonia	O
.	O

Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
(	O
APACHE	O
)	O
scores	O
and	O
several	O
plasma	O
biological	O
markers	O
have	O
been	O
identified	O
to	O
predict	O
the	O
death	B-PROC
or	O
treatment	O
outcome	O
of	O
sepsis	O
induced	O
ALI	O
.	O

TITLE	O
:	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
for	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
After	O
Pneumonectomy	O
.	O

Since	O
glycyrrhizin	O
is	O
a	O
competitive	O
inhibitor	O
of	O
high	O
mobility	O
group	O
box	O
-	O
1	O
(	O
HMGB1	O
),	O
we	O
confirmed	O
that	O
TLR4	O
and	O
RAGE	O
(£	O
associated	O
with	O
PEDV	O
pathogenesis	B-PROC
during	O
the	O
infection	O
in	O
Vero	O
cells	O
.	O

Results	O
from	O
in	O
silico	O
patients	O
with	O
mild	O
or	O
moderate	O
ARDS	O
suggest	O
that	O
the	O
detrimental	O
effects	O
of	O
RMs	O
on	O
cardiac	O
output	O
can	O
potentially	O
outweigh	O
the	O
positive	O
effects	O
of	O
alveolar	O
recruitment	O
on	O
oxygenation	B-PROC
,	O
resulting	O
in	O
overall	O
reductions	O
in	O
tissue	O
oxygen	O
delivery	O
.	O

Eighteen	O
patients	O
utilized	O
our	O
ECMO	O
transport	B-PROC
system	O
from	O
December	O
2011	O
to	O
September	O
2015	O
.	O

The	O
survival	O
rate	O
of	O
the	O
ECMO	O
-	O
transport	B-PROC
group	O
was	O
comparable	O
to	O
the	O
conventional	O
transport	B-PROC
or	O
the	O
non	O
-	O
transport	B-PROC
group	O
(	O
both	O
p	O
=	O
1	O
.	O
000	O
).	O

Employing	O
long	O
RT	O
-	O
PCR	O
with	O
Illumina	O
sequencing	O
,	O
we	O
quantified	O
the	O
gene	B-PROC
mutation	I-PROC
load	O
at	O
0	O
.	O
5	O
%	O
mutation	O
frequency	O
for	O
the	O
4529	O
bp	O
-	O
domain	O
spanning	O
the	O
Spike	O
gene	O
(	O
4086	O
bp	O
)	O
of	O
HCoV	O
-	O
OC43	O
in	O
four	O
upper	O
respiratory	O
clinical	O
specimens	O
obtained	O
during	O
acute	O
illness	O
.	O

Anxiety	O
symptoms	O
were	O
evaluated	O
with	O
the	O
Generalized	O
Anxiety	O
Disorder	O
7	O
-	O
item	O
scale	O
and	O
anger	O
was	O
assessed	O
with	O
the	O
State	O
-	O
Trait	O
Anger	O
Expression	B-PROC
Inventory	O
at	O
four	O
to	O
six	O
months	O
after	O
release	O
from	O
isolation	O
for	O
MERS	O
.	O

ABSTRACT	O
:	O
The	O
study	O
reports	O
the	O
development	B-PROC
of	O
a	O
polymerase	O
cross	O
-	O
linking	O
spiral	O
reaction	O
(	O
PCLSR	O
)	O
for	O
the	O
detection	O
of	O
African	O
swine	O
fever	B-PROC
virus	O
(	O
ASFV	O
)	O
DNA	O
in	O
blood	O
collected	O
from	O
infected	O
pigs	O
and	O
wild	O
boars	O
.	O

This	O
study	O
compared	O
the	O
expression	B-PROC
profile	O
of	O
genes	O
related	O
to	O
immune	B-PROC
responses	I-PROC
in	O
tracheal	O
samples	O
after	O
challenge	O
with	O
two	O
Brazilian	O
field	O
isolates	O
(	O
A	O
and	O
B	O
)	O
of	O
IBV	O
from	O
the	O
same	O
genotype	O
,	O
associating	O
these	O
responses	O
with	O
viral	B-PROC
replication	I-PROC
and	O
with	O
pathological	O
changes	O
in	O
trachea	O
and	O
kidney	O
.	O

RESULTS	O
:	O
The	O
univariate	O
logistic	O
regression	O
analysis	O
showed	O
that	O
the	O
patients	O
with	O
hemoglobin	O
<	O
90	O
g	O
/	O
L	O
,	O
plasma	O
albumin	O
<	O
30	O
g	O
/	O
L	O
,	O
C	O
-	O
reactive	O
protein	O
>	O
30	O
mg	O
/	O
L	O
,	O
procalcitonin	O
>	O
10	O
ng	O
/	O
mL	O
,	O
alanine	O
aminotransferase	O
>	O
100	O
U	O
/	O
L	O
,	O
or	O
aspartate	O
aminotransferase	O
>	O
100	O
U	O
/	O
L	O
had	O
poor	O
prognosis	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
that	O
those	O
with	O
congenital	O
dysplasia	O
of	O
the	O
airway	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
circulatory	B-PROC
complications	O
,	O
electrolyte	O
and	O
acid	O
-	O
base	O
disturbance	O
,	O
or	O
more	O
than	O
three	O
complications	O
also	O
had	O
poor	O
prognosis	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
The	O
development	B-PROC
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
antibody	B-PROC
-	O
based	O
assays	O
is	O
important	O
for	O
detecting	O
infected	O
animals	O
,	O
confirming	O
previous	O
virus	O
exposure	O
,	O
and	O
monitoring	O
sow	O
herd	B-PROC
immunity	I-PROC
.	O

However	O
,	O
the	O
potential	O
cross	O
-	O
reactivity	O
among	O
porcine	O
coronaviruses	O
is	O
a	O
major	O
concern	O
for	O
the	O
development	B-PROC
of	O
pathogen	O
-	O
specific	O
assays	O
.	O

One	O
hundred	O
and	O
forty	O
-	O
six	O
patients	O
(	O
69	O
%)	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
54	O
(	O
26	O
%)	O
died	B-PROC
in	O
the	O
ICU	O
.	O

b	O
)	O
Case	O
-	O
control	O
study	O
matching	O
the	O
15	O
ECMO	O
cases	O
with	O
the	O
52	O
severe	O
ARDS	O
treated	O
between	O
2005	O
and	O
2011	O
in	O
which	O
alternative	O
rescue	O
treatments	O
(	O
prone	O
ventilation	O
,	O
tracheal	O
gas	O
insufflation	O
(	O
TGI	O
)	O
and	O
/	O
or	O
the	O
administration	O
of	O
inhaled	B-PROC
nitric	O
oxide	O
(	O
iNO	O
))	O
were	O
used	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
causes	O
lethal	O
disease	O
in	O
humans	O
,	O
which	O
is	O
characterized	O
by	O
exacerbated	O
inflammatory	B-PROC
response	I-PROC
and	O
extensive	O
lung	O
pathology	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
application	O
of	O
nsp5	O
-	O
ELISA	O
for	O
the	O
detection	O
of	O
antibody	B-PROC
to	O
infectious	O
bronchitis	O
virus	O
.	O

The	O
host	O
factors	O
associated	O
with	O
high	O
CFR	O
were	O
pre	O
-	O
existing	O
pneumonia	O
,	O
smoking	O
history	O
,	O
an	O
incubation	O
period	O
of	O
less	O
than	O
5	O
days	O
,	O
leukocytosis	O
,	O
abnormal	O
renal	B-PROC
function	I-PROC
at	O
diagnosis	O
,	O
and	O
respiratory	O
symptoms	O
such	O
as	O
sputum	O
and	O
dyspnea	O
.	O

The	O
conditions	O
surrounding	O
MERS	O
-	O
CoV	O
exposure	O
and	O
the	O
underlying	O
poor	O
pulmonary	B-PROC
function	I-PROC
due	O
to	O
a	O
smoking	O
history	O
or	O
pre	O
-	O
existing	O
pneumonia	O
may	O
explain	O
the	O
high	O
CFR	O
in	O
hospital	O
B	O
.	O
The	O
clinical	O
features	O
described	O
above	O
may	O
enable	O
prediction	O
of	O
the	O
prognosis	O
of	O
MERS	O
cases	O
.	O

When	O
support	O
with	O
mechanical	O
ventilation	O
failed	O
,	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
was	O
initiated	O
.	O

The	O
levels	O
of	O
tumor	O
necrosis	B-PROC
factor	O
(	O
TNF	O
-	O
α	O
),	O
interleukin	O
6	O
(	O
IL	O
-	O
6	O
),	O
and	O
IL	O
-	O
10	O
in	O
serum	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
measured	O
using	O
the	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

The	O
main	O
histopathological	O
findings	O
in	O
the	O
lungs	O
of	O
rhesus	O
macaques	O
and	O
common	O
marmosets	O
were	O
varying	O
degrees	O
of	O
pulmonary	O
lesions	O
,	O
including	O
pneumonia	O
,	O
pulmonary	O
oedema	O
,	O
haemorrhage	O
,	O
degeneration	O
and	O
necrosis	B-PROC
of	O
the	O
pneumocytes	O
and	O
bronchial	O
epithelial	O
cells	O
,	O
and	O
inflammatory	O
cell	O
infiltration	O
.	O

One	O
contributing	O
factor	O
would	O
be	O
the	O
intra	O
-	O
recombination	B-PROC
between	O
subgroups	O
.	O

Secondary	O
outcomes	O
included	O
effects	O
of	O
prone	O
position	O
on	O
oxygenation	B-PROC
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
first	O
discovered	O
in	O
late	O
2012	O
and	O
has	O
gone	O
on	O
to	O
cause	O
over	O
1800	O
infections	O
and	O
650	O
deaths	B-PROC
.	O

ABSTRACT	O
:	O
Positive	O
-	O
strand	O
RNA	O
(+	O
RNA	O
)	O
viruses	O
(	O
e	O
.	O
g	O
.	O
poliovirus	O
,	O
hepatitis	O
C	O
virus	O
,	O
dengue	O
virus	O
,	O
SARS	O
-	O
coronavirus	O
)	O
remodel	O
cellular	O
membranes	O
to	O
form	O
so	O
-	O
called	O
viral	B-PROC
replication	I-PROC
compartments	O
(	O
VRCs	O
),	O
which	O
are	O
the	O
sites	O
where	O
viral	O
RNA	O
genome	O
replication	O
takes	O
place	O
.	O

TITLE	O
:	O
Dynamic	O
gene	B-PROC
expression	I-PROC
analysis	O
in	O
a	O
H1N1	O
influenza	O
virus	O
mouse	O
pneumonia	O
model	O
.	O

An	O
interesting	O
feature	O
is	O
the	O
dynamic	O
change	O
in	O
Ubl	O
,	O
which	O
shows	O
a	O
rigid	O
conformation	O
in	O
the	O
free	O
form	O
of	O
Plpro	O
but	O
is	O
fully	O
flexible	O
upon	O
the	O
binding	O
of	O
ubiquitin	B-PROC
.	O

ABSTRACT	O
:	O
IFIT1	O
(	O
IFN	O
-	O
induced	O
protein	O
with	O
tetratricopeptide	O
repeats	O
-	O
1	O
)	O
is	O
an	O
effector	O
of	O
the	O
host	O
innate	O
immune	O
antiviral	B-PROC
response	I-PROC
that	O
prevents	O
propagation	O
of	O
virus	B-PROC
infection	I-PROC
by	O
selectively	O
inhibiting	O
translation	B-PROC
of	O
viral	O
mRNA	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
risk	O
factors	O
(	O
RFs	O
)	O
for	O
the	O
development	B-PROC
of	O
bacterial	O
complications	O
and	O
the	O
prolonged	O
course	O
of	O
influenza	O
and	O
other	O
acute	O
respiratory	O
viral	B-PROC
infections	I-PROC
(	O
ARVIs	O
)	O
among	O
inpatients	O
treated	O
in	O
Russian	O
healthcare	O
facilities	O
in	O
the	O
post	O
-	O
pandemic	O
period	O
;	O
to	O
determine	O
the	O
clinical	O
presentation	O
of	O
the	O
disease	O
(	O
flu	O
-	O
like	O
syndrome	O
)	O
in	O
risk	O
-	O
group	O
people	O
and	O
to	O
evaluate	O
the	O
efficacy	O
of	O
antiviral	O
therapy	O
with	O
arbidol	O
(	O
umifenovir	O
).	O

In	O
multiple	O
infections	B-PROC
,	I-PROC
viral	I-PROC
load	O
cannot	O
be	O
used	O
to	O
differentiate	O
between	O
disease	O
causing	O
virus	O
and	O
innocent	O
bystanders	O
.	O

CONCLUSIONS	O
:	O
Although	O
correlations	O
between	O
CT	O
values	O
and	O
clinical	O
parameters	O
in	O
patients	O
with	O
single	O
and	O
multiple	O
viral	B-PROC
infection	I-PROC
were	O
found	O
,	O
the	O
clinical	O
importance	O
of	O
these	O
findings	O
is	O
limited	O
because	O
individual	O
differences	O
in	O
host	O
-,	O
viral	O
and	O
laboratory	O
factors	O
complicate	O
the	O
interpretation	O
of	O
statistically	O
significant	O
findings	O
.	O

Furthermore	O
,	O
identification	O
of	O
pathogens	O
other	O
than	O
GAS	O
,	O
may	O
lead	O
the	O
way	O
for	O
earlier	O
bacterial	O
diagnosis	O
and	O
timely	O
intervention	O
before	O
abscess	O
formation	B-PROC
in	O
sore	O
throat	O
patients	O
.	O

The	O
development	B-PROC
of	O
anti	O
-	O
FN	O
antibodies	O
in	O
FN	O
-	O
positive	O
PTA	O
patients	O
.	O

Because	O
immune	O
suppression	B-PROC
is	O
a	O
major	O
component	O
in	O
the	O
pathology	O
of	O
FIP	O
,	O
we	O
hypothesized	O
that	O
treatment	O
with	O
an	O
immune	O
system	O
stimulant	O
would	O
increase	O
survival	O
times	O
of	O
cats	O
with	O
dry	O
FIP	O
.	O

ABSTRACT	O
:	O
A	O
fatal	O
case	O
of	O
meningoencephalitis	O
was	O
reported	O
in	O
a	O
13	O
-	O
year	O
-	O
old	O
Koninklijk	O
Warmbloed	O
Paard	O
Nederland	O
stallion	O
,	O
suspected	O
of	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
(	O
WNV	O
)	O
infection	O
,	O
in	O
the	O
Piedmont	O
region	O
of	O
Italy	O
.	O

This	O
suggests	O
that	O
occludin	O
internalization	O
by	O
macropinocytosis	B-PROC
or	O
a	O
macropinocytosis	B-PROC
-	O
like	O
process	O
is	O
involved	O
in	O
the	O
virus	O
entry	O
events	O
.	O

ABSTRACT	O
:	O
Autophagy	B-PROC
is	O
a	O
basic	O
biological	O
metabolic	B-PROC
process	I-PROC
involving	O
in	O
intracellular	O
membrane	B-PROC
transport	B-PROC
pathways	B-PROC
that	O
recycle	O
cellular	O
components	O
and	O
eliminate	O
intracellular	O
microorganisms	O
within	O
the	O
lysosome	O
.	O

However	O
,	O
some	O
pathogens	O
,	O
including	O
viruses	O
,	O
have	O
evolved	O
unique	O
trick	O
to	O
escape	O
or	O
exploit	O
autophagy	B-PROC
.	O

Mechanistically	O
,	O
neuraminidase	O
inhibition	B-PROC
assay	O
and	O
hemagglutination	B-PROC
inhibition	B-PROC
assay	O
suggested	O
that	O
N30	O
did	O
not	O
directly	O
target	O
the	O
two	O
envelope	O
glycoproteins	O
required	O
for	O
viral	O
adsorption	O
or	O
release	O
.	O

Based	O
on	O
these	O
findings	O
,	O
we	O
further	O
confirmed	O
that	O
N30	O
provided	O
a	O
strong	O
inhibition	B-PROC
on	O
the	O
replication	O
of	O
respiratory	O
syncytial	O
virus	O
,	O
coronavirus	O
,	O
enterovirus	O
71	O
and	O
a	O
diverse	O
strains	O
of	O
coxsackie	O
B	O
virus	O
.	O

Whether	O
some	O
factors	O
affect	O
virus	B-PROC
replication	I-PROC
and	O
proliferation	O
had	O
not	O
been	O
fully	O
understood	O
in	O
the	O
course	O
of	O
nerve	O
damage	O
caused	O
by	O
PHEV	O
infection	O
.	O

In	O
recent	O
years	O
,	O
some	O
reports	O
suggested	O
that	O
miRNA	O
might	O
play	O
a	O
key	O
regulatory	O
role	O
in	O
viral	B-PROC
infection	I-PROC
.	O

In	O
this	O
study	O
,	O
we	O
found	O
the	O
miR	O
-	O
21a	O
-	O
5p	O
is	O
notably	O
up	O
-	O
regulated	O
in	O
the	O
brains	O
of	O
mice	O
and	O
N2a	O
cells	O
infected	O
with	O
PHEV	O
,	O
and	O
it	O
down	O
-	O
regulated	O
the	O
expression	B-PROC
of	O
CASK	O
-	O
interactive	O
protein1	O
(	O
Caskin1	O
)	O
by	O
directly	O
targeting	B-PROC
the	O
3	O
'-	O
UTR	O
of	O
Caskin1	O
using	O
a	O
Dual	O
-	O
Luciferase	O
reporter	O
assay	O
.	O

These	O
poor	O
results	O
may	O
be	O
caused	O
in	O
part	O
by	O
three	O
unique	O
pharmacological	O
challenges	O
presented	O
by	O
ARDS	O
:	O
(	O
1	O
)	O
Patients	O
with	O
ARDS	O
are	O
fragile	O
because	O
of	O
concomitant	O
multiple	O
organ	O
dysfunction	O
,	O
so	O
they	O
do	O
not	O
tolerate	O
off	O
-	O
target	O
side	O
effects	O
of	O
drugs	O
;	O
(	O
2	O
)	O
inhaled	B-PROC
drug	O
delivery	O
is	O
impeded	O
by	O
the	O
column	O
of	O
proteinaceous	O
fluid	O
covering	O
the	O
injured	O
alveoli	O
;	O
and	O
(	O
3	O
)	O
ARDS	O
is	O
heterogeneous	O
in	O
its	O
underlying	O
pathophysiology	O
,	O
so	O
targeting	B-PROC
one	O
pathway	B-PROC
is	O
unlikely	O
to	O
improve	O
most	O
patients	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
papain	O
-	O
like	O
proteases	O
(	O
PLPs	O
)	O
can	O
act	O
as	O
proteases	O
that	O
process	O
virus	O
-	O
encoded	O
large	O
replicase	O
polyproteins	O
and	O
also	O
as	O
deubiquitinating	B-PROC
(	O
DUB	O
)	O
enzymes	O
.	O

Like	O
the	O
PLPs	O
of	O
other	O
coronaviruses	O
(	O
CoVs	O
),	O
the	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
PLP	O
catalyzes	O
proteolysis	B-PROC
of	O
Gly	O
-	O
Gly	O
dipeptide	O
bonds	O
to	O
release	O
mature	O
cleavage	B-PROC
products	O
.	O

TITLE	O
:	O
Extracellular	O
matrix	O
in	O
the	O
CNS	O
induced	O
by	O
neuropathogenic	O
viral	B-PROC
infection	I-PROC
.	O

Then	O
,	O
cl	O
-	O
2	O
invades	O
the	O
ventricle	O
and	O
ventricular	O
wall	O
along	O
the	O
newly	O
assembled	O
ERfibs	O
after	O
infection	O
,	O
using	O
them	O
as	O
a	O
pathway	B-PROC
from	O
the	O
meninges	O
,	O
the	O
initial	O
site	O
of	O
infection	O
.	O

mpIL	O
-	O
22	O
up	O
-	O
regulated	O
the	O
expression	B-PROC
of	O
the	O
antimicrobial	O
peptide	O
beta	O
-	O
defensin	O
(	O
BD	O
-	O
2	O
),	O
cytokine	O
IL	O
-	O
18	O
and	O
IFN	O
-	O
λ	O
.	O

Lung	O
-	O
morphology	O
is	O
one	O
of	O
the	O
ARDS	O
-	O
phenotypes	O
and	O
physiological	O
studies	O
suggest	O
different	O
responses	O
in	O
terms	O
of	O
positive	O
-	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
-	O
pressure	O
(	O
PEEP	O
)	O
and	O
recruitment	O
-	O
manoeuvres	O
(	O
RM	O
)	O
according	O
to	O
loss	O
of	O
aeration	O
.	O

It	O
is	O
ingested	O
as	O
an	O
oral	O
prodrug	O
that	O
is	O
rapidly	O
metabolized	B-PROC
by	O
carboxylesterase	O
1	O
(	O
CES1	O
)	O
to	O
its	O
active	O
form	O
,	O
oseltamivir	O
carboxylate	O
.	O

Therefore	O
,	O
development	B-PROC
of	O
effective	O
prophylactic	O
vaccine	O
needs	O
to	O
be	O
urgently	O
explored	O
given	O
that	O
there	O
are	O
no	O
approved	O
prophylactics	O
or	O
therapeutics	O
for	O
humans	O
or	O
animals	O
to	O
date	O
.	O

TITLE	O
:	O
The	O
answer	O
is	O
blowing	O
in	O
the	O
wind	O
:	O
an	O
uncommon	O
cause	O
for	O
severe	O
ARDS	O
accompanied	O
by	O
circulatory	B-PROC
insufficiency	O
requiring	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

Lack	O
of	O
autopsies	O
from	O
MERS	O
cases	O
has	O
hindered	O
understanding	O
of	O
MERS	O
-	O
CoV	O
pathogenesis	B-PROC
.	O

In	O
this	O
study	O
,	O
we	O
produced	O
PEDV	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
composed	O
of	O
S	O
,	O
M	O
,	O
and	O
E	O
proteins	O
with	O
a	O
baculovirus	O
expression	B-PROC
system	O
and	O
tested	O
them	O
via	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
and	O
Western	O
blot	O
analysis	O
.	O

TITLE	O
:	O
Ribonuclease	O
L	O
mediates	O
the	O
cell	O
-	O
lethal	O
phenotype	O
of	O
double	O
-	O
stranded	O
RNA	B-PROC
editing	I-PROC
enzyme	O
ADAR1	O
deficiency	O
in	O
a	O
human	O
cell	O
line	O
.	O

Comparison	O
of	O
particle	O
stability	O
and	O
protein	O
corona	O
formation	B-PROC
in	O
media	O
containing	O
sera	O
from	O
different	O
species	O
suggests	O
that	O
NPpT	O
-	O
CA	O
has	O
been	O
activated	O
and	O
opsonized	O
in	O
mouse	O
blood	O
to	O
a	O
greater	O
extent	O
than	O
those	O
in	O
bovine	O
serum	O
-	O
containing	O
medium	O
,	O
thus	O
losing	O
the	O
benefits	O
of	O
pH	O
-	O
sensitivity	O
expected	O
from	O
in	O
vitro	O
experiments	O
.	O

In	O
particular	O
,	O
the	O
development	B-PROC
of	O
single	O
molecules	O
targeting	B-PROC
two	O
proteins	O
(	O
dual	O
inhibitors	O
)	O
is	O
one	O
of	O
the	O
current	O
main	O
goals	O
in	O
drug	O
discovery	O
.	O

Sentinel	O
pigs	O
in	O
the	O
low	O
biosecurity	O
group	O
(	O
LB	O
)	O
became	O
PEDV	O
positive	O
after	O
the	O
first	O
movement	B-PROC
of	O
study	O
personnel	O
from	O
the	O
INF	O
group	O
.	O

However	O
,	O
rectal	O
swabs	O
from	O
pigs	O
in	O
the	O
medium	O
biosecurity	O
(	O
MB	O
)	O
and	O
high	O
biosecurity	O
(	O
HB	O
)	O
groups	O
were	O
negative	O
during	O
the	O
10	O
consecutive	O
days	O
of	O
movements	B-PROC
and	O
remained	O
negative	O
through	O
24	O
days	O
post	O
movement	B-PROC
(	O
dpm	O
)	O
when	O
the	O
first	O
trial	O
was	O
terminated	O
.	O

In	O
addition	O
,	O
at	O
1	O
dpm	O
,	O
2	O
hair	O
/	O
face	O
swabs	O
from	O
MB	O
personnel	O
were	O
positive	O
;	O
however	O
,	O
transmission	B-PROC
of	I-PROC
virus	I-PROC
was	O
not	O
detected	O
.	O

ISGs	O
may	O
directly	O
act	O
on	O
the	O
invading	O
pathogen	O
or	O
can	O
either	O
positively	O
or	O
negatively	O
regulate	O
the	O
innate	O
and	O
adaptive	B-PROC
immune	I-PROC
response	I-PROC
.	O

CRFK	O
cells	O
infected	O
with	O
FIPV	O
79	O
-	O
1146	O
showed	O
an	O
increase	O
in	O
the	O
expression	B-PROC
of	O
interferon	O
-	O
related	O
genes	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
MX1	O
,	O
viperin	O
,	O
CXCL10	O
,	O
CCL8	O
,	O
RANTES	O
,	O
KC	O
,	O
MCP1	O
,	O
and	O
IL8	O
.	O

In	O
addition	O
,	O
an	O
increase	O
in	O
the	O
expression	B-PROC
of	O
the	O
above	O
cytokines	O
as	O
well	O
as	O
GM	O
-	O
CSF	O
and	O
IFNγ	O
was	O
also	O
detected	O
in	O
the	O
PBMC	O
,	O
serum	O
,	O
and	O
peritoneal	O
effusions	O
of	O
FCoV	O
-	O
positive	O
cats	O
.	O

In	O
this	O
study	O
,	O
our	O
findings	O
were	O
the	O
first	O
to	O
demonstrate	O
that	O
LiCl	O
inhibition	B-PROC
of	O
the	O
FMDV	O
replication	O
.	O

Autopsies	O
of	O
patients	O
that	O
died	B-PROC
from	O
SARS	O
also	O
showed	O
fibrosis	O
to	O
varying	O
extents	O
.	O

We	O
captured	O
two	O
states	O
of	O
the	O
RBD	O
with	O
receptor	O
binding	O
region	O
either	O
buried	O
(	O
lying	O
state	O
)	O
or	O
exposed	O
(	O
standing	B-PROC
state	O
),	O
demonstrating	O
an	O
inherently	O
flexible	O
RBD	O
readily	O
recognized	O
by	O
the	O
receptor	O
.	O

A	O
dysregulation	O
in	O
this	O
wound	B-PROC
healing	B-PROC
process	I-PROC
leads	O
to	O
fibrosis	O
.	O

Core	O
temperature	O
,	O
hemodynamics	B-PROC
,	O
serum	O
glucose	O
and	O
electrolytes	O
,	O
and	O
P	O
/	O
F	O
were	O
sequentially	O
measured	O
,	O
and	O
medians	O
(	O
interquartile	O
ranges	O
)	O
presented	O
,	O
28	O
-	O
day	O
ventilator	O
-	O
free	O
days	O
,	O
and	O
hospital	O
mortality	O
were	O
calculated	O
in	O
historical	O
controls	O
and	O
eight	O
cooled	O
patients	O
.	O

Patients	O
completed	O
the	O
Nijmegen	O
score	O
and	O
underwent	O
a	O
hyperventilation	O
provocation	O
test	O
(	O
HVPT	O
)	O
and	O
arterial	O
blood	B-PROC
gas	I-PROC
and	O
cardiopulmonary	O
tests	O
.	O

Rectal	O
swabs	O
collected	O
from	O
the	O
inoculated	O
pigs	O
on	O
days	O
3	O
and	O
7	O
post	O
-	O
inoculation	O
were	O
tested	O
by	O
using	O
PEDV	O
-	O
specific	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
and	O
the	O
proportion	O
of	O
pigs	O
in	O
each	O
group	O
that	O
became	O
infected	O
with	O
PEDV	O
was	O
assessed	O
.	O

Development	B-PROC
of	O
features	O
of	O
macrophage	B-PROC
activation	I-PROC
syndrome	O
and	O
death	B-PROC
were	O
more	O
common	O
among	O
multiple	O
organ	O
failure	O
cases	O
with	O
any	O
of	O
the	O
phenotypes	O
(	O
macrophage	B-PROC
activation	I-PROC
syndrome	O
:	O
10	O
/	O
37	O
,	O
27	O
%;	O
death	B-PROC
:	O
8	O
/	O
37	O
,	O
22	O
%)	O
compared	O
to	O
multiple	O
organ	O
failure	O
cases	O
without	O
any	O
phenotype	O
(	O
macrophage	B-PROC
activation	I-PROC
syndrome	O
:	O
1	O
/	O
38	O
,	O
3	O
%;	O
p	O
=	O
0	O
.	O
003	O
and	O
death	B-PROC
:	O
0	O
/	O
38	O
,	O
0	O
%;	O
p	O
=	O
0	O
.	O
002	O
).	O

Extending	O
on	O
our	O
current	O
knowledge	O
of	O
MERS	O
,	O
vaccination	O
of	O
dromedary	O
camels	O
to	O
induce	O
mucosal	B-PROC
immunity	I-PROC
could	O
be	O
a	O
promising	O
approach	O
to	O
diminish	O
MERS	O
-	O
CoV	O
transmission	O
to	O
humans	O
.	O

Subcellular	O
localization	B-PROC
analysis	O
of	O
SMAD3	O
and	O
SMAD7	O
indicated	O
that	O
non	O
-	O
SMAD	O
pathways	B-PROC
in	O
TGF	O
-	O
β1	O
signaling	B-PROC
involved	O
in	O
the	O
production	O
of	O
Type	O
I	O
collagen	O
in	O
transfected	O
cells	O
with	O
pSARS	O
-	O
PLpro	O
.	O

Moreover	O
,	O
selective	O
inhibitors	O
TGF	O
-	O
βRI	O
and	O
STAT6	O
(	O
AS1517499	O
)	O
ascertained	O
that	O
STAT6	O
activation	O
was	O
required	O
for	O
PLpro	O
-	O
induced	O
TGF	O
-	O
β1	O
-	O
dependent	O
up	B-PROC
-	I-PROC
regulation	B-PROC
of	O
Type	O
I	O
collagen	O
in	O
human	O
lung	O
epithelial	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
international	O
community	O
vastly	O
underestimates	O
the	O
risk	O
and	O
scale	O
of	O
our	O
shared	O
vulnerability	O
to	O
fast	O
moving	B-PROC
pathogens	O
.	O

Here	O
,	O
I	O
offer	O
a	O
pathway	B-PROC
to	O
preparedness	O
for	O
,	O
and	O
rapid	O
response	O
to	O
,	O
infectious	O
disease	O
threats	O
:	O
robust	O
and	O
resilient	O
national	O
health	O
systems	O
;	O
strong	O
institutions	O
capable	O
of	O
leading	O
,	O
particularly	O
the	O
World	O
Health	O
Organization	O
;	O
and	O
investments	O
in	O
research	O
and	O
development	B-PROC
.	O

TITLE	O
:	O
The	O
effect	O
of	O
diatomaceous	O
earth	O
in	O
live	O
,	O
attenuated	O
infectious	O
bronchitis	O
vaccine	O
,	O
immune	B-PROC
responses	I-PROC
,	O
and	O
protection	O
against	O
challenge	O
.	O

Massive	O
application	O
and	O
generation	O
of	O
a	O
protective	O
local	O
mucosal	O
and	O
humoral	B-PROC
immunity	I-PROC
with	O
no	O
adverse	O
effects	O
is	O
the	O
main	O
goal	O
for	O
this	O
strategy	O
.	O

The	O
patient	O
was	O
44	O
years	O
old	O
and	O
had	O
symptoms	O
including	O
high	O
fever	B-PROC
,	O
dry	O
cough	O
with	O
a	O
little	O
phlegm	O
,	O
and	O
shortness	O
of	O
breath	O
,	O
which	O
are	O
roughly	O
consistent	O
with	O
those	O
associated	O
with	O
MERS	O
,	O
and	O
had	O
had	O
close	O
contact	O
with	O
individuals	O
with	O
confirmed	O
cases	O
of	O
MERS	O
.	O
After	O
one	O
month	O
of	O
therapy	O
with	O
antiviral	O
,	O
anti	O
-	O
infection	O
,	O
and	O
immune	O
-	O
enhancing	O
agents	O
,	O
the	O
patient	O
recovered	O
in	O
the	O
hospital	O
and	O
was	O
discharged	O
.	O

TITLE	O
:	O
[	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
:	O
System	O
selection	O
,	O
(	O
contra	O
)	O
indications	O
,	O
and	O
management	O
].	O

Cell	B-PROC
survival	I-PROC
and	O
viral	O
inhibition	B-PROC
were	O
determined	O
by	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
reduction	O
assay	O
and	O
confirmed	O
by	O
immunofluorescence	O
.	O

Serial	O
measurements	O
of	O
blood	B-PROC
gases	I-PROC
were	O
performed	O
every	O
30	O
minutes	O
until	O
the	O
partial	B-PROC
pressure	I-PROC
of	I-PROC
oxygen	I-PROC
/	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
ratio	O
dropped	O
below	O
150	O
on	O
two	O
consecutive	O
readings	O
.	O

In	O
an	O
immunofluorescence	O
assay	O
,	O
these	O
cardenolides	O
were	O
found	O
to	O
diminish	O
the	O
expressions	O
of	O
TGEV	O
nucleocapsid	O
and	O
spike	O
protein	O
,	O
which	O
was	O
used	O
as	O
an	O
indication	O
for	O
viral	B-PROC
replication	I-PROC
;	O
block	O
TGEV	O
infection	O
induced	O
apoptosis	B-PROC
and	O
cytopathic	O
effects	O
;	O
and	O
impart	O
the	O
same	O
trend	O
of	O
inhibitory	O
activity	O
against	O
Na	O

The	O
latter	O
function	O
involves	O
reversing	O
the	O
post	B-PROC
-	I-PROC
translational	B-PROC
modification	I-PROC
of	O
cellular	O
proteins	O
conjugated	O
with	O
either	O
ubiquitin	B-PROC
(	O
Ub	B-PROC
)	O
or	O
Ub	B-PROC
-	O
like	O
interferon	O
-	O
stimulated	O
gene	O
product	O
15	O
(	O
ISG15	O
).	O

Despite	O
these	O
complications	O
,	O
some	O
studies	O
have	O
shown	O
a	O
decrease	O
in	O
the	O
rates	O
of	O
orotracheal	O
intubation	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
low	O
severity	O
scores	O
,	O
hemodynamic	B-PROC
stability	O
,	O
and	O
the	O
absence	O
of	O
other	O
organ	O
dysfunctions	O
.	O

ABSTRACT	O
:	O
Chronic	O
alcohol	O
exposure	O
is	O
a	O
clinically	O
important	O
risk	O
factor	O
for	O
the	O
development	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
the	O
most	O
severe	O
form	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

To	O
ameliorate	O
the	O
effects	O
of	O
future	O
outbreaks	O
as	O
well	O
as	O
to	O
prepare	O
for	O
biodefense	O
,	O
a	O
process	O
for	O
the	O
production	O
of	O
a	O
recombinant	O
protein	O
vaccine	O
candidate	O
is	O
under	O
development	B-PROC
.	O

Previously	O
,	O
we	O
reported	O
the	O
5	O
L	O
scale	O
expression	B-PROC
and	O
purification	O
of	O
a	O
promising	O
recombinant	O
SARS	O
vaccine	O
candidate	O
,	O
RBD219	O
-	O
N1	O
,	O
the	O
218	O
-	O
amino	O
acid	O
residue	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
coronavirus	O
expressed	B-PROC
in	O
yeast	O
-	O
Pichia	O
pastoris	O
X	O
-	O
33	O
.	O

Based	O
on	O
oxygenation	B-PROC
index	O
(	O
PaO	B-PROC
After	O
excluding	O
patients	O
who	O
did	O
not	O
meet	O
the	O
inclusion	O
criteria	O
and	O
loss	O
to	O
follow	O
-	O
up	O
,	O
the	O
final	O
89	O
patients	O
were	O
enrolled	O
in	O
the	O
analysis	O
.	O

After	O
the	O
remove	O
of	O
trachea	O
tube	O
,	O
available	O
oxygenation	B-PROC
supports	O
include	O
nasal	O
cannula	O
,	O
venturi	O
mask	O
,	O
non	O
-	O
invasive	O
ventilator	O
and	O
high	O
flow	O
nasal	O
cannula	O
(	O
HFNC	O
).	O

In	O
vitro	O
,	O
both	O
pharmacological	O
inhibitors	O
(	O
AG1478	O
and	O
451	O
)	O
and	O
si	O
-	O
RNA	B-PROC
silencing	I-PROC
of	O
EGFR	O
significantly	O
inhibited	O
LPS	O
-	O
induced	O
EGFR	O
signaling	B-PROC
activation	O
and	O
inflammatory	B-PROC
response	I-PROC
in	O
human	O
lung	O
epithelial	O
cells	O
or	O
macrophages	O
.	O

We	O
isolated	O
a	O
fully	O
human	O
neutralizing	O
antibody	B-PROC
,	O
MCA1	O
,	O
from	O
a	O
human	O
survivor	O
.	O

The	O
article	O
argues	O
that	O
to	O
realize	O
the	O
full	O
potential	O
of	O
a	O
transparent	O
disease	O
outbreak	O
reporting	O
process	O
,	O
there	O
is	O
a	O
need	O
for	O
a	O
human	O
rights	O
framework	O
that	O
expressly	O
articulates	O
its	O
right	O
to	O
receive	O
reports	O
and	O
outlines	O
appropriate	O
behaviour	B-PROC
for	O
the	O
WHO	O
,	O
states	O
,	O
and	O
non	O
-	O
state	O
actors	O
.	O

CONCLUSIONS	O
:	O
Mark	O
hypophosphatemia	O
and	O
hypokalemia	O
may	O
be	O
presenting	O
electrolyte	O
abnormalities	O
in	O
a	O
patient	O
with	O
acute	O
leukaemia	O
,	O
and	O
these	O
may	O
be	O
indicators	O
of	O
aggressive	B-PROC
tumour	O
genesis	O
.	O

Two	O
hours	O
following	O
the	O
injury	O
,	O
decreased	O
mean	O
arterial	O
blood	B-PROC
pressure	I-PROC
(	O
60	O
-	O
70	O
mmHg	O
)	O
and	O
cardiac	O
index	O
(<	O
2	O
L	O
.	O
min	O
-	O
1	O
.	O
m	O
-	O
2	O
)	O
were	O
observed	O
in	O
the	O
animals	O
in	O
the	O
SS	O
group	O
,	O
while	O
systemic	B-PROC
vascular	I-PROC
resistance	I-PROC
index	O
was	O
increased	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
developed	O
a	O
novel	O
porcine	O
model	O
of	O
septic	O
shock	O
induced	O
by	O
ARDS	O
due	O
to	O
severe	O
MRSA	O
pneumonia	O
with	O
characteristic	O
hyperdynamic	O
and	O
hypodynamic	O
phases	O
in	O
24	O
h	O
,	O
which	O
mimicked	O
the	O
hemodynamic	B-PROC
changing	O
of	O
septic	O
shock	O
in	O
human	O
.	O

In	O
neonatal	O
gnotobiotic	O
pigs	O
,	O
the	O
icPC22A	O
-	O
S1Δ197	O
virus	O
caused	O
mild	O
to	O
moderate	O
diarrhea	O
,	O
lower	O
titers	O
of	O
viral	B-PROC
shedding	I-PROC
,	O
and	O
no	O
mortality	O
,	O
whereas	O
the	O
icPC22A	O
virus	O
caused	O
severe	O
diarrhea	O
and	O
100	O
%	O
mortality	O
.	O

This	O
study	O
reports	O
a	O
TaqMan	O
probe	O
-	O
based	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
(	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
)	O
for	O
rapid	O
and	O
accurate	O
identification	O
of	O
GII	O
-	O
1	O
lineage	O
(	O
formerly	O
D1466	O
-	O
like	O
variant	O
)	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

The	O
pathogenesis	B-PROC
of	O
viral	O
FH	O
includes	O
virus	O
-	O
induced	O
immune	O
activation	O
,	O
inflammation	O
,	O
and	O
subsequent	O
hepatic	O
apoptosis	B-PROC
and	O
necrosis	B-PROC
.	O

IL	O
-	O
33	O
is	O
a	O
member	O
of	O
the	O
IL	O
-	O
1	O
-	O
related	O
cytokines	O
,	O
considered	O
to	O
be	O
an	O
""""	O
alarmin	O
""""	O
that	O
participates	O
in	O
various	O
diseases	O
,	O
but	O
its	O
precise	O
role	O
in	O
the	O
coagulation	B-PROC
of	O
FH	O
is	O
not	O
very	O
clear	O
.	O

With	O
regard	O
to	O
adaptive	O
immune	O
parameters	O
such	O
as	O
IgY	O
concentration	O
in	O
blood	O
and	O
infectious	O
bursal	O
disease	O
virus	O
(	O
IBDV	O
)-	O
specific	O
antibody	B-PROC
titres	O
,	O
the	O
Hellevad	O
and	O
Hisex	O
chickens	O
had	O
lower	O
levels	O
than	O
the	O
Bovans	O
.	O

How	O
the	O
differences	O
observed	O
in	O
growth	B-PROC
and	O
immune	O
parameters	O
in	O
the	O
three	O
chicken	O
lines	O
influence	O
the	O
immune	O
protection	O
against	O
infection	O
needs	O
to	O
be	O
studied	O
further	O
.	O

RESULTS	O
:	O
Flow	O
cytometry	O
markers	O
CD38	O
and	O
CD73	O
characterizing	O
murine	O
Bmem	O
from	O
lymphoid	O
tissue	O
showed	O
more	O
diverse	O
expression	B-PROC
patterns	O
on	O
corresponding	O
CNS	O
-	O
derived	O
B	O
cell	O
subsets	O
.	O

The	O
genome	O
of	O
strain	O
CU	O
/	O
1	O
/	O
2014	O
is	O
closely	O
related	O
to	O
vaccine	O
strain	O
H120	O
but	O
showed	O
genome	O
-	O
wide	O
point	B-PROC
mutations	I-PROC
that	O
lead	O
to	O
27	O
,	O
14	O
,	O
11	O
,	O
1	O
,	O
1	O
,	O
2	O
,	O
2	O
,	O
and	O
2	O
amino	O
acid	O
differences	O
between	O
the	O
two	O
strains	O
in	O
1a	O
,	O
1b	O
,	O
S	O
,	O
3a	O
,	O
M	O
,	O
4b	O
,	O
4c	O
,	O
and	O
N	O
proteins	O
,	O
respectively	O
,	O
suggesting	O
that	O
strain	O
CU	O
/	O
1	O
/	O
2014	O
is	O
probably	O
a	O
revertant	O
of	O
the	O
vaccine	O
strain	O
H120	O
and	O
evolved	O
by	O
accumulation	O
of	O
point	B-PROC
mutations	I-PROC
.	O

The	O
identification	O
of	O
risk	O
factors	O
for	O
increased	O
viral	B-PROC
shedding	I-PROC
that	O
may	O
potentially	O
result	O
in	O
increased	O
interspecies	O
transmission	O
is	O
important	O
to	O
prevent	O
viral	O
spillovers	O
from	O
bats	O
to	O
other	O
animals	O
,	O
including	O
humans	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
for	O
refractory	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
rapidly	O
expanding	O
technique	O
.	O

Totals	O
of	O
353	O
and	O
299	O
differentially	O
expressed	B-PROC
proteins	O
were	O
identified	O
upon	O
YC2014	O
and	O
CV777	O
infection	O
,	O
respectively	O
.	O

YC2014	O
could	O
activate	O
NF	O
-	O
κB	O
pathway	B-PROC
more	O
intensively	O
than	O
CV777	O
.	O

TITLE	O
:	O
Discovery	O
of	O
a	O
novel	O
canine	O
respiratory	O
coronavirus	O
support	O
genetic	B-PROC
recombination	I-PROC
among	O
betacoronavirus1	O
.	O

Migration	B-PROC
of	O
fibroblasts	O
toward	O
the	O
fibrotic	O
lesions	O
plays	O
an	O
important	O
role	O
in	O
pulmonary	O
fibrosis	O
.	O

Since	O
each	O
restriction	O
site	O
leaves	O
a	O
unique	O
overhang	O
between	O
adjoining	O
fragments	O
,	O
reconstruction	O
of	O
the	O
full	O
-	O
length	O
genome	O
can	O
be	O
achieved	O
through	O
a	O
standard	O
DNA	B-PROC
ligation	I-PROC
comprised	O
of	O
equal	O
molar	O
ratios	O
of	O
each	O
fragment	O
.	O

The	O
aim	O
of	O
our	O
review	O
is	O
to	O
evaluate	O
whether	O
GPC3	O
has	O
utility	O
as	O
a	O
disease	O
-	O
specific	O
biomarker	O
,	O
to	O
discuss	O
the	O
potential	O
involvement	O
of	O
GPC3	O
in	O
cell	O
biology	O
,	O
and	O
to	O
consider	O
the	O
changes	O
of	O
GPC3	O
gene	O
and	O
protein	B-PROC
expression	B-PROC
and	O
regulation	B-PROC
in	O
hepatocellular	O
carcinoma	O
,	O
lung	O
cancer	O
,	O
severe	O
pneumonia	O
,	O
and	O
ARDS	O
.	O

Modulating	O
miR	O
-	O
142	O
-	O
5p	O
activity	O
by	O
microRNA	O
mimics	O
or	O
inhibitors	O
induced	O
neurodegeneration	O
,	O
including	O
stunted	O
axon	O
elongation	O
,	O
unstable	O
dendritic	O
spine	O
formation	B-PROC
,	O
and	O
irregular	O
swelling	O
and	O
disconnection	O
in	O
neurites	O
.	O

The	O
role	O
of	O
respiratory	O
viral	B-PROC
infections	I-PROC
in	O
patients	O
presenting	O
with	O
a	O
clinical	O
picture	O
of	O
sepsis	O
is	O
underestimated	O
.	O

Blood	O
samples	O
(	O
309	O
)	O
were	O
randomly	O
collected	O
from	O
pigs	O
at	O
farms	O
throughout	O
T	O
&	O
T	O
.	O
Serum	O
samples	O
were	O
tested	O
for	O
the	O
presence	O
of	O
antibodies	O
to	O
the	O
aforementioned	O
viruses	O
using	O
commercial	O
ELISA	O
kits	O
,	O
and	O
the	O
circulating	O
strains	O
of	O
SwIV	O
were	O
identified	O
by	O
the	O
hemagglutination	B-PROC
inhibition	B-PROC
test	O
(	O
HIT	O
).	O

Our	O
results	O
showed	O
that	O
TMPRSS2	O
and	O
MSPL	O
played	O
significant	O
roles	O
in	O
the	O
stages	O
of	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
and	O
virus	O
-	O
cell	B-PROC
fusion	I-PROC
,	O
whereas	O
HAT	O
and	O
DESC1	O
exhibited	O
weaker	O
effects	O
.	O

The	O
MV	O
time	O
before	O
ECMO	O
independently	O
predicted	O
hospital	O
death	B-PROC
in	O
adult	O
respiratory	O
ECMO	O
here	O
.	O

They	O
also	O
experienced	O
a	O
more	O
significant	O
deterioration	O
in	O
respiratory	B-PROC
function	I-PROC
during	O
MV	O
before	O
the	O
institution	O
of	O
ECMO	O
.	O

Neonatal	O
complications	O
resulting	O
from	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	O
)	O
and	O
sepsis	O
were	O
more	O
common	O
in	O
the	O
non	O
-	O
obstetric	O
causes	O
group	O
;	O
however	O
,	O
neurological	O
development	B-PROC
impairment	O
was	O
more	O
common	O
in	O
the	O
obstetric	O
causes	O
group	O
.	O

TITLE	O
:	O
A	O
molecular	O
survey	O
for	O
selected	O
viral	O
enteropathogens	O
revealed	O
a	O
limited	O
role	O
of	O
Canine	O
circovirus	O
in	O
the	O
development	B-PROC
of	O
canine	O
acute	O
gastroenteritis	O
.	O

This	O
study	O
supports	O
the	O
role	O
of	O
CanineCV	O
as	O
a	O
co	O
-	O
pathogen	O
in	O
the	O
development	B-PROC
of	O
gastrointestinal	O
disease	O
,	O
mainly	O
acting	O
in	O
synergism	B-PROC
with	O
other	O
enteric	O
viruses	O
.	O

TITLE	O
:	O
Evaluation	O
and	O
Comparison	O
of	O
the	O
Pathogenicity	O
and	O
Host	O
Immune	B-PROC
Responses	I-PROC
Induced	O
by	O
a	O
G2b	O
Taiwan	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
(	O
Strain	O
Pintung	O
52	O
)	O
and	O
Its	O
Highly	O
Cell	O
-	O
Culture	O
Passaged	O
Strain	O
in	O
Conventional	O
5	O
-	O
Week	O
-	O
Old	O
Pigs	O
.	O

Compared	O
to	O
PEDVPT	O
-	O
P5	O
,	O
PEDVPT	O
-	O
P96	O
inoculation	O
induced	O
none	O
-	O
to	O
-	O
mild	O
diarrhea	O
and	O
lower	O
,	O
delayed	O
fecal	O
viral	B-PROC
shedding	I-PROC
.	O

The	O
present	O
study	O
confirmed	O
the	O
pathogenicity	O
of	O
the	O
PEDVPT	O
isolate	O
in	O
conventional	O
post	O
-	O
weaning	B-PROC
pigs	O
.	O

ABSTRACT	O
:	O
In	O
the	O
contemporary	O
ICU	O
,	O
mechanically	O
ventilated	O
patients	O
may	O
not	O
have	O
arterial	O
blood	B-PROC
gas	I-PROC
measurements	O
available	O
at	O
relevant	O
timepoints	O
.	O

We	O
studied	O
1	O
,	O
034	O
arterial	O
blood	B-PROC
gases	I-PROC
from	O
703	O
patients	O
;	O
650	O
arterial	O
blood	B-PROC
gases	I-PROC
were	O
associated	O
with	O
SpO2	O
less	O
than	O
or	O
equal	O
to	O
96	O
%.	O

TITLE	O
:	O
Clinicopathological	O
spectrum	O
of	O
snake	O
bite	B-PROC
-	O
induced	O
acute	O
kidney	O
injury	O
from	O
India	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
one	O
patients	O
were	O
diagnosed	O
with	O
snake	O
bite	B-PROC
-	O
induced	O
AKI	O
.	O

Main	O
complications	O
were	O
:	O
Gastrointestinal	O
bleed	O
(	O
12	O
.	O
5	O
%),	O
seizure	O
/	O
encephalopathy	O
(	O
10	O
.	O
2	O
%),	O
hypertension	O
,	O
pneumonia	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
disseminated	O
intravascular	O
coagulation	B-PROC
(	O
9	O
.	O
1	O
%	O
each	O
),	O
hypotension	O
and	O
multi	O
organ	O
failure	O
(	O
MOF	O
)	O
(	O
4	O
.	O
5	O
%	O
each	O
).	O

One	O
hundred	O
and	O
ten	O
(	O
90	O
.	O
9	O
%)	O
patient	O
survived	O
and	O
11	O
(	O
9	O
.	O
1	O
%)	O
patients	O
died	B-PROC
.	O

Their	O
plasma	O
concentrations	O
of	O
kallistatin	O
,	O
kallikrein	O
,	O
tumor	O
necrosis	B-PROC
factor	O
(	O
TNF	O
)-	O
α	O
,	O
interleukin	O
(	O
IL	O
)-	O
1β	O
,	O
IL	O
-	O
6	O
,	O
and	O
IL	O
-	O
8	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

They	O
bind	O
and	O
remove	O
ubiquitin	B-PROC
(	O
Ub	O
)	O
and	O
interferon	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
from	O
cellular	O
proteins	O
to	O
suppress	O
host	O
antiviral	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
.	O

TITLE	O
:	O
The	O
Epidemiology	O
of	O
Hospital	O
Death	B-PROC
Following	O
Pediatric	O
Severe	O
Sepsis	O
:	O
When	O
,	O
Why	O
,	O
and	O
How	O
Children	O
With	O
Sepsis	O
Die	O
.	O

ABSTRACT	O
:	O
The	O
epidemiology	O
of	O
in	O
-	O
hospital	O
death	B-PROC
after	O
pediatric	O
sepsis	O
has	O
not	O
been	O
well	O
characterized	O
.	O

We	O
investigated	O
the	O
timing	O
,	O
cause	O
,	O
mode	O
,	O
and	O
attribution	O
of	O
death	B-PROC
in	O
children	O
with	O
severe	O
sepsis	O
,	O
hypothesizing	O
that	O
refractory	O
shock	O
leading	O
to	O
early	O
death	B-PROC
is	O
rare	O
in	O
the	O
current	O
era	O
.	O

Time	O
to	O
death	B-PROC
from	O
sepsis	O
recognition	O
,	O
cause	O
and	O
mode	O
of	O
death	B-PROC
,	O
and	O
attribution	O
of	O
death	B-PROC
to	O
sepsis	O
were	O
determined	O
from	O
medical	O
records	O
.	O

The	O
evolution	B-PROC
and	O
ecology	O
of	O
coronaviruses	O
in	O
rodent	O
have	O
not	O
been	O
fully	O
investigated	O
.	O

Comparing	O
the	O
normal	O
transcription	B-PROC
regulatory	O
sequence	O
(	O
TRS	O
),	O
3	O
variant	O
TRS	O
sequences	O
upstream	O
the	O
spike	O
(	O
S	O
),	O
ORF3	O
,	O
and	O
ORF8	O
genes	O
were	O
found	O
in	O
the	O
genome	O
of	O
AcCoV	O
-	O
JC34	O
.	O

The	O
most	O
significant	O
increase	O
in	O
the	O
use	O
of	O
ECMO	O
as	O
a	O
replacement	O
lung	B-PROC
function	I-PROC
began	O
after	O
the	O
publication	O
of	O
the	O
CESAR	O
study	O
in	O
2009	O
,	O
which	O
demonstrated	O
a	O
decrease	O
in	O
mortality	O
of	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
treated	O
with	O
ECMO	O
,	O
compared	O
with	O
conservative	O
treatment	O
.	O

The	O
prone	O
posture	O
results	O
in	O
more	O
uniform	O
pulmonary	O
blood	B-PROC
flow	I-PROC
when	O
compared	O
with	O
the	O
supine	O
posture	O
,	O
due	O
to	O
an	O
anatomical	O
bias	O
for	O
greater	O
blood	B-PROC
flow	I-PROC
to	O
dorsal	O
lung	O
regions	O
.	O

We	O
hypothesized	O
that	O
neurocognitive	O
outcomes	O
following	O
treatment	O
would	O
be	O
related	O
to	O
both	O
improved	O
cognition	B-PROC
and	O
white	O
matter	O
integrity	O
.	O

Future	O
research	O
should	O
examine	O
whether	O
any	O
additional	O
improvements	O
in	O
neurocognition	O
and	O
white	O
matter	O
integrity	O
among	O
SVRs	O
occur	O
with	O
longer	O
follow	O
-	O
up	O
periods	B-PROC
.	O

After	O
31	O
days	O
of	O
stabilization	O
by	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	B-PROC
)	O
and	O
lung	O
protective	O
ventilation	O
the	O
patient	O
was	O
weaned	B-PROC
of	O
ECMO	B-PROC
therapy	O
.	O

Mutations	O
of	O
these	O
connexin	B-PROC
(	O
Cx	O
)	O
proteins	O
cause	O
dysmyelinating	O
diseases	O
in	O
humans	O
.	O

TITLE	O
:	O
Cytoplasmic	O
tail	O
of	O
coronavirus	O
spike	O
protein	O
has	O
intracellular	O
targeting	B-PROC
signals	O
.	O

ABSTRACT	O
:	O
Intracellular	O
trafficking	B-PROC
and	O
localization	B-PROC
studies	O
of	O
spike	O
protein	O
from	O
SARS	O
and	O
OC43	O
showed	O
that	O
SARS	O
spike	O
protein	O
is	O
localized	O
in	O
the	O
ER	O
or	O
ERGIC	O
compartment	O
and	O
OC43	O
spike	O
protein	O
is	O
predominantly	O
localized	O
in	O
the	O
lysosome	O
.	O

The	O
sequence	O
alignment	O
using	O
Clustal	O
W	O
shows	O
that	O
the	O
signal	O
sequence	O
present	O
at	O
the	O
cytoplasmic	O
tail	O
plays	O
an	O
important	O
role	O
in	O
spike	O
protein	B-PROC
localization	I-PROC
.	O

This	O
study	O
sheds	O
some	O
light	O
on	O
the	O
role	O
of	O
cytoplasmic	O
tail	O
of	O
spike	O
protein	O
in	O
cell	O
-	O
to	O
-	O
cell	B-PROC
fusion	I-PROC
,	O
coronavirus	O
host	O
cell	B-PROC
fusion	I-PROC
and	O
subsequent	O
pathogenicity	O
.	O

Since	O
no	O
single	O
factor	O
has	O
been	O
identified	O
that	O
explains	O
the	O
complexity	O
of	O
HFRS	O
or	O
HPS	O
pathogenesis	B-PROC
,	O
it	O
has	O
been	O
suggested	O
that	O
a	O
cytokine	O
storm	O
may	O
play	O
a	O
crucial	O
role	O
in	O
the	O
manifestation	O
of	O
both	O
diseases	O
.	O

We	O
used	O
microarray	O
analysis	O
to	O
compare	O
changes	O
in	O
gene	B-PROC
expression	I-PROC
of	O
murine	O
lung	O
epithelial	O
cells	O
infected	O
individually	O
by	O
three	O
respiratory	O
viruses	O
causing	O
mild	O
(	O
rhinovirus	O
,	O
RV1B	O
),	O
moderate	O
(	O
coronavirus	O
,	O
MHV	O
-	O
1	O
),	O
and	O
severe	O
(	O
influenza	O
A	O
virus	O
,	O
PR8	O
)	O
disease	O
in	O
mice	O
.	O

PR8	O
altered	O
an	O
intermediate	O
number	O
of	O
genes	O
whose	O
expression	B-PROC
continued	O
to	O
change	O
through	O
24	O
hours	O
.	O

Our	O
comparative	O
approach	O
identified	O
universal	O
and	O
specific	O
transcriptional	B-PROC
signatures	O
of	O
virus	B-PROC
infection	I-PROC
that	O
can	O
be	O
used	O
to	O
distinguish	O
shared	O
and	O
virus	O
-	O
specific	O
mechanisms	O
of	O
pathogenesis	B-PROC
in	O
the	O
respiratory	O
tract	O
.	O

Recently	O
,	O
plant	O
expression	B-PROC
systems	O
have	O
gained	O
interest	O
as	O
an	O
alternative	O
for	O
the	O
production	O
of	O
antibodies	O
because	O
of	O
many	O
advantages	O
,	O
such	O
as	O
low	O
production	O
cost	O
,	O
lack	O
of	O
human	O
and	O
animal	O
pathogen	O
,	O
large	O
scalability	O
,	O
etc	O
.	O

This	O
review	O
gives	O
an	O
example	O
of	O
one	O
such	O
vaccine	O
platform	O
,	O
replication	O
-	O
deficient	O
simian	O
adenoviruses	O
,	O
and	O
describes	O
progress	O
in	O
human	O
and	O
livestock	O
vaccine	O
development	B-PROC
for	O
three	O
outbreak	O
pathogens	O
,	O
Ebola	O
virus	O
,	O
Rift	O
Valley	O
Fever	B-PROC
Virus	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
.	O

We	O
here	O
describe	O
two	O
sisters	O
,	O
born	O
to	O
non	O
-	O
consanguineous	O
Portuguese	O
parents	O
,	O
who	O
had	O
short	O
stature	O
and	O
presented	O
with	O
recurrent	O
episodes	O
of	O
severe	O
ELT	O
triggered	O
by	O
febrile	B-PROC
respiratory	O
viral	B-PROC
infections	I-PROC
since	O
early	O
childhood	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
MHV	O
N	O
protein	O
inhibited	O
Sendai	O
virus	O
and	O
poly	O
(	O
I	O
:	O
C	O
)-	O
induced	O
IFN	O
-	O
β	O
production	O
by	O
targeting	B-PROC
a	O
molecule	O
upstream	O
of	O
retinoic	O
acid	O
-	O
induced	O
gene	O
I	O
(	O
RIG	O
-	O
I	O
)	O
and	O
melanoma	O
differentiation	B-PROC
gene	O
5	O
(	O
MDA5	O
).	O

TITLE	O
:	O
Allelic	O
Variation	O
in	O
the	O
Toll	O
-	O
Like	O
Receptor	O
Adaptor	O
Protein	O
ABSTRACT	O
:	O
Host	O
genetic	O
variation	O
is	O
known	O
to	O
contribute	O
to	O
differential	O
pathogenesis	B-PROC
following	O
infection	O
.	O

To	O
this	O
end	O
a	O
recombination	B-PROC
with	O
synthetic	O
RNA	O
comprising	O
the	O
3	O
'-	O
end	O
of	O
the	O
IBV	O
genome	O
was	O
performed	O
by	O
introducing	O
the	O
complete	O
IBV	O
spike	O
gene	O
,	O
allowing	O
for	O
the	O
rescue	O
and	O
selection	O
of	O
candidate	O
recombinants	O
in	O
embryonated	O
chicken	O
eggs	O
.	O

Then	O
we	O
determine	O
the	O
basic	O
reproduction	B-PROC
number	O
of	O
the	O
MERS	O
-	O
CoV	O
in	O
South	O
Korea	O
in	O
2015	O
as	O
8	O
.	O
0977	O
.	O

There	O
was	O
no	O
intervention	O
to	O
control	O
the	O
infection	O
in	O
the	O
early	O
phase	O
of	O
the	O
outbreak	O
,	O
thus	O
the	O
data	O
used	O
here	O
provide	O
the	O
best	O
conditions	O
to	O
evaluate	O
the	O
epidemic	O
characteristics	O
of	O
MERS	O
,	O
such	O
as	O
the	O
basic	O
reproduction	B-PROC
number	O
.	O

Eleven	O
(	O
85	O
%)	O
reported	O
history	O
of	O
smoking	O
and	O
5	O
(	O
38	O
%)	O
used	O
inhaled	B-PROC
steroids	O
.	O

TITLE	O
:	O
Co	O
-	O
infection	O
of	O
H9N2	O
subtype	O
avian	O
influenza	O
virus	O
and	O
infectious	O
bronchitis	O
virus	O
decreases	O
SP	O
-	O
A	O
expression	B-PROC
level	O
in	O
chickens	O
.	O

ABSTRACT	O
:	O
Chicken	O
surfactant	O
protein	O
A	O
(	O
cSP	O
-	O
A	O
)	O
is	O
a	O
collectin	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
antiviral	O
immunity	B-PROC
.	O

Consequently	O
,	O
the	O
expression	B-PROC
level	O
of	O
cSP	O
-	O
A	O
in	O
the	O
AIV	O
+	O
IBV	O
co	O
-	O
infected	O
group	O
significantly	O
decreased	O
when	O
compared	O
to	O
the	O
AIV	O
-	O
infected	O
group	O
and	O
the	O
IBV	O
-	O
infected	O
group	O
by	O
qRT	O
-	O
PCR	O
,	O
ELISA	O
,	O
and	O
IHC	O
analysis	O
.	O

One	O
isolate	O
,	O
ck	O
/	O
CH	O
/	O
LSD	O
/	O
110857	O
,	O
was	O
shown	O
to	O
have	O
originated	O
from	O
recombination	B-PROC
events	O
between	O
H120	O
-	O
and	O
4	O
/	O
91	O
-	O
like	O
vaccine	O
strains	O
that	O
did	O
not	O
result	O
in	O
changes	O
of	O
antigenicity	O
and	O
pathogenicity	O
.	O

Virus	B-PROC
infection	I-PROC
experiments	O
showed	O
that	O
SD	O
caused	O
high	O
mortality	O
with	O
strong	O
respiratory	O
and	O
renal	O
pathogenicity	O
in	O
chickens	O
,	O
whereas	O
SZ	O
caused	O
milder	O
lesions	O
by	O
comparison	O
.	O

TITLE	O
:	O
Down	O
-	O
regulating	O
heat	B-PROC
shock	I-PROC
protein	O
27	O
is	O
involved	O
in	O
porcine	O
epidemic	O
diarrhea	O
virus	O
escaping	O
from	O
host	O
antiviral	O
mechanism	O
.	O

Tricuspid	O
annular	O
plane	O
systolic	O
excursion	O
(	O
TAPSE	O
),	O
tricuspid	O
peak	B-PROC
systolic	I-PROC
velocity	O
(	O
S	O
'),	O
RV	O
fractional	O
area	O
change	O
(	O
RVFAC	O
),	O
RVFWS	O
,	O
CVP	O
,	O
systolic	O
pulmonary	O
artery	O
pressure	O
(	O
SPAP	O
),	O
and	O
left	B-PROC
ventricular	I-PROC
ejection	I-PROC
fraction	O
(	O
LVEF	O
)	O
were	O
measured	O
.	O

A	O
ventilation	O
strategy	O
incorporating	O
very	O
high	O
carbon	O
dioxide	O
levels	O
to	O
allow	O
for	O
low	O
tidal	O
volumes	O
and	O
limited	O
inspiratory	B-PROC
pressures	O
is	O
feasible	O
in	O
children	O
.	O

Groups	O
3	O
to	O
4	O
received	O
intramuscular	O
injection	O
of	O
cyclophosphamide	O
to	O
induce	O
oxidative	O
stress	O
and	O
immunosuppression	B-PROC
.	O

The	O
dramatic	O
anthropogenic	O
,	O
behavioral	B-PROC
and	O
social	O
changes	O
that	O
have	O
affected	O
humanity	O
and	O
the	O
environment	O
in	O
the	O
past	O
century	O
have	O
accelerated	O
the	O
intrusion	O
of	O
novel	O
pathogens	O
into	O
the	O
global	O
human	O
population	O
,	O
sometimes	O
with	O
devastating	O
consequences	O
.	O

Atopic	O
sensitisation	B-PROC
was	O
found	O
in	O
21	O
.	O
4	O
%	O
of	O
the	O
patients	O
.	O

CT	O
was	O
performed	O
(	O
inspiratory	B-PROC
and	O
expiratory	B-PROC
)	O
at	O
baseline	O
each	O
hour	O
,	O
paired	O
inspiratory	B-PROC
and	O
expiratory	B-PROC
images	O
were	O
superimposed	O
and	O
voxels	O
tracked	O
in	O
sequential	O
scans	O
.	O

In	O
patients	O
with	O
ARDS	O
,	O
a	O
threshold	O
fraction	O
of	O
tissue	O
with	O
unstable	O
inflation	O
was	O
apparent	O
:	O
>	O
28	O
%	O
in	O
all	O
patients	O
who	O
died	B-PROC
and	O
≤	O
28	O
%	O
in	O
all	O
who	O
survived	O
,	O
whereas	O
segregation	O
of	O
survivors	O
versus	O
non	O
-	O
survivors	O
was	O
not	O
possible	O
based	O
on	O
oxygenation	B-PROC
or	O
lung	O
mechanics	O
.	O

We	O
found	O
that	O
SARS	O
S	O
residue	O
R667	O
,	O
a	O
previously	O
identified	O
trypsin	O
cleavage	B-PROC
site	O
,	O
is	O
also	O
required	O
for	O
S	O
protein	B-PROC
cleavage	I-PROC
by	O
TMPRSS2	O
.	O

The	O
cleavage	B-PROC
fragments	O
produced	O
by	O
trypsin	O
and	O
TMPRSS2	O
differed	O
in	O
their	O
decoration	O
with	O
N	O
-	O
glycans	O
,	O
suggesting	O
that	O
these	O
proteases	O
cleave	O
different	O
SARS	O
S	O
glycoforms	O
.	O

NF	O
-	O
κB	O
activation	O
induced	O
by	O
TGEV	O
infection	O
was	O
found	O
to	O
be	O
associated	O
with	O
two	O
convergent	O
pathways	B-PROC
,	O
IKK	O
-	O
2_IκBα	O
/	O
p65	O
and	O
JAK2	O
mediated	O
p65	O
phosphorylation	B-PROC
,	O
in	O
swine	O
testicular	O
cells	O
.	O

For	O
example	O
,	O
by	O
interacting	O
with	O
the	O
host	O
cell	O
to	O
create	O
an	O
optimal	O
environment	O
for	O
coronavirus	O
replication	O
,	O
by	O
altering	O
host	O
gene	B-PROC
expression	I-PROC
or	O
by	O
counteracting	O
the	O
host	O
'	O
s	O
antiviral	O
defenses	O
.	O

This	O
review	O
summarizes	O
our	O
current	O
understanding	O
of	O
coronavirus	O
-	O
host	O
interactions	O
at	O
the	O
level	O
of	O
the	O
infected	O
cell	O
,	O
with	O
special	O
attention	O
for	O
the	O
assembly	O
and	O
function	O
of	O
the	O
viral	O
RNA	O
-	O
synthesising	O
machinery	O
and	O
the	O
evasion	O
of	O
cellular	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
.	O

The	O
protocol	O
below	O
regards	O
exclusively	O
veno	O
-	O
venous	O
ECMO	O
treatment	O
as	O
a	O
support	O
for	O
blood	B-PROC
gas	I-PROC
conditioning	O
by	O
means	O
of	O
extracorporeal	O
circuit	O
in	O
adult	O
patients	O
with	O
severe	O
ARDS	O
.	O

V	O
-	O
V	O
ECMO	O
does	O
not	O
provide	O
treatment	O
for	O
acutely	O
and	O
severely	O
diseased	O
lungs	O
,	O
but	O
it	O
enables	O
patient	O
to	O
survive	O
the	O
critical	O
phase	O
of	O
severe	O
ARDS	O
until	O
recovery	O
of	O
lung	B-PROC
function	I-PROC
.	O

ABSTRACT	O
:	O
Influenza	O
virus	B-PROC
infection	I-PROC
often	O
causes	O
severe	O
disease	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

To	O
achieve	O
the	O
non	O
-	O
selective	O
amplification	O
and	O
recovery	O
of	O
low	O
abundance	O
genetic	O
sequences	O
,	O
a	O
simplified	O
Sequence	O
-	O
Independent	O
,	O
Single	O
-	O
Primer	O
Amplification	O
(	O
SISPA	O
)	O
technique	O
in	O
combination	O
with	O
MiSeq	O
platform	O
was	O
applied	O
to	O
target	O
negative	O
-	O
and	O
positive	O
-	O
sense	B-PROC
single	O
-	O
stranded	O
RNA	O
viral	O
sequences	O
.	O

Moreover	O
,	O
SISPA	O
analysis	O
applied	O
to	O
unknown	O
clinical	O
cases	O
of	O
mixed	O
viral	B-PROC
infections	I-PROC
produced	O
genome	O
assemblies	O
comprising	O
98	O
%	O
NDV	O
and	O
99	O
%	O
of	O
IBV	O
genomes	O
.	O

We	O
show	O
that	O
a	O
nucleotide	O
prodrug	O
,	O
GS	O
-	O
5734	O
,	O
currently	O
in	O
clinical	O
development	B-PROC
for	O
treatment	O
of	O
Ebola	O
virus	B-PROC
disease	I-PROC
,	O
can	O
inhibit	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
replication	O
in	O
multiple	O
in	O
vitro	O
systems	O
,	O
including	O
primary	O
human	O
airway	O
epithelial	O
cell	O
cultures	O
with	O
submicromolar	O
IC	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
common	O
sequela	O
of	O
severe	O
burns	O
and	O
inhalation	B-PROC
injury	O
.	O

The	O
massive	O
inflammatory	O
reaction	O
that	O
follows	O
deep	O
burn	O
injury	O
,	O
compounded	O
by	O
episodes	O
of	O
sepsis	O
and	O
organ	O
dysfunction	O
,	O
predisposes	O
patients	O
to	O
the	O
development	B-PROC
of	O
ARDS	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
frequency	O
of	O
respiratory	O
viral	B-PROC
infections	I-PROC
in	O
a	O
young	O
child	O
and	O
to	O
examine	O
the	O
duration	O
of	O
viral	O
genome	O
detection	O
in	O
clinical	O
specimens	O
.	O

A	O
total	O
of	O
284	O
nasal	O
swabs	O
were	O
collected	O
during	O
symptomatic	O
(	O
196	O
specimens	O
)	O
and	O
asymptomatic	O
(	O
88	O
specimens	O
)	O
periods	B-PROC
of	O
respiratory	O
symptoms	O
from	O
a	O
young	O
female	O
child	O
(	O
from	O
4	O
months	O
to	O
31	O
months	O
of	O
age	O
,	O
who	O
was	O
admitted	O
to	O
a	O
nursery	O
school	O
at	O
9	O
months	O
).	O

One	O
hundred	O
and	O
ninety	O
-	O
eight	O
of	O
the	O
tested	O
specimens	O
were	O
virus	O
positive	O
(	O
69	O
.	O
7	O
%)	O
(	O
symptomatic	O
periods	B-PROC
,	O
149	O
/	O
196	O
,	O
76	O
.	O
0	O
%;	O
asymptomatic	O
periods	B-PROC
,	O
49	O
/	O
88	O
,	O
55	O
.	O
7	O
%).	O

After	O
emergent	O
endovascular	O
patent	O
artery	O
occlusion	B-PROC
,	O
he	O
developed	O
Wallenberg	O
syndrome	O
and	O
experienced	O
apnea	O
and	O
a	O
conscious	O
disturbance	O
episode	O
due	O
to	O
CHS	O
on	O
postoperative	O
days	O
6	O
and	O
16	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
severe	O
empyema	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
caused	O
by	O
Slackia	O
exigua	O
requiring	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

TITLE	O
:	O
Determination	O
of	O
the	O
cell	O
tropism	B-PROC
of	O
serotype	O
1	O
feline	O
infectious	O
peritonitis	O
virus	O
using	O
the	O
spike	O
affinity	O
histochemistry	O
in	O
paraffin	O
-	O
embedded	O
tissues	O
.	O

The	O
first	O
case	O
was	O
a	O
13	O
-	O
year	O
-	O
old	O
patient	O
who	O
was	O
admitted	O
with	O
a	O
2	O
-	O
month	O
history	O
of	O
fever	B-PROC
,	O
weight	O
loss	O
,	O
night	O
sweats	O
,	O
and	O
cough	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
severe	O
clinical	O
condition	O
of	O
respiratory	O
failure	O
due	O
to	O
an	O
intense	O
inflammatory	B-PROC
response	I-PROC
with	O
different	O
etiologies	O
.	O

Downregulation	B-PROC
of	O
ACE2	O
is	O
always	O
associated	O
with	O
the	O
ALI	O
or	O
ARDS	O
induced	O
by	O
avian	O
influenza	O
virus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
,	O
respiratory	O
syncytial	O
virus	O
and	O
sepsis	O
.	O

Then	O
,	O
we	O
found	O
that	O
nonstructural	O
protein	O
1	O
and	O
viral	O
RNA	O
of	O
H5N1	O
contributed	O
to	O
the	O
induction	O
of	O
miR	O
-	O
200c	O
-	O
3p	O
during	O
viral	B-PROC
infection	I-PROC
.	O

From	O
160	O
-	O
220days	O
of	O
age	O
,	O
gilts	O
were	O
exposed	O
daily	O
to	O
vasectomized	O
boars	O
and	O
observed	O
for	O
behavioral	B-PROC
estrus	B-PROC
.	O

TITLE	O
:	O
Identification	O
of	O
microRNAs	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
based	O
on	O
microRNA	O
expression	B-PROC
profile	O
in	O
rats	O
.	O

Following	O
data	O
normalization	O
,	O
differentially	O
expressed	B-PROC
miRNAs	O
were	O
identified	O
using	O
the	O
t	O
‑	O
test	O
method	O
.	O

Additionally	O
,	O
the	O
target	O
genes	O
of	O
the	O
four	O
miRNAs	O
were	O
significantly	O
enriched	O
the	O
biological	B-PROC
processes	I-PROC
of	O
wounding	O
and	O
inflammatory	B-PROC
response	I-PROC
.	O

TITLE	O
:	O
Inhibition	B-PROC
of	O
NF	O
-	O
κB	O
activity	O
by	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
nonstructural	O
protein	O
1	O
for	O
innate	O
immune	B-PROC
evasion	I-PROC
.	O

Nsp1	O
interfered	O
the	O
phosphorylation	B-PROC
and	O
degradation	O
of	O
IκBα	O
,	O
and	O
thus	O
blocked	O
the	O
p65	O
activation	O
.	O

TITLE	O
:	O
Anasarca	O
,	O
Fever	B-PROC
,	O
Thrombocytopenia	O
,	O
Organomegaly	O
,	O
and	O
Multiorgan	O
Failure	O
in	O
a	O
24	O
-	O
Year	O
-	O
Old	O
Pregnant	O
Woman	O
.	O

An	O
effective	O
strategy	O
to	O
control	O
emergency	O
center	O
visits	O
by	O
non	O
-	O
urgent	O
febrile	B-PROC
patients	O
and	O
provide	O
proper	O
medical	O
services	O
is	O
urgently	O
needed	O
.	O

She	O
was	O
lethargic	O
and	O
had	O
orthostatic	B-PROC
hypotension	O
.	O

She	O
deteriorated	O
clinically	O
within	O
a	O
few	O
days	O
,	O
with	O
worsening	O
lethargy	O
and	O
the	O
development	B-PROC
of	O
respiratory	O
distress	O
along	O
with	O
profound	O
hypotension	O
.	O

Expert	O
commentary	O
:	O
Use	O
of	O
this	O
platform	O
can	O
substantially	O
accelerate	O
process	O
development	B-PROC
and	O
facilitate	O
licensure	O
because	O
of	O
the	O
substantial	O
existing	O
data	O
set	O
available	O
for	O
the	O
cell	O
matrix	O
.	O

In	O
addition	O
,	O
severe	O
signs	O
of	O
inflammation	O
at	O
initial	O
presentation	O
(	O
at	O
hospital	O
days	O
1	O
-	O
4	O
),	O
such	O
as	O
high	O
inducible	O
protein	O
-	O
10	O
(	O
p	O
=	O
0	O
.	O
0013	O
),	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
(	O
p	O
=	O
0	O
.	O
0007	O
)	O
and	O
interleukin	O
6	O
(	O
p	O
=	O
0	O
.	O
0007	O
)	O
concentrations	O
,	O
and	O
poor	O
viral	O
control	O
(	O
high	O
viral	O
load	O
at	O
hospital	O
days	O
5	O
-	O
10	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
without	O
adequate	O
antibody	B-PROC
titres	O
(	O
low	O
antibody	B-PROC
titre	O
at	O
hospital	O
days	O
11	O
-	O
16	O
,	O
p	O
=	O
0	O
.	O
07	O
)	O
during	O
the	O
course	O
of	O
disease	O
,	O
were	O
associated	O
with	O
mortality	O
.	O

As	O
with	O
ADE	O
of	O
FIPV	O
79	O
-	O
1146	O
infection	O
,	O
a	O
monoclonal	O
antibody	B-PROC
against	O
the	O
spike	O
protein	O
of	O
FCoV	O
(	O
mAb	O
6	O
-	O
4	O
-	O
2	O
)	O
enhanced	O
FECV	O
79	O
-	O
1683	O
replication	O
in	O
U937	O
cells	O
and	O
primary	O
feline	O
monocytes	O
.	O

A	O
total	O
of	O
29	O
left	O
-	O
over	O
lung	O
specimens	O
that	O
were	O
obtained	O
from	O
patients	O
who	O
died	B-PROC
from	O
severe	O
falciparum	O
malaria	O
were	O
examined	O
.	O

Although	O
coexistence	O
of	O
nsp3	O
and	O
nsp4	O
is	O
known	O
to	O
cause	O
membrane	O
rearrangement	B-PROC
,	O
the	O
mechanisms	O
underlying	O
the	O
interaction	O
of	O
these	O
two	O
proteins	O
remain	O
unclear	O
.	O

In	O
addition	O
,	O
we	O
revealed	O
that	O
the	O
nsp3	O
-	O
nsp4	O
interaction	O
is	O
not	O
sufficient	O
to	O
induce	O
membrane	O
rearrangement	B-PROC
,	O
suggesting	O
the	O
participation	O
of	O
other	O
factors	O
such	O
as	O
host	O
proteins	O
.	O

The	O
emergence	O
of	O
variant	O
IBV	O
strains	O
can	O
be	O
attributed	O
to	O
recombination	B-PROC
.	O

PPV	O
increased	O
PaO	B-PROC
CONCLUSIONS	O
:	O
Our	O
findings	O
suggest	O
that	O
PPV	O
may	O
improve	O
oxygenation	B-PROC
and	O
partially	O
improve	O
hemodynamic	B-PROC
parameters	O
during	O
acute	O
exacerbations	O
of	O
ILD	O
.	O

Herein	O
,	O
we	O
present	O
successful	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
support	O
for	O
rituximab	O
-	O
induced	O
ARDS	O
in	O
an	O
ABO	O
-	O
incompatible	O
living	O
donor	O
liver	O
transplantation	O
(	O
LDLT	O
)	O
recipient	O
.	O

Some	O
zoonotic	O
agents	O
are	O
""""	O
exotic	O
""""	O
for	O
Egypt	O
(	O
e	O
.	O
g	O
.,	O
MERS	O
-	O
CoV	O
and	O
Crimean	O
-	O
Congo	O
hemorrhagic	O
fever	B-PROC
virus	O
),	O
others	O
are	O
endemic	O
(	O
e	O
.	O
g	O
.,	O
Brucellosis	O
,	O
Schistosomiasis	O
and	O
Avian	O
influenza	O
).	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
has	O
been	O
reported	O
to	O
improve	O
outcomes	O
in	O
patients	O
with	O
refractory	O
respiratory	O
failure	O
.	O

Furthermore	O
,	O
these	O
cell	O
-	O
adapted	O
strains	O
elicited	O
potent	O
neutralizing	O
antibody	B-PROC
responses	I-PROC
in	O
immunized	O
pigs	O
.	O

However	O
,	O
Korean	O
PDCoV	O
strains	O
formed	O
different	O
branches	O
within	O
the	O
same	O
cluster	O
,	O
implying	O
continuous	O
evolution	B-PROC
in	O
the	O
field	O
.	O

The	O
sequence	O
analysis	O
revealed	O
that	O
the	O
S	O
genes	O
of	O
Vietnamese	O
PEDVs	O
were	O
heterogeneous	O
and	O
classified	O
into	O
four	O
genotypes	O
,	O
namely	O
North	O
America	O
and	O
Asian	O
non	O
-	O
S	O
INDEL	B-PROC
,	O
Asian	O
non	O
-	O
S	O
INDEL	B-PROC
,	O
new	O
S	O
INDEL	B-PROC
and	O
classical	O
S	O
INDEL	B-PROC
.	O

Recombinant	O
FIPVs	O
(	O
rFPIVs	O
)	O
expressing	O
mutant	O
and	O
/	O
or	O
FLAG	O
-	O
tagged	O
forms	O
of	O
7b	O
were	O
generated	O
and	O
used	O
to	O
investigate	O
the	O
expression	B-PROC
,	O
processing	O
,	O
glycosylation	B-PROC
,	O
localization	B-PROC
and	O
trafficking	B-PROC
of	O
the	O
7b	O
protein	O
in	O
rFIPV	O
-	O
infected	O
cells	O
,	O
focusing	O
on	O
a	O
previously	O
predicted	O
ER	O
retention	B-PROC
signal	O
,	O
KTEL	O
,	O
at	O
the	O
C	O
-	O
terminus	O
of	O
7b	O
.	O

Understanding	O
MERS	O
CoV	O
genetic	O
aspects	O
and	O
codon	O
usage	O
pattern	O
is	O
important	O
to	O
understand	O
MERS	O
CoV	O
survival	O
,	O
adaptation	B-PROC
,	O
evolution	B-PROC
,	O
resistance	B-PROC
to	O
innate	B-PROC
immunity	B-PROC
,	O
and	O
help	O
in	O
finding	O
the	O
unique	O
aspects	O
of	O
the	O
virus	O
for	O
future	O
drug	O
discovery	O
experiments	O
.	O

MERS	O
CoV	O
showed	O
high	O
ability	O
to	O
resist	O
the	O
innate	B-PROC
immune	I-PROC
response	I-PROC
by	O
showing	O
lower	O
CpG	O
frequencies	O
.	O

ABSTRACT	O
:	O
Incidences	O
of	O
emerging	O
/	O
re	O
-	O
emerging	O
deadly	O
viral	B-PROC
infections	I-PROC
have	O
significantly	O
affected	O
human	O
health	O
despite	O
extraordinary	O
progress	O
in	O
the	O
area	O
of	O
biomedical	O
knowledge	O
.	O

In	O
non	O
-	O
viral	O
DAD	O
,	O
main	O
immune	O
cell	O
alterations	O
were	O
found	O
at	O
the	O
small	O
airway	O
level	O
,	O
reinforcing	O
the	O
role	O
of	O
the	O
small	O
airways	O
in	O
the	O
pathogenesis	B-PROC
of	O
the	O
exudative	O
phase	O
of	O
DAD	O
.	O

Three	O
patients	O
(	O
5	O
.	O
9	O
%)	O
died	B-PROC
due	O
to	O
VGS	O
BSI	O
until	O
day	O
28	O
of	O
observation	O
.	O

Infectious	O
bronchitis	O
is	O
one	O
of	O
the	O
most	O
important	O
viral	B-PROC
infections	I-PROC
that	O
cause	O
huge	O
economic	O
loss	O
to	O
the	O
poultry	O
industry	O
worldwide	O
.	O

MERS	O
was	O
recently	O
identified	O
as	O
a	O
candidate	O
for	O
vaccine	O
development	B-PROC
,	O
but	O
most	O
efforts	O
focus	O
on	O
antibody	B-PROC
responses	I-PROC
,	O
which	O
are	O
often	O
transient	O
after	O
CoV	O
infections	O
.	O

ABSTRACT	O
:	O
Corona	O
viruses	O
cause	O
common	O
cold	B-PROC
,	O
and	O
infections	O
caused	O
by	O
corona	O
viruses	O
are	O
generally	O
self	O
-	O
resolving	O
.	O

The	O
patient	O
'	O
s	O
respiratory	O
status	O
continued	O
to	O
decline	O
postpartum	O
,	O
and	O
she	O
ultimately	O
required	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

Viral	O
adaptation	B-PROC
and	O
tissue	O
response	O
were	O
assessed	O
through	O
RNA	O
sequencing	O
.	O

Despite	O
aggressive	B-PROC
treatment	O
there	O
was	O
no	O
improvement	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
an	O
HIV	O
-	O
positive	O
man	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
pneumocystis	O
and	O
cytomegalovirus	O
pneumonia	O
.	O

Additionally	O
,	O
prediction	O
of	O
N	O
-	O
glycosylation	B-PROC
sites	O
showed	O
that	O
most	O
of	O
the	O
BR	O
-	O
I	O
variants	O
(	O
from	O
2003	O
to	O
early	O
2014	O
)	O
had	O
an	O
extra	O
site	O
at	O
amino	O
acid	O
position	O
20	O
,	O
whereas	O
the	O
newest	O
variants	O
lacked	O
this	O
extra	O
site	O
.	O

Here	O
,	O
the	O
evaluation	O
and	O
validation	O
of	O
two	O
newly	O
developed	O
reverse	B-PROC
transcription	B-PROC
-	O
insulated	O
isothermal	O
PCR	O
(	O
RT	O
-	O
iiPCR	O
)	O
methods	O
targeting	B-PROC
the	O
ORF1a	O
and	O
upE	O
genes	O
of	O
MERS	O
-	O
CoV	O
are	O
described	O
.	O

Recombinase	O
polymerase	O
amplification	O
(	O
RPA	O
),	O
as	O
an	O
isothermal	O
gene	B-PROC
amplification	I-PROC
technique	O
,	O
has	O
been	O
explored	O
for	O
the	O
molecular	O
detection	O
of	O
diverse	O
pathogens	O
.	O

TITLE	O
:	O
Pharmacological	O
modulation	O
of	O
C	O
-	O
X	O
-	O
C	O
motif	O
chemokine	O
receptor	O
4	O
influences	O
development	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
lung	O
ischaemia	O
-	O
reperfusion	O
injury	O
.	O

Twenty	O
-	O
eight	O
patients	O
(	O
60	O
.	O
9	O
%)	O
were	O
successfully	O
weaned	B-PROC
from	O
ECMO	O
and	O
22	O
patients	O
survived	O
(	O
47	O
.	O
8	O
%).	O

TITLE	O
:	O
Astragalus	O
polysaccharides	O
enhance	O
the	O
immune	B-PROC
response	I-PROC
to	O
avian	O
infectious	O
bronchitis	O
virus	O
vaccination	O
in	O
chickens	O
.	O

After	O
having	O
demonstrated	O
its	O
capability	O
to	O
significantly	O
improve	O
oxygenation	B-PROC
in	O
a	O
large	O
number	O
of	O
patients	O
,	O
sometimes	O
dramatically	O
,	O
this	O
procedure	O
has	O
been	O
found	O
to	O
prevent	O
ventilator	O
-	O
induced	O
lung	O
injury	O
,	O
the	O
primary	O
concern	O
for	O
the	O
intensivists	O
managing	O
ARDS	O
patients	O
.	O

At	O
the	O
end	O
,	O
significant	O
improvement	O
in	O
survival	O
has	O
been	O
demonstrated	O
in	O
the	O
most	O
severe	O
ARDS	O
patients	O
,	O
at	O
a	O
threshold	O
of	O
100	O
-	O
150	O
mmHg	O
PaO	B-PROC

In	O
the	O
present	O
review	O
article	O
,	O
we	O
present	O
physiologic	O
mechanisms	O
driving	O
spontaneous	O
breathing	B-PROC
,	O
with	O
emphasis	O
on	O
how	O
to	O
implement	O
basic	O
and	O
advanced	O
respiratory	O
monitoring	O
to	O
assess	O
lung	O
protection	O
during	O
spontaneous	O
assisted	O
ventilation	O
.	O

Nonetheless	O
,	O
risk	O
of	O
additional	O
lung	O
injury	O
is	O
not	O
completely	O
avoided	O
during	O
spontaneous	O
breathing	B-PROC
and	O
careful	O
monitoring	O
of	O
target	O
physiologic	O
variables	O
such	O
as	O
tidal	O
volume	O
(	O
Vt	O
)	O
and	O
driving	O
transpulmonary	O
pressure	O
should	O
be	O
applied	O
routinely	O
.	O

One	O
study	O
reported	O
bacterial	O
resistance	B-PROC
,	O
but	O
only	O
at	O
48	O
hours	O
(	O
thus	O
with	O
limited	O
applicability	O
for	O
this	O
review	O
).	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
Accessory	O
ORFs	O
Play	O
Key	O
Role	O
for	O
Infection	O
and	O
Pathogenesis	B-PROC
.	O

ABSTRACT	O
:	O
While	O
dispensable	O
for	O
viral	B-PROC
replication	I-PROC
,	O
coronavirus	O
(	O
CoV	O
)	O
accessory	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
proteins	O
often	O
play	O
critical	O
roles	O
during	O
infection	O
and	O
pathogenesis	B-PROC
.	O

Osteomyelitis	O
of	O
C1	O
/	O
C2	O
and	O
severe	O
muscle	B-PROC
wasting	I-PROC
required	O
a	O
prolonged	O
hospital	O
stay	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
the	O
effect	O
of	O
serum	O
antibody	B-PROC
abundance	O
against	O
bovine	O
coronavirus	O
on	O
bovine	O
coronavirus	O
shedding	O
and	O
risk	O
of	O
respiratory	O
tract	O
disease	O
in	O
beef	O
calves	O
from	O
birth	B-PROC
through	O
the	O
first	O
five	O
weeks	O
in	O
a	O
feedlot	O
.	O

Sequence	O
variation	O
among	O
coronavirus	O
detected	O
from	O
individual	O
bats	O
suggested	O
that	O
infection	O
occurred	O
prior	O
to	O
hibernation	B-PROC
,	O
and	O
that	O
the	O
virus	O
persisted	O
for	O
up	O
to	O
4	O
months	O
of	O
hibernation	B-PROC
in	O
the	O
laboratory	O
.	O

The	O
serum	O
levels	O
of	O
nine	O
cytokines	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
asthma	O
than	O
in	O
HCs	O
,	O
and	O
the	O
levels	O
of	O
IL	O
-	O
17A	O
and	O
SCF	B-PROC
were	O
significantly	O
different	O
between	O
uncontrolled	O
and	O
well	O
-	O
controlled	O
patient	O
groups	O
(	O
p	O
=	O
0	O
.	O
003	O
).	O

ABSTRACT	O
:	O
Molecular	O
detection	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
using	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
(	O
rRT	O
)-	O
PCR	O
assays	O
is	O
the	O
method	O
of	O
choice	O
for	O
diagnosis	O
of	O
MERS	O
.	O

To	O
confirm	O
the	O
autophagic	O
-	O
flux	O
(	O
entire	O
autophagy	B-PROC
pathway	B-PROC
),	O
autophagolysosomes	O
were	O
examined	O
by	O
an	O
immunofluorescence	O
assay	O
.	O

In	O
contrast	O
,	O
viral	O
RNA	O
circumvents	O
the	O
nsp1	O
-	O
mediated	O
translational	B-PROC
shutoff	O
for	O
an	O
efficient	O
propagation	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
amino	O
acid	O
residue	O
in	O
MERS	O
-	O
CoV	O
nsp1	O
that	O
differ	O
from	O
those	O
of	O
SARS	O
-	O
CoV	O
nsp1	O
,	O
and	O
that	O
appear	O
to	O
be	O
crucial	O
for	O
circumventing	O
the	O
translational	B-PROC
shutoff	O
.	O

In	O
addition	O
,	O
reverse	O
genetics	O
analysis	O
suggested	O
the	O
presence	O
of	O
a	O
cis	O
-	O
acting	O
element	O
at	O
the	O
5	O
'-	O
terminus	O
of	O
the	O
nsp1	O
-	O
coding	O
region	O
,	O
which	O
contributes	O
to	O
the	O
specific	O
recognition	O
of	O
viral	O
RNA	O
that	O
is	O
required	O
for	O
an	O
efficient	O
viral	B-PROC
replication	I-PROC
.	O

M2	O
,	O
especially	O
M2c	O
,	O
induced	O
Tregs	O
without	O
any	O
influence	O
on	O
Tregs	O
immunosuppression	B-PROC
function	O
.	O

Because	O
severe	O
pneumonia	O
is	O
the	O
main	O
cause	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
we	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
the	O
FER	O
polymorphism	B-PROC
rs4957796	O
on	O
the	O
90	O
-	O
day	O
survival	O
in	O
patients	O
with	O
ARDS	O
due	O
to	O
pneumonia	O
.	O

TITLE	O
:	O
Identification	O
of	O
two	O
mutation	O
sites	O
in	O
spike	O
and	O
envelope	O
proteins	O
mediating	O
optimal	O
cellular	O
infection	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
from	O
different	O
pathways	B-PROC
.	O

ABSTRACT	O
:	O
Entry	O
of	O
the	O
α	O
-	O
coronavirus	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
requires	O
specific	O
proteases	O
to	O
activate	O
spike	O
(	O
S	O
)	O
protein	O
for	O
the	O
membrane	B-PROC
fusion	I-PROC
of	O
the	O
virion	O
to	O
the	O
host	O
cell	O
following	O
receptor	O
binding	O
.	O

Docking	B-PROC
simulations	O
hypothesized	O
its	O
binding	O
to	O
two	O
RT	O
pockets	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
application	O
of	O
a	O
recombinant	O
M	O
protein	O
-	O
based	O
indirect	O
ELISA	O
for	O
the	O
detection	O
of	O
porcine	O
deltacoronavirus	O
IgG	O
antibodies	O
.	O

The	O
main	O
objectives	O
were	O
to	O
compare	O
two	O
different	O
ventilator	O
settings	O
on	O
Pseudomonas	O
aeruginosa	O
growth	B-PROC
in	O
lung	O
tissue	O
and	O
the	O
development	B-PROC
of	O
lung	O
injury	O
.	O

In	O
early	O
phase	O
pneumonia	O
,	O
protective	O
ventilation	O
with	O
lower	O
tidal	O
volume	O
and	O
higher	O
end	O
expiratory	B-PROC
pressure	O
has	O
the	O
potential	O
to	O
reduce	O
the	O
pulmonary	O
bacterial	O
burden	O
and	O
the	O
development	B-PROC
of	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
This	O
retrospective	O
single	O
-	O
center	O
study	O
investigated	O
the	O
incidence	O
of	O
neurologic	O
injury	O
as	O
determined	O
by	O
autopsy	O
or	O
cerebral	O
imaging	O
in	O
74	O
patients	O
undergoing	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Then	O
cytokines	O
including	O
lung	O
IL	O
-	O
6	O
,	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
10	O
and	O
plasma	O
HMGB1	O
,	O
apoptosis	B-PROC
of	O
splenic	O
immune	O
cells	O
and	O
Foxp3	O
level	O
on	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
were	O
studied	O
to	O
demonstrate	O
the	O
mechanisms	O
of	O
EP	O
administration	O
on	O
two	O
-	O
hit	O
mice	O
.	O

TITLE	O
:	O
Veno	O
-	O
veno	O
-	O
arterial	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
septic	O
-	O
induced	O
cardiomyopathy	O
due	O
to	O
severe	O
pulmonary	O
tuberculosis	O
.	O

Especially	O
,	O
pregnant	O
women	O
can	O
be	O
expected	O
as	O
highly	O
vulnerable	O
candidates	O
for	O
this	O
viral	B-PROC
infection	I-PROC
.	O

Globally	O
,	O
the	O
spreading	O
dynamics	O
and	O
evolution	B-PROC
of	O
the	O
QX	O
genotype	O
were	O
reconstructed	O
from	O
its	O
very	O
origin	O
to	O
nowadays	O
,	O
demonstrating	O
the	O
need	O
of	O
more	O
effective	O
direct	O
control	O
measures	O
,	O
particularly	O
within	O
each	O
country	O
.	O

The	O
purpose	O
of	O
this	O
review	O
article	O
is	O
to	O
discuss	O
the	O
state	O
of	O
knowledge	O
with	O
respect	O
to	O
ECMO	O
transport	B-PROC
with	O
special	O
emphasis	O
given	O
to	O
how	O
to	O
actually	O
undertake	O
such	O
complex	O
transports	O
.	O

The	O
findings	O
can	O
serve	O
as	O
a	O
guide	O
for	O
healthcare	O
practitioners	O
by	O
appropriately	O
identifying	O
and	O
managing	O
potential	O
patients	O
at	O
high	O
risk	O
of	O
death	B-PROC
.	O

The	O
cytokines	O
secreted	B-PROC
following	O
inflammasome	O
activation	O
,	O
which	O
include	O
IL	O
-	O
1	O
and	O
IL	O
-	O
18	O
,	O
regulate	O
cells	O
of	O
both	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	O
,	O
guiding	O
the	O
subsequent	O
immune	B-PROC
responses	I-PROC
.	O

In	O
this	O
study	O
,	O
we	O
used	O
murine	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
and	O
liver	O
to	O
assess	O
of	O
the	O
role	O
of	O
the	O
inflammasome	O
and	O
its	O
related	O
cytokines	O
on	O
pathogenesis	B-PROC
and	O
host	B-PROC
defense	I-PROC
during	O
viral	B-PROC
infection	I-PROC
.	O

In	O
addition	O
,	O
the	O
genetic	O
alterations	O
in	O
the	O
S1	O
gene	O
of	O
these	O
isolates	O
were	O
not	O
able	O
to	O
change	O
their	O
tissue	B-PROC
tropism	B-PROC
and	O
pathogenicity	O
,	O
but	O
did	O
seem	O
to	O
negatively	O
influence	O
the	O
effectiveness	O
of	O
the	O
host	O
immune	B-PROC
responses	I-PROC
against	O
these	O
viruses	O
,	O
and	O
favour	O
viral	O
persistence	O
.	O

ABSTRACT	O
:	O
The	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
S1	O
subunit	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
mediates	O
viral	O
attachment	O
to	O
host	O
cells	O
and	O
the	O
S2	O
subunit	O
is	O
responsible	O
for	O
membrane	B-PROC
fusion	I-PROC
.	O

This	O
activity	O
is	O
in	O
addition	O
to	O
its	O
viral	O
polypeptide	O
cleavage	B-PROC
function	O
.	O

Utilizing	O
this	O
structural	O
information	O
,	O
mutants	O
were	O
generated	O
that	O
lacked	O
appreciable	O
deISGylase	O
activity	O
but	O
retained	O
wild	O
-	O
type	O
deubiquitinase	B-PROC
and	O
peptide	O
cleavage	B-PROC
activities	O
.	O

IBV	O
replication	O
was	O
increased	O
by	O
blocking	O
caspase	B-PROC
activation	I-PROC
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
single	O
-	O
tube	O
one	O
-	O
step	O
reverse	B-PROC
transcription	B-PROC
loop	O
-	O
mediated	O
isothermal	O
amplification	O
(	O
RT	O
-	O
LAMP	O
)	O
assay	O
specific	O
for	O
nucleocapsid	O
gene	O
to	O
diagnose	O
and	O
monitor	O
PDCoV	O
infections	O
.	O

We	O
suggest	O
the	O
use	O
of	O
IV	O
methylprednisolone	O
1	O
mg	O
/	O
kg	O
/	O
day	O
in	O
patients	O
with	O
early	O
moderate	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PaO	B-PROC
Evidence	O
-	O
based	O
recommendations	O
for	O
the	O
use	O
of	O
corticosteroids	O
in	O
critically	O
ill	O
patients	O
with	O
sepsis	O
and	O
septic	O
shock	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
major	O
trauma	O
have	O
been	O
developed	O
by	O
a	O
multispecialty	O
task	O
force	O
.	O

TITLE	O
:	O
Vitamin	O
D	O
alleviates	O
lipopolysaccharide	O
‑	O
induced	O
acute	O
lung	O
injury	O
via	O
regulation	B-PROC
of	O
the	O
renin	O
‑	O
angiotensin	O
system	O
.	O

Results	O
from	O
reverse	B-PROC
transcription	O
‑	O
quantitative	O
polymerase	O
chain	O
reaction	O
,	O
western	O
blotting	O
and	O
ELISA	O
analysis	O
demonstrated	O
that	O
calcitriol	O
also	O
modulated	O
the	O
expression	B-PROC
of	O
members	O
of	O
the	O
renin	O
‑	O
angiotensin	O
system	O
(	O
RAS	O
),	O
including	O
angiotensin	O
(	O
Ang	O
)	O
I	O
‑	O
converting	O
enzymes	O
(	O
ACE	O
and	O
ACE2	O
),	O
renin	O
and	O
Ang	O
II	O
,	O
which	O
indicates	O
that	O
calcitriol	O
may	O
exert	B-PROC
protective	O
effects	O
on	O
LPS	O
‑	O
induced	O
lung	O
injury	O
,	O
at	O
least	O
partially	O
,	O
by	O
regulating	O
the	O
balance	B-PROC
between	O
the	O
expression	B-PROC
of	O
members	O
of	O
the	O
RAS	O
.	O

Results	O
presented	O
herein	O
offer	O
structure	O
-	O
activity	O
relationships	O
for	O
these	O
pathogens	O
in	O
terms	O
of	O
their	O
susceptibility	O
to	O
inhibition	B-PROC
by	O
polymers	O
,	O
and	O
for	O
polymers	O
in	O
terms	O
of	O
their	O
anionic	O
charge	O
and	O
hydrophobicity	O
that	O
make	O
up	O
broad	O
-	O
spectrum	O
antiviral	O
agents	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
novel	O
PELC	O
/	O
CpG	O
adjuvant	O
for	O
recombinant	O
H7HA	O
(	O
rH7HA	O
)	O
subunit	O
vaccine	O
development	B-PROC
.	O

Phylogenetic	O
analysis	O
showed	O
that	O
2016	O
PEDV	O
variants	O
belong	O
to	O
the	O
cluster	O
of	O
recombination	B-PROC
strains	O
but	O
form	O
a	O
new	O
branch	O
.	O

ABSTRACT	O
:	O
Outcomes	O
for	O
invasive	O
mechanical	O
ventilation	O
and	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
to	O
treat	O
acute	O
respiratory	O
failure	O
in	O
patients	O
with	O
mild	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
lung	O
disease	O
are	O
not	O
known	O
.	O

We	O
first	O
performed	O
a	O
thin	O
-	O
section	O
transmission	O
electron	O
microscopy	O
(	O
TEM	O
)	O
assay	O
to	O
characterize	O
the	O
kinetics	O
of	O
PHEV	O
,	O
and	O
we	O
found	O
that	O
viral	O
entry	O
and	O
transfer	O
occur	O
via	O
membranous	O
coating	O
-	O
mediated	O
endo	O
-	O
and	O
exocytosis	B-PROC
.	O

Intriguingly	O
,	O
PHEV	O
invasion	O
leads	O
to	O
rapid	O
actin	O
rearrangement	B-PROC
,	O
suggesting	O
that	O
the	O
intactness	O
and	O
dynamics	O
of	O
the	O
actin	O
cytoskeleton	O
are	O
positively	O
correlated	O
with	O
viral	O
endocytosis	B-PROC
.	O

We	O
next	O
investigated	O
the	O
trafficking	B-PROC
of	O
internalized	O
PHEV	O
and	O
found	O
that	O
Rab5	O
-	O
and	O
Rab7	O
-	O
dependent	O
pathways	B-PROC
are	O
required	O
for	O
the	O
initiation	O
of	O
a	O
productive	O
infection	O
.	O

ABSTRACT	O
:	O
Long	O
non	O
-	O
coding	O
RNAs	O
(	O
lncRNAs	O
)	O
regulate	O
a	O
variety	O
of	O
genes	O
and	O
biological	B-PROC
processes	I-PROC
.	O

The	O
relative	O
expression	B-PROC
of	O
lnc	O
-	O
IL7R	O
was	O
obtained	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O

TITLE	O
:	O
Physiologic	O
effects	O
of	O
alveolar	O
recruitment	O
and	O
inspiratory	B-PROC
pauses	O
during	O
moderately	O
-	O
high	O
-	O
frequency	O
ventilation	O
delivered	O
by	O
a	O
conventional	O
ventilator	O
in	O
a	O
severe	O
lung	O
injury	O
model	O
.	O

During	O
MHFPPV	O
set	O
with	O
RR	O
of	O
60	O
bpm	O
delivered	O
by	O
a	O
conventional	O
ventilator	O
in	O
severe	O
ARDS	O
swine	O
model	O
,	O
neither	O
the	O
inspiratory	B-PROC
pauses	O
or	O
PEEP	O
titration	O
after	O
recruitment	O
maneuver	O
allowed	O
reduction	O
of	O
VT	O
significantly	O
,	O
however	O
the	O
last	O
strategy	O
decreased	O
driving	O
pressures	O
and	O
improved	O
both	O
shunt	O
and	O
dead	B-PROC
space	O
.	O

Improved	O
gravitationally	O
dependent	O
regional	O
lung	B-PROC
compliance	I-PROC
could	O
support	O
the	O
selection	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
and	O
maximize	O
alveolar	O
recruitment	O
.	O

Although	O
the	O
host	O
-	O
feeding	O
patterns	O
for	O
many	O
of	O
these	O
Culex	O
species	O
are	O
well	O
studied	O
,	O
the	O
host	O
-	O
feeding	O
patterns	O
of	O
Culex	O
stigmatosoma	O
Dyar	O
are	O
relatively	O
poorly	O
studied	O
,	O
even	O
though	O
this	O
species	O
is	O
suspected	O
to	O
be	O
an	O
important	O
maintenance	O
vector	O
for	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
and	O
other	O
arboviruses	O
.	O

stigmatosoma	O
,	O
collected	O
from	O
30	O
sites	O
in	O
southern	O
California	O
from	O
2009	O
-	O
2012	O
,	O
were	O
processed	O
for	O
vertebrate	O
host	O
identification	O
by	O
nucleotide	O
sequencing	O
following	O
polymerase	O
chain	O
reaction	O
to	O
amplify	O
portions	O
of	O
the	O
cytochrome	B-PROC
oxidase	O
I	O
and	O
cytochrome	B-PROC
b	O
genes	O
of	O
vertebrate	O
animals	O
.	O

ABSTRACT	O
:	O
Ricin	O
,	O
a	O
plant	O
-	O
derived	O
toxin	O
originating	O
from	O
the	O
seeds	O
of	O
Ricinus	O
communis	O
(	O
castor	O
beans	O
),	O
is	O
one	O
of	O
the	O
most	O
lethal	O
toxins	O
known	O
,	O
particularly	O
if	O
inhaled	B-PROC
.	O

The	O
inflammatory	O
cytokine	O
levels	O
,	O
including	O
tumor	O
necrosis	B-PROC
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
and	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
),	O
were	O
examined	O
by	O
ELISA	O
assay	O
,	O
and	O
the	O
TLR4	O
and	O
NF	O
-	O
κBp65	O
expression	B-PROC
levels	O
were	O
evaluated	O
by	O
Real	O
time	O
-	O
PCR	O
and	O
western	O
blotting	O
.	O

The	O
designed	O
CovCore	O
proteins	O
were	O
prepared	O
by	O
chemical	O
synthesis	B-PROC
,	O
and	O
their	O
structures	O
were	O
determined	O
by	O
solution	O
NMR	O
or	O
X	O
-	O
ray	O
crystallography	O
.	O

ABSTRACT	O
:	O
Polytraumatised	O
patients	O
with	O
haemorrhagic	O
shock	O
are	O
prone	O
to	O
develop	O
systemic	O
complications	O
,	O
such	O
as	O
SIRS	O
(	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
),	O
ARDS	O
(	O
acute	O
respiratory	O
distress	O
syndrome	O
)	O
and	O
MOF	O
(	O
multiple	O
organ	O
failure	O
).	O

Seven	O
patients	O
were	O
transferred	O
to	O
our	O
center	O
for	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
consideration	O
(	O
all	O
within	O
72	O
hours	O
of	O
initiating	O
mechanical	O
ventilation	O
).	O

Three	O
patients	O
received	O
inhaled	B-PROC
nitric	O
oxide	O
,	O
and	O
four	O
patients	O
were	O
proned	O
as	O
rescue	O
therapy	O
before	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
was	O
initiated	O
.	O

If	O
high	O
plateau	O
,	O
driving	O
or	O
mean	O
airway	O
pressures	O
are	O
observed	O
,	O
prone	O
positioning	O
or	O
ultraprotective	O
ventilation	O
may	O
be	O
indicated	O
to	O
improve	O
oxygenation	B-PROC
without	O
additional	O
stress	O
and	O
strain	O
in	O
the	O
lung	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
cross	O
-	O
protective	O
immunity	B-PROC
of	O
a	O
US	O
spike	O
-	O
insertion	O
deletion	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
Iowa106	O
(	O
S	O
-	O
INDEL	B-PROC
)	O
strain	O
against	O
the	O
original	O
US	O
PEDV	O
(	O
PC21A	O
)	O
strain	O
in	O
nursing	B-PROC
piglets	O
.	O

Piglets	O
were	O
inoculated	O
orally	O
with	O
S	O
-	O
INDEL	B-PROC
,	O
PC21A	O
or	O
mock	O
.	O

S	O
-	O
INDEL	B-PROC
induced	O
partial	O
protective	O
immunity	B-PROC
against	O
the	O
original	O
US	O
PEDV	O
strain	O
.	O

TITLE	O
:	O
The	O
bulky	O
and	O
the	O
sweet	B-PROC
:	O
How	O
neutralizing	O
antibodies	O
and	O
glycan	O
receptors	O
compete	O
for	O
virus	O
binding	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
examine	O
levels	O
of	O
stress	O
and	O
professionalism	O
of	O
nurses	O
who	O
provided	O
nursing	B-PROC
care	O
during	O
the	O
2015	O
Middle	O
East	O
respiratory	O
syndrome	O
outbreak	O
based	O
on	O
their	O
experience	O
,	O
to	O
investigate	O
the	O
nurses	O
'	O
intention	O
to	O
respond	O
to	O
possible	O
future	O
outbreaks	O
in	O
relation	O
to	O
their	O
experience	O
during	O
the	O
outbreak	O
,	O
and	O
to	O
determine	O
the	O
relationship	O
between	O
the	O
outbreak	O
experience	O
and	O
nursing	B-PROC
intention	O
considering	O
stress	O
and	O
professionalism	O
.	O

The	O
overall	O
stress	O
,	O
professionalism	O
,	O
and	O
nursing	B-PROC
intention	O
scores	O
for	O
the	O
firsthand	O
experience	O
group	O
were	O
33	O
.	O
72	O
,	O
103	O
.	O
00	O
,	O
and	O
16	O
.	O
92	O
,	O
respectively	O
,	O
whereas	O
those	O
of	O
the	O
secondhand	O
experience	O
group	O
were	O
32	O
.	O
25	O
,	O
98	O
.	O
99	O
,	O
and	O
15	O
.	O
60	O
,	O
respectively	O
.	O

RESULTS	O
:	O
The	O
overall	O
stress	O
,	O
professionalism	O
,	O
and	O
nursing	B-PROC
intention	O
scores	O
for	O
the	O
firsthand	O
experience	O
group	O
were	O
33	O
.	O
72	O
,	O
103	O
.	O
00	O
,	O
and	O
16	O
.	O
92	O
,	O
respectively	O
,	O
whereas	O
those	O
of	O
the	O
secondhand	O
experience	O
group	O
were	O
32	O
.	O
25	O
,	O
98	O
.	O
99	O
,	O
and	O
15	O
.	O
60	O
,	O
respectively	O
.	O

Although	O
the	O
virus	B-PROC
neutralization	I-PROC
test	O
is	O
the	O
gold	O
standard	O
assay	O
for	O
MERS	O
diagnosis	O
and	O
for	O
investigating	O
the	O
zoonotic	O
reservoir	O
,	O
it	O
uses	O
live	O
virus	O
and	O
so	O
must	O
be	O
performed	O
in	O
high	O
containment	O
laboratories	O
.	O

Nasal	O
samples	O
from	O
camels	O
,	O
sheep	O
,	O
goats	O
,	O
and	O
cattle	O
were	O
examined	O
by	O
real	O
-	O
time	O
reverse	O
-	O
transcription	B-PROC
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
to	O
detect	O
MERS	O
-	O
CoV	O
RNA	O
,	O
and	O
the	O
Anti	O
-	O
MERS	O
ELISA	O
assay	O
was	O
performed	O
to	O
detect	O
camel	O
humeral	O
immune	B-PROC
response	I-PROC
(	O
IgG	O
)	O
to	O
MERS	O
-	O
CoV	O
S1	O
antigen	O
infection	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
rapid	O
immunochromatographic	O
strip	O
test	O
for	O
the	O
detection	O
of	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
.	O

Patients	O
in	O
the	O
orthopaedic	O
cohort	O
were	O
further	O
examined	O
for	O
pulmonary	O
complications	O
and	O
death	B-PROC
.	O

In	O
light	O
of	O
the	O
pathogenic	O
mechanism	O
of	O
feline	O
coronavirus	O
that	O
relies	O
on	O
endosomal	O
acidification	B-PROC
for	O
cytoplasmic	O
entry	O
,	O
a	O
novel	O
vacuolar	O
ATPase	O
blocker	O
,	O
diphyllin	O
,	O
and	O
its	O
nanoformulation	O
are	O
herein	O
investigated	O
for	O
their	O
antiviral	O
activity	O
against	O
the	O
type	O
II	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
).	O

Since	O
2012	O
,	O
2	O
,	O
040	O
cases	O
and	O
712	O
deaths	B-PROC
have	O
been	O
recorded	O
(	O
as	O
of	O
August	O
11	O
,	O
2017	O
),	O
representing	O
a	O
strikingly	O
high	O
case	O
fatality	O
rate	O
of	O
36	O
%.	O

This	O
review	O
will	O
focus	O
on	O
three	O
particular	O
areas	O
:	O
the	O
origins	O
and	O
evolution	B-PROC
of	O
MERS	O
-	O
CoV	O
,	O
the	O
challenges	O
and	O
achievements	O
in	O
the	O
development	B-PROC
of	O
MERS	O
-	O
CoV	O
animal	O
models	O
,	O
and	O
our	O
understanding	O
of	O
how	O
novel	O
proteins	O
unique	O
to	O
MERS	O
-	O
CoV	O
counter	O
the	O
host	O
immune	B-PROC
response	I-PROC
.	O

To	O
date	O
,	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
has	O
reported	O
1	O
,	O
797	O
laboratory	O
-	O
confirmed	O
cases	O
of	O
MERS	O
-	O
CoV	O
infection	O
since	O
June	O
2012	O
,	O
involving	O
687	O
deaths	B-PROC
in	O
27	O
different	O
countries	O
worldwide	O
.	O

This	O
is	O
the	O
first	O
study	O
in	O
the	O
field	O
of	O
animal	O
vaccines	O
demonstrating	O
that	O
intranasal	O
administration	O
of	O
chickens	O
with	O
antigens	O
(	O
NDV	O
and	O
IBV	O
)	O
encapsulated	O
with	O
chitosan	O
derivative	O
could	O
induce	O
humoral	O
,	O
cellular	O
,	O
and	O
mucosal	B-PROC
immune	I-PROC
responses	I-PROC
,	O
which	O
protected	O
chickens	O
from	O
the	O
infection	O
of	O
highly	O
virulent	O
NDV	O
and	O
IBV	O
.	O

RESULTS	O
:	O
None	O
of	O
the	O
patients	O
had	O
MERS	O
-	O
CoV	O
but	O
influenza	O
viruses	O
were	O
detected	O
in	O
12	O
.	O
7	O
%	O
with	O
high	O
circulation	B-PROC
of	O
influenza	O
A	O
/	O
H1N1	O
(	O
47	O
.	O
1	O
%).	O

Malarial	O
complications	O
are	O
the	O
main	O
cause	O
of	O
death	B-PROC
and	O
include	O
cerebral	O
malaria	O
and	O
malaria	O
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
MA	O
-	O
ARDS	O
).	O

Recombination	B-PROC
analysis	O
showed	O
potential	O
recombination	B-PROC
events	O
in	O
five	O
strains	O
from	O
dromedaries	O
in	O
Saudi	O
Arabia	O
,	O
with	O
recombination	B-PROC
between	O
lineage	O
B5	O
and	O
B3	O
in	O
four	O
strains	O
,	O
and	O
between	O
lineage	O
B3	O
and	O
B4	O
in	O
one	O
strain	O
.	O

The	O
spike	O
protein	O
showed	O
the	O
highest	O
number	O
of	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
,	O
especially	O
between	O
A2	O
and	O
other	O
lineages	O
,	O
and	O
contained	O
positively	O
selected	O
codons	O
.	O

The	O
implications	O
on	O
the	O
role	O
of	O
camels	O
in	O
the	O
evolution	B-PROC
of	O
MERS	O
-	O
CoV	O
are	O
discussed	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
bioinformatics	O
tools	O
to	O
predict	O
N	O
-	O
linked	O
glycosylation	B-PROC
sites	O
and	O
to	O
analyze	O
their	O
distribution	O
in	O
IBV	O
strains	O
and	O
variants	O
.	O

Each	O
year	O
,	O
the	O
Health	O
authority	O
of	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
,	O
in	O
coordination	B-PROC
with	O
international	O
health	O
authorities	O
,	O
updates	O
health	O
requirements	O
for	O
pilgrims	O
.	O

RESULTS	O
:	O
The	O
Hajj	O
and	O
Umrah	O
vaccine	O
requirements	O
include	O
mandatory	O
vaccinations	O
against	O
yellow	O
fever	B-PROC
,	O
quadrivalent	O
meningococcal	O
polysaccharide	O
(	O
every	O
3	O
years	O
)	O
or	O
conjugated	O
(	O
every	O
5	O
years	O
)	O
vaccines	O
and	O
poliomyelitis	O
vaccine	O
.	O

CONCLUSIONS	O
:	O
The	O
mandatory	O
vaccines	O
remain	O
the	O
same	O
with	O
continued	O
vigilance	O
for	O
the	O
development	B-PROC
of	O
any	O
new	O
or	O
emerging	O
infectious	O
diseases	O
.	O

The	O
four	O
markers	O
independently	O
associated	O
with	O
DAD	O
were	O
(	O
1	O
)	O
duration	O
of	O
evolution	B-PROC
(	O
OR	O
3	O
.	O
29	O
[	O
1	O
.	O
95	O
-	O
5	O
.	O
55	O
]	O
for	O
patients	O
with	O
ARDS	O
≥	O
3	O
days	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
(	O
2	O
)	O
degree	O
of	O
hypoxemia	O
(	O
OR	O
3	O
.	O
92	O
[	O
1	O
.	O
48	O
-	O
10	O
.	O
3	O
]	O
for	O
moderate	O
ARDS	O
and	O
6	O
.	O
18	O
[	O
2	O
.	O
34	O
-	O
16	O
.	O
3	O
]	O
for	O
severe	O
ARDS	O
,	O
p	O
<	O
0	O
.	O
01	O
for	O
both	O
),	O
(	O
3	O
)	O
increased	O
dynamic	O
driving	O
pressure	O
(	O
OR	O
1	O
.	O
06	O
[	O
1	O
.	O
04	O
-	O
1	O
.	O
09	O
],	O
p	O
=	O
0	O
.	O
007	O
),	O
and	O
(	O
4	O
)	O
radiographic	O
severity	O
(	O
OR	O
2	O
.	O
91	O
[	O
1	O
.	O
47	O
-	O
5	O
.	O
75	O
]	O
for	O
patients	O
with	O
diffuse	O
opacities	O
involving	O
the	O
four	O
quadrants	O
,	O
p	O
=	O
0	O
.	O
002	O
).	O

DAD	O
was	O
found	O
in	O
two	O
-	O
thirds	O
of	O
patients	O
with	O
a	O
ratio	O
of	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
≤	O
100	O
mmHg	O
and	O
opacities	O
involving	O
the	O
four	O
quadrants	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
an	O
xTAG	O
-	O
multiplex	O
PCR	O
array	O
for	O
the	O
detection	O
of	O
four	O
avian	O
respiratory	O
viruses	O
.	O

The	O
epidemic	O
level	O
of	O
MERS	O
-	O
CoV	O
infection	O
was	O
examined	O
in	O
Saudi	O
Arabia	O
by	O
the	O
Susceptible	O
-	O
Infectious	O
-	O
Recovered	O
(	O
SIR	O
)	O
model	O
using	O
a	O
Bayesian	O
approach	O
for	O
estimation	O
of	O
time	O
dependent	O
reproduction	B-PROC
number	O
(	O
R	O
)	O
across	O
a	O
two	O
-	O
year	O
interval	O
(	O
May	O
,	O
2013	O
-	O
May	O
,	O
2015	O
)	O
in	O
five	O
defined	O
clusters	O
,	O
followed	O
by	O
sensitivity	O
analysis	O
of	O
the	O
most	O
significant	O
clusters	O
.	O

Subsequently	O
,	O
it	O
was	O
re	O
-	O
designated	O
as	O
D	O
/	O
132	O
,	O
and	O
formed	O
a	O
new	O
serogroup	O
among	O
rotaviruses	O
,	O
the	O
group	O
D	O
rotavirus	O
(	O
RVD	B-PROC
).	O

Since	O
their	O
identification	O
,	O
RVs	O
are	O
the	O
leading	O
cause	O
of	O
enteritis	O
and	O
diarrhea	O
in	O
humans	O
and	O
various	O
animal	O
species	O
,	O
and	O
are	O
also	O
associated	O
with	O
abridged	O
growth	B-PROC
,	O
particularly	O
in	O
avian	O
species	O
.	O

TITLE	O
:	O
Feline	O
Infectious	O
Peritonitis	O
:	O
Immunohistochemical	O
Features	O
of	O
Ocular	B-PROC
Inflammation	O
and	O
the	O
Distribution	O
of	O
Viral	O
Antigens	O
in	O
Structures	O
of	O
the	O
Eye	O
.	O

This	O
study	O
characterized	O
the	O
ocular	B-PROC
lesions	O
of	O
FIP	O
including	O
the	O
expression	B-PROC
of	O
glial	O
fibrillary	O
acidic	O
protein	O
and	O
proliferating	O
cell	O
nuclear	O
antigen	O
by	O
Müller	O
cells	O
in	O
the	O
retina	O
in	O
cases	O
of	O
FIP	O
and	O
to	O
what	O
extent	O
macrophages	O
are	O
involved	O
in	O
ocular	B-PROC
inflammation	O
in	O
FIP	O
.	O

One	O
of	O
the	O
risk	O
factors	O
involved	O
in	O
the	O
acquisition	O
of	O
IPF	O
is	O
viral	B-PROC
infections	I-PROC
,	O
especially	O
respiratory	O
viruses	O
.	O

In	O
this	O
study	O
,	O
in	O
order	O
to	O
explore	O
an	O
efficient	O
oral	O
vaccine	O
against	O
PEDV	O
infection	O
,	O
a	O
mucosal	O
DC	O
-	O
targeting	B-PROC
oral	O
vaccine	O
was	O
developed	O
using	O

Based	O
on	O
the	O
structures	O
and	O
functions	O
of	O
these	O
structural	O
elements	O
,	O
we	O
discussed	O
the	O
evolution	B-PROC
of	O
PdCoV	O
spike	O
protein	O
in	O
relation	O
to	O
the	O
spike	O
proteins	O
from	O
other	O
coronavirus	O
genera	O
.	O

Furthermore	O
,	O
their	O
recovery	O
from	O
lung	O
injury	O
is	O
prolonged	O
,	O
weaning	B-PROC
from	O
mechanical	O
ventilation	O
less	O
successful	O
,	O
and	O
extubation	O
rate	O
slower	O
.	O

The	O
increasing	O
incidence	O
of	O
hospital	O
-	O
acquired	O
infections	O
caused	O
by	O
antibiotic	O
resistant	O
pathogens	O
could	O
be	O
minimized	O
by	O
point	O
-	O
of	O
-	O
care	O
microbial	O
analysis	O
as	O
well	O
as	O
rapid	O
screening	O
tests	O
of	O
bacteria	O
resistance	B-PROC
.	O

ABSTRACT	O
:	O
Respiratory	O
viral	B-PROC
infections	I-PROC
may	O
cause	O
serious	O
complications	O
for	O
older	O
adults	O
,	O
including	O
residents	O
of	O
long	O
-	O
term	O
care	O
facilities	O
(	O
LTCFs	O
).	O

Validation	O
studies	O
showed	O
that	O
the	O
use	O
of	O
the	O
two	O
most	O
stable	O
reference	O
genes	O
produced	O
accurate	O
and	O
more	O
robust	O
gene	B-PROC
expression	I-PROC
data	O
.	O

The	O
two	O
most	O
and	O
least	O
stable	O
reference	O
genes	O
obtained	O
in	O
the	O
study	O
,	O
were	O
further	O
used	O
for	O
candidate	O
target	O
gene	B-PROC
expression	I-PROC
data	O
normalisation	O
of	O
the	O
shell	O
gland	O
and	O
spleen	O
under	O
an	O
IBV	O
infection	O
model	O
.	O

Work	O
is	O
already	O
underway	O
to	O
develop	O
vaccines	O
against	O
a	O
number	O
of	O
other	O
outbreak	O
pathogens	O
and	O
we	O
will	O
also	O
review	O
progress	O
on	O
these	O
approaches	O
here	O
,	O
particularly	O
for	O
Lassa	O
fever	B-PROC
,	O
Nipah	O
and	O
MERS	O
.	O

We	O
did	O
not	O
detect	O
statistically	O
significant	O
differences	O
in	O
the	O
secondary	O
outcomes	O
multiple	O
organ	O
dysfunction	O
score	O
,	O
ventilation	O
time	O
and	O
time	O
course	O
of	O
oxygenation	B-PROC
.	O

Our	O
objective	O
was	O
to	O
investigate	O
the	O
factors	O
that	O
influence	O
the	O
inflammatory	B-PROC
response	I-PROC
of	O
patients	O
with	O
ARDS	O
undergoing	O
VV	O
ECMO	O
,	O
and	O
to	O
analyse	O
the	O
impact	O
of	O
this	O
response	O
on	O
hospital	O
mortality	O
.	O

Visual	O
analog	O
scale	O
(	O
VAS	O
)	O
score	O
,	O
Harris	O
score	O
and	O
Association	O
Research	O
Circulation	B-PROC
Osseous	O
(	O
ARCO	O
)	O
stage	O
of	O
imaging	O
examination	O
were	O
compared	O
among	O
those	O
before	O
treatment	O
,	O
and	O
at	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
years	O
after	O
treatment	O
.	O

At	O
month	O
6	O
after	O
ICU	O
admission	O
,	O
estimated	O
glomerular	B-PROC
filtration	I-PROC
rate	O
was	O
24	O
mL	O
/	O
min	O
/	O
1	O
.	O
73m	O
<	O
sup	O
>	O
2	O
</	O
sup	O
>.	O
Compelling	O
evidence	O
obtained	O
from	O
in	O
-	O
vitro	O
and	O
animal	O
studies	O
suggest	O
that	O
vitamin	O
C	O
,	O
a	O
circulating	O
antioxidant	O
,	O
may	O
be	O
a	O
valuable	O
adjunctive	O
therapy	O
in	O
critically	O
-	O
ill	O
patients	O
.	O

The	O
proposed	O
biomarker	O
model	O
consisting	O
of	O
six	O
metabolites	O
proline	O
,	O
lysine	O
/	O
arginine	O
,	O
taurine	O
,	O
threonine	O
and	O
glutamate	O
were	O
found	O
characteristic	O
of	O
ARDS	O
sub	O
-	O
stages	O
with	O
aberrant	O
metabolism	B-PROC
observed	O
mainly	O
in	O
arginine	O
,	O
proline	B-PROC
metabolism	I-PROC
,	O
lysine	B-PROC
synthesis	I-PROC
and	O
so	O
forth	O
correlating	O
to	O
diseased	O
metabotype	O
.	O

Combining	O
the	O
glycosylation	B-PROC
site	O
prediction	O
results	O
and	O
their	O
distribution	O
within	O
the	O
spatial	O
structure	O
of	O
the	O
S	O
protein	O
,	O
led	O
to	O
the	O
conclusion	O
that	O
the	O
observed	O
more	O
effective	O
host	O
immune	B-PROC
response	I-PROC
of	O
Zhejiang08	O
compared	O
to	O
CV777	O
was	O
possibly	O
associated	O
with	O
a	O
lack	O
of	O
the	O
potential	O
glycosylation	B-PROC
site	O
in	O
the	O
296	O
amino	O
acids	O
of	O
the	O
S	O
protein	O
.	O

PEDV	O
-	O
specific	O
IgG	O
and	O
IgA	O
antibody	B-PROC
titers	O
were	O
enhanced	O
in	O
pregnant	O
sows	O
immunized	O
with	O
PLGA	O
-	O
KAg	O
relative	O
to	O
the	O
titers	O
in	O
sows	O
inoculated	O
with	O
KAg	O
.	O

Interestingly	O
,	O
by	O
days	O
7	O
and	O
14	O
after	O
the	O
booster	O
immunization	O
,	O
pBH	O
-	O
S1	O
-	O
TM	O
-	O
1	O
-	O
EGFP	O
-	O
induced	O
antibody	B-PROC
titre	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
compared	O
to	O
attenuated	O
commercial	O
IBV	O
vaccine	O
;	O
however	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
pBH	O
-	O
S1	O
-	O
TM	O
-	O
1	O
-	O
EGFP	O
and	O
attenuated	O
commercial	O
MG	O
vaccine	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Feline	O
coronavirus	O
antibody	B-PROC
titer	O
in	O
cerebrospinal	O
fluid	O
from	O
cats	O
with	O
neurological	O
signs	O
.	O

The	O
siRNA	O
can	O
be	O
delivered	O
using	O
transfection	B-PROC
,	O
electroporation	O
and	O
viral	O
gene	O
transfer	O
.	O

Of	O
the	O
7	O
maternal	B-PROC
deaths	B-PROC
analyzed	O
by	O
the	O
expert	O
committee	O
,	O
anesthetic	O
complications	O
were	O
in	O
5	O
cases	O
the	O
main	O
cause	O
of	O
death	B-PROC
:	O
4	O
attributed	O
to	O
direct	O
causes	O
related	O
to	O
anesthetic	O
procedures	O
during	O
childbirth	B-PROC
and	O
1	O
to	O
indirect	O
cause	O
in	O
connection	O
with	O
an	O
ENT	O
complication	O
during	O
pregnancy	O
.	O

In	O
most	O
of	O
the	O
cases	O
analyzed	O
over	O
the	O
period	O
2010	O
-	O
2012	O
,	O
anesthesia	O
and	O
resuscitation	O
have	O
been	O
involved	O
in	O
the	O
occurrence	O
of	O
maternal	B-PROC
deaths	B-PROC
,	O
mainly	O
through	O
strategic	O
errors	O
in	O
the	O
management	O
of	O
patients	O
with	O
severe	O
pathology	O
before	O
delivery	O
,	O
as	O
well	O
as	O
through	O
insufficient	O
cardiac	O
resuscitation	O
duration	O
after	O
cardiac	O
arrest	O
.	O

The	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
were	O
significantly	O
lower	O
in	O
the	O
drug	O
-	O
associated	O
ARDS	O
group	O
than	O
in	O
the	O
non	O
-	O
drug	O
-	O
associated	O
ARDS	O
group	O
(	O
median	O
(	O
IQR	O
):	O
18	O
.	O
0	O
(	O
16	O
.	O
5	O
-	O
21	O
.	O
0	O
)	O
vs	O
23	O
.	O
0	O
(	O
18	O
.	O
0	O
-	O
26	O
.	O
0	O
),	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
the	O
arterial	O
oxygen	B-PROC
tension	I-PROC
/	O
fractional	O
inspired	B-PROC
oxygen	O
ratio	O
was	O
higher	O
(	O
148	O
.	O
0	O
(	O
114	O
.	O
1	O
-	O
177	O
.	O
5	O
)	O
vs	O
101	O
.	O
0	O
(	O
71	O
.	O
5	O
-	O
134	O
.	O
0	O
),	O
p	O
=	O
0	O
.	O
003	O
).	O

However	O
,	O
eight	O
domains	O
of	O
Nsp3	O
exist	O
in	O
all	O
known	O
CoVs	O
:	O
the	O
ubiquitin	B-PROC
-	O
like	O
domain	O
1	O
(	O
Ubl1	O
),	O
the	O
Glu	O
-	O
rich	O
acidic	O
domain	O
(	O
also	O
called	O
""""	O
hypervariable	O
region	O
"""),"	O
a	O
macrodomain	O
(	O
also	O
named	O
""""	O
X	O
domain	O
"""),"	O
the	O
ubiquitin	B-PROC
-	O
like	O
domain	O
2	O
(	O
Ubl2	O
),	O
the	O
papain	O
-	O
like	O
protease	O
2	O
(	O
PL2	O

ABSTRACT	O
:	O
Melanoma	O
differentiation	B-PROC
associated	O
gene	O
5	O
(	O
MDA5	O
)	O
and	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
-	O
I	O
(	O
RIG	O
-	O
I	O
)	O
selectively	O
sense	B-PROC
cytoplasmic	O
viral	O
RNA	O
to	O
induce	O
an	O
antiviral	O
immune	B-PROC
response	I-PROC
.	O

The	O
primary	O
endpoint	O
is	O
a	O
composite	O
endpoint	O
including	O
any	O
cause	O
of	O
death	B-PROC
at	O
28	O
days	O
and	O
days	O
free	O
of	O
mechanical	O
ventilation	O
within	O
28	O
days	O
among	O
survivors	O
.	O

Subjects	O
underwent	O
impedance	B-PROC
-	O
based	O
platelet	O
aggregometry	O
in	O
response	O
to	O
platelet	O
agonists	O
arachidonic	O
acid	O
,	O
adenosine	O
diphosphate	O
,	O
collagen	O
,	O
and	O
thrombin	O
receptor	O
activating	O
peptide	O
-	O
6	O
.	O

Cigarette	O
smoke	O
exposure	O
was	O
associated	O
with	O
increased	B-PROC
platelet	B-PROC
aggregation	I-PROC
upon	O
arrival	O
to	O
the	O
emergency	O
department	O
.	O

The	O
relationship	O
between	O
this	O
decline	O
in	O
platelet	B-PROC
aggregation	I-PROC
and	O
ARDS	O
differed	O
by	O
cigarette	O
smoke	O
exposure	O
status	O
,	O
suggesting	O
that	O
impaired	O
platelet	B-PROC
activation	I-PROC
differentially	O
affects	O
the	O
risk	O
of	O
ARDS	O
in	O
those	O
with	O
cigarette	O
smoke	O
exposure	O
(	O
arachidonic	O
acid	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
005	O
,	O
collagen	O
p	O
for	O
interaction	O
:	O
0	O
.	O
02	O
,	O
adenosine	O
diphosphate	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
05	O
).	O

SimPlot	O
and	O
Bootscan	O
analysis	O
of	O
the	O
complete	O
genomic	O
sequence	O
confirmed	O
this	O
hypothesis	O
,	O
where	O
it	O
showed	O
that	O
isolate	O
I1101	O
/	O
16	O
arose	O
through	O
recombination	B-PROC
events	O
between	O
ck	O
/	O
CH	O
/	O
LJL	O
/	O
140901	O
-	O
and	O
4	O
/	O
91	O
-	O
like	O
viruses	O
.	O

miR	O
-	O
223	O
expression	B-PROC
is	O
increased	O
in	O
the	O
lungs	O
of	O
MTD	O
-	O
induced	O
mice	O
or	O
ARDS	O
patients	O
following	O
trauma	O
/	O
transfusion	O
or	O
following	O
the	O
physiological	O
remission	O
of	O
ALI	O
/	O
ARDS	O
.	O

Other	O
studies	O
have	O
shown	O
that	O
MTD	O
-	O
induced	O
increases	O
in	O
miR	O
-	O
223	O
expression	B-PROC
are	O
mainly	O
contributed	O
by	O
Ly6G	O
+	O
neutrophils	O
from	O
the	O
haematopoietic	O
system	O
.	O

In	O
addition	O
,	O
MTD	O
-	O
induced	O
miR	O
-	O
223	O
expression	B-PROC
activates	O
a	O
negative	O
feedback	O
pathway	B-PROC
that	O
targets	O
the	O
inhibition	B-PROC
of	O
NLRP3	O
expression	B-PROC
and	O
IL	O
-	O
1β	O
release	O
;	O
therefore	O
,	O
miR	O
-	O
223	O
deficiency	O
can	O
lead	O
to	O
the	O
sustained	O
activation	O
of	O
NLRP3	O
-	O
IL	O
-	O
1β	O
.	O

The	O
patient	O
arrived	O
in	O
severe	O
respiratory	O
distress	O
with	O
a	O
pulse	B-PROC
oximetry	O
level	O
of	O
50	O
%	O
and	O
was	O
immediately	O
intubated	O
.	O

Parainfluenza	O
virus	O
1	O
-	O
4	O
and	O
parechovirus	O
were	O
found	O
to	O
increase	O
the	O
risk	O
of	O
death	B-PROC
(	O
p	O
<	O
0	O
.	O
05	O
).	O

We	O
describe	O
the	O
unusual	O
case	O
of	O
a	O
one	O
-	O
year	O
-	O
old	O
child	O
affected	O
by	O
short	O
bowel	O
syndrome	O
and	O
history	O
of	O
severe	O
cow	O
'	O
s	O
milk	O
allergy	B-PROC
(	O
CMA	O
)	O
and	O
anaphylactic	O
reaction	O
due	O
to	O
intravenous	O
administration	O
of	O
methyl	O
-	O
prednisolone	O
sodium	O
succinate	O
(	O
Solu	O
-	O
Medrol	O
40	O
mg	O
,	O
Pfizer	O
).	O

The	O
APACHE	O
II	O
score	O
,	O
serum	O
levels	O
of	O
procalcitonin	O
(	O
PCT	O
)	O
and	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
),	O
serum	O
creatinine	O
(	O
SCr	O
),	O
daily	O
tacrolimus	O
dose	O
,	O
and	O
NIV	O
support	O
condition	O
in	O
NIV	O
failure	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
NIV	O
success	O
group	O
[	O
APACHE	O
II	O
score	O
:	O
16	O
.	O
7	O
±	O
5	O
.	O
7	O
vs	O
.	O
10	O
.	O
3	O
±	O
2	O
.	O
1	O
,	O
PCT	O
(	O
μg	O
/	O
L	O
):	O
32	O
.	O
8	O
(	O
1	O
.	O
2	O
,	O
187	O
.	O
7	O
)	O
vs	O
.	O
0	O
.	O
3	O
(	O
0	O
.	O
1	O
,	O
2	O
.	O
9	O
),	O
BNP	O
(	O
ng	O
/	O
L	O
):	O
832	O
.	O
4	O
(	O
263	O
.	O
7	O
,	O
1	O
180	O
.	O
2	O
)	O
vs	O
.	O
157	O
.	O
0	O
(	O
33	O
.	O
9	O
,	O
218	O
.	O
5	O
),	O
SCr	O
(	O
μmol	O
/	O
L	O
):	O
284	O
.	O
8	O
(	O
90	O
.	O
5	O
,	O
474	O
.	O
2	O
)	O
vs	O
.	O
186	O
.	O
6	O
(	O
76	O
.	O
7	O
,	O
206	O
.	O
3	O
),	O
daily	O
tacrolimus	O
dose	O
(	O
mg	O
):	O
3	O
.	O
6	O
(	O
3	O
.	O
1	O
,	O
4	O
.	O
0	O
)	O
vs	O
.	O
2	O
.	O
6	O
(	O
2	O
.	O
0	O
,	O
3	O
.	O
5	O
),	O
inspiratory	B-PROC
positive	O
airway	O
pressure	O
(	O
IPAP	O
,	O
cmH	O
NIV	O
in	O
the	O
treatment	O
of	O
ARDS	O
caused	O
by	O
severe	O
pneumonia	O
after	O
kidney	O
transplantation	O
has	O
a	O
certain	O
value	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Nonstructural	O
Protein	O
16	O
Is	O
Necessary	O
for	O
Interferon	O
Resistance	B-PROC
and	O
Viral	O
Pathogenesis	B-PROC
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
encode	O
a	O
mixture	O
of	O
highly	O
conserved	O
and	O
novel	O
genes	O
,	O
as	O
well	O
as	O
genetic	O
elements	O
necessary	O
for	O
infection	O
and	O
pathogenesis	B-PROC
,	O
raising	O
the	O
possibility	O
of	O
common	O
targets	O
for	O
attenuation	O
and	O
therapeutic	O
design	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
if	O
mobile	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
reduces	O
patient	O
mortality	O
during	O
and	O
after	O
transport	B-PROC
of	O
patients	O
requiring	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
for	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
conducted	O
a	O
prospective	O
longitudinal	O
study	O
on	O
respiratory	O
viral	B-PROC
infections	I-PROC
(	O
RVIs	O
)	O
in	O
allo	O
-	O
HSCT	O
recipients	O
with	O
respiratory	O
symptoms	O
from	O
December	O
2013	O
until	O
June	O
2016	O
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
25	O
-	O
year	O
-	O
old	O
male	O
with	O
undiagnosed	O
leptospirosis	O
,	O
presenting	O
with	O
fever	B-PROC
and	O
severe	O
hypoxemic	O
respiratory	O
failure	O
,	O
returning	O
from	O
a	O
Costa	O
Rican	O
holiday	O
.	O

Updates	O
were	O
also	O
given	O
on	O
the	O
use	O
of	O
the	O
currently	O
licensed	O
neuraminidase	B-PROC
inhibitors	I-PROC
.	O

TITLE	O
:	O
Expression	B-PROC
and	O
Cleavage	B-PROC
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
nsp3	O
-	O
4	O
Polyprotein	O
Induce	O
the	O
Formation	B-PROC
of	O
Double	O
-	O
Membrane	O
Vesicles	O

ABSTRACT	O
:	O
More	O
than	O
a	O
decade	O
after	O
the	O
outbreak	O
of	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
SARS	O
in	O
Guangdong	O
province	O
and	O
Hong	O
Kong	O
SAR	O
of	O
China	O
in	O
2002	O
,	O
there	O
is	O
still	O
no	O
reoccurrence	O
,	O
but	O
the	O
evolution	B-PROC
and	O
recombination	B-PROC
of	O
the	O
coronaviruses	O
in	O
this	O
region	O
are	O
still	O
unknown	O
.	O

The	O
latter	O
provide	O
a	O
structural	O
scaffold	O
for	O
viral	B-PROC
replication	I-PROC
/	O
transcription	B-PROC
complexes	O
(	O
RTCs	O
)	O
and	O
help	O
to	O
sequester	O
RTC	O
components	O
from	O
recognition	O
by	O
cellular	O
factors	O
involved	O
in	O
antiviral	O
host	O
responses	O
.	O

Based	O
on	O
typical	O
clinical	O
features	O
,	O
and	O
on	O
positivity	O
for	O
serum	O
GD1b	O
-	O
IgM	O
antibodies	O
,	O
GBS	O
with	O
proximal	O
conduction	B-PROC
failure	O
at	O
multiple	O
radicular	O
levels	O
was	O
postulated	O
,	O
and	O
a	O
standard	O
regime	O
of	O
intravenous	O
immunoglobulin	B-PROC
was	O
administered	O
.	O

On	O
day	O
50	O
,	O
NCS	O
revealed	O
for	O
the	O
first	O
time	O
markedly	O
reduced	O
compound	O
muscle	O
action	B-PROC
potentials	I-PROC
and	O
sensory	O
nerve	O
action	B-PROC
potentials	I-PROC
in	O
all	O
tested	O
nerves	O
,	O
without	O
signs	O
of	O
demyelination	O
;	O
needle	O
electromyography	O
documented	O
widespread	O
denervation	O
.	O

Very	O
proximal	O
axonal	B-PROC
conduction	B-PROC
failure	O
with	O
late	O
distal	O
axonal	O
degeneration	O
should	O
be	O
taken	O
into	O
consideration	O
,	O
and	O
electrodiagnostic	O
follow	O
-	O
up	O
examinations	O
,	O
even	O
employing	O
unusual	O
techniques	O
,	O
are	O
recommended	O
over	O
several	O
weeks	O
after	O
disease	O
onset	O
.	O

TITLE	O
:	O
The	O
French	O
Infectious	O
Diseases	O
Society	O
'	O
s	O
readiness	O
and	O
response	O
to	O
epidemic	O
or	O
biological	O
risk	O
-	O
the	O
current	O
situation	O
following	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
and	O
Ebola	O
virus	B-PROC
disease	I-PROC
alerts	O
.	O

Therefore	O
,	O
development	B-PROC
of	O
novel	O
antiviral	O
treatment	O
strategies	O
is	O
urgently	O
required	O
.	O

Recent	O
experimental	O
studies	O
have	O
illustrated	O
how	O
several	O
regulatory	O
circuits	O
interact	O
during	O
pulmonary	O
inflammation	O
,	O
including	O
the	O
resolution	O
of	O
inflammation	O
,	O
the	O
inflammasome	O
,	O
autophagy	B-PROC
and	O
apoptosis	B-PROC
.	O

TITLE	O
:	O
Oral	O
immunization	O
with	O
a	O
Lactobacillus	O
casei	O
-	O
based	O
anti	O
-	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
vaccine	O
expressing	O
microfold	O
cell	O
-	O
targeting	B-PROC
peptide	O
Co1	O
fused	O
with	O
the	O
COE	O
antigen	O
of	O
PEDV	O
.	O

Finally	O
,	O
these	O
strains	O
were	O
evaluated	O
for	O
pathogenicity	O
in	O
nursing	B-PROC
piglets	O
(	O
1	O
-	O
4	O
days	O
old	O
).	O

PEDV	O
specifically	O
inhibited	O
IRF1	O
nuclear	B-PROC
translocation	B-PROC
.	O

Cell	O
entry	O
studies	O
demonstrated	O
that	O
three	O
newly	O
identified	O
SARSr	O
-	O
CoVs	O
with	O
different	O
S	O
protein	O
sequences	O
are	O
all	O
able	O
to	O
use	O
human	O
ACE2	O
as	O
the	O
receptor	O
,	O
further	O
exhibiting	O
the	O
close	O
relationship	O
between	O
strains	O
in	O
this	O
cave	O
and	O
SARS	O
-	O
CoV	O
.	O
This	O
work	O
provides	O
new	O
insights	O
into	O
the	O
origin	O
and	O
evolution	B-PROC
of	O
SARS	O
-	O
CoV	O
and	O
highlights	O
the	O
necessity	O
of	O
preparedness	O
for	O
future	O
emergence	O
of	O
SARS	O
-	O
like	O
diseases	O
.	O

ADP	O
-	O
ribosylation	O
of	O
N	O
protein	O
was	O
also	O
observed	O
in	O
cells	O
exogenously	O
expressing	O
N	O
protein	O
by	O
transduction	B-PROC
using	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
replicon	O
particles	O
(	O
VRPs	O
).	O

In	O
parallel	O
,	O
we	O
used	O
publicly	O
available	O
MERS	O
-	O
CoV	O
genomes	O
from	O
GenBank	O
to	O
create	O
a	O
phylogeographic	O
tree	O
,	O
detailing	O
geospatial	O
timeline	O
of	O
viral	O
evolution	B-PROC
.	O

Degenerated	O
neurons	O
were	O
found	O
in	O
the	O
cerebral	O
cortex	O
and	O
olfactory	B-PROC
tubercles	O
at	O
30	O
dpi	O
.	O

Measured	O
with	O
the	O
patient	O
in	O
the	O
supine	O
position	O
before	O
and	O
at	O
the	O
end	O
of	O
the	O
first	O
PP	O
session	O
,	O
PaO	B-PROC

The	O
medians	O
of	O
PaO	B-PROC
Since	O
the	O
duration	O
of	O
MV	O
before	O
ECMO	O
institution	O
was	O
strongly	O
correlated	O
to	O
the	O
outcome	O
of	O
adult	O
respiratory	O
ECMO	O
,	O
medical	O
centers	O
are	O
suggested	O
to	O
find	O
a	O
suitable	O
prognosticating	O
tool	O
to	O
determine	O
the	O
starting	O
point	O
of	O
respiratory	O
ECMO	O
among	O
their	O
candidates	O
with	O
different	O
duration	O
of	O
MV	O
.	O

Sleep	B-PROC
apnea	O
defined	O
as	O
an	O
apnea	O
-	O
hypopnea	O
index	O
(	O
AHI	O
)	O
≥	O
5	O
/	O
h	O
was	O
diagnosed	O
in	O
186	O
(	O
91	O
.	O
2	O
%)	O
patients	O
,	O
its	O
prevalence	O
being	O
higher	O
in	O
the	O
thrombolysis	O
(	O
96	O
.	O
4	O
%)	O
compared	O
to	O
the	O
nonthrombolysis	O
(	O
85	O
.	O
1	O
%)	O
group	O
(	O
p	O
=	O
0	O
.	O
007	O
).	O

In	O
multivariable	O
models	O
,	O
a	O
combination	O
of	O
Stimulation	O
-	O
2	O
(	O
ST2	O
;	O
odds	O
ratio	O
[	O
OR	O
],	O
2	O
.	O
8	O
;	O
P	O
<	O
.	O
001	O
)	O
and	O
IL	O
-	O
6	O
(	O
OR	O
,	O
1	O
.	O
4	O
;	O
P	O
=	O
.	O
025	O
)	O
was	O
the	O
best	O
panel	O
for	O
distinguishing	O
IPS	O
at	O
diagnosis	O
from	O
unaffected	O
controls	O
,	O
whereas	O
tumor	O
necrosis	B-PROC
factor	O
receptor	O
1	O
(	O
TNFR1	O
;	O
OR	O
,	O
2	O
.	O
9	O
;	O
P	O
=	O
.	O
002	O
)	O
was	O
the	O
best	O
marker	O
when	O
comparing	O
patients	O
with	O
IPS	O
and	O
viral	O
pneumonia	O
.	O

HCoV	O
-	O
229E	O
SL1	O
and	O
SL2	O
mutants	O
generated	O
by	O
reverse	O
genetics	O
were	O
used	O
to	O
study	O
the	O
effects	O
on	O
viral	B-PROC
replication	I-PROC
of	O
single	O
-	O
nucleotide	O
substitutions	O
predicted	O
to	O
destabilize	O
the	O
SL1	O
and	O
SL2	O
structures	O
.	O

Seven	O
-	O
days	O
-	O
ovariectomized	O
rats	O
were	O
subjected	O
to	O
intestinal	O
IR	O
by	O
occlusion	B-PROC
of	O
the	O
superior	O
mesenteric	O
artery	O
for	O
45	O
min	O
.	O

In	O
this	O
study	O
,	O
we	O
proposed	O
a	O
comparative	O
analysis	O
approach	O
and	O
built	O
a	O
model	O
to	O
simulate	O
outbreaks	O
of	O
3	O
different	O
in	O
-	O
flight	B-PROC
infections	O
in	O
a	O
similar	O
cabin	O
environment	O
,	O
that	O
is	O
,	O
influenza	O
A	O
H1N1	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
),	O
and	O
norovirus	O
.	O

PEDV	O
pathogenesis	B-PROC
is	O
strain	O
-	O
specific	O
,	O
and	O
studies	O
in	O
neonatal	O
pigs	O
have	O
demonstrated	O
that	O
the	O
PEDV	O
non	O
-	O
S	O
-	O
INDEL	B-PROC
strains	O
are	O
more	O
pathogenic	O
than	O
the	O
PEDV	O
S	O
-	O
INDEL	B-PROC
strains	O
.	O

An	O
81	O
-	O
year	O
-	O
old	O
previously	O
healthy	O
Korean	O
man	O
presented	O
with	O
cough	O
,	O
dyspnea	O
,	O
and	O
febrile	B-PROC
sensation	B-PROC
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
bilateral	O
central	O
retinal	O
artery	O
occlusion	B-PROC
with	O
both	O
anterior	O
and	O
posterior	O
ischemic	O
optic	O
neuropathy	O
,	O
presumed	O
due	O
to	O
the	O
combination	O
of	O
severe	O
systemic	O
hypotension	O
,	O
hypoxemia	O
due	O
to	O
the	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
prolonged	O
prone	O
positioning	O
.	O

We	O
examined	O
the	O
association	O
of	O
two	O
major	O
BCCE	O
-	O
detected	O
abnormalities	O
(	O
left	B-PROC
ventricular	I-PROC
ejection	I-PROC
fraction	O
<	O
40	O
%	O
and	O
severe	O
ACP	O
)	O
with	O
ICU	O
/	O
hospital	O
mortality	O
and	O
ICU	O
/	O
hospital	O
length	O
of	O
stay	O
.	O

Extensive	O
but	O
incomplete	O
deletion	O
of	O
ABCA3	O
caused	O
alveolar	O
injury	O
and	O
inflammation	O
,	O
and	O
it	O
initiated	O
proliferation	O
of	O
progenitor	O
cells	O
,	O
restoring	O
ABCA3	O
expression	B-PROC
,	O
lung	O
structure	O
,	O
and	O
function	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
this	O
model	O
to	O
investigate	O
the	O
regulatory	O
mechanism	O
in	O
the	O
early	O
inflammatory	B-PROC
response	I-PROC
during	O
acute	O
lung	O
injury	O
.	O

We	O
compared	O
the	O
demographic	O
and	O
clinical	O
characteristics	O
at	O
admission	O
between	O
severe	O
pneumonia	O
patients	O
with	O
and	O
without	O
ARDS	O
development	B-PROC
,	O
followed	O
by	O
analysis	O
of	O
potential	O
predictors	O
for	O
ARDS	O
development	B-PROC
and	O
mortality	O
.	O

Herein	O
,	O
we	O
review	O
these	O
emerging	O
viral	O
pathogens	O
in	O
China	O
and	O
focus	O
on	O
how	O
surveillance	O
by	O
pathogen	O
genomics	O
has	O
been	O
employed	O
to	O
discover	O
and	O
annotate	O
novel	O
pathogenic	O
agents	O
,	O
identify	O
natural	O
reservoirs	O
,	O
monitor	O
the	O
transmission	O
events	O
and	O
delineate	O
their	O
evolution	B-PROC
and	O
adaption	B-PROC
to	O
the	O
human	O
host	O
.	O

In	O
summary	O
,	O
genomic	O
sequencing	O
has	O
become	O
a	O
standard	O
research	O
tool	O
in	O
the	O
field	O
of	O
emerging	O
infectious	O
diseases	O
which	O
has	O
been	O
proven	O
invaluable	O
in	O
containing	O
these	O
viral	B-PROC
infections	I-PROC
and	O
reducing	O
burden	O
of	O
disease	O
in	O
humans	O
and	O
animals	O
.	O

ABSTRACT	O
:	O
Mannose	O
-	O
binding	O
lectin	O
(	O
MBL	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
innate	B-PROC
immune	I-PROC
response	I-PROC
.	O

Results	O
are	O
expressed	B-PROC
as	O
median	O
and	O
interquartile	O
range	O
.	O

TITLE	O
:	O
Adaptive	O
evolution	B-PROC
influences	O
the	O
infectious	O
dose	O
of	O
MERS	O
-	O
CoV	O
necessary	O
to	O
achieve	O
severe	O
respiratory	O
disease	O
.	O

One	O
of	O
the	O
proposed	O
mechanisms	O
involves	O
increased	O
adhesion	O
of	O
sickle	O
red	O
cells	O
to	O
pulmonary	O
microvasculature	B-PROC
in	O
the	O
presence	O
of	O
hypoxia	O
.	O

The	O
authors	O
discovered	O
that	O
TGEV	O
induces	O
an	O
epithelial	B-PROC
-	I-PROC
mesenchymal	I-PROC
transition	I-PROC
-	O
like	O
phenotype	O
that	O
augments	O
cell	B-PROC
adhesion	I-PROC
proteins	O
mediating	O
the	O
attachment	O
of	O
ETEC	O
to	O
intestinal	O
epithelial	O
cells	O
.	O

Within	O
the	O
lipoprotein	O
family	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
),	O
primarily	O
composed	O
of	O
apolipoprotein	B-PROC
A1	O
(	O
apoA	O
-	O
I	O
)	O
and	O
phospholipids	O
,	O
measuring	O
a	O
mere	O
10	O
nm	O
,	O
is	O
the	O
smallest	O
and	O
densest	O
particle	O
.	O

TITLE	O
:	O
Hemodynamic	B-PROC
profile	O
of	O
pulmonary	O
hypertension	O
(	O
PH	O
)	O
in	O
ARDS	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
describe	O
the	O
hemodynamic	B-PROC
characteristics	O
of	O
PH	O
secondary	O
to	O
ARDS	O
,	O
in	O
relation	O
with	O
respiratory	O
parameters	O
.	O

Individual	O
characteristics	O
:	O
PaO2	O
/	O
FiO2	O
=	O
110	O
±	O
60	O
mmHg	O
,	O
alveolar	O
-	O
arterial	O
oxygen	O
gradient	O
(	O
A	O
-	O
aO2	O
)	O
=	O
549	O
±	O
148	O
.	O
9	O
mmHg	O
,	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
=	O
8	O
.	O
7	O
±	O
3	O
.	O
5	O
cmH	O

This	O
study	O
is	O
the	O
first	O
to	O
employ	O
two	O
syndromic	O
TaqMan	O
Array	O
Cards	O
for	O
the	O
simultaneous	O
survey	O
of	O
57	O
different	O
organisms	O
to	O
better	O
characterize	O
the	O
type	O
and	O
prevalence	O
of	O
detected	O
agents	O
among	O
febrile	B-PROC
patients	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
recombinase	O
polymerase	O
amplification	O
combined	O
with	O
lateral	O
-	O
flow	O
dipstick	O
assay	O
for	O
detection	O
of	O
bovine	O
ephemeral	O
fever	B-PROC
virus	O
.	O

RPA	O
primers	O
and	O
LF	O
probes	O
were	O
designed	O
by	O
targeting	B-PROC
the	O
specific	O
G	O
gene	O
,	O
and	O
the	O
amplification	O
product	O
can	O
be	O
visualized	O
on	O
a	O
simple	O
lateral	O
flow	O
dipstick	O
with	O
the	O
naked	O
eyes	O
.	O

ABSTRACT	O
:	O
Porcine	O
reproductive	B-PROC
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
and	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
are	O
highly	O
virulent	O
and	O
contagious	O
porcine	O
pathogens	O
that	O
cause	O
tremendous	O
economic	O
losses	O
to	O
the	O
swine	O
industry	O
worldwide	O
.	O

Extracorporeal	O
membrane	O
oxygenation	B-PROC
was	O
instituted	O
in	O
17	O
patients	O
;	O
15	O
of	O
these	O
patients	O
required	O
CRRT	O
.	O

TITLE	O
:	O
Memory	B-PROC
CD8	O
T	O
cells	O
mediate	O
severe	O
immunopathology	O
following	O
respiratory	O
syncytial	O
virus	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Accessory	O
proteins	O
8b	O
and	O
8ab	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
suppress	O
the	O
interferon	O
signaling	B-PROC
pathway	I-PROC
by	O
mediating	O
ubiquitin	B-PROC
-	O
dependent	O
rapid	O
degradation	O
of	O
interferon	O
regulatory	O
factor	O
3	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
protective	O
efficacy	O
of	O
this	O
DC	O
-	O
targeting	B-PROC
vaccine	O
by	O
immunizing	O
sows	O
at	O
5	O
and	O
2	O
weeks	O
prior	O
to	O
farrowing	B-PROC
and	O
by	O
challenging	O
the	O
5	O
-	O
day	O
-	O
old	O
piglets	O
with	O
PEDV	O
.	O

Bundle	O
treatment	O
group	O
was	O
given	O
bundle	O
treatment	O
on	O
the	O
basis	O
of	O
conventional	O
treatment	O
,	O
including	O
isolation	O
,	O
anti	O
-	O
virus	O
,	O
respiratory	O
support	O
,	O
restrictive	O
fluid	O
management	O
,	O
immunotherapy	O
,	O
inhibition	B-PROC
of	O
inflammation	O
,	O
antibiotic	O
therapy	O
,	O
nutritional	O
support	O
,	O
prevention	O
of	O
hospital	O
acquired	O
infection	O
(	O
HAP	O
),	O
individual	O
sedation	O
,	O
continuous	O
blood	O
purification	O
(	O
CBP	O
)	O
for	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
and	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
patients	O
,	O
and	O
intensive	O
care	O
.	O

The	O
clinical	O
data	O
of	O
patients	O
,	O
including	O
gender	O
,	O
age	O
,	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
blood	B-PROC
pressure	I-PROC
within	O
24	O
hours	O
after	O
admission	O
to	O
the	O
hospital	O
,	O
indicators	O
of	O
blood	O
routine	O
and	O
blood	O
biochemistry	O
,	O
severity	O
of	O
disease	O
,	O
severity	O
of	O
trauma	O
,	O
whether	O
received	O
the	O
emergency	O
intubation	O
or	O
surgery	O
within	O
24	O
hours	O
or	O
not	O
,	O
whether	O
developed	O
sepsis	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
during	O
hospitalization	O
,	O
were	O
recorded	O
,	O
and	O
univariate	O
analysis	O
was	O
conducted	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
characterized	O
by	O
acute	O
hypoxic	O
respiratory	O
dysfunction	O
or	O
failure	O
,	O
is	O
a	O
manifestation	O
of	O
multiple	O
organ	O
failure	O
(	O
MOF	O
)	O
in	O
the	O
lung	O
,	O
which	O
often	O
caused	O
by	O
various	O
non	O
-	O
cardiac	O
reasons	O
,	O
included	O
severe	O
trauma	O
,	O
infection	O
,	O
shock	O
;	O
and	O
the	O
most	O
common	O
risk	O
factor	O
is	O
sepsis	O
which	O
would	O
cause	O
uncontrolled	O
host	B-PROC
response	I-PROC
to	O
infecting	O
factors	O
.	O

Heparin	O
-	O
coated	O
ECMO	O
-	O
circuits	O
are	O
currently	O
standard	O
of	O
care	O
,	O
in	O
addition	O
to	O
heparin	O
based	O
anticoagulation	B-PROC
(	O
AC	O
)	O
regimen	O
guided	O
by	O
activated	O
clotting	B-PROC
time	O
(	O
ACT	O
)	O
or	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
aPTT	O
).	O

We	O
hypothesized	O
,	O
that	O
there	O
are	O
coagulation	B-PROC
parameters	O
that	O
are	O
indices	O
for	O
a	O
higher	O
risk	O
of	O
hemorrhage	O
under	O
veno	O
-	O
venous	O
(	O
VV	O
)-	O
ECMO	O
therapy	O
.	O

However	O
,	O
in	O
the	O
clinical	O
setting	O
,	O
spontaneous	O
respiration	B-PROC
has	O
been	O
indicated	O
only	O
in	O
mild	O
ARDS	O
.	O

Peak	O
transpulmonary	O
pressure	O
correlated	O
positively	O
with	O
IL	O
-	O
6	O
[	O
Spearman	O
'	O
s	O
rho	O
(	O
ρ	O
)	O
=	O
0	O
.	O
62	O
,	O
P	O
=	O
0	O
.	O
0007	O
]	O
and	O
CINC	O
-	O
1	O
expressions	O
(	O
ρ	O
=	O
0	O
.	O
50	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
negatively	O
with	O
E	O
-	O
cadherin	O
expression	B-PROC
(	O
ρ	O
=	O
-	O
0	O
.	O
67	O
,	O
P	O
=	O
0	O
.	O
0002	O
).	O

Peak	O
transpulmonary	O
pressure	O
correlated	O
positively	O
with	O
IL	O
-	O
6	O
[	O
Spearman	O
'	O
s	O
rho	O
(	O
ρ	O
)	O
=	O
0	O
.	O
62	O
,	O
P	O
=	O
0	O
.	O
0007	O
]	O
and	O
CINC	O
-	O
1	O
expressions	O
(	O
ρ	O
=	O
0	O
.	O
50	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
negatively	O
with	O
E	O
-	O
cadherin	O
expression	B-PROC
(	O
ρ	O
=	O
-	O
0	O
.	O
67	O
,	O
P	O
=	O
0	O
.	O
0002	O
).	O

Toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
),	O
an	O
essential	O
LPS	O
signaling	B-PROC
receptor	O
,	O
plays	O
a	O
critical	O
role	O
in	O
the	O
activation	O
of	O
innate	B-PROC
immunity	B-PROC
.	O

Furthermore	O
,	O
UTI	O
significantly	O
attenuated	O
LPS	O
-	O
induced	O
increases	O
in	O
TLR4	O
protein	B-PROC
expression	B-PROC
and	O
NF	O
-	O
κB	O
activation	O
in	O
lung	O
tissues	O
.	O

Similarly	O
,	O
UTI	O
markedly	O
attenuated	O
TLR4	O
expression	B-PROC
and	O
NF	O
-	O
κB	O
activation	O
in	O
LPS	O
-	O
stimulated	O
BEAS	O
-	O
2B	O
cells	O
.	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
infection	O
causes	O
meningoencephalitis	O
by	O
disrupting	O
the	O
neuro	O
-	O
glial	O
and	O
glial	O
-	O
pial	O
homeostasis	B-PROC
.	O

Recent	O
studies	O
suggest	O
that	O
MHV	O
infection	O
alters	O
gap	O
junction	O
protein	O
connexin	B-PROC
43	O
(	O
Cx43	O
)-	O
mediated	O
intercellular	B-PROC
communication	I-PROC
in	O
brain	O
and	O
primary	O
cultured	O
astrocytes	O
.	O

Our	O
results	O
show	O
that	O
MHV	O
infection	O
reduces	O
total	O
Cx43	O
levels	O
and	O
causes	O
its	O
intracellular	B-PROC
retention	I-PROC
in	O
the	O
perinuclear	O
compartments	O
reducing	O
its	O
surface	O
expression	B-PROC
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
MHV	O
infection	O
can	O
directly	O
affect	O
expression	B-PROC
and	O
cellular	O
distribution	O
of	O
Cx43	O
resulting	O
in	O
loss	O
of	O
Cx43	O
-	O
mediated	O
GJIC	O
in	O
meningeal	O
fibroblasts	O
,	O
which	O
may	O
be	O
associated	O
with	O
altered	O
BBB	O
function	O
observed	O
in	O
acute	O
infection	O
.	O

TITLE	O
:	O
Regional	O
,	O
age	O
and	O
respiratory	O
-	O
secretion	B-PROC
-	O
specific	O
prevalence	O
of	O
respiratory	O
viruses	O
associated	O
with	O
asthma	O
exacerbation	O
:	O
a	O
literature	O
review	O
.	O

This	O
protein	O
is	O
also	O
involved	O
in	O
FCoV	O
tropism	B-PROC
and	O
virulence	B-PROC
,	O
as	O
well	O
as	O
in	O
the	O
switch	O
from	O
enteric	O
disease	O
to	O
FIP	O
.	O

The	O
most	O
common	O
adverse	O
events	O
were	O
headache	O
(	O
n	O
=	O
6	O
[	O
21	O
%]	O
in	O
participants	O
who	O
received	O
SAB	O
-	O
301	O
and	O
n	O
=	O
2	O
[	O
20	O
%]	O
in	O
those	O
receiving	O
placebo	O
),	O
albuminuria	O
(	O
n	O
=	O
5	O
[	O
18	O
%]	O
vs	O
n	O
=	O
2	O
[	O
20	O
%]),	O
myalgia	O
(	O
n	O
=	O
3	O
[	O
11	O
%]	O
vs	O
n	O
=	O
1	O
[	O
10	O
%]),	O
increased	O
creatine	O
kinase	O
(	O
n	O
=	O
3	O
[	O
11	O
%]	O
vs	O
1	O
[	O
10	O
%]),	O
and	O
common	O
cold	B-PROC
(	O
n	O
=	O
3	O
[	O
11	O
%]	O
vs	O
n	O
=	O
2	O
[	O
20	O
%]).	O

However	O
,	O
broilers	O
supplemented	O
with	O
0	O
mg	O
/	O
kg	O
of	O
VE	O
had	O
lower	O
antibody	B-PROC
titers	O
against	O
SRBC	O
than	O
those	O
fed	O
100	O
mg	O
/	O
kg	O
of	O
VE	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
at	O
the	O
24th	O
day	O
.	O

The	O
qualification	O
of	O
emergency	O
staff	O
,	O
the	O
organizational	O
aspects	O
and	O
the	O
occurrence	O
of	O
critical	O
events	O
during	O
transport	B-PROC
were	O
analyzed	O
.	O

When	O
a	O
critical	O
event	O
occurred	O
,	O
the	O
PaO	B-PROC
The	O
transport	B-PROC
of	O
critically	O
ill	O
patients	O
is	O
associated	O
with	O
potential	O
risks	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
Almitrine	O
Infusion	O
During	O
Veno	O
-	O
Venous	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
for	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
in	O
Adults	O
.	O

A	O
focal	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
inhaled	B-PROC
nitric	O
oxide	O
therapy	O
were	O
more	O
frequent	O
in	O
patients	O
with	O
a	O
positive	O
response	O
to	O
almitrine	O
.	O

SPC	O
deficiency	O
in	O
patients	O
and	O
mouse	O
models	O
is	O
associated	O
with	O
increased	O
inflammation	O
and	O
delayed	O
repair	B-PROC
,	O
but	O
the	O
key	O
drivers	O
of	O
SPC	O
-	O
regulated	O
inflammation	O
in	O
response	O
to	O
injury	O
are	O
largely	O
unknown	O
.	O

The	O
level	O
of	O
suppressor	O
of	O
cytokine	B-PROC
signaling	B-PROC
3	O
,	O
an	O
anti	O
-	O
inflammatory	O
mediator	O
that	O
decreases	O
pSTAT3	O
signaling	B-PROC
,	O
was	O
significantly	O
decreased	O
in	O
the	O
BAL	O
fluid	O
of	O
SPC	O
-	O
TK	O
/	O
SPC	O
-	O
KO	O
mice	O
.	O

Bat	O
CoVs	O
exhibit	O
both	O
extensive	O
genetic	O
diversity	O
and	O
a	O
broad	O
geographic	O
range	O
,	O
indicative	O
of	O
a	O
long	O
-	O
standing	B-PROC
host	O
association	O
.	O

The	O
results	O
of	O
this	O
study	O
will	O
be	O
valuable	O
for	O
further	O
research	O
of	O
PDCoV	O
genetic	O
evolution	B-PROC
and	O
development	B-PROC
of	O
effective	O
diagnostic	O
reagents	O
,	O
assays	O
and	O
potential	O
vaccines	O
against	O
newly	O
emerged	O
PDCoV	O
strains	O
.	O

Virus	O
-	O
induced	O
excessive	O
inflammatory	B-PROC
response	I-PROC
contributes	O
to	O
severe	O
disease	O
and	O
high	O
mortality	O
rates	O
.	O

Combined	O
,	O
our	O
results	O
suggest	O
that	O
endogenous	O
galectin	O
-	O
3	O
enhances	O
the	O
effects	O
of	O
H5N1	O
infection	O
by	O
promoting	O
host	O
inflammatory	B-PROC
responses	I-PROC
and	O
regulating	O
IL	O
-	O
1β	O
production	O
by	O
macrophages	O
via	O
interaction	O
with	O
NLRP3	O
.	O

By	O
suggesting	O
methods	O
to	O
evaluate	O
the	O
field	O
epidemiologist	O
system	O
and	O
training	O
programs	O
and	O
by	O
suggesting	O
ways	O
for	O
the	O
Korea	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
to	O
conduct	B-PROC
evaluations	O
on	O
its	O
own	O
,	O
the	O
present	O
study	O
provides	O
supporting	O
evidence	O
for	O
improvement	O
of	O
systems	O
for	O
training	O
of	O
experts	O
in	O
epidemiological	O
investigations	O
.	O

Thus	O
,	O
this	O
movement	B-PROC
of	O
pigs	O
is	O
suggested	O
as	O
the	O
main	O
way	O
for	O
introducing	O
PEDV	O
to	O
Ecuador	O
.	O

None	O
of	O
the	O
50	O
contacts	O
tested	O
positive	O
for	O
MERS	O
-	O
CoV	O
.	O
Resolution	O
of	O
the	O
fever	B-PROC
was	O
accompanied	O
by	O
an	O
increase	O
in	O
oxygen	O
requirements	O
and	O
respiratory	O
rate	O
also	O
lasting	O
several	O
days	O
.	O

RESULTS	O
:	O
Although	O
all	O
nasopharyngeal	O
samples	O
were	O
negative	O
,	O
MERS	O
CoV	O
infection	O
was	O
confirmed	O
by	O
reverse	B-PROC
transcription	B-PROC
-	O
polymerase	O
chain	O
reaction	O
of	O
the	O
E	O
gene	O
(	O
UpE	O
)	O
and	O
open	O
reading	O
frame	O
(	O
ORF1b	O
)	O
on	O
sputum	O
samples	O
.	O

TITLE	O
:	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
-	O
Induced	O
Epidermal	O
Growth	B-PROC
Factor	O
Receptor	B-PROC
Activation	I-PROC
Impairs	O
the	O
Antiviral	O
Activity	O
of	O
Type	O
I	O
Interferon	O
.	O

Further	O
analysis	O
revealed	O
that	O
inhibition	B-PROC
of	O
EGFR	O
produced	O
augmentation	O
of	O
type	O
I	O
interferon	O
genes	O
.	O

Similar	O
to	O
the	O
case	O
of	O
EGFR	O
,	O
specific	O
inhibition	B-PROC
of	O
STAT3	O
by	O
either	O
inhibitor	O
or	O
siRNA	O
increased	O
the	O
antiviral	O
activity	O
of	O
interferon	O
and	O
resulted	O
in	O
decreased	O
PEDV	O
RNA	O
levels	O
,	O
and	O
vice	O
versa	O
.	O

The	O
data	O
on	O
STAT3	O
depletion	O
in	O
combination	O
with	O
EGFR	O
activation	O
suggest	O
that	O
the	O
attenuation	O
of	O
antiviral	O
activity	O
by	O
EGFR	O
activation	O
requires	O
activation	O
of	O
the	O
STAT3	B-PROC
signaling	B-PROC
pathway	I-PROC
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
PEDV	O
-	O
induced	O
EGFR	O
activation	O
serves	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
type	O
I	O
interferon	O
response	O
and	O
provides	O
a	O
novel	O
therapeutic	O
target	O
for	O
virus	B-PROC
infection	I-PROC
.	O

However	O
,	O
unique	O
properties	O
of	O
SECD	O
,	O
such	O
as	O
ineffective	O
immunity	B-PROC
through	O
parenteral	O
vaccination	O
and	O
a	O
low	O
oral	O
infectious	O
dose	O
,	O
play	O
a	O
major	O
role	O
in	O
management	O
of	O
SECD	O
.	O

TITLE	O
:	O
Detection	O
of	O
Zika	O
virus	O
using	O
reverse	O
-	O
transcription	B-PROC
LAMP	O
coupled	O
with	O
reverse	O
dot	O
blot	O
analysis	O
in	O
saliva	O
.	O

In	O
this	O
study	O
,	O
fattening	O
pigs	O
and	O
suckling	O
piglets	O
(	O
n	O
=	O
105	O
)	O
on	O
farms	O
with	O
no	O
prior	O
PED	O
history	O
were	O
monitored	O
after	O
an	O
acute	O
outbreak	O
of	O
the	O
disease	O
,	O
caused	O
by	O
an	O
S	O
INDEL	B-PROC
strain	O
of	O
PED	O
virus	O
(	O
PEDV	O
).	O

The	O
results	O
showed	O
that	O
the	O
expression	B-PROC
of	O
RNA	O
virus	O
pattern	O
recognition	O
receptors	O
(	O
TLR3	O
,	O
7	O
,	O
and	O
MDA5	O
),	O
antimicrobial	O
peptides	O
(	O
avian	O
β	O
-	O
defensins	O
,	O
including	O
AvBD1	O
,	O
2	O
,	O
4	O
-	O
6	O
and	O
cathelicidins	O
,	O
including	O
CATH1	O
and	O
3	O
),	O
and	O
interferons	O
(	O
IFNα	O
,	O
β	O
,	O
γ	O
,	O
λ	O
)	O
were	O
upregulated	O
,	O
and	O
the	O
expression	B-PROC
of	O
cyclooxygenase	O
2	O
(	O
PG	O
synthase	O
)	O
and	O
the	O
level	O
of	O
PGE2	O
were	O
increased	O
in	O
the	O
uterine	O
mucosa	O
following	O
aIBV	O
inoculation	O
.	O

mTOR	B-PROC
signaling	B-PROC
pathway	I-PROC
activator	O
-	O
MHY1485	O
,	O
and	O
inhibitor	O
-	O
PP242	O
were	O
used	O
to	O
study	O
the	O
antiviral	O
function	O
.	O

This	O
review	O
describes	O
the	O
potential	O
of	O
this	O
platform	O
to	O
develop	O
new	O
vaccines	O
against	O
emerging	O
viral	B-PROC
diseases	I-PROC
.	O

Most	O
deaths	B-PROC
in	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
are	O
not	O
directly	O
related	O
to	O
lung	O
damage	O
but	O
to	O
extrapulmonary	O
multisystem	O
organ	O
failure	O
.	O

After	O
immunization	O
,	O
significantly	O
higher	O
levels	O
of	O
anti	O
-	O
PEDV	O
specific	O
IgG	O
antibodies	O
with	O
PEDV	O
neutralizing	O
activity	O
in	O
the	O
sera	O
and	O
mucosal	O
sIgA	O
antibodies	O
in	O
the	O
tractus	O
genitalis	O
,	O
intestinal	O
mucus	O
,	O
and	O
stools	O
were	O
detected	O
in	O
mice	O
orally	O
administered	O
with	O
the	O
recombinant	O
strain	O
pPG	O
-	O
COE	O
-	O
Col	O
-	O
DCpep	O
/	O
L393	O
,	O
which	O
expressed	B-PROC
DCpep	O
and	O
Col	O
targeting	B-PROC
ligands	O
fused	O
with	O
the	O
PEDV	O
COE	O
antigen	O
,	O
compared	O
to	O
mice	O
orally	O
immunized	O
with	O
the	O
recombinant	O
strain	O
pPG	O
-	O
COE	O
/	O
L393	O
without	O
the	O
DCpep	O
and	O
Col	O
targeting	B-PROC
ligands	O
.	O

The	O
intestinal	O
M	O
cells	O
-	O
and	O
DCs	O
-	O
targeting	B-PROC
oral	O
delivery	O
of	O
genetically	O
engineered	O
Lactobacillus	O
expressing	O
the	O
COE	O
antigen	O
of	O
PEDV	O
can	O
efficiently	O
induce	O
anti	O
-	O
PEDV	O
mucosal	O
,	O
humoral	O
,	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
via	O
oral	O
administration	O
,	O
suggesting	O
a	O
promising	O
vaccine	O
strategy	O
against	O
PEDV	O
infection	O
.	O

RESULTS	O
:	O
After	O
immunization	O
,	O
significantly	O
higher	O
levels	O
of	O
anti	O
-	O
PEDV	O
specific	O
IgG	O
antibodies	O
with	O
PEDV	O
neutralizing	O
activity	O
in	O
the	O
sera	O
and	O
mucosal	O
sIgA	O
antibodies	O
in	O
the	O
tractus	O
genitalis	O
,	O
intestinal	O
mucus	O
,	O
and	O
stools	O
were	O
detected	O
in	O
mice	O
orally	O
administered	O
with	O
the	O
recombinant	O
strain	O
pPG	O
-	O
COE	O
-	O
Col	O
-	O
DCpep	O
/	O
L393	O
,	O
which	O
expressed	B-PROC
DCpep	O
and	O
Col	O
targeting	B-PROC
ligands	O
fused	O
with	O
the	O
PEDV	O
COE	O
antigen	O
,	O
compared	O
to	O
mice	O
orally	O
immunized	O
with	O
the	O
recombinant	O
strain	O
pPG	O
-	O
COE	O
/	O
L393	O
without	O
the	O
DCpep	O
and	O
Col	O
targeting	B-PROC
ligands	O
.	O

TITLE	O
:	O
PED	O
subunit	O
vaccine	O
based	O
on	O
COE	O
domain	O
replacement	O
of	O
flagellin	O
domain	O
D3	O
improved	O
specific	O
humoral	O
and	O
mucosal	B-PROC
immunity	I-PROC
in	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
multifunctional	O
Ebola	O
virus	O
(	O
EBOV	O
)	O
VP35	O
protein	O
is	O
a	O
key	O
determinant	O
of	O
virulence	B-PROC
.	O

Based	O
on	O
our	O
biochemical	O
results	O
and	O
in	O
agreement	O
with	O
previous	O
experimental	O
observations	O
,	O
we	O
have	O
built	O
an	O
in	O
silico	O
3D	O
model	O
of	O
the	O
so	O
-	O
far	O
structurally	O
unsolved	O
EBOV	O
VP35	O
CC	O
domain	O
and	O
performed	O
self	O
-	O
assembly	O
homo	O
-	O
oligomerization	O
simulations	O
by	O
means	O
of	O
molecular	B-PROC
dynamics	I-PROC
.	O

A	O
4	O
-	O
year	O
-	O
old	O
girl	O
with	O
acute	O
lymphoblastic	O
leukemia	O
who	O
received	O
maintenance	O
chemotherapy	O
in	O
an	O
outpatient	O
clinic	O
developed	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
.	O

Venoarteria	O
-	O
ECMO	O
may	O
be	O
chosen	O
for	O
multiple	O
trauma	O
patients	O
with	O
ARDS	O
,	O
and	O
respiratory	O
and	O
circulatory	B-PROC
failure	O
.	O

Lack	O
of	O
acclimation	B-PROC
to	O
heat	O
and	O
physical	O
fitness	O
decreases	O
the	O
survival	O
of	O
heat	O
stroked	O
dogs	O
.	O

At	O
the	O
systemic	O
level	O
,	O
blood	O
pooling	O
within	O
the	O
large	O
internal	O
organs	O
(	O
e	O
.	O
g	O
.,	O
spleen	O
,	O
liver	O
)	O
is	O
a	O
major	O
contributor	O
to	O
the	O
development	B-PROC
of	O
shock	O
and	O
consequent	O
intestinal	O
ischemia	O
,	O
hypoxia	O
and	O
endothelial	O
hyperpermeability	O
,	O
commonly	O
occurring	O
in	O
heatstroke	O
patients	O
.	O

This	O
is	O
a	O
case	O
report	O
of	O
a	O
child	O
with	O
SWS	O
who	O
had	O
a	O
febrile	B-PROC
illness	O
and	O
epileptic	O
seizures	O
which	O
led	O
to	O
severe	O
rhabdomyolysis	O
outside	O
the	O
context	O
of	O
anaesthesia	O
,	O
and	O
we	O
would	O
like	O
to	O
draw	O
the	O
attention	O
of	O
clinicians	O
to	O
this	O
potential	O
complication	O
.	O

ABSTRACT	O
:	O
The	O
hexameric	O
α	O
-	O
helical	O
coiled	O
-	O
coil	O
formed	O
between	O
the	O
C	O
-	O
terminal	O
and	O
N	O
-	O
terminal	O
heptad	O
repeat	O
(	O
CHR	O
and	O
NHR	O
)	O
regions	O
of	O
class	O
I	O
viral	O
fusion	O
proteins	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
the	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	O
membranes	O
and	O
provides	O
a	O
clear	O
starting	O
point	O
for	O
molecular	B-PROC
mimicry	I-PROC
that	O
drives	O
viral	O
fusion	O
inhibitor	O
design	O
.	O

The	O
resultant	O
stapled	O
peptide	O
P21S10	O
could	O
effectively	O
inhibit	O
infection	O
by	O
MERS	O
-	O
CoV	O
pseudovirus	O
and	O
its	O
spike	O
protein	O
-	O
mediated	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
;	O
additionally	O
,	O
P21S10	O
exhibits	O
improved	O
pharmacokinetic	O
properties	O
than	O
HR2P	O
-	O
M2	O
,	O
suggesting	O
strong	O
potential	O
for	O
development	B-PROC
as	O
an	O
anti	O
-	O
MERS	O
-	O
CoV	O
therapeutic	O
.	O

ABSTRACT	O
:	O
During	O
pneumonia	O
,	O
pathogen	B-PROC
-	I-PROC
host	I-PROC
interaction	I-PROC
evokes	O
inflammation	O
and	O
lung	O
barrier	O
dysfunction	O
.	O

TITLE	O
:	O
Tools	O
to	O
study	O
pathogen	B-PROC
-	I-PROC
host	I-PROC
interactions	I-PROC
in	O
bats	O
.	O

Progress	O
in	O
understanding	O
bat	O
-	O
virus	O
interactions	O
and	O
the	O
isolation	O
of	O
bat	O
-	O
borne	O
viruses	O
has	O
been	O
accelerated	O
in	O
recent	O
years	O
by	O
the	O
development	B-PROC
of	O
susceptible	O
bat	O
cell	O
lines	O
.	O

TITLE	O
:	O
Dexmedetomidine	O
-	O
treated	O
hyperventilation	O
syndrome	O
triggered	O
by	O
the	O
distress	O
related	O
with	O
a	O
urinary	O
catheter	O
after	O
general	B-PROC
anesthesia	I-PROC
:	O
a	O
case	O
report	O
.	O

This	O
protein	O
is	O
composed	O
of	O
an	O
N	O
-	O
terminal	O
receptor	O
-	O
binding	O
domain	O
(	O
S1	O
)	O
and	O
a	O
C	O
-	O
terminal	O
trans	O
-	O
membrane	B-PROC
fusion	I-PROC
domain	O
(	O
S2	O
).	O

The	O
severe	O
inflammatory	O
cascades	O
impaired	O
the	O
regulation	B-PROC
of	O
vascular	O
endothelial	O
barrier	O
and	O
vascular	B-PROC
permeability	I-PROC
.	O

This	O
article	O
reviews	O
the	O
current	O
clinical	O
and	O
basic	O
research	O
on	O
the	O
pathogenesis	B-PROC
of	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
including	O
information	O
on	O
the	O
microenvironment	O
,	O
vascular	O
endothelial	O
barrier	O
and	O
immune	O
mechanisms	O
,	O
to	O
offer	O
a	O
strong	O
foundation	O
for	O
developing	O
therapeutic	O
interventions	O
.	O

Pharmacologic	O
therapies	O
such	O
as	O
β2	O
agonists	O
,	O
statins	O
,	O
and	O
keratinocyte	O
growth	B-PROC
factor	O
,	O
which	O
targeted	B-PROC
pathophysiologic	O
alterations	O
in	O
ARDS	O
,	O
were	O
not	O
beneficial	O
and	O
demonstrated	O
possible	O
harm	O
.	O

Complete	O
genome	O
sequence	O
analyses	O
indicated	O
this	O
PEDV	O
variant	O
was	O
genetically	O
similar	O
to	O
US	O
non	O
-	O
S	O
INDEL	B-PROC
strain	O
but	O
had	O
a	O
continuous	O
600	O
-	O
nt	O
(	O
200	O
-	O
aa	O
)	O
deletion	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
spike	O
gene	O
compared	O
to	O
non	O
-	O
S	O
INDEL	B-PROC
PEDVs	O
.	O

Caesarean	O
section	O
(	O
CS	O
)	O
may	O
be	O
the	O
most	O
used	O
mode	O
and	O
labour	B-PROC
induction	O
could	O
be	O
another	O
option	O
.	O

Maternal	O
oxygenation	B-PROC
was	O
improved	O
after	O
delivery	O
and	O
ECMO	O
was	O
successfully	O
discontinued	O
.	O

Data	O
from	O
clinical	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
suggest	O
that	O
virus	O
-	O
induced	O
cytokine	O
dysregulation	O
could	O
be	O
a	O
contributory	O
factor	O
to	O
the	O
pathogenesis	B-PROC
of	O
human	O
H5N1	O
disease	O
.	O

Hence	O
,	O
the	O
reduction	O
in	O
APN	O
expression	B-PROC
represents	O
another	O
component	O
of	O
the	O
anti	O
-	O
PEDV	O
infection	O
response	O
initiated	O
by	O
ADAM17	O
.	O

We	O
report	O
in	O
detail	O
two	O
cases	O
of	O
fulminant	O
idiopathic	O
acute	O
lung	O
injury	O
requiring	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
previously	O
healthy	O
young	O
adults	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
one	O
of	O
whom	O
required	O
lung	O
transplantation	O
.	O

ABSTRACT	O
:	O
Survivors	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
experience	O
severe	O
muscle	B-PROC
wasting	I-PROC
.	O

TITLE	O
:	O
Alpha	O
/	O
Beta	O
Interferon	O
(	O
IFN	O
-	O
α	O
/	O
β	O
)	O
Signaling	B-PROC
in	O
Astrocytes	O
Mediates	O
Protection	O
against	O
Viral	O
Encephalomyelitis	O
and	O
Regulates	O
IFN	O
-	O
γ	O
-	O
Dependent	O
Responses	O
.	O

This	O
rearrangement	B-PROC
was	O
validated	O
through	O
the	O
analysis	O
of	O
sub	O
-	O
genomic	O
mRNAs	O
from	O
infected	O
cells	O
.	O

Hence	O
,	O
development	B-PROC
of	O
a	O
specific	O
vaccine	O
to	O
guard	O
against	O
their	O
potential	O
threat	O
is	O
important	O
.	O

TITLE	O
:	O
Engineering	O
a	O
stable	O
CHO	O
cell	O
line	O
for	O
the	O
expression	B-PROC
of	O
a	O
MERS	O
-	O
coronavirus	O
vaccine	O
antigen	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
infected	O
at	O
least	O
2040	O
patients	O
and	O
caused	O
712	O
deaths	B-PROC
since	O
its	O
first	O
appearance	O
in	O
2012	O
,	O
yet	O
neither	O
pathogen	O
-	O
specific	O
therapeutics	O
nor	O
approved	O
vaccines	O
are	O
available	O
.	O

The	O
adCHO	O
-	O
expressed	B-PROC
S377	O
-	O
588	O
-	O
Fc	O
recombinant	O
protein	O
demonstrated	O
functionality	O
and	O
binding	O
specificity	O
identical	O
to	O
those	O
of	O
the	O
protein	O
from	O
transiently	O
transfected	O
HEK293T	O
cells	O
.	O

TITLE	O
:	O
Intravenous	O
immunoglobulin	B-PROC
fails	O
to	O
improve	O
ARDS	O
in	O
patients	O
undergoing	O
ECMO	O
therapy	O
.	O

To	O
support	O
the	O
immunological	O
response	O
in	O
this	O
patient	O
collective	O
,	O
we	O
used	O
intravenous	O
IgM	O
immunoglobulin	B-PROC
therapy	O
to	O
enhance	O
the	O
likelihood	O
of	O
pulmonary	O
recovery	O
.	O

ARDS	O
patients	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
who	O
were	O
placed	O
on	O
ECMO	O
and	O
treated	O
with	O
(	O
IVIG	O
group	O
;	O
The	O
baseline	O
characteristics	O
did	O
not	O
differ	O
between	O
the	O
groups	O
,	O
although	O
the	O
IVIG	O
group	O
showed	O
a	O
significantly	O
reduced	O
oxygenation	B-PROC
index	O
compared	O
to	O
the	O
control	O
group	O
.	O

No	O
cross	B-PROC
reactivity	I-PROC
was	O
observed	O
with	O
canine	O
distemper	O
virus	O
,	O
canine	O
adenovirus	O
,	O
and	O
canine	O
coronavirus	O
.	O

The	O
rate	O
of	O
treatment	O
change	O
(	O
RTC	O
)	O
was	O
established	O
according	O
to	O
whether	O
the	O
OLB	O
pathology	O
report	O
resulted	O
in	O
:	O
a	O
)	O
the	O
prescription	O
or	O
discontinuation	O
of	O
an	O
antimicrobial	O
;	O
b	O
)	O
the	O
indication	O
of	O
new	O
procedures	O
;	O
c	O
)	O
medical	O
interconsultation	O
;	O
or	O
d	O
)	O
limitation	O
of	O
therapeutic	O
effort	B-PROC
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
:	O
what	O
we	O
learned	B-PROC
from	O
the	O
2015	O
outbreak	O
in	O
the	O
Republic	O
of	O
Korea	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
we	O
developed	O
a	O
monoclonal	O
antibody	B-PROC
-	O
based	O
rapid	O
nucleocapsid	O
protein	O
detection	O
assay	O
for	O
diagnosis	O
of	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
humans	O
and	O
dromedary	O
camels	O
.	O

hMPV	O
was	O
further	O
detected	O
in	O
several	O
cases	O
of	O
SARS	O
and	O
it	O
was	O
the	O
only	O
virus	O
detected	O
in	O
three	O
deaths	B-PROC
.	O

These	O
findings	O
indicate	O
that	O
hMPV	O
is	O
in	O
circulation	B-PROC
in	O
southern	O
Brazil	O
and	O
highlight	O
the	O
importance	O
of	O
diagnosing	O
hMPV	O
for	O
influenza	O
-	O
like	O
illness	O
in	O
the	O
population	O
.	O

Replacement	O
of	O
H209	O
with	O
Ala	O
had	O
no	O
effect	O
on	O
receptor	O
binding	O
,	O
but	O
in	O
murine	O
17Cl	O
.	O
1	O
cells	O
mutant	O
H209A	O
MHV	O
-	O
A59	O
showed	O
delayed	O
growth	B-PROC
kinetics	O
and	O
was	O
readily	O
outcompeted	O
by	O
wild	O
-	O
type	O
virus	O
when	O
mixed	O
together	O
,	O
indicating	O
that	O
the	O
H209A	O
mutation	O
caused	O
a	O
defect	O
in	O
virus	O
fitness	O
.	O

Inflammatory	O
stress	O
and	O
immune	O
parameters	O
including	O
procalcitonin	O
(	O
PCT	O
),	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
),	O
and	O
tumor	O
necrosis	B-PROC
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
),	O
and	O
CD4	O
Seventy	O
patients	O
with	O
severe	O
pneumonia	O
were	O
enrolled	O
.	O

The	O
prolonged	O
increased	O
CD3	O
+	O
CD16	O
+	O
NKT	O
cell	O
levels	O
may	O
sustain	O
peripheral	O
inflammation	O
and	O
/	O
or	O
the	O
anti	B-PROC
-	I-PROC
viral	I-PROC
response	I-PROC
.	O

The	O
late	O
reduction	O
(	O
potential	O
depletion	O
)	O
of	O
γ	O
/	O
δ	O
T	O
lymphocytes	O
and	O
CD3	O
+	O
CD4	O
+	O
CD8α	O
-	O
naïve	O
Th	O
lymphocytes	O
paralleled	O
with	O
the	O
delayed	O
increase	O
of	O
CD3	O
+	O
CD4	O
+	O
CD8α	O
+	O
memory	B-PROC
and	O
CD3	O
+	O
CD4	O
-	O
CD8α	O
/	O
β	O
+	O
cytotoxic	O
T	O
lymphocytes	O
.	O

Overall	O
,	O
these	O
features	O
demonstrate	O
that	O
the	O
more	O
severe	O
clinical	O
signs	O
observed	O
upon	O
infection	O
with	O
the	O
HP	O
PR40	O
strain	O
are	O
sustained	O
by	O
remarkable	O
changes	O
in	O
the	O
peripheral	O
blood	O
distribution	O
of	O
immune	O
cells	O
and	O
provide	O
further	O
insights	O
into	O
the	O
immune	O
regulation	B-PROC
/	O
immunopathogenesis	O
induced	O
by	O
PRRSV	O
-	O
1	O
subtype	O
1	O
European	O
isolates	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
nsp7	O
protein	O
localized	O
in	O
the	O
cytoplasm	O
down	O
-	O
regulates	O
interleukin	O
8	O
expression	B-PROC
in	O
porcine	O
intestinal	O
epithelial	O
cell	O
.	O

Previous	O
studies	O
suggest	O
that	O
the	O
TGEV	O
non	O
-	O
structural	O
protein	O
7	O
(	O
nsp7	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
viral	B-PROC
assembly	I-PROC
process	O
.	O

The	O
clinical	O
presentation	O
of	O
MERS	O
-	O
CoV	O
infection	O
ranges	O
from	O
asymptomatic	O
to	O
very	O
severe	O
disease	O
,	O
and	O
the	O
classical	O
presentation	O
includes	O
fever	B-PROC
,	O
cough	O
chills	O
,	O
sore	O
throat	O
,	O
myalgia	O
,	O
and	O
arthralgia	O
.	O

Drinking	B-PROC
camel	O
milk	O
was	O
reported	O
by	O
24	O
.	O
1	O
%	O
of	O
CAM	O
users	O
,	O
whereas	O
camel	O
urine	O
was	O
consumed	O
by	O
15	O
.	O
7	O
%.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
is	O
a	O
major	O
structural	O
component	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
which	O
is	O
predicted	O
to	O
be	O
a	O
multifunctional	O
protein	O
in	O
viral	B-PROC
replication	I-PROC
.	O

ABSTRACT	O
:	O
Nucleoside	O
and	O
nucleotide	O
analogs	O
have	O
played	O
significant	O
roles	O
in	O
antiviral	O
therapies	O
and	O
are	O
valued	O
for	O
their	O
impressive	O
potency	O
and	O
high	O
barrier	O
to	O
resistance	B-PROC
.	O

Phylogenetic	O
analysis	O
based	O
on	O
S	O
gene	O
sequences	O
revealed	O
that	O
all	O
the	O
recent	O
field	O
PEDVs	O
were	O
genetically	O
distinct	O
from	O
the	O
classical	O
Japanese	O
strains	O
,	O
and	O
were	O
classified	O
into	O
three	O
genotypes	O
:	O
North	O
American	O
(	O
NA	O
),	O
S	O
INDEL	B-PROC
,	O
and	O
Asian	O
non	O
-	O
S	O
INDEL	B-PROC
.	O

Although	O
the	O
RT	O
-	O
LAMP	O
assay	O
is	O
less	O
sensitive	O
than	O
real	O
time	O
reverse	B-PROC
transcription	B-PROC
PCR	O
(	O
RT	O
-	O
PCR	O
),	O
it	O
can	O
be	O
performed	O
without	O
the	O
need	O
of	O
expensive	O
equipment	O
and	O
with	O
less	O
hands	O
-	O
on	O
time	O
.	O

The	O
30	O
-	O
day	O
coprimary	O
outcomes	O
were	O
major	O
adverse	O
cardiovascular	O
events	O
(	O
MACEs	O
)	O
(	O
a	O
composite	O
of	O
death	B-PROC
,	O
myocardial	O
infarction	O
,	O
or	O
stroke	O
),	O
and	O
net	O
adverse	O
clinical	O
events	O
(	O
NACEs	O
)	O
(	O
a	O
composite	O
of	O
MACEs	O
or	O
major	O
bleeding	O
).	O

Compared	O
with	O
the	O
UFH	O
and	O
UFH	O
+	O
GPI	O
groups	O
,	O
bivalirudin	O
reduced	O
bleeding	O
,	O
mainly	O
the	O
most	O
severe	O
bleeds	O
,	O
including	O
fatal	O
and	O
nonaccess	O
site	O
-	O
related	O
events	O
,	O
as	O
well	O
as	O
transfusion	O
rates	O
and	O
the	O
need	O
for	O
surgical	O
access	O
site	O
repair	B-PROC
.	O

To	O
understanding	O
the	O
epidemiological	O
role	O
of	O
camels	O
in	O
the	O
transmission	O
of	O
MERS	O
-	O
CoV	O
,	O
we	O
utilized	O
an	O
iterative	O
empirical	O
process	O
in	O
Geographic	O
Information	O
System	O
(	O
GIS	O
)	O
to	O
identify	O
and	O
qualify	O
potential	O
hotspots	O
for	O
maintenance	O
and	O
circulation	B-PROC
of	O
MERS	O
-	O
CoV	O
,	O
and	O
produced	O
risk	O
-	O
based	O
surveillance	O
sites	O
in	O
Kenya	O
.	O

The	O
selection	O
of	O
binding	O
fragments	O
from	O
phage	O
display	O
libraries	O
has	O
proven	O
significant	O
for	O
routine	O
isolation	O
of	O
invaluable	O
peptides	O
,	O
antibodies	O
,	O
and	O
antibody	B-PROC
-	O
like	O
domains	O
for	O
diagnostic	O
and	O
therapeutic	O
applications	O
.	O

A	O
total	O
of	O
360	O
patients	O
with	O
confirmed	O
pneumonia	O
who	O
were	O
evaluated	O
for	O
MERS	O
-	O
CoV	O
infection	O
by	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
between	O
September	O
1	O
,	O
2012	O
and	O
June	O
1	O
,	O
2016	O
at	O
King	O
Abdulaziz	O
Medical	O
City	O
in	O
Riyadh	O
and	O
King	O
Fahad	O
General	O
Hospital	O
in	O
Jeddah	O
,	O
were	O
included	O
.	O

It	O
is	O
mostly	O
caused	O
by	O
dysregulation	O
of	O
the	O
alternative	B-PROC
complement	B-PROC
pathway	I-PROC
.	O

Cobalamin	O
C	O
(	O
Cbl	O
C	O
)	O
defect	O
is	O
a	O
genetic	O
disorder	O
of	O
cobalamin	B-PROC
metabolism	I-PROC
and	O
is	O
a	O
rare	O
cause	O
of	O
HUS	O
.	O

Therefore	O
,	O
we	O
considered	O
a	O
second	O
mechanism	O
in	O
the	O
pathogenesis	B-PROC
as	O
complement	O
dysregulation	O
and	O
gave	O
eculizumab	O
to	O
the	O
patient	O
.	O

The	O
rates	O
of	O
coexisting	O
diabetes	O
mellitus	O
,	O
hyperpyrexia	O
,	O
and	O
bloody	O
sputum	B-PROC
production	I-PROC
were	O
significantly	O
higher	O
in	O
the	O
H7N9	O
group	O
than	O
in	O
the	O
H1N1	O
group	O
(	O
P	O
<	O
.	O
05	O
).	O

Autophagy	B-PROC
,	O
a	O
homeostatic	B-PROC
degradative	O
process	O
that	O
breaks	O
down	O
protein	O
aggregates	O
and	O
damaged	O
organelles	O
,	O
promotes	O
replication	O
of	O
multiple	O
plus	O
-	O
strand	O
viruses	O
.	O

Induction	O
of	O
autophagic	O
signals	O
promotes	O
EV	O
-	O
D68	O
replication	O
,	O
but	O
the	O
virus	O
inhibits	O
the	O
downstream	O
degradative	O
steps	O
of	O
autophagy	B-PROC
in	O
multiple	O
ways	O
.	O

ABSTRACT	O
:	O
The	O
'	O
Therapeutics	O
discovery	O
:	O
From	O
bench	O
to	O
first	O
in	O
-	O
human	O
trials	O
'	O
conference	O
,	O
held	O
at	O
the	O
King	O
Abdullah	O
International	O
Medical	O
Research	O
Center	O
(	O
KAIMRC	O
),	O
Ministry	O
of	O
National	O
Guard	O
Health	O
Affairs	O
(	O
MNGHA	O
),	O
Kingdom	O
of	O
Saudi	O
Arabia	O
(	O
KSA	O
)	O
from	O
October	O
10	O
-	O
12	O
,	O
2017	O
,	O
provided	O
a	O
unique	O
opportunity	O
for	O
experts	O
worldwide	O
to	O
discuss	O
advances	O
in	O
drug	O
discovery	O
and	O
development	B-PROC
,	O
focusing	O
on	O
phase	O
I	O
clinical	O
trials	O
.	O

The	O
sows	O
were	O
categorized	O
into	O
six	O
groups	O
based	O
on	O
the	O
period	O
in	O
which	O
they	O
were	O
exposed	O
to	O
PED	O
virus	O
between	O
days	O
0	O
-	O
30	O
(	O
G1	O
),	O
31	O
-	O
60	O
(	O
G2	O
),	O
61	O
-	O
90	O
(	O
G3	O
),	O
or	O
after	O
91	O
days	O
of	O
pregnancy	O
(	O
G4	O
),	O
during	O
lactation	B-PROC
(	O
L	O
),	O
and	O
after	O
weaning	B-PROC
(	O
W	O
).	O

CONCLUSIONS	O
Despite	O
its	O
rare	O
occurrence	O
,	O
SR	O
due	O
to	O
B	O
.	O
microti	O
infection	O
is	O
a	O
dreaded	O
complication	O
that	O
can	O
rapidly	O
progress	O
to	O
hemorrhagic	O
shock	O
and	O
death	B-PROC
.	O

The	O
precise	O
role	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
in	O
the	O
timing	O
and	O
frequency	O
of	O
new	O
-	O
onset	O
diffuse	O
myocardial	O
calcification	B-PROC
deserves	O
further	O
investigation	O
.	O

Areas	O
covered	O
:	O
Several	O
mechanisms	O
of	O
VILI	O
have	O
been	O
described	O
,	O
such	O
as	O
:	O
inspiratory	B-PROC
and	O
/	O
or	O
expiratory	B-PROC
stress	O
inducing	O
overdistension	O
(	O
volutrauma	O
);	O
interfaces	O
between	O
collapsed	O
or	O
edema	O
-	O
filled	O
alveoli	O
with	O
surrounding	O
open	O
alveoli	O
,	O
acting	O
as	O
stress	O
raisers	O
;	O
alveoli	O
that	O
repetitively	O
open	O
and	O
close	O
during	O
tidal	O
breathing	B-PROC
(	O
atelectrauma	O
);	O
and	O
peripheral	O
airway	O
dynamics	O
.	O

TITLE	O
:	O
Exogenous	O
surfactant	O
as	O
a	O
bridge	O
to	O
prolonged	O
""""	O
total	O
lung	O
rest	O
""""	O
in	O
severely	O
injured	O
patient	O
during	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

Simultaneous	O
implementation	O
of	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
together	O
with	O
surfactant	O
application	O
allowed	O
prolonged	O
disconnection	O
of	O
patient	O
from	O
mechanical	O
ventilation	O
"("""	O
total	O
lung	O
rest	O
""""	O
mode	O
).	O

ABSTRACT	O
:	O
Dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
is	O
a	O
receptor	O
for	O
MERS	O
-	O
CoV	O
.	O
The	O
soluble	O
form	O
of	O
DPP4	O
(	O
sDPP4	O
)	O
circulates	O
systematically	O
and	O
can	O
competitively	O
inhibit	O
MERS	O
-	O
CoV	O
entry	B-PROC
into	I-PROC
host	I-PROC
cells	O
.	O

Cell	B-PROC
death	I-PROC
and	O
tissue	O
inflammation	O
form	O
a	O
positive	O
feedback	O
cycle	O
,	O
ultimately	O
leading	O
to	O
exaggerated	O
inflammation	O
and	O
development	B-PROC
of	O
disease	O
.	O

Logistic	O
regression	O
analysis	O
with	O
mortality	O
as	O
response	O
showed	O
NRBC	O
positivity	O
per	O
se	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
mortality	O
in	O
ARDS	O
with	O
a	O
doubled	O
risk	O
for	O
ICU	O
death	B-PROC
(	O
OR	O
2	O
.	O
03	O
;	O
95	O
%	O
CI	O
1	O
.	O
16	O
-	O
3	O
.	O
55	O
;	O
p	O
<	O
0	O
.	O
05	O
).	O

A	O
cutoff	O
level	O
of	O
220	O
NRBC	O
/	O
µl	O
was	O
associated	O
with	O
a	O
more	O
than	O
tripled	O
risk	O
of	O
ICU	O
death	B-PROC
(	O
OR	O
3	O
.	O
2	O
;	O
95	O
%	O
CI	O
1	O
.	O
93	O
-	O
5	O
.	O
35	O
;	O
p	O
<	O
0	O
.	O
0001	O
).	O

His	O
clinical	O
history	O
confirms	O
the	O
necessity	O
of	O
quickly	O
detecting	O
this	O
restrictive	O
syndrome	O
within	O
an	O
obstructive	O
background	O
,	O
before	O
its	O
evolution	B-PROC
towards	O
a	O
severe	O
acute	O
respiratory	O
failure	O
,	O
where	O
therapeutic	O
approximations	O
can	O
have	O
dramatic	O
repercussions	O
on	O
the	O
patient	O
'	O
s	O
health	O
.	O

NaCl	O
,	O
ventilation	O
with	O
low	O
peak	O
inspiratory	B-PROC
pressure	O
(	O
PIP	O
),	O
i	O
.	O
t	O
.	O

The	O
two	O
-	O
hit	O
lung	O
injury	O
models	O
described	O
,	O
resulting	O
in	O
additive	O
but	O
differential	O
acute	O
lung	O
injury	O
recaptures	O
the	O
clinical	O
relevant	O
multifactorial	O
etiology	O
of	O
ALI	O
and	O
could	O
be	O
a	O
valuable	O
tool	O
in	O
translational	B-PROC
research	O
.	O

Scientifically	O
,	O
H	O
.	O
cordata	O
has	O
shown	O
to	O
target	O
several	O
signaling	B-PROC
pathways	B-PROC
and	O
found	O
to	O
effectively	O
reduce	O
the	O
oxidative	O
stress	O
and	O
inflammation	O
.	O

In	O
addition	O
to	O
EVLW	O
more	O
than	O
10	O
mL	O
/	O
kg	O
,	O
PVPI	O
more	O
than	O
three	O
suggests	O
increased	B-PROC
vascular	I-PROC
permeability	I-PROC
(	O
i	O
.	O
e	O
.,	O
ARDS	O
),	O
and	O
PVPI	O
less	O
than	O
2	O
represent	O
normal	O
vascular	B-PROC
permeability	I-PROC
(	O
i	O
.	O
e	O
.,	O
cardiogenic	O
pulmonary	O
edema	O
).	O

The	O
delirium	O
duration	O
was	O
correlated	O
with	O
reduced	O
cognitive	O
performance	O
in	O
motor	B-PROC
skills	I-PROC
,	O
memory	B-PROC
function	I-PROC
,	O
and	O
learning	B-PROC
efficiency	O
.	O

ABSTRACT	O
:	O
Identification	O
of	O
cellular	O
receptors	O
used	O
by	O
coronavirus	O
(	O
CoV	O
)	O
entry	O
into	O
the	O
host	O
cells	O
is	O
critical	O
to	O
an	O
understanding	O
of	O
pathogenesis	B-PROC
and	O
to	O
development	B-PROC
of	O
intervention	O
strategies	O
.	O

No	O
antigen	O
-	O
specific	O
T	O
-	O
cell	O
immunity	B-PROC
was	O
detected	O
after	O
vaccination	O
based	O
on	O
the	O
interferon	O
-	O
γ	O
ELISpot	O
assay	O
.	O

Both	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
were	O
shown	O
to	O
express	O
proteins	O
with	O
the	O
potential	O
to	O
evade	O
early	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
.	O

The	O
Human	O
Antiviral	B-PROC
Response	I-PROC
PCR	O
array	O
was	O
used	O
to	O
profile	O
the	O
antiviral	O
gene	B-PROC
expression	I-PROC
in	O
HEK	O
-	O
293	O
cells	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
confirm	O
the	O
role	O
of	O
HCoV	O
-	O
OC43	O
structural	O
and	O
accessory	O
proteins	O
in	O
antagonising	O
antiviral	O
gene	B-PROC
expression	I-PROC
.	O

At	O
the	O
same	O
time	O
,	O
the	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
has	O
increased	O
among	O
patients	O
with	O
severe	O
ARDS	O
.	O

TITLE	O
:	O
Infection	O
,	O
genetic	O
and	O
virulence	B-PROC
characteristics	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
northwest	O
China	O
.	O

Typical	O
clinical	O
symptoms	O
of	O
the	O
disease	O
included	O
severe	O
diarrhea	O
,	O
vomiting	O
,	O
dehydration	O
and	O
death	B-PROC
.	O

In	O
order	O
to	O
identify	O
the	O
pathogen	O
,	O
27	O
intestinal	O
samples	O
were	O
collected	O
from	O
dead	B-PROC
piglets	O
in	O
Shaanxi	O
,	O
Gansu	O
and	O
Qinghai	O
provinces	O
and	O
from	O
Ningxia	O
Hui	O
Autonomous	O
Region	O
.	O

ABSTRACT	O
:	O
Recent	O
virus	O
epidemics	O
and	O
rising	O
antibiotic	O
resistance	B-PROC
highlight	O
the	O
importance	O
of	O
hygiene	O
measures	O
to	O
prevent	O
and	O
control	O
outbreaks	O
.	O

RESULTS	O
:	O
PVP	O
-	O
I	O
gargle	O
/	O
mouthwash	O
diluted	O
1	O
:	O
30	O
(	O
equivalent	O
to	O
a	O
concentration	O
of	O
0	O
.	O
23	O
%	O
PVP	O
-	O
I	O
)	O
showed	O
effective	O
bactericidal	B-PROC
activity	I-PROC
against	O
Klebsiella	O
pneumoniae	O
and	O
Streptococcus	O
pneumoniae	O
and	O
rapidly	O
inactivated	O
SARS	O
-	O
CoV	O
,	O
MERS	O
-	O
CoV	O
,	O
influenza	O
virus	O
A	O
(	O
H1N1	O
)	O
and	O
rotavirus	O
after	O
15	O
s	O
of	O
exposure	O
.	O

TITLE	O
:	O
Successful	O
Use	O
of	O
Veno	O
-	O
Venous	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
in	O
an	O
Adult	O
Patient	O
with	O
Sickle	O
Cell	O
Anemia	O
and	O
Severe	O
Acute	O
Chest	O
Syndrome	O
.	O

Here	O
,	O
we	O
report	O
the	O
effect	O
of	O
R	O
-	O
848	O
when	O
adjuvanted	O
with	O
live	O
or	O
inactivated	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
vaccines	O
with	O
special	O
emphasis	O
on	O
mucosal	B-PROC
immunity	I-PROC
.	O

ABSTRACT	O
:	O
The	O
U	O
.	O
S	O
.	O
Military	O
no	O
longer	O
maintains	O
overseas	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
capability	O
for	O
patients	O
with	O
severe	O
lung	O
injury	O
including	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

However	O
,	O
conventional	O
inactivate	O
IBV	O
vaccines	O
usually	O
elicit	O
reduced	O
mucosal	B-PROC
immune	I-PROC
responses	I-PROC
and	O
local	O
protection	O
.	O

The	O
results	O
indicated	O
that	O
IBV	O
-	O
CS	O
vaccine	O
administered	O
alone	O
or	O
associated	O
with	O
a	O
live	O
attenuated	O
heterologous	O
vaccine	O
induced	O
both	O
humoral	O
and	O
cell	O
-	O
mediated	O
immune	B-PROC
responses	I-PROC
at	O
the	O
primary	O
site	O
of	O
viral	B-PROC
replication	I-PROC
,	O
and	O
provided	O
an	O
effective	O
protection	O
against	O
IBV	O
infection	O
at	O
local	O
(	O
trachea	O
)	O
and	O
systemic	O
(	O
kidney	O
)	O
sites	O
.	O

A	O
cascade	O
of	O
events	O
tends	O
to	O
occur	O
in	O
severe	O
haemotoxic	O
envenomation	O
such	O
as	O
bleeding	O
disorders	O
,	O
hypotension	O
/	O
circulatory	B-PROC
shock	O
,	O
intravascular	O
haemolysis	B-PROC
,	O
disseminated	O
intravascular	O
coagulation	B-PROC
and	O
acute	O
respiratory	O
disease	O
syndrome	O
(	O
ARDS	O
).	O

Our	O
results	O
suggest	O
that	O
TM	O
-	O
TM	O
interactions	O
are	O
important	O
in	O
the	O
fusion	O
protein	B-PROC
function	I-PROC
of	O
diverse	O
viral	O
families	O
.	O

TITLE	O
:	O
Role	O
of	O
animal	O
movement	B-PROC
and	O
indirect	O
contact	O
among	O
farms	O
in	O
transmission	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
due	O
to	O
severe	O
influenza	O
A	O
H1N1	O
pneumonitis	O
would	O
result	O
in	O
impaired	O
pulmonary	B-PROC
functions	I-PROC
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
after	O
hospital	O
discharge	O
.	O

Pulmonary	B-PROC
functions	I-PROC
and	O
exercise	O
capacity	O
included	O
TLC	O
,	O
forced	B-PROC
vital	I-PROC
capacity	I-PROC
(	O
FVC	B-PROC
),	O
forced	B-PROC
expiratory	I-PROC
volume	I-PROC
in	O
the	O
first	O
second	O
(	O
FEV	O
The	O
impaired	O
pulmonary	B-PROC
functions	I-PROC
and	O
exercise	O
capacity	O
in	O
the	O
survivors	O
of	O
H1N1	O
-	O
ARDS	O
improved	O
soon	O
at	O
3	O
months	O
after	O
hospital	O
discharge	O
.	O

As	O
of	O
Feb	O
28	O
,	O
2018	O
,	O
2182	O
cases	O
of	O
MERS	O
-	O
CoV	O
infection	O
(	O
with	O
779	O
deaths	B-PROC
)	O
in	O
27	O
countries	O
were	O
reported	O
to	O
WHO	O
worldwide	O
,	O
with	O
most	O
being	O
reported	O
in	O
Saudi	O
Arabia	O
(	O
1807	O
cases	O
with	O
705	O
deaths	B-PROC
).	O

TITLE	O
:	O
Effects	O
of	O
hypervariable	O
regions	O
in	O
spike	O
protein	O
on	O
pathogenicity	O
,	O
tropism	B-PROC
,	O
and	O
serotypes	O
of	O
infectious	O
bronchitis	O
virus	O
.	O

There	O
were	O
no	O
instances	O
of	O
filter	O
retention	B-PROC
or	O
arterial	O
trauma	O
due	O
to	O
filter	O
manipulation	O
.	O

Forty	O
-	O
three	O
patients	O
with	O
severe	O
ARDS	O
were	O
treated	O
with	O
prone	O
positioning	O
,	O
and	O
27	O
(	O
63	O
%)	O
died	B-PROC
in	O
the	O
intensive	O
care	O
unit	O
.	O

Furthermore	O
,	O
compared	O
with	O
the	O
sham	O
treatment	O
control	O
,	O
apoptosis	B-PROC
of	O
splenic	O
cells	O
was	O
less	O
pronounced	O
in	O
the	O
splenic	O
white	O
pulp	O
of	O
treated	O
mice	O
,	O
and	O
greater	O
number	O
of	O
proliferating	O
splenic	O
cells	O
,	O
particularly	O
in	O
the	O
red	O
pulp	O
,	O
was	O
observed	O
.	O

TITLE	O
:	O
Lectin	O
Affinity	O
Plasmapheresis	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
-	O
Coronavirus	O
and	O
Marburg	O
Virus	O
Glycoprotein	O
Elimination	B-PROC
.	O

Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
(	O
ECMO	O
)	O
can	O
be	O
used	O
as	O
a	O
""""	O
bridge	O
to	O
recovery	O
"""."	O

In	O
particular	O
,	O
we	O
briefly	O
review	O
the	O
mechanism	B-PROC
of	I-PROC
action	I-PROC
of	O
neuromuscular	O
blockades	O
,	O
the	O
latest	O
published	O
evidence	O
supporting	O
their	O
use	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
current	O
recommendations	O
for	O
their	O
utilization	O
in	O
clinical	O
practice	O
.	O

Inclusion	O
criteria	O
for	O
ECMO	O
included	O
severe	O
hypoxemia	O
,	O
uncompensated	O
hypercapnia	O
,	O
or	O
elevated	O
end	O
-	O
inspiratory	B-PROC
plateau	O
pressures	O
despite	O
low	O
tidal	O
volume	O
ventilation	O
.	O

TITLE	O
:	O
Selective	O
Packaging	O
in	O
Murine	O
Coronavirus	O
Promotes	O
Virulence	B-PROC
by	O
Limiting	O
Type	O
I	O
Interferon	O
Responses	O
.	O

Antibody	B-PROC
responses	I-PROC
were	O
assessed	O
in	O
serum	O
,	O
colostrum	O
and	O
milk	O
of	O
immunized	O
gilts	O
,	O
and	O
passive	O
transfer	O
of	O
antibodies	O
was	O
evaluated	O
in	O
piglet	O
sera	O
.	O

Since	O
the	O
implementation	O
of	O
the	O
protocol	O
,	O
we	O
have	O
successfully	O
initiated	O
prone	O
positioning	O
of	O
2	O
patients	O
with	O
ARDS	O
before	O
transport	B-PROC
to	O
an	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
-	O
and	O
continuous	O
renal	O
replacement	O
therapy	O
-	O
capable	O
teaching	O
hospital	O
.	O

Interestingly	O
,	O
Th1	B-PROC
cell	I-PROC
activation	I-PROC
was	O
induced	O
by	O
immunization	O
schedules	O
including	O
Ad5	O
/	O
MERS	O
,	O
but	O
not	O
by	O
those	O
including	O
only	O
spike	O
protein	O
nanoparticles	O
.	O

We	O
found	O
that	O
the	O
virus	O
employs	O
caveolin	O
-	O
1	O
dependent	O
endocytosis	B-PROC
for	O
the	O
entry	O
and	O
the	O
scission	O
of	O
virus	O
-	O
containing	O
vesicles	O
from	O
the	O
cell	O
surface	O
is	O
dynamin	O
-	O
dependent	O
.	O

TITLE	O
:	O
A	O
fatal	O
case	O
associated	O
with	O
respiratory	O
syncytial	O
virus	B-PROC
infection	I-PROC
in	O
a	O
young	O
child	O
.	O

The	O
RSV	O
strain	O
detected	O
in	O
this	O
patient	O
was	O
subtyped	O
as	O
RSVB9	O
,	O
and	O
no	O
mutation	O
was	O
found	O
in	O
the	O
six	O
antigenic	O
sites	O
for	O
targeted	B-PROC
drugs	O
or	O
vaccines	O
.	O

Second	O
,	O
to	O
help	O
radiologists	O
differentiate	O
viral	B-PROC
infections	I-PROC
,	O
viruses	O
in	O
the	O
same	O
viridae	O
that	O
have	O
similar	O
pathogenesis	B-PROC
and	O
can	O
have	O
similar	O
imaging	O
characteristics	O
are	O
shown	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
fluorescent	O
reverse	B-PROC
transcription	B-PROC
loop	O
-	O
mediated	O
isothermal	O
amplification	O
(	O
RT	O
-	O
LAMP	O
)	O
using	O
quenching	O
probes	O
for	O
the	O
detection	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

China	O
has	O
experienced	O
unprecedented	O
economic	O
growth	B-PROC
since	O
the	O
1980s	O
.	O

Integration	B-PROC
of	O
additional	O
Big	O
Data	O
sources	O
and	O
advances	O
in	O
analytical	O
capacity	O
could	O
further	O
strengthen	O
the	O
GPHIN	O
'	O
s	O
capability	O
for	O
timely	O
detection	O
and	O
early	O
warning	O
.	O

We	O
determined	O
that	O
GS	O
-	O
441524	O
was	O
non	O
-	O
toxic	O
in	O
feline	O
cells	O
at	O
concentrations	O
as	O
high	O
as	O
100	O
uM	O
and	O
effectively	O
inhibited	O
FIPV	O
replication	O
in	O
cultured	O
CRFK	O
cells	O
and	O
in	O
naturally	O
infected	O
feline	O
peritoneal	O
macrophages	O
at	O
concentrations	O
as	O
low	O
as	O
1	O
uM	O
.	O
We	O
determined	O
the	O
pharmacokinetics	B-PROC
of	O
GS	O
-	O
441524	O
in	O
cats	O
in	O
vivo	O
and	O
established	O
a	O
dosage	O
that	O
would	O
sustain	O
effective	O
blood	O
levels	O
for	O
24	O
h	O
.	O
In	O
an	O
experimental	O
FIPV	O
infection	O
of	O
cats	O
,	O
GS	O
-	O
441524	O
treatment	O
caused	O
a	O
rapid	O
reversal	O
of	O
disease	O
signs	O
and	O
return	O
to	O
normality	O
with	O
as	O
little	O
as	O
two	O
weeks	O
of	O
treatment	O
in	O
10	O
/	O
10	O
cats	O
and	O
with	O
no	O
apparent	O
toxicity	O
.	O

TITLE	O
:	O
HCoV	O
-	O
229E	O
spike	O
protein	O
fusion	O
activation	O
by	O
trypsin	O
-	O
like	O
serine	O
proteases	O
is	O
mediated	O
by	O
proteolytic	B-PROC
processing	I-PROC
in	O
the	O
S2	O
'	O
region	O
.	O

Using	O
Au	O
NP	O
-	O
modified	O
graphene	O
nanosheet	O
(	O
Au	O
-	O
GN	O
)	O
as	O
the	O
substrate	O
,	O
antibody	B-PROC
-	O
antigen	O
reaction	O
as	O
the	O
recognition	O
unit	O
,	O
rolling	O
circle	O
amplification	O
(	O
RCA	O
)	O
for	O
signal	O
enhancement	O
,	O
and	O
assembled	O
cascade	O
Ru	O
-	O
DNA	O
nanotags	O
as	O
signal	O
label	O
,	O
the	O
proposed	O
platform	O
behaved	O
with	O
good	O
specificity	O
and	O
sensitivity	O
.	O

TITLE	O
:	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
for	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

RESULTS	O
:	O
At	O
60	O
days	O
,	O
44	O
of	O
124	O
patients	O
(	O
35	O
%)	O
in	O
the	O
ECMO	O
group	O
and	O
57	O
of	O
125	O
(	O
46	O
%)	O
in	O
the	O
control	O
group	O
had	O
died	B-PROC
(	O
relative	O
risk	O
,	O
0	O
.	O
76	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
0	O
.	O
55	O
to	O
1	O
.	O
04	O
;	O
P	O
=	O
0	O
.	O
09	O
).	O

METHODS	O
:	O
A	O
focused	O
set	O
of	O
thienyl	O
chalcone	O
derivaties	O
II	O
-	O
VI	O
was	O
screened	O
for	O
selected	O
viruses	O
Hepatitis	O
B	O
virus	O
(	O
HBV	O
),	O
Herpes	O
simplex	O
virus	O
1	O
(	O
HSV	O
-	O
1	O
),	O
Human	O
cytomegalovirus	O
(	O
HCMV	O
),	O
Dengue	O
virus	O
2	O
(	O
DENV2	O
),	O
Influenza	O
A	O
(	O
H1N1	O
)	O
virus	O
,	O
MERS	O
coronavirus	O
,	O
Poliovirus	O
1	O
(	O
PV	O
1	O
),	O
Rift	O
Valley	O
fever	B-PROC
(	O
RVF	O
),	O
Tacaribe	O
virus	O
(	O
TCRV	O
),	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
(	O
VEE	O
)	O
and	O
Zika	O
virus	O
(	O
ZIKV	O
)	O
using	O
the	O
National	O
Institute	O
of	O
Allergy	B-PROC
and	O
Infectious	O
Diseases	O
(	O
NIAID	O
)'	O
s	O
Division	O
of	O
Microbiology	O
and	O
Infectious	O
Diseases	O
(	O
DMID	O
)	O
antiviral	O
screening	O
program	O
.	O

On	O
these	O
models	O
,	O
pathogenesis	B-PROC
and	O
epidemiology	O
of	O
these	O
diseases	O
were	O
studied	O
.	O

Several	O
important	O
pathogenic	O
mechanisms	O
common	O
for	O
various	O
hemorrhagic	O
fevers	B-PROC
were	O
studied	O
on	O
experimental	O
SHF	O
of	O
macaques	O
.	O

To	O
assess	O
the	O
association	O
of	O
qSOFA	O
with	O
excess	O
hospital	O
death	B-PROC
among	O
patients	O
with	O
suspected	O
infection	O
in	O
LMICs	O
and	O
to	O
compare	O
qSOFA	O
with	O
the	O
systemic	O
inflammatory	B-PROC
response	I-PROC
syndrome	O
(	O
SIRS	O
)	O
criteria	O
.	O

The	O
results	O
demonstrated	O
that	O
PEDV	O
infection	O
induces	O
cell	B-PROC
cycle	I-PROC
arrest	I-PROC
at	O
G0	O
/	O
G1	B-PROC
phase	I-PROC
in	O
Vero	O
cells	O
,	O
while	O
UV	O
-	O
inactivated	O
PEDV	O
does	O
not	O
cause	O
cell	B-PROC
cycle	I-PROC
arrest	I-PROC
.	O

In	O
addition	O
,	O
PEDV	O
infection	O
of	O
the	O
cells	O
synchronized	O
in	O
various	O
stages	O
of	O
cell	B-PROC
cycle	I-PROC
showed	O
that	O
viral	O
subgenomic	O
RNA	O
and	O
virus	O
titer	O
were	O
higher	O
in	O
the	O
cells	O
released	O
from	O
G0	O
/	O
G1	B-PROC
phase	I-PROC
synchronized	O
cells	O
than	O
that	O
in	O
the	O
cells	O
released	O
from	O
the	O
G1	O
/	O
S	B-PROC
phase	I-PROC
and	O
G2	O
/	O
M	B-PROC
phase	I-PROC
synchronized	O
or	O
asynchronous	O
cells	O
after	O
18	O
h	O
p	O
.	O
i	O
..	O

The	O
identified	O
critical	O
residues	O
by	O
MD	O
simulation	O
and	O
residues	O
at	O
the	O
a	O
and	O
d	O
positions	O
of	O
HR	O
helix	O
were	O
strong	O
stabilizers	B-PROC
of	O
HR	O
recognition	O
.	O

ABSTRACT	O
:	O
Chimeric	O
antigen	O
receptor	O
(	O
CAR	O
)	O
therapy	O
targeting	B-PROC
CD19	O
is	O
an	O
effective	O
treatment	O
for	O
refractory	O
B	O
cell	O
malignancies	O
,	O
especially	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O

TITLE	O
:	O
Development	B-PROC
of	O
pooled	O
testing	O
system	O
for	O
porcine	O
epidemic	O
diarrhoea	O
using	O
real	O
-	O
time	O
fluorescent	O
reverse	O
-	O
transcription	B-PROC
loop	O
-	O
mediated	O
isothermal	O
amplification	O
assay	O
.	O

Our	O
data	O
provide	O
new	O
insights	O
into	O
the	O
specific	O
antibody	B-PROC
repertoires	O
and	O
the	O
molecular	O
determinants	O
of	O
neutralization	O
during	O
natural	O
MERS	O
-	O
CoV	O
infection	O
in	O
humans	O
.	O

Regarding	O
perioperative	O
administration	O
of	O
sivelestat	O
sodium	O
hydrate	O
,	O
the	O
postoperative	O
arterial	O
oxygen	B-PROC
partial	I-PROC
pressure	I-PROC
-	O
to	O
-	O
fractional	O
inspired	B-PROC
oxygen	O
ratio	O
(	O
P	O
/	O
F	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
levels	O
in	O
the	O
administration	O
group	O
were	O
significantly	O
better	O
than	O
those	O
in	O
the	O
non	O
-	O
administration	O
group	O
on	O
postoperative	O
days	O
4	O
(	O
P	O
=	O
0	O
.	O
035	O
)	O
and	O
5	O
(	O
P	O
=	O
0	O
.	O
037	O
),	O
respectively	O
.	O

It	O
is	O
linked	O
to	O
common	O
cold	B-PROC
symptoms	O
in	O
healthy	O
adults	O
.	O

She	O
needed	O
immediate	O
oxygen	O
supply	O
,	O
while	O
ABGs	O
deteriorated	O
and	O
chest	O
imaging	O
and	O
PaO	B-PROC

Since	O
the	O
first	O
case	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
was	O
reported	O
on	O
May	O
20	O
,	O
2015	O
in	O
South	O
Korea	O
,	O
186	O
people	O
,	O
including	O
health	O
care	O
workers	O
,	O
were	O
infected	O
,	O
and	O
36	O
died	B-PROC
.	O

RevMan	O
software	O
from	O
the	O
Cochrane	O
Collaboration	O
was	O
used	O
to	O
a	O
conduct	B-PROC
meta	O
-	O
analysis	O
.	O

This	O
leads	O
to	O
an	O
impaired	O
translation	B-PROC
of	O
viral	O
RNA	O
.	O

ABSTRACT	O
:	O
Malaria	O
is	O
a	O
serious	O
disease	O
and	O
was	O
responsible	O
for	O
429	O
,	O
000	O
deaths	B-PROC
in	O
2015	O
.	O

With	O
a	O
rapid	O
increase	O
in	O
the	O
number	O
of	O
VNP	O
variants	O
and	O
their	O
potential	O
applications	O
in	O
nanomedicine	O
,	O
the	O
properties	O
they	O
acquire	O
in	O
the	O
bloodstream	B-PROC
need	O
to	O
be	O
investigated	O
.	O

Here	O
we	O
describe	O
a	O
few	O
general	O
methods	O
to	O
isolate	O
and	O
study	O
the	O
VNP	O
-	O
protein	O
corona	O
complexes	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
impact	O
of	O
protein	O
corona	O
on	O
molecular	B-PROC
recognition	I-PROC
of	O
VNPs	O
by	O
target	O
cells	O
,	O
and	O
clearance	O
by	O
phagocytes	O
.	O

TITLE	O
:	O
Ulk1	O
Governs	O
Nerve	O
Growth	B-PROC
Factor	O
/	O
TrkA	O
Signaling	B-PROC
by	O
Mediating	O
Rab5	O
GTPase	O
Activation	O
in	O
Porcine	O
Hemagglutinating	O
Encephalomyelitis	O
Virus	O
-	O
Induced	O
Neurodegenerative	O
Disorders	O
.	O

Morphogenesis	B-PROC
assessments	O
in	O
the	O
primary	O
cortical	O
neurons	O
revealed	O
that	O
overexpression	B-PROC
or	O
mutations	O
of	O
Ulk1	O
modulated	O
neurite	B-PROC
outgrowth	I-PROC
,	O
collateral	B-PROC
sprouting	I-PROC
,	O
and	O
endosomal	B-PROC
transport	B-PROC
.	O

These	O
activated	O
macrophages	O
ingested	O
antigen	O
and	O
migrated	O
to	O
pulmonary	O
lymph	O
nodes	O
,	O
and	O
enhanced	O
both	O
innate	O
and	O
adaptive	O
immunity	B-PROC
after	O
heterologous	O
virus	B-PROC
infection	I-PROC
.	O

Together	O
,	O
the	O
data	O
indicate	O
that	O
the	O
nose	O
and	O
upper	O
airway	O
remotely	O
prime	O
the	O
lung	O
immunity	B-PROC
to	O
protect	O
the	O
lungs	O
from	O
direct	O
viral	B-PROC
infections	I-PROC
.	O

Positive	O
end	O
expiratory	B-PROC
pressure	O
and	O
serum	O
creatinine	O
are	O
independently	O
associated	O
with	O
AKI	O
.	O

Demographics	O
,	O
total	O
body	O
surface	O
area	O
(	O
TBSA	O
)	O
burn	O
,	O
the	O
presence	O
of	O
mouth	O
and	O
nose	O
burn	O
,	O
ABSI	O
,	O
inhalation	B-PROC
injury	O
,	O
and	O
clinical	O
outcomes	O
for	O
each	O
patient	O
were	O
analysed	O
for	O
association	O
with	O
inpatient	O
ARDS	O
based	O
on	O
the	O
Berlin	O
definition	O
.	O

TITLE	O
:	O
Antiviral	O
drug	O
screening	O
by	O
assessing	O
epithelial	O
functions	O
and	O
innate	B-PROC
immune	I-PROC
responses	I-PROC
in	O
human	O
3D	O
airway	O
epithelium	O
model	O
.	O

MucilAir	O
™,	O
a	O
human	O
standardized	O
air	O
-	O
liquid	O
interface	O
3D	O
airway	O
epithelial	O
culture	O
holds	O
in	O
vitro	O
specific	O
mechanisms	O
to	O
counter	O
invaders	O
comparable	O
to	O
the	O
in	O
vivo	O
situation	O
,	O
such	O
as	O
mucus	B-PROC
production	I-PROC
,	O
mucociliary	O
clearance	O
,	O
and	O
secretion	B-PROC
of	O
defensive	O
molecules	O
.	O

TITLE	O
:	O
Rapid	O
development	B-PROC
and	O
evaluation	O
of	O
a	O
live	O
-	O
attenuated	O
QX	O
-	O
like	O
infectious	O
bronchitis	O
virus	O
vaccine	O
.	O

In	O
this	O
study	O
,	O
we	O
established	O
a	O
nucleic	O
acid	O
visualization	O
technique	O
that	O
combines	O
the	O
reverse	B-PROC
transcription	B-PROC
loop	O
-	O
mediated	O
isothermal	O
amplification	O
technique	O
and	O
a	O
vertical	O
flow	O
visualization	O
strip	O
(	O
RT	O
-	O
LAMP	O
-	O
VF	O
)	O
to	O
detect	O
the	O
N	O
gene	O
of	O
MERS	O
-	O
CoV	O
.	O
The	O
RT	O
-	O
LAMP	O
-	O
VF	O
assay	O
was	O
performed	O
in	O
a	O
constant	O
temperature	O
water	O
bath	O
for	O
30	O
min	O
,	O
and	O
the	O
result	O
was	O
visible	O
by	O
the	O
naked	O
eye	O
within	O
5	O
min	O
.	O

ABSTRACT	O
:	O
Cases	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
continue	O
to	O
occur	O
,	O
making	O
it	O
one	O
of	O
the	O
WHO	O
´	O
s	O
targets	O
for	O
accelerated	O
vaccine	O
development	B-PROC
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
N	O
protein	O
causes	O
endoplasmic	O
reticulum	O
stress	O
,	O
up	O
-	O
regulates	O
interleukin	O
-	O
8	O
expression	B-PROC
and	O
its	O
subcellular	O
localization	B-PROC
in	O
the	O
porcine	O
intestinal	O
epithelial	O
cell	O
.	O

But	O
the	O
incidence	O
of	O
AKI	O
and	O
the	O
total	O
fluid	O
volume	O
during	O
EGDT	O
were	O
not	O
significantly	O
different	O
between	O
the	O
senior	O
group	O
and	O
the	O
younger	O
group	O
[	O
incidence	O
of	O
AKI	O
:	O
74	O
.	O
1	O
％	O
(	O
152	O
/	O
205	O
)	O
vs	O
.	O
69	O
.	O
4	O
％	O
(	O
213	O
/	O
307	O
),	O
total	O
fluid	O
volume	O
(	O
mL	O
):	O
2	O
769	O
±	O
1	O
589	O
vs	O
.	O
2	O
804	O
±	O
1	O
611	O
,	O
both	O
P	O
＞	O
0	O
.	O
05	O
].	O
Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
incidence	O
of	O
ARDS	O
was	O
higher	O
in	O
the	O
high	O
-	O
PCT	O
group	O
[	O
86	O
.	O
4	O
％	O
(	O
133	O
/	O
154	O
)	O
vs	O
.	O
78	O
.	O
5	O
％	O
(	O
281	O
/	O
358	O
),	O
P	O
＜	O
0	O
.	O
05	O
].	O
But	O
the	O
incidences	O
of	O
AKI	O
and	O
cardiac	O
insufficiency	O
were	O
not	O
significantly	O
differentiated	B-PROC
between	O
the	O
high	O
-	O
PCT	O
group	O
and	O
the	O
control	O
group	O
[	O
77	O
.	O
9	O
％	O
(	O
120	O
/	O
154	O
)	O
vs	O
.	O
68	O
.	O
4	O
％	O
(	O
245	O
/	O
358	O
),	O
58	O
.	O
4	O
％	O
(	O
90	O
/	O
154	O
)	O
vs	O
.	O
63	O
.	O
4	O
％	O
(	O
227	O
/	O
358	O
),	O
both	O
P	O
＞	O
0	O
.	O
05	O
].	O
Multiple	O
logistic	O
regression	O
analysis	O
showed	O
that	O
the	O
risk	O
factors	O
of	O
increase	O
in	O
mortality	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
septic	O
shock	O
included	O
old	O
age	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1	O
.	O
782	O
,	O
95	O
％	O
confidence	O
interval	O
(	O
95	O
％	O
CI	O
)	O
=	O
1	O
.	O
173	O
-	O
2	O
.	O
708	O
,	O
P	O
=	O
0	O
.	O
007	O
],	O
ARDS	O
(	O
OR	O
=	O
1	O
.	O
786	O
,	O
95	O
％	O
CI	O
=	O
1	O
.	O
028	O
-	O
3	O
.	O
102	O
,	O
P	O
=	O
0	O
.	O
040	O
),	O
AKI	O
(	O
OR	O
=	O
1	O
.	O
878	O
,	O
95	O
％	O
CI	O
=	O
1	O
.	O
145	O
-	O
3	O
.	O
079	O
,	O
P	O
=	O
0	O
.	O
012	O
),	O
and	O
cardiac	O
insufficiency	O
(	O
OR	O
=	O
4	O
.	O
177	O
,	O
95	O
％	O
CI	O
=	O
2	O
.	O
505	O
-	O
6	O
.	O
966	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
except	O
for	O
gender	O
(	O
OR	O
=	O
1	O
.	O
112	O
,	O
95	O
％	O
CI	O
=	O
0	O
.	O
736	O
-	O
1	O
.	O
680	O
,	O
P	O
=	O
0	O
.	O
614	O
).	O

The	O
contact	O
-	O
dependent	O
growth	B-PROC
inhibition	B-PROC
toxin	O
CdiA	O
-	O
CT	O

The	O
other	O
two	O
trials	O
reported	O
the	O
lowest	O
peripheral	O
capillary	B-PROC
oxygen	I-PROC
saturation	I-PROC
readings	O
during	O
bronchoscopy	O
or	O
intubation	O
.	O

Sera	O
were	O
tested	O
for	O
CRCoV	O
antibody	B-PROC
using	O
competitive	O
ELISA	O
and	O
results	O
expressed	B-PROC
as	O
percent	O
of	O
inhibition	B-PROC
(	O
POI	O
).	O

Making	O
use	O
of	O
our	O
already	O
described	O
animal	O
model	O
of	O
HCoV	O
neuropathogenesis	O
,	O
we	O
describe	O
the	O
route	O
of	O
neuropropagation	O
from	O
the	O
nasal	O
cavity	O
to	O
the	O
olfactory	B-PROC
bulb	O
and	O
piriform	O
cortex	O
and	O
then	O
the	O
brain	O
stem	O
.	O

Our	O
work	O
,	O
therefore	O
,	O
identifies	O
processes	O
that	O
may	O
govern	O
the	O
severity	O
and	O
nature	O
of	O
HCoV	O
OC43	O
neuropathogenesis	O
and	O
will	O
make	O
possible	O
the	O
development	B-PROC
of	O
therapeutic	O
strategies	O
to	O
prevent	O
occurrences	O
.	O

TITLE	O
:	O
Prolonged	O
Evolution	B-PROC
of	O
Virus	O
-	O
Specific	O
Memory	B-PROC
T	O
Cell	O
Immunity	B-PROC
after	O
Severe	O
Avian	O
Influenza	O
A	O
(	O
H7N9	O
)	O
Virus	B-PROC
Infection	I-PROC
.	O

Humoral	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
were	O
analyzed	O
in	O
sequential	O
samples	O
obtained	O
at	O
1	O
.	O
5	O
to	O
4	O
months	O
,	O
6	O
to	O
8	O
months	O
,	O
and	O
12	O
to	O
15	O
months	O
postinfection	O
.	O

The	O
patient	O
died	B-PROC
on	O
day	O
25	O
post	O
-	O
transplantation	O
secondary	O
to	O
the	O
development	B-PROC
of	O
hemophagocytic	O
syndrome	O
and	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
Poliovirus	O
induces	O
autophagic	O
signaling	B-PROC
independent	O
of	O
the	O
ULK1	O
complex	O
.	O

Our	O
data	O
suggest	O
that	O
PV	O
has	O
a	O
finely	O
-	O
tuned	O
relationship	O
with	O
the	O
autophagic	O
machinery	O
,	O
generating	O
autophagosomes	O
without	O
using	O
the	O
primary	O
autophagy	B-PROC
signaling	B-PROC
pathway	I-PROC
.	O

With	O
a	O
multidisciplinary	O
translational	B-PROC
approach	O
,	O
we	O
studied	O
EVs	O
from	O
the	O
blood	O
of	O
33	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
.	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
induces	O
caspase	B-PROC
-	I-PROC
dependent	I-PROC
apoptosis	B-PROC
through	O
activation	O
of	O
the	O
cytochrome	B-PROC
c	I-PROC
-	O
mediated	O
intrinsic	O
mitochondrial	O
pathway	B-PROC
.	O

The	O
ELISA	O
results	O
showed	O
that	O
higher	O
level	O
of	O
secreted	B-PROC
IL	O
-	O
1beta	O
varies	O
,	O
depending	O
on	O
the	O
viral	O
interference	O
conditions	O
between	O
both	O
viruses	O
,	O
during	O
mixed	O
infections	O
.	O

TITLE	O
:	O
Effects	O
of	O
dietary	O
yeast	O
nucleotides	O
supplementation	O
on	O
intestinal	O
barrier	O
function	O
,	O
intestinal	O
microbiota	O
,	O
and	O
humoral	B-PROC
immunity	I-PROC
in	O
specific	O
pathogen	O
-	O
free	O
chickens	O
.	O

At	O
day	O
17	O
,	O
the	O
intestinal	B-PROC
development	B-PROC
,	O
expression	B-PROC
of	O
intestinal	O
barrier	O
-	O
related	O
genes	O
and	O
microbiota	O
were	O
evaluated	O
.	O

TITLE	O
:	O
A	O
Novel	O
Nanobody	O
Targeting	B-PROC
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
Receptor	O
-	O
Binding	O
Domain	O
Has	O
Potent	O
Cross	O
-	O
Neutralizing	O
Activity	O
and	O
Protective	O
Efficacy	O
against	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
The	O
newly	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
continues	O
to	O
infect	O
humans	O
and	O
camels	O
,	O
calling	O
for	O
efficient	O
,	O
cost	O
-	O
effective	O
,	O
and	O
broad	O
-	O
spectrum	O
strategies	O
to	O
control	O
its	O
spread	O
.	O

TITLE	O
:	O
Organelle	O
dynamics	O
and	O
viral	B-PROC
infections	I-PROC
:	O
at	O
cross	O
roads	O
.	O

TITLE	O
:	O
Lead	O
Molecule	O
Prediction	O
and	O
Characterization	O
for	O
Designing	O
MERS	O
-	O
CoV	O
3C	O
-	O
like	O
Protease	B-PROC
Inhibitors	I-PROC
:	O
An	O
In	O
silico	O
Approach	O
.	O

Lead	O
like	O
compounds	O
and	O
drug	O
molecules	O
which	O
are	O
capable	O
of	O
inhibiting	O
3C	O
-	O
like	O
protease	O
was	O
identified	O
by	O
structure	O
-	O
based	O
virtual	O
screening	O
and	O
ligand	B-PROC
-	O
based	O
virtual	O
screening	O
method	O
.	O

Further	O
,	O
the	O
compounds	O
were	O
validated	O
through	O
absorption	O
,	O
distribution	O
,	O
metabolism	B-PROC
and	O
excretion	B-PROC
filtering	O
.	O

RESULTS	O
87	O
(	O
22	O
.	O
9	O
%)	O
cats	O
died	B-PROC
or	O
were	O
euthanized	O
before	O
discharge	O
from	O
the	O
hospital	O
.	O

Tracheal	O
aspirate	O
culture	O
and	O
blood	O
culture	O
showed	O
bacterial	O
growth	B-PROC
of	O
Cupriavidus	O
pauculus	O
.	O

Clinical	O
improvement	O
cannot	O
always	O
be	O
expected	O
in	O
spite	O
of	O
targeted	B-PROC
antibiotic	O
therapy	O
.	O

All	O
infected	O
pigs	O
showed	O
clinical	O
signs	O
with	O
the	O
non	O
-	O
InDel	B-PROC
strain	O
although	O
only	O
the	O
inoculated	O
and	O
direct	O
contact	O
pigs	O
showed	O
clinical	O
signs	O
in	O
the	O
InDel	B-PROC
strain	O
group	O
.	O

We	O
report	O
herein	O
on	O
the	O
successful	O
treatment	O
of	O
a	O
two	O
-	O
year	O
-	O
old	O
female	O
child	O
with	O
TB	O
pneumonia	O
-	O
induced	O
severe	O
ARDS	O
complicated	O
with	O
disseminated	O
intravascular	O
coagulation	B-PROC
(	O
DIC	O
).	O

FVW	O
at	O
the	O
6	O
%	O
level	O
can	O
be	O
used	O
as	O
a	O
potential	O
phytogenic	O
feed	O
stuff	O
in	O
growing	O
layer	O
hen	O
rations	O
with	O
respect	O
to	O
improving	O
the	O
immune	B-PROC
response	I-PROC
without	O
affecting	O
normal	O
weight	O
gain	O
.	O

The	O
National	O
Institute	O
of	O
Health	O
/	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
Panel	O
redefined	O
sepsis	O
as	O
a	O
""""	O
severe	O
endothelial	O
dysfunction	O
syndrome	O
in	O
response	O
to	O
intravascular	O
and	O
extravascular	O
infections	O
causing	O
reversible	O
or	O
irreversible	O
injury	O
to	O
the	O
microcirculation	B-PROC
responsible	O
for	O
multiple	O
organ	O
failure	O
.	O

While	O
very	O
early	O
control	O
of	O
sepsis	O
-	O
causing	O
bacterial	O
,	O
fungal	O
and	O
viral	B-PROC
infections	I-PROC
remains	O
crucial	O
for	O
the	O
treatment	O
of	O
sepsis	O
,	O
supportive	O
measures	O
are	O
likewise	O
necessary	O
to	O
maintain	O
blood	B-PROC
pressure	I-PROC
,	O
respiration	B-PROC
,	O
and	O
kidney	B-PROC
function	I-PROC
.	O

Nevertheless	O
,	O
formal	O
evaluation	O
of	O
the	O
responses	O
to	O
previous	O
public	O
health	O
emergencies	O
have	O
sometimes	O
been	O
limited	O
,	O
so	O
lessons	O
learned	B-PROC
may	O
not	O
be	O
reflected	O
in	O
updated	O
plans	O
,	O
thereby	O
risking	O
mistakes	O
being	O
repeated	O
in	O
future	O
.	O

By	O
double	O
IF	O
and	O
TUNEL	O
staining	O
,	O
most	O
PDCoV	O
antigen	O
-	O
positive	O
IPEC	O
-	O
J2	O
cells	O
failed	O
to	O
show	O
TUNEL	O
-	O
positive	O
signals	O
,	O
indicating	O
that	O
PDCoV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	O
may	O
not	O
undergo	O
apoptosis	B-PROC
,	O
but	O
rather	O
necrosis	B-PROC
,	O
similar	O
to	O
necrotic	B-PROC
cell	B-PROC
death	I-PROC
of	O
infected	O
enterocytes	O
in	O
vivo	O
.	O

Meanwhile	O
,	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
in	O
the	O
neutralizing	O
epitopes	O
may	O
have	O
conferred	O
the	O
capacity	O
for	O
immune	B-PROC
evasion	I-PROC
in	O
these	O
PEDV	O
field	O
strains	O
.	O

Since	O
its	O
first	O
description	O
,	O
it	O
has	O
undergone	O
intensive	O
research	O
in	O
the	O
past	O
few	O
decades	O
to	O
understand	O
its	O
pathogenesis	B-PROC
and	O
therapies	O
.	O

TITLE	O
:	O
Production	O
of	O
Recombinant	O
N	O
Protein	O
of	O
Infectious	O
Bronchitis	O
Virus	O
Using	O
the	O
Baculovirus	O
Expression	B-PROC
System	O
and	O
Its	O
Assessment	O
as	O
a	O
Diagnostic	O
Antigen	O
.	O

TITLE	O
:	O
Gastrointestinal	O
microbiota	O
contributes	O
to	O
the	O
development	B-PROC
of	O
murine	O
transfusion	O
-	O
related	O
acute	O
lung	O
injury	O
.	O

Heatmap	O
cluster	O
analysis	O
showed	O
that	O
the	O
vast	O
majority	O
of	O
the	O
viral	O
groups	O
were	O
differentially	O
expressed	B-PROC
in	O
miRNA	O
compared	O
with	O
the	O
control	O
group	O
,	O
Go	O
analysis	O
showed	O
that	O
miRNAs	O
are	O
widely	O
involved	O
in	O
combination	O
,	O
binding	O
protein	O
,	O
protein	O
kinase	O
activity	O
,	O
transfer	O
enzyme	O
activity	O
,	O
phosphorus	O
containing	O
radicals	O
transfer	O
,	O
phosphotransferase	O
enzyme	O
activity	O
and	O
other	O
biological	O
effects	O
.	O

The	O
key	O
residues	O
for	O
binding	O
are	O
identified	O
through	O
site	B-PROC
-	I-PROC
directed	I-PROC
mutagenesis	I-PROC
.	O

This	O
case	O
report	O
describes	O
an	O
example	O
in	O
which	O
intraoperative	O
prone	O
positioning	O
improved	O
oxygenation	B-PROC
in	O
a	O
patient	O
after	O
aspiration	O
of	O
gastric	O
contents	O
on	O
induction	O
of	O
general	B-PROC
anesthesia	I-PROC
.	O

The	O
performance	O
of	O
FilmArray	O
Respiratory	O
Panel	O
,	O
AnyplexII	O
RV16	O
,	O
and	O
Argene	O
was	O
compared	O
using	O
clinical	O
respiratory	O
samples	O
(	O
n	O
=	O
224	O
,	O
comprising	O
189	O
nasopharyngeal	O
swabs	O
in	O
Universal	O
Transport	B-PROC
Medium	O
(	O
UTM	O
)	O
and	O
35	O
endotracheal	O
aspirates	O
),	O
based	O
on	O
common	O
overlapping	O
targets	O
across	O
the	O
platforms	O
.	O

Two	O
patients	O
(	O
2	O
%)	O
died	B-PROC
.	O

Two	O
patients	O
(	O
2	O
%)	O
died	B-PROC
.	O

Coombs	O
and	O
Gell	O
classified	O
hypersensitivity	B-PROC
reactions	I-PROC
into	O
four	O
forms	O
.	O

In	O
this	O
study	O
,	O
we	O
reexamined	O
furin	O
usage	O
by	O
MERS	O
-	O
CoV	O
using	O
a	O
real	O
-	O
time	O
PCR	O
-	O
based	O
virus	O
cell	O
entry	O
assay	O
after	O
inhibition	B-PROC
of	O
cellular	O
proteases	O
.	O

Along	O
with	O
clinical	O
and	O
demographic	O
data	O
,	O
early	O
measurements	O
of	O
plasma	O
biomarkers	O
such	O
as	O
TIMP	O
-	O
3	O
may	O
help	O
identify	O
patients	O
at	O
higher	O
risk	O
of	O
ARDS	O
and	O
death	B-PROC
after	O
severe	O
isolated	O
TBI	O
.	O

An	O
open	O
lung	O
strategy	O
with	O
a	O
stepwise	O
recruitment	O
maneuver	O
permitted	O
a	O
higher	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
and	O
improved	O
oxygenation	B-PROC
without	O
any	O
cardiac	O
impairment	O
.	O

One	O
reason	O
that	O
picornaviruses	O
induce	O
the	O
autophagy	B-PROC
pathway	B-PROC
is	O
to	O
provide	O
membrane	O
scaffolds	O
for	O
RNA	B-PROC
replication	I-PROC
complexes	O
.	O

ABSTRACT	O
:	O
The	O
molecular	O
mechanisms	O
underlying	O
the	O
pathogenesis	B-PROC
of	O
human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
infection	O
are	O
poorly	O
understood	O
.	O

Notably	O
,	O
tractable	O
mouse	O
genetics	O
combined	O
with	O
hCoV	O
reverse	O
genetic	O
systems	O
has	O
afforded	O
the	O
concomitant	O
manipulation	O
of	O
virus	O
and	O
host	O
genetics	O
to	O
evaluate	O
virus	B-PROC
-	I-PROC
host	I-PROC
interaction	I-PROC
networks	O
in	O
disease	O
.	O

MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
is	O
a	O
key	O
target	O
for	O
development	B-PROC
of	O
MERS	O
vaccines	O
.	O

In	O
this	O
review	O
,	O
we	O
illustrate	O
the	O
structure	O
and	O
function	O
of	O
S	O
protein	O
as	O
a	O
vaccine	O
target	O
,	O
describe	O
available	O
animal	O
models	O
for	O
evaluating	O
MERS	O
vaccines	O
,	O
and	O
summarize	O
recent	O
progress	O
on	O
MERS	O
-	O
CoV	O
S	O
-	O
based	O
vaccines	O
,	O
focusing	O
on	O
their	O
ability	O
to	O
elicit	O
antibody	B-PROC
and	O
/	O
or	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
,	O
neutralizing	O
antibodies	O
,	O
and	O
protection	O
against	O
MERS	O
-	O
CoV	O
infection	O
in	O
different	O
models	O
.	O

Distinctively	O
high	O
frequencies	O
of	O
MERS	O
coronavirus	O
-	O
reactive	O
CD8	O
+	O
T	O
cells	O
were	O
also	O
observed	O
in	O
patients	O
with	O
severe	O
/	O
moderate	O
illness	O
,	O
whereas	O
antibody	B-PROC
and	O
CD4	O
+	O
T	O
-	O
cell	O
responses	O
were	O
minimally	O
detected	O
at	O
this	O
stage	O
.	O

At	O
the	O
convalescent	O
phase	O
,	O
disease	O
severity	O
-	O
dependent	O
antibody	B-PROC
responses	I-PROC
emerged	O
and	O
antigen	O
-	O
reactive	O
cells	O
were	O
identified	O
in	O
both	O
T	O
-	O
cell	O
subsets	O
.	O

Here	O
,	O
we	O
constructed	O
expression	B-PROC
plasmids	O
as	O
well	O
as	O
recombinant	O
PEDV	O
carrying	O
myc	O
-	O
tagged	O
ORF3	O
to	O
assess	O
their	O
expression	B-PROC
and	O
subcellular	O
localization	B-PROC
in	O
both	O
transfected	O
and	O
infected	O
cells	O
.	O

We	O
also	O
demonstrated	O
that	O
both	O
full	O
-	O
length	O
and	O
naturally	O
truncated	O
ORF3	O
proteins	O
could	O
interact	O
with	O
the	O
S	O
protein	O
but	O
with	O
different	O
binding	O
affinity	O
,	O
which	O
correlate	O
with	O
the	O
ability	O
of	O
the	O
protein	O
to	O
regulate	O
virus	B-PROC
replication	I-PROC
in	O
cell	O
culture	O
.	O

Owing	O
to	O
its	O
antigenic	B-PROC
variation	I-PROC
,	O
prevention	O
of	O
the	O
diseases	O
caused	O
by	O
this	O
virus	O
is	O
difficult	O
.	O

Several	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
-	O
approved	O
therapies	O
exist	O
that	O
impede	O
activated	O
lymphocytes	O
from	O
entering	O
the	O
CNS	O
thereby	O
limiting	O
new	O
lesion	O
formation	B-PROC
in	O
patients	O
with	O
relapse	O
-	O
remitting	O
forms	O
of	O
MS	O
.	O

ABSTRACT	O
:	O
GSK3532795	O
,	O
formerly	O
known	O
as	O
BMS	O
-	O
955176	O
(	O
1	O
),	O
is	O
a	O
potent	O
,	O
orally	O
active	O
,	O
second	O
-	O
generation	O
HIV	O
-	O
1	O
maturation	B-PROC
inhibitor	O
(	O
MI	O
)	O
that	O
advanced	O
through	O
phase	O
IIb	O
clinical	O
trials	O
.	O

Patients	O
were	O
followed	O
for	O
6	O
days	O
for	O
the	O
development	B-PROC
of	O
ARDS	O
according	O
to	O
Berlin	O
Criteria	O
.	O

The	O
main	O
clinical	O
manifestations	O
are	O
fever	B-PROC
,	O
chills	O
,	O
generalized	O
myalgia	O
,	O
cough	O
,	O
shortness	O
of	O
breath	O
,	O
nausea	O
,	O
vomiting	O
and	O
diarrhea	O
.	O

TITLE	O
:	O
Systemic	O
and	O
mucosal	O
humoral	B-PROC
immune	I-PROC
responses	I-PROC
induced	O
by	O
the	O
JY	O
-	O
adjuvanted	O
nasal	O
spray	O
H7N9	O
vaccine	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
first	O
case	O
of	O
human	O
avian	O
influenza	O
A	O
(	O
H7N9	O
)	O
virus	B-PROC
infection	I-PROC
in	O
2013	O
,	O
five	O
H7N9	O
epidemics	O
have	O
occurred	O
in	O
China	O
,	O
all	O
of	O
which	O
caused	O
severe	O
diseases	O
,	O
including	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
the	O
fatality	O
rates	O
of	O
these	O
epidemics	O
were	O
as	O
high	O
as	O
30	O
-	O
40	O
%.	O

More	O
important	O
,	O
immunization	O
of	O
mice	O
with	O
HBD	O
2	O
-	O
conjugated	O
S	O
RBD	O
enhanced	O
the	O
immunogenicity	O
of	O
the	O
S	O
RBD	O
and	O
elicited	O
a	O
higher	O
S	O
RBD	O
-	O
specific	O
neutralizing	O
antibody	B-PROC
response	I-PROC
than	O
S	O
RBD	O
alone	O
.	O

Clinical	O
signs	O
were	O
observed	O
mainly	O
in	O
suckling	O
and	O
fattening	O
animals	O
,	O
while	O
mortality	O
rates	O
were	O
higher	O
in	O
piglets	O
,	O
reaching	B-PROC
50	O
%.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
is	O
increasingly	O
used	O
in	O
the	O
management	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
describe	O
our	O
experience	O
with	O
three	O
consecutive	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
supported	O
with	O
right	O
jugular	O
-	O
femoral	O
configuration	O
of	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
without	O
therapeutic	O
anticoagulation	B-PROC
as	O
an	O
alternative	O
to	O
lung	O
-	O
protective	O
mechanical	O
ventilation	O
.	O

Patients	O
received	O
oral	O
nutrition	B-PROC
and	O
ambulated	O
daily	O
.	O

ABSTRACT	O
:	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
causes	O
a	O
highly	O
contagious	O
respiratory	O
,	O
reproductive	B-PROC
and	O
urogenital	O
tract	O
disease	O
in	O
chickens	O
worldwide	O
,	O
resulting	O
in	O
substantial	O
economic	O
losses	O
for	O
the	O
poultry	O
industry	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	B-PROC
,	O
docking	B-PROC
studies	O
and	O
biological	O
screening	O
of	O
2	O
-	O
thiazolyl	O
substituted	O
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1H	O
-	O
naphtho	O
[	O
1	O
,	O
2	O
-	O
e	O
][	O
1	O
,	O
3	O
]	O
oxazines	O
as	O
potent	O
HIV	O
-	O
1	O
reverse	B-PROC
transcriptase	I-PROC
inhibitors	I-PROC
.	O

Following	O
microbial	O
infection	O
,	O
there	O
is	O
often	O
robust	O
chemokine	O
signaling	B-PROC
elicited	O
from	O
infected	O
cells	O
,	O
which	O
contributes	O
to	O
both	O
innate	O
and	O
adaptive	B-PROC
immune	I-PROC
responses	I-PROC
that	O
control	O
growth	B-PROC
of	O
the	O
invading	O
pathogen	O
.	O

Chemokines	O
are	O
expressed	B-PROC
and	O
contribute	O
to	O
defense	O
as	O
well	O
as	O
chronic	O
disease	O
by	O
attracting	O
targeted	B-PROC
populations	O
of	O
leukocytes	O
to	O
the	O
CNS	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
nsp1	O
suppresses	O
host	O
gene	B-PROC
expression	I-PROC
in	O
expressed	B-PROC
cells	O
by	O
inhibiting	O
translation	B-PROC
and	O
inducing	O
endonucleolytic	O
cleavage	B-PROC
of	O
host	O
mRNAs	O
,	O
the	O
latter	O
of	O
which	O
leads	O
to	O
mRNA	B-PROC
decay	I-PROC
.	O

The	O
subsequent	O
diagnosis	O
of	O
antisynthetase	O
syndrome	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
unusual	O
,	O
even	O
more	O
so	O
when	O
a	O
veino	O
-	O
veinous	O
(	O
VV	O
)	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
required	O
.	O

All	O
patients	O
after	O
recent	O
allogeneic	O
(	O
allo	O
-)	O
SCT	O
have	O
died	B-PROC
.	O

The	O
role	O
of	O
ventilation	O
in	O
removing	O
exhaled	B-PROC
airborne	O
bio	O
-	O
aerosols	O
and	O
preventing	O
cross	O
infections	O
has	O
been	O
multidisciplinary	O
extensively	O
studied	O
after	O
the	O
SARS	O
outbreak	O
in	O
2003	O
.	O

The	O
impacts	O
of	O
different	O
airflow	B-PROC
patterns	O
on	O
removing	O
large	O
droplets	O
and	O
fine	O
droplet	O
nuclei	O
were	O
discussed	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
diagnostic	O
system	O
for	O
detection	O
of	O
specific	O
antibodies	O
and	O
antigens	O
against	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

TITLE	O
:	O
Interhospital	O
transport	B-PROC
of	O
ARDS	O
patients	O
on	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

According	O
to	O
Berlin	O
definition	O
of	O
ARDS	O
,	O
this	O
is	O
defined	O
based	O
on	O
the	O
timings	O
,	O
radiographic	O
changes	O
,	O
edema	O
formation	B-PROC
,	O
and	O
severity	O
on	O
the	O
PaO	B-PROC

ABSTRACT	O
:	O
The	O
coronavirus	O
spike	O
protein	O
and	O
the	O
influenza	O
virus	O
hemagglutinin	O
are	O
class	O
I	O
viral	O
membrane	B-PROC
fusion	I-PROC
proteins	O
.	O

TITLE	O
:	O
Management	O
of	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
with	O
H1N1	O
Influenza	O
Virus	O
in	O
Pregnancy	O
:	O
Successful	O
Mechanical	O
Ventilation	O
and	O
Weaning	B-PROC
with	O
Airway	O
Pressure	O
Release	O
Ventilation	O
.	O

It	O
has	O
been	O
utilised	O
as	O
a	O
viral	O
vector	O
to	O
develop	O
many	O
vaccines	O
against	O
cancer	O
and	O
infectious	O
diseases	O
such	O
as	O
malaria	O
,	O
HIV	O
/	O
AIDS	O
,	O
influenza	O
,	O
and	O
tuberculosis	O
,	O
MERS	O
-	O
CoV	O
,	O
and	O
Ebola	O
virus	B-PROC
infection	I-PROC
.	O

A	O
number	O
of	O
promoters	O
were	O
described	O
or	O
optimised	O
to	O
improve	O
the	O
development	B-PROC
of	O
MVA	O
based	O
vaccines	O
such	O
as	O
p7	O
.	O
5	O
,	O
pF11	O
,	O
and	O
mH5	O
promoters	O
.	O

As	O
a	O
result	O
,	O
laboratories	O
are	O
building	O
capacity	O
,	O
conducting	B-PROC
more	O
advanced	O
and	O
sophisticated	O
research	O
,	O
increasing	O
their	O
staff	O
,	O
and	O
establishing	O
reference	O
collections	O
of	O
dangerous	O
pathogens	O
in	O
an	O
attempt	O
to	O
reduce	O
the	O
impact	O
of	O
infectious	O
disease	O
outbreaks	O
and	O
to	O
characterise	O
disease	O
-	O
causing	O
agents	O
.	O

A	O
comprehensive	O
approach	O
for	O
disease	O
prevention	O
,	O
detection	O
and	O
response	O
,	O
however	O
,	O
requires	O
a	O
coordinated	O
and	O
joint	O
effort	B-PROC
among	O
governments	O
,	O
communities	O
,	O
donors	O
and	O
international	O
networks	O
to	O
invest	O
effectively	O
in	O
prevention	O
systems	O
that	O
can	O
identify	O
early	O
signals	O
of	O
the	O
emergence	O
,	O
spillover	O
and	O
spread	O
of	O
animal	O
pathogens	O
at	O
the	O
local	O
level	O
.	O

ABSTRACT	O
:	O
Targeted	B-PROC
therapies	O
,	O
molecules	O
in	O
full	O
expansion	O
,	O
are	O
not	O
free	O
of	O
side	O
effects	O
that	O
can	O
lead	O
patients	O
to	O
intensive	O
care	O
.	O

The	O
main	O
cardiovascular	O
side	O
effects	O
requiring	O
ICU	O
are	O
heart	O
failure	O
,	O
which	O
is	O
generally	O
reversible	O
,	O
severe	O
hypertension	O
,	O
thrombotic	O
and	O
ischemic	O
events	O
,	O
and	O
rhythm	B-PROC
disturbances	O
.	O

Remarkably	O
,	O
4	O
mAbs	O
(	O
designed	O
2G8	O
,	O
2B11	O
,	O
3D9	O
,	O
1E3	O
)	O
neutralized	O
virus	B-PROC
infection	I-PROC
potently	O
,	O
of	O
which	O
2B11	O
and	O
1E3	O
targeted	B-PROC
the	O
conformational	O
epitope	O
of	O
the	O
PEDV	O
S	O
protein	O
.	O

In	O
contrast	O
,	O
despite	O
causing	O
low	O
or	O
no	O
mortality	O
depending	O
on	O
the	O
age	O
of	O
the	O
infected	O
chickens	O
,	O
the	O
Malaysian	O
variant	O
strain	O
showed	O
high	O
tissue	B-PROC
tropism	B-PROC
for	O
the	O
respiratory	O
tract	O
compared	O
with	O
the	O
QX	O
-	O
like	O
strain	O
.	O

Hybridization	B-PROC
between	O
multiplexed	O
PCR	O
products	O
and	O
the	O
labeled	O
fluorescence	O
microspheres	O
was	O
detected	O
in	O
a	O
high	O
throughput	O
format	O
using	O
a	O
Luminex	O
fluorescence	O
reader	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
community	O
acquired	O
pneumonia	O
(	O
CAP	O
)	O
caused	O
by	O
viruses	O
can	O
develop	O
severe	O
complications	O
,	O
which	O
result	O
in	O
hospitalization	O
and	O
death	B-PROC
.	O

Strong	O
variation	O
in	O
seasonal	O
distribution	O
was	O
shown	O
in	O
viral	B-PROC
infections	I-PROC
,	O
with	O
peak	O
months	O
from	O
December	O
to	O
February	O
.	O

In	O
addition	O
,	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
>	O
246	O
IU	O
/	O
L	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
7	O
.	O
06	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
):	O
2	O
.	O
15	O
-	O
23	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
001	O
],	O
and	O
serum	O
calcium	O
<	O
2	O
.	O
18	O
mmol	O
/	O
L	O
(	O
OR	O
=	O
6	O
.	O
67	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
42	O
-	O
31	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
016	O
)	O
were	O
associated	O
with	O
death	B-PROC
.	O

Viruses	O
play	O
an	O
important	O
role	O
in	O
CAP	O
patients	O
with	O
fever	B-PROC
,	O
a	O
systematic	O
clinical	O
,	O
radiological	O
and	O
biological	O
analysis	O
of	O
these	O
patients	O
can	O
contribute	O
to	O
effective	O
therapy	O
that	O
may	O
prevent	O
the	O
development	B-PROC
of	O
CAP	O
and	O
improve	O
the	O
outcomes	O
.	O

The	O
present	O
work	O
showed	O
an	O
elaborate	O
analysis	O
evidence	O
of	O
viral	B-PROC
infection	I-PROC
among	O
fever	B-PROC
CAP	O
inpatients	O
.	O

He	O
developed	O
a	O
fever	B-PROC
of	O
39	O
°	O
C	O
with	O
respiratory	O
distress	O
and	O
was	O
transported	O
by	O
ambulance	O
to	O
his	O
usual	O
doctor	O
.	O

Demographic	O
inference	O
of	O
viral	O
effective	O
population	O
size	O
over	O
time	O
indicated	O
similar	O
dynamics	O
for	O
both	O
lineages	O
,	O
characterized	O
by	O
exponential	O
growth	B-PROC
since	O
the	O
early	O
1980s	O
,	O
followed	O
by	O
a	O
significant	O
bottleneck	O
in	O
2003	O
and	O
another	O
increase	O
after	O
2004	O
.	O

CONCLUSIONS	O
:	O
Although	O
fatalities	O
from	O
septicemia	O
after	O
uterine	O
artery	O
embolization	O
have	O
been	O
reported	O
,	O
aseptic	O
inflammatory	B-PROC
responses	I-PROC
to	O
uterine	O
degeneration	O
can	O
also	O
lead	O
to	O
multiorgan	O
failure	O
.	O

TITLE	O
:	O
Antiviral	O
innate	B-PROC
immune	I-PROC
response	I-PROC
in	O
non	O
-	O
myeloid	O
cells	O
is	O
augmented	O
by	O
chloride	O
ions	O
via	O
an	O
increase	O
in	O
intracellular	O
hypochlorous	O
acid	O
levels	O
.	O

TITLE	O
:	O
Oral	O
immunization	O
with	O
a	O
novel	O
attenuated	O
Salmonella	O
Gallinarum	O
encoding	O
infectious	O
bronchitis	O
virus	O
spike	O
protein	O
induces	O
protective	O
immune	B-PROC
responses	I-PROC
against	O
fowl	O
typhoid	O
and	O
infectious	O
bronchitis	O
in	O
chickens	O
.	O

ABSTRACT	O
:	O
Pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
an	O
important	O
cause	O
of	O
deaths	B-PROC
in	O
critically	O
ill	O
children	O
admitted	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
.	O

Prone	O
positioning	O
and	O
early	O
neuromuscular	B-PROC
blockade	I-PROC
have	O
demonstrated	O
mortality	O
benefit	O
,	O
and	O
clinical	O
guidelines	O
now	O
recommend	O
their	O
use	O
.	O

TITLE	O
:	O
Major	O
Infectious	O
Diseases	O
ABSTRACT	O
:	O
Infectious	O
diseases	O
were	O
responsible	O
for	O
the	O
largest	O
global	O
burden	O
of	O
premature	O
death	B-PROC
and	O
disability	O
until	O
the	O
end	O
of	O
the	O
twentieth	O
century	O
,	O
when	O
that	O
distinction	O
passed	O
to	O
noncommunicable	O
diseases	O
.	O

Corticosteroid	O
use	O
in	O
viral	O
pneumonia	O
may	O
provoke	O
mortality	O
and	O
longer	O
viral	B-PROC
shedding	I-PROC
time	O
.	O

Like	O
cocaine	O
,	O
methamphetamine	O
blocks	O
reuptake	B-PROC
of	O
monoamine	O
transporters	O
,	O
but	O
also	O
stimulates	O
dopamine	O
release	O
and	O
has	O
a	O
longer	O
duration	O
of	O
action	O
.	O

Sequences	O
were	O
obtained	O
from	O
amplicons	O
using	O
consensus	O
primers	O
targeting	B-PROC
conserved	O
genes	O
of	O
the	O
virus	O
families	O
Paramyxoviridae	O
,	O
Coronaviridae	O
,	O
Adenoviridae	O
,	O
and	O
Herpesviridae	O
.	O

We	O
conducted	O
a	O
retrospective	O
review	O
of	O
patients	O
with	O
acute	O
leukemia	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
requiring	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
at	O
our	O
facility	O
from	O
July	O
2015	O
through	O
August	O
2017	O
.	O

Although	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
post	O
-	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplant	O
is	O
associated	O
with	O
poorer	O
outcomes	O
,	O
our	O
data	O
suggest	O
that	O
salvage	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
is	O
a	O
viable	O
option	O
to	O
manage	O
moderate	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
while	O
completing	O
therapeutic	O
chemotherapy	O
and	O
following	O
in	O
the	O
peri	O
-	O
induction	O
phase	O
of	O
acute	O
leukemia	O
.	O

Our	O
investigation	O
proved	O
the	O
strong	O
regulatory	O
roles	O
of	O
CVC1303	O
on	O
PEDV	O
-	O
specific	O
IgG	O
and	O
IgG1	O
antibody	B-PROC
and	O
cytokines	O
productions	O
,	O
and	O
the	O
significant	O
increased	O
CD3	O
+	O
CD4	O
+	O
T	O
cells	O
subpopulation	O
and	O
expressions	O
of	O
co	O
-	O
stimulatory	O
molecules	O
on	O
dendritic	O
cells	O
in	O
the	O
immunized	O
mice	O
.	O

ABSTRACT	O
:	O
Infrared	O
(	O
IR	O
)	O
modalities	O
represent	O
the	O
only	O
currently	O
viable	O
mass	O
fever	B-PROC
screening	O
approaches	O
for	O
outbreaks	O
of	O
infectious	O
disease	O
pandemics	O
such	O
as	O
Ebola	O
virus	B-PROC
disease	I-PROC
and	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

TITLE	O
:	O
Attenuation	O
of	O
Influenza	O
A	O
Virus	B-PROC
Disease	I-PROC
Severity	O
by	O
Viral	O
Coinfection	O
in	O
a	O
Mouse	O
Model	O
.	O

Disease	O
attenuation	O
was	O
associated	O
with	O
an	O
early	O
inflammatory	B-PROC
response	I-PROC
in	O
the	O
lungs	O
and	O
enhanced	O
clearance	O
of	O
PR8	O
.	O

Isolate	O
LDL	O
/	O
150434	O
-	O
II	O
was	O
a	O
novel	O
variant	O
that	O
originated	O
from	O
recombination	B-PROC
events	O
between	O
H120	O
and	O
ck	O
/	O
CH	O
/	O
LDT3	O
/	O
03	O
-	O
like	O
viruses	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
sensitive	O
and	O
specific	O
xMAP	O
assay	O
for	O
detection	O
of	O
antibodies	O
against	O
infectious	O
laryngotracheitis	O
and	O
bronchitis	O
viruses	O
.	O

Furthermore	O
,	O
levels	O
of	O
CXCL	O
-	O
7	O
,	O
a	O
platelet	O
-	O
derived	O
chemokine	O
,	O
were	O
higher	O
in	O
the	O
BALF	O
from	O
the	O
control	O
group	O
,	O
indicating	O
that	O
OLA	O
protects	O
the	O
lungs	O
by	O
suppressing	O
platelet	B-PROC
activation	I-PROC
.	O

In	O
this	O
study	O
,	O
coated	O
PEDV	O
-	O
loaded	O
microspheres	O
with	O
the	O
size	O
range	O
of	O
700	O
-	O
900	O
μm	O
in	O
diameter	O
were	O
developed	O
by	O
centrifugal	O
granulation	O
-	O
fluidized	O
bed	O
coating	O
and	O
demonstrated	O
as	O
an	O
effective	O
oral	O
delivery	O
system	O
to	O
protect	O
PEDV	O
antigens	O
against	O
the	O
complex	O
gastrointestinal	O
environment	O
by	O
detecting	O
the	O
live	O
virus	O
particles	O
in	O
microspheres	O
after	O
the	O
simulated	O
gastric	O
fluid	O
treatment	O
and	O
the	O
PEDV	O
RNA	O
in	O
fecal	O
swabs	O
collected	O
from	O
all	O
weaned	B-PROC
piglets	O
(	O
100	O
%)	O
orally	O
inoculated	O
with	O
coated	O
PEDV	O
-	O
loaded	O
microspheres	O
.	O

Weaned	B-PROC
piglets	O
orally	O
immunized	O
with	O
coated	O
PEDV	O
-	O
loaded	O
microspheres	O
developed	O
higher	O
levels	O
of	O
PEDV	O
-	O
specific	O
antibodies	O
(	O
IgG	O
and	O
IgA	O
)	O
in	O
their	O
sera	O
and	O
saliva	O
than	O
those	O
negative	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
001	O
or	O
p	O
<	O
0	O
.	O
01	O
).	O

Furthermore	O
,	O
neutralization	O
assays	O
demonstrated	O
that	O
serum	O
antibodies	O
in	O
coated	O
PEDV	O
-	O
loaded	O
microspheres	O
groups	O
could	O
significantly	O
inhibit	O
virus	B-PROC
infection	I-PROC
in	O
Vero	O
cells	O
,	O
compared	O
to	O
PEDV	O
only	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Partial	O
neuromuscular	O
blockage	O
to	O
promote	O
weaning	B-PROC
from	O
mechanical	O
ventilation	O
in	O
severe	O
ARDS	O
:	O
A	O
case	O
report	O
.	O

For	O
elevated	O
plateau	O
airway	O
pressures	O
,	O
we	O
suggest	O
first	O
decreasing	O
tidal	O
volumes	O
,	O
followed	O
by	O
neuromuscular	B-PROC
blockade	I-PROC
,	O
modification	O
of	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
,	O
and	O
prone	O
positioning	O
.	O

Whereas	O
the	O
variability	O
of	O
virulence	B-PROC
among	O
reservoir	O
-	O
borne	O
viruses	O
is	O
unknown	O
,	O
it	O
is	O
generally	O
assumed	O
that	O
the	O
emergence	O
of	O
epidemic	O
viruses	O
from	O
animal	O
reservoirs	O
requires	O
human	O
adaptation	B-PROC
.	O

ABSTRACT	O
:	O
The	O
ongoing	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infections	O
pose	O
threats	O
to	O
public	O
health	O
worldwide	O
,	O
making	O
an	O
understanding	O
of	O
MERS	O
pathogenesis	B-PROC
and	O
development	B-PROC
of	O
effective	O
medical	O
countermeasures	O
(	O
MCMs	O
)	O
urgent	O
.	O

Despite	O
the	O
importance	O
of	O
lysosomal	O
proteases	O
in	O
both	O
coronavirus	O
entry	O
and	O
cell	O
metabolism	B-PROC
,	O
the	O
correlation	O
between	O
lysosomal	O
proteases	O
and	O
cell	O
tropism	B-PROC
of	O
coronaviruses	O
has	O
not	O
been	O
established	O
.	O

Our	O
results	O
showed	O
that	O
lysosomal	O
proteases	O
from	O
bat	O
cells	O
support	O
coronavirus	O
spike	O
-	O
mediated	O
pseudovirus	O
entry	O
and	O
cell	B-PROC
-	I-PROC
cell	I-PROC
fusion	I-PROC
more	O
effectively	O
than	O
their	O
counterparts	O
from	O
human	O
cells	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
not	O
a	O
failure	O
of	O
the	O
neurological	O
command	O
of	O
the	O
ventilatory	O
muscles	O
or	O
of	O
the	O
ventilatory	O
muscles	O
;	O
it	O
is	O
an	O
oxygenation	B-PROC
defect	O
.	O

Assuming	O
an	O
improved	O
overall	O
status	O
,	O
PaO	B-PROC

The	O
infection	O
was	O
introduced	O
by	O
import	O
of	O
two	O
breeding	B-PROC
boars	O
which	O
were	O
placed	O
in	O
provisional	O
quarantine	O
in	O
a	O
unit	O
not	O
strictly	O
separated	O
from	O
other	O
healthy	O
pigs	O
in	O
the	O
same	O
building	O
.	O

The	O
infection	O
gradually	O
spread	O
to	O
the	O
farrowing	B-PROC
area	O
and	O
throughout	O
the	O
farm	O
in	O
two	O
weeks	O
and	O
later	O
to	O
another	O
nearby	O
farm	O
.	O

Yellow	O
watery	O
diarrhoea	O
accompanied	O
by	O
dehydration	O
and	O
death	B-PROC
was	O
observed	O
in	O
piglets	O
with	O
a	O
mortality	O
ranging	O
from	O
30	O
to	O
35	O
%.	O

In	O
addition	O
,	O
when	O
fcwf	O
-	O
4	O
cells	O
were	O
adsorbed	O
by	O
FIPV	O
and	O
then	O
stimulated	O
with	O
Poly	O
(	O
I	O
:	O
C	O
),	O
type	O
II	O
FCoV	O
infection	O
inhibited	O
Poly	O
(	O
I	O
:	O
C	O
)-	O
induced	O
IFNβ	O
gene	B-PROC
expression	I-PROC
.	O

Furthermore	O
,	O
10	O
purifying	O
selection	O
sites	O
in	O
S	O
gene	O
indicated	O
an	O
adaptive	O
evolution	B-PROC
of	O
PEDV	O
in	O
central	O
China	O
swine	O
herds	O
.	O

TITLE	O
:	O
Simple	O
,	O
Rapid	O
and	O
Sensitive	O
Portable	O
Molecular	O
Diagnosis	O
of	O
SFTS	O
Virus	O
Using	O
Reverse	O
Transcriptional	B-PROC
Loop	O
-	O
Mediated	O
Isothermal	O
Amplification	O
(	O
RT	O
-	O
LAMP	O
).	O

Chlordecone	O
also	O
accelerated	O
the	O
death	B-PROC
of	O
mice	O
infected	O
by	O
murine	O
hepatitis	O
virus	O
and	O
enhanced	O
the	O
entry	O
of	O
the	O
virus	O
into	O
the	O
cervical	O
spinal	O
cord	O
in	O
infected	O
mice	O
,	O
leading	O
to	O
considerable	O
neurological	O
damage	O
.	O

TITLE	O
:	O
Zoonotic	O
Viral	B-PROC
Diseases	I-PROC
of	O
Equines	O
and	O
Their	O
Impact	O
on	O
Human	O
and	O
Animal	O
Health	O
.	O

Hendra	O
virus	O
(	O
HeV	O
)	O
causes	O
respiratory	O
and	O
neurological	O
disease	O
and	O
death	B-PROC
in	O
man	O
and	O
horses	O
.	O

We	O
tested	O
sera	O
by	O
an	O
indirect	O
fluorescence	O
antibody	B-PROC
test	O
for	O
antibodies	O
to	O
canine	O
distemper	O
virus	O
(	O
CDV	O
),	O
canine	O
coronavirus	O
(	O
CCV	O
),	O
canine	O
parvovirus	O
type	O
2	O
(	O
CPV	O
-	O
2	O
),	O
canine	O
adenovirus	O
,	O
canine	O
parainfluenza	O
virus	O
type	O
2	O
(	O
CPIV	O
-	O
2	O
),	O
and	O
canine	O
herpesvirus	O
type	O
1	O
(	O
CHV	O
-	O
1	O
).	O

We	O
used	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
detection	O
of	O
antibodies	O
to	O
hepatitis	O
E	O
virus	O
,	O
bluetongue	O
virus	O
,	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
(	O
WNV	O
),	O
and	O
Aujeszky	O
'	O
s	O
disease	O
virus	O
(	O
ADV	O
).	O

One	O
was	O
a	O
69	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
been	O
treated	O
with	O
combination	O
fluconazole	O
and	O
liposomal	O
amphotericin	O
for	O
over	O
6	O
weeks	O
,	O
with	O
persistent	O
fever	B-PROC
and	O
pneumonia	O
.	O

TITLE	O
:	O
Interplay	O
between	O
coronavirus	O
,	O
a	O
cytoplasmic	O
RNA	O
virus	O
,	O
and	O
nonsense	B-PROC
-	I-PROC
mediated	I-PROC
mRNA	B-PROC
decay	I-PROC
pathway	B-PROC
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
),	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
CoV	O
,	O
are	O
enveloped	O
RNA	O
viruses	O
that	O
carry	O
a	O
large	O
positive	O
-	O
sense	B-PROC
single	O
-	O
stranded	O
RNA	O
genome	O
and	O
cause	O
a	O
variety	O
of	O
diseases	O
in	O
humans	O
and	O
domestic	O
animals	O
.	O

Nonsense	B-PROC
-	I-PROC
mediated	I-PROC
decay	I-PROC
(	O
NMD	B-PROC
)	O
is	O
a	O
eukaryotic	O
RNA	B-PROC
surveillance	I-PROC
pathway	B-PROC
that	O
detects	O
mRNAs	O
harboring	O
aberrant	O
features	O
and	O
targets	O
them	O
for	O
degradation	O
.	O

Although	O
CoV	O
mRNAs	O
are	O
of	O
cytoplasmic	O
origin	O
,	O
the	O
presence	O
of	O
several	O
NMD	B-PROC
-	O
inducing	O
features	O
(	O
including	O
multiple	O
ORFs	O
with	O
internal	O
termination	O
codons	O
that	O
create	O
a	O
long	O
3	O
'	O
untranslated	O
region	O
)	O
in	O
CoV	O
mRNAs	O
led	O
us	O
to	O
explore	O
the	O
interplay	O
between	O
the	O
NMD	B-PROC
pathway	B-PROC
and	O
CoVs	O
.	O

Our	O
data	O
further	O
suggest	O
that	O
the	O
NMD	B-PROC
pathway	B-PROC
interferes	O
with	O
optimal	O
viral	B-PROC
replication	I-PROC
by	O
degrading	O
viral	O
mRNAs	O
early	O
in	O
infection	O
,	O
before	O
sufficient	O
accumulation	O
of	O
N	O
protein	O
.	O

Our	O
study	O
presents	O
clear	O
evidence	O
for	O
the	O
biological	O
importance	O
of	O
the	O
NMD	B-PROC
pathway	B-PROC
in	O
controlling	O
the	O
stability	O
of	O
mRNAs	O
and	O
the	O
efficiency	O
of	O
replication	O
of	O
a	O
cytoplasmic	O
RNA	O
virus	O
.	O

No	O
statistically	O
significant	O
correlations	O
between	O
the	O
healthcare	O
workers	O
'	O
perceptions	O
of	O
hand	O
hygiene	O
practices	O
and	O
healthcare	O
workers	O
'	O
actual	O
behaviors	B-PROC
were	O
evident	O
.	O

TITLE	O
:	O
[	O
Modified	O
David	O
-	O
Komeda	O
Repair	B-PROC
for	O
Ventricular	O
Septal	O
Perforation	O
Complicated	O
with	O
Severe	O
Postoperative	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
;	O
Report	O
of	O
a	O
Case	O
].	O

In	O
spite	O
of	O
intense	O
study	O
,	O
it	O
remains	O
unclear	O
whether	O
the	O
deletion	O
actually	O
reflects	O
adaptation	B-PROC
to	O
humans	O
.	O

ABSTRACT	O
:	O
Venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
is	O
increasingly	O
being	O
used	O
to	O
support	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
but	O
its	O
cost	O
-	O
effectiveness	O
is	O
unknown	O
.	O

Venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
or	O
standard	O
lung	O
protective	O
ventilation	O
.	O

Moreover	O
,	O
silencing	O
of	O
ssc_circ_009380	O
inhibited	O
accumulation	O
of	O
p65	O
in	O
nucleus	O
and	O
phosphorylation	B-PROC
of	O
IκB	O
-	O
α	O
.	O

The	O
different	O
receptor	O
requirements	O
for	O
TGEV	O
and	O
PEDV	O
have	O
important	O
implications	O
in	O
the	O
development	B-PROC
of	O
new	O
genetic	O
tools	O
for	O
the	O
control	O
of	O
enteric	O
disease	O
in	O
pigs	O
.	O

Supplemental	O
100	O
%	O
fractional	O
inspired	B-PROC
oxygen	O
(	O
FiO	O

Treatment	O
of	O
TGEV	O
-	O
infected	O
ST	O
cells	O
and	O
IPEC	O
-	O
J2	O
cells	O
with	O
the	O
NF	O
-	O
κB	O
-	O
specific	O
inhibitor	O
caused	O
the	O
down	B-PROC
-	I-PROC
regulation	B-PROC
of	O
pro	O
-	O
inflammatory	O
cytokine	O
expression	B-PROC
,	O
but	O
did	O
not	O
significantly	O
affect	O
TGEV	O
replication	O
.	O

A	O
previously	O
healthy	O
4	O
-	O
year	O
-	O
old	O
girl	O
was	O
brought	O
to	O
a	O
hospital	O
with	O
first	O
-	O
time	O
febrile	B-PROC
generalized	O
tonic	O
-	O
clonic	O
convulsions	O
,	O
which	O
lasted	O
approximately	O
40	O
min	O
.	O

TITLE	O
:	O
[	O
Individualized	O
vancomycin	O
dosing	O
for	O
a	O
patient	O
diagnosed	O
as	O
severe	O
acute	O
pancreatitis	O
with	O
concurrent	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
and	O
continuous	O
veno	O
-	O
venous	O
hemofiltration	O
therapy	O
:	O
a	O
case	O
report	O
].	O

ABSTRACT	O
:	O
Pharmacokinetic	O
parameters	O
can	O
be	O
significantly	O
altered	O
for	O
acute	O
kidney	O
injury	O
(	O
AKI	O
),	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
and	O
continuous	O
veno	O
-	O
venous	O
hemofiltration	O
therapy	O
(	O
CVVH	O
).	O

ABSTRACT	O
:	O
Several	O
successful	O
uses	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
patients	O
with	O
novel	O
HIV	O
/	O
AIDS	O
infection	O
have	O
been	O
reported	O
;	O
however	O
,	O
the	O
therapeutic	O
keys	O
have	O
not	O
always	O
been	O
discussed	O
.	O

TITLE	O
:	O
Preparedness	O
for	O
rapid	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
introduction	O
for	O
pediatric	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
case	O
report	O
.	O

Acute	O
respiratory	O
failure	O
has	O
been	O
shown	O
to	O
yield	O
a	O
similar	O
echocardiographic	O
appearance	O
in	O
experimental	O
conditions	O
due	O
to	O
the	O
resultant	O
pulmonary	O
vasoconstriction	B-PROC
.	O

We	O
investigated	O
the	O
role	O
of	O
PHD2	O
in	O
ECs	O
during	O
endotoxin	O
-	O
induced	O
lung	O
inflammatory	B-PROC
responses	I-PROC
with	O
EC	O
-	O
specific	O
PHD2	O
inducible	O
knockout	O
mice	O
.	O

The	O
presence	O
of	O
PAstV	O
and	O
PSaV	O
was	O
studied	O
in	O
411	O
rectal	O
swabs	O
collected	O
from	O
healthy	O
(	O
n	O
=	O
251	O
)	O
and	O
diarrheic	O
(	O
n	O
=	O
160	O
)	O
pigs	O
of	O
different	O
age	O
categories	O
:	O
suckling	O
(	O
n	O
=	O
143	O
),	O
weaned	B-PROC
(	O
n	O
=	O
147	O
)	O
and	O
fattening	O
(	O
n	O
=	O
121	O
)	O
animals	O
on	O
farms	O
in	O
Slovakia	O
.	O

Access	O
to	O
dangerous	O
pathogens	O
should	O
be	O
appropriately	O
regulated	O
,	O
without	O
reducing	O
progress	O
in	O
the	O
development	B-PROC
of	O
countermeasures	O
.	O

ABSTRACT	O
:	O
In	O
this	O
work	O
we	O
report	O
a	O
parallel	O
application	O
of	O
both	O
docking	B-PROC
-	O
and	O
shape	O
-	O
based	O
virtual	O
screening	O
(	O
VS	O
)	O
methods	O
,	O
followed	O
by	O
Molecular	B-PROC
Dynamics	I-PROC
simulations	O
(	O
MDs	O
),	O
for	O
discovering	O
new	O
compounds	O
able	O
to	O
inhibit	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
reverse	O
transcriptase	B-PROC
(	O
RT	O
)	O
RNA	B-PROC
-	I-PROC
dependent	I-PROC
DNA	I-PROC
polymerase	I-PROC
activity	I-PROC
.	O

TITLE	O
:	O
Protease	B-PROC
inhibitors	I-PROC
broadly	O
effective	O
against	O
feline	O
,	O
ferret	O
and	O
mink	O
coronaviruses	O
.	O

In	O
the	O
second	O
assessment	O
of	O
the	O
high	O
-	O
risk	O
group	O
,	O
the	O
sleep	B-PROC
and	O
numbness	O
subscale	O
scores	O
from	O
the	O
IES	O
-	O
R	O
differed	O
depending	O
on	O
the	O
implementation	O
of	O
home	O
quarantine	O
,	O
and	O
the	O
intrusion	O
subscale	O
scores	O
differed	O
depending	O
on	O
the	O
performance	O
of	O
MERS	O
-	O
related	O
tasks	O
.	O

ABSTRACT	O
:	O
Bayesian	O
analysis	O
of	O
clinical	O
trial	O
data	O
may	O
provide	O
useful	O
information	O
to	O
aid	O
in	O
study	O
interpretation	O
,	O
especially	O
when	O
trial	O
evidence	O
suggests	O
that	O
the	O
benefits	O
of	O
an	O
intervention	O
are	O
uncertain	O
,	O
such	O
as	O
in	O
a	O
trial	O
that	O
evaluated	O
early	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Herein	O
,	O
we	O
employed	O
a	O
bioinorganic	O
perspective	O
to	O
develop	O
an	O
SAR	O
for	O
inhibition	B-PROC
of	O
the	O
metalloenzyme	O
influenza	O
RNA	O
polymerase	O
PA	O

In	O
18	O
.	O
2	O
%	O
of	O
the	O
negative	O
viral	B-PROC
infections	I-PROC
,	O
only	O
S	O
.	O
pneumoniae	O
was	O
identified	O
.	O

TITLE	O
:	O
Generation	O
and	O
characterization	O
of	O
a	O
monoclonal	O
antibody	B-PROC
against	O
MERS	O
-	O
CoV	O
targeting	B-PROC
the	O
spike	O
protein	O
using	O
a	O
synthetic	O
peptide	O
epitope	O
-	O
CpG	O
-	O
DNA	O
-	O
liposome	O
complex	O
.	O

Thus	O
,	O
we	O
successfully	O
produced	O
a	O
monoclonal	O
antibody	B-PROC
directed	O
against	O
the	O
RBD	O
domain	O
of	O
the	O
S	O
protein	O
which	O
could	O
be	O
used	O
in	O
the	O
development	B-PROC
of	O
diagnostics	O
and	O
therapeutic	O
applications	O
in	O
the	O
future	O
.	O

TITLE	O
:	O
Spontaneous	O
Breathing	B-PROC
in	I-PROC
Early	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
:	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
characteristics	O
and	O
outcomes	O
of	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
or	O
without	O
spontaneous	O
breathing	B-PROC
and	O
to	O
investigate	O
whether	O
the	O
effects	O
of	O
spontaneous	O
breathing	B-PROC
on	O
outcome	O
depend	O
on	O
acute	O
respiratory	O
distress	O
syndrome	O
severity	O
.	O

Spontaneous	O
breathing	B-PROC
is	O
not	O
associated	O
with	O
worse	O
outcomes	O
and	O
may	O
hasten	O
liberation	O
from	O
the	O
ventilator	O
and	O
from	O
ICU	O
.	O

ABSTRACT	O
:	O
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
a	O
class	O
of	O
noncoding	O
RNAs	O
involved	O
in	O
posttranscriptional	B-PROC
regulation	I-PROC
of	I-PROC
gene	I-PROC
expression	I-PROC
and	O
many	O
critical	O
roles	O
in	O
numerous	O
biological	B-PROC
processes	I-PROC
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
regulatory	O
relationship	O
between	O
miRNA	O
-	O
221	O
-	O
5p	O
and	O
PEDV	O
infection	O
,	O
finding	O
that	O
miR	O
-	O
221	O
-	O
5p	O
overexpression	B-PROC
inhibited	O
PEDV	O
replication	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
and	O
that	O
silencing	O
endogenous	O
miR	O
-	O
221	O
-	O
5p	O
enhanced	O
viral	B-PROC
replication	I-PROC
.	O

We	O
subsequently	O
identified	O
NF	O
-	O
κB	O
-	O
inhibitor	O
α	O
and	O
suppressor	O
of	O
cytokine	B-PROC
signaling	B-PROC
1	O
,	O
negative	O
regulators	O
of	O
the	O
NF	O
-	O
κB	O
pathway	B-PROC
,	O
as	O
miR	O
-	O
221	O
-	O
5p	O
targets	O
.	O

Of	O
678	O
patients	O
who	O
underwent	O
HSCT	O
during	O
the	O
study	O
period	O
,	O
112	O
(	O
17	O
%)	O
developed	O
HCoV	O
infection	O
,	O
making	O
HCoV	O
the	O
fourth	O
most	O
common	O
respiratory	O
viral	B-PROC
infection	I-PROC
.	O

Annual	O
epidemics	O
of	O
seasonal	O
influenza	O
cause	O
an	O
estimated	O
3	O
-	O
5	O
million	O
cases	O
of	O
severe	O
illness	O
and	O
more	O
than	O
500	O
000	O
deaths	B-PROC
,	O
with	O
the	O
prospect	O
of	O
pandemic	O
influenza	O
viruses	O
causing	O
far	O
greater	O
impact	O
.	O

TITLE	O
:	O
Lung	O
Repair	B-PROC
and	O
Regeneration	B-PROC
in	O
ARDS	O
:	O
Role	O
of	O
PECAM1	O
and	O
Wnt	O
Signaling	B-PROC
.	O

Supportive	O
treatment	O
includes	O
the	O
use	O
of	O
lung	O
-	O
protective	O
ventilatory	O
strategies	O
that	O
decrease	O
the	O
work	B-PROC
of	I-PROC
breathing	B-PROC
,	O
can	O
improve	O
oxygenation	B-PROC
,	O
and	O
minimize	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

TITLE	O
:	O
Transforming	O
Growth	B-PROC
Factor	O
-	O
β1	O
in	O
predicting	O
early	O
lung	O
fibroproliferation	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
Epidemics	O
such	O
as	O
viral	O
haemorrhagic	O
fevers	B-PROC
,	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
or	O
yet	O
unknown	O
ones	O
have	O
few	O
chances	O
of	O
disappearing	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
characterized	O
by	O
severe	O
inflammatory	B-PROC
response	I-PROC
and	O
hypoxemia	O
.	O

ABSTRACT	O
:	O
Recent	O
years	O
have	O
seen	O
extremely	O
fast	O
development	B-PROC
of	O
new	O
viral	O
nanovaccines	O
and	O
diagnostic	O
agents	O
using	O
nanostructures	O
prepared	O
by	O
biological	O
and	O
chemical	O
synthesis	B-PROC
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
S1	O
protein	O
is	O
the	O
critical	O
inducer	O
of	O
apoptosis	B-PROC
.	O

Expression	B-PROC
of	O
S1	O
proteins	O
of	O
the	O
coronavirus	O
tested	O
in	O
this	O
study	O
could	O
all	O
induce	O
cell	O
apoptosis	B-PROC
suggesting	O
S1	O
maybe	O
is	O
an	O
effective	O
inducer	O
in	O
Coronavirus	O
-	O
induced	O
cell	O
apoptosis	B-PROC
and	O
targeting	B-PROC
S1	O
protein	B-PROC
expression	B-PROC
probably	O
is	O
a	O
promising	O
strategy	O
to	O
inhibit	O
coronavirus	O
infection	O
and	O
thus	O
mediated	O
apoptosis	B-PROC
on	O
host	O
cells	O
.	O

These	O
two	O
motifs	O
synergistically	O
regulate	O
the	O
level	O
of	O
S	O
expressed	B-PROC
on	O
the	O
cell	O
surface	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
Competencies	O
for	O
Respiratory	O
Protection	O
for	O
Health	O
Care	O
Workers	O
.	O

Neutralizing	O
IL	O
-	O
33	O
in	O
culture	O
medium	O
with	O
specific	O
antibodies	O
suppressed	O
the	O
expression	B-PROC
and	O
secretion	B-PROC
of	O
MMP2	O
and	O
MMP9	O
in	O
LPS	O
-	O
treated	O
alveolar	O
macrophages	O
.	O

Moreover	O
,	O
a	O
potential	O
cathepsin	O
L	O
cleavage	B-PROC
site	O
in	O
MERS	O
-	O
S	O
has	O
been	O
reported	O
.	O

Arrhythmia	O
was	O
the	O
most	O
common	O
cardiovascular	O
disease	O
(	O
16	O
.	O
7	O
%),	O
followed	O
by	O
acute	O
coronary	O
syndrome	O
(	O
12	O
.	O
0	O
%)	O
and	O
heart	O
failure	O
(	O
9	O
.	O
1	O
%);	O
the	O
main	O
nervous	O
system	O
diseases	O
were	O
stroke	O
(	O
20	O
.	O
9	O
%);	O
respiratory	O
diseases	O
mainly	O
included	O
severe	O
pneumonia	O
(	O
8	O
.	O
3	O
%);	O
digestive	B-PROC
system	O
diseases	O
were	O
mainly	O
with	O
digestive	B-PROC
tract	O
bleeding	O
(	O
4	O
.	O
4	O
%).	O

Cardiovascular	O
and	O
cerebrovascular	O
diseases	O
,	O
respiratory	O
and	O
digestive	B-PROC
diseases	O
are	O
the	O
main	O
causes	O
of	O
acute	O
critical	O
diseases	O
in	O
department	O
of	O
emergency	O
of	O
Xuanwu	O
Hospital	O
Capital	O
Medical	O
University	O
in	O
2017	O
.	O

Death	B-PROC
resulted	O
in	O
8	O
/	O
32	O
(	O
25	O
%)	O
HCWs	O
including	O
all	O
5	O
HCWs	O
with	O
chronic	O
renal	O
impairment	O
at	O
baseline	O
.	O

Dengue	O
Fever	B-PROC
Detecting	O
System	O
Using	O
Peak	O
-	O
detection	O
of	O
Data	O
from	O
Contactless	O
Doppler	O
Radar	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
recombination	B-PROC
event	O
located	O
within	O
the	O
P1A	O
domain	O
of	O
nebovirus	O
VP1	O
.	O

ABSTRACT	O
:	O
The	O
in	O
ovo	O
delivery	O
of	O
cytosine	O
-	O
guanosine	O
(	O
CpG	O
)	O
oligodeoxynucleotides	O
(	O
ODNs	O
)	O
protects	O
chickens	O
against	O
many	O
bacterial	O
and	O
viral	B-PROC
infections	I-PROC
,	O
by	O
activating	O
the	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
21	O
signaling	B-PROC
pathway	I-PROC
.	O

Overall	O
,	O
it	O
may	O
be	O
inferred	O
that	O
CpG	O
ODNs	O
,	O
when	O
delivered	O
in	O
ovo	O
,	O
provide	O
protection	O
against	O
IBV	O
infection	O
induced	O
morbidity	O
and	O
mortality	O
with	O
an	O
enhanced	O
immune	B-PROC
response	I-PROC
.	O

TITLE	O
:	O
Management	O
and	O
weaning	B-PROC
from	O
mechanical	O
ventilation	O
in	O
neurologic	O
patients	O
.	O

At	O
48	O
hours	O
,	O
NMBAs	O
improved	O
oxygenation	B-PROC
(	O
weighted	O
mean	O
differences	O
[	O
WMD	O
],	O
27	O
.	O
98	O
;	O
95	O
%	O
CI	O
,	O
7	O
.	O
45	O
-	O
48	O
.	O
51	O
;	O
p	O
=	O
0	O
.	O
008	O
;	O
I	O
=	O
44	O
.	O
2	O
%;	O
4	O
trials	O
,	O
212	O
patients	O
).	O

However	O
,	O
NMBAs	O
have	O
no	O
effect	O
on	O
reduction	O
of	O
oxygenation	B-PROC
at	O
24	O
hours	O
(	O
WMD	O
,	O
26	O
.	O
83	O
;	O
95	O
%	O
CI	O
,	O
-	O
5	O
.	O
89	O
to	O
59	O
.	O
55	O
;	O
p	O
=	O
0	O
.	O
108	O
;	O
I	O
=	O
82	O
.	O
4	O
%;	O
4	O
trials	O
,	O
447	O
patients	O
),	O
and	O
plateau	O
pressure	O
(	O
WMD	O
,	O
0	O
.	O
43	O
;	O
95	O
%	O
CI	O
,	O
-	O
0	O
.	O
46	O
to	O
1	O
.	O
31	O
;	O
p	O
=	O
0	O
.	O
345	O
;	O
4	O
trials	O
,	O
455	O
patients	O
)	O
as	O
well	O
as	O
positive	O
end	O
expiratory	B-PROC
pressure	O
(	O
WMD	O
,	O
0	O
.	O
10	O
;	O
95	O
%	O
CI	O
,	O
-	O
0	O
.	O
47	O
to	O
0	O
.	O
67	O
;	O
p	O
=	O
0	O
.	O
73	O
;	O
4	O
trials	O
,	O
455	O
patients	O
)	O
at	O
48	O
hours	O
.	O

TITLE	O
:	O
Pathobiological	O
and	O
Genomic	O
Characterization	O
of	O
a	O
Cold	B-PROC
-	O
Adapted	O
Infectious	O
Bronchitis	O
Virus	O
(	O
BP	O
-	O
caKII	O
).	O

During	O
the	O
late	O
phase	O
(	O
day	O
10	O
),	O
both	O
lung	O
mechanics	O
and	O
the	O
cell	O
/	O
cytokine	O
homeostasis	B-PROC
recovered	O
in	O
LPS	O
-	O
treated	O
wt	O
mice	O
.	O

Only	O
one	O
third	O
of	O
the	O
patients	O
were	O
discharged	O
home	O
,	O
considering	O
the	O
aging	B-PROC
population	O
with	O
multiple	O
comorbidities	O
in	O
the	O
ICUs	O
in	O
Japan	O
.	O

S	O
is	O
the	O
primary	O
target	O
for	O
MERS	O
-	O
CoV	O
vaccine	O
and	O
antibody	B-PROC
development	B-PROC
,	O
and	O
it	O
has	O
become	O
increasingly	O
important	O
to	O
understand	O
MERS	O
-	O
CoV	O
antibody	B-PROC
binding	O
specificity	O
and	O
function	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
high	O
-	O
throughput	O
protein	O
binding	O
inhibition	B-PROC
assay	O
using	O
image	O
cytometry	O
.	O

Binding	O
inhibition	B-PROC
results	O
were	O
comparable	O
with	O
those	O
described	O
in	O
previous	O
literature	O
for	O
MERS	O
-	O
CoV	O
spike	O
monomer	O
and	O
showed	O
similar	O
patterns	O
as	O
neutralization	O
results	O
.	O

ABSTRACT	O
:	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
a	O
major	O
pathogen	O
of	O
the	O
domestic	O
fowl	O
,	O
exhibits	O
extensive	O
antigenic	B-PROC
variation	I-PROC
.	O

ABSTRACT	O
:	O
As	O
key	O
regulators	O
of	O
cell	B-PROC
signaling	I-PROC
,	O
protein	O
kinases	O
(	O
PKs	O
)	O
are	O
attractive	O
targets	O
for	O
therapeutic	O
intervention	O
in	O
a	O
variety	O
of	O
diseases	O
.	O

TITLE	O
:	O
Trans	O
-	O
Esophageal	O
Doppler	O
Assessment	O
of	O
Acute	O
Hemodynamic	B-PROC
Changes	O
Due	O
to	O
Prone	O
Positioning	O
in	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Patients	O
.	O

RESULTS	O
:	O
The	O
baseline	O
hemodynamic	B-PROC
variables	O
of	O
26	O
included	O
patients	O
were	O
:	O
CI	O
3	O
.	O
5	O
(	O
3	O
.	O
1	O
-	O
4	O
.	O
3	O
)	O
L	O
/	O
min	O
/	O
m	O
,	O
peak	O
velocity	O
(	O
PV	O
)	O
83	O
.	O
2	O
(	O
60	O
.	O
9	O
-	O
99	O
.	O
3	O
)	O
cm	O
/	O
s	O
,	O
flow	O
time	O
corrected	O
(	O
FTc	O
)	O
341	O
(	O
283	O
-	O
377	O
)	O
ms	O
,	O
mean	O
acceleration	O
(	O
MA	O
)	O
9	O
.	O
0	O
(	O
7	O
.	O
04	O
-	O
11	O
.	O
7	O
)	O
m	O
/	O
s	O
.	O

ABSTRACT	O
:	O
A	O
boy	O
aged	O
6	O
years	O
and	O
3	O
months	O
developed	O
upper	O
respiratory	O
tract	O
infection	O
and	O
pyrexia	B-PROC
2	O
months	O
ago	O
and	O
was	O
given	O
oral	O
administration	O
of	O
nimesulide	O
by	O
his	O
parents	O
according	O
to	O
directions	O
.	O

Half	O
an	O
hour	O
later	O
,	O
the	O
boy	O
experienced	O
convulsions	O
and	O
cardiopulmonary	O
arrest	O
,	O
and	O
emergency	O
examination	O
found	O
hypoketotic	O
hypoglycemia	O
,	O
metabolic	B-PROC
acidosis	O
,	O
significant	O
increases	O
in	O
serum	O
aminotransferases	O
and	O
creatine	O
kinase	O
,	O
and	O
renal	O
damage	O
.	O

Recovery	O
of	O
consciousness	O
and	O
vital	O
signs	O
was	O
achieved	O
after	O
cardiopulmonary	O
resuscitation	O
,	O
but	O
severe	O
mental	O
and	O
movement	B-PROC
regression	O
was	O
observed	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
with	O
prone	O
position	O
ventilation	O
successfully	O
rescues	O
infantile	O
pertussis	O
:	O
a	O
case	O
report	O
and	O
literature	O
review	O
.	O

This	O
virus	O
is	O
lethal	O
and	O
is	O
a	O
close	O
relative	O
of	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
which	O
is	O
responsible	O
for	O
more	O
than	O
3000	O
deaths	B-PROC
in	O
2002	O
-	O
2003	O
.	O

ABSTRACT	O
:	O
To	O
summarize	O
results	O
of	O
the	O
most	O
recent	O
trials	O
on	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
VV	O
-	O
ECMO	O
)	O
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
to	O
elaborate	O
on	O
the	O
unmet	O
needs	O
regarding	O
VV	O
-	O
ECMO	O
management	O
in	O
this	O
setting	O
.	O

In	O
dogs	O
,	O
information	O
on	O
the	O
clinical	O
presentation	O
of	O
PVOD	O
is	O
scarce	O
and	O
the	O
cause	O
and	O
pathogenesis	B-PROC
of	O
this	O
disease	O
is	O
still	O
unknown	O
.	O

TITLE	O
:	O
Co	O
-	O
localization	B-PROC
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
dipeptidyl	O
peptidase	O
-	O
4	O
in	O
the	O
respiratory	O
tract	O
and	O
lymphoid	O
tissues	O
of	O
pigs	O
and	O
llamas	O
.	O

However	O
,	O
upon	O
experimental	O
infection	O
,	O
we	O
found	O
that	O
the	O
IBV	O
isolate	O
originating	O
from	O
AB	O
was	O
different	O
to	O
the	O
one	O
that	O
originated	O
in	O
SK	O
due	O
to	O
higher	O
tracheal	O
lesion	O
scores	O
and	O
lower	O
lung	O
viral	B-PROC
replication	I-PROC
and	O
lower	O
genome	O
loads	O
in	O
cecal	O
tonsils	O
.	O

The	O
in	O
vitro	O
results	O
indicated	O
that	O
LPS	O
time	O
-	O
dependently	O
enhanced	O
TRIM8	O
expression	B-PROC
in	O
lung	O
epithelial	O
cells	O
.	O

Furthermore	O
,	O
TRIM8	O
knockdown	O
evidently	O
improved	O
nuclear	O
factor	O
-	O
erythroid	O
2	O
related	O
factor	O
2	O
(	O
Nrf2	O
)	O
and	O
heme	O
oxygenase	B-PROC
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
expressions	O
in	O
lung	O
of	O
LPS	O
-	O
treated	O
mice	O
.	O

However	O
,	O
the	O
function	O
of	O
circRNAs	O
during	O
viral	B-PROC
infection	I-PROC
remains	O
largely	O
unknown	O
.	O

The	O
diagnosis	O
can	O
be	O
difficult	O
as	O
excessive	O
urine	O
output	O
and	O
high	O
serum	O
sodium	O
can	O
often	O
be	O
attributed	O
to	O
high	O
insensible	B-PROC
water	I-PROC
loss	I-PROC
in	O
the	O
extremely	O
premature	O
newborn	O
.	O

TITLE	O
:	O
Publisher	O
Correction	O
:	O
Stabilized	O
coronavirus	O
spikes	O
are	O
resistant	O
to	O
conformational	O
changes	O
induced	O
by	O
receptor	O
recognition	O
or	O
proteolysis	B-PROC
.	O

DPP4	O
was	O
expressed	B-PROC
in	O
the	O
five	O
bat	O
cells	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
,	O
with	O
significantly	O
higher	O
mRNA	B-PROC
expression	B-PROC
levels	O
than	O
those	O
in	O
non	O
-	O
susceptible	O
cells	O
(	O
P	O
=	O
0	O
.	O
0174	O
),	O
supporting	O
that	O
DPP4	O
expression	B-PROC
is	O
critical	O
for	O
MERS	O
-	O
CoV	O
infection	O
in	O
bats	O
.	O

While	O
TAT	O
peptides	O
facilitate	O
active	O
endocytosis	B-PROC
of	O
the	O
carriers	O
,	O
we	O
observed	O
that	O
these	O
peptides	O
did	O
not	O
promote	O
endosomal	O
escape	O
or	O
enhanced	O
intracellular	O
availability	O
of	O
doxorubicin	O
.	O

Arterial	O
blood	B-PROC
gases	I-PROC
were	O
drawn	O
to	O
verify	O
the	O
PaO2	O
and	O
the	O
SpO2	O
/	O
SaO2	B-PROC
correlation	O
.	O

Whole	O
-	O
lung	O
computed	O
tomography	O
analysis	O
and	O
pulmonary	B-PROC
function	I-PROC
test	O
were	O
performed	O
at	O
1	O
and	O
6	O
months	O
of	O
follow	O
-	O
up	O
.	O

At	O
6	O
months	O
driving	O
pressure	O
was	O
associated	O
with	O
lower	O
FVC	B-PROC
independently	O
on	O
tidal	O
volume	O
,	O
plateau	O
pressure	O
and	O
baseline	O
static	O
respiratory	O
compliance	O
after	O
adjustments	O
(	O
r	O
Even	O
in	O
patients	O
ventilated	O
with	O
protective	O
tidal	O
volume	O
,	O
higher	O
driving	O
pressure	O
is	O
associated	O
with	O
worse	O
long	O
-	O
term	O
pulmonary	B-PROC
function	I-PROC
and	O
structure	O
.	O

TITLE	O
:	O
Structural	O
basis	O
of	O
development	B-PROC
of	O
multi	O
-	O
epitope	O
vaccine	O
against	O
Middle	O
East	O
respiratory	O
syndrome	O
using	O
in	O
silico	O
approach	O
.	O

To	O
standardize	O
the	O
indirect	O
ELISA	O
development	B-PROC
,	O
serum	O
dilutions	O
(	O
1	O
:	O
100	O
,	O
1	O
:	O
200	O
and	O
1	O
:	O
400	O
)	O
and	O
different	O
concentrations	O
of	O
purified	O
rN	O
antigen	O
(	O
50	O
,	O
100	O
and	O
200	O
ng	O
/	O
well	O
)	O
were	O
tested	O
.	O

Insertion	O
of	O
a	O
SPECT	O
-	O
compatible	O
reporter	O
gene	O
into	O
a	O
virus	O
may	O
provide	O
insight	O
into	O
mechanisms	O
of	O
pathogenesis	B-PROC
and	O
viral	O
tropism	B-PROC
.	O

Clinical	O
management	O
of	O
the	O
same	O
complicating	O
pregnancy	O
presents	O
unique	O
challenges	O
balancing	B-PROC
maternal	O
and	O
fetal	O
well	O
-	O
being	O
.	O

Particularly	O
in	O
Pakistan	O
,	O
respiratory	O
infections	O
account	O
for	O
20	O
%	O
to	O
30	O
%	O
of	O
all	O
deaths	B-PROC
of	O
children	O
.	O

This	O
paper	O
aims	O
to	O
emphasise	O
the	O
need	O
for	O
standard	O
methods	O
to	O
record	O
the	O
incidence	O
and	O
etiology	O
of	O
associated	O
pathogens	O
in	O
order	O
to	O
provide	O
effective	O
treatment	O
against	O
viral	B-PROC
infections	I-PROC
of	O
the	O
respiratory	O
tract	O
and	O
to	O
reduce	O
death	B-PROC
rates	O
.	O

Undifferentiated	O
fever	B-PROC
challenges	O
physicians	O
to	O
correctly	O
diagnose	O
and	O
includes	O
ma	O
-	O
laria	O
,	O
dengue	O
,	O
and	O
enteric	O
fever	B-PROC
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
the	O
results	O
of	O
an	O
airflow	B-PROC
investigation	O
conducted	O
on	O
7	O
June	O
2015	O
as	O
part	O
of	O
a	O
series	O
of	O
epidemiologic	O
investigations	O
at	O
Pyeongtaek	O
St	O
.	O
Mary	O
'	O
s	O
Hospital	O
,	O
South	O
Korea	O
,	O
were	O
investigated	O
.	O

Influenza	O
epidemic	O
periods	B-PROC
were	O
retrieved	O
from	O
primary	O
care	O
sentinel	O
influenza	O
surveillance	O
data	O
.	O

In	O
this	O
Gem	O
,	O
we	O
discuss	O
recent	O
insights	O
into	O
how	O
tetraspanins	O
assemble	O
viral	O
entry	O
and	O
exit	O
platforms	O
on	O
cell	O
membranes	O
,	O
and	O
we	O
speculate	O
that	O
tetraspanins	O
contribute	O
to	O
nonviral	O
membrane	B-PROC
fusions	I-PROC
by	O
similar	O
mechanisms	O
.	O

TITLE	O
:	O
Cytokine	O
-	O
Mediated	O
Tissue	O
Injury	O
in	O
Non	O
-	O
human	O
Primate	O
Models	O
of	O
Viral	B-PROC
Infections	I-PROC
.	O

This	O
unusual	O
neurological	O
complication	O
could	O
result	O
in	O
additional	O
complications	O
including	O
ventilator	O
associated	O
pneumonia	O
,	O
prolonged	O
hospital	O
stay	O
and	O
then	O
would	O
further	O
increase	O
the	O
death	B-PROC
rate	O
,	O
and	O
huge	O
costs	O
.	O

Using	O
the	O
GST	O
pull	O
-	O
down	O
approach	O
and	O
a	O
CO	O
-	O
IP	O
assay	O
,	O
the	O
M	O
protein	O
was	O
found	O
to	O
interact	O
with	O
porcine	O
intestinal	O
cells	O
via	O
eukaryotic	O
translation	B-PROC
initiation	I-PROC
factor	O
4	O
-	O
alpha	O
(	O
EIF4A2	O
),	O
an	O
essential	O
component	O
of	O
the	O
cellular	O
translational	B-PROC
machinery	O
.	O

ABSTRACT	O
:	O
A	O
44	O
-	O
year	O
-	O
old	O
male	O
with	O
ongoing	O
chest	O
pain	O
and	O
left	B-PROC
ventricular	I-PROC
ejection	I-PROC
fraction	O
<	O
20	O
%	O
was	O
transferred	O
from	O
a	O
peripheral	O
hospital	O
with	O
intra	O
-	O
aortic	O
balloon	O
pump	O
placement	O
following	O
a	O
non	O
-	O
ST	O
-	O
elevation	O
myocardial	O
infarction	O
(	O
STEMI	O
).	O

TITLE	O
:	O
[	O
The	O
first	O
case	O
of	O
severe	O
avian	O
influenza	O
A	O
(	O
H7N9	O
)	O
in	O
Guangdong	O
Province	O
in	O
2018	O
successfully	O
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
].	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
PEDV	O
can	O
be	O
shed	O
in	O
semen	O
from	O
SPF	O
(	O
specific	O
pathogens	O
free	O
)	O
boars	O
infected	O
by	O
a	O
French	O
S	O
-	O
InDel	B-PROC
PEDV	O
strain	O
(	O
PEDV	O
/	O
FR	O
/	O
001	O
/	O
2014	O
)	O
and	O
in	O
case	O
of	O
positive	O
semen	O
to	O
determine	O
the	O
infectivity	O
of	O
that	O
semen	O
.	O

Currently	O
there	O
are	O
no	O
effective	O
treatments	O
or	O
vaccines	O
for	O
PDCoV	O
.	O
In	O
particular	O
,	O
the	O
pathogenesis	B-PROC
of	O
PDCoV	O
infection	O
is	O
still	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
reported	O
that	O
inoculating	O
conventional	O
weaned	B-PROC
piglets	O
with	O
1	O
×	O
10	O

TITLE	O
:	O
The	O
Sudden	O
Infant	O
Death	B-PROC
Syndrome	O
mechanism	O
of	O
death	B-PROC
may	O
be	O
a	O
non	O
-	O
septic	O
hyper	O
-	O
dynamic	O
shock	O
.	O

ABSTRACT	O
:	O
Sudden	O
Infant	O
Death	B-PROC
Syndrome	O
(	O
SIDS	O
)	O
mechanisms	O
of	O
death	B-PROC
remains	O
obscured	O
.	O

TITLE	O
:	O
Development	B-PROC
of	O
a	O
SYBR	O
green	O
-	O
based	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
for	O
rapid	O
detection	O
of	O
the	O
emerging	O
swine	O
acute	O
diarrhea	O
syndrome	O
coronavirus	O
.	O

In	O
this	O
study	O
,	O
a	O
SYBR	O
green	O
-	O
based	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
technique	O
was	O
established	O
for	O
rapid	O
detection	O
and	O
monitoring	O
of	O
this	O
emerging	O
virus	O
.	O

ABSTRACT	O
:	O
Spotted	O
fever	B-PROC
group	O
of	O
rickettsial	O
infections	O
are	O
emerging	O
in	O
Sri	O
Lanka	O
.	O

Regarding	O
the	O
clinical	O
aspects	O
of	O
pulmonary	O
complications	O
,	O
the	O
most	O
frequent	O
were	O
ARDS	O
,	O
atelectasisand	O
bronchopneumopathies	O
,	O
determined	O
by	O
the	O
etiological	O
factors	O
that	O
had	O
caused	O
the	O
acute	O
kidney	O
injury	O
in	O
the	O
first	O
place	O
,	O
and	O
by	O
the	O
acute	O
kidney	O
injury	O
-	O
induced	O
physiological	B-PROC
effects	I-PROC
.	O

ABSTRACT	O
:	O
Although	O
several	O
reports	O
suggest	O
that	O
the	O
entry	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
depends	O
on	O
lipid	O
rafts	O
and	O
low	O
pH	O
,	O
the	O
endocytic	O
route	O
and	O
intracellular	O
trafficking	B-PROC
are	O
unclear	O
.	O

The	O
transition	O
in	O
husbandry	O
leading	O
to	O
high	O
density	O
camel	O
farming	O
along	O
with	O
increased	O
exposure	O
to	O
humans	O
,	O
combined	O
with	O
the	O
increase	O
of	O
camel	O
movement	B-PROC
for	O
the	O
racing	O
and	O
breeding	B-PROC
industry	O
,	O
have	O
led	O
to	O
a	O
convergence	O
of	O
factors	O
driving	O
spillover	O
of	O
MERS	O
-	O
CoV	O
from	O
camels	O
to	O
humans	O
.	O

TITLE	O
:	O
Rasburicase	O
induced	O
severe	O
hemolysis	B-PROC
and	O
methemoglobinemia	O
in	O
a	O
Caucasian	O
patient	O
complicated	O
by	O
acute	O
renal	O
failure	O
and	O
ARDS	O
.	O

He	O
also	O
had	O
a	O
discrepancy	O
of	O
the	O
transcutaneous	O
saturation	O
(	O
75	O
%)	O
and	O
the	O
saturation	O
in	O
an	O
arterial	O
blood	B-PROC
gas	I-PROC
value	O
(	O
99	O
%).	O

However	O
,	O
there	O
is	O
a	O
paucity	O
of	O
literature	O
on	O
using	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
VV	O
ECMO	O
)	O
to	O
treat	O
ARDS	O
in	O
patients	O
with	O
extremity	O
obesity	O
[	O
Ull	O
2015	O
;	O
Belliato	O
2016	O
;	O
Kadakia	O
2017	O
]-	O
a	O
population	O
that	O
is	O
often	O
inherently	O
discriminated	O
against	O
with	O
regards	O
to	O
advanced	O
medical	O
and	O
surgical	O
therapies	O
because	O
of	O
the	O
practical	O
challenges	O
of	O
treating	O
someone	O
of	O
great	O
size	O
as	O
well	O
as	O
the	O
inherent	O
social	O
(	O
and	O
professional	O
)	O
biases	O
against	O
such	O
patients	O
.	O

He	O
developed	O
a	O
high	O
fever	B-PROC
soon	O
after	O
lymphography	O
,	O
followed	O
by	O
severe	O
ARDS	O
requiring	O
artificial	O
respiration	B-PROC
5	O
days	O
later	O
.	O

Interleukin	O
(	O
IL	O
)-	O
6	O
acts	O
as	O
a	O
mediator	O
between	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
reactivity	O
by	O
initiating	O
trans	O
-	O
and	O
classical	O
-	O
signaling	B-PROC
,	O
respectively	O
.	O

TITLE	O
:	O
Identification	O
and	O
formation	B-PROC
mechanism	O
of	O
a	O
novel	O
noncoding	O
RNA	O
produced	O
by	O
avian	O
infectious	O
bronchitis	O
virus	O
.	O

Clinical	O
manifestations	O
vary	O
significantly	O
depending	O
on	O
the	O
type	O
of	O
virus	O
and	O
the	O
type	O
and	O
degree	O
of	O
immunosuppression	B-PROC
,	O
ranging	O
from	O
asymptomatic	O
or	O
mild	O
disease	O
to	O
rapidly	O
progressive	O
fatal	O
pneumonia	O
Infections	O
in	O
this	O
population	O
are	O
characterized	O
by	O
a	O
high	O
rate	O
of	O
progression	O
from	O
upper	O
to	O
lower	O
respiratory	O
tract	O
infection	O
and	O
prolonged	O
viral	B-PROC
shedding	I-PROC
.	O

Effective	O
control	O
of	O
virus	B-PROC
replication	I-PROC
is	O
nonetheless	O
associated	O
with	O
tissue	O
damage	O
,	O
characterized	O
by	O
demyelinating	O
lesions	O
.	O

TITLE	O
:	O
Combining	O
a	O
Fusion	O
Inhibitory	O
Peptide	O
Targeting	B-PROC
the	O
MERS	O
-	O
CoV	O
S2	O
Protein	O
HR1	O
Domain	O
and	O
a	O
Neutralizing	O
Antibody	B-PROC
Specific	O
for	O
the	O
S1	O
Protein	O
Receptor	O
-	O
Binding	O
Domain	O
(	O
RBD	O
)	O
Showed	O
Potent	O
Synergism	B-PROC
against	O
Pseudotyped	O
MERS	O
-	O
CoV	O
with	O
or	O
without	O
Mutations	O
in	O
RBD	O
.	O

This	O
included	O
feed	O
suppliers	O
,	O
animal	O
movement	B-PROC
,	O
animal	O
transportation	O
companies	O
,	O
semen	O
suppliers	O
and	O
a	O
complete	O
network	O
with	O
all	O
service	O
providers	O
.	O

Here	O
,	O
the	O
role	O
of	O
Poldip2	O
in	O
regulating	O
vascular	B-PROC
permeability	I-PROC
and	O
inflammation	O
in	O
a	O
mouse	O
model	O
of	O
ARDS	O
was	O
assessed	O
.	O

Heterozygous	O
deletion	O
of	O
Poldip2	O
was	O
found	O
to	O
reduce	O
LPS	O
-	O
induced	O
mortality	O
within	O
20	O
h	O
,	O
lung	O
inflammatory	O
signaling	B-PROC
,	O
and	O
leukocyte	O
infiltration	O
.	O

ABSTRACT	O
:	O
The	O
protein	O
kinase	O
RIPK1	O
plays	O
a	O
crucial	O
role	O
at	O
the	O
crossroad	O
of	O
stress	O
-	O
induced	O
signaling	B-PROC
pathways	B-PROC
that	O
affects	O
cell	O
'	O
s	O
decision	O
to	O
live	O
or	O
die	O
.	O

Site	O
-	O
specific	O
editing	O
of	O
pAPN	O
reduced	O
TGEV	O
proliferation	O
in	O
ST	O
cells	O
by	O
96	O
%-	O
99	O
%	O
at	O
different	O
time	O
periods	B-PROC
post	O
-	O
infection	O
.	O

The	O
model	O
that	O
included	O
all	O
four	O
variables	O
proved	O
best	O
to	O
identify	O
patients	O
with	O
the	O
highest	O
or	O
lowest	O
risk	O
of	O
death	B-PROC
(	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
,	O
0	O
.	O
86	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
84	O
-	O
0	O
.	O
88	O
).	O

Brief	O
rationale	O
:	O
We	O
present	O
an	O
original	O
research	O
article	O
and	O
literature	O
review	O
entitled	O
""""	O
Comprehensive	O
treatment	O
in	O
severe	O
dengue	O
during	O
preterm	O
and	O
term	O
labor	B-PROC
:	O
could	O
tocolysis	O
be	O
useful	O
?	O

We	O
concluded	O
that	O
although	O
tocolysis	O
is	O
not	O
regularly	O
used	O
in	O
patients	O
with	O
dengue	O
fever	B-PROC
,	O
our	O
results	O
suggest	O
that	O
our	O
protocol	O
could	O
benefit	O
pregnant	O
patients	O
with	O
thrombocytopenia	O
due	O
to	O
dengue	O
;	O
however	O
,	O
prospective	O
studies	O
which	O
determine	O
the	O
safety	O
and	O
effectiveness	O
of	O
our	O
intervention	O
are	O
needed	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
can	O
manifest	O
as	O
a	O
mild	O
illness	O
,	O
acute	O
respiratory	O
distress	O
,	O
organ	O
failure	O
,	O
or	O
death	B-PROC
.	O

However	O
,	O
few	O
options	O
remain	O
in	O
cases	O
of	O
refractory	O
hypoxemia	O
on	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

Collectively	O
,	O
our	O
study	O
identifies	O
a	O
basic	O
lipogenic	O
transactivation	B-PROC
event	O
with	O
broad	O
relevance	O
to	O
human	O
viral	B-PROC
infections	I-PROC
and	O
represents	O
SREBP	O
as	O
a	O
potential	O
target	O
for	O
the	O
development	B-PROC
of	O
broad	O
-	O
spectrum	O
antiviral	O
strategies	O
.	O

Equine	O
coronavirus	O
and	O
Salmonella	O
infections	O
share	O
clinical	O
features	O
,	O
suggesting	O
both	O
diseases	O
should	O
be	O
differential	O
diagnoses	O
for	O
horses	O
with	O
fever	B-PROC
and	O
enteric	O
clinical	O
signs	O
.	O

RESULTS	O
:	O
Most	O
common	O
presenting	O
complaints	O
were	O
fever	B-PROC
and	O
colic	O
and	O
were	O
similar	O
across	O
groups	O
.	O

We	O
engineered	O
a	O
biotin	O
ligase	O
into	O
a	O
coronaviral	O
replication	O
/	O
transcription	B-PROC
complex	O
(	O
RTC	O
)	O
and	O
identified	O
>	O
500	O
host	O
proteins	O
constituting	O
the	O
RTC	O
microenvironment	O
.	O

Collectively	O
,	O
we	O
establish	O
a	O
spatial	O
link	O
between	O
viral	O
RNA	B-PROC
synthesis	I-PROC
and	O
diverse	O
host	O
factors	O
of	O
unprecedented	O
breadth	O
.	O

These	O
data	O
indicate	O
that	O
MERS	O
-	O
CoV	O
infection	O
induces	O
overactivation	O
of	O
complement	O
,	O
which	O
may	O
contribute	O
to	O
pyroptosis	B-PROC
and	O
inflammation	O
.	O

TITLE	O
:	O
Pathogenicity	O
and	O
immunogenicity	O
of	O
attenuated	O
porcine	O
epidemic	O
diarrhea	O
virus	O
PC22A	O
strain	O
in	O
conventional	O
weaned	B-PROC
pigs	O
.	O

PEDV	O
PC22A	O
P100C4	O
and	O
P120	O
were	O
fully	O
attenuated	O
in	O
weaned	B-PROC
pigs	O
but	O
failed	O
to	O
elicit	O
protection	O
against	O
virulent	O
P3	O
challenge	O
.	O

Although	O
the	O
IBVPR03	O
strain	O
is	O
S1	O
-	O
genotyped	O
as	O
Massachusetts	O
with	O
a	O
high	O
genomic	O
similarity	O
to	O
the	O
H	O
-	O
120	O
vaccine	O
strains	O
,	O
surprisingly	O
,	O
we	O
found	O
no	O
tropism	B-PROC
or	O
pathogenicity	O
to	O
the	O
trachea	O
in	O
birds	O
infected	O
with	O
this	O
strain	O
.	O

The	O
results	O
of	O
complete	O
genome	O
sequence	O
analysis	O
confirmed	O
the	O
previously	O
identified	O
recombination	B-PROC
events	O
in	O
the	O
four	O
IBV	O
strains	O
and	O
revealed	O
additional	O
recombination	B-PROC
events	O
in	O
different	O
genomic	O
regions	O
of	O
strains	O
I0718	O
/	O
17	O
and	O
I0724	O
/	O
17	O
,	O
suggesting	O
that	O
the	O
two	O
strains	O
originated	O
from	O
multiple	O
recombination	B-PROC
events	O
between	O
4	O
/	O
91	O
-	O
like	O
and	O
YX10	O
-	O
like	O
viruses	O
.	O

Both	O
patients	O
were	O
diagnosed	O
with	O
AE	O
-	O
IPF	O
accompanying	O
acute	O
pertussis	O
infection	O
based	O
on	O
chest	O
computed	O
tomography	O
and	O
serum	O
pertussis	O
toxin	O
antibody	B-PROC
>	O
100	O
EU	O
/	O
mL	O
.	O
Both	O
patients	O
were	O
treated	O
with	O
macrolide	O
antibiotics	O
and	O
systemic	O
corticosteroids	O
.	O

Post	B-PROC
-	I-PROC
translational	B-PROC
modifications	I-PROC
of	O
viral	O
proteins	O
introduced	O
by	O
ISG15	O
have	O
also	O
been	O
observed	O
to	O
directly	O
affect	O
the	O
function	O
of	O
numerous	O
viral	O
proteins	O
.	O

Piglets	O
orally	O
administered	O
scFvs	O
showed	O
no	O
to	O
mild	O
clinical	O
symptoms	O
,	O
significantly	O
less	O
viral	B-PROC
shedding	I-PROC
,	O
no	O
mortality	O
and	O
no	O
intestinal	O
lesions	O
.	O

For	O
building	O
up	O
more	O
suitable	O
animal	O
models	O
,	O
we	O
compare	O
the	O
current	O
animal	O
models	O
recapitulating	O
pathogenesis	B-PROC
and	O
summarize	O
the	O
potential	O
role	O
of	O
host	O
receptors	O
contributing	O
to	O
diverse	O
host	O
affinity	O
in	O
various	O
species	O
.	O

Furthermore	O
,	O
the	O
PEDV	O
N	O
protein	O
harbouring	O
truncations	O
of	O
amino	O
acids	O
(	O
aa	O
)	O
1	O
to	O
170	O
or	O
aa	O
125	O
to	O
301	O
was	O
demonstrated	O
to	O
cross	O
-	O
react	O
with	O
the	O
anti	O
-	O
TGEV	O
N	O
polyclonal	O
antibody	B-PROC
(	O
PAb	B-PROC
),	O
whereas	O
the	O
truncation	O
-	O
expressing	O
aa	O
302	O
to	O
401	O
resulted	O
in	O
a	O
specific	O
reaction	O
with	O
the	O
anti	O
-	O
PEDV	O
N	O
PAb	B-PROC
but	O
not	O
with	O
the	O
anti	O
-	O
TGEV	O
N	O
PAb	B-PROC
.	O

The	O
clinical	O
signs	O
and	O
pathogenesis	B-PROC
of	O
the	O
three	O
viruses	O
are	O
similar	O
.	O

As	O
compared	O
with	O
pressure	O
-	O
volume	O
curve	O
,	O
the	O
EIT	O
-	O
guided	O
PEEP	O
titration	O
may	O
be	O
associated	O
with	O
improved	O
oxygenation	B-PROC
,	O
compliance	O
,	O
driving	O
pressure	O
,	O
and	O
weaning	B-PROC
success	O
rate	O
.	O

Primary	O
analysis	O
focused	O
on	O
the	O
association	O
between	O
sVE	O
-	O
cadherin	O
levels	O
and	O
the	O
development	B-PROC
of	O
AKI	O
,	O
AKI	O
-	O
RRT	O
,	O
other	O
organ	O
dysfunction	O
as	O
defined	O
by	O
Brussels	O
organ	O
failure	O
scores	O
,	O
pulmonary	O
versus	O
non	O
-	O
pulmonary	O
sepsis	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
in	O
-	O
hospital	O
mortality	O
.	O

Shedding	O
of	O
sVE	O
-	O
cadherin	O
is	O
associated	O
with	O
severe	O
acute	O
kidney	O
injury	O
and	O
with	O
more	O
severe	O
organ	O
dysfunction	O
in	O
patients	O
with	O
sepsis	O
,	O
suggesting	O
that	O
breakdown	B-PROC
of	O
endothelial	O
adherens	O
junctions	O
may	O
contribute	O
to	O
the	O
pathogenesis	B-PROC
of	O
organ	O
dysfunction	O
in	O
sepsis	O
.	O

CONCLUSIONS	O
:	O
Shedding	O
of	O
sVE	O
-	O
cadherin	O
is	O
associated	O
with	O
severe	O
acute	O
kidney	O
injury	O
and	O
with	O
more	O
severe	O
organ	O
dysfunction	O
in	O
patients	O
with	O
sepsis	O
,	O
suggesting	O
that	O
breakdown	B-PROC
of	O
endothelial	O
adherens	O
junctions	O
may	O
contribute	O
to	O
the	O
pathogenesis	B-PROC
of	O
organ	O
dysfunction	O
in	O
sepsis	O
.	O

Sixteen	O
patients	O
(	O
13	O
.	O
9	O
%)	O
died	B-PROC
.	O

Our	O
previous	O
work	O
revealed	O
that	O
extracellular	O
vesicle	O
(	O
EV	O
)-	O
mediated	O
inflammasome	O
signaling	B-PROC
plays	O
a	O
crucial	O
role	O
in	O
the	O
pathophysiology	O
of	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)-	O
induced	O
lung	O
injury	O
.	O

Delivery	O
of	O
serum	O
-	O
derived	O
EVs	O
to	O
HMVEC	O
-	O
L	O
activated	O
the	O
inflammasome	O
and	O
resulted	O
in	O
endothelial	O
cell	O
pyroptosis	B-PROC
.	O

In	O
terms	O
of	O
gene	B-PROC
expression	I-PROC
(	O
mRNA	O
)	O
in	O
blood	O
there	O
have	O
been	O
found	O
to	O
be	O
increases	O
in	O
neutrophil	O
-	O
related	O
genes	O
in	O
sepsis	O
-	O
induced	O
and	O
influenza	O
-	O
induced	O
ARDS	O
,	O
but	O
whole	O
blood	O
expression	B-PROC
does	O
not	O
give	O
a	O
robust	O
diagnostic	O
test	O
for	O
ARDS	O
.	O

These	O
viruses	O
are	O
well	O
-	O
recognized	O
for	O
their	O
ability	O
to	O
change	O
tissue	B-PROC
tropism	B-PROC
,	O
to	O
hurdle	O
the	O
interspecies	O
barriers	O
and	O
to	O
adapt	O
ecological	O
variations	O
.	O

LCA60	O
is	O
a	O
MERS	O
-	O
CoV	O
-	O
neutralizing	O
monoclonal	O
antibody	B-PROC
isolated	O
from	O
a	O
convalescent	O
MERS	O
patient	O
.	O

ABSTRACT	O
:	O
The	O
occurrence	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
significantly	O
increases	O
the	O
mortality	O
and	O
morbidity	O
of	O
major	O
burns	O
;	O
there	O
are	O
few	O
laboratory	O
markers	O
that	O
predict	O
the	O
development	B-PROC
of	O
ARDS	O
in	O
severe	O
burns	O
.	O

ABSTRACT	O
:	O
Enveloped	O
viruses	O
such	O
as	O
coronaviruses	O
or	O
influenza	O
virus	O
require	O
proteolytic	B-PROC
cleavage	B-PROC
of	O
their	O
fusion	O
protein	O
to	O
be	O
able	O
to	O
infect	O
the	O
host	O
cell	O
.	O

We	O
also	O
used	O
this	O
method	O
in	O
combination	O
with	O
bioinformatics	O
to	O
test	O
furin	O
cleavage	B-PROC
activity	O
of	O
feline	O
coronavirus	O
spike	O
proteins	O
from	O
different	O
serotypes	O
and	O
strains	O
.	O

While	O
HIV	O
-	O
1	O
vaccine	O
development	B-PROC
has	O
been	O
a	O
driving	O
force	O
behind	O
these	O
technologies	O
and	O
concepts	O
,	O
clinical	O
proof	O
-	O
of	O
-	O
concept	O
for	O
structure	O
-	O
based	O
vaccine	O
design	O
may	O
first	O
be	O
achieved	O
for	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
where	O
conformation	O
-	O
dependent	O
access	O
to	O
neutralization	O
-	O
sensitive	O
epitopes	O
on	O
the	O
fusion	O
glycoprotein	O
determines	O
the	O
capacity	O
to	O
induce	O
potent	O
neutralizing	O
activity	O
.	O

Expression	B-PROC
of	O
genes	O
encoding	O
transcription	B-PROC
factors	O
STAT1	O
and	O
2	O
,	O
regulating	O
signalling	B-PROC
pathways	B-PROC
,	O
particularly	O
of	O
the	O
interferons	O
,	O
was	O
also	O
higher	O
.	O

TITLE	O
:	O
Research	O
on	O
the	O
Mechanism	O
of	O
Cross	O
-	O
species	O
Infection	O
and	O
Transmission	O
for	O
Animal	O
-	O
origin	O
Emerging	O
and	O
Re	O
-	O
emerging	O
Zoonosis	O
Has	O
Won	O
Support	O
by	O
the	O
National	O
Key	O
Research	O
and	O
Development	B-PROC
Program	O
of	O
China	O
.	O

Omega	O
-	O
3	O
PUFAs	O
administration	O
was	O
associated	O
with	O
a	O
significant	O
improvement	O
in	O
early	O
PaO	B-PROC

Five	O
days	O
post	O
-	O
challenge	O
,	O
viral	O
load	O
,	O
clinical	O
signs	O
,	O
ciliostasis	O
,	O
tracheal	O
histopathology	O
,	O
and	O
antibody	B-PROC
titers	O
in	O
serum	O
and	O
tears	O
were	O
evaluated	O
.	O

The	O
present	O
study	O
describes	O
development	B-PROC
and	O
evaluation	O
of	O
a	O
multiplexed	O
magnetic	O
microsphere	O
immunoassay	O
(	O
MMIA	O
)	O
to	O
simultaneously	O
detect	O
immunoglobulin	B-PROC
G	O
(	O
IgG	O
)	O
antibodies	O
specific	O
for	O
recombinant	O
nucleocapsid	O
proteins	O
(	O
recN	O
)	O
from	O
hCoVs	O
229E	O
,	O
NL63	O
,	O
OC43	O
,	O
HKU1	O
,	O
SARS	O
-	O
CoV	O
,	O
and	O
MERS	O
-	O
CoV	O
.	O
We	O
used	O
paired	O
human	O
sera	O
to	O
screen	O
for	O
IgG	O
with	O
reactivity	O
against	O
six	O
hCoVs	O
to	O
determine	O
assay	O
sensitivity	O
,	O
specificity	O
and	O
reproducibility	O
.	O

E	O
.	O
coli	O
isolates	O
from	O
calves	O
with	O
diarrhea	O
showed	O
a	O
much	O
higher	O
resistance	B-PROC
profile	O
with	O
16	O
(	O
53	O
.	O
3	O
%)	O
multiresistant	O
isolates	O
.	O

Finally	O
,	O
several	O
approaches	O
to	O
minimize	O
P	O
-	O
SILI	O
while	O
maintaining	O
some	O
diaphragm	O
activity	O
(	O
e	O
.	O
g	O
.	O
partial	O
neuromuscular	B-PROC
blockade	I-PROC
,	O
high	O
PEEP	O
)	O
appear	O
promising	O
.	O

TITLE	O
:	O
Evidence	O
for	O
Cross	O
-	O
Protection	O
Against	O
Subsequent	O
Febrile	B-PROC
Respiratory	O
Illness	O
Episodes	O
From	O
Prior	O
Infections	O
by	O
Different	O
Viruses	O
Among	O
Singapore	O
Military	O
Recruits	O
2009	O
-	O
2014	O
.	O

If	O
mechanical	O
ventilation	O
is	O
needed	O
,	O
ventilation	O
modes	O
allowing	O
spontaneous	O
breathing	B-PROC
seem	O
beneficial	O
(	O
quality	O
of	O
evidence	O
[	O
QoE	O
]:	O
very	O
low	O
).	O

Recommendations	O
for	O
patients	O
undergoing	O
mechanical	O
ventilation	O
include	O
lung	O
-	O
protective	O
ventilation	O
,	O
early	O
sponta	O
-	O
neous	O
breathing	B-PROC
and	O
mobilization	O
,	O
weaning	B-PROC
protocols	O
,	O
and	O
,	O
for	O
those	O
with	O
severe	O
impairment	O
of	O
gas	O
exchange	O
,	O
prone	O
positioning	O
.	O

CONCLUSIONS	O
:	O
Recommendations	O
for	O
patients	O
undergoing	O
mechanical	O
ventilation	O
include	O
lung	O
-	O
protective	O
ventilation	O
,	O
early	O
sponta	O
-	O
neous	O
breathing	B-PROC
and	O
mobilization	O
,	O
weaning	B-PROC
protocols	O
,	O
and	O
,	O
for	O
those	O
with	O
severe	O
impairment	O
of	O
gas	O
exchange	O
,	O
prone	O
positioning	O
.	O

A	O
recombination	B-PROC
event	O
in	O
S	O
gene	O
of	O
PEDV	O
/	O
Belgorod	O
/	O
dom	O
/	O
2008	O
was	O
detected	O
.	O

An	O
arterial	O
blood	B-PROC
gas	I-PROC
(	O
ABG	O
)	O
specifically	O
tests	O
blood	O
taken	O
from	O
an	O
artery	O
.	O

Though	O
the	O
patient	O
was	O
treated	O
with	O
intubation	O
and	O
mechanical	O
ventilation	O
(	O
MV	O
),	O
his	O
oxygenation	B-PROC
was	O
still	O
not	O
stable	O
.	O

In	O
contrast	O
,	O
the	O
propagation	O
of	O
icPEDV	O
-	O
EnUmt	O
was	O
impaired	O
in	O
porcine	O
epithelial	O
cells	O
(	O
LLC	O
-	O
PK1	O
),	O
where	O
we	O
detected	O
an	O
early	O
and	O
robust	O
transcriptional	B-PROC
activation	I-PROC
of	O
type	O
I	O
and	O
type	O
III	O
IFNs	O
.	O

Infection	O
of	O
piglets	O
with	O
the	O
parental	O
Colorado	O
strain	O
,	O
icPEDV	O
-	O
wt	O
,	O
or	O
icPEDV	O
-	O
EnUmt	O
revealed	O
that	O
all	O
viruses	O
replicated	O
in	O
the	O
gut	O
and	O
induced	O
diarrhea	O
;	O
however	O
,	O
there	O
was	O
reduced	O
viral	B-PROC
shedding	I-PROC
and	O
mortality	O
in	O
the	O
icPEDV	O
-	O
EnUmt	O
-	O
infected	O
animals	O
.	O

These	O
results	O
indicate	O
that	O
scFv	O
antibodies	O
provide	O
protection	O
against	O
viral	B-PROC
infection	I-PROC
in	O
vitro	O
and	O
may	O
be	O
a	O
therapeutic	O
candidate	O
for	O
both	O
prevention	O
and	O
treatment	O
of	O
TGEV	O
infection	O
in	O
swine	O
.	O

ABSTRACT	O
:	O
In	O
this	O
Annual	O
Review	O
Issue	O
of	O
The	O
Journal	O
of	O
Pathology	O
,	O
we	O
present	O
15	O
invited	O
reviews	O
on	O
topical	O
aspects	O
of	O
pathology	O
,	O
ranging	O
from	O
the	O
impacts	O
of	O
the	O
microbiome	O
in	O
human	O
disease	O
through	O
mechanisms	O
of	O
cell	B-PROC
death	I-PROC
and	O
autophagy	B-PROC
to	O
recent	O
advances	O
in	O
immunity	B-PROC
and	O
the	O
uses	O
of	O
genomics	O
for	O
understanding	O
,	O
classifying	O
and	O
treating	O
human	O
cancers	O
.	O

The	O
assay	O
specifically	O
detected	O
PEDV	O
and	O
PCV3	O
,	O
with	O
no	O
fluorescence	O
detected	O
for	O
other	O
non	O
-	O
targeted	B-PROC
pig	O
pathogens	O
.	O

Others	O
,	O
such	O
as	O
rhabdomyolysis	O
and	O
malignant	O
hyperthermia	B-PROC
,	O
may	O
produce	O
serious	O
medical	O
complications	O
.	O

ABSTRACT	O
:	O
In	O
the	O
Berlin	O
definition	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
stratified	O
into	O
three	O
stages	O
according	O
to	O
oxygenation	B-PROC
severity	O
at	O
the	O
onset	O
.	O

Multivariate	O
analyses	O
revealed	O
that	O
elevated	O
blood	O
lactate	O
level	O
(≥	O
2	O
.	O
0	O
mmol	O
/	O
L	O
)	O
and	O
increased	O
HRCT	O
scores	O
were	O
significantly	O
associated	O
with	O
weaning	B-PROC
failure	O
and	O
30	O
-	O
day	O
mortality	O
of	O
the	O
patients	O
with	O
ARDS	O
.	O

In	O
addition	O
,	O
the	O
overexpression	B-PROC
of	O
miR	O
‑	O
223	O
reduced	O
inflammation	O
and	O
suppressed	O
the	O
NLRP3	O
inflammasome	O
and	O
TLR4	O
/	O
NF	O
‑	O
κB	O
signaling	B-PROC
pathway	I-PROC
via	O
RHOB	O
in	O
the	O
in	O
vitro	O
model	O
.	O

Duration	O
of	O
antibiotic	O
therapy	O
and	O
additional	O
anticoagulation	B-PROC
treatment	O
are	O
still	O
under	O
discussion	O
.	O

Fourteen	O
patients	O
were	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
and	O
six	O
patients	O
died	B-PROC
(	O
five	O
premature	O
deaths	B-PROC
).	O

TITLE	O
:	O
Kaempferol	O
reduces	O
K63	O
-	O
linked	O
polyubiquitination	B-PROC
to	O
inhibit	O
nuclear	O
factor	O
-	O
κB	O
and	O
inflammatory	B-PROC
responses	I-PROC
in	O
acute	O
lung	O
injury	O
in	O
mice	O
.	O

Our	O
study	O
shows	O
that	O
KPF	O
is	O
effective	O
in	O
reducing	O
lung	O
damage	O
induced	O
by	O
LPS	O
by	O
modulating	O
TRAF6	O
polyubiquitination	B-PROC
.	O

TITLE	O
:	O
Longitudinal	O
active	O
sampling	O
for	O
respiratory	O
viral	B-PROC
infections	I-PROC
across	O
age	O
groups	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyse	O
the	O
metabolomics	O
of	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
for	O
the	O
identification	O
of	O
metabolic	B-PROC
markers	O
with	O
potential	O
diagnostic	O
and	O
prognostic	O
value	O
.	O

p53	O
has	O
also	O
been	O
shown	O
to	O
be	O
important	O
for	O
responses	O
to	O
certain	O
viral	B-PROC
infections	I-PROC
.	O

The	O
test	O
results	O
were	O
consistent	O
with	O
the	O
results	O
from	O
traditional	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
or	O
reverse	B-PROC
transcription	B-PROC
-	O
PCR	O
analyses	O
.	O

The	O
engineered	O
oligomeric	O
Nbs	O
were	O
very	O
stable	O
under	O
extreme	O
conditions	O
,	O
including	O
low	O
or	O
high	O
pH	O
,	O
protease	O
(	O
pepsin	O
),	O
chaotropic	O
denaturant	O
(	O
urea	O
),	O
and	O
high	B-PROC
temperature	I-PROC
.	O

Importantly	O
,	O
Di	O
-	O
Nb	O
and	O
Tri	O
-	O
Nb	O
exerted	B-PROC
significantly	O
elevated	O
broad	O
-	O
spectrum	O
neutralizing	O
activity	O
against	O
at	O
least	O
19	O
human	O
and	O
camel	O
MERS	O
-	O
CoV	O
strains	O
isolated	O
in	O
different	O
countries	O
and	O
years	O
.	O

Although	O
the	O
precise	O
pathogenesis	B-PROC
of	O
CRS	O
and	O
neurotoxicity	O
aren	O
'	O
t	O
fully	O
elucidated	O
,	O
risk	O
factors	O
and	O
mitigation	O
strategies	O
have	O
been	O
reported	O
.	O

Together	O
,	O
these	O
data	O
determined	O
that	O
PEDV	O
nsp4	O
could	O
upregulate	O
pro	O
-	O
inflammatory	O
cytokine	O
and	O
chemokine	O
expression	B-PROC
,	O
inhibiting	O
viral	B-PROC
replication	I-PROC
in	O
vitro	O
.	O

We	O
identified	O
dampened	O
transcriptional	B-PROC
priming	O
,	O
a	O
novel	O
splice	O
variant	O
and	O
an	O
altered	O
leucine	O
-	O
rich	O
repeat	O
domain	O
of	O
bat	O
NLRP3	O
as	O
the	O
cause	O
.	O

Therefore	O
,	O
further	O
efforts	O
might	O
be	O
needed	O
to	O
control	O
the	O
increasing	O
impacts	O
of	O
zoonotic	O
viral	B-PROC
disease	I-PROC
.	O

TITLE	O
:	O
An	O
updated	O
roadmap	O
for	O
MERS	O
-	O
CoV	O
research	O
and	O
product	O
development	B-PROC
:	O
focus	O
on	O
diagnostics	O
.	O

However	O
,	O
for	O
new	O
test	O
development	B-PROC
,	O
sourcing	O
clinical	O
material	O
continues	O
to	O
be	O
a	O
major	O
challenge	O
to	O
achieving	O
assay	O
validation	O
.	O

Respiratory	O
viral	B-PROC
infections	I-PROC
may	O
be	O
associated	O
with	O
acute	O
rejection	O
and	O
chronic	O
lung	O
allograft	O
dysfunction	O
in	O
lung	O
transplant	O
recipients	O
.	O

Treatment	O
with	O
neuraminidase	B-PROC
inhibitors	I-PROC
and	O
other	O
antivirals	O
is	O
reviewed	O
.	O

Here	O
,	O
we	O
report	O
that	O
deletion	O
of	O
one	O
of	O
these	O
proline	O
residues	O
,	O
resulting	O
in	O
RSA59	O
(	O
P	O
),	O
significantly	O
affected	O
neural	O
cell	O
syncytia	O
formation	B-PROC
and	O
viral	O
titers	O
postinfection	O

TITLE	O
:	O
Design	O
,	O
Synthesis	B-PROC
and	O
Evaluation	O
of	O
Novel	O
Heteroaryldihydropyrimidines	O
Derivatives	O
as	O
Non	O
-	O
nucleoside	O
Hepatitis	O
B	O
Virus	O
Inhibitors	O
by	O
Exploring	O
the	O
Solvent	O
-	O
exposed	O
Region	O
.	O

Antibiotics	O
were	O
commonly	O
prescribed	O
in	O
the	O
setting	O
of	O
a	O
viral	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Chicken	O
anaemia	O
virus	O
enhances	O
and	O
prolongs	O
subsequent	O
avian	O
influenza	O
(	O
H9N2	O
)	O
and	O
infectious	O
bronchitis	O
viral	B-PROC
infections	I-PROC
.	O

ABSTRACT	O
:	O
Recombination	B-PROC
events	O
are	O
known	O
to	O
contribute	O
to	O
the	O
emergence	O
of	O
novel	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
genotypes	O
.	O

The	O
first	O
IBV	O
infection	O
induced	O
poor	O
protective	O
immunity	B-PROC
in	O
this	O
farm	O
,	O
permitting	O
a	O
second	O
IBV	O
infection	O
to	O
occur	O
.	O

In	O
viral	B-PROC
replication	I-PROC
,	O
non	O
-	O
structural	O
protein	O
5	O
(	O
Nsp5	O
),	O
also	O
termed	O
main	O
protease	O
(	O
M	O

TITLE	O
:	O
Growth	B-PROC
enhancement	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
in	O
Vero	O
E6	O
cells	O
expressing	O
PEDV	O
nucleocapsid	O
protein	O
.	O

Lower	O
median	O
peak	O
inspiratory	B-PROC
pressure	O
and	O
median	O
dynamic	O
driving	O
pressure	O
were	O
observed	O
in	O
the	O
extended	O
group	O
24	O
hours	O
after	O
ECMO	O
support	O
.	O

ABSTRACT	O
:	O
Guinea	O
fowl	O
coronavirus	O
(	O
GfCoV	O
)	O
causes	O
fulminating	O
enteritis	O
that	O
can	O
result	O
in	O
a	O
daily	O
death	B-PROC
rate	O
of	O
20	O
%	O
in	O
guinea	O
fowl	O
flocks	O
.	O

Based	O
on	O
lessons	O
learned	B-PROC
from	O
SARS	O
and	O
MERS	O
outbreaks	O
,	O
lack	O
of	O
drugs	O
capable	O
of	O
pan	O
-	O
coronavirus	O
antiviral	O
activity	O
increases	O
the	O
vulnerability	O
of	O
public	O
health	O
systems	O
to	O
a	O
highly	O
pathogenic	O
coronavirus	O
pandemic	O
.	O

ABSTRACT	O
:	O
Type	O
-	O
I	O
IFNs	O
(	O
IFN	O
-	O
I	O
)	O
provide	O
a	O
key	O
mediator	O
of	O
innate	O
antiviral	B-PROC
response	I-PROC
during	O
virus	O
proliferation	O
.	O

Findings	O
from	O
this	O
study	O
provides	O
novel	O
perspective	O
to	O
advance	O
the	O
understanding	O
in	O
the	O
pathogenesis	B-PROC
of	O
PEDV	O
.	O

It	O
involves	O
the	O
installment	O
of	O
either	O
single	O
ubiquitin	B-PROC
(	O
Ub	O
)	O
moieties	O
or	O
one	O
of	O
eight	O
different	O
polyUb	O
linkage	B-PROC
types	O
,	O
each	O
giving	O
a	O
distinct	O
cellular	O
outcome	O
.	O

The	O
Ub	O
system	O
displays	O
significant	O
crosstalk	B-PROC
with	O
structurally	O
homologous	O
ubiquitin	B-PROC
-	O
like	O
proteins	O
(	O
Ubls	O
),	O
including	O
SUMO	O
,	O
Nedd8	O
,	O
and	O
ISG15	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
5F	O
-	O
ADB	O
/	O
FUB	O
-	O
AMB	O
abuse	O
:	O
Drug	O
-	O
induced	O
or	O
drug	O
-	O
related	O
death	B-PROC
?	O

TITLE	O
:	O
Frequency	O
of	O
molecular	O
detection	O
of	O
equine	O
coronavirus	O
in	O
faeces	O
and	O
nasal	O
secretions	O
in	O
277	O
horses	O
with	O
acute	O
onset	O
of	O
fever	B-PROC
.	O

In	O
the	O
same	O
population	O
9	O
.	O
0	O
%	O
of	O
horses	O
tested	O
qPCR	O
-	O
positive	O
for	O
EHV	O
-	O
4	O
,	O
6	O
.	O
1	O
%	O
for	O
EIV	O
,	O
4	O
.	O
3	O
%	O
for	O
The	O
present	O
study	O
results	O
showed	O
that	O
7	O
.	O
2	O
%	O
of	O
horses	O
with	O
acute	O
onset	O
of	O
fever	B-PROC
tested	O
qPCR	O
-	O
positive	O
for	O
ECoV	O
in	O
feces	O
,	O
highlighting	O
the	O
importance	O
of	O
testing	O
such	O
horses	O
for	O
ECoV	O
in	O
feces	O
.	O

The	O
various	O
prevalence	O
factors	O
associated	O
with	O
ECoV	O
qPCR	O
-	O
positive	O
status	O
likely	O
relate	O
to	O
the	O
high	O
infectious	O
nature	O
of	O
ECoV	O
and	O
breed	B-PROC
-	O
specific	O
differences	O
in	O
management	O
and	O
husbandry	O
practices	O
.	O

In	O
this	O
study	O
,	O
we	O
confirm	O
that	O
N	O
-	O
linked	O
glycosylation	B-PROC
occurs	O
at	O
two	O
predicted	O
sites	O
in	O
the	O
M	O
protein	O
ectodomain	O
of	O
infectious	O
bronchitis	O
coronavirus	O
(	O
IBV	O
).	O

TITLE	O
:	O
PEDV	O
and	O
PDCoV	O
Pathogenesis	B-PROC
:	O

The	O
Interplay	O
Between	O
Host	O
Innate	B-PROC
Immune	I-PROC
Responses	I-PROC
and	O
Porcine	O
Enteric	O
Coronaviruses	O
.	O

Lymphocyte	B-PROC
proliferation	I-PROC
assay	O
results	O
showed	O
that	O
the	O
recombinant	O
L	O
.	O
lactis	O
pNZ8149	O
-	O
S1	O
/	O
NZ3900	O
significantly	O
stimulated	O
the	O
proliferation	O
of	O
splenic	O
lymphocytes	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
incidence	O
of	O
cannula	O
-	O
related	O
thrombosis	O
and	O
its	O
risk	O
factors	O
after	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

We	O
analyzed	O
consecutive	O
patients	O
with	O
severe	O
respiratory	O
failure	O
(	O
PaO2	O
/	O
FIO2	O
<	O
85	O
mm	O
Hg	O
and	O
/	O
or	O
respiratory	O
acidosis	O
with	O
pH	O
<	O
7	O
.	O
25	O
)	O
who	O
were	O
successfully	O
treated	O
with	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
in	O
a	O
medical	O
ICU	O
between	O
2010	O
and	O
2017	O
.	O

A	O
list	O
of	O
TTD	O
includes	O
infections	O
caused	O
by	O
human	O
T	O
-	O
lymphotropic	O
virus	O
1	O
,	O
cytomegalovirus	O
and	O
West	B-PROC
Nile	I-PROC
virus	I-PROC
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
malaria	O
,	O
Chagas	O
disease	O
,	O
babesiosis	O
,	O
leishmaniasis	O
,	O
variant	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
,	O
Zika	O
,	O
Dengue	O
,	O
Chikungunya	O
,	O
and	O
anaplasmosis	O
.	O

Its	O
use	O
has	O
increased	O
markedly	O
in	O
the	O
last	O
decade	O
,	O
initially	O
in	O
response	O
to	O
severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
)	O
in	O
adults	O
during	O
the	O
2009	O
H1N1	O
influenza	O
epidemic	O
and	O
continuing	O
with	O
the	O
increasing	O
acceptance	O
of	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
(	O
ECMO	B-PROC
)	O
for	O
the	O
treatment	O
of	O
severe	O
respiratory	O
failure	O
in	O
adults	O
from	O
other	O
causes	O
.	O
1	O
We	O
highlight	O
the	O
use	O
of	O
ECMO	B-PROC
,	O
particularly	O
at	O
our	O
institution	O
.	O

Additional	O
studies	O
to	O
investigate	O
the	O
bacterial	O
,	O
pharmacologic	O
,	O
and	O
immunologic	B-PROC
factors	I-PROC
related	O
to	O
treatment	O
outcome	O
along	O
with	O
measures	O
to	O
improve	O
public	O
awareness	O
should	O
be	O
prioritized	O
.	O

The	O
most	O
distinctive	O
feature	O
of	O
LBRF	O
,	O
the	O
relapse	O
phenomenon	O
,	O
is	O
attributable	O
to	O
antigenic	B-PROC
variation	I-PROC
of	O
borrelial	O
outer	O
-	O
membrane	O
lipoprotein	O
.	O

Development	B-PROC
of	O
biodosimetry	O
assays	O
for	O
triage	O
and	O
treatment	O
requires	O
knowledge	O
of	O
the	O
radiation	O
dose	O
-	O
volume	O
effect	O
for	O
the	O
bone	O
marrow	O
(	O
BM	O
).	O

No	O
high	O
-	O
grade	O
fever	B-PROC
,	O
weight	O
loss	O
>	O
10	O
%,	O
dehydration	O
or	O
respiratory	O
distress	O
was	O
observed	O
.	O

It	O
is	O
possible	O
that	O
immunosuppression	B-PROC
by	O
FPV	O
played	O
a	O
role	O
in	O
the	O
unprecedented	O
T	O
.	O
foetus	O
infection	O
intensity	O
observed	O
histologically	O
.	O

ABSTRACT	O
:	O
The	O
main	O
immunogenic	O
protein	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
is	O
the	O
spike	O
protein	O
(	O
S	O
protein	O
),	O
which	O
plays	O
an	O
important	O
role	O
in	O
receptor	O
binding	O
,	O
membrane	B-PROC
fusion	I-PROC
,	O
and	O
viral	O
invasion	O
of	O
the	O
host	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
Dynamics	O
and	O
Antibody	B-PROC
Responses	I-PROC
among	O
Clinically	O
Diverse	O
Patients	O
,	O
Saudi	O
Arabia	O
.	O

We	O
present	O
2	O
patients	O
with	O
deranged	O
coagulation	B-PROC
after	O
liver	O
rupture	O
successfully	O
treated	O
by	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

Damage	O
caused	O
by	O
inhalation	B-PROC
of	O
thermal	O
or	O
chemical	O
irritants	O
,	O
including	O
toxic	O
fumes	O
and	O
chemicals	O
,	O
leads	O
to	O
respiratory	O
cilia	O
and	O
epithelial	O
cell	O
injuries	O
,	O
which	O
turn	O
to	O
severe	O
bronchospasm	O
and	O
alveolar	O
damage	O
and	O
results	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

One	O
of	O
these	O
host	O
factors	O
,	O
the	O
MERS	O
-	O
CoV	O
receptor	O
dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP4	O
),	O
may	O
be	O
a	O
critical	O
determinant	O
because	O
it	O
is	O
variably	O
expressed	B-PROC
in	O
MERS	O
-	O
CoV	O
-	O
susceptible	O
species	O
as	O
well	O
as	O
in	O
humans	O
.	O

Interestingly	O
,	O
we	O
also	O
demonstrated	O
that	O
while	O
the	O
V672F	O
mutation	O
is	O
critical	O
for	O
the	O
syncytium	B-PROC
formation	I-PROC
in	O
VeroE6	O
-	O
APN	O
cells	O
,	O
it	O
exerts	B-PROC
a	O
minimal	O
effect	O
in	O
Huh	O
-	O
7	O
cells	O
,	O
thereby	O
suggesting	O
the	O
difference	O
in	O
receptor	O
preference	O
of	O
PEDV	O
among	O
host	O
cells	O
.	O

Glycosylation	B-PROC
sites	O
in	O
the	O
spike	O
protein	O
are	O
highly	O
conserved	O
across	O
viral	O
genotypes	O
,	O
suggesting	O
an	O
important	O
role	O
for	O
this	O
modification	O
in	O
the	O
virus	O
life	O
cycle	O
.	O

Coronaviruses	O
,	O
including	O
MERS	O
-	O
CoV	O
,	O
potently	O
suppress	O
the	O
activation	O
of	O
these	O
pathways	B-PROC
,	O
inducing	O
only	O
modest	O
host	O
responses	O
.	O

Statistical	O
analysis	O
showed	O
a	O
highly	O
significant	O
difference	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
in	O
the	O
frequency	O
of	O
single	O
infections	O
compared	O
to	O
mixed	O
ones	O
with	O
the	O
exception	O
of	O
weaned	B-PROC
pigs	O
,	O
in	O
which	O
group	O
additionally	O
most	O
viruses	O
were	O
detected	O
.	O

This	O
simple	O
yet	O
flexible	O
model	O
can	O
easily	O
be	O
incorporated	O
into	O
existing	O
tools	O
for	O
outbreak	O
reconstruction	O
and	O
should	O
permit	O
a	O
better	O
integration	B-PROC
of	O
genomic	O
and	O
epidemiological	O
data	O
for	O
inferring	O
transmission	O
chains	O
.	O

ABSTRACT	O
:	O
Dengue	O
(	O
DENV	O
)	O
viral	B-PROC
infection	I-PROC
is	O
a	O
global	O
public	O
health	O
problem	O
that	O
infrequently	O
develops	O
life	O
threatening	O
diseases	O
such	O
as	O
dengue	O
hemorrhagic	O
fever	B-PROC
(	O
DFS	O
)	O
and	O
dengue	O
shock	O
syndrome	O
(	O
DSS	O
).	O

ABSTRACT	O
:	O
Heparin	O
has	O
been	O
used	O
for	O
decades	O
as	O
an	O
anticoagulant	O
in	O
patients	O
on	O
mechanical	O
circulatory	B-PROC
support	O
,	O
which	O
includes	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
and	O
ventricular	O
assist	O
devices	O
.	O

Our	O
results	O
suggest	O
that	O
nsp1	O
,	O
alone	O
,	O
can	O
regulate	O
multiple	O
steps	O
of	O
gene	B-PROC
expression	I-PROC
including	O
nuclear	O
-	O
cytoplasmic	B-PROC
transport	B-PROC
.	O

TITLE	O
:	O
High	O
Prevalence	O
of	O
Viral	B-PROC
Infections	I-PROC
Among	O
Hospitalized	O
Pneumonia	O
Patients	O
in	O
Equatorial	O
Sarawak	O
,	O
Malaysia	O
.	O

We	O
report	O
that	O
a	O
medium	O
MP	O
(	O
4	O
mg	O
/	O
kg	O
)	O
dose	O
significantly	O
reduced	O
inflammation	O
and	O
coagulation	B-PROC
disorders	O
,	O
as	O
well	O
as	O
acute	O
-	O
phase	O
mortality	O
.	O

Reversion	O
to	O
virulence	B-PROC
experiments	O
revealed	O
that	O
the	O
S	O
DEL5	O
/	O
ORF3	O
strain	O
retains	O
its	O
attenuated	O
phenotype	O
and	O
genetic	O
stability	O
after	O
five	O
successive	O
passages	O
in	O
susceptible	O
piglets	O
.	O

Pregnant	O
sows	O
were	O
primed	O
orally	O
with	O
an	O
S	O
DEL5	O
/	O
ORF3	O
live	O
vaccine	O
and	O
boosted	O
intramuscularly	O
twice	O
with	O
a	O
commercial	O
killed	O
vaccine	O
at	O
2	O
-	O
week	O
intervals	O
prior	O
to	O
parturition	B-PROC
.	O

We	O
projected	O
monthly	O
numbers	O
of	O
noncitizen	O
arrivals	O
and	O
indices	O
of	O
services	O
for	O
3	O
travel	O
-	O
related	O
service	O
sectors	O
during	O
and	O
after	O
the	O
MERS	O
outbreak	O
(	O
June	O
2015	O
to	O
June	O
2016	O
)	O
using	O
seasonal	O
autoregressive	O
integrated	O
moving	B-PROC
average	O
models	O
.	O

Both	O
patients	O
tragically	O
died	B-PROC
following	O
suffocation	O
from	O
solid	O
food	O
aspiration	O
of	O
full	O
meals	O
that	O
were	O
ingested	O
6	O
and	O
8	O
hours	O
before	O
delivery	O
,	O
respectively	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
whether	O
machine	O
learning	B-PROC
algorithms	O
can	O
be	O
used	O
to	O
assess	O
risk	O
and	O
dynamically	O
identify	O
patient	O
-	O
specific	O
modifiable	O
factors	O
critical	O
to	O
patient	O
trajectory	O
for	O
multiple	O
key	O
outcomes	O
after	O
severe	O
injury	O
.	O

ABSTRACT	O
:	O
PDCoV	O
(	O
Porcine	O
Deltacoronavirus	O
)	O
is	O
a	O
novel	O
porcine	O
coronavirus	O
that	O
causes	O
intestinal	O
necrosis	B-PROC
of	O
piglets	O
,	O
thinning	O
of	O
the	O
intestinal	O
wall	O
and	O
severe	O
villus	O
atrophy	O
in	O
the	O
small	O
intestine	O
.	O

With	O
the	O
development	B-PROC
of	O
the	O
research	O
,	O
a	O
large	O
number	O
of	O
lncRNAs	O
related	O
to	O
PDCoV	O
infection	O
have	O
been	O
discovered	O
.	O

Highest	O
rates	O
of	O
viral	B-PROC
infections	I-PROC
were	O
reported	O
for	O
RSV	O
,	O
PIV	O
,	O
and	O
adenovirus	O
.	O

Herein	O
,	O
we	O
report	O
a	O
rare	O
case	O
of	O
delayed	O
retroperitoneal	O
hemorrhage	O
during	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
VV	O
-	O
ECMO	O
).	O

TITLE	O
:	O
Main	O
factors	O
influencing	O
recovery	O
in	O
MERS	O
Co	O
-	O
V	O
patients	O
using	O
machine	O
learning	B-PROC
.	O

The	O
concern	O
is	O
magnified	O
by	O
rapid	O
population	O
growth	B-PROC
in	O
areas	O
with	O
weak	O
health	O
systems	O
,	O
urbanization	O
,	O
globalization	O
,	O
climate	O
change	O
,	O
civil	O
conflict	O
,	O
and	O
the	O
changing	O
nature	O
of	O
pathogen	O
transmission	O
between	O
human	O
and	O
animal	O
populations	O
.	O

All	O
participants	O
stated	O
that	O
the	O
most	O
important	O
standard	O
precaution	O
that	O
should	O
be	O
applied	O
when	O
seeing	B-PROC
a	O
case	O
of	O
MERS	O
-	O
CoV	O
infection	O
is	O
hand	O
washing	O
,	O
whereas	O
97	O
.	O
6	O
%	O
stated	O
that	O
the	O
most	O
important	O
respiratory	O
precaution	O
to	O
prevent	O
transmission	O
of	O
respiratory	O
infections	O
in	O
PHC	O
setting	O
when	O
seeing	B-PROC
a	O
case	O
of	O
MERS	O
-	O
CoV	O
infection	O
is	O
masking	O
and	O
separation	O
of	O
suspected	O
MERS	O
-	O
CoV	O
patients	O
,	O
and	O
81	O
.	O
2	O
%	O
stated	O
that	O
upon	O
exit	O
from	O
the	O
room	O
of	O
a	O
MERS	O
-	O
CoV	O
patient	O
,	O
the	O
physician	O
should	O
remove	O
and	O
discard	O
personal	O
protective	O
equipment	O
.	O

ABSTRACT	O
:	O
In	O
severe	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
data	O
are	O
lacking	O
on	O
methods	O
to	O
measure	O
and	O
set	O
optimal	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
.	O

TITLE	O
:	O
Exposure	O
to	O
Atmospheric	O
Ultrafine	O
Particles	O
Induces	O
Severe	O
Lung	O
Inflammatory	B-PROC
Response	I-PROC
and	O
Tissue	B-PROC
Remodeling	I-PROC
in	O
Mice	O
.	O

ABSTRACT	O
:	O
Antibody	B-PROC
phage	O
display	O
has	O
been	O
pivotal	O
in	O
the	O
quest	O
to	O
generate	O
human	O
monoclonal	O
antibodies	O
for	O
biomedical	O
and	O
research	O
applications	O
.	O

TITLE	O
:	O
Expression	B-PROC
profile	O
analysis	O
of	O
5	O
-	O
day	O
-	O
old	O
neonatal	O
piglets	O
infected	O
with	O
porcine	O
Deltacoronavirus	O
.	O

Therefore	O
,	O
it	O
can	O
be	O
preliminarily	O
concluded	O
that	O
PPAR	O
differential	O
expression	B-PROC
caused	O
by	O
PDCoV	O
was	O
mostly	O
associated	O
with	O
weight	O
loss	O
and	O
death	B-PROC
from	O
emaciation	O
.	O

Normal	O
hematologic	B-PROC
function	I-PROC
and	O
the	O
absence	O
of	O
standard	O
exclusion	O
criteria	O
used	O
for	O
therapeutic	O
clinical	O
trials	O
in	O
ARDS	O
were	O
protective	O
.	O

Thus	O
,	O
using	O
an	O
experimental	O
and	O
translational	B-PROC
approach	O
,	O
we	O
test	O
the	O
hypothesis	O
that	O
a	O
tight	O
regulation	B-PROC
of	O
UTC	O
is	O
mandatory	O
to	O
fine	O
-	O
tune	O
host	B-PROC
response	I-PROC
,	O
and	O
,	O
subsequently	O
to	O
prevent	O
emergence	O
of	O
an	O
aberrant	O
response	O
leading	O
to	O
excessive	O
tissue	O
damages	O
,	O
and	O
eventually	O
,	O
ARDS	O
.	O

Diagnostic	O
delay	O
(	O
aRR	O
,	O
1	O
.	O
137	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
006	O
-	O
1	O
.	O
285	O
)	O
and	O
health	O
-	O
system	O
delays	O
(	O
aRR	O
,	O
1	O
.	O
217	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
003	O
-	O
1	O
.	O
476	O
)	O
were	O
significantly	O
longer	O
in	O
patients	O
who	O
died	B-PROC
.	O

Respiratory	O
viruses	O
are	O
commonly	O
detected	O
in	O
both	O
symptomatic	O
and	O
asymptomatic	O
periods	B-PROC
.	O

Interestingly	O
,	O
the	O
ORF3	O
protein	B-PROC
expression	B-PROC
was	O
diminished	O
in	O
VPS36	O
-	O
overexpressing	O
cells	O
,	O
an	O
effect	O
that	O
could	O
not	O
be	O
restored	O
by	O
treatment	O
of	O
lysosomal	O
inhibitors	O
.	O

ABSTRACT	O
:	O
The	O
tumor	B-PROC
suppressor	I-PROC
protein	O
P53	O
is	O
strongly	O
involved	O
in	O
orchestrating	O
cellular	O
defenses	O
in	O
the	O
diverse	O
variety	O
of	O
human	O
tissues	O
.	O

(	O
Gene	O
Ontology	O
)	O
GO	O
annotation	O
and	O
functional	O
enrichment	O
analysis	O
indicated	O
that	O
all	O
of	O
the	O
DEGs	O
(	O
differentially	O
expressed	B-PROC
genes	O
)	O
were	O
annotated	O
into	O
biological	B-PROC
process	I-PROC
,	O
cellular	O
component	O
and	O
molecular	O
function	O
.	O

Extracorporeal	O
life	O
support	O
can	O
provide	O
adequate	O
oxygenation	B-PROC
while	O
allowing	O
the	O
lungs	O
to	O
rest	O
and	O
heal	B-PROC
,	O
which	O
might	O
be	O
an	O
ideal	O
therapy	O
in	O
this	O
patient	O
group	O
,	O
although	O
long	O
-	O
term	O
clinical	O
and	O
radiological	O
outcomes	O
are	O
not	O
known	O
.	O

In	O
two	O
patients	O
,	O
long	O
-	O
term	O
functional	O
and	O
neuropsychological	O
outcomes	O
showed	O
similar	O
limitations	O
to	O
what	O
is	O
seen	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
who	O
are	O
not	O
supported	O
with	O
extracorporeal	O
life	O
support	O
and	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
without	O
blastomycosis	O
,	O
but	O
worse	O
pulmonary	B-PROC
function	I-PROC
outcomes	O
in	O
the	O
form	O
of	O
obstructive	O
and	O
restrictive	O
changes	O
that	O
correlated	O
with	O
the	O
radiological	O
imaging	O
.	O

In	O
this	O
study	O
,	O
the	O
pro	O
-	O
apoptotic	O
effect	O
of	O
PEDV	O
was	O
examined	O
in	O
Vero	O
cells	O
and	O
we	O
observed	O
that	O
PEDV	O
infection	O
increased	O
MDM2	O
and	O
CBP	O
,	O
promoted	O
p53	O
phosphorylation	B-PROC
at	O
serine	O
20	O
and	O
,	O
promoted	O
p53	O
nuclear	B-PROC
translocation	B-PROC
,	O
leading	O
to	O
p53	O
activation	O
in	O
Vero	O
cells	O
.	O

Treatment	O
with	O
the	O
p53	O
inhibitor	O
PFT	O
-	O
α	O
could	O
significantly	O
inhibit	O
PEDV	O
-	O
induced	O
apoptosis	B-PROC
.	O

Moreover	O
,	O
further	O
inhibition	B-PROC
tests	O
were	O
established	O
to	O
prove	O
that	O
p53	O
was	O
regulated	O
by	O
ROS	O
in	O
PEDV	O
-	O
induced	O
apoptosis	B-PROC
.	O

Due	O
to	O
the	O
severe	O
hypoxemia	O
,	O
he	O
was	O
started	O
on	O
iNO	O
via	O
the	O
breathing	B-PROC
circuit	O
of	O
the	O
ventilator	O
at	O
a	O
concentration	O
of	O
20	O
parts	O
per	O
million	O
(	O
ppm	O
)	O
with	O
steady	O
improvement	O
in	O
oxygenation	B-PROC
after	O
1	O
hour	O
with	O
a	O
PaO2	O
of	O
81	O
mmHg	O
on	O
the	O
same	O
ventilator	O
setting	O
.	O

Its	O
effects	O
on	O
PVR	O
may	O
be	O
useful	O
in	O
the	O
setting	O
of	O
acute	O
pulmonary	O
emboli	O
where	O
vascular	O
obstruction	O
and	O
vasoconstriction	B-PROC
contribute	O
to	O
increased	O
pulmonary	O
arterial	B-PROC
pressure	I-PROC
and	O
PVR	O
which	O
can	O
present	O
as	O
acute	O
right	O
heart	O
failure	O
.	O

ORF3a	O
induced	O
pro	O
-	O
IL	O
-	O
1β	O
transcription	B-PROC
through	O
activation	O
of	O
NF	O
-	O
κB	O
,	O
which	O
was	O
mediated	O
by	O
TRAF3	O
-	O
dependent	O
ubiquitination	B-PROC
and	O
processing	O
of	O
p105	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
reveal	O
a	O
new	O
mechanism	O
by	O
which	O
SARS	O
-	O
CoV	O
ORF3a	O
protein	O
activates	O
NF	O
-	O
κB	O
and	O
the	O
NLRP3	O
inflammasome	O
by	O
promoting	O
TRAF3	O
-	O
dependent	O
ubiquitination	B-PROC
of	O
p105	O
and	O
ASC	O
.-	O
Siu	O
,	O
K	O
.-	O
L	O
.,	O
Yuen	O
,	O
K	O
.-	O
S	O
.,	O
Castaño	O
-	O
Rodriguez	O
,	O
C	O
.,	O
Ye	O
,	O
Z	O
.-	O
W	O
.,	O
Yeung	O
,	O
M	O
.-	O
L	O
.,	O
Fung	O
,	O
S	O
.-	O
Y	O
.,	O
Yuan	O
,	O
S	O
.,	O
Chan	O
,	O
C	O
.-	O
P	O
.,	O
Yuen	O
,	O
K	O
.-	O
Y	O
.,	O
Enjuanes	O
,	O
L	O
.,	O
Jin	O
,	O
D	O
.-	O
Y	O
.	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
ORF3a	O
protein	O
activates	O
the	O
NLRP3	O
inflammasome	O
by	O
promoting	O
TRAF3	O
-	O
dependent	O
ubiquitination	B-PROC
of	O
ASC	O
.	O

The	O
value	O
of	O
antibody	B-PROC
tests	O
based	O
on	O
these	O
peptides	O
in	O
differentiating	O
between	O
the	O
enteric	O
and	O
FIP	O
forms	O
of	O
feline	O
coronavirus	O
infection	O
remains	O
to	O
be	O
determined	O
.	O

The	O
intra	O
-	O
abdominal	O
pressure	O
(	O
IAP	O
)	O
applied	O
to	O
Glasgow	O
Coma	O
Scale	O
(	O
GCS	O
),	O
Acute	O
Physiology	O
,	O
shock	O
,	O
Systemic	O
Inflammatory	B-PROC
Response	I-PROC
Syndrome	O
(	O
SIRS	O
),	O
central	O
venous	B-PROC
oxygen	I-PROC
saturation	I-PROC
and	O
Chronic	O
Health	O
Evaluation	O
(	O
APACHE	O
II	O
)	O
score	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
addition	O
,	O
healthcare	O
worker	O
participants	O
providing	O
care	O
to	O
infected	O
participants	O
were	O
recruited	O
to	O
wear	O
a	O
polytetrafluoroethylene	O
(	O
PTFE	O
)	O
filter	O
cassette	O
in	O
their	O
breathing	B-PROC
zones	O
.	O

The	O
new	O
development	B-PROC
of	O
DIC	O
and	O
persistent	O
DIC	O
from	O
days	O
0	O
to	O
3	O
were	O
associated	O
with	O
a	O
high	O
incidence	O
of	O
MODS	O
and	O
low	O
survival	O
probability	O
.	O

ABSTRACT	O
:	O
Lower	O
respiratory	O
infections	O
remain	O
one	O
of	O
the	O
top	O
global	O
causes	O
of	O
death	B-PROC
and	O
the	O
emergence	O
of	O
new	O
diseases	O
continues	O
to	O
be	O
a	O
concern	O
.	O

Year	O
of	O
infection	O
(	O
2013	O
-	O
2018	O
)	O
and	O
having	O
no	O
comorbidities	O
were	O
independent	O
protective	O
factors	O
against	O
death	B-PROC
among	O
secondary	O
healthcare	O
workers	O
cases	O
.	O

Therefore	O
,	O
the	O
development	B-PROC
of	O
a	O
sensitive	O
,	O
specific	O
,	O
and	O
easily	O
performed	O
assay	O
is	O
crucial	O
for	O
the	O
rapid	O
detection	O
and	O
surveillance	O
of	O
IBV	O
infections	O
.	O

Eligible	O
SP	O
patients	O
at	O
admission	O
from	O
January	O
2013	O
to	O
June	O
2017	O
were	O
prospectively	O
enrolled	O
,	O
and	O
ARDS	O
development	B-PROC
within	O
hospital	O
stay	O
was	O
identified	O
.	O

Risk	O
factors	O
for	O
ARDS	O
development	B-PROC
in	O
SP	O
patients	O
were	O
analyzed	O
by	O
univariate	O
and	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

The	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
analysis	O
with	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
was	O
performed	O
for	O
the	O
predictive	O
value	O
of	O
endocan	O
for	O
ARDS	O
development	B-PROC
.	O

In	O
postsurgical	O
sepsis	O
,	O
older	O
age	O
,	O
admission	O
from	O
the	O
hospital	O
ward	O
,	O
multiple	O
organ	O
dysfunction	O
syndrome	O
at	O
sepsis	O
recognition	O
,	O
and	O
cardiovascular	O
and	O
respiratory	O
comorbidities	O
were	O
independent	O
risk	O
factors	O
for	O
death	B-PROC
.	O

In	O
medical	O
sepsis	O
,	O
resource	O
-	O
limited	O
region	O
,	O
hospital	O
-	O
acquired	O
infection	O
,	O
multiple	O
organ	O
dysfunction	O
syndrome	O
at	O
sepsis	O
recognition	O
,	O
higher	O
Pediatric	O
Index	O
of	O
Mortality	O
-	O
3	O
score	O
,	O
and	O
malignancy	O
were	O
independent	O
risk	O
factors	O
for	O
death	B-PROC
.	O

In	O
this	O
study	O
,	O
a	O
total	O
of	O
190	O
faecal	O
samples	O
from	O
dairy	O
calves	O
with	O
diarrhoea	O
were	O
collected	O
from	O
14	O
farms	O
in	O
six	O
Chinese	O
provinces	O
,	O
and	O
BCoV	O
was	O
detected	O
in	O
18	O
.	O
95	O
%	O
(	O
36	O
/	O
190	O
)	O
of	O
the	O
samples	O
by	O
reverse	O
transcriptase	B-PROC
polymerase	O
chain	O
reaction	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
critical	O
genes	O
associated	O
with	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
virulence	B-PROC
,	O
we	O
compared	O
the	O
genome	O
sequences	O
of	O
virulent	O
YN	O
strain	O
and	O
its	O
attenuated	O
strain	O
aYN	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
autophagosome	B-PROC
formation	I-PROC
and	O
apparent	O
autophagic	O
flux	O
are	O
induced	O
in	O
cells	O
infected	O
with	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
-	O
a	O
gammacoronavirus	O
.	O

Approximately	O
806	O
patients	O
have	O
died	B-PROC
.	O

Our	O
main	O
goals	O
are	O
to	O
highlight	O
and	O
describe	O
the	O
current	O
knowledge	O
of	O
both	O
the	O
innate	O
and	O
adaptive	B-PROC
immune	I-PROC
responses	I-PROC
to	O
MERS	O
-	O
CoV	O
and	O
the	O
current	O
state	O
of	O
MERS	O
-	O
CoV	O
vaccine	O
development	B-PROC
.	O

ABSTRACT	O
:	O
To	O
describe	O
(	O
1	O
)	O
the	O
energy	B-PROC
transfer	I-PROC
from	O
the	O
ventilator	O
to	O
the	O
lungs	O
,	O
(	O
2	O
)	O
the	O
match	O
between	O
venous	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	B-PROC
)	O
oxygen	O
transfer	O
and	O
patient	O
oxygen	O
consumption	O
(	O
VO2	O
),	O
(	O
3	O
)	O
carbon	O
dioxide	O
removal	O
with	O
ECMO	B-PROC
,	O
and	O
(	O
4	O
)	O
the	O
potential	O
effect	O
of	O
systemic	O
venous	O
oxygenation	B-PROC
on	O
pulmonary	O
artery	O
pressure	O
.	O

Venous	O
blood	O
oxygenation	B-PROC
through	O
the	O
ECMO	O
circuit	O
may	O
drive	O
the	O
PO2	B-PROC
stimulus	O
of	O
pulmonary	O
hypoxic	O
vasoconstriction	B-PROC
to	O
normal	O
values	O
.	O

TITLE	O
:	O
Synthesis	B-PROC
and	O
biological	O
evaluation	O
of	O
dihydroquinazoline	O
-	O
2	O
-	O
amines	O
as	O
potent	O
non	B-PROC
-	I-PROC
nucleoside	I-PROC
reverse	I-PROC
transcriptase	I-PROC
inhibitors	I-PROC
of	O
wild	O
-	O
type	O
and	O
mutant	O
HIV	O
-	O
1	O
strains	O
.	O

TITLE	O
:	O
The	O
coronavirus	O
macrodomain	O
is	O
required	O
to	O
prevent	O
PARP	O
-	O
mediated	O
inhibition	B-PROC
of	O
virus	B-PROC
replication	I-PROC
and	O
enhancement	O
of	O
IFN	O
expression	B-PROC
.	O

TITLE	O
:	O
Venovenous	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
in	O
a	O
Gravid	O
Patient	O
with	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
:	O
A	O
Case	O
Report	O
.	O

Analyses	O
of	O
nucleotide	O
and	O
deduced	O
amino	O
acid	O
sequences	O
showed	O
that	O
NB1	O
differed	O
from	O
18	O
other	O
Korean	O
PEDV	O
mostly	O
in	O
4	O
protein	O
coding	O
genes	O
:	O
ORF1a	O
,	O
ORF1b	O
,	O
S	O
,	O
and	O
N	O
.	O
Two	O
amino	B-PROC
acid	I-PROC
substitutions	I-PROC
(	O
V635E	O
and	O
Y681Q	O
)	O
in	O
the	O
COE	O
and	O
S1D	O
neutralizing	O
epitopes	O
of	O
NB1	O
resulted	O
in	O
antigenic	O
index	O
alteration	O
of	O
the	O
adjacent	O
sites	O
,	O
one	O
of	O
which	O
contributed	O
to	O
a	O
mutation	O
that	O
escaped	O
neutralizing	O
antibodies	O
.	O

Isavuconazole	O
is	O
an	O
alternative	O
in	O
case	O
of	O
intolerance	B-PROC
to	O
voriconazole	O
,	O
drug	O
-	O
drug	B-PROC
interactions	I-PROC
,	O
renal	O
impairment	O
,	O
or	O
if	O
a	O
spectrum	O
of	O
activity	O
including	O
the	O
majority	O
of	O
Mucorales	O
is	O
desired	O
.	O

We	O
assessed	O
the	O
clinical	O
characteristics	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
illness	O
(	O
SARI	O
)	O
evolving	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
the	O
factors	O
related	O
to	O
death	B-PROC
.	O

The	O
Causes	O
of	O
Canine	O
Myocarditis	O
and	O
Myocardial	O
Fibrosis	O
Are	O
Elusive	O
by	O
Targeted	B-PROC
Molecular	O
Testing	O
:	O

PDCoV	O
infection	O
also	O
increased	O
the	O
number	O
of	O
autophagosome	O
-	O
like	O
vesicles	O
in	O
the	O
cytoplasm	O
of	O
cells	O
,	O
and	O
the	O
autophagy	B-PROC
response	O
was	O
detected	O
by	O
LC3	O
I	O
/	O
II	O
and	O
p62	O
Western	O
blot	O
analysis	O
.	O

Pearson	O
test	O
was	O
used	O
to	O
analyze	O
the	O
correlation	O
between	O
neutral	O
red	O
phagocytosis	B-PROC
function	O
of	O
macrophages	O
and	O
alkaline	O
phosphatase	O
activity	O
and	O
other	O
indicators	O
.	O

Compared	O
with	O
the	O
survival	O
group	O
,	O
the	O
death	B-PROC
group	O
was	O
older	O
(	O
years	O
old	O
:	O
58	O
.	O
50	O
±	O
14	O
.	O
86	O
vs	O
.	O
46	O
.	O
67	O
±	O
13	O
.	O
40	O
),	O
APACHE	O
II	O
score	O
was	O
higher	O
(	O
21	O
.	O
50	O
±	O
3	O
.	O
93	O
vs	O
.	O
13	O
.	O
58	O
±	O
4	O
.	O
12	O
),	O
neutral	O
red	O
phagocytosis	B-PROC
ability	O
and	O
alkaline	O
phosphatase	O
activity	O
of	O
alveolar	O
macrophages	O
were	O
significantly	O
decreased	O
(	O
A	O
value	O
:	O
0	O
.	O
265	O
±	O
0	O
.	O
050	O
vs	O
.	O
0	O
.	O
338	O
±	O
0	O
.	O
016	O
;	O
μmol	O
/	O
L	O
:	O
12	O
.	O
06	O
±	O
1	O
.	O
24	O
vs	O
.	O
17	O
.	O
96	O
±	O
3	O
.	O
90	O
),	O
and	O
the	O
length	O
of	O
ICU	O
stay	O
was	O
significantly	O
longer	O
(	O
days	O
:	O
22	O
.	O
00	O
±	O
14	O
.	O
59	O
vs	O
.	O
11	O
.	O
50	O
±	O
3	O
.	O
17	O
),	O
hospitalization	O
cost	O
was	O
significantly	O
increased	O
(	O
10	O
thousand	O
Yuan	O
:	O
24	O
.	O
17	O
±	O
11	O
.	O
02	O
vs	O
.	O
13	O
.	O
44	O
±	O
3	O
.	O
53	O
),	O
the	O
total	O
hospitalization	O
time	O
was	O
shorter	O
(	O
days	O
:	O
25	O
.	O
25	O
±	O
15	O
.	O
01	O
vs	O
.	O
35	O
.	O
67	O
±	O
8	O
.	O
58	O
),	O
and	O
the	O
difference	O
was	O
statistically	O
significant	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
neutral	O
red	O
phagocytosis	B-PROC
ability	O
of	O
alveolar	O
macrophages	O
in	O
ARDS	O
patients	O
caused	O
by	O
abdominal	O
infection	O
was	O
negatively	O
correlated	O
with	O
age	O
,	O
APACHE	O
II	O
score	O
and	O
the	O
length	O
of	O
ICU	O
stay	O
(	O
r	O
value	O
was	O
-	O
0	O
.	O
328	O
,	O
-	O
0	O
.	O
572	O
,	O
-	O
0	O
.	O
809	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
);	O
alkaline	O
phosphatase	O
activity	O
was	O
negatively	O
correlated	O
with	O
age	O
,	O
APACHE	O
II	O
score	O
,	O
the	O
length	O
of	O
ICU	O
stay	O
and	O
hospitalization	O
expenses	O
(	O
r	O
value	O
was	O
-	O
0	O
.	O
334	O
,	O
-	O
0	O
.	O
583	O
,	O
-	O
0	O
.	O
470	O
,	O
-	O
0	O
.	O
517	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

ROC	O
curve	O
analysis	O
showed	O
that	O
the	O
AUC	O
of	O
neutral	O
red	O
phagocytosis	B-PROC
ability	O
for	O
prognosis	O
of	O
ARDS	O
patients	O
caused	O
by	O
abdominal	O
infection	O
was	O
0	O
.	O
948	O
,	O
and	O
the	O
sensitivity	O
and	O
specificity	O
were	O
91	O
.	O
7	O
%	O
and	O
87	O
.	O
5	O
%	O
when	O
the	O
off	O
-	O
cut	O
value	O
was	O
0	O
.	O
317	O
.	O

The	O
alveolar	O
macrophage	O
phagocytosis	B-PROC
dysfunction	O
in	O
ARDS	O
patients	O
caused	O
by	O
severe	O
abdominal	O
infection	O
was	O
not	O
only	O
related	O
to	O
the	O
severity	O
of	O
the	O
disease	O
,	O
but	O
also	O
increased	O
the	O
medical	O
burden	O
of	O
patients	O
,	O
and	O
significantly	O
affected	O
the	O
mortality	O
of	O
such	O
patients	O
.	O

TITLE	O
:	O
Early	O
Neuromuscular	B-PROC
Blockade	I-PROC
in	O
the	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

ABSTRACT	O
:	O
Bovine	O
coronavirus	O
(	O
BCV	O
)	O
is	O
associated	O
with	O
respiratory	O
infections	O
in	O
cattle	O
of	O
all	O
ages	O
;	O
however	O
,	O
a	O
temporal	O
study	O
to	O
evaluate	O
the	O
effect	O
of	O
BCV	O
immunity	B-PROC
on	O
virus	O
shedding	O
and	O
bovine	O
respiratory	O
disease	O
(	O
BRD	O
)	O
incidence	O
in	O
pre	O
-	O
weaned	B-PROC
beef	O
calves	O
has	O
not	O
been	O
reported	O
.	O

Two	O
hundred	O
forty	O
-	O
eight	O
of	O
the	O
817	O
study	O
calves	O
(	O
30	O
.	O
4	O
%)	O
were	O
treated	O
for	O
BRD	O
prior	O
to	O
weaning	B-PROC
;	O
246	O
of	O
those	O
were	O
from	O
a	O
single	O
herd	O
involved	O
in	O
two	O
outbreaks	O
of	O
BRD	O
leading	O
to	O
mass	O
treatment	O
of	O
all	O
calves	O
in	O
that	O
group	O
.	O

O	O
.	O
Mühlemann	O
and	O
Volker	O
Thiel	O
teamed	O
up	O
to	O
unravel	O
the	O
roles	O
of	O
NMD	B-PROC
and	O
SGs	O
,	O
and	O
their	O
interconnections	O
in	O
defending	O
cells	O
from	O
alphavirus	O
and	O
coronavirus	O
infections	O
.	O

We	O
discuss	O
the	O
growing	O
efforts	O
to	O
exploit	O
viral	O
glycobiology	O
in	O
the	O
development	B-PROC
of	O
anti	O
-	O
viral	O
vaccines	O
and	O
therapies	O
.	O

Anti	O
-	O
CoV	O
drug	O
development	B-PROC
has	O
long	O
been	O
challenged	O
by	O
the	O
activity	O
of	O
a	O
3	O
'	O
to	O
5	O
'	O
proofreading	O
exoribonuclease	O
unique	O
to	O
CoVs	O
.	O

This	O
review	O
will	O
discuss	O
progress	O
made	O
in	O
the	O
development	B-PROC
of	O
antiviral	O
nucleoside	O
and	O
nucleotide	O
analogues	O
targeting	B-PROC
viral	O
RNA	B-PROC
synthesis	I-PROC
as	O
effective	O
therapeutics	O
against	O
CoV	O
infections	O
and	O
propose	O
promising	O
strategies	O
for	O
combination	O
therapy	O
.	O

The	O
expression	B-PROC
of	O
nucleotide	O
-	O
binding	O
oligomerization	O
domain	O
containing	O
2	O
(	O
Nod2	O
),	O
type	O
I	O
interferons	O
,	O
(	O
IFNs	O
),	O
and	O
proinflammatory	O
mediators	O
was	O
enhanced	O
in	O
S	O
RBD	O
-	O
HBD	O
2	O
-	O
treated	O
THP	O
-	O
1	O
cells	O
.	O

Finally	O
,	O
HBD	O
2	O
-	O
conjugated	O
S	O
RBD	O
interacted	O
with	O
C	O
-	O
C	O
chemokine	O
receptor	O
2	O
(	O
CCR2	O
),	O
and	O
Nod2	O
was	O
involved	O
in	O
HBD	O
2	O
-	O
mediated	O
CCR2	O
signaling	B-PROC
,	O
which	O
was	O
associated	O
with	O
the	O
activation	O
and	O
M1	O
polarization	O
of	O
THP	O
-	O
1	O
cells	O
.	O

TITLE	O
:	O
Single	O
intranasal	O
immunization	O
with	O
chimpanzee	O
adenovirus	O
-	O
based	O
vaccine	O
induces	O
sustained	O
and	O
protective	O
immunity	B-PROC
against	O
MERS	O
-	O
CoV	O
infection	O
.	O

The	O
interacting	O
regions	O
were	O
identified	O
and	O
can	O
be	O
considered	O
common	O
across	O
CoVs	O
,	O
which	O
provides	O
new	O
insights	O
into	O
the	O
Replication	O
and	O
Transcription	B-PROC
Complex	O
(	O
RTC	O
)	O
of	O
CoVs	O
.	O

The	O
interferon	O
(	O
IFN	O
)-	O
mediated	O
antiviral	B-PROC
response	I-PROC
is	O
an	O
important	O
component	O
of	O
virus	O
-	O
host	O
interactions	O
and	O
plays	O
an	O
essential	O
role	O
in	O
inhibiting	O
virus	B-PROC
infection	I-PROC
.	O

However	O
,	O
PDCoV	O
N	O
protein	O
restrained	O
the	O
pRiplet	O
binding	O
pRIG	O
-	O
I	O
to	O
inhibit	O
pRIG	O
-	O
I	O
K63	O
-	O
linked	O
polyubiquitination	B-PROC
.	O

The	O
novel	O
findings	O
provide	O
a	O
new	O
insight	O
into	O
PDCoV	O
on	O
evading	O
the	O
host	O
innate	B-PROC
immune	I-PROC
response	I-PROC
and	O
may	O
provide	O
new	O
therapeutic	O
targets	O
and	O
more	O
efficacious	O
vaccines	O
strategies	O
for	O
PDCoV	O
infections	O
.	O

TITLE	O
:	O
Fever	B-PROC
in	O
travellers	O
returning	O
from	O
the	O
tropics	O
.	O

The	O
receptor	O
-	O
interacting	O
site	O
is	O
conserved	O
in	O
all	O
coronavirus	O
S	O
glycoproteins	O
that	O
engage	O
9	O
-	O
O	O
-	O
acetyl	O
-	O
sialogycans	O
,	O
with	O
an	O
architecture	O
similar	O
to	O
those	O
of	O
the	O
ligand	B-PROC
-	O
binding	O
pockets	O
of	O
coronavirus	O
hemagglutinin	O
esterases	O
and	O
influenza	O
virus	O
C	O
/	O
D	O
hemagglutinin	O
-	O
esterase	O
fusion	O
glycoproteins	O
.	O

Comparisons	O
were	O
conducted	O
between	O
influenza	O
and	O
non	O
-	O
influenza	O
viral	B-PROC
infection	I-PROC
groups	O
.	O

Among	O
all	O
the	O
potential	O
targets	O
of	O
MERS	O
-	O
CoV	O
,	O
the	O
spike	O
glycoprotein	O
(	O
S	O
)	O
has	O
been	O
the	O
most	O
well	O
-	O
studied	O
due	O
to	O
its	O
critical	O
role	O
in	O
mediating	O
viral	O
entry	O
and	O
in	O
inducing	O
a	O
protective	O
antibody	B-PROC
response	I-PROC
in	O
infected	O
individuals	O
.	O

Larger	O
degree	O
of	O
maternal	O
heart	O
rate	O
reactivity	O
to	O
buprenorphine	O
administration	O
was	O
related	O
to	O
more	O
severe	O
NAS	O
expression	B-PROC
.	O

TITLE	O
:	O
Frequency	O
of	O
ABSTRACT	O
:	O
Calf	O
diarrhea	O
is	O
a	O
common	O
cause	O
of	O
pre	O
-	O
weaning	B-PROC
morbidity	O
and	O
mortality	O
in	O
cattle	O
operations	O
.	O

TITLE	O
:	O
Sustained	O
safe	O
and	O
effective	O
anticoagulation	B-PROC
using	O
Edoxaban	O
via	O
percutaneous	O
endoscopic	O
gastrostomy	O
.	O

However	O
,	O
there	O
is	O
no	O
compelling	O
evidence	O
supporting	O
the	O
use	O
of	O
direct	O
oral	O
anticoagulant	O
in	O
individuals	O
who	O
are	O
intubated	O
or	O
have	O
a	O
percutaneous	O
endoscopic	O
gastrostomy	O
(	O
PEG	O
):	O
patients	O
with	O
several	O
co	O
-	O
morbidities	O
are	O
underrepresented	O
in	O
clinical	O
trials	O
,	O
so	O
the	O
best	O
long	O
-	O
term	O
strategy	O
for	O
anticoagulation	B-PROC
is	O
difficult	O
to	O
ascertain	O
.	O

When	O
severe	O
acute	O
respiratory	O
syndrome	O
corona	O
virus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
West	B-PROC
Nile	I-PROC
Virus	I-PROC
emerged	O
it	O
was	O
the	O
NAT	O
that	O
enabled	O
the	O
manufacturers	O
and	O
transfusion	O
centres	O
to	O
instantly	O
introduce	O
sensitive	O
and	O
specific	O
screening	O
tests	O
.	O

Thus	O
,	O
antibody	B-PROC
and	O
antigen	O
testing	O
may	O
be	O
dispensable	O
in	O
the	O
long	O
run	O
,	O
particularly	O
in	O
the	O
combination	O
of	O
NAT	O
testing	O
with	O
pathogen	O
reduction	O
.	O

Inhaled	B-PROC
corticosteroids	O
and	O
other	O
anti	O
-	O
inflammatory	O
drugs	O
are	O
very	O
effective	O
in	O
patients	O
with	O
inflammatory	O
lung	O
disorders	O
,	O
but	O
their	O
long	O
-	O
term	O
use	O
is	O
associated	O
with	O
severe	O
side	O
effects	O
.	O

This	O
article	O
reports	O
the	O
spleen	O
-	O
mediated	O
systemic	O
inflammatory	B-PROC
response	I-PROC
,	O
the	O
role	O
of	O
inflammatory	O
mediators	O
in	O
the	O
development	B-PROC
of	O
ARDS	O
,	O
and	O
the	O
current	O
state	O
of	O
research	O
on	O
ARDS	O
treatment	O
to	O
explore	O
new	O
approaches	O
to	O
the	O
prevention	O
and	O
treatment	O
of	O
traumatic	O
ARDS	O
.	O

There	O
is	O
further	O
scope	O
for	O
the	O
synthesis	B-PROC
and	O
evaluation	O
of	O
novel	O
thiazole	O
compounds	O
by	O
taking	O
the	O
most	O
active	O
compounds	O
as	O
lead	O
structures	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
further	O
scope	O
for	O
the	O
synthesis	B-PROC
and	O
evaluation	O
of	O
novel	O
thiazole	O
compounds	O
by	O
taking	O
the	O
most	O
active	O
compounds	O
as	O
lead	O
structures	O
.	O

Opening	O
the	O
lung	O
procedure	O
was	O
safe	O
in	O
all	O
patients	O
with	O
optimal	O
PEEP	O
of	O
14	O
.	O
8	O
±	O
1	O
.	O
8	O
cmH	O
It	O
is	O
necessary	O
to	O
conduct	B-PROC
further	O
trials	O
to	O
find	O
out	O
the	O
effectiveness	O
of	O
this	O
ventilation	O
strategy	O
on	O
burns	O
injury	O
induced	O
ARDS	O
.	O

RESULTS	O
:	O
Opening	O
the	O
lung	O
procedure	O
was	O
safe	O
in	O
all	O
patients	O
with	O
optimal	O
PEEP	O
of	O
14	O
.	O
8	O
±	O
1	O
.	O
8	O
cmH	O
CONCLUSIONS	O
:	O
It	O
is	O
necessary	O
to	O
conduct	B-PROC
further	O
trials	O
to	O
find	O
out	O
the	O
effectiveness	O
of	O
this	O
ventilation	O
strategy	O
on	O
burns	O
injury	O
induced	O
ARDS	O
.	O

Data	O
collection	O
consisted	O
of	O
patient	O
demographics	O
,	O
respiratory	O
variables	O
and	O
arterial	O
blood	B-PROC
gas	I-PROC
analysis	O
.	O

ABSTRACT	O
:	O
Autosomal	O
recessive	O
IRF7	O
and	O
IRF9	O
deficiencies	O
impair	O
type	O
I	O
and	O
III	O
IFN	O
immunity	B-PROC
and	O
underlie	O
severe	O
influenza	O
pneumonitis	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
ginseng	O
stem	O
-	O
leaf	O
saponins	O
(	O
GSLS	O
)	O
in	O
combination	O
with	O
selenium	O
(	O
Se	O
)	O
for	O
their	O
adjuvant	O
effect	O
on	O
the	O
immune	B-PROC
response	I-PROC
to	O
vaccination	O
against	O
NDV	O
and	O
IBV	O
in	O
chickens	O
.	O

In	O
addition	O
,	O
GSLS	O
-	O
Se	O
enhanced	O
lymphocyte	B-PROC
proliferation	I-PROC
and	O
production	O
of	O
IFN	O
-	O
γ	O
and	O
IL	O
-	O
4	O
.	O

ABSTRACT	O
:	O
Community	O
-	O
acquired	O
pneumonia	O
(	O
CAP	O
)	O
is	O
the	O
leading	O
cause	O
of	O
child	O
death	B-PROC
worldwide	O
.	O

The	O
majority	O
of	O
patients	O
presented	O
with	O
pneumonia	O
,	O
with	O
symptoms	O
including	O
fever	B-PROC
(≥	O
37	O
.	O
5	O
°	O
C	O
),	O
labored	O
breathing	B-PROC
,	O
and	O
cough	O
,	O
and	O
with	O
a	O
history	O
of	O
travel	O
to	O
the	O
Middle	O
East	O
.	O

We	O
present	O
a	O
case	O
report	O
of	O
a	O
2	O
-	O
month	O
-	O
old	O
infant	O
affected	O
by	O
a	O
bronchiolitis	O
RSV	O
-	O
positive	O
,	O
with	O
syndrome	O
of	O
inappropriate	O
antidiuretic	O
hormone	B-PROC
secretion	I-PROC
(	O
SIADH	O
)	O
correlated	O
seizure	O
and	O
encephalopathy	O
.	O

In	O
both	O
organs	O
,	O
the	O
MBL	O
-	O
positive	O
cells	O
occupy	O
antigen	O
-	O
exposed	O
areas	O
,	O
indicating	O
that	O
GC	O
formation	B-PROC
depends	O
on	O
resident	O
precursors	O
of	O
dendritic	O
cells	O
.	O

Here	O
,	O
we	O
used	O
whole	O
-	O
transcriptome	O
sequencing	O
(	O
RNASeq	O
)	O
and	O
ribosome	O
profiling	O
(	O
RiboSeq	O
)	O
to	O
delineate	O
gene	B-PROC
expression	I-PROC
in	O
the	O
IBV	O
M41	O
-	O
CK	O
and	O
Beau	O
-	O
R	O
strains	O
at	O
subcodon	O
resolution	O
.	O

RNASeq	O
facilitated	O
a	O
comparative	O
analysis	O
of	O
viral	O
RNA	B-PROC
synthesis	I-PROC
and	O
revealed	O
two	O
novel	O
transcription	B-PROC
junction	O
sites	O
in	O
the	O
attenuated	O
Beau	O
-	O
R	O
strain	O
,	O
one	O
of	O
which	O
would	O
generate	O
a	O
sgmRNA	O
encoding	O
a	O
ribosomally	O
occupied	O
open	O
reading	O
frame	O
(	O
dORF	O
)	O
located	O
downstream	O
of	O
the	O
nucleocapsid	O
coding	O
region	O
.	O

RiboSeq	O
permitted	O
quantification	O
of	O
the	O
translational	B-PROC
efficiency	O
of	O
virus	O
gene	B-PROC
expression	I-PROC
and	O
identified	O
,	O
for	O
the	O
first	O
time	O
,	O
sites	O
of	O
ribosomal	O
pausing	O
on	O
the	O
genome	O
.	O

Analysis	O
of	O
differential	B-PROC
gene	B-PROC
expression	I-PROC
in	O
infected	O
primary	O
chick	O
kidney	O
cells	O
indicated	O
that	O
the	O
host	O
cell	O
response	O
to	O
IBV	O
occurs	O
primarily	O
at	O
the	O
level	O
of	O
transcription	B-PROC
,	O
with	O
global	O
upregulation	B-PROC
of	O
immune	O
-	O
related	O
mRNA	O
transcripts	O
following	O
infection	O
and	O
comparatively	O
modest	O
changes	O
in	O
the	O
translation	B-PROC
efficiencies	O
of	O
host	O
genes	O
.	O

TITLE	O
:	O
Design	O
,	O
Synthesis	B-PROC
,	O
and	O
Anti	O
-	O
RNA	O
Virus	O
Activity	O
of	O
6	O
'-	O
Fluorinated	O
-	O
Aristeromycin	O
Analogues	O
.	O

ABSTRACT	O
:	O
Smoke	O
inhalation	B-PROC
injury	O
(	O
SII	O
)	O
causes	O
30	O
%	O
to	O
40	O
%	O
mortality	O
and	O
will	O
increase	O
as	O
a	O
cause	O
of	O
death	B-PROC
during	O
prolonged	O
field	O
care	O
.	O

We	O
previously	O
designed	O
an	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
system	O
to	O
evaluate	O
mucosa	O
thickness	O
(	O
MT	O
)	O
after	O
smoke	O
inhalation	B-PROC
,	O
but	O
the	O
analysis	O
relied	O
on	O
manual	O
segmentation	B-PROC
.	O

A	O
tissue	O
segmentation	B-PROC
algorithm	O
based	O
on	O
graph	O
theory	O
was	O
used	O
to	O
reconstruct	O
a	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
model	O
of	O
lower	O
respiratory	O
tract	O
and	O
estimate	O
PAV	O
.	O

ABSTRACT	O
:	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
highly	O
prevalent	O
in	O
broiler	O
chickens	O
despite	O
extensive	O
vaccination	O
commonly	O
conducted	O
early	O
after	O
hatch	B-PROC
.	O

Results	O
show	O
that	O
vaccination	O
on	O
day	O
1	O
of	O
age	O
elicits	O
significantly	O
lower	O
systemic	O
and	O
mucosal	O
antibody	B-PROC
responses	I-PROC
compared	O
with	O
vaccination	O
at	O
later	O
time	O
points	O
in	O
the	O
life	O
of	O
the	O
chicken	O
.	O

The	O
recruitment	O
or	O
expansion	O
of	O
cluster	O
of	O
differentiation	B-PROC
(	O
CD	O
)	O
4	O

Pilgrims	O
had	O
a	O
higher	O
rate	O
of	O
correct	O
responses	O
on	O
each	O
question	O
at	O
the	O
time	O
they	O
completed	O
the	O
second	O
questionnaire	O
,	O
as	O
compared	O
with	O
the	O
first	O
,	O
with	O
11	O
of	O
13	O
questions	O
answered	O
significantly	O
better	O
after	O
delivery	O
of	O
educational	O
information	O
about	O
MERS	O
-	O
CoV	O
.	O
However	O
,	O
although	O
the	O
rate	O
of	O
correct	O
answers	O
to	O
the	O
questions	O
about	O
routes	O
of	O
transmission	O
,	O
symptoms	O
,	O
preventive	O
behaviours	O
to	O
adopt	O
in	O
case	O
of	O
fever	B-PROC
and	O
time	O
delay	O
between	O
return	O
and	O
potential	O
MERS	O
-	O
CoV	O
occurrence	O
increased	O
significantly	O
after	O
receiving	O
the	O
information	O
,	O
the	O
rates	O
remained	O
below	O
50	O
%.	O

A	O
fully	O
human	O
polyclonal	O
IgG	O
antibody	B-PROC
(	O
SAB	O
-	O
301	O
)	O
was	O
safe	O
and	O
well	O
tolerated	O
in	O
healthy	O
individuals	O
and	O
this	O
agent	O
may	O
deserve	O
further	O
testing	O
for	O
efficacy	O
.	O

Consensus	O
on	O
the	O
best	O
way	O
to	O
conduct	B-PROC
simulation	O
of	O
exposure	O
and	O
assessment	O
of	O
outcome	O
is	O
urgently	O
needed	O
.	O

ABSTRACT	O
:	O
In	O
an	O
attempt	O
to	O
produce	O
heterocyclic	O
compounds	O
based	O
on	O
1	O
,	O
3	O
,	O
4	O
-	O
oxadiazole	O
derivatives	O
with	O
potential	O
antiviral	O
activity	O
,	O
synthesis	B-PROC
of	O
compound	O
1	O
[	O
2	O
-(	O
5	O
-	O
thioxo	O
-	O
4	O
,	O
5	O
-	O
dihydro	O
-	O
1	O
,	O
3	O
,	O
4	O
-	O
oxadiazol	O
-	O
2	O
-	O
yl	O
)	O
acetonitrile	O
]	O
was	O
performed	O
through	O
the	O
reaction	O
of	O
cyanoacetic	O
acid	O
hydrazide	O
with	O
carbon	O
disulfide	O
in	O
alcoholic	O
potassium	O
hydroxide	O
.	O

Furthermore	O
,	O
cyclic	O
ketones	O
were	O
subjected	O
to	O
the	O
synthesis	B-PROC
of	O
fused	O
thiophene	O
derivatives	O
4a	O
,	O
b	O
via	O
reaction	O
with	O
compound	O
1	O
in	O
the	O
presence	O
of	O
elemental	O
sulfur	O
.	O

Seven	O
of	O
the	O
patients	O
with	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
died	B-PROC
(	O
7	O
/	O
39	O
,	O
17	O
.	O
9	O
%).	O

Primers	O
targeted	B-PROC
the	O
5	O
'-	O
untranslated	O
region	O
(	O
5	O
'-	O
UTR	O
)	O
of	O
IBV	O
genome	O
and	O
the	O
conserved	O
region	O
of	O
NDV	O
large	O
polymerase	O
gene	O
(	O
LP	O
).	O

ABSTRACT	O
:	O
Tight	O
junction	O
proteins	O
are	O
important	O
for	O
the	O
maintenance	O
and	O
repair	B-PROC
of	O
the	O
intestinal	O
mucosal	O
barrier	O
.	O

In	O
PEDV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	O
,	O
the	O
mRNA	B-PROC
expression	B-PROC
of	O
the	O
six	O
tight	O
junction	O
proteins	O
showed	O
a	O
downward	O
trend	O
;	O
in	O
particular	O
,	O
the	O
expression	B-PROC
of	O
the	O
Occludin	O
and	O
Claudin	O
-	O
4	O
genes	O
was	O
significantly	O
lower	O
(	O
p	O
⟨	O
0	O
.	O
01	O
).	O

These	O
data	O
suggest	O
that	O
the	O
expression	B-PROC
of	O
these	O
six	O
tight	O
junction	O
proteins	O
,	O
especially	O
Occludin	O
and	O
Claudin	O
-	O
4	O
,	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
integrity	O
of	O
the	O
intestinal	O
mucosal	O
barrier	O
and	O
resistance	B-PROC
to	O
PEDV	O
infection	O
in	O
piglets	O
.	O

In	O
this	O
study	O
,	O
samples	O
from	O
bats	O
collected	O
from	O
caves	O
in	O
Ruhengeri	O
,	O
Rwanda	O
,	O
were	O
tested	O
for	O
the	O
presence	O
of	O
corona	O
-	O
and	O
paramyxoviral	O
RNA	O
using	O
reverse	B-PROC
transcription	B-PROC
PCR	O
assays	O
.	O

Chest	O
trauma	O
alone	O
and	O
especially	O
its	O
combination	O
with	O
TBI	O
represent	O
high	O
-	O
risk	O
injury	O
patterns	O
for	O
the	O
development	B-PROC
of	O
pneumonia	O
,	O
which	O
forms	O
the	O
strongest	O
predictor	O
of	O
mortality	O
in	O
poly	O
-	O
traumatized	O
patients	O
.	O

Thus	O
,	O
the	O
inflammatory	B-PROC
responses	I-PROC
were	O
reduced	O
.	O

Human	O
H7N9	O
influenza	O
viruses	O
are	O
resistant	O
to	O
amantadines	O
and	O
some	O
strains	O
are	O
also	O
resistant	O
to	O
neuraminidase	B-PROC
inhibitors	I-PROC
greatly	O
limiting	O
the	O
options	O
for	O
treatment	O
.	O

While	O
showing	O
different	O
compositions	O
and	O
structures	O
,	O
these	O
peripheral	O
elements	O
are	O
topologically	O
equivalent	O
β	O
-	O
sandwich	O
-	O
core	O
insertions	O
,	O
highlighting	O
a	O
divergent	O
evolution	B-PROC
process	O
for	O
betaCoVs	O
to	O
form	O
different	O
lineages	O
.	O

Initially	O
,	O
he	O
had	O
difficulty	O
swallowing	B-PROC
solids	O
,	O
but	O
it	O
has	O
progressed	O
to	O
difficulty	O
with	O
liquids	O
.	O

In	O
the	O
intestine	O
,	O
long	O
-	O
term	O
persistence	O
of	O
immunity	B-PROC
is	O
related	O
to	O
CD4	O

Clinicians	O
should	O
be	O
aware	O
that	O
polycythemia	O
and	O
hyperviscosity	O
may	O
impair	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
support	O
and	O
that	O
acute	O
normovolemic	O
hemodilution	O
may	O
be	O
a	O
safe	O
and	O
efficient	O
procedure	O
to	O
address	O
such	O
matter	O
.	O

Results	O
showed	O
that	O
ARDS	O
onset	O
was	O
earlier	O
in	O
the	O
study	O
group	O
(	O
5	O
.	O
9	O
±.	O
7	O
vs	O
.	O
9	O
.	O
2	O
±	O
.	O
9	O
days	O
postburn	O
respectively	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
blood	O
oxygenation	B-PROC
disorder	O
was	O
more	O
severe	O
(	O
PaO2	O
/	O
FiO2	O
:	O
117	O
.	O
8	O
±	O
6	O
.	O
1	O
vs	O
.	O
125	O
.	O
9	O
±	O
6	O
.	O
5	O
respectively	O
;	O
p	O
<	O
.	O
01	O
).	O

TITLE	O
:	O
The	O
Establishment	O
and	O
Validation	O
of	O
the	O
Human	O
U937	O
Cell	O
Line	O
as	O
a	O
Cellular	O
Model	O
to	O
Screen	O
Immunomodulatory	O
Agents	O
Regulating	O
Cytokine	O
Release	O
Induced	O
by	O
Influenza	O
Virus	B-PROC
Infection	I-PROC
.	O

First	O
,	O
we	O
found	O
that	O
IBV	O
stimulation	O
did	O
not	O
enhance	O
the	O
maturation	B-PROC
ability	O
of	O
avian	O
DCs	O
.	O

TITLE	O
:	O
A	O
30	O
-	O
year	O
retrospective	O
study	O
on	O
causes	O
of	O
death	B-PROC
in	O
childhood	O
-	O
onset	O
systemic	O
lupus	O
erythematosus	O
in	O
a	O
tertiary	O
care	O
centre	O
in	O
Southern	O
Thailand	O
.	O

ABSTRACT	O
:	O
We	O
set	O
out	O
to	O
determine	O
the	O
causes	O
of	O
death	B-PROC
in	O
childhood	O
-	O
onset	O
systemic	O
lupus	O
erythematosus	O
(	O
cSLE	O
).	O

This	O
is	O
the	O
first	O
study	O
to	O
show	O
that	O
a	O
high	O
fat	O
diet	O
leads	O
to	O
altered	O
FASN	O
expression	B-PROC
in	O
the	O
lung	O
and	O
that	O
both	O
a	O
high	O
fat	O
diet	O
and	O
reduced	O
FASN	O
expression	B-PROC
in	O
alveolar	O
epithelial	O
cells	O
promote	O
lung	O
injury	O
.	O

ARDS	O
is	O
associated	O
with	O
staphylococcal	O
phosphatidylinositol	O
-	O
specific	O
phospholipase	O
C	O
(	O
PI	O
-	O
PLC	O
);	O
however	O
,	O
the	O
role	O
of	O
PI	O
-	O
PLC	O
in	O
the	O
pathogenesis	B-PROC
and	O
progression	O
of	O
ARDS	O
remains	O
unknown	O
.	O

SP	O
-	O
D	O
levels	O
increased	O
1	O
.	O
6	O
-	O
fold	O
following	O
surgical	O
repair	B-PROC
of	O
the	O
diaphragm	O
and	O
were	O
significantly	O
higher	O
in	O
the	O
second	O
week	O
following	O
surgery	O
when	O
compared	O
to	O
pre	O
-	O
operative	O
levels	O
(	O
p	O
<	O
0	O
.	O
03	O
).	O

Further	O
experiments	O
indicate	O
that	O
the	O
neutralization	O
by	O
7D10	O
is	O
not	O
solely	O
dependent	O
on	O
the	O
inhibition	B-PROC
of	O
DPP4	O
binding	O
,	O
but	O
also	O
acts	O
after	O
viral	O
cell	B-PROC
attachment	I-PROC
,	O
inhibiting	O
the	O
pre	O
-	O
fusion	O
to	O
post	O
-	O
fusion	O
conformational	B-PROC
change	I-PROC
of	O
the	O
spike	O
.	O

The	O
main	O
objectives	O
of	O
the	O
study	O
is	O
to	O
characterize	O
the	O
pattern	O
of	O
the	O
MERS	O
outbreak	O
in	O
South	O
Korea	O
based	O
on	O
a	O
basic	O
reproductive	B-PROC
ratio	O
,	O
the	O
probability	O
of	O
ultimate	O
extinction	O
of	O
the	O
disease	O
,	O
and	O
the	O
spatio	O
-	O
temporal	O
proximity	O
of	O
occurrence	O
between	O
patients	O
.	O

TITLE	O
:	O
Scaffold	O
hybridization	B-PROC
strategy	O
towards	O
potent	O
hydroxamate	O
-	O
based	O
inhibitors	O
of	O
ABSTRACT	O
:	O
Infections	O
with	O

TITLE	O
:	O
Screening	O
and	O
treatment	O
of	O
obstructive	O
sleep	B-PROC
apnea	O
in	O
acute	O
coronary	O
syndrome	O
.	O

The	O
objectives	O
of	O
the	O
present	O
study	O
were	O
to	O
assess	O
the	O
effect	O
of	O
biosecurity	O
measures	O
and	O
intervention	O
practices	O
to	O
control	O
PED	O
on	O
time	O
to	O
absence	O
of	O
clinical	O
signs	O
(	O
TAC	O
)	O
and	O
number	O
of	O
dead	B-PROC
suckling	O
piglets	O
during	O
TAC	O
.	O

Regarding	O
the	O
effect	O
of	O
biosecurity	O
measures	O
during	O
PED	O
outbreak	O
on	O
TAC	O
and	O
DP	O
/	O
S	O
,	O
longer	O
TAC	O
was	O
observed	O
in	O
Actinobacillus	O
pleuropneumoniae	O
-	O
positive	O
farms	O
and	O
farms	O
outsourcing	O
pig	O
transport	B-PROC
to	O
the	O
slaughterhouse	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Mechanism	O
of	O
Cxc	O
Chemokine	O
Ligand	B-PROC
5	O
(	O
CXCL5	O
)/	O
Cxc	O
Chemokine	O
Receptor	O
2	O
(	O
CXCR2	O
)	O
Bio	O
-	O
Axis	O
in	O
Mice	O
with	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

Subsequent	O
proteolysis	B-PROC
induces	O
simultaneous	O
packing	O
of	O
the	O
remaining	O
unpacked	O
HRs	O
upon	O
assembly	O
of	O
three	O
HRs	O
at	O
the	O
central	O
axis	O
to	O
generate	O
a	O
six	O
-	O
helix	O
bundle	O
.	O

ABSTRACT	O
:	O
Influenza	O
virus	O
affects	O
the	O
respiratory	O
tract	O
by	O
direct	O
viral	B-PROC
infection	I-PROC
or	O
by	O
damage	O
from	O
the	O
immune	O
system	O
response	O
.	O

The	O
predictors	O
of	O
death	B-PROC
were	O
age	O
>	O
65	O
years	O
,	O
male	O
gender	O
,	O
and	O
associated	O
comorbidities	O
particularly	O
diabetes	O
mellitus	O
,	O
hypertension	O
,	O
and	O
chronic	O
kidney	O
diseases	O
.	O

The	O
prognosis	O
is	O
poor	O
with	O
over	O
50	O
%	O
of	O
patients	O
dying	B-PROC
during	O
hospital	O
admission	O
from	O
progressive	O
respiratory	O
failure	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
incidence	O
,	O
outcomes	O
,	O
and	O
risk	O
factors	O
of	O
postoperative	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
patients	O
undergoing	O
surgical	O
repair	B-PROC
for	O
acute	O
type	O
A	O
aortic	O
dissection	O
.	O

TITLE	O
:	O
Unfolded	O
protein	O
response	O
regulates	O
P53	O
expression	B-PROC
in	O
the	O
pulmonary	O
endothelium	O
.	O

Small	O
animal	O
models	O
of	O
emerging	O
viral	O
pathogenesis	B-PROC
are	O
crucial	O
to	O
better	O
understand	O
the	O
virus	O
and	O
host	O
factors	O
driving	O
disease	O
progression	O
.	O

We	O
recently	O
generated	O
a	O
mouse	O
model	O
for	O
MERS	O
-	O
CoV	O
pathogenesis	B-PROC
through	O
the	O
humanization	O
of	O
the	O
orthologous	O
entry	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
).	O

Blood	O
and	O
fecal	O
samples	O
were	O
collected	O
twice	O
from	O
the	O
same	O
animals	O
;	O
17	O
post	O
-	O
weaned	B-PROC
calves	O
with	O
diarrhea	O
(	O
first	O
)	O
and	O
15	O
post	O
-	O
weaned	B-PROC
calves	O
that	O
recovered	O
from	O
diarrhea	O
(	O
second	O
).	O

Deaths	B-PROC
within	O
7	O
days	O
after	O
visiting	O
an	O
ER	O
were	O
analyzed	O
to	O
evaluate	O
the	O
impact	O
of	O
the	O
reduction	O
in	O
ER	O
visits	O
on	O
mortality	O
.	O

In	O
the	O
ICU	O
,	O
mechanical	O
ventilation	O
with	O
low	O
tidal	O
volume	O
and	O
high	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
was	O
administered	O
and	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
was	O
set	O
up	O
for	O
treating	O
severe	O
ARDS	O
.	O

Solving	O
the	O
crystal	O
structure	O
of	O
full	O
-	O
length	O
TGEV	O
at	O
1	O
.	O
85	O
-	O
Å	O
resolution	O
and	O
conducting	B-PROC
several	O
biochemical	O
analyses	O
,	O
we	O
observed	O
that	O
a	O
specific	O
motif	O
(	O
amino	O
acids	O
91	O
-	O
95	O
)	O
of	O
alphacoronavirus	O
nsp1	O
is	O
a	O
conserved	O
region	O
that	O
inhibits	O
host	O
protein	B-PROC
synthesis	I-PROC
.	O

TITLE	O
:	O
Differential	O
neurodegenerative	O
phenotypes	O
are	O
associated	O
with	O
heterogeneous	O
voiding	B-PROC
dysfunction	O
in	O
a	O
coronavirus	O
-	O
induced	O
model	O
of	O
multiple	O
sclerosis	O
.	O

Genetic	O
and	O
antigenic	O
analyses	O
indicated	O
that	O
the	O
S	O
-	O
DEL	O
isolates	O
are	O
most	O
closely	O
related	O
to	O
the	O
primary	O
strain	O
identified	O
from	O
the	O
initial	O
exposure	O
at	O
the	O
same	O
farm	O
,	O
but	O
the	O
virus	O
appears	O
to	O
undergo	O
continuous	O
evolution	B-PROC
,	O
possibly	O
leading	O
to	O
antigenic	O
drift	O
under	O
recurrent	O
or	O
endemic	O
pressure	O
.	O

ABSTRACT	O
:	O
BACKGROUND	O
This	O
study	O
investigated	O
the	O
risk	O
factors	O
affecting	O
development	B-PROC
and	O
prognosis	O
of	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

In	O
contrast	O
,	O
delayed	O
IFN	O
-	O
β	O
treatment	O
failed	O
to	O
effectively	O
inhibit	O
virus	B-PROC
replication	I-PROC
,	O
increased	O
infiltration	O
and	O
activation	O
of	O
monocytes	O
,	O
macrophages	O
,	O
and	O
neutrophils	O
in	O
the	O
lungs	O
,	O
and	O
enhanced	O
proinflammatory	O
cytokine	O
expression	B-PROC
,	O
resulting	O
in	O
fatal	O
pneumonia	O
in	O
an	O
otherwise	O
sublethal	O
infection	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
spike	O
(	O
S	O
)	O
proteins	O
of	O
the	O
prototypic	O
Arabian	O
MERS	O
-	O
CoV	O
strain	O
,	O
human	O
betacoronavirus	O
2c	O
EMC	O
/	O
2012	O
,	O
and	O
the	O
above	O
stated	O
African	O
MERS	O
-	O
CoV	O
variants	O
do	O
not	O
appreciably	O
differ	O
in	O
expression	B-PROC
,	O
DPP4	O
binding	O
and	O
ability	O
to	O
drive	O
entry	O
into	O
target	O
cells	O
.	O

Although	O
he	O
performed	O
well	O
on	O
both	O
non	O
-	O
invasive	O
and	O
invasive	O
mechanical	O
ventilation	O
,	O
his	O
oxygenation	B-PROC
continued	O
to	O
deteriorate	O
.	O

On	O
the	O
other	O
hand	O
,	O
there	O
are	O
also	O
voices	B-PROC
that	O
generally	O
criticize	O
an	O
increasing	O
""""	O
interventionalism	O
"""."	O

Moreover	O
,	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
may	O
be	O
considered	O
as	O
an	O
early	O
strategy	O
for	O
adults	O
with	O
severe	O
ARDS	O
receiving	O
lung	O
protective	O
ventilation	O
.	O

TITLE	O
:	O
Obstructive	O
sleep	B-PROC
apnoea	O
in	O
acute	O
coronary	O
syndrome	O
.	O

On	O
the	O
one	O
hand	O
,	O
OSA	O
in	O
patients	O
with	O
ACS	O
may	O
worsen	O
prognosis	O
;	O
on	O
the	O
other	O
hand	O
,	O
OSA	O
-	O
related	O
hypoxaemia	O
could	O
favour	O
the	O
development	B-PROC
of	O
coronary	O
collaterals	O
,	O
thereby	O
exerting	B-PROC
a	O
protective	O
effect	O
.	O

Recombinant	O
protein	O
-	O
based	O
vaccines	O
are	O
usually	O
formulated	O
with	O
aluminum	O
(	O
alum	O
)-	O
based	O
adjuvants	O
to	O
ensure	O
an	O
adequate	O
immune	B-PROC
response	I-PROC
.	O

The	O
reported	O
isolate	O
was	O
identified	O
by	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PROC
PCR	O
assay	O
targeting	B-PROC
nucleocapsid	O
(	O
N	O
)	O
gene	O
and	O
,	O
further	O
characterized	O
by	O
full	O
-	O
length	O
spike	O
(	O
S1	O
)	O
gene	O
sequencing	O
.	O

TITLE	O
:	O
[	O
Acute	O
kidney	O
failure	O
in	O
differentiation	B-PROC
syndrome	O
:	O
a	O
possible	O
complication	O
during	O
therapy	O
with	O
differentiating	O
agents	O
for	O
acute	O
promyelocytic	O
leukemia	O
.	O

The	O
clinical	O
manifestations	O
of	O
DS	O
,	O
after	O
induction	O
therapy	O
with	O
differentiating	O
agents	O
,	O
include	O
unexplained	O
fever	B-PROC
,	O
acute	O
respiratory	O
distress	O
with	O
interstitial	O
pulmonary	O
infiltrates	O
,	O
unexplained	O
hypotension	O
,	O
peripheral	O
edema	O
,	O
congestive	O
heart	O
failure	O
and	O
acute	O
renal	O
failure	O
.	O

Tissue	O
culture	O
-	O
adapted	O
type	O
I	O
FCoV	O
shows	O
reduced	O
FIP	O
induction	O
in	O
experimental	O
infections	O
,	O
which	O
complicates	O
the	O
understanding	O
of	O
FIP	O
pathogenesis	B-PROC
caused	O
by	O
type	O
I	O
FCoV	O
.	O
We	O
previously	O
found	O
that	O
the	O
type	O
I	O
FCoV	O
strain	O
C3663	O
efficiently	O
induces	O
FIP	O
in	O
specific	O
-	O
pathogen	O
-	O
free	O
cats	O
through	O
the	O
naturally	O
infectious	O
route	O
.	O

We	O
successfully	O
generated	O
recombinant	O
virus	O
(	O
rC3663	O
)	O
from	O
Fcwf	O
-	O
4	O
cells	O
transfected	O
with	O
infectious	O
cDNA	O
that	O
showed	O
growth	B-PROC
kinetics	O
similar	O
to	O
those	O
shown	O
by	O
the	O
parental	O
virus	O
.	O

Real	O
-	O
time	O
quantitative	O
PCR	O
was	O
used	O
to	O
quantify	O
the	O
mRNA	B-PROC
expression	B-PROC
of	O
inflammatory	O
factors	O
.	O

In	O
ST	O
and	O
IPEC	O
-	O
J2	O
cells	O
,	O
TGEV	O
exhibited	O
a	O
dose	O
-	O
dependent	O
inhibition	B-PROC
of	O
NF	O
-	O
κB	O
activity	O
.	O

Our	O
previous	O
study	O
showed	O
that	O
PEDV	O
ORF3	O
has	O
expression	B-PROC
characteristic	O
of	O
aggregation	O
in	O
cytoplasm	O
,	O
but	O
its	O
biological	B-PROC
function	I-PROC
remains	O
elusive	O
.	O

TITLE	O
:	O
Interferon	O
gamma	O
inhibits	O
transmissible	O
gastroenteritis	O
virus	B-PROC
infection	I-PROC
mediated	O
by	O
an	O
IRF1	O
signaling	B-PROC
pathway	I-PROC
.	O

Mechanistically	O
,	O
using	O
overexpression	B-PROC
and	O
functional	O
knockdown	O
experiments	O
,	O
we	O
demonstrated	O
that	O
porcine	O
interferon	O
regulatory	O
factor	O
1	O
(	O
poIRF1	O
)	O
elicited	O
by	O
IFN	O
-	O
γ	O
primarily	O
mediated	O
IFN	O
-	O
γ	O
signaling	B-PROC
cascades	O
and	O
the	O
inhibition	B-PROC
of	O
TGEV	O
infection	O
by	O
IFN	O
-	O
γ	O
.	O

After	O
starting	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
,	O
patients	O
were	O
switched	O
to	O
the	O
bi	O
-	O
level	O
positive	O
airway	O
pressure	O
mode	O
with	O
1	O
second	O
of	O
24	O
cm	O
H2O	O
high	O
pressure	O
and	O
2	O
seconds	O
of	O
12	O
cm	O
H2O	O
low	O
pressure	O
for	O
24	O
hours	O
.	O

A	O
computer	O
-	O
generated	O
allocation	O
sequence	O
randomized	O
patients	O
to	O
receive	O
each	O
of	O
the	O
following	O
three	O
experimental	O
steps	O
:	O
1	O
)	O
high	O
pressure	O
24	O
cm	O
H2O	O
and	O
low	O
pressure	O
20	O
cm	O
H2O	O
(	O
very	O
high	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
-	O
very	O
low	O
driving	O
pressure	O
);	O
2	O
)	O
high	O
pressure	O
24	O
cm	O
H2O	O
and	O
low	O
pressure	O
5	O
cm	O
H2O	O
(	O
low	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
-	O
high	O
driving	O
pressure	O
);	O
and	O
3	O
)	O
high	O
pressure	O
17	O
cm	O
H2O	O
and	O
low	O
pressure	O
5	O
cm	O
H2O	O
(	O
low	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
-	O
low	O
driving	O
pressure	O
).	O

Swabs	O
were	O
taken	O
during	O
stable	O
periods	B-PROC
(	O
n	O
=	O
1909	O
),	O
at	O
URTI	O
onset	O
(	O
n	O
=	O
391	O
),	O
10	O
days	O
after	O
the	O
URTI	O
(	O
n	O
=	O
356	O
)	O
and	O
during	O
an	O
AECOPD	O
(	O
n	O
=	O
177	O
)	O
and	O
tested	O
using	O
a	O
multiplex	O
nucleic	O
acid	O
amplification	O
test	O
.	O

Patients	O
with	O
a	O
viral	B-PROC
infection	I-PROC
at	O
URTI	O
onset	O
did	O
not	O
have	O
a	O
higher	O
incidence	O
of	O
exacerbation	O
than	O
patients	O
without	O
viral	B-PROC
infection	I-PROC
(	O
p	O
=	O
0	O
.	O
993	O
).	O

TITLE	O
:	O
MiR	O
-	O
150	O
attenuates	O
LPS	O
-	O
induced	O
acute	O
lung	O
injury	O
via	O
targeting	B-PROC
AKT3	O
.	O

In	O
-	O
vitro	O
assays	O
demonstrated	O
that	O
miR	O
-	O
150	O
alleviated	O
LPS	O
-	O
induced	O
A549	O
cell	O
apoptosis	B-PROC
,	O
autophagy	B-PROC
,	O
and	O
release	O
of	O
inflammatory	O
cytokines	O
.	O

In	O
conclusion	O
,	O
miR	O
-	O
150	O
alleviated	O
LPS	O
-	O
induced	O
acute	O
lung	O
injury	O
via	O
directly	O
targeting	B-PROC
AKT3	O
expression	B-PROC
or	O
regulating	O
JNK	O
and	O
NF	O
-	O
κB	O
pathways	B-PROC
,	O
which	O
may	O
be	O
a	O
promising	O
therapeutic	O
strategy	O
to	O
treat	O
ALI	O
/	O
ARDS	O
.	O

In	O
the	O
control	O
group	O
,	O
patients	O
received	O
a	O
tidal	O
volume	O
of	O
6	O
mL	O
/	O
kg	O
per	O
predicted	O
bodyweight	O
and	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
was	O
selected	O
according	O
to	O
a	O
low	O
PEEP	O
and	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
table	O
,	O
and	O
early	O
prone	O
position	O
was	O
encouraged	O
.	O

Subcellular	O
localization	B-PROC
analyses	O
revealed	O
that	O
the	O
MERS	O
-	O
CoV	O
M	O
protein	O
is	O
retained	O
intracellularly	O
in	O
the	O

We	O
found	O
that	O
the	O
serum	O
immunoglobulin	B-PROC
levels	O
were	O
in	O
the	O
normal	O
range	O
in	O
70	O
%	O
of	O
the	O
children	O
.	O

As	O
a	O
proof	O
-	O
of	O
-	O
principle	O
,	O
we	O
demonstrate	O
that	O
host	O
gene	B-PROC
expression	I-PROC
can	O
be	O
modulated	O
post	O
-	O
differentiation	B-PROC
via	O
inducible	O
short	O
hairpin	O
(	O
sh	O
)	O
RNA	O
-	O
mediated	O
knockdown	O
.	O

TITLE	O
:	O
Lung	O
Recruitability	O
in	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Requiring	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
.	O

Patients	O
with	O
potential	O
for	O
lung	O
recruitment	O
above	O
the	O
median	O
had	O
significantly	O
shorter	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
duration	O
(	O
8	O
vs	O
13	O
d	O
;	O
p	O
=	O
0	O
.	O
013	O
)	O
and	O
shorter	O
ICU	O
stay	O
(	O
15	O
vs	O
22	O
d	O
;	O
p	O
=	O
0	O
.	O
028	O
),	O
but	O
mortality	O
was	O
not	O
statistically	O
different	O
(	O
24	O
%	O
vs	O
46	O
%;	O
p	O
=	O
0	O
.	O
159	O
).	O

The	O
positive	O
result	O
of	O
IgM	O
and	O
IgG	O
was	O
considered	O
the	O
application	O
of	O
ganglioside	O
and	O
blood	B-PROC
-	I-PROC
brain	I-PROC
barrier	I-PROC
might	O
be	O
damaged	O
after	O
meningioma	O
surgery	O
which	O
eased	O
the	O
drug	O
to	O
enter	O
the	O
cerebrospinal	B-PROC
fluid	I-PROC
circulation	B-PROC
and	O
induced	O
lesions	O
,	O
therefore	O
the	O
etiology	O
on	O
this	O
GBS	O
case	O
was	O
of	O
high	O
confidence	O
of	O
administrating	O
ganglioside	O
drugs	O
.	O

TITLE	O
:	O
Continuous	O
Positive	O
Airway	O
Pressure	O
Use	O
for	O
Obstructive	O
Sleep	B-PROC
Apnea	O
in	O
Acute	O
,	O
Traumatic	O
Tetraplegia	O
.	O

After	O
conducting	B-PROC
univariate	O
analysis	O
of	O
risk	O
factors	O
,	O
statistically	O
significant	O
risk	O
factors	O
affecting	O
the	O
development	B-PROC
of	O
ROP	O
in	O
our	O
study	O
were	O
:	O
low	O
gestational	O
age	O
,	O
low	O
birth	B-PROC
weight	O
,	O
type	O
of	O
multiple	O
gestation	B-PROC
,	O
the	O
presence	O
of	O
affected	O
sibling	O
,	O
low	O
level	O
of	O
Hemoglobin	O
at	O
birth	B-PROC
,	O
respiratory	O
distress	O
syndrome	O
,	O
low	O
Hemoglobin	O
level	O
,	O
blood	O
transfusion	O
and	O
days	O
on	O
oxygen	O
supplements	O
with	O
either	O
mechanical	O
,	O
non	O
-	O
mechanical	O
methods	O
or	O
both	O
combined	O
.	O

High	O
bilirubin	O
levels	O
were	O
found	O
as	O
a	O
protective	O
factor	O
against	O
the	O
development	B-PROC
of	O
ROP	O
.	O

ABSTRACT	O
:	O
India	O
is	O
one	O
of	O
the	O
seven	O
identified	O
countries	O
in	O
South	O
-	O
East	O
Asia	O
region	O
regularly	O
reporting	O
dengue	O
fever	B-PROC
(	O
DF	O
)/	O
dengue	O
hemorrhagic	O
fever	B-PROC
(	O
DHF	O
)	O
outbreaks	O
.	O

An	O
induced	O
-	O
fit	O
docking	B-PROC
analysis	O
revealed	O
that	O
S1	O
and	O
S2	O
sites	O
play	O
a	O
role	O
in	O
interaction	O
with	O
flavonoids	O
.	O

Moreover	O
,	O
in	O
short	O
-	O
term	O
sequential	O
forecasts	O
,	O
the	O
sub	O
-	O
epidemic	O
model	O
was	O
able	O
to	O
forecast	O
the	O
second	O
surge	O
in	O
case	O
incidence	O
for	O
this	O
outbreak	O
,	O
which	O
was	O
not	O
possible	O
using	O
the	O
simple	O
growth	B-PROC
models	O
.	O

RESULTS	O
:	O
The	O
sub	O
-	O
epidemic	O
wave	O
model	O
outperforms	O
simpler	O
growth	B-PROC
models	O
in	O
short	O
-	O
term	O
forecasts	O
based	O
on	O
performance	O
metrics	O
that	O
account	O
for	O
the	O
uncertainty	O
of	O
the	O
predictions	O
namely	O
the	O
mean	O
interval	O
score	O
(	O
MIS	O
)	O
and	O
the	O
coverage	O
of	O
the	O
95	O
%	O
prediction	O
interval	O
.	O

TITLE	O
:	O
The	O
Curious	O
Case	O
of	O
the	O
Nidovirus	O
Exoribonuclease	O
:	O
Its	O
Role	O
in	O
RNA	B-PROC
Synthesis	I-PROC
and	O
Replication	O
Fidelity	O
.	O

Coumarin	O
-	O
based	O
molecules	O
already	O
proved	O
to	O
act	O
as	O
HIV	O
-	O
1	O
Protease	O
(	O
PR	O
)	O
or	O
Integrase	O
(	O
IN	O
)	O
inhibitors	O
and	O
also	O
to	O
target	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-PROC
(	O
RT	O
),	O
blocking	O
the	O
DNA	O
-	O
dependent	O
DNA	O
-	O
polymerase	O
activity	O
or	O
the	O
RNA	O
-	O
dependent	O
DNA	O
-	O
polymerase	O
activity	O
working	O
as	O
common	O
NNRTIs	O
.	O

Here	O
we	O
report	O
that	O
ORF8b	O
,	O
an	O
accessory	O
protein	O
of	O
MERS	O
-	O
CoV	O
,	O
strongly	O
inhibits	O
both	O
MDA5	O
-	O
and	O
RIG	O
-	O
I	O
-	O
mediated	O
activation	O
of	O
interferon	O
beta	O
promoter	O
activity	O
while	O
downstream	O
signaling	B-PROC
molecules	O
were	O
left	O
largely	O
unaffected	O
.	O

Following	O
the	O
formation	B-PROC
and	O
implementation	O
of	O
the	O
mPATH	O
team	O
at	O
our	O
Level	O
I	O
trauma	O
center	O
,	O
a	O
retrospective	O
cohort	O
study	O
was	O
performed	O
comparing	O
patients	O
in	O
the	O
year	O
immediately	O
prior	O
to	O
the	O
introduction	O
of	O
the	O
mPATH	O
team	O
(	O
n	O
=	O
60	O
)	O
to	O
those	O
in	O
the	O
first	O
full	O
year	O
following	O
implementation	O
(	O
n	O
=	O
70	O
).	O

The	O
primary	O
endpoint	O
was	O
length	O
of	O
stay	O
;	O
secondary	O
endpoints	O
were	O
time	O
to	O
tracheostomy	O
,	O
days	O
to	O
evaluation	O
by	O
occupational	O
,	O
physical	O
,	O
and	O
speech	B-PROC
therapy	O
,	O
30	O
-	O
day	O
readmission	O
,	O
and	O
30	O
-	O
day	O
mortality	O
.	O

Influenza	O
A	O
virus	B-PROC
infection	I-PROC
was	O
found	O
in	O
83	O
.	O
1	O
%	O
of	O
the	O
patients	O
.	O

The	O
impact	O
of	O
these	O
respiratory	O
viral	B-PROC
infections	I-PROC
remained	O
significant	O
in	O
women	O
(	O
3	O
.	O
8	O
%,	O
12	O
.	O
1	O
%,	O
and	O
67	O
.	O
4	O
%,	O
respectively	O
,	O
P	O
<	O
.	O
05	O
)	O
and	O
in	O
older	O
patients	O
(	O
10	O
.	O
7	O
%,	O
14	O
.	O
6	O
%,	O
and	O
118	O
.	O
2	O
%,	O
respectively	O
,	O
P	O
<	O
.	O
05	O
).	O

TITLE	O
:	O
Recruitment	O
maneuver	O
leads	O
to	O
increased	O
expression	B-PROC
of	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

A	O
DNA	O
vaccine	O
was	O
constructed	O
with	O
the	O
TGEV	O
S1	O
gene	O
to	O
induce	O
immune	B-PROC
response	I-PROC
in	O
an	O
experimental	O
mouse	O
model	O
;	O
pIL	O
-	O
12	O
was	O
chosen	O
as	O
the	O
immunological	O
adjuvant	O
within	O
this	O
DNA	O
vaccine	O
.	O

In	O
addition	O
,	O
a	O
second	O
Tom20	O
recognition	O
motif	O
was	O
identified	O
further	O
downstream	O
(	O
residues	O
61	O
-	O
65	O
),	O
although	O
the	O
mitochondrial	B-PROC
translocation	I-PROC
evoked	O
by	O
these	O
residues	O
seemed	O
less	O
efficient	O
as	O
a	O
diffuse	O
cytoplasmic	O
distribution	O
was	O
also	O
observed	O
.	O

Assessing	O
the	O
spatiotemporal	O
distribution	O
of	O
FCoV	O
3b	O
did	O
not	O
provide	O
convincing	O
evidence	O
of	O
dynamic	O
shuttling	O
behaviour	B-PROC
between	O
the	O
nucleoli	O
and	O
the	O
mitochondria	O
.	O

In	O
the	O
NIV	O
group	O
,	O
PaO	B-PROC

TITLE	O
:	O
Peptide	O
presentation	O
by	O
bat	O
MHC	B-PROC
class	O
I	O
provides	O
new	O
insight	O
into	O
the	O
antiviral	O
immunity	B-PROC
of	O
bats	O
.	O

The	O
association	O
between	O
myocardial	O
calcification	B-PROC
and	O
tumor	O
lysis	B-PROC
syndrome	O
has	O
not	O
been	O
reported	O
to	O
date	O
.	O

Transthoracic	O
echocardiogram	O
revealed	O
diffuse	O
severe	O
hypokinesis	O
with	O
decreased	O
left	B-PROC
ventricular	I-PROC
ejection	I-PROC
fraction	O
.	O

Microscopically	O
,	O
myocardial	O
fibers	O
were	O
granularly	O
basophilic	O
in	O
that	O
area	O
and	O
were	O
revealed	O
as	O
calcium	B-PROC
deposits	I-PROC
by	O
Von	O
Kossa	O
staining	O
.	O

He	O
was	O
diagnosed	O
with	O
myocardial	O
calcification	B-PROC
.	O

The	O
drastic	O
increase	O
in	O
the	O
serum	O
phosphorus	O
level	O
caused	O
by	O
tumor	O
lysis	B-PROC
syndrome	O
seemed	O
to	O
be	O
associated	O
with	O
myocardial	O
calcification	B-PROC
.	O

An	O
increase	O
in	O
the	O
levels	O
of	O
mRNAs	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
interleukin	O
-	O
1β	O
(	O
IL	O
-	O
1β	O
)	O
and	O
tumor	O
necrosis	B-PROC
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
was	O
also	O
observed	O
in	O
PEDV	O
-	O
infected	O
G3BP1	O
depleted	O
cells	O
compared	O
to	O
PEDV	O
-	O
infected	O
control	O
cells	O
.	O

ABSTRACT	O
:	O
Our	O
Cooling	O
to	O
Help	O
Injured	O
Lungs	O
(	O
CHILL	O
)	O
trial	O
of	O
therapeutic	O
hypothermia	O
in	O
ARDS	O
includes	O
neuromuscular	B-PROC
blockade	I-PROC
(	O
NMB	O
)	O
as	O
an	O
inclusion	O
criterion	O
to	O
avoid	O
shivering	O
.	O

In	O
this	O
study	O
,	O
a	O
TGEV	O
oral	O
vaccine	O
was	O
generated	O
by	O
transferring	O
a	O
eukaryotic	O
expression	B-PROC
recombinant	O
plasmid	O
carrying	O
the	O
SAD	O
(	O
A	O
and	O
D	O
antigenic	O
sites	O
of	O
the	O
S	O
protein	O
)	O
epitope	O
of	O
TGEV	O
into	O
a	O
swine	O
-	O
origin	O
Lactobacillus	O
acidophilus	O
(	O
L	O
.	O
acidophilus	O
).	O

Despite	O
the	O
introduction	O
of	O
effective	O
antibiotics	O
and	O
intensive	O
supportive	O
care	O
in	O
the	O
20th	O
century	O
,	O
death	B-PROC
rates	O
from	O
community	O
-	O
acquired	O
pneumonia	O
among	O
patients	O
in	O
the	O
intensive	O
care	O
unit	O
remain	O
as	O
high	O
as	O
35	O
%.	O

TITLE	O
:	O
Epitope	O
mapping	O
and	O
cellular	B-PROC
localization	I-PROC
of	O
swine	O
acute	O
diarrhea	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	O
using	O
a	O
novel	O
monoclonal	O
antibody	B-PROC
.	O

ABSTRACT	O
:	O
Genetic	B-PROC
recombination	I-PROC
has	O
frequently	O
been	O
observed	O
in	O
coronaviruses	O
.	O

The	O
patterns	O
of	O
recombination	B-PROC
differed	O
geographically	O
across	O
the	O
African	O
region	O
,	O
highlighting	O
a	O
mosaic	O
structure	O
of	O
DcCoV	O
-	O
HKU23	O
genomes	O
circulating	O
in	O
dromedaries	O
.	O

Our	O
results	O
highlighted	O
active	O
recombination	B-PROC
of	O
coronaviruses	O
circulating	O
in	O
dromedaries	O
and	O
are	O
also	O
relevant	O
to	O
the	O
emergence	O
and	O
evolution	B-PROC
of	O
other	O
betacoronaviruses	O
,	O
including	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

It	O
can	O
cause	O
ARDS	O
and	O
other	O
respiratory	O
illnesses	O
such	O
as	O
bronchitis	O
,	O
metal	O
fumes	O
fever	B-PROC
and	O
chronic	O
pneumonitis	O
.	O

Here	O
,	O
we	O
describe	O
the	O
use	O
of	O
Crispr	O
/	O
Cas	O
technology	O
to	O
disrupt	O
type	O
I	O
IFN	O
signaling	B-PROC
in	O
two	O
feline	O
cell	O
lines	O
,	O
AK	O
-	O
D	O
and	O
Fcwf	O
-	O
4	O
CU	O
,	O
and	O
evaluate	O
the	O
replication	O
kinetics	O
of	O
a	O
serotype	O
I	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
within	O
these	O
cells	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
replication	O
of	O
FIPV	O
is	O
enhanced	O
by	O
ectopic	B-PROC
expression	B-PROC
of	O
a	O
host	O
serine	O
protease	O
,	O
TMPRSS2	O
,	O
in	O
these	O
cells	O
.	O

ABSTRACT	O
:	O
In	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
),	O
right	O
ventricular	O
(	O
RV	O
failure	O
)	O
and	O
dilation	O
have	O
been	O
investigated	O
with	O
the	O
use	O
of	O
echocardiography	O
,	O
whereas	O
RV	O
hypertrophy	O
has	O
not	O
been	O
addressed	O
in	O
the	O
literature	O
.	O

Diabetic	O
mice	O
had	O
fewer	O
inflammatory	O
monocyte	O
/	O
macrophages	O
and	O
CD4	O
+	O
T	O
cells	O
,	O
which	O
correlated	O
with	O
lower	O
levels	O
of	O
Ccl2	O
and	O
Cxcl10	O
expression	B-PROC
.	O

In	O
order	O
to	O
track	O
the	O
genetic	O
evolutionary	O
of	O
IBV	O
isolates	O
circulating	O
in	O
yellow	O
chickens	O
,	O
we	O
continued	O
to	O
conduct	B-PROC
the	O
genetic	O
analyses	O
of	O
the	O
structural	O
genes	O
S1	O
,	O
E	O
,	O
M	O
,	O
and	O
N	O
from	O
64	O
IBV	O
isolates	O
in	O
southern	O
China	O
during	O
2009	O
-	O
2017	O
.	O

The	O
studies	O
of	O
MERS	O
patients	O
with	O
severe	O
disease	O
and	O
experimentally	O
infected	O
animals	O
showed	O
that	O
robust	O
viral	B-PROC
replication	I-PROC
and	O
intensive	O
proinflammatory	O
response	O
in	O
lung	O
tissues	O
contribute	O
to	O
high	O
pathogenicity	O
of	O
MERS	O
-	O
CoV	O
.	O
We	O
sought	O
to	O
identify	O
pattern	O
recognition	O
receptor	O
(	O
PRR	O
)	O
signaling	B-PROC
pathway	I-PROC
(	O
s	O
)	O
that	O
mediates	O
the	O
inflammatory	O
cascade	O
in	O
human	O
macrophages	O
upon	O
MERS	O
-	O
CoV	O
infection	O
.	O

The	O
authors	O
identify	O
the	O
need	O
for	O
international	O
collaboration	O
to	O
conduct	B-PROC
MERS	O
coronavirus	O
(	O
CoV	O
)	O
surveillance	O
in	O
animals	O
in	O
the	O
Middle	O
East	O
,	O
since	O
the	O
emergence	O
of	O
new	O
MERS	O
-	O
CoV	O
variants	O
with	O
the	O
ability	O
to	O
sustain	O
efficient	O
person	O
-	O
to	O
-	O
person	O
transmission	O
is	O
a	O
genuine	O
threat	O
.	O

The	O
S1	O
gene	O
has	O
1	O
,	O
620	O
nucleotides	O
and	O
encoded	O
a	O
polypeptide	O
of	O
540	O
amino	O
acids	O
with	O
typical	O
coronavirus	O
cleavage	B-PROC
recognition	O
sites	O
of	O
HRRR	O
.	O

The	O
kidneys	O
of	O
dead	B-PROC
birds	O
were	O
swollen	O
and	O
pale	O
and	O
exhibited	O
severe	O
urate	O
deposition	O
.	O

Research	O
findings	O
indicate	O
that	O
PDCoV	O
has	O
evolved	O
strategies	O
to	O
escape	O
innate	B-PROC
immune	I-PROC
response	I-PROC
in	O
host	O
cells	O
,	O
but	O
mechanism	O
of	O
PDCoV	O
in	O
innate	O
immune	B-PROC
modulation	I-PROC
is	O
not	O
well	O
understood	O
.	O

The	O
enrichment	O
results	O
indicated	O
that	O
extensive	O
gene	O
functions	O
and	O
signaling	B-PROC
pathways	B-PROC
including	O
innate	O
immune	O
-	O
associated	O
functions	O
and	O
pathways	B-PROC
were	O
affected	O
by	O
PDCoV	O
infection	O
.	O

Additionally	O
,	O
16	O
of	O
the	O
host	O
cell	O
endogenous	O
miRNAs	O
were	O
predicted	O
as	O
potential	O
contributors	O
to	O
the	O
modulation	O
of	O
innate	B-PROC
immune	I-PROC
response	I-PROC
affected	O
by	O
PDCoV	O
.	O
Our	O
research	O
findings	O
indicated	O
that	O
the	O
innate	O
immune	O
-	O
associated	O
genes	O
and	O
signaling	B-PROC
pathways	B-PROC
in	O
PK	O
-	O
15	O
cells	O
could	O
be	O
modified	O
by	O
the	O
infection	O
of	O
PDCoV	O
,	O
which	O
provides	O
a	O
fundamental	O
foundation	O
for	O
further	O
studies	O
to	O
better	O
understand	O
the	O
mechanism	O
of	O
PDCoV	O
infections	O
,	O
so	O
as	O
to	O
effectively	O
control	O
and	O
prevent	O
PDCoV	O
-	O
induced	O
swine	O
diarrheal	O
disease	O
outbreaks	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
used	O
bovine	O
pulmonary	O
arterial	O
cells	O
in	O
order	O
to	O
investigate	O
the	O
effects	O
of	O
GHRH	O
and	O
its	O
antagonistic	O
and	O
agonistic	O
analogs	O
in	O
key	O
intracellular	O
pathways	B-PROC
that	O
regulate	O
endothelial	O
permeability	O
.	O

In	O
contrast	O
,	O
both	O
GHRH	O
and	O
GHRH	O
agonist	O
MR409	O
exerted	B-PROC
the	O
opposite	O
effects	O
.	O

This	O
is	O
the	O
first	O
report	O
on	O
cell	O
adaption	B-PROC
of	O
a	O
virulent	O
SADS	O
-	O
CoV	O
strain	O
,	O
which	O
gives	O
information	O
on	O
the	O
potential	O
virulence	B-PROC
determinants	O
of	O
SADS	O
-	O
CoV	O
.	O

The	O
integrin	O
αv	O
and	O
β3	O
subunits	O
were	O
both	O
involved	O
in	O
the	O
enhancement	O
of	O
PEDV	O
infection	O
,	O
the	O
Arg	O
-	O
Gly	O
-	O
Asp	O
peptides	O
targeting	B-PROC
integrin	O
αvβ3	O
significantly	O
inhibited	O
replication	O
of	O
PEDV	O
in	O
Vero	O
E6	O
cells	O
,	O
and	O
co	O
-	O
expression	B-PROC
of	O
integrin	O
αvβ3	O
with	O
pAPN	O
significantly	O
enhanced	O
replication	O
of	O
PEDV	O
in	O
Vero	O
E6	O
and	O
BHK	O
-	O
21	O
cells	O
.	O

The	O
results	O
of	O
this	O
study	O
may	O
explain	O
the	O
observed	O
absence	O
of	O
clinical	O
resistance	B-PROC
to	O
the	O
long	O
-	O
term	O
antiviral	O
treatment	O
in	O
the	O
patients	O
.	O

RESULTS	O
:	O
Our	O
findings	O
suggest	O
that	O
vaccination	O
strategies	O
targeting	B-PROC
patients	O
and	O
healthcare	O
workers	O
,	O
which	O
have	O
been	O
disproportionately	O
affected	O
during	O
past	O
outbreaks	O
,	O
and	O
assuming	O
two	O
vaccination	O
coverage	O
levels	O
at	O
50	O
and	O
75	O
%	O
have	O
the	O
potential	O
to	O
avert	O
nearly	O
50	O
%	O
or	O
more	O
of	O
MERS	O
or	O
SARS	O
cases	O
.	O

Furthermore	O
,	O
1	O
airport	O
baggage	O
handler	O
who	O
was	O
admitted	O
to	O
hospital	O
A	O
before	O
rash	O
onset	O
infected	O
2	O
healthcare	O
workers	O
(	O
HCWs	O
)	O
known	O
to	O
have	O
2	O
doses	O
of	O
MMR	B-PROC
vaccination	O
with	O
positive	O
measles	O
IgG	O
and	O
lower	O
viral	O
loads	O
in	O
respiratory	O
specimens	O
.	O

TGEV	O
infection	O
provokes	O
mitochondrial	O
damage	O
of	O
porcine	O
intestinal	O
epthelial	O
cell	O
(	O
IPEC	O
),	O
which	O
is	O
responsible	O
for	O
inflammation	O
and	O
cell	B-PROC
death	I-PROC
.	O

Silencing	O
HK2	O
enhanced	O
TGEV	O
-	O
induced	O
mPTP	O
opening	O
,	O
while	O
no	O
effect	O
on	O
NF	O
-	O
κB	O
pathway	B-PROC
.	O

TITLE	O
:	O
Successful	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
Group	O
A	O
streptococcus	O
induced	O
toxic	O
shock	O
syndrome	O
in	O
the	O
third	O
trimester	O
of	O
pregnancy	O
-	O
effectiveness	O
of	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
:	O
A	O
case	O
report	O
.	O

TITLE	O
:	O
Human	O
virome	O
in	O
nasopharynx	O
and	O
tracheal	O
secretion	B-PROC
samples	O
.	O

Central	O
public	O
health	O
laboratories	O
use	O
reverse	B-PROC
transcription	B-PROC
-	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
for	O
diagnosis	O
of	O
respiratory	O
viruses	O
,	O
but	O
this	O
protocol	O
identifies	O
only	O
specific	O
targets	O
,	O
resulted	O
in	O
inconclusive	O
diagnosis	O
for	O
many	O
samples	O
.	O

Here	O
we	O
report	O
a	O
56	O
-	O
year	O
-	O
old	O
male	O
patient	O
who	O
initially	O
presented	O
with	O
breathlessness	O
and	O
eosinophilia	O
,	O
subsequent	O
development	B-PROC
of	O
respiratory	O
failure	O
and	O
admission	O
to	O
ITU	O
for	O
non	O
-	O
invasive	O
ventilation	O
.	O

Finally	O
,	O
perspectives	O
for	O
use	O
of	O
the	O
reviewed	O
knowledge	O
for	O
the	O
development	B-PROC
of	O
novel	O
antiviral	O
strategies	O
will	O
be	O
sketched	O
.	O

In	O
particular	O
,	O
concerns	O
and	O
precautions	O
have	O
increased	O
regarding	O
the	O
use	O
of	O
aerosol	O
-	O
generating	O
medical	O
procedures	O
when	O
treating	O
patients	O
with	O
such	O
viral	B-PROC
infections	I-PROC
.	O

As	O
limited	O
therapeutic	O
antibody	B-PROC
is	O
accumulated	O
in	O
lung	O
tissue	O
following	O
systemic	O
administration	O
,	O
inhalation	B-PROC
is	O
newly	O
recognized	O
as	O
an	O
alternative	O
,	O
possibly	O
better	O
,	O
route	O
of	O
therapeutic	O
antibody	B-PROC
for	O
pulmonary	O
diseases	O
.	O

A	O
real	O
-	O
time	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
detect	O
ECoV	O
RNA	O
.	O

We	O
also	O
identified	O
parallel	O
downstream	O
processes	O
that	O
were	O
altered	O
during	O
influenza	O
pathogenesis	B-PROC
.	O

She	O
developed	O
very	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
which	O
was	O
treated	O
with	O
rescue	O
high	O
-	O
frequency	O
oscillation	O
),	O
hemodynamic	B-PROC
instability	O
,	O
acute	O
kidney	O
injury	O
,	O
rhabdomyolysis	O
,	O
and	O
remained	O
comatose	O
with	O
a	O
Glasgow	O
Coma	O
Scale	O
score	O
of	O
3	O
and	O
gasping	O
respirations	B-PROC
for	O
67	O
hours	O
(	O
when	O
the	O
Glasgow	O
Coma	O
Scale	O
score	O
improved	O
to	O
6	O
,	O
with	O
tachypnea	O
to	O
Paco	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
is	O
a	O
technique	O
involving	O
oxygenation	B-PROC
of	O
blood	O
and	O
elimination	B-PROC
of	O
carbon	O
dioxide	O
in	O
patients	O
with	O
life	O
-	O
threatening	O
,	O
but	O
potentially	O
reversible	O
conditions	O
.	O

In	O
addition	O
,	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
reduces	O
or	O
eliminates	O
the	O
risk	O
of	O
lung	O
damage	O
associated	O
with	O
invasive	O
mechanical	O
ventilation	O
in	O
patients	O
with	O
severe	O
ARDS	O
(	O
acute	O
respiratory	O
distress	O
syndrome	O
).	O

Therefore	O
,	O
a	O
need	O
exists	O
for	O
a	O
safer	O
and	O
more	O
effective	O
method	O
of	O
oxygenation	B-PROC
for	O
patients	O
with	O
ARDS	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
role	O
of	O
viral	B-PROC
infections	I-PROC
in	O
the	O
pathogenesis	B-PROC
of	O
primary	O
acquired	O
nasolacrimal	O
duct	O
obstruction	O
.	O

During	O
dacryocystorhinostomy	O
,	O
tissue	O
biopsy	O
sample	O
(	O
2	O
×	O
2	O
mm	O
)	O
was	O
taken	O
from	O
the	O
junction	O
area	O
of	O
the	O
lacrimal	O
sac	B-PROC
and	O
nasolacrimal	O
duct	O
.	O

While	O
overexpression	B-PROC
of	O
GILT	O
inhibited	O
the	O
entry	O
mediated	O
by	O
envelope	O
glycoproteins	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
Ebola	O
virus	O
(	O
EBOV	O
)	O
and	O
Lassa	O
fever	B-PROC
virus	O
(	O
LASV	O
),	O
depletion	O
of	O
GILT	O
enhanced	O
the	O
entry	O
mediated	O
by	O
these	O
viral	O
envelope	O
glycoproteins	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	B-PROC
as	O
rescue	O
therapy	O
for	O
severe	O
hypoxemic	O
respiratory	O
failure	O
.	O

Adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
often	O
the	O
final	O
common	O
pathway	B-PROC
of	O
various	O
pathologies	O
affecting	O
adults	O
and	O
causing	O
hypoxemic	O
respiratory	O
failure	O
.	O

These	O
difficulties	O
include	O
ventilation	O
issues	O
,	O
hypoxemia	O
(	O
especially	O
as	O
related	O
to	O
recirculation	O
or	O
low	O
ECMO	O
-	O
flow	O
-	O
to	O
-	O
cardiac	O
-	O
output	O
ratio	O
),	O
sepsis	O
,	O
malfunctioning	O
critical	O
circuit	O
components	O
,	O
lack	O
of	O
clarity	O
regarding	O
optimal	O
hemoglobin	O
levels	O
,	O
hematological	O
/	O
anticoagulation	B-PROC
complications	O
,	O
and	O
right	O
ventricular	O
(	O
RV	O
)	O
dysfunction	O
.	O

Four	O
days	O
after	O
surgery	O
,	O
the	O
cat	O
re	O
-	O
presented	O
with	O
anorexia	O
and	O
acute	O
onset	O
of	O
expiratory	B-PROC
dyspnoea	O
.	O

The	O
BCoV	O
antigen	O
distribution	O
was	O
prominent	O
within	O
the	O
necrotic	B-PROC
crypts	O
in	O
the	O
jejunum	O
and	O
cryptic	O
micro	O
-	O
abscesses	O
in	O
the	O
colon	O
and	O
ileum	O
.	O

Furthermore	O
,	O
we	O
found	O
bat	O
HKU8r	O
-	O
CoV	O
NP	O
antibody	B-PROC
in	O
73	O
(	O
12	O
.	O
5	O
%)	O
of	O
the	O
MERS	O
-	O
CoV	O
RBD	O
positive	O
and	O
NP	O
negative	O
samples	O
,	O
yet	O
found	O
only	O
3	O
(	O
0	O
.	O
43	O
%)	O
of	O
the	O
HKU8r	O
-	O
CoV	O
S1	O
antibody	B-PROC
in	O
the	O
same	O
samples	O
.	O

Fortunately	O
,	O
the	O
child	O
responded	O
well	O
and	O
weaned	B-PROC
off	O
the	O
ventilator	O
over	O
few	O
days	O
.	O

Both	O
DNA	O
and	O
RNA	O
were	O
sequenced	O
simultaneously	O
using	O
an	O
Illumina	O
library	O
preparation	O
protocol	O
with	O
in	O
-	O
house	O
adaptations	B-PROC
.	O

TITLE	O
:	O
One	O
-	O
step	O
triplex	O
reverse	O
-	O
transcription	B-PROC
PCR	O
detection	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
,	O
porcine	O
sapelovirus	O
,	O
and	O
porcine	O
sapovirus	O
.	O

Infection	O
with	O
mutant	O
IBV	O
induces	O
severe	O
encephalitis	O
and	O
breaks	O
the	O
blood	B-PROC
-	I-PROC
brain	I-PROC
barrier	I-PROC
.	O

Furthermore	O
,	O
whole	O
-	O
genome	O
sequencing	O
identified	O
13	O
amino	O
acid	O
changes	O
in	O
P120	O
,	O
which	O
might	O
be	O
responsible	O
for	O
the	O
attenuated	O
virulence	B-PROC
of	O
P120	O
.	O

ABSTRACT	O
:	O
The	O
syndrome	O
of	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(	O
DRESS	O
)	O
is	O
a	O
rare	O
,	O
yet	O
potentially	O
fatal	O
hypersensitivity	B-PROC
reaction	I-PROC
,	O
most	O
commonly	O
associated	O
with	O
anticonvulsants	O
,	O
sulfonamides	O
,	O
and	O
allopurinol	O
.	O

The	O
reaction	O
commonly	O
manifests	O
as	O
a	O
febrile	B-PROC
skin	O
eruption	O
with	O
lymphadenopathy	O
and	O
malaise	O
between	O
two	O
and	O
eight	O
weeks	O
following	O
drug	O
exposure	O
.	O

Pulmonary	O
symptoms	O
may	O
precede	O
development	B-PROC
of	O
the	O
other	O
more	O
common	O
symptoms	O
and	O
signs	O
of	O
the	O
syndrome	O
,	O
or	O
they	O
might	O
develop	O
later	O
in	O
the	O
course	O
of	O
the	O
disease	O
.	O

Data	O
of	O
personnel	O
location	O
and	O
movement	B-PROC
,	O
personal	O
protection	O
equipment	O
and	O
hand	O
hygiene	O
was	O
recorded	O
.	O

The	O
main	O
mode	O
of	O
transmission	O
of	O
SARS	O
-	O
CoV	O
is	O
through	O
inhalation	B-PROC
of	O
respiratory	O
droplets	O
.	O

TITLE	O
:	O
Protostemonine	O
alleviates	O
heat	O
-	O
killed	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
-	O
induced	O
acute	O
lung	O
injury	O
through	O
MAPK	O
and	O
NF	O
-	O
κB	O
signaling	B-PROC
pathways	B-PROC
.	O

In	O
addition	O
,	O
PSN	O
decreased	O
the	O
content	O
of	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
6	O
and	O
the	O
expression	B-PROC
of	O
iNOS	O
,	O
as	O
well	O
as	O
the	O
production	O
of	O
NO	O
in	O
HKMRSA	O
-	O
induced	O
bone	O
marrow	O
derived	O
macrophages	O
(	O
BMDMs	O
).	O

CEPI	O
has	O
also	O
played	O
a	O
leading	O
role	O
in	O
fostering	O
institutional	O
partnerships	O
between	O
public	O
-	O
sector	O
and	O
private	O
-	O
sector	O
organisations	O
to	O
optimise	O
allocation	O
of	O
resources	O
for	O
vaccine	O
development	B-PROC
against	O
its	O
priority	O
pathogens	O
.	O

In	O
addition	O
,	O
the	O
transcriptional	B-PROC
level	O
of	O
MDA5	O
was	O
upregulated	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
upon	O
DEV	O
infection	O
.	O

We	O
also	O
showed	O
that	O
there	O
was	O
an	O
association	O
between	O
MDA5	O
and	O
laboratory	O
of	O
genetics	O
and	O
physiology	O
2	O
(	O
LGP2	O
)	O
in	O
antiviral	O
signaling	B-PROC
.	O

Long	O
noncoding	O
RNAs	O
(	O
lncRNAs	O
)	O
play	O
important	O
roles	O
in	O
a	O
number	O
of	O
biological	B-PROC
process	I-PROC
including	O
inflammation	O
response	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
selected	O
cardiotropic	O
pathogens	O
in	O
the	O
myocardium	O
of	O
adult	O
dogs	O
with	O
unexplained	O
myocardial	O
and	O
rhythm	B-PROC
disorders	O
or	O
with	O
congenital	O
heart	O
disease	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
prevalence	O
of	O
nucleic	O
acid	O
from	O
selected	O
cardiotropic	O
pathogens	O
in	O
endomyocardial	O
biopsy	O
samples	O
from	O
dogs	O
with	O
unexplained	O
myocardial	O
and	O
rhythm	B-PROC
disorders	O
(	O
UMRD	O
)	O
and	O
compare	O
prevalence	O
with	O
that	O
for	O
a	O
group	O
of	O
control	O
dogs	O
with	O
congenital	O
heart	O
disease	O
(	O
CHD	O
).	O

Vaccination	O
of	O
pregnant	O
sows	O
with	O
live	O
attenuated	O
vaccines	O
(	O
LAVs	O
)	O
is	O
the	O
most	O
effective	O
strategy	O
to	O
induce	O
lactogenic	O
immunity	B-PROC
in	O
the	O
sows	O
,	O
which	O
provides	O
A	O
passive	O
protection	O
of	O
suckling	O
piglets	O
against	O
PEDV	O
via	O
the	O
colostrum	O
(	O
beestings	O
,	O
or	O
first	O
milk	O
)	O
and	O
milk	O
.	O

With	O
the	O
successful	O
development	B-PROC
of	O
reverse	O
genetics	O
systems	O
for	O
PEDV	O
,	O
we	O
also	O
discuss	O
how	O
to	O
use	O
them	O
to	O
generate	O
promising	O
LAV	O
candidates	O
that	O
are	O
safe	O
,	O
effective	O
and	O
genetically	O
stable	O
.	O

Here	O
,	O
we	O
describe	O
the	O
generation	O
of	O
antibody	B-PROC
-	O
peptide	O
bispecific	O
fusion	O
proteins	O
,	O
each	O
of	O
which	O
contains	O
an	O
anti	O
-	O
MERS	O
-	O
CoV	O
single	O
-	O
chain	O
antibody	B-PROC
m336	O
(	O
or	O
normal	O
human	O
IgG1	O
CH3	O
domain	O
as	O
a	O
control	O
)	O
linked	O
with	O
,	O
or	O
without	O
,	O
a	O
MERS	O
-	O
CoV	O
fusion	O
inhibitory	O
peptide	O
HR2P	O
.	O

A	O
total	O
of	O
107	O
cases	O
of	O
MERS	O
-	O
CoV	O
,	O
including	O
18	O
deaths	B-PROC
(	O
overall	O
case	O
fatality	O
rate	O
(	O
CFR	O
),	O
16	O
.	O
8	O
%;	O
male	O
-	O
specific	O
CFR	O
was	O
17	O
.	O
5	O
%	O
[	O
14	O
/	O
80	O
]	O
and	O
female	O
-	O
specific	O
CFR	O
was	O
14	O
.	O
8	O
%	O
[	O
4	O
/	O
27	O
])	O
were	O
reported	O
to	O
WHO	O
from	O
the	O
National	O
International	O
Health	O
Regulation	B-PROC
Focal	O
Points	O
of	O
Saudi	O
Arabia	O
and	O
Oman	O
.	O

Following	O
the	O
development	B-PROC
of	O
tissue	O
culture	O
adapted	O
strains	O
of	O
PDCoV	O
,	O
it	O
is	O
now	O
possible	O
to	O
address	O
questions	O
regarding	O
virus	O
-	O
host	O
cell	B-PROC
interactions	I-PROC
for	O
this	O
genera	O
of	O
coronavirus	O
.	O

All	O
positive	O
-	O
strand	O
RNA	O
viruses	O
induce	O
the	O
rearrangement	B-PROC
of	O
cellular	O
membranes	O
during	O
virus	B-PROC
replication	I-PROC
to	O
support	O
viral	O
RNA	B-PROC
synthesis	I-PROC
,	O
forming	O
the	O
replication	O
organelle	O
.	O

TITLE	O
:	O
Methadone	O
associated	O
long	O
term	O
hearing	B-PROC
loss	O
and	O
nephrotoxicity	O
;	O
a	O
case	O
report	O
and	O
literature	O
review	O
.	O

Herein	O
we	O
report	O
a	O
case	O
of	O
methadone	O
poisoning	O
with	O
rhabdomyolysis	O
,	O
acute	O
kidney	O
injury	O
,	O
and	O
persistent	O
hearing	B-PROC
loss	O
documented	O
by	O
a	O
2	O
year	O
follow	O
up	O
.	O

We	O
found	O
that	O
rOC43	O
-	O
ns2DelRluc	O
was	O
fatal	O
to	O
suckling	O
mice	O
after	O
intranasal	O
inoculation	O
,	O
and	O
that	O
viral	O
titers	O
and	O
Rluc	O
expression	B-PROC
were	O
detected	O
in	O
the	O
brains	O
and	O
spinal	O
cords	O
of	O
mice	O
infected	O
with	O
rOC43	O
-	O
ns2DelRluc	O
.	O

Further	O
,	O
tests	O
for	O
anti	O
-	O
glomerular	O
basement	O
membrane	O
antibody	B-PROC
,	O
myeloperoxidase	O
-	O
ANCA	O
,	O
and	O
proteinase	B-PROC
3	O
-	O
ANCA	O
revealed	O
negative	O
results	O
.	O

The	O
evolution	B-PROC
was	O
favorable	O
in	O
77	O
%,	O
with	O
no	O
patient	O
lost	O
to	O
follow	O
-	O
up	O
,	O
but	O
7	O
/	O
24	O
(	O
29	O
%)	O
died	B-PROC
,	O
either	O
before	O
the	O
initiation	O
of	O
therapy	O
(	O
Miliary	O
tuberculosis	O
is	O
an	O
acute	O
and	O
severe	O
form	O
of	O
life	O
-	O
threatening	O
tuberculosis	O
.	O

TITLE	O
:	O
Long	O
-	O
term	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
after	O
severe	O
blunt	O
traumatic	O
lung	O
injury	O
in	O
a	O
child	O
.	O

Therefore	O
,	O
researches	O
targeting	B-PROC
these	O
viruses	O
have	O
been	O
required	O
.	O

The	O
syndrome	O
starts	O
during	O
infancy	O
with	O
recurrent	O
relapses	O
of	O
osteomyelitis	O
typically	O
associated	O
with	O
fever	B-PROC
,	O
congenital	O
dyserythropoietic	O
anemia	O
(	O
CDA	O
),	O
and	O
often	O
neutrophilic	B-PROC
dermatosis	O
.	O

ABSTRACT	O
:	O
Feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
is	O
a	O
fatal	O
disease	O
that	O
poses	O
several	O
challenges	O
for	O
veterinarians	O
:	O
clinical	O
signs	O
and	O
laboratory	O
changes	O
are	O
non	O
-	O
specific	O
,	O
and	O
there	O
are	O
two	O
pathotypes	O
of	O
the	O
etiologic	O
agent	O
feline	O
coronavirus	O
(	O
FCoV	O
),	O
sometimes	O
referred	O
to	O
as	O
feline	O
enteric	O
coronavirus	O
(	O
FECV	O
)	O
and	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
that	O
vary	O
fundamentally	O
in	O
their	O
virulence	B-PROC
,	O
but	O
are	O
indistinguishable	O
by	O
a	O
number	O
of	O
diagnostic	O
methods	O
.	O

The	O
susceptibility	O
of	O
the	O
newborn	O
infant	O
with	O
neonatal	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
NARDS	O
)	O
to	O
exogenous	O
surfactant	O
is	O
linked	O
with	O
a	O
suppression	B-PROC
of	O
most	O
of	O
the	O
immunologic	O
responses	O
by	O
the	O
innate	O
immune	O
system	O
,	O
however	O
,	O
additional	O
corticosteroids	O
applied	O
in	O
any	O
severe	O
pediatric	O
lung	O
disease	O
with	O
inflammatory	O
background	O
do	O
not	O
reduce	O
morbidity	O
or	O
mortality	O
and	O
may	O
even	O
cause	O
harm	O
.	O

However	O
,	O
viral	O
distribution	O
and	O
viral	B-PROC
shedding	I-PROC
showed	O
that	O
the	O
viral	O
loads	O
of	O
rIBYZ	O
-	O
ScAUG3a	O
were	O
lower	O
than	O
those	O
of	O
rIBYZ	O
in	O
tissue	O
samples	O
and	O
swab	O
specimens	O
.	O

These	O
findings	O
may	O
be	O
used	O
in	O
vaccination	O
trials	O
for	O
the	O
development	B-PROC
of	O
a	O
new	O
live	O
-	O
attenuated	O
vaccine	O
.	O

In	O
addition	O
,	O
artificial	O
changes	O
in	O
mortalin	O
expression	B-PROC
affected	O
the	O
cell	O
entry	O
of	O
transferrin	O
,	O
further	O
confirming	O
the	O
above	O
results	O
.	O

In	O
the	O
absence	O
of	O
a	O
targeted	B-PROC
vaccine	O
or	O
a	O
pathogen	O
-	O
specific	O
antiviral	O
,	O
broad	O
-	O
spectrum	O
antivirals	O
would	O
function	O
to	O
limit	O
virus	O
spread	O
.	O

TITLE	O
:	O
Nucleocapsid	O
Protein	B-PROC
Recruitment	I-PROC
to	O
Replication	O
-	O
Transcription	B-PROC
Complexes	O
Plays	O
a	O
Crucial	O
Role	O
in	O
Coronaviral	O
Life	O
Cycle	O
.	O

ABSTRACT	O
:	O
Influenza	O
virus	B-PROC
infection	I-PROC
is	O
responsible	O
for	O
significant	O
morbidity	O
and	O
mortality	O
in	O
the	O
pediatric	O
and	O
pregnant	O
women	O
populations	O
,	O
with	O
deaths	B-PROC
frequently	O
caused	O
by	O
severe	O
influenza	O
-	O
associated	O
lower	O
respiratory	O
tract	O
infection	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

High	O
levels	O
of	O
viral	B-PROC
infection	I-PROC
or	O
high	O
levels	O
of	O
inflammation	O
in	O
the	O
lower	O
airways	O
can	O
contribute	O
to	O
ARDS	O
.	O

Infants	O
with	O
multiviral	O
bronchiolitis	O
have	O
higher	O
odds	O
of	O
PICU	O
admission	O
compared	O
with	O
those	O
with	O
a	O
single	O
or	O
nondetectable	O
viral	B-PROC
infection	I-PROC
.	O

CONCLUSIONS	O
:	O
Infants	O
with	O
multiviral	O
bronchiolitis	O
have	O
higher	O
odds	O
of	O
PICU	O
admission	O
compared	O
with	O
those	O
with	O
a	O
single	O
or	O
nondetectable	O
viral	B-PROC
infection	I-PROC
.	O

Of	O
88	O
pediatric	O
patients	O
with	O
ALCAPA	O
after	O
surgical	O
repair	B-PROC
,	O
37	O
.	O
5	O
%	O
developed	O
early	O
FO	O
,	O
defined	O
as	O
fluid	O
accumulation	O
≥	O
5	O
%	O
within	O
the	O
period	O
from	O
surgery	O
until	O
midnight	O
of	O
postoperative	O
day	O
1	O
.	O

Viral	B-PROC
shedding	I-PROC
studies	O
of	O
asymptomatic	O
MERS	O
infections	O
have	O
demonstrated	O
the	O
potential	O
to	O
transmit	O
MERS	O
-	O
CoV	O
to	O
others	O
.	O

TITLE	O
:	O
Development	B-PROC
and	O
Validation	O
of	O
a	O
S1	O
Protein	O
-	O
Based	O
ELISA	O
for	O
the	O
Specific	O
Detection	O
of	O
Antibodies	O
against	O
Equine	O
Coronavirus	O
.	O

Finally	O
,	O
we	O
found	O
that	O
the	O
addition	O
of	O
exogenous	O
trypsin	O
also	O
rescues	O
HKU5	O
-	O
CoV	O
,	O
a	O
second	O
bat	O
group	O
2c	O
CoV	O
.	O
Together	O
,	O
these	O
results	O
indicate	O
that	O
proteolytic	B-PROC
cleavage	B-PROC
of	O
the	O
spike	O
,	O
not	O
receptor	O
binding	O
,	O
is	O
the	O
primary	O
infection	O
barrier	O
for	O
these	O
two	O
group	O
2c	O
CoVs	O
.	O

Coupled	O
with	O
receptor	O
binding	O
,	O
proteolytic	B-PROC
activation	O
offers	O
a	O
new	O
parameter	O
to	O
evaluate	O
the	O
emergence	O
potential	O
of	O
bat	O
CoVs	O
and	O
offers	O
a	O
means	O
to	O
recover	B-PROC
previously	O
unrecoverable	O
zoonotic	O
CoV	O
strains	O
.	O

Virulence	B-PROC
and	O
pathogenicity	O
of	O
passage	O
levels	O
15	O
and	O
90	O
of	O
isolates	O
773	O
and	O
794	O
were	O
compared	O
using	O
histopathology	O
,	O
ciliostasis	O
and	O
potency	O
tests	O
.	O

General	O
management	O
includes	O
physical	O
examination	O
,	O
pulse	B-PROC
oximetry	O
and	O
arterial	O
blood	B-PROC
gases	I-PROC
.	O

Mechanical	O
ventilation	O
with	O
continuous	O
-	O
positive	O
-	O
airway	O
-	O
pressure	O
or	O
intubation	O
/	O
tracheotomy	O
with	O
high	O
positive	O
-	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
-	O
pressure	O
may	O
be	O
necessary	O
.	O

In	O
severe	O
ARDS	O
,	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
can	O
be	O
considered	O
.	O

TITLE	O
:	O
Discovery	O
of	O
dihydroxyindole	O
-	O
2	O
-	O
carboxylic	O
acid	O
derivatives	O
as	O
dual	O
allosteric	O
HIV	O
-	O
1	O
Integrase	O
and	O
Reverse	O
Transcriptase	B-PROC
associated	O
Ribonuclease	O
H	O
inhibitors	O
.	O

No	O
deaths	B-PROC
were	O
caused	O
by	O
uncontrollable	O
hypoxemia	O
.	O

Our	O
results	O
showed	O
that	O
MAb	O
binds	O
to	O
the	O
virus	O
surface	O
spike	O
,	O
allowing	O
it	O
to	O
undergo	O
conformational	O
changes	O
and	O
become	O
prone	O
to	O
proteolytic	B-PROC
activation	O
.	O

Clinicopathological	O
features	O
include	O
fever	B-PROC
,	O
vasculitis	O
,	O
and	O
serositis	O
,	O
with	O
or	O
without	O
effusions	O
;	O
all	O
of	O
which	O
indicate	O
a	O
pro	O
-	O
inflammatory	O
state	O
with	O
cytokine	O
release	O
.	O

ABSTRACT	O
:	O
As	O
a	O
World	O
Health	O
Organization	O
Research	O
and	O
Development	B-PROC
Blueprint	O
priority	O
pathogen	O
,	O
there	O
is	O
a	O
need	O
to	O
better	O
understand	O
the	O
geographic	O
distribution	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
its	O
potential	O
to	O
infect	O
mammals	O
and	O
humans	O
.	O

Further	O
detailed	O
analysis	O
is	O
required	O
to	O
delineate	O
the	O
mechanisms	O
of	O
how	O
ORF8b	O
inhibits	O
the	O
MDA5	O
/	O
RIG	O
-	O
I	O
receptor	B-PROC
signaling	B-PROC
pathway	B-PROC
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
coronavirus	O
infection	O
into	O
established	O
hDDP4	O
-	O
transgenic	O
mice	O
accelerates	O
lung	O
damage	O
via	O
activation	O
of	O
the	O
pro	O
-	O
inflammatory	B-PROC
response	I-PROC
and	O
pulmonary	O
fibrosis	O
.	O

TITLE	O
:	O
Identification	O
of	O
6	O
'-	O
β	O
-	O
fluoro	O
-	O
homoaristeromycin	O
as	O
a	O
potent	O
inhibitor	O
of	O
chikungunya	O
virus	B-PROC
replication	I-PROC
.	O

We	O
determined	O
the	O
prevalence	O
of	O
MERS	O
-	O
CoV	O
infection	O
,	O
age	O
-	O
associated	O
patterns	O
of	O
infection	O
,	O
and	O
undertook	O
phylogeographical	O
and	O
migration	B-PROC
analyses	O
to	O
determine	O
intercountry	O
virus	O
transmission	O
after	O
local	O
lineage	O
establishment	O
.	O

Genetic	O
or	O
pharmacological	O
inhibition	B-PROC
of	O
SKP2	O
decreases	O
BECN1	O
ubiquitination	B-PROC
,	O
decreases	O
BECN1	O
degradation	O
and	O
enhances	O
autophagic	O
flux	O
.	O

The	O
data	O
indicated	O
that	O
U655	O
>	O
G	O
change	O
in	O
S	O
gene	O
(	O
S219A	O
in	O
S	O
protein	O
)	O
was	O
required	O
to	O
confer	O
enteric	O
tropism	B-PROC
to	O
a	O
respiratory	O
virus	O
that	O
already	O
contains	O
the	O
pAPN	O
and	O
sialic	O
acid	O
binding	O
domains	O
in	O
its	O
S	O
protein	O
.	O

We	O
postulated	O
that	O
the	O
effect	O
of	O
these	O
residues	O
in	O
enteric	O
tropism	B-PROC
may	O
be	O
mediated	O
by	O
the	O
modification	O
of	O
both	O
glycosaminoglycan	O
binding	O
and	O
S	O
protein	O
structure	O
.	O

TITLE	O
:	O
Antiviral	O
activity	O
of	O
interleukin	O
-	O
11	O
as	O
a	O
response	O
to	O
porcine	O
epidemic	O
diarrhea	O
virus	B-PROC
infection	I-PROC
.	O

However	O
,	O
little	O
is	O
known	O
of	O
the	O
role	O
of	O
IL	O
-	O
11	O
during	O
viral	B-PROC
infections	I-PROC
.	O

In	O
this	O
study	O
,	O
IL	O
-	O
11	O
expression	B-PROC
at	O
mRNA	O
and	O
protein	O
levels	O
were	O
found	O
to	O
be	O
high	O
in	O
Vero	O
cells	O
and	O
the	O
jejunum	O
of	O
piglets	O
during	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
infection	O
,	O
while	O
IL	O
-	O
11	O
expression	B-PROC
was	O
found	O
to	O
be	O
positively	O
correlated	O
with	O
the	O
level	O
of	O
viral	B-PROC
infection	I-PROC
.	O

Her	O
newborn	O
and	O
children	O
of	O
all	O
recovered	O
women	O
were	O
healthy	O
at	O
birth	B-PROC
.	O

Pregnant	O
women	O
with	O
H1N1	O
infection	O
are	O
at	O
higher	O
risk	O
of	O
pneumonia	O
and	O
death	B-PROC
than	O
other	O
women	O
in	O
the	O
reproductive	B-PROC
period	O
.	O

TITLE	O
:	O
Overexpression	B-PROC
of	O
MALAT1	O
Relates	O
to	O
Lung	O
Injury	O
through	O
Sponging	O
miR	O
-	O
425	O
and	O
Promoting	O
Cell	O
Apoptosis	B-PROC
during	O
ARDS	O
.	O

MALAT1	O
interacted	O
with	O
miR	O
-	O
425	O
and	O
protected	O
phosphatase	O
and	O
tensin	O
homolog	O
(	O
PTEN	O
)	O
expression	B-PROC
in	O
A549	O
and	O
HFL	O
-	O
1	O
cells	O
.	O

Disease	O
involving	O
all	O
three	O
Yang	O
channels	O
is	O
the	O
core	O
of	O
the	O
pathogenesis	B-PROC
of	O
Chaige	O
Jieji	O
Decoction	O
syndrome	O
,	O
in	O
which	O
headache	O
is	O
the	O
key	O
indications	O
.	O

Moreover	O
,	O
it	O
can	O
protect	O
lung	O
and	O
diaphragm	B-PROC
function	I-PROC
during	O
assisted	O
ventilation	O
through	O
control	O
of	O
the	O
respiratory	O
effort	B-PROC
.	O

With	O
the	O
aim	O
of	O
evaluating	O
the	O
selectivity	O
of	O
action	O
of	O
this	O
class	O
of	O
compounds	O
,	O
a	O
wide	O
spectrum	O
of	O
RNA	O
(	O
positive	O
-	O
and	O
negative	O
-	O
sense	B-PROC
),	O
double	O
-	O
stranded	O
(	O
dsRNA	O
)	O
or	O
DNA	O
viruses	O
were	O
also	O
assayed	O
.	O

Investigators	O
focusing	O
on	O
the	O
CoVs	O
have	O
developed	O
several	O
methodologies	O
that	O
effectively	O
distinguish	O
these	O
different	O
cell	O
entry	O
pathways	B-PROC
.	O

While	O
the	O
specific	O
methods	O
described	O
herein	O
were	O
utilized	O
to	O
reveal	O
MERS	O
-	O
CoV	O
entry	O
pathways	B-PROC
,	O
they	O
are	O
equally	O
suited	O
for	O
other	O
CoVs	O
,	O
as	O
well	O
as	O
other	O
protease	O
-	O
dependent	O
viral	O
species	O
.	O

Here	O
,	O
we	O
describe	O
protocols	O
of	O
deducing	O
the	O
crystal	O
structure	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
helicase	O
in	O
detail	O
,	O
which	O
include	O
protein	B-PROC
expression	B-PROC
,	O
purification	O
,	O
crystallization	O
,	O
enzymatic	O
characterization	O
,	O
and	O
structure	O
determination	O
.	O

The	O
ongoing	O
threat	O
to	O
global	O
public	O
health	O
and	O
the	O
need	O
for	O
novel	O
therapeutic	O
countermeasures	O
have	O
driven	O
the	O
development	B-PROC
of	O
animal	O
models	O
that	O
can	O
reproducibly	O
replicate	O
the	O
pathology	O
associated	O
with	O
MERS	O
-	O
CoV	O
in	O
human	O
infections	O
.	O

Following	O
virus	B-PROC
infection	I-PROC
,	O
the	O
beneficial	O
or	O
deleterious	O
role	O
of	O
infiltrating	O
neutrophils	O
and	O
monocyte	O
-	O
macrophages	O
is	O
determined	O
largely	O
by	O
their	O
ability	O
to	O
secrete	B-PROC
inflammatory	O
cytokines	O
and	O
chemokines	O
.	O

We	O
also	O
describe	O
a	O
simple	O
method	O
to	O
measure	O
intracellular	O
cytokine	B-PROC
production	I-PROC
to	O
evaluate	O
the	O
inflammatory	O
activity	O
of	O
neutrophils	O
and	O
IMMs	O
in	O
a	O
mouse	O
model	O
of	O
human	O
coronavirus	O
infection	O
.	O

Lung	O
infection	O
is	O
a	O
common	O
clinical	O
feature	O
and	O
contributes	O
to	O
disease	O
severity	O
as	O
well	O
as	O
viral	B-PROC
transmission	I-PROC
.	O

She	O
developed	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
was	O
strongly	O
considered	O
for	O
being	O
placed	O
on	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

ABSTRACT	O
:	O
A	O
53	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
a	O
tertiary	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
severe	O
community	O
-	O
acquired	O
pneumonia	O
that	O
necessitated	O
maximum	O
supportive	O
care	O
with	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
.	O

ABSTRACT	O
:	O
Feline	O
infectious	O
peritonitis	O
(	O
FIP	O
),	O
caused	O
by	O
virulent	O
feline	O
coronavirus	O
,	O
is	O
the	O
leading	O
infectious	O
cause	O
of	O
death	B-PROC
in	O
cats	O
.	O

ABSTRACT	O
:	O
Hypoxemic	O
patients	O
often	O
desaturate	O
further	O
with	O
movement	B-PROC
and	O
transport	B-PROC
.	O

Extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
use	O
is	O
increasing	O
in	O
frequency	O
for	O
patients	O
with	O
refractory	O
hypoxemia	O
,	O
and	O
with	O
increasing	O
regionalization	B-PROC
of	O
care	O
,	O
safe	O
transport	B-PROC
of	O
hypoxemic	O
patients	O
only	O
becomes	O
more	O
important	O
.	O

Of	O
34	O
children	O
with	O
PARDS	O
managed	O
with	O
HFOV	O
after	O
failure	O
of	O
conventional	O
ventilation	O
to	O
improve	O
oxygenation	B-PROC
,	O
8	O
survived	O
.	O

TITLE	O
:	O
Inactivation	O
of	O
three	O
emerging	O
viruses	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
Crimean	O
-	O
Congo	O
haemorrhagic	O
fever	B-PROC
virus	O
and	O
Nipah	O
virus	O
-	O
in	O
platelet	O
concentrates	O
by	O
ultraviolet	O
C	O
light	O
and	O
in	O
plasma	O
by	O
methylene	O
blue	O
plus	O
visible	O
light	O
.	O

Treatment	O
for	O
structural	O
valve	O
deterioration	O
(	O
SVD	O
)	O
included	O
surgical	O
explant	O
and	O
valve	O
-	O
in	O
-	O
valve	O
(	O
V	O
-	O
in	O
-	O
V	O
)	O
transcatheter	O
aortic	O
valve	O
implantation	B-PROC
(	O
TAVI	O
).	O

TITLE	O
:	O
High	O
expression	B-PROC
of	O
long	O
non	O
-	O
coding	O
RNA	O
MALAT1	O
correlates	O
with	O
raised	O
acute	O
respiratory	O
distress	O
syndrome	O
risk	O
,	O
disease	O
severity	O
,	O
and	O
increased	O
mortality	O
in	O
sepstic	O
patients	O
.	O

We	O
introduce	O
a	O
new	O
concept	O
related	O
to	O
the	O
non	O
-	O
taxonomical	O
classification	O
and	O
differentiation	B-PROC
among	O
FCoVs	O
by	O
analyzing	O
and	O
comparing	O
the	O
genetic	O
,	O
structural	O
,	O
and	O
functional	O
characteristics	O
of	O
FCoV	O
and	O
the	O
FCoV	O
S	O
protein	O
among	O
the	O
two	O
serotypes	O
and	O
FCoV	O
biotypes	O
.	O

To	O
monitor	O
bovine	O
farm	O
biosecurity	O
levels	O
,	O
one	O
-	O
step	O
multiplex	O
reverse	B-PROC
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
the	O
simultaneous	O
detection	O
of	O
group	O
A	O
rotavirus	O
(	O
RVA	O
),	O
bovine	O
torovirus	O
(	O
BToV	O
),	O
bovine	O
enterovirus	O
(	O
BEV	O
),	O
and	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
was	O
designed	O
,	O
with	O
the	O
aim	O
of	O
configuring	O
candidates	O
for	O
""""	O
viral	O
pathogen	O
indicators	O
"""."	O

Disease	O
,	O
lung	O
lesion	O
,	O
and	O
viral	B-PROC
replication	I-PROC
progressions	O
were	O
slower	O
in	O
the	O
MERS	O
-	O
CoV	O
aerosol	O
-	O
infected	O
mice	O
than	O
in	O
the	O
MERS	O
-	O
CoV	O
instillation	O
-	O
inoculated	O
mice	O
.	O

The	O
results	O
showed	O
that	O
the	O
number	O
of	O
patients	O
with	O
combined	O
symptoms	O
of	O
fever	B-PROC
/	O
sore	O
throat	O
and	O
fever	B-PROC
/	O
cough	O
/	O
SOB	O
was	O
significantly	O
higher	O
in	O
confirmed	O
cases	O
than	O
in	O
non	O
-	O
confirmed	O
cases	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Three	O
intramuscular	O
or	O
oral	O
vaccinations	O
with	O
rAd	O
-	O
LTB	O
-	O
COE	O
at	O
two	O
-	O
week	O
intervals	O
induced	O
robust	O
humoral	O
and	O
mucosal	B-PROC
immune	I-PROC
responses	I-PROC
.	O

Patients	O
with	O
A	O
(	O
H7N9	O
)	O
virus	B-PROC
infection	I-PROC
who	O
survived	O
severe	O
disease	O
mounted	O
higher	O
antibody	B-PROC
responses	I-PROC
that	O
persisted	O
for	O
longer	O
periods	B-PROC
compared	O
with	O
those	O
that	O
experienced	O
moderate	O
disease	O
.	O

ABSTRACT	O
:	O
In	O
2017	O
the	O
German	O
Clinical	O
Guideline	O
for	O
Treating	O
Acute	O
Respiratory	O
Insufficiency	O
with	O
Invasive	O
Ventilation	O
and	O
Extracorporeal	O
Membrane	O
Oxygenation	B-PROC
:	O
Evidence	O
-	O
Based	O
Recommendations	O
were	O
released	O
.	O

However	O
,	O
NMBAs	O
had	O
no	O
effect	O
on	O
oxygenation	B-PROC
(	O
Pao2	O
:	O
Fio2	O
ratios	O
)	O
(	O
MD	O
18	O
.	O
41	O
mm	O
Hg	O
,	O
95	O
%	O
CI	O
-	O
0	O
.	O
33	O
,	O
37	O
.	O
14	O
,	O
I2	O
=	O
72	O
%)	O
at	O
24	O
hours	O
.	O

ABSTRACT	O
:	O
The	O
evidence	O
of	O
improved	O
survival	O
with	O
the	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
is	O
still	O
uncertain	O
.	O

Both	O
may	O
be	O
clinically	O
indistinguishable	O
and	O
present	O
as	O
an	O
acute	O
icterohemorrhagic	O
febrile	B-PROC
syndrome	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
homologous	B-PROC
recombination	B-PROC
may	O
occur	O
and	O
contribute	O
to	O
the	O
2019	O
-	O
nCoV	O
cross	O
-	O
species	O
transmission	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
immunological	O
efficacy	O
of	O
the	O
vaccine	O
candidates	O
in	O
BALB	O
/	O
c	O
mice	O
in	O
terms	O
of	O
the	O
levels	O
of	O
humoral	O
and	O
cellular	B-PROC
immune	I-PROC
responses	I-PROC
.	O

TITLE	O
:	O
Gross	O
and	O
Histopathological	O
Findings	O
in	O
the	O
First	O
Reported	O
Vaping	O
-	O
Induced	O
Lung	O
Injury	O
Death	B-PROC
in	O
the	O
United	O
States	O
.	O

One	O
death	B-PROC
attributed	O
to	O
vaping	O
is	O
presented	O
with	O
emphasis	O
on	O
the	O
gross	O
and	O
histopathological	O
findings	O
from	O
the	O
autopsy	O
.	O

These	O
findings	O
were	O
correlated	O
with	O
the	O
patient	O
'	O
s	O
clinical	O
course	O
and	O
medicolegal	O
investigation	O
to	O
determine	O
the	O
cause	O
of	O
death	B-PROC
.	O

We	O
defined	O
persistent	O
severe	O
ARDS	O
as	O
a	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
to	O
fraction	O
of	O
inspired	B-PROC
oxygen	O
ratio	O
(	O
PaO2	O
:	O
FiO2	O
)	O
of	O
equal	O
to	O
or	O
less	O
than	O
100	O
mmHg	O
on	O
the	O
second	O
study	O
day	O
following	O
enrollment	O
.	O

Five	O
family	O
members	O
(	O
aged	O
36	O
-	O
66	O
years	O
)	O
presented	O
with	O
fever	B-PROC
,	O
upper	O
or	O
lower	O
respiratory	O
tract	O
symptoms	O
,	O
or	O
diarrhoea	O
,	O
or	O
a	O
combination	O
of	O
these	O
3	O
-	O
6	O
days	O
after	O
exposure	O
.	O

Furthermore	O
,	O
its	O
new	O
orf8	O
likely	O
encodes	O
a	O
secreted	B-PROC
protein	O
with	O
an	O
alpha	O
-	O
helix	O
,	O
following	O
with	O
a	O
beta	O
-	O
sheet	O
(	O
s	O
)	O
containing	O
six	O
strands	O
.	O

The	O
workflow	O
reliably	O
detects	O
2019	O
-	O
nCoV	O
,	O
and	O
further	O
discriminates	O
2019	O
-	O
nCoV	O
from	O
SARS	O
-	O
CoV	O
.	O
Through	O
coordination	B-PROC
between	O
academic	O
and	O
public	O
laboratories	O
,	O
we	O
confirmed	O
assay	O
exclusivity	O
based	O
on	O
297	O
original	O
clinical	O
specimens	O
containing	O
a	O
full	O
spectrum	O
of	O
human	O
respiratory	O
viruses	O
.	O

The	O
deaths	B-PROC
included	O
13	O
males	O
and	O
4	O
females	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
)	O
is	O
primarily	O
associated	O
with	O
common	O
cold	B-PROC
in	O
children	O
,	O
elderly	O
and	O
immunocompromised	O
individuals	O
.	O

Pseudotyped	O
virus	O
bearing	O
the	O
I507	O
L	O
mutation	O
in	O
RBD	O
showed	O
enhanced	O
entry	B-PROC
into	I-PROC
host	I-PROC
cells	O
as	O
compared	O
to	O
the	O
prototype	O
virus	O
.	O

One	O
of	O
these	O
patients	O
died	B-PROC
.	O

Our	O
objectives	O
were	O
to	O
characterize	O
the	O
genetic	O
relationships	O
of	O
the	O
2019	O
-	O
nCoV	O
and	O
to	O
search	O
for	O
putative	O
recombination	B-PROC
within	O
the	O
subgenus	O
of	O
sarbecovirus	O
.	O

As	O
of	O
December	O
2019	O
,	O
CEPI	O
has	O
committed	O
to	O
investing	O
up	O
to	O
$	O
706	O
million	O
in	O
vaccine	O
development	B-PROC
.	O

ABSTRACT	O
:	O
Positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
(	O
PEEP	O
)	O
at	O
minimum	O
respiratory	O
elastance	O
during	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
may	O
improve	O
patient	O
care	O
and	O
outcome	O
.	O

Patients	O
had	O
clinical	O
manifestations	O
of	O
fever	B-PROC
(	O
82	O
[	O
83	O
%]	O
patients	O
),	O
cough	O
(	O
81	O
[	O
82	O
%]	O
patients	O
),	O
shortness	O
of	O
breath	O
(	O
31	O
[	O
31	O
%]	O
patients	O
),	O
muscle	O
ache	O
(	O
11	O
[	O
11	O
%]	O
patients	O
),	O
confusion	O
(	O
nine	O
[	O
9	O
%]	O
patients	O
),	O
headache	O
(	O
eight	O
[	O
8	O
%]	O
patients	O
),	O
sore	O
throat	O
(	O
five	O
[	O
5	O
%]	O
patients	O
),	O
rhinorrhoea	O
(	O
four	O
[	O
4	O
%]	O
patients	O
),	O
chest	O
pain	O
(	O
two	O
[	O
2	O
%]	O
patients	O
),	O
diarrhoea	O
(	O
two	O
[	O
2	O
%]	O
patients	O
),	O
and	O
nausea	O
and	O
vomiting	O
(	O
one	O
[	O
1	O
%]	O
patient	O
).	O

TITLE	O
:	O
Reduced	O
cortical	O
arousability	O
to	O
nocturnal	O
apneic	O
episodes	O
in	O
patients	O
with	O
wake	B-PROC
-	O
up	O
ischemic	O
stroke	O
.	O

This	O
suggests	O
that	O
bat	O
immune	O
defenses	O
may	O
drive	O
the	O
evolution	B-PROC
of	O
faster	O
transmitting	O
viruses	O
,	O
and	O
while	O
bats	O
are	O
well	O
protected	O
from	O
the	O
harmful	O
effects	O
of	O
their	O
own	O
prolific	O
viruses	O
,	O
other	O
creatures	O
like	O
humans	O
are	O
not	O
.	O

CONCLUSIONS	O
:	O
Our	O
case	O
emphasizes	O
the	O
diagnostic	O
challenges	O
of	O
HLH	O
,	O
in	O
a	O
patient	O
with	O
EBV	O
infection	O
whose	O
evolution	B-PROC
was	O
hindered	O
by	O
a	O
severe	O
epistaxis	O
,	O
with	O
potentially	O
fatal	O
outcome	O
.	O

Large	O
cities	O
overseas	O
with	O
close	O
transport	B-PROC
links	O
to	O
China	O
could	O
also	O
become	O
outbreak	O
epicentres	O
,	O
unless	O
substantial	O
public	O
health	O
interventions	O
at	O
both	O
the	O
population	O
and	O
personal	O
levels	O
are	O
implemented	O
immediately	O
.	O

From	O
2675	O
studies	O
,	O
we	O
included	O
five	O
RCTs	O
in	O
the	O
analysis	O
,	O
for	O
a	O
total	O
of	O
1461	O
patients	O
with	O
a	O
mean	O
PaO	B-PROC
NMBA	O
improves	O
oxygenation	B-PROC
only	O
after	O
48	O
h	O
in	O
moderate	O
,	O
severe	O
ARDS	O
patients	O
and	O
has	O
a	O
lower	O
barotrauma	O
risk	O
without	O
affecting	O
ICU	O
weakness	O
.	O

TITLE	O
:	O
Isolated	O
Pauci	O
-	O
Immune	O
Pulmonary	O
Capillaritis	O
Associated	O
with	O
Hydrocarbon	O
Inhalation	B-PROC
and	O
Marijuana	O
Smoking	O
:	O
An	O
Unusual	O
Case	O
of	O
Severe	O
Hypoxemia	O
.	O

TITLE	O
:	O
Prone	O
positioning	O
monitored	O
by	O
electrical	B-PROC
impedance	I-PROC
tomography	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
on	O
veno	O
-	O
venous	O
ECMO	O
.	O

We	O
observed	O
that	O
TGEVs	O
could	O
be	O
internalized	O
through	O
clathrin	O
-	O
and	O
caveolae	B-PROC
-	I-PROC
mediated	I-PROC
endocytosis	I-PROC
,	O
and	O
the	O
internalization	O
of	O
TGEVs	O
was	O
almost	O
completed	O
within	O
~	O
2	O
minutes	O
after	O
TGEVs	O
attached	O
to	O
the	O
cell	O
membrane	O
.	O

The	O
impact	O
of	O
chronic	O
comorbidities	O
on	O
clinical	O
outcomes	O
,	O
in	O
particular	O
,	O
pulmonary	O
disease	O
and	O
immunosuppression	B-PROC
,	O
were	O
analyzed	O
.	O

Median	O
age	O
and	O
oxygenation	B-PROC
indexes	O
were	O
2	O
.	O
8	O
(	O
0	O
.	O
6	O
,	O
8	O
.	O
3	O
)	O
years	O
and	O
10	O
.	O
6	O
(	O
7	O
.	O
6	O
,	O
15	O
.	O
4	O
),	O
respectively	O
.	O

As	O
of	O
24	O
January	O
2020	O
,	O
there	O
were	O
887	O
confirmed	O
cases	O
of	O
2019	O
-	O
nCoV	O
infection	O
,	O
including	O
26	O
deaths	B-PROC
,	O
reported	O
in	O
China	O
and	O
other	O
countries	O
.	O

These	O
data	O
demonstrate	O
that	O
Nox2	O
/	O
ROS	O
/	O
ZO	O
-	O
1	O
axis	O
is	O
of	O
great	O
importance	O
in	O
AECs	O
damage	O
induced	O
by	O
LPS	O
,	O
and	O
the	O
utilization	O
of	O
VAS2870	O
to	O
inhibit	O
this	O
pathway	B-PROC
might	O
lighten	O
LPS	O
-	O
induced	O
ARDS	O
.	O

With	O
a	O
death	B-PROC
toll	O
exceeding	O
that	O
of	O
the	O
SARS	O
-	O
CoV	O
outbreak	O
back	O
in	O
2002	O
and	O
2003	O
in	O
China	O
,	O
2019	O
-	O
nCoV	O
has	O
led	O
to	O
a	O
public	O
health	O
emergency	O
of	O
international	O
concern	O
,	O
putting	O
all	O
health	O
organizations	O
on	O
high	O
alert	O
.	O

TITLE	O
:	O
Immunoinformatics	O
-	O
aided	O
identification	O
of	O
T	O
cell	O
and	O
B	O
cell	O
epitopes	O
in	O
the	O
surface	O
glycoprotein	O
of	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
The	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
outbreak	O
has	O
caused	O
a	O
large	O
number	O
of	O
deaths	B-PROC
with	O
thousands	O
of	O
confirmed	O
cases	O
worldwide	O
,	O
especially	O
in	O
East	O
Asia	O
.	O

TITLE	O
:	O
Learning	B-PROC
from	O
the	O
Past	O
:	O
Possible	O
Urgent	O
Prevention	O
and	O
Treatment	O
Options	O
for	O
Severe	O
Acute	O
Respiratory	O
Infections	O
Caused	O
by	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
With	O
the	O
current	O
trajectory	O
of	O
the	O
2019	O
-	O
nCoV	O
outbreak	O
unknown	O
,	O
public	O
health	O
and	O
medicinal	O
measures	O
will	O
both	O
be	O
needed	O
to	O
contain	O
spreading	O
of	O
the	O
virus	O
and	O
to	O
optimize	O
patient	O
outcomes	O
.	O

We	O
used	O
the	O
serial	O
intervals	O
(	O
SI	O
)	O
of	O
infection	O
caused	O
by	O
two	O
other	O
well	O
-	O
known	O
coronaviruses	O
(	O
CoV	O
),	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
CoVs	O
,	O
as	O
approximations	O
of	O
the	O
unknown	O
SI	O
for	O
2019	O
-	O
nCoV	O
to	O
estimate	O
We	O
confirmed	O
that	O
the	O
initial	O
growth	B-PROC
phase	O
followed	O
an	O
exponential	O
growth	B-PROC
pattern	I-PROC
.	O

TITLE	O
:	O
Fatal	O
fulminant	O
hemolysis	B-PROC
-	O
associated	O
pulmonary	O
embolism	O
in	O
mixed	O
-	O
type	O
autoimmune	O
hemolytic	O
anemia	O
:	O
A	O
case	O
report	O
.	O

According	O
to	O
the	O
characteristics	O
of	O
bronchoscopy	O
,	O
it	O
is	O
necessary	O
to	O
formulate	O
the	O
procedure	O
,	O
requirements	O
and	O
precautions	O
when	O
conducting	B-PROC
bronchoscopy	O
in	O
the	O
current	O
epidemic	O
situation	O
.	O

ABSTRACT	O
:	O
Respiratory	O
viral	B-PROC
infections	I-PROC
can	O
increase	O
the	O
risk	O
of	O
chronic	O
lung	O
allograft	O
dysfunction	O
after	O
lung	O
transplantation	O
,	O
but	O
the	O
mechanisms	O
are	O
unknown	O
.	O

Circulating	O
exosomes	O
isolated	O
from	O
lung	O
transplant	O
recipients	O
diagnosed	O
with	O
respiratory	O
viral	B-PROC
infections	I-PROC
contained	O
lung	O
self	O
-	O
antigens	O
,	O
viral	O
antigens	O
,	O
and	O
20S	O
proteasome	B-PROC
and	O
elicited	O
immune	B-PROC
responses	I-PROC
to	O
lung	O
self	O
-	O
antigens	O
that	O
resulted	O
in	O
development	B-PROC
of	O
chronic	O
lung	O
allograft	O
dysfunction	O
in	O
immunized	O
mice	O
.	O

RESULTS	O
:	O
Exosomes	O
containing	O
self	O
-	O
antigens	O
,	O
20S	O
proteasome	B-PROC
,	O
and	O
viral	O
antigens	O
were	O
detected	O
at	O
significantly	O
higher	O
levels	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
serum	O
of	O
recipients	O
with	O
symptomatic	O
respiratory	O
viral	B-PROC
infections	I-PROC
(	O
n	O
=	O
35	O
)	O
as	O
compared	O
with	O
stable	O
controls	O
(	O
n	O
=	O
32	O
).	O

Among	O
the	O
confirmed	O
cases	O
,	O
1527	O
were	O
severe	O
cases	O
,	O
171	O
had	O
recovered	O
and	O
been	O
discharged	O
at	O
home	O
,	O
and	O
213	O
died	B-PROC
.	O

TITLE	O
:	O
Ruscogenin	O
alleviates	O
LPS	O
-	O
induced	O
pulmonary	O
endothelial	B-PROC
cell	I-PROC
apoptosis	I-PROC
by	O
suppressing	O
TLR4	O
signaling	B-PROC
.	O

Ruscogenin	O
(	O
RUS	O
)	O
has	O
been	O
found	O
to	O
exert	B-PROC
significant	O
protective	O
effect	O
on	O
ALI	O
induced	O
by	O
lipopolysaccharides	O
(	O
LPS	O
),	O
but	O
there	O
is	O
little	O
information	O
about	O
its	O
role	O
in	O
LPS	O
-	O
induced	O
pulmonary	O
endothelial	B-PROC
cell	I-PROC
apoptosis	I-PROC
.	O

In	O
murine	O
lung	O
vascular	O
endothelial	O
cells	O
(	O
MLECs	O
)	O
we	O
further	O
confirmed	O
that	O
RUS	O
(	O
1	O
μmol	O
/	O
L	O
)	O
markedly	O
ameliorated	O
MLECs	O
apoptosis	B-PROC
by	O
suppressing	O
TLR4	O
signaling	B-PROC
.	O

ABSTRACT	O
:	O
Coronavirus	O
(	O
CoV	O
)	O
envelope	O
(	O
E	O
)	O
protein	O
is	O
a	O
small	O
structural	O
protein	O
critical	O
for	O
virion	O
morphogenesis	B-PROC
and	O
release	O
.	O

ABSTRACT	O
:	O
Genetic	O
perturbation	O
screens	O
using	O
RNA	B-PROC
interference	I-PROC
(	O
RNAi	B-PROC
)	O
have	O
been	O
conducted	O
successfully	O
to	O
identify	O
host	O
factors	O
that	O
are	O
essential	O
for	O
the	O
life	O
cycle	O
of	O
bacteria	O
or	O
viruses	O
.	O

We	O
validated	O
the	O
detected	O
host	O
factors	O
experimentally	O
using	O
pharmacological	O
inhibition	B-PROC
and	O
an	O
additional	O
siRNA	O
screen	O
and	O
found	O
that	O
some	O
of	O
the	O
predicted	O
host	O
factors	O
indeed	O
influence	O
the	O
replication	O
of	O
these	O
pathogens	O
.	O

Adult	O
patients	O
with	O
at	O
least	O
48	O
h	O
of	O
mechanical	O
ventilation	O
(	O
MV	O
),	O
under	O
volume	O
controlled	O
ventilation	O
and	O
an	O
oxygenation	B-PROC
index	O
less	O
than	O
300	O
mmHg	O
were	O
included	O
.	O

With	O
increasing	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
from	O
0	O
to	O
20	O
cmH	O
In	O
early	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
Functional	O
Respiratory	O
Imaging	O
gives	O
an	O
innovative	O
insight	O
into	O
the	O
relationship	O
between	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
-	O
induced	O
bronchial	O
distension	O
and	O
recruitment	O
,	O
positive	O
end	B-PROC
-	I-PROC
expiratory	I-PROC
pressure	O
-	O
induced	O
lung	O
recruitment	O
and	O
hyperinflation	O
and	O
lung	O
morphology	O
.	O

Immunoglobulin	B-PROC
G	O
was	O
delivered	O
to	O
some	O
critically	O
ill	O
patients	O
according	O
to	O
their	O
conditions	O
.	O

Comprehensive	O
control	O
and	O
preventive	O
activities	O
should	O
include	O
actions	O
such	O
as	O
the	O
elimination	B-PROC
or	O
reduction	O
of	O
rat	O
and	O
mouse	O
populations	O
,	O
sanitary	O
education	O
,	O
reduction	O
of	O
shelters	O
for	O
the	O
animals	O
,	O
and	O
restriction	O
of	O
the	O
access	O
of	O
rodents	O
to	O
residences	O
,	O
water	O
,	O
and	O
food	O
supplies	O
.	O

In	O
the	O
early	O
stages	O
of	O
this	O
epidemic	O
the	O
case	O
fatality	O
rate	O
is	O
estimated	O
to	O
be	O
approximately	O
2	O
%,	O
with	O
the	O
majority	O
of	O
deaths	B-PROC
occurring	O
in	O
special	O
populations	O
.	O

This	O
paper	O
summarizes	O
important	O
considerations	O
regarding	O
patient	O
screening	O
,	O
environmental	O
controls	O
,	O
personal	O
protective	O
equipment	O
,	O
resuscitation	O
measures	O
(	O
including	O
intubation	O
),	O
and	O
critical	O
care	O
unit	O
operations	O
planning	O
as	O
we	O
prepare	O
for	O
the	O
possibility	O
of	O
new	O
imported	O
cases	O
or	O
local	O
outbreaks	O
of	O
2019	O
-	O
nCoV	O
.	O
Although	O
understanding	O
of	O
the	O
2019	O
-	O
nCoV	O
virus	O
is	O
evolving	O
,	O
lessons	O
learned	B-PROC
from	O
prior	O
infectious	O
disease	O
challenges	O
such	O
as	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
will	O
hopefully	O
improve	O
our	O
state	O
of	O
readiness	O
regardless	O
of	O
the	O
number	O
of	O
cases	O
we	O
eventually	O
manage	O
in	O
Canada	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
pneumonia	O
originating	O
in	O
Wuhan	O
,	O
China	O
,	O
has	O
generated	O
24	O
,	O
500	O
confirmed	O
cases	O
,	O
including	O
492	O
deaths	B-PROC
,	O
as	O
of	O
5	O
February	O
2020	O
.	O

With	O
specific	O
anti	O
-	O
Ebola	O
medications	O
,	O
most	O
patients	O
can	O
survive	O
Ebola	O
virus	B-PROC
infection	I-PROC
.	O

TITLE	O
:	O
Overlapping	O
and	O
discrete	O
aspects	O
of	O
the	O
pathology	O
and	O
pathogenesis	B-PROC
of	O
the	O
emerging	O
human	O
pathogenic	O
coronaviruses	O
SARS	O
-	O
CoV	O
,	O
MERS	O
-	O
CoV	O
,	O
and	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
First	O
reported	O
from	O
Wuhan	O
,	O
The	O
People	O
'	O
s	O
Republic	O
of	O
China	O
,	O
on	O
31	O
December	O
2019	O
,	O
the	O
ongoing	O
outbreak	O
of	O
a	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
causes	O
great	O
global	O
concerns	O
.	O

In	O
this	O
mini	O
-	O
review	O
,	O
we	O
provide	O
a	O
brief	O
introduction	O
to	O
the	O
pathology	O
and	O
pathogenesis	B-PROC
of	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
and	O
extrapolate	O
this	O
knowledge	O
to	O
the	O
newly	O
identified	O
2019	O
-	O
nCoV	O
.	O

The	O
number	O
of	O
confirmed	O
cases	O
and	O
deaths	B-PROC
continued	O
to	O
rise	O
.	O

In	O
this	O
article	O
,	O
we	O
discuss	O
the	O
possible	O
functional	O
consequences	O
of	O
this	O
cleavage	B-PROC
site	O
in	O
the	O
viral	O
cycle	O
,	O
pathogenicity	O
and	O
its	O
potential	O
implication	O
in	O
the	O
development	B-PROC
of	O
antivirals	O
.	O

ABSTRACT	O
:	O
The	O
indications	O
for	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
ECMO	O
)	O
are	O
expanding	O
.	O

The	O
epidemic	O
quickly	O
disseminated	O
from	O
Wuhan	O
and	O
as	O
at	O
12	O
February	O
2020	O
,	O
45	O
,	O
179	O
cases	O
have	O
been	O
confirmed	O
in	O
25	O
countries	O
,	O
including	O
1	O
,	O
116	O
deaths	B-PROC
.	O

ABSTRACT	O
:	O
Necrosis	B-PROC
with	O
inflammation	O
plays	O
a	O
crucial	O
role	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Next	O
,	O
we	O
utilised	O
a	O
mouse	O
model	O
of	O
severe	O
ARDS	O
induced	O
with	O
high	O
-	O
dose	O
lipopolysaccharide	O
and	O
found	O
that	O
lung	O
injury	O
was	O
mainly	O
due	O
to	O
RIPK3	O
-	O
mixed	O
lineage	O
kinase	O
domain	O
-	O
like	O
pseudokinase	O
(	O
MLKL	O
)-	O
mediated	O
necroptosis	B-PROC
and	O
endothelial	O
dysfunction	O
.	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
(	O
HCoV	O
)	O
are	O
common	O
causes	O
of	O
respiratory	O
illnesses	O
(	O
RI	O
)	O
despite	O
preexisting	O
humoral	B-PROC
immunity	I-PROC
.	O

The	O
overall	O
mortality	O
was	O
11	O
.	O
5	O
%,	O
the	O
non	O
-	O
survivors	O
revealed	O
significantly	O
higher	O
D	O
-	O
dimer	O
and	O
fibrin	O
degradation	O
product	O
(	O
FDP	O
)	O
levels	O
,	O
longer	O
prothrombin	O
time	O
and	O
activated	O
partial	O
thromboplastin	O
time	O
compared	O
to	O
survivors	O
on	O
admission	O
(	O
P	O
<	O
.	O
05	O
);	O
71	O
.	O
4	O
%	O
of	O
non	O
-	O
survivors	O
and	O
0	O
.	O
6	O
%	O
survivors	O
met	O
the	O
criteria	O
of	O
disseminated	O
intravascular	O
coagulation	B-PROC
during	O
their	O
hospital	O
stay	O
.	O

TITLE	O
:	O
[	O
Several	O
suggestion	O
of	O
operation	O
for	O
colorectal	O
cancer	O
under	O
the	O
outbreak	O
of	O
Corona	O
Virus	B-PROC
Disease	I-PROC
19	O
in	O
China	O
].	O

Fever	B-PROC
after	O
surgery	O
must	O
be	O
carefully	O
differentiated	B-PROC
whether	O
it	O
'	O
s	O
caused	O
by	O
post	O
-	O
surgery	O
abdominal	O
infection	O
/	O
inflammation	O
or	O
NCP	O
.	O

TITLE	O
:	O
Real	O
-	O
Time	O
Estimation	O
of	O
the	O
Risk	O
of	O
Death	B-PROC
from	O
Novel	O
Coronavirus	O
(	O
COVID	O
-	O
19	O
)	O
Infection	O
:	O
Inference	O
Using	O
Exported	O
Cases	O
.	O

ABSTRACT	O
:	O
In	O
December	O
2019	O
,	O
China	O
diagnosed	O
the	O
first	O
patient	O
with	O
2019	O
novel	O
coronavirus	O
disease	O
(	O
COVID	O
-	O
19	O
),	O
and	O
the	O
following	O
development	B-PROC
of	O
the	O
epidemic	O
had	O
a	O
huge	O
impact	O
on	O
China	O
and	O
the	O
whole	O
world	O
.	O

(	O
11	O
)	O
Avoid	O
unnecessary	O
bronchial	O
hygiene	O
therapy	O
;	O
(	O
12	O
)	O
For	O
patients	O
who	O
need	O
aerosol	O
therapy	O
,	O
dry	O
powder	O
inhaler	O
metered	O
dose	O
inhaler	O
with	O
spacer	O
is	O
recommended	O
for	O
spontaneous	O
breathing	B-PROC
patients	O
;	O
while	O
vibrating	O
mesh	O
nebulizer	O
is	O
recommended	O
for	O
ventilated	O
patients	O
and	O
additional	O
filter	O
is	O
recommended	O
to	O
be	O
placed	O
at	O
the	O
expiratory	B-PROC
port	O
of	O
ventilation	O
during	O
nebulization	O
.	O

The	O
patients	O
treated	O
in	O
the	O
burn	O
and	O
wound	O
care	O
ward	O
are	O
susceptible	O
to	O
viral	B-PROC
infection	I-PROC
because	O
of	O
disease	O
,	O
age	O
and	O
other	O
factors	O
,	O
so	O
it	O
is	O
very	O
important	O
to	O
manage	O
the	O
burn	O
and	O
wound	O
care	O
ward	O
during	O
the	O
prevention	O
and	O
control	O
of	O
NCP	O
epidemic	O
.	O

This	O
study	O
provides	O
several	O
complete	O
genomes	O
of	O
HCoV	O
-	O
NL63	O
and	O
improves	O
our	O
understanding	O
of	O
HCoV	O
-	O
NL63	O
evolution	B-PROC
in	O
China	O
.	O

During	O
the	O
formation	B-PROC
of	O
the	O
coronaviral	O
replication	O
/	O
transcription	B-PROC
complex	O
,	O
essential	O
steps	O
include	O
processing	O
of	O
the	O
conserved	O
polyprotein	O
nsp7	O
-	O
10	O
region	O
by	O
the	O
main	O
protease	O
Mpro	O
and	O
subsequent	O
complex	O
formation	B-PROC
of	O
the	O
released	O
nsp	O
'	O
s	O
.	O

Host	O
Factors	O
Affecting	O
Generation	O
of	O
Immunity	B-PROC
Against	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
in	O
Pregnant	O
and	O
Lactating	O
Swine	O
and	O
Passive	O
Protection	O
of	O
Neonates	O
.	O

Delay	O
of	O
non	O
-	O
emergency	O
dental	O
service	O
will	O
have	O
a	O
potential	O
impact	O
on	O
the	O
experience	O
,	O
cognition	B-PROC
,	O
treatment	O
and	O
rehabilitation	O
of	O
patients	O
with	O
oral	O
diseases	O
.	O

Some	O
cases	O
can	O
develop	O
into	O
ARDS	O
,	O
or	O
even	O
death	B-PROC
.	O

For	O
NCP	O
patients	O
with	O
mechanical	O
ventilation	O
,	O
reasonable	O
sedation	O
and	O
analgesia	B-PROC
strategies	O
should	O
be	O
formulated	O
;	O
delirium	O
should	O
not	O
be	O
ignored	O
.	O

In	O
addition	O
,	O
there	O
is	O
up	B-PROC
regulation	B-PROC
of	O
inflammatory	O
factors	O
in	O
patients	O
with	O
severe	O
NCP	O
,	O
but	O
the	O
effect	O
of	O
renal	O
replacement	O
therapy	O
needs	O
to	O
be	O
further	O
confirmed	O
by	O
clinical	O
research	O
.	O

The	O
above	O
underlying	O
diseases	O
and	O
ages	O
of	O
patients	O
are	O
the	O
susceptibility	O
factors	O
of	O
corona	O
virus	B-PROC
disease	I-PROC
2019	O
released	O
by	O
National	O
Health	O
Commission	O
of	O
China	O
.	O

We	O
also	O
demonstrated	O
that	O
trypsin	O
promotes	O
PDCoV	O
replication	O
by	O
enhancing	O
cell	O
-	O
to	O
-	O
cell	O
membrane	B-PROC
fusion	I-PROC
.	O

TITLE	O
:	O
Swine	O
acute	O
diarrhea	O
syndrome	O
coronavirus	O
-	O
induced	O
apoptosis	B-PROC
is	O
caspase	O
-	O
and	O
cyclophilin	B-PROC
D	O
-	O
dependent	O
.	O

ADE	O
modulates	O
the	O
immune	B-PROC
response	I-PROC
and	O
can	O
elicit	O
sustained	O
inflammation	O
,	O
lymphopenia	O
,	O
and	O
/	O
or	O
cytokine	O
storm	O
,	O
one	O
or	O
all	O
of	O
which	O
have	O
been	O
documented	O
in	O
severe	O
cases	O
and	O
deaths	B-PROC
.	O

ADE	O
also	O
requires	O
prior	O
exposure	O
to	O
similar	O
antigenic	O
epitopes	O
,	O
presumably	O
circulating	O
in	O
local	O
viruses	O
,	O
making	O
it	O
a	O
possible	O
explanation	O
for	O
the	O
observed	O
geographic	O
limitation	O
of	O
severe	O
cases	O
and	O
deaths	B-PROC
.	O

Meanwhile	O
,	O
it	O
is	O
also	O
crucial	O
to	O
speed	O
up	O
the	O
development	B-PROC
of	O
vaccines	O
and	O
drugs	O
for	O
treatment	O
,	O
which	O
will	O
enable	O
us	O
to	O
defeat	O
COVID	O
-	O
19	O
as	O
soon	O
as	O
possible	O
.	O

TITLE	O
:	O
Inhibitory	O
effects	O
of	O
glycopyrronium	O
,	O
formoterol	O
,	O
and	O
budesonide	O
on	O
coronavirus	O
HCoV	O
-	O
229E	O
replication	O
and	O
cytokine	B-PROC
production	I-PROC
by	O
primary	O
cultures	O
of	O
human	O
nasal	O
and	O
tracheal	O
epithelial	O
cells	O
.	O

Pretreatment	O
of	O
HNE	O
and	O
HTE	O
cells	O
with	O
glycopyrronium	O
or	O
formoterol	O
decreased	O
viral	O
RNA	O
levels	O
and	O
/	O
or	O
titers	O
,	O
the	O
expression	B-PROC
of	O
the	O
HCoV	O
-	O
229E	O
receptor	O
CD13	O
,	O
the	O
number	O
and	O
fluorescence	O
intensity	O
of	O
acidic	O
endosomes	O
where	O
HCoV	O
-	O
229E	O
RNA	O
enters	O
the	O
cytoplasm	O
,	O
and	O
the	O
infection	O
-	O
induced	O
production	O
of	O
cytokines	O
,	O
including	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
IFN	O
-	O
β	O
.	O

Pretreatment	O
with	O
formoterol	O
increased	O
cAMP	O
levels	O
and	O
treatment	O
with	O
cAMP	O
decreased	O
viral	O
titers	O
,	O
CD13	O
expression	B-PROC
,	O
and	O
the	O
fluorescence	O
intensity	O
of	O
acidic	O
endosomes	O
.	O

For	O
cases	O
of	O
severe	O
illness	O
,	O
early	O
and	O
also	O
short	O
periods	B-PROC
of	O
moderate	O
glucocorticoid	O
was	O
supported	O
.	O

Antimicrobial	O
prophylaxis	O
should	O
be	O
prescribed	O
rationally	O
and	O
was	O
not	O
recommended	O
except	O
for	O
patients	O
with	O
long	O
course	O
of	O
disease	O
,	O
repeated	O
fever	B-PROC
and	O
elevated	O
procalcitonin	O
(	O
PCT	O
),	O
meanwhile	O
secondary	O
fungal	O
infection	O
should	O
be	O
concerned	O
.	O

After	O
adjustment	O
for	O
potential	O
confounding	O
factors	O
,	O
older	O
age	O
,	O
elevated	O
lactate	O
level	O
and	O
elevated	O
creatinine	O
level	O
were	O
the	O
independent	O
risk	O
factors	O
for	O
death	B-PROC
.	O

AVNP2	O
also	O
alleviated	O
the	O
decline	O
of	O
long	B-PROC
-	I-PROC
term	I-PROC
potentiation	I-PROC
(	O
LTP	B-PROC
)	O
and	O
the	O
decreased	O
density	O
of	O
dendritic	O
spines	O
in	O
the	O
CA1	O
region	O
induced	O
by	O
C6	O
.	O

In	O
the	O
ongoing	O
COVID	O
-	O
19	O
epidemic	O
,	O
health	O
authorities	O
must	O
cope	O
with	O
the	O
uncertainty	O
in	O
the	O
risk	O
of	O
death	B-PROC
from	O
COVID	O
-	O
19	O
,	O
and	O
high	O
-	O
risk	O
individuals	O
should	O
be	O
identified	O
using	O
approaches	O
that	O
can	O
address	O
the	O
abovementioned	O
three	O
problems	O
.	O

At	O
an	O
interval	O
of	O
2	O
to	O
3	O
days	O
,	O
tear	O
and	O
conjunctival	O
secretions	O
were	O
collected	O
twice	O
with	O
disposable	O
sampling	O
swabs	O
for	O
reverse	O
-	O
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
.	O

ABSTRACT	O
:	O
From	O
the	O
beginning	O
of	O
2002	O
and	O
2012	O
,	O
severe	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
crossed	O
the	O
species	O
barriers	O
to	O
infect	O
humans	O
,	O
causing	O
thousands	O
of	O
infections	O
and	O
hundreds	O
of	O
deaths	B-PROC
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Background	O
Chest	O
CT	O
is	O
used	O
for	O
diagnosis	O
of	O
2019	O
novel	O
coronavirus	O
disease	O
(	O
COVID	O
-	O
19	O
),	O
as	O
an	O
important	O
complement	O
to	O
the	O
reverse	O
-	O
transcription	B-PROC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
tests	O
.	O

By	O
deeply	O
investigating	O
and	O
analyzing	O
the	O
problems	O
existed	O
in	O
the	O
current	O
Chinese	O
disease	O
control	O
and	O
prevention	O
system	O
,	O
and	O
learning	B-PROC
the	O
experiences	O
from	O
the	O
disease	O
control	O
and	O
prevention	O
systems	O
of	O
other	O
countries	O
,	O
the	O
expert	O
group	O
suggested	O
the	O
following	O
recommendations	O
,	O
included	O
the	O
enhance	O
and	O
update	O
the	O
laws	O
related	O
to	O
public	O
health	O
,	O
build	O
up	O
advanced	O
institution	O
mechanisms	O
that	O
meet	O
current	O
social	O
status	O
,	O
reform	O
current	O
emergency	O
response	O
system	O
,	O
clarify	O
the	O
dominance	O
and	O
function	O
of	O
disease	O
control	O
and	O
prevention	O
system	O
in	O
Health	O
China	O
developing	O
,	O
and	O
speed	O
up	O
the	O
construction	O
of	O
a	O
modern	O
information	O
system	O
,	O
talented	O
professional	O
groups	O
,	O
and	O
advanced	O
culture	O
.	O

The	O
interface	O
formed	O
a	O
conserved	O
hydrophobic	O
cavity	O
suitable	O
for	O
targeted	B-PROC
drug	O
screening	O
.	O

Older	O
patients	O
(>	O
65	O
years	O
)	O
with	O
comorbidities	O
and	O
ARDS	O
are	O
at	O
increased	O
risk	O
of	O
death	B-PROC
.	O

ABSTRACT	O
:	O
Coronavirus	O
Disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
is	O
an	O
emerging	O
disease	O
with	O
a	O
rapid	O
increase	O
in	O
cases	O
and	O
deaths	B-PROC
since	O
its	O
first	O
identification	O
in	O
Wuhan	O
,	O
China	O
,	O
in	O
December	O
2019	O
.	O

Although	O
these	O
measures	O
might	O
not	O
prevent	O
widespread	O
transmission	O
of	O
the	O
virus	O
in	O
the	O
United	O
States	O
,	O
they	O
are	O
being	O
implemented	O
to	O
1	O
)	O
slow	O
the	O
spread	O
of	O
illness	O
;	O
2	O
)	O
provide	O
time	O
to	O
better	O
prepare	O
state	O
and	O
local	O
health	O
departments	O
,	O
health	O
care	O
systems	O
,	O
businesses	O
,	O
educational	O
organizations	O
,	O
and	O
the	O
general	O
public	O
in	O
the	O
event	O
that	O
widespread	O
transmission	O
occurs	O
;	O
and	O
3	O
)	O
better	O
characterize	O
COVID	O
-	O
19	O
to	O
guide	O
public	O
health	O
recommendations	O
and	O
the	O
development	B-PROC
and	O
deployment	O
of	O
medical	O
countermeasures	O
,	O
including	O
diagnostics	O
,	O
therapeutics	O
,	O
and	O
vaccines	O
.	O

TITLE	O
:	O
Disposable	O
DNA	B-PROC
Amplification	I-PROC
Chips	O
with	O
Integrated	O
Low	O
-	O
Cost	O
Heaters	O
.	O

This	O
paper	O
describes	O
the	O
development	B-PROC
of	O
a	O
fabrication	O
process	O
and	O
the	O
proof	O
-	O
of	O
-	O
principle	O
of	O
a	O
disposable	O
DNA	B-PROC
amplification	I-PROC
chip	O
with	O
an	O
integrated	O
heater	O
.	O

The	O
majority	O
of	O
infected	O
patients	O
had	O
a	O
history	O
of	O
exposure	O
in	O
Wuhan	O
or	O
to	O
infected	O
patients	O
and	O
mostly	O
presented	O
with	O
fever	B-PROC
and	O
cough	O
.	O

Next	O
,	O
we	O
chose	O
13	O
Major	B-PROC
Histocompatibility	I-PROC
Complex	I-PROC
-(	O
MHC	B-PROC
)	O
I	O
and	O
3	O
MHC	B-PROC
-	O
II	O
epitopes	O
,	O
having	O
antigenic	O
properties	O
.	O

We	O
estimated	O
the	O
basic	O
reproduction	B-PROC
number	O
from	O
the	O
initial	O
period	O
of	O
the	O
outbreak	O
using	O
(	O
SEIR	O
)	O
models	O
.	O

The	O
basic	O
reproduction	B-PROC
rate	O
was	O
initially	O
4	O
times	O
higher	O
on	O
-	O
board	O
compared	O
to	O
the	O
${	O
R	O
}	O
_0	O
$	O
in	O
the	O
epicentre	O
in	O
Wuhan	O
,	O
but	O
the	O
countermeasures	O
lowered	O
it	O
substantially	O
.	O

It	O
is	O
timely	O
to	O
systematically	O
review	O
the	O
potential	O
of	O
these	O
interventions	O
,	O
including	O
those	O
for	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
,	O
to	O
guide	O
policymakers	O
globally	O
on	O
their	O
prioritization	O
of	O
resources	O
for	O
research	O
and	O
development	B-PROC
.	O

Combining	O
the	O
guidelines	O
for	O
diagnosis	O
and	O
treatment	O
of	O
tumors	O
with	O
our	O
clinical	O
experience	O
,	O
in	O
this	O
epidemic	O
period	O
,	O
we	O
discuss	O
the	O
strategies	O
for	O
diagnosis	O
,	O
treatment	O
,	O
and	O
follow	O
-	O
up	O
of	O
malignant	O
tumors	O
of	O
the	O
digestive	B-PROC
system	O
in	O
this	O
article	O
.	O

I	O
consider	O
the	O
options	O
of	O
drug	O
repurposing	O
,	O
developing	O
neutralizing	O
monoclonal	O
antibody	B-PROC
therapy	O
,	O
and	O
an	O
oligonucleotide	O
strategy	O
targeting	B-PROC
the	O
viral	O
RNA	O
genome	O
,	O
emphasizing	O
the	O
promise	O
and	O
pitfalls	O
of	O
these	O
approaches	O
.	O

The	O
sequence	O
of	O
the	O
ACE2	O
-	O
Fc	O
protein	O
is	O
provided	O
to	O
investigators	O
,	O
allowing	O
its	O
possible	O
use	O
in	O
recombinant	O
protein	B-PROC
expression	B-PROC
systems	O
to	O
start	O
producing	O
drug	O
today	O
to	O
treat	O
patients	O
under	O
compassionate	O
use	O
,	O
while	O
formal	O
clinical	O
trials	O
are	O
later	O
undertaken	O
.	O

One	O
patient	O
had	O
persistent	O
,	O
low	O
-	O
grade	O
upper	O
respiratory	O
tract	O
symptoms	O
without	O
fever	B-PROC
.	O

Convalescent	O
patients	O
refer	O
to	O
recovered	O
non	O
-	O
febrile	B-PROC
patients	O
without	O
respiratory	O
symptoms	O
who	O
had	O
two	O
successive	O
(	O
minimum	O
24	O
h	O
sampling	O
interval	O
)	O
negative	O
RT	O
-	O
PCR	O
results	O
for	O
viral	O
RNA	O
from	O
oropharyngeal	O
swabs	O
.	O

The	O
duration	O
of	O
RNA	O
detection	O
may	O
relate	O
to	O
host	O
cell	O
immunity	B-PROC
.	O

ABSTRACT	O
:	O
The	O
ongoing	O
new	O
coronavirus	O
pneumonia	O
(	O
Corona	O
Virus	B-PROC
Disease	I-PROC
2019	O
,	O
COVID	O
-	O
19	O
)	O
outbreak	O
is	O
spreading	O
in	O
China	O
,	O
but	O
it	O
has	O
not	O
yet	O
reached	O
its	O
peak	O
.	O

The	O
COVID	O
-	O
19	O
confirmed	O
and	O
death	B-PROC
cases	O
in	O
Hubei	O
province	O
accounted	O
for	O
59	O
.	O
91	O
%	O
(	O
5806	O
/	O
9692	O
)	O
and	O
95	O
.	O
77	O
%	O
(	O
204	O
/	O
213	O
)	O
of	O
the	O
total	O
cases	O
in	O
China	O
respectively	O
.	O

RESULTS	O
:	O
The	O
COVID	O
-	O
19	O
confirmed	O
and	O
death	B-PROC
cases	O
in	O
Hubei	O
province	O
accounted	O
for	O
59	O
.	O
91	O
%	O
(	O
5806	O
/	O
9692	O
)	O
and	O
95	O
.	O
77	O
%	O
(	O
204	O
/	O
213	O
)	O
of	O
the	O
total	O
cases	O
in	O
China	O
respectively	O
.	O

Patients	O
treated	O
with	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
n	O
=	O
10	O
)	O
due	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
patients	O
treated	O
with	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
(	O
n	O
=	O
8	O
)	O
due	O
to	O
cardiocirculatory	O
failure	O
.	O

Therapy	O
protocols	O
for	O
treating	O
extracorporeal	O
membrane	O
oxygenation	B-PROC
-	O
associated	O
coagulopathy	O
should	O
be	O
further	O
validated	O
in	O
large	O
-	O
scale	O
prospective	O
clinical	O
investigations	O
.	O

In	O
this	O
study	O
,	O
sequence	O
analysis	O
,	O
modeling	O
,	O
and	O
docking	B-PROC
are	O
used	O
to	O
build	O
a	O
model	O
for	O
Wuhan	O
COVID	O
-	O
19	O
RdRp	O
.	O

The	O
estimated	O
number	O
of	O
new	O
infections	O
among	O
passengers	O
without	O
close	O
contact	O
was	O
very	O
small	O
from	O
5	O
February	O
on	O
which	O
a	O
movement	B-PROC
restriction	O
policy	O
was	O
imposed	O
.	O

Movement	B-PROC
restriction	O
greatly	O
reduced	O
the	O
number	O
of	O
infections	O
from	O
5	O
February	O
onwards	O
.	O

In	O
order	O
to	O
minimise	O
cross	O
-	O
infection	O
of	O
COVID	O
-	O
19	O
,	O
a	O
triage	O
system	O
was	O
set	O
up	O
to	O
identify	O
patients	O
with	O
fever	B-PROC
,	O
respiratory	O
symptoms	O
,	O
acute	O
conjunctivitis	O
or	O
recent	O
travel	O
to	O
outbreak	O
areas	O
and	O
to	O
encourage	O
these	O
individuals	O
to	O
postpone	O
their	O
appointments	O
for	O
at	O
least	O
14	O
days	O
.	O

In	O
West	O
China	O
Hospital	O
,	O
Emergency	O
Department	O
(	O
ED	O
)	O
undertook	O
the	O
mission	O
of	O
clinical	O
reception	B-PROC
,	O
primary	O
diagnosis	O
,	O
and	O
interim	O
treatment	O
for	O
the	O
suspected	O
cases	O
of	O
COVID	O
-	O
19	O
.	O

With	O
the	O
deeper	O
cognition	B-PROC
of	O
COVID	O
-	O
19	O
and	O
accumulation	O
of	O
clinical	O
experience	O
,	O
we	O
proposed	O
the	O
recommendations	O
for	O
pulmonary	O
rehabilitation	O
of	O
COVID	O
-	O
19	O
in	O
adults	O
based	O
on	O
the	O
opinions	O
of	O
front	O
-	O
line	O
clinical	O
experts	O
involved	O
in	O
the	O
management	O
of	O
this	O
epidemic	O
and	O
a	O
review	O
of	O
the	O
relevant	O
literature	O
and	O
evidences	O
:	O
1	O
.	O

TITLE	O
:	O
[	O
Analysis	O
on	O
the	O
epidemic	O
factors	O
for	O
the	O
Corona	O
Virus	B-PROC
Disease	I-PROC
].	O

Through	O
a	O
series	O
of	O
drug	O
repurposing	O
screening	O
campaigns	O
,	O
niclosamide	O
,	O
an	O
FDA	O
-	O
approved	O
anthelminthic	O
drug	O
,	O
was	O
found	O
to	O
be	O
effective	O
against	O
various	O
viral	B-PROC
infections	I-PROC
with	O
nanomolar	O
to	O
micromolar	O
potency	O
such	O
as	O
SARS	O
-	O
CoV	O
,	O
MERS	O
-	O
CoV	O
,	O
ZIKV	O
,	O
HCV	O
,	O
and	O
human	O
adenovirus	O
,	O
indicating	O
its	O
potential	O
as	O
an	O
antiviral	O
agent	O
.	O

TITLE	O
:	O
Pretreatment	O
of	O
nafithromycin	O
attenuates	O
inflammatory	B-PROC
response	I-PROC
in	O
murine	O
lipopolysaccharide	O
induced	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
following	O
an	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
a	O
life	O
threatening	O
inflammatory	O
condition	O
predominantly	O
characterized	O
by	O
vascular	O
protein	O
leakage	O
,	O
neutrophil	B-PROC
recruitment	I-PROC
and	O
overexpression	B-PROC
of	O
proinflammatory	O
cytokines	O
.	O

We	O
evaluated	O
the	O
recovery	O
from	O
lung	O
damage	O
and	O
femoral	O
head	O
necrosis	B-PROC
in	O
an	O
observational	O
cohort	O
study	O
of	O
SARS	O
patients	O
using	O
pulmonary	O
CT	O
scans	O
,	O
hip	O
joint	O
MRI	O
examinations	O
,	O
pulmonary	B-PROC
function	I-PROC
tests	O
and	O
hip	O
joint	B-PROC
function	I-PROC
questionnaires	O
.	O

,	O
the	O
outbreak	O
of	O
COVID	O
-	O
19	O
in	O
Wuhan	O
has	O
spread	O
rapidly	O
due	O
to	O
population	O
movement	B-PROC
during	O
the	O
Spring	O
Festival	O
holidays	O
.	O

By	O
summarized	O
our	O
modelling	O
and	O
assessing	O
ideas	O
,	O
the	O
model	O
formulations	O
vary	O
from	O
autonomous	O
to	O
non	O
-	O
autonomous	O
dynamic	O
systems	O
,	O
the	O
risk	O
assessment	O
index	O
changes	O
from	O
the	O
basic	O
regeneration	B-PROC
number	O
to	O
the	O
effective	O
regeneration	B-PROC
number	O
,	O
and	O
the	O
epidemic	O
development	B-PROC
and	O
assessment	O
evolve	O
from	O
the	O
early	O
SEIHR	O
transmission	O
model	O
-	O
based	O
dynamics	O
to	O
the	O
recent	O
dynamics	O
which	O
are	O
mainly	O
associated	O
with	O
the	O
variation	O
of	O
the	O
isolated	O
and	O
suspected	O
population	O
sizes	O
.	O

SARS	O
-	O
CoV	O
-	O
2	O
evolves	O
in	O
vivo	O
after	O
infection	O
,	O
which	O
may	O
affect	O
its	O
virulence	B-PROC
,	O
infectivity	O
,	O
and	O
transmissibility	O
.	O

Healthcare	O
workers	O
(	O
HCWs	O
)	O
are	O
at	O
high	O
risk	O
while	O
combating	O
COVID	O
-	O
19	O
at	O
the	O
very	O
frontline	O
,	O
and	O
nosocomial	O
outbreaks	O
among	O
HCWs	O
are	O
not	O
unusual	O
in	O
similar	O
settings	O
;	O
the	O
2003	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
outbreak	O
led	O
to	O
over	O
966	O
HCW	O
infections	O
with	O
1	O
.	O
4	O
%	O
deaths	B-PROC
in	O
mainland	O
China	O
[	O
2	O
].	O

As	O
of	O
11	O
February	O
2020	O
,	O
3019	O
HCWs	O
might	O
have	O
been	O
infected	O
with	O
2019	O
-	O
nCov	O
in	O
China	O
,	O
1716	O
HCW	O
cases	O
were	O
confirmed	O
by	O
nucleic	O
acid	O
testing	O
[	O
3	O
],	O
and	O
at	O
least	O
6	O
HCWs	O
died	B-PROC
,	O
including	O
the	O
famous	O
whistleblower	O
Dr	O
Li	O
Wenliang	O
.	O

TITLE	O
:	O
The	O
Effects	O
of	O
Social	O
Support	O
on	O
Sleep	B-PROC
Quality	O
of	O
Medical	O
Staff	O
Treating	O
Patients	O
with	O
Coronavirus	O
Disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
in	O
January	O
and	O
February	O
2020	O
in	O
China	O
.	O

TITLE	O
:	O
Comparison	O
of	O
Fixed	O
-	O
Dose	O
Inhaled	B-PROC
Epoprostenol	O
and	O
Inhaled	B-PROC
Nitric	O
Oxide	O
for	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
in	O
Critically	O
Ill	O
Adults	O
.	O

In	O
this	O
study	O
,	O
we	O
review	O
observational	O
clinical	O
data	O
linking	O
development	B-PROC
of	O
CMV	O
reactivation	O
with	O
worse	O
outcomes	O
in	O
patients	O
in	O
the	O
intensive	O
care	O
unit	O
,	O
discuss	O
potential	O
biologically	O
plausible	O
mechanisms	O
for	O
a	O
causal	O
association	O
,	O
and	O
summarize	O
results	O
of	O
initial	O
interventional	O
trials	O
that	O
examined	O
the	O
effects	O
of	O
CMV	O
prevention	O
.	O

TITLE	O
:	O
Nonstructural	O
proteins	O
NS7b	O
and	O
NS8	O
are	O
likely	O
to	O
be	O
phylogenetically	O
associated	O
with	O
evolution	B-PROC
of	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
The	O
seventh	O
novel	O
human	O
infecting	O
Betacoronavirus	O
that	O
causes	O
pneumonia	O
(	O
2019	O
novel	O
coronavirus	O
,	O
2019	O
-	O
nCoV	O
)	O
originated	O
in	O
Wuhan	O
,	O
China	O
.	O

ABSTRACT	O
:	O
Another	O
animal	O
to	O
human	O
transmission	O
of	O
a	O
coronavirus	O
occurred	O
in	O
December	O
2019	O
on	O
a	O
live	O
animal	O
market	O
in	O
the	O
Chinese	O
city	O
of	O
Wuhan	O
causing	O
an	O
epidemic	O
in	O
China	O
,	O
reaching	B-PROC
now	O
different	O
continents	O
.	O

ABSTRACT	O
:	O
Since	O
December	O
2019	O
,	O
Corona	O
Virus	B-PROC
Disease	I-PROC
(	O
COVID	O
-	O
19	O
),	O
a	O
new	O
emerging	O
infection	O
disease	O
occurred	O
in	O
Wuhan	O
,	O
has	O
spread	O
in	O
27	O
countries	O
and	O
regions	O
.	O

ABSTRACT	O
:	O
To	O
date	O
,	O
the	O
controlling	O
of	O
outbreak	O
of	O
corona	O
virus	B-PROC
disease	I-PROC
2019	O
(	O
COVID	O
-	O
19	O
)	O
has	O
entered	O
into	O
a	O
critical	O
period	O
in	O
China	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
outbreak	O
in	O
2003	O
resulted	O
in	O
more	O
than	O
8000	O
cases	O
and	O
800	O
deaths	B-PROC
.	O

Five	O
cases	O
(	O
20	O
.	O
8	O
%)	O
developed	O
symptoms	O
(	O
fever	B-PROC
,	O
cough	O
,	O
fatigue	O
,	O
etc	O
.)	O
during	O
hospitalization	O
.	O

AST	O
and	O
ALT	O
each	O
rose	O
to	O
about	O
1	O
,	O
000	O
U	O
/	O
L	O
on	O
day	O
-	O
2	O
of	O
admission	O
,	O
and	O
rose	O
to	O
≥	O
6	O
,	O
000	O
U	O
/	O
L	O
on	O
day	O
-	O
3	O
,	O
with	O
development	B-PROC
of	O
severe	O
hepatic	O
encephalopathy	O
and	O
severe	O
coagulopathy	O
.	O

Extra	O
vascular	O
fibrin	O
deposition	O
and	O
abnormalities	O
in	O
the	O
fibrinolysis	B-PROC
are	O
the	O
major	O
clinical	O
manifestations	O
of	O
lung	O
diseases	O
such	O
as	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
most	O
severe	O
form	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Our	O
results	O
support	O
current	O
proposals	O
for	O
the	O
length	O
of	O
quarantine	O
or	O
active	O
monitoring	O
of	O
persons	O
potentially	O
exposed	O
to	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
although	O
longer	O
monitoring	O
periods	B-PROC
might	O
be	O
justified	O
in	O
extreme	O
cases	O
.	O

None	O
of	O
the	O
patients	O
developed	O
severe	O
COVID	O
-	O
19	O
pneumonia	O
or	O
died	B-PROC
,	O
as	O
of	O
Feb	O
4	O
,	O
2020	O
.	O

The	O
relatively	O
high	O
mortality	O
rates	O
associated	O
with	O
these	O
three	O
novel	O
human	O
coronavirus	O
infections	O
,	O
SARS	O
-	O
CoV	O
,	O
MERS	O
-	O
CoV	O
,	O
and	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
has	O
suggested	O
that	O
pro	O
-	O
inflammatory	B-PROC
responses	I-PROC
might	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	B-PROC
.	O

MiRNAs	O
contribute	O
to	O
RNA	O
virus	O
pathogenesis	B-PROC
by	O
promoting	O
antiviral	O
immune	B-PROC
response	I-PROC
,	O
enhancing	O
viral	B-PROC
replication	I-PROC
,	O
or	O
altering	O
miRNA	O
-	O
mediated	O
host	O
gene	B-PROC
regulation	I-PROC
.	O

This	O
implies	O
higher	O
codon	O
bias	O
and	O
higher	O
gene	B-PROC
expression	I-PROC
efficiency	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
structural	O
proteins	O
.	O

Pangolin	O
Beta	O
-	O
CoV	O
showed	O
little	O
differences	O
with	O
SARS	O
-	O
CoV	O
-	O
2	O
ENc	O
values	O
,	O
compared	O
with	O
SARS	O
,	O
bat	O
SARS	O
,	O
and	O
MERS	O
CoV	O
.	O
CONCLUSIONS	O
:	O
Extreme	O
bias	O
and	O
lower	O
ENc	O
values	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
especially	O
in	O
Spike	O
,	O
Envelope	O
,	O
and	O
Mpro	O
genes	O
,	O
are	O
suggestive	O
for	O
higher	O
gene	B-PROC
expression	I-PROC
efficiency	O
,	O
compared	O
with	O
SARS	O
,	O
bat	O
SARS	O
,	O
and	O
MERS	O
CoVs	O
.	O

We	O
hope	O
that	O
open	O
access	O
to	O
this	O
reagent	O
will	O
expedite	O
development	B-PROC
of	O
medical	O
countermeasures	O
.	O

Two	O
percentage	O
were	O
Influenza	O
A	O
positive	O
and	O
1	O
%	O
positive	O
for	O
influenza	O
B	O
.	O
Mixed	O
viral	B-PROC
infection	I-PROC
was	O
observed	O
in	O
7	O
%.	O

Pandemics	O
can	O
not	O
only	O
interrupt	O
an	O
organisation	B-PROC
'	O
s	O
operations	O
and	O
compromise	O
long	O
-	O
term	O
viability	O
of	O
an	O
enterprise	O
,	O
but	O
also	O
disrupt	O
the	O
provision	O
of	O
critical	O
functions	O
.	O

The	O
most	O
common	O
symptoms	O
were	O
fever	B-PROC
,	O
shortness	O
of	O
breath	O
,	O
expectoration	O
,	O
fatigue	O
,	O
dry	O
cough	O
and	O
myalgia	O
.	O

A	O
meta	O
-	O
analysis	O
of	O
eligible	O
studies	O
that	O
summarized	O
the	O
prevalence	O
of	O
cardiovascular	O
metabolic	B-PROC
diseases	O
in	O
COVID	O
-	O
19	O
and	O
compared	O
the	O
incidences	O
of	O
the	O
comorbidities	O
in	O
ICU	O
/	O
severe	O
and	O
non	O
-	O
ICU	O
/	O
severe	O
patients	O
was	O
performed	O
.	O

This	O
urgent	O
situation	O
is	O
pressing	O
the	O
world	O
to	O
respond	O
with	O
the	O
development	B-PROC
of	O
novel	O
vaccine	O
or	O
a	O
small	O
molecule	O
therapeutics	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

TITLE	O
:	O
Estimating	O
the	O
reproductive	B-PROC
number	O
and	O
the	O
outbreak	O
size	O
of	O
Novel	O
Coronavirus	O
disease	O
(	O
COVID	O
-	O
19	O
)	O
using	O
mathematical	O
model	O
in	O
Republic	O
of	O
Korea	O
.	O

ABSTRACT	O
:	O
As	O
of	O
22	O
February	O
2020	O
,	O
more	O
than	O
77662	O
cases	O
of	O
confirmed	O
COVID	O
-	O
19	O
have	O
been	O
documented	O
globally	O
with	O
over	O
2360	O
deaths	B-PROC
.	O

Common	O
presentations	O
of	O
confirmed	O
cases	O
include	O
fever	B-PROC
,	O
fatigue	O
,	O
dry	O
cough	O
,	O
upper	O
airway	O
congestion	O
,	O
sputum	B-PROC
production	I-PROC
,	O
shortness	O
of	O
breath	O
,	O
myalgia	O
/	O
arthralgia	O
with	O
lymphopenia	O
,	O
prolonged	O
prothrombin	O
time	O
,	O
elevated	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
elevated	O
lactate	O
dehydrogenase	O
.	O

TITLE	O
:	O
Coronavirus	O
disease	O
-	O
2019	O
:	O
is	O
fever	B-PROC
an	O
adequate	O
screening	O
for	O
the	O
returning	O
travelers	O
?	O

The	O
analysis	O
showed	O
that	O
the	O
viral	O
pp1ab	O
has	O
not	O
changed	O
in	O
most	O
isolates	O
throughout	O
the	O
outbreak	O
time	O
,	O
but	O
interestingly	O
a	O
deletion	O
of	O
8	O
aa	O
in	O
the	O
virulence	B-PROC
factor	O
nonstructural	O
protein	O
1	O
was	O
found	O
in	O
a	O
virus	O
isolated	O
from	O
a	O
Japanese	O
patient	O
that	O
did	O
not	O
display	O
critical	O
symptoms	O
.	O

In	O
this	O
study	O
,	O
we	O
screened	O
these	O
chemical	O
structures	O
from	O
traditional	O
Chinese	O
medicinal	O
compounds	O
proven	O
to	O
show	O
antiviral	O
activity	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
the	O
similar	O
chemical	O
structures	O
through	O
a	O
molecular	O
docking	B-PROC
study	O
to	O
target	O
RdRp	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
SARS	O
-	O
CoV	O
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Moreover	O
,	O
one	O
π	O
-	O
cation	O
interaction	O
was	O
formed	O
between	O
theaflavin	O
and	O
Arg553	O
from	O
the	O
Blind	O
Docking	B-PROC
server	O
.	O

TITLE	O
:	O
Risk	O
Factors	O
Associated	O
With	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
and	O
Death	B-PROC
in	O
Patients	O
With	O
Coronavirus	O
Disease	O
2019	O
Pneumonia	O
in	O
Wuhan	O
,	O
China	O
.	O

Although	O
high	O
fever	B-PROC
was	O
associated	O
with	O
the	O
development	B-PROC
of	O
ARDS	O
,	O
it	O
was	O
also	O
associated	O
with	O
better	O
outcomes	O
among	O
patients	O
with	O
ARDS	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
density	O
of	O
the	O
expression	B-PROC
levels	O
of	O
ACE2	O
in	O
the	O
CNS	O
,	O
the	O
host	O
-	O
virus	O
interaction	O
and	O
relate	O
it	O
to	O
the	O
pathogenesis	B-PROC
and	O
complications	O
seen	O
in	O
the	O
recent	O
cases	O
resulting	O
from	O
the	O
COVID	O
-	O
19	O
outbreak	O
.	O

Our	O
estimates	O
of	O
the	O
risk	O
for	O
death	B-PROC
in	O
Wuhan	O
reached	O
values	O
as	O
high	O
as	O
12	O
%	O
in	O
the	O
epicenter	O
of	O
the	O
epidemic	O
and	O
≈	O
1	O
%	O
in	O
other	O
,	O
more	O
mildly	O
affected	O
areas	O
.	O

Protein	O
-	O
protein	O
docking	B-PROC
was	O
performed	O
to	O
test	O
the	O
four	O
regions	O
of	O
the	O
spike	O
that	O
fit	O
tightly	O
in	O
the	O
GRP78	O
Substrate	O
Binding	O
Domain	O
β	O
(	O
SBDβ	O
).	O

The	O
docking	B-PROC
pose	O
revealed	O
the	O
involvement	O
of	O
the	O
SBDβ	O
of	O
GRP78	O
and	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
the	O
coronavirus	O
spike	O
protein	O
in	O
recognition	O
of	O
the	O
host	O
cell	O
receptor	O
.	O

ABSTRACT	O
:	O
Since	O
December	O
2019	O
,	O
more	O
than	O
79	O
,	O
000	O
people	O
have	O
been	O
diagnosed	O
with	O
infection	O
of	O
the	O
Corona	O
Virus	B-PROC
Disease	I-PROC
2019	O
(	O
COVID	O
-	O
19	O
).	O

TITLE	O
:	O
Single	O
-	O
cell	O
RNA	O
-	O
seq	O
data	O
analysis	O
on	O
the	O
receptor	O
ACE2	O
expression	B-PROC
reveals	O
the	O
potential	O
risk	O
of	O
different	O
human	O
organs	O
vulnerable	O
to	O
2019	O
-	O
nCoV	O
infection	O
.	O

This	O
study	O
may	O
provide	O
potential	O
clues	O
for	O
further	O
investigation	O
of	O
the	O
pathogenesis	B-PROC
and	O
route	O
of	O
2019	O
-	O
nCoV	O
infection	O
.	O

We	O
used	O
univariable	O
and	O
multivariable	O
logistic	O
regression	O
methods	O
to	O
explore	O
the	O
risk	O
factors	O
associated	O
with	O
in	O
-	O
hospital	O
death	B-PROC
.	O

Cytokine	O
IL	O
-	O
37	O
has	O
the	O
ability	O
to	O
suppress	O
innate	O
and	O
acquired	B-PROC
immune	I-PROC
response	I-PROC
and	O
also	O
has	O
the	O
capacity	O
to	O
inhibit	O
inflammation	O
by	O
acting	O
on	O
IL	O
-	O
18Rα	O
receptor	O
.	O

In	O
the	O
absence	O
of	O
a	O
known	O
efficient	O
therapy	O
and	O
because	O
of	O
the	O
situation	O
of	O
a	O
public	O
-	O
health	O
emergency	O
,	O
it	O
made	O
sense	B-PROC
to	O
investigate	O
the	O
possible	O
effect	O
of	O
chloroquine	O
/	O
hydroxychloroquine	O
against	O
SARS	O
-	O
CoV	O
-	O
2	O
since	O
this	O
molecule	O
was	O
previously	O
described	O
as	O
a	O
potent	O
inhibitor	O
of	O
most	O
coronaviruses	O
,	O
including	O
SARS	O
-	O
CoV	O
-	O
1	O
.	O

Patients	O
who	O
were	O
transferred	O
to	O
intensive	O
care	O
units	O
(	O
ICU	O
)	O
had	O
significantly	O
longer	O
duration	O
of	O
fever	B-PROC
as	O
compared	O
to	O
those	O
not	O
in	O
ICU	O
(	O
31	O
days	O
v	O
.	O
s	O
.	O
9	O
days	O
after	O
onset	O
of	O
symptoms	O
,	O
respectively	O
,	O
P	O
<	O
0	O
.	O
0001	O
).	O

The	O
median	O
duration	O
to	O
negative	O
reverse	O
-	O
transcriptase	B-PROC
PCR	O
tests	O
of	O
upper	O
respiratory	O
tract	O
samples	O
was	O
11	O
days	O
(	O
95	O
CIs	O
:	O
10	O
-	O
12	O
days	O
).	O

We	O
prospectively	O
collect	O
blood	B-PROC
coagulation	I-PROC
data	O
in	O
these	O
patients	O
and	O
in	O
40	O
healthy	O
controls	O
during	O
the	O
same	O
period	O
.	O

The	O
clinical	O
features	O
include	O
fever	B-PROC
,	O
coughing	O
,	O
shortness	O
of	O
breath	O
,	O
and	O
inflammatory	O
lung	O
infiltration	O
.	O

The	O
outcome	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
is	O
largely	O
determined	O
by	O
virus	B-PROC
-	I-PROC
host	I-PROC
interaction	I-PROC
.	O

ABSTRACT	O
:	O
As	O
an	O
atypical	O
pneumonia	O
began	O
to	O
appear	O
in	O
December	O
2019	O
,	O
Zhou	O
et	O
al	O
.	O
worked	O
with	O
remarkable	O
speed	O
to	O
identify	O
the	O
associated	O
virus	O
,	O
determine	O
its	O
relationship	O
to	O
animal	O
viruses	O
,	O
and	O
evaluate	O
factors	O
conferring	O
infection	O
susceptibility	O
and	O
resistance	B-PROC
.	O

After	O
adjustment	O
,	O
those	O
with	O
refractory	O
COVID	O
-	O
19	O
were	O
also	O
more	O
likely	O
to	O
have	O
a	O
male	O
sex	O
and	O
manifestations	O
of	O
anorexia	O
and	O
fever	B-PROC
on	O
admission	O
,	O
and	O
receive	O
oxygen	O
,	O
expectorant	O
and	O
adjunctive	O
agents	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
when	O
considering	O
the	O
factors	O
of	O
disease	O
severity	O
on	O
admission	O
,	O
mechanical	O
ventilation	O
,	O
and	O
ICU	O
transfer	O
.	O

ABSTRACT	O
:	O
The	O
Corona	O
Virus	B-PROC
Disease	I-PROC
2019	O
(	O
COVID	O
-	O
19	O
)	O
outbroke	O
in	O
Wuhan	O
,	O
China	O
in	O
December	O
2019	O
and	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
outbroke	O
in	O
Guangzhou	O
,	O
China	O
in	O
2003	O
were	O
caused	O
by	O
highly	O
pathogenic	O
coronaviruses	O
with	O
high	O
homology	O
.	O

Several	O
studies	O
have	O
been	O
done	O
to	O
estimate	O
the	O
basic	O
reproduction	B-PROC
number	O
in	O
the	O
early	O
phase	O
of	O
this	O
outbreak	O
,	O
yet	O
there	O
are	O
no	O
reliable	O
estimates	O
of	O
case	O
fatality	O
rate	O
(	O
CFR	O
)	O
for	O
COVID	O
-	O
19	O
to	O
date	O
.	O

A	O
Review	O
of	O
Coronaviruses	O
and	O
Ocular	B-PROC
Implications	O
in	O
Humans	O
and	O
Animals	O
.	O

We	O
hope	O
that	O
this	O
article	O
will	O
serve	O
as	O
a	O
start	O
for	O
further	O
research	O
into	O
the	O
ocular	B-PROC
implications	O
of	O
human	O
CoV	O
infections	O
.	O

Most	O
patients	O
with	O
confirmed	O
or	O
suspected	O
COVID	O
19	O
presented	O
with	O
fever	B-PROC
and	O
dry	O
cough	O
and	O
demonstrated	O
bilateral	O
multiple	O
mottling	O
and	O
ground	O
-	O
glass	O
opacity	O
on	O
chest	O
computed	O
tomography	O
scans	O
.	O

For	O
656	O
patients	O
,	O
fever	B-PROC
(	O
88	O
.	O
7	O
%,	O
95	O
%	O
CI	O
84	O
.	O
5	O
-	O
92	O
.	O
9	O
%),	O
cough	O
(	O
57	O
.	O
6	O
%,	O
95	O
%	O
CI	O
40	O
.	O
8	O
-	O
74	O
.	O
4	O
%)	O
and	O
dyspnea	O
(	O
45	O
.	O
6	O
%,	O
95	O
%	O
CI	O
10	O
.	O
9	O
-	O
80	O
.	O
4	O
%)	O
were	O
the	O
most	O
prevalent	O
manifestations	O
.	O

We	O
show	O
a	O
broad	O
spectrum	O
of	O
fusion	O
inhibition	B-PROC
by	O
GA	O
of	O
all	O
three	O
classes	O
of	O
fusion	O
proteins	O
including	O
HIV	O
,	O
Ebola	O
virus	O
(	O
EBOV	O
),	O
influenza	O
A	O
virus	O
(	O
IAV	O
)	O
and	O
Epstein	O
Barr	O
virus	O
(	O
EBV	O
).	O

TITLE	O
:	O
Risk	O
Factors	O
of	O
Healthcare	O
Workers	O
with	O
Corona	O
Virus	B-PROC
Disease	I-PROC
2019	O
:	O
A	O
Retrospective	O
Cohort	O
Study	O
in	O
a	O
Designated	O
Hospital	O
of	O
Wuhan	O
in	O
China	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
management	O
and	O
safety	O
of	O
epidural	O
or	O
general	B-PROC
anesthesia	I-PROC
for	O
Cesarean	O
delivery	O
in	O
parturients	O
with	O
coronavirus	O
disease	O
(	O
COVID	O
-	O
19	O
)	O
and	O
their	O
newborns	O
,	O
and	O
to	O
evaluate	O
the	O
standardized	O
procedures	O
for	O
protecting	O
medical	O
staff	O
.	O

There	O
were	O
no	O
deaths	B-PROC
or	O
serious	O
neonatal	O
asphyxia	O
events	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
disease	O
2019	O
(	O
COVID	O
-	O
2019	O
)	O
has	O
been	O
recognized	O
as	O
a	O
global	O
threat	O
,	O
and	O
several	O
studies	O
are	O
being	O
conducted	O
using	O
various	O
mathematical	O
models	O
to	O
predict	O
the	O
probable	O
evolution	B-PROC
of	O
this	O
epidemic	O
.	O

We	O
failed	O
to	O
identify	O
SARS	O
-	O
CoV	O
-	O
2	O
in	O
all	O
the	O
products	O
of	O
conception	B-PROC
and	O
the	O
newborns	O
.	O

Reported	O
symptoms	O
include	O
fever	B-PROC
,	O
cough	O
,	O
fatigue	O
,	O
pneumonia	O
,	O
headache	O
,	O
diarrhea	O
,	O
hemoptysis	O
,	O
and	O
dyspnea	O
.	O

In	O
addition	O
,	O
active	O
adjuvant	O
therapy	O
is	O
also	O
important	O
,	O
such	O
as	O
correcting	O
coagulation	B-PROC
dysfunction	O
,	O
providing	O
proper	O
nutritional	O
support	O
,	O
accurate	O
volume	O
control	O
,	O
and	O
safe	O
individualized	O
blood	O
glucose	O
monitoring	O
and	O
control	O
.	O

TITLE	O
:	O
Coronavirus	O
Endoribonuclease	O
and	O
Deubiquitinating	B-PROC
Interferon	O
Antagonists	O
Differentially	O
Modulate	O
the	O
Host	B-PROC
Response	I-PROC
during	O
Replication	O
in	O
Macrophages	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
host	O
transcriptional	B-PROC
response	O
to	O
infection	O
with	O
murine	O
coronaviruses	O
encoding	O
independent	O
mutations	O
in	O
one	O
of	O
two	O
different	O
viral	O
antagonists	O
:	O
the	O
deubiquitinase	B-PROC
(	O
DUB	O
)	O
within	O
nonstructural	O
protein	O
3	O
or	O
the	O
endoribonuclease	O
(	O
EndoU	O
)	O
within	O
nonstructural	O
protein	O
15	O
.	O

Materials	O
and	O
Methods	O
During	O
January	O
16	O
to	O
February	O
17	O
,	O
2020	O
,	O
90	O
patients	O
(	O
male	O
:	O
female	O
,	O
33	O
:	O
57	O
;	O
mean	O
age	O
,	O
45	O
years	O
)	O
with	O
COVID	O
-	O
19	O
pneumonia	O
were	O
prospectively	O
enrolled	O
and	O
followed	O
up	O
until	O
they	O
were	O
discharged	O
or	O
died	B-PROC
,	O
or	O
until	O
the	O
end	O
of	O
the	O
study	O
.	O

Materials	O
and	O
Methods	O
In	O
this	O
retrospective	O
and	O
multi	O
-	O
center	O
study	O
,	O
a	O
deep	O
learning	B-PROC
model	O
,	O
COVID	O
-	O
19	O
detection	O
neural	B-PROC
network	I-PROC
(	O
COVNet	O
),	O
was	O
developed	O
to	O
extract	O
visual	O
features	O
from	O
volumetric	O
chest	O
CT	O
exams	O
for	O
the	O
detection	O
of	O
COVID	O
-	O
19	O
.	O

The	O
article	O
presents	O
basic	O
information	O
about	O
etiology	O
,	O
pathogenesis	B-PROC
and	O
diagnostics	O
(	O
with	O
particular	O
emphasis	O
on	O
the	O
importance	O
of	O
tomocomputer	O
imaging	O
),	O
clinical	O
picture	O
,	O
treatment	O
and	O
prevention	O
of	O
the	O
infection	O
.	O

ABSTRACT	O
:	O
In	O
December	O
2019	O
,	O
a	O
new	O
outbreak	O
of	O
corona	O
virus	B-PROC
disease	I-PROC
2019	O
began	O
to	O
occur	O
.	O

Based	O
on	O
our	O
experience	O
with	O
laparoscopic	O
colorectal	O
operation	O
,	O
we	O
propose	O
some	O
surgery	O
strategies	O
for	O
colorectal	O
cancer	O
patients	O
under	O
the	O
corona	O
virus	B-PROC
disease	I-PROC
2019	O
(	O
COVID	O
-	O
19	O
)	O
situation	O
:	O
the	O
screening	O
process	O
should	O
be	O
strictly	O
carried	O
out	O
before	O
surgery	O
to	O
reduce	O
the	O
risk	O
of	O
nosocomial	O
infection	O
in	O
the	O
later	O
stage	O
;	O
laparoscopic	O
-	O
assisted	O
surgery	O
is	O
recommended	O
for	O
radical	O
surgery	O
for	O
patients	O
with	O
colorectal	O
cancer	O
;	O
strict	O
aerosol	O
management	O
must	O
be	O
made	O
during	O
the	O
operation	O
;	O
natural	O
orifice	O
specimen	O
extraction	O
surgery	O
and	O
transanal	O
total	O
mesorectal	O
excision	O
are	O
should	O
be	O
performed	O
prudently	O
;	O
scientific	O
and	O
reasonable	O
prophylactic	O
stoma	O
should	O
be	O
done	O
;	O
personnel	O
protection	O
in	O
surgical	O
ward	O
and	O
operation	O
room	O
must	O
be	O
strengthened	O
.	O

ABSTRACT	O
:	O
Corona	O
virus	B-PROC
disease	I-PROC
2019	O
(	O
COVID	O
-	O
19	O
)	O
is	O
currently	O
raging	O
in	O
China	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
patient	O
with	O
severe	O
chemical	O
gas	O
inhalation	B-PROC
lung	O
injury	O
who	O
failed	O
to	O
respond	O
to	O
traditional	O
mechanical	O
ventilation	O
and	O
was	O
subsequently	O
treated	O
with	O
awake	O
ECMO	O
combined	O
with	O
CRRT	O
.	O

So	O
far	O
,	O
actions	O
have	O
been	O
taken	O
including	O
but	O
not	O
limited	O
to	O
nationwide	O
actions	O
and	O
online	O
education	O
regarding	O
special	O
procedures	O
of	O
airway	O
management	O
,	O
oxygen	O
therapy	O
,	O
ventilation	O
support	O
,	O
hemodynamic	B-PROC
management	O
,	O
sedation	O
,	O
and	O
analgesia	B-PROC
.	O

Timely	O
,	O
but	O
not	O
premature	O
,	O
intubation	O
is	O
crucial	O
to	O
counter	O
a	O
progressively	O
enlarging	O
oxygen	B-PROC
debt	I-PROC
despite	O
high	O
-	O
flow	O
oxygen	O
therapy	O
and	O
bilevel	O
positive	O
airway	O
pressure	O
ventilation	O
.	O

All	O
of	O
them	O
accepted	O
mechanical	O
ventilation	O
,	O
intravenous	O
immunoglobulin	B-PROC
(	O
IVIG	O
),	O
blood	O
transfusion	O
,	O
glucocorticoid	O
,	O
and	O
multi	O
-	O
anti	O
-	O
infectious	O
therapy	O
.	O

Here	O
,	O
we	O
describe	O
the	O
development	B-PROC
of	O
PRESCIENT	O
(	O
Platform	O
for	O
the	O
Rapid	O
Evaluation	O
of	O
antibody	B-PROC
SucCess	O
using	O
Integrated	O
microfluidics	O
ENabled	O
Technology	O
),	O
a	O
droplet	O
microfluidic	O
system	O
that	O
can	O
enable	O
high	O
-	O
throughput	O
single	O
-	O
cell	O
resolution	O
identification	O
of	O
nAb	O
repertoires	O
elicited	O
in	O
response	O
to	O
viral	B-PROC
infection	I-PROC
.	O

The	O
presented	O
strategy	O
and	O
platform	O
have	O
the	O
potential	O
to	O
identify	O
and	O
investigate	O
neutralizing	O
activities	O
against	O
a	O
broad	O
range	O
of	O
potential	O
infectious	O
agents	O
for	O
which	O
nAbs	O
have	O
yet	O
to	O
be	O
discovered	O
,	O
significantly	O
advancing	O
the	O
nAb	O
identification	O
process	O
as	O
well	O
as	O
reinvigorating	O
the	O
field	O
of	O
Ab	O
discovery	O
,	O
characterization	O
,	O
and	O
development	B-PROC
.	O

HCQ	O
is	O
likely	O
to	O
attenuate	O
the	O
severe	O
progression	O
of	O
COVID	O
-	O
19	O
,	O
inhibiting	O
the	O
cytokine	O
storm	O
by	O
suppressing	O
T	B-PROC
cell	I-PROC
activation	I-PROC
.	O

The	O
majority	O
of	O
the	O
causes	O
of	O
death	B-PROC
were	O
due	O
to	O
multi	O
-	O
organ	O
failure	O
and	O
septic	O
shock	O
.	O

The	O
pathogenesis	B-PROC
of	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
in	O
humans	O
remains	O
unclear	O
.	O

More	O
recent	O
research	O
highlights	O
the	O
importance	O
of	O
the	O
environmental	O
factors	O
,	O
especially	O
temperature	O
and	O
humidity	O
,	O
in	O
modulating	O
host	O
intrinsic	O
,	O
innate	O
,	O
and	O
adaptive	B-PROC
immune	I-PROC
responses	I-PROC
to	O
viral	B-PROC
infections	I-PROC
in	O
the	O
respiratory	O
tract	O
.	O

Several	O
integrated	O
,	O
random	O
-	O
access	O
,	O
point	O
-	O
of	O
-	O
care	O
molecular	O
devices	O
are	O
currently	O
under	O
development	B-PROC
for	O
fast	O
and	O
accurate	O
diagnosis	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
infections	O
.	O

Fortunately	O
,	O
all	O
patients	O
did	O
not	O
need	O
ICU	O
care	O
and	O
were	O
discharged	O
from	O
hospital	O
without	O
death	B-PROC
.	O

We	O
found	O
genomic	O
and	O
evolutionary	O
evidence	O
of	O
the	O
occurrence	O
of	O
a	O
SARS	O
-	O
CoV	O
-	O
2	O
-	O
like	O
CoV	O
(	O
named	O
Pangolin	O
-	O
CoV	O
)	O
in	O
dead	B-PROC
Malayan	O
pangolins	O
.	O

In	O
addition	O
,	O
the	O
intrinsic	O
growth	B-PROC
rate	O
was	O
estimated	O
at	O
0	O
.	O
6	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
6	O
,	O
0	O
.	O
7	O
)	O
and	O
the	O
scaling	O
of	O
growth	B-PROC
parameter	O
was	O
estimated	O
at	O
0	O
.	O
8	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
,	O
0	O
.	O
8	O
),	O
indicating	O
sub	O
-	O
exponential	O
growth	B-PROC
dynamics	O
of	O
COVID	O
-	O
19	O
.	O

TITLE	O
:	O
Hiding	O
in	O
Plain	O
Sight	B-PROC
:	O
an	O
Approach	O
to	O
Treating	O
Patients	O
with	O
Severe	O
COVID	O
-	O
19	O
Infection	O
.	O

It	O
includes	O
a	O
description	O
of	O
hazard	O
group	O
3	O
organisms	O
to	O
which	O
SARS	O
-	O
CoV	O
-	O
2	O
has	O
been	O
assigned	O
,	O
a	O
brief	O
description	O
of	O
what	O
is	O
currently	O
known	O
about	O
the	O
pathological	O
and	O
autopsy	O
findings	O
in	O
COVID	O
-	O
19	O
,	O
a	O
summary	O
of	O
the	O
recommendations	O
for	O
conducting	B-PROC
autopsies	O
in	O
suspected	O
COVID	O
-	O
19	O
cases	O
and	O
the	O
techniques	O
for	O
making	O
the	O
diagnosis	O
at	O
autopsy	O
.	O

The	O
median	O
duration	O
of	O
IgM	O
and	O
IgA	O
antibody	B-PROC
detection	O
were	O
5	O
days	O
(	O
IQR	O
3	O
-	O
6	O
),	O
while	O
IgG	O
was	O
detected	O
on	O
14	O
days	O
(	O
IQR	O
10	O
-	O
18	O
)	O
after	O
symptom	O
onset	O
,	O
with	O
a	O
positive	O
rate	O
of	O
85	O
.	O
4	O
%,	O
92	O
.	O
7	O
%	O
and	O
77	O
.	O
9	O
%	O
respectively	O
.	O

Herein	O
we	O
report	O
a	O
case	O
of	O
a	O
COVID	O
-	O
19	O
infection	O
in	O
a	O
solid	O
organ	O
transplant	O
recipient	O
,	O
in	O
which	O
the	O
first	O
clinical	O
symptoms	O
were	O
of	O
gastrointestinal	O
viral	B-PROC
disease	I-PROC
and	O
fever	B-PROC
,	O
which	O
further	O
progressed	O
to	O
respiratory	O
symptoms	O
in	O
48h	O
.	O

TITLE	O
:	O
Guide	O
to	O
the	O
Forensic	O
Pathology	O
Practice	O
on	O
Death	B-PROC
Cases	O
Related	O
to	O
Corona	O
Virus	B-PROC
Disease	I-PROC
2019	O
（	O
COVID	O
-	O
19	O
）	O
（	O
Trial	O
Draft	O
）.	O

TITLE	O
:	O
Review	O
and	O
Prospect	O
of	O
Pathological	O
Features	O
of	O
Corona	O
Virus	B-PROC
Disease	I-PROC
.	O

We	O
also	O
conducted	O
""""	O
CellPhoneDB	O
""""	O
analysis	O
to	O
understand	O
the	O
cell	O
crosstalk	B-PROC
between	O
CoV	O
-	O
targets	O
and	O
their	O
surrounding	O
cells	O
across	O
different	O
tissues	O
.	O

It	O
is	O
concluded	O
that	O
the	O
problem	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
is	O
probably	O
being	O
overestimated	O
,	O
as	O
2	O
.	O
6	O
million	O
people	O
die	O
of	O
respiratory	O
infections	O
each	O
year	O
compared	O
with	O
less	O
than	O
4000	O
deaths	B-PROC
for	O
SARS	O
-	O
CoV	O
-	O
2	O
at	O
the	O
time	O
of	O
writing	O
.	O

Being	O
obligate	O
intracellular	O
parasites	O
,	O
viruses	O
rely	O
on	O
the	O
protein	B-PROC
synthesis	I-PROC
machinery	O
of	O
host	O
cells	O
to	O
support	O
replication	O
,	O
and	O
not	O
surprisingly	O
,	O
many	O
viral	O
proteins	O
are	O
subjected	O
to	O
PTMs	O
.	O

STAT3	O
exhibits	O
a	O
proviral	O
function	O
in	O
several	O
viral	B-PROC
infections	I-PROC
,	O
including	O
those	O
of	O
HBV	O
,	O
HCV	O
,	O
HSV	O
-	O
1	O
,	O
varicella	O
zoster	O
virus	O
,	O
human	O
CMV	O
and	O
measles	O
virus	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
:	O
pathogenesis	B-PROC
and	O
therapeutic	O
developments	O
.	O

The	O
structural	O
proteins	O
encounter	O
cellular	O
membranes	O
at	O
both	O
entry	O
and	O
exit	O
of	O
the	O
virus	O
while	O
the	O
nonstructural	O
proteins	O
reorganize	O
cellular	O
membranes	O
to	O
benefit	O
virus	B-PROC
replication	I-PROC
.	O

As	O
little	O
is	O
currently	O
known	O
about	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
it	O
is	O
likely	O
that	O
lessons	O
learned	B-PROC
from	O
these	O
major	O
epidemics	O
can	O
be	O
applied	O
to	O
the	O
new	O
pandemic	O
,	O
including	O
the	O
use	O
of	O
novel	O
immunosuppressive	O
drugs	O
.	O

ABSTRACT	O
:	O
As	O
of	O
February	O
29	O
,	O
2020	O
,	O
more	O
than	O
85	O
,	O
000	O
cases	O
of	O
coronavirus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
have	O
been	O
reported	O
from	O
China	O
and	O
53	O
other	O
countries	O
with	O
2	O
,	O
924	O
deaths	B-PROC
.	O

Hospitalized	O
adult	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
with	O
any	O
one	O
of	O
the	O
following	O
criteria	O
will	O
be	O
eligible	O
to	O
receive	O
lopinavir	O
/	O
ritonavir	O
for	O
14	O
days	O
after	O
obtaining	O
written	O
informed	O
consent	O
:	O
(	O
i	O
)	O
respiratory	O
distress	O
with	O
respiratory	O
rate	O
≥	O
22	O
/	O
min	O
or	O
SpO2	O
of	O
<	O
94	O
per	O
cent	O
;	O
(	O
ii	O
)	O
lung	O
parenchymal	O
infiltrates	O
on	O
chest	O
X	O
-	O
ray	O
;	O
(	O
iii	O
)	O
hypotension	O
defined	O
as	O
systolic	O
blood	B-PROC
pressure	I-PROC
<	O
90	O
mmHg	O
or	O
need	O
for	O
vasopressor	O
/	O
inotropic	O
medication	O
;	O
(	O
iv	O
)	O
new	O
-	O
onset	O
organ	O
dysfunction	O
;	O
and	O
(	O
v	O
)	O
high	O
-	O
risk	O
groups	O
-	O
age	O
>	O
60	O
yr	O
,	O
diabetes	O
mellitus	O
,	O
renal	O
failure	O
,	O
chronic	O
lung	O
disease	O
and	O
immunocompromised	O
persons	O
.	O

Suggested	O
treatment	O
included	O
providing	O
oxygen	O
,	O
inhalations	B-PROC
,	O
nutritional	O
support	O
and	O
maintaining	O
fluids	O
and	O
electrolyte	O
balances	O
.	O

In	O
this	O
survey	O
of	O
heath	O
care	O
workers	O
in	O
hospitals	O
equipped	O
with	O
fever	B-PROC
clinics	O
or	O
wards	O
for	O
patients	O
with	O
COVID	O
-	O
19	O
in	O
Wuhan	O
and	O
other	O
regions	O
in	O
China	O
,	O
participants	O
reported	O
experiencing	O
psychological	O
burden	O
,	O
especially	O
nurses	O
,	O
women	O
,	O
those	O
in	O
Wuhan	O
,	O
and	O
frontline	O
health	O
care	O
workers	O
directly	O
engaged	O
in	O
the	O
diagnosis	O
,	O
treatment	O
,	O
and	O
care	O
for	O
patients	O
with	O
COVID	O
-	O
19	O
.	O

However	O
,	O
as	O
of	O
this	O
moment	O
no	O
information	O
has	O
been	O
reported	O
on	O
the	O
possibility	O
of	O
viral	B-PROC
transmission	I-PROC
,	O
even	O
to	O
professionals	O
,	O
via	O
this	O
route	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
2019	O
novel	O
coronavirus	O
:	O
implication	O
for	O
development	B-PROC
of	O
RBD	O
protein	O
as	O
a	O
viral	O
attachment	O
inhibitor	O
and	O
vaccine	O
.	O

Ensuring	O
that	O
systems	O
enable	O
safe	O
and	O
coordinated	O
movement	B-PROC
of	O
critically	O
ill	O
patients	O
,	O
staff	O
,	O
and	O
equipment	O
is	O
important	O
to	O
improve	O
ECMO	O
access	O
.	O

ABSTRACT	O
:	O
COVID	O
-	O
19	O
(	O
Corona	O
Virus	B-PROC
Disease	I-PROC
2019	O
)	O
has	O
significantly	O
resulted	O
in	O
a	O
large	O
number	O
of	O
psychological	O
consequences	O
.	O

We	O
sample	O
and	O
analyze	O
the	O
Weibo	O
posts	O
from	O
17	O
,	O
865	O
active	O
Weibo	O
users	O
using	O
the	O
approach	O
of	O
Online	O
Ecological	O
Recognition	O
(	O
OER	O
)	O
based	O
on	O
several	O
machine	O
-	O
learning	B-PROC
predictive	O
models	O
.	O

Although	O
feline	O
viral	B-PROC
diseases	I-PROC
can	O
pose	O
serious	O
health	O
hazards	O
to	O
pet	O
cats	O
,	O
commercialized	O
preventative	O
vaccines	O
are	O
lacking	O
.	O

LH	O
significantly	O
inhibits	O
the	O
SARS	O
-	O
COV	O
-	O
2	O
replication	O
,	O
affects	O
virus	O
morphology	O
and	O
exerts	B-PROC
anti	O
-	O
inflammatory	O
activity	O
in	O
vitro	O
.	O

Finally	O
,	O
there	O
were	O
low	O
levels	O
of	O
polymorphisms	B-PROC
,	O
in	O
the	O
spike	O
genes	O
.	O

Scientists	O
are	O
racing	O
towards	O
the	O
development	B-PROC
of	O
treatment	O
for	O
COVID	O
-	O
19	O
.	O

Clinical	O
trials	O
targeting	B-PROC
patients	O
with	O
severe	O
ARDS	O
will	O
be	O
best	O
poised	O
to	O
detect	O
measurable	O
differences	O
in	O
these	O
outcomes	O
.	O

Due	O
to	O
its	O
high	O
pathogenicity	O
and	O
infectivity	O
and	O
the	O
lack	O
of	O
effective	O
vaccines	O
and	O
therapeutics	O
,	O
live	O
SARS	O
-	O
CoV	O
-	O
2	O
has	O
to	O
be	O
handled	O
under	O
biosafety	O
level	O
3	O
conditions	O
,	O
which	O
has	O
hindered	O
the	O
development	B-PROC
of	O
vaccines	O
and	O
therapeutics	O
.	O

However	O
,	O
using	O
Q	O
-	O
UEL	O
systems	O
to	O
access	O
relevant	O
and	O
emerging	O
literature	O
,	O
and	O
to	O
interact	O
with	O
standard	O
publically	O
available	O
bioinformatics	O
tools	O
on	O
the	O
Internet	O
,	O
did	O
help	O
quickly	O
identify	O
sequences	O
of	O
amino	O
acids	O
that	O
are	O
well	O
conserved	O
across	O
many	O
coronaviruses	O
including	O
2019	O
-	O
nCoV	O
.	O
KRSFIEDLLFNKV	O
was	O
found	O
to	O
be	O
particularly	O
well	O
conserved	O
in	O
this	O
study	O
and	O
corresponds	O
to	O
the	O
region	O
around	O
one	O
of	O
the	O
known	O
cleavage	B-PROC
sites	O
of	O
the	O
SARS	O
virus	O
that	O
are	O
believed	O
to	O
be	O
required	O
for	O
virus	B-PROC
activation	I-PROC
for	O
cell	O
entry	O
.	O

Patients	O
in	O
the	O
death	B-PROC
group	O
had	O
a	O
significantly	O
longer	O
time	O
of	O
illness	O
onset	O
to	O
hospitalization	O
(	O
10	O
.	O
0	O
[	O
6	O
.	O
5	O
,	O
12	O
.	O
0	O
]	O
days	O
vs	O
.	O
7	O
.	O
0	O
[	O
5	O
.	O
0	O
,	O
10	O
.	O
0	O
]	O
days	O
,	O
Z	O
=	O
3	O
.	O
216	O
,	O
P	O
=	O
0	O
.	O
001	O
).	O

Angioinvasive	O
aspergillosis	O
can	O
even	O
result	O
in	O
fatal	O
pulmonary	O
embolism	O
;	O
hence	O
,	O
early	O
targeted	B-PROC
testing	O
for	O

Risk	O
factors	O
for	O
death	B-PROC
within	O
28	O
days	O
were	O
also	O
evaluated	O
.	O

The	O
outcomes	O
of	O
interest	O
were	O
diagnosis	O
of	O
ARDS	O
up	O
to	O
seven	O
days	O
after	O
admission	O
and	O
death	B-PROC
within	O
28	O
days	O
.	O

Factors	O
independently	O
related	O
to	O
the	O
occurrence	O
of	O
ARDS	O
were	O
age	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
1	O
.	O
04	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
02	O
-	O
1	O
.	O
06	O
;	O
P	O
<	O
0	O
.	O
001	O
),	O
inhalation	B-PROC
injury	O
(	O
HR	O
=	O
2	O
.	O
50	O
;	O
95	O
%	O
CI	O
1	O
.	O
25	O
-	O
5	O
.	O
02	O
;	O
P	O
=	O
0	O
.	O
01	O
),	O
and	O
static	O
compliance	O
(	O
HR	O
=	O
0	O
.	O
97	O
;	O
95	O
%	O
CI	O
0	O
.	O
94	O
-	O
0	O
.	O
99	O
;	O
P	O
=	O
0	O
.	O
03	O
).	O

Age	O
and	O
inhalation	B-PROC
injury	O
were	O
independent	O
factors	O
for	O
ARDS	O
.	O

More	O
than	O
150	O
,	O
000	O
confirmed	O
cases	O
worldwide	O
are	O
reported	O
by	O
the	O
SARS	O
-	O
CoV2	O
,	O
with	O
more	O
than	O
5	O
,	O
000	O
COVID	O
-	O
19	O
-	O
related	O
deaths	B-PROC
on	O
March	O
14th	O
,	O
2020	O
.	O

TITLE	O
:	O
Analysis	O
of	O
Epidemiological	O
and	O
Clinical	O
features	O
in	O
older	O
patients	O
with	O
Corona	O
Virus	B-PROC
Disease	I-PROC
2019	O
(	O
COVID	O
-	O
19	O
)	O
out	O
of	O
Wuhan	O
.	O

ABSTRACT	O
:	O
This	O
commentary	O
seeks	O
to	O
share	O
some	O
key	O
insights	O
relevant	O
to	O
optimizing	O
COVID	O
-	O
19	O
candidate	O
therapeutics	O
that	O
were	O
learned	B-PROC
from	O
attempts	O
to	O
optimize	O
anti	O
-	O
infective	O
posology	O
in	O
settings	O
where	O
quality	O
and	O
timely	O
availability	O
of	O
data	O
is	O
challenging	O
,	O
with	O
particular	O
focus	O
on	O
influenza	O
,	O
including	O
experiences	O
from	O
H5N1	O
and	O
pH1N1	O
outbreaks	O
.	O

Results	O
Among	O
the	O
61	O
cases	O
of	O
children	O
who	O
died	B-PROC
of	O
viral	O
pneumonia	O
,	O
most	O
were	O
within	O
2	O
years	O
old	O
（	O
83	O
.	O
61	O
%）,	O
and	O
a	O
large	O
proportion	O
died	B-PROC
within	O
2	O
weeks	O
after	O
the	O
onset	O
of	O
the	O
disease	O
（	O
91	O
.	O
80	O
%）.	O

